PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wang, J; Al-Lamki, RS; Zhang, H; Kirkiles-Smith, N; Gaeta, ML; Thiru, S; Pober, JS; Bradley, JR				Wang, J; Al-Lamki, RS; Zhang, H; Kirkiles-Smith, N; Gaeta, ML; Thiru, S; Pober, JS; Bradley, JR			Histamine antagonizes tumor necrosis factor (TNF) signaling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; LEUKOCYTE ADHESION MOLECULE-1; PHORBOL-MYRISTATE ACETATE; ACTIVATED PROTEIN-KINASE; ALPHA CONVERTING-ENZYME; MAST-CELLS; PRECURSOR; EXPRESSION; METALLOPROTEINASE; TRANSDUCTION	Tumor necrosis factor (TNF) activates pro-inflammatory functions of vascular endothelial cells (EC) through binding to receptor type 1 (TNFR1) molecules expressed on the cell surface. The majority of TNFR1 molecules are localized to the Golgi apparatus. Soluble forms of TNFR1 (as well as of TNFR2) can be shed from the EC surface and inhibit TNF actions. The relationships among cell surface, Golgi-associated, and shed forms of TNFR1 are unclear. Here we report that histamine causes transient loss of surface TNFR1, TNFR1 shedding, and mobilization of TNFR1 molecules from the Golgi in cultured human EC. The Golgi pool of TNFR1 serves both to replenish cell surface receptors and as a source of shed receptor. Histamine-induced shedding is blocked by TNF-alpha protease inhibitor, an inhibitor of TNF-alpha-converting enzyme, and through the H1 receptor via a MEK-1/p42 and p44 mitogen-activated protein kinase pathway. Cultured EC with histamine-induced surface receptor loss become transiently refractory to TNF. Histamine injection into human skin engrafted on immunodeficient mice similarly caused shedding of TNFR1 and diminished TNF-mediated induction of endothelial adhesion molecules. These results both clarify relationships among TNFR1 populations and reveal a novel anti-inflammatory activity of histamine.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Pathol, Cambridge CB2 2QQ, England; Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdepartmental Program Vasc Biol & Transplanta, New Haven, CT 06511 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Yale University	Bradley, JR (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Med, Box 157,Level 5,Hills Rd, Cambridge CB2 2QQ, England.			Bradley, John/0000-0002-7774-8805; Wang, Jun/0000-0003-3667-3760				Aksentijevich I, 2001, AM J HUM GENET, V69, P301, DOI 10.1086/321976; Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bolz SS, 1997, CARDIOVASC RES, V36, P437, DOI 10.1016/S0008-6363(97)00197-1; BRADLEY JR, 1995, AM J PATHOL, V146, P27; BRADLEY JR, 1995, AM J PATHOL, V147, P627; BUXBAUM JD, 1994, P NATL ACAD SCI USA, V91, P4489, DOI 10.1073/pnas.91.10.4489; Cui XL, 2002, J CLIN INVEST, V110, P515, DOI 10.1172/JCI200213847; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Dri P, 2000, J IMMUNOL, V165, P2165, DOI 10.4049/jimmunol.165.4.2165; Furuta GT, 1997, GASTROENTEROLOGY, V113, P1560, DOI 10.1053/gast.1997.v113.pm9352858; Gaeta ML, 2000, LAB INVEST, V80, P1185, DOI 10.1038/labinvest.3780126; Galon J, 2000, CURR OPIN IMMUNOL, V12, P479, DOI 10.1016/S0952-7915(00)00124-2; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HWANG CD, 1993, J IMMUNOL, V151, P5631; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; Jones SJ, 1999, J IMMUNOL, V162, P1042; Karmann K, 1996, J EXP MED, V184, P173, DOI 10.1084/jem.184.1.173; Krauss S, 2000, FASEB J, V14, P2581, DOI 10.1096/fj.00-0064com; Ledgerwood EC, 1999, LAB INVEST, V79, P1041; LEUNG DYM, 1991, J CLIN INVEST, V87, P1805, DOI 10.1172/JCI115201; Li Y, 2001, MICROVASC RES, V61, P253, DOI 10.1006/mvre.2001.2304; Madge LA, 1999, J BIOL CHEM, V274, P13643, DOI 10.1074/jbc.274.19.13643; Madge LA, 2001, EXP MOL PATHOL, V70, P317, DOI 10.1006/exmp.2001.2368; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Merlos-Suarez A, 1999, BIOCHEM SOC T, V27, P243, DOI 10.1042/bst0270243; Miki I, 1996, CELL IMMUNOL, V171, P285; Mills J, 1997, J NEUROSCI, V17, P9415; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; MURRAY AG, 1994, P NATL ACAD SCI USA, V91, P9146, DOI 10.1073/pnas.91.19.9146; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Robinson AJ, 2001, BRIT J PHARMACOL, V133, P1378, DOI 10.1038/sj.bjp.0704200; Schlondorff J, 2000, BIOCHEM J, V347, P131, DOI 10.1042/0264-6021:3470131; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; SLOWIK MR, 1993, AM J PATHOL, V143, P1724; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; van Mourik JA, 2002, HISTOCHEM CELL BIOL, V117, P113, DOI 10.1007/s00418-001-0368-9; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200; Zhang ZL, 2001, FASEB J, V15, P303	50	73	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21751	21760		10.1074/jbc.M212662200	http://dx.doi.org/10.1074/jbc.M212662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12646554	hybrid			2022-12-27	WOS:000183354200056
J	Banyard, J; Bao, L; Zetter, BR				Banyard, J; Bao, L; Zetter, BR			Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XIII-COLLAGEN; XVII COLLAGEN; GROWTH-FACTOR; FURIN; ADHESION; EXPRESSION; INTEGRINS; COMPONENT; PRECURSOR; PROTEIN	We have identified a transmembrane collagen, collagen XXIII, in rat prostate carcinoma cells. Differential display of mRNA expression in prostate carcinoma sublines with varying metastatic potential revealed overexpression of this transcript in the metastatic AT6.1 subline. cDNA cloning identified a 2733-bp transcript from AT6.1 RNA, encoding a protein of 532 amino acids, together with a 3067-bp human homologue, resulting in a 540-amino acid protein. Collagen XXIII is predicted to be a type II membrane protein consisting of an aminoterminal cytoplasmic domain, a transmembrane region, and three collagenous domains flanked by short noncollagenous domains. Collagen XXIII is a new member of the transmembrane collagen family, showing structural homology with the transmembrane collagens XIII and XXV. We present evidence that collagen XXIII is expressed as a similar to75-kDa protein at the cell surface and that it can be cleaved by furin protease activity. Cleavage results in a similar to60-kDa soluble protein that forms a multimeric complex and exhibits a low affinity interaction with heparin.	Harvard Univ, Childrens Hosp, Sch Med, ProgramVasc Biol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Zetter, BR (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, ProgramVasc Biol, Enders 1074,300 Longwood Ave, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; DAVIS GE, 1992, BIOCHEM BIOPH RES CO, V182, P1025, DOI 10.1016/0006-291X(92)91834-D; Eyal Y, 1999, BIOTECHNIQUES, V27, P656, DOI 10.2144/99274bm04; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hagg P, 2001, MATRIX BIOL, V19, P727, DOI 10.1016/S0945-053X(00)00119-0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hopkinson SB, 1998, J INVEST DERMATOL, V111, P1015, DOI 10.1046/j.1523-1747.1998.00452.x; ISAACS JT, 1986, PROSTATE, V9, P261, DOI 10.1002/pros.2990090306; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Kvist AP, 1999, MATRIX BIOL, V18, P261, DOI 10.1016/S0945-053X(99)00018-9; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; Miyoshi E, 1997, J BIOL CHEM, V272, P14349, DOI 10.1074/jbc.272.22.14349; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nykvist P, 2000, J BIOL CHEM, V275, P8255, DOI 10.1074/jbc.275.11.8255; Nykvist P, 2001, J BIOL CHEM, V276, P38673, DOI 10.1074/jbc.M102589200; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; RUGGIERO F, 1994, EXP CELL RES, V210, P215, DOI 10.1006/excr.1994.1032; Schacke H, 1998, J BIOL CHEM, V273, P25937, DOI 10.1074/jbc.273.40.25937; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; Tu HM, 2002, J BIOL CHEM, V277, P23092, DOI 10.1074/jbc.M107583200; [No title captured]	32	66	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20989	20994		10.1074/jbc.M210616200	http://dx.doi.org/10.1074/jbc.M210616200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12644459	hybrid			2022-12-27	WOS:000183230500071
J	Liu, Y; Shi, ZQ; Silveira, A; Liu, JZ; Sawadogo, M; Yang, HM; Feng, X				Liu, Y; Shi, ZQ; Silveira, A; Liu, JZ; Sawadogo, M; Yang, HM; Feng, X			Involvement of upstream stimulatory factors 1 and 2 in RANKL-induced transcription of tartrate-resistant acid phosphatase gene during osteoclast differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR RECEPTOR; BONE-RESORPTION; FUNCTIONAL DOMAINS; TERMINAL KINASE; MULTIPLE FORMS; FACTOR USF; T-CELLS; LIGAND; ACTIVATION	Tartrate-resistant acid phosphatase ( TRAP) plays an important role in bone resorption. TRAP expression in osteoclasts is regulated by receptor activator of NF-kappaB ( RANKL), a potent activator of osteoclast differentiation. However, the molecular mechanism underlying the RANKL-induced TRAP expression remains unknown. Here we show that two regions in the mouse TRAP promoter (one at - 1858 to - 1239 and the other at - 1239 to - 1039, relative to the translation start site) are implicated in RANKL- induced TRAP transcription in RAW264.7 cells. A detailed characterization of the region at - 1239 to - 1039 identifies a 12-bp sequence, AGC-CACGTGGTG, that specifically binds nuclear proteins from RAW264.7 cells and primary bone marrow macrophages (BMMs) in an electrophoretic mobility shift assay ( EMSA). Moreover, the binding is significantly enhanced in EMSA with nuclear extracts from RANKL-treated RAW264.7 cells and BMMs, suggesting that the 12-bp sequence may be involved in RANKL- induced TRAP transcription. Various assays reveal that nuclear proteins binding to the 12-bp sequence are upstream stimulatory factors (USF) 1 and 2. Importantly, mutation of the USF-binding site partially blocks RANKL-induced TRAP transcription in RAW264.7 cells, confirming that USF1 and USF2 are functionally involved in RANKL- induced TRAP transcription. In summary, our data show that USF1 and USF2 play a functional role in RANKL- dependent TRAP expression during osteoclast differentiation.	Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Alabama System; University of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer Center	Feng, X (corresponding author), Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA.							Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Angel NZ, 2000, J BONE MINER RES, V15, P103, DOI 10.1359/jbmr.2000.15.1.103; BAKER RE, 1989, J BIOL CHEM, V264, P10843; BARDOT O, 1993, BIOCHEM BIOPH RES CO, V192, P37, DOI 10.1006/bbrc.1993.1378; Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763; BERBEN G, 1990, YEAST, V6, P451, DOI 10.1002/yea.320060510; Blair HC, 1998, BIOESSAYS, V20, P837, DOI 10.1002/(SICI)1521-1878(199810)20:10<837::AID-BIES9>3.3.CO;2-4; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CASSADY AI, 1993, GENE, V130, P201, DOI 10.1016/0378-1119(93)90420-8; CLARK SA, 1989, J BONE MINER RES, V4, P399; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Daumer KM, 2002, J BONE MINER RES, V17, P1701, DOI 10.1359/jbmr.2002.17.9.1701; Feng X, 2001, J CLIN INVEST, V107, P1137, DOI 10.1172/JCI12040; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907; Hayman AR, 1996, DEVELOPMENT, V122, P3151; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JOHNSON DR, 1990, BONE MINER, V8, P109, DOI 10.1016/0169-6009(90)90114-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105; Luchin A, 2001, J BIOL CHEM, V276, P36703, DOI 10.1074/jbc.M106418200; Luchin A, 2000, J BONE MINER RES, V15, P451, DOI 10.1359/jbmr.2000.15.3.451; Luo X, 1996, MOL CELL BIOL, V16, P1367; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Mansky KC, 2002, J LEUKOCYTE BIOL, V71, P304; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; OGAWA N, 1990, MOL CELL BIOL, V10, P2224, DOI 10.1128/MCB.10.5.2224; REDDY SV, 1995, J BONE MINER RES, V10, P601; REDDY SV, 1993, J BONE MINER RES, V8, P1263; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; Schwartz CJE, 2001, EMBO J, V20, P510, DOI 10.1093/emboj/20.3.510; Schwartzberg PL, 1997, GENE DEV, V11, P2835, DOI 10.1101/gad.11.21.2835; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo-123-5-2600; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; UDAGAWA N, 1989, ENDOCRINOLOGY, V125, P1805, DOI 10.1210/endo-125-4-1805; UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260; Vaananen HK, 2000, J CELL SCI, V113, P377; Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YAZIJI H, 1995, AM J CLIN PATHOL, V104, P397; ZAIDI M, 1989, BIOCHEM BIOPH RES CO, V159, P68, DOI 10.1016/0006-291X(89)92405-4	53	29	29	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20603	20611		10.1074/jbc.M212093200	http://dx.doi.org/10.1074/jbc.M212093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663664	hybrid			2022-12-27	WOS:000183230500021
J	Su, Y; Zhou, AW; Al-Lamki, RS; Karet, FE				Su, Y; Zhou, AW; Al-Lamki, RS; Karet, FE			The a-subunit of the V-type H+-ATPase interacts with phosphofructokinase-1 in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED VESICLE; TURTLE URINARY-BLADDER; AMINO-TERMINAL DOMAIN; VACUOLAR PROTON PUMP; TRANSLOCATING ATPASE; GENE ENCODES; BINDING; VPH1P; EXPRESSION; TRANSPORT	V-type or H+-ATPases are a family of ATP-dependent proton pumps that move protons across the plasma membrane at specialized sites such as kidney epithelial cells and osteoclasts as well as acidifying intracellular compartments. The 100-kDa polytopic a-subunit of this group of ATPases is suggested to play an important role in coupling the two functions of the pump, ATP hydrolysis and proton transport. In man, different a-subunit isoforms are encoded by four genes. ATP6V0A4 encodes a4, which is expressed apically in alpha-intercalated cells in both human and mouse kidney. We sought binding partners for the C terminus of a4 in order to address its potential role in the H+-ATPase complex. Random peptide phage display analysis revealed a consensus motif (WLELRP) with almost complete homology to part of the enzyme phosphofructokinase 1 (PFK-1). Activity of this enzyme is the rate-limiting step in glycolysis. Specificity of a4 binding to this peptide was confirmed by enzyme-linked immunosorbent assay. Protein-protein interaction was further demonstrated by co-immunoprecipitation of a4 with PFK-1 from solubilized human kidney membrane proteins. An in vitro bead-bound PFK-1 pull-down assay showed that this interaction was also true for the ubiquitously expressed a1 subunit. Finally, PFK-1 co-immunolocalized with a4 in alpha-intercalated cells in the collecting ducts of human kidney. These findings indicate a direct link between V-type H+-ATPases and glycolysis via the C-terminal region of the a-subunit of the pump and suggest a novel regulatory mechanism between H+-ATPase function and energy supply. This interaction between the a-subunit and PFK-1 also provides new evidence that the C terminus of this subunit lies cytoplasmically in vivo.	Univ Cambridge, Dept Med Genet, Cambridge CB2 2XY, England; Univ Cambridge, Dept Haematol, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Cambridge CB2 2XY, England; Univ Cambridge, Div Nephrol, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Karet, FE (corresponding author), Addenbrookes Hosp, Cambridge Inst Med Res, Box 139, Cambridge CB2 2XY, England.			Karet, Fiona/0000-0002-2457-2869; ZHOU, Aiwu/0000-0002-2555-5091				BEAUWENS R, 1976, J GEN PHYSIOL, V68, P421, DOI 10.1085/jgp.68.4.421; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Brown D, 1996, J EXP BIOL, V199, P2345; Clarke M, 2002, J CELL SCI, V115, P2893; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; DUNAWAY GA, 1983, MOL CELL BIOCHEM, V52, P75; ELSON A, 1990, GENOMICS, V7, P47, DOI 10.1016/0888-7543(90)90517-X; Fillingame RH, 1997, J EXP BIOL, V200, P217; Forgac M, 2000, J EXP BIOL, V203, P71; Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131; Futai M, 1996, J BIOENERG BIOMEMBR, V28, P409, DOI 10.1007/BF02113982; GILLESPIE J, 1991, FEBS LETT, V282, P69, DOI 10.1016/0014-5793(91)80446-A; GLUCK S, 1987, J BIOL CHEM, V262, P15780; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; Kemp RG, 2002, BIOCHEMISTRY-US, V41, P9426, DOI 10.1021/bi020110d; KEMP RG, 1987, BIOCHEMISTRY-US, V26, P3443, DOI 10.1021/bi00386a029; Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1998, J BIOL CHEM, V273, P6717, DOI 10.1074/jbc.273.12.6717; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YL, 1999, BIOCHEMISTRY-US, V38, P16407, DOI 10.1021/bi991761l; Lu M, 2002, J BIOL CHEM, V277, P38409, DOI 10.1074/jbc.M203521200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MANOLSON MF, 1992, J BIOL CHEM, V267, P14294; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; NAKAJIMA H, 1990, BIOCHEM BIOPH RES CO, V173, P1317, DOI 10.1016/S0006-291X(05)80931-3; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; STEINMETZ PR, 1981, J MEMBRANE BIOL, V59, P27, DOI 10.1007/BF01870818; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; VIK SB, 1994, J BIOL CHEM, V269, P30364; VORA S, 1982, ISOZYMES-CURR T BIOL, V6, P119; Weber J, 1997, FEBS LETT, V412, P169, DOI 10.1016/S0014-5793(97)00773-4; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; ZHANG JM, 1994, J BIOL CHEM, V269, P23518; ZHENG RL, 1994, J BIOL CHEM, V269, P18475	46	94	97	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20013	20018		10.1074/jbc.M210077200	http://dx.doi.org/10.1074/jbc.M210077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649290	hybrid			2022-12-27	WOS:000183078000058
J	Auzanneau, C; Thoreau, V; Kitzis, A; Becq, F				Auzanneau, C; Thoreau, V; Kitzis, A; Becq, F			A novel voltage-dependent chloride current activated by extracellular acidic pH in cultured rat Sertoli cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; CL-CHANNEL; SECRETION; MEMBRANE; OOCYTES; GLUCOSE; PROTEIN; CLONING; MEMBERS; FAMILY	Sertoli cells from mammalian testis are key cells involved in development and maintenance of stem cell spermatogonia as well as secretion of a chloride- and potassium-rich fluid into the lumen of seminiferous tubules. Using whole-cell patch clamp experiments, a novel chloride current was identified. It is activated only in the presence of an extracellular acidic pH, with an estimated half-maximal activation at pH 5.5. The current is strongly outwardly rectifying, activated with a fast time-dependent onset of activation but a slow time-dependent kinetic at depolarization pulses. The pH-activated chloride current was not detected at physiological or basic pH and is not sensitive to intracellular or extracellular Ca2+ variation. Diphenylamine-2-carboxylic acid and 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid blocked the induced currents, and its anionic selectivity sequence was Cl- > Br- > I- > gluconate. We have performed a reverse transcription-PCR analysis to search for voltage-dependent chloride rClC channels in cultured rat Sertoli cells. Among the nine members of the family only rClC-2, rClC-3, rClC-6, and rClC-7 have been identified. The inwardly rectifying rClC-2 chloride current was activated by hyperpolarization but not by pH variation. A different depolarization-activated outwardly rectifying chloride current was activated only by hypotonic challenge and may correspond either to rClC-3 or rClC-6. Immunolocalization experiments demonstrate that rClC-7 resides in the intracellular compartment of Sertoli cells. This study provides the first functional identification of a native acid-activated chloride current. Based on our molecular analysis of rClC proteins, this new chloride current does not correspond to rClC-2, rClC-3, rClC-6, or rClC-7 channels. The potential physiological role of this native current in an epithelial cell from the reproductive system is discussed.	Univ Poitiers, CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, F-86022 Poitiers, France; CHU Poitiers, UPRES EA 2622, Lab Genet Cellulaire & Mol, F-86022 Poitiers, France	Centre National de la Recherche Scientifique (CNRS); Universite de Poitiers; CHU Poitiers; Universite de Poitiers	Becq, F (corresponding author), Univ Poitiers, CNRS, UMR 6558, Lab Biomembranes & Signalisat Cellulaire, 40 Ave Recteur Pineau, F-86022 Poitiers, France.	frederic.becq@univ-poitiers.fr	Becq, Frederic/P-9233-2016	Becq, Frederic/0000-0003-3915-0973				Boockfor FR, 1998, AM J PHYSIOL-CELL PH, V274, pC922, DOI 10.1152/ajpcell.1998.274.4.C922; Bosl MR, 2001, EMBO J, V20, P1289, DOI 10.1093/emboj/20.6.1289; Brandt S, 1995, FEBS LETT, V377, P15, DOI 10.1016/0014-5793(95)01298-2; Breton S, 1998, AM J PHYSIOL-CELL PH, V275, pC1134, DOI 10.1152/ajpcell.1998.275.4.C1134; Buyse G, 1998, BIOCHEM J, V330, P1015, DOI 10.1042/bj3301015; Diewald L, 2002, BIOCHEM BIOPH RES CO, V291, P421, DOI 10.1006/bbrc.2002.6462; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hamamah S, 1998, HUM REPROD, V13, P20, DOI 10.1093/humrep/13.suppl_4.20; Jackson VN, 1997, BIOCHEM J, V324, P447, DOI 10.1042/bj3240447; JEGOU B, 1992, BAILLIERE CLIN ENDOC, V6, P273, DOI 10.1016/S0950-351X(05)80151-X; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kawasaki E, 1999, BRAIN RES, V838, P166, DOI 10.1016/S0006-8993(99)01730-8; Kawasaki Masanobu, 1999, American Journal of Physiology, V277, pC948; KIEFERLE S, 1994, P NATL ACAD SCI USA, V91, P6943, DOI 10.1073/pnas.91.15.6943; Kornak U, 2001, CELL, V104, P205, DOI 10.1016/S0092-8674(01)00206-9; Lalevee N, 1997, BIOL REPROD, V56, P680, DOI 10.1095/biolreprod56.3.680; Lalevee N, 1999, J MEMBRANE BIOL, V169, P167, DOI 10.1007/s002329900528; LIN H, 1994, EXP EYE RES, V59, P679, DOI 10.1006/exer.1994.1153; Mauduit C, 1999, HUM REPROD UPDATE, V5, P535, DOI 10.1093/humupd/5.5.535; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; Riera MF, 2002, J ENDOCRINOL, V173, P335, DOI 10.1677/joe.0.1730335; ROBINSON R, 1981, BIOL REPROD, V24, P1032, DOI 10.1095/biolreprod24.5.1032; RUSSEL LD, 1993, SERTOLI CELL, P270; Rychkov GY, 1996, J PHYSIOL-LONDON, V497, P423, DOI 10.1113/jphysiol.1996.sp021778; STEINMEYER K, 1991, NATURE, V354, P301, DOI 10.1038/354301a0; Steinmeyer K, 1995, J BIOL CHEM, V270, P31172, DOI 10.1074/jbc.270.52.31172; Taranta A, 1997, MOL CELL ENDOCRINOL, V126, P117, DOI 10.1016/S0303-7207(96)03973-1; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Vanoye CG, 2002, J PHYSIOL-LONDON, V539, P373, DOI 10.1113/jphysiol.2001.013115; VERHOEVEN G, 1979, MOL CELL ENDOCRINOL, V13, P241, DOI 10.1016/0303-7207(79)90084-4; Waldegger S, 2000, J BIOL CHEM, V275, P24527, DOI 10.1074/jbc.M001987200	38	49	49	1	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19230	19236		10.1074/jbc.M301096200	http://dx.doi.org/10.1074/jbc.M301096200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637509	hybrid			2022-12-27	WOS:000182932200067
J	Chen, SJ; Nguyen, N; Tamura, K; Karin, M; Tukey, RH				Chen, SJ; Nguyen, N; Tamura, K; Karin, M; Tukey, RH			The role of the Ah receptor and p38 in Benzo[a]pyrene-7,8-dihydrodiol and Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; TOBACCO-SMOKE CARCINOGENS; OXIDE-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; POLY(ADP-RIBOSE) POLYMERASE; NH2-TERMINAL KINASE-1; METABOLIC-ACTIVATION; DEATH RECEPTORS; PROTEIN-KINASES; P450 1A1	Polycyclic aromatic hydrocarbons (PAHs) are ubiquitous contaminants in the environment. Benzo[ a] pyrene ( B[ a] P), a prototypical member of this class of chemicals, affects cellular signal transduction pathways and induces apoptosis. In this study, the proximate carcinogen of B[ a] P metabolism, trans-7,8-dihydroxy-7,8-dihydrobenzo[ a] pyrene ( B[ a] P-7,8-dihydrodiol) and the ultimate carcinogen, B[ a]P-r-7,t-8-dihydrodiol-t-9,10-epoxide(+/-) ( BPDE-2) were found to induce apoptosis in human HepG2 cells. Apoptosis initiated by B[ a] P-7,8-dihydrodiol was linked to activation of the Ah receptor and induction of CYP1A1, an event that can lead to the formation of BPDE-2. With both B[ a] P-7,8-dihydrodiol and BPDE-2 treatment, changes in anti- and pro-apoptotic events in the Bcl-2 family of proteins correlated with the release of mitochondrial cytochrome c and caspase activation. The onset of apoptosis as monitored by caspase activation was linked to mitogen-activated protein ( MAP) kinases. Utilizing mouse hepa1c1c7 cells and the Arnt-deficient BPRc1 cells, activation of MAP kinase p38 by B[a]P-7,8-dihydrodiol was shown to be Ah receptor-dependent, indicating that metabolic activation by CYP1A1 was required. This was in contrast to p38 activation by BPDE-2, an event that was independent of Ah receptor function. Confirmation that MAP kinases play a critical role in BPDE-2-induced apoptosis was shown by inhibiting caspase activation of poly( ADP-ribose) polymerase 1 (PARP-1) by chemical inhibitors of p38 and ERK1/2. Furthermore, mouse embryo p38(-/-) fibroblasts were shown to be resistant to the actions of BPDE-2-induced apoptosis as determined by annexin V analysis, cytochrome c release, and cleavage of PARP-1. These results confirm that the Ah receptor plays a critical role in B[ a] P-7,8-dihydrodiol-induced apoptosis while p38 MAP kinase links the actions of an electrophilic metabolite like BPDE-2 to the regulation of programmed cell death.	Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biochem, Lab Environm Toxicol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Tukey, RH (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Environm Toxicol, La Jolla, CA 92093 USA.			Chen, Shujuan/0000-0002-1068-195X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES10337] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bostrom CE, 2002, ENVIRON HEALTH PERSP, V110, P451, DOI 10.1289/ehp.02110s3451; Boulares AH, 2002, CANCER RES, V62, P4439; Boulares AH, 2002, J BIOL CHEM, V277, P372, DOI 10.1074/jbc.M107738200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen YH, 1996, J BIOL CHEM, V271, P26261, DOI 10.1074/jbc.271.42.26261; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chiarugi A, 2002, TRENDS PHARMACOL SCI, V23, P122, DOI 10.1016/S0165-6147(00)01902-7; Chiarugi A, 2002, SCIENCE, V297, P200, DOI 10.1126/science.1074592; Chin BY, 1998, AM J PHYSIOL-LUNG C, V275, pL942, DOI 10.1152/ajplung.1998.275.5.L942; CONNEY AH, 1994, DRUG METAB REV, V26, P125, DOI 10.3109/03602539409029788; CONNEY AH, 1982, CANCER RES, V42, P4875; Corchero J, 2001, PHARMACOGENETICS, V11, P1, DOI 10.1097/00008571-200102000-00001; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Gradin K, 1996, MOL CELL BIOL, V16, P5221; GROVER PL, 1973, BIOCHEM PHARMACOL, V22, P661, DOI 10.1016/0006-2952(73)90398-5; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; ISRAEL DI, 1984, J BIOL CHEM, V259, P5400; Jyonouchi H, 1999, CARCINOGENESIS, V20, P139, DOI 10.1093/carcin/20.1.139; KAPITULNIK J, 1978, CANCER RES, V38, P354; KOURI RE, 1980, JNCI-J NATL CANCER I, V64, P617; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lei W, 1998, CANCER RES, V58, P2102; LEVIN W, 1977, CANCER RES, V37, P2721; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; MCMANUS ME, 1990, PROG CLIN BIOL RES, V340, P139; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ortiz MA, 2001, CANCER RES, V61, P8504; Page TJ, 2002, MOL PHARMACOL, V62, P313, DOI 10.1124/mol.62.2.313; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; POSTLIND H, 1993, TOXICOL APPL PHARM, V118, P255, DOI 10.1006/taap.1993.1031; Roth W, 2002, NAT MED, V8, P216, DOI 10.1038/nm0302-216; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Salas VM, 1998, TOXICOL APPL PHARM, V151, P367, DOI 10.1006/taap.1998.8455; Sanchez-Prieto R, 2000, CANCER RES, V60, P2464; Shimada T, 1999, CHEM RES TOXICOL, V12, P623, DOI 10.1021/tx990028s; Shimada T, 2002, CARCINOGENESIS, V23, P1199, DOI 10.1093/carcin/23.7.1199; SHIMADA T, 1989, CANCER RES, V49, P6304; Shimada T, 2001, DRUG METAB DISPOS, V29, P1176; Shimada T, 1996, CANCER RES, V56, P2979; SHIMADA T, 1994, CARCINOGENESIS, V15, P2523, DOI 10.1093/carcin/15.11.2523; SIMS P, 1974, NATURE, V252, P326, DOI 10.1038/252326a0; Soldani C, 2002, APOPTOSIS, V7, P321, DOI 10.1023/A:1016119328968; Soucek P, 1995, BIOCHEMISTRY-US, V34, P16013, DOI 10.1021/bi00049a015; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; THAKKER DR, 1976, P NATL ACAD SCI USA, V73, P3381, DOI 10.1073/pnas.73.10.3381; Wani MA, 1999, CARCINOGENESIS, V20, P765, DOI 10.1093/carcin/20.5.765; WISLOCKI PG, 1976, CANCER RES, V36, P3350; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; YUEH MF, 2003, J BIOL CHEM; Zhuang SG, 2000, J BIOL CHEM, V275, P25939, DOI 10.1074/jbc.M001185200	62	65	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19526	19533		10.1074/jbc.M300780200	http://dx.doi.org/10.1074/jbc.M300780200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637498	hybrid			2022-12-27	WOS:000182932200103
J	Goerges, AL; Nugent, MA				Goerges, AL; Nugent, MA			Regulation of vascular endothelial growth factor binding and activity by extracellular pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; FIBROBLAST-GROWTH; CELL-SURFACE; FACTOR EXPRESSION; FACTOR VEGF; TUMOR PH; ANGIOGENESIS; RECEPTOR; MATRIX; MOLECULES	Angiogenesis, the growth of new blood vessels, is regulated by a number of factors, including hypoxia and vascular endothelial growth factor ( VEGF). Although the effects of hypoxia have been studied intensely, less attention has been given to other extracellular parameters such as pH. Thus, the present study investigates the consequences of acidic pH on VEGF binding and activity in endothelial cell cultures. We found that the binding of VEGF(165) and VEGF(121) to endothelial cells increased as the extracellular pH was decreased from 7.5 to 5.5. Binding of VEGF(165) and VEGF(121) to endothelial extracellular matrix was also increased at acidic pH. These effects were, in part, a reflection of increased heparin binding, because VEGF(165) and VEGF(121) showed increased retention on heparin-Sepharose at pH 5.5 compared with pH 7.5. Consistent with these findings, soluble heparin competed for VEGF binding to endothelial cells under acidic conditions. However, at neutral pH ( 7.5) low concentrations of heparin (0.1-1.0 mug/ml) potentiated VEGF binding. Extracellular pH also regulated VEGF activation of the extracellular signal-regulated kinases 1 and 2 (Erk1/2). VEGF(165) and VEGF(121) activation of Erk1/ 2 at pH 7.5 peaked after 5 min, whereas at pH 6.5 the peak was shifted to 10 min. At pH 5.5, neither VEGF isoform was able to activate Erk1/ 2, suggesting that the increased VEGF bound to the cells at low pH was sequestered in a stored state. Therefore, extracellular pH might play an important role in regulating VEGF interactions with cells and the extracellular matrix, which can modulate VEGF activity.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Nugent, MA (corresponding author), Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.			Nugent, Matthew/0000-0002-8630-4712	NHLBI NIH HHS [HL56200] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056200] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akimoto T, 2002, AM J PHYSIOL-REG I, V283, pR487, DOI 10.1152/ajpregu.00699.2001; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Brogi E, 1996, J CLIN INVEST, V97, P469, DOI 10.1172/JCI118437; Burbridge M F, 1999, Angiogenesis, V3, P281, DOI 10.1023/A:1009092511894; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; DANGELO G, 1995, P NATL ACAD SCI USA, V92, P6374, DOI 10.1073/pnas.92.14.6374; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fannon M, 2000, BIOCHEMISTRY-US, V39, P1434, DOI 10.1021/bi991895z; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsten KE, 2001, J CELL PHYSIOL, V189, P356, DOI 10.1002/jcp.10033; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105; MOSCATELLI D, 1988, J CELL BIOL, V107, P753, DOI 10.1083/jcb.107.2.753; NUGENT MA, 1992, BIOCHEMISTRY-US, V31, P8876, DOI 10.1021/bi00152a026; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson CJ, 2001, J CELL SCI, V114, P853; Sasisekharan R, 1997, Angiogenesis, V1, P45, DOI 10.1023/A:1018318914258; Sharma B, 1998, J CLIN INVEST, V102, P1599, DOI 10.1172/JCI3793; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; TANNOCK IF, 1972, BRIT J RADIOL, V45, P515, DOI 10.1259/0007-1285-45-535-515; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; Veikkola T, 2000, CANCER RES, V60, P203; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; Wahl ML, 2000, GEN PHARMACOL-VASC S, V35, P277, DOI 10.1016/S0306-3623(01)00115-X; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; WIKEHOOLEY JL, 1984, EUR J CANCER CLIN ON, V20, P619, DOI 10.1016/0277-5379(84)90006-3; Woods A, 1998, MATRIX BIOL, V17, P477, DOI 10.1016/S0945-053X(98)90095-6; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	41	55	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19518	19525		10.1074/jbc.M211208200	http://dx.doi.org/10.1074/jbc.M211208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637571	hybrid			2022-12-27	WOS:000182932200102
J	Kim, M; Ahn, JW; Jin, UH; Choi, D; Paek, KH; Pai, HS				Kim, M; Ahn, JW; Jin, UH; Choi, D; Paek, KH; Pai, HS			Activation of the programmed cell death pathway by inhibition of proteasome function in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPERSENSITIVE RESPONSE; ARABIDOPSIS-THALIANA; DISEASE RESISTANCE; UBIQUITIN SYSTEM; 26S PROTEASOME; CYTOCHROME-C; APOPTOSIS; TOBACCO; MITOCHONDRIA; EXPRESSION	Proteasomes constitute the major machinery to degrade or process proteins by ATP/ubiquitin-mediated proteolysis. Recent findings suggest a pivotal role of the ubiquitin/ proteasome pathway in the regulation of apoptosis in animal cells. Here we show that virus-induced gene silencing of two different subunits of the 26 S proteasome, the alpha6 subunit of the 20 S proteasome and RPN9 subunit of 19 S regulatory complex, both activated the programmed cell death (PCD) program, accompanied by reduced proteasome activity and accumulation of polyubiquitinated proteins. These results demonstrate that disruption of proteasome function leads to PCD in plant cells. The affected cells showed morphological markers of PCD, including nuclear condensation and DNA fragmentation, accompanied by the 10-fold higher production of reactive oxygen species and increased ion leakage for 3-fold. Similar to apoptosis in animal system, mitochondrial membrane potential was decreased, cytochrome c released from mitochondria to cytosol, and caspase 9- and caspase 3-like proteolytic activities detected in the cells. Interestingly, this proteasome-mediated PCD stimulated the expression of only a subset of transcripts that are highly induced during pathogen-mediated hypersensitive response cell death, indicating that the two PCD pathways are differentially regulated. Taken together, these results provide the first direct evidence that proteasomes play a role in the regulatory program of PCD in plants. Controlled inhibition of proteasome activities may be involved in developmentally or environmentally activated plant cell death programs.	Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305600, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea University	Pai, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, POB 115, Taejon 305600, South Korea.		Choi, Doil/F-5002-2011					Angell SM, 1999, PLANT J, V20, P357, DOI 10.1046/j.1365-313X.1999.t01-1-00597.x; Austin MJ, 2002, SCIENCE, V295, P2077, DOI 10.1126/science.1067747; Azevedo C, 2002, SCIENCE, V295, P2073, DOI 10.1126/science.1067554; Balk J, 1999, FEBS LETT, V463, P151, DOI 10.1016/S0014-5793(99)01611-7; Basset G, 2002, PLANT PHYSIOL, V128, P1149, DOI 10.1104/pp.010612; BECKER F, 1993, PLANT J, V3, P875, DOI 10.1111/j.1365-313X.1993.00875.x; Beers EP, 2000, PLANT MOL BIOL, V44, P399, DOI 10.1023/A:1026556928624; Bethke PC, 2001, PLANT J, V25, P19, DOI 10.1046/j.1365-313x.2001.00930.x; Callis J, 2000, CURR OPIN PLANT BIOL, V3, P381, DOI 10.1016/S1369-5266(00)00100-X; D'Silva I, 1998, EXP CELL RES, V245, P389, DOI 10.1006/excr.1998.4256; del Pozo O, 1998, CURR BIOL, V8, P1129, DOI 10.1016/S0960-9822(98)70469-5; Doelling JH, 2001, PLANT J, V27, P393, DOI 10.1046/j.1365-313X.2001.01106.x; EMORI Y, 1991, MOL CELL BIOL, V11, P344, DOI 10.1128/MCB.11.1.344; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Girod PA, 1999, PLANT CELL, V11, P1457; Gray WM, 2002, CURR BIOL, V12, pR352, DOI 10.1016/S0960-9822(02)00857-6; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Grimm L M, 1999, Results Probl Cell Differ, V23, P209; Heath MC, 2000, PLANT MOL BIOL, V44, P321, DOI 10.1023/A:1026592509060; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Korthout HAAJ, 2000, FEBS LETT, V475, P139, DOI 10.1016/S0014-5793(00)01643-4; Lacomme C, 1999, P NATL ACAD SCI USA, V96, P7956, DOI 10.1073/pnas.96.14.7956; Lam E, 2001, NATURE, V411, P848, DOI 10.1038/35081184; Lee SS, 2003, PLANT J, V33, P825, DOI 10.1046/j.1365-313X.2003.01672.x; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Liu Y, 2002, PLANT CELL, V14, P1483, DOI 10.1105/tpc.002493; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Mlejnek P, 2002, PLANTA, V215, P158, DOI 10.1007/s00425-002-0733-5; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; OZAKI M, 1992, J BIOL CHEM, V267, P21678; Peart JR, 2002, P NATL ACAD SCI USA, V99, P10865, DOI 10.1073/pnas.152330599; Pontier D, 1999, PLANT MOL BIOL, V39, P1243, DOI 10.1023/A:1006133311402; Pontier D, 1998, MOL PLANT MICROBE IN, V11, P544, DOI 10.1094/MPMI.1998.11.6.544; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun YL, 1999, FEBS LETT, V462, P317, DOI 10.1016/S0014-5793(99)01539-2; Swidzinski JA, 2002, PLANT J, V30, P431, DOI 10.1046/j.1365-313X.2002.01301.x; Tsujimoto Y, 2002, BIOCHIMIE, V84, P187, DOI 10.1016/S0300-9084(02)01370-6; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wertz IE, 1996, TRENDS BIOCHEM SCI, V21, P359, DOI 10.1016/0968-0004(96)40002-0; WILSON I, 1997, CURR BIOL, V7, P175; Woffenden BJ, 1998, PLANT PHYSIOL, V118, P419, DOI 10.1104/pp.118.2.419; Wojcik C, 2002, J BIOL CHEM, V277, P6188, DOI 10.1074/jbc.M109996200; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Xu Y, 2000, PLANT PHYSIOL, V122, P1323, DOI 10.1104/pp.122.4.1323; Zhang H, 2001, ANAL BIOCHEM, V298, P170, DOI 10.1006/abio.2001.5348	54	169	180	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19406	19415		10.1074/jbc.M210539200	http://dx.doi.org/10.1074/jbc.M210539200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637532	hybrid			2022-12-27	WOS:000182932200089
J	Baker, KM; Wei, G; Schaffner, AE; Ostrowski, MC				Baker, KM; Wei, G; Schaffner, AE; Ostrowski, MC			Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORADIC BREAST-CANCER; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTORS; OVARIAN-CANCER; CELL-CYCLE; MATRIX METALLOPROTEINASES; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; REMODELING COMPLEXES; GENE-EXPRESSION	Ets-2 is a transcriptional activator that can be modulated by ras-dependent phosphorylation. Evidence is presented indicating that ets-2 can also act as a transcriptional repressor. In the breast cancer cell line MCF-7, exogenous ets-2 repressed the activity of a BRCA1 promoter-luciferase reporter dependent on a conserved ets-2-binding site in this promoter. Conditional overproduction of ets-2 in MCF-7 cells resulted in repression of endogenous BRCA1 mRNA expression. To address the mechanism by which ets-2 could act as a repressor, a biochemical approach was used to identify proteins that interacted with the ets-2 pointed domain. From this analysis, components of the mammalian SWI/SNF chromatin remodeling complex were found to interact with ets-2. Brg-1, the ATP-hydrolyzing component of the SWI/SNF complex, along with the BAF57/p50 and Ini1 subunits could be co-immunoprecipitated from cells with ets-2. The pointed domain of ets-2 directly interacted in vitro with the C-terminal region of Brg-1 in a phosphorylation-dependent manner. The combination of Brg-1 and ets-2 could repress the BRCA1 promoter reporter in transfection assays. These results support a role for ets-2 as a repressor and indicate that components of the mammalian SNF/SWI complex are required as co-repressors.	Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Ostrowski, MC (corresponding author), Ohio State Univ, Dept Mol Genet, 484 W 12th Ave, Columbus, OH 43210 USA.		Ostrowski, Michael/H-3108-2011	Ostrowski, Michael/0000-0003-2948-6297	NCI NIH HHS [CA-53271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Foos G, 2001, METHOD ENZYMOL, V333, P61; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Fowles LF, 1998, MOL CELL BIOL, V18, P5148, DOI 10.1128/MCB.18.9.5148; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Ha HY, 2001, CANCER RES, V61, P984; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; Hager GL, 2001, PROG NUCLEIC ACID RE, V66, P279; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LANGER SJ, 1988, MOL CELL BIOL, V8, P3872, DOI 10.1128/MCB.8.9.3872; Liu R, 2001, CELL, V106, P309, DOI 10.1016/S0092-8674(01)00446-9; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Patton SE, 1998, CANCER RES, V58, P2253; Rabault B, 1996, ONCOGENE, V13, P877; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Sif S, 2001, GENE DEV, V15, P603, DOI 10.1101/gad.872801; Smith JL, 2000, MOL CELL BIOL, V20, P8026, DOI 10.1128/MCB.20.21.8026-8034.2000; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; Sudarsanam P, 2000, TRENDS GENET, V16, P345, DOI 10.1016/S0168-9525(00)02060-6; Suen TC, 1999, J BIOL CHEM, V274, P31297, DOI 10.1074/jbc.274.44.31297; Thakur S, 1999, J BIOL CHEM, V274, P8837, DOI 10.1074/jbc.274.13.8837; Thant AA, 1997, FEBS LETT, V406, P28, DOI 10.1016/S0014-5793(97)00230-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Ueno H, 1997, CANCER RES, V57, P2055; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WASYLYK C, 1992, CELL GROWTH DIFFER, V3, P617; Weng LP, 1999, CANCER RES, V59, P5808; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	47	67	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17876	17884		10.1074/jbc.M209480200	http://dx.doi.org/10.1074/jbc.M209480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637547	hybrid, Green Published			2022-12-27	WOS:000182838300037
J	Mathieu, N; Spicuglia, S; Gorbatch, S; Cabaud, O; Fernex, C; Verthuy, C; Hempel, WM; Hueber, AO; Ferrier, P				Mathieu, N; Spicuglia, S; Gorbatch, S; Cabaud, O; Fernex, C; Verthuy, C; Hempel, WM; Hueber, AO; Ferrier, P			Assessing the role of the T cell receptor beta gene enhancer in regulating coding joint formation during V(D)J recombination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLELIC EXCLUSION; THYMOCYTE DIFFERENTIATION; CD4(+)CD8(+) THYMOCYTE; BCL-2 EXPRESSION; DEFICIENT MICE; RAG PROTEINS; B-CELLS; LOCUS; DNA; ACCESSIBILITY	To assess the role of the T cell receptor (TCR) beta gene enhancer (Ebeta) in regulating the processing of VDJ recombinase-generated coding ends, we assayed TCRbeta rearrangement of Ebeta-deleted (DeltaEbeta) thymocytes in which cell death is inhibited via expression of a Bcl-2 transgene. Compared with DeltaEbeta, DeltaEbeta Bcl-2 thymocytes show a small accumulation of TCRbeta standard recombination products, including coding ends, that involves the proximal Dbeta-Jbeta and Vbeta14 loci but not the distal 5' Vbeta genes. These effects are detectable in double negative pro-T cells, predominate in double positive pre-T cells, and correlate with regional changes in chromosomal structure during double negative-to-double positive differentiation. We propose that Ebeta, by driving long range nucleoprotein interactions and the control of locus expression and chromatin structure, indirectly contributes to the stabilization of coding ends within the recombination processing complexes. The results also illustrate Ebeta-dependent and -independent changes in chromosomal structure, suggesting distinct modes of regulation of TCRbeta allelic exclusion depending on the position within the locus.	Univ Mediterranee, CNRS, INSERM, Ctr Immunol Marseille Luminy, F-13288 Marseille, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Ferrier, P (corresponding author), CIML, Case 906, F-13288 Marseille 9, France.		Anne-Odile, Hueber/G-4352-2013; Anne-Odile, Hueber/P-9860-2019; Spicuglia, Salvatore/L-2268-2016	Anne-Odile, Hueber/0000-0003-3816-2446; Anne-Odile, Hueber/0000-0003-3816-2446; Spicuglia, Salvatore/0000-0002-8101-7108				Akashi K, 1997, CELL, V89, P1033, DOI 10.1016/S0092-8674(00)80291-3; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Chattopadhyay S, 1998, J BIOL CHEM, V273, P29838, DOI 10.1074/jbc.273.45.29838; Chattopadhyay S, 1998, J IMMUNOL, V160, P1256; Chen F, 2001, J IMMUNOL, V166, P1771, DOI 10.4049/jimmunol.166.3.1771; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Glusman G, 2001, IMMUNITY, V15, P337, DOI 10.1016/S1074-7613(01)00200-X; Guo J, 2002, NAT IMMUNOL, V3, P469, DOI 10.1038/ni791; Hempel WM, 1998, GENE DEV, V12, P2305, DOI 10.1101/gad.12.15.2305; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Jenuwein T, 1997, NATURE, V385, P269, DOI 10.1038/385269a0; Khor B, 2002, CURR OPIN IMMUNOL, V14, P230, DOI 10.1016/S0952-7915(02)00326-6; Krangel MS, 2001, J EXP MED, V193, pF27, DOI 10.1084/jem.193.7.F27; KRIMPENFORT P, 1988, EMBO J, V7, P745, DOI 10.1002/j.1460-2075.1988.tb02871.x; Laird DJ, 2000, P NATL ACAD SCI USA, V97, P6924, DOI 10.1073/pnas.97.13.6924; Lang J, 1997, J EXP MED, V186, P1513, DOI 10.1084/jem.186.9.1513; Leduc I, 2000, J IMMUNOL, V165, P1364, DOI 10.4049/jimmunol.165.3.1364; LEWIS SM, 1994, ADV IMMUNOL, V56, P29; LINETTE GP, 1994, IMMUNITY, V1, P197, DOI 10.1016/1074-7613(94)90098-1; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Maraskovsky E, 1997, CELL, V89, P1011, DOI 10.1016/S0092-8674(00)80289-5; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi M, 2001, EMBO J, V20, P6927, DOI 10.1093/emboj/20.23.6927; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Mundy CL, 2002, MOL CELL BIOL, V22, P69, DOI 10.1128/MCB.22.1.69-77.2002; Neiditch MB, 2002, MOL CELL, V9, P871, DOI 10.1016/S1097-2765(02)00494-X; PIRCHER H, 1990, EUR J IMMUNOL, V20, P417, DOI 10.1002/eji.1830200227; RATHBUN G, 1989, NATURE, V342, P863, DOI 10.1038/342863a0; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Roth DB, 2000, CELL, V103, P699, DOI 10.1016/S0092-8674(00)00173-2; Saintigny Y, 2001, EMBO J, V20, P2596, DOI 10.1093/emboj/20.10.2596; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Sekiguchi J, 2001, P NATL ACAD SCI USA, V98, P3243, DOI 10.1073/pnas.051632098; Senoo M, 2001, INT IMMUNOL, V13, P1405, DOI 10.1093/intimm/13.11.1405; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Sieh P, 2001, J IMMUNOL, V167, P2121, DOI 10.4049/jimmunol.167.4.2121; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tevelev A, 2000, J BIOL CHEM, V275, P8341, DOI 10.1074/jbc.275.12.8341; Tillman RE, 2002, J EXP MED, V195, P309, DOI 10.1084/jem.20011803; Tripathi R, 2002, J IMMUNOL, V168, P2316, DOI 10.4049/jimmunol.168.5.2316; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; Whitehurst CE, 2001, MOL IMMUNOL, V38, P55, DOI 10.1016/S0161-5890(01)00031-1; Young F, 1997, IMMUNITY, V6, P23, DOI 10.1016/S1074-7613(00)80239-3; ZHU CM, 1995, IMMUNITY, V2, P101, DOI 10.1016/1074-7613(95)90082-9	51	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18101	18109		10.1074/jbc.M212647200	http://dx.doi.org/10.1074/jbc.M212647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639959	hybrid			2022-12-27	WOS:000182838300067
J	Kornilova, AY; Das, C; Wolfe, MS				Kornilova, AY; Das, C; Wolfe, MS			Differential effects of inhibitors on the gamma-secretase complex - Mechanistic implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-APP; PRESENILIN; IDENTIFICATION; NICASTRIN; TARGETS; PATHWAY; APH-1; PEN-2	gamma-Secretase is a protease complex of four integral membrane proteins, with presenilin (PS) as the apparent catalytic component, and this enzyme processes the transmembrane domains of a variety of substrates, including the amyloid beta-protein precursor and the Notch receptor. Here we explore the mechanisms of structurally diverse gamma-secretase inhibitors by examining their ability to displace an active site-directed photoprobe from PS heterodimers. Most gamma-secretase inhibitors, including a potent inhibitor of the PS-like signal peptide peptidase, blocked the photoprobe from binding to PS1, indicating that these compounds either bind directly to the active site or alter it through an allosteric interaction. Conversely, some reported inhibitors failed to displace this interaction, demonstrating that these compounds do not interfere with the protease by affecting its active site. Differential effects of the inhibitors with respect to photoprobe displacement and in cell-based and cell-free assays suggest that these compounds are important mechanistic tools for deciphering the workings of this intramembrane-cleaving protease complex and its similarity to other polytopic aspartyl proteases.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Wolfe, MS (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA.	mwolfe@rics.bwh.harvard.edu	Das, Chittaranjan/AAM-1686-2020		NIA NIH HHS [AG17574] Funding Source: Medline; NINDS NIH HHS [NS41355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017574] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; McLendon C, 2000, FASEB J, V14, P2383; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 2001, J MED CHEM, V44, P2039, DOI 10.1021/jm0004897; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu ZH, 1996, J AM CHEM SOC, V118, P5846, DOI 10.1021/ja954069w	25	100	107	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16470	16473		10.1074/jbc.C300019200	http://dx.doi.org/10.1074/jbc.C300019200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12644463	hybrid			2022-12-27	WOS:000182818600004
J	Huang, WC; Chen, JJ; Chen, CC				Huang, WC; Chen, JJ; Chen, CC			c-Src-dependent tyrosine phosphorylation of IKK beta is involved in tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN-KINASE-C; HUMAN-ENDOTHELIAL-CELLS; EPITHELIAL ICAM-1 EXPRESSION; DIFFERENTIAL REGULATION; MONOCYTE ADHESION; ACTIVATION; PATHWAY; COMPLEX; LFA-1	The signaling pathway involved in tumor necrosis factor-alpha (TNF-alpha)-induced intercellular adhesion molecule-1 (ICAM-1) expression was further studied in human A549 epithelial cells. TNF-alpha- or 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ICAM-1 promoter activity was inhibited by a protein kinase C (PKC) inhibitor (staurosporine), tyrosine kinase inhibitors (genistein and herbimycin A), or an Src-specific tyrosine kinase inhibitor (PP2). TNF-alpha- or TPA-induced IkappaB kinase (IKK) activation was also blocked by these inhibitors, which slightly reversed TNF-alpha-induced but completely reversed TPA-induced IkappaBalpha degradation. c-Src and Lyn, two members of the Src kinase family, were abundantly expressed in A549 cells, and their activation by TNF-alpha or TPA was inhibited by the same inhibitors. Furthermore, the dominant-negative c-Sre (KM) mutant inhibited induction of ICAM-1 promoter activity by TNF-alpha or TPA. Overexpression of the constitutively active PKCalpha or wild-type c-Src plasmids induced ICAM-1 promoter activity, this effect being inhibited by the dominant-negative c-Src (KAI) or IKKbeta (KM) mutant but not by the nuclear factor-kappaB-inducing kinase (NIK) (KA) mutant. The c-Src (KM) mutant failed to block induction of ICAM-1 promoter activity caused by overexpression of wild-type NIK. In co-immunoprecipitation and immunoblot experiments, IKKbeta was found to be associated with c-Src and to be phosphorylated on tyrosine residues after TNF-alpha or TPA treatment. Two tyrosine residues, Tyr(188) and Tyr(199), near the activation loop of IKKbeta, were identified as being important for NF-kappaB activation. Substitution of these residues with phenylalanines abolished ICAM-1 promoter activity and c-Src-dependent phosphorylation of IKKbeta induced by TNF-alpha or TPA. These data suggest that, in addition to activating NIK, TNF-alpha also activates PKC-dependent c-Sre. These two pathways converge at IKKbeta and go on to activate NF-kappaB, via serine phosphorylation and degradation of IkappaB-alpha, and, finally, to initiate ICAM-1 expression.	Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 10018, Taiwan	National Taiwan University	Chen, CC (corresponding author), Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1,Jen Ai Rd,1st Sect, Taipei 10018, Taiwan.		Chen, Jun-Jie/E-1894-2012; Huang, Wei-Chien/H-3126-2019; CHEN, JUNJIE/HHM-8428-2022; Huang, Wei-Chien/D-1740-2012	Huang, Wei-Chien/0000-0001-6467-8716; Huang, Wei-Chien/0000-0001-6467-8716; CHEN, CHING-CHOW/0000-0002-7810-0939				Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BLOEMEN PGM, 1993, AM J RESP CELL MOL, V9, P586, DOI 10.1165/ajrcmb/9.6.586; Brandt D, 2002, J BIOL CHEM, V277, P20903, DOI 10.1074/jbc.M200946200; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; CARLOS T, 1991, BLOOD, V77, P2266; Chang YJ, 2002, J BIOL CHEM, V277, P7118, DOI 10.1074/jbc.M109924200; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen CC, 2000, MOL PHARMACOL, V58, P1479, DOI 10.1124/mol.58.6.1479; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; LANE TA, 1989, BIOCHEM BIOPH RES CO, V161, P945, DOI 10.1016/0006-291X(89)91334-X; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Petro JB, 2000, J EXP MED, V191, P1745, DOI 10.1084/jem.191.10.1745; POBER JS, 1986, J IMMUNOL, V137, P1893; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1988, CELL, V52, P925, DOI 10.1016/0092-8674(88)90434-5; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Ten RM, 1999, J IMMUNOL, V163, P3851; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214, DOI 10.1165/ajrcmb/7.2.214; VORABERGER G, 1991, J IMMUNOL, V147, P2777; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WERTHEIMER SJ, 1992, J BIOL CHEM, V267, P12030; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1999, MOL CELL BIOL, V19, P4547	45	116	118	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9944	9952		10.1074/jbc.M208521200	http://dx.doi.org/10.1074/jbc.M208521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645577	hybrid			2022-12-27	WOS:000181524000142
J	Tsuchida, A; Okajima, T; Furukawa, K; Ando, T; Ishida, H; Yoshida, A; Nakamura, Y; Kannagi, R; Kiso, M; Furukawa, K				Tsuchida, A; Okajima, T; Furukawa, K; Ando, T; Ishida, H; Yoshida, A; Nakamura, Y; Kannagi, R; Kiso, M; Furukawa, K			Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; EXPRESSION CLONING; GENOMIC ANALYSIS; TYPE-1 CHAIN; ANTIGENS; BETA-1,3-GALACTOSYLTRANSFERASE; GLYCOSPHINGOLIPIDS; DETERMINES; ADHESION; SIALYL	Biosynthesis of disialyl Lewis a (Le(a)) was analyzed using previously cloned ST6GalNAc V and ST6GalNAc VI, which were responsible for the synthesis of alpha-series gangliosides. Among lactotetraosylceramide (Lc4), neolactotetraosylceramide, and their sialyl forms, only sialyl Lc4 was sialylated with ST6GalNAc V and ST6GalNAc VI. The products were confirmed to be disialyl Lea in TLC-immunostaining. Compared with the original substrate GM1b, the synthetic rates of disialyl Le(a) were 22 and 38% with ST6GalNAc V and ST6GalNAc VI, respectively. Since sialyl Lea could not be converted to disialyl Lea, disialyl Lea was produced only from disialyl Lc4. Therefore, it appears that ST6GalNAc V/VI and fucosyltransferase III (FUT-3) compete for sialyl Lc4, their common substrate. The results of either one transfection or co-transfection of two genes into COS1 cells revealed that both ST6GalNAc VI and FUT-3 contributed in the synthesis of disialyl Le(a) but partly compete with each other. Many colon cancer cell lines expressed the ST6GalNAc VI gene more or less, and some of them actually expressed disialyl Le(a). None of them expressed ST6GalNAc V. These results suggested the novel substrate specificity of ST6GalNAc VI, which is responsible for the synthesis of disialyl Le(a) but not for alpha-series gangliosides in human colon tissues.	Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, Nagoya, Aichi 4660065, Japan; Gifu Univ, Dept Appl Bioorgan Chem, Gifu 5011193, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Aichi Canc Ctr, Program Mol Pathol, Res Inst, Nagoya, Aichi 4648681, Japan	Nagoya University; Gifu University; Kirin Brewery Company Limited; Aichi Cancer Center	Furukawa, K (corresponding author), Nagoya Univ, Dept Biochem 2, Sch Med, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.		Okajima, Tetsuya/I-7332-2014; Kannagi, Reiji/Q-6459-2018	Okajima, Tetsuya/0000-0002-3677-648X; Kannagi, Reiji/0000-0003-4202-2921				BARA J, 1986, AM J CLIN PATHOL, V85, P152, DOI 10.1093/ajcp/85.2.152; FUKUYA S, 1994, J BIOL CHEM, V269, P32418; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; ITZKOWITZ SH, 1988, CANCER RES, V48, P3834; KANNAGI R, 1988, CANCER RES, V48, P3856; KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212; Kudo T, 1998, LAB INVEST, V78, P797; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; Kurosawa N, 1996, J BIOL CHEM, V271, P15109, DOI 10.1074/jbc.271.25.15109; Kurosawa N, 2000, J BIOCHEM-TOKYO, V127, P845, DOI 10.1093/oxfordjournals.jbchem.a022678; KUSUNOKI S, 1993, BRAIN RES, V623, P83, DOI 10.1016/0006-8993(93)90013-D; Lee YC, 1999, J BIOL CHEM, V274, P11958, DOI 10.1074/jbc.274.17.11958; Miyazaki H, 1997, J BIOL CHEM, V272, P24794, DOI 10.1074/jbc.272.40.24794; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NUDELMAN E, 1986, J BIOL CHEM, V261, P5487; Okajima T, 2000, J BIOL CHEM, V275, P6717, DOI 10.1074/jbc.275.10.6717; Okajima T, 1999, J BIOL CHEM, V274, P30557, DOI 10.1074/jbc.274.43.30557; REUTTER W, 1981, SIALIC ACIDS CHEM ME, P263; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P455; TAKADA A, 1993, CANCER RES, V53, P354; TSUJI S, 1996, GLYCOBIOLOGY, V6, P5; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMASHIRO S, 1995, J BIOL CHEM, V270, P6149, DOI 10.1074/jbc.270.11.6149	25	59	61	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22787	22794		10.1074/jbc.M211034200	http://dx.doi.org/10.1074/jbc.M211034200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668675	hybrid			2022-12-27	WOS:000183503900082
J	Singha, NC; Vlamis-Gardikas, A; Holmgren, A				Singha, NC; Vlamis-Gardikas, A; Holmgren, A			Real-time kinetics of the interaction between the two subunits, Escherichia coli thioredoxin and gene 5 protein of phage T7 DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CONFERS PROCESSIVITY; MONOCLONAL-ANTIBODY; MUTANT THIOREDOXINS; REDUCED FORM; BINDING; BACTERIOPHAGE-T7; RESOLUTION; ACID	T7 phage DNA polymerase is a tight 1: 1 complex of the gene 5 protein ( g5p) ( 80 kDa) of phage T7 and thioredoxin ( 12 kDa) from the Escherichia coli host. The holoenzyme is essential for the replication of the phage. We estimated the real- time kinetics and thermodynamics of the interaction of g5p with thioredoxin ( wild type and mutants) using surface plasmon resonance. Thioredoxin was immobilized on a CM5 sensor chip through a six- carbon spacer ( 6- amino- n- hexanoic acid) using standard amine coupling. Reduced thioredoxin bound g5p but oxidized thioredoxin did not. The association and dissociation phases of the complex fit a two- exponential model with an apparent equilibrium dissociation constant ( K-D) of 2.2 nM for thioredoxin with 4.7 x 10(4).M-1 . s(-1) and 10.5 x 10(-5) . s(-1) as the corresponding association ( k(a)) and dissociation ( k(d)) rate constants. The strong binding of g5p to thioredoxin is therefore due to fast association and very slow dissociation, a situation similar to antigen- antibody interactions. Thioredoxin mutants P34S, D26A, K57M, D26A/ K57M, W31F, W31Y, K36A, K36E, and Y49F had KD values in the range of 1 to 8 nM, whereas mutant W28A had a K-D of 12.5 nM. No detectable interaction was observed for mutants P40G, W31H, W31A, and C35A. The effect of temperature on K-D and the changes in enthalpy (-DeltaH = 20.2 kcal .M-1) and entropy (TDeltaS = -8.4 kcal . M-1) upon formation of the complex suggested that the interaction is driven by an increase in enthalpy and opposed by a decrease in entropy.	Karolinska Inst, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				ALDER S, 1983, J BIOL CHEM, V258, P6956; [Anonymous], 1990, CURRENT RES PROTEIN, P449; BARISAS BG, 1971, BIOCHEMISTRY-US, V10, P2816; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; CHAMBERLIN M, 1974, J VIROL, V14, P509, DOI 10.1128/JVI.14.3.509-516.1974; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dyson HJ, 1997, BIOCHEMISTRY-US, V36, P2622, DOI 10.1021/bi961801a; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; England P, 1997, BIOCHEMISTRY-US, V36, P164, DOI 10.1021/bi961419y; Gleason F.K., 1988, FEMS MICROBIOL REV, V4, P271; GLEASON FK, 1990, BIOCHEMISTRY-US, V29, P3701, DOI 10.1021/bi00467a016; Hanin V, 1997, MOL IMMUNOL, V34, P829, DOI 10.1016/S0161-5890(97)00119-3; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1975, P NATL ACAD SCI USA, V72, P2305, DOI 10.1073/pnas.72.6.2305; HOLMGREN A, 1981, J BIOL CHEM, V256, P3118; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUBER HE, 1987, J BIOL CHEM, V262, P16224; JANIN J, 1990, J BIOL CHEM, V265, P16027; JENG MF, 1994, STRUCTURE, V2, P853, DOI 10.1016/S0969-2126(94)00086-7; JOHNSTON MF, 1974, BIOCHEMISTRY-US, V13, P390, DOI 10.1021/bi00699a026; KALLIS GB, 1980, J BIOL CHEM, V255, P261; KATTI SK, 1990, J MOL BIOL, V212, P167, DOI 10.1016/0022-2836(90)90313-B; KELLEY RF, 1992, BIOCHEMISTRY-US, V31, P5434, DOI 10.1021/bi00139a003; KRAUSE G, 1991, J BIOL CHEM, V266, P4056; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7603, DOI 10.1021/bi00244a032; LUNN CA, 1984, J BIOL CHEM, V259, P469; MARK DF, 1976, P NATL ACAD SCI USA, V73, P780, DOI 10.1073/pnas.73.3.780; NAVARRO JA, 1991, BIOCHEMISTRY-US, V30, P2192, DOI 10.1021/bi00222a024; NIKKOLA M, 1993, BIOCHEMISTRY-US, V32, P5093, DOI 10.1021/bi00070a017; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; REUTIMANN H, 1985, P NATL ACAD SCI USA, V82, P6783, DOI 10.1073/pnas.82.20.6783; ROSS PD, 1981, BIOCHEMISTRY-US, V20, P3096, DOI 10.1021/bi00514a017; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; Slaby I, 1996, J BIOL CHEM, V271, P3091, DOI 10.1074/jbc.271.6.3091; Slaby I, 1991, Protein Expr Purif, V2, P270, DOI 10.1016/1046-5928(91)90083-U; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STONE MJ, 1993, BIOCHEMISTRY-US, V32, P426, DOI 10.1021/bi00053a007; TABOR S, 1987, J BIOL CHEM, V262, P16212; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712	53	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21421	21428		10.1074/jbc.M302310200	http://dx.doi.org/10.1074/jbc.M302310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670954	hybrid			2022-12-27	WOS:000183354200016
J	Ahn, W; Lee, MG; Kim, KH; Muallem, S				Ahn, W; Lee, MG; Kim, KH; Muallem, S			Multiple effects of SERCA2b mutations associated with Darier's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; CALCIUM-PUMP PROTEIN; OLIGOMERIC STRUCTURE; CELL-ADHESION; CA2+ PUMP; CADHERINS; MORPHOGENESIS; INACTIVATION; ATP2A2; DISSOCIATION	Darier's disease (DD) is an autosomal dominant disorder caused by mutations in the ATP2A2 gene, encoding sarco/endoplasmic reticulum Ca2+-ATPase pump type 2b isoform (SERCA2b). Although >100 mutations in the ATP2A2 gene were identified, no apparent relation between genotype/phenotype emerged. In this work, we analyzed 12 DD-associated mutations from all of the regions of SERCA2b to study the underlying pathologic mechanism of DD and to elucidate the role of dimerization in SERCA2b activity. Most mutations markedly affected protein expression, partially because of enhanced proteasome-mediated degradation. All of the mutants showed lower activity than the wild type pump. Notably, several mutants that cause relatively severe phenotype of DD inhibited the activity of the endogenous and the co-expressed wild type SERCA2b. Importantly, these effects were not attributed to changes in passive Ca2+ leak, inositol 1,4,5-trisphosphate receptor activity, or sensitivity to inositol 1,4,5-trisphosphate. Rather, co-immunoprecipitation experiments showed that SERCA2b monomers interact to influence the activity of each other. These findings reveal multiple molecular mechanisms to account for the plethora of pathologic states observed in DD and provide the first evidence for the importance of SERCA2b dimerization in pump function in vivo.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Yonsei Univ, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Brain Korea 21 Project Med Sci, Seoul 120752, South Korea	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yonsei University; Yonsei University	Muallem, S (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Shmuel.Muallem@UTSouthwestern.edu	Lee, Min Goo/D-5635-2012; Lee, Min Goo/AAS-4636-2020	Lee, Min Goo/0000-0001-7436-012X; Lee, Min Goo/0000-0001-7436-012X	NIDCR NIH HHS [DE13902] Funding Source: Medline; NIDDK NIH HHS [DK 38939] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038939] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baba-Aissa F, 1998, MOL CHEM NEUROPATHOL, V33, P199, DOI 10.1007/BF02815182; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; Bruses JL, 2000, CURR OPIN CELL BIOL, V12, P593, DOI 10.1016/S0955-0674(00)00137-X; BURGE SM, 1992, J AM ACAD DERMATOL, V27, P40, DOI 10.1016/0190-9622(92)70154-8; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Carvalho-Alves PC, 2000, BBA-BIOMEMBRANES, V1467, P73, DOI 10.1016/S0005-2736(00)00206-6; CASTELLANI L, 1989, J CELL BIOL, V108, P511, DOI 10.1083/jcb.108.2.511; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P1997; Chami M, 2001, J CELL BIOL, V153, P1301, DOI 10.1083/jcb.153.6.1301; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hakuno M, 2000, BRIT J DERMATOL, V142, P702, DOI 10.1046/j.1365-2133.2000.03415.x; HYMEL L, 1984, J BIOL CHEM, V259, P4890; Kiselyov K, 2003, CELL SIGNAL, V15, P243, DOI 10.1016/S0898-6568(02)00074-8; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Liu XB, 1998, J BIOL CHEM, V273, P33295, DOI 10.1074/jbc.273.50.33295; NAPOLITANO CA, 1983, BIOPHYS J, V42, P119, DOI 10.1016/S0006-3495(83)84377-X; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Palm T, 2001, BIOL CHEM, V382, P417, DOI 10.1515/BC.2001.051; Periasamy M, 1999, J BIOL CHEM, V274, P2556, DOI 10.1074/jbc.274.4.2556; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; Ranscht B, 2000, INT J DEV NEUROSCI, V18, P643, DOI 10.1016/S0736-5748(00)00030-7; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; Sakuntabhai A, 1999, HUM MOL GENET, V8, P1611, DOI 10.1093/hmg/8.9.1611; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Shull GE, 2000, EUR J BIOCHEM, V267, P5284, DOI 10.1046/j.1432-1327.2000.01568.x; SKERJANC IS, 1993, FEBS LETT, V336, P168, DOI 10.1016/0014-5793(93)81633-B; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tavadia S, 2001, CLIN EXP DERMATOL, V26, P696, DOI 10.1046/j.1365-2230.2001.00921.x; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Zhao XS, 2001, EMBO J, V20, P2680, DOI 10.1093/emboj/20.11.2680	38	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20795	20801		10.1074/jbc.M301638200	http://dx.doi.org/10.1074/jbc.M301638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670936	hybrid			2022-12-27	WOS:000183230500047
J	Shirley, AM; Chapple, C				Shirley, AM; Chapple, C			Biochemical characterization of sinapoylglucose : choline sinapoyltransferase, a serine carboxypeptidase-like protein that functions as an acyltransferase in plant secondary metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAPHANUS-SATIVUS L; YEAST CARBOXYPEPTIDASE; SINAPINE SYNTHASE; ARABIDOPSIS; WHEAT; PURIFICATION; SEEDS; 1-SINAPOYLGLUCOSE; TRANSACYLATION; BIOSYNTHESIS	Recently, serine carboxypeptidase-like (SCPL) proteins that catalyze transacylation reactions in plant secondary metabolism have been identified from wild tomato and Arabidopsis. These include sinapoylglucose: choline sinapoyltransferase (SCT), an enzyme that functions in Arabidopsis sinapate ester synthesis. SCT and the other known SCPL acyltransferases all share the conserved serine, aspartic acid, and histidine residues employed for catalysis by classical serine carboxypeptidases, although the importance of these residues and the mechanism by which this class of SCPL proteins catalyze acyltransferase reactions is unknown. To characterize further SCT and its catalytic mechanism, we have employed the Saccharomyces cerevisiae vacuolar protein localization 1 mutant, which secretes the serine carboxypeptidase, carboxypeptidase Y, and other proteins normally targeted to the vacuole. When expressed in this strain, SCT is similarly secreted. SCT has been purified from the yeast medium and used for kinetic characterization of the protein. Immunological analysis of SCT has revealed that the expected 50-kDa mature protein is proteolytically processed in yeast and in planta, most likely resulting in the production of a heterodimer derived from a 30- and 17-kDa polypeptide.	Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Chapple, C (corresponding author), Purdue Univ, Dept Biochem, W Lafayette, IN 47907 USA.		Chapple, Clint CS/Q-5456-2017	Chapple, Clint CS/0000-0002-5195-562X				BAMFORTH CW, 1979, J I BREWING, V85, P334, DOI 10.1002/j.2050-0416.1979.tb03937.x; BECH LM, 1989, J BIOL CHEM, V262, P13726; Booij-James IS, 2000, PLANT PHYSIOL, V124, P1275, DOI 10.1104/pp.124.3.1275; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDDAM K, 1987, CARLSBERG RES COMMUN, V52, P297, DOI 10.1007/BF02907172; CHAPPLE CCS, 1992, PLANT CELL, V16, P735; CLAUSEN S, 1982, PHYTOCHEMISTRY, V21, P917, DOI 10.1016/0031-9422(82)80093-9; CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYME, P148; ENDRIZZI JA, 1994, BIOCHEMISTRY-US, V33, P11106, DOI 10.1021/bi00203a007; Fleming SM, 2000, BIOCHEMISTRY-US, V39, P1522, DOI 10.1021/bi9923095; GHANGAS GS, 1993, P NATL ACAD SCI USA, V90, P9911, DOI 10.1073/pnas.90.21.9911; GHANGAS GS, 1995, ARCH BIOCHEM BIOPHYS, V316, P370, DOI 10.1006/abbi.1995.1049; GMELIN R, 1970, PHYTOCHEMISTRY, V9, P667, DOI 10.1016/S0031-9422(00)85712-X; GRAWE W, 1986, Z NATURFORSCH C, V41, P28; HAMMERTON RW, 1986, PLANT PHYSIOL, V80, P692, DOI 10.1104/pp.80.3.692; Hanes CS, 1932, BIOCHEM J, V26, P1406, DOI 10.1042/bj0261406; Hause B, 2002, PLANTA, V215, P26, DOI 10.1007/s00425-001-0716-y; HAYASHI R, 1975, J BIOL CHEM, V250, P5221; HAYASHI R, 1973, J BIOL CHEM, V248, P8366; HOBSONFROHOCK A, 1977, BRIT POULTRY SCI, V18, P539, DOI 10.1080/00071667708416400; JOHNSTON JR, 1994, MOL GENETICS YEAST P, P121; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY LG, 1995, PLANT PHYSIOL, V109, P1159, DOI 10.1104/pp.109.4.1159; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; Lehfeldt C, 2000, PLANT CELL, V12, P1295, DOI 10.1105/tpc.12.8.1295; Li AX, 1999, PLANT PHYSIOL, V121, P453, DOI 10.1104/pp.121.2.453; Li AX, 2000, P NATL ACAD SCI USA, V97, P6902, DOI 10.1073/pnas.110154197; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LIAO DI, 1992, BIOCHEMISTRY-US, V31, P9796, DOI 10.1021/bi00155a037; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; Lorenzen M, 1996, PLANT PHYSIOL, V112, P1625, DOI 10.1104/pp.112.4.1625; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MIKOLA L, 1986, PLANT PHYSIOL, V81, P823, DOI 10.1104/pp.81.3.823; NIELSEN TL, 1990, APPL MICROBIOL BIOT, V33, P307, DOI 10.1007/BF00164527; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PETERSON LM, 1982, ANAL BIOCHEM, V125, P420, DOI 10.1016/0003-2697(82)90024-0; Sambrook J., 2002, MOL CLONING LAB MANU; SHARMA V, 1985, PLANTA, V163, P563, DOI 10.1007/BF00392714; Shirley AM, 2001, PLANT J, V28, P83, DOI 10.1046/j.1365-313X.2001.01123.x; STRACK D, 1983, Z NATURFORSCH C, V38, P21; STRACK D, 1981, Z NATURFORSCH C, V36, P215; UMETSU H, 1983, PHYTOCHEMISTRY, V22, P591, DOI 10.1016/0031-9422(83)83054-4; URBAN P, 1994, EUR J BIOCHEM, V222, P843, DOI 10.1111/j.1432-1033.1994.tb18931.x; VOGT T, 1993, ARCH BIOCHEM BIOPHYS, V300, P622, DOI 10.1006/abbi.1993.1086; WAJANT H, 1994, PLANT MOL BIOL, V26, P735, DOI 10.1007/BF00013758	45	56	60	4	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19870	19877		10.1074/jbc.M302362200	http://dx.doi.org/10.1074/jbc.M302362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657648	hybrid			2022-12-27	WOS:000183078000039
J	Wang, B; Alam, SL; Meyer, HH; Payne, M; Stemmler, TL; Davis, DR; Sundquist, WI				Wang, B; Alam, SL; Meyer, HH; Payne, M; Stemmler, TL; Davis, DR; Sundquist, WI			Structure and ubiquitin interactions of the conserved zinc finger domain of Npl4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ELONGATION-FACTOR TFIIS; TORSION ANGLE DYNAMICS; CRYSTAL-STRUCTURE; ENDOPLASMIC-RETICULUM; COUPLING-CONSTANTS; HYDROGEN-BONDS; BINDING DOMAIN; UBA DOMAINS; SH3 DOMAIN	Ubiquitylated proteins are directed into a large number of different cellular pathways through interactions with effector proteins that contain conserved ubiquitin binding motifs. Here, we report the solution structure and ubiquitin binding properties of one such motif, the Npl4 zinc finger or RanBP2/Nup358 zinc finger (NZF) domain. Npl4 NZF forms a compact module composed of four antiparallel beta-strands linked by three ordered loops. A single zinc ion is coordinated by four conserved cysteines from the first and third loops, which form two rubredoxin knuckles. Npl4 NZF binds specifically, but weakly, to free ubiquitin using a conserved (TF14)-T-13 dipeptide to interact with the "Ile-44" surface of ubiquitin. Our studies reveal the structure of this versatile class of protein binding domains and provide a means for identifying the subset of NZF domains likely to bind ubiquitin.	Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84132 USA; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Wayne State University; Yale University	Sundquist, WI (corresponding author), Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA.	wes@biochem.utah.edu	Meyer, Hemmo/GNH-5784-2022	Meyer, Hemmo/0000-0003-1883-1796; Stemmler, Timothy/0000-0002-6298-088X	NCRR NIH HHS [RR13030] Funding Source: Medline; NIDDK NIH HHS [R01 DK068139] Funding Source: Medline; NIGMS NIH HHS [1R01 GM60919, R01 GM055508, R01 GM55508, R01 GM060919] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR013030] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060919, R01GM055508] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADMAN E, 1975, P NATL ACAD SCI USA, V72, P4854, DOI 10.1073/pnas.72.12.4854; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; BALLARDIN A, 1978, BIOCHEMISTRY-US, V17, P4443, DOI 10.1021/bi00614a014; BAX A, 1994, METHOD ENZYMOL, V239, P79; Bays NW, 2002, CURR BIOL, V12, pR366, DOI 10.1016/S0960-9822(02)00862-X; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; BLAKE PR, 1994, ADV BIOPH C, V4, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Chen HT, 2000, PROTEIN SCI, V9, P1743, DOI 10.1110/ps.9.9.1743; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Fauser S, 2001, MAMM GENOME, V12, P406, DOI 10.1007/s003350010291; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; GARRETT DS, 1994, J MAGN RESON SER B, V104, P99, DOI 10.1006/jmrb.1994.1061; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; GRAHAM WH, 1992, BIOPOLYMERS, V32, P1755, DOI 10.1002/bip.360321216; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hammarstrom A, 1996, BIOCHEMISTRY-US, V35, P12723, DOI 10.1021/bi961149j; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Martinez-Noel G, 1999, FEBS LETT, V454, P257, DOI 10.1016/S0014-5793(99)00823-6; Martinez-Yamout M, 2000, J MOL BIOL, V300, P805, DOI 10.1006/jmbi.2000.3923; Meissner A, 2000, J MAGN RESON, V143, P387, DOI 10.1006/jmre.1999.1998; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Pellecchia M, 2001, J AM CHEM SOC, V123, P4633, DOI 10.1021/ja005850t; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; QIAN XQ, 1993, NATURE, V365, P277, DOI 10.1038/365277a0; QIAN XQ, 1993, BIOCHEMISTRY-US, V32, P9944, DOI 10.1021/bi00089a010; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Sarisky CA, 2001, J MOL BIOL, V307, P1411, DOI 10.1006/jmbi.2000.4345; Scheuring S, 2001, J MOL BIOL, V312, P469, DOI 10.1006/jmbi.2001.4917; Shekhtman A, 2002, BIOCHEM BIOPH RES CO, V296, P1222, DOI 10.1016/S0006-291X(02)02006-5; Sieker LC, 2000, J BIOL INORG CHEM, V5, P505, DOI 10.1007/PL00021450; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Strack B, 2002, J VIROL, V76, P5472, DOI 10.1128/JVI.76.11.5472-5479.2002; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; VanDemark AP, 2002, CURR OPIN STRUC BIOL, V12, P822, DOI 10.1016/S0959-440X(02)00389-5; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wang B, 1998, STRUCTURE, V6, P555, DOI 10.1016/S0969-2126(98)00058-6; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Yaseen NR, 1999, P NATL ACAD SCI USA, V96, P5516, DOI 10.1073/pnas.96.10.5516; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	73	121	123	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20225	20234		10.1074/jbc.M300459200	http://dx.doi.org/10.1074/jbc.M300459200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644454	Green Accepted, hybrid			2022-12-27	WOS:000183078000084
J	Liu, JJ; Hou, SC; Shen, CKJ				Liu, JJ; Hou, SC; Shen, CKJ			Erythroid gene suppression by NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR NF-E2; DNA-BINDING PROTEIN; GLOBIN GENE; ALPHA-GLOBIN; MAMMALIAN-CELLS; IN-VITRO; EXPRESSION; ENHANCER; FAMILY	NF-kappaB/Rel transcription factors play essential roles to mediate the immune response and apoptosis, and they have also been implicated in cellular differentiation such as erythropoiesis. To elucidate the possible role(s) of NF-kappaB in erythroid gene regulation and erythropoiesis, we have carried out transient transfection studies of the human embryonic/ fetal erythroid cell line K562 and mouse adult erythroid MEL cells. It is shown that tumor necrosis factor-alpha represses the transcription activity directed by either alpha or zeta globin promoter in a dose-dependent manner. Furthermore, different NF-kappaB family members could effectively repress the transfected alpha-like globin promoters in K562 as well as in MEL cells. The involvement of NF-kappaB pathway is supported by the ability of a NF-kappaB-specific, dominant negative mutant to block the tumor necrosis factor-alpha or p65-mediated suppression of the alpha-like globin promoter activities. The suppression appears to be mediated through cis-linked HS-40 enhancer. Finally, stably transfected K562 cells overexpressing p65 contain reduced amounts of the p45/ NF-E2 RNA and functional NF-E2 proteins. Our studies have identified a new set of targets of NF-kappaB. We suggest that the relatively high activity of the NF-kappaB pathway in early erythroid progenitors is involved in the suppression of erythroid-specific genes. Later in differentiation, together with other changes, the decline of the amounts of the NF-kappaB family of factors leads to derepression and consequent increase of NF-E2, which in turn would activate a subset of erythroid-specific genes.	Acad Sinica, Inst Mol Biol, Nankang, Taiwan; Natl Taiwan Univ, Inst Mol Med, Taipei 115, Taiwan; Natl Def Univ, Coll Life Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Defense University - Taiwan	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Nankang, Taiwan.		shen, Che-Kun James/L-1343-2015					Amrolia PJ, 1997, P NATL ACAD SCI USA, V94, P10051, DOI 10.1073/pnas.94.19.10051; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Blau C A, 1994, Curr Opin Hematol, V1, P136; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Daftari P, 1999, ONCOGENE, V18, P5482, DOI 10.1038/sj.onc.1202916; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Engel JD, 2000, CELL, V100, P499, DOI 10.1016/S0092-8674(00)80686-8; Ferry AE, 1997, J BIOL CHEM, V272, P20030, DOI 10.1074/jbc.272.32.20030; Foo SY, 1999, TRENDS GENET, V15, P229; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; HIGGS DR, 1989, BLOOD, V73, P1081; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IP YT, 1991, CELL, V64, P439; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; Nagai T, 1998, J BIOL CHEM, V273, P5358, DOI 10.1074/jbc.273.9.5358; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; ROMBEL I, 1995, P NATL ACAD SCI USA, V92, P6454, DOI 10.1073/pnas.92.14.6454; Sambrook J., 2002, MOL CLONING LAB MANU; SATMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DIS, P66; Sayer MS, 2000, J BIOL CHEM, V275, P25292, DOI 10.1074/jbc.M908695199; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; STRAUSS EC, 1992, MOL CELL BIOL, V12, P2135, DOI 10.1128/MCB.12.5.2135; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wen SC, 2000, MOL CELL BIOL, V20, P1993, DOI 10.1128/MCB.20.6.1993-2003.2000; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144; ZHANG QY, 1995, J BIOL CHEM, V270, P8501, DOI 10.1074/jbc.270.15.8501	53	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19534	19540		10.1074/jbc.M212278200	http://dx.doi.org/10.1074/jbc.M212278200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642582	hybrid			2022-12-27	WOS:000182932200104
J	Pace, A; Garcia-Marin, LJ; Tapia, JA; Bragado, MJ; Jensen, RT				Pace, A; Garcia-Marin, LJ; Tapia, JA; Bragado, MJ; Jensen, RT			Phosphospecific site tyrosine phosphorylation of p125(FAK) and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; GROWTH-FACTOR; LOOP PHOSPHORYLATION; TERMINAL DOMAIN; DIFFERENT MODES; PKC-DELTA; ANG-II; PROTEIN; PYK2; RAT	The focal adhesion kinases, p125(FAK) and proline-rich kinase 2 (PYK2), are involved in numerous processes as adhesion, cytoskeletal changes, and growth. These kinases have 45% homology and share three tyrosine phosphorylation (TyrP) sites. Little information exists on the ability of stimulants to cause TyrP of each kinase site and the cellular mechanism involved. We explored the ability of the neurotransmitter/hormone, CCK, to stimulate TyrP at each site. In rat pancreatic acini, CCK stimulated TyrP at each site in both kinases. TyrP was rapid except for pY397FAK. The magnitude of TyrP differed with the different FAK and PYK2 sites. The CCK dose-response curve for TyrP for sites in each kinase was similar. CCK-JMV, an agonist of the high affinity receptor state and antagonist of the low affinity receptor state, was less efficacious than CCK at each FAK/PYK2 site and inhibited CCK maximal stimulation. Thapsigargin decreased CCK-stimulated TyrP of pY402PYK2 and pY925FAK but not the other sites. GF109203X reduced TyrP of only the PYK2 sites, pY402 and pY580. GF109203X with thapsigargin decreased TyrP of pY402PYK2 and the three FAK sites more than either inhibitor alone. Basal TyrP of pY397FAK was greater than other sites. These results demonstrate that CCK stimulates tyrosine phosphorylation of each of the three homologous phosphorylation sites in FAK and PYK2. However, CCK-stimulated TyrP at these sites differs in kinetics, magnitude, and participation of the high/low affinity receptor states and by protein kinase C and [Ca2+](i). These results show that phosphorylation of these different sites is differentially regulated and involves different intracellular mechanisms in the same cell.	NIDDK, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; Univ Extremadura, Dept Fisiol, Caceres 10071, Spain; Univ Extremadura, Dept Bioquim Biol Mol & Genet, Caceres 10071, Spain	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Universidad de Extremadura; Universidad de Extremadura	Jensen, RT (corresponding author), NIDDK, Digest Dis Branch, NIH, Bldg 10,Rm 9C-103,10 Ctr Dr,MSC 1804, Bethesda, MD 20892 USA.	robertj@bdg10.niddk.nih.gov	Garcia-Marin, Luis J/L-4680-2014; Tapia, Jose A./C-5181-2008; Bragado, M Julia/L-6988-2014	Garcia-Marin, Luis J/0000-0002-1795-7381; Tapia, Jose A./0000-0002-3614-6867; Bragado, M Julia/0000-0001-7770-0775				Andreev J, 1999, MOL CELL BIOL, V19, P2338; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Dabrowski A, 1996, J BIOL CHEM, V271, P5686, DOI 10.1074/jbc.271.10.5686; Derkinderen P, 2001, J BIOL CHEM, V276, P38289; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Dikic Ivan, 1999, Cell Biochemistry and Biophysics, V30, P369, DOI 10.1007/BF02738120; Ferris HA, 1999, BIOCHEMISTRY-US, V38, P1497, DOI 10.1021/bi981903w; GALAS MC, 1988, AM J PHYSIOL, V254, pG176, DOI 10.1152/ajpgi.1988.254.2.G176; Garcia LJ, 1999, ADV MOL CELL ENDOCR, V3, P119; Garcia LJ, 1997, BBA-MOL CELL RES, V1358, P189, DOI 10.1016/S0167-4889(97)00056-6; Garcia LJ, 1997, BIOCHEM J, V327, P461; Gardner Jerry D., 1993, P151; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; HUANG S, 1994, J BIOL CHEM, V269, P26121; HUCKLE WR, 1992, P NATL ACAD SCI USA, V89, P8837, DOI 10.1073/pnas.89.18.8837; Jensen Robert T., 1994, P1377; JENSEN RT, 1982, J BIOL CHEM, V257, P5554; JENSEN RT, 1989, TRENDS PHARMACOL SCI, V10, P418, DOI 10.1016/0165-6147(89)90192-2; Jeon SH, 2001, BIOCHEM BIOPH RES CO, V282, P1026, DOI 10.1006/bbrc.2001.4686; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V290, P1470, DOI 10.1006/bbrc.2002.6350; Keogh RJ, 2002, BIOCHEM BIOPH RES CO, V294, P1001, DOI 10.1016/S0006-291X(02)00568-5; KITSUKAWA Y, 1994, AM J PHYSIOL, V266, pG613, DOI 10.1152/ajpgi.1994.266.4.G613; Laser M, 2000, J BIOL CHEM, V275, P35624, DOI 10.1074/jbc.M006124200; Lev S, 1999, MOL CELL BIOL, V19, P2278; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Liddle RA., 1994, GUT PEPTIDES BIOCH P; Lobo M, 2000, BIOCHEM BIOPH RES CO, V276, P1068, DOI 10.1006/bbrc.2000.3547; MATOZAKI T, 1989, AM J PHYSIOL, V257, pG594, DOI 10.1152/ajpgi.1989.257.4.G594; MATOZAKI T, 1990, J BIOL CHEM, V265, P6247; Maulik G, 2002, CLIN CANCER RES, V8, P620; MENOZZI D, 1991, J BIOL CHEM, V266, P10385; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Owen JD, 1999, MOL CELL BIOL, V19, P4806; PEIKIN SR, 1978, AM J PHYSIOL, V235, pE743, DOI 10.1152/ajpendo.1978.235.6.E743; POLLO DA, 1994, BBA-MOL CELL RES, V1224, P127, DOI 10.1016/0167-4889(94)90120-1; Raja S, 1997, J BIOL CHEM, V272, P10941; RAMBAUD JC, 1988, GUT, V29, P537, DOI 10.1136/gut.29.4.537; RELOU IA, 2003, BIOCHEM J, V15, P407; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Rosado JA, 1998, BBA-MOL CELL RES, V1404, P412, DOI 10.1016/S0167-4889(98)00072-X; ROZENGURT E, 1995, CANCER SURV, V24, P81; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; SATO S, 1989, AM J PHYSIOL, V257, pG202, DOI 10.1152/ajpgi.1989.257.2.G202; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786; Seufferlein T, 1996, MOL BIOL CELL, V7, P1865, DOI 10.1091/mbc.7.12.1865; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; Siciliano JC, 1996, J BIOL CHEM, V271, P28942, DOI 10.1074/jbc.271.46.28942; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; STARK HA, 1989, BIOCHIM BIOPHYS ACTA, V1010, P145, DOI 10.1016/0167-4889(89)90154-7; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tapia JA, 2002, BBA-MOL CELL RES, V1593, P99, DOI 10.1016/S0167-4889(02)00346-4; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vadlamudi RK, 2002, J CELL PHYSIOL, V190, P189, DOI 10.1002/JCP.10054; Wang JG, 2001, BIOCHEM BIOPH RES CO, V288, P356, DOI 10.1006/bbrc.2001.5775; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; Wrenn RW, 2001, BIOCHEM BIOPH RES CO, V282, P882, DOI 10.1006/bbrc.2001.4657; Wu SS, 2002, AM J PHYSIOL-CELL PH, V282, pC1432, DOI 10.1152/ajpcell.00323.2001; Yule David I., 1994, P1447; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	75	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19008	19016		10.1074/jbc.M300832200	http://dx.doi.org/10.1074/jbc.M300832200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651850	hybrid			2022-12-27	WOS:000182932200038
J	Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C				Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C			Direct detection of Fe(IV)=O intermediates in the cytochrome alpha alpha 3 oxidase from Paracoccus denitrificans/H2O2 reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN EVIDENCE; C-OXIDASE; HYDROGEN-PEROXIDE; ELECTRON-TRANSFER; THERMUS-THERMOPHILUS; AMBIENT-TEMPERATURE; DIOXYGEN ACTIVATION; OXYGEN ACTIVATION; BACILLUS-SUBTILIS; CARBON-MONOXIDE	We report the first evidence for the formation of the "607- and 580-nm forms" in the cytochrome oxidase aa(3)/ H2O2 reaction without the involvement of tyrosine 280. The pK(a) of the 607-580-nm transition is 7.5. The 607-nm form is also formed in the mixed valence cytochrome oxidase/O-2 reaction in the absence of tyrosine 280. Steady-state resonance Raman characterization of the reaction products of both the wild-type and Y280H cytochrome aa(3) from Paracoccus denitrificans indicate the formation of six-coordinate low spin species, and do not support, in contrast to previous reports, the formation of a porphyrin pi-cation radical. We observe three oxygen isotope-sensitive Raman bands in the oxidized wildtype aa(3)/H2O2 reaction at 804, 790, and 358 cm(-1). The former two are assigned to the Fe(IV) = O stretching mode of the 607- and 580- nm forms, respectively. The 14 cm(-1) frequency difference between the oxoferryl species is attributed to variations in the basicity of the proximal to heme a(3) His-411, induced by the oxoferryl conformations of the heme a(3)-Cu-B pocket during the 607 - 580- nm transition. We suggest that the 804 - 790 cm(-1) oxoferryl transition triggers distal conformational changes that are subsequently communicated to the proximal His-411 heme a(3) site. The 358 cm(-1) mode has been found for the first time to accumulate with the 804 cm(-1) mode in the peroxide reaction. These results indicate that the mechanism of oxygen reduction must be reexamined.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Goethe Univ Frankfurt, Biozentrum, Inst Biochem, D-60439 Frankfurt, Germany	University of Crete; Goethe University Frankfurt	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.	varotsis@edu.uoc.gr		Varotsis, Constantinos/0000-0003-2771-8891; Pinakoulaki, Eftychia/0000-0003-3320-6112				BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; Bassan A, 2002, J AM CHEM SOC, V124, P11056, DOI 10.1021/ja026488g; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Einarsdottir O, 2002, J INORG BIOCHEM, V91, P87, DOI 10.1016/S0162-0134(02)00377-X; FABIAN M, 1995, BIOCHEMISTRY-US, V34, P13802, DOI 10.1021/bi00042a011; Fabian M, 1999, P NATL ACAD SCI USA, V96, P13114, DOI 10.1073/pnas.96.23.13114; Fabian M, 2001, BIOCHEMISTRY-US, V40, P1867, DOI 10.1021/bi002373i; Fabian M, 1999, BIOCHEMISTRY-US, V38, P6270, DOI 10.1021/bi982541v; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; Han S, 2000, J BIOL CHEM, V275, P1910, DOI 10.1074/jbc.275.3.1910; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HAN SW, 1990, NATURE, V348, P89, DOI 10.1038/348089a0; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; HAYASHI Y, 1978, ARCH BIOCHEM BIOPHYS, V190, P446, DOI 10.1016/0003-9861(78)90297-7; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kannt A, 1998, BIOPHYS J, V74, P708, DOI 10.1016/S0006-3495(98)73996-7; Kim Y, 2001, J AM CHEM SOC, V123, P757, DOI 10.1021/ja0027867; Kitagawa T, 2000, J INORG BIOCHEM, V82, P9, DOI 10.1016/S0162-0134(00)00155-0; KONSTANTINOV AA, 1992, FEBS LETT, V312, P71, DOI 10.1016/0014-5793(92)81412-F; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; MCDONALD MR, 1995, INORG CHEM, V34, P229, DOI 10.1021/ic00105a038; McDonald MR, 1997, INORG CHEM, V36, P3119, DOI 10.1021/ic9608713; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; Morgan JE, 2001, BIOCHEMISTRY-US, V40, P6882, DOI 10.1021/bi010246w; OERTLING WA, 1988, BIOCHEMISTRY-US, V27, P5395, DOI 10.1021/bi00415a002; OERTLING WA, 1990, INORG CHEM, V29, P2633, DOI 10.1021/ic00339a021; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; Ogura T, 1996, J AM CHEM SOC, V118, P5443, DOI 10.1021/ja951922i; OGURA T, 1993, J AM CHEM SOC, V115, P8527, DOI 10.1021/ja00072a002; OGURA T, 1990, J BIOL CHEM, V265, P14721; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; PALMER G, 1998, EBEC SHORT REP, V10, P85; Pecoraro C, 2001, BIOCHEMISTRY-US, V40, P9695, DOI 10.1021/bi010115v; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; Pinakoulaki E, 2002, J BIOL CHEM, V277, P13563, DOI 10.1074/jbc.M112200200; POULOS TL, 1988, ADV INORG BIOCHEM, V7, P1; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P8580, DOI 10.1021/bi952096t; Proshlyakov DA, 1996, BIOCHEMISTRY-US, V35, P76, DOI 10.1021/bi9511705; PROSHLYAKOV DA, 1994, J BIOL CHEM, V269, P29385; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; Rigby SEJ, 2000, BIOCHEMISTRY-US, V39, P5921, DOI 10.1021/bi992614q; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Sundaramoorthy M, 1995, STRUCTURE, V3, P1367, DOI 10.1016/S0969-2126(01)00274-X; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Uchida T, 2000, BIOCHEMISTRY-US, V39, P6669, DOI 10.1021/bi992538r; VAROTSIS C, 1993, P NATL ACAD SCI USA, V90, P237, DOI 10.1073/pnas.90.1.237; VAROTSIS C, 1990, APPL SPECTROSC, V44, P742, DOI 10.1366/0003702904087550; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; VAROTSIS C, 1995, BBA-BIOENERGETICS, V1231, P111, DOI 10.1016/0005-2728(95)00076-U; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; VAROTSIS C, 1990, J AM CHEM SOC, V112, P1297, DOI 10.1021/ja00159a091; VAROTSIS C, 1990, J BIOL CHEM, V265, P11131; VAROTSIS CA, 1995, J AM CHEM SOC, V117, P11260, DOI 10.1021/ja00150a025; Varotsis Constantinos, 1993, V226, P409; Verkhovsky MI, 1996, P NATL ACAD SCI USA, V93, P12235, DOI 10.1073/pnas.93.22.12235; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; Vygodina TV, 1998, BIOCHEMISTRY-US, V37, P3053, DOI 10.1021/bi971876u; WENG LC, 1991, BIOCHEMISTRY-US, V30, P5727, DOI 10.1021/bi00237a014; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WRIGGLESWORTH JM, 1984, BIOCHEM J, V217, P715, DOI 10.1042/bj2170715; WU W, 1992, J AM CHEM SOC, V114, P1182, DOI 10.1021/ja00030a009; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	69	32	32	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18761	18766		10.1074/jbc.M211925200	http://dx.doi.org/10.1074/jbc.M211925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637529	hybrid			2022-12-27	WOS:000182932200009
J	Grant, GA; Hu, ZQ; Xu, XL				Grant, GA; Hu, ZQ; Xu, XL			Hybrid tetramers reveal elements of cooperativity in Escherichia coli D-3-phosphoglycerate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-LACTATE DEHYDROGENASE; MODULATED ALLOSTERIC REGULATION; EFFECTOR-BINDING; PHOSPHOGLYCERATE DEHYDROGENASE; DOMAIN INTERFACE; INHIBITION; MECHANISM; ACTIVATION; ENZYMES; SITE	D-3-Phosphoglycerate dehydrogenase from Escherichia coli is a tetramer of identical subunits that is inhibited when L-serine binds at allosteric sites between subunits. Co-expression of two genes, the native gene containing a charge difference mutation and a gene containing a mutation that eliminates serine binding, produces hybrid tetramers that can be separated by ion exchange chromatography. Activity in the hybrid tetramer with only a single intact serine binding site is inhibited by similar to58% with a Hill coefficient of 1. Thus, interaction at a single regulatory domain interface does not, in itself, lead to the positive cooperativity of inhibition manifest in the native enzyme. Tetramers with only two intact serine binding sites purify as a mixture that displays a maximum inhibition level that is less than that of native enzyme, suggesting the presence of a population of tetramers that are unable to be fully inhibited. Differential analysis of this mixture supports the conclusion that it contains two forms of the tetramer. One form contains two intact serine binding sites at the same interface and is not fully inhibitable. The second form is a fully inhibitable population that has one serine binding site at each interface. Overall, the hybrid tetramers show that the positive cooperativity observed for serine binding is mediated across the nucleotide binding domain interface, and the negative cooperativity is mediated across the regulatory domain interface. That is, they reveal a pattern in which the binding of serine at one interface leads to negative cooperativity of binding of a subsequent serine at the same interface and positive cooperativity of binding of a subsequent serine to the opposite interface. This trend is propagated to subsequent binding sites in the tetramer such that the negative cooperativity that is originally manifest at one interface is decreased by subsequent binding of ligand at the opposite interface.	Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Grant, GA (corresponding author), Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, Box 8103,660 S Euclid Ave, St Louis, MO 63110 USA.							AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; AlRabiee R, 1996, J BIOL CHEM, V271, P13013, DOI 10.1074/jbc.271.22.13013; BELL JE, 1988, PROTEINS ENZYMES, P465; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Fushinobu S, 1998, J BIOL CHEM, V273, P2971, DOI 10.1074/jbc.273.5.2971; Fushinobu S, 1996, J BIOL CHEM, V271, P25611, DOI 10.1074/jbc.271.41.25611; Grant GA, 2000, BIOCHEMISTRY-US, V39, P7316, DOI 10.1021/bi000218y; Grant GA, 1999, PROTEIN SCI, V8, P2501; Grant GA, 1996, PROTEIN SCI, V5, P34; Grant GA, 2002, J BIOL CHEM, V277, P39548, DOI 10.1074/jbc.M208019200; Grant GA, 2001, J BIOL CHEM, V276, P17844, DOI 10.1074/jbc.M009957200; Grant GA, 2001, J BIOL CHEM, V276, P1078, DOI 10.1074/jbc.M007512200; GRANT GA, BIOCHEMISTRY, V38, P16548; IWATA S, 1994, NAT STRUCT BIOL, V1, P176, DOI 10.1038/nsb0394-176; Neet K E, 1980, Methods Enzymol, V64, P139; Nelson SW, 2002, J BIOL CHEM, V277, P15539, DOI 10.1074/jbc.M112304200; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179; Zhao GS, 1996, J BACTERIOL, V178, P232, DOI 10.1128/jb.178.1.232-239.1996	22	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18170	18176		10.1074/jbc.M213050200	http://dx.doi.org/10.1074/jbc.M213050200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644455	hybrid			2022-12-27	WOS:000182838300076
J	Ollagnier-de Choudens, S; Nachin, L; Sanakis, Y; Loiseau, L; Barras, F; Fontecave, M				Ollagnier-de Choudens, S; Nachin, L; Sanakis, Y; Loiseau, L; Barras, F; Fontecave, M			SufA from Erwinia chrysanthemi - Characterization of a scaffold protein required for iron-sulfur cluster assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; ESCHERICHIA-COLI; BIOTIN SYNTHASE; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; MITOCHONDRIAL PROTEINS; 2FE-2S CLUSTER; NIFS GENE; ISCU; BIOGENESIS	SufA is a component of the recently discovered suf operon, which has been shown to play an important function in bacteria during iron-sulfur cluster biosynthesis and resistance to oxidative stress. The SufA protein from Erwinia chrysanthemi, a Gram-negative plant pathogen, has been purified to homogeneity and characterized. It is a homodimer with the ability to assemble rather labile [2Fe-2S] and [4Fe-4S] clusters as shown by Mossbauer spectroscopy. These clusters can be transferred to apoproteins such as ferredoxin or biotin synthase during a reaction that is not inhibited by bathophenanthroline, an iron chelator. Cluster assembly in these proteins is much more efficient when iron and sulfur are provided by holoSufA than by free iron sulfate and sodium sulfide. We propose the function of SufA is that of a scaffold protein for [Fe-S] cluster assembly and compare it to IscA, a member of the isc operon also involved in cluster biosynthesis in both prokaryotes and eukaryotes. Mechanistic and physiological implications of these results are also discussed.	Univ Grenoble 1, CNRS,UMR 5047, CEA,Dept Response & Dynam Cellulaire Chim Biochim, Lab Chim & Biochim,Ctr Redox Biol, F-38054 Grenoble 09, France; Univ Gothenburg, S-40530 Gothenburg, Sweden; Natl Ctr Sci Res Demokritos, Inst Sci Mat, Athens 15310, Greece; Univ Ioannina, Dept Biol Applicat & Technol, GR-45110 Ioannina, Greece; CNRS, IBSM, Lab Chim Bacterienne, F-13402 Marseille 20, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Gothenburg; National Centre of Scientific Research "Demokritos"; University of Ioannina; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS,UMR 5047, CEA,Dept Response & Dynam Cellulaire Chim Biochim, Lab Chim & Biochim,Ctr Redox Biol, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr		Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Barras, Frederic/0000-0003-3458-2574				Agar JN, 2000, J BIOL INORG CHEM, V5, P167, DOI 10.1007/s007750050361; Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; ASHTON WT, 1978, J HETEROCYCLIC CHEM, V15, P489, DOI 10.1002/jhet.5570150324; Beinert H, 2000, J BIOL INORG CHEM, V5, P2, DOI 10.1007/s007750050002; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Flint DH, 1996, J BIOL CHEM, V271, P16068; Frazzon J, 2001, P NATL ACAD SCI USA, V98, P14751, DOI 10.1073/pnas.011579098; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; Hantke K, 2002, J MOL MICROB BIOTECH, V4, P217; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Kato S, 2002, P NATL ACAD SCI USA, V99, P5948, DOI 10.1073/pnas.082123599; Kaut A, 2000, J BIOL CHEM, V275, P15955, DOI 10.1074/jbc.M909502199; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Krebs C, 2001, BIOCHEMISTRY-US, V40, P14069, DOI 10.1021/bi015656z; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Li J, 2001, J BIOL CHEM, V276, P1503, DOI 10.1074/jbc.M007198200; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Mansy SS, 2002, J BIOL CHEM, V277, P21397, DOI 10.1074/jbc.M201439200; Manzella L, 1998, YEAST, V14, P839, DOI 10.1002/(SICI)1097-0061(19980630)14:9<839::AID-YEA283>3.0.CO;2-A; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Morimoto K, 2002, FEBS LETT, V519, P123, DOI 10.1016/S0014-5793(02)02736-9; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Nishio K, 2000, J BIOL CHEM, V275, P22615, DOI 10.1074/jbc.C000279200; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Ollagnier-de Choudens S, 2002, J BIOL CHEM, V277, P13449, DOI 10.1074/jbc.M111324200; Ollagnier-de-Choudens S, 2002, FEBS LETT, V532, P465, DOI 10.1016/S0014-5793(02)03733-X; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; Ollagnier-de-Choudens S, 2002, BIOCHEMISTRY-US, V41, P9145, DOI 10.1021/bi0122011; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Pelzer W, 2000, FEBS LETT, V476, P134, DOI 10.1016/S0014-5793(00)01711-7; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Schilke B, 1999, P NATL ACAD SCI USA, V96, P10206, DOI 10.1073/pnas.96.18.10206; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291; Tokumoto U, 2002, J BIOCHEM, V131, P713, DOI 10.1093/oxfordjournals.jbchem.a003156; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Voisine C, 2000, MOL CELL BIOL, V20, P3677, DOI 10.1128/MCB.20.10.3677-3684.2000; Voisine C, 2001, P NATL ACAD SCI USA, V98, P1483, DOI 10.1073/pnas.98.4.1483; Wu G, 2002, BIOCHEMISTRY-US, V41, P5024, DOI 10.1021/bi016073s; Wu G, 2002, J BIOL INORG CHEM, V7, P526, DOI 10.1007/s00775-001-0330-2; Wu SP, 2002, BIOCHEMISTRY-US, V41, P8876, DOI 10.1021/bi0256781; Yuvaniyama P, 2000, P NATL ACAD SCI USA, V97, P599, DOI 10.1073/pnas.97.2.599; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	69	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17993	18001		10.1074/jbc.M300285200	http://dx.doi.org/10.1074/jbc.M300285200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637501	hybrid			2022-12-27	WOS:000182838300052
J	Boutaud, O; Li, JY; Zagol, I; Shipp, EA; Davies, SS; Roberts, LJ; Oates, JA				Boutaud, O; Li, JY; Zagol, I; Shipp, EA; Davies, SS; Roberts, LJ; Oates, JA			Levuglandinyl adducts of proteins are formed via a prostaglandin H-2 synthase-dependent pathway after platelet activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; COVALENT BINDING; LYSYL ADDUCTS; IDENTIFICATION; ENDOPEROXIDES; PRODUCTS	The product of oxygenation of arachidonic acid by the prostaglandin H synthases (PGHS), prostaglandin H-2 (PGH(2)), undergoes rearrangement to the highly reactive gamma-ketoaldehydes, levuglandin (LG) E-2, and LGD(2). We have demonstrated previously that LGE(2) reacts with the epsilon-amine of lysine to form both the levuglandinyl-lysine Schiff base and the pyrrole-derived levuglandinyl-lysine lactam adducts. We also have reported that these levuglandinyl-lysine adducts are formed on purified PGHSs following the oxygenation of arachidonic acid. We now present evidence that the levuglandinyl-lysine lactam adduct is formed in human platelets upon activation with exogenous arachidonic acid or thrombin. After proteolytic digestion of the platelet proteins, and isolation of the adducted amino acid residues, this adduct was identified by liquid chromatography-tandem mass spectrometry. We also demonstrate that formation of these adducts is inhibited by indomethacin, a PGHS inhibitor, and is enhanced by an inhibitor of thromboxane synthase. These data establish that levuglandinyl-lysine adducts are formed via a PGHS-dependent pathway in whole cells, even in the presence of an enzyme that metabolizes PGH(2). They also demonstrate that a physiological stimulus is sufficient to lead to the lipid modification of proteins through the levuglandin pathway in human platelets.	Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Boutaud, O (corresponding author), Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA.	olivier.boutaud@vanderbilt.edu		Davies, Sean/0000-0001-9879-8062	NCI NIH HHS [CA 68485] Funding Source: Medline; NIGMS NIH HHS [GM 15431, GM 42056] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, P50GM015431, R37GM042056, R01GM042056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernoud-Hubac N, 2001, J BIOL CHEM, V276, P30964, DOI 10.1074/jbc.M103768200; Boutaud O, 2002, J NEUROCHEM, V82, P1003, DOI 10.1046/j.1471-4159.2002.01064.x; Boutaud O, 2002, P NATL ACAD SCI USA, V99, P7130, DOI 10.1073/pnas.102588199; Boutaud O, 2001, BIOCHEMISTRY-US, V40, P6948, DOI 10.1021/bi002629k; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; LAGARDE M, 1980, THROMB RES, V17, P581, DOI 10.1016/0049-3848(80)90098-5; LECOMTE M, 1990, J BIOL CHEM, V265, P5178; MILLER DB, 1990, J ORG CHEM, V55, P3164, DOI 10.1021/jo00297a036; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; SALOMON RG, 1984, J AM CHEM SOC, V106, P8296, DOI 10.1021/ja00338a050; WILSON AGE, 1979, PROSTAGLANDINS, V18, P409, DOI 10.1016/S0090-6980(79)80060-X	15	29	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16926	16928		10.1074/jbc.M300940200	http://dx.doi.org/10.1074/jbc.M300940200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637576	hybrid			2022-12-27	WOS:000182818600065
J	Hannah, BLA; Misenheimer, TM; Annis, DS; Mosher, DF				Hannah, BLA; Misenheimer, TM; Annis, DS; Mosher, DF			A polymorphism in thrombospondin-1 associated with familial premature coronary heart disease causes a local change in conformation of the Ca2+-binding repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOMERIC MATRIX PROTEIN; MULTIPLE EPIPHYSEAL DYSPLASIA; PLATELET THROMBOSPONDIN; GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; ENDOPLASMIC-RETICULUM; COMP GENE; PSEUDOACHONDROPLASIA; MUTATIONS; CALCIUM	A single nucleotide polymorphism that substitutes a serine for an asparagine at residue 700 in the Ca2+ binding repeats of thrombospondin-1 is associated with familial premature coronary heart disease. We expressed the Ca2+-binding repeats alone (Ca) or with the third epidermal growth factor-like module (E3Ca), without (Asn-700) or with (Ser-700) the disease-associated polymorphism. The intrinsic fluorescence of a single tryptophan (Trp-698) adjacent to the polymorphic residue was quenched cooperatively by adding Ca2+. The third epidermal growth factor-like repeat dramatically altered the Ca2+ -dependent fluorescence transition for the Asn-700 constructs; the half-effective concentration (EC50) of Ca Asn-700 was 390 muM, and the EC50 of E3Ca Asn-700 was 70 muM. The Ser-700 polymorphism shifted the EC50 to higher Ca2+ concentrations (Ca Ser-700 EC50 of 950 pm and E3Ca Ser-700 EC50 of 110 pm). This destabilizing effect is due to local conformational changes, as the Ser-700 polymorphism did not influence the secondary structure of E3Ca or Ca as assessed by far UV circular dichroism. At 200 pm Ca2+, in which both E3Ca Asn-700 and Ser-700 are in the Ca2+-replete conformation at 37 degreesC, the fluorescence of E3Ca Ser-700 reverted to the Ca2+-depleted spectrum at 50degreesC compared with 65degreesC for E3Ca Asn-700. These findings indicate that the Ser-700 polymorphism subtly but significantly sensitizes the calcium-binding repeats to removal of Ca2+ and thermal denaturation.	Univ Wisconsin, Med Sci Ctr, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA; Univ Wisconsin, Med Scientist Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Hannah, BLA (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Med, Madison, WI 53706 USA.	bahannah@students.wisc.edu			NHLBI NIH HHS [HL54462] Funding Source: Medline; NIGMS NIH HHS [T32 GM08688] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008688] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; ADAMS JC, 1995, THROMBOSPONDIN GENE, P16; Adolph KW, 2001, GENE, V269, P177, DOI 10.1016/S0378-1119(01)00441-3; Alonso MT, 1998, CELL CALCIUM, V24, P87, DOI 10.1016/S0143-4160(98)90076-8; *AM HEART ASS, 2000, 2001 HEART STROK STA, P18; Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; Briggs MD, 2002, HUM MUTAT, V19, P465, DOI 10.1002/humu.10066; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; Chen H, 2000, J BIOL CHEM, V275, P26538, DOI 10.1074/jbc.M909780199; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; CREIGHTON TE, 1997, PROTEIN STRUCTURE PR, P279; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Delot E, 1999, HUM MOL GENET, V8, P123, DOI 10.1093/hmg/8.1.123; DIXIT VM, 1986, J BIOL CHEM, V261, P1962; GALVIN NJ, 1985, J CELL BIOL, V101, P1434, DOI 10.1083/jcb.101.4.1434; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; Hecht JT, 2001, MATRIX BIOL, V20, P251, DOI 10.1016/S0945-053X(01)00136-6; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; Kiryushko DV, 2002, PFLUG ARCH EUR J PHY, V443, P643, DOI 10.1007/s00424-001-0739-z; Kleerekoper Q, 2002, J BIOL CHEM, V277, P10581, DOI 10.1074/jbc.M109944200; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P219; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1983, J BIOL CHEM, V258, P2098; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MAJACK RA, 1987, J BIOL CHEM, V262, P8821; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; Misenheimer TM, 2001, J BIOL CHEM, V276, P45882, DOI 10.1074/jbc.M104218200; Mosher DF, 2002, METHOD CELL BIOL, V69, P69, DOI 10.1016/S0091-679X(02)69008-9; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Pimanda JE, 2002, BLOOD, V100, P2832, DOI 10.1182/blood-2002-03-0770; RAUGI GJ, 1990, AM J PATHOL, V137, P179; SPEZIALE MV, 1990, J BIOL CHEM, V265, P17859; Susic S, 1997, CLIN GENET, V51, P219; Thur J, 2001, J BIOL CHEM, V276, P6083, DOI 10.1074/jbc.M009512200; Topol EJ, 2001, CIRCULATION, V104, P2641, DOI 10.1161/hc4701.100910; TURK JL, 1986, ARCH BIOCHEM BIOPHYS, V245, P446, DOI 10.1016/0003-9861(86)90236-5; Vranka J, 2001, MATRIX BIOL, V20, P439, DOI 10.1016/S0945-053X(01)00148-2; Xie LJ, 2001, J EXP MED, V193, P1341, DOI 10.1084/jem.193.12.1341; YABKOWITZ R, 1993, J CELL PHYSIOL, V157, P24, DOI 10.1002/jcp.1041570104	44	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8929	8934		10.1074/jbc.M211185200	http://dx.doi.org/10.1074/jbc.M211185200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643280	hybrid			2022-12-27	WOS:000181524000010
J	Yang, L; Ross, K; Qwarnstrom, EE				Yang, L; Ross, K; Qwarnstrom, EE			RelA control of I kappa B alpha phosphorylation - A positive feedback loop for high affinity NF-kappa B complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GREEN FLUORESCENT PROTEIN; SIGNAL-INDUCED DEGRADATION; REGULATES DNA-BINDING; NUCLEAR EXPORT SIGNAL; LIVING CELLS; TRANSCRIPTIONAL ACTIVATION; IKK-ALPHA; LOCALIZATION; BETA	NF-kappaB-IkappaB complex formation regulates the level and specificity of NF-kappaB activity. Quantitative analyses showed that RelA-NF-kappaB-induced IkappaBalpha binding is regulated through inhibitor retention and phosphorylation. RelA caused an increase in IkappaBalpha phosphorylation and in degradation, which was enhanced monotonically with inhibitor concentration. In vivo analysis demonstrated the RelA-induced IkappaBalpha/RelA interactions to be specific, saturable, and phosphorylation-dependent. In addition, it showed that phosphorylation regulates both the level and affinity of the complexes and demonstrated an increased average affinity to coincide with reduction in the level of complexes during cytokine-induced pathway activation. The data show that RelA regulation of NF-kappaB-IkappaBalpha complex formation is IkappaBalpha phosphorylation-dependent and that IkappaBalpha/NF-kappaB binding is dynamic and determined by concentration of the subunits. In addition, they suggest that regulation of both complex levels and affinities through phosphorylation, with effects on the system steady state, participate in selective activation of the NF-kappaB pathway.	Univ Sheffield, Sch Med, Div Genom Med, Cell Biol Unit, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Cell Biol Unit, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			Qwarnstrom, Eva/0000-0003-4417-8663				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; HERMAN B, 1989, METHOD CELL BIOL, V30, P219; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XQ, 1999, J BIOL CHEM, V274, P21244, DOI 10.1074/jbc.274.30.21244; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Prigent M, 2000, J BIOL CHEM, V275, P36441, DOI 10.1074/jbc.M004751200; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Schooley K, 2003, BIOCHEM J, V369, P331, DOI 10.1042/BJ20020253; Szollosi J, 1998, CYTOMETRY, V34, P159; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yang L, 2001, BIOCHEM BIOPH RES CO, V285, P603, DOI 10.1006/bbrc.2001.5205; Zaccolo M, 2000, IUBMB LIFE, V49, P375; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	49	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	2003	278	33					30881	30888		10.1074/jbc.M212216200	http://dx.doi.org/10.1074/jbc.M212216200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	710AN	12663663	hybrid			2022-12-27	WOS:000184658800060
J	Alefantis, T; Barmak, K; Harhaj, EW; Grant, C; Wigdahl, B				Alefantis, T; Barmak, K; Harhaj, EW; Grant, C; Wigdahl, B			Characterization of a nuclear export signal within the human T cell leukemia virus type I transactivator protein tax	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NUCLEOTIDE-SEQUENCE ANALYSIS; CREB BINDING-PROTEIN; LEPTOMYCIN-B; CRM1; LYMPHOCYTES; EXPRESSION; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION	Human T cell leukemia virus type I (HTLV-I) is the etiologic agent of adult T cell leukemia and HTLV-I-associated myelopathy/ tropical spastic paraparesis. The HTLV-I transactivator protein Tax plays an integral role in the etiology of adult T cell leukemia, as expression of Tax in T lymphocytes has been shown to result in immortalization. In addition, Tax is known to interface with numerous transcription factor families, including activating transcription factor/cAMP response element-binding protein and nuclear factor-kappaB, requiring Tax to localize to both the nucleus and cytoplasm. In this report, the nucleocytoplasmic localization of Tax was examined in Jurkat, HeLa, and U-87 MG cells. The results reported herein indicate that Tax contains a leucine-rich nuclear export signal (NES) that, when fused to green fluorescent protein (GFP), can direct nuclear export via the CRM-1 pathway, as determined by leptomycin B inhibition of nuclear export. However, cytoplasmic localization of full-length Tax was not altered by treatment with leptomycin B, suggesting that native Tax utilizes another nuclear export pathway. Additional support for the presence of a functional NES has also been shown because the NES mutant Tax(L200A)-GFP localized to the nuclear membrane in the majority of U-87 MG cells. Evidence has also been provided suggesting that the Tax NES likely exists as a conditionally masked signal because the truncation mutant TaxDelta214-GFP localized constitutively to the cytoplasm. These results suggest that Tax localization may be directed by specific changes in Tax conformation or by specific interactions with cellular proteins leading to changes in the availability of the Tax NES and nuclear localization signal.	Penn State Univ, Coll Med, Dept Microbiol & Immunol H107, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Wigdahl, B (corresponding author), Penn State Univ, Coll Med, Dept Microbiol & Immunol H107, 500 Univ Dr,POB 850, Hershey, PA 17033 USA.		Barmak, Katayun/AFU-8454-2022	Barmak, Katayun/0000-0003-0070-158X	NATIONAL CANCER INSTITUTE [R01CA054559] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54559] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akaoka H, 1996, J VIROL, V70, P8727, DOI 10.1128/JVI.70.12.8727-8736.1996; Akaoka H, 2001, VIRUS RES, V78, P57, DOI 10.1016/S0168-1702(01)00284-2; Barmak K, 2003, VIROLOGY, V308, P1, DOI 10.1016/S0042-6822(02)00091-0; Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; Bex F, 1997, J VIROL, V71, P3484, DOI 10.1128/JVI.71.5.3484-3497.1997; Bex F, 1999, J VIROL, V73, P738, DOI 10.1128/JVI.73.1.738-745.1999; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cartwright P, 2000, CELL MOL LIFE SCI, V57, P1193, DOI 10.1007/PL00000759; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FONTES JD, 1993, J VIROL, V67, P4436, DOI 10.1128/JVI.67.7.4436-4441.1993; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Giebler HA, 1997, MOL CELL BIOL, V17, P5156, DOI 10.1128/MCB.17.9.5156; GITLIN SD, 1991, J VIROL, V65, P2612, DOI 10.1128/JVI.65.5.2612-2621.1991; Grant C, 2002, J CELL PHYSIOL, V190, P133, DOI 10.1002/JCP.10053; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; Gu JJ, 2001, MOL CELL BIOL, V21, P8533, DOI 10.1128/MCB.21.24.8533-8546.2001; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LINDHOLM P F, 1990, New Biologist, V2, P1034; LINDHOLM PF, 1992, J VIROL, V66, P1294, DOI 10.1128/JVI.66.3.1294-1302.1992; MAJOR M, 1995, AIDS RES HUM RETROV, V11, P415, DOI 10.1089/aid.1995.11.415; Mori N, 2002, BLOOD, V99, P1341, DOI 10.1182/blood.V99.4.1341; MUKHOPADHYAYA R, 1993, AIDS RES HUM RETROV, V9, P109, DOI 10.1089/aid.1993.9.109; Nicot C, 1998, J VIROL, V72, P6777, DOI 10.1128/JVI.72.8.6777-6784.1998; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAINE E, 1991, VIROLOGY, V182, P111, DOI 10.1016/0042-6822(91)90654-T; RATNER L, 1991, AIDS RES HUM RETROV, V7, P923, DOI 10.1089/aid.1991.7.923; RENJIFO B, 1995, J VIROL, V69, P2611, DOI 10.1128/JVI.69.4.2611-2616.1995; Rosin O, 1998, J BIOL CHEM, V273, P6698, DOI 10.1074/jbc.273.12.6698; Semmes OJ, 1996, J VIROL, V70, P6347, DOI 10.1128/JVI.70.9.6347-6357.1996; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Szymocha R, 2000, J NEUROVIROL, V6, P350, DOI 10.3109/13550280009030761; Szymocha R, 2000, AIDS RES HUM RETROV, V16, P1723, DOI 10.1089/08892220050193218; Udalova IA, 1998, J BIOL CHEM, V273, P21178, DOI 10.1074/jbc.273.33.21178; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WESSNER R, 1995, J NEUROVIROL, V1, P62, DOI 10.3109/13550289509111011; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yao Y, 2000, LEUKEMIA, V14, P535; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	53	78	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21814	21822		10.1074/jbc.M211576200	http://dx.doi.org/10.1074/jbc.M211576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670929	hybrid			2022-12-27	WOS:000183354200064
J	Le, HT; Schaldach, CM; Firestone, GL; Bjeldanes, LF				Le, HT; Schaldach, CM; Firestone, GL; Bjeldanes, LF			Plant-derived 3,3 '-diindolylmethane is a strong androgen antagonist in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE ARREST; BRASSICA VEGETABLES; BINDING DOMAIN; RECEPTOR; ANTIGEN; BREAST; INDOLE-3-CARBINOL; APOPTOSIS; GENE; ACTIVATION	3,3'-Diindolylmethane ( DIM) is a major digestive product of indole-3-carbinol, a potential anticancer component of cruciferous vegetables. Our results indicate that DIM exhibits potent antiproliferative and antiandrogenic properties in androgen-dependent human prostate cancer cells. DIM suppresses cell proliferation of LNCaP cells and inhibits dihydrotestosterone (DHT) stimulation of DNA synthesis. These activities were not produced in androgen-independent PC-3 cells. Moreover, DIM inhibited endogenous PSA transcription and reduced intracellular and secreted PSA protein levels induced by DHT in LNCaP cells. Also, DIM inhibited, in a concentration-dependent manner, the DHT-induced expression of a prostate-specific antigen promoter-regulated reporter gene construct in transiently transfected LNCaP cells. Similar effects of DIM were observed in PC-3 cells only when these cells were cotransfected with a wild-type androgen receptor expression plasmid. Using fluorescence imaging with green fluorescent protein androgen receptor and Western blot analysis, we demonstrated that DIM inhibited androgen-induced androgen receptor (AR) translocation into the nucleus. Results of receptor binding assays indicated further that DIM is a strong competitive inhibitor of DHT binding to the AR. Results of structural modeling studies showed that DIM is remarkably similar in conformational geometry and surface charge distribution to an established synthetic AR antagonist, although the atomic compositions of the two substances are quite different. Taken together with our published reports of the estrogen agonist activities of DIM, the present results establish DIM as a unique bifunctional hormone disrupter. To our knowledge, DIM is the first example of a pure androgen receptor antagonist from plants.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Bjeldanes, LF (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.	lfb@nature.berkeley.edu			NIEHS NIH HHS [P30-ES01896] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BJELDANES LF, 1991, P NATL ACAD SCI USA, V88, P9543, DOI 10.1073/pnas.88.21.9543; BRADFIELD CA, 1987, J TOXICOL ENV HEALTH, V21, P311, DOI 10.1080/15287398709531021; BRADLOW HL, 1991, CARCINOGENESIS, V12, P1571, DOI 10.1093/carcin/12.9.1571; Chen I, 1998, CARCINOGENESIS, V19, P1631, DOI 10.1093/carcin/19.9.1631; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; Chinni SR, 2002, CLIN CANCER RES, V8, P1228; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; COHEN P, 1994, J ENDOCRINOL, V142, P407, DOI 10.1677/joe.0.1420407; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; Denis L, 1999, EUR UROL, V35, P377, DOI 10.1159/000019912; Dixon SC, 2001, PHARMACOL REV, V53, P73; Duffy MJ, 1996, ANN CLIN BIOCHEM, V33, P511, DOI 10.1177/000456329603300604; Ge XK, 1996, BIOCHEM BIOPH RES CO, V228, P153, DOI 10.1006/bbrc.1996.1631; Ge XK, 1999, ANTICANCER RES, V19, P3199; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; GROSE KR, 1992, CHEM RES TOXICOL, V5, P188, DOI 10.1021/tx00026a007; GRUBBS CJ, 1995, ANTICANCER RES, V15, P709; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; Hong C, 2002, BIOCHEM PHARMACOL, V63, P1085, DOI 10.1016/S0006-2952(02)00856-0; Hong CB, 2002, CARCINOGENESIS, V23, P1297, DOI 10.1093/carcin/23.8.1297; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kawata M, 2001, ARCH HISTOL CYTOL, V64, P353, DOI 10.1679/aohc.64.353; Kolonel LN, 2000, CANCER EPIDEM BIOMAR, V9, P795; Kristal AR, 2002, NUTR CANCER, V42, P1, DOI 10.1207/S15327914NC421_1; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; LINDZEY J, 1994, VITAM HORM, V49, P383; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Riby JE, 2000, BIOCHEMISTRY-US, V39, P910, DOI 10.1021/bi9919706; Riby JE, 2000, BIOCHEM PHARMACOL, V60, P167, DOI 10.1016/S0006-2952(00)00307-5; Roy AK, 2001, ANN NY ACAD SCI, V949, P44; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Saitoh M, 2002, MOL ENDOCRINOL, V16, P694, DOI 10.1210/me.16.4.694; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; Small EJ, 1998, DRUG AGING, V13, P71, DOI 10.2165/00002512-199813010-00007; Terry P, 2002, NUTR CANCER, V42, P25, DOI 10.1207/S15327914NC421_4; Terry P, 2001, JAMA-J AM MED ASSOC, V285, P2975, DOI 10.1001/jama.285.23.2975; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; VERNON SE, 1983, J UROLOGY, V130, P95, DOI 10.1016/S0022-5347(17)50977-5; Voorrips LE, 2000, AM J EPIDEMIOL, V152, P1081, DOI 10.1093/aje/152.11.1081; WANG M, 1991, DIFFERENTIATION, V48, P115, DOI 10.1111/j.1432-0436.1991.tb00250.x; WARRIAR N, 1994, PROSTATE, V24, P176, DOI 10.1002/pros.2990240403; WATTENBERG LW, 1978, CANCER RES, V38, P1410; WATTENBERG LW, 1980, J ENVIRON PATHOL TOX, V3, P35; Webber MM, 1995, CLIN CANCER RES, V1, P1089; Webber MM, 1997, PROSTATE, V30, P58; Wilson WD, 1997, CHEM PHYS LETT, V267, P431, DOI 10.1016/S0009-2614(97)00135-8; Wingo PA, 1997, CA-CANCER J CLIN, V47, P239, DOI 10.3322/canjclin.47.4.239	51	156	171	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21136	21145		10.1074/jbc.M300588200	http://dx.doi.org/10.1074/jbc.M300588200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665522	hybrid			2022-12-27	WOS:000183230500090
J	Snyder, JT; Singer, AU; Wing, MR; Harden, TK; Sondek, J				Snyder, JT; Singer, AU; Wing, MR; Harden, TK; Sondek, J			The pleckstrin homology domain of phospholipase C-beta(2) as an effector site for Rac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-BINDING DOMAIN; BETA-GAMMA-SUBUNITS; ADRENERGIC-RECEPTOR KINASE; RHO GTPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; INOSITOL TRISPHOSPHATE; CRYSTAL-STRUCTURE; HIGH-AFFINITY; PH DOMAINS; C-EPSILON	Increasing evidence links the activation of Rho family GTPases to the stimulation of lipid hydrolysis catalyzed by phospholipase C ( PLC)-beta isozymes. To better define this relationship, members of a library of recombinant Rho GTPases were screened for their capacity to directly engage various purified PLC-beta isozymes. Of the 17 tested members of the Rho family, only the active isoforms of Rac (Rac1, Rac2, and Rac3) both stimulate PLC-beta activity in vivo and bind PLC-beta(2) and PLC-beta(3), but not PLC-beta(1), in vitro. Furthermore, the recognition site for Rac GTPases was localized to the pleckstrin homology (PH) domain of PLC-beta(2), and this PH domain is fully sufficient to selectively interact with the active versions of the Rac GTPases, but not with other similar Rho GTPases. Together, these findings present a quantitative evaluation of the direct interactions between Rac GTPases and PLC-beta isozymes and define a novel role for the PH domain of PLC-beta(2) as a putative effector site for Rac GTPases.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Neurobiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Harden, TK (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.	tkh@med.unc.edu	, Proteomics Core UNC/AFQ-7201-2022	Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536, P01GM065533, R01GM062299, R01GM057391] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57391, GM29536, GM62299, GM65533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Manan N, 1999, NATURE, V399, P379, DOI 10.1038/20726; Abrams CS, 1996, BBA-MOL CELL RES, V1314, P233, DOI 10.1016/S0167-4889(96)00109-7; Barr AJ, 2000, BIOCHEMISTRY-US, V39, P1800, DOI 10.1021/bi992021f; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Blake BL, 2001, J BIOL CHEM, V276, P49267, DOI 10.1074/jbc.M106565200; BLANK JL, 1992, J BIOL CHEM, V267, P23069; Blomberg N, 1999, TRENDS BIOCHEM SCI, V24, P441, DOI 10.1016/S0968-0004(99)01472-3; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BROWN HA, 1991, MOL PHARMACOL, V40, P648; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; Day YSN, 2002, PROTEIN SCI, V11, P1017, DOI 10.1110/ps.4330102; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; Illenberger D, 2003, J BIOL CHEM, V278, P8645, DOI 10.1074/jbc.M211971200; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Illenberger D, 1997, EUR J BIOCHEM, V246, P71, DOI 10.1111/j.1432-1033.1997.t01-1-00071.x; Illenberger D, 1998, EMBO J, V17, P6241, DOI 10.1093/emboj/17.21.6241; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A; Kuang YN, 1996, P NATL ACAD SCI USA, V93, P2964, DOI 10.1073/pnas.93.7.2964; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; Morreale A, 2000, NAT STRUCT BIOL, V7, P384; Mott HR, 1999, NATURE, V399, P384, DOI 10.1038/20732; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Paulssen RH, 1996, J BIOL CHEM, V271, P26622, DOI 10.1074/jbc.271.43.26622; Philip F, 2002, FEBS LETT, V531, P28, DOI 10.1016/S0014-5793(02)03411-7; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; REMMERS AE, 1994, J BIOL CHEM, V269, P13771; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Runnels LW, 1996, BIOCHEMISTRY-US, V35, P16824, DOI 10.1021/bi961606w; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Sankaran B, 1998, J BIOL CHEM, V273, P7148, DOI 10.1074/jbc.273.12.7148; Sawai T, 1999, BIOL PHARM BULL, V22, P229; Scarlata S, 2002, BIOCHEMISTRY-US, V41, P7092, DOI 10.1021/bi025625j; Singer AU, 2002, NAT STRUCT BIOL, V9, P32, DOI 10.1038/nsb731; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Vetter IR, 1999, NATURE, V398, P39, DOI 10.1038/17969; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang TL, 2000, J BIOL CHEM, V275, P7466, DOI 10.1074/jbc.275.11.7466; Wang TL, 1999, BIOCHEMISTRY-US, V38, P1517, DOI 10.1021/bi982008f; Wing MR, 2001, J BIOL CHEM, V276, P48257, DOI 10.1074/jbc.C100574200; Xu NZ, 1996, CELL MOL NEUROBIOL, V16, P51, DOI 10.1007/BF02578386	57	81	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21099	21104		10.1074/jbc.M301418200	http://dx.doi.org/10.1074/jbc.M301418200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657629	hybrid			2022-12-27	WOS:000183230500085
J	Spicer, AP; Joo, A; Bowling, RA				Spicer, AP; Joo, A; Bowling, RA			A hyaluronan binding link protein gene family whose members are physically linked adjacent to chrondroitin sulfate proteoglycan core protein genes - The missing links	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BRAIN-DEVELOPMENT; CELL-ADHESION; DOMAIN; NEUROCAN; GENOME; MODULE; BRAL1; IDENTIFICATION; CARBOHYDRATE	We describe a vertebrate hyaluronan and proteoglycan binding link protein gene family (HAPLN), consisting of four members including cartilage link protein. The encoded proteins share 45 - 52% overall amino acid identity. In contrast to the average sequence identity between family members, the sequence conservation between vertebrate species was very high. Human and mouse link proteins share 81 - 96% amino acid sequence identity. Two of the four link protein genes (HAPLN2 and HAPLN4) were restricted in expression to the brain/central nervous system, while one of the four genes (HAPLN3) was widely expressed. Genomic structures revealed that all four HAPLN genes were similar in exon-intron organization and were also similar in genomic organization to the 5' exons for the CSPG core protein genes. Strikingly, all four HAPLN genes were located immediately adjacent to the four CSPG core protein genes creating four pairs of CSPG- HAPLN genes within the mammalian genome. Furthermore, the two brain-specific HAPLN genes ( HAPLN2 and HAPLN4) were physically linked to the brain-specific CSPG genes encoding brevican and neurocan, respectively. The tight physical association of the HAPLN and CSPG genes supports a hypothesis that the first HAPLN gene arose as a partial gene duplication event from an ancestral CSPG gene. There is some degree of coordinated expression of each gene pair. Collectively, the four HAPLN genes are expressed by most tissue types, reflecting the fundamental importance of the hyaluronan-dependent extracellular matrix to tissue architecture and function in vertebrate species. Comparison of the genomic structures for the HAPLN, CSPG genes and other members of the link module superfamily provide strong support for a common evolutionary origin from an ancestral gene containing one link module encoding exon.	Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; University of Texas Health Science Center Houston	Spicer, AP (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Inst Biosci & Technol, Ctr Extracellular Matrix Biol, Houston, TX 77030 USA.	aspicer@ibt.tamu.edu						Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; FALTZ LL, 1979, J BIOL CHEM; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Friedman R, 2001, GENOME RES, V11, P1842, DOI 10.1101/gr.200601; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; Hirakawa S, 2000, BIOCHEM BIOPH RES CO, V276, P982, DOI 10.1006/bbrc.2000.3583; Hubbard T, 2002, NUCLEIC ACIDS RES, V30, P38, DOI 10.1093/nar/30.1.38; Kobayashi H, 1999, ENDOCRINOLOGY, V140, P3835, DOI 10.1210/en.140.8.3835; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LESLEY J, 1998, FRONT BIOSCI, V3, P616; Mahoney DJ, 2001, J BIOL CHEM, V276, P22764, DOI 10.1074/jbc.M100666200; Miura R, 1999, J BIOL CHEM, V274, P11431, DOI 10.1074/jbc.274.16.11431; Mjaatvedt CH, 1998, DEV BIOL, V202, P56, DOI 10.1006/dbio.1998.9001; MORGELIN M, 1994, BIOPHYS CHEM, V50, P113, DOI 10.1016/0301-4622(94)85024-0; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nomoto H, 2002, ACTA MED OKAYAMA, V56, P25; OHNO S, 1993, CURR OPIN GENET DEV, V3, P911, DOI 10.1016/0959-437X(93)90013-F; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Rauch U, 2001, CELL MOL LIFE SCI, V58, P1842, DOI 10.1007/PL00000822; Tsifrina E, 1999, AM J PATHOL, V155, P1625, DOI 10.1016/S0002-9440(10)65478-8; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Watanabe H, 1999, NAT GENET, V21, P225, DOI 10.1038/6016; Yamaguchi Y, 2000, CELL MOL LIFE SCI, V57, P276, DOI 10.1007/PL00000690; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhou XH, 2001, MOL CELL BIOL, V21, P5970, DOI 10.1128/MCB.21.17.5970-5978.2001	34	128	137	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21083	21091		10.1074/jbc.M213100200	http://dx.doi.org/10.1074/jbc.M213100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663660	hybrid			2022-12-27	WOS:000183230500083
J	Witherow, DS; Tovey, SC; Wang, Q; Willars, GB; Slepak, VZ				Witherow, DS; Tovey, SC; Wang, Q; Willars, GB; Slepak, VZ			G beta 5 center dot RGS7 inhibits G alpha q-mediated signaling via a direct protein-protein interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RGS PROTEINS; FLUORESCENT PROTEIN; GAMMA-SUBUNIT; IN-VITRO; MEMBRANE; BINDING; DOMAIN; BETA; TRANSDUCIN	A subfamily of regulators of G protein signaling (RGS) proteins consisting of RGS6, -7, -9, and -11 is characterized by the presence of a unique Ggamma-like domain through which they form obligatory dimers with the G protein subunit Gbeta5 in vivo. In Caenorhabditis elegans, orthologs of Gbeta5.RGS dimers are implicated in regulating both Galpha(i) and Galpha(q) signaling, and in cell-based assays these dimers regulate Galpha(i/o)- and Galpha(q/11)-mediated pathways. However, initial studies with purified Gbeta5.RGS6 or Gbeta5.RGS7 showed that they only serve as GTPase activating proteins for Galpha(o). Pull-down assays and coimmunoprecipitation with these dimers failed to detect their binding to either Galpha(o) or Galpha(q), indicating that the interaction might require additional factors present in vivo. Here, we asked if the RGS7.Gbeta5 complex binds to Galpha(q) using fluorescence resonance energy transfer (FRET) in transiently transfected mammalian cells. RGS7, Gbeta5, and Galpha subunits were tagged with yellow variants of green fluorescent protein. First we confirmed the functional activity of the fusion proteins by co-immunoprecipitation and also their effect on signaling. Second, we again demonstrate the interaction between RGS7 and Gbeta5 using FRET. Finally, using both FRET spectroscopy on cell suspensions and microscopy of individual cells, we showed FRET between the yellow fluorescence protein-tagged RGS7.Gbeta5 complex and cyan fluorescence protein-tagged Galpha(q), indicating a direct interaction between these molecules.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Neurosci Program, Miami, FL 33136 USA; Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Miami; University of Miami; University of Leicester	Slepak, VZ (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, R-189,1600 NW 10th Ave, Miami, FL 33136 USA.			Witherow, D. Scott/0000-0002-7344-1574	NATIONAL EYE INSTITUTE [R01EY012982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060019] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12982] Funding Source: Medline; NIGMS NIH HHS [R01 GM060019, R01 GM060019-03S1, R01 GM060019-02, R01 GM060019-02S1, R01 GM 600019, R01 GM060019-01, R01 GM060019-03] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benzing T, 2000, J BIOL CHEM, V275, P28167; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DiBello PR, 1998, J BIOL CHEM, V273, P5780, DOI 10.1074/jbc.273.10.5780; Dulin NO, 1999, MOL CELL BIOL, V19, P714; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; Hausmann ON, 2002, EUR J NEUROSCI, V15, P602, DOI 10.1046/j.1460-9568.2002.01916.x; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Hooks SB, 2003, J BIOL CHEM, V278, P10087, DOI 10.1074/jbc.M211382200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Lan KL, 2000, J BIOL CHEM, V275, P33497, DOI 10.1074/jbc.M005785200; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Siegel R. M., 2000, SCI STKE, V2000, ppl1; Simonds W F, 2000, Pharm Acta Helv, V74, P333, DOI 10.1016/S0031-6865(99)00043-6; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wieland T, 1997, J BIOL CHEM, V272, P8853; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	36	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21307	21313		10.1074/jbc.M212884200	http://dx.doi.org/10.1074/jbc.M212884200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670932	hybrid			2022-12-27	WOS:000183230500109
J	Bosch, L; Ramon, E; del Valle, LJ; Garriga, P				Bosch, L; Ramon, E; del Valle, LJ; Garriga, P			Structural and functional role of helices I and II in rhodopsin - A novel interplay evidenced by mutations at Gly-51 and Gly-89 in the transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; DOMINANT RETINITIS-PIGMENTOSA; AMINO-ACID SUBSTITUTION; INTRADISCAL DOMAIN; CONSTITUTIVE ACTIVATION; MONOCLONAL-ANTIBODIES; POINT MUTANTS; GENE; EXPRESSION; BOVINE	The naturally occurring mutations G51A and G51V in transmembrane helix I and G89D in the transmembrane helix II of rhodopsin are associated with the retinal degenerative disease autosomal dominant retinitis pigmentosa. To probe the orientation and packing of helices I and II a number of replacements at positions 51 and 89 were prepared by using site-directed mutagenesis, and the corresponding proteins expressed in COS-1 cells were characterized. Mutations at position 51 ( G51V and G51L) bound retinal like wild-type rhodopsin but had thermally destabilized structures in the dark, altered photobleaching behavior, destabilized metarhodopsin II active conformations, and were severely defective in signal transduction. The effects observed can be correlated with the size of the mutated side chains that would interfere with specific interhelical interaction with Val-300 in helix VII. Mutations at position 89 had sensitivity to charge, as in G89K and G89D mutants, which showed reduced transducin activation. G89K showed a second absorbing species in the UV region at 350 nm, suggesting a charge effect of the introduced lysine. Increased formation of non-active forms of rhodopsin, like metarhodopsin III, may have some influence in the molecular defect underlying retinitis pigmentosa in the mutants studied. At the structural level, the effect of the mutations analyzed can be rationalized assuming a very specific set of tertiary interactions in the interhelical packing of the transmembrane segments of rhodopsin.	Univ Politecn Cataluna, Ctr Mol Biotechnol, Dept Engn Quim, Terrassa 08222, Catalonia, Spain	Universitat Politecnica de Catalunya	Garriga, P (corresponding author), Univ Politecn Cataluna, Ctr Mol Biotechnol, Dept Engn Quim, Colom 1, Terrassa 08222, Catalonia, Spain.	pere.garriga@upc.es	Del Valle, Luis J./I-1342-2015; Garriga, Pere/C-1949-2017; Bosch-Presegué, Laia/Z-1351-2019	Del Valle, Luis J./0000-0001-9916-1741; Garriga, Pere/0000-0003-4234-8382; Bosch-Presegué, Laia/0000-0001-8025-2416				ALKORTA I, 1994, PROTEIN ENG, V7, P1231, DOI 10.1093/protein/7.10.1231; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Arshavsky VY, 2002, ANNU REV PHYSIOL, V64, P153, DOI 10.1146/annurev.physiol.64.082701.102229; Berson EL, 2002, INVEST OPHTH VIS SCI, V43, P3027; BERSON EL, 1993, INVEST OPHTH VIS SCI, V34, P1659; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Burns ME, 2001, ANNU REV NEUROSCI, V24, P779, DOI 10.1146/annurev.neuro.24.1.779; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; del Valle LJ, 2003, J BIOL CHEM, V278, P4719, DOI 10.1074/jbc.M210760200; DOI T, 1990, P NATL ACAD SCI USA, V87, P4991, DOI 10.1073/pnas.87.13.4991; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; FAHMY K, 1993, BIOCHEMISTRY-US, V32, P7229, DOI 10.1021/bi00079a020; Farrar GJ, 2002, EMBO J, V21, P857, DOI 10.1093/emboj/21.5.857; FARRENS DL, 1995, J BIOL CHEM, V270, P5073, DOI 10.1074/jbc.270.10.5073; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRETTI L, 1986, P NATL ACAD SCI USA, V83, P599, DOI 10.1073/pnas.83.3.599; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; FRYXELL KJ, 1987, EMBO J, V6, P443, DOI 10.1002/j.1460-2075.1987.tb04774.x; Gales C, 2000, J BIOL CHEM, V275, P17321, DOI 10.1074/jbc.M909801199; Garriga P, 2002, FEBS LETT, V528, P17, DOI 10.1016/S0014-5793(02)03241-6; Garriga P, 1996, P NATL ACAD SCI USA, V93, P4560, DOI 10.1073/pnas.93.10.4560; GARTNER W, 1995, PHOTOCHEM PHOTOBIOL, V62, P1, DOI 10.1111/j.1751-1097.1995.tb05231.x; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Govaerts C, 2001, J BIOL CHEM, V276, P22991, DOI 10.1074/jbc.M102244200; Gripentrog JM, 2000, BIOCHEM J, V352, P399, DOI 10.1042/0264-6021:3520399; Han M, 1998, BIOCHEMISTRY-US, V37, P8253, DOI 10.1021/bi980147r; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; Heck M, 2003, J BIOL CHEM, V278, P3162, DOI 10.1074/jbc.M209675200; HICKS D, 1986, EXP EYE RES, V42, P55, DOI 10.1016/0014-4835(86)90017-5; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; JAGER F, 1994, BIOCHEMISTRY-US, V33, P7389; Janz JM, 2003, J BIOL CHEM, V278, P16982, DOI 10.1074/jbc.M210567200; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Liu X, 1996, P NATL ACAD SCI USA, V93, P4554, DOI 10.1073/pnas.93.10.4554; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; MACKE JP, 1993, AM J HUM GENET, V53, P80; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Miura S, 2003, J BIOL CHEM, V278, P3720, DOI 10.1074/jbc.M211338200; Miura S, 2002, J BIOL CHEM, V277, P24299, DOI 10.1074/jbc.M202743200; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Prioleau C, 2002, J BIOL CHEM, V277, P36577, DOI 10.1074/jbc.M206223200; Ramon E, 2003, J BIOL CHEM, V278, P6427, DOI 10.1074/jbc.M210929200; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; Sakmar TP, 2002, ANNU REV BIOPH BIOM, V31, P443, DOI 10.1146/annurev.biophys.31.082901.134348; SAKMAR TP, 1991, P NATL ACAD SCI USA, V88, P3079, DOI 10.1073/pnas.88.8.3079; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; TING TD, 1993, METH NEUROSCI, V15, P180; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501	61	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20203	20209		10.1074/jbc.M301319200	http://dx.doi.org/10.1074/jbc.M301319200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660238	hybrid			2022-12-27	WOS:000183078000081
J	Paul, S; Planque, S; Zhou, YX; Taguchi, H; Bhatia, G; Karle, S; Hanson, C; Nishiyama, Y				Paul, S; Planque, S; Zhou, YX; Taguchi, H; Bhatia, G; Karle, S; Hanson, C; Nishiyama, Y			Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODIES; LIGHT-CHAIN; PROTEOLYTIC ANTIBODIES; SITE; MECHANISM; BINDING; NEUTRALIZATION; HYDROLYSIS; RECEPTOR; DOMAIN	We report the results of efforts to strengthen and direct the natural nucleophilic activity of antibodies (Abs) for the purpose of specific cleavage of the human immunodeficiency virus-1 coat protein gp120. Phosphonate diester groups previously reported to form a covalent bond with the active site nucleophile of serine proteases ( Paul, S., Tramontano, A., Gololobov, G., Zhou, Y. X., Taguchi, H., Karle, S., Nishiyama, Y., Planque, S., and George, S. ( 2001) J. Biol. Chem. 276, 28314 - 28320) were placed on Lys side chains of gp120. Seven monoclonal Abs raised by immunization with the covalently reactive analog of gp120 displayed irreversible binding to this compound ( binding resistant to dissociation with the denaturant SDS). Catalytic cleavage of biotinylated gp120 by three monoclonal antibodies was observed. No cleavage of albumin and the extracellular domain of the epidermal growth factor receptor was detected. Cleavage of model peptide substrates occurred on the C- terminal side of basic amino acids, and K-m for this reaction was similar to200-fold greater than that for gp120 cleavage, indicating Ab specialization for the gp120 substrate. A hapten phosphonate diester devoid of gp120 inhibited the catalytic activity with exceptional potency, confirming that the reaction proceeds via a serine protease mechanism. Irreversible binding of the hapten phosphonate diester by polyclonal IgG from mice immunized with gp120 covalently reactive analog was increased compared with similar preparations from animals immunized with control gp120, indicating induction of Ab nucleophilicity. These findings suggest the feasibility of raising antigen-specific proteolytic antibodies on demand by covalent immunization.	Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, Houston, TX 77030 USA; Calif Dept Hlth Serv, Viral & Rickettsial Dis Lab, Richmond, CA 94804 USA	University of Texas System; California Department of Health Care Services	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, Chem Immunol Res Ctr, MSB 2-250,6431 Fannin, Houston, TX 77030 USA.				NIAID NIH HHS [AI31268, AI46029] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI046029, R01AI031268, R21AI031268] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bangale Y, 2003, FASEB J, V17, P628, DOI 10.1096/fj.02-0475com; Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BRADEN BC, 1995, FASEB J, V1, P9; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; GREEN NM, 1965, BIOCHEM J, V94, P23; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; KALAGA R, 1995, J IMMUNOL, V155, P2695; Karle S, 2003, VACCINE, V21, P1213, DOI 10.1016/S0264-410X(02)00504-2; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Lefevre S, 2001, FEBS LETT, V489, P25, DOI 10.1016/S0014-5793(01)02075-0; Moore J, 1997, AIDS RES HUM RETROV, V13, P733, DOI 10.1089/aid.1997.13.733; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; NODA Y, 1994, BIOPOLYMERS, V34, P217, DOI 10.1002/bip.360340208; Nossal GJV, 2002, IMMUNOL REV, V185, P15, DOI 10.1034/j.1600-065X.2002.18503.x; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; Paul S, 1996, MOL BIOTECHNOL, V5, P197, DOI 10.1007/BF02900358; PAUL S, 1990, J BIOL CHEM, V265, P11910; POLLACK SJ, 1989, J AM CHEM SOC, V111, P5961, DOI 10.1021/ja00197a078; RAO G, 1991, J PROTEIN CHEM, V10, P117, DOI 10.1007/BF01024661; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Sun JL, 2001, J IMMUNOL, V167, P5775, DOI 10.4049/jimmunol.167.10.5775; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Taguchi H, 2002, BIOORG MED CHEM LETT, V12, P3167, DOI 10.1016/S0960-894X(02)00640-6; TAWFIK DS, 1995, P NATL ACAD SCI USA, V92, P2145, DOI 10.1073/pnas.92.6.2145; TRAMONTANO A, 1986, P NATL ACAD SCI USA, V83, P6736, DOI 10.1073/pnas.83.18.6736; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	36	55	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20429	20435		10.1074/jbc.M300870200	http://dx.doi.org/10.1074/jbc.M300870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665517	hybrid			2022-12-27	WOS:000183078000109
J	Rahman, MM; Miyamoto, H; Takatera, H; Yeh, SY; Altuwaijri, S; Chang, CS				Rahman, MM; Miyamoto, H; Takatera, H; Yeh, SY; Altuwaijri, S; Chang, CS			Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COACTIVATOR; HORMONE; BLOCKADE; CLONING; LIGAND; GENE; TRANSACTIVATION; CASTRATION; INDUCTION; CARCINOMA	Although the progression of prostate cancer initially is dependent on androgens, tumor progression to an androgen-independent growth eventually occurs in most of patients treated with androgen ablation and/or antiandrogen therapy. After the initial response, antiandrogens lose their efficacy and eventually act as agonists to promote androgen receptor (AR)-mediated growth of prostate cancer cells. An aberrant regulation of AR activity, presumably by AR coregulators, may contribute to this acquired agonist activity of antiandrogens. Using an in vitro mutagenesis and a double-negative selection in yeast two-hybrid screening, we have identified a dominant-negative AR coregulator ARA70 (dARA70N), which can inhibit AR transcriptional activity by inactivating the normal function of ARA70 in the LNCaP cells. Whereas ARA70 in oligomeric form interacts with AR and enhances its transcriptional activity, dARA70N lacks AR interaction and might retain the ability to form a non-functional heteromer with ARA70 and interrupt AR transcriptional activity without a change in AR protein itself. The addition of dARA70N reduces the agonist activity and rescues the normal function of antiandrogens in prostate cancer cells. RNA-interference-mediated silencing of ARA70 gene further confirms these observations. Taken together, these findings indicate that ARA70 may contribute to the acquired agonist activity of antiandrogens and plays an important role in making prostate cancer cells resistant to androgen ablation and/or antiandrogen therapy. ARA70 may, thus, be a critical target for developing therapeutic agents against AR-mediated progression of prostate cancer.	Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Ctr Canc, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Chang, CS (corresponding author), Univ Rochester, Med Ctr, Dept Biochem, George Whipple Lab Canc Res, Rochester, NY 14642 USA.	Chang@urmc.rochester.edu		Chang, Chawnshang/0000-0001-8510-3516; Miyamoto, Hiroshi/0000-0001-7610-7769	NCI NIH HHS [CA-71570] Funding Source: Medline; NIDDK NIH HHS [DK-60905] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060905] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGOULNIK I, 2000, KEYST S NUCL REC STE, P116; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Culig Z, 1999, BRIT J CANCER, V81, P242, DOI 10.1038/sj.bjc.6690684; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Dalesio O, 2000, LANCET, V355, P1491; Denis LJ, 2000, SEMIN SURG ONCOL, V18, P52, DOI 10.1002/(SICI)1098-2388(200001/02)18:1<52::AID-SSU8>3.0.CO;2-6; DOPALBHAI K, 2003, J BIOL CHEM, V278, P8118; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Gao TS, 1999, MOL ENDOCRINOL, V13, P1645, DOI 10.1210/me.13.10.1645; Goktas S, 1999, SEMIN ONCOL, V26, P162; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Han GZ, 2001, J BIOL CHEM, V276, P11204, DOI 10.1074/jbc.M008207200; Hecker A, 2003, FEBS LETT, V535, P49, DOI 10.1016/S0014-5793(02)03856-5; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; Kang HY, 1999, J BIOL CHEM, V274, P8570, DOI 10.1074/jbc.274.13.8570; Kelly WK, 1998, EUR UROL, V34, P18, DOI 10.1159/000052292; KELLY WK, 1993, J CLIN ONCOL, V11, P607, DOI 10.1200/JCO.1993.11.4.607; LABRIE F, 1993, CLIN INVEST MED, V16, P475; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P11083, DOI 10.1073/pnas.95.19.11083; Miyamoto H, 2002, J BIOL CHEM, V277, P4609, DOI 10.1074/jbc.M108312200; Miyamoto H, 1998, P NATL ACAD SCI USA, V95, P7379, DOI 10.1073/pnas.95.13.7379; Miyamoto H, 2000, INT J UROL, V7, P32; Palmberg C, 1999, EUR UROL, V36, P191, DOI 10.1159/000067996; Schellhammer PF, 1996, UROLOGY, V47, P622, DOI 10.1016/S0090-4295(96)00002-7; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Truica CI, 2000, CANCER RES, V60, P4709; WESTIN P, 1995, AM J PATHOL, V146, P1368; YEH S, 1999, LANCET, V349, P852; Yeh Shuyuan, 1999, Keio Journal of Medicine, V48, P87; Yeh SY, 1999, ENDOCRINE, V11, P195, DOI 10.1385/ENDO:11:2:195; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zhou ZX, 2002, MOL ENDOCRINOL, V16, P287, DOI 10.1210/me.16.2.287	39	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19619	19626		10.1074/jbc.M210941200	http://dx.doi.org/10.1074/jbc.M210941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649293	hybrid			2022-12-27	WOS:000183078000009
J	Young, JI; Sedivy, JM; Smith, JR				Young, JI; Sedivy, JM; Smith, JR			Telomerase expression in normal human fibroblasts stabilizes DNA 5-methylcytosine transferase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLTRANSFERASE INHIBITION; CELL-CYCLE; TRANSFORMATION; METHYLATION; SENESCENCE; IMMORTALIZATION; TUMORIGENESIS; MAINTENANCE; ANTISENSE; GENE	The finite proliferative potential of normal human fibroblasts can be overcome, a process commonly called immortalization, by the introduction of the catalytic subunit of human telomerase. In contrast to malignant transformation, the pattern of gene expression remains largely unmodified in telomerase-induced immortalization. Here we show evidence that suggests that the maintenance of a "young" pattern of gene expression by telomerization is mediated, at least in part, by a novel function of human telomerase that involves regulation of DNA methyltransferase I gene expression.	Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Brown Univ, Dept Biochem Mol Biol & Cell Biol, Providence, RI 02912 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Brown University	Young, JI (corresponding author), Baylor Coll Med, Roy M & Phyllis Gough Huffington Ctr Aging, Houston, TX 77030 USA.				NIA NIH HHS [AG13663] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG013663] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS RLP, 1979, BIOCHIM BIOPHYS ACTA, V561, P345, DOI 10.1016/0005-2787(79)90143-6; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; Giles KM, 2003, J BIOL CHEM, V278, P2937, DOI 10.1074/jbc.M208439200; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HOALVANHELDEN EG, 1989, MUTAT RES, V219, P263, DOI 10.1016/0921-8734(89)90027-1; HOLLIDAY R, 1986, EXP CELL RES, V166, P543, DOI 10.1016/0014-4827(86)90499-4; HOLLIDAY R, 2001, STEM CELL BIOL; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; MACLEOD AR, 1995, J BIOL CHEM, V270, P8037, DOI 10.1074/jbc.270.14.8037; Milutinovic S, 2000, J BIOL CHEM, V275, P6353, DOI 10.1074/jbc.275.9.6353; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Ramchandani S, 1997, P NATL ACAD SCI USA, V94, P684, DOI 10.1073/pnas.94.2.684; ROULEAU J, 1995, J BIOL CHEM, V270, P1595, DOI 10.1074/jbc.270.4.1595; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; VERTINO PM, 1994, CELL GROWTH DIFFER, V5, P1395; Wei S, 1999, CANCER RES, V59, P1539; WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891; Young JI, 2001, J BIOL CHEM, V276, P19610, DOI 10.1074/jbc.M009470200	29	55	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19904	19908		10.1074/jbc.M301685200	http://dx.doi.org/10.1074/jbc.M301685200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665523	hybrid			2022-12-27	WOS:000183078000044
J	Grimshaw, JPA; Jelesarov, I; Siegenthaler, RK; Christen, P				Grimshaw, JPA; Jelesarov, I; Siegenthaler, RK; Christen, P			Thermosensor action of GrpE - The DnaK chaperone system at heat shock temperatures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; PROTEIN; HSP70; RECEPTOR; BINDING; CYCLE; CHANNEL; GENE	Temperature directly controls functional properties of the DnaK/DnaJ/GrpE chaperone system. The rate of the high to low affinity conversion of DnaK shows a non-Arrhenius temperature dependence and above similar to40 degreesC even decreases. In the same temperature range, the ADP/ATP exchange factor GrpE undergoes an extensive, fully reversible thermal transition (Grimshaw, J. P. A., Jelesarov, I., Schonfeld, H. J., and Christen, P. (2001) J. Biol. Chem. 276, 6098-6104). To show that this transition underlies the thermal regulation of the chaperone system, we introduced an intersubunit disulfide bond into the paired long helices of the GrpE dimer. The transition was absent in disulfide-linked GrpE R40C but was restored by reduction. With disulfide-stabilized GrpE, the rate of ADP/ATP exchange and conversion of DnaK from its ADP-liganded high affinity R state to the ATP-liganded low affinity T state continuously increased with increasing temperature. With reduced GrpE R40C, the conversion became slower at temperatures >40 degreesC, as observed with wild-type GrpE. Thus, the long helix pair in the GrpE dimer acts as a thermosensor that, by decreasing its ADP/ATP exchange activity, induces a shift of the DnaK.substrate complexes toward the high affinity R state and in this way adapts the DnaK/DnaJ/GrpE system to heat shock conditions.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; CASPERS P, 1994, CELL MOL BIOL, V40, P635; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Gelinas AD, 2002, J MOL BIOL, V323, P131, DOI 10.1016/S0022-2836(02)00915-4; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Groemping Y, 2001, J MOL BIOL, V314, P167, DOI 10.1006/jmbi.2001.5116; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; HARTL FU, 1992, ANNU REV BIOPH BIOM, V21, P293, DOI 10.1146/annurev.bb.21.060192.001453; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; Hurme R, 1997, CELL, V90, P55, DOI 10.1016/S0092-8674(00)80313-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P1334; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Servant P, 2000, P NATL ACAD SCI USA, V97, P3538, DOI 10.1073/pnas.070426197; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	41	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19048	19053		10.1074/jbc.M300924200	http://dx.doi.org/10.1074/jbc.M300924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639955	hybrid			2022-12-27	WOS:000182932200044
J	Jiang, ZH; Tang, H; Havlioglu, N; Zhang, XC; Stamm, S; Yan, RQ; Wu, JY				Jiang, ZH; Tang, H; Havlioglu, N; Zhang, XC; Stamm, S; Yan, RQ; Wu, JY			Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; FAMILIAL FRONTOTEMPORAL DEMENTIA; MULTIPLE SYSTEM TAUOPATHY; SR PROTEINS; MICROTUBULE-BINDING; ALZHEIMERS-DISEASE; PRESENILE-DEMENTIA; PICKS-DISEASE; 5'-SPLICE-SITE SELECTION; MISSENSE MUTATION	Mutations in the human tau gene leading to aberrant splicing have been identified in FTDP-17, an autosomal dominant hereditary neurodegenerative disorder. Molecular mechanisms by which such mutations cause tau aberrant splicing were not understood. We characterized two mutations in exon 10 of the tau gene, N279K and Del280K. Our results revealed an exonic splicing enhancer element located in exon 10. The activity of this AG-rich splicing enhancer was altered by N279K and Del280K mutations. This exonic enhancer element interacts with human Tra2beta protein. The interaction between Tra2beta and the exonic splicing enhancer correlates with the activity of this enhancer element in stimulating splicing. Biochemical studies including in vitro splicing and RNA interference experiments in transfected cells support a role for Tra2beta protein in regulating alternative splicing of human tau gene. Our results implicate the human tau gene as a target gene for the alternative splicing regulator Tra2beta, suggesting that Tra2beta may play a role in aberrant tau exon 10 alternative splicing and in the pathogenesis of tauopathies.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; Pharmacia Corp, Dept Cell & Mol Biol, Kalamazoo, MI 49007 USA	Washington University (WUSTL); Washington University (WUSTL); University of Erlangen Nuremberg; Pfizer	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA.	jwu@molecool.wustl.edu	Tang, Hao/G-9841-2011	Yan, Riqiang/0000-0001-7195-7617	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03, R01 EY014576] Funding Source: Medline; NIA NIH HHS [R01 AG017518] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967, R01 GM53945/AG17518, R01 GM070967-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967, R01GM053945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREADIS A, 1992, BIOCHEMISTRY-US, V31, P10626, DOI 10.1021/bi00158a027; Baker M, 1997, ANN NEUROL, V42, P794, DOI 10.1002/ana.410420516; Beil B, 1997, DNA CELL BIOL, V16, P679, DOI 10.1089/dna.1997.16.679; BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BRANDT R, 1993, J BIOL CHEM, V268, P3414; Bugiani O, 1999, J NEUROPATH EXP NEUR, V58, P667, DOI 10.1097/00005072-199906000-00011; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; CLEVELAND DW, 1977, J MOL BIOL, V116, P227, DOI 10.1016/0022-2836(77)90214-5; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; Cote J, 2001, P NATL ACAD SCI USA, V98, P938, DOI 10.1073/pnas.031564098; D'Souza I, 1999, P NATL ACAD SCI USA, V96, P5598, DOI 10.1073/pnas.96.10.5598; Daoud R, 2002, J NEUROSCI, V22, P5889; Dayanandan R, 1999, FEBS LETT, V446, P228, DOI 10.1016/S0014-5793(99)00222-7; DeTure M, 2000, BRAIN RES, V853, P5, DOI 10.1016/S0006-8993(99)02124-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Dumanchin C, 1998, HUM MOL GENET, V7, P1825, DOI 10.1093/hmg/7.11.1825; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; FU XD, 1995, RNA, V1, P663; Gao QS, 2000, J NEUROCHEM, V74, P490, DOI 10.1046/j.1471-4159.2000.740490.x; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Goode BL, 1997, MOL BIOL CELL, V8, P353, DOI 10.1091/mbc.8.2.353; Goode BL, 2000, J BIOL CHEM, V275, P38182, DOI 10.1074/jbc.M007489200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Grover A, 1999, J BIOL CHEM, V274, P15134, DOI 10.1074/jbc.274.21.15134; Hasegawa M, 1998, FEBS LETT, V437, P207, DOI 10.1016/S0014-5793(98)01217-4; Hasegawa M, 1999, FEBS LETT, V443, P93, DOI 10.1016/S0014-5793(98)01696-2; Hastings ML, 2001, CURR OPIN CELL BIOL, V13, P302, DOI 10.1016/S0955-0674(00)00212-X; Hastings ML, 2001, RNA, V7, P471, DOI 10.1017/S1355838201002552; Hoffman BE, 2000, MOL CELL BIOL, V20, P181, DOI 10.1128/MCB.20.1.181-186.2000; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Iijima M, 1999, NEUROREPORT, V10, P497, DOI 10.1097/00001756-199902250-00010; Iseki E, 2001, ACTA NEUROPATHOL, V102, P285; Jiang ZH, 2000, MOL CELL BIOL, V20, P4036, DOI 10.1128/MCB.20.11.4036-4048.2000; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KANAI Y, 1992, EMBO J, V11, P3953, DOI 10.1002/j.1460-2075.1992.tb05489.x; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; Lapham J, 1997, RNA, V3, P950; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Lippa CF, 2000, ANN NEUROL, V48, P850, DOI 10.1002/1531-8249(200012)48:6<850::AID-ANA5>3.3.CO;2-M; Mandelkow E, 1999, NATURE, V402, P588, DOI 10.1038/45095; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Miyamoto K, 2001, ANN NEUROL, V50, P117, DOI 10.1002/ana.1083; Nacharaju P, 1999, FEBS LETT, V447, P195, DOI 10.1016/S0014-5793(99)00294-X; Neumann M, 2001, ANN NEUROL, V50, P503, DOI 10.1002/ana.1223; NEVE RL, 1986, MOL BRAIN RES, V1, P271, DOI 10.1016/0169-328X(86)90033-1; Pastor P, 2001, ANN NEUROL, V49, P263, DOI 10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K; Poorkaj P, 1998, ANN NEUROL, V43, P815, DOI 10.1002/ana.410430617; Preuss U, 1997, J CELL SCI, V110, P789; Rizzini C, 2000, J NEUROPATH EXP NEUR, V59, P990, DOI 10.1093/jnen/59.11.990; Rizzu P, 1999, AM J HUM GENET, V64, P414, DOI 10.1086/302256; Rosso SM, 2002, ANN NEUROL, V51, P373, DOI 10.1002/ana.10140; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SEIWERT SD, 1993, MOL CELL BIOL, V13, P3135, DOI 10.1128/MCB.13.6.3135; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Spillantini MG, 1998, AM J PATHOL, V153, P1359, DOI 10.1016/S0002-9440(10)65721-5; Spillantini MG, 1997, P NATL ACAD SCI USA, V94, P4113, DOI 10.1073/pnas.94.8.4113; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Spillantini MG, 2000, ANN NEUROL, V48, P939; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Tolnay M, 2000, NEUROPATH APPL NEURO, V26, P368, DOI 10.1046/j.1365-2990.2000.00109.x; Varani L, 2000, NUCLEIC ACIDS RES, V28, P710, DOI 10.1093/nar/28.3.710; WANG J, 1995, RNA, V1, P335; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Yasuda M, 2000, ANN NEUROL, V47, P422, DOI 10.1002/1531-8249(200004)47:4<422::AID-ANA4>3.0.CO;2-G; Yu YT, 1999, METHODS, V18, P13, DOI 10.1006/meth.1999.0752; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363	80	90	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18997	19007		10.1074/jbc.M301800200	http://dx.doi.org/10.1074/jbc.M301800200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649279	Green Accepted, hybrid			2022-12-27	WOS:000182932200037
J	Moreau, C; Cartron, PF; Hunt, A; Meflah, K; Green, DR; Evan, G; Vallette, FM; Juin, P				Moreau, C; Cartron, PF; Hunt, A; Meflah, K; Green, DR; Evan, G; Vallette, FM; Juin, P			Minimal BH3 peptides promote cell death by antagonizing anti-apoptotic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; OUTER MITOCHONDRIAL-MEMBRANE; SMALL-MOLECULE INHIBITORS; BCL-2 FAMILY MEMBERS; INTRACELLULAR-LOCALIZATION; CONFORMATIONAL CHANGE; BAX OLIGOMERIZATION; INDUCE APOPTOSIS; X-L; SURVIVAL	The pro-apoptotic "BH3 domain-only" proteins of the Bcl-2 family ( e. g. Bid and Bad) transduce multiple death signals to the mitochondrion. They interact with the anti-apoptotic Bcl-2 family members and induce apoptosis by a mechanism that requires the presence of at least one of the multidomain pro-apoptotic proteins Bax or Bak. Although the BH3 domain of Bid can promote the pro-apoptotic assembly and function of Bax/Bak by itself, other BH3 domains do not function as such. The latter point raises the question of whether, and how, these BH3 domains induce apoptosis. We show here that a peptide comprising the minimal BH3 domain from Bax induces apoptosis but is unable to stimulate the apoptotic activity of microinjected recombinant Bax. This relies on the inability of the peptide to directly induce Bax translocation to mitochondria or a change in its conformation. This peptide nevertheless interferes with Bax/Bcl-xL interactions in vitro and stimulates the apoptotic activity of Bax when combined with Bcl-xL. Similarly, a peptide derived from the BH3 domain of Bad stimulates Bax activity only in the presence of Bcl-xL. Thus, BH3 domains do not necessarily activate multidomain pro-apoptotic proteins directly but promote apoptosis by releasing active multidomain pro-apoptotic proteins from their anti-apoptotic counterparts.	INSERM, U419, F-44035 Nantes, France; Univ Calif San Francisco, San Francisco Canc Ctr, San Francisco, CA 94123 USA; La Jolla Inst Allergy & Immunol, San Diego, CA 92121 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Francisco; La Jolla Institute for Immunology	Juin, P (corresponding author), INSERM, U419, 9 Quai Moncousu, F-44035 Nantes, France.		Green, Douglas R/N-8083-2018; JUIN, Philippe/Q-1338-2019; Vallette, Francois M/K-9047-2015; JUIN, Philippe P/H-3636-2014; Cartron, Pierre Francois/K-9802-2015; Vallette, Francois/N-2361-2018	Green, Douglas R/0000-0002-7332-1417; JUIN, Philippe/0000-0002-4997-3888; Vallette, Francois M/0000-0002-3296-8572; JUIN, Philippe P/0000-0002-4997-3888; Cartron, Pierre-Francois/0000-0002-3393-784X; Vallette, Francois/0000-0003-0802-0519				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Cartron PF, 2002, FEBS LETT, V512, P95, DOI 10.1016/S0014-5793(02)02227-5; Cartron PF, 2002, HUM MOL GENET, V11, P675, DOI 10.1093/hmg/11.6.675; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degterev A, 2001, J CELL BIOL, V155, P695, DOI 10.1083/jcb.200110147; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finnegan NM, 2001, BRIT J CANCER, V85, P115, DOI 10.1054/bjoc.2001.1850; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hunt A, 2001, SCIENCE, V293, P1784, DOI 10.1126/science.1065206; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nomura M, 1999, CANCER RES, V59, P5542; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Ruffolo SC, 2000, CELL DEATH DIFFER, V7, P1101, DOI 10.1038/sj.cdd.4400739; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Shangary S, 2002, BIOCHEMISTRY-US, V41, P9485, DOI 10.1021/bi025605h; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Terradillos O, 2002, FEBS LETT, V522, P29, DOI 10.1016/S0014-5793(02)02871-5; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; von Ahsen O, 2000, J CELL BIOL, V150, P1027, DOI 10.1083/jcb.150.5.1027; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	47	74	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19426	19435		10.1074/jbc.M209472200	http://dx.doi.org/10.1074/jbc.M209472200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642586	hybrid			2022-12-27	WOS:000182932200091
J	Stolz, J; Vielreicher, M				Stolz, J; Vielreicher, M			Tpn1p, the plasma membrane vitamin B-6 transporter of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE-CYTOSINE PERMEASE; GENE FAMILIES; YEAST; BIOSYNTHESIS; PYRIDOXINE; PROTEIN; SEQUENCE; RESISTANCE; EXPRESSION; GENOME	Pyridoxine (PN) is a metabolic precursor of pyridoxal phosphate that functions as a cofactor of many enzymes in amino acid metabolism. PN, pyridoxal, and pyridoxamine are collectively referred to as vitamin B-6, and mammalian organisms depend on its uptake from the diet. In addition to the ability to use extracellular vitamin B-6, most unicellular organisms are also capable of synthesizing PN to generate pyridoxal phosphate. Here, we report the isolation of Saccharomyces cerevisiae mutants that have lost the ability to transport PN across the plasma membrane. We used these mutants to isolate TPN1, the first known gene encoding a transport protein for vitamin B-6. Tpn1p is a member of the purine-cytosine permease family within the major facilitator superfamily. The protein functions as a proton symporter, localizes to the plasma membrane, and has high affinity for PN. TPN1 mutants lost the ability to utilize extracellular PN, pyridoxal, and pyridoxamine, showing that there is no other transporter for vitamin B-6 encoded in the genome. Amino acid substitutions that led to a loss of Tpn1p function localized to transmembrane domain 4 within the 12-transmembrane domain protein. Moreover, expression of TPN1 was regulated and increased with decreasing concentrations of vitamin B-6 in the medium. We also provide evidence that of the highly conserved SNZ and SNO genes in S. cerevisiae, only the protein encoded by SNZ1 is required for vitamin B-6 biosynthesis.	Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, D-93040 Regensburg, Germany	University of Regensburg	Stolz, J (corresponding author), Univ Regensburg, Lehrstuhl Zellbiol & Pflanzenphysiol, Univ St 31, D-93040 Regensburg, Germany.	juergen.stolz@biologie.uni-regensburg.de	Vielreicher, Martin/L-1768-2013	Vielreicher, Martin/0000-0002-7515-1431				ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ball Maria M., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P347; Bean LE, 2001, GENETICS, V157, P1067; Bilski P, 2000, PHOTOCHEM PHOTOBIOL, V71, P129, DOI 10.1562/0031-8655(2000)071&lt;0129:SIPVBP&gt;2.0.CO;2; BOWMAN BB, 1990, ANN NY ACAD SCI, V585, P106, DOI 10.1111/j.1749-6632.1990.tb28046.x; Braun EL, 1996, J BACTERIOL, V178, P6865, DOI 10.1128/jb.178.23.6865-6872.1996; BRETHES D, 1992, EUR J BIOCHEM, V210, P785, DOI 10.1111/j.1432-1033.1992.tb17481.x; Casaregola S, 2001, INT J SYST EVOL MICR, V51, P1607, DOI 10.1099/00207713-51-4-1607; CHEVALLIER MR, 1975, J BACTERIOL, V122, P629, DOI 10.1128/JB.122.2.629-641.1975; DEMPSEY WB, 1987, ESCHERICHIA COLI SAL, V1, P539; Drewke C, 2001, VITAM HORM, V61, P121; Eddy AA, 1996, MICROBIOL-UK, V142, P449, DOI 10.1099/13500872-142-3-449; Ehrenshaft M, 1998, MOL CELL, V1, P603, DOI 10.1016/S1097-2765(00)80060-X; Ehrenshaft M, 1999, P NATL ACAD SCI USA, V96, P9374, DOI 10.1073/pnas.96.16.9374; Ehrenshaft M, 1999, CURR GENET, V34, P478, DOI 10.1007/s002940050423; Ehrenshaft M, 2001, J BACTERIOL, V183, P3383, DOI 10.1128/JB.183.11.3383-3390.2001; Galperin MY, 1997, MOL MICROBIOL, V24, P443, DOI 10.1046/j.1365-2958.1997.3671706.x; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; Henderson PJF, 1993, CURR OPIN CELL BIOL, V5, P708, DOI 10.1016/0955-0674(93)90144-F; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; Kucharczyk R, 1998, FEBS LETT, V424, P127, DOI 10.1016/S0014-5793(98)00153-7; MIDDLETON HM, 1977, J NUTR, V107, P126, DOI 10.1093/jn/107.1.126; Mittenhuber G, 2001, J MOL MICROB BIOTECH, V3, P1; Natarajan K, 2001, MOL CELL BIOL, V21, P4347, DOI 10.1128/MCB.21.13.4347-4368.2001; Nelissen B, 1997, FEMS MICROBIOL REV, V21, P113, DOI 10.1111/j.1574-6976.1997.tb00347.x; Osmani AH, 1999, J BIOL CHEM, V274, P23565, DOI 10.1074/jbc.274.33.23565; Padilla PA, 1998, J BACTERIOL, V180, P5718, DOI 10.1128/JB.180.21.5718-5726.1998; POLAK A, 1973, EUR J BIOCHEM, V32, P276, DOI 10.1111/j.1432-1033.1973.tb02608.x; REICHERT U, 1974, BIOCHIM BIOPHYS ACTA, V356, P108, DOI 10.1016/0005-2736(74)90298-3; Rodriguez-Navarro S, 2002, YEAST, V19, P1261, DOI 10.1002/yea.916; Said HM, 2002, AM J PHYSIOL-RENAL, V282, pF465, DOI 10.1152/ajprenal.00267.2001; SHANE B, 1976, J BIOL CHEM, V251, P1042; Stolz J, 2003, YEAST, V20, P221, DOI 10.1002/yea.959; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WEBER E, 1990, MOL MICROBIOL, V4, P585, DOI 10.1111/j.1365-2958.1990.tb00627.x; Yagi T, 1996, BIOSCI BIOTECH BIOCH, V60, P893, DOI 10.1271/bbb.60.893	43	59	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18990	18996		10.1074/jbc.M300949200	http://dx.doi.org/10.1074/jbc.M300949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649274	hybrid			2022-12-27	WOS:000182932200036
J	Chang, DW; Ditsworth, D; Liu, HT; Srinivasula, SM; Alnemri, ES; Yang, XL				Chang, DW; Ditsworth, D; Liu, HT; Srinivasula, SM; Alnemri, ES; Yang, XL			Oligomerization is a general mechanism for the activation of apoptosis initiator and inflammatory procaspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE; CYTOCHROME-C; CASPASE-2; APAF-1	Proteolytic activation of initiator procaspases is a crucial step in the cellular commitment to apoptosis. Alternative models have been postulated for the activation mechanism, namely the oligomerization or induced proximity model and the allosteric regulation model. While the former holds that procaspases become activated upon proper oligomerization by an adaptor protein, the latter states that the adaptor is an allosteric regulator for procaspases. The allosteric regulation model has been applied for the activation of procaspase-9 by apoptotic protease-activating factor (Apaf-1) in an oligomeric complex known as the apoptosome. Using approaches that allow for controlled oligomerization, we show here that aggregation of multiple procaspase-9 molecules can induce their activation independent of the apoptosome. Oligomerization-induced procaspase-9 activation, both within the apoptosome and in artificial systems, requires stable homophilic association of the protease domains, raising the possibility that the function of Apaf-1 is not only to oligomerize procaspase-9 but also to maintain the interaction of the caspase-9 protease domain after processing. In addition, we provide biochemical evidence that other apoptosis initiator caspases (caspase-2 and -10) as well as a procaspase involved in inflammation (murine caspase-11) are also activated by oligomerization. Thus, oligomerization of precursor molecules appears to be a general mechanism for the activation of both apoptosis initiator and inflammatory procaspases.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Jefferson University; Jefferson University	Yang, XL (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.	xyang@mail.med.upenn.edu	Alnemri, Emad S/B-4526-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline; NIGMS NIH HHS [GM60911] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang XD, 2001, GENE DEV, V15, P2922; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1998, SCIENCE, V281, P1355, DOI 10.1126/science.281.5381.1355; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	28	54	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16466	16469		10.1074/jbc.C300089200	http://dx.doi.org/10.1074/jbc.C300089200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637514	hybrid			2022-12-27	WOS:000182818600003
J	Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF				Koc, A; Wheeler, LJ; Mathews, CK; Merrill, GF			Replication-independent MCB gene induction and deoxyribonucleotide accumulation at G(1)/S in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; DNA-BINDING ACTIVITY; S-PHASE; RIBONUCLEOTIDE REDUCTASE; DEPENDENT TRANSCRIPTION; BUDDING YEAST; THIOREDOXIN; PROTEIN; AP-1; IDENTIFICATION	In Saccharomyces cerevisiae, many genes encoding enzymes involved in deoxyribonucleotide synthesis are expressed preferentially near the G(1)/S boundary of the! cell cycle. The relationship between the induction of deoxyribonucleotide-synthesizing genes, deoxyribonucleoside triphosphate levels, and replication initiation was investigated using a factor-synchronized wildtype yeast or dbf4 yeast that are temperature-sensitive for replication initiation. Neither the timing nor extent of gene induction was inhibited when a factor-arrested dbf4 cells were released into medium containing the ribonucleotide reductase inhibitor hydroxyurea, which blocks replication fork progression, or were released at 37 degreesC, which blocks replication origin firing. Thus, the induction of deoxyribonucleotide-synthesizing genes at G(1)/S was fully independent of DNA chain elongation or initiation. Deoxyribonucleoside triphosphate levels increased severalfold at G(1)/S in wild-type cells and in,dbf4 mutants incubated at the non-permissive temperature. Thus, deoxyribonucleoside triphosphate accumulation, like the induction of deoxyribonucleotide-synthesizing genes, was not dependent on replication initiation. Deoxyribonucleoside triphosphate accumulation at G(1)/S was suppressed in cells lacking Swi6, a transcription factor required for normal cell cycle regulation of deoxyribonucleotide-synthesizing genes. The results suggest that cells use gene induction at G(1)/S as a mechanism to pre-emptively, rather than reflexively, increase the synthesis of DNA precursors to meet the demand of the replication forks for deoxyribonucleotides.	Oregon State Univ, Genet Program, Corvallis, OR 97331 USA; Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University; Oregon State University	Merrill, GF (corresponding author), Oregon State Univ, Genet Program, Corvallis, OR 97331 USA.		KOÇ, AHMET/ABI-3322-2020	KOÇ, AHMET/0000-0003-3484-2137	NATIONAL CANCER INSTITUTE [R01CA082633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000210] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER; NCI NIH HHS [CA82633] Funding Source: Medline; NIEHS NIH HHS [ES00210] Funding Source: Medline; NIGMS NIH HHS [GM55134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BJURSELL KG, 1972, EUR J BIOCHEM, V29, P348, DOI 10.1111/j.1432-1033.1972.tb01995.x; CHAPMAN JW, 1989, EXP CELL RES, V180, P419, DOI 10.1016/0014-4827(89)90068-2; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOSTER R, 1993, MOL CELL BIOL, V13, P3792, DOI 10.1128/MCB.13.6.3792; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEREFORD LM, 1981, CELL, V24, P367, DOI 10.1016/0092-8674(81)90326-3; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; JOHNSTON LH, 1982, MOL GEN GENET, V186, P445, DOI 10.1007/BF00729467; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; KOHALMI SE, 1991, J MOL BIOL, V220, P933, DOI 10.1016/0022-2836(91)90364-C; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; MULLER EGD, 1994, J BIOL CHEM, V269, P24466; NORDENSKJOLD BA, 1970, J BIOL CHEM, V245, P5360; NORTH TW, 1980, J BIOL CHEM, V255, P6640; Partridge JF, 1997, J BIOL CHEM, V272, P9071; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHMIDT EE, 1989, J BIOL CHEM, V264, P21247; Sclafani RA, 2000, J CELL SCI, V113, P2111; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x	34	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9345	9352		10.1074/jbc.M213013200	http://dx.doi.org/10.1074/jbc.M213013200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643263	hybrid			2022-12-27	WOS:000181524000062
J	Seong, HA; Kim, KT; Ha, H				Seong, HA; Kim, KT; Ha, H			Enhancement of B-MYB transcriptional activity by ZPR9, a novel zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; NECROSIS-FACTOR RECEPTOR; RETINOIC ACID RECEPTOR; C-MYB; A-MYB; CYTOPLASMIC DOMAIN; LEUCINE-ZIPPER; FACTOR FAMILY; GENE-PRODUCT; TRANSACTIVATION	By using the yeast two-hybrid system, the zinc finger protein ZPR9 was identified as one of the B-MYB interacting proteins that associates with the carboxyl-terminal conserved region of B-MYB. ZPR9 was found to form in vivo complexes with B-MYB, as demonstrated by in vivo binding assay and coimmunoprecipitation experiments of the endogenously and exogenously expressed proteins. Deletion analysis revealed that this binding was mediated by all three functional domains, an amino-terminal DNA-binding domain, a transactivation domain, and a carboxyl-terminal conserved region of B-MYB. We show that the interaction of ZPR9 with B-MYB is functional because cotransfection of ZPR9 significantly up-regulates B-MYB transcriptional activity in a dose-dependent manner. In addition, coexpression of ZPR9 with B-MYB caused the accumulation of B-MYB, as well as ZPR9, in the nucleus. Furthermore, constitutive expression of ZPR9 in human neuroblastoma cells induces apoptosis in the presence of retinoic acid. These results strongly suggest that ZPR9 plays an important role in modulation of the transactivation by B-MYB and cellular growth of neuroblastoma cells.	Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea	Chungbuk National University; Pohang University of Science & Technology (POSTECH)	Ha, H (corresponding author), Chungbuk Natl Univ, Sch Life Sci, Dept Biochem, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea.	hyunha@cbucc.chungbuk.ac.kr		KIM, KYONG-TAI/0000-0001-7292-2627				Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; FAVIER D, 1994, ONCOGENE, V9, P305; GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797; Gil M, 1998, IMMUNOL LETT, V64, P79, DOI 10.1016/S0165-2478(98)00081-9; GOLAY J, 1991, BLOOD, V77, P149; Gonda TJ, 1996, CURR TOP MICROBIOL, V211, P99; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; Heyer BS, 1997, MOL REPROD DEV, V47, P148, DOI 10.1002/(SICI)1098-2795(199706)47:2&lt;148::AID-MRD4&gt;3.0.CO;2-M; Heyer BS, 1999, DEV DYNAM, V215, P344; HU HM, 1994, J BIOL CHEM, V269, P30069; Ishida T, 1996, P NATL ACAD SCI USA, V93, P9437, DOI 10.1073/pnas.93.18.9437; Jung H, 2001, J BIOL CHEM, V276, P15504, DOI 10.1074/jbc.M009620200; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; Kaspar P, 1999, J BIOL CHEM, V274, P14422, DOI 10.1074/jbc.274.20.14422; Kim T, 1999, FEBS LETT, V460, P363, DOI 10.1016/S0014-5793(99)01375-7; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; Lipsick JS, 1996, ONCOGENE, V13, P223; Melino G, 1997, EXP CELL RES, V235, P55, DOI 10.1006/excr.1997.3656; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pfitzner E, 1998, P NATL ACAD SCI USA, V95, P5539, DOI 10.1073/pnas.95.10.5539; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Seong HA, 2002, BIOCHEM J, V361, P597, DOI 10.1042/0264-6021:3610597; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; WU RY, 1994, J BIOL CHEM, V269, P25085; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Ying GG, 2000, J BIOL CHEM, V275, P4152, DOI 10.1074/jbc.275.6.4152; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	41	34	37	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9655	9662		10.1074/jbc.M207478200	http://dx.doi.org/10.1074/jbc.M207478200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645566	hybrid			2022-12-27	WOS:000181524000103
J	Guo, XC; Gerl, RE; Schrader, JW				Guo, XC; Gerl, RE; Schrader, JW			Defining the involvement of p38 alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TNF-ALPHA PRODUCTION; T-CELLS; CELLULAR STRESSES; SUBSTRATE-SPECIFICITY; SIGNALING PATHWAY; GAMMA EXPRESSION; NITRIC-OXIDE; MAST-CELLS; P38 GROUP	Despite its lack of specificity, the inhibitor SB 203580 has been widely used to implicate p38 mitogen-activated protein kinase ( MAPK) in the synthesis of many cytokines. Here we show unequivocally that the production of interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor alpha (TNFalpha) requires p38 MAPK activity by demonstrating that the inhibitory effects of SB 203580 were reversed by expression of an SB 203580-resistant form of p38alpha (SBR-p38alpha) that fails to bind to SB 203580. This strategy established the requirement for p38 activity for the lipopolysaccharide-stimulated production of IL-10, IL-1beta, and IL-6 by the monocytic cell WEHI 274 and the production of IL-6 and TNFalpha stimulated by ligation of the Fc-gamma receptor of the mast cell MC/9. Expression of SBR-p38alpha) in primary macrophages abrogated the ability of SB 203580 to inhibit the lipopolysaccharide-stimulated production of TNFalpha but not of IL-10. Expression of SBR-p38alpha in primary T lymphocytes abrogated the ability of SB 203580 to inhibit the production of interferon-gamma induced by co-ligation of CD3 and CD28 but not the production of interferon-gamma or IL-10 induced by IL-12. These results suggest that the levels of p38 MAPK activity required for maximal cytokine production vary with different cytokines and stimuli.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.							Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Feng GJ, 1999, J IMMUNOL, V163, P6403; Fernandez E, 2000, BLOOD, V95, P1356, DOI 10.1182/blood.V95.4.1356.004k23_1356_1361; Foey AD, 1998, J IMMUNOL, V160, P920; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Graves JD, 1996, P NATL ACAD SCI USA, V93, P13814, DOI 10.1073/pnas.93.24.13814; Guan ZH, 1997, J BIOL CHEM, V272, P8083, DOI 10.1074/jbc.272.12.8083; Gum RJ, 1998, J BIOL CHEM, V273, P15605, DOI 10.1074/jbc.273.25.15605; Hale KK, 1999, J IMMUNOL, V162, P4246; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Ishizuka T, 1998, J IMMUNOL, V161, P3624; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; KUMAR S, 1995, J BIOL CHEM, V270, P29043, DOI 10.1074/jbc.270.49.29043; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Lian JP, 1999, J IMMUNOL, V163, P4527; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rincon M, 1998, EMBO J, V17, P2817, DOI 10.1093/emboj/17.10.2817; Salmon RA, 2001, EUR J IMMUNOL, V31, P3218, DOI 10.1002/1521-4141(200111)31:11<3218::AID-IMMU3218>3.0.CO;2-9; Salmon RA, 1997, J IMMUNOL, V159, P5309; Salojin KV, 1999, J IMMUNOL, V163, P844; Schafer PH, 1999, J IMMUNOL, V162, P659; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; Tamura K, 2000, CELL, V102, P221, DOI 10.1016/S0092-8674(00)00027-1; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; WELHAM MJ, 1992, J IMMUNOL, V149, P2772; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Winston BW, 1997, J IMMUNOL, V159, P4491; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang SM, 2000, J IMMUNOL, V165, P1374, DOI 10.4049/jimmunol.165.3.1374	50	71	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22237	22242		10.1074/jbc.M300847200	http://dx.doi.org/10.1074/jbc.M300847200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12637577	hybrid			2022-12-27	WOS:000183503900009
J	Phillips, C; Gunderson, S				Phillips, C; Gunderson, S			Sequences adjacent to the 5 ' splice site control U1A binding upstream of the IgM heavy chain secretory poly(A) site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL DIFFERENTIATION; TERMINAL RNP DOMAIN; MESSENGER-RNA; PREMESSENGER RNA; HALF-LIFE; STEM-LOOP; PROTEIN; POLYADENYLATION; SPECIFICITY; COMPLEX	We have recently shown that the stability of the alternatively expressed immunoglobulin M heavy chain secretory mRNA is developmentally regulated by U1A. U1A binds novel non-consensus sites upstream of the secretory poly(A) site and inhibits poly(A) tail addition in undifferentiated cells. U1A's dependence for binding and function upon a stem-loop structure has been extensively characterized for the consensus sites. We therefore probed the structure surrounding the novel U1A binding sites. We show that two of the three novel binding sites represent the major single-stranded regions upstream of the secretory poly(A) site, consistent with a major role at this site. The strength of binding and ability of U1A to inhibit poly(A) polymerase correlate with the accessibility of the novel sites. However, long range interactions are responsible for maintaining them in an open configuration. Mutation of an RNase V1-sensitive site 102 nucleotides upstream, directly adjacent to the competing 5' splice site, changes the structure of one the U1A binding sites and thus abolishes the binding of the second U1A molecule and the ability of U1A ability to inhibit poly(A) polymerase activity at this site. These sites bind U1A via its N-terminal domain but with a 10-fold lower affinity than U1 small nuclear RNA. This lower binding affinity is more conducive to U1A's regulation of poly(A) tail addition to heterologous mRNA.	Rutgers State Univ, Nelson Labs, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick	Phillips, C (corresponding author), Rutgers State Univ, Nelson Labs, Rm 322,604 Allison Rd, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allain FHT, 1997, EMBO J, V16, P5764, DOI 10.1093/emboj/16.18.5764; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Beck DL, 1998, RNA, V4, P331; BERBERICH I, 1990, EUR J IMMUNOL, V20, P445, DOI 10.1002/eji.1830200233; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; COX A, 1989, NUCLEIC ACIDS RES, V17, P10439, DOI 10.1093/nar/17.24.10439; EARLY P, 1980, CELL, V20, P313, DOI 10.1016/0092-8674(80)90617-0; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; EdwaldsGilbert G, 1997, NUCLEIC ACIDS RES, V25, P2547, DOI 10.1093/nar/25.13.2547; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Gubser CC, 1996, BIOCHEMISTRY-US, V35, P2253, DOI 10.1021/bi952319f; Gunderson SI, 1997, GENE DEV, V11, P761, DOI 10.1101/gad.11.6.761; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Gunnewiek JMTK, 2000, MOL CELL BIOL, V20, P2209, DOI 10.1128/MCB.20.6.2209-2217.2000; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HALL KB, 1994, BIOCHEMISTRY-US, V33, P10076, DOI 10.1021/bi00199a035; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; Huttenhofer A, 1996, RNA, V2, P354; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MASON JO, 1988, GENE DEV, V2, P1003, DOI 10.1101/gad.2.8.1003; MURTHY KGK, 1995, GENE DEV, V9, P2672, DOI 10.1101/gad.9.21.2672; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAN T, 1992, NATURE, V358, P560, DOI 10.1038/358560a0; Phillips C, 1999, NUCLEIC ACIDS RES, V27, P429, DOI 10.1093/nar/27.2.429; Phillips C, 1997, NUCLEIC ACIDS RES, V25, P2344, DOI 10.1093/nar/25.12.2344; Phillips C, 2001, EMBO J, V20, P6443, DOI 10.1093/emboj/20.22.6443; Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050; Rimmele ME, 1998, RNA, V4, P1386, DOI 10.1017/S1355838298981171; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCOTT GK, 1993, MOL CELL BIOL, V13, P2247, DOI 10.1128/MCB.13.4.2247; STUMP WT, 1995, RNA, V1, P55; Teunissen SWM, 1997, BIOCHEMISTRY-US, V36, P1782, DOI 10.1021/bi9623237; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; Varani L, 2000, NAT STRUCT BIOL, V7, P329; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	39	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22102	22111		10.1074/jbc.M301349200	http://dx.doi.org/10.1074/jbc.M301349200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670951	hybrid			2022-12-27	WOS:000183354200098
J	Zhang, WY; Crocker, E; McLaughlin, S; Smith, SO				Zhang, WY; Crocker, E; McLaughlin, S; Smith, SO			Binding of peptides with basic and aromatic residues to bilayer membranes - Phenylalanine in the myristoylated alanine-rich C kinase substrate effector domain penetrates into the hydrophobic core of the bilayer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; OVERHAUSER ENHANCEMENT SPECTROSCOPY; SPINNING NMR-SPECTROSCOPY; CROSS-RELAXATION RATES; SOLID-STATE NMR; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHOLIPID-VESICLES; ETHANOL DISTRIBUTION; LIPID BILAYERS; FATTY-ACIDS	Electrostatic interactions with positively charged regions of membrane- associated proteins such as myristoylated alanine- rich C kinase substrate ( MARCKS) may have a role in regulating the level of free phosphatidylinositol 4,5- bisphosphate ( PI( 4,5) P-2) in plasma membranes. Both the MARCKS protein and a peptide corresponding to the effector domain ( an unstructured region that contains 13 basic residues and 5 phenylalanines), MARCKS-( 151 - 175), laterally sequester the polyvalent lipid PI( 4,5) P2 in the plane of a bilayer membrane with high affinity. We used high resolution magic angle spinning NMR to establish the location of MARCKS( 151 - 175) in membrane bilayers, which is necessary to understand the sequestration mechanism. Measurements of cross- relaxation rates in two- dimensional nuclear Overhauser enhancement spectroscopy NMR experiments show that the five Phe rings of MARCKS( 151 - 175) penetrate into the acyl chain region of phosphatidylcholine bilayers containing phosphatidylglycerol or PI( 4,5) P-2. Specifically, we observed strong crosspeaks between the aromatic protons of the Phe rings and the acyl chain protons of the lipids, even for very short ( 50 ms) mixing times. The position of the Phe rings implies that the adjacent positively charged amino acids in the peptide are close to the level of the negatively charged lipid phosphates. The deep location of the MARCKS peptide in the polar head group region should enhance its electrostatic sequestration of PI( 4,5) P2 by an " image charge" mechanism. Moreover, this location has interesting implications for membrane curvature and local surface pressure effects and may be relevant to a wide variety of other proteins with basic- aromatic clusters, such as phospholipase D, GAP43, SCAMP2, and the N- methyl- D- aspartate receptor.	SUNY Stony Brook, Dept Biochem & Cell Biol, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Phys & Astron, Ctr Struct Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Physiol & Biophys, Ctr Struct Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Smith, SO (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Ctr Struct Biol, 450 Life Sci Bldg,Z-5115, Stony Brook, NY 11794 USA.	steven.o.smith@sunysb.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046732, R01GM024971, R55GM046732, R37GM024971] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 46732, GM 24971] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1992, BIOCHEMISTRY-US, V31, P5322, DOI 10.1021/bi00138a011; ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Arbuzova A, 2002, BIOCHEM J, V362, P1, DOI 10.1042/0264-6021:3620001; Baldus M, 2002, PROG NUCL MAG RES SP, V41, P1, DOI 10.1016/S0079-6565(02)00007-9; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bouchard M, 1995, BIOPHYS J, V69, P1933, DOI 10.1016/S0006-3495(95)80063-9; Braun P, 1999, BIOCHEMISTRY-US, V38, P9778, DOI 10.1021/bi990923a; Chou JJ, 2002, J AM CHEM SOC, V124, P2450, DOI 10.1021/ja017875d; Contreras LM, 2001, BIOPHYS J, V80, P2273, DOI 10.1016/S0006-3495(01)76199-1; Cremona O, 2001, J CELL SCI, V114, P1041; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Davis JH, 1995, BIOPHYS J, V69, P1917, DOI 10.1016/S0006-3495(95)80062-7; Eilers M, 2002, BIOPHYS J, V82, P2720, DOI 10.1016/S0006-3495(02)75613-0; ELLENA JF, 1985, J AM CHEM SOC, V107, P1530, DOI 10.1021/ja00292a013; Feller SE, 1999, J AM CHEM SOC, V121, P8963, DOI 10.1021/ja991456n; Feller SE, 2002, BIOPHYS J, V82, P1396, DOI 10.1016/S0006-3495(02)75494-5; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Gambhir A, 2003, BIOPHYS J, V84, p131A; Gawrisch K, 2002, CHEM PHYS LIPIDS, V116, P135, DOI 10.1016/S0009-3084(02)00024-5; HILGEMANN DW, 2001, SCI STKE; Holte LL, 1997, BIOCHEMISTRY-US, V36, P4669, DOI 10.1021/bi9626416; Hurley JH, 2002, CELL, V111, P143, DOI 10.1016/S0092-8674(02)01044-9; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Huster D, 1999, J PHYS CHEM B, V103, P243, DOI 10.1021/jp983428h; Huster D, 1999, J AM CHEM SOC, V121, P1992, DOI 10.1021/ja9838413; Huster D, 2002, J AM CHEM SOC, V124, P874, DOI 10.1021/ja017001r; Huster D, 2001, ANGEW CHEM INT EDIT, V40, P1056, DOI 10.1002/1521-3773(20010316)40:6<1056::AID-ANIE10560>3.0.CO;2-7; Irvine R, 2000, SCI STKE, pre1; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; Kumashiro KK, 1998, J AM CHEM SOC, V120, P5043, DOI 10.1021/ja972655e; Levitt M. H., 2001, SPIN DYNAMICS; London E, 2002, CURR TOP MEMBR, V52, P89; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.biophys.18.1.113; MIYAZAKI J, 1992, BIOCHIM BIOPHYS ACTA, V1103, P62, DOI 10.1016/0005-2736(92)90057-S; OLDFIELD E, 1987, BIOCHEMISTRY-US, V26, P6919, DOI 10.1021/bi00396a009; PEITZSCH RM, 1993, BIOCHEMISTRY-US, V32, P10436, DOI 10.1021/bi00090a020; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; Rauch ME, 2002, J BIOL CHEM, V277, P14068, DOI 10.1074/jbc.M109572200; ROUX M, 1988, EUR BIOPHYS J BIOPHY, V16, P267, DOI 10.1007/BF00254062; Sciorra VA, 2002, J CELL BIOL, V159, P1039, DOI 10.1083/jcb.200205056; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; SEELIG J, 1987, BIOCHEMISTRY-US, V26, P7535, DOI 10.1021/bi00398a001; Segrest JP, 2002, CURR TOP MEMBR, V52, P397; SIMON SA, 1982, J PHYS CHEM-US, V86, P1449, DOI 10.1021/j100397a048; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Smith SO, 1996, Q REV BIOPHYS, V29, P395, DOI 10.1017/S0033583500005898; Underhill DM, 1998, J BIOL CHEM, V273, P33619, DOI 10.1074/jbc.273.50.33619; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; Victor K, 1999, BIOCHEMISTRY-US, V38, P12527, DOI 10.1021/bi990847b; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; XU ZC, 1986, BIOPHYS J, V49, P779, DOI 10.1016/S0006-3495(86)83705-5; Yau WM, 1998, BIOCHEMISTRY-US, V37, P14713, DOI 10.1021/bi980809c; YOUNG LRD, 1988, BIOCHEMISTRY-US, V27, P5281	60	104	107	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21459	21466		10.1074/jbc.M301652200	http://dx.doi.org/10.1074/jbc.M301652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670959	hybrid			2022-12-27	WOS:000183354200020
J	Smith, BD; Soellner, MB; Raines, RT				Smith, BD; Soellner, MB; Raines, RT			Potent inhibition of ribonuclease A by oligo(vinylsulfonic acid)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							6-PHOSPHOGLUCONATE DEHYDROGENASE; CRYPTOCOCCUS-NEOFORMANS; SALT CONCENTRATION; CRYSTAL-STRUCTURE; ENZYMES; INACTIVATION; SUBSTRATE; MECHANISM; COMPLEX; ORIGIN	Ribonuclease A (RNase A) can make multiple contacts with an RNA substrate. In particular, the enzymatic active site and adjacent subsites bind sequential phosphoryl groups in the RNA backbone through Coulombic interactions. Here, oligomers of vinylsulfonic acid (OVS) are shown to be potent inhibitors of RNase A that exploit these interactions. Inhibition is competitive with substrate and has K-i = 11 pM in assays at low salt concentration. The effect of salt concentration on inhibition indicates that nearly eight favorable Coulombic interactions occur in the RNase A.OVS complex. The phosphonic acid and sulfuric acid analogs of OVS are also potent inhibitors although slightly less effective. OVS is also shown to be a contaminant of MES and other buffers that contain sulfonylethyl groups. Oligomers greater than nine units in length can be isolated from commercial MES buffer. Inhibition by contaminating OVS is responsible for the apparent decrease in catalytic activity that has been observed in assays of RNase A at low salt concentration. Thus, OVS is both a useful inhibitor of RNase A and a potential bane to chemists and biochemists who use ethanesulfonic acid buffers.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719				ALTHAUS IW, 1992, EXPERIENTIA, V48, P1127, DOI 10.1007/BF01948005; BACH MK, 1964, BIOCHIM BIOPHYS ACTA, V91, P619, DOI 10.1016/0926-6550(64)90010-6; BRESLOW DS, 1954, J AM CHEM SOC, V76, P6399, DOI 10.1021/ja01653a045; CHAMBON P, 1967, BIOCHIM BIOPHYS ACTA, V149, P584, DOI 10.1016/0005-2787(67)90186-4; CHENG TC, 1974, J BIOL CHEM, V249, P1781; Ciglic MI, 1998, BIOCHEMISTRY-US, V37, P4008, DOI 10.1021/bi972203e; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DELROSAR.EJ, 1969, BIOCHEMISTRY-US, V8, P1884, DOI 10.1021/bi00833a017; EDELHOCH H, 1956, J BIOL CHEM, V219, P351; FELLIG J, 1959, ARCH BIOCHEM BIOPHYS, V85, P313, DOI 10.1016/0003-9861(59)90496-5; Fisher BM, 1998, J BIOL CHEM, V273, P34134, DOI 10.1074/jbc.273.51.34134; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; HENDERSON PJ, 1972, BIOCHEM J, V127, P321, DOI 10.1042/bj1270321; HEYMANN H, 1958, ARCH BIOCHEM BIOPHYS, V73, P366, DOI 10.1016/0003-9861(58)90282-0; IRIE M, 1965, J BIOCHEM-TOKYO, V57, P355, DOI 10.1093/oxfordjournals.jbchem.a128089; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; Kim BM, 1999, PROTEIN SCI, V8, P430; KIM JS, 1993, J BIOL CHEM, V268, P17392; Kobe B, 1996, J MOL BIOL, V264, P1028, DOI 10.1006/jmbi.1996.0694; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LIBONATI M, 1992, MOL CELL BIOCHEM, V117, P139; LITTAUER UZ, 1962, BIOCHIM BIOPHYS ACTA, V61, P609, DOI 10.1016/0926-6550(62)90114-7; MACH B, 1968, P NATL ACAD SCI USA, V59, P445, DOI 10.1073/pnas.59.2.445; NELSON CA, 1961, J BIOL CHEM, V236, P3173; Niehaus WG, 1995, ARCH BIOCHEM BIOPHYS, V324, P325, DOI 10.1006/abbi.1995.0045; NIEHAUS WG, 1993, MYCOPATHOLOGIA, V123, P155, DOI 10.1007/BF01111266; Park C, 2000, FEBS LETT, V468, P199, DOI 10.1016/S0014-5793(00)01227-8; Park C, 2003, BIOCHEMISTRY-US, V42, P3509, DOI 10.1021/bi026076k; Park C, 2001, J AM CHEM SOC, V123, P11472, DOI 10.1021/ja0164834; Park C, 2001, METHOD ENZYMOL, V341, P81, DOI 10.1016/S0076-6879(01)41146-3; Raines RT, 1998, CHEM REV, V98, P1045, DOI 10.1021/cr960427h; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RICHARDS FM, 1971, ENZYMES, V4, P647; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; Russo A, 2001, METHOD ENZYMOL, V341, P629, DOI 10.1016/S0076-6879(01)41181-5; Russo N, 1999, J BIOL CHEM, V274, P14902, DOI 10.1074/jbc.274.21.14902; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; SELA M, 1962, J BIOL CHEM, V237, P418; STOWELL JK, 1995, J ORG CHEM, V60, P6930, DOI 10.1021/jo00126a051; UI N, 1971, BIOCHIM BIOPHYS ACTA, V229, P567; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; YAKOVLEV GI, 1992, EUR J BIOCHEM, V204, P187, DOI 10.1111/j.1432-1033.1992.tb16622.x; ZOLLNER N, 1953, AM J PHYSIOL, V173, P223, DOI 10.1152/ajplegacy.1953.173.2.223	46	62	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20934	20938		10.1074/jbc.M301852200	http://dx.doi.org/10.1074/jbc.M301852200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649287	hybrid			2022-12-27	WOS:000183230500064
J	Valgardsdottir, R; Prydz, H				Valgardsdottir, R; Prydz, H			Transport signals and transcription-dependent nuclear localization of the putative DEAD-box helicase MDDX28	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; EXPORT SIGNALS; GENE ENCODES; PROTEIN; MITOCHONDRIAL; TRANSLOCATION; SEQUENCE; DOMAINS; CRM1; INHIBITOR	The human protein MDDX28 is a putative RNA helicase and a nucleocytoplasmic shuttling protein also localized to the mitochondria. Its localization is novel among RNA helicases. We have studied its intracellular targeting signals and show that the first 20 amino acids of MDDX28 are necessary and sufficient for both mitochondrial import and nuclear export of the protein. Mutation of the five leucines in the sequence to alanines abolished the mitochondrial targeting signal as well as greatly reducing the nuclear export signal, indicating that these signal sequences are highly overlapping. Two short stretches of basic amino acids separated by 44 residues were both necessary and sufficient for full nuclear localization. However, they were not absolutely essential, because the protein was present in 7% of the nuclei when both signals were mutated. This indicates that MDDX28 contains another unidentified weak nuclear localization signal(s). Three basic domains in the N-terminal half of the protein and its RNA binding ability were essential for nucleolar localization as well as transcription-inhibition-dependent localization to nuclear subcompartments. Two of these basic domains were the same as those constituting the nuclear localization signal, suggesting that they are responsible for bringing the protein into the nucleus to the sites of RNA binding. Our results indicate that MDDX28 nucleo-cytoplasmic shuttling is dependent on the availability of nascent RNA.	Univ Oslo, Biotechnol Ctr Oslo, N-0349 Oslo, Norway	University of Oslo	Prydz, H (corresponding author), Univ Oslo, Biotechnol Ctr Oslo, Gaustadalleen 21, N-0349 Oslo, Norway.	hans.prydz@biotek.uio.no						Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Askjaer P, 2000, J BIOL CHEM, V275, P11561, DOI 10.1074/jbc.275.16.11561; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; Carmo-Fonseca M, 2002, CELL, V108, P513, DOI 10.1016/S0092-8674(02)00650-5; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Chiodi I, 2000, J CELL SCI, V113, P4043; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; HALL MN, 1990, P NATL ACAD SCI USA, V87, P6954, DOI 10.1073/pnas.87.18.6954; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hock R, 1998, EMBO J, V17, P6992, DOI 10.1093/emboj/17.23.6992; Husberg C, 2001, J BIOL CHEM, V276, P17641, DOI 10.1074/jbc.M007951200; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; Lakshmipathy U, 1999, MOL CELL BIOL, V19, P3869; Le Panse S, 1999, J CELL SCI, V112, P2145; Lithgow T, 2000, FEBS LETT, V476, P22, DOI 10.1016/S0014-5793(00)01663-X; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; Mohr S, 2002, CELL, V109, P769, DOI 10.1016/S0092-8674(02)00771-7; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; Ossareh-Nazari B, 2001, TRAFFIC, V2, P684, DOI 10.1034/j.1600-0854.2001.21002.x; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Schmitt C, 1999, EMBO J, V18, P4332, DOI 10.1093/emboj/18.15.4332; Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052; Shibata K, 2000, GENOME RES, V10, P1757, DOI 10.1101/gr.152600; SHUNU C, 2002, FEBS LETT, V484, P22; SLUSHER LB, 1991, P NATL ACAD SCI USA, V88, P9789, DOI 10.1073/pnas.88.21.9789; STUURMAN N, 1992, J CELL SCI, V101, P773; Sudbeck P, 1997, J BIOL CHEM, V272, P27848, DOI 10.1074/jbc.272.44.27848; Valgardsdottir R, 2001, J BIOL CHEM, V276, P32056, DOI 10.1074/jbc.M011629200; VANDROMME M, 1995, P NATL ACAD SCI USA, V92, P4646, DOI 10.1073/pnas.92.10.4646; Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499; Weil R, 1999, MOL CELL BIOL, V19, P6345; Willer M, 1999, CURR BIOL, V9, P1085, DOI 10.1016/S0960-9822(99)80477-1; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21146	21154		10.1074/jbc.M300888200	http://dx.doi.org/10.1074/jbc.M300888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663657	hybrid			2022-12-27	WOS:000183230500091
J	Ceci, P; Ilari, A; Falvo, E; Chiancone, E				Ceci, P; Ilari, A; Falvo, E; Chiancone, E			The Dps protein of Agrobacterium tumefaciens does not bind to DNA but protects it toward oxidative cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PROTEIN; ESCHERICHIA-COLI; LISTERIA-INNOCUA; STREPTOCOCCUS-MUTANS; HELICOBACTER-PYLORI; IRON; FERRITIN; STRESS; MOLSCRIPT; HOMOLOG	Agrobacterium tumefaciens Dps ( DNA-binding proteins from starved cells), encoded by the dps gene located on the circular chromosome of this plant pathogen, was cloned, and its structural and functional properties were determined in vitro. In Escherichia coli Dps, the family prototype, the DNA binding properties are thought to be associated with the presence of the lysine-containing N-terminal tail that extends from the protein surface into the solvent. The x-ray crystal structure of A. tumefaciens Dps shows that the positively charged N-terminal tail, which is 11 amino acids shorter than in the E. coli protein, is blocked onto the protein surface. This feature accounts for the lack of interaction with DNA. The intersubunit ferroxidase center characteristic of Dps proteins is conserved and confers to the A. tumefaciens protein a ferritin-like activity that manifests itself in the capacity to oxidize and incorporate iron in the internal cavity and to release it after reduction. In turn, sequestration of Fe( II) correlates with the capacity of A. tumefaciens Dps to reduce the production of hydroxyl radicals from H2O2 through Fenton chemistry. These data demonstrate conclusively that DNA protection from oxidative damage in vitro does not require formation of a Dps-DNA complex. In vivo, the hydroxyl radical scavenging activity of A. tumefaciens Dps may be envisaged to act in concert with catalase A to counteract the toxic effect of H2O2, the major component of the plant defense system when challenged by the bacterium.	Univ Roma La Sapienza, Consiglio Nazl, Ric Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Chiancone, E (corresponding author), Univ Roma La Sapienza, Consiglio Nazl, Ric Inst Mol Biol & Pathol, Dept Biochem Sci A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Ilari, Andrea/T-5501-2017	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Falvo, Elisabetta/0000-0001-9584-8669; Ceci, Pierpaolo/0000-0001-7712-8430				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; BOTWELL TH, 1955, BIOCHEM J, V59, P599; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Bruns CM, 1999, J MOL BIOL, V288, P427, DOI 10.1006/jmbi.1999.2697; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; Dukan S, 1999, J BIOL CHEM, V274, P26027, DOI 10.1074/jbc.274.37.26027; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Gupta S, 2002, PROTEIN ENG, V15, P503, DOI 10.1093/protein/15.6.503; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; Ilari A, 2002, J BIOL CHEM, V277, P37619, DOI 10.1074/jbc.M206186200; Ishikawa T, 2003, J BACTERIOL, V185, P1010, DOI 10.1128/JB.185.3.1010-1017.2003; KLEE H, 1987, ANNU REV PLANT PHYS, V38, P467, DOI 10.1146/annurev.pp.38.060187.002343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papinutto E, 2002, J BIOL CHEM, V277, P15093, DOI 10.1074/jbc.M112378200; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Suzuki K, 2001, DNA RES, V8, P141, DOI 10.1093/dnares/8.4.141; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; Wolf SG, 1999, NATURE, V400, P83, DOI 10.1038/21918; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; Xu XQ, 2001, MOL MICROBIOL, V42, P645, DOI 10.1046/j.1365-2958.2001.02653.x; Yamamoto Y, 2000, J BACTERIOL, V182, P3740, DOI 10.1128/JB.182.13.3740-3747.2000; Yamamoto Y, 2002, J BACTERIOL, V184, P2931, DOI 10.1128/JB.184.11.2931-2939.2002; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Zanotti G, 2002, J MOL BIOL, V323, P125, DOI 10.1016/S0022-2836(02)00879-3; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150	35	113	119	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20319	20326		10.1074/jbc.M302114200	http://dx.doi.org/10.1074/jbc.M302114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660233	hybrid			2022-12-27	WOS:000183078000095
J	Fujimoto, Z; Kaneko, S; Momma, M; Kobayashi, H; Mizuno, H				Fujimoto, Z; Kaneko, S; Momma, M; Kobayashi, H; Mizuno, H			Crystal structure of rice alpha-galactosidase complexed with D-galactose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORTIERELLA-VINACEA; CATALYTIC NUCLEOPHILE; SUBSTRATE-SPECIFICITY; GLYCOSIDE HYDROLASES; PURIFICATION; SEQUENCE; CRYSTALLIZATION; CDNA; GALACTOMANNAN; PURPUROGENUM	alpha-Galactosidases catalyze the hydrolysis of alpha-1,6-linked galactosyl residues from galacto-oligosaccharides and polymeric galacto-(gluco) mannans. The crystal structure of rice alpha-galactosidase has been determined at 1.5Angstrom resolution using the multiple isomorphous replacement method. The structure consisted of a catalytic domain and a C-terminal domain and was essentially the same as that of alpha-N-acetylgalactosaminidase, which is the same member of glycosyl hydrolase family 27. The catalytic domain had a (beta/alpha)(8)-barrel structure, and the C-terminal domain was made up of eight beta-strands containing a Greek key motif. The structure was solved as a complex with D-galactose, providing a mode of substrate binding in detail. The D-galactose molecule was found bound in the active site pocket on the C-terminal side of the central beta-barrel of the catalytic domain. The D-galactose molecule consisted of a mixture of two anomers present in a ratio equal to their natural abundance. Structural comparisons of rice alpha-galactosidase with chicken alpha-N-acetylgalactosaminidase provided further understanding of the substrate recognition mechanism in these enzymes.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Natl Food Res Inst, Biol Funct Div, Tsukuba, Ibaraki 3058642, Japan	National Institute of Agrobiological Sciences - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Mizuno, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058602, Japan.			Fujimoto, Zui/0000-0002-3551-6854				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADY RO, 1967, NEW ENGL J MED, V276, P1163, DOI 10.1056/NEJM196705252762101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Courtois J.E., 1966, METHODS ENZYMOLOGY, P565; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DEY PM, 1993, BIOTECHNOL APPL BIOC, V17, P361; Elgavish S, 1997, TRENDS BIOCHEM SCI, V22, P462, DOI 10.1016/S0968-0004(97)01146-8; Fujimoto Z, 2002, ACTA CRYSTALLOGR D, V58, P1374, DOI 10.1107/S0907444902010168; Garman SC, 2002, STRUCTURE, V10, P425, DOI 10.1016/S0969-2126(02)00726-8; GOLUBEV AM, 1993, J MOL BIOL, V231, P933, DOI 10.1006/jmbi.1993.1340; Hart DO, 2000, BIOCHEMISTRY-US, V39, P9826, DOI 10.1021/bi0008074; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 2000, PLANT PHYSIOL, V124, P1515, DOI 10.1104/pp.124.4.1515; Ishiguro M, 2001, APPL ENVIRON MICROB, V67, P1601, DOI 10.1128/AEM.67.4.1601-1616.2001; KANEKO R, 1990, AGR BIOL CHEM TOKYO, V54, P237, DOI 10.1080/00021369.1990.10869898; KANEKO R, 1991, AGR BIOL CHEM TOKYO, V55, P109, DOI 10.1080/00021369.1991.10870536; Kim WD, 2002, PHYTOCHEMISTRY, V61, P621, DOI 10.1016/S0031-9422(02)00368-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Ly HD, 2000, CARBOHYD RES, V329, P539, DOI 10.1016/S0008-6215(00)00214-7; MCCLEARY BV, 1983, PHYTOCHEMISTRY, V22, P649, DOI 10.1016/S0031-9422(00)86956-3; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MURALI R, 1994, J MOL BIOL, V239, P578, DOI 10.1006/jmbi.1994.1397; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; REID JS, 1985, BIOCH STORAGE CARBOH, P205; REID JSG, 1992, BIOCHEM SOC T, V20, P23, DOI 10.1042/bst0200023; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; Shibuya H, 1995, BIOSCI BIOTECH BIOCH, V59, P2333, DOI 10.1271/bbb.59.2333; Shibuya H, 1999, BIOSCI BIOTECH BIOCH, V63, P1096, DOI 10.1271/bbb.63.1096; Shibuya H, 1998, APPL ENVIRON MICROB, V64, P4489; Shibuya H, 1997, BIOSCI BIOTECH BIOCH, V61, P592, DOI 10.1271/bbb.61.592; SHIBUYA H, 1995, BIOSCI BIOTECH BIOCH, V59, P1345, DOI 10.1271/bbb.59.1345; YAMANE T, 1971, SUCR BELGE, V90, P345; Yoshida S, 1997, BIOSCI BIOTECH BIOCH, V61, P359, DOI 10.1271/bbb.61.359	40	93	98	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20313	20318		10.1074/jbc.M302292200	http://dx.doi.org/10.1074/jbc.M302292200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657636	hybrid			2022-12-27	WOS:000183078000094
J	Hartgroves, LC; Lin, J; Langen, H; Zech, T; Weiss, A; Harder, T				Hartgroves, LC; Lin, J; Langen, H; Zech, T; Weiss, A; Harder, T			Synergistic assembly of linker for activation of T cells signaling protein complexes in T cell plasma membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE C-GAMMA-1; MEDIATED ACTIVATION; TYROSINE RESIDUES; RECEPTOR; LAT; TRANSDUCTION; IDENTIFICATION; ACCUMULATION; PLC-GAMMA-1	Transmembrane adaptor molecule LAT ( linker for activation of T cells) forms a central scaffold for signaling protein complexes that accumulate in the vicinity of activated T cell antigen receptors (TCR). Here we used biochemical analysis of immunoisolated plasma membrane domains and fluorescence imaging of green fluorescence protein-tagged signaling proteins to investigate the contributions of different tyrosine-based signaling protein docking sites of LAT to the formation of LAT signaling protein assemblies in TCR membrane domains. We found that the phospholipase C gamma docking site of LAT and different Grb2/Gads docking sites function in an interdependent fashion and synergize to accumulate LAT, Grb2, and phospholipase C gamma in TCR signaling assemblies. Two-dimensional gels showed that Grb2 is a predominant cytoplasmic adaptor in the isolated LAT signaling complexes, whereas Gads, Crk-1, and Grap are present in lower amounts. Taken together our data suggest a synergistic assembly of multimolecular TCR . LAT signal transduction complexes in T cell plasma membrane domains.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	University of Oxford; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Roche Holding	Harder, T (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	thomas.harder@path.ox.ac.uk		Zech, Tobias/0000-0001-8394-088X				Antelmann H, 1997, ELECTROPHORESIS, V18, P1451, DOI 10.1002/elps.1150180820; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Bunnell SC, 2001, IMMUNITY, V14, P315, DOI 10.1016/S1074-7613(01)00112-1; Celis JE, 1998, CELL BIOLOGY - A LABOARATORY HANDBOOK, 2ND EDITION, VOL 4, P375; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HARDER T, 2001, SCI STKE; Leo A, 2002, J CLIN INVEST, V109, P301; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; Samelson LE, 2002, ANNU REV IMMUNOL, V20, P371, DOI 10.1146/annurev.immunol.20.092601.111357; SCHATTEN G, 1986, EXP CELL RES, V166, P191, DOI 10.1016/0014-4827(86)90519-7; Tanimura N, 2003, J CELL BIOL, V160, P125, DOI 10.1083/jcb.200207096; Tomlinson MG, 2000, IMMUNOL TODAY, V21, P584, DOI 10.1016/S0167-5699(00)01716-3; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898-6568(01)00191-7; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhu NH, 2003, J IMMUNOL, V170, P325, DOI 10.4049/jimmunol.170.1.325	25	42	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20389	20394		10.1074/jbc.M301212200	http://dx.doi.org/10.1074/jbc.M301212200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646565	hybrid			2022-12-27	WOS:000183078000104
J	Helfenbein, KG; Ellis, TP; Dieckmann, CL; Tzagoloff, A				Helfenbein, KG; Ellis, TP; Dieckmann, CL; Tzagoloff, A			ATP22, a nuclear gene required for expression of the F-0 sector of mitochondrial ATPase in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE SYSTEM; ESCHERICHIA-COLI; ROTARY MOTOR; YEAST; SYNTHASE; IDENTIFICATION; COMPLEX; SUBUNIT; PROTEINS; MUTANTS	Expression of the mitochondrial proton-translocating ATPase of Saccharomyces cerevisiae has been shown to depend on chaperones that target the F-1 and F-0 sectors of this inner membrane complex. Here we report a new gene, designated ATP22 ( reading frame YDR350C on chromosome IV), that provides an essential function in the assembly of F0. ATP22 was cloned by transformation of C208/L2, a strain previously assigned to complementation group G99 of a collection of respiration-defective nuclear pet mutants. C208/L2 and the other atp22 mutants have oligomycin-insensitive F-1-ATPase, suggesting that the lesion is confined to F-0. This is supported by the sedimentation properties of the mutant ATPase and results of immunochemical analysis of F-0 subunit polypeptides. Northern analysis of ATPase transcripts and in vivo pulse labeling of the mitochondrial translation products in the mutant indicate normal expression of subunits 6, 8, and 9, the three mitochondrial gene products of F-0. Atp22p therefore functions at a posttranslational stage in assembly of F-0. Localization studies indicate Atp22p to be a component of the mitochondrial inner membrane. Protease protection experiments further indicate that Atp22p faces the matrix side of the membrane where most of the ATPase proteins are located and assembled.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	Columbia University; University of Arizona	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet.bio.columbia.edu			NHLBI NIH HHS [HL2274, R01 HL022174] Funding Source: Medline; NIGMS NIH HHS [GM34893] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL022174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ACKERMAN SH, 1991, FEBS LETT, V278, P234, DOI 10.1016/0014-5793(91)80124-L; ACKERMAN SH, 1990, J BIOL CHEM, V265, P9952; ALWINE JC, 1977, P NATL ACAD SCI USA, V74, P5350, DOI 10.1073/pnas.74.12.5350; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Barrientos A, 2002, EMBO J, V21, P43, DOI 10.1093/emboj/21.1.43; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BEILHARZ MW, 1982, FEBS LETT, V147, P235, DOI 10.1016/0014-5793(82)81049-1; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CAMOUGRAND N, 1995, J MOL BIOL, V247, P588, DOI 10.1006/jmbi.1995.0165; CATTERAL.WA, 1973, J BIOL CHEM, V248, P7427; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fillingame RH, 2000, J EXP BIOL, V203, P9; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KAGAWA Y, 1966, J BIOL CHEM, V241, P2461; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACREADIE IG, 1983, NUCLEIC ACIDS RES, V11, P4435, DOI 10.1093/nar/11.13.4435; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAXAM AM, 1980, METHOD ENZYMOL, V65, P49; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; PAUL MF, 1989, EUR J BIOCHEM, V185, P163, DOI 10.1111/j.1432-1033.1989.tb15098.x; Paul MF, 2000, J BIOL CHEM, V275, P29238, DOI 10.1074/jbc.M004546200; PAYNE MJ, 1991, CURR GENET, V19, P343, DOI 10.1007/BF00309594; PELISSIER P, 1995, CURR GENET, V27, P409, DOI 10.1007/BF00311209; PENEFSKY HS, 1965, J BIOL CHEM, V240, P4694; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHATZ G, 1968, J BIOL CHEM, V243, P2192; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1971, J BIOL CHEM, V246, P7328; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; WALLENFELS K, 1962, METHOD ENZYMOL, V5, P212, DOI 10.1016/S0076-6879(62)05207-6; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1	50	33	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19751	19756		10.1074/jbc.M301679200	http://dx.doi.org/10.1074/jbc.M301679200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646576	hybrid			2022-12-27	WOS:000183078000025
J	Bergqvist, A; Sundstrom, S; Dimberg, LY; Gylfe, E; Masucci, MG				Bergqvist, A; Sundstrom, S; Dimberg, LY; Gylfe, E; Masucci, MG			The hepatitis C virus core protein modulates T cell responses by inducing spontaneous and altering T-cell receptor-triggered Ca2+ oscillations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOTOXIN-BETA RECEPTOR; NONSTRUCTURAL 5A PROTEIN; BLOOD MONONUCLEAR-CELLS; GENE-EXPRESSION; ENDOPLASMIC-RETICULUM; INOCULATED CHIMPANZEES; MEMBRANE-PERMEABILITY; OXIDATIVE STRESS; ANTIGEN RECEPTOR; IMMUNE-RESPONSE	Alterations of cytokine responses are thought to favor the establishment of persistent hepatitis C virus (HCV) infection, enhancing the risk of liver cirrhosis and hepatocellular carcinoma. Expression of the HCV core (C) protein modulates transcription of the IL-2 promoter in T lymphocytes by activating the nuclear factor of activated T lymphocyte (NFAT) pathway. Here we report on the effect of HCV C on Ca2+ signaling, which is essential for activation of NFAT. Expression of HCV C correlated with increased levels of cytosolic Ca2+ and spontaneous Ca2+ oscillations in transfected Jurkat cells. Triggering of the T-cell receptor induced a prolonged Ca2+ response characterized by vigorous high frequent oscillations in a high proportion of the responding cells. This was associated with decreased sizes and accelerated emptying of the intracellular calcium stores. The effect of HCV C on calcium mobilization was not dependent on phospholipase C-gamma(1) (PLC-gamma) activity or increased inositol 1,4,5-trisphosphate (IP3) production and did not require functional IP3 receptors, suggesting that insertion of the viral protein in the endoplasmic reticulum membrane may be sufficient to promote Ca2+ leakage with dramatic downstream consequences on the magnitude and duration of the response. Our data suggest that expression of HCV C in infected T lymphocytes may contribute to the establishment of persistent infections by inducing Ca2+ oscillations that regulate both the efficacy and information content of Ca2+ signals and are ultimately responsible for induction of gene expression and functional differentiation.	Karolinska Inst, Ctr Microbiol & Tumor Biol, MTC, SE-17177 Stockholm, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75237 Uppsala, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Cell Biol, SE-75237 Uppsala, Sweden	Karolinska Institutet; Uppsala University; Uppsala University	Bergqvist, A (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, MTC, Box 280, SE-17177 Stockholm, Sweden.		Berqgvist, Anders/ABA-5530-2021; Masucci, Maria/AAC-6666-2019; Masucci, Maria G/B-8588-2009	Masucci, Maria/0000-0002-5541-2809; Bergqvist, Anders/0000-0002-5789-8777; Gylfe, Erik/0000-0002-8414-2107				Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; ALTER MJ, 1997, HEPATOLOGY S1, V26, P62; Bassett SE, 1999, J VIROL, V73, P1118, DOI 10.1128/JVI.73.2.1118-1126.1999; Bassett SE, 1998, J VIROL, V72, P2589, DOI 10.1128/JVI.72.4.2589-2599.1998; Bergqvist A, 2001, J VIROL, V75, P772, DOI 10.1128/JVI.75.2.772-781.2001; BLIGHT K, 1994, HEPATOLOGY, V20, P553, DOI 10.1016/0270-9139(94)90087-6; BOUFFARD P, 1992, J INFECT DIS, V166, P1276, DOI 10.1093/infdis/166.6.1276; Bronowicki JP, 1998, HEPATOLOGY, V28, P211, DOI 10.1002/hep.510280127; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; Chen CM, 1997, J VIROL, V71, P9417, DOI 10.1128/JVI.71.12.9417-9426.1997; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; CRIBIER B, 1995, J GEN VIROL, V76, P2485, DOI 10.1099/0022-1317-76-10-2485; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GYLFE E, 1988, J BIOL CHEM, V263, P5044; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Large MK, 1999, J IMMUNOL, V162, P931; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Martire G, 2001, VIROLOGY, V280, P176, DOI 10.1006/viro.2000.0733; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; Moradpour D, 1996, J MED VIROL, V48, P234, DOI 10.1002/(SICI)1096-9071(199603)48:3<234::AID-JMV4>3.0.CO;2-9; Moriya K, 2001, CANCER RES, V61, P4365; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Putney JW, 2001, J CELL SCI, V114, P2223; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Ronnstrand L, 1999, J BIOL CHEM, V274, P22089, DOI 10.1074/jbc.274.31.22089; Seow HF, 1998, VET IMMUNOL IMMUNOP, V63, P139, DOI 10.1016/S0165-2427(98)00090-7; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; Soguero C, 2002, J VIROL, V76, P9345, DOI 10.1128/JVI.76.18.9345-9354.2002; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TIAN P, 1995, J VIROL, V69, P5763, DOI 10.1128/JVI.69.9.5763-5772.1995; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; WEISS A, 1984, J IMMUNOL, V133, P123; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; [No title captured]	59	53	54	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18877	18883		10.1074/jbc.M300185200	http://dx.doi.org/10.1074/jbc.M300185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639962	hybrid			2022-12-27	WOS:000182932200023
J	Ley, R; Balmanno, K; Hadfield, K; Weston, C; Cook, SJ				Ley, R; Balmanno, K; Hadfield, K; Weston, C; Cook, SJ			Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBER; CELL-CYCLE ARREST; MOLECULAR-CLONING; APOPTOSIS; SURVIVAL; KINASES; IDENTIFICATION; EXPRESSION; ERK5/BMK1; ISOFORMS	Both the ERK and phosphatidylinositol 3'-kinase (PI3K) signaling pathways can protect cells from apoptosis following withdrawal of survival factors. We have previously shown that the ERK1/2 pathway acts independently of PI3K to block expression of the BH3-only protein, Bim(EL), and prevent serum withdrawal-induced cell death, although the precise mechanism by which ERK reduced Bim(EL) levels was unclear. By comparing Bim mRNA and Bim protein, expression we now show that the rapid expression of Bim(EL) following serum withdrawal cannot be accounted for simply by increases in mRNA following inhibition of PI3K. In cells maintained in serum Bim(EL) is a phosphoprotein. We show that activation of the ERK1/2 pathway is both necessary and sufficient to promote Bim(EL) phosphorylation and that this leads to a substantial increase in turnover of the Bim(EL) protein. ERK1/2-dependent degradation of Bim(EL) proceeds via the proteasome pathway because it is blocked by proteasome inhibitors and is defective at the restrictive temperature in cells with a temperature-sensitive mutation in the E1 component of the ubiquitin-conjugating system. Finally, co-transfection of Bim(EL) and FLAG-ubiquitin causes the accumulation of polyubiquitinated forms of Bim, and this requires the ERK1/2 pathway. Our findings provide new insights into the regulation of Bim and the role of the ERK pathway in cell survival.	Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Cook, SJ (corresponding author), Babraham Inst, Signalling Programme, Inositide Lab, Cambridge CB2 4AT, England.			Balmanno, Kathryn/0000-0002-6417-3889	Biotechnology and Biological Sciences Research Council [BBS/E/B/0000C199, BBS/E/B/0000H457] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Biswas SC, 2002, J BIOL CHEM, V277, P49511, DOI 10.1074/jbc.M208086200; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Garner AP, 2002, ONCOGENE, V21, P8089, DOI 10.1038/sj.onc.1206000; Geetha T, 2003, J BIOL CHEM, V278, P4730, DOI 10.1074/jbc.M208468200; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hsu SY, 1998, MOL ENDOCRINOL, V12, P1432, DOI 10.1210/me.12.9.1432; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KULKA RG, 1988, J BIOL CHEM, V263, P15726; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Miyashita MUT, 2001, FEBS LETT, V509, P135, DOI 10.1016/S0014-5793(01)03145-3; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Squires MS, 2002, BIOCHEM J, V366, P673, DOI 10.1042/BJ20020372; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	30	495	503	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18811	18816		10.1074/jbc.M301010200	http://dx.doi.org/10.1074/jbc.M301010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646560	hybrid			2022-12-27	WOS:000182932200015
J	Lauer-Fields, JL; Sritharan, T; Stack, MS; Nagase, H; Fields, GB				Lauer-Fields, JL; Sritharan, T; Stack, MS; Nagase, H; Fields, GB			Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and-9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COLLAGEN ALPHA-1(IV)531-543; DEGRADATION SEQUENCE-ANALYSIS; IV COLLAGEN; TISSUE INHIBITOR; PEPTIDE MODELS; CELL-MIGRATION; MELANOMA-CELLS; CLEAVAGE SITE; MATRIX-METALLOPROTEINASE-9; ACTIVATION	The role of proteases in the tumor cell invasion process is multifaceted. Members of the matrix metalloproteinase (MMP) family have been implicated in primary and metastatic tumor growth, angiogenesis, and degradation of extracellular matrix (ECM) components. Differentiating between the up-regulation of MMP production and the presence of activated MMPs can be difficult but may well dictate which MMPs are critical to invasion. Because the hydrolysis of collagens is one of the committed steps in ECM turnover, we have investigated selective MMP action on collagenous substrates as a means to evaluate active MMPs. Two triple-helical peptide (THP) models of the MMP-9 cleavage site in type V collagen, alpha1(V)436-450 THP and alpha1(V)436-447 fTHP, were hydrolyzed by MMP-2 and MMP-9 at the Gly-Val bond, analogous to the bond cleaved by MMP-9 in the corresponding native collagen. Kinetic analyses showed k(cat)/K-m values of 14,002 and 5,449 s(-1)M(-1) for MMP-2 and -9 hydrolysis of alpha1(V)436-447 fTHP, respectively. These values, along with individual k(cat) and K-m values, are comparable with collagen hydrolysis by MMP-2 and -9. Neither THP was hydrolyzed by MMP-1, -3, -13, or -14. alpha1(V)436-447 fTHP and a general fluorogenic THP were used to screen for triple-helical peptidase activity in alpha(2)beta(1) integrin-stimulated melanoma cells. Binding of the alpha(2)beta(1) integrin resulted in the production of substantial triple-helical peptidase activity, the majority (>95%) of which was non-MMP-2/-9. THPs were found to provide highly selective substrates for members of the MMP family and can be used to evaluate active MMP production in cellular systems.	Florida Atlantic Univ, Dept Chem & Biochem, Boca Raton, FL 33431 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	State University System of Florida; Florida Atlantic University; Northwestern University; Imperial College London; University of Oxford	Fields, GB (corresponding author), Florida Atlantic Univ, Dept Chem & Biochem, 777 Glades Rd, Boca Raton, FL 33431 USA.	fieldsg@fau.edu			NCI NIH HHS [CA 98799, CA 77402] Funding Source: Medline; NIAMS NIH HHS [AR 39189] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098799, R01CA077402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039189] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Corcoran ML, 1996, ENZYME PROTEIN, V49, P7, DOI 10.1159/000468613; Deryugina EI, 1998, CANCER RES, V58, P3743; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; FIELDS CG, 1993, PEPTIDE RES, V6, P39; FIELDS GB, 1991, J THEOR BIOL, V153, P585, DOI 10.1016/S0022-5193(05)80157-2; FIELDS GB, 2001, PEPTIDES WAVE FUTURE, P975; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Henkel W, 1999, BIOCHEMISTRY-US, V38, P13610, DOI 10.1021/bi9905157; Hofmann UB, 2000, J INVEST DERMATOL, V115, P337, DOI 10.1046/j.1523-1747.2000.00068.x; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; ITOH Y, 1995, BIOCHEM J, V308, P645, DOI 10.1042/bj3080645; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Knauper V, 1996, J BIOL CHEM, V271, P1544, DOI 10.1074/jbc.271.3.1544; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Knight CG, 1998, J BIOL CHEM, V273, P33287, DOI 10.1074/jbc.273.50.33287; Knutson JR, 1996, MOL BIOL CELL, V7, P383, DOI 10.1091/mbc.7.3.383; LABROSSE KR, 1976, ANAL BIOCHEM, V70, P218, DOI 10.1016/S0378-5173(83)90103-5; Lauer JL, 1998, BIOCHEMISTRY-US, V37, P5279, DOI 10.1021/bi972958l; Lauer-Fields JL, 2000, J CHROMATOGR A, V890, P117, DOI 10.1016/S0021-9673(00)00396-4; Lauer-Fields JL, 2000, J BIOL CHEM, V275, P13282, DOI 10.1074/jbc.275.18.13282; Lauer-Fields JL, 2002, BIOL CHEM, V383, P1095, DOI 10.1515/BC.2002.118; Lauer-Fields JL, 2002, BIOPOLYMERS, V66, P19, DOI 10.1002/bip.10201; Lauer-Fields JL, 2001, BIOCHEMISTRY-US, V40, P5795, DOI 10.1021/bi0101190; MACDOUGALL JR, 1995, CANCER RES, V55, P4174; McCawley LJ, 2000, MOL MED TODAY, V6, P149, DOI 10.1016/S1357-4310(00)01686-5; MILES AJ, 1994, J BIOL CHEM, V269, P30939; MILES AJ, 1995, J BIOL CHEM, V270, P29047, DOI 10.1074/jbc.270.49.29047; Mitchell PG, 1996, J CLIN INVEST, V97, P761, DOI 10.1172/JCI118475; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nagase H, 1996, BIOPOLYMERS, V40, P399, DOI 10.1002/(SICI)1097-0282(1996)40:4<399::AID-BIP5>3.0.CO;2-R; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; NIYIBIZI C, 1994, BIOCHEM BIOPH RES CO, V202, P328, DOI 10.1006/bbrc.1994.1931; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Ottl J, 2000, CHEM BIOL, V7, P119, DOI 10.1016/S1074-5521(00)00077-6; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; Stolow MA, 1996, MOL BIOL CELL, V7, P1471, DOI 10.1091/mbc.7.10.1471; Vo HP, 1998, INT J ONCOL, V13, P1127; Woessner J.F., 2000, PROTEIN PROFILE SER; Xia T, 1996, BBA-PROTEIN STRUCT M, V1293, P259, DOI 10.1016/0167-4838(95)00259-6; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yang MZ, 1998, J BIOL CHEM, V273, P17893, DOI 10.1074/jbc.273.28.17893; YOUNG TN, 1995, J BIOL CHEM, V270, P999, DOI 10.1074/jbc.270.3.999; Yu YC, 1998, J AM CHEM SOC, V120, P9979, DOI 10.1021/ja981654z; Yu YC, 1996, J AM CHEM SOC, V118, P12515, DOI 10.1021/ja9627656; ZUCKER S, 1994, CLIN EXP METASTAS, V12, P13, DOI 10.1007/BF01784329	57	83	89	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18140	18145		10.1074/jbc.M211330200	http://dx.doi.org/10.1074/jbc.M211330200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642591	hybrid			2022-12-27	WOS:000182838300072
J	Grewal, T; de Diego, I; Kirchhoff, MF; Tebar, F; Heeren, J; Rinninger, F; Enrich, C				Grewal, T; de Diego, I; Kirchhoff, MF; Tebar, F; Heeren, J; Rinninger, F; Enrich, C			High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SELECTIVE LIPID UPTAKE; HUMAN SKIN FIBROBLASTS; PLASMA-MEMBRANE; CHOLESTEROL EFFLUX; SR-BI; BINDING; CELLS; RAF-1; COMPLEXES	High density lipoprotein (HDL) stimulates multiple signaling pathways. HDL-induced activation of the mitogen-activated protein kinase (MAPK) pathway can be mediated by protein kinase C (PKC) and/or pertussis toxin-sensitive G-proteins. Although HDL-induced activation of MAPK involves Raf-1, Mek, and Erk1/2, the upstream contribution of p21(ras) (Ras) on the activation of Raf-1 and MAPK remains elusive. Here we examine the effect of HDL on Ras activity and demonstrate that HDL induces PKC-independent activation of Ras that is completely blocked by pertussis toxin, thus implicating heterotrimeric G-proteins. In addition, the HDL-induced activation of Ras is inhibited by a neutralizing antibody against scavenger receptor type BI. We conclude that the binding of HDL to scavenger receptor type BI activates Ras in a PKC-independent manner with subsequent induction of the MAPK signaling cascade.	Univ Barcelona, Fac Med, IDIBAPS, Dept Cellular Biol, Barcelona 08036, Spain; Univ Hamburg, Hosp Eppendorf, Inst Med Biochem & Mol Biol, Dept Mol Cell Biol, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Dept Internal Med, D-20246 Hamburg, Germany	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Hamburg; University of Hamburg	Enrich, C (corresponding author), Univ Barcelona, Fac Med, IDIBAPS, Dept Cellular Biol, Casanova 143, Barcelona 08036, Spain.		de Diego Martinez, Iñaki/AAB-4712-2019; Tebar, Francesc/H-1498-2015; Eckhardt, Erik/G-1567-2010	de Diego Martinez, Iñaki/0000-0002-6156-4032; Tebar, Francesc/0000-0002-9522-9726; Grewal, Thomas/0000-0002-7937-8887; Enrich, Carlos/0000-0003-0382-2993				Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calvo M, 2000, ELECTROPHORESIS, V21, P3386, DOI 10.1002/1522-2683(20001001)21:16<3386::AID-ELPS3386>3.3.CO;2-C; Cockerill GW, 1999, INT REV CYTOL, V188, P257; Deeg MA, 1997, ARTERIOSCL THROM VAS, V17, P1667, DOI 10.1161/01.ATV.17.9.1667; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Fidge NH, 1999, J LIPID RES, V40, P187; Frank PG, 2001, AM J PHYSIOL-CELL PH, V280, pC1204, DOI 10.1152/ajpcell.2001.280.5.C1204; Garver WS, 1997, ARTERIOSCL THROM VAS, V17, P2698, DOI 10.1161/01.ATV.17.11.2698; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Ikemoto M, 2000, P NATL ACAD SCI USA, V97, P6538, DOI 10.1073/pnas.100114397; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Nofer JR, 2002, ATHEROSCLEROSIS, V161, P1, DOI 10.1016/S0021-9150(01)00651-7; Nofer JR, 2001, THROMB HAEMOSTASIS, V85, P730; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pons M, 2001, FEBS LETT, V501, P69, DOI 10.1016/S0014-5793(01)02635-7; RINNINGER F, 1994, HEPATOLOGY, V19, P1100, DOI 10.1002/hep.1840190507; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Webb BLJ, 2000, BRIT J PHARMACOL, V130, P1433, DOI 10.1038/sj.bjp.0703452; Xu SZ, 1997, J LIPID RES, V38, P1289; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986	28	64	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16478	16481		10.1074/jbc.C300085200	http://dx.doi.org/10.1074/jbc.C300085200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637559	hybrid			2022-12-27	WOS:000182818600006
J	Huang, XL; Pawliczak, R; Yao, XL; Cowan, MJ; Gladwin, MT; Walter, MJ; Holtzman, MJ; Madara, P; Logun, C; Shelhamer, JH				Huang, XL; Pawliczak, R; Yao, XL; Cowan, MJ; Gladwin, MT; Walter, MJ; Holtzman, MJ; Madara, P; Logun, C; Shelhamer, JH			Interferon-gamma induces p11 gene and protein expression in human epithelial cells through interferon-gamma-activated sequences in the p11 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ANNEXIN-II TETRAMER; INTERCELLULAR-ADHESION MOLECULE-1; HUMAN EPIDERMAL-KERATINOCYTES; CYTOKINE-INDUCED EXPRESSION; CALCIUM-BINDING PROTEINS; GROWTH-FACTOR-ALPHA; IFN-GAMMA; PROSTAGLANDIN GENERATION; PLASMINOGEN ACTIVATION	The effect of interferon (IFN)-gamma on p11 expression was studied in two human epithelial cell lines (BEAS-2B and HeLa). Treatment with IFN-gamma resulted in increased steady-state levels of p11 mRNA and protein expression, with a time-dependent and dose-dependent effect. Transient transfection experiments of a reporter gene construct containing -1498 bp of the 5'-flanking region of the p11 promoter demonstrated that IFN-gamma induced p11 gene expression at the transcriptional level. These effects were inhibited at the promoter and protein levels by a specific JAK-2 kinase inhibitor, AG-490. Functional analysis of the p11 promoter indicates that two T-activated sequence elements (GAS) located at positions - 1219 and - 1090 are important for the induction of the p11 promoter by IFN-gamma. Transfection of mutated reporter constructs demonstrated that the mutation at the GAS-2 site (-1090) inhibited the p11 promoter activity, with a reduction of about similar to73% and mutation at the GAS-3 site (- 1219) eliminated about 26% of the p11 promoter activity. A STAT1 dominant negative mutant vector at Tyr-701 (JAK kinase phosphorylation site) blocked the effect of IFN-gamma on the p11 promoter activity. IFN-gamma induced a rapid tyrosine phosphorylation and nuclear translocation of STAT1 protein, which is involved in the binding to the GAS-2 site in the p11 promoter by EMSA analysis. These data suggest that IFN-gamma-induced p11 expression is mediated through the binding of STAT1 to GAS sites in the p11 promoter. Inhibition of p11 expression by inhibitory antisense RNAs (iRNA) treatment resulted in enhanced IFN-gamma and calcium ionophor-stimulated arachidonic acid release suggesting that at least in part IFN-gamma-stimulated p11 expression may serve a counterregulatory role.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Med Univ Lodz, Dept Clin Immunol & Allergy, PL-92213 Lodz, Poland	National Institutes of Health (NIH) - USA; Washington University (WUSTL); Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,Rm 7D43,10 Ctr Dr,MSC1662, Bethesda, MD 20892 USA.		Pawliczak, Rafa/S-2021-2019; Pawliczak, Rafal Tomasz/S-9649-2016	Pawliczak, Rafa/0000-0001-6784-453X; 	CLINICAL CENTER [Z01CL000182, Z01CL001160, ZIACL000182] Funding Source: NIH RePORTER	CLINICAL CENTER		Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; BENNION SD, 1995, J INVEST DERMATOL, V105, pS71, DOI 10.1111/1523-1747.ep12316107; Bovolenta C, 1999, J IMMUNOL, V162, P323; Chun SY, 2001, ENDOCRINOLOGY, V142, P2311, DOI 10.1210/en.142.6.2311; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dolan-O'Keefe M, 2000, AM J PHYSIOL-LUNG C, V278, pL649, DOI 10.1152/ajplung.2000.278.4.L649; Dong YS, 1999, J IMMUNOL, V162, P4731; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; Fitzpatrick SL, 2000, BIOCHEMISTRY-US, V39, P1021, DOI 10.1021/bi991411z; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gladwin MT, 2000, AM J PHYSIOL-LUNG C, V279, pL1103, DOI 10.1152/ajplung.2000.279.6.L1103; HARDER T, 1992, GENE, V113, P269, DOI 10.1016/0378-1119(92)90406-F; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; Hsu SY, 1997, MOL ENDOCRINOL, V11, P1858, DOI 10.1210/me.11.12.1858; Kalvakolanu DV, 1996, CANCER INVEST, V14, P25, DOI 10.3109/07357909609018435; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Lee YJ, 1996, J IMMUNOL, V157, P1559; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Ma JX, 2000, J BIOL CHEM, V275, P12806, DOI 10.1074/jbc.275.17.12806; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MASIAKOWSKI P, 1990, J NEUROSCI RES, V27, P264, DOI 10.1002/jnr.490270304; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; NAKATA T, 1990, J CELL BIOL, V110, P13, DOI 10.1083/jcb.110.1.13; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; PONZONI M, 1992, FEBS LETT, V310, P17, DOI 10.1016/0014-5793(92)81136-A; PONZONI M, 1993, BIOCHEM J, V294, P893, DOI 10.1042/bj2940893; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; ROSENMAN SJ, 1995, J IMMUNOL, V154, P1888; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WU T, 1994, J CLIN INVEST, V93, P571, DOI 10.1172/JCI117009; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	44	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9298	9308		10.1074/jbc.M212704200	http://dx.doi.org/10.1074/jbc.M212704200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645529	hybrid			2022-12-27	WOS:000181524000055
J	Raasi, S; Pickart, CM				Raasi, S; Pickart, CM			Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; PROTEIN-PROTEIN INTERACTIONS; DAMAGE-INDUCIBLE PROTEINS; DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; MULTIUBIQUITIN-CHAIN; DEGRADATION SIGNAL; BINDING PROTEIN; YEAST; ENZYME	Most substrates of the 26 S proteasome are recognized only following conjugation to a Lys(48)-linked polyubiquitin chain. Rad(23) is one member of a family of proteins that possesses an N-terminal ubiquitin-like domain (UbL) and a C-terminal ubiquitin-associated domain(s) (UBA). Recent studies have shown that LTbLs interact with 26 S proteasomes, whereas UBAs bind polyubiquitin chains. These biochemical properties suggest that UbL-UBA proteins may shuttle polyubiquitinated substrates to proteasomes. Here we show that contrary to prediction from this model, the effect of human Rad23A on the degradation of polyubiquitinated substrates catalyzed by purified proteasomes is exclusively inhibitory. Strong inhibition is dependent on the presence of both UBAs, independent of the UbL, and can be explained by competition between the UBA domains and the proteasome for binding to substrate-linked polyubiquitin chains. The UBA domains bind Lys(48)-linked polyubiquitin chains in strong preference to Lys(63) or Lys(29)-linked chains, leading to selective inhibition of the assembly and disassembly of Lys(48)-linked chains. These results place constraints on the mechanism(s) by which UbL-UBA proteins promote proteasome-catalyzed proteolysis and reveal new properties of UBA domains.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Pickart, CM (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biochem & Mol Biol, 615 N Wolfe St, Baltimore, MD 21205 USA.				NIDDK NIH HHS [DK46984] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046984] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amerik AY, 1997, EMBO J, V16, P4826; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Bertolaet BL, 2001, J MOL BIOL, V313, P955, DOI 10.1006/jmbi.2001.5105; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Elder RT, 2002, NUCLEIC ACIDS RES, V30, P581, DOI 10.1093/nar/30.2.581; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Gillette TG, 2001, GENE DEV, V15, P1528, DOI 10.1101/gad.869601; HAAS AL, 1985, J BIOL CHEM, V260, P2464; Haldeman MT, 1997, BIOCHEMISTRY-US, V36, P10526, DOI 10.1021/bi970750u; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Lommel L, 2002, CURR GENET, V42, P9, DOI 10.1007/s00294-002-0332-9; Lommel L, 2000, NUCLEIC ACIDS RES, V28, P4839, DOI 10.1093/nar/28.24.4839; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01	61	193	200	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8951	8959		10.1074/jbc.M212841200	http://dx.doi.org/10.1074/jbc.M212841200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643283	hybrid			2022-12-27	WOS:000181524000013
J	Vishnyakova, TG; Bocharov, AV; Baranova, IN; Chen, ZG; Remaley, AT; Csako, G; Eggerman, TL; Patterson, AP				Vishnyakova, TG; Bocharov, AV; Baranova, IN; Chen, ZG; Remaley, AT; Csako, G; Eggerman, TL; Patterson, AP			Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; SELECTIVE LIPID UPTAKE; BACTERIAL LIPOPOLYSACCHARIDE; SR-BI; ADRENOCORTICAL-CELLS; APOPTOTIC THYMOCYTES; PLASMA-LIPOPROTEINS; HDL CHOLESTEROL; KUPFFER CELLS; ENDOTOXIN	Scavenger receptor, class B, type I (SR-BI) mediates selective uptake of high density lipoprotein (HDL) cholesteryl ester. SR-BI recognizes HDL, low density lipoprotein (LDL), exchangeable apolipoproteins, and protein-free lipid vesicles containing negatively charged phospholipids. Lipopolysaccharides (LPS) are highly glycosylated anionic phospholipids contributing to septic shock. Despite significant structural similarities between anionic phospholipids and LPS, the role of SR-BI in LPS uptake is unknown. Cla-1, the human SR-BI orthologue, was determined to be a LPS-binding protein and endocytic receptor mediating the binding and internalization of lipoprotein-free, monomerized LPS. LPS strongly competed with HDL, lipid-free apoA-I and apoA-II for HDL binding to the mouse RAW cells. Stably transfected HeLa cells expressing Cla-1-bound LPS with a K-d of about 16 mug/ml, and had a 3-4-fold increase in binding capacity and LPS uptake. Bodipy-labeled LPS uptake was found to initially accumulate in the plasma membrane and subsequently in a perinuclear region identified predominantly as the Golgi complex. Bodipy-LPS and Alexa-apoA-I had staining that colocalized on the cell surface and intracellularly indicating similar transport mechanisms. When associated with HDL, LPS uptake was increased in Cla-1 overexpressing HeLa cells by 5-10-fold. Cla-1-associated H-3-LPS uptake exceeded I-125-apolipoprotein uptake by 5-fold indicating a selective LPS uptake. Upon interacting with Cla-1 overexpressing HeLa cells, the complex (Bodipy-LPS/Alexa 488 apolipoprotein-labeled HDL) bound and was internalized as a holoparticle. Intracellularly, LPS and apolipoproteins were sorted to different intracellular compartments. With LPS-associated HDL, intracellular LPS colocalized predominantly with transferrin, indicating delivery to an endocytic recycling compartment. Our study reveals a close similarity between Cla-1-mediated selective LPS uptake and the recently described selective lipid sorting by rodent SR-BI. In summary, Cla-1 was found to bind and internalize monomerized and HDL-associated LPS, indicating that Cla-1 may play important role in septic shock by affecting LPS cellular uptake and clearance.	NIH, Dept Lab Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NHLBI, NIH, Bethesda, MD 20892 USA; NIDDK, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bocharov, AV (corresponding author), NIH, Dept Lab Med, Warren G Magnuson Clin Ctr, Bldg 10, Bethesda, MD 20892 USA.		Eckhardt, Erik/G-1567-2010		CLINICAL CENTER [Z01CL010306] Funding Source: NIH RePORTER	CLINICAL CENTER		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Bocharov AV, 2001, BIOCHEMISTRY-US, V40, P4407, DOI 10.1021/bi001503k; Buechler C, 1999, BIOCHEM BIOPH RES CO, V262, P251, DOI 10.1006/bbrc.1999.1193; BURRELL R, 1994, CIRC SHOCK, V43, P137; COHEN J, 1985, LANCET, V2, P1069; de Haas CJC, 2000, J IMMUNOL METHODS, V242, P79, DOI 10.1016/S0022-1759(00)00207-6; FREUDENBERG MA, 1980, INFECT IMMUN, V28, P373; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GARCIA R, 1990, P SOC EXP BIOL MED, V193, P280; Garcia R, 1999, BBA-MOL BASIS DIS, V1454, P1, DOI 10.1016/S0925-4439(99)00015-0; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Hailman E, 1996, J BIOL CHEM, V271, P12172, DOI 10.1074/jbc.271.21.12172; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Imachi H, 2000, LAB INVEST, V80, P263, DOI 10.1038/labinvest.3780029; Khovidhunkit W, 2001, J LIPID RES, V42, P1636; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Levels JHM, 2001, INFECT IMMUN, V69, P2821, DOI 10.1128/IAI.69.5.2821-2828.2001; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; MATHISON JC, 1985, AM J PATHOL, V120, P79; MIYAZAKI A, 1994, J BIOL CHEM, V269, P5264; MUNFORD RS, 1981, J CLIN INVEST, V68, P1503, DOI 10.1172/JCI110404; Murao K, 1997, J BIOL CHEM, V272, P17551, DOI 10.1074/jbc.272.28.17551; Netea MG, 1998, CYTOKINE, V10, P766, DOI 10.1006/cyto.1998.0364; Pajkrt D, 1996, J EXP MED, V184, P1601, DOI 10.1084/jem.184.5.1601; PARKER TS, 1995, INFECT IMMUN, V63, P253, DOI 10.1128/IAI.63.1.253-258.1995; Periti P, 1999, INT J ANTIMICROB AG, V12, P97, DOI 10.1016/S0924-8579(99)00044-8; READ TE, 1993, EUR HEART J, V14, P125; Reaven E, 2001, P NATL ACAD SCI USA, V98, P1613, DOI 10.1073/pnas.98.4.1613; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; SCHAEFER EJ, 1981, J LIPID RES, V22, P217; Schulthess G, 2000, BIOCHEMISTRY-US, V39, P12623, DOI 10.1021/bi0011633; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; SINN HJ, 1988, ANAL BIOCHEM, V170, P186, DOI 10.1016/0003-2697(88)90107-8; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti BL, 2000, BBA-MOL CELL BIOL L, V1529, P276, DOI 10.1016/S1388-1981(00)00154-2; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; ULEVITCH RJ, 1978, IMMUNOCHEMISTRY, V15, P157, DOI 10.1016/0161-5890(78)90144-X; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; van OOsten M, 2001, J ENDOTOXIN RES, V7, P381, DOI 10.1177/09680519010070050601; van Oosten M, 1998, INFECT IMMUN, V66, P5107, DOI 10.1128/IAI.66.11.5107-5112.1998; Williams DL, 2000, ENDOCR RES, V26, P639, DOI 10.3109/07435800009048584; Xu SZ, 1997, J LIPID RES, V38, P1289; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160	51	117	120	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22771	22780		10.1074/jbc.M211032200	http://dx.doi.org/10.1074/jbc.M211032200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12651854	hybrid			2022-12-27	WOS:000183503900080
J	Miller, WE; Houtz, DA; Nelson, CD; Kolattukudy, PE; Lefkowitz, RJ				Miller, WE; Houtz, DA; Nelson, CD; Kolattukudy, PE; Lefkowitz, RJ			G-protein-coupled receptor (GPCR) kinase phosphorylation and beta-arrestin recruitment regulate the constitutive signaling activity of the human cytomegalovirus US28 GPCR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; CHEMOKINE RECEPTOR; KAPOSIS-SARCOMA; MURINE CYTOMEGALOVIRUS; SELECTIVE REGULATION; CC-CHEMOKINES; DESENSITIZATION; ENDOCYTOSIS; IDENTIFICATION; EXPRESSION	Phosphorylation of G- protein- coupled receptors ( GPCRs) by GRKs and subsequent recruitment of beta- arrestins to agonist- occupied receptors serves to terminate or attenuate signaling by blocking G- proteins from further interaction with the receptors. Human cytomegalovirus encodes a GPCR termed US28 that is homologous to the human chemokine family of GPCRs but differs from the cellular receptors in that it maintains high constitutive activity in the absence of agonist. Although US28 is constitutively active, mechanisms that regulate this activity are unknown. We provide evidence that US28 is constitutively phosphorylated by GRKs in cells and that in consequence, beta- arrestin 2 is localized to the plasma membrane. Deletion of the carboxyl terminal 40 amino acids in US28 generates a receptor that is severely impaired in its ability to become phosphorylated and recruit beta- arrestin and accordingly demonstrates increased inositol phosphate signaling. This result indicates that the carboxyl terminus of US28 contains an important signaling regulatory region and mutational analysis deleting carboxyl terminal serines identified serine 323 as a critical residue within this region. In addition, overexpression of wild type GRK5 leads to hyperphosphorylation of US28 that results in a decrease of inositol phosphate accumulation. These results are consistent with the hypothesis that GRK phosphorylation and recruitment of beta- arrestin to the US28 viral GPCR attenuates signaling to the traditional Galpha(q)- stimulated inositol phosphate pathway. Finally, in contrast to the results with inositol phosphate signaling, we provide evidence that the US28 carboxyl- terminal phosphorylation sites and beta- arrestin- interacting domain are required for maximal activation of the p38 mitogen-activated protein kinase. Taken together, these results indicate that US28 interacts with these important regulatory proteins to control multiple aspects of signal transmission. Understanding the regulation of viral GPCRs by GRKs and beta- arrestins will provide important new insights into not only aspects of viral pathogenesis but also basic mechanisms of receptor signaling.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Biochem, Durham, NC 27710 USA; Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA	University System of Ohio; University of Cincinnati; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University System of Ohio; University of Cincinnati; University System of Ohio; Ohio State University	Miller, WE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA.		kolattukudy, pappachan e/A-1350-2012; Lefkowitz, Robert/AAW-2649-2021	Miller, William/0000-0001-6900-4884	NHLBI NIH HHS [HL 16037] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Beisser PS, 1998, J VIROL, V72, P2352, DOI 10.1128/JVI.72.3.2352-2363.1998; Beisser PS, 2002, CURR TOP MICROBIOL, V269, P203; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; Davis-Poynter NJ, 1999, INTERVIROLOGY, V42, P331, DOI 10.1159/000053969; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/y96-124; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; Freedman NJ, 1997, J BIOL CHEM, V272, P17734, DOI 10.1074/jbc.272.28.17734; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; GAO JL, 1994, J BIOL CHEM, V269, P28539; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Isegawa Y, 1998, J VIROL, V72, P6104, DOI 10.1128/JVI.72.7.6104-6112.1998; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; Koenig JA, 1997, TRENDS PHARMACOL SCI, V18, P276, DOI 10.1016/S0165-6147(97)01091-2; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Lefkowitz R J, 1998, Adv Pharmacol, V42, P416; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Milne RSB, 2000, J IMMUNOL, V164, P2396, DOI 10.4049/jimmunol.164.5.2396; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; Mueller SG, 1997, J BIOL CHEM, V272, P8207, DOI 10.1074/jbc.272.13.8207; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Pitcher JA, 1998, J BIOL CHEM, V273, P12316, DOI 10.1074/jbc.273.20.12316; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Randolph-Habecker J, 2002, CYTOKINE, V19, P37, DOI 10.1006/cyto.2002.0874; Richardson RM, 2000, J BIOL CHEM, V275, P9201, DOI 10.1074/jbc.275.13.9201; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Sallese M, 2001, TRENDS PHARMACOL SCI, V22, P168, DOI 10.1016/S0165-6147(00)01641-2; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Waldhoer M, 2003, J BIOL CHEM, V278, P19473, DOI 10.1074/jbc.M213179200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002	59	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21663	21671		10.1074/jbc.M303219200	http://dx.doi.org/10.1074/jbc.M303219200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668664	hybrid			2022-12-27	WOS:000183354200045
J	Sharma, GD; He, JC; Bazan, HEP				Sharma, GD; He, JC; Bazan, HEP			p38 and ERK1/2 coordinate cellular migration and proliferation in epithelial wound healing - Evidence of cross-talk activation between MAP kinase cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KERATINOCYTE GROWTH-FACTOR; PROTEIN-KINASE; IN-VITRO; PATHWAY; CELLS; EXPRESSION; HGF; KGF; INHIBITION; APOPTOSIS	One important action of growth factors is their participation in tissue repair; however, the signaling pathways involved are poorly understood. In a model of corneal wound healing, we found that two paracrine growth factors, hepatocyte growth factor (HGF) and keratinocyte growth factor (KGF), induced rapid and marked activation and prompt nuclear accumulation of phospho-p38 (p-p38) and -ERK1/2 (p-ERK1/2), but not of JNK (p-JNK1/2), in corneal epithelial cells. Interruption of p38 and ERK1/2 signaling pathways by pretreatment with inhibitors SB203580 and PD98059 and subsequent stimulation with HGF or KGF abolished the activation and nuclear localization. Inhibition of either one of these mitogen-activated protein kinases, p38 or ERK1/2, induced a robust cross-activation of the other. In immunofluorescence studies of wounded cornea, p-p38, unlike p-ERK1/2, was immediately detectable in epithelium after injury. Inhibition of p38 by SB203580 blocked migration of epithelial cells almost completely. In contrast, PD98059 seemed to slightly increase the migration, through concomitant activation of p38. Unlike ERK1/2, p38 did not significantly contribute to proliferation of epithelial cells. Inhibition of either the ERK1/2 or p38 pathway resulted in delayed corneal epithelial wound healing. Interruption of both signaling cascades additively inhibited the wound-healing process. These findings demonstrate that both p38 and ERK1/2 coordinate the dynamics of wound healing: while growth factor-stimulated p38 induces epithelial migration, ERK1/2 activation induces proliferation. The cross-talk between these two signal cascades and the selective action of p38 in migration appear to be important to corneal wound healing, and possibly wound healing in general, and may offer novel drug targets for tissue repair.	Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Bazan, HEP (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Ophthalmol, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.				NATIONAL EYE INSTITUTE [P30EY002377, R01EY006635] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 06635, P30 EY 02377] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; BRAZZELL RK, 1991, INVEST OPHTH VIS SCI, V32, P336; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Chandrasekher G, 2002, INVEST OPHTH VIS SCI, V43, P1422; Chandrasekher G, 2001, EXP EYE RES, V73, P191, DOI 10.1006/exer.2001.1026; Chandrasekher G, 1999, CURR EYE RES, V18, P168, DOI 10.1076/ceyr.18.3.168.5372; Chung EH, 1999, INVEST OPHTH VIS SCI, V40, P1952; Edin ML, 2001, EXP CELL RES, V270, P214, DOI 10.1006/excr.2001.5345; Foreman DM, 1996, EXP EYE RES, V62, P555, DOI 10.1006/exer.1996.0065; HANNA C, 1966, AM J OPHTHALMOL, V61, P55, DOI 10.1016/0002-9394(66)90747-1; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Hurst J, 1999, INVEST OPHTH VIS SCI, V40, P790; Iijima K, 2002, CIRCULATION, V105, P2404, DOI 10.1161/01.CIR.0000016349.36385.FB; Imanishi J, 2000, PROG RETIN EYE RES, V19, P113, DOI 10.1016/S1350-9462(99)00007-5; Joyce NC, 1996, INVEST OPHTH VIS SCI, V37, P645; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Liang QW, 1998, INVEST OPHTH VIS SCI, V39, P1329; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Rieck PW, 2001, EXP EYE RES, V73, P639, DOI 10.1006/exer.2001.1067; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Schilling-Schon A, 2000, EXP EYE RES, V71, P583, DOI 10.1006/exer.2000.0918; SOTOZONO C, 1995, INVEST OPHTH VIS SCI, V36, P1524; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Tangkijvanich P, 2002, J CELL PHYSIOL, V191, P351, DOI 10.1002/jcp.10112; Wilson SE, 1999, EXP EYE RES, V68, P377, DOI 10.1006/exer.1998.0603; WILSON SE, 1994, EXP EYE RES, V59, P665, DOI 10.1006/exer.1994.1152; WILSON SE, 1993, INVEST OPHTH VIS SCI, V34, P2544; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Zieske JD, 2000, PROG RETIN EYE RES, V19, P257, DOI 10.1016/S1350-9462(99)00018-X	30	280	290	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21989	21997		10.1074/jbc.M302650200	http://dx.doi.org/10.1074/jbc.M302650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663671	hybrid			2022-12-27	WOS:000183354200085
J	Park, TS; O'Brien, DJ; Carman, GM				Park, TS; O'Brien, DJ; Carman, GM			Phosphorylation of CTP synthetase on Ser(36), Ser(330), Ser(354), and Ser(454) regulates the levels of CTP and phosphatidylcholine synthesis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; POLYACRYLAMIDE GEL-ELECTROPHORESIS; CYTIDINE TRIPHOSPHATE SYNTHETASE; CYTOSINE INDUCES APOPTOSIS; LEUKEMIC CELL-LINE; PHOSPHOLIPID BIOSYNTHESIS; HIERARCHICAL PHOSPHORYLATION; LYMPHOBLASTIC-LEUKEMIA; MOLECULAR-CLONING; GENE-PRODUCT	The Saccharomyces cerevisiae URA7-encoded CTP synthetase is phosphorylated and stimulated by protein kinase C. We examined the hypothesis that Ser(36), Ser(330), Ser(354), and Ser(454), contained in a protein kinase C sequence motif in CTP synthetase, were target sites for the kinase. Synthetic peptides containing a phosphorylation motif at these serine residues served as substrates for protein kinase C in vitro. Ser-->Ala (S36A, S330A, S354A, and S454A) mutations in CTP synthetase were constructed by site-directed mutagenesis and expressed normally in a ura7 ura8 double mutant that lacks CTP synthetase activity. The CTP synthetase activity in extracts from cells bearing the S36A, S354A, and S454A mutant enzymes was reduced when compared with cells bearing the wild type enzyme. Kinetic analysis of purified mutant enzymes showed that the S36A and S354A mutations caused a decrease in the V-max of the reaction. This regulation could be attributed in part by the effects phosphorylation has on the nucleotide-dependent oligomerization of CTP synthetase. In contrast, CTP synthetase activity in cells bearing the S330A mutant enzyme was elevated, and kinetic analysis of purified enzyme showed that the S330A mutation caused an elevation in the V-max of the reaction. In vitro data indicated that phosphorylation of CTP synthetase at Ser(330) affected the phosphorylation of the enzyme at another site. The phosphorylation of CTP synthetase at Ser(36), Ser(330), Ser(354), and Ser(454) residues was physiologically relevant. Cells bearing the S36A, S354A, and S454A mutations had reduced CTP levels, whereas cells with the S330A mutation had elevated CTP levels. The alterations in CTP levels correlated with the regulatory effects CTP has on the pathways responsible for the synthesis of the membrane phospholipid phosphatidylcholine.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NIGMS NIH HHS [GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONSSON B, 1994, J BIOL CHEM, V269, P16821; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bearne SL, 2001, BIOCHEM J, V356, P223, DOI 10.1042/0264-6021:3560223; BELL RM, 1991, J BIOL CHEM, V266, P4661; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; Bischoff KM, 1998, ANAL BIOCHEM, V260, P1, DOI 10.1006/abio.1998.2680; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; CULBERTSON MR, 1975, GENETICS, V80, P23; DOWNES CP, 1990, EUR J BIOCHEM, V193, P1, DOI 10.1111/j.1432-1033.1990.tb19297.x; ESKO JD, 1980, J BIOL CHEM, V255, P4474; EXTON JH, 1990, J BIOL CHEM, V265, P1; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Greenberg ML, 1996, MICROBIOL REV, V60, P1; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; Hendriks EF, 1998, BBA-GENE STRUCT EXPR, V1399, P213, DOI 10.1016/S0167-4781(98)00108-0; HOMANN MJ, 1987, J BACTERIOL, V169, P533, DOI 10.1128/jb.169.2.533-539.1987; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jicha GA, 1999, J NEUROCHEM, V72, P214, DOI 10.1046/j.1471-4159.1999.0720214.x; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; KIZAKI H, 1980, CANCER RES, V40, P3921; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE C, 1987, ANAL BIOCHEM, V166, P308, DOI 10.1016/0003-2697(87)90579-3; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; LEVITZKI A, 1972, BIOCHEMISTRY-US, V11, P241, DOI 10.1021/bi00752a015; LIEBERMAN I, 1956, J BIOL CHEM, V222, P765; LONG CW, 1967, J BIOL CHEM, V242, P4715; LUO KX, 1991, METHOD ENZYMOL, V201, P149; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Mahony TJ, 1998, FEMS MICROBIOL LETT, V165, P153; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NADKARNI AK, 1995, J BIOL CHEM, V270, P24982, DOI 10.1074/jbc.270.42.24982; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Ostrander DB, 1998, J BIOL CHEM, V273, P18992, DOI 10.1074/jbc.273.30.18992; OZIERKALOGEROPOULOS O, 1991, MOL GEN GENET, V231, P7, DOI 10.1007/BF00293815; OZIERKALOGEROPOULOS O, 1994, MOL GEN GENET, V242, P431, DOI 10.1007/BF00281793; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Pappas A, 1998, J BIOL CHEM, V273, P15954, DOI 10.1074/jbc.273.26.15954; Pappas A, 1999, BIOCHEMISTRY-US, V38, P16671, DOI 10.1021/bi9920127; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCLAFANI RA, 1984, P NATL ACAD SCI-BIOL, V81, P5821, DOI 10.1073/pnas.81.18.5821; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; TRACH K, 1988, J BACTERIOL, V170, P4194, DOI 10.1128/jb.170.9.4194-4208.1988; Van Kuilenburg ABP, 2000, ADV EXP MED BIOL, V486, P257; van Kuilenburg ABP, 2000, BBA-GENE STRUCT EXPR, V1492, P548, DOI 10.1016/S0167-4781(00)00141-X; VANCE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; VANDENBERG AA, 1995, EUR J CANCER, V31A, P108, DOI 10.1016/0959-8049(94)00442-8; VANDENBERG AA, 1993, EUR J BIOCHEM, V216, P161; VANNE DE, 1991, BIOCH LIPIDS LIPOPRO, P205; Verschuur AC, 1998, ADV EXP MED BIOL, V431, P667; Verschuur AC, 2000, ADV EXP MED BIOL, V486, P319; Verschuur AC, 2001, LEUKEMIA RES, V25, P891, DOI 10.1016/S0145-2126(01)00047-9; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Wadskov-Hansen SLL, 2001, J BIOL CHEM, V276, P38002; WARNER JR, 1991, METHOD ENZYMOL, V194, P423; WATANABE M, 1994, J BIOL CHEM, V269, P16829; WEBER G, 1980, LIFE SCI, V27, P793, DOI 10.1016/0024-3205(80)90333-1; Weber G, 1978, Adv Enzyme Regul, V17, P1; WENG M, 1986, J BIOL CHEM, V261, P5568; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; Xie ZG, 1998, P NATL ACAD SCI USA, V95, P12346, DOI 10.1073/pnas.95.21.12346; YAMAUCHI M, 1990, EMBO J, V9, P2095, DOI 10.1002/j.1460-2075.1990.tb07377.x; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yang WL, 1996, J BIOL CHEM, V271, P11113, DOI 10.1074/jbc.271.19.11113; YANG WL, 1994, BIOCHEMISTRY-US, V33, P10785, DOI 10.1021/bi00201a028; YANG WL, 1995, J BIOL CHEM, V270, P14983, DOI 10.1074/jbc.270.25.14983	93	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20785	20794		10.1074/jbc.M301394200	http://dx.doi.org/10.1074/jbc.M301394200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670958	hybrid			2022-12-27	WOS:000183230500046
J	Young, RM; Holowka, D; Baird, B				Young, RM; Holowka, D; Baird, B			A lipid raft environment enhances Lyn kinase activity by protecting the active site tyrosine from dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-EPSILON-RI; AFFINITY IGE RECEPTOR; RBL-2H3 MAST-CELLS; SRC FAMILY KINASES; MEMBRANE DOMAINS; BIOLOGICAL-MEMBRANES; ANCHORED PROTEINS; PLASMA-MEMBRANES; BETA-SUBUNIT; PHOSPHORYLATION	The plasma membrane contains ordered lipid domains, commonly called lipid rafts, enriched in cholesterol, sphingolipids, and certain signaling proteins. Lipid rafts play a structural role in signal initiation by the high affinity receptor for IgE. Cross-linking of IgE-receptor complexes by antigen causes their coalescence with lipid rafts, where they are phosphorylated by the Src family tyrosine kinase, Lyn. To understand how lipid rafts participate in functional coupling between Lyn and FcepsilonRI, we investigated whether the lipid raft environment influences the specific activity of Lyn. We used differential detergent solubility and sucrose gradient fractionation to isolate Lyn from raft and nonraft regions of the plasma membrane in the presence or absence of tyrosine phosphatase inhibitors. We show that Lyn recovered from lipid rafts has a substantially higher specific activity than Lyn from nonraft environments. Furthermore, this higher specific activity correlates with increased tyrosine phosphorylation at the active site loop of the kinase domain. Based on these results, we propose that lipid rafts exclude a phosphatase that negatively regulates Lyn kinase activity by constitutive dephosphorylation of the kinase domain tyrosine residue of Lyn. In this model, cross-linking of FcepsilonRI promotes its proximity to active Lyn in a lipid raft environment.	Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14850 USA	Cornell University	Baird, B (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Baker Lab, Ithaca, NY 14850 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007273] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI22449] Funding Source: Medline; NIGMS NIH HHS [T32-GM07273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER G, 1991, J BIOL CHEM, V266, P22613; BARSUMIAN EL, 1981, EUR J IMMUNOL, V11, P317, DOI 10.1002/eji.1830110410; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Field KA, 1997, J BIOL CHEM, V272, P4276, DOI 10.1074/jbc.272.7.4276; Fridriksson EK, 1999, BIOCHEMISTRY-US, V38, P8056, DOI 10.1021/bi9828324; Gidwani A, 2001, BIOCHEMISTRY-US, V40, P12422, DOI 10.1021/bi010496c; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; HATA A, 1994, MOL CELL BIOL, V14, P7306, DOI 10.1128/MCB.14.11.7306; Hibbs ML, 1997, INT J BIOCHEM CELL B, V29, P397, DOI 10.1016/S1357-2725(96)00104-5; Holowka D, 2000, J CELL SCI, V113, P1009; Holowka D, 2001, SEMIN IMMUNOL, V13, P99, DOI 10.1006/smim.2000.0301; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; Honda ZI, 2000, MOL CELL BIOL, V20, P1759, DOI 10.1128/MCB.20.5.1759-1771.2000; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kovarova M, 2001, MOL CELL BIOL, V21, P8318, DOI 10.1128/MCB.21.24.8318-8328.2001; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIU PS, 1995, J BIOL CHEM, V270, P27179, DOI 10.1074/jbc.270.45.27179; Mao SY, 1997, J BIOL CHEM, V272, P14067, DOI 10.1074/jbc.272.22.14067; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MENON AK, 1986, J CELL BIOL, V102, P541, DOI 10.1083/jcb.102.2.541; Ohtake H, 2002, J IMMUNOL, V168, P2087, DOI 10.4049/jimmunol.168.5.2087; Parravicini V, 2002, NAT IMMUNOL, V3, P741, DOI 10.1038/ni817; Peirce M, 2000, J BIOL CHEM, V275, P34976, DOI 10.1074/jbc.M005819200; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SOTIRELLIS N, 1995, J BIOL CHEM, V270, P29773; SWIETER M, 1995, J IMMUNOL, V155, P5330; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Torigoe C, 2001, BIOCHEMISTRY-US, V40, P4016, DOI 10.1021/bi0027534; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Vonakis BM, 2001, J BIOL CHEM, V276, P1041, DOI 10.1074/jbc.M003397200; Wang TY, 2001, BIOCHEMISTRY-US, V40, P13031, DOI 10.1021/bi0112311; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; YAMASHITA T, 1994, P NATL ACAD SCI USA, V91, P11251, DOI 10.1073/pnas.91.23.11251; Yanagi S, 1996, J BIOL CHEM, V271, P30487, DOI 10.1074/jbc.271.48.30487	45	141	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20746	20752		10.1074/jbc.M211402200	http://dx.doi.org/10.1074/jbc.M211402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670955	hybrid			2022-12-27	WOS:000183230500041
J	Sellers, JA; Hou, L; Athar, H; Hussain, MM; Shelness, GS				Sellers, JA; Hou, L; Athar, H; Hussain, MM; Shelness, GS			A Drosophila microsomal triglyceride transfer protein homolog promotes the assembly and secretion of human apolipoprotein B - Implications for human and insect lipid transport and metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; ABETALIPOPROTEINEMIA GENE; GENOME SEQUENCE; EXPRESSION; VITELLOGENIN; BINDING; CELLS; MODEL; LIPOPHORIN; IDENTIFICATION	The assembly and secretion of triglyceride-rich lipoproteins in vertebrates requires apolipoprotein B ( apoB) and the endoplasmic reticulum-localized cofactor, microsomal triglyceride transfer protein (MTP). Invertebrates, particularly insects, transport the majority of their neutral and polar lipids in lipophorins; however, the assembly of lipophorin precursor particles was presumed to be MTP-independent. A Drosophila melanogaster expressed gene sequence (CG9342), displaying 23% identity with human MTP, was recently identified. When coexpressed in COS cells, CG9342 promoted the assembly and secretion of apoB34 and apoB41 (N-terminal 34 and 41% of human apoB). The apoB34-containing particles assembled by human MTP and CG9342 displayed similar peak densities of similar to1.169 g/ml and similar lipid compositions. However, CG9342 displayed differential sensitivities to two inhibitors of human MTP and low vesicle-based lipid transfer activity, in vitro. In addition, important predicted structural distinctions exist between the human and Drosophila proteins suggesting overlapping but not identical functional roles. We conclude that CG9342 and human MTP are orthologs that share only a subset of functions, consistent with known differences in intracellular and extracellular aspects of vertebrate and invertebrate lipid transport and metabolism.	Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Suny Downstate Med Ctr, Dept Anat & Cell Biol & Pediat, Brooklyn, NY 11203 USA	Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Shelness, GS (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, 300 S Hawthorne Rd, Winston Salem, NC 27157 USA.	gshelnes@wfubmc.edu			NHLBI NIH HHS [HL07867, HL49373, HL64272] Funding Source: Medline; NIDDK NIH HHS [DK46900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272, P01HL049373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046900, R01DK046900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; Anderson TA, 1998, STRUCT FOLD DES, V6, P895, DOI 10.1016/S0969-2126(98)00091-4; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Babin PJ, 1999, J MOL EVOL, V49, P150, DOI 10.1007/PL00006528; BAKER ME, 1988, BIOCHEM J, V255, P1057, DOI 10.1042/bj2551057; Bakillah A, 2000, BIOCHEMISTRY-US, V39, P4892, DOI 10.1021/bi9924009; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Canavoso LE, 2001, ANNU REV NUTR, V21, P23, DOI 10.1146/annurev.nutr.21.1.23; Chang G, 2002, CURR OPIN DRUG DISC, V5, P562; Dashti N, 2002, BIOCHEMISTRY-US, V41, P6978, DOI 10.1021/bi011757l; Davidson NO, 2000, ANNU REV NUTR, V20, P169, DOI 10.1146/annurev.nutr.20.1.169; ESSER V, 1988, J BIOL CHEM, V263, P13282; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; Gordon DA, 2000, BBA-MOL CELL BIOL L, V1486, P72, DOI 10.1016/S1388-1981(00)00049-4; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gretch DG, 1996, J BIOL CHEM, V271, P8682, DOI 10.1074/jbc.271.15.8682; Hamilton RL, 1998, J LIPID RES, V39, P1543; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Hui TY, 2002, J LIPID RES, V43, P785; Hussain MM, 2000, ATHEROSCLEROSIS, V148, P1; Hussain MM, 2003, J LIPID RES, V44, P22, DOI 10.1194/jlr.R200014-JLR200; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANNEL WB, 1992, CORONARY HEART DIS E, P67; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Kutty RK, 1996, J BIOL CHEM, V271, P20641, DOI 10.1074/jbc.271.34.20641; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OHLENDORF DH, 1977, J BIOL CHEM, V252, P7992; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; Pennington JE, 1996, J LIPID RES, V37, P1144; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Read J, 2000, J BIOL CHEM, V275, P30372, DOI 10.1074/jbc.C000364200; Robl JA, 2001, J MED CHEM, V44, P851, DOI 10.1021/jm000494a; RYAN RO, 1986, J BIOL CHEM, V261, P563; Segrest JP, 1999, J LIPID RES, V40, P1401; Sellers JA, 2001, J LIPID RES, V42, P1897; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHELNESS GS, 1994, J BIOL CHEM, V269, P9310; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SHOULDERS CC, 1994, NAT STRUCT BIOL, V1, P285, DOI 10.1038/nsb0594-285; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Stapleton M, 2002, GENOME RES, V12, P1294, DOI 10.1101/gr.269102; SWIFT LL, 1995, J LIPID RES, V36, P395; VANDERHORST DJ, 1990, BIOCHIM BIOPHYS ACTA, V1047, P195, DOI 10.1016/0005-2760(90)90518-3; WAHLI W, 1988, TRENDS GENET, V4, P227, DOI 10.1016/0168-9525(88)90155-2; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WEERS PMM, 1993, J BIOL CHEM, V268, P4300; WEERS PMM, 1992, J LIPID RES, V33, P485; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; YAO ZM, 1991, J BIOL CHEM, V266, P3300	58	49	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20367	20373		10.1074/jbc.M300271200	http://dx.doi.org/10.1074/jbc.M300271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657646	hybrid			2022-12-27	WOS:000183078000101
J	Taylor, ER; Hurrell, F; Shannon, RJ; Lin, TK; Hirst, J; Murphy, MP				Taylor, ER; Hurrell, F; Shannon, RJ; Lin, TK; Hirst, J; Murphy, MP			Reversible glutathionylation of complex I increases mitochondrial superoxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; TUMOR-NECROSIS-FACTOR; OXIDATIVE STRESS; NITRIC-OXIDE; PERMEABILITY TRANSITION; HEART-MITOCHONDRIA; UBIQUINONE OXIDOREDUCTASE; RADICAL GENERATION; HYDROGEN-PEROXIDE; OXYGEN RADICALS	Increased production of reactive oxygen species (ROS) by mitochondria is involved in oxidative damage to the organelle and in committing cells to apoptosis or senescence, but the mechanisms of this increase are unknown. Here we show that ROS production by mitochondrial complex I increases in response to oxidation of the mitochondrial glutathione pool. This correlates with thiols on the 51- and 75-kDa subunits of complex I forming mixed disulfides with glutathione. Glutathionylation of complex I increases superoxide production by the complex, and when the mixed disulfides are reduced, superoxide production returns to basal levels. Within intact mitochondria oxidation of the glutathione pool to glutathione disulfide also leads to glutathionylation of complex I, which correlates with increased superoxide formation. In this case, most of this superoxide is converted to hydrogen peroxide, which can then diffuse into the cytoplasm. This mechanism of reversible mitochondrial ROS production suggests how mitochondria might regulate redox signaling and shows how oxidation of the mitochondrial glutathione pool could contribute to the pathological changes that occur to mitochondria during oxidative stress.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Murphy, Michael P/C-2120-2009; Hirst, Judy/F-4803-2011	Murphy, Michael P/0000-0003-1115-9618; Hirst, Judy/0000-0001-8667-6797				Balijepalli S, 1999, NEUROPHARMACOLOGY, V38, P567, DOI 10.1016/S0028-3908(98)00215-9; Balijepalli S, 1999, NEUROSCI LETT, V272, P203, DOI 10.1016/S0304-3940(99)00593-5; Barja G, 1999, METHODS AGING RES, P533; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; Borutaite V, 2000, FEBS LETT, V467, P155, DOI 10.1016/S0014-5793(00)01140-6; BOVERIS A, 1984, METHOD ENZYMOL, V105, P429; BURCH HB, 1957, METHOD ENZYMOL, V3, P960, DOI 10.1016/S0076-6879(57)03485-0; Burdon RH, 1996, BIOCHEM SOC T, V24, P1028, DOI 10.1042/bst0241028; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CHAUDIERE J, 1984, J BIOL CHEM, V259, P1043; COOPER JM, 1992, BIOCHIM BIOPHYS ACTA, V1101, P198, DOI 10.1016/S0005-2728(05)80019-2; DAVEY GP, 1992, BIOCHEM J, V288, P439, DOI 10.1042/bj2880439; DIMONTE DA, 1992, ANN NEUROL, V32, pS111, DOI 10.1002/ana.410320719; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fratelli M, 2002, P NATL ACAD SCI USA, V99, P3505, DOI 10.1073/pnas.052592699; Genova ML, 2001, FEBS LETT, V505, P364, DOI 10.1016/S0014-5793(01)02850-2; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GRIFFITH OW, 1985, P NATL ACAD SCI USA, V82, P4668, DOI 10.1073/pnas.82.14.4668; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jenner P, 1993, ACTA NEUROL SCAND  S, V146, P6; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lin TK, 2002, J BIOL CHEM, V277, P17048, DOI 10.1074/jbc.M110797200; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; MARTENSSON J, 1990, P NATL ACAD SCI USA, V87, P7185, DOI 10.1073/pnas.87.18.7185; MEREDITH J, 1982, J BIOL CHEM, V257, P3747; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Pani G, 2000, BIOCHEM J, V347, P173, DOI 10.1042/0264-6021:3470173; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Rustin P, 2002, NAT GENET, V30, P352, DOI 10.1038/ng0402-352; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Tabrizi SJ, 2000, ANN NEUROL, V47, P80; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Tyler D. D., 1967, METHOD ENZYMOL, V10, P75, DOI DOI 10.1016/0076-6879(67)10014-1; VINOGRADOV AD, 1995, FEBS LETT, V370, P83, DOI 10.1016/0014-5793(95)00803-H; Walker JE, 1995, METHOD ENZYMOL, V260, P14, DOI 10.1016/0076-6879(95)60127-9; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Werhahn W, 2002, ELECTROPHORESIS, V23, P640, DOI 10.1002/1522-2683(200202)23:4&lt;640::AID-ELPS640&gt;3.0.CO;2-F	57	328	342	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19603	19610		10.1074/jbc.M209359200	http://dx.doi.org/10.1074/jbc.M209359200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649289	hybrid			2022-12-27	WOS:000183078000007
J	Borgland, SL; Connor, M; Osborne, PB; Furness, JB; Christie, MJ				Borgland, SL; Connor, M; Osborne, PB; Furness, JB; Christie, MJ			Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX OCCUPANCY MECHANISMS; BETA-ADRENERGIC-RECEPTOR; LOCUS-CERULEUS NEURONS; COUPLED RECEPTOR; POTASSIUM CONDUCTANCE; CALCIUM-CHANNELS; NG108-15 CELLS; N-TYPE; HOMOLOGOUS DESENSITIZATION; STIMULUS AMPLIFICATION	The differential ability of various mu-opioid receptor ( MOP) agonists to induce rapid receptor desensitization and endocytosis of MOP could arise simply from differences in their efficacy to activate G proteins or, alternatively, be due to differential capacity for activation of other signaling processes. We used AtT20 cells stably expressing a low density of FLAG-tagged MOP to compare the efficacies of a range of agonists to 1) activate G proteins using inhibition of calcium channel currents (I-Ca) as a reporter before and after inactivation of a fraction of receptors by beta-chlornaltrexamine, 2) produce rapid, homologous desensitization of ICa inhibition, and 3) internalize receptors. Relative efficacies determined for G protein coupling were [ Tyr-D-Ala-Gly-MePhe-Glyol] enkephalin ( DAMGO) (1) greater than or equal to methadone (0.98) > morphine (0.58) > pentazocine (0.15). The same rank order of efficacies for rapid desensitization of MOP was observed, but greater concentrations of agonist were required than for G protein activation. By contrast, relative efficacies for promoting endocytosis of MOP were DAMGO (1) > methadone (0.59) >> morphine (0.07) greater than or equal to pentazocine (0.03). These results indicate that the efficacy of opioids to produce activation of G proteins and rapid desensitization is distinct from their capacity to internalize mu-opioid receptors but that, contrary to some previous reports, morphine can produce rapid, homologous desensitization of MOP.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; Univ Sydney, Med Fdn, Sydney, NSW 2006, Australia; Univ Sydney, Pain Management Res Inst, Sydney, NSW 2006, Australia; Univ New S Wales, Prince Wales Med Res Inst, Randwick, NSW 2031, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3010, Australia	University of Sydney; University of Sydney; University of Sydney; Prince Wales Medical Research Institute; University of New South Wales Sydney; University of Melbourne	Connor, M (corresponding author), Univ Sydney, Dept Pharmacol, D06, Sydney, NSW 2006, Australia.	markc@pharmacol.usyd.edu.au	Furness, John B/B-2763-2016; Connor, Mark/A-4197-2008; Osborne, Peregrine/C-5907-2008; Christie, MacDonald J/F-4724-2013; Borgland, Stephanie/M-2936-2016; Borgland, Stephanie/GPC-5260-2022	Furness, John B/0000-0002-0219-3438; Connor, Mark/0000-0003-2538-2001; Osborne, Peregrine/0000-0002-8458-4159; Christie, MacDonald J/0000-0002-0622-609X; Borgland, Stephanie/0000-0001-7546-5687; Borgland, Stephanie/0000-0001-7546-5687	NIDA NIH HHS [DA13926-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA013926] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abbadie C, 2001, NEUROREPORT, V12, P3069, DOI 10.1097/00001756-200110080-00017; Alvarez VA, 2002, J NEUROSCI, V22, P5769; ARDEN JR, 1995, J NEUROCHEM, V65, P1636; Avalos M, 2001, J PHARMACOL TOX MET, V45, P17, DOI 10.1016/S1056-8719(01)00118-6; Beaumont V, 1998, J BIOL CHEM, V273, P33174, DOI 10.1074/jbc.273.50.33174; BESSE JC, 1976, J PHARMACOL EXP THER, V197, P66; Blanchet C, 2002, P NATL ACAD SCI USA, V99, P4674, DOI 10.1073/pnas.072075399; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 2002, J NEUROSCI, V22, P10494; Bourinet E, 1996, P NATL ACAD SCI USA, V93, P1486, DOI 10.1073/pnas.93.4.1486; Burford NT, 1998, EUR J PHARMACOL, V342, P123, DOI 10.1016/S0014-2999(97)01556-2; Bushell T, 2002, MOL PHARMACOL, V61, P55, DOI 10.1124/mol.61.1.55; Capeyrou R, 1997, FEBS LETT, V415, P200, DOI 10.1016/S0014-5793(97)01124-1; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Chavkin C, 2001, MOL PHARMACOL, V60, P20, DOI 10.1124/mol.60.1.20; Chen Y, 2000, J NEUROPHYSIOL, V83, P1273, DOI 10.1152/jn.2000.83.3.1273; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Colecraft HM, 2001, J NEUROSCI, V21, P1137; CONCHON S, 1994, FEBS LETT, V349, P365, DOI 10.1016/0014-5793(94)00703-9; Connor M, 1996, BRIT J PHARMACOL, V119, P1614, DOI 10.1111/j.1476-5381.1996.tb16080.x; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fiorillo CD, 1996, J NEUROSCI, V16, P1479; Furchgott RF., 1966, ADV DRUG RES, V3, P21; Grady EF, 1997, AM J PHYSIOL-GASTR L, V273, pG586, DOI 10.1152/ajpgi.1997.273.3.G586; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS GC, 1991, J NEUROSCI, V11, P2574; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IVARSSON M, 1989, PHARMACOL TOXICOL, V65, P368, DOI 10.1111/j.1600-0773.1989.tb01190.x; JAMES MK, 1989, J PHARMACOL EXP THER, V249, P61; January B, 1997, J BIOL CHEM, V272, P23871, DOI 10.1074/jbc.272.38.23871; KASAI H, 1991, P NATL ACAD SCI USA, V88, P8855, DOI 10.1073/pnas.88.19.8855; Keith DE, 1998, MOL PHARMACOL, V53, P377, DOI 10.1124/mol.53.3.377; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kenakin T, 2002, ANNU REV PHARMACOL, V42, P349, DOI 10.1146/annurev.pharmtox.42.091401.113012; Kenakin T, 1999, TRENDS PHARMACOL SCI, V20, P400, DOI 10.1016/S0165-6147(99)01361-9; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1997, J NEUROCHEM, V69, P1767; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kramer HK, 2000, NEUROPHARMACOLOGY, V39, P1707, DOI 10.1016/S0028-3908(99)00243-9; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Liu JG, 1999, EUR J PHARMACOL, V374, P301, DOI 10.1016/S0014-2999(99)00322-2; LUINI A, 1986, J NEUROSCI, V6, P3128; MACKIE K, 1995, J NEUROSCI, V15, P6552; Mak CK, 1996, NEUROPHARMACOLOGY, V35, P549, DOI 10.1016/0028-3908(96)84625-9; MCFADZEAN I, 1989, EUR J NEUROSCI, V1, P141, DOI 10.1111/j.1460-9568.1989.tb00781.x; McQuay H, 1999, LANCET, V353, P2229, DOI 10.1016/S0140-6736(99)03528-X; Morikawa H, 1999, PFLUG ARCH EUR J PHY, V438, P423, DOI 10.1007/PL00008091; Morikawa H, 1998, BRIT J PHARMACOL, V123, P1111, DOI 10.1038/sj.bjp.0701733; NOMURA K, 1994, J PHARMACOL EXP THER, V270, P466; OSBORNE PB, 1995, BRIT J PHARMACOL, V115, P925, DOI 10.1111/j.1476-5381.1995.tb15899.x; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Samoriski GM, 2000, J PHARMACOL EXP THER, V294, P500; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Southwell BR, 1998, NEUROSCIENCE, V87, P925, DOI 10.1016/S0306-4522(98)00176-6; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; Szekeres PG, 1998, MOL PHARMACOL, V53, P759, DOI 10.1124/mol.53.4.759; Tallent M, 1998, NEUROSCIENCE, V85, P873, DOI 10.1016/S0306-4522(97)00675-1; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; Trzeciakowski JP, 1999, J THEOR BIOL, V198, P329, DOI 10.1006/jtbi.1999.0919; Trzeciakowski JP, 1999, J THEOR BIOL, V198, P347, DOI 10.1006/jtbi.1999.0920; Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; WILDING TJ, 1995, J NEUROSCI, V15, P4124; Yarygin KN, 1998, BRAIN RES, V791, P99, DOI 10.1016/S0006-8993(98)00084-5; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	80	133	139	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18776	18784		10.1074/jbc.M300525200	http://dx.doi.org/10.1074/jbc.M300525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642578	hybrid			2022-12-27	WOS:000182932200011
J	Hohl, M; Thorel, F; Clarkson, SG; Scharer, OD				Hohl, M; Thorel, F; Clarkson, SG; Scharer, OD			Structural determinants for substrate binding and catalysis by the structure-specific endonuclease XPG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-REPAIR; RNA-POLYMERASE; OPEN COMPLEX; PROTEIN; RAD2; TRANSCRIPTION; REPLICATION; EXONUCLEASE; NUCLEASES	XPG belongs to the Fen1 family of structure-specific nucleases and is responsible for the 3' endonucleolytic incision during mammalian nucleotide excision repair. In addition, it has ill-defined roles in the transcription-coupled repair of oxidative DNA damage and likely also in transcription that are independent of its nuclease activity. We have used DNA binding and footprinting assays with various substrates to gain insight into how XPG interacts with DNA. Ethylation interference footprinting revealed that XPG binds to its substrates through interaction with the phosphate backbone on one face of the helix, mainly to the double-stranded DNA. By comparing DNA binding and cleavage activity using single-/double-stranded DNA junction substrates differing in the length of the single-stranded regions, we have found that the 3' but not the 5' single-stranded arm was necessary for DNA binding and incision activity. Furthermore, we show that although a 5' overhang is not required for XPG activity, an overhang containing double-stranded DNA near the junction inhibits the nuclease but not substrate binding activity. Apparently, junction accessibility or flexibility is important for catalysis but not binding of XPG. These results show that XPG has distinct requirements for binding and cleaving DNA substrates.	Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland; Ctr Med Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Zurich; University of Geneva	Scharer, OD (corresponding author), Univ Zurich, Inst Mol Canc Res, August Forel Str 7, CH-8008 Zurich, Switzerland.	scharer@imr.unizh.ch	Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715				Araujo SJ, 2001, MOL CELL BIOL, V21, P2281, DOI 10.1128/MCB.21.7.2281-2291.2001; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; CLOUD KG, 1995, MUTAT RES LETT, V347, P55, DOI 10.1016/0165-7992(95)90070-5; Constantinou A, 1999, J BIOL CHEM, V274, P5637, DOI 10.1074/jbc.274.9.5637; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Dervan JJ, 2002, P NATL ACAD SCI USA, V99, P8542, DOI 10.1073/pnas.082241699; Enzlin JH, 2002, EMBO J, V21, P2045, DOI 10.1093/emboj/21.8.2045; Evans E, 1997, EMBO J, V16, P625, DOI 10.1093/emboj/16.3.625; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Iyer N, 1996, BIOCHEMISTRY-US, V35, P2157, DOI 10.1021/bi9524124; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; LARSON CJV, 1996, NUCL ACIDS, P324; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Lee B, 2002, NUCLEIC ACIDS RES, V30, P942, DOI 10.1093/nar/30.4.942; Lee BI, 1999, J BIOL CHEM, V274, P37763, DOI 10.1074/jbc.274.53.37763; Lee SK, 2002, CELL, V109, P823, DOI 10.1016/S0092-8674(02)00795-X; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Lilley DMJ, 2000, Q REV BIOPHYS, V33, P109, DOI 10.1017/S0033583500003590; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; Mu D, 1997, J BIOL CHEM, V272, P28971, DOI 10.1074/jbc.272.46.28971; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; ODONOVAN A, 1994, J BIOL CHEM, V269, P15965; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Park MS, 1997, J BIOL CHEM, V272, P27823, DOI 10.1074/jbc.272.44.27823; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHERLY D, 1993, NATURE, V363, P182, DOI 10.1038/363182a0; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Shiomi N, 2001, MUTAT RES-DNA REPAIR, V487, P127, DOI 10.1016/S0921-8777(01)00111-2; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; Stary A, 2002, BIOCHIMIE, V84, P49, DOI 10.1016/S0300-9084(01)01358-X; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Stucki M, 2001, J BIOL CHEM, V276, P7843, DOI 10.1074/jbc.M008829200; Suck D, 1997, BIOPOLYMERS, V44, P405, DOI 10.1002/(SICI)1097-0282(1997)44:4<405::AID-BIP5>3.0.CO;2-L; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; vanGool AJ, 1997, EMBO J, V16, P4155, DOI 10.1093/emboj/16.14.4155; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1997, J BIOL CHEM, V272, P16030, DOI 10.1074/jbc.272.25.16030; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200	49	56	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19500	19508		10.1074/jbc.M213155200	http://dx.doi.org/10.1074/jbc.M213155200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644470	Green Published, hybrid			2022-12-27	WOS:000182932200100
J	Jeffrey, JL; Feng, JY; Qi, CCR; Anderson, KS; Furman, PA				Jeffrey, JL; Feng, JY; Qi, CCR; Anderson, KS; Furman, PA			Dioxolane guanosine 5 '-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase - Steady state and pre-steady state kinetic analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE INHIBITORS; DRUG-RESISTANCE; ANTIRETROVIRAL DRUGS; NUCLEOSIDE ANALOG; MUTATIONS K65R; DNA-SYNTHESIS; MECHANISM; SENSITIVITY; VARIANTS	The frequency of human immunodeficiency virus, type 1 (HIV-1) mutations in response to antiviral therapy and resulting drug resistance is of major concern. Amdoxovir ((-)-beta-D-2,6-diaminopurine dioxolane), the prodrug of dioxolane guanosine (DXG), is currently in phase I/II clinical development for the treatment of HIV-1 infection. In vitro, HIV-1 mutants resistant to 3'-azido-3'-deoxythymidine (M41L/D67N/K70R/T215Y/K219Q) and (-)beta-L-2',3'-dideoxy-3'-thiacytidine (3TC) (M184V) remain sensitive to DXG. HIV-1 with the reverse transcriptase mutations K65R, L74V, and/or Q151M were less sensitive to DXG, whereas the mutation K103N re-sensitized the virus to the inhibitory effect of DXG. In order to understand these observations at the enzyme level, we investigated the inhibition of the HIV-1 reverse transcriptase-catalyzed viral DNA synthesis by dioxolane guanosine 5'-triphosphate (DXG-TP), 3'-azido-3'-deoxythymidine-TP, and 3TC-TP by using steady state kinetic analysis and the incorporation of DXG-5'-monophosphate by using pre-steady state kinetic analysis. This mechanistic study provided detailed information on the amdoxovir-related drug resistance at a molecular level. Overall, the enzymatic data correlated well with the antiviral data obtained from cell culture experiments and further supported the use of amdoxovir for the treatment of nucleoside reverse transcriptase inhibitor-experienced patients.	Gilead Sci Inc, Triangle Pharmaceut Inc, Durham, NC 27717 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Gilead Sciences; Yale University	Feng, JY (corresponding author), Gilead Sci Inc, Triangle Pharmaceut Inc, Durham, NC 27717 USA.	joy.feng@gilead.com			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Bacheler LT, 1999, DRUG RESIST UPDATE, V2, P56, DOI 10.1054/drup.1998.0064; Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Boden D, 1998, ANTIMICROB AGENTS CH, V42, P2775, DOI 10.1128/AAC.42.11.2775; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; Deval J, 2002, J BIOL CHEM, V277, P42097, DOI 10.1074/jbc.M206725200; Dunne AL, 2001, AIDS, V15, P1471, DOI 10.1097/00002030-200108170-00003; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; Furman PA, 2001, ANTIMICROB AGENTS CH, V45, P158, DOI 10.1128/AAC.45.1.158-165.2001; Gu ZX, 1999, ANTIMICROB AGENTS CH, V43, P2376, DOI 10.1128/AAC.43.10.2376; GU ZX, 1994, ANTIMICROB AGENTS CH, V38, P275, DOI 10.1128/AAC.38.2.275; Harris D, 1998, J BIOL CHEM, V273, P33624, DOI 10.1074/jbc.273.50.33624; Hopkins AL, 1996, J MED CHEM, V39, P1589, DOI 10.1021/jm960056x; Hsiou Y, 2001, J MOL BIOL, V309, P437, DOI 10.1006/jmbi.2001.4648; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kaushik N, 1997, BIOCHEMISTRY-US, V36, P14430, DOI 10.1021/bi970645k; Kaushik N, 2000, BIOCHEMISTRY-US, V39, P2912, DOI 10.1021/bi991376w; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; KIM HO, 1993, J MED CHEM, V36, P519, DOI 10.1021/jm00057a001; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LAETHEM KV, 2001, AIDS, V15, P553; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MELLORS JW, 1996, P 5 INT WORKSH HIV D; MEWSHAW JP, 2002, AIDS, V29, P11; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Naeger LK, 2001, ANTIVIR THER, V6, P115; Naeger LK, 2002, ANTIMICROB AGENTS CH, V46, P2179, DOI 10.1128/AAC.46.7.2179-2184.2002; *NAT DAT CORP, 2002, HLTH RET AUD; Rousseau MN, 2001, J ACQ IMMUN DEF SYND, V26, P36, DOI 10.1097/00126334-200101010-00005; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Selmi B, 2001, J BIOL CHEM, V276, P48466, DOI 10.1074/jbc.M107003200; SELMI B, 2002, DART FRONTIERS DRUG; Shahs FS, 2000, J BIOL CHEM, V275, P27037; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; SHIRASAKA T, 1995, P NATL ACAD SCI USA, V92, P2398, DOI 10.1073/pnas.92.6.2398; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; Smith RH, 1998, THEOCHEM-J MOL STRUC, V423, P67, DOI 10.1016/S0166-1280(97)00071-7; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002; Wilson JE, 1996, METHOD ENZYMOL, V275, P398	46	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18971	18979		10.1074/jbc.M210113200	http://dx.doi.org/10.1074/jbc.M210113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651859	hybrid			2022-12-27	WOS:000182932200034
J	Tendeng, C; Krin, E; Soutourina, OA; Marin, A; Danchin, A; Bertin, PN				Tendeng, C; Krin, E; Soutourina, OA; Marin, A; Danchin, A; Bertin, PN			A novel H-NS-like protein from an antarctic psychrophilic bacterium reveals a crucial role for the N-terminal domain in thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-STRUCTURING PROTEIN; NUCLEOID-ASSOCIATED PROTEIN; ESCHERICHIA-COLI; GENOME SEQUENCE; DNA; ENZYMES; BINDING; SHOCK; OLIGOMERIZATION; IDENTIFICATION	We describe here new members of the H-NS protein family identified in a psychrotrophic Acinetobacter spp. bacterium collected in Siberia and in a psychrophilic Psychrobacter spp. bacterium collected in Antarctica. Both are phylogenetically closely related to the HvrA and SPB Rhodobacter transcriptional regulators. Their amino acid sequence shares 40% identity, and their predicted secondary structure displays a structural and functional organization in two modules similar to that of H-NS in Escherichia coli. Remarkably, the Acinetobacter protein fully restores to the wild-type H-NS-dependent phenotypes, whereas the Psychrobacter protein is no longer able to reverse the effects of H-NS deficiency in an E. coli mutant strain above 30 degreesC. Moreover, in vitro experiments demonstrate that the ability of the Psychrobacter H-NS protein to bind curved DNA and to form dimers is altered at 37 degreesC. The construction of hybrid proteins containing the N- or the C-terminal part of E. coli H-NS fused to the C- or N- terminal part of the Psychrobacter protein demonstrates the role of the N-terminal domain in this process. Finally, circular dichroism analysis of purified H-NS proteins suggests that, as compared with the E. coli and Acinetobacter proteins, the alpha-helical domain displays weaker intermolecular interactions in the Psychrobacter protein, which may account for the low thermal stability observed at 37 degreesC.	Inst Pasteur, Unite Genet Genomes Bacteriens, F-75724 Paris 15, France; Ecole Polytech, Biochim Lab, F-91128 Palaiseau, France; Univ Paris 06, Atelier Bioinformat, F-75005 Paris, France; HKU Pasteur Res Ctr, Pokfulam, Hong Kong, Peoples R China; Univ Strasbourg, CNRS, FRE 2326, Lab Dynam Evolut & Express Genomes Microorganisme, F-67083 Strasbourg, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut Polytechnique de Paris; UDICE-French Research Universities; Sorbonne Universite; University of Hong Kong; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Bertin, PN (corresponding author), Univ Strasbourg, Lab Dynam Evolut & Express Genomes Microorganisme, 28 Rue Goethe, F-67000 Strasbourg, France.	bertin@gem.u-strasbg.fr	Soutourina, Olga/F-2042-2015	Philippe, Bertin/0000-0003-1158-6396; Danchin, Antoine/0000-0002-6350-5001; Soutourina, Olga/0000-0001-6439-7228				Berger F, 1996, J BACTERIOL, V178, P2999, DOI 10.1128/jb.178.11.2999-3007.1996; Bertin P, 1999, MOL MICROBIOL, V31, P319, DOI 10.1046/j.1365-2958.1999.01176.x; Bertin P, 2001, BIOCHIMIE, V83, P235, DOI 10.1016/S0300-9084(01)01247-0; Bowman JP, 1996, INT J SYST BACTERIOL, V46, P841, DOI 10.1099/00207713-46-4-841; BRUNI CB, 1977, J BACTERIOL, V130, P4, DOI 10.1128/JB.130.1.4-10.1977; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; DERSCH P, 1994, MOL GEN GENET, V245, P255, DOI 10.1007/BF00283274; Di Fraia R, 2000, EUR J BIOCHEM, V267, P121, DOI 10.1046/j.1432-1327.2000.00972.x; Dorman CJ, 1999, TRENDS MICROBIOL, V7, P124, DOI 10.1016/S0966-842X(99)01455-9; Feller G, 1997, CELL MOL LIFE SCI, V53, P830, DOI 10.1007/s000180050103; Feller G, 1996, FEMS MICROBIOL REV, V18, P189, DOI 10.1016/0168-6445(96)00011-3; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Gerday C, 2000, TRENDS BIOTECHNOL, V18, P103, DOI 10.1016/S0167-7799(99)01413-4; Gianese G, 2001, PROTEIN ENG, V14, P141, DOI 10.1093/protein/14.3.141; GOUNOT AM, 1991, J APPL BACTERIOL, V71, P386, DOI 10.1111/j.1365-2672.1991.tb03806.x; Goyard S, 1997, MOL MICROBIOL, V24, P815, DOI 10.1046/j.1365-2958.1997.3891753.x; Hommais F, 2001, MOL MICROBIOL, V40, P20, DOI 10.1046/j.1365-2958.2001.02358.x; JACQUET M, 1971, BIOCHEM BIOPH RES CO, V45, P1597, DOI 10.1016/0006-291X(71)90204-X; Krin E, 2001, FEMS MICROBIOL LETT, V199, P229, DOI 10.1016/S0378-1097(01)00186-0; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; LaurentWinter C, 1997, EUR J BIOCHEM, V244, P767, DOI 10.1111/j.1432-1033.1997.00767.x; LEJEUNE P, 1989, MOL GEN GENET, V218, P361, DOI 10.1007/BF00331292; MARGESIN R, 1994, J BIOTECHNOL, V33, P1, DOI 10.1016/0168-1656(94)90093-0; MARIN A, 2002, IUL BIOTECH, V3, P227; May BJ, 2001, P NATL ACAD SCI USA, V98, P3460, DOI 10.1073/pnas.051634598; Michel V, 1997, J BACTERIOL, V179, P7331, DOI 10.1128/jb.179.23.7331-7342.1997; MILLER JH, 1972, EXPT MOL GENETICS, P456; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; Renzoni D, 2001, J MOL BIOL, V306, P1127, DOI 10.1006/jmbi.2001.4471; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; Schroder O, 2002, BIOL CHEM, V383, P945, DOI 10.1515/BC.2002.101; SHINDO H, 1995, FEBS LETT, V360, P125, DOI 10.1016/0014-5793(95)00079-O; Shindo H, 1999, FEBS LETT, V455, P63, DOI 10.1016/S0014-5793(99)00862-5; Simpson AJG, 2000, NATURE, V406, P151, DOI 10.1038/35018003; Smyth CP, 2000, MOL MICROBIOL, V36, P962, DOI 10.1046/j.1365-2958.2000.01917.x; Soutourina O, 1999, J BACTERIOL, V181, P7500, DOI 10.1128/JB.181.24.7500-7508.1999; Soutourina OA, 2002, MICROBIOL-SGM, V148, P1543, DOI 10.1099/00221287-148-5-1543; Soutourina OA, 2001, APPL ENVIRON MICROB, V67, P3852, DOI 10.1128/AEM.67.9.3852-3859.2001; Spurio R, 1997, EMBO J, V16, P1795, DOI 10.1093/emboj/16.7.1795; Sun K, 1998, FEMS MICROBIOL LETT, V164, P375, DOI 10.1111/j.1574-6968.1998.tb13112.x; Taguchi S, 1999, J BIOCHEM, V126, P689, DOI 10.1093/oxfordjournals.jbchem.a022504; Tendeng C, 2000, J BACTERIOL, V182, P2026, DOI 10.1128/JB.182.7.2026-2032.2000; Thieringer HA, 1998, BIOESSAYS, V20, P49; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIPPNER D, 1995, J BIOL CHEM, V270, P22243, DOI 10.1074/jbc.270.38.22243; Williams RM, 1997, FEMS MICROBIOL LETT, V156, P175, DOI 10.1016/S0378-1097(97)00397-2; Xu Y, 1998, MICROBIOL-SGM, V144, P1435, DOI 10.1099/00221287-144-5-1435	49	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18754	18760		10.1074/jbc.M211766200	http://dx.doi.org/10.1074/jbc.M211766200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637536	hybrid			2022-12-27	WOS:000182932200008
J	Won, J; Kim, DY; La, M; Kim, D; Meadows, GG; Joe, CO				Won, J; Kim, DY; La, M; Kim, D; Meadows, GG; Joe, CO			Cleavage of 14-3-3 protein by caspase-3 facilitates bad interaction with Bcl-x(L) during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; CYTOCHROME-C; SIGNALING PROTEINS; MITOCHONDRIA; KINASE; DEATH; PHOSPHORYLATION; BINDING; RELEASE; COMPLEXES	The 14-3-3epsilon protein was identified as one of the caspase-3 substrates by the modified yeast two-hybrid system. The cellular 14-3-3epsilon protein was also cleaved in response to the treatment of apoptosis inducers in cultured mammalian cells. Asp(238) of the 14-3-3epsilon protein was determined as the site of cleavage by caspase-3. The affinity of the cleaved 14-3-3 mutant protein (D238) to Bad, a death-promoting Bcl-2 family protein, was lower than that of wild type or the uncleavable mutant 14-3-3epsilon protein (D238A). However, Bad associated with the cellular Bcl-x(L) more effectively in human 293T cells coexpressing Bad with the truncated form of the 14-3-3epsilon protein ( D238) than in control cells co-expressing Bad with wild type or the uncleavable mutant 14-3-3epsilon protein ( D238A). The present study suggests that the cleavage of 14-3-3 protein during apoptosis promotes cell death by releasing the associated Bad from the 14-3-3 protein and facilitates Bad translocation to the mitochondria and its interaction with Bcl-x(L).	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Washington State Univ, Canc Prevent & Res Ctr, Dept Pharmaceut Sci, Pullman, WA 99164 USA	Korea Advanced Institute of Science & Technology (KAIST); Washington State University	Joe, CO (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.							AGUAN K, 1990, NUCLEIC ACIDS RES, V18, P1071, DOI 10.1093/nar/18.4.1071; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim JW, 2000, J CELL SCI, V113, P955; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Lizcano JM, 2000, BIOCHEM J, V349, P547, DOI 10.1042/bj3490547; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Miller D K, 1997, Semin Immunol, V9, P35, DOI 10.1006/smim.1996.0058; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; Villa P, 1997, TRENDS BIOCHEM SCI, V22, P388, DOI 10.1016/S0968-0004(97)01107-9; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	34	65	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19347	19351		10.1074/jbc.M213098200	http://dx.doi.org/10.1074/jbc.M213098200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12657644	hybrid			2022-12-27	WOS:000182932200082
J	Kitada, H; Miyata, M; Nakamura, T; Tozawa, A; Honma, W; Shimada, M; Nagata, K; Sinal, CJ; Guo, GL; Gonzalez, FJ; Yamazoe, Y				Kitada, H; Miyata, M; Nakamura, T; Tozawa, A; Honma, W; Shimada, M; Nagata, K; Sinal, CJ; Guo, GL; Gonzalez, FJ; Yamazoe, Y			Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALT EXPORT PUMP; FARNESOID-X-RECEPTOR; BILE-ACID; NUCLEAR RECEPTOR; LIQUID-CHROMATOGRAPHY; MOLECULAR-CLONING; GENE-EXPRESSION; PROTEIN-3 MRP3; MOUSE-LIVER; RAT	Supplement of 1% lithocholic acid (LCA) in the diet for 5-9 days resulted in elevated levels of the marker for liver damage aspartate aminotransferase and alkaline phosphatase activities in both farnesoid X receptor (FXR)-null and wild-type female mice. The levels were clearly higher in wild-type mice than in FXR-null mice, despite the diminished expression of a bile salt export pump in the latter. Consistent with liver toxicity marker activities, serum and liver levels of bile acids, particularly LCA and taurolithocholic acid, were clearly higher in wild-type mice than in FXR-null mice after 1% LCA supplement. Marked increases in hepatic sulfating activity for LCA (5.5-fold) and hydroxysteroid sulfotransferase (St) 2a (5.8-fold) were detected in liver of FXR-null mice. A 7.4-fold higher 3alpha-sulfated bile acid concentration was observed in bile of FXR-null mice fed an LCA diet compared with that of wild-type mice. Liver St2a content was inversely correlated with levels of alkaline phosphatase. In contrast, microsomal LCA 6beta-hydroxylation was not increased and was in fact lower in FXR-null mice compared in wild-type mice. Clear decreases in mRNA encoding sodium taurocholate cotransporting polypeptide, organic anion transporting polypeptide 1, and liver-specific organic anion transporter-1 function in bile acid import were detected in LCA-fed mice. These transporter levels are higher in FXR-null mice than wild-type mice after 1% LCA supplement. No obvious changes were detected in the Mrp2, Mrp3, and Mrp4 mRNAs. These results indicate hydroxysteroid sulfotransferase-mediated LCA sulfation as a major pathway for protection against LCA-induced liver damage. Furthermore, Northern blot analysis using FXR-null, pregnane X receptor-null, and FXR-pregnane X receptor double-null mice suggests a repressive role of these nuclear receptors on basal St2a expression.	Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 9808578, Japan; NCI, Metab Lab, NIH, Bethesda, MD 20892 USA	Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miyata, M (corresponding author), Tohoku Univ, Grad Sch Pharmaceut Sci, Div Drug Metab & Mol Toxicol, Aoba Ku, Sendai, Miyagi 9808578, Japan.			Sinal, Christopher/0000-0001-8301-3349				Akita H, 2001, BBA-BIOMEMBRANES, V1511, P7, DOI 10.1016/S0005-2736(00)00355-2; Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; Araya Z, 1999, BBA-MOL CELL BIOL L, V1438, P47, DOI 10.1016/S1388-1981(99)00031-1; CAREY MC, 1979, BIOCHIM BIOPHYS ACTA, V575, P16, DOI 10.1016/0005-2760(79)90126-7; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; COWEN AE, 1975, GASTROENTEROLOGY, V69, P59; DIONNE S, 1994, BIOCHEM PHARMACOL, V48, P1187, DOI 10.1016/0006-2952(94)90156-2; Gerloff T, 1998, J BIOL CHEM, V273, P10046, DOI 10.1074/jbc.273.16.10046; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hirohashi T, 2000, J BIOL CHEM, V275, P2905, DOI 10.1074/jbc.275.4.2905; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hofmann Alan F., 1994, P677; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; Kato T, 1996, DIGEST DIS SCI, V41, P1564, DOI 10.1007/BF02087901; KONG ANT, 1993, PHARMACEUT RES, V10, P627, DOI 10.1023/A:1018926825475; KONG ANT, 1994, CHEM-BIOL INTERACT, V92, P161, DOI 10.1016/0009-2797(94)90061-2; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; KUIPERS F, 1986, AM J PHYSIOL, V251, pG189, DOI 10.1152/ajpgi.1986.251.2.G189; Kullak-Ublick GA, 2000, SEMIN LIVER DIS, V20, P273, DOI 10.1055/s-2000-9426; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; MAKINO I, 1974, J LIPID RES, V15, P132; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; OELBERG DG, 1984, J CLIN INVEST, V73, P1507, DOI 10.1172/JCI111356; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Runge-Morris M, 1999, MOL PHARMACOL, V56, P1198, DOI 10.1124/mol.56.6.1198; Schuetz EG, 2001, J BIOL CHEM, V276, P39411, DOI 10.1074/jbc.M106340200; Shimada M, 2001, BRAIN RES, V920, P222, DOI 10.1016/S0006-8993(01)03061-X; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Song CS, 2001, J BIOL CHEM, V276, P42549, DOI 10.1074/jbc.M107557200; Sonoda J, 2002, P NATL ACAD SCI USA, V99, P13801, DOI 10.1073/pnas.212494599; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; STIEHL A, 1974, EUR J CLIN INVEST, V4, P59, DOI 10.1111/j.1365-2362.1974.tb00373.x; STIEHL A, 1975, GASTROENTEROLOGY, V68, P534; Suzuki H, 1998, SEMIN LIVER DIS, V18, P359, DOI 10.1055/s-2007-1007170; TAKIKAWA H, 1991, BIOCHIM BIOPHYS ACTA, V1091, P173, DOI 10.1016/0167-4889(91)90058-6; Takikawa H, 1984, Gastroenterol Jpn, V19, P104; TAZUKE Y, 1994, BIOSCI BIOTECH BIOCH, V58, P889, DOI 10.1271/bbb.58.889; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; XEI W, 2001, P NATL ACAD SCI USA, V98, P3375; YAMADA J, 1991, ANAL BIOCHEM, V199, P132, DOI 10.1016/0003-2697(91)90280-7; Yousef IM, 1997, DRUG METAB REV, V29, P167, DOI 10.3109/03602539709037579; Yu JH, 2002, J BIOL CHEM, V277, P31441, DOI 10.1074/jbc.M200474200	47	125	128	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17838	17844		10.1074/jbc.M210634200	http://dx.doi.org/10.1074/jbc.M210634200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637555	hybrid			2022-12-27	WOS:000182838300032
J	Van Impe, K; De Corte, V; Eichinger, L; Bruyneel, E; Mareel, M; Vandekerckhove, JL; Gettemans, J				Van Impe, K; De Corte, V; Eichinger, L; Bruyneel, E; Mareel, M; Vandekerckhove, JL; Gettemans, J			The nucleo-cytoplasmic actin-binding protein CapG lacks a nuclear export sequence present in structurally related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; SIGNAL; PHOSPHORYLATION; LOCALIZATION; EXPRESSION; TRANSPORT; RNAS; GELSOLIN; RECEPTOR; COFILIN	Despite thorough structure-function analyses, it remains unclear how CapG, a ubiquitous F-actin barbed end capping protein that controls actin microfilament turnover in cells, is able to reside in the nucleus and cytoplasm, whereas structurally related actin-binding proteins are predominantly cytoplasmic. Here we report the molecular basis for the different subcellular localization of CapG, severin, and fragminP. Green fluorescent protein-tagged fragminP and severin accumulate in the nucleus upon treatment of transfected cells with the CRM1 inhibitor leptomycin B. We identified a nuclear export sequence in severin and fragminP, which is absent in CapG. Deletion of amino acids Met(1)-Leu(27) resulted in nuclear accumulation of severin and fragminP. Tagging this sequence to CapG triggered nuclear export, whereas mutation of single leucine residues (Leu(17), Leu(21), and Leu(27)) in the export sequence inhibited nuclear export. Based on these findings, a nuclear export signal was identified in myopodin, a muscle-specific actin-binding protein, and the Bloom syndrome protein, a RecQ-like helicase. Deletion of the myopodin nuclear export sequence blocked invasion into collagen type I of C2C12 cells transiently overexpressing myopodin. Our findings explain regulated subcellular targeting of distinct classes of actin-binding proteins.	Univ Ghent VIB, Fac Med & Hlth Sci, Dept Biochem,Rommelaere Inst, B-9000 Ghent, Belgium; Univ Cologne, Fak Med, Inst Biochem 1, D-50931 Cologne, Germany; Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium	Flanders Institute for Biotechnology (VIB); Ghent University; University of Cologne; Ghent University; Ghent University Hospital	Gettemans, J (corresponding author), Univ Ghent VIB, Fac Med & Hlth Sci, Dept Biochem,Rommelaere Inst, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@rug.ac.be	Eichinger, Ludwig/AAJ-8895-2021	Eichinger, Ludwig/0000-0003-1594-6117				ANDRE E, 1988, J BIOL CHEM, V263, P722; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BRACKE ME, 2001, METASTASIS RES PROTO, P81; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK AM, 1988, DEV BIOL, V128, P30, DOI 10.1016/0012-1606(88)90263-1; Constantin B, 1998, J CELL SCI, V111, P1695; Dobbelstein M, 1997, EMBO J, V16, P4276, DOI 10.1093/emboj/16.14.4276; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Heger P, 2001, TRAFFIC, V2, P544, DOI 10.1034/j.1600-0854.2001.20804.x; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hofmann W, 2001, J CELL BIOL, V152, P895, DOI 10.1083/jcb.152.5.895; JOHNSTON PA, 1990, J BIOL CHEM, V265, P17946; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MERTENS N, 1995, GENE, V164, P9, DOI 10.1016/0378-1119(95)00505-Z; Nagaoka R, 1996, CELL MOTIL CYTOSKEL, V35, P200, DOI 10.1002/(SICI)1097-0169(1996)35:3<200::AID-CM3>3.0.CO;2-C; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nebl G, 1996, J BIOL CHEM, V271, P26276, DOI 10.1074/jbc.271.42.26276; OHTA Y, 1989, J BIOL CHEM, V264, P16143; ONODA K, 1993, CELL MOTIL CYTOSKEL, V26, P227, DOI 10.1002/cm.970260306; ONODA K, 1993, J BIOL CHEM, V268, P4106; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; Samstag Y, 1996, J IMMUNOL, V156, P4167; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Sklyarova T, 2002, J BIOL CHEM, V277, P39840, DOI 10.1074/jbc.M207052200; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Ting HJ, 2002, P NATL ACAD SCI USA, V99, P661, DOI 10.1073/pnas.022469899; TJampens D, 1997, J CELL SCI, V110, P1215; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wada A, 1998, EMBO J, V17, P1635, DOI 10.1093/emboj/17.6.1635; Weins A, 2001, J CELL BIOL, V155, P393, DOI 10.1083/jcb.200012039; WEN W, 1994, J BIOL CHEM, V269, P32214; Witke W, 2001, J CELL BIOL, V154, P775, DOI 10.1083/jcb.200101113; Wulfkuhle JD, 1999, J CELL SCI, V112, P2125	38	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17945	17952		10.1074/jbc.M209946200	http://dx.doi.org/10.1074/jbc.M209946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637565	hybrid			2022-12-27	WOS:000182838300045
J	Albert, CJ; Thukkani, AK; Heuertz, RM; Slungaard, A; Hazen, SL; Ford, DA				Albert, CJ; Thukkani, AK; Heuertz, RM; Slungaard, A; Hazen, SL; Ford, DA			Eosinophil peroxidase-derived reactive brominating species target the vinyl ether bond of plasmalogens generating a novel chemoattractant, alpha-bromo fatty aldehyde	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELOPEROXIDASE TARGET; HYPOCHLOROUS ACID; PROTEIN ADDUCTS; CHLORIDE SYSTEM; ANIMAL-CELLS; OXIDATION; IDENTIFICATION; CHOLESTEROL; NEUTROPHIL; PHAGOCYTES	Plasmalogens are a subclass of glycerophospholipids that are enriched in the plasma membrane of many mammalian cells. The vinyl ether bond of plasmalogens renders them susceptible to oxidation. Accordingly, it was hypothesized that reactive brominating species, a unique oxidant formed at the sites of eosinophil activation, such as in asthma, might selectively target plasmalogens for oxidation. Here we show that reactive brominating species produced by the eosinophil peroxidase system of activated eosinophils attack the vinyl ether bond of plasmalogens. Reactive brominating species produced by eosinophil peroxidase target the vinyl ether bond of plasmalogens resulting in the production of a neutral lipid and lysophosphatidylcholine. Chromatographic and mass spectrometric analyses of this neutral lipid demonstrated that it was 2-bromohexadecanal (2-BrHDA). Reactive brominating species produced by eosinophil peroxidase attacked the plasmalogen vinyl ether bond at acidic pH. Bromide was the preferred substrate for eosinophil peroxidase, and chloride was not appreciably used even at a 1000-fold molar excess. Furthermore, 2-BrHDA production elicited by eosinophil peroxidase-derived reactive brominating species in the presence of 100 pm NaBr doubled with the addition of 100 mm NaCl. The potential physiological significance of this pathway was suggested by the demonstration that 2-BrHDA was produced by phorbol myristate acetate-stimulated eosinophils and by the demonstration that 2-BrHDA is a phagocyte chemoattractant. Taken together, the present studies demonstrate the targeting of the vinyl ether bond of plasmalogens by the reactive brominating species produced by eosinophil peroxidase and by activated eosinophils, resulting in the production of brominated fatty aldehydes.	St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Hlth Sci Ctr, Dept Internal Med, St Louis, MO 63104 USA; St Louis Univ, Hlth Sci Ctr, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Univ Minnesota, Dept Med, Sect Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA	Saint Louis University; Saint Louis University; Saint Louis University; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Minnesota System; University of Minnesota Twin Cities	Ford, DA (corresponding author), St Louis Univ, Sch Med, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Hazen, Stanley L/ABD-5845-2021; Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560	NHLBI NIH HHS [HL61878, R01 HL 42665, HL70937, HL51199] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL070937, R01HL042665, R01HL051199] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2002, J BIOL CHEM, V277, P4694, DOI 10.1074/jbc.M110875200; Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; Aldridge RE, 2002, FREE RADICAL BIO MED, V33, P847, DOI 10.1016/S0891-5849(02)00976-0; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Caldwell RA, 1998, CIRC RES, V83, P533, DOI 10.1161/01.RES.83.5.533; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V327, P227, DOI 10.1006/abbi.1996.0114; Carr AC, 1997, REDOX REP, V3, P263, DOI 10.1080/13510002.1997.11747122; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V332, P63, DOI 10.1006/abbi.1996.0317; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CURZIO M, 1982, RES COMMUN CHEM PATH, V36, P463; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GUTHMANN F, 1995, INT J BIOCHEM CELL B, V27, P1021, DOI 10.1016/1357-2725(95)00078-4; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Hartley DP, 1997, CHEM RES TOXICOL, V10, P895, DOI 10.1021/tx960181b; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101, DOI 10.1164/ajrccm.165.1.2104131; IDE M, 1994, J IMMUNOL METHODS, V168, P187, DOI 10.1016/0022-1759(94)90054-X; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Mitra SN, 2000, REDOX REP, V5, P215, DOI 10.1179/135100000101535771; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MURPHY EJ, 1992, LIPIDS, V27, P150, DOI 10.1007/BF02535816; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; POST JA, 1988, FEBS LETT, V240, P78, DOI 10.1016/0014-5793(88)80343-0; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; RUSTOW B, 1994, BIOCHEM J, V302, P665; TEITZ NW, 1999, TEITZ TXB CLIN CHEM, P2216; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200; van Dalen CJ, 2001, BIOCHEM J, V358, P233, DOI 10.1042/0264-6021:3580233; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	45	35	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8942	8950		10.1074/jbc.M211634200	http://dx.doi.org/10.1074/jbc.M211634200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643282	hybrid			2022-12-27	WOS:000181524000012
J	Kalinina, EV; Fricker, LD				Kalinina, EV; Fricker, LD			Palmitoylation of carboxypeptidase D - Implications for intracellular trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI-NETWORK; METALLOCARBOXYPEPTIDASE-D; ATT-20 CELLS; CYTOPLASMIC DOMAIN; LOCALIZATION; PROTEINS; ENZYME; EXPRESSION; PITUITARY; RECEPTOR	Covalent lipid modifications mediate protein-membrane and protein-protein interactions and are often essential for function. The purposes of this study were to examine the Cys residues of the transmembrane domain of metallocarboxypeptidase D (CPD) that could be a target for palmitoylation and to clarify the function of this modification. CPD is an integral membrane protein that cycles between the trans Golgi network and the plasma membrane. We constructed AtT-20 cells stably expressing various constructs carrying a reporter protein (albumin) fused to a transmembrane domain and the CPD cytoplasmic tail. Some of the constructs contained the three Cys residues present in the CPD transmembrane region, while other constructs contained Ala in place of the Cys. Constructs carrying Cys residues were palmitoylated, while those constructs lacking the Cys residues were not. Because palmitoylation of several proteins affects their association with cholesterol and sphingolipid-rich membrane domains or caveolae, we tested endogenous CPD and several of the reporter constructs for resistance to extraction with Triton X-100. A construct containing the Cys residues of the CPD transmembrane domain was soluble in Triton X-100 as was endogenous palmitoylated CPD, indicating that palmitoylation does not target CPD to detergent-resistant membrane rafts. Interestingly, constructs of CPD that lack palmitoylation sites have an increased half-life, a slightly more diffuse steady-state localization, and a slower rate of exit from the Golgi as compared with constructs containing palmitoylation sites. Thus, the covalent attachment of palmitic acid to the Cys residues of CPD has a functional significance in the trafficking of the protein.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Fricker, LD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Kalinina, Elena/D-9252-2012	Kalinina, Elena/0000-0003-0180-090X	NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [K02 DA00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK55711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Fan XM, 1999, DNA CELL BIOL, V18, P121, DOI 10.1089/104454999315501; Fricker L. D., 2002, ENZYMES, V23, P421; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1349; Hawtin SR, 2001, J BIOL CHEM, V276, P38139; Ishikawa T, 1998, GENE, V215, P361, DOI 10.1016/S0378-1119(98)00270-4; Kalinina E, 2002, J CELL BIOCHEM, V85, P101, DOI 10.1002/jcb.10112; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MITRA A, 1994, J BIOL CHEM, V269, P19876; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Schweizer A, 1999, BIOCHEM J, V340, P649, DOI 10.1042/0264-6021:3400649; Sidyelyeva G, 2002, J BIOL CHEM, V277, P49613, DOI 10.1074/jbc.M209652200; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Tan FL, 1997, BIOCHEM J, V327, P81, DOI 10.1042/bj3270081; Urban S, 1999, J BIOL CHEM, V274, P5707, DOI 10.1074/jbc.274.9.5707; van de Loo JWHP, 2000, BIOCHEM J, V352, P827, DOI 10.1042/0264-6021:3520827; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1997, ENDOCRINOLOGY, V138, P4883, DOI 10.1210/en.138.11.4883; Varlamov O, 1998, J CELL SCI, V111, P877; Varlamov O, 2001, J CELL SCI, V114, P311; Varlamov O, 1999, J BIOL CHEM, V274, P14040, DOI 10.1074/jbc.274.20.14040; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897	32	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9244	9249		10.1074/jbc.M209379200	http://dx.doi.org/10.1074/jbc.M209379200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643288	hybrid			2022-12-27	WOS:000181524000048
J	Wiley, DJ; Marcus, S; D'Urso, G; Verde, F				Wiley, DJ; Marcus, S; D'Urso, G; Verde, F			Control of cell polarity in fission yeast by association of Orb6p kinase with the highly conserved protein methyltransferase Skb1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOTONIC-DYSTROPHY KINASE; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; HUMAN HOMOLOG; CYCLE; ENCODES; MORPHOGENESIS; INTERACTS; BINDING; GROWTH	In the fission yeast Schizosaccharomyces pombe, proper establishment and maintenance of cell polarity require Orb6p, a highly conserved serine/threonine kinase involved in regulating both cell morphogenesis and cell cycle control. Orb6p localizes to the cell tips during interphase and to the cell septum during mitosis. To investigate the mechanisms involved in Orb6p function, we conducted a two-hybrid screen to identify proteins that interact with Orb6p. Using this approach, we identified Skb1p, a highly conserved protein methyltransferase that has been implicated previously in cell cycle control, in the coordination of cell cycle progression with morphological changes, and in hyperosmotic stress response. We found that Skb1p associates with Orb6p in S. pombe cells and that the two proteins interact directly in vitro. Loss of Skb1p exacerbates the phenotype of orb6 mutants, suggesting that Skb1p and Orb6p functionally interact in S. pombe cells. Our results suggest that Skb1p affects the intracellular localization of Orb6p and that loss of Skb1p leads to a redistribution of the Orb6p kinase away from the cell tips. Furthermore, we found that Orb6p kinase activity is strongly increased following exposure to salt shock, suggesting that Orb6p has a role in cell response to hyperosmotic stress. Previous studies have shown that Skb1p interacts with the fission yeast p21-activated kinase homologue Pak1p/Shk1p to regulate cell polarity and cell cycle progression. Our findings identify Orb6p as an additional target for Skb1p and suggest a novel function for Skb1p in the control of cell polarity by regulating the subcellular localization of Orb6p.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Miami; University of Texas System; UTMD Anderson Cancer Center	Verde, F (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	fverde@miami.edu			NIGMS NIH HHS [R01GM53239] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053239] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bao SL, 2001, J BIOL CHEM, V276, P14549, DOI 10.1074/jbc.C100096200; Bidlingmaier S, 2001, MOL CELL BIOL, V21, P2449, DOI 10.1128/MCB.21.7.2449-2462.2001; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; DRUBIN DG, 2000, CELL POLARITY; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Gilbreth M, 1998, P NATL ACAD SCI USA, V95, P14781, DOI 10.1073/pnas.95.25.14781; Gilbreth M, 1996, P NATL ACAD SCI USA, V93, P13802, DOI 10.1073/pnas.93.24.13802; Hou MC, 2003, J CELL SCI, V116, P125, DOI 10.1242/jcs.00206; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Lew DJ, 2000, CURR OPIN GENET DEV, V10, P47, DOI 10.1016/S0959-437X(99)00051-9; Longtine MS, 2000, MOL CELL BIOL, V20, P4049, DOI 10.1128/MCB.20.11.4049-4061.2000; MA KJ, 1996, GENE DEV, V10, P1327; Ma XJ, 2000, TRENDS BIOCHEM SCI, V25, P11, DOI 10.1016/S0968-0004(99)01509-1; MARCUS S, 1995, P NATL ACAD SCI USA, V92, P6180, DOI 10.1073/pnas.92.13.6180; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; MITCHISON JM, 1985, J CELL SCI, V75, P357; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; OTTILIE S, 1995, EMBO J, V14, P5908, DOI 10.1002/j.1460-2075.1995.tb00278.x; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; Racki WJ, 2000, EMBO J, V19, P4524, DOI 10.1093/emboj/19.17.4524; Shulewitz MJ, 1999, MOL CELL BIOL, V19, P7123; STREIBLOVA E, 1972, Z ALLG MIKROBIOL, V12, P673, DOI 10.1002/jobm.3630120808; VERDE F, 1995, J CELL BIOL, V131, P1529, DOI 10.1083/jcb.131.6.1529; Verde F, 1998, P NATL ACAD SCI USA, V95, P7526, DOI 10.1073/pnas.95.13.7526; YARDEN O, 1992, EMBO J, V11, P2159, DOI 10.1002/j.1460-2075.1992.tb05275.x; Zallen JA, 2000, MOL BIOL CELL, V11, P3177, DOI 10.1091/mbc.11.9.3177	31	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					25256	25263		10.1074/jbc.M209703200	http://dx.doi.org/10.1074/jbc.M209703200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12646585	hybrid			2022-12-27	WOS:000183824800120
J	Hirata, T; Iwamoto-Kihara, A; Sun-Wada, GH; Okajima, T; Wada, Y; Futai, M				Hirata, T; Iwamoto-Kihara, A; Sun-Wada, GH; Okajima, T; Wada, Y; Futai, M			Subunit rotation of vacuolar-type proton pumping ATPase - Relative rotation of the G and c subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H+-ATPASE; CROSS-LINKING; MUTATIONAL ANALYSIS; TORQUE GENERATION; MOLECULAR-CLONING; PLASMA-MEMBRANE; GAMMA-SUBUNIT; A3 ISOFORM; V-ATPASE; SYNTHASE	Vacuolar-type ATPases V1V0 (V-ATPases) are found ubiquitously in the endomembrane organelles of eukaryotic cells. In this study, we genetically introduced a His tag and a biotin tag onto the c and G subunits, respectively, of Saccharomyces cerevisiae V-ATPase. Using this engineered enzyme, we observed directly the continuous counter-clockwise rotation of an actin filament attached to the G subunit when the enzyme was immobilized on a glass surface through the c subunit. V-ATPase generated essentially the same torque as the F-ATPase (ATP synthase). The rotation was inhibited by concanamycin and nitrate but not by azide. These results demonstrated that the V- and F-ATPase carry out a common rotational catalysis.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan; Osaka Univ, Inst Sci & Ind Res, Nanosci & Nanotechnol Ctr, Osaka 5670047, Japan; Japan Sci & Technol Corp, CREST, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Life Sci, Tokyo 1538902, Japan	Osaka University; Osaka University; Japan Science & Technology Agency (JST); University of Tokyo	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp		Okajima, Toshihide/0000-0003-1733-9580				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bowman BJ, 2002, J BIOL CHEM, V277, P3965, DOI 10.1074/jbc.M109756200; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Curtis KK, 2002, J BIOL CHEM, V277, P2716, DOI 10.1074/jbc.M107777200; Curtis KK, 2002, J BIOL CHEM, V277, P8979, DOI 10.1074/jbc.M111708200; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Futai M, 2000, J EXP BIOL, V203, P107; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; HANADA H, 1990, BIOCHEM BIOPH RES CO, V170, P873, DOI 10.1016/0006-291X(90)92172-V; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; HOLLIDAY LS, 2003, CALCIFIED TISSUE INT, V15, P15; Huss M, 2002, J BIOL CHEM, V277, P40544, DOI 10.1074/jbc.M207345200; IHARA K, 1992, J EXP BIOL, V172, P475; Iko Y, 2001, J BIOL CHEM, V276, P47508, DOI 10.1074/jbc.M108803200; Imai-Senga Y, 2002, GENE, V289, P7, DOI 10.1016/S0378-1119(02)00542-5; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; KANE PM, 1989, J BIOL CHEM, V264, P19236; Lee BS, 1999, J BIOL CHEM, V274, P29164, DOI 10.1074/jbc.274.41.29164; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Murata Y, 2002, J BIOL CHEM, V277, P36296, DOI 10.1074/jbc.M200586200; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishio K, 2002, P NATL ACAD SCI USA, V99, P13448, DOI 10.1073/pnas.202149599; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NOUMI T, 1991, P NATL ACAD SCI USA, V88, P1938, DOI 10.1073/pnas.88.5.1938; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Oka T, 1998, J BIOL CHEM, V273, P22570, DOI 10.1074/jbc.273.35.22570; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SIKORSKI RS, 1989, GENETICS, V122, P19; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2003, GENE, V302, P147, DOI 10.1016/S0378-1119(02)01099-5; Sun-Wada GH, 2002, J BIOL CHEM, V277, P18098, DOI 10.1074/jbc.M111567200; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; Sze H, 2002, TRENDS PLANT SCI, V7, P157, DOI 10.1016/S1360-1385(02)02240-9; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Toyomura T, 2003, J BIOL CHEM, V278, P22023, DOI 10.1074/jbc.M302436200; Turina P, 2003, EMBO J, V22, P418, DOI 10.1093/emboj/cdg073; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Wada Y, 2000, BBA-BIOENERGETICS, V1459, P499, DOI 10.1016/S0005-2728(00)00189-4; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yokoyama K, 2000, J BIOL CHEM, V275, P13955, DOI 10.1074/jbc.275.18.13955; ZHANG JM, 1994, J BIOL CHEM, V269, P23518	58	138	147	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23714	23719		10.1074/jbc.M302756200	http://dx.doi.org/10.1074/jbc.M302756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12670943	hybrid			2022-12-27	WOS:000183638600065
J	Collet, JP; Lesty, C; Montalescot, G; Weisel, JW				Collet, JP; Lesty, C; Montalescot, G; Weisel, JW			Dynamic changes of fibrin architecture during fibrin formation and intrinsic fibrinolysis of fibrin-rich clots	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ACUTE MYOCARDIAL-INFARCTION; CONFOCAL MICROSCOPY; LYSIS; THROMBOLYSIS; RESISTANCE; ELECTRON; DISSOLUTION; TURBIDITY; ABCIXIMAB	Clotting and fibrinolysis are initiated simultaneously in vivo, and fibrinolysis usually occurs without any individualized lysis front ( intrinsic fibrinolysis). We have developed a novel model to assess whether morphological changes resulting from intrinsic fibrinolysis are similar to those previously reported at the lysis front using externally applied lytic agents. Fibrin assembly and fibrinolysis were followed in real- time by confocal microscopy using gold- labeled fibrinogen molecules. An increase in fiber absorbance ( 30%, p < 0.01) and a decrease in fiber diameter ( 60%, p < 0.01) due to the ongoing accumulation and packing of fibrin molecules were the most significant detectable features occurring during fibrin assembly. Similar features with a similar magnitude were observed during fibrin dissolution, but in the reverse order and with a 3- fold increase in duration. Then, lysing fibers were progressively transected laterally, and thinner fibers were cleaved at a 2.5- fold faster rate than thicker fibers ( p < 0.001). Frayed lysing fibers were seen to interact progressively with adjoining fibers ( agglomeration), leading to a 76 and 88% increase in the network pore diameter ( p < 0.05) and fiber diameter ( p < 0.01), respectively. At the maximum decrease in fiber absorbance ( 46%, p < 0.05), the network suddenly collapsed with the release of large fragments that gradually vanished. Morphological changes of fibrin that occur during intrinsic fibrinolysis are similar as those observed next to the lysis front, although they are not restricted spatially to the clot/ surrounding milieu interface but are observed through the entire clot.	CHU Pitie Salpetriere, Inst Cardiol, AP HP, F-75013 Paris, France; CHU Pitie Salpetriere, Hematol Lab, F-75013 Paris, France; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Pennsylvania	Collet, JP (corresponding author), CHU Pitie Salpetriere, Inst Cardiol, AP HP, 47 Blvd Hosp, F-75013 Paris, France.							Anand S, 1996, CIRCULATION, V94, P763, DOI 10.1161/01.CIR.94.4.763; BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230; BRAATEN JV, 1993, BLOOD, V81, P1290; BRAATEN JV, 1994, BLOOD, V83, P982; CARR ME, 1995, BLOOD COAGUL FIBRIN, V6, P567, DOI 10.1097/00001721-199509000-00011; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; Collet JP, 2002, CIRC RES, V90, P428, DOI 10.1161/hh0402.105095; Collet JP, 2001, CIRCULATION, V103, P2328; Collet JP, 2000, ARTERIOSCL THROM VAS, V20, P1354, DOI 10.1161/01.ATV.20.5.1354; Collett JP, 2001, ARTERIOSCL THROM VAS, V21, P142, DOI 10.1161/01.ATV.21.1.142; Crespo J, 1995, SIGNAL PROCESS, V47, P201, DOI 10.1016/0165-1684(95)00108-5; DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6; Diamond SL, 1999, ANNU REV BIOMED ENG, V1, P427, DOI 10.1146/annurev.bioeng.1.1.427; GABRIEL DA, 1992, J BIOL CHEM, V267, P24259; Handt S, 1996, BLOOD, V87, P4204, DOI 10.1182/blood.V87.10.4204.bloodjournal87104204; *ISIS 2 COLL GROUP, 1988, LANCET, V330, P1287; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; Kolev K, 1997, J BIOL CHEM, V272, P13666, DOI 10.1074/jbc.272.21.13666; KUNITADA S, 1992, BLOOD, V79, P1420; LESTY C, 1986, CYTOMETRY, V7, P117, DOI 10.1002/cyto.990070202; Russ J. C., 2016, IMAGE PROCESSING HDB, V7th; SABOVIC M, 1989, THROMB HAEMOSTASIS, V62, P1083; Sakharov DV, 1996, J BIOL CHEM, V271, P2133, DOI 10.1074/jbc.271.4.2133; SERRA J, 1988, IMAGE ANAL MATH MORP, V2, P110; Sinkovic A, 1998, AM HEART J, V136, P406, DOI 10.1016/S0002-8703(98)70213-3; SUENSON E, 1984, EUR J BIOCHEM, V149, P193; Veklich Y, 1998, BLOOD, V92, P4721, DOI 10.1182/blood.V92.12.4721.424k13_4721_4729; Weisel JW, 1999, THROMB HAEMOSTASIS, V82, P277; WEISEL JW, 1992, BIOPHYS J, V63, P111, DOI 10.1016/S0006-3495(92)81594-1; Zhu YH, 1999, CIRCULATION, V99, P3050, DOI 10.1161/01.CIR.99.23.3050	30	105	107	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21331	21335		10.1074/jbc.M212734200	http://dx.doi.org/10.1074/jbc.M212734200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12642590	hybrid			2022-12-27	WOS:000183354200005
J	Grimm, C; Kraft, R; Sauerbruch, S; Schultz, G; Harteneck, C				Grimm, C; Kraft, R; Sauerbruch, S; Schultz, G; Harteneck, C			Molecular and functional characterization of the melastatin-related cation channel TRPM3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION-CHANNEL; SECONDARY HYPOCALCEMIA; RECEPTOR; PROTEIN; FAMILY; LTRPC2; CELLS; IDENTIFICATION; HYPOMAGNESEMIA; MELANOMA	Proteins of the mammalian TRP ( transient receptor potential) family form a heterogenous group of cation channels important for cellular Ca2+ signaling and homeostasis. Here we present the full- length sequence of TRPM3, a member of the melastatin- like subfamily ( TRPM) of TRP channels. TRPM3 expression was found in human kidney and brain. HEK293 cells transiently transfected with TRPM3 showed a constitutive Ca2+ and Mn2+ entry. Whole- cell patch clamp experiments confirmed the spontaneous activity of TRPM3 and revealed permeability ratios P-Ca/P-Na of 1.57 and P-Na/P-Cs of 0.75. In cell- attached patches, spontaneous inward and outward currents were observed. At negative membrane potentials and in the presence of either 140 mM Cs+, 140 mM Na+, or 100 mM Ca2+ in the pipette solution, the single channel conductance levels were 133, 83, and 65 pS, respectively. The Ca2+ entry in TRPM3- expressing HEK293 cells increased during treatment with hypotonic extracellular solution. The reduction of extracellular osmolarity was accompanied by cell swelling, suggesting volume- regulated activity of TRPM3. From its function and expression in human kidney, we propose a role of TRPM3 in renal Ca2+ homeostasis.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany; Free Univ Berlin, Fachbereich Biol Chem Pharm, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Harteneck, C (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.		Grimm, Christian/ABF-9121-2020; Kraft, Robert/E-9199-2011	Grimm, Christian/0000-0002-0177-5559; Kraft, Robert/0000-0002-5774-6001				Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Duncan LM, 1998, CANCER RES, V58, P1515; Duncan LM, 2001, J CLIN ONCOL, V19, P568, DOI 10.1200/JCO.2001.19.2.568; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hermosura MC, 2002, J PHYSIOL-LONDON, V539, P445, DOI 10.1113/jphysiol.2001.013361; Hunter JJ, 1998, GENOMICS, V54, P116, DOI 10.1006/geno.1998.5549; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Launay P, 2002, CELL, V109, P397, DOI 10.1016/S0092-8674(02)00719-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Perez CA, 2002, NAT NEUROSCI, V5, P1169, DOI 10.1038/nn952; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Watanabe H, 2002, J BIOL CHEM, V277, P47044, DOI 10.1074/jbc.M208277200; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu XZS, 2001, P NATL ACAD SCI USA, V98, P10692, DOI 10.1073/pnas.191360198	30	247	265	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21493	21501		10.1074/jbc.M300945200	http://dx.doi.org/10.1074/jbc.M300945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672799	hybrid			2022-12-27	WOS:000183354200024
J	Ashby, MC; Camello-Almaraz, C; Gerasimenko, OV; Petersen, OH; Tepikin, AV				Ashby, MC; Camello-Almaraz, C; Gerasimenko, OV; Petersen, OH; Tepikin, AV			Long distance communication between muscarinic receptors and Ca2+ release channels revealed by carbachol uncaging in cell-attached patch pipette	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC ACINAR-CELLS; CYCLIC ADP-RIBOSE; INOSITOL TRISPHOSPHATE; POLARIZED EXPRESSION; RYANODINE RECEPTORS; EXOCRINE PANCREAS; CALCIUM; OSCILLATIONS; MITOCHONDRIA; SIGNALS	We have investigated the characteristics of cytosolic Ca2+ signals induced by muscarinic receptor activation of pancreatic acinar cells that reside within intact pancreatic tissue. We show that these cells exhibit global Ca2+ waves and local apical Ca2+ spikes. This is the first evidence for local Ca2+ signaling in undissociated pancreatic tissue. The mechanism of formation of localized Ca2+ signals was examined using a novel approach involving photolysis of caged carbachol inside a patch pipette attached to the basal surface of an acinar unit. This local activation of basal muscarinic receptors elicited local cytosolic Ca2+ spikes in the apical pole more than 15 mum away from the site of stimulation. In some experiments, local basal receptor activation elicited a Ca2+ wave that started in the apical pole and then spread toward the base. Currently, there are two competing hypotheses for preferential apical Ca2+ signaling. One invokes the need for structural proximity of the cholinergic receptors and the Ca2+ release channels in the apical pole, whereas the other postulates long distance communication between basal receptors and the channels. Our intrapipette uncaging experiments provide definitive evidence for long distance communication between basal muscarinic receptors and apical Ca2+ release channels.	Univ Liverpool, MRC, Secretory Control Res Grp, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Ashby, MC (corresponding author), Univ Bristol, Sch Med, Dept Anat, Ctr Synapt Plastic, Univ Walk, Bristol BS8 1TD, Avon, England.		Petersen, Ole H/E-8708-2010; Gerasimenko, Oleg/A-6622-2010; Camello, Cristina/K-8238-2014	Gerasimenko, Oleg/0000-0003-2573-8258; Camello, Cristina/0000-0003-0882-8497; Petersen, Ole/0000-0002-6998-0380; Tepikin, Alexei/0000-0002-8172-7513; Ashby, Michael/0000-0002-8593-8473				Ashby MC, 2002, PHYSIOL REV, V82, P701, DOI 10.1152/physrev.00006.2002; Ashby MC, 2002, J CELL BIOL, V158, P283, DOI 10.1083/jcb.200112025; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; BURGOYNE RD, 1995, TRENDS NEUROSCI, V18, P191, DOI 10.1016/0166-2236(95)93900-I; Cancela JM, 2002, EMBO J, V21, P909, DOI 10.1093/emboj/21.5.909; Cancela JM, 2001, ANNU REV PHYSIOL, V63, P99, DOI 10.1146/annurev.physiol.63.1.99; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; Meldolesi J, 2001, PROG NEUROBIOL, V65, P309, DOI 10.1016/S0301-0082(01)00004-1; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Motta PM, 1997, MICROSC RES TECHNIQ, V37, P384, DOI 10.1002/(SICI)1097-0029(19970601)37:5/6<384::AID-JEMT3>3.3.CO;2-L; NIELSEN SP, 1972, J PHYSIOL-LONDON, V223, P685, DOI 10.1113/jphysiol.1972.sp009869; Park MK, 2001, P NATL ACAD SCI USA, V98, P10948, DOI 10.1073/pnas.181353798; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; ROSENZWEIG SA, 1983, J CELL BIOL, V96, P1288, DOI 10.1083/jcb.96.5.1288; Shin DM, 2001, J BIOL CHEM, V276, P44146, DOI 10.1074/jbc.M105203200; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; Thomason PA, 2002, CURR BIOL, V12, pR399, DOI 10.1016/S0960-9822(02)00885-0; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; Tinel H, 1999, EMBO J, V18, P4999, DOI 10.1093/emboj/18.18.4999; Voronina S, 2002, J PHYSIOL-LONDON, V539, P41, DOI 10.1113/jphysiol.2001.013134; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9	31	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20860	20864		10.1074/jbc.M302599200	http://dx.doi.org/10.1074/jbc.M302599200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657637	hybrid			2022-12-27	WOS:000183230500055
J	Fasolini, M; Wu, XQ; Flocco, M; Trosset, JY; Oppermann, U; Knapp, S				Fasolini, M; Wu, XQ; Flocco, M; Trosset, JY; Oppermann, U; Knapp, S			Hot spots in Tcf4 for the interaction with beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR LEF-1; PROTEIN INTERFACES; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; COMPLEX; BINDING; THERMODYNAMICS; CADHERIN; EFFECTOR; ICAT	The interaction of beta-catenin with T-cell factor (Tcf) 4 plays a central role in the Wnt signaling pathway and has been discussed as a possible site of intervention for the development of anti-cancer drugs. In this study, we performed Ala-scanning mutagenesis of all Tcf4 residues in the Tcf-beta-catenin interface and studied the binding energetics of these mutants using isothermal titration calorimetry. Binding of Tcf4 was found to be highly cooperative. Single site mutations of most Tcf4 residues resulted in a significant reduction in binding enthalpies but in similar binding constants as compared with wild type Tcf4. Interestingly, this was also true for residues that are disordered in the reported crystal structures. The mutation D16A caused the largest reduction in binding constant (50-fold) accompanied by a large unfavorable enthalpy change (DeltaDeltaH(obs)) of +8 kcal/mol at 25 degreesC. In contrast, the mutation of the Tcf residues Glu(24) and Glu(28), which have been proposed as an interaction hot spot due to their location in a field of strong positive electrostatic potential on the beta-catenin surface ( charge button), resulted only in a significant reduction of binding enthalpies, which were largely compensated for by unfavorable entropic contributions to the binding. Other mutations that significantly reduced Tcf binding constants were D11A and alanine mutations of the hydrophobic residues Leu(41), Val(44), and Leu(48). The measured thermodynamic data are discussed with the available structural information of Tcf-beta-catenin crystal structures and allow us to propose possible sites for development of Tcf antagonists.	Pharmacia Corp, Discovery Res Oncol, Dept Chem, I-20014 Nerviano, Italy; Karolinska Inst, S-17177 Stockholm, Sweden	Pfizer; Karolinska Institutet	Knapp, S (corresponding author), Pharmacia Corp, Discovery Res Oncol, Dept Chem, Viale Pasteur 10, I-20014 Nerviano, Italy.		Knapp, Stefan/AAG-2347-2019	Knapp, Stefan/0000-0001-5995-6494				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Berglund H, 1995, J AM CHEM SOC, V117, P12883, DOI 10.1021/ja00156a036; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; CARLSON M, 1991, J APPL CRYSTALLOGR, V24, P958; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Frisch C, 1997, J MOL BIOL, V267, P696, DOI 10.1006/jmbi.1997.0892; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Knapp S, 2001, J MOL BIOL, V306, P1179, DOI 10.1006/jmbi.2001.4463; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LADBURY JE, 1994, J MOL BIOL, V238, P669, DOI 10.1006/jmbi.1994.1328; Lundback T, 1998, J MOL BIOL, V276, P775, DOI 10.1006/jmbi.1997.1558; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Sheinerman FB, 2000, CURR OPIN STRUC BIOL, V10, P153, DOI 10.1016/S0959-440X(00)00065-8; Sheinerman FB, 2002, J MOL BIOL, V318, P161, DOI 10.1016/S0022-2836(02)00030-X; Shih IM, 2000, CANCER RES, V60, P1671; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; von Kries JP, 2000, NAT STRUCT BIOL, V7, P800; XIE D, 1994, PROTEINS, V19, P291, DOI 10.1002/prot.340190404	32	69	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21092	21098		10.1074/jbc.M301781200	http://dx.doi.org/10.1074/jbc.M301781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657632	hybrid			2022-12-27	WOS:000183230500084
J	Maurer, JA; Dougherty, DA				Maurer, JA; Dougherty, DA			Generation and evaluation of a large mutational library from the Escherichia coli mechanosensitive channel of large conductance, MscL - Implications for channel gating and evolutionary design	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; ION-CHANNEL; MYCOBACTERIUM-TUBERCULOSIS; STRETCH-INACTIVATION; POTASSIUM CHANNEL; SINGLE RESIDUE; K+ CHANNEL; MECHANISM; ACTIVATION	Random mutagenesis of the mechanosensitive channel of large conductance ( MscL) from Escherichia coli coupled with a high-throughput functional screen has provided new insights into channel structure and function. Complementary interactions of conserved residues proposed in a computational model for gating have been evaluated, and important functional regions of the channel have been identified. Mutational analysis shows that the proposed S1 helix, despite having several highly conserved residues, can be heavily mutated without significantly altering channel function. The pattern of mutations that make MscL more difficult to gate suggests that MscL senses tension with residues located near the lipid headgroups of the bilayer. The range of phenotypical changes seen has implications for a proposed model for the evolutionary origin of mechanosensitive channels.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA	California Institute of Technology	Dougherty, DA (corresponding author), CALTECH, Div Chem & Chem Engn, 1200 E Calif Blvd,Mail Code 164-30 Cr, Pasadena, CA 91125 USA.			Maurer, Joshua/0000-0002-6663-0721	NIGMS NIH HHS [GM-08501, GM-62532] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062532] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ajouz B, 2000, J BIOL CHEM, V275, P1015, DOI 10.1074/jbc.275.2.1015; BETANZOS M, 2002, NAT STRUCT BIOL, V9; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Blount P, 1996, P NATL ACAD SCI USA, V93, P11652, DOI 10.1073/pnas.93.21.11652; Blount P, 1997, J BIOL CHEM, V272, P32150, DOI 10.1074/jbc.272.51.32150; BRIGHTGAERTNER E, 1972, BIOCHIM BIOPHYS ACTA, V270, P40, DOI 10.1016/0005-2760(72)90175-0; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Cruickshank CC, 1997, BIOPHYS J, V73, P1925, DOI 10.1016/S0006-3495(97)78223-7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elmore DE, 2002, BIOPHYS J, V82, p628A; Elmore DE, 2001, BIOPHYS J, V81, P1345, DOI 10.1016/S0006-3495(01)75791-8; Gu CX, 2001, BIOPHYS J, V80, P2678, DOI 10.1016/S0006-3495(01)76237-6; Gu LQ, 1998, BIOPHYS J, V74, P2889, DOI 10.1016/S0006-3495(98)77995-0; Gullingsrud J, 2001, BIOPHYS J, V80, P2074, DOI 10.1016/S0006-3495(01)76181-4; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Hase CC, 1997, J MEMBRANE BIOL, V157, P17, DOI 10.1007/s002329900212; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jones SE, 2000, BIOCHEM BIOPH RES CO, V279, P208, DOI 10.1006/bbrc.2000.3921; Kloda A, 2001, CELL BIOCHEM BIOPHYS, V34, P349, DOI 10.1385/CBB:34:3:349; Kong YF, 2002, P NATL ACAD SCI USA, V99, P5999, DOI 10.1073/pnas.092051099; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LUGTENBERG EJJ, 1976, BIOCHIM BIOPHYS ACTA, V441, P38, DOI 10.1016/0005-2760(76)90279-4; Martinac B, 2002, P NATL ACAD SCI USA, V99, P4308, DOI 10.1073/pnas.072632899; Martinac B, 2001, CELL PHYSIOL BIOCHEM, V11, P61, DOI 10.1159/000047793; Maurer JA, 2000, J BIOL CHEM, V275, P22238, DOI 10.1074/jbc.M003056200; Maurer JA, 2001, BBA-BIOMEMBRANES, V1514, P165, DOI 10.1016/S0005-2736(01)00390-X; Okada K, 2002, J BIOL CHEM, V277, P27682, DOI 10.1074/jbc.M202497200; Ou XR, 1998, P NATL ACAD SCI USA, V95, P11471, DOI 10.1073/pnas.95.19.11471; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Perozo E, 2002, NATURE, V418, P942, DOI 10.1038/nature00992; RAO JKM, 1987, INT J PEPT PROT RES, V29, P276; Sukharev S, 2001, BIOPHYS J, V81, P917, DOI 10.1016/S0006-3495(01)75751-7; Sukharev S, 2001, NATURE, V409, P720, DOI 10.1038/35055559; Sukharev SI, 1999, J GEN PHYSIOL, V113, P525, DOI 10.1085/jgp.113.4.525; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; SUUTARI M, 1994, CRIT REV MICROBIOL, V20, P285, DOI 10.3109/10408419409113560; SUUTARI M, 1993, ARCH MICROBIOL, V159, P119, DOI 10.1007/BF00250270; Tabarean IV, 2002, BIOPHYS J, V82, P2982, DOI 10.1016/S0006-3495(02)75639-7; Wood JM, 1999, MICROBIOL MOL BIOL R, V63, P230, DOI 10.1128/MMBR.63.1.230-262.1999; Yoshimura K, 1999, BIOPHYS J, V77, P1960, DOI 10.1016/S0006-3495(99)77037-2; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	42	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21076	21082		10.1074/jbc.M302892200	http://dx.doi.org/10.1074/jbc.M302892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670944	hybrid, Green Accepted			2022-12-27	WOS:000183230500082
J	Morohashi, K; Minami, M; Takase, H; Hotta, Y; Hiratsuka, K				Morohashi, K; Minami, M; Takase, H; Hotta, Y; Hiratsuka, K			Isolation and characterization of a novel GRAS gene that regulates meiosis-associated gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCARECROW GENE; GIBBERELLIN RESPONSES; SIGNAL-TRANSDUCTION; NUCLEAR RECEPTOR; ARABIDOPSIS; FAMILY; ENCODES; PATHWAY; PROTEIN; TRANSCRIPTION	GRAS protein is a family of plant-specific proteins that plays a role in various developmental processes. Here we report a novel GRAS protein from lily, designated LlSCL (Lilium longiflorum Scarecrow-like), dominantly expressed at the premeiotic phase within anthers. The LlSCL protein has two highly basic regions, and transient expression analyses of dissected GFP-LlSCL fusion proteins showed that both basic regions are important for the nuclear localization. A series of transcriptional activation experiments of truncated LlSCL proteins fused to the yeast GAL4 DNA-binding domain clearly demonstrated that the amino terminus of the LlSCL protein has a strong activity of transcriptional activation in the yeast as well as in the plant cell. Further investigation on the effect of the LlSCL protein on the transcriptional activity of the meiosis-associated promoter revealed that in pollen mother cells of the lily, the activity of the meiosis-associated promoter is specifically enhanced by LlSCL protein co-expression. These results suggest that LlSCL is involved in transcriptional regulation during microsporogenesis within the lily anther.	Yokohama Natl Univ, Div Plant Biotechnol, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan; Niigata Univ Hlth & Welf, Dept Hlth & Nutr, Niigata 9503198, Japan	Yokohama National University; Nara Institute of Science & Technology; Niigata University	Hiratsuka, K (corresponding author), Yokohama Natl Univ, Div Plant Biotechnol, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan.		Morohashi, Kengo/AAV-2545-2021; Morohashi, Kengo/C-5511-2014					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bolle C, 2000, GENE DEV, V14, P1269; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Couteau F, 1999, PLANT CELL, V11, P1623, DOI 10.1105/tpc.11.9.1623; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; ERICKSON RO, 1948, AM J BOT, V35, P729, DOI 10.2307/2438154; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOTTA Y, 1985, CELL, V40, P785, DOI 10.1016/0092-8674(85)90338-1; Ikeda A, 2001, PLANT CELL, V13, P999, DOI 10.1105/tpc.13.5.999; Itoh H, 2002, PLANT CELL, V14, P57, DOI 10.1105/tpc.010319; Kobayashi T, 1994, DNA Res, V1, P15, DOI 10.1093/dnares/1.1.15; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lim J, 2000, PLANT CELL, V12, P1307, DOI 10.1105/tpc.12.8.1307; Liu LS, 1999, EUR J BIOCHEM, V262, P247, DOI 10.1046/j.1432-1327.1999.00349.x; Minami M, 2001, PLANT BIOTECHNOL-NAR, V18, P71; MOROHASHI K, 2000, PLANT BIOTECHNOL, V17, P131, DOI DOI 10.5511/PLANTBIOTECHNOLOGY.17.131; Mousavi A, 1999, PLANT CELL PHYSIOL, V40, P406, DOI 10.1093/oxfordjournals.pcp.a029556; Ogawa M, 2000, GENE, V245, P21, DOI 10.1016/S0378-1119(00)00018-4; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Richards DE, 2000, BIOESSAYS, V22, P573, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;573::AID-BIES10&gt;3.0.CO;2-H; Sassa N, 2001, PLANT CELL PHYSIOL, V42, P385, DOI 10.1093/pcp/pce048; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; TRIEZENBERG SJ, 1995, CURR OPIN GENET DEV, V5, P190, DOI 10.1016/0959-437X(95)80007-7; UEFUJI H, 2001, PLANT BIOTECHNOL, V18, P151; Wen CK, 2002, PLANT CELL, V14, P87, DOI 10.1105/tpc.010325	31	106	118	2	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20865	20873		10.1074/jbc.M301712200	http://dx.doi.org/10.1074/jbc.M301712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657631	hybrid			2022-12-27	WOS:000183230500056
J	Shi, XP; Tugusheva, K; Bruce, JE; Lucka, A; Wu, GX; Chen-Dodson, E; Price, E; Li, YM; Xu, M; Huang, Q; Sardana, MK; Hazuda, DJ				Shi, XP; Tugusheva, K; Bruce, JE; Lucka, A; Wu, GX; Chen-Dodson, E; Price, E; Li, YM; Xu, M; Huang, Q; Sardana, MK; Hazuda, DJ			beta-secretase cleavage at amino acid residue 34 in the amyloid beta peptide is dependent upon gamma-secretase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; ASPARTYL PROTEASE; PRESENILIN-1; INHIBITOR; BACE1; GENERATION; COMPARTMENT; DOMAIN; SITE	The amyloid beta peptides (Abeta) are the major components of the senile plaques characteristic of Alzheimer's disease. Abeta peptides are generated from the cleavage of amyloid precursor protein (APP) by beta- and gamma-secretases. beta-Secretase ( BACE), a type-I transmembrane aspartyl protease, cleaves APP first to generate a 99-amino acid membrane-associated fragment (CT99) containing the N terminus of Abeta peptides. gamma-Secretase, a multi-protein complex, then cleaves within the transmembrane region of CT99 to generate the C termini of Abeta peptides. The production of Abeta peptides is, therefore, dependent on the activities of both BACE and gamma-secretase. The cleavage of APP by BACE is believed to be a prerequisite for gamma-secretase-mediated processing. In the present study, we provide evidence both in vitro and in cells that BACE-mediated cleavage between amino acid residues 34 and 35 ( Abeta-34 site) in the Abeta region is dependent on gamma-secretase activity. In vitro, the Abeta-34 site is processed specifically by BACE1 and BACE2, but not by cathepsin D, a closely related aspartyl protease. Moreover, the cleavage of the Abeta-34 site by BACE1 or BACE2 occurred only when Abeta 1-40 peptide, a gamma-secretase cleavage product, was used as substrate, not the non-cleaved CT99. In cells, overexpression of BACE1 or BACE2 dramatically increased the production of the Abeta 1-34 species. More importantly, the cellular production of Abeta 1 - 34 species induced by overexpression of BACE1 or BACE2 was blocked by a number of known gamma-secretase inhibitors in a concentration-dependent manner. These gamma-secretase inhibitors had no effect on enzymatic activity of BACE1 or BACE2 in vitro. Our data thus suggest that gamma-secretase cleavage of CT99 is a prerequisite for BACE-mediated processing at Abeta- 34 site. Therefore, BACE and gamma-secretase activity can be mutually dependent.	Merck Res Labs, Dept Biol Chem, West Point, PA 19486 USA	Merck & Company	Shi, XP (corresponding author), Merck Res Labs, Dept Biol Chem, WP16-205, West Point, PA 19486 USA.	xiao-ping_shi@merck.com						Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Beher D, 2002, J NEUROCHEM, V82, P563, DOI 10.1046/j.1471-4159.2002.00985.x; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P12450, DOI 10.1021/bi001494f; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Farzan M, 2000, P NATL ACAD SCI USA, V97, P9712, DOI 10.1073/pnas.160115697; Fluhrer R, 2003, J BIOL CHEM, V278, P5531, DOI 10.1074/jbc.M211485200; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Huse JT, 2002, J BIOL CHEM, V277, P16278, DOI 10.1074/jbc.M111141200; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shi XP, 2002, NEUROBIOL AGING, V23, pS180; Shi XP, 2001, J BIOL CHEM, V276, P10366, DOI 10.1074/jbc.M009200200; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Turner RT, 2001, BIOCHEMISTRY-US, V40, P10001, DOI 10.1021/bi015546s; Vandermeeren M, 2001, NEUROSCI LETT, V315, P145, DOI 10.1016/S0304-3940(01)02369-2; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VIGOPELFREY C, 1993, J NEUROCHEM, V61, P1965, DOI 10.1111/j.1471-4159.1993.tb09841.x; Yan RQ, 2001, J BIOL CHEM, V276, P34019, DOI 10.1074/jbc.M105583200; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200	31	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21286	21294		10.1074/jbc.M209859200	http://dx.doi.org/10.1074/jbc.M209859200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665519	hybrid			2022-12-27	WOS:000183230500107
J	Ha, H; Kwak, HB; Lee, SK; Na, DS; Rudd, CE; Lee, ZH; Kim, HH				Ha, H; Kwak, HB; Lee, SK; Na, DS; Rudd, CE; Lee, ZH; Kim, HH			Membrane rafts play a crucial role in receptor activator of nuclear factor kappa B signaling and osteoclast function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; LIPID RAFTS; PHOSPHATIDYLINOSITOL 3-KINASE; DEFECTIVE INTERLEUKIN-1; BINDING PROTEIN; BONE-RESORPTION; FAMILY-MEMBER; TRAF FAMILY; ASSOCIATION; DIFFERENTIATION	Membrane lipid rafts play a key role in immune cell activation by recruiting and excluding specific signaling components of immune cell surface receptors upon the receptor engagement. Despite this, the role of these microdomains in the regulation of osteoclasts as controlled by receptor activator of nuclear factor kappaB ( RANK) has yet to be established. In this study, we demonstrate that the raft microdomain expression plays an essential role in osteoclast function and differentiation. Expression of raft component flotillin greatly increased during osteoclast differentiation, whereas engagement of RANK induced the translocation of tumor necrosis factor receptor-associated factor 6 to rafts where Src was constitutively resident. Disruption of rafts blocked TRAF6 translocation and Akt activation by RANK ligand in osteoclasts and further reduced the survival of osteoclasts. Actin ring formation and bone resorption by osteoclasts were also found to require the integrity of rafts. Our observations demonstrate for the first time that RANK-mediated signaling and osteoclast function are critically dependent on the expression and integrity of raft membrane microdomains.	Chosun Univ, Sch Dent, Gwangju 501759, South Korea; Chosun Univ, Natl Res Lab Bone Metab, Gwangju 501759, South Korea; Chosun Univ, Res Ctr Proteineous Mat, Gwangju 501759, South Korea; Univ Ulsan, Coll Med, Dept Biochem, Seoul 138736, South Korea; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Haematol, London W12 ONN, England	Chosun University; Chosun University; Chosun University; University of Ulsan; Imperial College London	Kim, HH (corresponding author), Chosun Univ, Sch Dent, 375 Seosuk Dong, Gwangju 501759, South Korea.	hhbkim@snu.ac.kr	Lee, SeungKu/GSN-5012-2022; Rudd, Christopher E/ABF-7259-2021; Rudd, Christopher E/GOH-2021-2022	Lee, SeungKu/0000-0001-5120-5557; Rudd, Christopher E/0000-0001-5295-9019				Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200; Arron JR, 2002, J EXP MED, V196, P923, DOI 10.1084/jem.20020774; Bilderback TR, 1997, J BIOL CHEM, V272, P10922; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Cottin V, 2002, J IMMUNOL, V168, P4095, DOI 10.4049/jimmunol.168.8.4095; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; HORNE WC, 1992, J CELL BIOL, V119, P1003, DOI 10.1083/jcb.119.4.1003; Hostager BS, 2000, J BIOL CHEM, V275, P15392, DOI 10.1074/jbc.M909520199; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Iwamoto T, 2001, J BIOL CHEM, V276, P46031, DOI 10.1074/jbc.M104464200; Jimi E, 1999, J IMMUNOL, V163, P434; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim HH, 1999, FEBS LETT, V443, P297, DOI 10.1016/S0014-5793(98)01731-1; Ko YG, 1999, J IMMUNOL, V162, P7217; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lakkakorpi PT, 1997, EXP CELL RES, V237, P296, DOI 10.1006/excr.1997.3797; Lakkakorpi PT, 1999, J BIOL CHEM, V274, P4900, DOI 10.1074/jbc.274.8.4900; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485; Martin M, 2001, J EXP MED, V194, P1675, DOI 10.1084/jem.194.11.1675; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Shin JN, 2002, J BIOL CHEM, V277, P8346, DOI 10.1074/jbc.M110964200; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Tansey MG, 2000, NEURON, V25, P611, DOI 10.1016/S0896-6273(00)81064-8; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Udagawa N., 2002, PRINCIPLES BONE BIOL, V2nd ed.; Vereb G, 2000, P NATL ACAD SCI USA, V97, P6013, DOI 10.1073/pnas.97.11.6013; Vidalain PO, 2000, EMBO J, V19, P3304, DOI 10.1093/emboj/19.13.3304; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xing LP, 2001, GENE DEV, V15, P241, DOI 10.1101/gad.840301; ZHANG D, 1995, J CELL SCI, V108, P2285	50	99	107	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18573	18580		10.1074/jbc.M212626200	http://dx.doi.org/10.1074/jbc.M212626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637570	hybrid			2022-12-27	WOS:000182838300129
J	Pankov, R; Cukierman, E; Clark, K; Matsumoto, K; Hahn, C; Poulin, B; Yamada, KM				Pankov, R; Cukierman, E; Clark, K; Matsumoto, K; Hahn, C; Poulin, B; Yamada, KM			Specific beta(1) integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; INTESTINAL EPITHELIAL-CELLS; BETA-1 CYTOPLASMIC DOMAIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODY; FIBRONECTIN RECEPTOR; EXTRACELLULAR-MATRIX; PLASMA-MEMBRANE; STIMULATED AKT	Integrin transmembrane receptors generate multiple signals, but how they mediate specific signaling is not clear. Here we test the hypothesis that particular sequences along the beta(1) integrin cytoplasmic domain may exist that are intimately related to specific integrin-mediated signaling pathways. Using systematic alanine mutagenesis of amino acids conserved between different beta integrin cytoplasmic domains, we identified the tryptophan residue at position 775 of human beta(1) integrin as specific and necessary for integrin-mediated protein kinase B/Akt survival signaling. Stable expression of a beta(1) integrin mutated at this amino acid in GD25 beta(1)-null cells resulted in reduction of Akt phosphorylation at both Ser(473) and Thr(308) activation sites. As a consequence, the cells were substantially more sensitive to serum starvation-induced apoptosis when compared with cells expressing wild type beta(1) integrin. This inactivation of Akt resulted from increased dephosphorylation by a localized active population of protein phosphatase 2A. Both Akt and protein phosphatase 2A were present in beta(1) integrin-organized cytoplasmic complexes, but the activity of this phosphatase was 2.5 times higher in the complexes organized by the mutant integrin. The mutation of Trp(775) specifically affected Akt signaling, without effects on other integrin-activated pathways including phosphoinositide 3-kinase, MAPK, JNK, and p38 nor did it influence activation of the integrin-responsive kinases focal adhesion kinase and Src. The identification of Trp(775) as a specific site for integrin-mediated Akt signaling supports the concept of specificity of signaling along the integrin cytoplasmic domain.	NIDCR, CDBRB, NIH, Bethesda, MD 20892 USA; NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Pankov, R (corresponding author), NIDCR, CDBRB, NIH, Bldg 30,Rm 421,30 Convent Dr MSC 4370, Bethesda, MD 20892 USA.	roumen.pankov@nih.gov	Pankov, Roumen G/B-3284-2014; Cukierman, Edna/A-3951-2013; Pankov, Roumen/AAK-3205-2021; cukierman, edna/AAU-8932-2020	Pankov, Roumen G/0000-0002-3157-3659; Pankov, Roumen/0000-0002-3157-3659; cukierman, edna/0000-0002-1452-9576; Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Alahari SK, 2002, INT REV CYTOL, V220, P145; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; ARGRAVES WS, 1987, J CELL BIOL, V105, P1183, DOI 10.1083/jcb.105.3.1183; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bodeau AL, 2001, J CELL SCI, V114, P2795; Bokel C, 2002, DEV CELL, V3, P311, DOI 10.1016/S1534-5807(02)00265-4; BRIESEWITZ R, 1995, MOL BIOL CELL, V6, P997, DOI 10.1091/mbc.6.8.997; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calderwood DA, 1999, J BIOL CHEM, V274, P28071, DOI 10.1074/jbc.274.40.28071; Calderwood DA, 2002, J BIOL CHEM, V277, P21749, DOI 10.1074/jbc.M111996200; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; Damsky CH, 2002, CURR OPIN CELL BIOL, V14, P594, DOI 10.1016/S0955-0674(02)00368-X; Danilkovitch A, 2000, MOL CELL BIOL, V20, P2218, DOI 10.1128/MCB.20.6.2218-2227.2000; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Erdreich-Epstein A, 2000, CANCER RES, V60, P712; FASSLER R, 1995, J CELL BIOL, V128, P979, DOI 10.1083/jcb.128.5.979; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GILMORE AP, 1993, J CELL BIOL, V122, P337, DOI 10.1083/jcb.122.2.337; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; HEMLER ME, 1984, J IMMUNOL, V132, P3011; HONEYMAN TW, 1983, BIOCHEM J, V212, P489, DOI 10.1042/bj2120489; HORWITZ A, 1986, NATURE, V320, P531, DOI 10.1038/320531a0; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ilic D, 1998, J CELL BIOL, V143, P547; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JOHNSON RP, 1994, J BIOL CHEM, V269, P12611; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaapa A, 1999, EXP CELL RES, V250, P524, DOI 10.1006/excr.1999.4533; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; LACALLE RA, 1989, GENE, V79, P375, DOI 10.1016/0378-1119(89)90220-5; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; Liu SC, 2000, J CELL SCI, V113, P3563; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Meier R, 1998, EMBO J, V17, P7294, DOI 10.1093/emboj/17.24.7294; MIEKKA SI, 1982, THROMB RES, V27, P1, DOI 10.1016/0049-3848(82)90272-9; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Mulrooney J, 2000, EXP CELL RES, V258, P332, DOI 10.1006/excr.2000.4964; Mulrooney JP, 2001, J CELL SCI, V114, P2525; OTEY CA, 1993, J BIOL CHEM, V268, P21193; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; RESZKA AA, 1992, J CELL BIOL, V117, P1321, DOI 10.1083/jcb.117.6.1321; Sakai T, 1998, J CELL BIOL, V141, P527, DOI 10.1083/jcb.141.2.527; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Sontag E, 2001, CELL SIGNAL, V13, P7, DOI 10.1016/S0898-6568(00)00123-6; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; TAPLEY P, 1989, ONCOGENE, V4, P325; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tran H, 2002, J CELL SCI, V115, P2031; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; Wennerberg K, 1998, J CELL SCI, V111, P1117; Wennerberg K, 2000, MOL CELL BIOL, V20, P5758, DOI 10.1128/MCB.20.15.5758-5765.2000; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; Yellaturu CR, 2002, J BIOL CHEM, V277, P40148, DOI 10.1074/jbc.M206376200; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	91	83	84	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18671	18681		10.1074/jbc.M300879200	http://dx.doi.org/10.1074/jbc.M300879200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637511	hybrid			2022-12-27	WOS:000182838300140
J	Takemoto-Kimura, S; Terai, H; Takamoto, M; Ohmae, S; Kikumura, S; Segi, E; Arakawa, Y; Furuyashiki, T; Narumiya, S; Bito, H				Takemoto-Kimura, S; Terai, H; Takamoto, M; Ohmae, S; Kikumura, S; Segi, E; Arakawa, Y; Furuyashiki, T; Narumiya, S; Bito, H			Molecular cloning and characterization of CLICK-III/CaMKI gamma, a novel membrane-anchored neuronal Ca2+/calmodulin-dependent protein kinase (CaMK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; RAT-BRAIN; SYNAPTIC PLASTICITY; CREB PHOSPHORYLATION; GENE-EXPRESSION; IV KINASE; CALMODULIN; ACTIVATION; CALCIUM	During a screen for novel putative Ca2+/calmodulin-dependent protein kinase (CaMK)-like CREB kinases (CLICKs), we have cloned a full-length cDNA for CLICK-III/CaMKIgamma, an isoform of the CaMKI family with an extended C-terminal domain ending with CAAX motif (where AA is aliphatic acid). As expected from the similarity of its kinase domain with the other CaMKI isoforms, full activation of CLICK-III/CaMKIgamma required both Ca2+/CaM and phosphorylation by CaMKK. We also found that Ca2+/cAMP-response element-binding protein (CREB) was a good substrate for CLICK-III/CaMKIgamma, at least in vitro. Interestingly enough, CLICKIII/CaMKIgamma transcripts were most abundant in neurons, with the highest levels in limited nuclei such as the central nucleus of the amygdala (CeA) and the ventromedial hypothalamus. Consistent with the presence of the CAAX motif, CLICK-III/CaMKIgamma was found to be anchored to various membrane compartments, especially to Golgi and plasma membranes. Both point mutation in the CAAX motif and treatment with compactin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, disrupted such membrane localization, suggesting that membrane localization of CLICK-III/CaMKIgamma occurred in a prenylation-dependent way. These findings provide a novel mechanism by which neuronal CaMK activity could be targeted to specific membrane compartments.	Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan; Japan Sci & Technol Corp, PRESTO, Sakyo Ku, Kyoto 6068315, Japan; Univ Tokyo, Grad Sch Med, Dept Neurochem, Bunkyo Ku, Tokyo 1130033, Japan	Kyoto University; Japan Science & Technology Agency (JST); University of Tokyo	Bito, H (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068315, Japan.		Bito, Haruhiko/A-8635-2008; Furuyashiki, Tomoyuki/B-8760-2014; Furuyashiki, Tomoyuki/AAG-5283-2019; Arakawa, Yoshiki/H-6067-2017	Furuyashiki, Tomoyuki/0000-0001-8089-8399; Furuyashiki, Tomoyuki/0000-0001-8089-8399; Arakawa, Yoshiki/0000-0003-4626-4645; Segi-Nishida, Eri/0000-0002-0803-6513; Bito, Haruhiko/0000-0001-6315-9594; Ohmae, Shogo/0000-0003-1726-4961				Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Bito H, 1998, CELL CALCIUM, V23, P143, DOI 10.1016/S0143-4160(98)90113-0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; El-Husseini AED, 2002, NAT REV NEUROSCI, V3, P791, DOI 10.1038/nrn940; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Flanagan-Cato LM, 2001, HORM BEHAV, V40, P178, DOI 10.1006/hbeh.2001.1679; Fujisawa H, 2001, J BIOCHEM-TOKYO, V129, P193, DOI 10.1093/oxfordjournals.jbchem.a002843; FUKUNAGA K, 1995, J BIOL CHEM, V270, P6119, DOI 10.1074/jbc.270.11.6119; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Harris KM, 1999, CURR OPIN NEUROBIOL, V9, P343, DOI 10.1016/S0959-4388(99)80050-6; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hudmon A, 2002, ANNU REV BIOCHEM, V71, P473, DOI 10.1146/annurev.biochem.71.110601.135410; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kasahara J, 2001, J BIOL CHEM, V276, P24044, DOI 10.1074/jbc.M100247200; KENNEDY MB, 1994, ANNU REV BIOCHEM, V63, P571, DOI 10.1146/annurev.biochem.63.1.571; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Kutzleb C, 1998, J CELL BIOL, V143, P795, DOI 10.1083/jcb.143.3.795; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; Matthies H, 1997, NEUROSCIENCE, V79, P341, DOI 10.1016/S0306-4522(96)00703-8; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Naito Y, 1997, J BIOL CHEM, V272, P32704, DOI 10.1074/jbc.272.51.32704; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; OIDA H, 1995, BRIT J PHARMACOL, V116, P2828, DOI 10.1111/j.1476-5381.1995.tb15933.x; OKUNO S, 1994, J BIOCHEM, V116, P923, DOI 10.1093/oxfordjournals.jbchem.a124617; Picciotto M R, 1996, Adv Pharmacol, V36, P251, DOI 10.1016/S1054-3589(08)60585-2; PICCIOTTO MR, 1995, SYNAPSE, V20, P75, DOI 10.1002/syn.890200111; RIBAR TJ, 2002, J NEUROSCI, V20, P1; Sakagami H, 2000, EUR J NEUROSCI, V12, P89, DOI 10.1046/j.1460-9568.2000.00883.x; Schneggenburger R, 2002, TRENDS NEUROSCI, V25, P206, DOI 10.1016/S0166-2236(02)02139-2; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; Ueda T, 1999, J NEUROCHEM, V73, P2119; Verploegen S, 2000, BLOOD, V96, P3215; Wei F, 2002, NAT NEUROSCI, V5, P573, DOI 10.1038/nn0602-855; WOODS SC, 1999, FUNDAMENTAL NEUROSCI, P1090; Yokokura H, 1997, ADV SEC MESS PHOSPH, V31, P151; Yokokura H, 1997, BBA-PROTEIN STRUCT M, V1338, P8, DOI 10.1016/S0167-4838(97)00004-6; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	53	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18597	18605		10.1074/jbc.M300578200	http://dx.doi.org/10.1074/jbc.M300578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637513	hybrid			2022-12-27	WOS:000182838300132
J	Wiebe, MS; Nowling, TK; Rizzino, A				Wiebe, MS; Nowling, TK; Rizzino, A			Identification of novel domains within Sox-2 and Sox-11 involved in autoinhibition of DNA binding and partnership specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; TRANSCRIPTIONAL ACTIVATION DOMAINS; PROTEIN-PROTEIN INTERACTIONS; SYNERGISTIC ACTION; GLIAL-CELLS; GENE; ETS-1; EXPRESSION; ENHANCER; COMPLEX	Sox transcription factors play key regulatory roles throughout development, binding DNA through a consensus (A/T)(A/T)CAA(A/T)G sequence. Although many different Sox proteins bind to this sequence, it has been observed that gene regulatory elements are commonly responsive to only a small subset of the entire family, implying that regulatory mechanisms exist to permit selective DNA binding and/or transactivation by Sox family members. To identify and explore the mechanisms modulating gene activation by Sox proteins further, we compared the function of Sox-2 and Sox-11. This led to the discovery that Sox proteins are regulated differentially at multiple levels, including transactivation, protein partnerships with Pit-Oct-Unc (POU) transcription factors, and DNA binding autoregulation. Specifically, we determined that Sox-11 activates transcription more strongly than Sox-2 and that the transactivation domain of Sox-11 is primarily responsible for this capability. Additionally, we demonstrate that the Sox-11 DNA binding domain is responsible for selective cooperation with the POU factor Brn-2. This requirement cannot be replaced by the DNA binding domain of Sox-2, indicating that the DNA binding domain of Sox proteins is critical for Sox-POU partnerships. Interestingly, we have also determined that a conserved domain of Sox-11 has the novel capability of autoinhibiting its ability to bind DNA in vitro and to activate gene expression in vivo. Our findings suggest that the autoinhibitory domain can repress promiscuous binding of Sox-11 to DNA and plays an important role in regulating the recruitment of Sox-11 to specific genes.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 986805 Nebraska Med Ctr, Omaha, NE 68198 USA.		Wiebe, Matt/AAC-4642-2021; Wiebe, Matthew/X-5007-2019	Wiebe, Matthew/0000-0001-6337-6556	NCI NIH HHS [CA 74771, CA 36727, CA 09476] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009476, R01CA074771, P30CA036727] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1; Collignon J, 1996, DEVELOPMENT, V122, P509; Cowley DO, 2000, GENE DEV, V14, P366; CURATOLA AM, 1990, MOL CELL BIOL, V10, P2475, DOI 10.1128/MCB.10.6.2475; Das D, 2001, J BIOL CHEM, V276, P32597, DOI 10.1074/jbc.M011792200; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; ISACKSON PJ, 1983, BIOCHIM BIOPHYS ACTA, V748, P436, DOI 10.1016/0167-4838(83)90190-5; Jay P, 1997, HUM MOL GENET, V6, P1069, DOI 10.1093/hmg/6.7.1069; Johnson LR, 1998, MOL REPROD DEV, V50, P377; Kamachi Y, 1998, DEVELOPMENT, V125, P2521; Kamachi Y, 2001, GENE DEV, V15, P1272, DOI 10.1101/gad.887101; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Kanda H, 1998, GENE, V211, P251, DOI 10.1016/S0378-1119(98)00100-0; Katan-Khaykovich Y, 2001, EUR J BIOCHEM, V268, P3108, DOI 10.1046/j.1432-1327.2001.02211.x; KELLY D, 1995, MOL REPROD DEV, V40, P135, DOI 10.1002/mrd.1080400202; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P16050, DOI 10.1074/jbc.273.26.16050; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lee KB, 2000, J MOL BIOL, V304, P135, DOI 10.1006/jmbi.2000.4206; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; Mirmira RG, 2000, J BIOL CHEM, V275, P14743, DOI 10.1074/jbc.275.19.14743; Nishimoto M, 1999, MOL CELL BIOL, V19, P5453; NOWLING T, 2002, J BIOL CHEM; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Peirano RI, 2000, NUCLEIC ACIDS RES, V28, P3047, DOI 10.1093/nar/28.16.3047; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Ramstein J, 1999, EUR J BIOCHEM, V260, P692, DOI 10.1046/j.1432-1327.1999.00185.x; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; Stemmer C, 2002, J BIOL CHEM, V277, P1092, DOI 10.1074/jbc.M109503200; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; UWANOGHO D, 1995, MECH DEVELOP, V49, P23, DOI 10.1016/0925-4773(94)00299-3; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhao Q, 2000, J MOL BIOL, V296, P509, DOI 10.1006/jmbi.1999.3457	44	52	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17901	17911		10.1074/jbc.M212211200	http://dx.doi.org/10.1074/jbc.M212211200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637543	Green Published, hybrid			2022-12-27	WOS:000182838300040
J	Yun, CY; Velazquez-Dones, AL; Lyman, SK; Fu, XD				Yun, CY; Velazquez-Dones, AL; Lyman, SK; Fu, XD			Phosphorylation-dependent and -independent nuclear import of RS domain-containing splicing factors and regulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBNUCLEAR LOCALIZATION; RICH DOMAINS; PROTEIN; SR; BETA; TRANSPORTIN-SR2; RECEPTOR; ABSENCE; EXPORT; RAN	SR proteins and related RS domain-containing polypeptides are an important class of splicing regulators in higher eukaryotic cells. The RS domain facilitates nuclear import of SR proteins and mediates protein-protein interactions during spliceosome assembly; both functions appear to subject to regulation by phosphorylation. Previous studies have identified two nuclear import receptors for SR proteins, transportin-SR1 and transportin-SR2. Here we show that transportin-SR1 and transportin-SR2 are the alternatively spliced products of the same gene and that transportin-SR2 is the predominant transcript in most cells and tissues examined. While both receptors import typical SR proteins in a phosphorylation-dependent manner, they differentially import the RS domain-containing splicing regulators hTra2alpha and hTra2beta in different phosphorylation states. We suggest that differential regulation of nuclear import may serve as a mechanism for homeostasis of RS domain-containing splicing factors and regulators in the nucleus and for selective cellular responses to signaling.	Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of California System; University of California San Diego; Scripps Research Institute	Fu, XD (corresponding author), Univ Calif San Diego, Dept Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	xdfu@ucsd.edu			NIGMS NIH HHS [GM52872] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052872] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Allemand E, 2002, MOL BIOL CELL, V13, P2436, DOI 10.1091/mbc.E02-02-0102; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Burge CB, 1999, RNA WORLD, P525; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cazalla D, 2002, MOL CELL BIOL, V22, P6871, DOI 10.1128/MCB.22.19.6871-6882.2002; CINGOLANI G, 1990, NATURE, V99, P221; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; FU XD, 1995, RNA, V1, P663; Gilbert W, 2001, RNA, V7, P302, DOI 10.1017/S1355838201002369; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; Hofmann Y, 2000, P NATL ACAD SCI USA, V97, P9618, DOI 10.1073/pnas.160181697; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Kataoka N, 1999, J CELL BIOL, V145, P1145, DOI 10.1083/jcb.145.6.1145; Lai MC, 2001, P NATL ACAD SCI USA, V98, P10154, DOI 10.1073/pnas.181354098; Lai MC, 2000, J BIOL CHEM, V275, P7950, DOI 10.1074/jbc.275.11.7950; Lam MHC, 1999, J BIOL CHEM, V274, P7391, DOI 10.1074/jbc.274.11.7391; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; Palacios I, 1997, EMBO J, V16, P6783, DOI 10.1093/emboj/16.22.6783; Palmeri D, 1999, MOL CELL BIOL, V19, P1218; Paschal BM, 1996, P NATL ACAD SCI USA, V93, P7679, DOI 10.1073/pnas.93.15.7679; Pemberton LF, 1997, J CELL BIOL, V139, P1645, DOI 10.1083/jcb.139.7.1645; Prasad J, 1999, MOL CELL BIOL, V19, P6991; Sanford JR, 2001, P NATL ACAD SCI USA, V98, P10184, DOI 10.1073/pnas.181340498; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; Shin CS, 2002, CELL, V111, P407, DOI 10.1016/S0092-8674(02)01038-3; Tacke R, 1998, CELL, V93, P139, DOI 10.1016/S0092-8674(00)81153-8; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Truant R, 1999, MOL CELL BIOL, V19, P1210; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yeakley JM, 1999, J CELL BIOL, V145, P447, DOI 10.1083/jcb.145.3.447; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	38	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18050	18055		10.1074/jbc.M211714200	http://dx.doi.org/10.1074/jbc.M211714200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637531	hybrid			2022-12-27	WOS:000182838300060
J	Lam, BJ; Bakshi, A; Ekinci, FY; Webb, J; Graveley, BR; Hertel, KJ				Lam, BJ; Bakshi, A; Ekinci, FY; Webb, J; Graveley, BR; Hertel, KJ			Enhancer-dependent 5 '-splice site control of fruitless pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DROSOPHILA DOUBLESEX GENE; SR PROTEINS; SEXUAL-DIFFERENTIATION; 5-SPLICE-SITE RECOGNITION; REGULATORY ELEMENTS; ALTERNATIVE EXON; TRANSFORMER; SELECTION; DIVERSITY	The Drosophila fruitless ( fru) gene encodes a transcription factor that essentially regulates all aspects of male courtship behavior. The use of alternative 5 '- splice sites generates fru isoforms that determine gender- appropriate sexual behaviors. Alternative splicing of fru is regulated by TRA and TRA2 and depends on an exonic splicing enhancer ( fruRE) consisting of three 13- nucleotide repeat elements, nearly identical to those that regulate alternative sex- specific 3 '- splice site choice in the doublesex ( dsx) gene. dsx has provided a useful model system to investigate the mechanisms of enhancer- dependent 3 '- splice site choice. However, little is known about enhancer- dependent regulation of alternative 5 '-splice sites. The mechanisms of this process were investigated using an in vitro system in which recombinant TRA/ TRA2 could activate the female- specific 5 '- splice site of fru. Mutational analysis demonstrated that one 13- nucleotide repeat element within the fruRE is required and sufficient to activate the regulated female-specific splice site. As was established for dsx, the fruRE can be replaced by a short element encompassing tandem 13- nucleotide repeat elements, by heterologous splicing enhancers, and by artificially tethering a splicing activator to the pre- mRNA. Complementation experiments showed that Ser/ Arg- rich proteins facilitate enhancer- dependent 5 '- splice site activation. We conclude that splicing enhancers function similarly in activating regulated 5 '- and 3 '- splice sites. These results suggest that exonic splicing enhancers recruit multiple spliceosomal components required for the initial recognition of 5 '- and 3 '- splice sites.	Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of California System; University of California Irvine; University of Connecticut	Hertel, KJ (corresponding author), Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.	khertel@uci.edu	Graveley, Brenton R/C-3108-2013	Hertel, Klemens/0000-0002-7560-9529; Graveley, Brenton/0000-0001-5777-5892	NIGMS NIH HHS [R01 GM062287, R01 GM062516, R01 GM062516-02, GM62287, GM62516] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062516, R01GM062287] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BLACK DL, 1995, RNA, V1, P763; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Burge CB, 1999, RNA WORLD, P525; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cote J, 1999, NUCLEIC ACIDS RES, V27, P2529, DOI 10.1093/nar/27.12.2529; D'Souza I, 2000, J BIOL CHEM, V275, P17700, DOI 10.1074/jbc.M909470199; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du HS, 2002, NATURE, V419, P86, DOI 10.1038/nature00947; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; Expert-Bezancon A, 2002, J BIOL CHEM, V277, P16614, DOI 10.1074/jbc.M201083200; Fujii S, 2002, EMBO J, V21, P5353, DOI 10.1093/emboj/cdf556; Graveley BR, 2001, RNA, V7, P806, DOI 10.1017/S1355838201010317; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; HOROWITZ DS, 1994, TRENDS GENET, V10, P100, DOI 10.1016/0168-9525(94)90233-X; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Li XL, 2000, RNA, V6, P1847, DOI 10.1017/S1355838200000674; Lim SR, 2001, J BIOL CHEM, V276, P45476, DOI 10.1074/jbc.M107632200; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lorson CL, 2000, HUM MOL GENET, V9, P259, DOI 10.1093/hmg/9.2.259; Lund M, 2002, RNA, V8, P166, DOI 10.1017/S1355838202010786; LYNCH KW, 1995, GENE DEV, V9, P284, DOI 10.1101/gad.9.3.284; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MCKEOWN M, 1988, CELL, V53, P887, DOI 10.1016/S0092-8674(88)90369-8; Modafferi EF, 1999, RNA, V5, P687, DOI 10.1017/S1355838299990155; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NAGOSHI RN, 1988, CELL, V53, P229, DOI 10.1016/0092-8674(88)90384-4; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; Reed R, 1996, CURR OPIN GENET DEV, V6, P215, DOI 10.1016/S0959-437X(96)80053-0; REED R, 1997, EUKARYOTIC MRNA PROC, P103; Rio Donald C., 1992, Gene Expression, V2, P1; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; TAYLOR BJ, 1994, DEV GENET, V15, P275, DOI 10.1002/dvg.1020150309; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Zhu J, 2001, MOL CELL, V8, P1351, DOI 10.1016/S1097-2765(01)00409-9; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	64	29	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22740	22747		10.1074/jbc.M301036200	http://dx.doi.org/10.1074/jbc.M301036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12646561	Green Accepted, Green Published, hybrid			2022-12-27	WOS:000183503900076
J	Kim, GS; Hong, JS; Kim, SW; Koh, JM; An, CS; Choi, JY; Cheng, SL				Kim, GS; Hong, JS; Kim, SW; Koh, JM; An, CS; Choi, JY; Cheng, SL			Leptin induces apoptosis via ERK/cPLA2/cytochrome C pathway in human bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); HUMAN POLY(ADP-RIBOSE) POLYMERASE; CYTOCHROME-C; OB/OB MICE; DNA-REPAIR; LONG FORM; OB-R; RECEPTOR; EXPRESSION; DIFFERENTIATION	Leptin, the Ob gene product, has emerged recently as a key regulator of bone mass. However, the mechanism mediating leptin effect remains controversial. Because the action of leptin is dependent on its receptors, we analyzed their expression in osteoblast-lineage primary human bone marrow stromal cells (hBMSC). Both the short and long forms of leptin receptors were detected in hBMSC. Leptin significantly decreased the viability of hBMSC. This cytotoxic effect was prevented by Z-ValAla-Asp-fluoromethylketone, a pan-caspase inhibitor, implicating that leptin-induced hBMSC death was caspase-dependent. Further investigation demonstrated that leptin activated caspase-3 and caspase-9, but not caspase-8, and increased the cleavage of poly-(ADP- ribose) polymerase and cytochrome c release into cytosol. Leptin activated ERK, but not p38 and JNK, and up-regulated cPLA2 activity; the latter was abolished by pre-treatment of cells with the MEK inhibitor (PD98059 or U0126) or cPLA2 inhibitor (AACOCF3). PD98059, U0126, and AACOCF3 also diminished the leptin-induced cytochrome c release into cytosol, cell death, and caspase-3 activation. These data indicated that leptin induced hBMSC apoptosis via ERK/cPLA2/cytochrome c pathway with activation of caspase-9 and caspase-3, and cleavage of poly(ADP-ribose) polymerase. To our knowledge, this is the first study demonstrating the direct detrimental effect of leptin on bone cells.	Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, Seoul 138736, South Korea; Asan Inst Life Sci, Seoul 138736, South Korea; Seoul Natl Univ, Coll Nat Sci, Sch Biol Sci, Seoul 151742, South Korea; Kyungpook Natl Univ, Dept Biochem, Taegu 700721, South Korea; Washington Univ, Sch Med, Dept Med, Div Bone & Mineral Dis, St Louis, MO 63110 USA	University of Ulsan; Seoul National University (SNU); Kyungpook National University; Washington University (WUSTL)	Kim, GS (corresponding author), Univ Ulsan, Coll Med, Div Endocrinol & Metab, Asan Med Ctr, 388-1 Poongnap Dong, Seoul 138736, South Korea.							Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; BOULIKAS T, 1991, ANTICANCER RES, V11, P489; Caprio M, 2001, TRENDS ENDOCRIN MET, V12, P65, DOI 10.1016/S1043-2760(00)00352-0; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Cohen B, 2001, J BIOL CHEM, V276, P7697, DOI 10.1074/jbc.C000634200; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Enari M, 1996, EUR J BIOCHEM, V236, P533, DOI 10.1111/j.1432-1033.1996.t01-1-00533.x; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Gimble JM, 1998, CRIT REV EUKAR GENE, V8, P141, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.30; Gordeladze JO, 2002, J CELL BIOCHEM, V85, P825, DOI 10.1002/jcb.10156; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hock JM, 2001, J BONE MINER RES, V16, P975, DOI 10.1359/jbmr.2001.16.6.975; Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200; Howard JK, 1999, J CLIN INVEST, V104, P1051, DOI 10.1172/JCI6762; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim CH, 1997, ENDOCR RES, V23, P181, DOI 10.3109/07435809709031852; Kim TD, 2000, COMPOS STRUCT, V49, P21, DOI 10.1016/S0263-8223(99)00122-1; Konopleva M, 1999, BLOOD, V93, P1668, DOI 10.1182/blood.V93.5.1668.405a15_1668_1676; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lee YJ, 2002, FEBS LETT, V528, P43, DOI 10.1016/S0014-5793(02)02889-2; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin J, 2000, DOMEST ANIM ENDOCRIN, V19, P53, DOI 10.1016/S0739-7240(00)00064-3; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Park KS, 1997, DIABETES, V46, P1230, DOI 10.2337/diabetes.46.7.1230; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; PUZAS JE, 1985, ENDOCRINOLOGY, V116, P2463, DOI 10.1210/endo-116-6-2463; Qian H, 1998, ENDOCRINOLOGY, V139, P791, DOI 10.1210/en.139.2.791; Reseland JE, 2001, J BONE MINER RES, V16, P1426, DOI 10.1359/jbmr.2001.16.8.1426; ROBEY PG, 1985, CALCIFIED TISSUE INT, V37, P453, DOI 10.1007/BF02557826; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P9558, DOI 10.1073/pnas.95.16.9558; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; Soldatenkov VA, 1996, INT J ONCOL, V9, P547; Steppan CM, 2000, REGUL PEPTIDES, V92, P73, DOI 10.1016/S0167-0115(00)00152-X; SURYAWAN A, 1993, COMP BIOCHEM PHYS A, V105, P485, DOI 10.1016/0300-9629(93)90424-3; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093, DOI 10.1074/jbc.272.10.6093; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thomas T, 1999, ENDOCRINOLOGY, V140, P1630, DOI 10.1210/en.140.4.1630; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799; YAMANAKA H, 1988, J BIOL CHEM, V263, P3879; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	65	102	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21920	21929		10.1074/jbc.M204598200	http://dx.doi.org/10.1074/jbc.M204598200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665505	hybrid			2022-12-27	WOS:000183354200077
J	Larrivee, B; Lane, DR; Pollet, I; Olive, PL; Humphries, RK; Karsan, A				Larrivee, B; Lane, DR; Pollet, I; Olive, PL; Humphries, RK; Karsan, A			Vascular endothelial growth factor receptor-2 induces survival of hematopoietic progenitor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELLS; C-KIT; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING PATHWAYS; SELF-RENEWAL; APOPTOSIS; PROLIFERATION; ACTIVATION; DIFFERENTIATION; VASCULOGENESIS	Vascular endothelial growth factor ( VEGF) and its receptors play an essential role in the formation and maintenance of the hematopoietic and vascular compartments. The VEGF receptor-2 (VEGFR-2) is expressed on a population of hematopoietic cells, although its role in hematopoiesis is still unclear. In this report, we have utilized a strategy to selectively activate VEGFR-2 and study its effects in primary bone marrow cells. We found that VEGFR-2 can maintain the hematopoietic progenitor population in mouse bone marrow cultured in the absence of exogenous cytokines. Maintenance of the hematopoietic progenitor population is due to increased cell survival with minimal effect on proliferation. Progenitor survival is mainly mediated by activation of the phosphatidylinositol 3'-kinase/Akt pathway. Although VEGFR-2 also activated Erk1/2 mitogen-activated protein kinase, it did not induce cell proliferation, and blockade of this pathway only partially decreased VEGFR-2-mediated survival of hematopoietic progenitors. Thus, the role of VEGFR-2 in hematopoiesis is likely to maintain survival of hematopoietic progenitors through the activation of antiapoptotic pathways.	Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 1Z4, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 1L3, Canada; British Columbia Canc Agcy, Terry Fox Labs, Vancouver, BC V5Z 1L3, Canada	University of British Columbia; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency; British Columbia Cancer Agency	Karsan, A (corresponding author), British Columbia Canc Res Ctr, Dept Med Biophys, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Pollet, Ingrid Louise/O-5031-2019; Karsan, Aly/K-2067-2015	Pollet, Ingrid Louise/0000-0001-7207-8294; Humphries, Richard/0000-0003-0540-7005; Larrivee, Bruno/0000-0003-1388-3108				Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Blau C A, 1999, Prog Exp Tumor Res, V36, P162; Blau CA, 1997, P NATL ACAD SCI USA, V94, P3076, DOI 10.1073/pnas.94.7.3076; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Choi K, 1998, DEVELOPMENT, V125, P725; Choi K, 2002, J HEMATOTH STEM CELL, V11, P91, DOI 10.1089/152581602753448568; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Duriez PJ, 2000, J BIOL CHEM, V275, P18099, DOI 10.1074/jbc.M908925199; Eichmann A, 1997, P NATL ACAD SCI USA, V94, P5141, DOI 10.1073/pnas.94.10.5141; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967; Gehling UM, 2000, BLOOD, V95, P3106; Gerber HP, 2002, NATURE, V417, P954, DOI 10.1038/nature00821; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Hattori K, 2001, J EXP MED, V193, P1005, DOI 10.1084/jem.193.9.1005; Hidaka M, 1999, P NATL ACAD SCI USA, V96, P7370, DOI 10.1073/pnas.96.13.7370; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jin LQ, 1998, P NATL ACAD SCI USA, V95, P8093, DOI 10.1073/pnas.95.14.8093; Jin LQ, 2000, NAT GENET, V26, P64, DOI 10.1038/79194; Jin LQ, 1998, BLOOD, V91, P890, DOI 10.1182/blood.V91.3.890.890_890_897; Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Larrivee B, 2000, INT J MOL MED, V5, P447; Liu Q, 1997, J IMMUNOL, V159, P829; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Otto KG, 2001, BLOOD, V97, P3662, DOI 10.1182/blood.V97.11.3662; Otto KG, 2001, BLOOD, V98, P2077, DOI 10.1182/blood.V98.7.2077; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Richard RE, 2000, BLOOD, V95, P430, DOI 10.1182/blood.V95.2.430; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Schuh AC, 1999, P NATL ACAD SCI USA, V96, P2159, DOI 10.1073/pnas.96.5.2159; Selheim F, 2002, FEBS LETT, V512, P107, DOI 10.1016/S0014-5793(02)02232-9; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Sui XW, 2000, BRIT J HAEMATOL, V110, P63, DOI 10.1046/j.1365-2141.2000.02145.x; Thakker GD, 1999, J BIOL CHEM, V274, P10002, DOI 10.1074/jbc.274.15.10002; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Traver D, 2002, CELL, V108, P731, DOI 10.1016/S0092-8674(02)00686-4; Whitney ML, 2001, J BIOL CHEM, V276, P41191, DOI 10.1074/jbc.M103191200; Xaus J, 2001, IMMUNOBIOLOGY, V204, P543, DOI 10.1078/0171-2985-00091; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6; Zeng H, 2001, BLOOD, V98, P328, DOI 10.1182/blood.V98.2.328; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhao SM, 2002, EMBO J, V21, P2159, DOI 10.1093/emboj/21.9.2159; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	52	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22006	22013		10.1074/jbc.M212158200	http://dx.doi.org/10.1074/jbc.M212158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668684	hybrid			2022-12-27	WOS:000183354200087
J	Tremblay, JJ; Viger, RS				Tremblay, JJ; Viger, RS			Transcription factor GATA-4 is activated by phosphorylation of serine 261 via the cAMP/protein kinase A signaling pathway in gonadal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTANCE GENE-TRANSCRIPTION; NUCLEAR RECEPTOR SF-1; BINDING-PROTEIN-BETA; CYCLIC-AMP; SERTOLI CELLS; MOUSE TESTIS; LEYDIG-CELLS; STAR GENE; EXPRESSION; ENDOTHELIN-1	Gonadal gene expression is regulated by pituitary hormones acting through the cAMP/protein kinase A (PKA) signal transduction pathway. The downstream molecular effectors of these signals, however, have yet to be fully understood. We have recently shown that cAMP stimulation of gonadal cells leads to phosphorylation of the transcription factor GATA-4, a key regulator of gonadal gene expression, thus suggesting that this factor might be a novel target for the cAMP/PKA signaling pathway. We now show that the rapid phosphorylation of GATA-4 induced by cAMP in vivo can be blocked by a PKA-specific inhibitor but not by mitogen-activated protein kinase inhibitors, indicating that GATA-4 is predominantly phosphorylated by PKA in response to cAMP in gonadal cells. In addition, using in vitro kinase assays, we show that PKA phosphorylation of GATA-4 occurs predominantly on an evolutionarily conserved serine residue located at position 261. Phosphorylation of GATA-4 Ser(261) by PKA enhances its transcriptional activity on different gonadal promoters, an effect that was markedly reduced with a S261A mutant. Moreover, the S261A mutant blunted cAMP-induced promoter activity in gonadal cells. Finally, PKA-dependent phosphorylation of GATA-4 also led to enhanced recruitment of the CREB-binding protein coactivator. This recruitment and transcriptional cooperation were dramatically impaired with the S261A mutant. Thus, our results identify GATA-4 as a novel downstream effector of cAMP/PKA signaling in gonadal cells, where phosphorylation of Ser261 and recruitment of CREB-binding protein likely represent a key mechanism for conveying the cAMP responsiveness of gonadal genes that lack classical cAMP regulatory elements.	CHU Laval, Ctr Rech, Ontogeny & Reproduct Res Unit, St Foy, PQ G1V 4G2, Canada; Univ Laval, Ctr Rech Biol Reprod, Dept Obstet & Gynecol, St Foy, PQ G1V 4G2, Canada	Laval University; Laval University	Viger, RS (corresponding author), CHU Laval, Ctr Rech, Ontogeny & Reproduct Res Unit, Rm T1-49,2705 Blvd Laurier, St Foy, PQ G1V 4G2, Canada.		Tremblay, Jacques J./AAO-2491-2021	Tremblay, Jacques J./0000-0002-4738-6284				ASCOLI M, 1981, ENDOCRINOLOGY, V108, P88, DOI 10.1210/endo-108-1-88; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Christenson LK, 1999, J BIOL CHEM, V274, P26591, DOI 10.1074/jbc.274.37.26591; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; Dai YS, 2001, J BIOL CHEM, V276, P37178, DOI 10.1074/jbc.M103731200; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Hales DB, 2001, ENDOCRINOLOGY, V142, P974, DOI 10.1210/en.142.3.974; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hautala N, 2001, CIRCULATION, V103, P730; Heikinheimo M, 1997, ENDOCRINOLOGY, V138, P3505, DOI 10.1210/en.138.8.3505; ITO E, 1993, NATURE, V362, P466, DOI 10.1038/362466a0; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KEENEY DS, 1995, MOL ENDOCRINOL, V9, P1091, DOI 10.1210/me.9.8.1091; Kerkela R, 2002, J BIOL CHEM, V277, P13752, DOI 10.1074/jbc.M105736200; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Kiiveri S, 2002, ENDOCRINOLOGY, V143, P3136, DOI 10.1210/endo.143.8.8939; Kiiveri S, 2002, ENDOCR RES, V28, P647, DOI 10.1081/ERC-120016980; Kitta K, 2001, BIOCHEM J, V359, P375, DOI 10.1042/0264-6021:3590375; LEUNG PCK, 1992, ENDOCR REV, V13, P476, DOI 10.1210/er.13.3.476; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; McCoard SA, 2001, BIOL REPROD, V65, P366, DOI 10.1095/biolreprod65.2.366; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; Parker KL, 2002, RECENT PROG HORM RES, V57, P19, DOI 10.1210/rp.57.1.19; Patel MV, 2001, J INVEST DERMATOL, V117, P1559, DOI 10.1046/j.0022-202x.2001.01587.x; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Robert NM, 2002, ENDOCRINOLOGY, V143, P3963, DOI 10.1210/en.2002-220280; SADOVSKY Y, 1995, P NATL ACAD SCI USA, V92, P10939, DOI 10.1073/pnas.92.24.10939; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHINODA K, 1995, DEV DYNAM, V204, P22, DOI 10.1002/aja.1002040104; Siggers P, 2002, MECH DEVELOP, V111, P159, DOI 10.1016/S0925-4773(01)00602-5; Silverman E, 1999, J BIOL CHEM, V274, P17987, DOI 10.1074/jbc.274.25.17987; Song KH, 2001, ENDOCRINOLOGY, V142, P5116, DOI 10.1210/en.142.12.5116; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Tremblay AJ, 2001, BIOL REPROD, V64, P1191, DOI 10.1095/biolreprod64.4.1191; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Tremblay JJ, 2001, ENDOCRINOLOGY, V142, P977, DOI 10.1210/en.142.3.977; Tremblay JJ, 2002, ENDOCRINOLOGY, V143, P3935, DOI 10.1210/en.2002-220413; Tremblay JJ, 2001, MOL ENDOCRINOL, V15, P1636, DOI 10.1210/me.15.9.1636; Viger RS, 1998, DEVELOPMENT, V125, P2665; Wooton-Kee CR, 2000, ENDOCRINOLOGY, V141, P1345, DOI 10.1210/en.141.4.1345; Yanazume T, 2002, J BIOL CHEM, V277, P8618, DOI 10.1074/jbc.M107924200; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759; Zhang PL, 1996, MOL ENDOCRINOL, V10, P147, DOI 10.1210/me.10.2.147; Zhang ZF, 2002, ENDOCRINOLOGY, V143, P829, DOI 10.1210/en.143.3.829	52	76	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22128	22135		10.1074/jbc.M213149200	http://dx.doi.org/10.1074/jbc.M213149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670947	hybrid			2022-12-27	WOS:000183354200101
J	Ciszak, EM; Korotchkina, LG; Dominiak, PM; Sidhu, S; Patel, MS				Ciszak, EM; Korotchkina, LG; Dominiak, PM; Sidhu, S; Patel, MS			Structural basis for flip-flop action of thiamin pyrophosphate-dependent enzymes revealed by human pyruvate dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BENZOYLFORMATE DECARBOXYLASE; MULTIENZYME COMPLEXES; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; DIPHOSPHATE; MOTIF; SITES; TRANSKETOLASE; INTERMEDIATE	The derivative of vitamin B1, thiamin pyrophosphate, is a cofactor of enzymes performing catalysis in pathways of energy production. In alpha(2)beta(2)-heterotetrameric human pyruvate dehydrogenase, this cofactor is used to cleave the C-alpha-C(=O) bond of pyruvate followed by reductive acetyl transfer to lipoyl-dihydrolipoamide acetyltransferase. The dynamic nonequivalence of two, otherwise chemically equivalent, catalytic sites has not yet been understood. To understand the mechanism of action of this enzyme, we determined the crystal structure of the holo-form of human pyruvate dehydrogenase at 1.95-Angstrom resolution. We propose a model for the flip-flop action of this enzyme through a concerted similar to2-Angstrom shuttle-like motion of its heterodimers. Similarity of thiamin pyrophosphate binding in human pyruvate dehydrogenase with functionally related enzymes suggests that this newly defined shuttle-like motion of domains is common to the family of thiamin pyrophosphate-dependent enzymes.	NASA, Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA; Univ Space Res Assoc, Huntsville, AL 35812 USA; SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	National Aeronautics & Space Administration (NASA); NASA Marshall Space Flight Center; Universities Space Research Association (USRA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ciszak, EM (corresponding author), NASA, Marshall Space Flight Ctr, Biol & Phys Space Res Lab, Huntsville, AL 35812 USA.	Ewa.M.Ciszak@nasa.gov	Dominiak, Paulina Maria/K-7882-2019; Dominiak, Paulina M/U-5181-2018	Dominiak, Paulina M/0000-0002-1466-1243	NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; Arjunan P, 2002, BIOCHEMISTRY-US, V41, P5213, DOI 10.1021/bi0118557; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chabriere E, 2001, SCIENCE, V294, P2559, DOI 10.1126/science.1066198; Ciszak E, 2001, ACTA CRYSTALLOGR D, V57, P465, DOI 10.1107/S0907444901000427; DELANO WL, 2002, PHYMOL MOL GRAPHICS; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; Fiedler E, 2002, P NATL ACAD SCI USA, V99, P591, DOI 10.1073/pnas.022510999; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; Khailova L, 1990, BIOCH PHYSL TDP ENZY, P251; KHAILOVA LS, 1985, BIOCHEM INT, V11, P509; Kleiger G, 2001, BIOCHEMISTRY-US, V40, P14484, DOI 10.1021/bi011016k; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200; Kovina MV, 1998, FEBS LETT, V440, P81, DOI 10.1016/S0014-5793(98)01423-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lobell M, 1996, J AM CHEM SOC, V118, P1867, DOI 10.1021/ja951830t; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan K, 1998, BIOCHEMISTRY-US, V37, P1357, DOI 10.1021/bi971835y; Pang SS, 2002, J MOL BIOL, V317, P249, DOI 10.1006/jmbi.2001.5419; PERHAM RN, 1996, ALPHA KETO ACID DEHY, P1; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Sergienko EA, 2000, BIOCHEMISTRY-US, V39, P13862, DOI 10.1021/bi001214w; Sergienko EA, 2002, BIOCHEMISTRY-US, V41, P3952, DOI 10.1021/bi011860a; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Yi JZ, 1996, J BIOL CHEM, V271, P33192, DOI 10.1074/jbc.271.52.33192	33	111	122	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21240	21246		10.1074/jbc.M300339200	http://dx.doi.org/10.1074/jbc.M300339200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651851	hybrid, Green Submitted			2022-12-27	WOS:000183230500102
J	Fringer, J; Grinnell, F				Fringer, J; Grinnell, F			Fibroblast quiescence in floating collagen matrices - Decrease in serum activation of MEK and RAF but not Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; CONTRACTION; MYOFIBROBLASTS; INTEGRINS; APOPTOSIS; MEMBRANE	Fibroblasts synthesize, organize, and maintain connective tissues during development and in response to injury and fibrotic disease. Studies on cells in three-dimensional collagen matrices have shown that fibroblasts switch between proliferative and quiescence phenotypes, depending upon whether matrices are attached or floating during matrix remodeling. Previous work showed that cell signaling through the ERK pathway was decreased in fibroblasts in floating matrices. In the current research, we extend the previous findings to show that serum stimulation of fibroblasts in floating matrices does not result in ERK translocation to the nucleus. In addition, there was decreased serum activation of upstream members of the ERK signaling pathway, MEK and Raf, even though Ras became GTP loaded. The findings suggest that quiescence of fibroblasts in floating collagen matrices may result from a defect in Ras coupling to its downstream effectors.	Univ Texas, Dept Cell Biol, SW Med Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Grinnell, F (corresponding author), Univ Texas, Dept Cell Biol, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	frederick.grinnell@utsouthwestern.edu			NIGMS NIH HHS [GM31321] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031321, R01GM031321] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; Fringer J, 2001, J BIOL CHEM, V276, P31047, DOI 10.1074/jbc.M101898200; Fucini RV, 1999, J BIOL CHEM, V274, P18651, DOI 10.1074/jbc.274.26.18651; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Graf R, 2002, APOPTOSIS, V7, P493, DOI 10.1023/A:1020634924760; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Grinnell F, 1999, EXP CELL RES, V248, P608, DOI 10.1006/excr.1999.4440; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; HE YJ, 1994, J CELL BIOL, V126, P457, DOI 10.1083/jcb.126.2.457; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Kessler D, 2001, J BIOL CHEM, V276, P36575, DOI 10.1074/jbc.M101602200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lorena D, 2002, WOUND REPAIR REGEN, V10, P86, DOI 10.1046/j.1524-475X.2002.00201.x; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Mio T, 1996, IN VITRO CELL DEV-AN, V32, P427; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; NISHIYAMA T, 1989, MATRIX, V9, P193, DOI 10.1016/S0934-8832(89)80050-2; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pozzi M, 1998, J CELL BIOL, V142, P587; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Rosenfeldt H, 2000, J BIOL CHEM, V275, P3088, DOI 10.1074/jbc.275.5.3088; Schlaepfer DD, 1998, TRENDS CELL BIOL, V8, P151, DOI 10.1016/S0962-8924(97)01172-0; SCHOR SL, 1980, J CELL SCI, V41, P159; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SETH A, 1992, J BIOL CHEM, V267, P24796; Stacey D, 2002, CURR OPIN GENET DEV, V12, P44, DOI 10.1016/S0959-437X(01)00262-3; Tamariz E, 2002, MOL BIOL CELL, V13, P3915, DOI 10.1091/mbc.E02-05-0291; Tian B, 2002, J BIOL CHEM, V277, P24667, DOI 10.1074/jbc.M203565200; Tilbrook PA, 2001, ARCH BIOCHEM BIOPHYS, V396, P128, DOI 10.1006/abbi.2001.2577; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vaughan MB, 2000, EXP CELL RES, V257, P180, DOI 10.1006/excr.2000.4869; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75; YOSHIZATO K, 1984, ANN PLAS SURG, V13, P9, DOI 10.1097/00000637-198407000-00002; Zhu YK, 2001, IN VITRO CELL DEV-AN, V37, P10; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	54	38	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20612	20617		10.1074/jbc.M212365200	http://dx.doi.org/10.1074/jbc.M212365200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663662	hybrid			2022-12-27	WOS:000183230500022
J	Kreiling, JL; Byrd, JC; Deisz, RJ; Mizukami, IF; Todd, RF; MacDonald, RG				Kreiling, JL; Byrd, JC; Deisz, RJ; Mizukami, IF; Todd, RF; MacDonald, RG			Binding of urokinase-type plasminogen activator receptor (uPAR) to the mannose 6-phosphate/insulin-like growth factor II receptor - Contrasting interactions of full-length and soluble forms of uPAR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II/MANNOSE 6-PHOSPHATE RECEPTOR; IGF-II; LIGAND-BINDING; MANNOSE-6-PHOSPHATE RECEPTOR; PERINATAL LETHALITY; MISSENSE MUTATIONS; BETA-GALACTOSIDASE; CELLULAR RECEPTOR; CANCER CELLS; IN-VIVO	Urokinase-type plasminogen activator receptor ( uPAR) binding by the mannose 6-phosphate/insulinlike growth factor II receptor ( Man-6-P/IGF2R) is considered important to Man-6-P/IGF2R tumor suppressor function via regulation of cell surface proteolytic activity. Our goal was to map the uPAR binding site of the Man-6-P/IGF2R by analyzing the uPAR binding characteristics of a panel of minireceptors containing different regions of the Man-6-P/IGF2R extracytoplasmic domain. Coimmunoprecipitation assays revealed that soluble recombinant uPAR ( suPAR) bound the Man-6-P/IGF2R at two distinct sites, one localized to the amino-terminal end of the Man-6-P/IGF2R extracytoplasmic domain ( repeats 1 - 3) and the other to the more carboxyl-terminal end ( repeats 7 - 9). These sites correspond with the positions of the two Man-6-P binding domains of Man-6-P/ IGF2R. Indeed, the suPAR-Man-6-P/IGF2R interaction was inhibited by Man-6-P, and binding-competent suPAR species represented a minor percentage ( 8 - 30%) of the suPAR present. In contrast, Man-6-P/ IGF2R binding of endogenous, full-length uPAR solubilized from plasma membranes of the prostate cancer cell line, PC-3, was not inhibited by Man-6-P. Further studies showed that very little (< 5%) endogenous uPAR was Man-6-P/ IGF2R binding-competent. We conclude that, contrary to previous reports, the interaction between uPAR and Man-6-P/ IGF2R is a low percentage binding event and that suPAR and full-length uPAR bind the Man-6-P/ IGF2R by different mechanisms.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	MacDonald, RG (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 600 S 42nd St, Omaha, NE 68198 USA.		Todd, Robert/GWM-4486-2022		NCI NIH HHS [5R01CA91885] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091885] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACHBAROU A, 1994, CANCER RES, V54, P2372; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; Byrd JC, 2000, J BIOL CHEM, V275, P18638, DOI 10.1074/jbc.M000010200; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Byrd JC, 2000, J BIOL CHEM, V275, P18647, DOI 10.1074/jbc.M001273200; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Dahms NM, 1996, BIOCHEM SOC T, V24, P136, DOI 10.1042/bst0240136; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; Dahms NM, 2002, BBA-GEN SUBJECTS, V1572, P317, DOI 10.1016/S0304-4165(02)00317-3; DeLeon DD, 1996, ENDOCRINOLOGY, V137, P1851, DOI 10.1210/en.137.5.1851; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, ONCOGENE, V10, P1725; Devi GR, 1998, MOL ENDOCRINOL, V12, P1661, DOI 10.1210/me.12.11.1661; Devi GR, 1999, CANCER RES, V59, P4314; ELLIS V, 1989, J BIOL CHEM, V264, P2185; FILSON AJ, 1993, DEVELOPMENT, V118, P731; Garmroudi F, 1996, MOL ENDOCRINOL, V10, P642, DOI 10.1210/me.10.6.642; GARMROUDI F, 1994, J BIOL CHEM, V269, P26944; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; Hancock MK, 2002, J BIOL CHEM, V277, P47205, DOI 10.1074/jbc.M208534200; Hankins GR, 1996, ONCOGENE, V12, P2003; KIESS W, 1990, EUR J BIOCHEM, V190, P71, DOI 10.1111/j.1432-1033.1990.tb15547.x; KIESS W, 1989, J BIOL CHEM, V264, P4710; Kong FM, 2000, ONCOGENE, V19, P1572, DOI 10.1038/sj.onc.1203437; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; Leksa V, 2002, J BIOL CHEM, V277, P40575, DOI 10.1074/jbc.M207979200; Linnell J, 2001, J BIOL CHEM, V276, P23986, DOI 10.1074/jbc.M100700200; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; MACDONALD RG, 1991, ENDOCRINOLOGY, V128, P413, DOI 10.1210/endo-128-1-413; Marron-Terada PG, 2000, BIOCHEMISTRY-US, V39, P2243, DOI 10.1021/bi992226o; MIZUKAMI IF, 1994, CLIN IMMUNOL IMMUNOP, V71, P96, DOI 10.1006/clin.1994.1057; Mohan PM, 1999, CANCER RES, V59, P3369; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NIELSEN LS, 1988, J BIOL CHEM, V263, P2358; Nykjaer A, 1998, J CELL BIOL, V141, P815, DOI 10.1083/jcb.141.3.815; O'Gorman DB, 1999, CANCER RES, V59, P5692; O'Gorman DB, 2002, ENDOCRINOLOGY, V143, P4287, DOI 10.1210/en.2002-220548; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ploug M, 1998, J BIOL CHEM, V273, P13933, DOI 10.1074/jbc.273.22.13933; PLOUG M, 1991, J BIOL CHEM, V266, P1926; PURCHIO AF, 1988, J BIOL CHEM, V263, P14211; RONNE E, 1991, FEBS LETT, V288, P233, DOI 10.1016/0014-5793(91)81042-7; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; Xing RH, 1997, CANCER RES, V57, P3585	55	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20628	20637		10.1074/jbc.M302249200	http://dx.doi.org/10.1074/jbc.M302249200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665524	hybrid			2022-12-27	WOS:000183230500025
J	Schmierer, B; Schuster, MK; Shkumatava, A; Kuchler, K				Schmierer, B; Schuster, MK; Shkumatava, A; Kuchler, K			Activin A signaling induces Smad2, but not Smad3, requiring protein kinase A activity in granulosa cells from the avian ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PORCINE FOLLICULAR-FLUID; FUNCTIONAL-CHARACTERIZATION; STRUCTURAL BASIS; DOMESTIC-FOWL; RAT OVARY; INHIBIN-A; RECEPTOR; ACTIVATION; EXPRESSION	Activin A signaling is an important regulator of ovarian granulosa cell function. The cytosolic signal transducer Smad2 is most highly expressed in chicken granulosa cells (cGC) of preovulatory follicles. Moreover, Smad2 shows predominant nuclear localization in freshly isolated cGC, indicating active Smad signaling in vivo. Primary cGC cultured in vitro require activin A to sustain high Smad2 levels, which otherwise drop dramatically in the absence of activin A. This activin A-dependent Smad2 expression is abrogated by protein kinase A (PKA) inhibitors, suggesting a role for PKA in activin signaling. In the absence of activin A, strong PKA activators such as follicle-stimulating hormone (FSH) and 8-bromo-cyclic AMP fail to elicit Smad2 induction. However, FSH and 8-bromo-cyclic AMP boost activin A-dependent Smad2 up-regulation, giving rise to Smad2 levels similar to expression in vivo levels. Interestingly, the effect is specific for Smad2, since expression of the structurally and functionally closely related Smad3 remains entirely unaffected. Hence, activin A induces Smad2, but not Smad3, to high levels requiring PKA activation. Since Smad2 and Smad3 target distinct yet overlapping sets of TGF-beta/activin-responsive genes, the selective Smad2 induction by FSH/activin A could allow FSH to efficiently modulate the transcriptional readout of activin A signaling in avian granulosa cells.	Univ & BioCenter Vienna, Inst Med Biochem, Dept Mol Genet, A-1030 Vienna, Austria	University of Vienna	Kuchler, K (corresponding author), Univ & BioCenter Vienna, Inst Med Biochem, Dept Mol Genet, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	kaku@mol.univie.ac.at	Schmierer, Bernhard/P-4208-2019; kuchler, karl/AAL-6937-2020; Schmierer, Bernhard/C-1416-2009	Schmierer, Bernhard/0000-0002-9082-7022; kuchler, karl/0000-0003-2719-5955; Schmierer, Bernhard/0000-0002-9082-7022				Amsterdam A, 2002, MOL CELL ENDOCRINOL, V187, P69, DOI 10.1016/S0303-7207(01)00701-8; Babu PS, 2000, J BIOL CHEM, V275, P27615; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BURGER HG, 1988, ENDOCRINOLOGY, V122, P1701; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; Crepieux P, 2001, ONCOGENE, V20, P4696, DOI 10.1038/sj.onc.1204632; Das S, 1996, ENDOCRINOLOGY, V137, P967, DOI 10.1210/en.137.3.967; Drummond AE, 2002, ENDOCRINOLOGY, V143, P1423, DOI 10.1210/en.143.4.1423; El-Hefnawy T, 2001, ENDOCRINOLOGY, V142, P4357, DOI 10.1210/en.142.10.4357; ERICKSON GF, 1978, ENDOCRINOLOGY, V103, P1960, DOI 10.1210/endo-103-5-1960; Findlay JK, 1999, TRENDS ENDOCRIN MET, V10, P183, DOI 10.1016/S1043-2760(98)00144-1; FINDLAY JK, 1993, BIOL REPROD, V48, P15, DOI 10.1095/biolreprod48.1.15; Findlay JK, 2001, MOL CELL ENDOCRINOL, V180, P139, DOI 10.1016/S0303-7207(01)00521-4; FINDLAY JK, 1993, OVARY, P413; GILBERT AB, 1977, J REPROD FERTIL, V50, P179, DOI 10.1530/jrf.0.0500179; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Joore J, 1998, MECH DEVELOP, V79, P5, DOI 10.1016/S0925-4773(98)00152-X; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; LING N, 1985, P NATL ACAD SCI USA, V82, P7217, DOI 10.1073/pnas.82.21.7217; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mather JP, 1997, P SOC EXP BIOL MED, V215, P209; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; Mulheron G.W., 1993, OVARY, P337; Nagarajan RP, 2000, BIOCHEM J, V350, P253, DOI 10.1042/0264-6021:3500253; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PERRY MM, 1978, J ANAT, V125, P481; Piek E, 1999, J CELL SCI, V112, P4557; Piek E, 2001, J BIOL CHEM, V276, P19945, DOI 10.1074/jbc.M102382200; RIVIER J, 1985, BIOCHEM BIOPH RES CO, V133, P120, DOI 10.1016/0006-291X(85)91849-2; ROBERTSON DM, 1985, BIOCHEM BIOPH RES CO, V126, P220, DOI 10.1016/0006-291X(85)90594-7; Salvador LM, 2001, J BIOL CHEM, V276, P40146, DOI 10.1074/jbc.M106710200; Schmierer B, 2003, BIOL REPROD, V68, P620, DOI 10.1095/biolreprod.102.008714; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Takenoshita S, 1998, GENOMICS, V48, P1, DOI 10.1006/geno.1997.5149; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Weinstein M, 2000, CYTOKINE GROWTH F R, V11, P49, DOI 10.1016/S1359-6101(99)00028-3; WOODRUFF TK, 1993, ENDOCRINOLOGY, V132, P725, DOI 10.1210/en.132.2.725; WOODRUFF TK, 1993, ENDOCRINOLOGY, V133, P2998, DOI 10.1210/en.133.6.2998; Wu G, 2000, SCIENCE, V287, P92, DOI 10.1126/science.287.5450.92; Yagi K, 1999, J BIOL CHEM, V274, P703, DOI 10.1074/jbc.274.2.703; Yakmovych I, 2001, FASEB J, V15, P553; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	23	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21197	21203		10.1074/jbc.M212425200	http://dx.doi.org/10.1074/jbc.M212425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665510	hybrid			2022-12-27	WOS:000183230500097
J	Verma, R; Wharram, B; Kovari, I; Kunkel, R; Nihalani, D; Wary, KK; Wiggins, RC; Killen, P; Holzman, LB				Verma, R; Wharram, B; Kovari, I; Kunkel, R; Nihalani, D; Wary, KK; Wiggins, RC; Killen, P; Holzman, LB			Fyn binds to and phosphorylates the kidney slit diaphragm component nephrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL NEPHROTIC SYNDROME; ZIPPER-BEARING KINASE; SIGNAL-TRANSDUCTION; LIPID RAFTS; GLOMERULAR PROTEIN; PODOCYTE STRUCTURE; TYROSINE KINASES; FINNISH TYPE; MICE; GENE	Recent investigations have focused on characterizing the molecular components of the podocyte intercellular junction, because several of these components, including Nephrin, are functionally necessary for development of normal podocyte structure and filter integrity. Accumulating evidence suggests that the Nephrin-associated protein complex is a signaling nexus. As such, Nephrin-dependent signaling might be mediated in part through Nephrin phosphorylation. Described are biochemical and mouse genetics experiments demonstrating that membrane-associated Nephrin is tyrosine-phosphorylated by the Src family kinase Fyn. Nephrin fractionated in detergent-resistant glomerular membrane fractions with Fyn and Yes. Fyn directly bound Nephrin via its SH3 domain, and Fyn directly phosphorylated Nephrin. Glomeruli in which Fyn, Yes, or Fyn and Yes were genetically deleted in mice were characterized to explore the relationship between these kinases and Nephrin. Fyn deletion resulted in coarsening of podocyte foot processes and marked attenuation of Nephrin phosphorylation in isolated glomerular detergent-resistant membrane fractions. Yes deletion had no identifiable effect on podocyte morphology but dramatically increased Nephrin phosphorylating activity. Similar to Fyn deletion, simultaneous deletion of Fyn and Yes reduced Nephrin phosphorylating activity. These results demonstrate that endogenous Fyn catalyzes Nephrin phosphorylation in podocyte detergent-resistant membrane fractions. Although Yes appears to effect the regulation of Nephrin phosphorylation, the mechanism by which this occurs requires investigation.	Univ Michigan, Sch Med, Div Nephrol, Dept Internal Med, Ann Arbor, MI 48109 USA; Dept Vet Affairs, Ann Arbor, MI 48105 USA; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Texas Med Ctr, Ctr Extracellular Matrix Biol, Inst Biosci & Technol, Houston, TX 77030 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Baylor College of Medicine	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Div Nephrol, Dept Internal Med, 1560 MSRB 2, Ann Arbor, MI 48109 USA.		nihalani, deepak/AAK-9453-2020	Holzman, Lawrence/0000-0002-8961-234X; Wary, Kishore/0000-0001-8851-8565; Wiggins, Roger/0000-0002-1166-2849				Boute N, 2000, NAT GENET, V24, P349, DOI 10.1038/74166; Cary LA, 2000, NATURE, V404, P945, DOI 10.1038/35010257; HOLMBERG C, 1995, PEDIATR NEPHROL, V9, P87, DOI 10.1007/BF00858984; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514; LAINE J, 1993, KIDNEY INT, V44, P867, DOI 10.1038/ki.1993.324; Mata M, 1996, J BIOL CHEM, V271, P16888, DOI 10.1074/jbc.271.28.16888; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Oved S, 2002, NATURE, V416, P133, DOI 10.1038/416133a; Putaala H, 2001, HUM MOL GENET, V10, P1, DOI 10.1093/hmg/10.1.1; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; Rivera J, 2002, CURR OPIN IMMUNOL, V14, P688, DOI 10.1016/S0952-7915(02)00396-5; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; Sheng M, 2002, SCIENCE, V298, P776, DOI 10.1126/science.1075333; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; Smoyer WE, 1998, J MOL MED, V76, P172, DOI 10.1007/s001090050206; Somlo S, 2000, NAT GENET, V24, P333, DOI 10.1038/74139; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4; Wharram BL, 2000, J CLIN INVEST, V106, P1281, DOI 10.1172/JCI7236; Yu CCK, 2001, CURR BIOL, V11, P34, DOI 10.1016/S0960-9822(00)00024-5	31	186	195	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20716	20723		10.1074/jbc.M301689200	http://dx.doi.org/10.1074/jbc.M301689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668668	hybrid			2022-12-27	WOS:000183230500037
J	Zhang, HB; Nohr, J; Jensen, CH; Petersen, RK; Bachmann, E; Teisner, B; Larsen, LK; Mandrup, S; Kristiansen, K				Zhang, HB; Nohr, J; Jensen, CH; Petersen, RK; Bachmann, E; Teisner, B; Larsen, LK; Mandrup, S; Kristiansen, K			Insulin-like growth factor-1/insulin bypasses Pref-1/FA1-mediated inhibition of adipocyte differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3-L1 PREADIPOCYTE DIFFERENTIATION; CIRCULATING GENE-PRODUCT; ACTIVATED PROTEIN-KINASE; FETAL ANTIGEN-1 MFA1; FACTOR-I; ADIPOSE CONVERSION; TRANSCRIPTIONAL REGULATION; RETINOBLASTOMA PROTEIN; DNA-SYNTHESIS; S6 KINASE	Pref-1 is a highly glycosylated Delta-like transmembrane protein containing six epidermal growth factor-like repeats in the extracellular domain. Pref-1 is abundantly expressed in preadipocytes, but expression is down-regulated during adipocyte differentiation. Forced expression of Pref-1 in 3T3-L1 cells was reported to inhibit adipocyte differentiation. Here we show that efficient and regulated processing of Pref-1 occurs in 3T3-L1 preadipocytes releasing most of the extracellular domain as a 50-kDa heterogeneous protein, previously isolated and characterized as FA1. Unexpectedly, we found that forced expression of the soluble form, FA1, or full-length Pref-1 did not inhibit adipocyte differentiation of 3T3-L1 cells when differentiation was induced by standard treatment with methylisobutylxanthine, dexamethasone, and high concentrations of insulin. However, forced expression of either form of Pref-1/FA1 in 3T3-L1 or 3T3-F442A cells inhibited adipocyte differentiation when insulin or insulin-like growth factor-1 (IGF-1) was omitted from the differentiation mixture. We demonstrate that the level of the mature form of the IGF-1 receptor is reduced and that IGF-1-dependent activation of p42/p44 mitogen-activated protein kinases (MAPKs) is compromised in preadipocytes with forced expression of Pref-1. This is accompanied by suppression of clonal expansion and terminal differentiation. Accordingly, supplementation with insulin or IGF-1 rescued p42/p44 MAPK activation, clonal expansion, and adipocyte differentiation in a dose-dependent manner.	Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Univ So Denmark, Dept Immunol & Microbiol, DK-5000 Odense C, Denmark; Rheoscience, DK-2610 Rodovre, Denmark	University of Southern Denmark; University of Southern Denmark	Kristiansen, K (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.	kak@bmb.sdu.dk	Mandrup, Susanne/B-6693-2008; Jensen, Charlotte Harken/AAZ-1738-2020; Kristiansen, Karsten/J-5148-2014; Jensen, Charlotte Harken/P-4612-2014	Jensen, Charlotte Harken/0000-0001-9683-8761; Kristiansen, Karsten/0000-0002-6024-0917; Jensen, Charlotte Harken/0000-0001-9683-8761; Mandrup, Susanne/0000-0002-0961-5787				Bachmann E, 1996, J REPROD FERTIL, V107, P279; Bauer SR, 1998, MOL CELL BIOL, V18, P5247, DOI 10.1128/MCB.18.9.5247; BIRGITTE U, 1999, J BIOL CHEM, V43, P30864; BONEY CM, 1994, ENDOCRINOLOGY, V135, P1863, DOI 10.1210/en.135.5.1863; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Carlsson C, 1997, ENDOCRINOLOGY, V138, P3940, DOI 10.1210/en.138.9.3940; DEDORA JF, 1997, MOL CELL BIOL, V17, P6068; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; FAY TN, 1988, EUR J OBSTET GYN R B, V29, P73, DOI 10.1016/0028-2243(88)90167-0; GAO X, 1991, BIOCHEM BIOPH RES CO, V179, P280, DOI 10.1016/0006-291X(91)91366-K; Garces C, 1997, J BIOL CHEM, V272, P29729, DOI 10.1074/jbc.272.47.29729; Garces C, 1999, DIFFERENTIATION, V64, P103, DOI 10.1007/s002580050265; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; Hansen LH, 1998, MOL ENDOCRINOL, V12, P1140, DOI 10.1210/me.12.8.1140; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HELMAN LJ, 1990, NUCLEIC ACIDS RES, V18, P685; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; IGNOTZ RA, 1985, P NATL ACAD SCI USA, V82, P8530, DOI 10.1073/pnas.82.24.8530; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; JENSEN CH, 1994, EUR J BIOCHEM, V225, P83, DOI 10.1111/j.1432-1033.1994.00083.x; JENSEN CH, 1993, HUM REPROD, V8, P635, DOI 10.1093/oxfordjournals.humrep.a138110; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; KELLER DC, 1993, BLOOD, V82, P1428; Krogh TN, 1997, EUR J BIOCHEM, V244, P334, DOI 10.1111/j.1432-1033.1997.00334.x; LABORDA J, 1993, J BIOL CHEM, V268, P3817; LEE YL, 1995, BBA-GENE STRUCT EXPR, V1261, P223; Liu KN, 2002, MOL CELL ENDOCRINOL, V194, P51, DOI 10.1016/S0303-7207(02)00188-0; MACDOUGALD OA, 1994, J BIOL CHEM, V269, P19041; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; Mandrup S, 1997, J BIOL CHEM, V272, P5367, DOI 10.1074/jbc.272.9.5367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Mei BS, 2002, BIOCHEM J, V364, P137, DOI 10.1042/bj3640137; Moon YS, 2002, MOL CELL BIOL, V22, P5585, DOI 10.1128/MCB.22.15.5585-5592.2002; Moore KA, 1997, P NATL ACAD SCI USA, V94, P4011, DOI 10.1073/pnas.94.8.4011; MORGAN RA, 1992, NUCLEIC ACIDS RES, V20, P1293, DOI 10.1093/nar/20.6.1293; MORIKAWA M, 1982, CELL, V29, P783, DOI 10.1016/0092-8674(82)90440-8; NIXON T, 1984, ENDOCRINOLOGY, V114, P527, DOI 10.1210/endo-114-2-527; OHSUMI J, 1991, FEBS LETT, V288, P13, DOI 10.1016/0014-5793(91)80991-B; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prusty D, 2002, J BIOL CHEM, V277, P46226, DOI 10.1074/jbc.M207776200; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; Rosen ED, 2000, GENE DEV, V14, P1293; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Ruiz-Hidalgo MJ, 2002, EXP CELL RES, V274, P178, DOI 10.1006/excr.2001.5464; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SCHMIDT W, 1990, J BIOL CHEM, V265, P15489; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Smas CM, 1998, J BIOL CHEM, V273, P31751, DOI 10.1074/jbc.273.48.31751; Smas CM, 1997, MOL CELL BIOL, V17, P977, DOI 10.1128/MCB.17.2.977; SMAS CM, 1994, BIOCHEMISTRY-US, V33, P9257, DOI 10.1021/bi00197a029; SMAS CM, 1993, CELL, V73, P725, DOI 10.1016/0092-8674(93)90252-L; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Sorisky A, 1999, CRIT REV CL LAB SCI, V36, P1, DOI 10.1080/10408369991239169; STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; Yarwood SJ, 1999, J BIOL CHEM, V274, P8662, DOI 10.1074/jbc.274.13.8662; YIN TG, 1992, J BIOL CHEM, V267, P8347	63	41	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20906	20914		10.1074/jbc.M300022200	http://dx.doi.org/10.1074/jbc.M300022200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651852	hybrid			2022-12-27	WOS:000183230500061
J	Nagy, T; Nurizzo, D; Davies, GJ; Biely, P; Lakey, JH; Bolam, DN; Gilbert, HJ				Nagy, T; Nurizzo, D; Davies, GJ; Biely, P; Lakey, JH; Bolam, DN; Gilbert, HJ			The alpha-glucuronidase, GlcA67A, of Cellvibrio japonicus utilizes the carboxylate and methyl groups of aldobiouronic acid as important substrate recognition determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROLASE FAMILY 10; CELLULOSA XYLANASE; TRICHODERMA-REESEI; ACTIVE-SITE; BINDING; XYLOOLIGOSACCHARIDES; SPECIFICITY; REFINEMENT; RESIDUES; ENZYMES	alpha-Glucuronidases are key components of the ensemble of enzymes that degrade the plant cell wall. They hydrolyze the alpha1,2-glycosidic bond between 4-O-methyl-D-glucuronic acid (4-O-MeGlcA) and the xylan or xylooligosaccharide backbone. Here we report the crystal structure of an inactive mutant (E292A) of the alpha-glucuronidase, GlcA67A, from Cellvibrio japonicus in complex with its substrate. The data show that the 4-O-methyl group of the substrate is accommodated within a hydrophobic sheath flanked by Val-210 and Trp-160, whereas the carboxylate moiety is located within a positively charged region of the substrate-binding pocket. The carboxylate side chains of Glu-393 and Asp-365, on the "beta-face" of 4-O-MeGlcA, form hydrogen bonds with a water molecule that is perfectly positioned to mount a nucleophilic attack at the anomeric carbon of the target glycosidic bond, providing further support for the view that, singly or together, these amino acids function as the catalytic base. The capacity of reaction products and product analogues to inhibit GlcA67A shows that the 4-O-methyl group, the carboxylate, and the xylose sugar of aldobiouronic acid all play an important role in substrate binding. Site-directed mutagenesis informed by the crystal structure of enzyme-ligand complexes was used to probe the importance of highly conserved residues at the active site of GlcA67A. The biochemical properties of K288A, R325A, and K360A show that a constellation of three basic amino acids ( Lys-288, Arg-325, and Lys-360) plays a critical role in binding the carboxylate moiety of 4-O-MeGlcA. Disruption of the apolar nature of the pocket created by Val-210 (V210N and V210S) has a detrimental effect on substrate binding, although the reduction in affinity is not reflected by an inability to accommodate the 4-O-methyl group. Replacing the two tryptophan residues that stack against the sugar rings of the substrate with alanine (W160A and W543A) greatly reduced activity.	Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Univ York, Dept Chem, Struct Biol Lab, York YO10 5DD, N Yorkshire, England; Slovak Acad Sci, Inst Chem, Bratislava 84238, Slovakia	Newcastle University - UK; University of York - UK; Slovak Academy of Sciences	Gilbert, HJ (corresponding author), Univ Newcastle Upon Tyne, Sch Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	H.J.Gilbert@Newcastle.ac.uk	Biely, Peter/ABF-3465-2020; Davies, Gideon J/A-9042-2011	Biely, Peter/0000-0002-9915-7707; Davies, Gideon J/0000-0002-7343-776X; Bolam, David/0000-0003-0314-3122				Andrews SR, 2000, J BIOL CHEM, V275, P23027, DOI 10.1074/jbc.M000128200; Biely P, 2000, BBA-GEN SUBJECTS, V1474, P360, DOI 10.1016/S0304-4165(00)00029-5; Biely P, 2000, ANAL BIOCHEM, V286, P289, DOI 10.1006/abio.2000.4810; BRETT CT, 1996, PHYSL BIOCH PLANT CE, V1, P16; BRONNENMEIER K, 1995, MICROBIOL-SGM, V141, P2033, DOI 10.1099/13500872-141-9-2033; Charnock SJ, 1998, J BIOL CHEM, V273, P32187, DOI 10.1074/jbc.273.48.32187; Charnock SJ, 1997, J BIOL CHEM, V272, P2942, DOI 10.1074/jbc.272.5.2942; COUGHLAN MP, 1993, BIOTECHNOL APPL BIOC, V17, P259; Coutinho PM, 1999, ROY SOC CH, P3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Koivula A, 2002, J AM CHEM SOC, V124, P10015, DOI 10.1021/ja012659q; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy T, 2002, J BACTERIOL, V184, P4925, DOI 10.1128/JB.184.17.4925-4929.2002; Nurizzo D, 2002, STRUCTURE, V10, P547, DOI 10.1016/S0969-2126(02)00742-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt A, 1999, BIOCHEMISTRY-US, V38, P2403, DOI 10.1021/bi982108l; Sinnott ML, 1998, BIOCHEM SOC T, V26, P160, DOI 10.1042/bst0260160; STRYER L, 2002, BIOCHEMISTRY-US, P50; TULL D, 1994, BIOCHEMISTRY-US, V33, P6363, DOI 10.1021/bi00186a041; UCHIDA H, 1992, BIOSCI BIOTECH BIOCH, V56, P1608, DOI 10.1271/bbb.56.1608; WIGLEY DB, 1987, BIOCHEM BIOPH RES CO, V149, P927, DOI 10.1016/0006-291X(87)90497-9; Zaide G, 2001, EUR J BIOCHEM, V268, P3006, DOI 10.1046/j.1432-1327.2001.02193.x	25	25	26	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20286	20292		10.1074/jbc.M302205200	http://dx.doi.org/10.1074/jbc.M302205200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654910	hybrid			2022-12-27	WOS:000183078000091
J	Nakagawa, T; Hirano, Y; Inomata, A; Yokota, S; Miyachi, K; Kaneda, M; Umeda, M; Furukawa, K; Omata, S; Horigome, T				Nakagawa, T; Hirano, Y; Inomata, A; Yokota, S; Miyachi, K; Kaneda, M; Umeda, M; Furukawa, K; Omata, S; Horigome, T			Participation of a fusogenic protein, glyceraldehyde-3-phosphate dehydrogenase, in nuclear membrane assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY BILIARY-CIRRHOSIS; LAMIN-B RECEPTOR; CELL-FREE SYSTEM; FORMATION INVITRO; PORE COMPLEXES; GTP HYDROLYSIS; EGG EXTRACTS; RAN GTPASE; ENVELOPE; FUSION	We found an autoimmune serum, K199, that strongly suppresses nuclear membrane assembly in a cell-free system involving a Xenopus egg extract. Four different antibodies that suppress nuclear assembly were affinity-purified from the serum using Xenopus egg cytosol proteins. Three proteins recognized by these antibodies were identified by partial amino acid sequencing to be glyceraldehyde-3-phosphate dehydrogenase (GAPDH), fructose-1,6-bisphosphate aldolase, and the regulator of chromatin condensation 1. GAPDH is known to be a fusogenic protein. To verify the participation of GAPDH in nuclear membrane fusion, authentic antibodies against human and rat GAPDH were applied, and strong suppression of nuclear assembly at the nuclear membrane fusion step was observed. The nuclear assembly activity suppressed by antibodies was recovered on the addition of purified chicken GAPDH. A peptide with the sequence of amino acid residues 70-94 of GAPDH, which inhibits GAPDH-induced phospholipid vesicle fusion, inhibited nuclear assembly at the nuclear membrane fusion step. We propose that GAPDH plays a crucial role in the membrane fusion step in nuclear assembly in a Xenopus egg extract cell-free system.	Niigata Univ, Fac Sci, Dept Biochem, Niigata 9502181, Japan; Niigata Univ, Grad Sch Sci & Technol, Course Funct Biol, Niigata 9502181, Japan; Yamanashi Med Univ, Biol Lab, Tamaho, Yamanashi 4093898, Japan; Hlth Sci Res Inst, Keigu Med Clin, Kanagawa 2300023, Japan; Tokyo Metropolitan Inst Med Sci, Dept Inflammat Res, Bunkyo Ku, Tokyo 1130021, Japan; Niigata Univ, Ctr Instrumental Anal, Niigata 9502181, Japan	Niigata University; Niigata University; University of Yamanashi; Tokyo Metropolitan Institute of Medical Science; Niigata University	Horigome, T (corresponding author), Niigata Univ, Fac Sci, Dept Biochem, Igarashi 2, Niigata 9502181, Japan.	thori@chem.sc.niigata-u.ac.jp	Hirano, Yasuhiro/AAN-4617-2021	Hirano, Yasuhiro/0000-0001-7339-4053				ARCARI P, 1989, BIOCHEM GENET, V27, P439, DOI 10.1007/BF02399673; BENAVENTE R, 1989, CHROMOSOMA, V98, P233, DOI 10.1007/BF00327308; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; Bodoor K, 1999, J CELL SCI, V112, P2253; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Clarke PR, 2001, TRENDS CELL BIOL, V11, P366, DOI 10.1016/S0962-8924(01)02071-2; de Arcuri BF, 1999, BIOCHEM BIOPH RES CO, V262, P586, DOI 10.1006/bbrc.1999.1243; Drummond S, 1999, J CELL BIOL, V144, P225, DOI 10.1083/jcb.144.2.225; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASER PE, 1995, BIOCHEMISTRY-US, V34, P12193, DOI 10.1021/bi00038a013; Han XL, 1998, BBA-BIOMEMBRANES, V1414, P95, DOI 10.1016/S0005-2736(98)00154-0; Haraguchi T, 2000, J CELL SCI, V113, P779; Hessler RJ, 1998, J LEUKOCYTE BIOL, V63, P331, DOI 10.1002/jlb.63.3.331; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Imai N, 1997, J BIOCHEM-TOKYO, V122, P1024; Kaneda M, 1997, J BIOCHEM-TOKYO, V122, P1233; Kawahire S, 1997, J BIOCHEM-TOKYO, V121, P881, DOI 10.1093/oxfordjournals.jbchem.a021669; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; KONSTANTINOV K, 1995, CLIN IMMUNOL IMMUNOP, V74, P89, DOI 10.1006/clin.1995.1013; KUMAGAI H, 1983, J BIOCHEM-TOKYO, V93, P1259, DOI 10.1093/oxfordjournals.jbchem.a134260; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Marshall ICB, 1997, TRENDS CELL BIOL, V7, P69, DOI 10.1016/S0962-8924(96)10047-7; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Miyachi K, 1996, MOL BIOL REP, V23, P227, DOI 10.1007/BF00351173; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; NICKELLS RW, 1988, J CELL BIOL, V107, P1901, DOI 10.1083/jcb.107.5.1901; NICKOWITZ RE, 1994, GASTROENTEROLOGY, V106, P193, DOI 10.1016/S0016-5085(94)95333-3; NISHITANI H, 1990, J BIOCHEM-TOKYO, V107, P228, DOI 10.1093/oxfordjournals.jbchem.a123031; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PIECHACZYK M, 1984, NATURE, V312, P469, DOI 10.1038/312469a0; Rape M, 2001, CELL, V107, P667, DOI 10.1016/S0092-8674(01)00595-5; ROBBINS AR, 1995, J CELL BIOL, V130, P1093, DOI 10.1083/jcb.130.5.1093; Sasagawa S, 1999, EUR J CELL BIOL, V78, P593, DOI 10.1016/S0171-9335(99)80025-9; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Takano M, 2002, EUR J BIOCHEM, V269, P943, DOI 10.1046/j.0014-2956.2001.02730.x; Ukaji F, 1999, ANN RHEUM DIS, V58, P169, DOI 10.1136/ard.58.3.169; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang CM, 2001, CURR BIOL, V11, P208, DOI 10.1016/S0960-9822(01)00053-7	54	55	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20395	20404		10.1074/jbc.M210824200	http://dx.doi.org/10.1074/jbc.M210824200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651855	hybrid			2022-12-27	WOS:000183078000105
J	Chiang, YC; Teng, SC; Su, YN; Hsieh, FJ; Wu, KJ				Chiang, YC; Teng, SC; Su, YN; Hsieh, FJ; Wu, KJ			c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; S-PHASE; NUCLEAR-LOCALIZATION; MYC/MAX/MAD NETWORK; TARGETED DISRUPTION; ESTROGEN-RECEPTOR; CATALYTIC SUBUNIT; MAMMALIAN-CELLS; MRE11 COMPLEX; BINDING	The c-myc proto-oncogene encodes a ubiquitous transcription factor involved in the control of cell growth and implicated in inducing tumorigenesis. Understanding the function of c-Myc and its role in cancer depends upon the identification of c-Myc target genes. Nijmegen breakage syndrome (NBS) is a chromosomal-instability syndrome associated with cancer predisposition, radiosensitivity, and chromosomal instability. The NBS gene product, NBS1 (p95 or nibrin), is a part of the hMre11 complex, a central player associated with double-strand break (DSB) repair. NBS1 contains domains characteristic for proteins involved in DNA repair, recombination, and replication. Here we show that c-Myc directly activates NBS1. c-Myc-mediated induction of NBS1 gene transcription occurs in different tissues, is independent of cell proliferation, and is mediated by a c-Myc binding site in the intron 1 region of NBS1 gene. Overexpression of NBS1 in Rat1a cells increased cell proliferation. These results indicate that NBS1 is a direct transcriptional target of c-Myc and links the function of c-Myc to the regulation of DNA DSB repair pathway operating during DNA replication.	Natl Taiwan Univ, Coll Med, Dept Med Genet, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Dept Obstet & Gynecol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 100, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Wu, KJ (corresponding author), Natl Taiwan Univ, Coll Med, Dept Med Genet, Taipei 100, Taiwan.	kjwu@ha.mc.ntu.edu.tw	Chiang, Yun/GRJ-5251-2022; Wu, Kou-Juey/P-4654-2015	TENG, SHU-CHUN/0000-0002-6492-2560				BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Costanzo V, 2001, MOL CELL, V8, P137, DOI 10.1016/S1097-2765(01)00294-5; Dang CV, 1999, MOL CELL BIOL, V19, P1; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Kang J, 2002, EMBO J, V21, P1447, DOI 10.1093/emboj/21.6.1447; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Lutz W, 2002, BBA-REV CANCER, V1602, P61, DOI 10.1016/S0304-419X(02)00036-7; Maser RS, 2001, MOL CELL BIOL, V21, P6006, DOI 10.1128/MCB.21.17.6006-6016.2001; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; SASSON S, 1991, PATHOL BIOL, V39, P59; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; VANDERZWET MK, 1999, MUTAT RES, V434, P17; Varon R, 2001, CANCER RES, V61, P3570; Watson JD, 2002, J BIOL CHEM, V277, P36921, DOI 10.1074/jbc.M201493200; Wilda M, 2000, HUM MOL GENET, V9, P1739, DOI 10.1093/hmg/9.12.1739; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Wu KJ, 2002, ONCOGENE, V21, P7872, DOI 10.1038/sj.onc.1205986; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	42	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19286	19291		10.1074/jbc.M212043200	http://dx.doi.org/10.1074/jbc.M212043200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637527	hybrid			2022-12-27	WOS:000182932200074
J	Mishra, SK; Mazumdar, A; Vadlamudi, RK; Li, F; Wang, RA; Yu, W; Jordan, VC; Santen, RJ; Kumar, R				Mishra, SK; Mazumdar, A; Vadlamudi, RK; Li, F; Wang, RA; Yu, W; Jordan, VC; Santen, RJ; Kumar, R			MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE ACETYLTRANSFERASE ACTIVITY; NUCLEAR RECEPTOR; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; COMPLEX; COREPRESSOR; ACETYLATION; ACTIVATION; BINDING; PHOSPHORYLATION	The transcriptional activity of estrogen receptor-alpha (ER-alpha) is modified by coactivators, corepressors, and chromatin remodeling complexes. We have previously shown that the metastasis-associated protein-1 (MTA1), a component of histone deacetylase and nucleosome remodeling complexes, represses ER-driven transcription by recruiting histone deacetylases to the estrogen receptor element (ERE)-containing target gene chromatin in breast cancer cells. Using a yeast two-hybrid screening to clone MTA1-interacting proteins, we identified a previously uncharacterized molecule, which we named as MTA1-interacting coactivator (MICoA). Our findings suggest that estrogen signaling promotes nuclear translocation of MICoA and that MICoA interacts with MTA1 both in vitro and in vivo. MICoA binds to the C-terminal region of MTA1, whereas MTA1 binds to the N-terminal MICoA containing one nuclear receptor interaction LSRLL motif. We showed that MICoA is an ER coactivator, cooperates with other ER coactivators, stimulates ER-transactivation functions, and associates with the endogenous ER and its target gene promoter chromatin. MTA1 also repressed MICoA-mediated stimulation of ERE-mediated transcription in the presence of ER and ER variants with naturally occurring mutations, such as D351Y and K303R, and that it interfered with the association of MICoA with the ER-target gene chromatin. Because chromatin is a highly dynamic structure and because MTA1 and MICoA could be detected within the same complex, these findings suggest that MTA1 and MICoA might transmodulate functions of each other and any potential deregulation of MTA1 is likely to contribute to the functional inactivation of the ER pathway, presumably by derecruitment of MICoA from ER target promoter chromatin.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	University of Texas System; UTMD Anderson Cancer Center; University of Virginia; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Kumar, R (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rkumar@mdanderson.org	Wang, Brian/HGA-9535-2022; JORDAN, V.Craig/AAX-3562-2020	Mishra, Sandip/0000-0002-0776-6581	NATIONAL CANCER INSTITUTE [R01CA084456] Funding Source: NIH RePORTER; NCI NIH HHS [CA84456, CA80066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; BOYD J, 1996, CELLULAR MOL MECH HO, P151; CATHERINO WH, 1995, MOL ENDOCRINOL, V9, P1053, DOI 10.1210/me.9.8.1053; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Espinos E, 1999, MOL CELL BIOL, V19, P3474; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097-2765(01)00429-4; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; GEORGE FW, 1988, PHYSL REPRODUCTION, V1, P3; Glass CK, 2000, GENE DEV, V14, P121; Graham JD, 2000, STEROIDS, V65, P579, DOI 10.1016/S0039-128X(00)00116-1; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Inoue M, 1996, CYTOGENET CELL GENET, V73, P134; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Jepsen K, 2002, J CELL SCI, V115, P689; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Levenson AS, 2001, J STEROID BIOCHEM, V76, P61, DOI 10.1016/S0960-0760(00)00143-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lomvardas S, 2002, MOL CELL, V9, P209, DOI 10.1016/S1097-2765(02)00463-X; Mahoney MG, 2002, ONCOGENE, V21, P2161, DOI 10.1038/sj.onc.1205277; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Mazumdar A, 2001, NAT CELL BIOL, V3, P30, DOI 10.1038/35050532; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McMahon C, 1999, P NATL ACAD SCI USA, V96, P5382, DOI 10.1073/pnas.96.10.5382; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Sassone-Corsi P, 2002, SCIENCE, V296, P2176, DOI 10.1126/science.1070963; Schafer JM, 2000, CANCER RES, V60, P5097; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Song RX, 2002, MOL CELL ENDOCRINOL, V193, P29, DOI 10.1016/S0303-7207(02)00093-X; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yamamoto Y, 2001, J BIOL CHEM, V276, P42684, DOI 10.1074/jbc.M107844200; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	57	53	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19209	19219		10.1074/jbc.M301968200	http://dx.doi.org/10.1074/jbc.M301968200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639951	hybrid			2022-12-27	WOS:000182932200065
J	Nagai, K; Arai, H; Yanagita, M; Matsubara, T; Kanamori, H; Nakano, T; Iehara, N; Fukatsu, A; Kita, T; Doi, T				Nagai, K; Arai, H; Yanagita, M; Matsubara, T; Kanamori, H; Nakano, T; Iehara, N; Fukatsu, A; Kita, T; Doi, T			Growth arrest-specific gene 6 is involved in glomerular hypertrophy in the early stage of diabetic nephropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESANGIAL CELL-PROLIFERATION; EXTRACELLULAR-MATRIX; GAS6; WARFARIN; MICE; GLOMERULONEPHRITIS; INHIBITION; THROMBOSIS; ANTAGONIST; MECHANISM	Nephropathy is one of the most common complications of diabetes mellitus. Glomerular hypertrophy is a hallmark in the early phase of the nephropathy. The mechanism of glomerular hypertrophy, however, remains incompletely understood. We have reported that Gas6 (growth arrest-specific gene 6) and its receptor, Axl, play a key role in the development of glomerulonephritis. Here we show the important role of Gas6/Axl in the pathogenesis of diabetic glomerular hypertrophy. In streptozotocin (STZ)-induced diabetic rats, mesangial and glomerular hypertrophy and an increase in the glomerular filtration rate (GFR) and albuminuria were observed after 12 weeks of STZ injection. The glomerular expression of Gas6 and Axl was increased in those rats. Administration of warfarin inhibited mesangial and glomerular hypertrophy and the increase in GFR and albuminuria in STZ rats. Moreover, we found less mesangial hypertrophy in STZ-treated Gas6 knockout mice than control mice. In vitro we found that stimulation of mesangial cells with Gas6 resulted in mesangial cell hypertrophy. Thus we have found a novel mechanism of glomerular hypertrophy through the Gas6/Axl-mediated pathway in the development of diabetic nephropathy. Inhibition of the Gas6/Axl pathway in diabetic patients might be beneficial to slow down the progression of diabetic nephropathy.	Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Artificial Kidneys, Kyoto 6068507, Japan; Shionogi & Co Ltd, Discovery Res Lab, Osaka 5530002, Japan; Univ Tokushima, Dept Clin Biol & Med, Tokushima 7708503, Japan	Kyoto University; Kyoto University; Kyoto University; Shionogi & Company Limited; Tokushima University	Nagai, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Geriatr Med, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.		Arai, Hidenori/P-9816-2017; FUKATSU, ATSUSHI/R-7941-2019	Arai, Hidenori/0000-0002-9000-6849; Yanagita, Motoko/0000-0002-0339-9008				Angelillo-Scherrer A, 2001, NAT MED, V7, P215, DOI 10.1038/84667; BOJESTIG M, 1994, NEW ENGL J MED, V330, P15, DOI 10.1056/NEJM199401063300103; Booth SL, 2000, NUTR REV, V58, P20, DOI 10.1111/j.1753-4887.2000.tb01820.x; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; Flyvbjerg A, 1999, DIABETES, V48, P377, DOI 10.2337/diabetes.48.2.377; Gallus AS, 2000, MED J AUSTRALIA, V172, P600, DOI 10.5694/j.1326-5377.2000.tb124127.x; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P2132, DOI 10.1093/ndt/17.12.2132; HOLFORD NHG, 1986, CLIN PHARMACOKINET, V11, P483, DOI 10.2165/00003088-198611060-00005; Hostetter TH, 2001, J CLIN INVEST, V107, P161, DOI 10.1172/JCI12066; Kaizu Kazo, 1991, Journal of Diabetic Complications, V5, P92, DOI 10.1016/0891-6632(91)90030-S; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; Lehmann R, 2000, CLIN CHIM ACTA, V297, P135, DOI 10.1016/S0009-8981(00)00240-0; MACKAY K, 1988, KIDNEY INT, V33, P677, DOI 10.1038/ki.1988.53; MAKINO H, 1992, VIRCHOWS ARCH B, V62, P19, DOI 10.1007/BF02899661; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1997, BIOCHEM J, V323, P387, DOI 10.1042/bj3230387; Pippin JW, 1997, J CLIN INVEST, V100, P2512, DOI 10.1172/JCI119793; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schulman S, 2000, NEW ENGL J MED, V342, P1953, DOI 10.1056/NEJM200006293422604; Stockelman MG, 1998, AM J PHYSIOL-RENAL, V275, pF154, DOI 10.1152/ajprenal.1998.275.1.F154; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; Yanagita M, 2002, J CLIN INVEST, V110, P239, DOI 10.1172/JCI200214861; Yanagita M, 2001, AM J PATHOL, V158, P1423, DOI 10.1016/S0002-9440(10)64093-X; Yanagita M, 2001, J BIOL CHEM, V276, P42364, DOI 10.1074/jbc.M107488200; Yanagita M, 1999, J AM SOC NEPHROL, V10, P2503; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; ZATZ R, 1985, P NATL ACAD SCI USA, V82, P5963, DOI 10.1073/pnas.82.17.5963; Ziswiler R, 1998, J AM SOC NEPHROL, V9, P2055; ZIYADEH FN, 1993, AM J KIDNEY DIS, V22, P736, DOI 10.1016/S0272-6386(12)80440-9	36	85	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18229	18234		10.1074/jbc.M213266200	http://dx.doi.org/10.1074/jbc.M213266200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644472	Green Submitted, hybrid			2022-12-27	WOS:000182838300084
J	Ancey, C; Kuster, A; Haan, S; Herrmann, A; Heinrich, PC; Muller-Newen, G				Ancey, C; Kuster, A; Haan, S; Herrmann, A; Heinrich, PC; Muller-Newen, G			A fusion protein of the gp130 and interleukin-6R alpha ligand-binding domains acts as a potent interleukin-6 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; SOLUBLE IL-6 RECEPTOR; MONOCLONAL-ANTIBODY; NONPEPTIDE ANTAGONIST; RHEUMATOID-ARTHRITIS; ACTIVATION; ASSOCIATION; EXPRESSION; COMPLEX; IDENTIFICATION	Interleukin (IL)-6 is involved in the maintenance and progression of several diseases such as multiple myeloma, rheumatoid arthritis, or osteoporosis. The present work aims at the development of an IL-6 inhibitor for the use in anti-cytokine therapies. The IL-6 receptor is composed of two different subunits, an alpha-subunit (IL-6Ralpha) that binds IL-6 with low affinity and a beta-subunit (gp130) that binds the IL-6.IL-6Ralpha complex with high affinity and as a result triggers intracellular signaling. In its soluble form, gp130 is a natural antagonist that neutralizes IL-6.soluble IL-6Ralpha complexes. It was our strategy to appropriately fuse the two receptor subunit fragments involved in IL-6 receptor complex formation to bind IL-6 with high affinity and to antagonize its effects. The ligand-binding domains of gp130 (D1-D2-D3) and IL-6Ralpha (D2-D3) were connected using three different linkers. The resulting constructs were expressed in stably transfected insect cells and tested for their ability to inhibit IL-6 activity in several in vitro systems. All fusion proteins were strong inhibitors of IL-6 signaling and abrogated IL-6-induced phosphorylation of STAT3, proliferation of transfected Ba/F3 cells, and induction of acute-phase protein synthesis. As intended, the fused receptors were much more effective than the separately expressed soluble receptor proteins. The fusion protein strategy presented here can also be applied to other cytokines that signal via receptors composed of two different subunits to design new potent inhibitors for anticytokine therapies.	Univ Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Heinrich, PC (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.							AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Chow DC, 2001, SCIENCE, V291, P2150, DOI 10.1126/science.1058308; Ciapponi L, 1997, NAT BIOTECHNOL, V15, P997, DOI 10.1038/nbt1097-997; Dahmen H, 1998, BIOCHEM J, V331, P695, DOI 10.1042/bj3310695; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; EHLERS M, 1994, J IMMUNOL, V153, P1744; Goldenberg MM, 1999, CLIN THER, V21, P75, DOI 10.1016/S0149-2918(00)88269-7; Hayashi M, 2002, P NATL ACAD SCI USA, V99, P14728, DOI 10.1073/pnas.232562799; Hayashi M, 2002, J PHARMACOL EXP THER, V303, P104, DOI 10.1124/jpet.102.036137; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HONDA M, 1992, J IMMUNOL, V148, P2175; HORSTEN U, 1995, FEBS LETT, V360, P43, DOI 10.1016/0014-5793(95)00053-C; Kurth I, 1999, J IMMUNOL, V162, P1480; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Moritz RL, 1999, GROWTH FACTORS, V16, P265, DOI 10.3109/08977199909069145; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; NARAZAKI M, 1993, BLOOD, V82, P1120, DOI 10.1182/blood.V82.4.1120.bloodjournal8241120; Pflanz S, 2000, J IMMUNOL, V165, P7042, DOI 10.4049/jimmunol.165.12.7042; RACADOT E, 1995, CYTOKINES MOL THER, V1, P133; SAVINO R, 1994, EMBO J, V13, P5863, DOI 10.1002/j.1460-2075.1994.tb06931.x; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Varghese JN, 2002, P NATL ACAD SCI USA, V99, P15959, DOI 10.1073/pnas.232432399; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; WENDLING D, 1993, J RHEUMATOL, V20, P259; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	33	29	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16968	16972		10.1074/jbc.C300081200	http://dx.doi.org/10.1074/jbc.C300081200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12646580	hybrid			2022-12-27	WOS:000182818600071
J	Ban, T; Hamada, D; Hasegawa, K; Naiki, H; Goto, Y				Ban, T; Hamada, D; Hasegawa, K; Naiki, H; Goto, Y			Direct observation of amyloid fibril growth monitored by thioflavin T fluorescence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-MICROGLOBULIN	Real-time monitoring of fibril growth is essential to clarify the mechanism of amyloid fibril formation. Thioflavin T (ThT) is a reagent known to become strongly fluorescent upon binding to amyloid fibrils. Here, we show that, by monitoring ThT fluorescence with total internal reflection fluorescence microscopy (TIRFM), amyloid fibrils of beta2-microgobulin (beta2-m) can be visualized without requiring covalent fluorescence labeling. One of the advantages of TIRFM would be that we selectively monitor fibrils lying along the slide glass, so that we can obtain the exact length of fibrils. This method was used to follow the kinetics of seed-dependent beta2-m fibril extension. The extension was unidirectional with various rates, suggesting the heterogeneity of the amyloid structures. Since ThT binding is common to all amyloid fibrils, the present method will have general applicability for the analysis of amyloid fibrils. We confirmed this with the octapeptide corresponding to the C terminus derived from human medin and the Alzheimer's amyloid beta-peptide.	Osaka Univ, Inst Prot Res, Osaka 5650871, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Osaka 5650871, Japan; Fukui Med Univ, Dept Pathol, Fukui 9101193, Japan; Japan Sci & Technol Corp, CREST, Fukui 9101193, Japan	Osaka University; Japan Science & Technology Agency (JST); University of Fukui; Japan Science & Technology Agency (JST)	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Hamada, Daizo/F-3307-2011; Naiki, Hironobu/G-5599-2014; Hamada, Daizo/N-1118-2016	Hamada, Daizo/0000-0002-1799-5476				BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; DePace AH, 2002, NAT STRUCT BIOL, V9, P389, DOI 10.1038/nsb786; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Fandrich M, 2002, EMBO J, V21, P5682, DOI 10.1093/emboj/cdf573; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Grimbergen RFP, 1999, ACTA CRYSTALLOGR A, V55, P84, DOI 10.1107/S0108767398008897; Haggqvist B, 1999, P NATL ACAD SCI USA, V96, P8669, DOI 10.1073/pnas.96.15.8669; Hamada D, 2002, PROTEIN SCI, V11, P2417, DOI 10.1110/ps.0217702; Hammarstrom P, 2001, SCIENCE, V293, P2459, DOI 10.1126/science.1062245; Hasegawa K, 1999, BIOCHEMISTRY-US, V38, P15514, DOI 10.1021/bi991161m; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Inoue Y, 2001, J BIOL CHEM, V276, P35227, DOI 10.1074/jbc.C100304200; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Ippel JH, 2002, P NATL ACAD SCI USA, V99, P8648, DOI 10.1073/pnas.132098999; Katou H, 2002, PROTEIN SCI, V11, P2218, DOI 10.1110/ps.0213202; Kozhukh GV, 2002, J BIOL CHEM, V277, P1310, DOI 10.1074/jbc.M108753200; Naiki H, 1997, AMYLOID, V4, P223, DOI 10.3109/13506129709003833; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Scheibel T, 2001, CURR BIOL, V11, P366, DOI 10.1016/S0960-9822(01)00099-9; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Yamasaki R, 1999, J MOL BIOL, V292, P965, DOI 10.1006/jmbi.1999.3129	24	285	291	3	69	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16462	16465		10.1074/jbc.C300049200	http://dx.doi.org/10.1074/jbc.C300049200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12646572	hybrid, Green Published			2022-12-27	WOS:000182818600002
J	Iwamoto, T; Okumura, S; Iwatsubo, K; Kawabe, JI; Ohtsu, K; Sakai, I; Hashimoto, Y; Izumitani, A; Sango, K; Ajiki, K; Toya, Y; Umemura, S; Goshima, Y; Arai, N; Vatner, SF; Ishikawa, Y				Iwamoto, T; Okumura, S; Iwatsubo, K; Kawabe, JI; Ohtsu, K; Sakai, I; Hashimoto, Y; Izumitani, A; Sango, K; Ajiki, K; Toya, Y; Umemura, S; Goshima, Y; Arai, N; Vatner, SF; Ishikawa, Y			Motor dysfunction in type 5 adenylyl cyclase-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPAMINE-RECEPTORS; GENE-EXPRESSION; D1; STRIATUM	Various neurotransmitters, such as dopamine, stimulate adenylyl cyclase to produce cAMP, which regulates neuronal functions. Genetic disruption of the type 5 adenylyl cyclase isoform led to a major loss of adenylyl cyclase activity in a striatum-specific manner with a small increase in the expression of a few other adenylyl cyclase isoforms. D1 dopaminergic agonist-stimulated adenylyl cyclase activity was attenuated, and this was accompanied by a decrease in the expression of the D1 dopaminergic receptor and G(s)alpha. D2 dopaminergic agonist-mediated inhibition of adenylyl cyclase activity was also blunted. Type 5 adenylyl cyclase-null mice exhibited Parkinsonian-like motor dysfunction, i.e. abnormal coordination and bradykinesia detected by Rotarod and pole test, respectively, and to a lesser extent locomotor impairment was detected by open field tests. Selective D1 or D2 dopaminergic stimulation improved some of these disorders in this mouse model, suggesting the partial compensation of each dopaminergic receptor signal through the stimulation of remnant adenylyl cyclase isoforms. These findings extend our knowledge of the role of an effector enzyme isoform in regulating receptor signaling and neuronal functions and imply that this isoform provides a site of convergence of both D1 and D2 dopaminergic signals and balances various motor functions.	Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Neuropharmacol, Yokohama, Kanagawa 2360004, Japan; Yokohama City Univ, Sch Med, Dept Med, Yokohama, Kanagawa 2360004, Japan; Tokyo Metropolitan Inst Neurosci, Dept Clin Neuropathol, Tokyo 1838526, Japan; Tokyo Metropolitan Inst Neurosci, Dept Anat & Embryol, Tokyo 1838526, Japan; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Yokohama City University; Yokohama City University; Yokohama City University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Ishikawa, Y (corresponding author), Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan.	ishikayo@umdnj.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL059729, P01HL059139] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; Brandon EP, 1998, J NEUROSCI, V18, P3639; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; GERFEN CR, 1990, SCIENCE, V250, P1429, DOI 10.1126/science.2147780; Gerfen CR, 2002, J NEUROSCI, V22, P5042, DOI 10.1523/JNEUROSCI.22-12-05042.2002; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; HARDMAN JG, 2001, GOODMAN GILMANS PHAR, P447; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HESS EJ, 1986, EUR J PHARMACOL, V121, P31, DOI 10.1016/0014-2999(86)90389-4; HESS EJ, 1987, MOL PHARMACOL, V31, P50; ISHIKAWA Y, 1994, J CLIN INVEST, V93, P2224, DOI 10.1172/JCI117219; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863; Lee KW, 2002, J NEUROSCI, V22, P7931; MARSHALL JF, 1989, BRAIN RES, V493, P247, DOI 10.1016/0006-8993(89)91160-8; Matsuura K, 1997, J NEUROSCI METH, V73, P45, DOI 10.1016/S0165-0270(96)02211-X; MONS N, 1994, MOL BRAIN RES, V22, P236, DOI 10.1016/0169-328X(94)90052-3; Mons N, 1998, LIFE SCI, V62, P1647, DOI 10.1016/S0024-3205(98)00122-2; Onda T, 2001, J BIOL CHEM, V276, P47785, DOI 10.1074/jbc.M107233200; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Smith DE, 2000, PEDIATR NEUROL, V23, P33, DOI 10.1016/S0887-8994(00)00134-X; Surmeier D J, 1998, Adv Pharmacol, V42, P1020; Taussig Ronald, 1998, Advances in Second Messenger and Phosphoprotein Research, V32, P81; XIE GX, 1994, P NATL ACAD SCI USA, V91, P3779, DOI 10.1073/pnas.91.9.3779; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	26	86	91	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16936	16940		10.1074/jbc.C300075200	http://dx.doi.org/10.1074/jbc.C300075200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12665504	hybrid			2022-12-27	WOS:000182818600067
J	Jackson, LK; Goldsmith, EJ; Phillips, MA				Jackson, LK; Goldsmith, EJ; Phillips, MA			X-ray structure determination of Trypanosoma brucei ornithine decarboxylase bound to D-ornithine and to G418 - Insights into substrate binding and ODC conformational flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTION SPECIFICITY; ANGSTROM RESOLUTION; POLYAMINES; ANALOGS; DIFLUOROMETHYLORNITHINE; INHIBITION; MECHANISM; CATALYSIS; ANTIZYME; TARGET	Ornithine decarboxylase (ODC) is a pyridoxal 5'-phosphate (PLP)-dependent enzyme that catalyzes the rate-determining step in the biosynthesis of polyamines. ODC is a proven drug target to treat African sleeping sickness. The x-ray crystal structure of Trypanosoma brucei ODC in complex with D-ornithine (D-Orn), a substrate analog, and G418 (Geneticin), a weak non-competitive inhibitor, was determined to 2.5-Angstrom resolution. D-Orn forms a Schiff base with PLP, and the side chain is in a similar position to that observed for putrescine and alpha-difluoromethylornithine in previous T. brucei ODC structures. The D-Orn carboxylate is positioned on the solvent-exposed side of the active site (si face of PLP), and Gly-199, Gly-362, and His-197 are the only residues within 4.2 Angstrom of this moiety. This structure confirms predictions that the carboxylate of D-Orn binds on the si face of PLP, and it supports a model in which the carboxyl group of the substrate L-Orn would be buried on the re face of the cofactor in a pocket that includes Phe-397, Tyr-389, Lys-69 ( methylene carbons), and Asp-361. Electron density for G418 was observed at the boundary between the two domains within each ODC monomer. A ten-amino acid loop region (392-401) near the 2-fold axis of the dimer interface, which contributes several residues that form the active site, is disordered in this structure. The disordering of residues in the active site provides a potential mechanism for inhibition by G418 and suggests that allosteric inhibition from this site is feasible.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@UTSouthwestern.edu			NIAID NIH HHS [R01 AI 34432] Funding Source: Medline; NIGMS NIH HHS [T32 GM 07062] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BACCHI CJ, 1980, SCIENCE, V210, P332, DOI 10.1126/science.6775372; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEY P, 1978, J MED CHEM, V21, P50, DOI 10.1021/jm00199a009; BITONTI AJ, 1985, BIOCHEM PHARMACOL, V34, P1773, DOI 10.1016/0006-2952(85)90648-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2001, BIOCHIMIE, V83, P319, DOI 10.1016/S0300-9084(01)01252-4; DANZIN C, 1981, J MED CHEM, V24, P16, DOI 10.1021/jm00133a005; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fairlamb Alan H., 1997, P149; Ferrer JL, 1999, NAT STRUCT BIOL, V6, P775, DOI 10.1038/11553; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; Grishin NV, 1996, PROTEINS, V24, P272, DOI 10.1002/(SICI)1097-0134(199602)24:2<272::AID-PROT17>3.0.CO;2-K; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Jackson LK, 2003, BIOCHEMISTRY-US, V42, P2933, DOI 10.1021/bi026795z; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUZOE FAS, 1993, ACTA TROP, V54, P153, DOI 10.1016/0001-706X(93)90089-T; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; Miller BG, 2002, ANNU REV BIOCHEM, V71, P847, DOI 10.1146/annurev.biochem.71.110601.135446; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OSTERMAN A, 1994, BIOCHEMISTRY-US, V33, P13662, DOI 10.1021/bi00250a016; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1995, J CELL BIOCHEM, P132; PHILLIPS MA, 1987, J BIOL CHEM, V262, P8721; POULIN R, 1992, J BIOL CHEM, V267, P150; Ray SS, 2002, STRUCTURE, V10, P1499, DOI 10.1016/S0969-2126(02)00880-8; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521	38	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22037	22043		10.1074/jbc.M300188200	http://dx.doi.org/10.1074/jbc.M300188200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672797	hybrid			2022-12-27	WOS:000183354200091
J	Ogihara, T; Watada, H; Kanno, R; Ikeda, F; Nomiyama, T; Tanaka, Y; Nakao, A; German, MS; Kojima, I; Kawamori, R				Ogihara, T; Watada, H; Kanno, R; Ikeda, F; Nomiyama, T; Tanaka, Y; Nakao, A; German, MS; Kojima, I; Kawamori, R			P38 MAPK is involved in activin A- and hepatocyte growth factor-mediated expression of pro-endocrine gene neurogenin 3 in AR42J-B13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA SIGNAL-TRANSDUCTION; FACTOR-RECEPTOR; SCATTER FACTOR; TRANSFORMING GROWTH-FACTOR-BETA-1; PANCREAS; DIFFERENTIATION; IDENTIFICATION; KINASE; PATHWAY; RHOA	Neurogenin3 ( ngn3) is a transcription factor that is essential for the differentiation of pancreatic endocrine cells. To investigate the signaling pathway that regulates ngn3 expression, we used AR42J- B13 cells as a model of the differentiation of pancreatic islets. In these cells, treatment with activin A and hepatocyte growth factor ( HGF) induced the expression of ngn3. Reporter gene analysis using human ngn3 gene ( NEUROG3) promoter fragments of various lengths identified the region between - 402 and - 327 bp of NEUROG3 as an activin A- and HGF- responsive DNA sequence. This DNA sequence normally functions as a repressor in AR42J- B13 cells, but treatment with activin A and HGF negates the repressor activity. Interestingly, function of the activin A- and HGF- responsive sequence was not influenced by the overexpression of the Smad inhibitory factor, Smad7. Instead, activin A and HGF activation was inhibited by overexpression of a dominant- negative mutant of transforming growth factor- beta- activated kinase 1 ( TAK1), or mitogen- activated protein kinase kinase 3 ( MKK3), or by treatment with a p38 MAPK- specific inhibitor, SB203580. Activin A and HGF function through the TAK1- MKK3- p38 MAPK pathway to relieve transcription repressors located between - 402 and - 326 bp on the NEUROG3 promoter, and consequently activate ngn3 expression and endocrine differentiation of AR42J- B13 cells.	Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Atopy Res Ctr Sch Med, Bunkyo Ku, Tokyo 1138421, Japan; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA; Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol & Mol Med, Maebashi, Gumma 3718512, Japan	Juntendo University; Juntendo University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Gunma University	Watada, H (corresponding author), Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.			Watada, Hirotaka/0000-0001-5961-1816				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Edlund H, 1999, CURR OPIN CELL BIOL, V11, P663, DOI 10.1016/S0955-0674(99)00033-2; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Gradwohl G, 2000, P NATL ACAD SCI USA, V97, P1607, DOI 10.1073/pnas.97.4.1607; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; GUGER KA, 1995, DEV BIOL, V172, P115, DOI 10.1006/dbio.1995.0009; Hebrok M, 1998, GENE DEV, V12, P1705, DOI 10.1101/gad.12.11.1705; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; Kim SK, 2000, GENE DEV, V14, P1866; Lee JC, 2001, DIABETES, V50, P928, DOI 10.2337/diabetes.50.5.928; Lim S, 2002, J BIOL CHEM, V277, P25040, DOI 10.1074/jbc.M203257200; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Muller M, 2002, MOL CELL BIOL, V22, P1060, DOI 10.1128/MCB.22.4.1060-1072.2002; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shiozaki S, 1999, BBA-MOL CELL RES, V1450, P1, DOI 10.1016/S0167-4889(99)00022-1; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; Wang L, 2002, J BIOL CHEM, V277, P47257, DOI 10.1074/jbc.M208573200; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Wilson ME, 2003, MECH DEVELOP, V120, P65, DOI 10.1016/S0925-4773(02)00333-7; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamaoka T, 1998, J CLIN INVEST, V102, P294, DOI 10.1172/JCI2769; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang YQ, 1999, DIABETOLOGIA, V42, P719, DOI 10.1007/s001250051220; Zhang YQ, 2001, DIABETES, V50, pS10, DOI 10.2337/diabetes.50.2007.S10	43	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21693	21700		10.1074/jbc.M302684200	http://dx.doi.org/10.1074/jbc.M302684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670941	hybrid			2022-12-27	WOS:000183354200049
J	Bagyinka, C; Osz, J; Szaraz, S				Bagyinka, C; Osz, J; Szaraz, S			Autocatalytic oscillations in the early phase of the photoreduced methyl viologen-initiated fast kinetic reaction of hydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFOVIBRIO-GIGAS; THIOCAPSA-ROSEOPERSICINA; CHROMATIUM-VINOSUM; ACTIVATION; STATES; FORMS	The kinetic characteristics of the hydrogen uptake reaction of hydrogenase, obtained by conventional activity measurements, led to the proposal of an autocatalytic reaction step in the hydrogenase cycle or during the activation process. The autocatalytic behavior of an enzyme reaction may result in oscillating concentrations of enzyme intermediates and/or products contributing to the autocatalytic step. This behavior has been investigated in the early phase of the hydrogenase-methyl viologen reaction. To measure fast hydrogenase kinetics, flash-reduced methyl viologen has been used as a light-induced trigger in transient kinetic phenomena associated with intermolecular electron transfer to hydrogenase. Here we report fast kinetic measurements of the hydrogenase-methyl viologen reaction by use of the excimer laser flash-reduced redox dye. The results are evaluated on the assumption of an autocatalytic reaction in the hydrogenase kinetic cycle. The kinetic constants of the autocatalytic reaction, i.e. the methyl viologen binding to and release from hydrogenase, were determined, and limits of the kinetic constants relating to the intramolecular (intraenzyme) reactions were set.	Hungarian Acad Sci, Inst Biophys, Biol Res Ctr, H-6701 Szeged, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center	Bagyinka, C (corresponding author), Temesvari Krt 62,POB 521, H-6701 Szeged, Hungary.		Bagyinka, Csaba/D-1600-2012					ANAND SR, 1965, BIOCHEMISTRY-US, V4, P2747, DOI 10.1021/bi00888a027; BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAGYINKA C, 1982, BIOCHEM J, V202, P255, DOI 10.1042/bj2020255; CAMMACK R, 1986, BIOCHIMIE, V68, P85, DOI 10.1016/S0300-9084(86)81072-0; CZEGE J, 1989, PHOTOCHEM PHOTOBIOL, V50, P697, DOI 10.1111/j.1751-1097.1989.tb04329.x; deLacey AL, 1997, J AM CHEM SOC, V119, P7181, DOI 10.1021/ja963802w; DER A, 1985, ANAL BIOCHEM, V150, P481, DOI 10.1016/0003-2697(85)90538-X; FERNANDEZ VM, 1984, BIOCHIM BIOPHYS ACTA, V790, P1, DOI 10.1016/0167-4838(84)90324-8; FERNANDEZ VM, 1985, BIOCHIM BIOPHYS ACTA, V832, P69, DOI 10.1016/0167-4838(85)90175-X; FISHER HF, 1954, J BIOL CHEM, V209, P569; KOVACS KL, 1990, FEMS MICROBIOL LETT, V87, P407, DOI 10.1016/0378-1097(90)90487-B; KOVACS KL, 1991, J BIOL CHEM, V266, P947; KRASNA AI, 1954, J AM CHEM SOC, V76, P3015, DOI 10.1021/ja01640a045; Lotka AJ, 1910, J PHYS CHEM-US, V14, P271, DOI 10.1021/j150111a004; Pershad HR, 1999, BIOCHEMISTRY-US, V38, P8992, DOI 10.1021/bi990108v; ROMANOVSKII JM, 1970, IS MATH BIOPHYSICS, P82; SHERMAN MB, 1991, J BACTERIOL, V173, P2576, DOI 10.1128/jb.173.8.2576-2580.1991; TIGYI G, 1986, BIOCHIMIE, V68, P69, DOI 10.1016/S0300-9084(86)81070-7; Vignais PM, 2001, FEMS MICROBIOL REV, V25, P455, DOI 10.1111/j.1574-6976.2001.tb00587.x; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; YAGI T, 1973, J BIOCHEM-TOKYO, V73, P1069, DOI 10.1093/oxfordjournals.jbchem.a130161	21	11	11	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20624	20627		10.1074/jbc.M300623200	http://dx.doi.org/10.1074/jbc.M300623200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663658	hybrid			2022-12-27	WOS:000183230500024
J	Denisov, AY; Madiraju, MSR; Chen, G; Khadir, A; Beauparlant, P; Attardo, G; Shore, GC; Gehring, K				Denisov, AY; Madiraju, MSR; Chen, G; Khadir, A; Beauparlant, P; Attardo, G; Shore, GC; Gehring, K			Solution structure of human BCL-w - Modulation of ligand binding by the C-terminal helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIAPOPTOTIC PROTEIN BCL-2; PROGRAMMED CELL-DEATH; PEPTIDE COMPLEX; FAMILY PROTEINS; APOPTOSIS; NMR; SURVIVAL; EXPRESSION; BCL-X(L); SPERMATOGENESIS	The structure of human BCL-w, an anti-apoptotic member of the BCL-2 family, was determined by triple-resonance NMR spectroscopy and molecular modeling. Introduction of a single amino acid substitution (P117V) significantly improved the quality of the NMR spectra obtained. The cytosolic domain of BCL-w consists of 8 alpha-helices, which adopt a fold similar to that of BCL-x(L), BCL-2, and BAX proteins. Pairwise root meant square deviation values were less than 3 Angstrom for backbone atoms of structurally equivalent regions. Interestingly, the C-terminal helix alpha8 of BCL-w folds into the BH3-binding hydrophobic cleft of the protein, in a fashion similar to the C-terminal transmembrane helix of BAX. A peptide corresponding to the BH3 region of the pro-apoptotic protein, BID, could displace helix alpha8 from the BCL-w cleft, resulting in helix unfolding. Deletion of helix alpha8 increased binding affinities of BCL-w for BAK and BID BH3-peptides, indicating that this helix competes for peptide binding to the hydrophobic cleft. These results suggest that although the cytosolic domain of BCL-w exhibits an overall structure similar to that of BCL-x(L) and BCL-2, the unique organization of its C-terminal helix may modulate BCL-w interactions with pro-apoptotic binding partners.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Montreal Joint Ctr Struct Biol, Montreal, PQ H3G 1Y6, Canada; GemminX Biotechnol Inc, Montreal, PQ H2X 4A5, Canada	McGill University; McGill University	Gehring, K (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.		Gehring, Kalle/N-2945-2019; Gehring, Kalle/I-4403-2013	Gehring, Kalle/0000-0001-6500-1184; Gehring, Kalle/0000-0001-6500-1184				Bairey O, 1999, CLIN CANCER RES, V5, P2860; Billeter M, 1995, J BIOMOL NMR, V5, P1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Gibson L, 1996, ONCOGENE, V13, P665; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang QL, 2002, P NATL ACAD SCI USA, V99, P3428, DOI 10.1073/pnas.062525799; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Liang H, 1997, J MOL BIOL, V274, P291, DOI 10.1006/jmbi.1997.1415; Losonczi JA, 2000, BIOCHEMISTRY-US, V39, P11024, DOI 10.1021/bi000919v; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Meehan T, 2001, CELL DEATH DIFFER, V8, P225, DOI 10.1038/sj.cdd.4400799; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesleh MF, 2002, J AM CHEM SOC, V124, P4206, DOI 10.1021/ja0178665; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PENG JW, 1994, METHOD ENZYMOL, V239, P563; Petros AM, 2000, PROTEIN SCI, V9, P2528, DOI 10.1017/S096183680000331X; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Print CG, 1998, P NATL ACAD SCI USA, V95, P12424, DOI 10.1073/pnas.95.21.12424; Rutledge SE, 2002, CURR OPIN CHEM BIOL, V6, P479, DOI 10.1016/S1367-5931(02)00352-6; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Shigemasa K, 2002, JPN J CANCER RES, V93, P542, DOI 10.1111/j.1349-7006.2002.tb01289.x; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; Voutsadakis IA, 2000, ACTA ONCOL, V39, P151, DOI 10.1080/028418600430707; Walker LSK, 2002, NAT REV IMMUNOL, V2, P11, DOI 10.1038/nri701; Wilson JW, 2000, BRIT J CANCER, V82, P178, DOI 10.1054/bjoc.1999.0897; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	45	100	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21124	21128		10.1074/jbc.M301798200	http://dx.doi.org/10.1074/jbc.M301798200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651847	hybrid			2022-12-27	WOS:000183230500088
J	Kawai, Y; Saito, A; Shibata, N; Kobayashi, M; Yamada, S; Osawa, T; Uchida, K				Kawai, Y; Saito, A; Shibata, N; Kobayashi, M; Yamada, S; Osawa, T; Uchida, K			Covalent binding of oxidized cholesteryl esters to protein - Implications for oxidative modification of low density lipoprotein and atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; MASS-SPECTROMETRY; SCAVENGER RECEPTOR; BOUND ALDEHYDES; IN-VIVO; MACROPHAGES; LDL; PHOSPHOLIPIDS; MALONDIALDEHYDE; CHROMATOGRAPHY	It has been proposed that plasma low density lipoproteins (LDL) undergo oxidative modification before they can produce foam cells in atherosclerosis. The oxidation of LDL generates a variety of reactive aldehydic products, which covalently bind to the LDL apolipoprotein B-100 (apoB). In the present study, to investigate the mechanisms contributing to the modification of LDL, we analyzed oxidized cholesteryl esters generated during the autoxidation of LDL and characterized their covalent binding to the lysine residues of LDL apoB. In addition, we raised a monoclonal antibody specific to a lysine-bound oxidized cholesteryl ester and determined its production in human atherosclerotic lesions. The peroxidation of LDL with Cu2+ produced 9-oxononanoylcholesterol (9-ONC) and 5-oxovaleroylcholesterol as the major oxidized cholesteryl esters. We observed that the levels of 9-ONC and 5-oxovaleroylcholesterol peaked at 12 h and significantly decreased thereafter. The reduction of the core aldehyde levels was accompanied by (i) the formation of free 7-ketocholesterol and 7-ketocholesteryl ester core aldehydes and (ii) an increase in the amounts of apoB-bound cholesterol and 7-ketocholesterol, suggesting that the cholesteryl ester core aldehydes were further converted to their 7-ketocholesterol- and apoB-bound derivatives. To detect the protein-bound 9-ONC, we raised the monoclonal antibody 2A81, directed against 9-ONC-modified protein, and found that it extensively recognized protein-bound cholesteryl ester core aldehydes. Agarose gel electrophoresis followed by immunoblot analysis of the oxidized LDL clearly demonstrated the formation of antigenic structures. Furthermore, immunohistochemical analysis of the atherosclerotic lesions from the human aorta showed that immunoreactive materials with mAb 2A81 were indeed present in the lesions, in which the intense immunoreactivity was mainly located in the macrophage-derived foam cells and the thickening neointima of the arterial walls. The results of this study suggest that the binding of cholesteryl ester core aldehydes to LDL might represent the process common to the oxidative modification of lipoproteins.	Nagoya Univ, Lab Food & Biodynam, Grad Sch Biogr Sci, Nagoya, Aichi 4648601, Japan; Tokyo Womens Med Univ, Dept Pathol, Tokyo 1628666, Japan; NOF Co, Tsukuba Res Lab, Tsukuba, Ibaraki 3002635, Japan	Nagoya University; Tokyo Women's Medical University	Uchida, K (corresponding author), Nagoya Univ, Lab Food & Biodynam, Grad Sch Biogr Sci, Nagoya, Aichi 4648601, Japan.		Kawai, Yoshichika/G-3231-2011	Uchida, Koji/0000-0003-3894-5299				BALL RY, 1987, BRIT J EXP PATHOL, V68, P427; Bolgar MS, 1996, J BIOL CHEM, V271, P27999, DOI 10.1074/jbc.271.45.27999; Bruenner BA, 1996, ANAL BIOCHEM, V241, P212, DOI 10.1006/abio.1996.0402; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gillotte KL, 2000, J LIPID RES, V41, P824; Girotti AW, 1998, J LIPID RES, V39, P1529; HABERLAND ME, 1988, SCIENCE, V241, P215, DOI 10.1126/science.2455346; Hoppe G, 1997, J LIPID RES, V38, P1347; Itabe H, 1998, PROG LIPID RES, V37, P181, DOI 10.1016/S0163-7827(98)00009-5; ITABE H, 1994, J BIOL CHEM, V269, P15274; KAMIDO H, 1992, LIPIDS, V27, P645, DOI 10.1007/BF02536126; KAMIDO H, 1992, FEBS LETT, V304, P269, DOI 10.1016/0014-5793(92)80635-T; Karten B, 1998, J LIPID RES, V39, P1508; Li W, 1998, ARTERIOSCL THROM VAS, V18, P177, DOI 10.1161/01.ATV.18.2.177; LYNCH SM, 1995, J BIOL CHEM, V270, P5158, DOI 10.1074/jbc.270.10.5158; MANDER EL, 1994, BBA-LIPID LIPID MET, V1212, P80, DOI 10.1016/0005-2760(94)90192-9; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; Ravandi A, 1997, LIPIDS, V32, P989, DOI 10.1007/s11745-997-0129-6; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1987, ARTERIOSCLEROSIS, V7, P135, DOI 10.1161/01.ATV.7.2.135; STEINBRECHER UP, 1989, J BIOL CHEM, V264, P15216; TERAO J, 1990, MEMBRANE LIPID OXIDA, V1, P219; TERTOV VV, 1995, BIOCHEM BIOPH RES CO, V214, P608, DOI 10.1006/bbrc.1995.2329; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1998, P NATL ACAD SCI USA, V95, P4882, DOI 10.1073/pnas.95.9.4882; Uchida K, 1997, ARCH BIOCHEM BIOPHYS, V346, P45, DOI 10.1006/abbi.1997.0266; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; Uchida K, 1995, ARCH BIOCHEM BIOPHYS, V324, P241, DOI 10.1006/abbi.1995.0036; WANG CJ, 1990, CHEM PHYS LIPIDS, V55, P265, DOI 10.1016/0009-3084(90)90164-M; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WITZ G, 1989, FREE RADICAL BIO MED, V7, P333, DOI 10.1016/0891-5849(89)90137-8; Yamada S, 2001, J LIPID RES, V42, P1187; Yancey PG, 1998, J LIPID RES, V39, P1349	37	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21040	21049		10.1074/jbc.M212426200	http://dx.doi.org/10.1074/jbc.M212426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663661	hybrid			2022-12-27	WOS:000183230500078
J	Bhavesh, NS; Sinha, R; Mohan, PMK; Hosur, RV				Bhavesh, NS; Sinha, R; Mohan, PMK; Hosur, RV			NMR elucidation of early folding hierarchy in HIV-1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; HYDROGEN-EXCHANGE; DYNAMIC CHARACTERIZATION; ALPHA-LACTALBUMIN; DENATURED STATE; X-RAY; INTERMEDIATE; APOMYOGLOBIN; SPECTROSCOPY; PREFERENCES	Folding studies on proteases by the conventional hydrogen exchange experiments are severely hampered because of interference from the autolytic reaction in the interpretation of the exchange data. We report here NMR identification of the hierarchy of early conformational transitions (folding propensities) in HIV-1 protease by systematic monitoring of the changes in the state of the protein as it is subjected to different degrees of denaturation by guanidine hydrochloride. Secondary chemical shifts, H-N-H-alpha coupling constants, H-1-N-15 nuclear Overhauser effects, and N-15 transverse relaxation parameters have been used to report on the residual structural propensities, motional restrictions, conformational transitions, etc., and the data suggest that even under the strongest denaturing conditions (6 M guanidine) hydrophobic clusters as well as different native and non-native secondary structural elements are transiently formed. These constitute the folding nuclei, which include residues spanning the active site, the hinge region, and the dimerization domain. Interestingly, the proline residues influence the structural propensities, and the small amino acids, Gly and Ala, enhance the flexibility of the protein. On reducing the denaturing conditions, partially folded forms appear. The residues showing high folding propensities are contiguous along the sequence at many locations or are in close proximity on the native protein structure, suggesting a certain degree of local cooperativity in the conformational transitions. The dimerization domain, the flaps, and their hinges seem to exhibit the highest folding propensities. The data suggest that even the early folding events may involve many states near the surface of the folding funnel.	Tata Inst Fundamental Res, Dept Chem Sci, Bombay 400005, Maharashtra, India	Tata Institute of Fundamental Research (TIFR)	Hosur, RV (corresponding author), Tata Inst Fundamental Res, Dept Chem Sci, Homi Bhabha Rd, Bombay 400005, Maharashtra, India.	hosur@tifr.res.in	Bhavesh, Neel Sarovar/F-3127-2015; Poluri, Krishna Mohan/H-6083-2013; Mohan, PM/C-9594-2018	Bhavesh, Neel Sarovar/0000-0002-7248-4978; Poluri, Krishna Mohan/0000-0003-3801-7134; Mohan, PM/0000-0001-6194-3772				Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Balbach J, 1999, J MOL BIOL, V285, P829, DOI 10.1006/jmbi.1998.2364; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; Barbar E, 1999, BIOPOLYMERS, V51, P191, DOI 10.1002/(SICI)1097-0282(1999)51:3<191::AID-BIP3>3.0.CO;2-B; Bhavesh NS, 2001, FEBS LETT, V509, P218, DOI 10.1016/S0014-5793(01)03066-6; Chamberlain AK, 2000, ADV PROTEIN CHEM, V53, P283; CHYAN CL, 1993, BIOCHEMISTRY-US, V32, P5681, DOI 10.1021/bi00072a025; Dabora JM, 1996, BIOCHEMISTRY-US, V35, P11951, DOI 10.1021/bi9611671; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 1998, NAT STRUCT BIOL, V5, P504, DOI 10.1038/744; Dyson HJ, 1996, ANNU REV PHYS CHEM, V47, P369, DOI 10.1146/annurev.physchem.47.1.369; Dyson HJ, 2001, METHOD ENZYMOL, V339, P258; Eliezer D, 2000, BIOCHEMISTRY-US, V39, P2894, DOI 10.1021/bi992545f; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Englander SW, 2000, ANNU REV BIOPH BIOM, V29, P213, DOI 10.1146/annurev.biophys.29.1.213; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; FERSHT AR, 1999, STRUCTURE MECH PROTE, P517; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Kazmirski SL, 2001, P NATL ACAD SCI USA, V98, P4349, DOI 10.1073/pnas.071054398; Killick TR, 1999, PROTEIN SCI, V8, P1286, DOI 10.1110/ps.8.6.1286; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Kumar M, 2002, BIOCHEM BIOPH RES CO, V294, P395, DOI 10.1016/S0006-291X(02)00482-5; Penkett CJ, 1997, J MOL BIOL, V274, P152, DOI 10.1006/jmbi.1997.1369; Pillai B, 2001, PROTEINS, V43, P57, DOI 10.1002/1097-0134(20010401)43:1<57::AID-PROT1017>3.0.CO;2-D; Plotkin SS, 2002, Q REV BIOPHYS, V35, P111, DOI 10.1017/S0033583502003761; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Raschke TM, 1999, NAT STRUCT BIOL, V6, P825; Raschke TM, 1997, NAT STRUCT BIOL, V4, P298, DOI 10.1038/nsb0497-298; RICHARDS FM, 2002, ADV PROT CHEM UNFOLD, V42; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Schwarzinger S, 2002, BIOCHEMISTRY-US, V41, P12681, DOI 10.1021/bi020381o; Schwarzinger S, 2001, J AM CHEM SOC, V123, P2970, DOI 10.1021/ja003760i; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Yao J, 2001, BIOCHEMISTRY-US, V40, P3561, DOI 10.1021/bi002776i	39	33	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19980	19985		10.1074/jbc.M301615200	http://dx.doi.org/10.1074/jbc.M301615200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644464	hybrid			2022-12-27	WOS:000183078000054
J	Zhou, RB; Wolk, CP				Zhou, RB; Wolk, CP			A two-component system mediates developmental regulation of biosynthesis of a heterocyst polysaccharide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-STRAIN PCC-7120; SIGNAL-TRANSDUCTION PROTEIN; ANABAENA SP; CYANOBACTERIUM-ANABAENA; ESCHERICHIA-COLI; PCC 7120; NOSTOC-PUNCTIFORME; MOLECULAR ANALYSIS; NITROGEN-FIXATION; HEPARAN-SULFATE	Some cyanobacteria couple oxygenic photosynthesis in vegetative cells with O-2-sensitive N-2 fixation in differentiated cells called heterocysts. Heterocyst differentiation involves extensive biochemical and structural changes that collectively permit heterocysts to assimilate N-2 aerobically and supply the products of N-2 fixation to vegetative cells. HepK and DevR are required for the development of functional heterocysts in Anabaena and Nostoc, respectively. We show that HepK is an autokinase and that Anabaena DevR(A) is its cognate response regulator, together comprising part or all of a two-component system that mediates developmental regulation of biosynthesis of a heterocyst envelope polysaccharide. Recombinant N-hexahistidine-tagged HepK (H(6)HepK), the cytoplasmic portion H-6'HepK of H(6)HepK, H(6)DevR, and H(6)DevR(A) were overexpressed in Escherichia coli and purified to homogeneity. H-6'HepK, but not H(6)HepK, autophosphorylates with [gamma-P-32]ATP. ADP, specifically, elicits dephosphorylation of phosphorylated H-6'HepK. The phosphoryl group of H-6'HepK is transferred rapidly and efficiently to both H(6)DevR and H(6)DevRA but not to His-tagged OmpR, whose cognate sensor kinase is EnvZ. Sequence comparisons, the results of site-specific mutagenesis, and tests of chemical stability support identification of HepK-His(348) and DevR-Asp(53) as the phosphorylated residues. The mutation HepK-H348A abolishes both in vitro autokinase activity and in vivo functionality of HepK. Heterocysts of both hepK Anabaena and devR(A) Anabaena lack an envelope polysaccharide layer and are nonfunctional. Consistent with the normal site of deposition of that polysaccharide, a hepK::gfp transcriptional fusion is expressed principally in proheterocysts. HepK/DevR(A) is the first two-component system identified that regulates the biosynthesis of a polysaccharide as part of a patterned differentiation process.	Michigan State Univ, MSU DOE Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA; Anhui Normal Univ, Coll Life Sci, Wuhu 241000, Anhui, Peoples R China	Michigan State University; United States Department of Energy (DOE); Michigan State University; Anhui Normal University	Wolk, CP (corresponding author), Michigan State Univ, MSU DOE Plant Res Lab, E Lansing, MI 48824 USA.	wolk@msu.edu						AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Bainbridge BW, 2001, ACTA ODONTOL SCAND, V59, P131, DOI 10.1080/000163501750266710; BLACK K, 1995, J BACTERIOL, V177, P6440, DOI 10.1128/jb.177.22.6440-6448.1995; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; CAI YP, 1990, J BACTERIOL, V172, P3138, DOI 10.1128/jb.172.6.3138-3145.1990; Callahan SM, 2001, MOL MICROBIOL, V40, P941, DOI 10.1046/j.1365-2958.2001.02437.x; Campbell EL, 1996, J BACTERIOL, V178, P2037, DOI 10.1128/jb.178.7.2037-2043.1996; CARDEMIL L, 1979, J BIOL CHEM, V254, P736; CARDEMIL L, 1981, J PHYCOL, V17, P234; CARDEMIL L, 1981, BIOCHIM BIOPHYS ACTA, V674, P265, DOI 10.1016/0304-4165(81)90384-6; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; Cheng HP, 1998, J BACTERIOL, V180, P5183, DOI 10.1128/JB.180.19.5183-5191.1998; DHARMAWARDENE MW, 1973, ARCH MIKROBIOL, V90, P281, DOI 10.1007/BF00408924; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; ELHAI J, 1990, EMBO J, V9, P3379, DOI 10.1002/j.1460-2075.1990.tb07539.x; Ellehauge E, 1998, MOL MICROBIOL, V30, P807, DOI 10.1046/j.1365-2958.1998.01113.x; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fabret C, 1999, J BACTERIOL, V181, P1975, DOI 10.1128/JB.181.7.1975-1983.1999; FAN Q, 2002, MICROBIAL PLANT META, P13; Federle MJ, 1999, J BACTERIOL, V181, P3649, DOI 10.1128/JB.181.12.3649-3657.1999; Fisher M, 2002, ANTICANCER RES, V22, P1737; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Hagen KD, 1999, J BACTERIOL, V181, P4430, DOI 10.1128/JB.181.14.4430-4434.1999; Heath A, 1999, INFECT IMMUN, V67, P5298, DOI 10.1128/IAI.67.10.5298-5305.1999; Hebbar PB, 2000, J BACTERIOL, V182, P3572, DOI 10.1128/JB.182.12.3572-3581.2000; Hidaka Y, 1997, FEBS LETT, V400, P238, DOI 10.1016/S0014-5793(96)01396-8; Hirsch AM, 1999, CURR OPIN PLANT BIOL, V2, P320, DOI 10.1016/S1369-5266(99)80056-9; HU NT, 1981, VIROLOGY, V114, P236, DOI 10.1016/0042-6822(81)90269-5; Hwang I, 2001, NATURE, V413, P383, DOI 10.1038/35096500; IUCHI S, 1992, J BACTERIOL, V174, P5617, DOI 10.1128/JB.174.17.5617-5623.1992; JIN SG, 1990, J BACTERIOL, V172, P525, DOI 10.1128/jb.172.2.525-530.1990; Kaneko T, 2001, DNA RES, V8, P205, DOI 10.1093/dnares/8.5.205; Koksharova OA, 2002, J BACTERIOL, V184, P3931, DOI 10.1128/JB.184.14.3931-3940.2002; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEE HS, 1993, J BACTERIOL, V175, P7683, DOI 10.1128/JB.175.23.7683-7688.1993; Liu DA, 2002, J BACTERIOL, V184, P6873, DOI 10.1128/JB.184.24.6873-6881.2002; Loomis WF, 1998, CURR OPIN MICROBIOL, V1, P643, DOI 10.1016/S1369-5274(98)80109-4; Lord E, 2000, TRENDS PLANT SCI, V5, P368, DOI 10.1016/S1360-1385(00)01744-1; Matsushita M, 2002, BIOORGAN MED CHEM, V10, P855, DOI 10.1016/S0968-0896(01)00355-8; MURRY MA, 1989, ARCH MICROBIOL, V151, P469, DOI 10.1007/BF00454860; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Ohmori M, 2001, DNA RES, V8, P271, DOI 10.1093/dnares/8.6.271; Pelley RP, 2000, CRIT REV ONCOGENESIS, V11, P189; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sasisekharan R, 2002, NAT REV CANCER, V2, P521, DOI 10.1038/nrc842; Shaulsky G, 1998, DEVELOPMENT, V125, P691; Showalter AM, 2001, CELL MOL LIFE SCI, V58, P1399, DOI 10.1007/PL00000784; Stephenson K., 2002, Current Drug Targets - Infectious Disorders, V2, P235, DOI 10.2174/1568005023342443; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK JB, 1978, P NATL ACAD SCI USA, V75, P3659, DOI 10.1073/pnas.75.8.3659; Thelen JJ, 1998, J BIOL CHEM, V273, P26618, DOI 10.1074/jbc.273.41.26618; THOMAS J, 1977, J BACTERIOL, V129, P1545, DOI 10.1128/JB.129.3.1545-1555.1977; Thomason P, 2000, J CELL SCI, V113, P3141; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WALSBY A E, 1985, Proceedings of the Royal Society of London Series B Biological Sciences, V226, P345, DOI 10.1098/rspb.1985.0099; Willats WGT, 2001, PLANT MOL BIOL, V47, P9, DOI 10.1023/A:1010662911148; Wolk C.P., 1994, MOL BIOL CYANOBACTER, P769, DOI DOI 10.1007/978-94-011-0227-8_27; Wolk CP, 2000, PROKARYOTIC DEVELOPMENT, P83; Wong FCY, 2001, J BACTERIOL, V183, P2654, DOI 10.1128/JB.183.8.2654-2661.2001; Wu JG, 1999, P NATL ACAD SCI USA, V96, P13068, DOI 10.1073/pnas.96.23.13068; Xu XD, 2001, J BACTERIOL, V183, P393, DOI 10.1128/JB.183.1.393-396.2001; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Zacharski LR, 2002, CURR OPIN PULM MED, V8, P379, DOI 10.1097/00063198-200209000-00006; Zhou RB, 2002, J BACTERIOL, V184, P2529, DOI 10.1128/JB.184.9.2529-2532.2002; Zhu JS, 1998, J BACTERIOL, V180, P4233, DOI 10.1128/JB.180.16.4233-4242.1998	70	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19939	19946		10.1074/jbc.M300577200	http://dx.doi.org/10.1074/jbc.M300577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637541	hybrid			2022-12-27	WOS:000183078000049
J	Ko, TP; Lin, JJ; Hu, CY; Hsu, YH; Wang, AHJ; Liaw, SH				Ko, TP; Lin, JJ; Hu, CY; Hsu, YH; Wang, AHJ; Liaw, SH			Crystal structure of yeast cytosine deaminase - Insights into enzyme mechanism and evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CYTIDINE DEAMINASE; GENE-THERAPY; ADENOSINE-DEAMINASE; CANCER; 5-FLUOROCYTOSINE; CATALYSIS; MOLSCRIPT	Yeast cytosine deaminase is an attractive candidate for anticancer gene therapy because it catalyzes the deamination of the prodrug 5-fluorocytosine to form 5-fluorouracil. We report here the crystal structure of the enzyme in complex with the inhibitor 2-hydroxypyrimidine at 1.6-Angstrom resolution. The protein forms a tightly packed dimer with an extensive interface of 1450 Angstrom(2) per monomer. The inhibitor was converted into a hydrated adduct as a transition-state analog. The essential zinc ion is ligated by the 4-hydroxyl group of the inhibitor together with His(62), Cys(91), and Cys(94) from the protein. The enzyme shares similar active-site architecture to cytidine deaminases and an unusually high structural homology to 5-aminoimidazole-4-carboxamide-ribonucleotide transformylase and thereby may define a new superfamily. The unique C-terminal tail is involved in substrate specificity and also functions as a gate controlling access to the active site. The complex structure reveals a closed conformation, suggesting that substrate binding seals the active-site entrance so that the catalytic groups are sequestered from solvent. A comparison of the crystal structures of the bacterial and fungal cytosine deaminases provides an elegant example of convergent evolution, where starting from unrelated ancestral proteins, the same metal-assisted deamination is achieved through opposite chiral intermediates within distinctly different active sites.	Natl Yang Ming Univ, Dept Life Sci, Taipei 11221, Taiwan; Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 11221, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 11221, Taiwan; Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Liaw, SH (corresponding author), Natl Yang Ming Univ, Dept Life Sci, Taipei 11221, Taiwan.	shliaw@ym.edu.tw	Lin, Jing-Jer/G-8068-2015	LIN, JING-JER/0000-0001-8250-7398				Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carlow D, 1998, BIOCHEMISTRY-US, V37, P11873, DOI 10.1021/bi980959n; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Greasley SE, 2001, NAT STRUCT BIOL, V8, P402, DOI 10.1038/87555; Greco O, 2001, J CELL PHYSIOL, V187, P22, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H; Hsu YH, 2003, ACTA CRYSTALLOGR D, V59, P950, DOI 10.1107/S0907444903005936; Ipata P L, 1978, Methods Enzymol, V51, P394; Ireton GC, 2002, J MOL BIOL, V315, P687, DOI 10.1006/jmbi.2001.5277; Johansson E, 2002, BIOCHEMISTRY-US, V41, P2563, DOI 10.1021/bi011849a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kievit E, 2000, CANCER RES, V60, P6649; Kievit E, 1999, CANCER RES, V59, P1417; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Liaw SH, 2003, J BIOL CHEM, V278, P4957, DOI 10.1074/jbc.M210795200; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miller CR, 2002, CANCER RES, V62, P773; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIYAMA T, 1985, CANCER RES, V45, P1753; Nyati MK, 2002, GENE THER, V9, P844, DOI 10.1038/sj.gt.3301706; REIZER J, 1994, PROTEIN SCI, V3, P853; Vauthey JN, 1996, BRIT J SURG, V83, P447, DOI 10.1002/bjs.1800830405; Wang ZM, 1998, BIOCHEMISTRY-US, V37, P8314, DOI 10.1021/bi980324o; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539; Wolan DW, 2002, BIOCHEMISTRY-US, V41, P15505, DOI 10.1021/bi020505x; Xiang SB, 1996, BIOCHEMISTRY-US, V35, P1335, DOI 10.1021/bi9525583; XIANG SB, 1995, BIOCHEMISTRY-US, V34, P4516, DOI 10.1021/bi00014a003; Xiang SB, 1997, BIOCHEMISTRY-US, V36, P4768, DOI 10.1021/bi963091e	30	101	102	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19111	19117		10.1074/jbc.M300874200	http://dx.doi.org/10.1074/jbc.M300874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637534	hybrid			2022-12-27	WOS:000182932200052
J	Tokuda, H; Harada, A; Hirade, K; Matsuno, H; Ito, H; Kato, K; Oiso, Y; Kozawa, O				Tokuda, H; Harada, A; Hirade, K; Matsuno, H; Ito, H; Kato, K; Oiso, Y; Kozawa, O			Incadronate amplifies prostaglandin F-2 alpha-induced vascular endothelial growth factor synthesis in osteoblasts - Enhancement of MAPK activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOINOSITIDE HYDROLYSIS; GENE-EXPRESSION; PHOSPHOLIPASE-D; CELL-LINE; ACTIVATION; DIFFERENTIATION; BISPHOSPHONATES; POTENT; BONE	We have previously reported that prostaglandin F-2alpha (PGF(2alpha)) activates p44/p42 mitogen-activated protein kinase (MAPK) through protein kinase C (PKC) in osteoblast-like MC3T3-E1 cells. In the present study, we investigated the mechanism of vascular endothelial growth factor (VEGF) synthesis induced by PGF(2alpha) and the effect of incadronate on the VEGF synthesis in these cells. PGF(2alpha) significantly stimulated the VEGF synthesis in a dose-dependent manner between 1 pM and 10 muM. Cycloheximide reduced the PGF(2alpha) effect. PGF(2alpha) increased the levels of mRNA for VEGF. Cloprostenol, a PGF(2alpha)-sensitive receptor agonist, potently induced the VEGF synthesis. Indomethacin, an inhibitor of cyclooxygenase, significantly reduced the PGF(2alpha)-induced VEGF synthesis. Bisindolylmaleimide, an inhibitor of PKC, reduced the PGF(2alpha)-induced VEGF synthesis. The VEGF synthesis induced by PGF(2alpha) was significantly attenuated in the PKC down-regulated cells. PGF(2alpha) elicited the translocation of PKCbetaI from cytosol to membrane fraction. PD98059 or U0126, inhibitors of MEK, suppressed the VEGF synthesis induced by PGF(2alpha). Farnesyltransferase inhibitor failed to affect the PGF(2alpha)-induced VEGF synthesis. Incadronate enhanced the synthesis of VEGF induced by PGF(2alpha). NaF-induced VEGF synthesis was also amplified by incadronate. PD98059 suppressed the enhancement by incadronate of PGF(2alpha)-induced VEGF synthesis. Incadronate markedly enhanced the phosphorylation of Raf-1, MEK1/2, and p44/p42 MAPK induced by PGF(2alpha) or 12-O-tetradecanoylphorbol-13-acetate, a PKC activator. Incadronate significantly enhanced the cloprostenol-increased level of VEGF concentration in mouse plasma in vivo. These results strongly suggest that PGF(2alpha) stimulates VEGF synthesis through the PKC-dependent activation of p44/p42 MAPK in osteoblasts and that the incadronate enhances the VEGF synthesis at the point between PKC and Raf-1.	Gifu Univ, Dept Pharmacol, Sch Med, Gifu 5008705, Japan; Chubu Natl Hosp, Dept Internal Med, Natl Inst Longev Sci, Aichi 4748511, Japan; Chubu Natl Hosp, Dept Orthopaed, Natl Inst Longev Sci, Aichi 4748511, Japan; Aichi Human Serv Ctr, Dept Biochem, Inst Dev Res, Aichi 4800391, Japan; Nagoya Univ, Dept Internal Med 1, Sch Med, Nagoya, Aichi 4668550, Japan	Gifu University; Nagoya University	Kozawa, O (corresponding author), Gifu Univ, Dept Pharmacol, Sch Med, Gifu 5008705, Japan.			Hirade, Kouseki/0000-0001-8367-602X; Ito, Hidenori/0000-0002-6527-477X				ALESSI DR, 1995, J BIOL CHEM, V270, P27484; DUKES M, 1974, NATURE, V250, P330, DOI 10.1038/250330a0; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fleisch H, 2002, PRINCIPLES BONE BIOL, V2nd, P1361; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Goad DL, 1996, ENDOCRINOLOGY, V137, P2262, DOI 10.1210/en.137.6.2262; Hamilton A., 1995, DRUG NEWS PERSPECT, V8, P138; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; Hatakeyama D, 2002, J CELL BIOCHEM, V85, P621, DOI 10.1002/jcb.10166; KATO K, 1993, J BIOCHEM-TOKYO, V114, P640, DOI 10.1093/oxfordjournals.jbchem.a124230; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; Kozawa O, 1997, AM J PHYSIOL-ENDOC M, V272, pE208, DOI 10.1152/ajpendo.1997.272.2.E208; KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014-4827(92)90158-5; KOZAWA O, 1994, J CELL BIOCHEM, V55, P373, DOI 10.1002/jcb.240550315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679; Miao LY, 2002, AM J PHYSIOL-HEART C, V283, pH983, DOI 10.1152/ajpheart.00141.2002; MIWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1229, DOI 10.1016/0006-291X(90)90817-7; NII A, 1994, TOXICOL PATHOL, V22, P536, DOI 10.1177/019262339402200509; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OBRIG TG, 1971, J BIOL CHEM, V246, P174; Pilbeam Carol C., 1996, P715; Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800; Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200; Reinholz GG, 2000, CANCER RES, V60, P6001; Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382; SAKAI T, 1992, CELL CALCIUM, V13, P329, DOI 10.1016/0143-4160(92)90068-4; SCHALAEPPI JM, 1997, ENDOCR RES, V23, P213; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Tokuda H, 1999, CELL SIGNAL, V11, P325, DOI 10.1016/S0898-6568(98)00048-5; Tokuda H, 2001, J ENDOCRINOL, V170, P629, DOI 10.1677/joe.0.1700629; TOKUDA H, 1992, J CELL BIOCHEM, V48, P262, DOI 10.1002/jcb.240480306; Tokuda H, 2000, J BONE MINER RES, V15, P2371, DOI 10.1359/jbmr.2000.15.12.2371; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Vitte C, 1996, ENDOCRINOLOGY, V137, P2324, DOI 10.1210/en.137.6.2324; Wang DS, 1996, J BONE MINER RES, V11, P472; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143	45	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18930	18937		10.1074/jbc.M209159200	http://dx.doi.org/10.1074/jbc.M209159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646577	hybrid			2022-12-27	WOS:000182932200029
J	Wang, WM; Lee, S; Steiglitz, BM; Scott, IC; Lebares, CC; Allen, ML; Brenner, MC; Takahara, K; Greenspan, DS				Wang, WM; Lee, S; Steiglitz, BM; Scott, IC; Lebares, CC; Allen, ML; Brenner, MC; Takahara, K; Greenspan, DS			Transforming growth factor-beta induces secretion of activated ADAMTS-2 - A procollagen IIIN-proteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; CHICK-EMBRYO TENDONS; EHLERS-DANLOS SYNDROME; SMOOTH-MUSCLE CELLS; I N-PROTEINASE; C-PROTEINASE; PARTIAL-PURIFICATION; BOVINE DERMATOSPARAXIS; PROPROTEIN CONVERTASES; FIBROBLAST-CULTURES	The metalloproteinase ADAMTS-2 has procollagen I N-proteinase activity capable of cleaving procollagens I and II N-propeptides in vitro, whereas mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin. Yet despite its important role in the regulation of collagen deposition, information regarding regulation and substrate specificity of ADAMTS-2 has remained sparse. Here we demonstrate that ADAMTS-2 can, like the procollagen C-proteinases, be regulated by transforming growth factor-beta1 (TGF-beta1), with implications for mechanisms whereby this growth factor effects net increases in formation of extracellular matrix. TGF-beta1 induced ADAMTS-2 mRNA similar to8-fold in MG-63 osteosarcoma cells in a dose- and time-dependent, cycloheximide-inhibitable manner, which appeared to operate at the transcriptional level. Secreted AD-AMTS-2 protein induced by TGF-beta1 was 132 kDa and was identical in size to the fully processed, active form of the protease. Biosynthetic processing of ADAMTS-2 to yield the 132-kDa form is shown to be a two-step process involving sequential cleavage by furin-like convertases at two sites. Surprisingly, purified recombinant AD-AMTS-2 is shown to cleave procollagen III N-propeptides as effectively as those of procollagens I and II, whereas processing of procollagen III is shown to be decreased in Ehlers-Danlos VIIC. Thus, the dogma that procollagen I and procollagen III N-proteinase activities are provided by separate enzymes appears to be false, whereas the phenotypes of dermatosparaxis and Ehlers-Danlos VIIC may arise from defects in both type I and type III collagen biosynthesis.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; FibroGen Inc, San Francisco, CA 94080 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; FibroGen	Greenspan, DS (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Lee, Seungbok/AAS-1529-2021	Lee, Seungbok/0000-0002-6620-6269; Greenspan, Daniel/0000-0001-8096-7446	NIAMS NIH HHS [AR47746] Funding Source: Medline; NIGMS NIH HHS [T32 GM07215, GM63471] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047746, R56AR047746] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007215, R01GM063471] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abbaszade I, 1999, J BIOL CHEM, V274, P23443, DOI 10.1074/jbc.274.33.23443; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BATEMAN JF, 1986, J BIOL CHEM, V261, P4198; Bernstein EF, 1996, J AM ACAD DERMATOL, V34, P209, DOI 10.1016/S0190-9622(96)80114-9; Blelloch R, 1999, NATURE, V399, P586, DOI 10.1038/21196; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7; COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724; Colige A, 1997, P NATL ACAD SCI USA, V94, P2374, DOI 10.1073/pnas.94.6.2374; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Feres EJ, 1995, J BIOL CHEM, V270, P30797, DOI 10.1074/jbc.270.51.30797; Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; HALILA R, 1986, BIOCHEM J, V239, P47, DOI 10.1042/bj2390047; HALILA R, 1984, BIOCHEMISTRY-US, V23, P1251, DOI 10.1021/bi00301a036; HOJIMA Y, 1989, J BIOL CHEM, V264, P11336; HOJIMA Y, 1994, J BIOL CHEM, V269, P11381; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Hulmes DJS, 1992, ESSAYS BIOCHEM, V27, P49; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; KESSLER E, 1986, COLLAGEN REL RES, V6, P249; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 2000, FEBS LETT, V478, P241, DOI 10.1016/S0014-5793(00)01854-8; LAPIERE CM, 1971, P NATL ACAD SCI USA, V68, P3054, DOI 10.1073/pnas.68.12.3054; LAWRENCE R, 1994, J BIOL CHEM, V269, P9603; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; LENAERS A, 1971, EUR J BIOCHEM, V23, P533, DOI 10.1111/j.1432-1033.1971.tb01651.x; Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008; Li SW, 2001, BIOCHEM J, V355, P271, DOI 10.1042/0264-6021:3550271; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NUSGENS BV, 1980, BIOCHEM J, V191, P699, DOI 10.1042/bj1910699; NUSGENS BV, 1992, NAT GENET, V1, P214, DOI 10.1038/ng0692-214; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; SCHNIEKE A, 1983, NATURE, V304, P315, DOI 10.1038/304315a0; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Shindo T, 2000, J CLIN INVEST, V105, P1345, DOI 10.1172/JCI8635; SMITH LT, 1992, AM J HUM GENET, V51, P235; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Suzuki N, 1996, DEVELOPMENT, V122, P3587; Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664; TUDERMAN L, 1978, BIOCHEMISTRY-US, V17, P2948, DOI 10.1021/bi00608a002; TUDERMAN L, 1982, EUR J BIOCHEM, V125, P545, DOI 10.1111/j.1432-1033.1982.tb06716.x; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; Vazquez F, 1999, J BIOL CHEM, V274, P23349, DOI 10.1074/jbc.274.33.23349	56	81	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19549	19557		10.1074/jbc.M300767200	http://dx.doi.org/10.1074/jbc.M300767200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646579	hybrid			2022-12-27	WOS:000182932200106
J	Rossman, KL; Cheng, L; Mahon, GM; Rojas, RJ; Snyder, JT; Whitehead, IP; Sondek, J				Rossman, KL; Cheng, L; Mahon, GM; Rojas, RJ; Snyder, JT; Whitehead, IP; Sondek, J			Multifunctional roles for the PH domain of Dbs in regulating rho GTPase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; PLECKSTRIN HOMOLOGY DOMAIN; HIGH-AFFINITY BINDING; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; ONCOGENIC DBL; TRANSFORMATION; RAC; IDENTIFICATION; MUTAGENESIS	Dbl family members are guanine nucleotide exchange factors specific for Rho guanosine triphosphatases (GTPases) and invariably possess tandem Dbl (DH) and pleckstrin homology (PH) domains. Dbs, a Dbl family member specific for Cdc42 and RhoA, exhibits transforming activity when overexpressed in NIH 3T3 mouse fibroblasts. In this study, the PH domain of Dbs was mutated to impair selectively either guanine nucleotide exchange or phosphoinositide binding in vitro and resulting physiological alterations were assessed. As anticipated, substitution of residues within the PH domain of Dbs integral to the interface with GTPases reduced nucleotide exchange and eliminated the ability of Dbs to transform NIH 3T3 cells. More interestingly, substitutions within the PH domain that prevent interaction with phosphoinositides yet do not alter in vitro activation of GTPases also do not transform NIH 3T3 cell and fail to activate RhoA in vivo despite proper subcellular localization. Therefore, the PH domain of Dbs serves multiple roles in the activation of GTPases and cannot be viewed as a simple membrane-anchoring device. In particular, the data suggest that binding of phosphoinositides to the PH domain within the context of membrane surfaces may direct orientations or conformations of the linked DH and PH domains to regulate GTPases activation.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07103 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Rutgers State University New Brunswick; Rutgers State University Medical Center	Sondek, J (corresponding author), Univ N Carolina, Dept Pharmacol, CB 7365,1106 MEJ Bldg, Chapel Hill, NC 27599 USA.			Sondek, John/0000-0002-1127-8310	NATIONAL CANCER INSTITUTE [R29CA077493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-77493] Funding Source: Medline; NIGMS NIH HHS [R01-GM62299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aghazadeh B, 1998, NAT STRUCT BIOL, V5, P1098, DOI 10.1038/4209; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cheng L, 2002, MOL CELL BIOL, V22, P6895, DOI 10.1128/MCB.22.19.6895-6905.2002; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Hoffman GR, 2002, FEBS LETT, V513, P85, DOI 10.1016/S0014-5793(01)03310-5; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Robbe K, 2003, J BIOL CHEM, V278, P4756, DOI 10.1074/jbc.M210412200; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; VAN AL, 1997, GENE DEV, V11, P2295; Vanni C, 2002, J BIOL CHEM, V277, P19745, DOI 10.1074/jbc.M111025200; Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3; Wells CD, 2001, J BIOL CHEM, V276, P28897, DOI 10.1074/jbc.M102913200; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	40	66	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18393	18400		10.1074/jbc.M300127200	http://dx.doi.org/10.1074/jbc.M300127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637522	Green Published			2022-12-27	WOS:000182838300105
J	Schonhoff, CM; Gaston, B; Mannick, JB				Schonhoff, CM; Gaston, B; Mannick, JB			Nitrosylation of cytochrome c during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING COMPLEX DISC; FAS-INDUCED APOPTOSIS; NITRIC-OXIDE; MONOCLONAL-ANTIBODY; PHOSPHOLIPID-VESICLES; PROTEASE CASCADE; RESONANCE RAMAN; S-NITROSYLATION; IONIC-STRENGTH; DEATH DOMAIN	Cytochrome c released from mitochondria into the cytoplasm plays a critical role in many forms of apoptosis by stimulating apoptosome formation and subsequent caspase activation. However, the mechanisms regulating cytochrome c apoptotic activity are not understood. Here we demonstrate that cytochrome c is nitrosylated on its heme iron during apoptosis. Nitrosylated cytochrome c is found predominantly in the cytoplasm in control cells. In contrast, when cytochrome c release from mitochondria is inhibited by overexpression of the anti-apoptotic proteins B cell lymphoma/leukemia (Bcl)-2 or Bcl-X-L, nitrosylated cytochrome c is found in the mitochondria. These data suggest that during apoptosis, cytochrome c is nitrosylated in mitochondria and then rapidly released into the cytoplasm in the absence of Bcl-2 or Bcl-X-L overexpression. In vitro nitrosylation of cytochrome c increases caspase-3 activation in cell lysates. Moreover, the inhibition of intracellular cytochrome c nitrosylation is associated with a decrease in apoptosis, suggesting that cytochrome c nitrosylation is a proapoptotic modification. We conclude that nitrosylation of the heme iron of cytochrome c may be a novel mechanism of apoptosis regulation.	Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Virginia, Sch Med, Dept Pediat, Charlottesville, VA 22908 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Virginia	Mannick, JB (corresponding author), Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA.							ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; ASCENZI P, 1994, J INORG BIOCHEM, V53, P273, DOI 10.1016/0162-0134(94)85114-X; Beltran B, 2002, P NATL ACAD SCI USA, V99, P8892, DOI 10.1073/pnas.092259799; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BRUDVIG GW, 1980, BIOCHEMISTRY-US, V19, P5275, DOI 10.1021/bi00564a020; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; CORTESE JD, 1992, BIOCHIM BIOPHYS ACTA, V1100, P189; DHEIN J, 1992, J IMMUNOL, V149, P3166; Fang KZ, 1998, BIOCHEM BIOPH RES CO, V252, P535, DOI 10.1006/bbrc.1998.9688; Feelisch M, 2002, FASEB J, V16, P1775, DOI 10.1096/fj.02-0363com; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HILDEBRANDT P, 1990, EUR BIOPHYS J, V18, P193, DOI 10.1007/BF02427378; Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jemmerson R, 1999, BIOCHEMISTRY-US, V38, P3599, DOI 10.1021/bi9809268; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kozlov AV, 1999, FEBS LETT, V454, P127, DOI 10.1016/S0014-5793(99)00788-7; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Mannick JB, 1997, J BIOL CHEM, V272, P24125, DOI 10.1074/jbc.272.39.24125; Marshall WL, 1999, VIROLOGY, V256, P1, DOI 10.1006/viro.1999.9599; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; Murad F, 1994, Adv Pharmacol, V26, P19, DOI 10.1016/S1054-3589(08)60049-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Orii Y, 1978, J Biochem, V84, P1542; Purring-Koch C, 2000, P NATL ACAD SCI USA, V97, P11928, DOI 10.1073/pnas.220416197; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Sharpe MA, 1998, BIOCHEM J, V332, P9, DOI 10.1042/bj3320009; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Takahashi A, 1997, ONCOGENE, V14, P2741, DOI 10.1038/sj.onc.1201131; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu TN, 2001, J BIOL CHEM, V276, P13034, DOI 10.1074/jbc.M009773200; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	97	104	4	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18265	18270		10.1074/jbc.M212459200	http://dx.doi.org/10.1074/jbc.M212459200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646553	hybrid			2022-12-27	WOS:000182838300089
J	Souto, RP; Vallega, G; Wharton, J; Vinten, J; Tranum-Jensen, J; Pilch, PF				Souto, RP; Vallega, G; Wharton, J; Vinten, J; Tranum-Jensen, J; Pilch, PF			Immunopurification and characterization of rat adipocyte caveolae suggest their dissociation from insulin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; PLASMA-MEMBRANE; CELL-SURFACE; LIPID RAFTS; GLUCOSE-TRANSPORT; ADIPOSE-CELLS; TYROSINE PHOSPHORYLATION; HETEROOLIGOMERIC COMPLEX; GLUT4-ENRICHED VESICLES; AMINE OXIDASE	Adipocytes play an important role in the insulin-dependent regulation of organismal fuel metabolism and express caveolae at levels as high or higher than any other cell type. Recently, a link between insulin signaling and caveolae has been suggested; nevertheless, adipocyte caveolae have been the subject of relatively few studies, and their contents have been minimally characterized. With the aid of a new monoclonal antibody, we developed a rapid procedure for the immunoisolation of caveolae derived from the plasma membrane of adipocytes, and we characterized their protein content. We find that immunopurified adipocyte caveolae have a relatively limited protein composition, and they lack the raft protein, flotillin, and insulin receptors. Immunogold labeling and electron microscopy of the adipocyte plasma membrane confirmed the lack of insulin receptors in caveolae. In addition to caveolins, the structural components of caveolae, their major protein constituents, are the semicarbazide-sensitive amine oxidase and the scavenger lipoprotein receptor CD36. The results are consistent with a role for caveolae in lipid flux in and of adipocytes.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark; Univ Copenhagen, Panum Inst, Dept Anat, DK-2200 Copenhagen N, Denmark	Boston University; University of Copenhagen; University of Copenhagen	Pilch, PF (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K412, Boston, MA 02118 USA.	ppilch@bu.edu	Souto, Ricardo/F-7828-2012	Souto, Ricardo/0000-0002-6281-5956; Pilch, Paul/0000-0003-1997-0499	NIDDK NIH HHS [DK56935, DK30425] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030425, R01DK056935] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bergman RN, 1997, RECENT PROG HORM RES, V52, P359; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bickel PE, 2002, AM J PHYSIOL-ENDOC M, V282, pE1, DOI 10.1152/ajpendo.2002.282.1.E1; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; CARPENTIER JL, 1976, J LIPID RES, V17, P335; CHAKRABARTI R, 1994, J BIOL CHEM, V269, P7926; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Enrique-Tarancon G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/jbc.273.14.8025; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; Fielding CJ, 2000, BBA-MOL CELL BIOL L, V1529, P210, DOI 10.1016/S1388-1981(00)00150-5; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Jalkanen S, 2001, EMBO J, V20, P3893, DOI 10.1093/emboj/20.15.3893; JAMES DE, 1988, NATURE, V333, P183, DOI 10.1038/333183a0; Jiang ZY, 2002, J BIOL CHEM, V277, P509, DOI 10.1074/jbc.M108280200; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, J CELL BIOL, V129, P999, DOI 10.1083/jcb.129.4.999; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Karlsson M, 2001, FASEB J, V15, P249, DOI 10.1096/fj.01-0646fje; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee J, 1997, BIOCHEMISTRY-US, V36, P2701, DOI 10.1021/bi961815g; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Malide D, 2000, J CELL SCI, V113, P4203; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Maxfield FR, 1997, ADV EXP MED BIOL, V419, P355; Moldes M, 1999, J BIOL CHEM, V274, P9515, DOI 10.1074/jbc.274.14.9515; Morris NJ, 1997, J BIOL CHEM, V272, P9388; Morrison RF, 2000, J NUTR, V130, p3116S, DOI 10.1093/jn/130.12.3116S; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nystrom FH, 1999, MOL ENDOCRINOL, V13, P2013, DOI 10.1210/me.13.12.2013; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Parton RG, 2002, J BIOL CHEM, V277, P46769, DOI 10.1074/jbc.M205683200; Parton RG, 2003, NAT REV MOL CELL BIO, V4, P162, DOI 10.1038/nrm1017; PILCH PF, 1983, J CELL BIOL, V96, P133, DOI 10.1083/jcb.96.1.133; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Razani B, 2001, J BIOL CHEM, V276, P38121; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Ros-Baro A, 2001, P NATL ACAD SCI USA, V98, P12050, DOI 10.1073/pnas.211341698; SATOH S, 1993, J BIOL CHEM, V268, P17820; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; THOIDIS G, 1993, J BIOL CHEM, V268, P11691; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Vainio S, 2002, EMBO REP, V3, P95, DOI 10.1093/embo-reports/kvf010; Vinten J, 2001, CELL TISSUE RES, V305, P99, DOI 10.1007/s004410100389; VOLDSTEDLUND M, 1993, J MEMBRANE BIOL, V136, P63; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Westermann M, 1999, HISTOCHEM CELL BIOL, V111, P71, DOI 10.1007/s004180050335; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962	80	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18321	18329		10.1074/jbc.M211541200	http://dx.doi.org/10.1074/jbc.M211541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637562	hybrid			2022-12-27	WOS:000182838300096
J	Bell, M; Engelberg, D				Bell, M; Engelberg, D			Phosphorylation of Tyr-176 of the yeast MAPK Hog1/p38 is not vital for Hog1 biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; PATHWAY; TRANSCRIPTION; STRESS; ERK2; KSS1	Mitogen-activated protein kinases are crucial components in the life of eukaryotic cells. The current dogma for MAPK activation is that dual phosphorylation of neighboring Thr and Tyr residues at the phosphorylation lip is an absolute requirement for their catalytic and biological activity. In this study we addressed the role of Tyr and Thr phosphorylation in the yeast MAPK Hog1/p38. Taking advantage of the recently isolated hyperactive mutants, whose intrinsic basal activity is independent of upstream regulation, we demonstrate that Tyr-176 is not required for basal catalytic and biological activity but is essential for the salt-induced amplification of Hog1 catalysis. We show that intact Thr-174 is absolutely essential for biology and catalysis of the mutants but is mainly required for structural reasons and not as a phosphoacceptor. The roles of Thr-174 and Tyr-176 in wild type Hog1 molecules were also tested. Unexpectedly we found that Hog1(Y176F) is biologically active, capable of induction of Hog1 target genes and of rescuing hog1Delta cells from osmotic stress. Hog1(Y176F) was not able, however, to mediate growth arrest induced by constitutively active MAPK kinase/Pbs2. We propose that Thr-174 is essential for stabilizing the basal active conformation, whereas Tyr-176 is not. Tyr-176 serves as a regulatory element required for stimuli-induced amplification of kinase activity.	Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Engelberg, D (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel.							Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Bellon S, 1999, STRUCTURE, V7, P1057, DOI 10.1016/S0969-2126(99)80173-7; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN W, 1987, CELL, V50, P1047, DOI 10.1016/0092-8674(87)90171-1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cohen P, 2001, EUR J BIOCHEM, V268, P5001, DOI 10.1046/j.0014-2956.2001.02473.x; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prowse CN, 2001, J BIOL CHEM, V276, P40817, DOI 10.1074/jbc.M105860200; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001	23	33	38	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14603	14606		10.1074/jbc.C300006200	http://dx.doi.org/10.1074/jbc.C300006200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637550	hybrid			2022-12-27	WOS:000182516100005
J	Slutsky, SG; Kamaraju, AK; Levy, AM; Chebath, J; Revel, M				Slutsky, SG; Kamaraju, AK; Levy, AM; Chebath, J; Revel, M			Activation of myelin genes during transdifferentiation from melanoma to glial cell phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SOX10; CULTURED SCHWANN-CELLS; INTERLEUKIN-6 RECEPTOR-INTERLEUKIN-6 CHIMERA; PROTEIN ZERO GENES; HUMAN MBP PROMOTER; WAARDENBURG-SYNDROME; GROWTH-INHIBITION; TRANSGENIC MICE; NERVOUS-SYSTEM; MESSENGER-RNA	Induction of myelin genes occurs around birth in the last stage of Schwann cells differentiation and is reactivated in case of nerve injury. Previous studies showed that activation of the gp130 receptor system, using as ligand interleukin-6 fused to its soluble receptor (IL6RIL6), causes induction of myelin genes such as myelin basic protein (MBP) and myelin protein zero (Po) in embryonic dorsal root ganglia Schwann cells. We also reported that in murine melanoma B16/F10.9 cells, IL6RIL6 causes a shut-off of melanogenesis mediated by a down-regulation of the paired-homeodomain factor Pax3. The present work demonstrates that these IL6RIL6-treated F10.9 cells undergo transdifferentiation to a myelinating glial phenotype characterized by induction of the transcriptional activities of both Po and MBP promoters and accumulation of myelin gene products. For both Po and MBP promoters, a repression by Pax3 and stimulation by Sox10 can be demonstrated. Because after IL6RIL6-treatment, Pax3 disappears from the F10.9 cells (as it does in mature myelinating Schwann cells) whereas the level of Sox10 rather increases, we modulated the relative level of these factors and show their involvement in the induction of myelin gene expression by IL6RIL6. In addition, however, we show that a C/G-rich CACC box in the Po promoter is required for activation by IL6RIL6, as well as by ectopic Sox10, and identify a Kruppel-type zinc finger factor acting through this CACC box, which stimulates Po promoter activity.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Revel, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.			Slutsky, Guy/0000-0001-5135-5694; Chebath, Judith/0000-0002-8151-7428				Bai LC, 2000, J BIOL CHEM, V275, P30725, DOI 10.1074/jbc.M004249200; Betz UAK, 1998, J EXP MED, V188, P1955, DOI 10.1084/jem.188.10.1955; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; Bondurand N, 2001, HUM MOL GENET, V10, P2783, DOI 10.1093/hmg/10.24.2783; BOSMAN C, 1995, TUMORI, V81, P208, DOI 10.1177/030089169508100312; Brown AM, 1997, J BIOL CHEM, V272, P28939, DOI 10.1074/jbc.272.46.28939; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; Cheng LL, 1996, NEURON, V16, P309, DOI 10.1016/S0896-6273(00)80049-5; Desarnaud F, 2000, BRAIN RES, V865, P12, DOI 10.1016/S0006-8993(00)02130-2; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; FORAN DR, 1992, J NEUROSCI, V12, P4890; Forghani R, 2001, J NEUROSCI, V21, P3780, DOI 10.1523/JNEUROSCI.21-11-03780.2001; GOUJETZALC C, 1993, EUR J NEUROSCI, V5, P624, DOI 10.1111/j.1460-9568.1993.tb00528.x; GOW A, 1992, J CELL BIOL, V119, P605, DOI 10.1083/jcb.119.3.605; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; Haggiag S, 1999, FEBS LETT, V457, P200, DOI 10.1016/S0014-5793(99)01040-6; Jessen KR, 1998, MICROSC RES TECHNIQ, V41, P393, DOI 10.1002/(SICI)1097-0029(19980601)41:5<393::AID-JEMT6>3.0.CO;2-R; JESSEN KR, 1991, GLIA, V4, P185, DOI 10.1002/glia.440040210; Kamachi Y, 2000, TRENDS GENET, V16, P182, DOI 10.1016/S0168-9525(99)01955-1; Kamaraju AK, 2002, J BIOL CHEM, V277, P15132, DOI 10.1074/jbc.M200004200; KATZ A, 1993, J IMMUNOTHER, V13, P98, DOI 10.1097/00002371-199302000-00004; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Kioussi C, 1996, TRENDS GENET, V12, P84, DOI 10.1016/0168-9525(96)81411-9; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Law DJ, 1999, BIOCHEM BIOPH RES CO, V262, P113, DOI 10.1006/bbrc.1999.1180; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1988, DEVELOPMENT, V102, P499; LI XB, 1994, J NEUROCHEM, V63, P28; Melnikova IN, 2000, NEUROPHARMACOLOGY, V39, P2615, DOI 10.1016/S0028-3908(00)00125-8; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIURA M, 1989, GENE, V75, P31; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MORGAN L, 1994, DEVELOPMENT, V120, P1399; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; Nagarajan R, 2001, NEURON, V30, P355, DOI 10.1016/S0896-6273(01)00282-3; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Saberan-Djoneidi D, 2000, GENE, V248, P223, DOI 10.1016/S0378-1119(00)00116-5; SPRINKLE TJ, 1985, NEUROCHEM RES, V10, P919, DOI 10.1007/BF00964629; Stoll G, 1999, BRAIN PATHOL, V9, P313; Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; TRAPP BD, 1988, J NEUROSCI, V8, P3515; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wegner M, 2000, GLIA, V29, P118, DOI 10.1002/(SICI)1098-1136(20000115)29:2<118::AID-GLIA4>3.0.CO;2-Q; WRABETZ L, 1993, J NEUROSCI RES, V36, P455, DOI 10.1002/jnr.490360412; Wrabetz L, 1998, J NEUROBIOL, V34, P10, DOI 10.1002/(SICI)1097-4695(199801)34:1<10::AID-NEU2>3.0.CO;2-F; ZHANG XP, 1993, J NEUROCHEM, V60, P2010, DOI 10.1111/j.1471-4159.1993.tb03485.x; Zorick TS, 1996, CURR OPIN CELL BIOL, V8, P870, DOI 10.1016/S0955-0674(96)80090-1; Zorick TS, 1999, DEVELOPMENT, V126, P1397	62	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8960	8968		10.1074/jbc.M210569200	http://dx.doi.org/10.1074/jbc.M210569200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643284	hybrid			2022-12-27	WOS:000181524000014
J	Glinkowska, M; Majka, J; Messer, W; Wegrzyn, G				Glinkowska, M; Majka, J; Messer, W; Wegrzyn, G			The mechanism of regulation of bacteriophage lambda p(R) promoter activity by Escherichia coli DnaA protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; REPLICATION; INITIATOR; PLASMIDS; EXPRESSION; ORIGIN; SWITCH	Apart from its function as an initiator of DNA replication, the Escherichia coli DnaA protein is also a specific transcription factor. It activates and represses a number of promoters. However, mechanisms of transcription stimulation by DnaA remained unknown. Bacteriophage lambdap(R) promoter is one of the promoters activated by DnaA. It was reported previously that DnaA binds downstream of the p(R) promoter and perhaps interacts with the RNA polymerase beta subunit. Here we demonstrate that DnaA positively regulates transcription from pR by stimulation of two steps in transcription initiation: RNA polymerase binding to the promoter region and promoter escape. For this transcription activation, two weak DnaA boxes located downstream of pR are necessary and sufficient. Such a mechanism of transcription activation and location of the activator-binding sites relative to the transcription start point are unusual in prokaryotes. Changes in the distance between the transcription start point and the first DnaA box by 5 and 10 bp and alterations in the orientation of these boxes did not abolish the stimulation of transcription by DnaA, but the efficiency of the promoter activation was different for various mutations. It seems plausible that formation of higher order nucleoprotein structures, involving DNA looping, is necessary for effective stimulation of the pR promoter. At high concentrations, DnaA is a repressor of pR rather than an activator. This repression was found to be because of inhibition of RNA polymerase binding to the promoter region.	Univ Gdansk, Dept Mol Biol, PL-80822 Gdansk, Poland; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Polish Acad Sci, Inst Oceanol, PL-81347 Gdynia, Poland	Fahrenheit Universities; University of Gdansk; Max Planck Society; Polish Academy of Sciences; Institute of Oceanology of the Polish Academy of Sciences	Wegrzyn, G (corresponding author), Univ Gdansk, Dept Mol Biol, Kladki 24, PL-80822 Gdansk, Poland.	wegrzyn@biotech.univ.gda.pl	Wegrzyn, Grzegorz/AAL-1179-2020; Wegrzyn, Grzegorz/ABD-6699-2020	Wegrzyn, Grzegorz/0000-0003-4042-7466	FOGARTY INTERNATIONAL CENTER [R03TW001244] Funding Source: NIH RePORTER; FIC NIH HHS [TW01244] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Baranska S, 2002, NUCLEIC ACIDS RES, V30, P1176, DOI 10.1093/nar/30.5.1176; Baranska S, 2001, MICROBIOL-UK, V147, P535, DOI 10.1099/00221287-147-3-535; Bolivar F, 1979, Methods Enzymol, V68, P245; Chamberlin Michael J., 1996, P7; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; Glinkowska M, 2001, MICROBIOL-SGM, V147, P1923, DOI 10.1099/00221287-147-7-1923; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; Konopa G, 1999, FEMS MICROBIOL LETT, V174, P25, DOI 10.1016/S0378-1097(99)00116-0; KUR J, 1987, J MOL BIOL, V198, P203, DOI 10.1016/0022-2836(87)90306-8; Langer U, 1996, MOL MICROBIOL, V21, P301, DOI 10.1046/j.1365-2958.1996.6481362.x; LEARN B, 1993, COLD SPRING HARB SYM, V58, P389, DOI 10.1101/SQB.1993.058.01.046; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; Messer W, 2001, BIOCHIMIE, V83, P5, DOI 10.1016/S0300-9084(00)01216-5; Quinones A, 1997, MOL MICROBIOL, V23, P1193, DOI 10.1046/j.1365-2958.1997.2961658.x; Rhodius VA, 1998, CURR OPIN MICROBIOL, V1, P152, DOI 10.1016/S1369-5274(98)80005-2; Sambrook J, 1989, MOL CLONING; SCHAEFER C, 1988, GENE, V73, P347, DOI 10.1016/0378-1119(88)90499-4; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Szalewska-Palasz A, 1998, MOL GEN GENET, V259, P679, DOI 10.1007/s004380050863; Szalewska-Palasz A, 1998, P NATL ACAD SCI USA, V95, P4241, DOI 10.1073/pnas.95.8.4241; TAYLOR K, 1995, FEMS MICROBIOL REV, V17, P109; TAYLOR K, 1998, MOL MICROBIOL, P81; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wegrzyn G, 1996, MOL GEN GENET, V252, P580; WEGRZYN G, 1995, GENE, V154, P47, DOI 10.1016/0378-1119(94)00849-N	28	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22250	22256		10.1074/jbc.M212492200	http://dx.doi.org/10.1074/jbc.M212492200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12654908	hybrid			2022-12-27	WOS:000183503900011
J	Kong, WY; Longaker, MT; Lorenz, HP				Kong, WY; Longaker, MT; Lorenz, HP			Molecular cloning and expression of keratinocyte proline-rich protein, a novel squamous epithelial marker isolated during skin development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; EPIDERMAL-KERATINOCYTES; PRECURSOR PROTEINS; LORICRIN; TRANSGLUTAMINASES; IDENTIFICATION; PROFILAGGRIN; TRICHOHYALIN; COMPONENTS; FILAGGRIN	We describe a novel rat cDNA named keratinocyte proline-rich protein (KPRP) isolated by RNA differential display during skin development. We determine that KPRP is expressed in stratified squamous epithelium, and its similar to2.8-kb cDNA encodes a 699-amino acid protein with high proline content (19%). KPRP is an insoluble protein, similar to most epidermal terminal differentiation-associated proteins. Immunoblot of the protein lysate from keratinocytes, using strong reducing conditions, demonstrates two KPRP bands of similar to76 and 55 kDa size. KPRP is expressed in stratified squamous epithelia of skin, tongue, and esophagus. The initiation of KPRP expression in fetal rat skin at E17, E18, E19, E20, and E21 was analyzed by reverse transcription-PCR. Fetal skin at E19 and later expresses KPRP. In situ hybridization of skin from E18, E19, and 4-day-old neonatal rats demonstrates that interfollicular and follicular keratinocytes express KPRP. Anti-KPRP antibody demonstrates KPRP protein localizes to all layers of stratified epithelia in skin, tongue, and esophagus. In cultured dermal keratinocytes, KPRP is diffusely distributed throughout the cytoplasm with denser staining adjacent to the nuclear and plasma membranes. Additionally, immunoreactive intracellular granules are observed during keratinocyte detachment from their plastic substrate. Rat KPRP has 89% homology to a mouse genomic DNA sequence and 56% homology to a human hypothetical protein. We conclude that KPRP may be a new epidermal terminal differentiation-related protein expressed in stratified squamous epithelia. KPRP is expressed by fetal dermal keratinocytes during late gestation and is a new marker of maturing epidermis during fetal skin development.	Stanford Univ, Pediat Surg Res Lab, Sch Med, Stanford, CA 94305 USA	Stanford University	Lorenz, HP (corresponding author), Stanford Univ, Pediat Surg Res Lab, Sch Med, 257 Campus Dr, Stanford, CA 94305 USA.				NIDCR NIH HHS [DE00463-03] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Akiyama M, 1999, J INVEST DERMATOL, V112, P903, DOI 10.1046/j.1523-1747.1999.00592.x; BACKENDORF C, 1992, NAT GENET, V2, P91, DOI 10.1038/ng1092-91; Cabral A, 2001, J CELL SCI, V114, P3837; Cabral A, 2001, J BIOL CHEM, V276, P19231, DOI 10.1074/jbc.M100336200; Dale BA, 1997, J INVEST DERMATOL, V108, P179, DOI 10.1111/1523-1747.ep12334205; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; Hitomi J, 1996, BIOCHEM BIOPH RES CO, V228, P757, DOI 10.1006/bbrc.1996.1728; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266; Ishida-Yamamoto A, 1998, HISTOL HISTOPATHOL, V13, P819, DOI 10.14670/HH-13.819; Ishida-Yamamoto A, 1999, J INVEST DERM SYMP P, V4, P145, DOI 10.1038/sj.jidsp.5640198; Jarnik M, 1996, J CELL SCI, V109, P1381; KARTASOVA T, 1996, J INVEST DERMATOL, V106; KOCH PJ, 2000, J CELL BIOL, V151; Koizumi H, 1996, BRIT J DERMATOL, V134, P686, DOI 10.1111/j.1365-2133.1996.tb06971.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lee CH, 2000, FEBS LETT, V477, P268, DOI 10.1016/S0014-5793(00)01806-8; Lee SC, 1999, J INVEST DERMATOL, V112, P882, DOI 10.1046/j.1523-1747.1999.00602.x; Makino T, 2001, J BIOL CHEM, V276, P47445, DOI 10.1074/jbc.M107512200; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; MEHREL T, 1990, CELL, V61, P1103, DOI 10.1016/0092-8674(90)90073-N; Robinson NA, 1997, J BIOL CHEM, V272, P12035, DOI 10.1074/jbc.272.18.12035; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1995, J BIOL CHEM, V270, P17702, DOI 10.1074/jbc.270.30.17702; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893	25	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22781	22786		10.1074/jbc.M210488200	http://dx.doi.org/10.1074/jbc.M210488200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668678	hybrid			2022-12-27	WOS:000183503900081
J	Benharouga, M; Sharma, M; So, J; Haardt, M; Drzymala, L; Popov, M; Schwapach, B; Grinstein, S; Du, K; Lukacs, GL				Benharouga, M; Sharma, M; So, J; Haardt, M; Drzymala, L; Popov, M; Schwapach, B; Grinstein, S; Du, K; Lukacs, GL			The role of the C terminus and Na+/H+ exchanger regulatory factor in the functional expression of cystic fibrosis transmembrane conductance regulator in nonpolarized cells and epithelia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDZ-INTERACTING DOMAIN; PROTEIN-KINASE-A; DEPENDENT REGULATION; PLASMA-MEMBRANE; FACTOR-I; CFTR; RECEPTOR; BINDING; EZRIN; LOCALIZATION	The conserved C-terminal peptide motif ((DTRL)-D-1476) of the cystic fibrosis transmembrane conductance regulator (CFTR) ensures high affinity binding to different PSD-95/Disc-large/zonula occludens-1 (PDZ) domain-containing molecules, including the Na+/H+ exchanger regulatory factor (NHERF)/ezrin-radixin- moesin-binding phosphoprotein of 50 kDa. The physiological relevance of NHERF binding to CFTR is not fully understood. Individuals with mutations resulting in premature termination of CFTR (S1455X or Delta26 CFTR) have moderately elevated sweat Cl- concentration, without an obvious lung and pancreatic phenotype, implying that the CFTR function is largely preserved. Surprisingly, when expressed heterologously, the Delta26 mutation was reported to abrogate channel activity by destabilizing the protein at the apical domain and inducing its accumulation at the basolateral membrane (Moyer, B., Denton, J., Karlson, K., Reynolds, D., Wang, S., Mickle, J., Milewski, M., Cutting, G., Guggino, W., Li, M., and Stanton, B. (1999) J. Clin. Invest. 104, 1353 - 1361). The goals of this study were to resolve the contrasting clinical and cellular phenotype of the Delta26 CFTR mutation and evaluate the role of NHERF in the functional expression of CFTR at the plasma membrane. Complex formation between CFTR and NHERF was disrupted by C-terminal deletions, C-terminal epitope tag attachments, or overexpression of a dominant negative NHERF mutant. These perturbations did not alter CFTR expression, metabolic stability, or function in nonpolarized cells. Likewise, inhibition of NHERF binding had no discernible effect on the apical localization of CFTR in polarized tracheal, pancreatic, intestinal, and kidney epithelia and did not influence the metabolic stability or the cAMP-dependent protein kinase-activated chloride channel conductance in polarized pancreatic epithelia. On the other hand, electrophysiological studies demonstrated that NHERF is able to stimulate the cAMP-dependent protein kinase-phosphorylated CFTR channel activity in intact cells. These results help to reconcile the discordant genotype-phenotype relationship in individuals with C-terminal truncations and indicate that apical localization of CFTR involves sorting signals other than the C-terminal 26 amino acid residues and the PDZ-binding motif in differentiated epithelia.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; ZMBH, INF 282, D-69120 Heidelberg, Germany	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ruprecht Karls University Heidelberg	Lukacs, GL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	glukacs@sickkids.ca	Haardt, Martin/B-5857-2011	Haardt, Martin/0000-0001-7810-975X; Lukacs, Gergely/0000-0003-0900-0675				Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Citi S, 1998, BBA-MOL CELL RES, V1448, P1, DOI 10.1016/S0167-4889(98)00125-6; de Beauregard MAC, 2000, EUR J CELL BIOL, V79, P795, DOI 10.1078/0171-9335-00116; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Gentzsch M, 2002, BIOCHEM J, V366, P541, DOI 10.1042/BJ20020511; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Gustafson CE, 1998, HISTOCHEM CELL BIOL, V110, P377, DOI 10.1007/s004180050298; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1999, J BIOL CHEM, V274, P24328, DOI 10.1074/jbc.274.34.24328; Hallows KR, 2000, J CLIN INVEST, V105, P1711, DOI 10.1172/JCI9622; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris BZ, 2001, J CELL SCI, V114, P3219; He JQ, 2001, J BIOL CHEM, V276, P41559, DOI 10.1074/jbc.M106859200; Hernando N, 2002, P NATL ACAD SCI USA, V99, P11957, DOI 10.1073/pnas.182412699; Hollande E, 1998, EUR J CELL BIOL, V76, P220, DOI 10.1016/S0171-9335(98)80037-X; Hu W, 2001, BIOCHEM J, V354, P561, DOI 10.1042/0264-6021:3540561; Jia YL, 1997, J BIOL CHEM, V272, P4978, DOI 10.1074/jbc.272.8.4978; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; Kartner N, 1998, METHOD ENZYMOL, V292, P629; Kleizen B, 2000, EUR J CELL BIOL, V79, P544, DOI 10.1078/0171-9335-00078; Lechardeur D, 2000, J CELL BIOL, V150, P321, DOI 10.1083/jcb.150.2.321; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Liedtke CM, 2002, J BIOL CHEM, V277, P22925, DOI 10.1074/jbc.M201917200; LUKACS GL, 1993, J BIOL CHEM, V268, P21592; MADDEN ME, 1988, PANCREAS, V3, P512, DOI 10.1097/00006676-198810000-00003; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mickle JE, 1998, HUM MOL GENET, V7, P729, DOI 10.1093/hmg/7.4.729; Mickle JE, 2000, MED CLIN N AM, V84, P597, DOI 10.1016/S0025-7125(05)70243-1; Milewski MI, 2001, J CELL SCI, V114, P719; Mohamed A, 1997, BIOCHEM J, V322, P259, DOI 10.1042/bj3220259; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; MORRIS AP, 1994, AM J PHYSIOL, V266, pC254, DOI 10.1152/ajpcell.1994.266.1.C254; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Naren AP, 2003, P NATL ACAD SCI USA, V100, P342, DOI 10.1073/pnas.0135434100; OSTEDGAARD L, 2002, PED PULM S, V24, P184; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Prince LS, 1999, J BIOL CHEM, V274, P3602, DOI 10.1074/jbc.274.6.3602; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Ramalho AS, 2002, AM J RESP CELL MOL, V27, P619, DOI 10.1165/rcmb.2001-0004OC; RaveHarel N, 1997, AM J HUM GENET, V60, P87; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; RIORDAN JR, 1989, SCIENCE, V245, P1066; Salvatore F, 2002, AM J MED GENET, V111, P88, DOI 10.1002/ajmg.10461; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Sharma M, 2001, J BIOL CHEM, V276, P8942, DOI 10.1074/jbc.M009172200; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Silver DL, 2002, J BIOL CHEM, V277, P34042, DOI 10.1074/jbc.M206584200; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Swiatecka-Urban A, 2002, J BIOL CHEM, V277, P40099, DOI 10.1074/jbc.M206964200; TROJAN J, 1994, P NATL ACAD SCI USA, V91, P6088, DOI 10.1073/pnas.91.13.6088; Voltz JW, 2001, ONCOGENE, V20, P6309, DOI 10.1038/sj.onc.1204774; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; Weinman EJ, 1998, J CLIN INVEST, V101, P2199, DOI 10.1172/JCI204; Weixel KM, 2000, J BIOL CHEM, V275, P3655, DOI 10.1074/jbc.275.5.3655; Zielenski J, 2000, RESPIRATION, V67, P117, DOI 10.1159/000029497	66	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22079	22089		10.1074/jbc.M301030200	http://dx.doi.org/10.1074/jbc.M301030200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12651858	hybrid			2022-12-27	WOS:000183354200096
J	Lara, P; Onate-Sanchez, L; Abraham, Z; Ferrandiz, C; Diaz, I; Carbonero, P; Vicente-Carbajosa, J				Lara, P; Onate-Sanchez, L; Abraham, Z; Ferrandiz, C; Diaz, I; Carbonero, P; Vicente-Carbajosa, J			Synergistic activation of seed storage protein gene expression in Arabidopsis by ABI3 and two bZIPs related to OPAQUE2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSPERM-SPECIFIC EXPRESSION; TRANSCRIPTIONAL ACTIVATOR; GCN4-LIKE MOTIF; B3 DOMAIN; PROMOTER; INTERACTS; ELEMENTS; RECOGNIZES; TARGET; BOX	The expression of many seed storage protein genes in cereals relies on transcription factors of the bZIP class, belonging to the maize OPAQUE2 family. Here, we describe a survey of such factors in the genome of Arabidopsis thaliana, and the characterization of two of them, AtbZIP10 and AtbZIP25. Expression analysis by in situ hybridization shows that the occurrence of their mRNAs in the seed starts from early stages of development, peaks at maturation, and declines later in seed development, matching temporally and spatially those of the seed storage protein genes encoding 2S albumins and cruciferins. Gel mobility shift assays showed that AtbZIP10 and AtbZIP25 bind the ACGT boxes present in At2S and CRU3 promoters. Moreover, using the yeast two-hybrid system we show that AtbZIP10 and AtbZIP25 can interact in vivo with ABI3, an important regulator of gene expression in the seed of Arabidopsis. Transient expression analyses of a reporter gene under the control of the At2S1 promoter in transgenic plants overexpressing ectopically AtbZIP10, AtbZIP25, and ABI3 reveal that none of these factors could activate significantly the reporter gene when expressed individually. However, co-expression of AtbZIP10/25 with ABI3 resulted in a remarkable increase in the activation capacity over the At2S1 promoter, suggesting that they are part of a regulatory complex involved in seed-specific expression. This study shows a common mechanism of ABI3 in regulating different seed-specific genes through combinatorial interactions with particular bZIP proteins and a conserved role of O2-like bZIPs in monocot and dicot species.	ETS Ingn Agron, Lab Bioquim & Biol Mol, Dept Biotecnol UPM, Madrid 28040, Spain		Vicente-Carbajosa, J (corresponding author), ETS Ingn Agron, Lab Bioquim & Biol Mol, Dept Biotecnol UPM, Madrid 28040, Spain.	jvicente@bit.etsia.upm.es	Ferrandiz, Cristina/E-6280-2015; Vicente-Carbajosa, Jesus/A-9368-2008; Oñate-Sánchez, Luis J/C-6274-2017; Diaz, Isabel/I-8840-2014	Ferrandiz, Cristina/0000-0002-2460-1068; Vicente-Carbajosa, Jesus/0000-0002-6332-1712; Oñate-Sánchez, Luis J/0000-0001-7047-5739; Diaz, Isabel/0000-0001-9865-902X				Albani D, 1997, PLANT CELL, V9, P171, DOI 10.1105/tpc.9.2.171; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Bensmihen S, 2002, PLANT CELL, V14, P1391, DOI 10.1105/tpc.000869; Carbonero P, 2000, SEED BIOLOGY: ADVANCES AND APPLICATIONS, P27, DOI 10.1079/9780851994048.0027; Chang JF, 1999, J MOL BIOL, V288, P941, DOI 10.1006/jmbi.1999.2711; Choi HI, 2000, J BIOL CHEM, V275, P1723, DOI 10.1074/jbc.275.3.1723; dePater S, 1996, PLANT MOL BIOL, V32, P515, DOI 10.1007/BF00019103; Diaz I, 2002, PLANT J, V29, P453, DOI 10.1046/j.0960-7412.2001.01230.x; DrogeLaser W, 1997, EMBO J, V16, P726, DOI 10.1093/emboj/16.4.726; Ellerstrom M, 1996, PLANT MOL BIOL, V32, P1019, DOI 10.1007/BF00041385; Ezcurra I, 1999, PLANT MOL BIOL, V40, P699, DOI 10.1023/A:1006206124512; Ezcurra I, 2000, PLANT J, V24, P57, DOI 10.1046/j.1365-313x.2000.00857.x; Ferrandiz C, 2000, DEVELOPMENT, V127, P725; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; GIRAUDAT J, 1992, PLANT CELL, V4, P1251, DOI 10.1105/tpc.4.10.1251; Hill A, 1996, J BIOL CHEM, V271, P3366, DOI 10.1074/jbc.271.7.3366; Hobo T, 1999, P NATL ACAD SCI USA, V96, P15348, DOI 10.1073/pnas.96.26.15348; Hoekstra FA, 2001, TRENDS PLANT SCI, V6, P431, DOI 10.1016/S1360-1385(01)02052-0; HUGHES DW, 1989, GENE DEV, V3, P358, DOI 10.1101/gad.3.3.358; IZAWA T, 1994, PLANT CELL, V6, P1277, DOI 10.1105/tpc.6.9.1277; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; Luerssen K, 1998, PLANT J, V15, P755, DOI 10.1046/j.1365-313X.1998.00259.x; MATZKE AJM, 1990, PLANT MOL BIOL, V14, P323, DOI 10.1007/BF00028769; MCCARTY DR, 1991, CELL, V66, P895, DOI 10.1016/0092-8674(91)90436-3; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; Nakamura S, 2001, PLANT J, V26, P627, DOI 10.1046/j.1365-313x.2001.01069.x; Nesi N, 2001, PLANT CELL, V13, P2099, DOI 10.1105/tpc.13.9.2099; Onate L, 1999, J BIOL CHEM, V274, P9175, DOI 10.1074/jbc.274.14.9175; Onodera Y, 2001, J BIOL CHEM, V276, P14139, DOI 10.1074/jbc.M007405200; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PIROVANO L, 1994, PLANT MOL BIOL, V24, P515, DOI 10.1007/BF00024119; Reidt W, 2000, PLANT J, V21, P401, DOI 10.1046/j.1365-313x.2000.00686.x; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHMIDT RJ, 1992, PLANT CELL, V4, P689, DOI 10.1105/tpc.4.6.689; SCHMIDT RJ, 1990, P NATL ACAD SCI USA, V74, P5463; Schwechheimer C, 1998, TRENDS PLANT SCI, V3, P378, DOI 10.1016/S1360-1385(98)01302-8; Singh KB, 1998, PLANT PHYSIOL, V118, P1111, DOI 10.1104/pp.118.4.1111; Stone SL, 2001, P NATL ACAD SCI USA, V98, P11806, DOI 10.1073/pnas.201413498; Suzuki A, 1998, PLANT CELL PHYSIOL, V39, P555, DOI 10.1093/oxfordjournals.pcp.a029404; Suzuki M, 1997, PLANT CELL, V9, P799, DOI 10.1105/tpc.9.5.799; TAKAIWA F, 1991, PLANT MOL BIOL, V16, P49, DOI 10.1007/BF00017916; Takaiwa F, 1996, PLANT MOL BIOL, V30, P1207, DOI 10.1007/BF00019553; vanderGeest AHM, 1996, PLANT MOL BIOL, V32, P579, DOI 10.1007/BF00020199; Vettore AL, 1998, PLANT MOL BIOL, V36, P249, DOI 10.1023/A:1005995806897; Vicente-Carbajosa J, 1998, PLANT J, V13, P629, DOI 10.1111/j.1365-313X.1998.00068.x; VicenteCarbajosa J, 1997, P NATL ACAD SCI USA, V94, P7685, DOI 10.1073/pnas.94.14.7685; Vincentz M, 1997, PLANT MOL BIOL, V34, P879, DOI 10.1023/A:1005874404706; WEISSHAAR B, 1991, EMBO J, V10, P1777, DOI 10.1002/j.1460-2075.1991.tb07702.x; Wobus U, 1999, CURR OPIN PLANT BIOL, V2, P33, DOI 10.1016/S1369-5266(99)80007-7; YUNES JA, 1994, PLANT CELL, V6, P237, DOI 10.1105/tpc.6.2.237	52	125	154	4	41	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21003	21011		10.1074/jbc.M210538200	http://dx.doi.org/10.1074/jbc.M210538200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657652	Green Accepted, hybrid			2022-12-27	WOS:000183230500073
J	Akbar, MT; Lundberg, AMC; Liu, K; Vidyadaran, S; Wells, KE; Dolatshad, H; Wynn, S; Wells, DJ; Latchman, DS; de Belleroche, J				Akbar, MT; Lundberg, AMC; Liu, K; Vidyadaran, S; Wells, KE; Dolatshad, H; Wynn, S; Wells, DJ; Latchman, DS; de Belleroche, J			The neuroprotective effects of heat shock protein 27 overexpression in transgenic animals against kainate-induced seizures and hippocampal cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL STRESS PROTEINS; KAINIC ACID; NEURONAL CELLS; CYTOCHROME-C; IN-VIVO; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; CARDIAC MYOCYTES; CULTURED NEURONS; GANGLION NEURONS	The 27-kDa heat shock protein (HSP27) has a potent ability to increase cell survival in response to a wide range of cellular challenges. In order to investigate the mode of action of HSP27 in vivo, we have developed transgenic lines, which express human HSP27 at high levels throughout the brain, spinal cord, and other tissues. In view of the particular property of HSP27 compared with other HSPs to protect neurons against apoptosis, we have tested these transgenic lines in a well established in vivo model of neurotoxicity produced by kainic acid, where apoptotic cell death occurs. Our results demonstrate for the first time the marked protective effects of HSP27 overexpression in vivo, which significantly reduces kainate-induced seizure severity and mortality rate (> 50%) in two independent lines and markedly reduces neuronal cell death in the CA3 region of hippocampus. This reduced seizure severity in HSP27 transgenic animals was associated with a marked attenuation of caspase 3 induction and apoptotic features. These studies clearly demonstrate that HSP27 has a major neuroprotective effect in the central nervous system in keeping with its properties demonstrated in culture and highlight an early stage in the cell death pathway that is affected by HSP27.	Charing Cross Hosp, Imperial Coll, Fac Med, Dept Neuromuscular Dis,Div Neurosci & Psychol Med, London W6 8RF, England; UCL, Inst Child Hlth, London WC1N 1EH, England	Imperial College London; University of London; University College London	de Belleroche, J (corresponding author), Charing Cross Hosp, Imperial Coll, Fac Med, Dept Neuromuscular Dis,Div Neurosci & Psychol Med, Fulham Palace Rd, London W6 8RF, England.	j.belleroche@imperial.ac.uk	Vidyadaran, Sharmili/S-9616-2019	Dolatshad, Hamid/0000-0002-4724-1720; Wells, Dominic/0000-0002-1425-6344				Akbar MT, 2001, MOL BRAIN RES, V93, P148, DOI 10.1016/S0169-328X(01)00199-1; Amin V, 1996, NEUROSCI LETT, V206, P45, DOI 10.1016/0304-3940(96)12421-6; AMIN V, 1995, NEUROSCI LETT, V200, P85, DOI 10.1016/0304-3940(95)12074-E; Becker AJ, 1999, MOL BRAIN RES, V67, P172, DOI 10.1016/S0169-328X(99)00060-1; BENARI Y, 1985, NEUROSCIENCE, V14, P375, DOI 10.1016/0306-4522(85)90299-4; Bengzon J, 1997, P NATL ACAD SCI USA, V94, P10432, DOI 10.1073/pnas.94.19.10432; Benjamin IJ, 1998, CIRC RES, V83, P117, DOI 10.1161/01.RES.83.2.117; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Brar BK, 1999, J MOL CELL CARDIOL, V31, P135, DOI 10.1006/jmcc.1998.0857; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; CARPER SW, 1990, NUCLEIC ACIDS RES, V18, P6457, DOI 10.1093/nar/18.21.6457; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chen ZG, 2002, BRAIN RES, V931, P135, DOI 10.1016/S0006-8993(02)02268-0; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cumming DVE, 1996, BASIC RES CARDIOL, V91, P79; Cumming DVE, 1996, J MOL CELL CARDIOL, V28, P2343, DOI 10.1006/jmcc.1996.0227; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Feder ME, 1999, ANNU REV PHYSIOL, V61, P243, DOI 10.1146/annurev.physiol.61.1.243; FROHLI E, 1993, GENE, V128, P273, DOI 10.1016/0378-1119(93)90574-M; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; HEADS RJ, 1995, J MOL CELL CARDIOL, V27, P1669, DOI 10.1016/S0022-2828(95)90722-X; Hu RQ, 1998, BRAIN RES, V810, P229, DOI 10.1016/S0006-8993(98)00863-4; Hutter JJ, 1996, CIRCULATION, V94, P1408, DOI 10.1161/01.CIR.94.6.1408; Juan TSC, 1996, ONCOGENE, V13, P749; Kaasinen K, 2000, EUR J NEUROSCI, V12, P540, DOI 10.1046/j.1460-9568.2000.00940.x; Kalwy SA, 2003, MOL BRAIN RES, V111, P91, DOI 10.1016/S0169-328X(02)00692-7; Kitamura Y, 1998, NEUROSCI LETT, V255, P57, DOI 10.1016/S0304-3940(98)00714-9; Lee JE, 2001, EXP NEUROL, V170, P129, DOI 10.1006/exnr.2000.7614; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MAILHOS C, 1993, NEUROSCIENCE, V55, P621, DOI 10.1016/0306-4522(93)90428-I; MAILHOS C, 1994, J NEUROCHEM, V63, P1787; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; Martin JL, 1997, CIRCULATION, V96, P4343; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pandey P, 2000, ONCOGENE, V19, P1975, DOI 10.1038/sj.onc.1203531; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; Paxinos G., 2001, MOUSE BRAIN STEREOTA; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; Puig B, 2002, NEUROSCI LETT, V321, P182, DOI 10.1016/S0304-3940(01)02518-6; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.0.CO;2-3; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; Royle SJ, 1999, BRAIN RES, V816, P337, DOI 10.1016/S0006-8993(98)01122-6; Samali A, 1996, EXP CELL RES, V223, P163, DOI 10.1006/excr.1996.0070; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; Sharp FR, 1999, TRENDS NEUROSCI, V22, P97, DOI 10.1016/S0166-2236(98)01392-7; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; UNEY JB, 1993, FEBS LETT, V334, P313, DOI 10.1016/0014-5793(93)80701-U; Wagstaff MJD, 1996, MOL BRAIN RES, V42, P236, DOI 10.1016/S0169-328X(96)00127-1; Wagstaff MJD, 1999, J BIOL CHEM, V274, P5061, DOI 10.1074/jbc.274.8.5061; Wyatt S, 1996, MOL BRAIN RES, V39, P52, DOI 10.1016/0169-328X(95)00352-S; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yenari MA, 1999, MOL MED TODAY, V5, P525, DOI 10.1016/S1357-4310(99)01599-3; Zhang JH, 2001, BIOCHEM BIOPH RES CO, V285, P1143, DOI 10.1006/bbrc.2001.5313	63	127	140	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19956	19965		10.1074/jbc.M207073200	http://dx.doi.org/10.1074/jbc.M207073200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639970	hybrid			2022-12-27	WOS:000183078000051
J	Cheema, SK; Mishra, SK; Rangnekar, VM; Tari, AM; Kumar, R; Lopez-Berestein, G				Cheema, SK; Mishra, SK; Rangnekar, VM; Tari, AM; Kumar, R; Lopez-Berestein, G			Par-4 transcriptionally regulates bcl-2 through a WT1-binding site on the bcl-2 promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDEPENDENT PROSTATE-CANCER; TUMOR-SUPPRESSOR WT1; T(14-18) LYMPHOMAS; PROTEIN PAR-4; CREB PROTEINS; RETINOIC ACID; B-CELLS; APOPTOSIS; GENE; EXPRESSION	Elevated expression levels of the bcl-2 proto-oncogene have been extensively correlated with the appearance of androgen independence in prostate cancer. Although bcl-2 was first cloned as the t(14:18) translocation breakpoint from human follicular B cell lymphoma, the mechanism of overexpression of bcl-2 is largely undefined for advanced prostate cancer because there are no gross alterations in the gene structure. We investigated the role of the product of the prostate apoptosis response gene-4 (Par-4) and the product of the Wilms' tumor 1 gene (WT1) in the regulation of Bcl-2 expression in prostate cancer cell lines. We observed growth arrest and apoptosis, upon decreasing Bcl-2 protein and transcript in the high Bcl-2-expressing, androgen-independent prostate cancer cell line, by all-trans-retinoic acid treatment (ATRA), but this did not occur in the androgen-dependent cell line expressing low levels of Bcl-2. The decrease in the Bcl-2 protein and transcript following all-trans-retinoic acid treatment was accompanied by changes in localization of Par-4 and an induction in the expression of WT1 protein. In stable clones expressing ectopic Par-4 and in ATRA-treated cells, we observed decreased Bcl-2 protein and transcript. This was accompanied by an induction in WT1 expression. The involvement of WT1 in the Par-4-mediated down-modulation of Bcl-2 was further defined by blocking endogenous WT1 expression, which resulted in an increase in Bcl-2 expression. Finally, we detected Par-4 and WT1 proteins binding to a previously identified WT1-binding site on the bcl-2 promoter both in vitro and in vivo leading to a decrease in transcription from the bcl-2 promoter. We conclude that Par-4 regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. These data also identify Par-4 nuclear localization as a novel mechanism for ATRA-mediated bcl-2 regulation.	Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carrier, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Kentucky, Dept Radiat Med, Lexington, KY 40536 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Kentucky	Lopez-Berestein, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Bioimmunotherapy, Sect Immunobiol & Drug Carrier, Box 422,1515 Holcombe Blvd, Houston, TX 77030 USA.			Mishra, Sandip/0000-0002-0776-6581				Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Boehrer S, 2001, Hematol J, V2, P103, DOI 10.1038/sj.thj.6200089; Boehrer S, 2002, CANCER RES, V62, P1768; Boghaert ER, 1997, CELL GROWTH DIFFER, V8, P881; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; COLOMBEL M, 1993, AM J PATHOL, V143, P390; DE LUCA LM, 1991, FASEB J, V5, P2924; DiazMeco MT, 1996, CELL, V86, P777, DOI 10.1016/S0092-8674(00)80152-X; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; Hall AK, 1996, ANTI-CANCER DRUG, V7, P312, DOI 10.1097/00001813-199605000-00012; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; HEWITT SM, 1995, CANCER RES, V55, P5386; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Johnstone RW, 1996, MOL CELL BIOL, V16, P6945; Kallakury BVS, 1996, MODERN PATHOL, V9, P41; Kyprianou N, 2000, HISTOL HISTOPATHOL, V15, P1211, DOI 10.14670/HH-15.1211; Lara PN, 1999, CANCER INVEST, V17, P137; Mayo MW, 1999, EMBO J, V18, P3990, DOI 10.1093/emboj/18.14.3990; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; Mishra SK, 2001, FEBS LETT, V507, P88, DOI 10.1016/S0014-5793(01)02951-9; Miyake H, 1999, CANCER RES, V59, P4030; Oh WK, 1999, J CLIN ONCOL, V17, P3664, DOI 10.1200/JCO.1999.17.11.3664; Page G, 1999, ONCOGENE, V18, P7265, DOI 10.1038/sj.onc.1203170; Pasquali D, 1996, J CLIN ENDOCR METAB, V81, P2186, DOI 10.1210/jc.81.6.2186; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; Qiu GF, 1999, ONCOGENE, V18, P623, DOI 10.1038/sj.onc.1202344; RAFFO AJ, 1995, CANCER RES, V55, P4438; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; REED JC, 1991, CANCER RES, V51, P6529; Richard DJ, 2001, GENE DEV, V15, P328, DOI 10.1101/gad.185901; Sells SF, 1997, MOL CELL BIOL, V17, P3823, DOI 10.1128/MCB.17.7.3823; SELLS SF, 1994, CELL GROWTH DIFFER, V5, P457; Smith MD, 1998, J BIOL CHEM, V273, P16715, DOI 10.1074/jbc.273.27.16715; Strasser A, 1997, BIOCHIM BIOPHYS ACTA, V1333, P151; Sundaresan A, 1997, CELL GROWTH DIFFER, V8, P1071; Tari AM, 2000, METHOD ENZYMOL, V313, P372; Trump DL, 1997, CANCER CHEMOTH PHARM, V39, P349, DOI 10.1007/s002800050582; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WERNER H, 1994, J BIOL CHEM, V269, P12577; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	49	94	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19995	20005		10.1074/jbc.M205865200	http://dx.doi.org/10.1074/jbc.M205865200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644474	hybrid			2022-12-27	WOS:000183078000056
J	Sawhney, RS; Sharma, B; Humphrey, LE; Brattain, MG				Sawhney, RS; Sharma, B; Humphrey, LE; Brattain, MG			Integrin alpha(2) and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-alpha-driven colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; MAMMALIAN-CELLS; ANIMAL-MODEL; REAL-TIME; EXPRESSION; CARCINOMA; RECEPTOR; CASCADE	Recently, we have shown that autocrine transforming growth factor-alpha (TGF-alpha) controls the expression of integrin alpha(2), cell adhesion to collagen IV and motility in highly progressed HCT116 colon cancer cells (Sawhney, R. S., Zhou, G-H. K., Humphrey, L. E., Ghosh, P., Kreisberg, J. I., and Brattain, M. G. (2002) J. Biol. Chem. 277, 75-86). We now report that expression of basal integrin alpha(2) and its biological effects are controlled by constitutive activation of the extracellular signal-regulated/mitogen-activated protein kinase (ERK/MAPK) pathway. Treatment of cells with selective mitogen-activated protein kinase kinase (MEK) inhibitors PD098059 and U0126 showed that integrin alpha(2) expression, cell adhesion, and activation of ERK are inhibited in a parallel concentration-dependent fashion. Moreover, autocrine TGF-alpha-mediated epidermal growth factor receptor activation was shown to control the constitutive activation of the ERK/MAPK pathway, since neutralizing antibody to the epidermal growth factor receptor was able to block basal ERK activity. TGF-alpha antisense-transfected cells also showed attenuated activation of ERK. Using a real time electric cell impedance sensing technique, it was shown that ERK-dependent integrin alpha(2)-mediated cell micromotion signaling is controlled by autocrine TGF-alpha. Thus, this study implicates ERK/MAPK signaling activated by endogenous TGF-alpha as one of the mechanistic features controlling metastatic spread.	Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Brattain, MG (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	michael.brattain@roswellpark.org		Sharma, Bhavya/0000-0003-4388-5702	NCI NIH HHS [CA 54807] Funding Source: Medline; PHS HHS [50457, 34432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRATTAIN MG, 1981, CANCER RES, V41, P1751; BRESALIER RS, 1987, INT J CANCER, V39, P625, DOI 10.1002/ijc.2910390514; BRESALIER RS, 1987, CANCER RES, V47, P1398; CARMICHAEL J, 1987, CANCER RES, V47, P936; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN JD, 1993, EXP CELL RES, V209, P216, DOI 10.1006/excr.1993.1304; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; Ho WC, 1997, MOL BIOL CELL, V8, P1863, DOI 10.1091/mbc.8.10.1863; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; Jiang DH, 1998, J CELL PHYSIOL, V175, P174, DOI 10.1002/(SICI)1097-4652(199805)175:2<174::AID-JCP7>3.3.CO;2-E; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200; LEE DC, 1995, PHARMACOL REV, V47, P51; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; Martin-Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521-1878(200007)22:7<637::AID-BIES6>3.0.CO;2-E; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Reddy L, 1998, EXP CELL RES, V245, P360, DOI 10.1006/excr.1998.4273; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Rigot V, 1998, J CELL SCI, V111, P3119; Sawhney RS, 2002, J BIOL CHEM, V277, P75, DOI 10.1074/jbc.M103268200; SCHLAEPFER DD, 1994, NATURE, V372, P786; SUN LZ, 1994, BIOCH MOL ASPECTS SE, V2, P495; Terada K, 1997, J BIOL CHEM, V272, P4544, DOI 10.1074/jbc.272.7.4544; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Venkateswarlu S, 2002, ONCOGENE, V21, P78, DOI 10.1038/sj.onc.1205011; Wegener J, 2000, EXP CELL RES, V259, P158, DOI 10.1006/excr.2000.4919; Wells A, 2000, ADV CANCER RES, V78, P31; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513; Zutter MM, 1999, BLOOD, V93, P1600, DOI 10.1182/blood.V93.5.1600.405k04_1600_1611	44	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19861	19869		10.1074/jbc.M213162200	http://dx.doi.org/10.1074/jbc.M213162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657625	hybrid			2022-12-27	WOS:000183078000038
J	Shim, M; Smart, RC				Shim, M; Smart, RC			Lithium stabilizes the CCAAT/enhancer-binding protein alpha (C/EBP alpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PROLIFERATION; GRANULOCYTIC DIFFERENTIATION; ADIPOCYTE DIFFERENTIATION; MYELOID-LEUKEMIA; IN-VIVO; EXPRESSION; TRANSCRIPTION; FAMILY; BETA; MICE	CCAAT/enhancer-binding protein alpha (C/EBPalpha), a basic leucine zipper transcription factor, is involved in mitotic growth arrest and differentiation. Given that numerous proteins involved in cell cycle regulation are degraded via the ubiquitin-proteasome system, we examined whether the C/EBPalpha protein is degraded via a proteasomal mechanism. In cycloheximide-treated BALB/MK2 keratinocytes we found that C/EBPalpha is a short-lived protein with a half-life of similar to1 h. Treatment with proteasome inhibitors, MG-132 or lactacystin, blocked the degradation of the C/EBPalpha protein. Higher molecular weight species of ubiquitinated C/EBPalpha were detected in BALB/MK2, and in vitro studies confirmed that C/EBPalpha is degraded by the proteasome in an ATP- and ubiquitin-dependent manner. GSK3 is a known C/EBPalpha kinase and treatment of keratinocytes with LiCl, an inhibitor of GSK3 resulted in: (i) a 5-fold increase in C/EBPalpha protein levels, (ii) increased electrophoretic mobility of C/EBPalpha, and (iii) no increase in C/EBPalpha mRNA levels suggesting that GSK3-mediated phosphorylation of C/EBPalpha may target it for proteasomal degradation. However, a mutant C/EBPalpha containing T to A mutations in the GSK3 phosphorylation sites (T222A and T226A) retained its response to LiCl, and additional pharmacological inhibitors of GSK3 did not alter C/EBPalpha levels indicating the effects of LiCl on C/EBPalpha are GSK3-independent. LiCl treatment of BALB/ MK2 cells inhibited C/EBPalpha degradation and produced a 6-fold increase in the half-life of C/EBPalpha protein. In vitro studies revealed that LiCl inhibited proteasome activity and the ensuing degradation of C/EBPalpha. These results demonstrate C/EBPalpha is degraded via a ubiquitin-dependent proteasomal pathway, and LiCl stabilizes C/EBPalpha through a GSK3-independent pathway involving direct inhibition of proteasome activity.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.			Smart, Robert/0000-0002-6767-6756	NCI NIH HHS [CA 46637] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046637, R29CA046637] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Diehl AM, 1996, J BIOL CHEM, V271, P7343, DOI 10.1074/jbc.271.13.7343; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Maki CG, 1996, CANCER RES, V56, P2649; Mao CD, 2001, J BIOL CHEM, V276, P26180, DOI 10.1074/jbc.M101188200; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Radomska HS, 1998, MOL CELL BIOL, V18, P4301, DOI 10.1128/MCB.18.7.4301; Rice AM, 2001, J BIOL CHEM, V276, P42722, DOI 10.1074/jbc.M106583200; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1999, MOL CELL BIOL, V19, P2936; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	42	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19674	19681		10.1074/jbc.M301356200	http://dx.doi.org/10.1074/jbc.M301356200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668682	hybrid			2022-12-27	WOS:000183078000016
J	Gaillard, H; Fitzgerald, DJ; Smith, CL; Peterson, CL; Richmond, TJ; Thoma, F				Gaillard, H; Fitzgerald, DJ; Smith, CL; Peterson, CL; Richmond, TJ; Thoma, F			Chromatin remodeling activities act on UV-damaged nucleosomes and modulate DNA damage accessibility to photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; YEAST SWI/SNF COMPLEX; RIBOSOMAL-RNA GENE; SACCHAROMYCES-CEREVISIAE; HISTONE OCTAMER; IN-VITRO; POSITIONED NUCLEOSOME; NONTRANSCRIBED STRAND; PYRIMIDINE DIMERS; CRYSTAL-STRUCTURE	Nucleosomes inhibit DNA repair in vitro, suggesting that chromatin remodeling activities might be required for efficient repair in vivo. To investigate how structural and dynamic properties of nucleosomes affect damage recognition and processing, we investigated repair of UV lesions by photolyase on a nucleosome positioned at one end of a 226-bp-long DNA fragment. Repair was slow in the nucleosome but efficient outside. No disruption or movement of the nucleosome was observed after UV irradiation and during repair. However, incubation with the nucleosome remodeling complex SWI/SNF and ATP altered the conformation of nucleosomal DNA as judged by UV photo-footprinting and promoted more homogeneous repair. Incubation with yISW2 and ATP moved the nucleosome to a more central position, thereby altering the repair pattern. This is the first demonstration that two different chromatin remodeling complexes can act on UV-damaged nucleosomes and modulate repair. Similar activities might relieve the inhibitory effect of nucleosomes on DNA repair processes in living cells.	ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland; ETH Honggerberg, Inst Mol Biol, Dept Biol, CH-8093 Zurich, Switzerland; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Massachusetts System; University of Massachusetts Worcester	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland.		Gaillard, Helene/M-2914-2014	Gaillard, Helene/0000-0002-5740-0641; Smith, Corey/0000-0002-9716-2545	NIGMS NIH HHS [R37 GM049650, R01 GM049650] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049650, R01GM049650] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexiadis V, 2002, GENE DEV, V16, P2767, DOI 10.1101/gad.1032102; Araki M, 2000, MUTAT RES-DNA REPAIR, V459, P147, DOI 10.1016/S0921-8777(99)00067-1; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Eberharter A, 2001, EMBO J, V20, P3781, DOI 10.1093/emboj/20.14.3781; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; GALE JM, 1987, P NATL ACAD SCI USA, V84, P6644, DOI 10.1073/pnas.84.19.6644; GALE JM, 1988, J MOL BIOL, V204, P949, DOI 10.1016/0022-2836(88)90054-X; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; Guzder SN, 1998, J BIOL CHEM, V273, P6292, DOI 10.1074/jbc.273.11.6292; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Kassabov SR, 2002, MOL CELL BIOL, V22, P7524, DOI 10.1128/MCB.22.21.7524-7534.2002; Kent NA, 2001, GENE DEV, V15, P619, DOI 10.1101/gad.190301; Kosmoski JV, 2001, P NATL ACAD SCI USA, V98, P10113, DOI 10.1073/pnas.181073398; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; Langst G, 2001, J CELL SCI, V114, P2561; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Liu XQ, 2000, BIOCHEMISTRY-US, V39, P557, DOI 10.1021/bi991771m; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; LOSA R, 1990, NUCLEIC ACIDS RES, V18, P3495, DOI 10.1093/nar/18.12.3495; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LYAMICHEV V, 1991, NUCLEIC ACIDS RES, V19, P4491, DOI 10.1093/nar/19.16.4491; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; MATSUMOTO H, 1994, PHOTOCHEM PHOTOBIOL, V60, P134, DOI 10.1111/j.1751-1097.1994.tb05079.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; Park H, 2002, P NATL ACAD SCI USA, V99, P15965, DOI 10.1073/pnas.242422699; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Peterson CL, 2000, FEBS LETT, V476, P68, DOI 10.1016/S0014-5793(00)01673-2; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; Schieferstein U, 1996, BIOCHEMISTRY-US, V35, P7705, DOI 10.1021/bi953011r; Sengupta SM, 2001, J BIOL CHEM, V276, P12636, DOI 10.1074/jbc.M010470200; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 2002, J MOL BIOL, V319, P395, DOI 10.1016/S0022-2836(02)00291-7; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Vande Berg BJ, 1998, J BIOL CHEM, V273, P20276, DOI 10.1074/jbc.273.32.20276; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; WANG ZG, 1991, J BIOL CHEM, V266, P22472; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285	65	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17655	17663		10.1074/jbc.M300770200	http://dx.doi.org/10.1074/jbc.M300770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637512	hybrid			2022-12-27	WOS:000182838300011
J	Ha, N; Ceryak, S; Patierno, SR				Ha, N; Ceryak, S; Patierno, SR			Chromium (VI) activates ataxia telangiectasia mutated (ATM) protein - Requirement of ATM for both apoptosis and recovery from terminal growth arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-DAMAGE; IONIZING-RADIATION; OXIDATIVE STRESS; CROSS-LINKS; HUMAN LUNG; DEREGULATED APOPTOSIS; MEDIATED REACTIONS; HUMAN FIBROBLASTS; STRAND BREAKS	The ataxia telangiectasia mutated (ATM) protein plays a central role in early stages of DNA double strand break (DSB) detection and controls cellular responses to this damage. Although hypersensitive to ionizing radiation-induced clonogenic lethality, ataxia telangiectasia cells are paradoxically deficient in their ability to undergo ionizing radiation-induced apoptosis. This contradiction illustrates the complexity of the central role of ATM in DNA damage response and the need for further understanding. Certain hexavalent chromium (Cr(VI)) compounds are implicated as occupational respiratory carcinogens at doses that are both genotoxic and cytotoxic. Cr(VI) induces a broad spectrum of DNA damage, but Cr(VI)-induced DSBs have not been reported. Here, we examined the role of ATM in the cellular response to Cr(VI) and found that Cr(VI) activates ATM. We also show that physiological targets of ATM, p53 Ser-15 and Chk2 Thr-68, were phosphorylated by Cr(VI) exposure in an ATM-dependent fashion. We found that ATM-/- cells were markedly resistant to Cr(VI)induced apoptosis but considerably more sensitive to Cr(VI)-induced clonogenic lethality than wild type cells, indicating that resistance to Cr(VI)-induced apoptosis did not confer a selective survival advantage. However, analysis of long term growth arrest revealed a striking difference: ATM-/- cells were markedly less able to recover from Cr(VI)-induced growth arrest. This indicates that terminal growth arrest is the fate of these apoptosis-resistant cells. In summary, ATM is involved in cellular response to a complex genotoxin that may not directly induce DSBs. Our data suggest that ATM is a major signal initiator for genotoxin-induced apoptosis but, paradoxically, also contributes to maintenance of cell survival by facilitating recovery/escape from terminal growth arrest. The results also strongly suggest that terminal growth arrest is not merely an extended or even irreversible form of checkpoint arrest, but instead an independent and unique cell fate pathway.	George Washington Univ, Med Ctr, Dept Pharmacol, Program Mol & Cellular Oncol, Washington, DC 20037 USA	George Washington University	Patierno, SR (corresponding author), George Washington Univ, Med Ctr, Dept Pharmacol, Program Mol & Cellular Oncol, 2300 I St NW, Washington, DC 20037 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009961] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05304, ES09961] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adamson AW, 2002, J BIOL CHEM, V277, P38222, DOI 10.1074/jbc.M204409200; Bagchi D, 2001, MOL CELL BIOCHEM, V222, P149, DOI 10.1023/A:1017958028256; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BRIDGEWATER LC, 1994, CARCINOGENESIS, V15, P2421, DOI 10.1093/carcin/15.11.2421; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANTONI O, 1984, CARCINOGENESIS, V5, P1207, DOI 10.1093/carcin/5.9.1207; Carlisle DL, 2000, MOL CARCINOGEN, V28, P111, DOI 10.1002/1098-2744(200006)28:2<111::AID-MC7>3.0.CO;2-Y; Carlisle DL, 2000, TOXICOL SCI, V55, P60, DOI 10.1093/toxsci/55.1.60; CERYAK S, 2003, IN PRESS MOL CELL BI; Duchaud E, 1996, CANCER RES, V56, P1400; Enns L, 1998, RADIAT RES, V150, P11, DOI 10.2307/3579639; Gadbois DM, 1997, CANCER RES, V57, P3174; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; Helleday T, 2000, ENVIRON MOL MUTAGEN, V35, P114, DOI 10.1002/(SICI)1098-2280(2000)35:2<114::AID-EM6>3.0.CO;2-Q; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Krepkiy D, 2001, MOL CELL BIOCHEM, V222, P213, DOI 10.1023/A:1017982717778; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Liu KJ, 2001, MOL CELL BIOCHEM, V222, P221, DOI 10.1023/A:1017938918686; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Miyakoda M, 2002, ONCOGENE, V21, P1090, DOI 10.1038/sj.onc.1205196; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; O'Brien TJ, 2002, DNA REPAIR, V1, P617, DOI 10.1016/S1568-7864(02)00078-2; Pritchard DE, 2001, CELL GROWTH DIFFER, V12, P487; Qian Y, 2001, MOL CELL BIOCHEM, V222, P199, DOI 10.1023/A:1017926531890; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shackelford RE, 2001, J BIOL CHEM, V276, P21951, DOI 10.1074/jbc.M011303200; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Singh J, 1998, TOXICOL SCI, V45, P72; Singh J, 1998, TOXICOL SCI, V46, P260, DOI 10.1093/toxsci/46.2.260; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vit JP, 2000, INT J RADIAT BIOL, V76, P841, DOI 10.1080/09553000050029002; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; XU J, 1994, CARCINOGENESIS, V15, P1443, DOI 10.1093/carcin/15.7.1443; Xu J, 1996, CARCINOGENESIS, V17, P1511, DOI 10.1093/carcin/17.7.1511; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Ye JP, 1999, J BIOL CHEM, V274, P34974, DOI 10.1074/jbc.274.49.34974; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang Z, 2001, MOL CELL BIOCHEM, V222, P77, DOI 10.1023/A:1017963307358	57	56	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17885	17894		10.1074/jbc.M210560200	http://dx.doi.org/10.1074/jbc.M210560200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637545	hybrid			2022-12-27	WOS:000182838300038
J	Jang, IH; Lee, S; Park, JB; Kim, JH; Lee, CS; Hur, EM; Kim, IS; Kim, KT; Yagisawa, H; Suh, PG; Ryu, SH				Jang, IH; Lee, S; Park, JB; Kim, JH; Lee, CS; Hur, EM; Kim, IS; Kim, KT; Yagisawa, H; Suh, PG; Ryu, SH			The direct interaction of phospholipase C-gamma 1 with phospholipase D2 is important for epidermal growth factor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RECEPTOR TYROSINE KINASE; SRC HOMOLOGY DOMAINS; PHOSPHATIDIC-ACID; SH3 DOMAIN; MEMBRANE DOMAINS; PLASMA-MEMBRANE; EGF RECEPTOR; PX DOMAINS; D ISOZYMES	The epidermal growth factor (EGF) receptor has an important role in cellular proliferation, and the enzymatic activity of phospholipase C (PLC)-gamma1 is regarded to be critical for EGF-induced mitogenesis. In this study, we report for the first time a phospholipase complex composed of PLC-gamma1 and phospholipase D2 (PLD2). PLC-gamma1 is co-immunoprecipitated with PLD2 in COS-7 cells. The results of in vitro binding analysis and co-immunoprecipitation analysis in COS-7 cells show that the Src homology (SH) 3 domain of PLC-gamma1 binds to the proline-rich motif within the Phox homology (PX) domain of PLD2. The interaction between PLC-gamma1 and PLD2 is EGF stimulation-dependent and potentiates EGF-induced inositol 1,4,5-trisphosphate (IP3) formation and Ca2+ increase. Mutating Pro-145 and Pro-148 within the PX domain of PLD2 to leucines disrupts the interaction between PLC-gamma1 and PLD2 and fails to potentiate EGF-induced IP3 formation and Ca2+ increase. However, neither PLD2 wild type nor PLD2 mutant affects the EGF-induced tyrosine phosphorylation of PLC-gamma1. These findings suggest that, upon EGF stimulation, PLC-gamma1 directly interacts with PLD2 and this interaction is important for PLC-gamma1 activity.	Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea; Himeji Inst Technol, Dept Life Sci, Himeji, Hyogo 6781297, Japan	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); University of Hyogo	Ryu, SH (corresponding author), Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea.		Suh, Pann-Ghill/F-3610-2010; Hur, Eun Mi/AAU-4906-2021; Yagisawa, Hitoshi/C-9305-2012	Yagisawa, Hitoshi/0000-0002-5365-4513; Jang, Il Ho/0000-0002-0820-3035; Ryu, Sung Ho/0000-0003-0913-3048; KIM, KYONG-TAI/0000-0001-7292-2627				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; Bae SS, 1998, J NEUROCHEM, V71, P178; Bae YS, 1998, J BIOL CHEM, V273, P4465, DOI 10.1074/jbc.273.8.4465; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; CHALLISS RAJ, 1990, BIOCHEM J, V265, P421, DOI 10.1042/bj2650421; Chang JS, 1997, CANCER RES, V57, P5465; Chattopadhyay A, 1999, J BIOL CHEM, V274, P26091, DOI 10.1074/jbc.274.37.26091; Ciardiello F, 2000, DRUGS, V60, P25, DOI 10.2165/00003495-200060001-00003; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Cross MJ, 1996, CURR BIOL, V6, P588, DOI 10.1016/S0960-9822(02)00545-6; Czarny M, 1999, J BIOL CHEM, V274, P2717, DOI 10.1074/jbc.274.5.2717; DANNIEL LW, 1999, BIOCHIM BIOPHYS ACTA, V1439, P265; DeBell KE, 1999, MOL CELL BIOL, V19, P7388; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GERGEL JR, 1994, BIOCHEMISTRY-US, V33, P14671, DOI 10.1021/bi00253a004; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hess JA, 1998, J BIOL CHEM, V273, P20517, DOI 10.1074/jbc.273.32.20517; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; Jones D, 1999, BBA-MOL CELL BIOL L, V1439, P229, DOI 10.1016/S1388-1981(99)00097-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim JH, 1999, J IMMUNOL, V163, P5462; Kim MJ, 2000, BIOCHEMISTRY-US, V39, P8674, DOI 10.1021/bi992558t; KIM UH, 1990, FEBS LETT, V270, P33, DOI 10.1016/0014-5793(90)81228-G; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee S, 2002, J BIOL CHEM, V277, P6542, DOI 10.1074/jbc.M108047200; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; MARTIN TFJ, 1991, PHARMACOL THERAPEUT, V49, P329, DOI 10.1016/0163-7258(91)90062-Q; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; NOH DY, 1994, CANCER, V73, P36, DOI 10.1002/1097-0142(19940101)73:1<36::AID-CNCR2820730108>3.0.CO;2-5; Pei ZD, 1998, FEBS LETT, V423, P53, DOI 10.1016/S0014-5793(98)00063-5; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1991, TRENDS BIOCHEM SCI, V16, P297, DOI 10.1016/0968-0004(91)90122-C; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Sciorra VA, 1999, EMBO J, V18, P5911, DOI 10.1093/emboj/18.21.5911; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Suh BC, 1999, BRIT J PHARMACOL, V126, P399, DOI 10.1038/sj.bjp.0702248; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Wang ZX, 1998, MOL CELL BIOL, V18, P590, DOI 10.1128/MCB.18.1.590; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Yu H, 1998, EXP CELL RES, V243, P113, DOI 10.1006/excr.1998.4132; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	70	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18184	18190		10.1074/jbc.M208438200	http://dx.doi.org/10.1074/jbc.M208438200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646582	hybrid, Green Published			2022-12-27	WOS:000182838300078
J	Komarova, EA; Neznanov, N; Komarov, PG; Chernov, MV; Wang, KH; Gudkov, AV				Komarova, EA; Neznanov, N; Komarov, PG; Chernov, MV; Wang, KH; Gudkov, AV			p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; TRANSCRIPTION FACTORS; RECEPTOR; HEAT-SHOCK-PROTEIN-70; ACTIVATION; THYMOCYTES; ELEMENTS; NEURONS; STRESS; CELLS	Pifithrin alpha (PFTalpha) is a chemical compound isolated for its ability to suppress p53-mediated transactivation. It can protect cells from p53-mediated apoptosis induced by various stimuli and reduce sensitivity of mice to gamma radiation. Identification of molecular targets of PFTalpha is likely to provide new insights into mechanisms of regulation of p53 pathway and is important for predicting potential risks associated with administration of PFTalpha-like p53 inhibitors in vivo. We found that PFTalpha, in addition to p53, can suppress heat shock and glucocorticoid receptor signaling but has no effect on nuclear factor-kappaB signaling. PFTalpha reduces activation of heat shock transcription factor (HSF1) and increases cell sensitivity to heat. Moreover, it reduces activation of glucocorticoid receptor and rescues mouse thymocytes in vitro and in vivo from apoptotic death after dexamethasone treatment. PFTalpha affected both signaling pathways in a p53-independent manner. These observations suggest that PFTalpha targets some unknowm factor that is common for three major signal transduction pathways.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Virol, Cleveland, OH 44195 USA; Quark Biotech Inc, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	gudkov@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NCI NIH HHS [CA 17579] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEERE HM, 2001, SCI STKE; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen YC, 1999, PHOTOCHEM PHOTOBIOL, V70, P78, DOI 10.1111/j.1751-1097.1999.tb01952.x; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Gordon SA, 1997, ARCH SURG-CHICAGO, V132, P1277; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Jakubowicz-Gil J, 2002, BIOCHEM PHARMACOL, V64, P1591, DOI 10.1016/S0006-2952(02)01356-4; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Komarova EA, 2001, BIOCHEM PHARMACOL, V62, P657, DOI 10.1016/S0006-2952(01)00733-X; Komarova EA, 1998, SEMIN CANCER BIOL, V8, P389, DOI 10.1006/scbi.1998.0101; Kondratov RV, 1996, MOL BIOL+, V30, P363; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Morimoto R I, 1996, EXS, V77, P139; Nakanoma T, 2001, INT J UROL, V8, P623, DOI 10.1046/j.1442-2042.2001.00389.x; Natoli G, 1998, J BIOL CHEM, V273, P31262, DOI 10.1074/jbc.273.47.31262; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; TRUSS M, 1991, MOL CELL BIOL, V11, P3247, DOI 10.1128/MCB.11.6.3247; WILLIAMS GT, 1990, MOL CELL BIOL, V10, P3125, DOI 10.1128/MCB.10.6.3125; Winoto A, 2002, CELL, V109, pS57, DOI 10.1016/S0092-8674(02)00710-9; Zhu XX, 2002, J MED CHEM, V45, P5090, DOI 10.1021/jm020044d	27	98	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 2	2003	278	18					15465	15468		10.1074/jbc.C300011200	http://dx.doi.org/10.1074/jbc.C300011200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	675EL	12637507	hybrid			2022-12-27	WOS:000182680000003
J	Gianni, D; Zambrano, N; Bimonte, M; Minopoli, G; Mercken, L; Talamo, F; Scaloni, A; Russo, T				Gianni, D; Zambrano, N; Bimonte, M; Minopoli, G; Mercken, L; Talamo, F; Scaloni, A; Russo, T			Platelet-derived growth factor induces the beta-gamma-secretase-mediated cleavage of Alzheimer's amyloid precursor protein through a Src-Rac-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; C-SRC; TYROSINE KINASE; INTRACELLULAR DOMAIN; MEMBRANE COMPARTMENT; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; RHO GTPASES; FE65; ACTIVATION	The beta-amyloid peptide (Abeta) present in the senile plaques of Alzheimer's disease derives from the cleavage of a membrane protein, named APP, driven by two enzymes, known as beta- and gamma-secretases. The mechanisms regulating this cleavage are not understood. We have developed an experimental system to identify possible extracellular signals able to trigger the cleavage of an APP-GaI4 fusion protein, which is detected by measuring the expression of the CAT gene transcribed under the control of the Gal4 transcription factor, which is released from the membrane upon the cleavage of APP-Gal4. By using this assay, we purified a protein contained in the C6 cell-conditioned medium, which activates the cleavage of APP-Gal4 and which we demonstrated to be PDGF-BB. The APP-Gal4 processing induced by PDGF is dependent on the gamma-secretase activity, being abolished by an inhibitor of this enzyme, and is the consequence of the activation of a pathway downstream of the PDGF-receptor, which includes the non-receptor tyrosine kinase Src and the small G-protein Rac1. These findings are confirmed by the observation that a constitutively active form of Src increases AP generation and that, in cells stably expressing APP, the generation of Abeta is strongly decreased by the Src tyrosine kinase inhibitor PP2.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy; CNR, ISPAAM, Prote & Mass Spectrometry Lab, I-80147 Naples, Italy; Aventis Pharma, Neurodegenerat Dis Grp, F-94400 Vitry Sur Seine, France; CEINGE Biotecnol Avanzate, I-80131 Naples, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto Per Il Sistema Produzione Animale In Ambiente Mediterraneo (ISPAAM-CNR); Sanofi-Aventis; Sanofi France; CEINGE Biotecnologie Avanzate	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.	russot@dbbm.unina.it	Zambrano, Nicola/B-9352-2014; RUSSO, Tommaso/K-1331-2016	Zambrano, Nicola/0000-0001-9395-3481; RUSSO, Tommaso/0000-0003-4426-0106; Scaloni, Andrea/0000-0001-9362-8515				Allegrin S, 2001, J BIOL CHEM, V276, P33526, DOI 10.1074/jbc.M104088200; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Barila D, 1998, NAT GENET, V18, P280, DOI 10.1038/ng0398-280; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CHENG B, 1995, J NEUROSCI, V15, P7095; Chiariello M, 2001, NAT CELL BIOL, V3, P580, DOI 10.1038/35078555; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FURTOSS O, 2002, EMBO J, V21, P514; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; Howell BW, 1999, MOL CELL BIOL, V19, P5179; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE RKK, 1995, P NATL ACAD SCI USA, V92, P8083, DOI 10.1073/pnas.92.17.8083; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Maccioni RB, 2001, EUR J BIOCHEM, V268, P1518, DOI 10.1046/j.1432-1327.2001.02024.x; MANESS PF, 1988, P NATL ACAD SCI USA, V85, P5001, DOI 10.1073/pnas.85.14.5001; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; Nikolic M, 2002, INT J BIOCHEM CELL B, V34, P731, DOI 10.1016/S1357-2725(01)00167-4; Nikolic M, 1998, NATURE, V395, P194, DOI 10.1038/26034; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; Nitsch RM, 1996, J BIOL CHEM, V271, P4188; Oumesmar BN, 1997, J NEUROSCI, V17, P125, DOI 10.1523/JNEUROSCI.17-01-00125.1997; Russo C, 2002, J BIOL CHEM, V277, P35282, DOI 10.1074/jbc.M110785200; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SILVA OABDE, 1993, NEUROSCIENCE, V57, P873, DOI 10.1016/0306-4522(93)90031-A; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; Suter DM, 2001, J CELL BIOL, V155, P427, DOI 10.1083/jcb.200107063; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Tarr PE, 2002, J BIOL CHEM, V277, P16798, DOI 10.1074/jbc.M110286200; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 2001, J MOL NEUROSCI, V17, P157, DOI 10.1385/JMN:17:2:157; WEERNINK PAO, 1995, J BIOL CHEM, V270, P2264, DOI 10.1074/jbc.270.5.2264; WESTERMANN R, 1988, J NEUROCHEM, V50, P1747, DOI 10.1111/j.1471-4159.1988.tb02474.x; YEH HJ, 1991, CELL, V64, P209, DOI 10.1016/0092-8674(91)90222-K; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; ZHAN X, 1994, J BIOL CHEM, V269, P20221; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	64	68	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9290	9297		10.1074/jbc.M211899200	http://dx.doi.org/10.1074/jbc.M211899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645527	hybrid			2022-12-27	WOS:000181524000054
J	Weigel, JA; Raymond, RC; McGary, C; Singh, A; Weigel, PH				Weigel, JA; Raymond, RC; McGary, C; Singh, A; Weigel, PH			A blocking antibody to the hyaluronan receptor for endocytosis (HARE) inhibits hyaluronan clearance by perfused liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; RAT-LIVER; BINDING PROTEINS; ACID; SULFATE; DISEASE; DEGRADATION; SERUM; OLIGOSACCHARIDES; MORPHOGENESIS	Hyaluronan (HA) and chondroitin sulfate clearance from lymph and blood is mediated by the hyaluronan receptor for endocytosis (HARE). The purification and molecular cloning (Zhou, B., Weigel, J. A., Saxena, A., and Weigel, P. H. (2002) Mol. Biol. Cell 13, 2853-2868) of this cell surface receptor were finally achieved after we developed monoclonal antibodies (mAbs) against HARE. There are actually two independent isoreceptors for HA, which in rat are designated the 175-kDa HARE and 300-kDa HARE. Only one mAb (number 174) effectively and completely blocked the specific uptake of I-125-HA at 37 degreesC by rat liver sinusoidal endothelial cells. I-125-HA binding to both the 175-kDa and 300-kDa HARE proteins in a ligand blot assay was almost completely inhibited by <1 mug/ml mAb-174, whereas mouse IgG had little or no effect. MAb-174 also performed very well in Western analysis, indirect fluorescence microscopy, and a variety of immuno-procedures. Immunohistochemistry using mAb-174 localized HARE to the sinusoidal cells of rat liver, spleen, and lymph node. Western analysis using mAb-174 revealed that the sizes of both HARE glycoproteins were the same in these three tissues. I-125-HA was taken up and degraded by excised rat livers that were continuously perfused ex vivo with a recirculating medium. This HA clearance and metabolism by liver, which is a physiological function of HARE, was very effectively blocked by mAb-174 but not by mouse IgG. The results indicate that mAb-174 will be a useful tool to study the functions of HARE and the physiological significance of RA clearance.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA; Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14642 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Rochester	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.				NIGMS NIH HHS [GM35978] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035978] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATANGELO G, 2000, NEW FRONTIERS MED SC; Banerji S, 1998, PROTEIN EXPRES PURIF, V14, P371, DOI 10.1006/prep.1998.0971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURD DAR, 1991, BRIT J PLAST SURG, V44, P579, DOI 10.1016/0007-1226(91)90093-Y; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Cantor JO, 1998, P SOC EXP BIOL MED, V217, P471; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; CLARKE BL, 1987, J BIOL CHEM, V262, P17384; Csoka TB, 1997, INVAS METAST, V17, P297; DEACIUC IV, 1993, HEPATOLOGY, V17, P266, DOI 10.1002/hep.1840170217; DEACIUC IV, 1993, BIOCHEM PHARMACOL, V46, P671, DOI 10.1016/0006-2952(93)90553-9; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Delpech B, 1997, J INTERN MED, V242, P41, DOI 10.1046/j.1365-2796.1997.00172.x; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; FRASER JRE, 1981, BIOCHEM J, V200, P415, DOI 10.1042/bj2000415; Gakunga P, 1997, DEVELOPMENT, V124, P3987; GOA KL, 1994, DRUGS, V47, P536, DOI 10.2165/00003495-199447030-00009; Horton MR, 2000, AM J PHYSIOL-LUNG C, V279, pL707, DOI 10.1152/ajplung.2000.279.4.L707; ITASAKA H, 1995, J SURG RES, V59, P589, DOI 10.1006/jsre.1995.1209; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurent T.C., 1991, DEGRADATION BIOACTIV, P249; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LAURENT TC, 1986, BIOCHEM J, V234, P653, DOI 10.1042/bj2340653; LUNDIN A, 1985, BRIT J DERMATOL, V112, P663, DOI 10.1111/j.1365-2133.1985.tb02334.x; Manek NJ, 2000, AM FAM PHYSICIAN, V61, P1795; Manicourt DH, 1999, ARTHRITIS RHEUM, V42, P1861, DOI 10.1002/1529-0131(199909)42:9<1861::AID-ANR10>3.0.CO;2-I; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; MCGARY CT, 1993, HEPATOLOGY, V18, P1465, DOI 10.1002/hep.1840180628; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Meyer K, 1934, J BIOL CHEM, V107, P629; Panay N, 1999, CURR OPIN OBSTET GYN, V11, P379, DOI 10.1097/00001703-199908000-00004; Rahmanian M, 1997, EXP CELL RES, V237, P223, DOI 10.1006/excr.1997.3792; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; RAJA RH, 1988, J BIOL CHEM, V263, P16661; Rao PN, 1996, LIVER, V16, P48; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SMEDSROD B, 1985, CELL TISSUE RES, V241, P639; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; Thylen A, 1999, CANCER-AM CANCER SOC, V86, P2000, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2000::AID-CNCR17>3.3.CO;2-E; Toole BP, 1997, J INTERN MED, V242, P35, DOI 10.1046/j.1365-2796.1997.00171.x; TURLEY EA, 1992, CANCER METAST REV, V11, P1, DOI 10.1007/BF00047598; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340; Yamada M, 1998, ACTA HAEMATOL-BASEL, V99, P212, DOI 10.1159/000040841; YannarielloBrown J, 1996, BIOCHEM BIOPH RES CO, V218, P314, DOI 10.1006/bbrc.1996.0055; YANNARIELLOBROWN J, 1992, BIOCHEMISTRY-US, V31, P576, DOI 10.1021/bi00117a039; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200; ZHOU B, 2003, IN PRESS GLYCOBIOLOG	53	63	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9808	9812		10.1074/jbc.M211462200	http://dx.doi.org/10.1074/jbc.M211462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645574	hybrid			2022-12-27	WOS:000181524000124
J	Ohshima, N; Takahashi, M; Hirose, F				Ohshima, N; Takahashi, M; Hirose, F			Identification of a human homologue of the DREF transcription factor with a potential role in regulation of the histone H1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION-RELATED ELEMENT; CELL NUCLEAR ANTIGEN; CHROMATIN-REMODELING FACTOR; EYE IMAGINAL DISC; DNA-REPLICATION; S-PHASE; DROSOPHILA-MELANOGASTER; BINDING-FACTOR; BOUNDARY-ELEMENT; CYCLE REGULATION	A human homologue (hDREF/KIAA0785) of Drosophila DREF, a transcriptional regulatory factor required for expression of genes involved in DNA replication and cell proliferation, was identified by BLAST search. Amino acid sequences corresponding to three regions highly conserved between two Drosophila species also proved to be very similar in the hDREF/KIAA0785 polypeptide. A consensus binding sequence (5'-TGTCG(C/T)GA(C/T)A) for hDREF/KIAA0785, determined by the CASTing method, overlapped with that for the Drosophila DREF (5'-TGTCGATA). We found hDREF/KIAA0785 binding sequences in the promoter regions of human genes related to cell proliferation. Analyses using a specific antibody revealed that an hDREF/KIAA0785 binds to the promoter region of the histone H1 gene. Co-transfection experiments with an hDREF/KIAA0785-expressing plasmid and a histone H1 promoter-directed luciferase reporter plasmid in HeLa cells revealed possible activation of the histone H1 promoter. Immunohistochemical analysis demonstrated that hDREF/KIAA0785 is localized in the nuclei. Although the expression level of the factor was found to be low in serum-deprived human normal fibroblasts, the amount was increased by adding serum to cultures and reached a maximum during S phase. RNA interference experiments targeting hDREF/KIAA0785 resulted in inhibition of S phase entry and reduction of histone H1 mRNA in HeLa cells. These results suggest that expression of hDREF/KIAA0785 may have a role in regulation of human genes related to cell proliferation.	Aichi Canc Ctr, Div Biochem, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Nagoya Grad Sch Med, Dept Pathol, Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan	Aichi Cancer Center; Nagoya University	Hirose, F (corresponding author), Aichi Canc Ctr, Div Biochem, Res Inst, Chikusa Ku, Nagoya, Aichi 4648681, Japan.		Takahashi, Masahide/AAN-4770-2020; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; Hirose, Fumiko/0000-0003-4586-4892				Albig W, 1997, GENE, V184, P141, DOI 10.1016/S0378-1119(96)00582-3; Aziz F, 1998, MOL BIOL REP, V25, P1, DOI 10.1023/A:1006888731301; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Bergman Y, 1998, BIOL CHEM, V379, P401; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLENCOWE BJ, 1994, J CELL BIOL, V127, P593, DOI 10.1083/jcb.127.3.593; COHEN B, 1991, MECH DEVELOP, V33, P229, DOI 10.1016/0925-4773(91)90030-A; COLLART DG, 1988, J BIOL CHEM, V263, P15860; Collins RT, 1999, EMBO J, V18, P7029, DOI 10.1093/emboj/18.24.7029; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DALTON S, 1988, EMBO J, V7, P49, DOI 10.1002/j.1460-2075.1988.tb02782.x; DALTON S, 1988, MOL CELL BIOL, V8, P4576, DOI 10.1128/MCB.8.10.4576; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOYLE HJ, 1989, GENE DEV, V3, P1518, DOI 10.1101/gad.3.10.1518; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elfring LK, 1998, GENETICS, V148, P251; Esposito T, 1999, HUM MOL GENET, V8, P61, DOI 10.1093/hmg/8.1.61; Fujita M, 1996, J BIOL CHEM, V271, P4349; Fujita M, 1997, J BIOL CHEM, V272, P10928; GALLINARI P, 1989, MOL CELL BIOL, V9, P1566, DOI 10.1128/MCB.9.4.1566; HALTINER MM, 1986, MOL CELL BIOL, V6, P277; Hart CM, 1997, MOL CELL BIOL, V17, P999, DOI 10.1128/MCB.17.2.999; Hart CM, 1999, CHROMOSOMA, V108, P375, DOI 10.1007/s004120050389; HEINTZ N, 1991, BIOCHIM BIOPHYS ACTA, V1088, P327, DOI 10.1016/0167-4781(91)90122-3; HIROSE F, 1994, J BIOL CHEM, V269, P2937; Hirose F, 1996, J BIOL CHEM, V271, P3930; Hirose F, 2001, MOL CELL BIOL, V21, P7231, DOI 10.1128/MCB.21.21.7231-7242.2001; HIROSE F, 1993, J BIOL CHEM, V268, P2092; Hirose F, 1999, MOL CELL BIOL, V19, P6020; HOCHHAUSER D, 1992, J BIOL CHEM, V267, P18961; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JORDANO J, 1988, ONCOGENE, V2, P359; Kudo S, 1998, MOL CELL BIOL, V18, P5492, DOI 10.1128/MCB.18.9.5492; LABELLA F, 1989, GENE DEV, V3, P1982, DOI 10.1101/gad.3.12a.1982; Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4; Matsukage A, 1995, GENE, V166, P233, DOI 10.1016/0378-1119(95)00586-2; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; NAGASE T, 1998, DNA RES, V5, P169; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; Ohno K, 1996, NUCLEIC ACIDS RES, V24, P3942, DOI 10.1093/nar/24.20.3942; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PLUMB M, 1984, P NATL ACAD SCI-BIOL, V81, P434, DOI 10.1073/pnas.81.2.434; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ryu JR, 1997, NUCLEIC ACIDS RES, V25, P794, DOI 10.1093/nar/25.4.794; Sambrook J., 2002, MOL CLONING LAB MANU; Sawado T, 1998, J BIOL CHEM, V273, P26042, DOI 10.1074/jbc.273.40.26042; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; Takahashi Y, 1996, J BIOL CHEM, V271, P14541, DOI 10.1074/jbc.271.24.14541; Takahashi Y, 1999, NUCLEIC ACIDS RES, V27, P510, DOI 10.1093/nar/27.2.510; VANWIJNEN AJ, 1988, NUCLEIC ACIDS RES, V16, P571, DOI 10.1093/nar/16.2.571; vanWijnen AJ, 1996, P NATL ACAD SCI USA, V93, P11516, DOI 10.1073/pnas.93.21.11516; vanWijnen AJ, 1997, J CELL BIOCHEM, V66, P512, DOI 10.1002/(SICI)1097-4644(19970915)66:4<512::AID-JCB10>3.0.CO;2-D; VAUGHAN PS, 1995, NATURE, V377, P362, DOI 10.1038/377362a0; Vaughan PS, 1998, J BIOL CHEM, V273, P194, DOI 10.1074/jbc.273.1.194; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x	59	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22928	22938		10.1074/jbc.M303109200	http://dx.doi.org/10.1074/jbc.M303109200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12663651	hybrid			2022-12-27	WOS:000183503900099
J	Drisaldi, B; Stewart, RS; Adles, C; Stewart, LR; Quaglio, E; Biasini, E; Fioriti, L; Chiesa, R; Harris, DA				Drisaldi, B; Stewart, RS; Adles, C; Stewart, LR; Quaglio, E; Biasini, E; Fioriti, L; Chiesa, R; Harris, DA			Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; CULTURED-CELLS; INTRACELLULAR-TRANSPORT; BIOCHEMICAL-PROPERTIES; INSERTIONAL MUTATION; PROTEIN; DISEASES; METABOLISM; EXPRESSION; APOPTOSIS	The cellular mechanisms by which prions cause neurological dysfunction are poorly understood. To address this issue, we have been using cultured cells to analyze the localization, biosynthesis, and metabolism of PrP molecules carrying mutations associated with familial prion diseases. We report here that mutant PrP molecules are delayed in their maturation to an endoglycosidase H- resistant form after biosynthetic labeling, suggesting that they are impaired in their exit from the endoplasmic reticulum ( ER). However, we find that proteasome inhibitors have no effect on the maturation or turnover of either mutant or wild- type PrP molecules. Thus, in contrast to recent studies from other laboratories, our work indicates that PrP is not subject to retrotranslocation from the ER into the cytoplasm prior to degradation by the proteasome. We find that in transfected cells, but not in cultured neurons, proteasome inhibitors cause accumulation of an unglycosylated, signal peptide- bearing form of PrP on the cytoplasmic face of the ER membrane. Thus, under conditions of elevated expression, a small fraction of PrP chains is not translocated into the ER lumen during synthesis, and is rapidly degraded in the cytoplasm by the proteasome. Finally, we report a previously unappreciated artifact caused by treatment of cells with proteasome inhibitors: an increase in PrP mRNA level and synthetic rate when the protein is expressed from a vector containing a viral promoter. We suggest that this phenomenon may explain some of the dramatic effects of proteasome inhibitors observed in other studies. Our results clarify the role of the proteasome in the cell biology of PrP, and suggest reasonable hypotheses for the molecular pathology of inherited prion diseases.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Mario Negri Inst Pharmacol Res, DTI, I-20157 Milan, Italy; Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy	Washington University (WUSTL); Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Harris, DA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Chiesa, Roberto/G-1561-2017; Fioriti, Luana/AAN-7207-2021; Biasini, Emiliano/A-3147-2011	Chiesa, Roberto/0000-0002-3842-3733; Biasini, Emiliano/0000-0002-3927-6341; fioriti, luana/0000-0003-2429-8967; Harris, David/0000-0002-6985-5790	NINDS NIH HHS [NS 35496] Funding Source: Medline; Telethon [139/B] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035496] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; Aridor M, 2000, SCIENCE, V287, P816, DOI 10.1126/science.287.5454.816; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; Aridor M, 2002, TRAFFIC, V3, P781, DOI 10.1034/j.1600-0854.2002.31103.x; Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Capellari S, 2000, AM J PATHOL, V157, P613, DOI 10.1016/S0002-9440(10)64572-5; Chiesa R, 2000, P NATL ACAD SCI USA, V97, P5574, DOI 10.1073/pnas.97.10.5574; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Lehmann S, 2000, J BIOL CHEM, V275, P1520; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Miller TM, 1996, J NEUROSCI, V16, P7487; Nakayama K, 2001, J IMMUNOL, V167, P1145, DOI 10.4049/jimmunol.167.3.1145; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; O'Hare T, 1999, J IMMUNOL, V163, P11; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Porcile C, 2002, ANN NY ACAD SCI, V973, P402, DOI 10.1111/j.1749-6632.2002.tb04673.x; Priola SA, 1998, J BIOL CHEM, V273, P11980, DOI 10.1074/jbc.273.19.11980; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Qu DF, 1996, J BIOL CHEM, V271, P22791, DOI 10.1074/jbc.271.37.22791; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wu HM, 2002, AM J RESP CELL MOL, V27, P234, DOI 10.1165/ajrcmb.27.2.4792; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Young Katherine, 1999, P139; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812; Zimmermann J, 2000, ONCOGENE, V19, P2913, DOI 10.1038/sj.onc.1203606	48	169	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21732	21743		10.1074/jbc.M213247200	http://dx.doi.org/10.1074/jbc.M213247200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663673	hybrid			2022-12-27	WOS:000183354200054
J	Liu, CY; Birk, DE; Hassell, JR; Kane, B; Kao, WWY				Liu, CY; Birk, DE; Hassell, JR; Kane, B; Kao, WWY			Keratocan-deficient mice display alterations in corneal structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCAN; LUMICAN; DECORIN; EXPRESSION	Keratocan ( Kera) is a cornea- specific keratan sulfate proteoglycan ( KSPG) in the adult vertebrate eye. It belongs to the small leucine- rich proteoglycan ( SLRP) gene family and is one of the major components of extracellular KSPG in the vertebrate corneal stroma. The Kera gene is expressed in ocular surface tissues including cornea and eyelids during morphogenesis. Corneal KSPGs play a pivotal role in matrix assembly, which is accountable for corneal transparency. In humans, mutations of the KERA gene are associated with cornea plana ( CNA2) that manifests decreases in vision acuity due to the flattened forward convex curvature of cornea. To investigate the biological role of the Kera gene and to establish an animal model for corneal plana, we generated Kera knockout mice via gene targeting. Northern and Western blotting and immunohistochemical analysis showed that no Kera mRNA or keratocan protein was detected in the Kera (-/-) cornea. The expression levels of other SLRP members including lumican, decorin, and fibromodulin were not altered in the Kera (-/-) cornea as compared with that of the wild- type littermates. Mice lacking keratocan have normal corneal transparency at the age of 12 months. However, they have a thinner corneal stroma and a narrower cornea-iris angle of the anterior segment in comparison to the wild- type littermates. As demonstrated by transmission electron microscopy, Kera (-/-) mice have larger stromal fibril diameters and less organized packing of collagen fibrils in stroma than those of wild type. Taken together, our results showed that ablation of the Kera gene resulted in subtle structural alterations of collagenous matrix and did not perturb the expression of other SLRPs in cornea. Keratocan thus plays a unique role in maintaining the appropriate corneal shape to ensure normal vision.	Univ Miami, Sch Med,Dept Ophthalmol, Bascom Palmer Eye Inst, McKnight Vis Res Ctr, Miami, FL 33136 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Cell Biol & Anat, Miami, FL 33136 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Univ S Florida, Shriners Hosp Children Tampa, Coll Med, Tampa, FL 33612 USA; Univ Cincinnati, Dept Ophthalmol, Cincinnati, OH 45267 USA	Bascom Palmer Eye Institute; University of Miami; Bascom Palmer Eye Institute; University of Miami; Bascom Palmer Eye Institute; University of Miami; Jefferson University; State University System of Florida; University of South Florida; University System of Ohio; University of Cincinnati	Liu, CY (corresponding author), Univ Miami, Sch Med,Dept Ophthalmol, Bascom Palmer Eye Inst, McKnight Vis Res Ctr, 1638 NW 10th Ave,Rm 621, Miami, FL 33136 USA.	cliu2@med.miami.edu	Birk, David/I-4072-2012	Birk, David/0000-0002-4865-9088; Liu, Chia-yang/0000-0002-8398-5516	NATIONAL EYE INSTITUTE [R01EY012486, R01EY011845, R01EY008104, R01EY005129, R37EY008104] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BETTELHEIM FA, 1975, BIOCHIM BIOPHYS ACTA, V381, P203, DOI 10.1016/0304-4165(75)90202-0; CHAKRAVARTI S, 2000, INVESTIG OPHTHALMOL, V11, P3365; CHARKRAVARTI S, 1998, J CELL BIOL, V112, P987; DOANE KJ, 1992, EXP CELL RES, V202, P113, DOI 10.1016/0014-4827(92)90410-A; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; HAHN RA, 1992, DEVELOPMENT, V115, P383; HASSELL JR, 1983, ARCH BIOCHEM BIOPHYS, V222, P362, DOI 10.1016/0003-9861(83)90532-5; Hay E.D., 1980, International Review of Cytology, V63, P263, DOI 10.1016/S0074-7696(08)61760-X; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; KAO WWY, 1983, J BIOL CHEM, V258, P7779; LEHMANN OJ, 2000, INVESTIG OPHTHALMOL, V42, P3118; LINSENMAYER TF, 1990, ANN NY ACAD SCI, V580, P143, DOI 10.1111/j.1749-6632.1990.tb17926.x; Liu CY, 1998, J BIOL CHEM, V273, P22584, DOI 10.1074/jbc.273.35.22584; Pellegata NS, 2000, NAT GENET, V25, P91, DOI 10.1038/75664; Pressman CL, 2000, GENESIS, V26, P15, DOI 10.1002/(SICI)1526-968X(200001)26:1<15::AID-GENE5>3.0.CO;2-V; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; RAWE IM, 1992, HISTOCHEM J, V24, P311, DOI 10.1007/BF01046162; Saika S, 2000, J BIOL CHEM, V275, P2607, DOI 10.1074/jbc.275.4.2607; Scott JE, 1996, BIOCHEMISTRY-US, V35, P8795, DOI 10.1021/bi960773t; SMITH RS, 2002, SYSTEMATIC EVALUATIO, P285; Tasheva ES, 2002, MOL VIS, V8, P407; Weber IT, 1996, J BIOL CHEM, V271, P31767, DOI 10.1074/jbc.271.50.31767; Ying SX, 1997, J BIOL CHEM, V272, P30306, DOI 10.1074/jbc.272.48.30306	23	142	150	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21672	21677		10.1074/jbc.M301169200	http://dx.doi.org/10.1074/jbc.M301169200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665512	hybrid			2022-12-27	WOS:000183354200046
J	Zhang, JJ; Zhang, YL; Inouye, M				Zhang, JJ; Zhang, YL; Inouye, M			Thermotoga maritima MazG protein has both nucleoside triphosphate pyrophosphohydrolase and pyrophosphatase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTT; STREPTOCOCCUS-PNEUMONIAE; METHANOCOCCUS-JANNASCHII; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; DNA-SYNTHESIS; CLONING; GENE; FAMILY; CDNA	MazG proteins form a widely conserved family among bacteria, but their cellular function is still unknown. Here we report that Thermotoga maritima MazG protein ( Tm- MazG), the product of the TM0913 gene, has both nucleoside triphosphate pyrophosphohydrolase ( NTPase) and pyrophosphatase activities. Tm- MazG catalyzes the hydrolysis of all eight canonical ribo- and deoxyribonucleoside triphosphates to their corresponding nucleoside monophosphates and PPi and subsequently hydrolyzes the resultant PPi to P-i. The NTPase activity with deoxyribonucleoside triphosphates as substrate is higher than corresponding ribonucleoside triphosphates. dGTP is the best substrate among the deoxyribonucleoside triphosphates, and GTP is the best among the ribonucleoside triphosphates. Both NTPase and pyrophosphatase activities were enhanced at higher temperatures and blocked by the alpha,beta-methyleneadenosine triphosphate, which cannot be hydrolyzed by Tm- MazG. Furthermore, PPi is an inhibitor for the Tm- MazG NTPase activity. Significant decreases in the NTPase activity and concomitant increases in the pyrophosphatase activity were observed when mutations were introduced at the highly conserved amino acid residues in Tm- MazG N- terminal region ( E41Q/ E42Q, E45Q, E61Q, R97A/ R98A, and K118A). These results demonstrated that Tm- MazG has dual enzymatic functions, NTPase and pyrophosphatase, and that these two enzymatic activities are coordinated.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.			Zhang, Junjie/0000-0001-8809-1485				Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; AKIYAMA M, 1989, P NATL ACAD SCI USA, V86, P3949, DOI 10.1073/pnas.86.11.3949; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BULLIONS LC, 1994, J BIOL CHEM, V269, P12339; CAI JP, 1995, CARCINOGENESIS, V16, P2343, DOI 10.1093/carcin/16.10.2343; Chung JH, 2001, NUCLEIC ACIDS RES, V29, P3099, DOI 10.1093/nar/29.14.3099; COX EC, 1973, GENETICS, V73, P67; Fujii Y, 1999, J BIOL CHEM, V274, P38251, DOI 10.1074/jbc.274.53.38251; Harris TK, 2000, BIOCHEMISTRY-US, V39, P1655, DOI 10.1021/bi9918745; Hwang KY, 1999, NAT STRUCT BIOL, V6, P691; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; KAMATH AV, 1993, GENE, V134, P99, DOI 10.1016/0378-1119(93)90180-B; Lin SR, 2001, J BIOL CHEM, V276, P18695, DOI 10.1074/jbc.M011084200; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Satoh T, 1999, BIOCHEMISTRY-US, V38, P1531, DOI 10.1021/bi981445r; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; VANDERHEIDEN BS, 1970, BIOCHIM BIOPHYS ACTA, V215, P555, DOI 10.1016/0304-4165(70)90109-1; Zhang JJ, 2002, J BACTERIOL, V184, P5323, DOI 10.1128/JB.184.19.5323-5329.2002	26	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21408	21414		10.1074/jbc.M213294200	http://dx.doi.org/10.1074/jbc.M213294200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657645	hybrid			2022-12-27	WOS:000183354200014
J	O'Neill, RJ; Vorob'eva, OV; Shahbakhti, H; Zmuda, E; Bhagwat, AS; Baldwin, GS				O'Neill, RJ; Vorob'eva, OV; Shahbakhti, H; Zmuda, E; Bhagwat, AS; Baldwin, GS			Mismatch uracil glycosylase from Escherichia coli - A general mismatch or a specific DNA glycosylase?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCISION-REPAIR; SHORT-PATCH REPAIR; CRYSTAL-STRUCTURE; PRIMARY SUBSTRATE; ENDONUCLEASE; MUG; 3,N-4-ETHENOCYTOSINE; RECOGNITION; STIMULATION; TURNOVER	The gene for the mismatch-specific uracil glycosylase ( MUG) was identified in the Escherichia coli genome as a sequence homolog of the mammalian thymine DNA glycosylase, with activity against uracil in U . G mismatches. Subsequently, 3,N-4-ethenocytosine (epsilonC), thymine, 5-hydroxymethyluracil, and 8-(hydroxymethyl)3, N-4-ethenocytosine have been proposed as possible substrates for this enzyme. The evaluation of various DNA adducts as substrates is complicated by the biphasic nature of the kinetics of this enzyme. Our results demonstrate that product release by the enzyme is very slow and hence comparing the "steady-state" parameters of the enzyme for different substrates is of limited use. Consequently, the ability of the enzyme to excise a variety of damage products of purines and pyrimidines was studied under single turnover conditions. Although the enzyme excised both epsilonC and U from DNA, the former adduct was significantly better as a substrate in terms of binding and hydrolysis. Some products of oxidative and alkylation damage are also moderately good substrates for the enzyme, but thymine is a poor substrate. This comparison of different substrates under single turnover conditions provides a rational basis for comparing substrates of MUG and we relate these conclusions to the known crystal structures of the enzyme and its catalytic mechanism.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England; Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Trevigen, Gaithersburg, MD 20877 USA	Imperial College London; Wayne State University	Baldwin, GS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Sir Alexander Flemming Bldg, London SW7 2AZ, England.		Kisil, Olga V/G-6580-2017; Bhagwat, Ashok/AAU-4186-2021; Bhagwat, Ashok/ABA-3861-2020	Kisil, Olga V/0000-0003-4799-1318; Bhagwat, Ashok/0000-0003-1188-0579; Baldwin, Geoffrey/0000-0003-4800-023X				Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; BALDWIN GS, 1995, BIOCHEMISTRY-US, V34, P705, DOI 10.1021/bi00002a038; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; Bartsch H, 2000, TOXICOLOGY, V153, P105, DOI 10.1016/S0300-483X(00)00307-3; Bhagwat AS, 2002, MOL MICROBIOL, V44, P1421, DOI 10.1046/j.1365-2958.2002.02989.x; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Hang B, 2002, BIOCHEMISTRY-US, V41, P2158, DOI 10.1021/bi011542b; Jiang YL, 2002, J BIOL CHEM, V277, P15385, DOI 10.1074/jbc.M200634200; Lieb M, 1996, MOL MICROBIOL, V20, P467, DOI 10.1046/j.1365-2958.1996.5291066.x; LINDAHL T, 1974, P NATL ACAD SCI USA, V71, P3649, DOI 10.1073/pnas.71.9.3649; Liu PF, 2002, CHEM RES TOXICOL, V15, P1001, DOI 10.1021/tx020030a; Liu X, 2002, J MOL BIOL, V321, P265, DOI 10.1016/S0022-2836(02)00623-X; Lutsenko E, 1999, J BIOL CHEM, V274, P31034, DOI 10.1074/jbc.274.43.31034; Mokkapati SK, 2001, MOL MICROBIOL, V41, P1101, DOI 10.1046/j.1365-2958.2001.02559.x; Pope MA, 2002, J BIOL CHEM, V277, P22605, DOI 10.1074/jbc.M203037200; Porello SL, 1998, BIOCHEMISTRY-US, V37, P14756, DOI 10.1021/bi981594+; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Saparbaev M, 2002, J BIOL CHEM, V277, P26987, DOI 10.1074/jbc.M111100200; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; SHAPIRO R, 1969, BIOCHEMISTRY-US, V8, P1806, DOI 10.1021/bi00833a004; SHAPIRO R, 1972, BIOCHEMISTRY-US, V11, P23, DOI 10.1021/bi00751a005; Sung JS, 2000, BIOCHEMISTRY-US, V39, P10224, DOI 10.1021/bi0007066; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; ZHANG WF, 1995, CHEM RES TOXICOL, V8, P148, DOI 10.1021/tx00043a020	29	49	51	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20526	20532		10.1074/jbc.M210860200	http://dx.doi.org/10.1074/jbc.M210860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668677	hybrid			2022-12-27	WOS:000183230500012
J	Sreenivas, A; Carman, GM				Sreenivas, A; Carman, GM			Phosphorylation of the yeast phospholipid synthesis regulatory protein Opi1p by protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDP-CHOLINE PATHWAY; TRANSCRIPTIONAL ACTIVATOR INO2; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE SYNTHESIS; NEGATIVE REGULATOR; SHUTTLE VECTORS; CTP SYNTHETASE; FACTOR PHO4; BIOSYNTHESIS; GENES	The Opi1p transcription factor plays a negative regulatory role in the expression of UAS(INO)-containing genes involved in phospholipid synthesis in the yeast Saccharomyces cerevisiae. The phosphorylation of Opi1p by protein kinase A (cAMP-dependent protein kinase) was examined in this work. Using a maltose-binding protein-Opi1p fusion protein as a substrate, protein kinase A activity was time- and dose-dependent and dependent on the concentrations of Opi1p and ATP. Protein kinase A phosphorylated Opi1p on multiple serine residues. The synthetic peptides SCRQKSQPSE and SQVRESLLNL containing the protein kinase A motif for Ser(31) and Ser(251), respectively, within Opi1p were substrates for protein kinase A. Phosphorylation of S31A and S251A mutant maltose-binding protein-Opi1p fusion proteins by protein kinase A was reduced when compared with the wild type protein, and phosphopeptides present in wild type Opi1p were absent from the S31A and S251A mutant proteins. In vivo labeling experiments showed that the extent of phosphorylation of the S31A and S251A mutant proteins was reduced when compared with the wild type protein. The physiological consequence of the phosphorylation of Opi1p at Ser(31) and Ser(251) was examined by measuring the effects of the S31A and S251A mutations on the expression of the UAS(INO)-containing gene INO1. The beta-galactosidase activity driven by an INO1-CYC-lacZ reporter gene in opi1Delta mutant cells expressing the S31A and S251A mutant Opi1p proteins was elevated 42 and 35%, respectively, in the absence of inositol and 55 and 52%, respectively, in the presence of inositol when compared with cells expressing wild type Opi1p. These data supported the conclusion that phosphorylation of Opi1p at Ser(31) and Ser(251) mediated the stimulation of the negative regulatory function of Opi1p on the expression of the INO1 gene.	Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Carman, GM (corresponding author), Rutgers State Univ, Dept Food Sci, Cook Coll, New Jersey Agr Expt Stn, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-50679] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; Calkhoven CF, 1996, BIOCHEM J, V317, P329, DOI 10.1042/bj3170329; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carman GM, 1996, J BIOL CHEM, V271, P13293, DOI 10.1074/jbc.271.23.13293; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; CULBERTSON MR, 1975, GENETICS, V80, P23; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Elkhaimi M, 2000, NUCLEIC ACIDS RES, V28, P3160, DOI 10.1093/nar/28.16.3160; Graves JA, 2000, GENETICS, V154, P1485; GRAVES JA, 1996, THESIS CARNEGIE MELL; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; HAID A, 1983, METHOD ENZYMOL, V96, P192; Harlow E., 1988, ANTIBODIES LAB MANUA; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Howe AG, 2002, J BIOL CHEM, V277, P44100, DOI 10.1074/jbc.M206643200; HUDAK KA, 1994, GENETICS, V136, P475; Hung W, 1997, EUR J BIOCHEM, V245, P241, DOI 10.1111/j.1432-1033.1997.00241.x; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kim KH, 1999, J BIOL CHEM, V274, P9531, DOI 10.1074/jbc.274.14.9531; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu C, 2000, J BIOL CHEM, V275, P31972, DOI 10.1074/jbc.M003055200; LOEWY BS, 1984, MOL CELL BIOL, V4, P2479, DOI 10.1128/MCB.4.11.2479; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; Park TS, 1999, BIOCHEMISTRY-US, V38, P8839, DOI 10.1021/bi990784x; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; SCHWANK S, 1995, NUCLEIC ACIDS RES, V23, P230, DOI 10.1093/nar/23.2.230; SIKORSKI RS, 1989, GENETICS, V122, P19; Sreenivas A, 2001, J BIOL CHEM, V276, P29915, DOI 10.1074/jbc.M105147200; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; Wagner C, 1999, YEAST, V15, P843, DOI 10.1002/(SICI)1097-0061(199907)15:10A<843::AID-YEA424>3.0.CO;2-M; Wagner C, 2001, MOL MICROBIOL, V41, P155, DOI 10.1046/j.1365-2958.2001.02495.x; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Yang WL, 1996, J BIOL CHEM, V271, P28777, DOI 10.1074/jbc.271.46.28777; Yu Y, 2002, J BIOL CHEM, V277, P34978, DOI 10.1074/jbc.M205316200; Zaremberg V, 2002, J BIOL CHEM, V277, P39035, DOI 10.1074/jbc.M207753200; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	69	34	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20673	20680		10.1074/jbc.M300132200	http://dx.doi.org/10.1074/jbc.M300132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668681	Green Published, hybrid			2022-12-27	WOS:000183230500031
J	Zackova, M; Skobisova, E; Urbankova, E; Jezek, P				Zackova, M; Skobisova, E; Urbankova, E; Jezek, P			Activating omega-6 polyunsaturated fatty acids and inhibitory purine nucleotides are high affinity Ligands for novel mitochondrial uncoupling proteins UCP2 and UCP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON TRANSPORT; SKELETAL-MUSCLE; GENE-EXPRESSION; UP-REGULATION; H+ TRANSPORT; COENZYME-Q; FLIP-FLOP; BINDING; MECHANISM; OBESITY	Human UCP2 and UCP3, expressed in yeast, were studied to establish their high affinity regulatory ligands. UCPn were reconstituted into liposomes and assayed for fatty acid (FA)-induced H+ efflux. All natural long chain FAs activated UCP2- and UCP3-mediated H+ translocation. Coenzyme Q(10) had no further significant activating effect. Evaluated parameters of FA activation (FA cycling) kinetics revealed the highest apparent affinity to UCP2 ( the lowest K-m values: 20 and 29 muM, respectively) for omega-6 polyunsaturated FAs (PUFAs), all-cis-8,11,14-eicosatrienoic and all-cis-6,9,12-octadecatrienoic acids, which are also the most potent agonists of the nuclear PPARbeta receptor in the activation of UCP2 transcription. omega-3 PUFA, cis-5,8,11,14,17-eicosapentaenoic acid had lower affinity (K-m, 50 muM), although as an omega-6 PUFA, arachidonic acid exhibited the same low affinity as lauric acid (K-m, similar to200 muM). These findings suggest a possible dual role of some PUFAs in activating both UCPn expression and uncoupling activity. UCP2 (UCP3)-dependent H+ translocation activated by all tested FAs was inhibited by purine nucleotides with apparent affinity to UCP2 (reciprocal K-i) decreasing in order: ADP>ATPsimilar toGTP>GDPmuch greater thanAMP. Also [H-3] GTP ([H-3] ATP) binding to isolated Escherichia coli (K-d, similar to5 muM) or yeast-expressed UCP2 (K-d, similar to1.5 muM) or UCP3 exhibited high affinity, similar to UCP1. The estimated number of [H-3] GTP high affinity (K-d, <0.4 mu M) binding sites was (in pmol/mg of protein) 182 in lung mitochondria, 74 in kidney, 28 in skeletal muscle, and similar to 20 in liver mitochondria. We conclude that purine nucleotides must be the physiological inhibitors of UCPn-mediated uncoupling in vivo.	Acad Sci Czech Republ, Dept 75, Inst Physiol, Prague 14220 4, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Jezek, P (corresponding author), Acad Sci Czech Republ, Dept 75, Inst Physiol, Videnska 1083, Prague 14220 4, Czech Republic.	jezek@biomed.cas.cz	Jezek, Petr/B-9264-2012	Jezek, Petr/0000-0002-2720-9395; Zackova, Marketa/0000-0002-5504-9851				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; Chevillotte E, 2001, J BIOL CHEM, V276, P10853, DOI 10.1074/jbc.M008010200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cline GW, 2001, J BIOL CHEM, V276, P20240, DOI 10.1074/jbc.M102540200; Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S; Deiana M, 2001, TOXICOL LETT, V123, P125, DOI 10.1016/S0378-4274(01)00372-1; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Engstova H, 2001, J BIOL CHEM, V276, P4683, DOI 10.1074/jbc.M009409200; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; FEIL S, 1994, EUR J BIOCHEM, V219, P681, DOI 10.1111/j.1432-1033.1994.tb19984.x; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hagen T, 2000, BIOCHEM BIOPH RES CO, V276, P642, DOI 10.1006/bbrc.2000.3535; Hagen T, 2000, BIOCHEMISTRY-US, V39, P5845, DOI 10.1021/bi992980+; Hagen T, 1999, FEBS LETT, V454, P201, DOI 10.1016/S0014-5793(99)00811-X; Hanak P, 2001, FEBS LETT, V495, P137, DOI 10.1016/S0014-5793(01)02338-9; Heidkaemper D, 2000, FEBS LETT, V480, P265, DOI 10.1016/S0014-5793(00)01949-9; Hinz W, 1999, FEBS LETT, V462, P411, DOI 10.1016/S0014-5793(99)01568-9; HUANG SG, 1995, BIOCHEMISTRY-US, V34, P349, DOI 10.1021/bi00001a043; Huang SG, 1998, J BIOL CHEM, V273, P859, DOI 10.1074/jbc.273.2.859; Jaburek M, 2001, J BIOL CHEM, V276, P31897, DOI 10.1074/jbc.M103507200; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jekabsons MB, 2002, BIOCHEM J, V366, P565, DOI 10.1042/BJ20020469; JEZEK P, 1988, J BIOENERG BIOMEMBR, V20, P603, DOI 10.1007/BF00768922; Jezek P, 2002, INT J BIOCHEM CELL B, V34, P1190, DOI 10.1016/S1357-2725(02)00061-4; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1999, FEBS LETT, V455, P79, DOI 10.1016/S0014-5793(99)00853-4; Jezek P, 1999, J BIOENERG BIOMEMBR, V31, P457, DOI 10.1023/A:1005496306893; Johnson MM, 1997, J NUTR, V127, P1435, DOI 10.1093/jn/127.8.1435; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kleinfeld AM, 1997, BIOCHEMISTRY-US, V36, P14146, DOI 10.1021/bi971440e; KLINGENBERG M, 1988, BIOCHEMISTRY-US, V27, P781, DOI 10.1021/bi00402a044; KLINGENBERG M, 1985, EMBO J, V4, P3087, DOI 10.1002/j.1460-2075.1985.tb04049.x; MURDZAINGLIS DL, 1991, J BIOL CHEM, V266, P11871; Nagase I, 2001, FEBS LETT, V494, P175, DOI 10.1016/S0014-5793(01)02341-9; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V257, P879, DOI 10.1006/bbrc.1999.0555; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	57	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20761	20769		10.1074/jbc.M212850200	http://dx.doi.org/10.1074/jbc.M212850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670931	hybrid			2022-12-27	WOS:000183230500043
J	Abbas, S; Abu-Amer, Y				Abbas, S; Abu-Amer, Y			Dominant-negative I kappa B facilitates apoptosis of osteoclasts by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TAT FUSION PROTEINS; OSTEOPROTEGERIN LIGAND; ACTIVATION; INHIBITION; DIFFERENTIATION; RECEPTOR; CASPASES; CELLS; BONE	Osteoclasts are the sole bone-resorbing cells. Heightened activity of these cells under pathological conditions leads to the development of bone loss diseases, such as osteolysis, osteoporosis, and rheumatoid arthritis. We have shown previously that tumor necrosis factor alpha-(TNF) strongly induces osteoclastogenesis of preosteoclasts and do so through activation of the transcription factor, NF-kappaB. Most importantly, recent studies have shown that NF-kappaB is required for the development of osteoclasts. This transcription factor has also been proven as an essential mediator of inflammatory diseases including those related to bone. In this regard, we have shown that various mutated forms of IkappaBalpha are potent inhibitors of osteoclastogenesis. In this study, we examined the direct effect of DN-IkappaB on mature and preosteoclast development in the presence of TNF. Our findings indicate that once committed to the osteoclastogenic pathway, preosteoclasts form giant and hyperactive osteoclasts in response to TNF. However, administration of DN-IkappaB to cultures prior to TNF exposure averts the osteoclastogenic effect of TNF into apoptosis. Screening potential mediators of DN-IkappaB and TNF-induced apoptosis shows that caspase 3, caspase 9, poly(ADP-ribose) polymerase, and Bax are activated, whereas levels of Bcl-X-L, cIAP-1, and TRAF6 were reduced. Taken together, these findings suggest that under conditions of NF-kappaB inactivity levels of pro-survival factors are diminished, which in turn facilitates TNF induction of pro-apoptotic factors leading to apoptosis.	Washington Univ, Sch Med, Dept Orthopaed, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Abu-Amer, Y (corresponding author), Washington Univ, Sch Med, Dept Orthoped Surg, 1 Barnes Hosp Plaza,11300 W Pavil,Campus Box 8233, St Louis, MO 63110 USA.	abuamery@msnotes.wustl.edu			NIAMS NIH HHS [AR-47443] Funding Source: Medline; NIDCR NIH HHS [DE-13754] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013754] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abu-Amer Y, 2000, J BIOL CHEM, V275, P27307; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Abu-Amer Y, 2001, J CLIN INVEST, V107, P1375, DOI 10.1172/JCI10530; Abu-Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200; AbuAmer Y, 1997, NAT MED, V3, P1189, DOI 10.1038/nm1197-1189; AbuAmer Y, 1997, J CLIN INVEST, V100, P1557, DOI 10.1172/JCI119679; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756-3282(99)00105-2; Darnay BG, 1998, J BIOL CHEM, V273, P20551, DOI 10.1074/jbc.273.32.20551; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Doyle BT, 2002, J LEUKOCYTE BIOL, V71, P247; Duckett CS, 2002, J CLIN INVEST, V109, P579, DOI 10.1172/JCI200215197; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Herrera B, 2002, FEBS LETT, V520, P93, DOI 10.1016/S0014-5793(02)02774-6; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; KODAMA H, 1991, J EXP MED, V173, P269, DOI 10.1084/jem.173.1.269; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; LI J, 1996, J BONE MINER RES S, V14, P149; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Schwarz EM, 2000, J ORTHOPAED RES, V18, P472, DOI 10.1002/jor.1100180321; Shalhoub V, 1999, J CELL BIOCHEM, V72, P251; SHERR CJ, 1990, BLOOD, V75, P1; SIEBENLIST U, 2001, P NATL ACAD SCI USA, V89, P4333; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200	46	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20077	20082		10.1074/jbc.M208619200	http://dx.doi.org/10.1074/jbc.M208619200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637573	hybrid			2022-12-27	WOS:000183078000065
J	Anisfeld, AM; Kast-Woelbern, HR; Meyer, ME; Jones, SA; Zhang, YQ; Williams, KJ; Willson, T; Edwards, PA				Anisfeld, AM; Kast-Woelbern, HR; Meyer, ME; Jones, SA; Zhang, YQ; Williams, KJ; Willson, T; Edwards, PA			Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; LOW-DENSITY-LIPOPROTEIN; ORPHAN NUCLEAR RECEPTOR; ACTIVATED RECEPTOR; BILE-ACID; REMNANT LIPOPROTEINS; LIPID HOMEOSTASIS; LIGAND CATABOLISM; APOLIPOPROTEIN-E; CULTURED-CELLS	Syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan that participates in the binding and internalization of extracellular ligands, was identified in a screen designed to isolate genes that are regulated by the farnesoid X-receptor (FXR, NR1H4). Treatment of human hepatocytes with either naturally occurring ( chenodeoxycholic acid) or synthetic (GW4064) FXR ligands resulted in both induction of SDC1 mRNA and enhanced binding, internalization, and degradation of low density lipoprotein. Transient transfection assays, using wild-type and mutant SDC1 promoter-luciferase genes, led to the identification of a nuclear hormone receptor-binding hexad arranged as a direct repeat separated by one nucleotide (DR-1) in the proximal promoter that was necessary and sufficient for activation by FXR. The wild-type, but not a mutated DR-1 element, conferred FXR responsiveness to a heterologous thymidine kinase promoter-reporter gene. Four murine FXR isoforms have been identified recently that differ either at their amino terminus and/or by the presence or absence of four amino acids in the hinge region. Interestingly, the activities of the human SDC1 promoter-reporter constructs were highly induced by the two FXR isoforms that do not contain the four-amino acid insert and were unresponsive to the isoforms containing the four amino acids. Thus, current studies demonstrate that hepatic SDC1 is induced in an FXR isoform-specific manner. Increased expression of SDC1 may account in part for the hypotriglyceridemic effect that can result from the administration of chenodeoxycholic acid to humans.	Univ Calif Los Angeles, Dept Med & Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA; Thomas Jefferson Univ, Dept Med, Div Endocrinol Diabet & Metab Dis, Dorrance H Hamilton Res Labs, Philadelphia, PA 19107 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; GlaxoSmithKline; Jefferson University	Edwards, PA (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, CHS 33-257,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		feinstein, doug/M-9414-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056984, R01HL068445, P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [P50-HL56984, HL30568, HL68445] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ananthanarayanan M, 2001, J BIOL CHEM, V276, P28857, DOI 10.1074/jbc.M011610200; BELL GD, 1973, BMJ-BRIT MED J, V3, P520, DOI 10.1136/bmj.3.5879.520; Carey DJ, 1997, BIOCHEM J, V327, P1; Edwards PA, 2002, J LIPID RES, V43, P2; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Fuki IV, 1997, J CLIN INVEST, V100, P1611, DOI 10.1172/JCI119685; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Huber RM, 2002, GENE, V290, P35, DOI 10.1016/S0378-1119(02)00557-7; JI ZS, 1994, J BIOL CHEM, V269, P13429; JI ZS, 1993, J BIOL CHEM, V268, P10160; Kast HR, 2002, J BIOL CHEM, V277, P2908, DOI 10.1074/jbc.M109326200; Kast HR, 2001, MOL ENDOCRINOL, V15, P1720, DOI 10.1210/me.15.10.1720; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Mahley RW, 1996, ISRAEL J MED SCI, V32, P414; Mahley RW, 1999, J LIPID RES, V40, P1; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Williams K J, 2001, Methods Mol Biol, V171, P457; Williams KJ, 1997, CURR OPIN LIPIDOL, V8, P253; WILLIAMS KJ, 1992, J BIOL CHEM, V267, P13284; WU GY, 1984, HEPATOLOGY, V4, P1190, DOI 10.1002/hep.1840040615; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Zhang YQ, 2003, J BIOL CHEM, V278, P104, DOI 10.1074/jbc.M209505200	38	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20420	20428		10.1074/jbc.M302505200	http://dx.doi.org/10.1074/jbc.M302505200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660231	hybrid			2022-12-27	WOS:000183078000108
J	Yu, SJ; Asa, SL; Weigel, RJ; Ezzat, S				Yu, SJ; Asa, SL; Weigel, RJ; Ezzat, S			Pituitary tumor AP-2 alpha recognizes a cryptic promoter in intron 4 of fibroblast growth factor receptor 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; GENOMIC STRUCTURE; BINDING-SITE; GENE; EXPRESSION; REGION; FGFR-4; TRANSACTIVATION; IDENTIFICATION; PROLIFERATION	Fibroblast growth factor receptors (FGFRs) have been implicated in a multitude of proliferative functions, and FGFR4 is expressed differentially in normal and neoplastic pituitary. Human pituitary tumors express a truncated FGFR4 isoform (ptd-FGFR4) for which transcription is initiated from a downstream alternative site. Analysis of FGFR4 intronic sequences predicted a possible promoter within intron 4 (In4) including a classic TATA box with a possible transcriptional start site in intron 5. We show here that the human In4 sequence can direct luciferase reporter activity in transfected pituitary GH4 cells. Four overlapping fragments (A1, A2, B1, and B2) of this intron were examined by electromobility shift assay using nuclear extracts from rat pituitary tumors. Of these, fragment B2 formed complexes with nuclear rat pituitary GH4 extracts that were competed specifically by wild type but not mutant oligonucleotides for the neural crest cell lineage-derived activating transcription factor AP-2. Conversely, an AP-2 consensus sequence probe was competed by the In4 B2 oligonucleotide but not by other fragments of the same intron. The In4 B2 complex was competed partially by NFkappaB, supershifted by an AP-2 alpha-specific antibody, and co-migrated with the same probe incubated with recombinant AP-2alpha protein. We also examined the ability of primary human pituitary tumor extracts to interact with the In4 B2 fragment. Pituitary tumor-In4 B2 complexes were competed specifically by wild type AP-2 but not mutant AP-2 oligonucleotides. Western blotting revealed higher levels of AP-2alpha expression in primary human pituitary tumors than in nontumorous tissue. Mutagenesis of the putative AP-2 binding site in In4 B2 resulted in a marked loss of promoter activity in a luciferase assay. AP-2alpha transfection in the presence of the histone deacetylase inhibitor trichostatin-A resulted in enhanced expression of endogenous ptd-FGFR4. These data indicate that a cryptic promoter within intron 4 binds AP-2alpha. AP-2alpha and chromatin changes may contribute to the utilization of an alternative transcription start site leading to the genesis of the tumorigenic ptd-FGFR4 isoform.	Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5G 2M9, Canada; Univ Toronto, Freeman Ctr Endocrine Oncol, Univ Hlth Network, Dept Pathol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Jefferson University	Ezzat, S (corresponding author), Univ Toronto, Mt Sinai Hosp, 600 Univ Ave,437, Toronto, ON M5G 1X5, Canada.			Asa, Sylvia/0000-0001-8418-5054; Weigel, Ronald/0000-0002-9249-0793				Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926; AVIVI A, 1992, ONCOGENE, V7, P1957; Becker M, 2000, BIOCHEM BIOPH RES CO, V276, P493, DOI 10.1006/bbrc.2000.3483; BISHOP JF, 1990, FEBS LETT, V264, P125, DOI 10.1016/0014-5793(90)80781-D; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; EZZAT S, 1995, J CLIN ENDOCR METAB, V80, P878, DOI 10.1210/jc.80.3.878; Fiorentini C, 2002, MOL ENDOCRINOL, V16, P353, DOI 10.1210/me.16.2.353; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; HAUSER F, 1994, FEBS LETT, V345, P225, DOI 10.1016/0014-5793(94)00444-7; Hughes SE, 1997, J HISTOCHEM CYTOCHEM, V45, P1005, DOI 10.1177/002215549704500710; IVERSON RA, 1990, MOL ENDOCRINOL, V4, P1564, DOI 10.1210/mend-4-10-1564; JOHNSTON CL, 1995, BIOCHEM J, V306, P609, DOI 10.1042/bj3060609; Katsel PL, 2001, J BIOL CHEM, V276, P752, DOI 10.1074/jbc.M007553200; Koritschoner NP, 1999, ONCOGENE, V18, P5904, DOI 10.1038/sj.onc.1202979; Kostrzewa M, 1998, MAMM GENOME, V9, P131, DOI 10.1007/s003359900703; Lecomte MJ, 1999, J NEUROCHEM, V73, P1806; McEwen DG, 1998, J BIOL CHEM, V273, P5349, DOI 10.1074/jbc.273.9.5349; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Pfisterer P, 2002, J BIOL CHEM, V277, P6637, DOI 10.1074/jbc.M108578200; Ren YS, 2001, J BIOL CHEM, V276, P17770, DOI 10.1074/jbc.M010307200; SAITO H, 1992, BIOCHEM BIOPH RES CO, V183, P688, DOI 10.1016/0006-291X(92)90537-U; TsaiMorris CH, 1996, J BIOL CHEM, V271, P14519, DOI 10.1074/jbc.271.24.14519; Yu SJ, 2002, MOL ENDOCRINOL, V16, P1069, DOI 10.1210/me.16.5.1069; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200	28	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19597	19602		10.1074/jbc.M212432200	http://dx.doi.org/10.1074/jbc.M212432200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642581	hybrid			2022-12-27	WOS:000183078000006
J	Hiol, A; Davey, PC; Osterhout, JL; Waheed, AA; Fischer, ER; Chen, CK; Milligan, G; Druey, KM; Jones, TLZ				Hiol, A; Davey, PC; Osterhout, JL; Waheed, AA; Fischer, ER; Chen, CK; Milligan, G; Druey, KM; Jones, TLZ			Palmitoylation regulates regulators of G-protein signaling (RGS) 16 function - I. Mutation of amino-terminal cysteine residues on RGS16 prevents its targeting to lipid rafts and palmitoylation of an internal cysteine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE LOCALIZATION; FUSION PROTEINS; ALPHA-SUBUNITS; BINDING; RECEPTOR; DOMAIN; G-ALPHA(13); ASSOCIATION; TRANSDUCIN; MODULATION	Regulators of G-protein signaling (RGS) proteins down-regulate signaling by heterotrimeric G-proteins by accelerating GTP hydrolysis on the Galpha subunits. Palmitoylation, the reversible addition of palmitate to cysteine residues, occurs on several RGS proteins and is critical for their activity. For RGS16, mutation of Cys-2 and Cys-12 blocks its incorporation of [H-3]palmitate and ability to turn-off G(i) and G(q) signaling and significantly inhibited its GTPase activating protein activity toward a Galpha subunit fused to the 5-hydroxytryptamine receptor 1A, but did not reduce its plasma membrane localization based on cell fractionation studies and immunoelectron microscopy. Palmitoylation can target proteins, including many signaling proteins, to membrane microdomains, called lipid rafts. A subpopulation of endogenous RGS16 in rat liver membranes and overexpressed RGS16 in COS cells, but not the nonpalmitoylated cysteine mutant of RGS16, localized to lipid rafts. However, disruption of lipid rafts by treatment with methyl-beta-cyclodextrin did not decrease the GTPase activating protein activity of RGS16. The lipid raft fractions were enriched in protein acyltransferase activity, and RGS16 incorporated [H-3] palmitate into a peptide fragment containing Cys-98, a highly conserved cysteine within the RGS box. These results suggest that the amino-terminal palmitoylation of an RGS protein promotes its lipid raft targeting that allows palmitoylation of a poorly accessible cysteine residue that we show in the accompanying article (Osterhout, J. L., Waheed, A. A., Hiol, A., Ward, R. J., Davey, P. C., Nini, L., Wang, J., Milligan, G., Jones, T. L. Z., and Druey, K. M. (2003) J. Biol. Chem. 278, 19309 19316) was critical for RGS16 and RGS4 GAP activity.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; NIAID, Microscopy Branch, NIH, Hamilton, MT 59840 USA; Univ Utah, Dept Ophthalmol, Salt Lake City, UT 84112 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Utah System of Higher Education; University of Utah; University of Glasgow	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.	tlzj@helix.nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Biotechnology and Biological Sciences Research Council [C17789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN WJ, 1989, METHOD CELL BIOL, V31, P553; Caron JM, 1997, MOL BIOL CELL, V8, P621, DOI 10.1091/mbc.8.4.621; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Galbiati F, 1999, J BIOL CHEM, V274, P5843, DOI 10.1074/jbc.274.9.5843; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; Kellett E, 1999, MOL PHARMACOL, V56, P684; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Milligan G, 2000, TRENDS PHARMACOL SCI, V21, P24, DOI 10.1016/S0165-6147(99)01404-2; Miura Y, 2001, BIOCHEMISTRY-US, V40, P15418, DOI 10.1021/bi015574a; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Morales J, 1998, MOL BIOL CELL, V9, P1, DOI 10.1091/mbc.9.1.1; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Osterhout JL, 2003, J BIOL CHEM, V278, P19309, DOI 10.1074/jbc.M210124200; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Ugur O, 2000, MOL BIOL CELL, V11, P1421, DOI 10.1091/mbc.11.4.1421; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Wedegaertner PB, 1998, BIOL SIGNAL RECEPT, V7, P125; Wolven A, 1997, MOL BIOL CELL, V8, P1159, DOI 10.1091/mbc.8.6.1159; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	49	59	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19301	19308		10.1074/jbc.M210123200	http://dx.doi.org/10.1074/jbc.M210123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642593	hybrid			2022-12-27	WOS:000182932200076
J	Takahashi, Y; Hayashi, I; Tominari, Y; Rikimaru, K; Morohashi, Y; Kan, T; Natsugari, H; Fukuyama, T; Tomita, T; Iwatsubo, T				Takahashi, Y; Hayashi, I; Tominari, Y; Rikimaru, K; Morohashi, Y; Kan, T; Natsugari, H; Fukuyama, T; Tomita, T; Iwatsubo, T			Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces A beta 42 generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; THYMOCYTE DEVELOPMENT; MUTANT PRESENILIN-2; C-TERMINUS; COMPLEX; STATE; SITE; ENDOPROTEOLYSIS; OVERPRODUCTION	Nonsteroidal anti-inflammatory drugs (NSAIDs) have been known to reduce risk for Alzheimer's disease. In addition to the anti-inflammatory effects of NSAIDs to block cylooxygenase, it has been shown recently that a subset of NSAIDs selectively inhibits the secretion of highly amyloidogenic Abeta42 from cultured cells, although the molecular target(s) of NSAIDs in reducing the activity of gamma-secretase for Abeta42 generation (gamma(42)-secretase) still remain unknown. Here we show that sulindac sulfide (SSide) directly acts on gamma-secretase and preferentially inhibits the gamma(42)-secretase activity derived from the 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate-solubilized membrane fractions of HeLa cells, in an in vitro gamma-secretase assay using recombinant amyloid beta precursor protein C100 as a substrate. SSide also inhibits activities for the generation of Abeta40 as well as for Notch intracellular domain at higher concentrations. Notably, SSide displayed linear noncompetitive inhibition profiles for gamma(42)-secretase in vitro. Our data suggest that SSide is a direct inhibitor of gamma-secretase that preferentially affects the gamma(42)-secretase activity.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Synthet Nat Prod Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Rat Med Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Iwatsubo, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	iwatsubo@mol.f.u-tokyo.ac.jp	Tomita, Taisuke/L-5427-2015	Tomita, Taisuke/0000-0002-0075-5943; Kan, Toshiyuki/0000-0002-9709-6365; Rikimaru, Kentaro/0000-0001-5106-5523				Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Durkin JT, 1999, J BIOL CHEM, V274, P20499, DOI 10.1074/jbc.274.29.20499; Esler WP, 2002, NAT CELL BIOL, V4, pE110, DOI 10.1038/ncb0502-e110b; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jantzen PT, 2002, J NEUROSCI, V22, P2246, DOI 10.1523/JNEUROSCI.22-06-02246.2002; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Kisselev AF, 1999, MOL CELL, V4, P395, DOI 10.1016/S1097-2765(00)80341-X; Levitan D, 2001, P NATL ACAD SCI USA, V98, P12186, DOI 10.1073/pnas.211321898; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Micchelli CA, 2002, FASEB J, V16, P79, DOI 10.1096/fj.02-0394fje; Morihara T, 2002, J NEUROCHEM, V83, P1009, DOI 10.1046/j.1471-4159.2002.01195.x; Morohashi Y, 2002, J BIOL CHEM, V277, P14965, DOI 10.1074/jbc.M200897200; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; Petit A, 2001, NAT CELL BIOL, V3, P507, DOI 10.1038/35074581; Schmidtke G, 2000, J BIOL CHEM, V275, P22056, DOI 10.1074/jbc.M002513200; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Takasugi N, 2002, J BIOL CHEM, V277, P50198, DOI 10.1074/jbc.M205352200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tian GC, 2002, J BIOL CHEM, V277, P31499, DOI 10.1074/jbc.M112328200; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Tomita T, 2001, J BIOL CHEM, V276, P33273, DOI 10.1074/jbc.M011152200; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1998, J MED CHEM, V41, P6, DOI 10.1021/jm970621b; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Zandi PP, 2001, NEUROBIOL AGING, V22, P811, DOI 10.1016/S0197-4580(01)00297-4; Zhang LL, 2001, BIOCHEMISTRY-US, V40, P5049, DOI 10.1021/bi0028800	46	173	197	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18664	18670		10.1074/jbc.M301619200	http://dx.doi.org/10.1074/jbc.M301619200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637581	hybrid			2022-12-27	WOS:000182838300139
J	Houde, C; Roy, S; Leung, N; Nicholson, DW; Beauchemin, N				Houde, C; Roy, S; Leung, N; Nicholson, DW; Beauchemin, N			The cell adhesion molecule CEACAM1-L is a substrate of caspase-3-mediated cleavage in apoptotic mouse intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CONVERTING-ENZYME; BILIARY GLYCOPROTEIN; POLY(ADP-RIBOSE) POLYMERASE; CYTOPLASMIC DOMAIN; CYTOCHROME-C; CASPASES; ACTIN; PROTEASE; MEMBERS; KINASE	The CEACAM1 cell adhesion molecule is a member of the carcinoembryonic antigen family. In the mouse, four distinct isoforms are generated by alternative splicing. These encode either two or four immunoglobulin domains linked through a transmembrane domain to a cytoplasmic domain that encompasses either a short 10-amino acid tail or a longer one of 73 amino acids. Inclusion of exon 7, well conserved in evolution, generates the long cytoplasmic domain. A potential caspase recognition site in mouse, rat, and human CEACAM1-L also becomes available within the peptide encoded by exon 7. We used CEACAM1-L-transfected mouse colon carcinoma CT51 cells treated with three different apoptotic agents to study its fate during cell death. We found that CEACAM1-L is cleaved resulting in rapid degradation of most of its 8-kDa cytoplasmic domain. Caspase-mediated cleavage was demonstrated using purified recombinant caspases. The long cytoplasmic domain was cleaved specifically by caspase-3 in vitro but not by caspase-7 or -8. Moreover cleavage of CEACAM1-L in apoptotic cells was blocked by addition of a selective caspase-3 inhibitor to the cultures. Using point and deletion mutants, the conserved DQRD motif in the membrane-proximal cytoplasmic domain was identified as a caspase cleavage site. We also show that once CEACAM1-L is caspase-cleaved it becomes a stronger adhesion molecule than both the shorter and the longer expressing isoforms.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; Merck Frosst Ctr Therapeut Res, Pointe Claire, PQ H9R 4P8, Canada	McGill University; McGill University; McGill University; McGill University; Merck & Company	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	nicole.beauchemin@mcgill.ca						Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brummer J, 2001, AM J PATHOL, V159, P537, DOI 10.1016/S0002-9440(10)61725-7; CHEUNG PH, 1993, J BIOL CHEM, V268, P24303; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Ebrahimnejad A, 2000, EXP CELL RES, V260, P365, DOI 10.1006/excr.2000.5026; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FRANGSMYR L, 1995, CANCER RES, V55, P2963; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Han BH, 2002, J BIOL CHEM, V277, P30128, DOI 10.1074/jbc.M202931200; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Ilan N, 2001, FASEB J, V15, P362, DOI 10.1096/fj.00-0372com; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kunath T, 1995, ONCOGENE, V11, P2375; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; Moffatt OD, 1999, J IMMUNOL, V162, P6800; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ROSENBERG M, 1993, CANCER RES, V53, P4938; Rotonda J, 1996, NAT STRUCT BIOL, V3, P619, DOI 10.1038/nsb0796-619; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; SKUBITZ KM, 1995, J IMMUNOL, V155, P5382; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VALLEJO AN, 1994, PCR METH APPL, V4, pS123; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	46	21	21	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16929	16935		10.1074/jbc.M301842200	http://dx.doi.org/10.1074/jbc.M301842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637508	hybrid			2022-12-27	WOS:000182818600066
J	Jazayeri, M; Andreyev, A; Will, Y; Ward, M; Anderson, CM; Clevenger, W				Jazayeri, M; Andreyev, A; Will, Y; Ward, M; Anderson, CM; Clevenger, W			Inducible expression of a dominant negative DNA polymerase-gamma depletes mitochondrial DNA and produces a rho(0) phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELL LINE; FUNCTIONAL-ANALYSIS; MYOCLONIC EPILEPSY; INSULIN-SECRETION; MUTATION; MTDNA; DISEASES; REPLICATION; DEFICIENCY; CREATION	We report the inducible, stable expression of a dominant negative form of mitochondria-specific DNA polymerase-gamma to eliminate mitochondrial DNA (mtDNA) from human cells in culture. HEK293 cells were transfected with a plasmid encoding inactive DNA polymerase-gamma harboring a D1135A substitution (POLGdn). The cells rapidly lost mtDNA (t(1/2) = 2-3 days) when expression of the transgene was induced. Concurrent reduction of mitochondrial encoded mRNA and protein, decreased cellular growth rate, and compromised respiration and mitochondrial membrane potential were observed. mtDNA depletion was reversible, as demonstrated by restoration of mtDNA copy number to normal within 10 days when the expression of POLGdn was suppressed following a 3-day induction period. Long term (20 days) expression of POLGdn completely eliminated mtDNA from the cells, resulting in p(0) cells that were respiration-deficient, lacked electron transport complex activities, and were auxotrophic for pyruvate and uridine. Fusion of the p(0) cells with human platelets yielded clonal cybrid cell lines that were populated exclusively with donor-derived mtDNA. Respiratory function, mitochondrial membrane potential, and electron transport activities were restored to normal in the cybrid cells. Inducible expression of a dominant negative DNA polymerase-gamma can yield mtDNA-deficient cell lines, which can be used to study the impact of specific mtDNA mutations on cellular physiology, and to investigate mitochondrial genome function and regulation.	MitoKor Inc, San Diego, CA 92121 USA		Anderson, CM (corresponding author), 11494 Sorrento Valley Rd, San Diego, CA 92121 USA.	andersonc@mitokor.com		Andreyev, Alexander Y./0000-0002-9246-9943; Ward, Manus/0000-0002-7085-9668				Anderson CM, 1999, DRUG DEVELOP RES, V46, P67, DOI 10.1002/(SICI)1098-2299(199901)46:1<67::AID-DDR10>3.0.CO;2-V; BEREITERHAHN J, 1978, J CELL SCI, V30, P99; Birch-Machin MA, 1993, METHODS TOXICOL, V2, P51; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; BOULET L, 1992, AM J HUM GENET, V51, P1187; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Clayton D A, 2000, Hum Reprod, V15 Suppl 2, P11; CLAYTON DA, 1991, TRENDS BIOCHEM SCI, V16, P107, DOI 10.1016/0968-0004(91)90043-U; Davis AF, 1996, NUCLEIC ACIDS RES, V24, P2753, DOI 10.1093/nar/24.14.2753; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; Errede B, 1978, Methods Enzymol, V53, P40; Fiskum G, 2000, METHOD ENZYMOL, V322, P222; FISKUM G, 1980, P NATL ACAD SCI-BIOL, V77, P3430, DOI 10.1073/pnas.77.6.3430; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; Gilkerson RW, 2000, FEBS LETT, V474, P1, DOI 10.1016/S0014-5793(00)01527-1; Hofhaus G, 1996, J BIOL CHEM, V271, P13155, DOI 10.1074/jbc.271.22.13155; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; JUKES TH, 1990, EXPERIENTIA, V46, P1117, DOI 10.1007/BF01936921; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819; Miller SW, 1996, J NEUROCHEM, V67, P1897; PHAM NA, 2001, 5 EUR M MIT PATH SEP; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Rothman SM, 1999, BIOCHEM SOC SYMP, V66, P111, DOI 10.1042/bss0660111; SAIKUMAR P, 1985, BIOCHIM BIOPHYS ACTA, V840, P127, DOI 10.1016/0304-4165(85)90169-2; Schapira AHV, 2000, CURR OPIN NEUROL, V13, P527, DOI 10.1097/00019052-200010000-00004; Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200; Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379; TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017; Trounce I, 1996, SOMAT CELL MOLEC GEN, V22, P81, DOI 10.1007/BF02374379; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541	41	55	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9823	9830		10.1074/jbc.M211730200	http://dx.doi.org/10.1074/jbc.M211730200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645575	hybrid			2022-12-27	WOS:000181524000126
J	Jiang, N; Benard, CY; Kebir, H; Shoubridge, EA; Hekimi, S				Jiang, N; Benard, CY; Kebir, H; Shoubridge, EA; Hekimi, S			Human CLK2 links cell cycle progression, apoptosis, and telomere length regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; C-ELEGANS; LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MAMMALIAN-CELLS; GENE-TRANSFER; PROTEIN; DNA; EXPRESSION	Mutations in the clk- 2 gene of the nematode Caenorhabditis elegans affect organismal features such as development, behavior, reproduction, and aging as well as cellular features such as the cell cycle, apoptosis, the DNA replication checkpoint, and telomere length. clk- 2 encodes a novel protein ( CLK- 2) with a unique homologue in each of the sequenced eukaryotic genomes. We have studied the human homologue of CLK- 2 ( hCLK2) to determine whether it affects the same set of cellular features as CLK- 2. We find that overexpression of hCLK2 decreases cell cycle length and that inhibition of hCLK2 expression arrests the cell cycle reversibly. Overexpression of hCLK2, however, renders the cell hypersensitive to apoptosis triggered by oxidative stress or DNA replication block and gradually increases telomere length. The evolutionary conservation of the pattern of cellular functions affected by CLK- 2 suggests that the function of hCLK2 in humans might also affect the same organismal features as in worms, including life span. Surprisingly, we find that hCLK2 is present in all cellular compartments and exists as a membrane- associated as well as a soluble form.	McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 1B1, Canada	McGill University; McGill University	Hekimi, S (corresponding author), McGill Univ, Dept Biol, 1205 Doctor Penfield Ave, Montreal, PQ H3A 1B1, Canada.		Benard, Claire/I-7526-2015	Kebir, Hania/0000-0001-6174-8846				Ahmed S, 2001, CURR BIOL, V11, P1934, DOI 10.1016/S0960-9822(01)00604-2; Benard C, 2002, MECH AGEING DEV, V123, P869, DOI 10.1016/S0047-6374(02)00024-6; Benard C, 2001, DEVELOPMENT, V128, P4045; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; DESJARDINS LM, 1995, EXP CELL RES, V216, P380, DOI 10.1006/excr.1995.1048; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Gartner A, 2000, MOL CELL, V5, P435, DOI 10.1016/S1097-2765(00)80438-4; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEKIMI S, 1995, GENETICS, V141, P1351; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; JAMIESON DJ, 1994, MICROBIOL-UK, V140, P3277, DOI 10.1099/13500872-140-12-3277; Kota RS, 1998, NUCLEIC ACIDS RES, V26, P1528, DOI 10.1093/nar/26.6.1528; Kota RS, 1999, CHROMOSOMA, V108, P278, DOI 10.1007/s004120050379; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Perls T, 2000, RES PRO CEL, V29, P1; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Runge KW, 1996, MOL CELL BIOL, V16, P3094; SANO M, 1994, J TOXICOL ENV HEALTH, V43, P339, DOI 10.1080/15287399409531925; Strobel G, 2002, MOL BIOL CELL, V13, P1439, DOI 10.1091/mbc.01-08-0396; Tissenbaum HA, 2002, DEV CELL, V2, P9, DOI 10.1016/S1534-5807(01)00098-3; Wang NS, 2001, J BIOL CHEM, V276, P44117, DOI 10.1074/jbc.M101958200; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	29	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21678	21684		10.1074/jbc.M300286200	http://dx.doi.org/10.1074/jbc.M300286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670948	hybrid			2022-12-27	WOS:000183354200047
J	Kremer, L; Dover, LG; Morbidoni, HR; Vilcheze, C; Maughan, WN; Baulard, A; Tu, SC; Honore, N; Deretic, V; Sacchettini, JC; Locht, C; Jacobs, WR; Besra, GS				Kremer, L; Dover, LG; Morbidoni, HR; Vilcheze, C; Maughan, WN; Baulard, A; Tu, SC; Honore, N; Deretic, V; Sacchettini, JC; Locht, C; Jacobs, WR; Besra, GS			Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; CATALASE-PEROXIDASE GENE; KETOACYL-ACP SYNTHASE; ISONIAZID RESISTANCE; ENZYMATIC CHARACTERIZATION; ESCHERICHIA-COLI; ENOYL REDUCTASE; BIOCHEMICAL-CHARACTERIZATION; DRUG ETHIONAMIDE; TUBERCULOSIS	Isoniazid (INH) remains one of the key drugs used to control tuberculosis, with the enoyl-AcpM reductase InhA being the primary target. However, based on the observation that INH-treated Mycobacterium tuberculosis overproduces KasA, an enzyme involved in the biosynthesis of mycolic acids, and induces the formation of a covalent complex consisting of AcpM, KasA, and INH, it has been proposed that KasA represents the primary target of INH. However, the relevance of this complex to INH action remains obscure. This study was aimed at clarifying the role of InhA and KasA in relation to INH activity. By using anti-KasA antibodies we detected the KasA-containing complex in INH-treated Mycobacterium smegmatis. In addition, INH-treated cells also produced constant levels of KasA that were not sequestered in the complex and presumably were sufficient to ensure mycolic acid biosynthesis. Interestingly, a furA-lacking strain induced the complex at lower concentrations of INH compared with the control strain, whereas higher INH concentrations were necessary to induce the complex in a strain that lacks katG, suggesting that INH needs to be activated by KatG to induce the KasA-containing complex. The InhA inhibitors ethionamide and diazaborine also induced the complex; thus, its formation was not specifically relevant to INH action but was because of InhA inhibition. In addition, in vitro assays using purified InhA and KasA demonstrated that KatG-activated INH, triclosan, and diazaborine inhibited InhA but not KasA activity. Moreover, several thermosensitive InhA mutant strains of M. smegmatis constitutively expressed the KasA-containing complex. This study provides the biochemical and genetic evidence. 1) Only inhibition of InhA, but not KasA, induces the KasA-containing complex. 2) INH is not part of the complex. 3) INH does not target KasA, consistent with InhA being the primary target of INH.	Inst Pasteur, Lab Mecanismes Mol Pathogenie Microbienne, INSERM, U447,IBL, F-59019 Lille, France; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Albert Einstein Coll Med, Howard Hughes Med Inst, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Univ Houston, Dept Biol, Houston, TX 77204 USA; Inst Pasteur, Unite Genet Mol Bacterienne, Paris, France; Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Birmingham; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Houston System; University of Houston; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of New Mexico; Texas A&M University System; Texas A&M University College Station	Kremer, L (corresponding author), Inst Pasteur, Lab Mecanismes Mol Pathogenie Microbienne, INSERM, U447,IBL, F-59019 Lille, France.	laurent.kremer@ibl.fr	Dover, Lynn George/Q-6778-2019; Locht, Camille/L-3516-2018; Dover, Lynn G/F-3021-2010; Kremer, Laurent/M-4935-2017; Baulard, Alain R/E-6830-2017	Dover, Lynn George/0000-0002-4776-2665; Dover, Lynn G/0000-0002-4776-2665; Kremer, Laurent/0000-0002-6604-4458; Baulard, Alain R/0000-0002-0150-5241; Jacobs, William/0000-0003-3321-3080; Besra, Gurdyal/0000-0002-5605-0395; Deretic, Vojo/0000-0002-3624-5208	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031139, R21AI043268, R01AI043268] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43268, AI 31139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1998, J INFECT DIS, V178, P769, DOI 10.1086/515362; Baulard AR, 2000, J BIOL CHEM, V275, P28326; Bergler H, 1996, EUR J BIOCHEM, V242, P689, DOI 10.1111/j.1432-1033.1996.0689r.x; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; Davis MC, 1998, BIOORG MED CHEM LETT, V8, P843, DOI 10.1016/S0960-894X(98)00126-7; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; Deretic V, 1996, NAT BIOTECHNOL, V14, P1557, DOI 10.1038/nbt1196-1557; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; Fan F, 2002, ANTIMICROB AGENTS CH, V46, P3343, DOI 10.1128/AAC.46.11.3343-3347.2002; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Heath RJ, 2001, PROG LIPID RES, V40, P467, DOI 10.1016/S0163-7827(01)00012-1; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KAWAGUCHI A, 1982, J BIOCHEM-TOKYO, V92, P7, DOI 10.1093/oxfordjournals.jbchem.a133933; Kremer L, 2000, J BIOL CHEM, V275, P16857, DOI 10.1074/jbc.M000569200; Kremer L, 2002, EXPERT OPIN INV DRUG, V11, P1033; Kremer L, 2002, MICROBIOL-SGM, V148, P3145, DOI 10.1099/00221287-148-10-3145; Kremer L, 2002, BIOCHEM J, V364, P423, DOI 10.1042/BJ20011628; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen MH, 2002, MOL MICROBIOL, V46, P453, DOI 10.1046/j.1365-2958.2002.03162.x; Lee ASG, 1999, ANTIMICROB AGENTS CH, V43, P2087, DOI 10.1128/AAC.43.8.2087; Lei BF, 2000, J BIOL CHEM, V275, P2520, DOI 10.1074/jbc.275.4.2520; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Marrakchi H, 2000, MICROBIOL-UK, V146, P289, DOI 10.1099/00221287-146-2-289; McMurry LM, 1999, ANTIMICROB AGENTS CH, V43, P711, DOI 10.1128/AAC.43.3.711; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; Mdluli K, 1998, SCIENCE, V280, P1607, DOI 10.1126/science.280.5369.1607; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; Miesel L, 1998, J BACTERIOL, V180, P2459, DOI 10.1128/JB.180.9.2459-2467.1998; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MORISAKI N, 1993, EUR J BIOCHEM, V211, P111, DOI 10.1111/j.1432-1033.1993.tb19876.x; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Parrish NM, 1999, J ANTIMICROB CHEMOTH, V43, P219, DOI 10.1093/jac/43.2.219; Phetsuksiri B, 1999, ANTIMICROB AGENTS CH, V43, P1042, DOI 10.1128/AAC.43.5.1042; Piatek AS, 2000, ANTIMICROB AGENTS CH, V44, P103, DOI 10.1128/AAC.44.1.103-110.2000; Price AC, 2001, J BIOL CHEM, V276, P6551, DOI 10.1074/jbc.M007101200; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Roujeinikova A, 1999, J BIOL CHEM, V274, P30811, DOI 10.1074/jbc.274.43.30811; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; SAMBROOK J, 1989, MOL CLOING LAB MANUA; SANDER P, 1995, MOL MICROBIOL, V16, P991, DOI 10.1111/j.1365-2958.1995.tb02324.x; Schaeffer ML, 2001, J BIOL CHEM, V276, P47029, DOI 10.1074/jbc.M108903200; Schweizer HP, 2001, FEMS MICROBIOL LETT, V202, P1, DOI 10.1111/j.1574-6968.2001.tb10772.x; Slayden RA, 2000, MOL MICROBIOL, V38, P514, DOI 10.1046/j.1365-2958.2000.02145.x; Slayden RA, 1996, ANTIMICROB AGENTS CH, V40, P2813, DOI 10.1128/AAC.40.12.2813; Slayden RA, 2000, MICROBES INFECT, V2, P659, DOI 10.1016/S1286-4579(00)00359-2; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; STOVER CK, 1991, NATURE, V351, P456, DOI 10.1038/351456a0; SUITTON B, 1912, CR HEBD ACAD SCI, V155, P860; TAKAYAMA K, 1973, ANTIMICROB AGENTS CH, V4, P62, DOI 10.1128/AAC.4.1.62; TAKAYAMA K, 1975, J LIPID RES, V16, P308; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; TSAY JT, 1992, J BACTERIOL, V174, P508, DOI 10.1128/jb.174.2.508-513.1992; Vannelli TA, 2002, J BIOL CHEM, V277, P12824, DOI 10.1074/jbc.M110751200; Vilcheze C, 2000, J BACTERIOL, V182, P4059, DOI 10.1128/JB.182.14.4059-4067.2000; Wei CJ, 2003, ANTIMICROB AGENTS CH, V47, P670, DOI 10.1128/AAC.47.2.670-675.2003; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; Zahrt TC, 2001, MOL MICROBIOL, V39, P1174, DOI 10.1046/j.1365-2958.2001.02321.x; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	70	62	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20547	20554		10.1074/jbc.M302435200	http://dx.doi.org/10.1074/jbc.M302435200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654922	hybrid			2022-12-27	WOS:000183230500015
J	Davis, FJ; Gupta, M; Camoretti-Mercado, B; Schwartz, RJ; Gupta, MP				Davis, FJ; Gupta, M; Camoretti-Mercado, B; Schwartz, RJ; Gupta, MP			Calcium/calmodulin-dependent protein kinase activates serum response factor transcription activity by its dissociation from histone deacetylase, HDAC4 - Implications in cardiac muscle gene regulation during hypertrophy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CAM KINASE; MADS BOX; EXPRESSION; LOCALIZATION; NUCLEAR; ELEMENT; DOMAIN; PHOSPHORYLATION; RECRUITMENT	Serum response factor (SRF) plays a pivotal role in cardiac myocyte development, muscle gene transcription, and hypertrophy. Previously, elevation of intracellular levels of Ca2+ was shown to activate SRF function without involving the Ets family of tertiary complex factors through an unknown regulatory mechanism. Here, we tested the hypothesis that the chromatin remodeling enzymes of class II histone deacetylases (HDAC4) regulate SRF activity in a Ca2+-sensitive manner. Expression of HDAC4 profoundly repressed SRF-mediated transcription in both muscle and nonmuscle cells. Protein interaction studies demonstrated physical association of HDAC4 with SRF in living cells. The SRF/HDAC4 co-association was disrupted by treatment of cells with hypertrophic agonists such as angiotensin-II and a Ca2+ ionophore, ionomycin. Furthermore, activation of Ca2+/calmodulin-dependent protein kinase (CaMK)-IV prevented SRF/HDAC4 interaction and derepressed SRF-dependent transcription activity. The SRF.HDAC4 complex was localized to the cell nucleus, and the activated CaMK-IV disrupted HDAC4/SRF association, leading to export of HDAC4 from the nucleus and stimulation of SRF transcription activity. Thus, these results identify SRF as a functional interacting target of HDAC4 and define a novel tertiary complex factor-independent mechanism for SRF activation by Ca2+/CaMK-mediated signaling.	Univ Chicago, Dept Surg, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Hope Childrens Hosp, Oak Lawn, IL 60453 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Chicago; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Baylor College of Medicine	Gupta, MP (corresponding author), Univ Chicago, Dept Surg, MC-5040,5841 S Maryland Ave, Chicago, IL 60637 USA.	mgupta@surgery.bsd.uchicago.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068083] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-68083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Belaguli NS, 1999, MOL CELL BIOL, V19, P4582; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; Borghi S, 2001, J CELL SCI, V114, P4477; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; Bristow MR, 1998, LANCET, V352, P8; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Cheng GM, 1999, J BIOL CHEM, V274, P12819, DOI 10.1074/jbc.274.18.12819; Davis FJ, 2002, AM J PHYSIOL-HEART C, V282, pH1521, DOI 10.1152/ajpheart.00844.2001; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gupta M, 2001, J BIOL CHEM, V276, P10413, DOI 10.1074/jbc.M008625200; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hines WA, 1999, MOL CELL BIOL, V19, P1841; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Kemp PR, 2000, BIOCHEM J, V345, P445, DOI 10.1042/0264-6021:3450445; Lu JR, 2000, MOL CELL, V6, P233, DOI 10.1016/S1097-2765(00)00025-3; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MISRA RP, 1994, J BIOL CHEM, V269, P25483; Moore ML, 2001, J BIOL CHEM, V276, P1026, DOI 10.1074/jbc.M009352200; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SRINIVASAN M, 1994, J CELL BIOL, V126, P839, DOI 10.1083/jcb.126.4.839; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; Wang AH, 1999, MOL CELL BIOL, V19, P7816; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593; Youn HD, 2000, J BIOL CHEM, V275, P22563, DOI 10.1074/jbc.C000304200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200; Zhang XM, 2001, AM J PHYSIOL-HEART C, V280, pH1782, DOI 10.1152/ajpheart.2001.280.4.H1782; Zhao X, 2001, J BIOL CHEM, V276, P35042, DOI 10.1074/jbc.M105086200; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697	54	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20047	20058		10.1074/jbc.M209998200	http://dx.doi.org/10.1074/jbc.M209998200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663674	hybrid			2022-12-27	WOS:000183078000062
J	Kwon, K; Cao, CY; Stivers, JT				Kwon, K; Cao, CY; Stivers, JT			A novel zinc snap motif conveys structural stability to 3-methyladenine DNA glycosylase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; METALLOREGULATORY PROTEIN; HETERONUCLEAR NMR; BINDING DOMAIN; RECOGNITION; COBALT(II); CARBOXYPEPTIDASE; SUPERFAMILY; RUBREDOXIN; NICKEL(II)	The Escherichia coli 3-methyladenine DNA glycosylase I ( TAG) is a DNA repair enzyme that excises 3-methyladenine in DNA and is the smallest member of the helix-hairpin-helix (HhH) superfamily of DNA glycosylases. Despite many studies over the last 25 years, there has been no suggestion that TAG was a metalloprotein. However, here we establish by heteronuclear NMR and other spectroscopic methods that TAG binds 1 eq of Zn2+ extremely tightly. A family of refined NMR structures shows that 4 conserved residues contributed from the amino- and carboxyl-terminal regions of TAG (Cys(4), His(17), His(175), and Cys(179)) form a Zn2+ binding site. The Zn2+ ion serves to tether the otherwise unstructured amino- and carboxyl-terminal regions of TAG. We propose that this unexpected "zinc snap" motif in the TAG family (CX12-17HXsimilar to150HX3C) serves to stabilize the HhH domain thereby mimicking the functional role of protein-protein interactions in larger HhH superfamily members.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM056834, GM46835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG JM, 1990, J BIOL CHEM, V265, P6513; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BOITEUX S, 1984, EMBO J, V3, P2569, DOI 10.1002/j.1460-2075.1984.tb02175.x; BORDEN KLB, 1995, EMBO J, V14, P5947, DOI 10.1002/j.1460-2075.1995.tb00283.x; BUBACCO L, 1992, BIOCHEMISTRY-US, V31, P9294, DOI 10.1021/bi00153a024; Bujnicki JM, 2002, DNA REPAIR, V1, P391, DOI 10.1016/S1568-7864(02)00017-4; DAIKUN GP, 1986, NATURE, V324, P698; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 2002, NAT STRUCT BIOL, V9, P659, DOI 10.1038/nsb829; Fromme JC, 2002, NAT STRUCT BIOL, V9, P544, DOI 10.1038/nsb809; Gilboa R, 2002, J BIOL CHEM, V277, P19811, DOI 10.1074/jbc.M202058200; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; LANE RW, 1977, J AM CHEM SOC, V99, P84, DOI 10.1021/ja00443a017; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MAY SW, 1978, BIOCHEMISTRY-US, V17, P3333, DOI 10.1021/bi00609a025; MENISSIERDEMURCIA J, 1989, J MOL BIOL, V210, P229, DOI 10.1016/0022-2836(89)90302-1; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NAVARATNAM S, 1989, J BIOL CHEM, V264, P16067; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; Outten CE, 2001, BIOCHEMISTRY-US, V40, P10417, DOI 10.1021/bi0155448; PELTON JG, 1993, PROTEIN SCI, V2, P543; RIAZUDDIN S, 1978, BIOCHEMISTRY-US, V17, P2110, DOI 10.1021/bi00604a014; ROSENBERG RC, 1975, J AM CHEM SOC, V97, P21, DOI 10.1021/ja00834a006; ROSENBERG RC, 1973, P NATL ACAD SCI USA, V70, P161, DOI 10.1073/pnas.70.1.161; SHAKA AJ, 1983, J MAGN RESON, V52, P335, DOI 10.1016/0022-2364(83)90207-X; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VASAK M, 1981, BIOCHEMISTRY-US, V20, P6659, DOI 10.1021/bi00526a021; Wyatt MD, 1999, BIOESSAYS, V21, P668, DOI 10.1002/(SICI)1521-1878(199908)21:8<668::AID-BIES6>3.3.CO;2-4	28	23	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19442	19446		10.1074/jbc.M300934200	http://dx.doi.org/10.1074/jbc.M300934200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654914	hybrid			2022-12-27	WOS:000182932200093
J	Patel, H; Di Pietro, E; MacKenzie, RE				Patel, H; Di Pietro, E; MacKenzie, RE			Mammalian fibroblasts lacking mitochondrial NAD(+)-dependent methylenetetrahydrofolate dehydrogenase-cyclohydrolase are glycine auxotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CARBON METABOLISM; SERINE HYDROXYMETHYLTRANSFERASE ISOZYMES; METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE; 5,10-METHYLENETETRAHYDROFOLATE DEHYDROGENASE; C1-TETRAHYDROFOLATE SYNTHASE; CELLS; SYNTHETASE; PURIFICATION; EXPRESSION; FOLATE	Primary fibroblasts established from embryos of NAD-dependent mitochondrial methylenetetrahydrofolate dehydrogenase-cyclohydrolase (NMDMC) knockout mice were spontaneously immortalized or transformed with SV40 Large T antigen. Mitotracker Red CMXRos staining of the cells indicates the presence of intact mitochondria with a membrane potential. The nmdmc((-/-)) cells are auxotrophic for glycine, demonstrating that NMDMC is the only methylenetetrahydrofolate dehydrogenase normally expressed in the mitochondria of these cell lines. Growth of null mutant but not wild type cells on complete medium with dialyzed serum is stimulated about 2-fold by added formate or hypoxanthine. Radiolabeling experiments demonstrated a 3-10x enhanced incorporation of radioactivity into DNA from formate relative to serine by nmdmc((-/-)) cells. The generation of one-carbon units by mitochondria in nmdmc((-/-)) cells is completely blocked, and the cytoplasmic folate pathways alone are insufficient for optimal purine synthesis. The results demonstrate a metabolic role for NMDMC in supporting purine biosynthesis. Despite the recognition of these metabolic defects in the mutant cell lines, the phenotype of nmdmc((-/-)) embryos that begin to die at E13.5 is not improved when pregnant dams are given a glycine-rich diet or daily injections of sodium formate.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	MacKenzie, RE (corresponding author), McGill Univ, Dept Biochem, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	Robert.Mackenzie@mcgill.ca						BARLOWE C K, 1988, Biofactors, V1, P171; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077; CYBULSKI RL, 1981, BIOCHIM BIOPHYS ACTA, V646, P329, DOI 10.1016/0005-2736(81)90339-4; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; Fu TF, 2001, ARCH BIOCHEM BIOPHYS, V393, P42, DOI 10.1006/abbi.2001.2471; GARROW TA, 1992, P NATL ACAD SCI USA, V89, P9151, DOI 10.1073/pnas.89.19.9151; Herbig K, 2002, J BIOL CHEM, V277, P38381, DOI 10.1074/jbc.M205000200; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; HOFFMAN RM, 1982, IN VITRO CELL DEV B, V18, P421; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; Kastanos EK, 1997, BIOCHEMISTRY-US, V36, P14956, DOI 10.1021/bi971610n; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; LIN BF, 1993, J BIOL CHEM, V268, P21674; LIN BF, 1994, J BIOL CHEM, V269, P9705; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1986, J BIOL CHEM, V261, P9509; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Minamikawa T, 1999, J CELL SCI, V112, P2419; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; Patel H, 2002, ARCH BIOCHEM BIOPHYS, V403, P145, DOI 10.1016/S0003-9861(02)00203-5; Pawelek PD, 1996, BBA-PROTEIN STRUCT M, V1296, P47, DOI 10.1016/0167-4838(96)00052-0; PELLETIER JN, 1995, BIOCHEMISTRY-US, V34, P12673, DOI 10.1021/bi00039a025; PERI KG, 1991, FEBS LETT, V294, P113, DOI 10.1016/0014-5793(91)81354-B; Piper MD, 2000, J BIOL CHEM, V275, P30987, DOI 10.1074/jbc.M004248200; SHANNON KW, 1986, J BIOL CHEM, V261, P2266; SMITH GK, 1990, ARCH BIOCHEM BIOPHYS, V283, P367, DOI 10.1016/0003-9861(90)90656-J; Tang BQ, 2000, CANCER RES, V60, P5543; THIGPEN AE, 1990, J BIOL CHEM, V265, P7907; TRENT DF, 1991, BIOCHEM PHARMACOL, V42, P1015, DOI 10.1016/0006-2952(91)90283-B; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; YANG XM, 1993, BIOCHEMISTRY-US, V32, P1118, DOI 10.1021/bi00092a022	35	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19436	19441		10.1074/jbc.M301718200	http://dx.doi.org/10.1074/jbc.M301718200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646567	hybrid			2022-12-27	WOS:000182932200092
J	Sabrane, K; Gambaryan, S; Brandes, RP; Holtwick, R; Voss, M; Kuhn, M				Sabrane, K; Gambaryan, S; Brandes, RP; Holtwick, R; Voss, M; Kuhn, M			Increased sensitivity to endothelial nitric oxide (NO) contributes to arterial normotension in mice with vascular smooth muscle-selective deletion of the atrial natriuretic peptide (ANP) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE RECEPTORS; BLOOD-PRESSURE; CELLS; LACKING; EXPRESSION; SYNTHASE; HYPERTENSION; RELAXATION; CORONARY; PROTEIN	Atrial natriuretic peptide (ANP) plays a key regulatory role in arterial blood pressure homeostasis. We recently generated mice with selective deletion of the ANP receptor, guanylyl cyclase-A (GC-A), in vascular smooth muscle (SMC GC-A knockout (KO) mice) and reported that resting arterial blood pressure was completely normal in spite of clear abolition of the direct vasodilating effects of ANP (Holtwick, R., Gotthardt, M., Skryabin, B., Steinmetz, M., Potthast, R., Zetsche, B., Hammer, R. E., Herz, J., and Kuhn M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 7142-7147). The purpose of this study was to clarify mechanisms compensating for the missing vasodilator responses to ANP. In particular, we analyzed the effect of the endothelial, cGMP-mediated vasodilators C-type natriuretic peptide and nitric oxide (NO). In isolated arteries from SMC GC-A KO mice, the vasorelaxing sensitivity to sodium nitroprusside and the endothelium-dependent vasodilator, acetylcholine, was significantly greater than in control mice. There was no difference in responses to C-type natriuretic peptide or to the activator of cGMP-dependent protein kinase I, 8-para-chlorophenylthio-cGMP. The aortic expression of soluble GC (sGC), but not of endothelial NO synthase or cGMP-dependent protein kinase I, was significantly increased in SMC GC-A KO mice. Chronic oral treatment with the NO synthase inhibitor N-w-nitro-L-arginine methyl ester increased arterial blood pressure, the effect being significantly enhanced in SMC GC-A KO mice. We conclude that SMC GC-A KO mice exhibit a higher vasodilating sensitivity to NO. This can be attributed to an enhanced expression of sGC, whereas the expression and/or activity levels of downstream cGMP-effector pathways are not involved. Increased vasodilating responsiveness to endothelial NO contributes to compensate for the missing vasodilating effect of ANP in SMC GC-A KO mice.	Univ Klinikum Munster, Inst Pharmacol & Toxicol, D-48149 Munster, Germany; Univ Wurzburg, Inst Clin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Frankfurt Klinikum, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	University of Munster; University of Wurzburg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Kuhn, M (corresponding author), Univ Klinikum Munster, Inst Pharmacol & Toxicol, Domagkstr 12, D-48149 Munster, Germany.	mkuhn@uni-muenster.de	Brandes, Ralf P/L-3058-2017; Gambaryan, Stepan/I-3940-2016	Brandes, Ralf P/0000-0002-8035-0048; Gambaryan, Stepan/0000-0002-1470-0791				Brandes RP, 2000, HYPERTENSION, V35, P231, DOI 10.1161/01.HYP.35.1.231; Brunner F, 2001, MICROVASC RES, V61, P102, DOI 10.1006/mvre.2000.2289; Chusho H, 2001, P NATL ACAD SCI USA, V98, P4016, DOI 10.1073/pnas.071389098; DREWETT JG, 1995, J BIOL CHEM, V270, P4668, DOI 10.1074/jbc.270.9.4668; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; EMORI T, 1993, ENDOCRINOLOGY, V133, P2474, DOI 10.1210/en.133.6.2474; GARBERS DL, 1994, J BIOL CHEM, V269, P30741; Holtwick R, 2002, P NATL ACAD SCI USA, V99, P7142, DOI 10.1073/pnas.102650499; Hussain MB, 2001, AM J PHYSIOL-HEART C, V280, pH1151, DOI 10.1152/ajpheart.2001.280.3.H1151; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; John SWM, 1996, AM J PHYSIOL-REG I, V271, pR109, DOI 10.1152/ajpregu.1996.271.1.R109; Kojda G, 1999, CARDIOVASC RES, V42, P206, DOI 10.1016/S0008-6363(98)00315-0; LEITMAN DC, 1986, J BIOL CHEM, V261, P1650; LEITMAN DC, 1986, BIOCHIM BIOPHYS ACTA, V885, P74, DOI 10.1016/0167-4889(86)90040-6; Li DC, 1999, AM J PHYSIOL-LUNG C, V277, pL841, DOI 10.1152/ajplung.1999.277.4.L841; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lopez MJ, 1997, J BIOL CHEM, V272, P23064, DOI 10.1074/jbc.272.37.23064; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Melo LG, 1998, AM J PHYSIOL-HEART C, V275, pH1826, DOI 10.1152/ajpheart.1998.275.5.H1826; MULVANY MJ, 1990, PHYSIOL REV, V70, P921, DOI 10.1152/physrev.1990.70.4.921; NAZARIO B, 1995, J CLIN INVEST, V95, P1151, DOI 10.1172/JCI117763; Oliver PM, 1997, P NATL ACAD SCI USA, V94, P14730, DOI 10.1073/pnas.94.26.14730; Pierkes M, 2002, CARDIOVASC RES, V53, P852, DOI 10.1016/S0008-6363(01)00543-0; RAVICHANDRAN LV, 1995, FEBS LETT, V374, P295, DOI 10.1016/0014-5793(95)01134-Z; Schlossmann J, 2000, NATURE, V404, P197, DOI 10.1038/35004606; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; STINGO AJ, 1992, AM J PHYSIOL, V263, pH1318, DOI 10.1152/ajpheart.1992.263.4.H1318; *US NAT I HLTH, 1996, NIH PUBL, V8523; WEI CM, 1994, BIOCHEM BIOPH RES CO, V205, P765, DOI 10.1006/bbrc.1994.2731; YONEMARU M, 1992, AM J PHYSIOL, V263, pL363, DOI 10.1152/ajplung.1992.263.3.L363; Zabel U, 2002, NAT CELL BIOL, V4, P307, DOI 10.1038/ncb775	32	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17963	17968		10.1074/jbc.M213113200	http://dx.doi.org/10.1074/jbc.M213113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637561	hybrid			2022-12-27	WOS:000182838300047
J	Shetty, S; Bdeir, K; Cines, DB; Idell, S				Shetty, S; Bdeir, K; Cines, DB; Idell, S			Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA LEVEL; GROWTH-FACTOR-BETA; POSTTRANSCRIPTIONAL REGULATION; IN-VIVO; EXTRACELLULAR-MATRIX; FIBRIN DEPOSITION; BINDING-PROTEIN; RECEPTOR; TYPE-1; VITRONECTIN	The plasminogen/plasmin system, urokinase-type plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1), influence extracellular proteolysis and cell migration in lung injury or neoplasia. In this study, we sought to determine whether tcuPA (two chain uPA) alters expression of its major inhibitor PAI-1 in lung epithelial cells. The expression of PAI-1 was evaluated at the protein and mRNA level by Western blot, immunoprecipitation, and Northern blot analyses. We found that tcuPA treatment enhanced PAI-1 protein and mRNA expression in Beas2B lung epithelial cells in a time- and concentration-dependent manner. The tcuPA-mediated induction of PAI-1 involves post-transcriptional control involving stabilization of PAI-1 mRNA. Inactivation of the catalytic activity of tcuPA had little effect on PAI-1 induction and the activity of the isolated amino-terminal fragment was comparable with full-length single- or two-chain uPA. In contrast, deletion of either the uPA receptor binding growth factor domain or kringle domain (<^>kringle) from full-length single chain uPA markedly attenuated the induction of PAI-1. Induction of PAI-1 by exposure of lung epithelial cells to uPA is a newly recognized pathway by which PAI-1 could regulate local fibrinolysis and urokinase-dependent cellular responses in the setting of lung inflammation or neoplasia.	Univ Texas Hlth Ctr, Lab C6, Dept Specialty Care Serv, Tyler, TX 75708 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Shetty, S (corresponding author), Univ Texas Hlth Ctr, Lab C6, Dept Specialty Care Serv, 11937 US Highway 271, Tyler, TX 75708 USA.	sreerama.shetty@uthct.edu			NHLBI NIH HHS [HL60169, R01-HL-62453-01, R01-HL71147-01, HL67381, HL66442] Funding Source: Medline; PHS HHS [R01-45018-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066442, R01HL062453, R01HL071147, R01HL067381, R01HL060169] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHBAROU A, 1994, CANCER RES, V54, P2372; ANDREASEN PA, 1987, MOL CELL BIOL, V7, P3021, DOI 10.1128/MCB.7.8.3021; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bdeir K, 2000, J BIOL CHEM, V275, P28532, DOI 10.1074/jbc.M001595200; BOHUSLAV J, 1995, J EXP MED, V181, P1381, DOI 10.1084/jem.181.4.1381; BOSMA PJ, 1991, J BIOL CHEM, V266, P17845; BOYD D, 1988, CANCER RES, V48, P3112; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carmeliet P, 1998, J CELL BIOL, V140, P233, DOI 10.1083/jcb.140.1.233; Carmeliet P, 1997, CIRC RES, V81, P829; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; CONESE M, 1994, J BIOL CHEM, V269, P17886; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DEPETRO G, 1994, EXP CELL RES, V213, P286, DOI 10.1006/excr.1994.1200; DULMER I, 1993, FEBS LETT, V322, P37; EHRLICH HJ, 1991, J CELL BIOL, V115, P1773, DOI 10.1083/jcb.115.6.1773; EMEIS JJ, 1986, J EXP MED, V163, P1260, DOI 10.1084/jem.163.5.1260; FATTAL PG, 1992, J BIOL CHEM, V267, P12412; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; Heaton JH, 1998, J BIOL CHEM, V273, P14261, DOI 10.1074/jbc.273.23.14261; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; IDELL S, 1992, AM J PHYSIOL, V263, pL487, DOI 10.1152/ajplung.1992.263.4.L487; IDELL S, 1995, AM J PATHOL, V147, P1318; IDELL S, 1994, AM J PHYSIOL-LUNG C, V267, pL693, DOI 10.1152/ajplung.1994.267.6.L693; Idell S, 1994, New Horiz, V2, P566; IDELL S, 1995, LUNG BIOL HEALTH DIS, V80, P743; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, EUR J BIOCHEM, V181, P103, DOI 10.1111/j.1432-1033.1989.tb14699.x; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; KOOISTRA T, 1989, THROMB HAEMOSTASIS, V62, P723; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LI H, 1994, J BIOL CHEM, V269, P8153; LIOTTA LA, 1991, CANCER INVEST, V9, P543, DOI 10.3109/07357909109018952; MAYER M, 1988, J BIOL CHEM, V263, P15688; Mazar A P, 1999, Angiogenesis, V3, P15, DOI 10.1023/A:1009095825561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIMURO J, 1989, J BIOL CHEM, V264, P936; Mukhina S, 2000, J BIOL CHEM, V275, P16450, DOI 10.1074/jbc.M909080199; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NGUYEN G, 1994, KIDNEY INT, V46, P208, DOI 10.1038/ki.1994.261; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; RABBANI SA, 1992, J BIOL CHEM, V267, P14151; SAWDEY M, 1989, J BIOL CHEM, V264, P10396; SEIFFERT D, 1990, J CELL BIOL, V111, P1283, DOI 10.1083/jcb.111.3.1283; Shetty S, 2002, MOL CELL BIOCHEM, V237, P55, DOI 10.1023/A:1016558200199; Shetty S, 2000, AM J PHYSIOL-LUNG C, V278, pL148, DOI 10.1152/ajplung.2000.278.1.L148; Shetty S, 2002, AM J PHYSIOL-LUNG C, V283, pL319, DOI 10.1152/ajplung.00395.2001; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; SHETTY S, 1995, ANTISENSE RES DEV, V5, P307, DOI 10.1089/ard.1995.5.307; Shetty S, 2000, J BIOL CHEM, V275, P13771, DOI 10.1074/jbc.275.18.13771; SHETTY S, 1995, AM J PHYSIOL-LUNG C, V268, pL972, DOI 10.1152/ajplung.1995.268.6.L972; Sidenius N, 2002, J BIOL CHEM, V277, P27982, DOI 10.1074/jbc.M111736200; Sitrin RG, 1999, J IMMUNOL, V163, P6193; SPRENGERS ED, 1987, BLOOD, V69, P381; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; Tillmann-Bogush M, 1999, J BIOL CHEM, V274, P1172, DOI 10.1074/jbc.274.2.1172; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551	68	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18124	18131		10.1074/jbc.M207445200	http://dx.doi.org/10.1074/jbc.M207445200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642587	hybrid			2022-12-27	WOS:000182838300070
J	Cohen, R; Elferink, LA; Atlas, D				Cohen, R; Elferink, LA; Atlas, D			The C2A domain of synaptotagmin alters the kinetics of voltagegated Ca2+ channels Ca(v)1.2 (Lc-type) and Ca(v)2.3 (R-type)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CALCIUM-CHANNEL; NEUROTRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; SNARE COMPLEX; TRANSMITTER RELEASE; ANTIBODY INJECTION; C(2)A DOMAIN; C-2 DOMAIN; IN-VIVO; EXOCYTOSIS	Biochemical and genetic studies implicate synaptotagmin (Syt 1) as a Ca2+ sensor for neuronal and neuroendocrine neurosecretion. Calcium binding to Syt 1 occurs through two cytoplasmic repeats termed the C2A and C2B domains. In addition, the C2A domain of Syt I has calcium-independent properties required for neurotransmitter release. For example, mutation of a polylysine motif (residues 189-192) reverses the inhibitory effect of injected recombinant Syt 1 C2A fragment on neurotransmitter release from PC12 cells. Here we examined the requirement of the C2A polylysine motif for Syt 1 interaction with the cardiac Ca(v)1.2 (L-type) and the neuronal Ca(v)2.3 (R-type) voltage-gated Ca2+ channels, two channels required for neurotransmission. We find that the C2A polylysine motif presents a critical interaction surface with Ca(v)1.2 and Ca(v)2.3 since truncated Syt 1 containing a mutated motif (Syt 1*(1-264)) was ineffective at modifying the channel kinetics. Mutating the polylysine motif also abolished C2A binding to Lc(753-893), the cytosolic interacting domain of Syt 1 at Cav1.2 alpha1 subunit. Syt I and Syt 1* harboring the mutation at the KKKK motif modified channel activation, while Syt 1* only partially reversed the syntaxin 1A effects on channel activity. This mutation would interfere with the assembly of Syt 1/channel/syntaxin into an exocytotic unit. The functional interaction of the C2A polylysine domain with Ca(v)1.2 and Ca(v)2.3 is consistent with tethering of the secretory vesicle to the Ca2+ channel. It indicates that calcium-independent properties of Syt 1 regulate voltage-gated Ca2+ channels and contribute to the molecular events underlying transmitter release.	Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Marine & Biomed Inst, Galveston, TX 77555 USA	Hebrew University of Jerusalem; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Atlas, D (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel.	datlas@vms.huji.ac.il						Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Atlas D, 2001, J NEUROCHEM, V77, P972, DOI 10.1046/j.1471-4159.2001.00347.x; Barg S, 2001, BIOPHYS J, V81, P3308, DOI 10.1016/S0006-3495(01)75964-4; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; Davis AF, 1999, NEURON, V24, P363, DOI 10.1016/S0896-6273(00)80850-8; Desai RC, 2000, J CELL BIOL, V150, P1125, DOI 10.1083/jcb.150.5.1125; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; ELFERINK LA, 1993, CELL, V72, P153, DOI 10.1016/0092-8674(93)90059-Y; Fergestad T, 2001, J NEUROSCI, V21, P9142, DOI 10.1523/JNEUROSCI.21-23-09142.2001; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; FUKUDA M, 1995, P NATL ACAD SCI USA, V92, P10708, DOI 10.1073/pnas.92.23.10708; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Kim K, 1997, P NATL ACAD SCI USA, V94, P14782, DOI 10.1073/pnas.94.26.14782; Lang JC, 1997, EMBO J, V16, P5837, DOI 10.1093/emboj/16.19.5837; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Littleton JT, 2001, J NEUROSCI, V21, P1421, DOI 10.1523/JNEUROSCI.21-05-01421.2001; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; Mackler JM, 2002, NATURE, V418, P340, DOI 10.1038/nature00846; Mackler JM, 2001, J COMP NEUROL, V436, P4, DOI 10.1002/cne.1049; MIKOSHIBA K, 1995, P NATL ACAD SCI USA, V92, P10703, DOI 10.1073/pnas.92.23.10703; Mochida S, 2000, NEUROSCI RES, V36, P175, DOI 10.1016/S0168-0102(99)00128-5; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Robinson IM, 2002, NATURE, V418, P336, DOI 10.1038/nature00915; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; Sheng ZH, 1997, P NATL ACAD SCI USA, V94, P5405, DOI 10.1073/pnas.94.10.5405; Shin OH, 2002, NAT NEUROSCI, V5, P649, DOI 10.1038/nn869; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; Thomas DM, 1999, MOL BIOL CELL, V10, P2285, DOI 10.1091/mbc.10.7.2285; Thomas DM, 1998, J NEUROSCI, V18, P3511; Tobi D, 1998, RECEPTOR CHANNEL, V6, P89; Ubach J, 2001, BIOCHEMISTRY-US, V40, P5854, DOI 10.1021/bi010340c; Wiser O, 1997, FEBS LETT, V404, P203, DOI 10.1016/S0014-5793(97)00130-0; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Wiser O, 2002, P NATL ACAD SCI USA, V99, P3968, DOI 10.1073/pnas.052017299; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721; Zor T, 1996, ANAL BIOCHEM, V236, P302, DOI 10.1006/abio.1996.0171	47	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9258	9266		10.1074/jbc.M210270200	http://dx.doi.org/10.1074/jbc.M210270200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645522	hybrid			2022-12-27	WOS:000181524000050
J	Song, ZY; Yao, XB; Wu, M				Song, ZY; Yao, XB; Wu, M			Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; CELL-DIVISION; PROMOTES APOPTOSIS; CASPASE ACTIVATION; INHIBITOR; PROTEIN; GENE; XIAP; EXPRESSION; SPINDLE	Survivin is a member of the inhibitor of apoptosis protein (IAP) family that has been implicated in both apoptosis inhibition and cell cycle control. However, its inhibitory mechanism and subcellular localization remain controversial. In this report, we provided evidence for the first time that Survivin physically interacts with Smac/DIABLO both in vitro and in vivo. A point mutation (D71R) in the baculovirus IAP repeat motif and a C-terminal deletion mutant (Surv-BIR) of Survivin fail to bind to Smac/DIABLO and abrogate its ability to inhibit apoptosis. The N-terminal of mature Smac/DIABLO is absolutely required for Survivin.Smac complex formation. Subcellular distributions of Survivin and Smac/DIABLO showed that they co-localized within the cytosol during interphase. In addition, Survivin was found to be incapable of binding to caspase. We also identified that the co-presence of Smac/DIABLO and XIAP was required for Survivin to inhibit caspase cleavage in a cell-free system. In conclusion, our results provide the first evidence that the interaction between Smac/DIABLO and Survivin is an essential step underling the inhibition of apoptosis induced by Taxol.	Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Key Lab Struct Biol, Hefei 230027, Anhui, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wu, M (corresponding author), Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Key Lab Struct Biol, Hefei 230027, Anhui, Peoples R China.	wumian88@yahoo.com	Yao, Xuebiao/P-5771-2014; Wu, Mian/H-2494-2018	Wu, Mian/0000-0002-2714-0500				Adida C, 1998, AM J PATHOL, V152, P43; Altieri DC, 1999, LAB INVEST, V79, P1327; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Banks DP, 2000, BLOOD, V96, P4002, DOI 10.1182/blood.V96.12.4002.h8004000c_4002_4003; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Conway EM, 2000, BLOOD, V95, P1435, DOI 10.1182/blood.V95.4.1435.004k01_1435_1442; Conway EM, 2002, GASTROENTEROLOGY, V123, P619, DOI 10.1053/gast.2002.34753; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Fortugno P, 2002, J CELL SCI, V115, P575; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Grossman D, 2001, J CLIN INVEST, V108, P991, DOI 10.1172/JCI200113345; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Lu CD, 1998, CANCER RES, V58, P1808; Mahotka C, 1999, CANCER RES, V59, P6097; Marone M, 2001, EXP CELL RES, V270, P1, DOI 10.1006/excr.2001.5326; Mesri M, 2001, J CLIN INVEST, V108, P981, DOI 10.1172/JCI12983; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Panvichian R, 1998, CANCER RES, V58, P4667; Reed JC, 1999, NAT CELL BIOL, V1, pE199, DOI 10.1038/70227; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Silke J, 2002, J CELL BIOL, V157, P115, DOI 10.1083/jcb.200108085; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200; Tamm I, 1998, CANCER RES, V58, P5315; Uren AG, 1998, TRENDS BIOCHEM SCI, V23, P159, DOI 10.1016/S0968-0004(98)01198-0; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P602; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Wheatley SP, 2001, CURR BIOL, V11, P886, DOI 10.1016/S0960-9822(01)00238-X; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Zhao J, 2000, J CELL SCI, V113, P4363	53	309	341	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23130	23140		10.1074/jbc.M300957200	http://dx.doi.org/10.1074/jbc.M300957200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12660240	hybrid			2022-12-27	WOS:000183503900121
J	Martin, GG; Danneberg, H; Kumar, LS; Atshaves, BP; Erol, E; Bader, M; Schroeder, F; Binas, B				Martin, GG; Danneberg, H; Kumar, LS; Atshaves, BP; Erol, E; Bader, M; Schroeder, F; Binas, B			Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; L-CELL-FIBROBLASTS; MEMBRANE-STRUCTURE; KNOCKOUT MICE; L-FABP; EXPRESSION; CHOLESTEROL; CHAIN; METABOLISM; TRANSPORT	Although liver fatty acid- binding protein ( L- FABP) is an important binding site for various hydrophobic ligands in hepatocytes, its in vivo significance is not understood. We have therefore created L- FABP null mice and report here their initial analysis, focusing on the impact of this mutation on hepatic fatty acid binding capacity, lipid composition, and expression of other lipid-binding proteins. Gel- filtered cytosol from L- FABP null liver lacked the main fatty acid binding peak in the fraction that normally comprises both L- FABP and sterol carrier protein- 2 ( SCP- 2). The binding capacity for cis- parinaric acid was decreased > 80% in this region. Molar ratios of cholesterol/ cholesterol ester, cholesteryl ester/ triglyceride, and cholesterol/ phospholipid were 2- to 3- fold greater, reflecting up to 3- fold absolute increases in specific lipid classes in the order cholesterol > cholesterol esters > phospholipids. In contrast, the liver pool sizes of nonesterified fatty acids and triglycerides were not altered. However, hepatic deposition of a bolus of intravenously injected [ (14)C] oleate was markedly reduced, showing altered lipid pool turnover. An increase of similar to 75% of soluble SCP- 2 but little or no change of other soluble ( glutathione S- transferase, albumin) and membrane ( fatty acid transport protein, CD36, aspartate aminotransferase, caveolin) fatty acid transporters was measured. These results ( i) provide for the first time a quantitative assessment of the contribution of L- FABP to cytosolic fatty acid binding capacity, ( ii) establish L- FABP as an important determinant of hepatic lipid composition and turnover, and ( iii) suggest that SCP- 2 contributes to the accumulation of cholesterol in L- FABP null liver.	Texas A&M Univ, Coll Vet Med, Dept Pathobiol, College Stn, TX 77843 USA; Texas A&M Univ, Coll Vet Med, Dept Physiol & Pharmacol, College Stn, TX 77843 USA; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Binas, B (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Pathobiol, Raymond Stotzer Pkwy, College Stn, TX 77843 USA.	bbinas@cvm.tamu.edu	Bader, Michael/K-2124-2013	Bader, Michael/0000-0003-4780-4164	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41402] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abumrad N, 1998, J LIPID RES, V39, P2309; Atshaves BP, 1999, J LIPID RES, V40, P610; Atshaves BP, 2002, AM J PHYSIOL-CELL PH, V283, pC688, DOI 10.1152/ajpcell.00586.2001; Atshaves BP, 2001, J BIOL CHEM, V276, P25324, DOI 10.1074/jbc.M100560200; Atshaves BP, 2000, J BIOL CHEM, V275, P36852, DOI 10.1074/jbc.M003434200; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; Coburn CT, 2000, J BIOL CHEM, V275, P32523, DOI 10.1074/jbc.M003826200; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Hui TY, 1998, J BIOL CHEM, V273, P27420, DOI 10.1074/jbc.273.42.27420; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; Jolly CA, 1997, ARCH BIOCHEM BIOPHYS, V341, P112, DOI 10.1006/abbi.1997.9957; Jolly CA, 1998, BBA-LIPID LIPID MET, V1390, P258, DOI 10.1016/S0005-2760(97)00186-0; Jolly CA, 2000, BBA-MOL CELL BIOL L, V1483, P185, DOI 10.1016/S1388-1981(99)00170-5; Kannenberg F, 1999, J BIOL CHEM, V274, P35455, DOI 10.1074/jbc.274.50.35455; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARZO A, 1971, CLIN CHEM, V17, P145; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1998, AM J PHYSIOL-GASTR L, V275, pG244, DOI 10.1152/ajpgi.1998.275.2.G244; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Murphy EJ, 2000, LIPIDS, V35, P729, DOI 10.1007/s11745-000-0579-x; NEMECZ G, 1991, J BIOL CHEM, V266, P17180; Owada Y, 2002, J INVEST DERMATOL, V118, P430, DOI 10.1046/j.0022-202x.2001.01616.x; PROWS DR, 1995, LIPIDS, V30, P907, DOI 10.1007/BF02537481; Pu LX, 1998, PROTEIN EXPRES PURIF, V13, P337, DOI 10.1006/prep.1998.0908; Rolf B, 1995, BBA-LIPID LIPID MET, V1259, P245, DOI 10.1016/0005-2760(95)00170-0; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Schaffer JE, 1995, TRENDS CARDIOVAS MED, V5, P218, DOI 10.1016/1050-1738(95)00102-6; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHROEDER F, 1993, MOL CELL BIOCHEM, V123, P73, DOI 10.1007/BF01076477; SCHROEDER F, 1989, SER SYMP AD, V1, P29; SCHROEDER F, 1995, BIOCHEMISTRY-US, V34, P11919, DOI 10.1021/bi00037a033; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; Schroeder F, 2001, MOL CELL BIOCHEM, V219, P127, DOI 10.1023/A:1010851130136; Schroeder F, 1998, CHEM PHYS LIPIDS, V92, P1, DOI 10.1016/S0009-3084(98)00003-6; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Starodub O, 2000, AM J PHYSIOL-CELL PH, V279, pC1259, DOI 10.1152/ajpcell.2000.279.4.C1259; Stolowich N, 1999, J BIOL CHEM, V274, P35425, DOI 10.1074/jbc.274.50.35425; Stolowich NJ, 2002, CELL MOL LIFE SCI, V59, P193, DOI 10.1007/s00018-002-8416-8; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Thompson J, 1999, BBA-MOL CELL BIOL L, V1441, P117, DOI 10.1016/S1388-1981(99)00146-8; Thompson J, 1997, J BIOL CHEM, V272, P7140, DOI 10.1074/jbc.272.11.7140; Thumser AEA, 1996, BIOCHEM J, V320, P729, DOI 10.1042/bj3200729; WILCE MCJ, 1994, BBA-PROTEIN STRUCT M, V1205, P1, DOI 10.1016/0167-4838(94)90086-8; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 1999, J LIPID RES, V40, P708; Zanlungo S, 2000, GASTROENTEROLOGY, V119, P1708, DOI 10.1053/gast.2000.20198; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	57	133	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21429	21438		10.1074/jbc.M300287200	http://dx.doi.org/10.1074/jbc.M300287200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670956	hybrid			2022-12-27	WOS:000183354200017
J	Martinez-Chantar, ML; Latasa, MU; Varela-Rey, M; Lu, SC; Garcia-Trevijano, ER; Mato, JM; Avila, MA				Martinez-Chantar, ML; Latasa, MU; Varela-Rey, M; Lu, SC; Garcia-Trevijano, ER; Mato, JM; Avila, MA			L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; MESSENGER-RNA STABILITY; S-ADENOSYLMETHIONINE; MOLECULAR-MECHANISMS; LIVER; METABOLISM; GROWTH; METHYLTHIOADENOSINE; PHOSPHORYLASE; INHIBITORS	In mammals, methionine adenosyltransferase (MAT), the enzyme responsible for S-adenosylmethionine (AdoMet) synthesis, is encoded by two genes, MAT1A and MAT2A. In liver, MAT1A expression is associated with high AdoMet levels and a differentiated phenotype, whereas MAT2A expression is associated with lower AdoMet levels and a dedifferentiated phenotype. In the current study, we examined regulation of MAT2A gene expression by L-methionine availability using HepG2 cells. In L-methionine-deficient cells, MAT2A gene expression is rapidly induced, and methionine adenosyltransferase activity is increased. Restoration of L-methionine rapidly down-regulates MAT2A mRNA levels; for this effect, L-methionine needs to be converted into AdoMet. This novel action of AdoMet is not mediated through a methyl transfer reaction. MAT2A gene expression was also regulated by 5'-methylthioadenosine, but this was dependent on 5'-methylthioadenosine conversion to methionine through the salvage pathway. The transcription rate of the MAT2A gene remained unchanged during L-methionine starvation; however, its mRNA half-life was significantly increased (from 100 min to more than 3 h). The effect of L-methionine withdrawal on MAT2A mRNA stabilization requires both gene transcription and protein synthesis. We conclude that MAT2A gene expression is modulated as an adaptive response of the cell to L-methionine availability through its conversion to AdoMet.	Univ Navarra, Fac Med, Div Hepatol & Terapia Genica, Lab Proteom Genom & Bioinformat, Pamplona 31008, Spain; Univ So Calif, Keck Sch Med, USC UCLA Res Ctr Alcohol Liver & Pancreat Dis, USC Res Ctr Liver Dis,Div Gastroenterol & Liver D, Los Angeles, CA 90033 USA	University of Navarra; University of Southern California	Avila, MA (corresponding author), Univ Navarra, Fac Med, Div Hepatol & Terapia Genica, Lab Proteom Genom & Bioinformat, Pamplona 31008, Spain.	maavila@unav.es	MATO, JOSE/A-5187-2011; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021; Lu, Shelly/AAH-5937-2021; Chantar, Maria Luz Martinez/F-5190-2011; Varela-Rey, Marta/C-5460-2019	MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Lu, Shelly/0000-0003-2128-5407; Chantar, Maria Luz Martinez/0000-0002-6446-9911; Latasa, Maria Ujue/0000-0002-0878-1337; Varela-Rey, Marta/0000-0002-2413-8659	NCCIH NIH HHS [R01 AT-1576] Funding Source: Medline; NIAAA NIH HHS [R01 AA-12677, R01 AA013847] Funding Source: Medline; NIDDK NIH HHS [R01 DK-51719] Funding Source: Medline; National Center for Complementary & Integrative Health [R01AT001576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA013847, R01AA012677] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Ansorena E, 2002, HEPATOLOGY, V35, P274, DOI 10.1053/jhep.2002.30419; Aulak KS, 1999, J BIOL CHEM, V274, P30424, DOI 10.1074/jbc.274.43.30424; AVILA MA, 1995, ONCOGENE, V10, P963; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Avila MA, 1998, GASTROENTEROLOGY, V114, P364, DOI 10.1016/S0016-5085(98)70489-5; Bateman A, 1997, TRENDS BIOCHEM SCI, V22, P12, DOI 10.1016/S0968-0004(96)30046-7; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; Cai JX, 1998, CANCER RES, V58, P1444; Cai JX, 1996, HEPATOLOGY, V24, P1090; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Carretero MV, 2001, BIOCHEM PHARMACOL, V61, P1119, DOI 10.1016/S0006-2952(01)00590-1; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dumontet C, 1996, ONCOL RES, V8, P469; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FINKELSTEIN JD, 1986, J BIOL CHEM, V261, P1582; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; Garcia-Trevijano ER, 2000, FASEB J, V14, P2511, DOI 10.1096/fj.00-0121com; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Garrow TA, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P145; HOFFMAN RM, 1985, ANTICANCER RES, V5, P1; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; KILBERG MS, 1993, ANNU REV NUTR, V13, P137, DOI 10.1146/annurev.nu.13.070193.001033; KILBERG MS, 1994, FASEB J, V8, P13, DOI 10.1096/fasebj.8.1.8299885; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; Latasa MU, 2001, FASEB J, V15, P1248, DOI 10.1096/fj.00-0556fjev1; Lombardini J B, 1970, Adv Enzyme Regul, V9, P349, DOI 10.1016/S0065-2571(71)80054-7; Lu S, 2000, NUTR CANCER, V38, P123, DOI 10.1207/S15327914NC381_17; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Maclean KN, 2002, J CELL PHYSIOL, V192, P81, DOI 10.1002/jcp.10118; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P47; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Olteanu H, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P135; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; PEGG AE, 1988, CANCER RES, V48, P759; Pegorier J P, 1998, Curr Opin Clin Nutr Metab Care, V1, P329, DOI 10.1097/00075197-199807000-00003; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; TABOR H, 1964, PHARMACOL REV, V16, P245; Tang BQ, 2000, CANCER RES, V60, P5543; VANLEUNGPINEA, 2002, J BIOL CHEM, V277, P16585; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WHITE MW, 1982, BIOCHEM PHARMACOL, V31, P503, DOI 10.1016/0006-2952(82)90151-4; WILLIAMSASHMAN HG, 1982, BIOCHEM PHARMACOL, V31, P277, DOI 10.1016/0006-2952(82)90171-X; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200	50	65	68	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19885	19890		10.1074/jbc.M211554200	http://dx.doi.org/10.1074/jbc.M211554200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660248	hybrid			2022-12-27	WOS:000183078000041
J	Mansouri, A; Ridgway, LD; Korapati, AL; Zhang, QX; Tian, L; Wang, YB; Siddik, ZH; Mills, GB; Claret, FX				Mansouri, A; Ridgway, LD; Korapati, AL; Zhang, QX; Tian, L; Wang, YB; Siddik, ZH; Mills, GB; Claret, FX			Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; PROTEIN-KINASE PATHWAY; JUN NH2-TERMINAL KINASE; CYTOCHROME-C RELEASE; DNA-DAMAGING AGENTS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; T-CELLS; GENOTOXIC STRESS; ANTICANCER DRUGS	The efficacy of cisplatin in cancer chemotherapy is limited by the development of resistance. Although the molecular mechanisms involved in chemoresistance are poorly understood, cellular response to cisplatin is known to involve activation of MAPK and other signal transduction pathways. An understanding of early signal transduction events in the response to cisplatin could be valuable for improving the efficacy of cancer therapy. We compared cisplatin-induced activation of three MAPKs, JNK, p38, and ERK, in a cisplatin-sensitive human ovarian carcinoma cell line (2008) and its resistant subclone (2008C13). The JNK and p38 pathways were activated differentially in response to cisplatin, with the cisplatin-sensitive cells showing prolonged activation (8-12 h) and the cisplatin-resistant cells showing only transient activation (1-3 h) of JNK and p38. In the sensitive cells, inhibition of cisplatin-induced JNK and p38 activation blocked cisplatin-induced apoptosis; persistent activation of JNK resulted in hyperphosphorylation of the c-Jun transcription factor, which in turn stimulated the transcription of an immediate downstream target, the death inducer Fas ligand (FasL). Sequestration of FasL by incubation with a neutralizing anti-FasL antibody inhibited cisplatin-induced apoptosis. In contrast, chemoresistance in 2008C13 cells was associated with failure to up-regulate FasL. Moreover, in these cells, selective stimulation of the JNK/p38 MAPK pathways by adenovirus-mediated delivery of recombinant MKK7 or MKK3 led to sensitization to apoptosis through reactivating FasL expression. Thus, the JNK > c-Jun > FasL > Fas pathway plays an important role in mediating cisplatin-induced apoptosis in ovarian cancer cells, and the duration of JNK activation is critical in determining whether cells survive or undergo apoptosis.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Claret, FX (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 1515 Holcombe Blvd,POB 317, Houston, TX 77030 USA.		Abdellah, Mansouri/B-3002-2017; Claret, Francois X/R-2104-2016	Abdellah, Mansouri/0000-0003-3856-5771; Claret, Francois X/0000-0003-4629-6495; Wang, Yibin/0000-0003-0852-0767	NCI NIH HHS [P30CA16672-24, CA16672, 5P50CA86369, R01 CA090853] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA090853] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; ANDREWS PA, 1988, CANCER RES, V48, P68; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Delmastro DA, 1997, CANCER CHEMOTH PHARM, V39, P245; Eichhorst ST, 2001, CANCER RES, V61, P243; Eichhorst ST, 2000, MOL CELL BIOL, V20, P7826, DOI 10.1128/MCB.20.20.7826-7837.2000; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 2000, BLOOD, V95, P301, DOI 10.1182/blood.V95.1.301.001k24_301_308; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KELLAND LR, 2000, PLATIMIUM BASED DRUG; KELLEY SL, 1988, SCIENCE, V241, P1813, DOI 10.1126/science.3175622; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lippert B., 1999, CISPLATIN CHEM BIOCH; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; MANSOURI A, 2003, IN PRESS ONCOL RES; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Sanchez-Perez I, 2000, ONCOGENE, V19, P5142, DOI 10.1038/sj.onc.1203887; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; SIDDIK ZH, 1987, ANAL BIOCHEM, V163, P21, DOI 10.1016/0003-2697(87)90087-X; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watson A, 1998, J NEUROSCI, V18, P751; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YOSHIDA M, 1994, CANCER RES, V54, P3468; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	67	302	328	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19245	19256		10.1074/jbc.M208134200	http://dx.doi.org/10.1074/jbc.M208134200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637505	hybrid			2022-12-27	WOS:000182932200069
J	Waldhoer, M; Casarosa, P; Rosenkilde, MM; Smit, MJ; Leurs, R; Whistler, JL; Schwartz, TW				Waldhoer, M; Casarosa, P; Rosenkilde, MM; Smit, MJ; Leurs, R; Whistler, JL; Schwartz, TW			The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor US28 camouflages agonism by mediating constitutive endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SARCOMA-ASSOCIATED HERPESVIRUS; CHEMOKINE RECEPTOR; NEUROKININ-1 RECEPTOR; SIGNALING PATHWAYS; INVERSE AGONISTS; BETA-ARRESTIN; ACTIVATION; EXPRESSION; DESENSITIZATION	US28 is one of four 7 transmembrane (7TM) chemokine receptors encoded by human cytomegalovirus and has been shown to both signal and endocytose in a ligand-independent, constitutively active manner. Here we show that the constitutive activity and constitutive endocytosis properties of US28 are separable entities in this viral chemokine receptor. We generated chimeric and mutant US28 proteins that were altered in either their constitutive endocytic ( US28 Delta300, US28 Delta317, US28-NK1-ctail, and US28-ORF74-ctail) or signaling properties ( US28R129A). By using this series of mutants, we show that the cytoplasmic tail domain of US28 per se regulates receptor endocytosis, independent of the signaling ability of the core domain of US28. The constitutive endocytic property of the US28 c-tail was transposable to other 7TM receptors, the herpes virus 8-encoded ORF74 and the tachykinin NK1 receptor (ORF74-US28-ctail and NK1-US28-ctail). Deletion of the US28 C terminus resulted in reduced constitutive endocytosis and consequently enhanced signaling capacity of all receptors tested as assessed by inositol phosphate turnover, NF-kappaB, and cAMP-responsive element-binding protein transcription assays. We further show that the constitutive endocytic property of US28 affects the action of its chemokine ligand fractalkine/CX(3)CL1 and show that in the absence of the US28 C terminus, fractalkine/ CX(3)CL1 acts as an agonist on US28. This demonstrates for the first time that the endocytic properties of a 7TM receptor can camouflage the agonist properties of a ligand.	Univ Calif San Francisco, Ernest Gallo Res Ctr, Emeryville, CA 94608 USA; Univ Copenhagen, Panum Inst, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; Free Univ Amsterdam, Leiden Amsterdam Ctr Drug Res, Div Med Chem, NL-1081 HV Amsterdam, Netherlands; 7TM Pharma AS, DK-2970 Horsholm, Denmark	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of Copenhagen; Leiden University; Leiden University - Excl LUMC; Vrije Universiteit Amsterdam	Waldhoer, M (corresponding author), Univ Calif San Francisco, Ernest Gallo Res Ctr, 5858 Horton St,Ste 200, Emeryville, CA 94608 USA.		Leurs, Rob/AAC-8508-2022; Leurs, Rob/ABB-4299-2021; Waldhoer, Maria/HDO-0619-2022	Leurs, Rob/0000-0003-1354-2848; Waldhoer, Maria/0000-0003-3534-1959; Schwartz, Thue W./0000-0002-0261-6904; Smit, Martine/0000-0003-2713-0238; Rosenkilde, Mette Marie/0000-0001-9600-3254				Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Bennett GL, 1997, METHOD ENZYMOL, V288, P134; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Corvilain B, 2001, CLIN ENDOCRINOL, V55, P143, DOI 10.1046/j.1365-2265.2001.01365.x; Dery O, 2001, AM J PHYSIOL-CELL PH, V280, pC1097, DOI 10.1152/ajpcell.2001.280.5.C1097; Ferrari SL, 2001, MOL ENDOCRINOL, V15, P149, DOI 10.1210/me.15.1.149; Fraile-Ramos A, 2003, TRAFFIC, V4, P243, DOI 10.1034/j.1600-0854.2003.00079.x; Fraile-Ramos A, 2002, TRAFFIC, V3, P218, DOI 10.1034/j.1600-0854.2002.030307.x; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Haskell CA, 2000, J BIOL CHEM, V275, P34183, DOI 10.1074/jbc.M005731200; JOHANSEN TE, 1990, FEBS LETT, V267, P289, DOI 10.1016/0014-5793(90)80947-H; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; McConalogue K, 1998, MOL BIOL CELL, V9, P2305, DOI 10.1091/mbc.9.8.2305; Miserey-Lenkei S, 2002, J BIOL CHEM, V277, P5891, DOI 10.1074/jbc.M108398200; Mokros T, 2002, J BIOL CHEM, V277, P45122, DOI 10.1074/jbc.M208214200; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; Percherancier Y, 2001, J BIOL CHEM, V276, P31936, DOI 10.1074/jbc.M104013200; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rosenkilde MM, 1999, J BIOL CHEM, V274, P956, DOI 10.1074/jbc.274.2.956; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Schmidlin F, 2002, P NATL ACAD SCI USA, V99, P3324, DOI 10.1073/pnas.052161299; SCHWARTZ TW, 1996, TXB RECEPTOR PHARM, P65; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Whistler JL, 2002, TRAFFIC, V3, P866, DOI 10.1034/j.1600-0854.2002.31203.x; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914	37	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19473	19482		10.1074/jbc.M213179200	http://dx.doi.org/10.1074/jbc.M213179200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646575	Green Published, hybrid			2022-12-27	WOS:000182932200097
J	Cameron, SJ; Malik, S; Akaike, M; Lerner-Marmarosh, N; Yan, C; Lee, JD; Abe, J; Yang, J				Cameron, SJ; Malik, S; Akaike, M; Lerner-Marmarosh, N; Yan, C; Lee, JD; Abe, J; Yang, J			Regulation of epidermal growth factor-induced connexin 43 gap junction communication by big mitogen-activated protein kinase 1/ERK5 but not ERK1/2 kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERCELLULAR COMMUNICATION; PROTEIN-KINASE-1 BMK1; WB CELLS; C-SRC; V-SRC; PHOSPHORYLATION; ERK5; CALMODULIN; INHIBITION; DISRUPTION	The gap junction protein, Cx43, plays a pivotal role in coupling cells electrically and metabolically, and the putative phosphorylation sites that modulate its function are reflected as changes in gap junction communication. Growth factor stimulation has been correlated with a decrease in gap junction communication and a parallel activation of ERK1/2; the inhibition of epidermal growth factor (EGF)-induced Cx43 gap junction uncoupling was observed by using the MEK1/2 inhibitor, PD98059. Because 1) BMK1/ERK5, another MAPK family member also activated by growth factors, possesses a phosphorylation motif similar to ERK1/2, and 2) it has been reported that PD98059 can inhibit not only MEK1/2-ERK1/2 but also MEK5-BMK1 activation, we investigated whether BMK1 can regulate EGF-induced Cx43 gap junction uncoupling and phosphorylation, comparing this to the role of ERK1/2 on Cx43 function and phosphorylation induced by EGF. Selective activation or inactivation of ERK1/2 by using a constitutively active form or a dominant negative form of MEK1 did not regulate Cx43 gap junction coupling. In contrast, we found that BMK1, selectively activated by constitutively active MEK5alpha, induced gap junction uncoupling, and the inhibition of BMK1 activation by transfection of dominant negative BMK1 prevented EGF-induced gap junction uncoupling. Activated BMK1 selectively phosphorylates Cx43 on Ser-255 in vitro and in vivo, but not on S279/S282, which are reported as the consensus phosphorylation sites for MAPK. Furthermore, by co-immunoprecipitation, we found that BMK1 directly associates with Cx43 in vivo. These data indicate that BMK1 is more important than ERK1/2 in EGF-mediated Cx43 gap junction uncoupling by association and Cx43 Ser-255 phosphorylation.	Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pharmacol Physiol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Anesthesiol, Rochester, NY 14642 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	University of Rochester; University of Rochester; University of Rochester; Scripps Research Institute	Abe, J (corresponding author), Univ Rochester, Med Ctr, Cardiovasc Res Ctr, Rochester, NY 14642 USA.	Jun-ichi_Abe@urmc.rochester.edu		Yan, Chen/0000-0002-1397-6358	NHLBI NIH HHS [R01 HL66919-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Duffy HS, 2002, J PHYSIOL-PARIS, V96, P243, DOI 10.1016/S0928-4257(02)00012-8; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; Gao ZH, 1999, J BIOL CHEM, V274, P5972, DOI 10.1074/jbc.274.9.5972; Giepmans BNG, 2001, CELL COMMUN ADHES, V8, P219, DOI 10.3109/15419060109080727; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; HII CST, 1995, CARCINOGENESIS, V16, P1505, DOI 10.1093/carcin/16.7.1505; Hossain MZ, 1998, J CELL PHYSIOL, V176, P332, DOI 10.1002/(SICI)1097-4652(199808)176:2<332::AID-JCP11>3.3.CO;2-O; Hossain MZ, 1999, J CELL PHYSIOL, V179, P87, DOI 10.1002/(SICI)1097-4652(199904)179:1<87::AID-JCP11>3.0.CO;2-K; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; Lau AF, 1996, J BIOENERG BIOMEMBR, V28, P359, DOI 10.1007/BF02110112; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Moorby C, 2001, EXP CELL RES, V271, P238, DOI 10.1006/excr.2001.5357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Rivedal E, 2001, CARCINOGENESIS, V22, P1543, DOI 10.1093/carcin/22.9.1543; Spray DC, 2001, HEART PHYSL PATHOPHY, V4, P149; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; WADE MH, 1986, SCIENCE, V232, P525, DOI 10.1126/science.3961495; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706	32	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18682	18688		10.1074/jbc.M213283200	http://dx.doi.org/10.1074/jbc.M213283200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637502	hybrid			2022-12-27	WOS:000182838300141
J	Chauhan, D; Li, GL; Hideshima, T; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Kharbanda, S; Anderson, KC				Chauhan, D; Li, GL; Hideshima, T; Podar, K; Mitsiades, C; Mitsiades, N; Munshi, N; Kharbanda, S; Anderson, KC			JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVERCOMES DRUG-RESISTANCE; CYTOCHROME-C; INDEPENDENT ACTIVATION; KINASE; STRESS; DEATH; SMAC/DIABLO; REQUIREMENT; INHIBITOR; INDUCTION	Smac, second mitochondria-derived activator of caspases, promotes apoptosis via activation of caspases. Previous studies have shown that c-Jun NH2-terminal kinase (JNK) is involved in regulating another mitochondrial protein, cytochrome c during apoptosis; however, the role of JNK in the release of mitochondrial Smac is unknown. Here we show that induction of apoptosis in multiple myeloma (MM) cells is associated with activation of JNK, translocation of JNK from cytosol to mitochondria, and release of Smac from mitochondria to cytosol. Blocking JNK either by dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor, SP600125, abrogates both stress-induced release of Smac and induction of apoptosis. These findings demonstrate that activation of JNK is an obligatory event for the release of Smac during stress-induced apoptosis in MM cells.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02215 USA.		Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; 	NCI NIH HHS [CA 78373] Funding Source: Medline; PHS HHS [50947] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chauhan D, 2002, BLOOD, V100, P2187, DOI 10.1182/blood-2002-02-0376; Chauhan D, 1997, ONCOGENE, V15, P837, DOI 10.1038/sj.onc.1201253; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gibson EM, 2002, J BIOL CHEM, V277, P10573, DOI 10.1074/jbc.M108366200; Hideshima T, 2001, CANCER RES, V61, P3071; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Kawasaki H, 1996, EUR J BIOCHEM, V241, P315, DOI 10.1111/j.1432-1033.1996.00315.x; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WILLIE AH, 1980, INT REV CYTOL, V68, P251; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	177	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17593	17596		10.1074/jbc.C300076200	http://dx.doi.org/10.1074/jbc.C300076200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12665525	hybrid			2022-12-27	WOS:000182838300003
J	Gokulan, K; Rupp, B; Pavelka, MS; Jacobs, WR; Sacchettini, JC				Gokulan, K; Rupp, B; Pavelka, MS; Jacobs, WR; Sacchettini, JC			Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacterial lysine biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC ORNITHINE DECARBOXYLASE; TRANSFER-RNA-SYNTHETASE; LYSA GENE; DENSITY-MODIFICATION; ANGSTROM RESOLUTION; UPSTREAM REGION; SEQUENCE; BINDING; PROGRAM; REFINEMENT	The Mycobacterium tuberculosis lysA gene encodes the enzyme meso-diaminopimelate decarboxylase (DAPDC), a pyridoxal-5'-phosphate (PLP)-dependent enzyme. The enzyme catalyzes the final step in the lysine biosynthetic pathway converting meso-diaminopimelic acid (DAP) to L-lysine. The lysA gene of M. tuberculosis H37Rv has been established as essential for bacterial survival in immunocompromised mice, demonstrating that de novo biosynthesis of lysine is essential for in vivo viability. Drugs targeted against DAPDC could be efficient anti-tuberculosis drugs, and the three-dimensional structure of DAPDC from M. tuberculosis complexed with reaction product lysine and the ternary complex with PLP and lysine in the active site has been determined. The first structure of a DAPDC confirms its classification as a fold type III PLP-dependent enzyme. The structure shows a stable 2-fold dimer in head-to-tail arrangement of a triose-phosphate isomerase (TIM) barrel-like alpha/beta domain and a C-terminal beta sheet domain, similar to the ornithine decarboxylase (ODC) fold family. PLP is covalently bound via an internal aldimine, and residues from both domains and both subunits contribute to the binding pocket. Comparison of the structure with eukaryotic ODCs, in particular with a difluoromethyl ornithine (DMFO)-bound ODC from Trypanosoma bruceii, indicates that corresponding DAP-analogues might be potential inhibitors for mycobacterial DAPDCs.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94551 USA; Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Texas A&M University System; Texas A&M University College Station; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Rupp, Bernhard/0000-0002-3300-6965; Jacobs, William/0000-0003-3321-3080; Gokulan, Kuppan/0000-0003-4045-5993	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062410] Funding Source: NIH RePORTER; NIGMS NIH HHS [P50 GM62410] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; ANDERSEN AB, 1993, GENE, V124, P105, DOI 10.1016/0378-1119(93)90768-X; ASADA Y, 1984, J BIOCHEM-TOKYO, V95, P277, DOI 10.1093/oxfordjournals.jbchem.a134594; Bourot S, 2000, J BIOL CHEM, V275, P1050, DOI 10.1074/jbc.275.2.1050; CHATTERJEE SP, 1994, PLANT MOL BIOL, V26, P285, DOI 10.1007/BF00039539; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cowtan KD, 1999, PROG BIOPHYS MOL BIO, V72, P245, DOI 10.1016/S0079-6107(99)00008-5; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; CUMMINS CS, 1996, J GEN MICROBIOL, V14, P583; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Grishin NV, 1999, BIOCHEMISTRY-US, V38, P15174, DOI 10.1021/bi9915115; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hendrickson WA, 1997, METHOD ENZYMOL, V276, P494, DOI 10.1016/S0076-6879(97)76074-9; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ioerger T R, 1999, Proc Int Conf Intell Syst Mol Biol, P130; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; Kantardjieff KA, 2002, ACTA CRYSTALLOGR D, V58, P735, DOI 10.1107/S0O907444901019588; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; MARCEL T, 1990, MOL MICROBIOL, V4, P1819, DOI 10.1111/j.1365-2958.1990.tb02030.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCANN PP, 1992, PHARMACOL THERAPEUT, V54, P195, DOI 10.1016/0163-7258(92)90032-U; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller J. H., 1972, EXPT MOL GENETICS, P431; MISONO H, 1986, AGR BIOL CHEM TOKYO, V50, P1455; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OGUIZA JA, 1993, J BACTERIOL, V175, P7356, DOI 10.1128/JB.175.22.7356-7362.1993; OSTERMAN AL, 1995, J BIOL CHEM, V270, P11797, DOI 10.1074/jbc.270.20.11797; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pavelka MS, 1996, J BACTERIOL, V178, P6496, DOI 10.1128/jb.178.22.6496-6507.1996; Pavelka MS, 1999, J BACTERIOL, V181, P4780, DOI 10.1128/JB.181.16.4780-4789.1999; POULIN R, 1992, J BIOL CHEM, V267, P150; SHARP PM, 1993, MOL MICROBIOL, V8, P200, DOI 10.1111/j.1365-2958.1993.tb01217.x; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHELDRICK GM, 1995, ACTA CRYSTALLOGR B, V51, P423, DOI 10.1107/S0108768195003661; STAGIER P, 1983, J BACTERIOL, V156, P1198; STROMINGER JL, 1962, FED PROC, V21, P134; SUNDHARA.G, 1967, J BIOL CHEM, V242, P3983; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; WHITE PJ, 1965, BIOCHEM J, V96, P75, DOI 10.1042/bj0960075	45	63	90	3	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18588	18596		10.1074/jbc.M301549200	http://dx.doi.org/10.1074/jbc.M301549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637582	hybrid			2022-12-27	WOS:000182838300131
J	Yamakita, Y; Oosawa, F; Yamashiro, S; Matsumura, F				Yamakita, Y; Oosawa, F; Yamashiro, S; Matsumura, F			Caldesmon inhibits Arp2/3-mediated actin nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT NETWORK FORMATION; SMOOTH-MUSCLE CALDESMON; ARP2/3 COMPLEX; NONMUSCLE CALDESMON; F-ACTIN; WASP/SCAR PROTEINS; POLYMERIZATION; PHOSPHORYLATION; TROPOMYOSIN; BINDING	The Arp2/3 complex greatly accelerates actin polymerization, which is thought to play a major role in cell motility by inducing membrane protrusions including ruffling movements. Membrane ruffles contain a variety of actin-binding proteins, which would modulate Arp2/3-dependent actin polymerization. However, their exact roles in actin polymerization remain to be established. Because caldesmon is present in membrane ruffles, as well as in stress fibers, it may alter Arp2/3-mediated actin polymerization. We have found that caldesmon greatly retards Arp2/3-induced actin polymerization. Kinetic analyses have revealed that caldesmon inhibits the nucleation process, whereas it does not largely reduce elongation. Caldesmon is found to inhibit binding of Arp2/3 to F-actin, which apparently reduces the ability of F-actin as a secondary activator of Arp2/3-mediated nucleation. We also have found that the inhibition of the binding between actin and caldesmon either by Ca2+/calmodulin or by phosphorylation with cdc2 kinase reverses the inhibitory effect of caldesmon on Arp2/3-induced actin polymerization. Our results suggest that caldesmon may be a key protein that modulates membrane ruffling and that this may involve changes in caldesmon phosphorylation and/or intracellular calcium concentrations during signal transduction.	Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, Piscataway, NJ 08854 USA; Aichi Inst Technol, Toyota 47003, Japan	Rutgers State University New Brunswick	Yamakita, Y (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Nelson Labs, Busch Campus, Piscataway, NJ 08854 USA.		Yamakita, Yoshihiko/A-3003-2016	Yamashiro, Shigeko/0000-0001-7207-9406; Matsumura, Fumio/0000-0002-8204-153X				Blanchoin L, 2001, CURR BIOL, V11, P1300, DOI 10.1016/S0960-9822(01)00395-5; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; BRETSCHER A, 1984, J BIOL CHEM, V259, P2873; CASTELLINO F, 1995, J CELL BIOL, V131, P1223, DOI 10.1083/jcb.131.5.1223; CHALOVICH JM, 1995, J BIOL CHEM, V270, P9911, DOI 10.1074/jbc.270.17.9911; Condeelis J, 2001, TRENDS CELL BIOL, V11, P288, DOI 10.1016/S0962-8924(01)02008-6; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; Goncharova EA, 2002, BIOL CHEM, V383, P115, DOI 10.1515/BC.2002.012; HALL A, 1993, PHILOS T ROY SOC B, V340, P267, DOI 10.1098/rstb.1993.0067; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; Hedges JC, 1998, AM J PHYSIOL-CELL PH, V275, pC527, DOI 10.1152/ajpcell.1998.275.2.C527; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Humphries CL, 2002, J CELL BIOL, V159, P993, DOI 10.1083/jcb.200206113; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; KOJIOWADA M, 1984, P NATL ACAD SCI USA, V81, P3133; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Lamb NJC, 1996, EUR J CELL BIOL, V69, P36; LEHMAN W, 1989, J MUSCLE RES CELL M, V10, P101, DOI 10.1007/BF01739966; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; LIM MS, 1986, BIOCHEM J, V238, P523, DOI 10.1042/bj2380523; Marchand JB, 2001, NAT CELL BIOL, V3, P76, DOI 10.1038/35050590; Matsumura F, 1993, CURR OPIN CELL BIOL, V5, P70, DOI 10.1016/S0955-0674(05)80010-9; Mullins RD, 1999, CURR OPIN STRUC BIOL, V9, P244; Oosawa F., 1975, THERMODYNAMICS POLYM; Pelham RJ, 2002, NATURE, V419, P82, DOI 10.1038/nature00999; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Stevenson V, 2002, CURR BIOL, V12, P705, DOI 10.1016/S0960-9822(02)00807-2; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; VOROTNIKOV AV, 1994, J MUSCLE RES CELL M, V15, P37, DOI 10.1007/BF00123831; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; YAMAKITA Y, 1990, J CELL BIOL, V111, P2487, DOI 10.1083/jcb.111.6.2487; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; Yamashiro S, 2001, MOL BIOL CELL, V12, P239, DOI 10.1091/mbc.12.1.239; YAMASHIRO S, 1994, INT C BIOPH BIOCH CE, P113; YAMASHIRO-MATSUMURA S, 1988, Protoplasma Supplementum, V2, P9; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V280, pC1680, DOI 10.1152/ajpcell.2001.280.6.C1680	47	42	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17937	17944		10.1074/jbc.M208739200	http://dx.doi.org/10.1074/jbc.M208739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637566	hybrid			2022-12-27	WOS:000182838300044
J	Shirotani, K; Edbauer, D; Capell, A; Schmitz, J; Steiner, H; Haass, C				Shirotani, K; Edbauer, D; Capell, A; Schmitz, J; Steiner, H; Haass, C			gamma-Secretase activity is associated with a conformational change of Nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-APP; PRECURSOR PROTEIN; PRESENILIN; COMPLEX; TRAFFICKING; APH-1; EXPRESSION; CLEAVAGE; PATHWAY; PEN-2	gamma-Secretase is a high molecular weight multicomponent protein complex with an unusual intramembrane-cleaving aspartyl protease activity. gamma-Secretase is intimately associated with Alzheimer disease because it catalyzes the proteolytic cleavage, which leads to the liberation of amyloid beta-peptide. At least presenilin (PS), Nicastrin (Nct), APH-1, and PEN-2 are constituents of the gamma-secretase complex, with PS apparently providing the active site of gamma-secretase. Expression of gamma-secretase complex components is tightly regulated, however little is known about the assembly of the complex. Here we demonstrate that Nct undergoes a major conformational change during the assembly of the gamma-secretase complex. The conformational change is directly associated with gamma-secretase function and involves the entire Nct ectodomain. Loss of function mutations generated by deletions failed to undergo the conformational change. Furthermore, the conformational alteration did not occur in the absence of PS. Our data thus suggest that gamma-secretase function critically depends on the structural "activation" of Nct.	Univ Munich, Lab Alzheimers & Parkinsons Dis, Dept Biochem, Adolf Butenandt Inst, D-80336 Munich, Germany	University of Munich	Steiner, H (corresponding author), Univ Munich, Lab Alzheimers & Parkinsons Dis, Dept Biochem, Adolf Butenandt Inst, Schillerstr 44, D-80336 Munich, Germany.	hsteiner@pbm.med.uni-muenchen.de; chaass@pbm.med.uni-muenchen.de	Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653				Brown AJ, 2002, MOL CELL, V10, P237, DOI 10.1016/S1097-2765(02)00591-9; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009	19	93	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16474	16477		10.1074/jbc.C300095200	http://dx.doi.org/10.1074/jbc.C300095200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12644462	hybrid			2022-12-27	WOS:000182818600005
J	Geymonat, M; Spanos, A; Walker, PA; Johnston, LH; Sedgwick, SG				Geymonat, M; Spanos, A; Walker, PA; Johnston, LH; Sedgwick, SG			In vitro regulation of budding yeast Bfa1/Bub2 GAP activity by Cdc5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE CDC5; SISTER-CHROMATID SEPARATION; SPINDLE POLE BODIES; MITOTIC EXIT; CELL-CYCLE; SCHIZOSACCHAROMYCES-POMBE; CHECKPOINT PATHWAY; EXCHANGE FACTOR; CYTOKINESIS; KINASE	The Cdc5 protein of budding yeast is a polo-like kinase that has multiple roles in mitosis including control of the mitotic exit network (MEN). MEN activity brings about loss of mitotic kinase activity so that the mitotic spindle is disassembled and cytokinesis can proceed. Activity of the MEN is regulated by a small GTPase, Tem1, which in turn is controlled by a two-component GTPase-activating protein (GAP) formed by Bfa1 and Bub2. Bfa1 has been identified as a regulatory target of Cdc5 but there are conflicting deductions from indirect in vivo assays as to whether phosphorylation inhibits or stimulates Bfa1 activity. To resolve this question, we have used direct in vitro assays to observe the effects of phosphorylation on Bfa1 activity. We show that when Bfa1 is phosphorylated by Cdc5, its GAP activity with Bub2 is inhibited although its ability to interact with Tem1 is unaffected. Thus, in vivo inactivation of Bfa1-Bub2 by Cdc5 would have a positive regulatory effect by increasing levels of Tem1-GTP so stimulating exit from mitosis.	Natl Inst Med Res, Div Yeast Genet, London NW7 1AA, England; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England	MRC National Institute for Medical Research; MRC National Institute for Medical Research	Sedgwick, SG (corresponding author), Natl Inst Med Res, Div Yeast Genet, Mill Hill, London NW7 1AA, England.							Adames NR, 2001, J CELL BIOL, V153, P159, DOI 10.1083/jcb.153.1.159; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Alexandru G, 2001, CELL, V105, P459, DOI 10.1016/S0092-8674(01)00362-2; Bardin AJ, 2000, CELL, V102, P21, DOI 10.1016/S0092-8674(00)00007-6; Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Fesquet D, 1999, EMBO J, V18, P2424, DOI 10.1093/emboj/18.9.2424; Fournier N, 2001, ARCH MICROBIOL, V175, P62, DOI 10.1007/s002030000238; Fraschini R, 1999, J CELL BIOL, V145, P979, DOI 10.1083/jcb.145.5.979; Geymonat M, 2002, J BIOL CHEM, V277, P28439, DOI 10.1074/jbc.M202540200; Giglione C, 2001, EUR J BIOCHEM, V268, P3275, DOI 10.1046/j.1432-1327.2001.02230.x; Guertin DA, 2002, DEV CELL, V3, P779, DOI 10.1016/S1534-5807(02)00367-2; Hofken T, 2002, EMBO J, V21, P4851, DOI 10.1093/emboj/cdf481; Hu FH, 2002, CELL CYCLE, V1, P351, DOI 10.4161/cc.1.5.154; Hu FH, 2001, CELL, V107, P655, DOI 10.1016/S0092-8674(01)00580-3; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Lee SE, 2001, J CELL SCI, V114, P2345; Lee SE, 2001, CURR BIOL, V11, P784, DOI 10.1016/S0960-9822(01)00228-7; Li R, 1999, P NATL ACAD SCI USA, V96, P4989, DOI 10.1073/pnas.96.9.4989; McCollum D, 2001, TRENDS CELL BIOL, V11, P89, DOI 10.1016/S0962-8924(00)01901-2; Pereira G, 2000, MOL CELL, V6, P1, DOI 10.1016/S1097-2765(05)00017-1; Pereira G, 2002, J CELL BIOL, V157, P367, DOI 10.1083/jcb.200112085; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SHOU WY, 2002, BMC MOL BIOL, V3; Song SG, 2001, J CELL BIOL, V152, P451, DOI 10.1083/jcb.152.3.451; Stegmeier F, 2002, CELL, V108, P207, DOI 10.1016/S0092-8674(02)00618-9; Tanaka K, 2001, EMBO J, V20, P1259, DOI 10.1093/emboj/20.6.1259; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Visintin R, 1998, MOL CELL, V2, P709, DOI 10.1016/S1097-2765(00)80286-5; Yoshida S, 2002, BIOCHEM BIOPH RES CO, V294, P687, DOI 10.1016/S0006-291X(02)00544-2; Yoshida S, 2002, CURR BIOL, V12, P944, DOI 10.1016/S0960-9822(02)00870-9	35	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14591	14594		10.1074/jbc.C300059200	http://dx.doi.org/10.1074/jbc.C300059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637549	hybrid			2022-12-27	WOS:000182516100002
J	Zhu, Y; Inouye, M				Zhu, Y; Inouye, M			Analysis of the role of the EnvZ linker region in signal transduction using a chimeric Tar/EnvZ receptor protein, Tez1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ASPARTATE RECEPTOR; HISTIDINE KINASE ENVZ; ESCHERICHIA-COLI; PHOSPHATASE-ACTIVITIES; FUNCTIONAL IMPORTANCE; OSMOSENSOR ENVZ; LIGAND-BINDING; DOMAIN; OSMOREGULATION; MUTAGENESIS	Tez1 is a chimeric protein in which the periplasmic and transmembrane domains of Tar, a chemosensor, are fused to the cytoplasmic catalytic domain of EnvZ, an osmosensing histidine kinase, through the EnvZ linker. Unlike Taz1 ( a similar hybrid with the Tar linker), Tez1 could not respond to Tar ligand, aspartate, whereas single Ala insertion at the transmembrane/ linker junction, as seen in Tez1A1, restored the aspartate- regulatable phenotype. Analysis of the Ala insertion site requirement and the nature of the insertion residue on the phenotype of Tez1 indicated that a junction region between the transmembrane domain and the predicted helix I in the linker is critical to signal transduction. Random mutagenesis revealed that P185Q mutation in the Tez1 linker restored the aspartate- regulatable phenotype. Substitution mutations at Pro- 185 further demonstrated that specific residues are required at this site for an aspartate response. None of the hybrid receptors constructed with different Tar/ EnvZ fusion sites in the linker could respond to aspartate, suggesting that specific interactions between the two predicted helices in the linker are important for the linker function. In addition, a mutation ( F220D) known to cause an OmpC(c) phenotype in EnvZ resulted in similar OmpC(c) phenotypes in both Tez1A1 and Tez1, indicating the importance of the predicted helix II in signal propagation. Together, we propose that the N- terminal junction region modulates the alignment between the two helices in the linker upon signal input. In turn helix II propagates the resultant conformational signal into the downstream catalytic domain of EnvZ to regulate its bifunctional enzymatic activities.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Inouye, M (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, FEMS MICROBIOL LETT, V176, P111, DOI 10.1016/S0378-1097(99)00197-4; BAUMGARTNER JW, 1994, J BACTERIOL, V176, P1157, DOI 10.1128/JB.176.4.1157-1163.1994; Butler SL, 1998, BIOCHEMISTRY-US, V37, P10746, DOI 10.1021/bi980607g; Chervitz SA, 1996, P NATL ACAD SCI USA, V93, P2545, DOI 10.1073/pnas.93.6.2545; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FORST S, 1987, J BIOL CHEM, V262, P16433; HARLOCKER SL, 1993, J BACTERIOL, V175, P1956, DOI 10.1128/JB.175.7.1956-1960.1993; Heinz DW, 1998, J MOL BIOL, V275, P635, DOI 10.1006/jmbi.1997.1490; Inouye M., 2003, HISTIDINE KINASES SI, P25; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KORETKE KK, 2003, HISTIDINE KINASES SI, P483; MARUYAMA IN, 1995, J MOL BIOL, V253, P530, DOI 10.1006/jmbi.1995.0571; MIZUNO T, 1986, J BACTERIOL, V168, P86, DOI 10.1128/jb.168.1.86-95.1986; MOE GR, 1989, P NATL ACAD SCI USA, V86, P5683, DOI 10.1073/pnas.86.15.5683; MURRE C, 1992, TRANSCRIPTIONAL REGU, V1, P961; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; Park H, 1997, J BACTERIOL, V179, P4382, DOI 10.1128/jb.179.13.4382-4390.1997; Park H, 1998, P NATL ACAD SCI USA, V95, P6728, DOI 10.1073/pnas.95.12.6728; Pratt L., 1995, 2 COMPONENT SIGNAL T, P105; Singh M, 1998, P NATL ACAD SCI USA, V95, P2738, DOI 10.1073/pnas.95.6.2738; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; Tao W, 2002, MOL MICROBIOL, V43, P459, DOI 10.1046/j.1365-2958.2002.02757.x; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1992, J BIOCHEM-TOKYO, V111, P707, DOI 10.1093/oxfordjournals.jbchem.a123823; TOKISHITA S, 1991, J BIOL CHEM, V266, P6780; Tomomori C, 1999, NAT STRUCT BIOL, V6, P729; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; Ward SM, 2002, MOL MICROBIOL, V44, P709, DOI 10.1046/j.1365-2958.2002.02902.x; WAUKAU J, 1992, J BACTERIOL, V174, P1522, DOI 10.1128/jb.174.5.1522-1527.1992; Williams SB, 1999, MOL MICROBIOL, V33, P1093, DOI 10.1046/j.1365-2958.1999.01562.x; WOLANIN PM, 2003, HISTIDINE KINASES SI, P73; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; Yeh JI, 1996, J MOL BIOL, V262, P186, DOI 10.1006/jmbi.1996.0507; Zhu Y, 2000, P NATL ACAD SCI USA, V97, P7808, DOI 10.1073/pnas.97.14.7808; Zhu Y, 2002, MOL MICROBIOL, V45, P653, DOI 10.1046/j.1365-2958.2002.03061.x	39	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22812	22819		10.1074/jbc.M300916200	http://dx.doi.org/10.1074/jbc.M300916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672798	hybrid			2022-12-27	WOS:000183503900085
J	Harendza, S; Lovett, DH; Panzer, U; Lukacs, Z; Kuhnl, P; Stahl, RAK				Harendza, S; Lovett, DH; Panzer, U; Lukacs, Z; Kuhnl, P; Stahl, RAK			Linked common polymorphisms in the gelatinase A promoter are associated with diminished transcriptional response to estrogen and genetic fitness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX METALLOPROTEINASE-2 GENE; EXPRESSION; CELL; ACTIVATION; ELEMENT; SP1; ANGIOGENESIS; ESTRADIOL; INVASION; YB-1	Gelatinase A ( matrix metalloproteinase- 2) plays a prominent role in multiple biologic processes. Prior studies have established critical roles for gelatinase A transcriptional regulation by defined enhancer elements. To determine possible functional single nucleotide polymorphisms within these elements, we determined the single nucleotide polymorphism distribution within 1,665 bp of the gelatinase A 5'-flanking region, using a healthy homogeneous Caucasian study group of 463 individuals. Among the polymorphisms detected, a G -->A transition at bp - 1575 was located immediately 5' to a half-palindromic potential estrogen receptor binding site. In estrogen receptor-positive MCF-7 cells the - 1575G allele functioned as an enhancer, whereas the - 1575A allele reduced transcription activity significantly. Gel shift assays confirmed that the differences in allelic expression affected binding of the estrogen receptor-alpha to this region. Cotransfection experiments with an estrogen receptor-alpha expression vector in MDA-MB-231 cells, which do not constitutively express an estrogen receptor, revealed that estrogen receptor is absolutely required for enhancing activity. Allelic distribution analysis indicated that a previously reported C-->T transition within an Sp1 binding site at - 1306 was in linkage disequilibrium with the - 1575G 3 A transition. Luciferase reporter studies of the linked variant - 1575A - 1306T allele versus the wild type - 1575G - 1306C allele demonstrated an additive reduction in estrogen-dependent reporter activity. The frequency of the - 1575G 3 A transition deviated significantly from the expected Hardy-Weinberg distribution in two independently assembled study populations consisting of healthy adult blood donors and newborns of Caucasian origin, both with a calculated 21% reduction in genetic fitness. Gelatinase A is a known estrogen-responsive gene and the demonstration of a loss of function polymorphism within an operational estrogen receptor binding site associated with a decrease in genetic fitness underscores the biologic significance of promoter polymorphism analyses.	Univ Hamburg, Dept Med, D-20246 Hamburg, Germany; Univ Hamburg, Div Nephrol, D-20246 Hamburg, Germany; Univ Hamburg, Dept Pediat, D-20246 Hamburg, Germany; Univ Hamburg, Dept Transfus Med & Transplantat Immunol, D-20246 Hamburg, Germany; Univ Calif San Francisco, Dept Med, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94121 USA	University of Hamburg; University of Hamburg; University of Hamburg; University of Hamburg; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Harendza, S (corresponding author), Univ Klinikum Hamburg Eppendorf, Zentrum Innere Med, Med Klin 4, Pavillon N26,Martinistr 52, D-20246 Hamburg, Germany.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039776, R56DK039776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Crescimanno C, 1996, EXP CELL RES, V227, P240, DOI 10.1006/excr.1996.0273; DIERICH A, 1987, EMBO J, V6, P2305, DOI 10.1002/j.1460-2075.1987.tb02505.x; Dubois B, 2000, J CLIN INVEST, V106, P627, DOI 10.1172/JCI10910; Duffy MJ, 2000, BREAST CANCER RES, V2, P252, DOI 10.1186/bcr65; FRISCH SM, 1990, MOL CELL BIOL, V10, P6524, DOI 10.1128/MCB.10.12.6524; Gao F, 2001, ENDOCRINE, V16, P47, DOI 10.1385/ENDO:16:1:47; Giannelli G, 1999, AM J PATHOL, V154, P1193, DOI 10.1016/S0002-9440(10)65371-0; Guccione M, 2002, AM J PHYSIOL-RENAL, V282, pF164, DOI 10.1152/ajprenal.0318.2000; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; Harendza S, 2000, J BIOL CHEM, V275, P19552, DOI 10.1074/jbc.M001322200; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; Itoh T, 1998, CANCER RES, V58, P1048; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; Kato T, 2001, FEBS LETT, V508, P187, DOI 10.1016/S0014-5793(01)02897-6; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; Martini PGV, 2001, ENDOCRINOLOGY, V142, P3493, DOI 10.1210/en.142.8.3493; Mertens PR, 1998, J BIOL CHEM, V273, P32957, DOI 10.1074/jbc.273.49.32957; Mertens PR, 1999, J AM SOC NEPHROL, V10, P2480; Mertens PR, 2002, J BIOL CHEM, V277, P24875, DOI 10.1074/jbc.M200445200; Mertens PR, 1997, J BIOL CHEM, V272, P22905, DOI 10.1074/jbc.272.36.22905; Noll WW, 2001, AM J PATHOL, V158, P691, DOI 10.1016/S0002-9440(10)64011-4; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200; PUISTOLA U, 1995, FERTIL STERIL, V64, P81, DOI 10.1016/S0015-0282(16)57659-6; Qin HW, 1999, J BIOL CHEM, V274, P29130, DOI 10.1074/jbc.274.41.29130; RAY JM, 1995, EMBO J, V14, P908, DOI 10.1002/j.1460-2075.1995.tb07072.x; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Shamamian P, 2001, J CELL PHYSIOL, V189, P197, DOI 10.1002/jcp.10014; Slaton JW, 2001, AM J PATHOL, V158, P735, DOI 10.1016/S0002-9440(10)64016-3; Tanney DC, 1998, DEV DYNAM, V213, P121, DOI 10.1002/(SICI)1097-0177(199809)213:1<121::AID-AJA12>3.0.CO;2-5; Vyhlidal C, 2000, J MOL ENDOCRINOL, V24, P329, DOI 10.1677/jme.0.0240329; Wingrove CS, 1998, BBA-MOL BASIS DIS, V1406, P169, DOI 10.1016/S0925-4439(97)00097-5; Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788; Zhang BP, 1999, HUM GENET, V105, P418, DOI 10.1007/s004390051124; Zhang YL, 2000, HYPERTENSION, V36, P970, DOI 10.1161/01.HYP.36.6.970	41	63	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20490	20499		10.1074/jbc.M211536200	http://dx.doi.org/10.1074/jbc.M211536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657623	hybrid			2022-12-27	WOS:000183230500008
J	Hazlett, KRO; Rusnak, F; Kehres, DG; Bearden, SW; La Vake, CJ; La Vake, ME; Maguire, ME; Perry, RD; Radolf, JD				Hazlett, KRO; Rusnak, F; Kehres, DG; Bearden, SW; La Vake, CJ; La Vake, ME; Maguire, ME; Perry, RD; Radolf, JD			The Treponema pallidum tro operon encodes a multiple metal transporter, a zinc-dependent transcriptional repressor, and a semi-autonomously expressed phosphoglycerate mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOSTRIDIUM-PASTEURIANUM RUBREDOXIN; CEREBROSPINAL-FLUID LEVELS; ESCHERICHIA-COLI; YERSINIA-PESTIS; BINDING PROTEIN; UPTAKE SYSTEM; STREPTOCOCCUS-PNEUMONIAE; STAPHYLOCOCCUS-AUREUS; MANGANESE HOMEOSTASIS; SUPEROXIDE REDUCTASE	The Treponema pallidum tro operon encodes an ABC transporter (TroABCD), a transcriptional repressor (TroR), and the essential glycolytic enzyme phosphoglycerate mutase (Gpm). The apparently discordant observations that the solute binding protein (TroA) binds Zn2+, whereas DNA binding by TroR in vitro is Mn2+-dependent, have generated uncertainty regarding the identities of the ligand(s) and co-repressor(s) of the permease. Moreover, this operonic structure suggests that Gpm expression, and hence glycolysis, the sole source of ATP for the bacterium, would be suspended during TroR-mediated repression. To resolve these discrepancies, we devised an experimental strategy permitting a more direct assessment of Tro operon function and regulation. We report that (i) apo-TroA has identical affinities for Zn2+ and Mn2+; (ii) the Tro transporter expressed in Escherichia coli imports Zn2+, Mn2+, and possibly iron; (iii) TroR represses transporter expression in E. coli at significantly lower concentrations of Zn2+ than of Mn2+; and (iv) TroR-mediated repression causes a disproportionately greater down-regulation of the transporter genes than of gpm. The much higher concentrations of Zn2+ than of Mn2+ in human body fluids suggests that Zn2+ is both the primary substrate and co-repressor of the permease in vivo. Our data also indicate that Gpm expression and, therefore, glycolysis would not be abrogated when T. pallidum encounters high Zn2+ levels.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Kentucky, Dept Microbiol Mol Genet & Immunol, Lexington, KY 40536 USA	University of Connecticut; University of Connecticut; University of Connecticut; Mayo Clinic; Case Western Reserve University; University of Kentucky	Hazlett, KRO (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, 263 Farmington Ave, Farmington, CT 06030 USA.				NIAID NIH HHS [AI25098, AI-10573, AI-26756] Funding Source: Medline; NIGMS NIH HHS [GM61748] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026756, F32AI010573, R29AI026756, R01AI025098, R37AI026756, R29AI025098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061748] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSHAKRA FR, 1989, FERTIL STERIL, V52, P307; Akins DR, 1997, J BACTERIOL, V179, P5076, DOI 10.1128/jb.179.16.5076-5086.1997; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Bartsevich VV, 1996, J BIOL CHEM, V271, P26057, DOI 10.1074/jbc.271.42.26057; Bearden SW, 1999, MOL MICROBIOL, V32, P403, DOI 10.1046/j.1365-2958.1999.01360.x; Benoit S, 2001, J BACTERIOL, V183, P4702, DOI 10.1128/JB.183.16.4702-4708.2001; Bhattacharyya-Pakrasi M, 2002, BIOCHEM SOC T, V30, P768, DOI 10.1042/bst0300768; Bremer H, 1996, ESCHERICHIA COLI SAL; Christianson DW, 1997, PROG BIOPHYS MOL BIO, V67, P217, DOI 10.1016/S0079-6107(97)88477-5; Claverys JP, 2001, RES MICROBIOL, V152, P231, DOI 10.1016/S0923-2508(01)01195-0; Deka RK, 1999, J BACTERIOL, V181, P4420, DOI 10.1128/JB.181.14.4420-4423.1999; Deka RK, 2002, J BIOL CHEM, V277, P41857, DOI 10.1074/jbc.M207402200; Dintilhac A, 1997, MOL MICROBIOL, V25, P727, DOI 10.1046/j.1365-2958.1997.5111879.x; EIDSNESS MK, 1992, PROTEIN ENG, V5, P367, DOI 10.1093/protein/5.4.367; FENNO JC, 1995, MOL MICROBIOL, V15, P849, DOI 10.1111/j.1365-2958.1995.tb02355.x; Fetherston JD, 1999, MOL MICROBIOL, V32, P289, DOI 10.1046/j.1365-2958.1999.01348.x; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Gong SM, 2001, INFECT IMMUN, V69, P2829, DOI 10.1128/IAI.67.5.2829-2837.2001; Grass G, 2002, J BACTERIOL, V184, P864, DOI 10.1128/JB.184.3.864-866.2002; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hantke K, 2001, BIOMETALS, V14, P239, DOI 10.1023/A:1012984713391; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hardham JM, 1997, GENE, V197, P47, DOI 10.1016/S0378-1119(97)00234-5; Hazlett KRO, 2002, METHOD ENZYMOL, V353, P140; Hazlett KRO, 2001, J EXP MED, V193, P1015, DOI 10.1084/jem.193.9.1015; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Horsburgh MJ, 2001, INFECT IMMUN, V69, P3744, DOI 10.1128/IAI.69.6.3744-3754.2001; Horsburgh MJ, 2002, MOL MICROBIOL, V44, P1269, DOI 10.1046/j.1365-2958.2002.02944.x; Jakubovics NS, 2001, MICROBIOL-SGM, V147, P1709, DOI 10.1099/00221287-147-7-1709; Jakubovics NS, 2000, MOL MICROBIOL, V38, P140, DOI 10.1046/j.1365-2958.2000.02122.x; Janulczyk R, 1999, MOL MICROBIOL, V34, P596, DOI 10.1046/j.1365-2958.1999.01626.x; Jimenez-Jimenez FJ, 1998, J NEURAL TRANSM, V105, P497, DOI 10.1007/s007020050073; Jovanovic T, 2000, J BIOL CHEM, V275, P28439, DOI 10.1074/jbc.M003314200; Kehres DG, 2000, MOL MICROBIOL, V36, P1085, DOI 10.1046/j.1365-2958.2000.01922.x; Kehres DG, 2002, J BACTERIOL, V184, P3159, DOI 10.1128/JB.184.12.3159-3166.2002; Kitten T, 2000, INFECT IMMUN, V68, P4441, DOI 10.1128/IAI.68.8.4441-4451.2000; KOLENBRANDER PE, 1997, J BACTERIOL, V180, P290; Lawrence MC, 1998, STRUCTURE, V6, P1553, DOI 10.1016/S0969-2126(98)00153-1; Lee YH, 2002, J BACTERIOL, V184, P2300, DOI 10.1128/JB.184.8.2300-2304.2002; Lee YH, 1999, NAT STRUCT BIOL, V6, P628; Lombard M, 2000, J BIOL CHEM, V275, P27021; Makui H, 2000, MOL MICROBIOL, V35, P1065, DOI 10.1046/j.1365-2958.2000.01774.x; Molina JA, 1998, J NEURAL TRANSM, V105, P479, DOI 10.1007/s007020050071; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; Oetjen J, 2002, INFECT IMMUN, V70, P5706, DOI 10.1128/IAI.70.10.5706-5714.2002; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Patzer SI, 2000, J BIOL CHEM, V275, P24321, DOI 10.1074/jbc.M001775200; Patzer SI, 2001, J BACTERIOL, V183, P4806, DOI 10.1128/JB.183.16.4806-4813.2001; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Payne Shelley M., 1993, Trends in Microbiology, V1, P66, DOI 10.1016/0966-842X(93)90036-Q; PENDRAK ML, 1991, BIOL MET, V4, P41, DOI 10.1007/BF01135556; PETILLOT Y, 1993, BIOCHEM J, V296, P657, DOI 10.1042/bj2960657; Posey JE, 1999, P NATL ACAD SCI USA, V96, P10887, DOI 10.1073/pnas.96.19.10887; Que Q, 2000, MOL MICROBIOL, V35, P1454, DOI 10.1046/j.1365-2958.2000.01811.x; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; Sarker MR, 1997, MOL MICROBIOL, V23, P410, DOI 10.1046/j.1365-2958.1997.t01-1-00190.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TRAMONT EC, 2000, PRINCIPLES PRACTICE, P2474; UMEYAMA T, 1986, FERTIL STERIL, V46, P494; VALLEE BL, 1959, PHYSIOL REV, V39, P443, DOI 10.1152/physrev.1959.39.3.443; Vasil ML, 1999, MOL MICROBIOL, V34, P399, DOI 10.1046/j.1365-2958.1999.01586.x; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J	63	60	62	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20687	20694		10.1074/jbc.M300781200	http://dx.doi.org/10.1074/jbc.M300781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668673	hybrid			2022-12-27	WOS:000183230500033
J	Koh, DCY; Wong, SM; Liu, DX				Koh, DCY; Wong, SM; Liu, DX			Synergism of the 3 '-untranslated region and an internal ribosome entry site differentially enhances the translation of a plant virus coat protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-BRONCHITIS VIRUS; CHLOROTIC RINGSPOT VIRUS; TRACT-BINDING PROTEIN; MESSENGER-RNA; POLIOVIRUS RNA; ENCEPHALOMYOCARDITIS VIRUS; INVITRO TRANSLATION; IN-VITRO; INITIATION; SEQUENCE	The use of internal ribosome entry sites (IRESs) is one of the unorthodox mechanisms exploited by viruses to initiate the translation of internal genes. Herein, we report a plant virus exploiting an IRES and its 3'-untranslated region (UTR) to express its internal genes, notably the 3'-proximal viral coat protein gene. Hibiscus chlorotic ringspot virus (HCRSV), a positive-strand nonpolyadenylated RNA virus, was demonstrated to harbor a unique 100-nucleotide (nt) IRES, located 124 nt upstream of the coat protein gene, that could function in wheat germ extract, rabbit reticulocyte lysate, and mammalian cells. In comparison with other known IRESs of picornaviruses and eukaryotic mRNAs, this 100-nt IRES is distinctively short and simple. The IRES activity was tested in homologous and heterologous bicistronic constructs, and the expression of the 3'-proximal gene was enhanced when the 3'-UTR was present. When the IRES element was bisected, each half still possessed IRES activity and could initiate internal translation on its own. Site-directed mutagenesis and deletion analyses revealed that the primary sequence within the 5' half was crucial for IRES activity, whereas the primary sequence of the second half and a GNRA motif were non-essential. To our knowledge, this is the first report describing a mechanism whereby an IRES, located in the 3' portion of the virus genome, co-operates with the 3'-UTR to enhance gene expression differentially.	Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Inst Mol Agrobiol, Singapore 117604, Singapore; Nanyang Technol Univ, Sch Biol Sci, Singapore 637616, Singapore	National University of Singapore; National University of Singapore; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Wong, SM (corresponding author), Natl Univ Singapore, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.		Wong, Sek-Man/I-2385-2012; Liu, Ding Xiang/A-2226-2011	Wong, Sek-Man/0000-0002-4620-3706; 				AGRANOVSKY A, 1999, MOL BIOL PLANT VIRUS, P99; Bergamini G, 2000, RNA, V6, P1781, DOI 10.1017/S1355838200001679; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; deQuinto SL, 1997, J VIROL, V71, P4171; DORNER AJ, 1984, J VIROL, V50, P507, DOI 10.1128/JVI.50.2.507-514.1984; Dorokhov YL, 2002, P NATL ACAD SCI USA, V99, P5301, DOI 10.1073/pnas.082107599; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GALLIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631, DOI 10.1093/nar/20.17.4631; Gallie DR, 1998, GENE, V216, P1, DOI 10.1016/S0378-1119(98)00318-7; Huang M, 2000, J VIROL, V74, P3149, DOI 10.1128/JVI.74.7.3149-3155.2000; Ito T, 1999, VIROLOGY, V254, P288, DOI 10.1006/viro.1998.9541; Ito T, 1998, J VIROL, V72, P8789, DOI 10.1128/JVI.72.11.8789-8796.1998; Ivanov PA, 1997, VIROLOGY, V232, P32, DOI 10.1006/viro.1997.8525; Jacobson A., 1996, TRANSLATIONAL CONTRO, P451; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Koh DCY, 2002, J VIROL, V76, P1144, DOI 10.1128/JVI.76.3.1144-1153.2002; Kolupaeva VG, 1996, RNA, V2, P1199; Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200; LIU DX, 1991, VIROLOGY, V184, P531, DOI 10.1016/0042-6822(91)90423-9; LIU DX, 1994, J VIROL, V68, P5772, DOI 10.1128/JVI.68.9.5772-5780.1994; Liu DX, 1997, J VIROL, V71, P1814, DOI 10.1128/JVI.71.3.1814-1820.1997; Madin K, 2000, P NATL ACAD SCI USA, V97, P559, DOI 10.1073/pnas.97.2.559; MATVEEVA OV, 1993, NUCLEIC ACIDS RES, V21, P1007, DOI 10.1093/nar/21.4.1007; Nateri AS, 2000, J VIROL, V74, P6269, DOI 10.1128/JVI.74.14.6269-6277.2000; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pilipenko EV, 2000, GENE DEV, V14, P2028; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; Proweller A, 1997, J BIOL CHEM, V272, P6004, DOI 10.1074/jbc.272.9.6004; Qu F, 2000, J VIROL, V74, P1085, DOI 10.1128/JVI.74.3.1085-1093.2000; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; TRONO D, 1988, J VIROL, V62, P2291, DOI 10.1128/JVI.62.7.2291-2299.1988; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7	32	30	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20565	20573		10.1074/jbc.M210212200	http://dx.doi.org/10.1074/jbc.M210212200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663666	hybrid			2022-12-27	WOS:000183230500017
J	Nam, Y; Weng, AP; Aster, JC; Blacklow, SC				Nam, Y; Weng, AP; Aster, JC; Blacklow, SC			Structural requirements for assembly of the CSL center dot Intracellular Notch1 center dot Mastermind-like 1 transcriptional activation complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROTEIN SECONDARY STRUCTURE; RBP-J-KAPPA; MELANOGASTER NOTCH RECEPTOR; DNA-BINDING PROTEIN; T-CELL LEUKEMIA; DROSOPHILA-MELANOGASTER; CRYSTAL-STRUCTURE; ANKYRIN REPEATS; HUMAN HOMOLOG	Ligand binding by Notch receptors triggers a series of proteolytic cleavages that liberate the intracellular portion of Notch (ICN) from the cell membrane, permitting it to translocate to the nucleus. Nuclear ICN binds to a highly conserved DNA-binding transcription factor called CSL ( also known as RBP-Jkappa, CBF1, Suppressor of Hairless, and Lag-1) and recruits Mastermind-like transcriptional co-activators to form a transcriptional activation complex. Using bioinformatics tools, we identified a Rel homology region (RHR) within CSL that was used as a guide to determine the minimal protein requirements for ternary complex formation. The RHR of CSL contains both the N- and C-terminal beta-sheet domains (RHR-n and RHR-c) of typical Rel transcription factors, as judged by circular dichroism spectra. Binding of monomeric CSL to DNA requires the entire RHR of CSL and an additional 125-residue N- terminal sequence, whereas binding to ICN requires only the RHR-n domain. Although the RAM (RBP-Jkappa( recombination-signal-sequence-binding protein for Jkappa genes)-associated molecule) domain of ICN is flexible and relatively unstructured as an isolated polypeptide in solution, it associates stably with CSL on DNA. Recruitment of Mastermind-like 1 (MAML1) to CSL . ICN complexes on DNA requires inclusion of the ankyrin repeat domain of ICN, and N- and C-terminal sequences of CSL extending beyond the DNA-binding region. The requirement for cooperative assembly of the MAML1 . ICN . CSL . DNA complex suggests that a primary function of ICN is to render CSL competent for MAML loading. On the basis of our results, we present a working structural model for the organization of the MAML1 . ICN . CSL . DNA complex.	Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Blacklow, SC (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	sblacklow@rics.bwh.harvard.edu	Weng, Andrew P/I-5015-2014	Weng, Andrew/0000-0001-7394-5425; Nam, Yunsun/0000-0002-7939-8626	NATIONAL CANCER INSTITUTE [R01CA082308, R56CA092433, R01CA092433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061001] Funding Source: NIH RePORTER; NCI NIH HHS [CA92433, CA82308] Funding Source: Medline; NHLBI NIH HHS [HL61001] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1983, P NATL ACAD SCI-BIOL, V80, P1977, DOI 10.1073/pnas.80.7.1977; ASTER J, 1994, COLD SPRING HARB SYM, V59, P125, DOI 10.1101/SQB.1994.059.01.016; Aster JC, 1997, J BIOL CHEM, V272, P11336; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Christensen S, 1996, DEVELOPMENT, V122, P1373; CHUNG CN, 1994, NUCLEIC ACIDS RES, V22, P2938, DOI 10.1093/nar/22.15.2938; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Fischer D, 1999, PROTEINS, P209; FORTINI ME, 1994, CELL, V79, P273, DOI 10.1016/0092-8674(94)90196-1; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsieh JJD, 1999, P NATL ACAD SCI USA, V96, P23, DOI 10.1073/pnas.96.1.23; Hsieh JJD, 1996, MOL CELL BIOL, V16, P952; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kato H, 1997, DEVELOPMENT, V124, P4133; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Michel F, 2001, EMBO J, V20, P6180, DOI 10.1093/emboj/20.22.6180; Minoguchi S, 1997, MOL CELL BIOL, V17, P2679, DOI 10.1128/MCB.17.5.2679; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Nam Y, 2002, CURR OPIN CHEM BIOL, V6, P501, DOI 10.1016/S1367-5931(02)00346-0; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Petcherski AG, 2000, CURR BIOL, V10, pR471, DOI 10.1016/S0960-9822(00)00577-7; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; TUN T, 1994, NUCLEIC ACIDS RES, V22, P965, DOI 10.1093/nar/22.6.965; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; YEDVOBNICK B, 1988, GENETICS, V118, P483; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14344, DOI 10.1021/bi011435h; Zweifel ME, 2001, BIOCHEMISTRY-US, V40, P14357, DOI 10.1021/bi011436+	43	157	183	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21232	21239		10.1074/jbc.M301567200	http://dx.doi.org/10.1074/jbc.M301567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12644465	hybrid			2022-12-27	WOS:000183230500101
J	Sarkar, B; Lu, JY; Schneider, RJ				Sarkar, B; Lu, JY; Schneider, RJ			Nuclear import and export functions in the different isoforms of the AUF1/heterogeneous nuclear ribonucleoprotein protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HNRNP A1; ARGININE METHYLATION; BINDING-PROTEIN; IN-VIVO; TRANSCRIPTION; DOMAIN; SIGNAL; AUF1; IDENTIFICATION	The heterogeneous nuclear ribonucleoprotein D family of proteins also known as AUF1 consists of four isoforms implicated in both nuclear and cytoplasmic functions. The AUF1 proteins are largely nuclear but also are found in the cytoplasm and are thought to undergo nucleocytoplasmic shuttling. The nucleocytoplasmic distribution and potential shuttling activity of the individual AUF1 isoforms have not been previously studied in detail. Therefore, we characterized the nucleocytoplasmic transport of each of the heterogeneous nuclear ribonucleoprotein D/AUF1 isoforms. All four AUF1 proteins were found to undergo rapid nucleocytoplasmic shuttling in a manner that is transcription-independent, carrier-mediated, and energy-requiring. Nucleocytoplasmic shuttling of the AUF1 proteins is shown to utilize a novel arrangement of nuclear import and export signals. Mutagenesis of the AUF1 proteins and fusion of polypeptides to a green fluorescent protein reporter demonstrated that a nuclear import signal is located in the C-terminal domain of the protein and is found only in the two smaller isoforms. Further mapping demonstrated that nuclear export is facilitated by sequences in AUF1 exon 7 found in the C-terminal domain of the two larger AUF1 isoforms. A subset of AUF1 proteins are shown to directly interact in vitro using purified recombinant proteins and in vivo in the absence of RNA. These results suggest that nuclear import of AUF1 is facilitated by sequences found only in the two smaller isoforms and that nuclear export is facilitated by sequences (exon 7 and the C-terminal domain) found only in the two larger isoforms. This novel arrangement of signals might represent a mechanism to assure co-shuttling of a subset of AUF1 proteins that interact in a heterocomplex.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Schneider, RJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	schner01@popmail.med.nyu.edu			NATIONAL CANCER INSTITUTE [T32CA009161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060428] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09161] Funding Source: Medline; NIGMS NIH HHS [GM60428] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; BRYS A, 1994, P NATL ACAD SCI USA, V91, P4915, DOI 10.1073/pnas.91.11.4915; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; DeMaria CT, 1997, J BIOL CHEM, V272, P27635, DOI 10.1074/jbc.272.44.27635; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fuentes-Panana EM, 2000, J VIROL, V74, P8166, DOI 10.1128/JVI.74.17.8166-8175.2000; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; Izaurralde E, 1998, RNA, V4, P351; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; Kawamura H, 2002, J BIOL CHEM, V277, P2732, DOI 10.1074/jbc.M108477200; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Kim S, 1997, BIOCHEMISTRY-US, V36, P5185, DOI 10.1021/bi9625509; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Laroia G, 2002, NUCLEIC ACIDS RES, V30, P3052, DOI 10.1093/nar/gkf444; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mattern KA, 1999, EXP CELL RES, V246, P461, DOI 10.1006/excr.1998.4267; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Michael WM, 1995, COLD SPRING HARB SYM, V60, P663, DOI 10.1101/SQB.1995.060.01.071; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Mili S, 2001, MOL CELL BIOL, V21, P7307, DOI 10.1128/MCB.21.21.7307-7319.2001; MOSER FG, 1975, J CELL BIOL, V66, P676, DOI 10.1083/jcb.66.3.676; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Siomi MC, 1998, MOL CELL BIOL, V18, P4141, DOI 10.1128/MCB.18.7.4141; Siomi MC, 1997, J CELL BIOL, V138, P1181, DOI 10.1083/jcb.138.6.1181; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Truant R, 1998, MOL CELL BIOL, V18, P1449, DOI 10.1128/MCB.18.3.1449; Vautier D, 2001, J CELL SCI, V114, P1521; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Weighardt F, 1999, J CELL SCI, V112, P1465; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	46	92	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20700	20707		10.1074/jbc.M301176200	http://dx.doi.org/10.1074/jbc.M301176200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668672	hybrid			2022-12-27	WOS:000183230500035
J	Furuta, T; Takemura, H; Liao, ZY; Aune, GJ; Redon, C; Sedelnikova, OA; Pilch, DR; Rogakou, EP; Celeste, A; Chen, HT; Nussenzweig, A; Aladjem, MI; Bonner, WM; Pommier, Y				Furuta, T; Takemura, H; Liao, ZY; Aune, GJ; Redon, C; Sedelnikova, OA; Pilch, DR; Rogakou, EP; Celeste, A; Chen, HT; Nussenzweig, A; Aladjem, MI; Bonner, WM; Pommier, Y			Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CHECKPOINTS; S-PHASE; PROTEIN-KINASE; 7-HYDROXYSTAUROSPORINE UCN-01; GENOMIC INSTABILITY; DAMAGE; REPAIR; CYTOTOXICITY; CAMPTOTHECIN; RADIATION	DNA double-strand breaks originating from diverse causes in eukaryotic cells are accompanied by the formation of phosphorylated H2AX (gammaH2AX) foci. Here we show that gammaH2AX formation is also a cellular response to topoisomerase I cleavage complexes known to induce DNA double-strand breaks during replication. In HCT116 human carcinoma cells exposed to the topoisomerase I inhibitor camptothecin, the resulting gammaH2AX formation can be prevented with the phosphatidylinositol 3-OH kinase-related kinase inhibitor wortmannin; however, in contrast to ionizing radiation, only camptothecin-induced gammaH2AX formation can be prevented with the DNA replication inhibitor aphidicolin and enhanced with the checkpoint abrogator 7-hydroxystaurosporine. This gammaH2AX formation is suppressed in ATR ( ataxia telangiectasia and Rad3-related) deficient cells and markedly decreased in DNA-dependent protein kinase-deficient cells but is not abrogated in ataxia telangiectasia cells, indicating that ATR and DNA-dependent protein kinase are the kinases primarily involved in gammaH2AX formation at the sites of replication-mediated DNA double-strand breaks. Mre11- and Nbs1-deficient cells are still able to form gammaH2AX. However, H2AX-/- mouse embryonic fibroblasts exposed to camptothecin fail to form Mre11, Rad50, and Nbs1 foci and are hypersensitive to camptothecin. These results demonstrate a conserved gammaH2AX response for double-strand breaks induced by replication fork collision. gammaH2AX foci are required for recruiting repair and checkpoint protein complexes to the replication break sites.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NCI, Expt Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Rm 5068A, Bethesda, MD 20892 USA.	pommier@nih.gov	Aune, Gregory/I-5895-2015; Aladjem, Mirit/G-2169-2010	Aune, Gregory/0000-0002-2750-6461; Aladjem, Mirit/0000-0002-1875-3110; Martin (nee Sedelnikova), Olga/0000-0003-3470-2935	NATIONAL CANCER INSTITUTE [ZIABC010411, Z01BC010411, Z01BC006150, ZIABC006150] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; ALLALUNISTURNER MJ, 1993, RADIAT RES, V134, P349, DOI 10.2307/3578196; Barnett AA, 1996, LANCET, V347, P1613; Bassing CH, 2002, P NATL ACAD SCI USA, V99, P8173, DOI 10.1073/pnas.122228699; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Busby EC, 2000, CANCER RES, V60, P2108; Caspari T, 2002, CURR BIOL, V12, pR105, DOI 10.1016/S0960-9822(02)00673-5; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CELIS JE, 1985, P NATL ACAD SCI USA, V82, P3262, DOI 10.1073/pnas.82.10.3262; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Green CM, 2002, EMBO REP, V3, P28, DOI 10.1093/embo-reports/kvf005; Grenon M, 2001, NAT CELL BIOL, V3, P844, DOI 10.1038/ncb0901-844; Guo N, 2002, CELL GROWTH DIFFER, V13, P77; HOLM C, 1989, CANCER RES, V49, P6365; Hoppe BS, 2000, RADIAT RES, V153, P125, DOI 10.1667/0033-7587(2000)153[0125:COTRMC]2.0.CO;2; HSIANG YH, 1989, CANCER RES, V49, P5077; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kobayashi J, 2002, CURR BIOL, V12, P1846, DOI 10.1016/S0960-9822(02)01259-9; Kohn EA, 2002, J BIOL CHEM, V277, P26553, DOI 10.1074/jbc.M202040200; Kraakman-van der Zwet M, 1999, MUTAT RES-DNA REPAIR, V434, P17, DOI 10.1016/S0921-8777(99)00009-9; Kuzminov A, 2001, P NATL ACAD SCI USA, V98, P8241, DOI 10.1073/pnas.131009198; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Liu CY, 2002, P NATL ACAD SCI USA, V99, P14970, DOI 10.1073/pnas.182557199; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Modesti M, 2001, CURR BIOL, V11, pR229, DOI 10.1016/S0960-9822(01)00112-9; Nitiss JL, 1998, BBA-GENE STRUCT EXPR, V1400, P63, DOI 10.1016/S0167-4781(98)00128-6; Noda W, 2002, NEW ENGL J MED, V346, P85, DOI 10.1056/NEJMoa003034; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pommier Y, 1994, Adv Pharmacol, V29B, P73; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; POWIS G, 1994, CANCER RES, V54, P2419; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shao RG, 1997, CANCER RES, V57, P4029; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; SMERDON MJ, 1983, BIOCHEMISTRY-US, V22, P3516, DOI 10.1021/bi00283a033; SNAPKA RM, 1986, MOL CELL BIOL, V6, P4221, DOI 10.1128/MCB.6.12.4221; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Stucky-Marshall L, 1999, CANCER NURS, V22, P212, DOI 10.1097/00002820-199906000-00004; Sugiyama K, 2000, INT J CANCER, V85, P703, DOI 10.1002/(SICI)1097-0215(20000301)85:5<703::AID-IJC17>3.0.CO;2-7; Takimoto C H, 1997, Oncology (Williston Park), V11, P1635; THATCHER TH, 1994, NUCLEIC ACIDS RES, V22, P174, DOI 10.1093/nar/22.2.174; TSAO YP, 1993, CANCER RES, V53, P5908; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vance JR, 2002, P NATL ACAD SCI USA, V99, P13669, DOI 10.1073/pnas.202242599; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; WEST MHP, 1980, BIOCHEMISTRY-US, V19, P3238, DOI 10.1021/bi00555a022; Yu Q, 2002, CANCER RES, V62, P5743; Zhu Q, 1997, ORAL ONCOL, V33B, P29, DOI 10.1016/S0964-1955(96)00038-3	71	369	387	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20303	20312		10.1074/jbc.M300198200	http://dx.doi.org/10.1074/jbc.M300198200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660252	hybrid			2022-12-27	WOS:000183078000093
J	Ghiselli, G; Coffee, N; Munnery, CE; Koratkar, R; Siracusa, LD				Ghiselli, G; Coffee, N; Munnery, CE; Koratkar, R; Siracusa, LD			The cohesin SMC3 is a target the for beta-catenin/TCF4 transactivation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; BASEMENT-MEMBRANE; CDNA CLONING; PROTEIN; COMPLEX; EXPRESSION; TCF; OVEREXPRESSION	The structural maintenance of chromosome protein SMC3 is a component of the cohesin complex that mediates sister chromatid cohesion and segregation in prokaryotes and eukaryotes. It is also present extracellularly in the form of a chondroitin sulfate proteoglycan known as bamacan. We have found previously that SMC3 expression is elevated in a large fraction of human colon carcinomas. The additional finding that the protein is significantly increased in the intestinal polyps of Apc(Min/+) mice has led us to hypothesize that SMC3 expression is linked to activation of the APC/beta-catenin/ TCF4 pathway. The immunohistochemical analysis of colon adenocarcinomas from clinical specimens revealed that beta-catenin and SMC3 antigens co- localize with maximal stain intensity within the transformed areas. Cloning and sequencing of 1578 bp of the human SMC3 promoter unveiled the presence of seven putative consensus sequences for beta-catenin/TCF4 binding, two of which are conserved in the mouse Smc3 promoter. Transient transfection experiments in HCT116 and SW480 human colon carcinoma cells using deletion and mutated promoter constructs in luciferase reporter vectors confirmed that the putative sites, the first located at -48 bp and the second located at -701 bp, are susceptible to beta-catenin/TCF4 transactivation. Co-transfection with a beta-catenin expression vector enhanced the promoter activity whereas E-cadherin had the opposite effect. Binding of beta-catenin/TCF4 complexes from SW480 nuclear extracts to these sequences was confirmed by electrophoretic shift and supershift mobility assays. Altogether these results are consistent with the idea that the beta-catenin/TCF4 transactivation pathway contributes to SMC3 overexpression in intestinal tumorigenesis.	Thomas Jefferson Univ, Dept Pathol & Cell Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Ghiselli, G (corresponding author), Thomas Jefferson Univ, Dept Pathol & Cell Biol, Rm JAH 371,1020 Locust St, Philadelphia, PA 19107 USA.	giancarlo.ghiselli@mail.tju.edu			NATIONAL CANCER INSTITUTE [R01CA082290, P01CA072027] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA72027, R01 CA82290, R01 CA82290-03S1] Funding Source: Medline; PHS HHS [T32-09678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CONOVER W. J, 1980, PRACTICAL NONPARAMET; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; Easwaran V, 1999, J BIOL CHEM, V274, P16641, DOI 10.1074/jbc.274.23.16641; Erickson AC, 2001, MATRIX BIOL, V19, P769, DOI 10.1016/S0945-053X(00)00126-8; Gaboli M, 2001, GENE DEV, V15, P1625, DOI 10.1101/gad.902301; Ghiselli G, 1999, J BIOL CHEM, V274, P17384, DOI 10.1074/jbc.274.24.17384; Ghiselli G, 2000, J BIOL CHEM, V275, P20235, DOI 10.1074/jbc.C000213200; Gupta K, 1998, ONCOGENE, V16, P1149, DOI 10.1038/sj.onc.1201634; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hirano T, 2002, GENE DEV, V16, P399, DOI 10.1101/gad.955102; Inomata M, 1996, CANCER RES, V56, P2213; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Jessberger R, 1996, EMBO J, V15, P4061, DOI 10.1002/j.1460-2075.1996.tb00779.x; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koh TJ, 2000, J CLIN INVEST, V106, P533, DOI 10.1172/JCI9476; Kolligs FT, 2002, CANCER CELL, V1, P145, DOI 10.1016/S1535-6108(02)00035-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Lee JY, 2001, ANNU REV CELL DEV BI, V17, P753, DOI 10.1146/annurev.cellbio.17.1.753; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salah SM, 2000, CHROMOSOMA, V109, P27, DOI 10.1007/s004120050409; SAMURA I, 2001, J CELL BIOL, V151, P749; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wu RR, 1997, J CELL BIOL, V136, P433, DOI 10.1083/jcb.136.2.433; Xu LF, 2000, GENE DEV, V14, P585; Yamada T, 2000, CANCER RES, V60, P4761; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhang XB, 2001, CANCER RES, V61, P6050	50	27	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20259	20267		10.1074/jbc.M209511200	http://dx.doi.org/10.1074/jbc.M209511200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651860	hybrid			2022-12-27	WOS:000183078000088
J	Kokura, K; Kim, H; Shinagawa, T; Khan, MM; Nomura, T; Ishii, S				Kokura, K; Kim, H; Shinagawa, T; Khan, MM; Nomura, T; Ishii, S			The Ski-binding protein C184M negatively regulates tumor growth factor-beta signaling by sequestering the Smad proteins in the cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; SNON; MAD; RETROVIRUSES; ONCOPROTEIN; ANTAGONIST; ONCOGENE; GENE	Ski is a transcriptional co-repressor and is involved in the negative regulation of tumor growth factor-beta (TGF-beta) signaling. To understand more fully the role of Ski in TGF-beta signaling, we searched for novel Ski-interacting proteins. The identified C184M protein consists of 189 amino acids and contains the leucine-rich region. An association between Ski and C184M involving the leucine-rich region of C184M and the C-terminal coiled-coil motif of Ski was confirmed by glutathione S-transferase pull-down and immunoprecipitation assays. The C184M protein is located in the cytosol, and the C184M and Ski signals are co-localized in the cytoplasm when C184M was co-expressed with Ski in CV-1 cells. The cytoplasmic C184M-Ski complex inhibited the nuclear translocation of Smad2. Consistent with this, the activity of promoter containing the Smad-binding sites was repressed by C184M, and the TGF-beta-induced growth inhibition of mink lung Mv1Lu cells was attenuated by the ectopic expression of C184M. Thus, C184M inhibits TGF-beta signaling in concert with Ski. In hepatocytes, which express significant levels of C184M, the Ski signals were found only in the cytoplasm, supporting the notion that C184M forms a complex with Ski in the cytosol.	RIKEN Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan	RIKEN	Ishii, S (corresponding author), RIKEN Tsukuba Inst, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.	sishii@rtc.riken.go.jp	Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; COLMENARES C, 1991, J VIROL, V65, P4929, DOI 10.1128/JVI.65.9.4929-4935.1991; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COSSET FL, 1995, J VIROL, V69, P7430, DOI 10.1128/JVI.69.12.7430-7436.1995; Golovkina TV, 1998, J VIROL, V72, P3066, DOI 10.1128/JVI.72.4.3066-3071.1998; Grimm OH, 2002, NAT CELL BIOL, V4, P519, DOI 10.1038/ncb812; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kokura K, 2001, J BIOL CHEM, V276, P34115, DOI 10.1074/jbc.M105747200; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Macias-Silva M, 2002, J BIOL CHEM, V277, P28483, DOI 10.1074/jbc.M202403200; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Reed JA, 2001, CANCER RES, V61, P8074; Sakuma-Takagi M, 1999, BIOCHEM BIOPH RES CO, V263, P737, DOI 10.1006/bbrc.1999.1462; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Shinagawa T, 2001, ONCOGENE, V20, P8100, DOI 10.1038/sj.onc.1204987; Stroschein SL, 2001, GENE DEV, V15, P2822; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	37	28	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20133	20139		10.1074/jbc.M210855200	http://dx.doi.org/10.1074/jbc.M210855200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646588	hybrid			2022-12-27	WOS:000183078000072
J	Miinalainen, IJ; Chen, ZJ; Torkko, JM; Pirila, PL; Sormunen, RT; Bergmann, U; Qin, YM; Hiltunen, JK				Miinalainen, IJ; Chen, ZJ; Torkko, JM; Pirila, PL; Sormunen, RT; Bergmann, U; Qin, YM; Hiltunen, JK			Characterization of 2-enoyl thioester reductase from mammals - An ortholog of Ybr026p/Mrf1 ' p of the yeast mitochondrial fatty acid synthesis type II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-CARRIER PROTEIN; SACCHAROMYCES-CEREVISIAE; LIPOIC ACID; NEUROSPORA-CRASSA; 2,4-DIENOYL-COA REDUCTASE; MOLECULAR-CLONING; ESCHERICHIA-COLI; RAT-LIVER; GENE; SYNTHASE	A data base search with YBR026c/MRF1', which encodes trans-2-enoyl thioester reductase of the intramitochondrial fatty acid synthesis (FAS) type II in yeast (Torkko, J.M., Koivuranta, K.T., Miinalainen, I.J., Yagi, A.I., Schmitz, W., Kastaniotis, A.J., Airenne, T.T., Gurvitz, A., and Hiltunen, K.J. (2001) Mol. Cell. Biol. 21, 6243-6253), revealed the clone AA393871 (HsNrbf-1, nuclear receptor binding factor 1) in human EST data bank. Expression of HsNrbf-1, tagged C-terminally with green fluorescent protein, in HeLa cells, resulted in a punctated fluorescence signal, superimposable with the MitoTracker Red dye. Wild-type polypeptide was immunoisolated from the extract of bovine heart mitochondria. Recombinant HsNrbf-1p reduces trans-2-enoyl-CoA to acyl-CoA with chain length from C6 to C16 in an NADPH-dependent manner with preference to medium chain length substrate. Furthermore, expression of HsNRBF-1 in the ybr026cDelta yeast strain restored mitochondrial respiratory function allowing growth on glycerol. These findings provide evidence that Nrbf-1ps act as a mitochondrial 2-enoyl thioester reductase, and mammalian cells may possess bacterial type fatty acid synthetase (FAS type II) in mitochondria, in addition to FAS type I in the cytoplasm.	Univ Oulu, Dept Biochem, Bioctr Oulu, FIN-90014 Oulu, Finland; Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland; Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	Finland National Institute for Health & Welfare; University of Oulu; University of Oulu; Ruhr University Bochum	Hiltunen, JK (corresponding author), Univ Oulu, Dept Biochem, Bioctr Oulu, PO 3000, FIN-90014 Oulu, Finland.	Kalervo.Hiltunen@oulu.fi		Miinalainen, Ilkka/0000-0002-3922-3442				Airenne TT, 2003, J MOL BIOL, V327, P47, DOI 10.1016/S0022-2836(03)00038-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; CAUGHEY I, 1982, EUR J BIOCHEM, V123, P553; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CVETANOVIC M, 1985, BIOCHEM J, V227, P49, DOI 10.1042/bj2270049; Das AK, 2000, J BIOL CHEM, V275, P24333, DOI 10.1074/jbc.M001168200; De Nys K, 2001, BBA-MOL CELL BIOL L, V1533, P66, DOI 10.1016/S1388-1981(01)00141-X; DOMMES V, 1984, J BIOL CHEM, V259, P1781; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; FILPPULA SA, 1995, J BIOL CHEM, V270, P27453, DOI 10.1074/jbc.270.46.27453; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Gurvitz A, 1997, J BIOL CHEM, V272, P22140, DOI 10.1074/jbc.272.35.22140; HAKKOLA EH, 1989, J HISTOCHEM CYTOCHEM, V37, P1863, DOI 10.1177/37.12.2584694; HARINGTON A, 1994, EMBO J, V13, P5531, DOI 10.1002/j.1460-2075.1994.tb06890.x; Heath RJ, 2000, NATURE, V406, P145, DOI 10.1038/35018162; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Helander HM, 1997, GENOMICS, V46, P112, DOI 10.1006/geno.1997.5004; Hoja U, 1998, EUR J BIOCHEM, V254, P520, DOI 10.1046/j.1432-1327.1998.2540520.x; Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001; Kolodziej SJ, 1996, J BIOL CHEM, V271, P28422, DOI 10.1074/jbc.271.45.28422; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; Masuda N, 1998, GENE, V221, P225, DOI 10.1016/S0378-1119(98)00461-2; MIKOLAJCZYK S, 1990, EUR J BIOCHEM, V187, P431, DOI 10.1111/j.1432-1033.1990.tb15322.x; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; NEAT CE, 1981, BIOCHEM J, V196, P149, DOI 10.1042/bj1960149; PARI G, 1991, MOL CELL BIOL, V11, P4796, DOI 10.1128/MCB.11.9.4796; Parikh SL, 2000, BIOCHEMISTRY-US, V39, P7645, DOI 10.1021/bi0008940; Pfanner N, 2000, CURR BIOL, V10, pR412, DOI 10.1016/S0960-9822(00)00507-8; Plesofsky N, 2000, BBA-MOL CELL RES, V1495, P223, DOI 10.1016/S0167-4889(99)00170-6; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SANADI DR, 1967, METHODS ENZYMOLOGY 4, V10, P297; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Schneider R, 1997, CURR GENET, V32, P384, DOI 10.1007/s002940050292; Schulte U, 2001, J BIOENERG BIOMEMBR, V33, P205, DOI 10.1023/A:1010730919074; SCHWEIZER E, 1970, P NATL ACAD SCI USA, V67, P660, DOI 10.1073/pnas.67.2.660; Smith J.A., 2000, CURRENT PROTOCOLS MO; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Triepels R, 1999, J INHERIT METAB DIS, V22, P163, DOI 10.1023/A:1005402020569; Vassault A, 1984, METHODS ENZYM ANAL, V3, P118; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; Wanders RJA, 2000, CELL BIOCHEM BIOPHYS, V32, P89, DOI 10.1385/CBB:32:1-3:89; Wharton DC., 1967, METHOD ENZYMOL, P245; YAMAZOE M, 1994, J BIOL CHEM, V269, P15244; Ylitalo K, 2001, BBA-BIOENERGETICS, V1504, P329, DOI 10.1016/S0005-2728(00)00261-9	50	59	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20154	20161		10.1074/jbc.M302851200	http://dx.doi.org/10.1074/jbc.M302851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654921	hybrid			2022-12-27	WOS:000183078000074
J	Nalaskowski, MM; Bertsch, U; Fanick, W; Stockebrand, MC; Schmale, H; Mayr, GW				Nalaskowski, MM; Bertsch, U; Fanick, W; Stockebrand, MC; Schmale, H; Mayr, GW			Rat inositol 1,4,5-trisphosphate 3-kinase C is enzymatically specialized for basal cellular inositol trisphosphate phosphorylation and shuttles actively between nucleus and cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEPTOMYCIN-B; PHOSPHOLIPASE-C; IN-VIVO; PROTEIN; EXPRESSION; BINDING; CLONING; EXPORT; HEXAKISPHOSPHATE; IDENTIFICATION	The calcium-liberating second messenger inositol 1,4,5-trisphosphate (Ins(1,4,5) P-3) is converted to inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4,5) P-4) by Ins(1,4,5) P-3 3-kinases (IP3Ks) that add a fourth phosphate group to the 3-position of the inositol ring. Two isoforms of IP3Ks ( named A and B) from different vertebrate species have been well studied. Recently the cloning and examination of a human full-length cDNA encoding a novel isoform, termed human IP3K-C (HsIP3K-C), has been reported. In the present study we report the cloning of a full-length cDNA encoding a rat homologue of HsIP3K-C with a unique mRNA expression pattern, which differs remarkably from the tissue distribution of HsIP3K-C. Of the rat tissues examined, rat IP3K-C ( RnIP3K-C) is mainly present in heart, brain, and testis and shows the strongest expression in an epidermal tissue, namely tongue epithelium. RnIP3K-C has a calculated molecular mass of similar to74.5 kDa and shows an overall identity of similar to75% with HsIP3K-C. A bacterially expressed, enzymatically active and Ca2+-calmodulin-regulated fragment of this isoform displays remarkable enzymatic properties like a very low K-m for Ins(1,4,5) P-3 (similar to0.2 muM), substrate inhibition by high concentrations of Ins( 1,4,5) P-3, allosteric product activation by Ins( 1,3,4,5) P-4 in absence of Ca2+-calmodulin (K-a(app) 0.52 muM), and the ability to efficiently phosphorylate a second InsP(3) substrate, inositol 2,4,5-trisphosphate, to inositol 2,4,5,6-tetrakisphosphate in the presence of Ins( 1,3,4,5) P-4. Furthermore, the RnIP3K-C fused with a fluorescent protein tag is actively transported into and out of the nucleus when transiently expressed in mammalian cells. A leucine-rich nuclear export signal and an uncharacterized nuclear import activity are localized in the N-terminal domain of the protein and determine its nucleocytoplasmic shuttling. These findings point to a particular role of RnIP3K-C in nuclear inositol trisphosphate phosphorylation and cellular growth.	Univ Hamburg, Hosp Eppendorf, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany; Univ Hamburg, Hosp Eppendorf, Inst Cell Biochem & Clin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg; University of Hamburg	Mayr, GW (corresponding author), Univ Hamburg, Hosp Eppendorf, Inst Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	mayr@uke.uni-hamburg.de						BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Bertsch U, 1999, GENE, V228, P61, DOI 10.1016/S0378-1119(99)00018-9; Bertsch U, 2000, J BIOL CHEM, V275, P1557, DOI 10.1074/jbc.275.3.1557; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Christophe D, 2000, CELL SIGNAL, V12, P337, DOI 10.1016/S0898-6568(00)00077-2; Clandinin TR, 1998, CELL, V92, P523, DOI 10.1016/S0092-8674(00)80945-9; Cocco L, 2001, BBA-MOL CELL BIOL L, V1530, P1, DOI 10.1016/S1388-1981(00)00169-4; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dewaste V, 2002, BIOCHEM BIOPH RES CO, V291, P400, DOI 10.1006/bbrc.2002.6456; Dewaste V, 2000, BIOCHEM J, V352, P343, DOI 10.1042/0264-6021:3520343; Drayer AL, 1996, BIOCHEM SOC T, V24, P1001, DOI 10.1042/bst0241001; FLEISCHER B, 1994, J BIOL CHEM, V269, P17826; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Fukuda M, 1997, BIOESSAYS, V19, P593, DOI 10.1002/bies.950190710; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GUSE AH, 1995, J CHROMATOGR B, V672, P189, DOI 10.1016/0378-4347(95)00219-9; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Luo HBR, 2002, BIOCHEMISTRY-US, V41, P2509, DOI 10.1021/bi0118153; MAJERUS PW, 1988, J BIOL CHEM, V263, P3051; MAYR GW, 1992, CARBOHYD RES, V234, P247, DOI 10.1016/0008-6215(92)85052-2; MAYR GW, 1988, BIOCHEM J, V254, P585, DOI 10.1042/bj2540585; MAYR GW, 1990, METHODS INOSITIDE RE, P83; Melen K, 1997, J BIOL CHEM, V272, P32353, DOI 10.1074/jbc.272.51.32353; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nalaskowski MM, 2002, BIOCHEM J, V366, P549, DOI 10.1042/BJ20020327; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; NIINOBE M, 1994, BIOCHEM BIOPH RES CO, V205, P1036, DOI 10.1006/bbrc.1994.2770; ROSS TS, 1992, J BIOL CHEM, V267, P19924; Saiardi A, 2000, J BIOL CHEM, V275, P24686, DOI 10.1074/jbc.M002750200; Schell MJ, 2001, J BIOL CHEM, V276, P37537, DOI 10.1074/jbc.M104101200; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Segel I.H., 1975, ENZYME KINETICS; Soriano S, 1997, BIOCHEM J, V324, P579, DOI 10.1042/bj3240579; STEPHENS L, 1993, J BIOL CHEM, V268, P4009; STEPHENS LR, 1991, BIOCHEM J, V275, P485, DOI 10.1042/bj2750485; VANWEYENBERG V, 1995, BIOCHEM J, V306, P429, DOI 10.1042/bj3060429; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	48	30	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19765	19776		10.1074/jbc.M211059200	http://dx.doi.org/10.1074/jbc.M211059200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649294	hybrid			2022-12-27	WOS:000183078000027
J	Townson, SM; Dobrzycka, KM; Lee, AV; Air, M; Deng, WL; Kang, KY; Jiang, SM; Kioka, N; Michaelis, K; Oesterreich, S				Townson, SM; Dobrzycka, KM; Lee, AV; Air, M; Deng, WL; Kang, KY; Jiang, SM; Kioka, N; Michaelis, K; Oesterreich, S			SAFB2, a new scaffold attachment factor homolog and estrogen receptor corepressor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DIHYDROFOLATE-REDUCTASE; BINDING-PROTEIN; HET/SAF-B; BIDIRECTIONAL PROMOTER; NUCLEAR-BODIES; G(1) CONTROL; GROWTH; BREAST; FAMILY; GENE	We have characterized previously the nuclear matrix protein/scaffold attachment factor (SAFB) as an estrogen receptor corepressor and as a potential tumor suppressor gene in breast cancer. A search of the human genome for other potential SAFB family members revealed that KIAA00138 (now designated as SAFB2) has high homology to SAFB (now designated as SAFB1). SAFB1 and SAFB2 are mapped adjacent to each other on chromosome 19p13.3 and are arranged in a bidirectional divergent configuration (head to head), being separated by a short(<500 bp) GC-rich intergenic region that can function as a bidirectional promoter. SAFB1 and SAFB2 share common functions but also have unique properties. As shown previously for SAFB1, SAFB2 functions as an estrogen receptor corepressor, and its overexpression results in inhibition of proliferation. SAFB1 and SAFB2 interact directly through a C-terminal domain, resulting in additive repression activity. They are coexpressed in a number of tissues, but unlike SAFB1, which is exclusively nuclear, SAFB2 is found in the cytoplasm as well as the nucleus. Consistent with its cytoplasmic localization, we detected an interaction between SAFB2 and vinexin, a protein involved in linking signaling to the cytoskeleton. Our findings suggest that evolutionary duplication of the SAFB gene has allowed it to retain crucial functions, but also to gain novel functions in the cytoplasm and/or nucleus.	Baylor Coll Med, Breast Ctr, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Kyoto Univ, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan	Baylor College of Medicine; Baylor College of Medicine; Kyoto University	Oesterreich, S (corresponding author), Baylor Coll Med, Breast Ctr, Dept Med, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	steffio@breastcenter.tmc.edu		Lee, Adrian/0000-0001-9917-514X; Kioka, Noriyuki/0000-0002-2708-537X	NCI NIH HHS [R01 CA-97213, K01 CA-77674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA077674, R01CA097213] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Achaz G, 2001, MOL BIOL EVOL, V18, P2280, DOI 10.1093/oxfordjournals.molbev.a003774; Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baylin SB, 1998, ADV CANCER RES, V72, P141; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chiodi I, 2000, J CELL SCI, V113, P4043; Cohen RN, 2000, MOL ENDOCRINOL, V14, P900, DOI 10.1210/me.14.6.900; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Denegri M, 2001, MOL BIOL CELL, V12, P3502, DOI 10.1091/mbc.12.11.3502; DuPont BR, 1997, CYTOGENET CELL GENET, V79, P284, DOI 10.1159/000134744; Force A, 1999, GENETICS, V151, P1531; FUJII H, 1992, FEBS LETT, V314, P33, DOI 10.1016/0014-5793(92)81455-U; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gunning P, 1998, ANNU REV CELL DEV BI, V14, P339, DOI 10.1146/annurev.cellbio.14.1.339; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jepsen K, 2002, J CELL SCI, V115, P689; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nadeau JH, 1997, GENETICS, V147, P1259; Nagase T, 1995, DNA Res, V2, P167, DOI 10.1093/dnares/2.4.167; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Oesterreich S, 2000, EUR J CANCER, V36, pS43; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; OESTERREICH S, 1993, CANCER RES, V53, P4443; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; Oesterreich S, 2001, BRIT J CANCER, V84, P493, DOI 10.1054/bjoc.2000.1606; Ohno S., 1970, EVOLUTION GENE DUPLI; Paggi MG, 2001, CANCER RES, V61, P4651; Platzer M, 1997, GENOME RES, V7, P592, DOI 10.1101/gr.7.6.592; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SHIMADA T, 1989, J BIOL CHEM, V264, P20171; SHINYA E, 1994, NUCLEIC ACIDS RES, V22, P2143, DOI 10.1093/nar/22.11.2143; Sidow A, 1996, CURR OPIN GENET DEV, V6, P715, DOI 10.1016/S0959-437X(96)80026-8; Stein L, 2001, NUCLEIC ACIDS RES, V29, P82, DOI 10.1093/nar/29.1.82; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Townson SM, 2000, CLIN CANCER RES, V6, P3788; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WALSH JB, 1995, GENETICS, V139, P421; Weighardt F, 1999, J CELL SCI, V112, P1465; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; YEE D, 1989, J BIOL CHEM, V264, P21439; Zamir I, 1996, MOL CELL BIOL, V16, P5458	60	67	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20059	20068		10.1074/jbc.M212988200	http://dx.doi.org/10.1074/jbc.M212988200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660241	hybrid			2022-12-27	WOS:000183078000063
J	Chalmers, S; Nicholls, DG				Chalmers, S; Nicholls, DG			The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; FREE CA-2+ CONCENTRATION; HEART-MITOCHONDRIA; CYCLOSPORINE-A; CYTOCHROME-C; DEHYDROGENASE-ACTIVITY; FOREBRAIN ISCHEMIA; RAT HIPPOCAMPUS; REDOX STATE; CA2+	Three sequential phases of mitochondrial calcium accumulation can be distinguished: matrix dehydrogenase regulation, buffering of extramitochondrial free calcium, and finally activation of the permeability transition. Relationships between these phases, free and total matrix calcium concentration, and phosphate concentration are investigated in rat liver and brain mitochondria. Slow, continuous calcium infusion is employed to avoid transient bioenergetic consequences of bolus additions. Liver and brain mitochondria undergo permeability transitions at precise matrix calcium loads that are independent of infusion rate. Cytochrome c release precedes the permeability transition. Cyclosporin A enhances the loading capacity in the presence or absence of acetoacetate. A remarkably constant free matrix calcium concentration, in the range 1-5 muM as monitored by matrix-loaded fura2-FF, was observed when total matrix calcium was increased from 10 to at least 500 nmol of calcium/mg of protein. Increasing phosphate decreased both the free matrix calcium and the matrix calcium-loading capacity. Thus the permeability transition is not triggered by a critical matrix free calcium concentration. The rate of hydrogen peroxide detection by Amplex Red decreased during calcium infusion arguing against a role for oxidative stress in permeability pore activation in this model. A transition between a variable and buffered matrix free calcium concentration occurred at 10 nmol of total matrix calcium/mg protein. The solubility product of amorphous Ca-3(PO4)(2) is consistent with the observed matrix free calcium concentration, and the matrix pH is proposed to play the major role in maintaining the low matrix free calcium concentration.	Buck Inst Age Res, Novato, CA 94945 USA	Buck Institute for Research on Aging	Nicholls, DG (corresponding author), Buck Inst Age Res, Novato, CA 94945 USA.		Chalmers, Susan/C-1392-2009; NICHOLLS, DAVID G/K-4300-2012	Chalmers, Susan/0000-0002-8073-7576; 				AL N, 1986, BIOCHEM J, V239, P31; ALLEN SP, 1992, J MOL CELL CARDIOL, V24, P765, DOI 10.1016/0022-2828(92)93390-6; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; COLL KE, 1982, J BIOL CHEM, V257, P8696; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; David G, 1999, J NEUROSCI, V19, P7495, DOI 10.1523/JNEUROSCI.19-17-07495.1999; DAVIS MH, 1987, BIOCHEM BIOPH RES CO, V149, P40, DOI 10.1016/0006-291X(87)91602-0; ERECINSKA M, 1992, CAN J PHYSIOL PHARM, V70, pS190, DOI 10.1139/y92-262; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; GRIFFITHS T, 1982, NEUROSCI LETT, V30, P329, DOI 10.1016/0304-3940(82)90421-9; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HANSFORD RG, 1994, J BIOENERG BIOMEMBR, V26, P495, DOI 10.1007/BF00762734; HANSFORD RG, 1982, J BIOENERG BIOMEMBR, V14, P361, DOI 10.1007/BF00743064; Huser J, 1999, BIOCHEM J, V343, P311, DOI 10.1042/0264-6021:3430311; Huser J, 1998, BIOPHYS J, V74, P2129, DOI 10.1016/S0006-3495(98)77920-2; Kramer R, 1998, EXP PHYSIOL, V83, P259, DOI 10.1113/expphysiol.1998.sp004111; LARSEN MJ, 1986, ARCH ORAL BIOL, V31, P757, DOI 10.1016/0003-9969(86)90008-7; LARSEN MJ, 1985, CALCIFIED TISSUE INT, V37, P189, DOI 10.1007/BF02554840; LEHNINGER AL, 1967, ADV ENZYMOL RAMB, V29, P259; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LUKACS GL, 1988, FEBS LETT, V229, P219, DOI 10.1016/0014-5793(88)80831-7; LUKACS GL, 1987, BIOCHEM J, V248, P609, DOI 10.1042/bj2480609; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; MCCORMACK JG, 1989, BIOCHIM BIOPHYS ACTA, V973, P420, DOI 10.1016/S0005-2728(89)80384-6; MORENOSANCHEZ R, 1988, BIOCHEM J, V256, P403, DOI 10.1042/bj2560403; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; NICHOLLS DG, 1980, BIOCHEM J, V186, P833, DOI 10.1042/bj1860833; NICHOLLS DG, 1978, BIOCHEM J, V176, P463, DOI 10.1042/bj1760463; NICHOLLS DG, 1980, BIOCHEM J, V188, P113, DOI 10.1042/bj1880113; Pitter JG, 2002, CELL CALCIUM, V31, P97, DOI 10.1054/ceca.2001.0264; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; Starkov AA, 2002, J NEUROCHEM, V83, P220, DOI 10.1046/j.1471-4159.2002.01153.x; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611, DOI 10.1152/jn.1996.76.3.1611; WUTHIER RE, 1985, CALCIFIED TISSUE INT, V37, P401, DOI 10.1007/BF02553710; Zago EB, 2000, FEBS LETT, V478, P29, DOI 10.1016/S0014-5793(00)01815-9; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; [No title captured]	46	300	307	2	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19062	19070		10.1074/jbc.M212661200	http://dx.doi.org/10.1074/jbc.M212661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12660243	hybrid			2022-12-27	WOS:000182932200046
J	Kumar, A; Knox, AJ; Boriek, AM				Kumar, A; Knox, AJ; Boriek, AM			CCAAT/enhancer-binding protein and activator protein-1 transcription factors regulate the expression of interleukin-8 through the mitogen-activated protein kinase pathways in response to mechanical stretch of human airway smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; INDUCED CARDIOMYOCYTE HYPERTROPHY; SIGNAL-TRANSDUCTION PATHWAYS; INTESTINAL EPITHELIAL-CELLS; ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; COOPERATIVE INTERACTION; INFLAMMATORY CYTOKINES; TYROSINE KINASES	Here we investigated the mechanisms by which mechanical stretch regulates the production of IL-8 in primary human airway smooth muscle cells (HASMC). Bronchial HASMC were subjected to cyclic mechanical stretch (12%, 1 Hz) using the computer-controlled Flex-cell Strain system. Mechanical stretch increased IL-8 mRNA expression and protein production. Cyclic stretch of HASMC also increased the kinase activities of ERK1/2, JNK1, p38, and the DNA binding activities of AP-1 and C/EBP transcription factors with little effect on NF-kappaB. The inhibition of AP-1 and C/EBP transcriptional activities blocked the production of IL-8 in culture supernatants. Furthermore, the inhibition of ERK1/2 and p38 but not JNK1 caused a significant downregulation in the expression and production of IL-8 in response to cyclic stretch. Although protein tyrosine kinases were required for the activation of both ERK1/2 and p38 kinase, stretch-activated channels, small GTPase proteins, and extracellular Ca2+ influx were required only for the activation of p38 kinase whereas phosphoinositide 3-kinase was needed for ERK1/2 activation. In addition, the phosphorylation of ERK1/2 was essential for the activation of AP-1 whereas p38 MAP kinase was needed for the activation of C/EBP. Our data demonstrate that the cyclic stretch of HASMC causes the increased production of IL-8 by activating the AP-1 and C/EBP transcription factors through the activation of ERK1/2 and p38 kinase signaling pathways.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG7 2RD, England	Baylor College of Medicine; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Suite 520B,1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Knox, Alan/0000-0002-5906-4143; Kumar, Ashok/0000-0001-8571-2848; Kumar, Ashok/0000-0002-2444-9529	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063134] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-63134] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Ahn JD, 2002, CIRC RES, V90, P1325, DOI 10.1161/01.RES.0000023200.19316.D5; Alcorn MJ, 2001, J VIROL, V75, P6450, DOI 10.1128/JVI.75.14.6450-6459.2001; Ameixa C, 2002, INFECT IMMUN, V70, P4743, DOI 10.1128/IAI.70.8.4743-4746.2002; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Eftmova T, 2002, J BIOL CHEM, V277, P31753, DOI 10.1074/jbc.M205098200; Furuichi S, 2002, RESPIROLOGY, V7, P193, DOI 10.1046/j.1440-1843.2002.00401.x; Gao HW, 2002, J BIOL CHEM, V277, P38827, DOI 10.1074/jbc.M206224200; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Hamill OP, 2001, PHYSIOL REV, V81, P685, DOI 10.1152/physrev.2001.81.2.685; Harant H, 1996, J BIOL CHEM, V271, P26954, DOI 10.1074/jbc.271.43.26954; Harris VK, 2001, ONCOGENE, V20, P1730, DOI 10.1038/sj.onc.1204249; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86, DOI 10.1165/ajrcmb.23.1.4014; Hipp MS, 2002, EUR J IMMUNOL, V32, P2208, DOI 10.1002/1521-4141(200208)32:8<2208::AID-IMMU2208>3.0.CO;2-2; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Ikeda M, 1999, BIOCHEM BIOPH RES CO, V257, P668, DOI 10.1006/bbrc.1999.0532; Ingber DE, 1998, BIOL BULL-US, V194, P323, DOI 10.2307/1543102; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; JUST I, 1995, J BIOL CHEM, V270, P13932, DOI 10.1074/jbc.270.23.13932; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kawano Yoji, 2002, Nagoya J Med Sci, V65, P1; Knox AJ, 2001, FASEB J, V15, P2480, DOI 10.1096/fj.01-0256com; Knox AJ, 2000, CLIN EXP ALLERGY, V30, P606; Ko KS, 2001, BIOCHEM BIOPH RES CO, V285, P1077, DOI 10.1006/bbrc.2001.5177; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; Lew AM, 1999, BIOCHEM J, V341, P647, DOI 10.1042/0264-6021:3410647; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; Lopez-Ilasaca M, 1998, BIOCHEM PHARMACOL, V56, P269, DOI 10.1016/S0006-2952(98)00059-8; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Miyauchi A, 2000, J BIOL CHEM, V275, P3335, DOI 10.1074/jbc.275.5.3335; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; Na YJ, 2001, INT IMMUNOPHARMACOL, V1, P1877, DOI 10.1016/S1567-5769(01)00113-8; Nemeth ZH, 2002, AM J PATHOL, V161, P987, DOI 10.1016/S0002-9440(10)64259-9; Osawa Y, 2002, INFECT IMMUN, V70, P6294, DOI 10.1128/IAI.70.11.6294-6301.2002; Oudin S, 2002, AM J RESP CELL MOL, V27, P107, DOI 10.1165/ajrcmb.27.1.4766; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, BRIT J PHARMACOL, V121, P579, DOI 10.1038/sj.bjp.0701152; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Refsnes M, 2001, TOXICOLOGY, V167, P145, DOI 10.1016/S0300-483X(01)00448-6; Ruoslahti E, 1997, SCIENCE, V276, P1345, DOI 10.1126/science.276.5317.1345; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; SADOSHIMA J, 1992, P NATL ACAD SCI USA, V89, P9905, DOI 10.1073/pnas.89.20.9905; Seow CY, 1998, AM J RESP CRIT CARE, V158, pS179, DOI 10.1164/ajrccm.158.supplement_2.13tac160; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Smith PG, 1998, EXP CELL RES, V239, P353, DOI 10.1006/excr.1997.3905; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; Strieter RM, 2002, AM J PHYSIOL-LUNG C, V283, pL688, DOI 10.1152/ajplung.00146.2002; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VANDENBURGH HH, 1982, J BIOL CHEM, V257, P13448; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; Wettschureck N, 2002, J MOL MED, V80, P629, DOI 10.1007/s00109-002-0370-2; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yamazaki T, 1996, J BIOL CHEM, V271, P3221, DOI 10.1074/jbc.271.6.3221; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; YASUMOTO K, 1992, J BIOL CHEM, V267, P22506	80	69	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18868	18876		10.1074/jbc.M212777200	http://dx.doi.org/10.1074/jbc.M212777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637525	hybrid			2022-12-27	WOS:000182932200022
J	Angermayr, M; Oechsner, U; Bandlow, W				Angermayr, M; Oechsner, U; Bandlow, W			Reb1p-dependent DNA bending effects nucleosome positioning and constitutive transcription at the yeast profilin promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEINS; RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; CHROMATIN STRUCTURE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; GENE; REB1P; SITE; SEQUENCE; ACTIVATION	The molecular basis of constitutive gene activation is largely unknown. The yeast profilin gene (PFY1), encoding a housekeeping component of the actin cytoskeleton, is constitutively transcribed at a moderate level. The PFY1 promoter dispenses with classical transactivators and a consensus TATA box; however, it contains a canonic site for the abundant multifunctional nuclear factor rDNA enhancer-binding protein (Reb1p) combined with a dA.dT element. Reb1p binds specifically in vitro. Mutation of this site reduces PFY1 expression to about 35%. A nucleosome-free gap of about 190 bp is centered at the genomic Reb1p binding site in vivo and spans the presumptive core promoter and transcriptional initiation sites. Nucleosomes at the border of the gap are positioned. Mutation of the Reb1p motif in the genomic PFY1 promoter abolishes nucleosome positioning, fills the gap with a non-positioned nucleosome, and reduces transcription by a factor of 3. From permutation studies we conclude that Reb1p induces a strong bend into the DNA. Phasing analyses indicate that it is directed toward the major groove. The data suggest that Reb1p plays an architectural role on DNA and that Reb1p-dependent DNA bending leads to a DNA conformation that is incompatible with packaging into nucleosomes and concomitantly facilitates constitutive transcription. In the absence of other transcription activators, Reb1p excludes nucleosomes and moderately stimulates transcription by distorting DNA.	Univ Munich, Bereich genet, Dept Biol 1, D-80638 Munich, Germany	University of Munich	Angermayr, M (corresponding author), Univ Munich, Bereich genet, Dept Biol 1, Maria Ward Str 1A, D-80638 Munich, Germany.							ACHSTETTER T, 1984, J BIOL CHEM, V259, P3344; ALMER A, 1986, EMBO J, V5, P2681, DOI 10.1002/j.1460-2075.1986.tb04551.x; Angermayr M, 2003, J BIOL CHEM, V278, P11026, DOI 10.1074/jbc.M210932200; Angermayr M, 1997, MOL GEN GENET, V256, P682, DOI 10.1007/s004380050616; Angermayr M, 2002, NUCLEIC ACIDS RES, V30, P4199, DOI 10.1093/nar/gkf551; Angermayr M, 1997, J BIOL CHEM, V272, P31630, DOI 10.1074/jbc.272.50.31630; ARCHER TK, 1991, MOL CELL BIOL, V11, P688, DOI 10.1128/MCB.11.2.688; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLSSON L, 1976, J MOL BIOL, V105, P353, DOI 10.1016/0022-2836(76)90098-X; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DURRIN LK, 1992, MOL CELL BIOL, V12, P1621, DOI 10.1128/MCB.12.4.1621; Erkine AM, 1996, MOL CELL BIOL, V16, P7004; FASCHER KD, 1990, EMBO J, V9, P2523, DOI 10.1002/j.1460-2075.1990.tb07432.x; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GARTENBERG MR, 1990, P NATL ACAD SCI USA, V87, P6034, DOI 10.1073/pnas.87.16.6034; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GOLDSCHMIDTCLERMONT PJ, 1991, CELL, V66, P419, DOI 10.1016/0092-8674(81)90002-7; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GRAHAM IR, 1994, MOL MICROBIOL, V12, P931, DOI 10.1111/j.1365-2958.1994.tb01081.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HARTWIG JH, 1989, J CELL BIOL, V109, P1571, DOI 10.1083/jcb.109.4.1571; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HERMANN H, 1992, GENE, V119, P137, DOI 10.1016/0378-1119(92)90079-5; HORIKOSHI M, 1992, P NATL ACAD SCI USA, V89, P1060, DOI 10.1073/pnas.89.3.1060; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P5479, DOI 10.1128/MCB.13.9.5479; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; KOO HS, 1988, P NATL ACAD SCI USA, V85, P1763, DOI 10.1073/pnas.85.6.1763; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANG WH, 1993, MOL CELL BIOL, V13, P649, DOI 10.1128/MCB.13.1.649; LANG WH, 1995, P NATL ACAD SCI USA, V92, P9781, DOI 10.1073/pnas.92.21.9781; LASSING I, 1988, J CELL BIOCHEM, V37, P255, DOI 10.1002/jcb.240370302; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOHR D, 1995, J BIOL CHEM, V270, P27671, DOI 10.1074/jbc.270.46.27671; LOHR D, 1985, NUCLEIC ACIDS RES, V13, P8409, DOI 10.1093/nar/13.23.8409; MAGDOLEN V, 1993, FEBS LETT, V316, P41, DOI 10.1016/0014-5793(93)81733-G; MAGDOLEN V, 1990, GENE, V90, P105, DOI 10.1016/0378-1119(90)90445-W; MAGDOLEN V, 1994, BBA-GENE STRUCT EXPR, V1218, P205, DOI 10.1016/0167-4781(94)90013-2; MAGDOLEN V, 1988, MOL CELL BIOL, V8, P5108, DOI 10.1128/MCB.8.12.5108; Maniatis T., 1982, MOL CLONING LAB MANU; MCBROOM LDB, 1994, J BIOL CHEM, V269, P16461; McLean M, 1995, MOL MICROBIOL, V18, P605, DOI 10.1111/j.1365-2958.1995.mmi_18040605.x; Moreira JMA, 2002, J BIOL CHEM, V277, P3202, DOI 10.1074/jbc.M108962200; MORROW BE, 1989, J BIOL CHEM, V264, P9061; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4726, DOI 10.1093/nar/21.20.4726; Oechsner U, 1998, MOL GEN GENET, V260, P417, DOI 10.1007/s004380050912; Packham EA, 1996, MOL GEN GENET, V250, P348; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PINA B, 1990, J MOL BIOL, V216, P975, DOI 10.1016/S0022-2836(99)80015-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Reagan MS, 1998, MOL GEN GENET, V259, P142, DOI 10.1007/s004380050799; REICHSTEIN E, 1979, J BIOL CHEM, V254, P6174; REMACLE JE, 1992, MOL CELL BIOL, V12, P5516, DOI 10.1128/MCB.12.12.5516; SCOTT EW, 1993, MOL CELL BIOL, V13, P543, DOI 10.1128/MCB.13.1.543; Sherman F., 1986, METHODS YEAST GENETI; STARR DB, 1995, J MOL BIOL, V250, P434; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; Svaren J, 1997, TRENDS BIOCHEM SCI, V22, P93, DOI 10.1016/S0968-0004(97)01001-3; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TANAKA S, 1992, EMBO J, V11, P1187, DOI 10.1002/j.1460-2075.1992.tb05159.x; Thoma F, 1996, METHOD ENZYMOL, V274, P197; THOMPSON JF, 1988, NUCLEIC ACIDS RES, V16, P9687, DOI 10.1093/nar/16.20.9687; TRAVERS AA, 1990, CELL, V60, P177, DOI 10.1016/0092-8674(90)90729-X; VIGNAIS ML, 1989, J BIOL CHEM, V264, P8463; VOJTEK A, 1991, CELL, V66, P497, DOI 10.1016/0092-8674(81)90013-1; WAY M, 1990, NATURE, V344, P292, DOI 10.1038/344292a0; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	81	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17918	17926		10.1074/jbc.M301806200	http://dx.doi.org/10.1074/jbc.M301806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637580	hybrid			2022-12-27	WOS:000182838300042
J	Peak, MM; Arbuckle, JL; Rodgers, KK				Peak, MM; Arbuckle, JL; Rodgers, KK			The central domain of core RAG1 preferentially recognizes single-stranded recombination signal sequence heptamer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V(D)J RECOMBINATION; OMENN-SYNDROME; STRUCTURE REQUIREMENTS; MUTATIONAL ANALYSIS; DNA-SEQUENCE; ACTIVE-SITE; AMINO-ACIDS; COMPLEX; CLEAVAGE; PROTEINS	RAG1 and RAG2 initiate V(D)J recombination by introducing DNA double strand breaks between each selected gene segment and its bordering recombination signal sequence (RSS) in a two-step mechanism in which the DNA is first nicked, followed by hairpin formation. The RSS consists of a conserved nonamer and heptamer sequence, in which the latter borders the site of DNA cleavage. A region within RAG1, referred to as the central domain (residues 528-760 of 1040 in the full-length protein), has been shown previously to bind specifically to the double-stranded (ds) RSS heptamer, but with both weak specificity and affinity. However, additional investigations into the RAG1-RSS heptamer interaction are required because the DNA substrate forms intermediate conformations during the V(D)J recombination reaction. These include the nicked and hairpin products, as well as likely base unpairing to produce single-stranded (ss) DNA near the cleavage site. Here, it was determined that although the central domain showed substantially higher binding affinity for ss and nicked versus ds substrate, the interaction with ss RSS was particularly robust. In addition, the central domain bound with greater sequence specificity to the ss RSS heptamer than to the ds form. This study provides important insight into the V(D)J recombination reaction, specifically that significant interaction of the RSS heptamer with RAG1 occurs only after the induction of conformational changes at the RSS heptamer.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Rodgers, KK (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.			Rodgers, Karla/0000-0002-7338-0281	NIAID NIH HHS [T32 AI007633] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Aidinis V, 2000, J IMMUNOL, V164, P5826, DOI 10.4049/jimmunol.164.11.5826; Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Arbuckle JL, 2001, J BIOL CHEM, V276, P37093, DOI 10.1074/jbc.M105988200; Corneo B, 2001, BLOOD, V97, P2772, DOI 10.1182/blood.V97.9.2772; Cuomo CA, 1996, MOL CELL BIOL, V16, P5683; Difilippantonio MJ, 1996, CELL, V87, P253, DOI 10.1016/S0092-8674(00)81343-4; Eastman QM, 1999, MOL CELL BIOL, V19, P3788; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Fugmann SD, 2001, MOL CELL, V8, P899, DOI 10.1016/S1097-2765(01)00352-5; Gellert M, 2002, ANNU REV BIOCHEM, V71, P101, DOI 10.1146/annurev.biochem.71.090501.150203; Godderz LJ, 2003, NUCLEIC ACIDS RES, V31, P2014, DOI 10.1093/nar/gkg281; Gomez CA, 2000, MOL CELL BIOL, V20, P5653, DOI 10.1128/MCB.20.15.5653-5664.2000; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; Huye LE, 2002, MOL CELL BIOL, V22, P3460, DOI 10.1128/MCB.22.10.3460-3473.2002; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Mo XM, 2000, NUCLEIC ACIDS RES, V28, P1228, DOI 10.1093/nar/28.5.1228; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; RAMSDEN DA, 1994, NUCLEIC ACIDS RES, V22, P1785, DOI 10.1093/nar/22.10.1785; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Rodgers KK, 1996, J MOL BIOL, V260, P70, DOI 10.1006/jmbi.1996.0382; Rodgers KK, 1999, NUCLEIC ACIDS RES, V27, P2938, DOI 10.1093/nar/27.14.2938; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; Swanson PC, 2002, MOL CELL BIOL, V22, P1340, DOI 10.1128/MCB.22.5.1340-1351.2002; Swanson PC, 1999, MOL CELL BIOL, V19, P3674; Swanson PC, 1998, IMMUNITY, V9, P115, DOI 10.1016/S1074-7613(00)80593-2; Tsai CL, 2002, GENE DEV, V16, P1934, DOI 10.1101/gad.984502; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81	34	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18235	18240		10.1074/jbc.M302041200	http://dx.doi.org/10.1074/jbc.M302041200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644467	hybrid			2022-12-27	WOS:000182838300085
J	Cornish, AL; Chong, MM; Davey, GM; Darwiche, R; Nicola, NA; Hilton, DJ; Kay, TW; Starr, R; Alexander, WS				Cornish, AL; Chong, MM; Davey, GM; Darwiche, R; Nicola, NA; Hilton, DJ; Kay, TW; Starr, R; Alexander, WS			Suppressor of cytokine signaling-1 regulates signaling in response to interleukin-2 and other gamma c-dependent cytokines in peripheral T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; IFN-GAMMA; LYMPHOID HOMEOSTASIS; IN-VIVO; MEMORY; DIFFERENTIATION; PROLIFERATION; RECEPTOR; NAIVE; MICE	Suppressor of cytokine signaling- 1 ( SOCS- 1) is an essential regulator of cytokine signaling. SOCS-1(-/-) mice die before weaning with a complex disease characterized by fatty degeneration and necrosis of the liver. This disease is mediated by interferon ( IFN) gamma as neonatal mortality fails to occur in SOCS-1(-/-) IFNgamma(-/-) mice. However, the immune system of healthy SOCS-1(-/-) IFNgamma(-/-) mice is dysregulated with a reduced ratio of CD4: CD8 T cells and increases in some aspects of T cell activation. SOCS-1(-/-) IFNgamma(-/-) mice also die before their wild type and IFNgamma(-/-) counterparts with a range of inflammatory conditions including pneumonia, gut infiltration, and skin ulceration, suggesting that SOCS- 1 controls not only IFNgamma signaling, but also other immunoregulatory factors. This study shows that T cells from SOCS- 1- deficient mice display hypersensitivity to cytokines that act through the gammac receptor. SOCS- 1 expression is induced by interleukin ( IL) 2, IL- 4, IL- 7, and IL- 15, and SOCS- 1-deficient T cells show increased proliferation and prolonged survival in response to IL- 2 and IL- 4. Furthermore, IL- 2 induced increased STAT5 phosphorylation and CD44 expression in SOCS- 1- deficient T cells compared with controls. Hypersensitivity to gammac- dependent cytokines may contribute to abnormal T cell function, as well as the pathology observed in mice lacking SOCS- 1.	Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital	Alexander, WS (corresponding author), Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Parkville, Vic 3050, Australia.	alexandw@wehi.edu.au	Chong, Mark/H-6684-2016; Hilton, Douglas J/C-7250-2013; Nicola, Nicos/D-2989-2011	Chong, Mark/0000-0002-3701-7397; Hilton, Douglas J/0000-0002-7698-2392; Nicola, Nicos/0000-0003-1054-7889; Davey, Gayle/0000-0002-9514-6023	NCI NIH HHS [CA-22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akashi K, 1998, IMMUNOL REV, V165, P13, DOI 10.1111/j.1600-065X.1998.tb01226.x; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Brysha M, 2001, J BIOL CHEM, V276, P22086, DOI 10.1074/jbc.M102737200; Bullen DVR, 2001, IMMUNOLOGY, V104, P92, DOI 10.1046/j.1365-2567.2001.01294.x; Chong MMW, 2003, IMMUNITY, V18, P475, DOI 10.1016/S1074-7613(03)00078-5; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; Cornish AL, 2003, J IMMUNOL, V170, P878, DOI 10.4049/jimmunol.170.2.878; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Dummer W, 2001, J IMMUNOL, V166, P2460, DOI 10.4049/jimmunol.166.4.2460; Eyles JL, 2002, J BIOL CHEM, V277, P43735, DOI 10.1074/jbc.M208586200; Fry TJ, 2001, TRENDS IMMUNOL, V22, P564, DOI 10.1016/S1471-4906(01)02028-2; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; GATELY MK, 1988, J IMMUNOL, V141, P189; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Geiselhart LA, 2001, J IMMUNOL, V166, P3019, DOI 10.4049/jimmunol.166.5.3019; GODFREY DI, 1994, J IMMUNOL, V152, P2729; Goldrath AW, 2002, J EXP MED, V195, P1515, DOI 10.1084/jem.20020033; Habib T, 2002, BIOCHEMISTRY-US, V41, P8725, DOI 10.1021/bi0202023; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Leung DTM, 2000, J IMMUNOL, V164, P3527, DOI 10.4049/jimmunol.164.7.3527; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Losman JA, 1999, J IMMUNOL, V162, P3770; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Marrack P, 1999, J EXP MED, V189, P521, DOI 10.1084/jem.189.3.521; Matsuda T, 2000, FEBS LETT, V472, P235, DOI 10.1016/S0014-5793(00)01444-7; MERTSCHING E, 1995, INT IMMUNOL, V7, P401, DOI 10.1093/intimm/7.3.401; Metcalf D, 2000, P NATL ACAD SCI USA, V97, P9174, DOI 10.1073/pnas.160255197; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Newton K, 2001, CURR BIOL, V11, P273, DOI 10.1016/S0960-9822(01)00067-7; Nicholson SE, 1999, EMBO J, V18, P375, DOI 10.1093/emboj/18.2.375; Ohya K, 1997, J BIOL CHEM, V272, P27178, DOI 10.1074/jbc.272.43.27178; Pallard C, 1999, IMMUNITY, V10, P525, DOI 10.1016/S1074-7613(00)80052-7; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; Sporri B, 2001, BLOOD, V97, P221, DOI 10.1182/blood.V97.1.221; Starr R, 1998, P NATL ACAD SCI USA, V95, P14395, DOI 10.1073/pnas.95.24.14395; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Surh CD, 2002, MICROBES INFECT, V4, P51, DOI 10.1016/S1286-4579(01)01509-X; Trop S, 2001, BLOOD, V97, P2269, DOI 10.1182/blood.V97.8.2269; VISSINGA CS, 1992, EXP HEMATOL, V20, P998; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yu CL, 1997, J BIOL CHEM, V272, P14017, DOI 10.1074/jbc.272.22.14017; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071; Zhang XH, 1998, IMMUNITY, V8, P591, DOI 10.1016/S1074-7613(00)80564-6	54	95	99	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22755	22761		10.1074/jbc.M303021200	http://dx.doi.org/10.1074/jbc.M303021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665516	hybrid			2022-12-27	WOS:000183503900078
J	Marie, N; Lecoq, I; Jauzac, P; Allouche, S				Marie, N; Lecoq, I; Jauzac, P; Allouche, S			Differential sorting of human delta-opioid receptors after internalization by peptide and alkaloid agonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SK-N-BE; NEUROBLASTOMA CELL-LINE; PROTEIN-COUPLED RECEPTORS; HAMSTER OVARY CELLS; MOLECULAR MECHANISMS; DOWN-REGULATION; INDUCED DESENSITIZATION; ENDOCYTOSIS; MU; PHOSPHORYLATION	Desensitization and internalization of G protein-coupled receptors observed after agonist activation are considered two important regulatory processes of receptor transduction. Endogenous human delta-opioid receptors (hDOR) are differentially regulated in terms of desensitization by peptide ([D-Pen(2,5)] enkephalin (DPDPE) and Deltorphin I) and alkaloid (etorphine) agonists in the neuroblastoma cell line SK-N-BE (Allouche, S., Roussel, M., Marie, N., and Jauzac, P. (1999) Eur. J. Pharmacol. 371, 235 - 240). In the present study, we examined the role of hDOR internalization and down-regulation in this differential desensitization. Sustained activation by peptides for 30 min caused a marked decrease of both [H-3] diprenorphine binding sites and hDOR immunoreactivity, observed in a Western blot, whereas a moderate reduction by 30% was observed after a 30- and 60-min etorphine exposure in binding experiments without opioid receptor degradation. Using fluorescence microscopy, we visualized hDOR internalization promoted by different agonists in SK-N-BE cells expressing FLAG-tagged hDOR. Agonist withdrawal results in a greater recycling process correlated with a stronger hDOR resensitization after etorphine treatment compared with DPDPE or Deltorphin I, as shown in binding, immunocytochemical, and functional experiments. This suggests a distinct sorting of opioid receptors after their internalization. We demonstrated a lysosomal hDOR targeting upon peptides by using chloroquine in binding, Western blot, and immunocytochemical experiments and by colocalization of this receptor with a late endosome marker. In contrast, when the recycling endosome blocker monensin was used, acceleration of desensitization associated with a strong intracellular immunostaining was observed upon etorphine treatment. The possibility of separate endocytic pathways responsible for the differential sorting of hDOR upon peptide and alkaloid ligand exposure was ruled out by binding and immunocytochemical experiments using sucrose hypertonic solution. First, these results showed complex relationships between hDOR internalization/ down-regulation and desensitization. Second, we demonstrated for the first time that the same receptor could undergo a distinct sorting after internalization by peptide and alkaloid agonists.	Univ Caen, Ctr Hosp & Univ Caen, Lab Pharmacol Mol Tolerance Opiaces, F-14033 Caen, France	CHU de Caen NORMANDIE; Universite de Caen Normandie	Allouche, S (corresponding author), CHU Caen, Biochim Lab A, Ave Cote Nacre, F-14033 Caen, France.	allouche-se@chu-caen.fr	Marie, Nicolas/I-9129-2014	Marie, Nicolas/0000-0002-6491-9898; Allouche, stephane/0000-0003-3134-7501				Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Allouche S, 1996, J NEUROCHEM, V67, P2461; Allouche S, 1999, BIOCHEM J, V342, P71, DOI 10.1042/0264-6021:3420071; Allouche S, 2000, BIOCHEM PHARMACOL, V59, P915, DOI 10.1016/S0006-2952(99)00404-9; Bot G, 1997, MOL PHARMACOL, V52, P272, DOI 10.1124/mol.52.2.272; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chaturvedi K, 2001, J BIOL CHEM, V276, P12345, DOI 10.1074/jbc.M008054200; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Hasbi A, 2000, J PHARMACOL EXP THER, V293, P237; Hasbi A, 1998, J NEUROCHEM, V70, P2129; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Jockers R, 1999, J BIOL CHEM, V274, P28900, DOI 10.1074/jbc.274.41.28900; JOSEPH DB, 1995, J PHARMACOL EXP THER, V272, P970; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Law PY, 2000, J BIOL CHEM, V275, P32057, DOI 10.1074/jbc.M002395200; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Namir N, 1997, J NEUROCHEM, V68, P1764; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Pak Y, 1996, MOL PHARMACOL, V50, P1214; PASTERNAK GW, 1993, CLIN NEUROPHARMACOL, V16, P1, DOI 10.1097/00002826-199302000-00001; POLASTRON J, 1994, J NEUROCHEM, V62, P898; PRATHER PL, 1994, J PHARMACOL EXP THER, V270, P177; RAYNOR K, 1994, J PHARMACOL EXP THER, V270, P1381; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; Trejo J, 1998, P NATL ACAD SCI USA, V95, P13698, DOI 10.1073/pnas.95.23.13698; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Zhu JM, 1998, J PHARMACOL EXP THER, V285, P28	35	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22795	22804		10.1074/jbc.M300084200	http://dx.doi.org/10.1074/jbc.M300084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12672796	hybrid			2022-12-27	WOS:000183503900083
J	Fourrier, L; Brooks, P; Malinge, JM				Fourrier, L; Brooks, P; Malinge, JM			Binding discrimination of MutS to a set of lesions and compound lesions (base damage and mismatch) reveals its potential role as a cisplatin-damaged DNA sensing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLESION SYNTHESIS; CELLULAR-RESPONSES; REPLICATIVE BYPASS; EXCISION-REPAIR; GPG ADDUCTS; RECOGNITION; OXALIPLATIN; RESISTANCE; MECHANISMS; MISPAIR	The DNA mismatch repair (MMR) system plays a critical role in sensitizing both prokaryotic and eukaryotic cells to the clinically potent anticancer drug cisplatin. It is thought to mediate cytotoxicity through recognition of cisplatin DNA lesions. This drug generates a range of lesions that may also give rise to compound lesions resulting from the misincorporation of a base during translesion synthesis. Using gel mobility shift competition assays and surface plasmon resonance, we have analyzed the interaction of Escherichia coli MutS protein with site-specifically modified DNA oligonucleotides containing each of the four cisplatin cross-links or a set of compound lesions. The major 1,2-d(GpG) cisplatin intrastrand cross-link was recognized with only a 1.5-fold specificity, whereas a 47-fold specificity was found with a natural G/T containing DNA substrate. The rate of association, k(on), for binding to the 1,2-d( GpG) adduct was 3.1 x 10(4) M-1 s(-1) and the specificity of binding was essentially dependent on k(off). DNA duplexes containing a single 1,2-d( ApG), 1,3-d(GpCpG) adduct, and an interstrand cross-link of cisplatin were not preferentially recognized. Among 12 DNA substrates, each containing a different cisplatin compound lesion derived from replicative misincorporation of one base opposite either of the 1,2-intrastrand adducts, 10 were specifically recognized including those that are more likely formed in vivo based on cisplatin mutation spectra. Moreover, among these lesions, two compound lesions formed when an adenine was misincorporated opposite a 1,2-d( GpG) adduct were not substrates for the MutY-dependent mismatch repair pathway. The ability of MutS to sense differentially various platinated DNA substrates suggests that cisplatin compound lesions formed during misincorporation of a base opposite either adducted base of both 1,2-intrastrand cross-links are more plausible critical lesions for MMR-mediated cisplatin cytotoxicity.	CNRS, Ctr Biophys Mol, F-45071 Orleans 02, France; Genoscope Ctr Natl Sequencage, F-91057 Evry, France	Centre National de la Recherche Scientifique (CNRS)	Malinge, JM (corresponding author), CNRS, Ctr Biophys Mol, Rue Charles Sadron, F-45071 Orleans 02, France.	malinge@cnrs-orleans.fr	Malinge, Jean-Marc/O-1131-2017	Malinge, Jean-Marc/0000-0002-6644-868X				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Babic I, 1996, MUTAT RES-FUND MOL M, V372, P87, DOI 10.1016/S0027-5107(96)00170-4; Berardini M, 2000, J BIOL CHEM, V275, P27851; Blackwell LJ, 2001, J BIOL CHEM, V276, P34339, DOI 10.1074/jbc.M104256200; Brown R, 2000, CANC DRUG DISC DEV, V7, P115; Brown R, 1997, ONCOGENE, V15, P45, DOI 10.1038/sj.onc.1201167; Cohen SM, 2001, PROG NUCLEIC ACID RE, V67, P93, DOI 10.1016/S0079-6603(01)67026-0; Cotton F.A., 1972, ADV INORGANIC CHEM, Vthird, P1145; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Duckett DR, 1996, P NATL ACAD SCI USA, V93, P6443, DOI 10.1073/pnas.93.13.6443; EASTMAN A, 1987, PHARMACOL THERAPEUT, V34, P155, DOI 10.1016/0163-7258(87)90009-X; Eastman A., 1999, CISPLATIN CHEM BIOCH, P111, DOI [DOI 10.1002/9783906390420.CH4, 10.1002/9783906390420.ch4]; Einhorn LH, 1997, CLIN CANCER RES, V3, P2630; Fink D, 1998, CLIN CANCER RES, V4, P1; Fishel R, 2001, CANCER RES, V61, P7369; FRAM RJ, 1985, MOL PHARMACOL, V28, P51; Galio L, 1999, NUCLEIC ACIDS RES, V27, P2325, DOI 10.1093/nar/27.11.2325; GIBBONS GR, 1991, CARCINOGENESIS, V12, P2253, DOI 10.1093/carcin/12.12.2253; GiraudPanis MJE, 1996, J BIOL CHEM, V271, P33148, DOI 10.1074/jbc.271.51.33148; Gong JG, 1999, NATURE, V399, P806; Henkels KM, 1997, CANCER RES, V57, P4488; House PG, 2001, PROG NUCLEIC ACID RE, V68, P349; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; JIRICNY J, 1988, NUCLEIC ACIDS RES, V16, P7843, DOI 10.1093/nar/16.16.7843; Johnson KA, 1999, J BIOL CHEM, V274, P27112, DOI 10.1074/jbc.274.38.27112; JONES M, 1987, GENETICS, V115, P605; Karran P, 2001, CARCINOGENESIS, V22, P1931, DOI 10.1093/carcin/22.12.1931; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; Malinge JM, 1999, J INORG BIOCHEM, V77, P23, DOI 10.1016/S0162-0134(99)00148-8; Malinge JM, 2000, PRACT APPROACH SER, P25; MAMENTA EL, 1994, CANCER RES, V54, P3500; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; Marsischky GT, 1999, J BIOL CHEM, V274, P26668, DOI 10.1074/jbc.274.38.26668; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; Munoz EF, 1996, CARCINOGENESIS, V17, P2741, DOI 10.1093/carcin/17.12.2741; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Patrick SM, 2002, J BIOL CHEM, V277, P16096, DOI 10.1074/jbc.M200816200; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; PILLAIRE MJ, 1994, NUCLEIC ACIDS RES, V22, P2519, DOI 10.1093/nar/22.13.2519; Reedijk J, 1999, CHEM REV, V99, P2499, DOI 10.1021/cr980422f; SCHWARTZ A, 1989, BIOCHEMISTRY-US, V28, P7975, DOI 10.1021/bi00446a001; SU SS, 1988, J BIOL CHEM, V263, P6829; Vaisman A, 2000, J BIOL CHEM, V275, P13017, DOI 10.1074/jbc.275.17.13017; Vaisman A, 1998, CANCER RES, V58, P3579; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; Wang HX, 1999, J BIOL CHEM, V274, P16894, DOI 10.1074/jbc.274.24.16894; Yamada M, 1997, NUCLEIC ACIDS RES, V25, P491, DOI 10.1093/nar/25.3.491; YAREMA KJ, 1995, NUCLEIC ACIDS RES, V23, P4066, DOI 10.1093/nar/23.20.4066; YAREMA KJ, 1994, J MOL BIOL, V236, P1034, DOI 10.1016/0022-2836(94)90010-8; Zdraveski ZZ, 2002, J BIOL CHEM, V277, P1255, DOI 10.1074/jbc.M105382200; Zdraveski ZZ, 2000, CHEM BIOL, V7, P39, DOI 10.1016/S1074-5521(00)00064-8; Zhang QM, 1998, NUCLEIC ACIDS RES, V26, P4669, DOI 10.1093/nar/26.20.4669	62	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21267	21275		10.1074/jbc.M301390200	http://dx.doi.org/10.1074/jbc.M301390200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654906	hybrid			2022-12-27	WOS:000183230500105
J	Madge, LA; Li, JH; Choi, JH; Pober, JS				Madge, LA; Li, JH; Choi, JH; Pober, JS			Inhibition of phosphatidylinositol 3-kinase sensitizes vascular endothelial cells to cytokine-initiated cathepsin-dependent apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; MEDIATED HEPATOCYTE APOPTOSIS; CYTOCHROME-C; FACTOR-ALPHA; TNF RECEPTOR; MITOCHONDRIAL RELEASE; SIGNALING PATHWAYS; DEATH; ACTIVATION	In the presence of cycloheximide, tumor necrosis factor or interleukin-1 initiates caspase activation, loss of mitochondrial membrane potential (DeltaPsi), DNA degradation, and nuclear condensation and fragmentation characteristic of apoptotic cell death in human vascular endothelial cells (EC). Inhibition of phosphatidylinositol 3-kinase (PI3K) by LY294002, but not inhibition of Akt by dominant-negative mutation, also sensitizes EC to cytokine-initiated apoptosis. Cytokine-initiated caspase activation is slower and comparatively less with LY294002 than with cycloheximide. Cycloheximide but not LY294002 decreases expression of c-FLIP ( cellular FLICE inhibitory protein), an inhibitor of caspase-8 activation. The caspase inhibitor zVADfmk completely blocks caspase activation, DNA degradation, and nuclear fragmentation in both cases but only prevents loss of DeltaPsi and cell death for cytokine plus cycloheximide treatment. In contrast, overexpression of Bcl-2 protects EC treated with cytokine plus LY294002 but not EC treated with cytokine plus cycloheximide. The cathepsin B inhibitor CA-074-Me prevents loss of DeltaPsi, caspase activation, and cell death for EC treated with cytokine plus LY294002 but has no effect on EC treated with cytokine plus cycloheximide. Cathepsin B translocates from lysosomes to cytosol following treatment with LY294002 prior to the activation of caspases. These results suggest that inhibition of PI3K allows cytokines to activate a cathepsin-dependent, mitochondrial death pathway in which caspase activation is secondary, is not inhibited by c-FLIP, and is not essential for cell death.	Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol, New Haven, CT 06536 USA	Yale University	Pober, JS (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, Interdept Program Vasc Biol, 333 Cedar St, New Haven, CT 06536 USA.		Choi, Jaehyuk/N-6532-2019	Choi, Jaehyuk/0000-0003-2379-2226	NHLBI NIH HHS [HL-36003, HL-62188] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036003, R01HL062188, R01HL036003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amstad PA, 2001, BIOTECHNIQUES, V31, P608, DOI 10.2144/01313pf01; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deas O, 1998, J IMMUNOL, V161, P3375; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Guicciardi ME, 2000, J CLIN INVEST, V106, P1127, DOI 10.1172/JCI9914; Guicciardi ME, 2001, AM J PATHOL, V159, P2045, DOI 10.1016/S0002-9440(10)63056-8; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Johnson DE, 2000, LEUKEMIA, V14, P1695, DOI 10.1038/sj.leu.2401879; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JH, 2002, AM J PATHOL, V161, P1485, DOI 10.1016/S0002-9440(10)64424-0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luschen S, 2000, J BIOL CHEM, V275, P24670, DOI 10.1074/jbc.M003280200; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Martin SJ, 2002, CELL, V109, P793, DOI 10.1016/S0092-8674(02)00802-4; Mathiasen IS, 2002, TRENDS MOL MED, V8, P212, DOI 10.1016/S1471-4914(02)02328-6; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ottilie S, 1997, J BIOL CHEM, V272, P30866, DOI 10.1074/jbc.272.49.30866; Ozes ON, 1999, NATURE, V401, P82; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Slowik MR, 1996, CIRC RES, V79, P736, DOI 10.1161/01.RES.79.4.736; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Werneburg NW, 2002, AM J PHYSIOL-GASTR L, V283, pG947, DOI 10.1152/ajpgi.00151.2002; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zheng L, 2000, J IMMUNOL, V164, P4665, DOI 10.4049/jimmunol.164.9.4665	45	48	53	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21295	21306		10.1074/jbc.M212837200	http://dx.doi.org/10.1074/jbc.M212837200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663669	hybrid			2022-12-27	WOS:000183230500108
J	Ogishima, T; Kinoshita, JY; Mitani, F; Suematsu, M; Ito, A				Ogishima, T; Kinoshita, JY; Mitani, F; Suematsu, M; Ito, A			Identification of outer mitochondrial membrane cytochrome b(5) as a modulator for androgen synthesis in Leydig cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; RAT-LIVER MICROSOMES; REDUCTASE-ACTIVITY; 17,20-LYASE ACTIVITY; ELECTRON-TRANSFER; HUMAN P450C17; C REDUCTASE; PURIFICATION; HEMOPROTEIN; ACID	Outer mitochondrial membrane cytochrome b(5) is an isoform of microsomal membrane cytochrome b(5). In rat testes the outer mitochondrial membrane cytochrome b(5) is present in both mitochondria and microsomes, whereas microsomal membrane cytochrome b(5) is undetectable. Outer mitochondrial membrane cytochrome b(5) present in the testis was localized in Leydig cells with cytochrome P-450(17alpha), which catalyzes androgenesis therein. We therefore analyzed the functions of outer mitochondrial membrane cytochrome b(5) in rat testis microsomes by using a proteoliposome system. In a low but physiological concentration of NADPH-cytochrome P-450 reductase and excess amount of progesterone, outer mitochondrial membrane cytochrome b5 stimulated the cytochrome P-450(17alpha)-catalyzed reactions, 17alpha-hydroxylation and C17-C20 bond cleavage. The effects were different from those by microsomal membrane cytochrome b(5) as follows: preferential elevation of the 17alpha-hydroxylase activity by outer mitochondrial membrane cytochrome b(5) in an amount-dependent manner versus that of the lyase activity by microsomal membrane cytochrome b(5) at the low concentration, and the inhibition of both activities at the high concentration. At a low concentration of progesterone reflecting a physiological cholesterol supply, outer mitochondrial membrane cytochrome b(5) elevated primarily the production of 17alpha-hydroxyprogesterone and then facilitated the conversion of the released intermediate to androstenedione. Thus, we demonstrated that outer mitochondrial membrane cytochrome b(5) and not microsomal membrane cytochrome b(5) functions as an activator for androgenesis in rat Leydig cells.	Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan; Keio Univ, Dept Biochem & Integrat Med Biol, Tokyo 1608582, Japan	Kyushu University; Keio University	Ogishima, T (corresponding author), Kyushu Univ, Fac Sci, Dept Chem, Fukuoka 8128581, Japan.		Suematsu, Makoto/I-8135-2013; Suematsu, Makoto/O-5762-2018	Suematsu, Makoto/0000-0002-7165-6336; Suematsu, Makoto/0000-0002-7165-6336				ABE K, 1979, EUR J BIOCHEM, V101, P423, DOI 10.1111/j.1432-1033.1979.tb19735.x; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; FRENCH JS, 1979, ARCH BIOCHEM BIOPHYS, V195, P565, DOI 10.1016/0003-9861(79)90383-7; FUKUSHIMA K, 1972, J BIOCHEM, V71, P447; GUENGERICH FP, 1986, J BIOL CHEM, V261, P5051; Guryev OL, 2001, BIOCHEMISTRY-US, V40, P5018, DOI 10.1021/bi002305w; HILDEBRANDT A, 1971, ARCH BIOCHEM BIOPHYS, V143, P66, DOI 10.1016/0003-9861(71)90186-X; ITO A, 1981, BIOCHEM BIOPH RES CO, V101, P591, DOI 10.1016/0006-291X(81)91300-0; ITO A, 1980, J BIOCHEM, V87, P73, DOI 10.1093/oxfordjournals.jbchem.a132754; ITO A, 1980, J BIOCHEM, V87, P63, DOI 10.1093/oxfordjournals.jbchem.a132753; KAWATA S, 1985, J BIOL CHEM, V260, P6609; KOMINAMI S, 1989, BIOCHIM BIOPHYS ACTA, V985, P293, DOI 10.1016/0005-2736(89)90415-X; KOMINAMI S, 1992, J STEROID BIOCHEM, V42, P57, DOI 10.1016/0960-0760(92)90011-7; KOMINAMI S, 1982, FLAVINS FLAVOPROTEIN, P715; Kuroda R, 1998, J BIOL CHEM, V273, P31097, DOI 10.1074/jbc.273.47.31097; Kuroda R, 1996, J BIOCHEM-TOKYO, V120, P828; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LEDERER F, 1983, EUR J BIOCHEM, V132, P95, DOI 10.1111/j.1432-1033.1983.tb07330.x; MITOMA JY, 1992, EMBO J, V11, P4197, DOI 10.1002/j.1460-2075.1992.tb05513.x; NISHINO H, 1986, J BIOCHEM, V100, P1523, DOI 10.1093/oxfordjournals.jbchem.a121859; OGISHIMA T, 1992, ENDOCRINOLOGY, V130, P2971, DOI 10.1210/en.130.5.2971; OMURA T, 1964, J BIOL CHEM, V239, P2370; OMURA T, 1970, J BIOCHEM-TOKYO, V67, P249, DOI 10.1093/oxfordjournals.jbchem.a129248; ONODA M, 1982, BIOCHEM BIOPH RES CO, V108, P454, DOI 10.1016/0006-291X(82)90850-6; OZOLS J, 1976, ANN CLIN RES, V8, P182; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHINZAWA K, 1985, BIOCHIM BIOPHYS ACTA, V833, P151; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soucy P, 2002, J STEROID BIOCHEM, V80, P71, DOI 10.1016/S0960-0760(01)00171-6; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; TAGASHIRA H, 1995, BIOCHEMISTRY-US, V34, P10939, DOI 10.1021/bi00034a028; VERGERES G, 1995, J BIOL CHEM, V270, P3414, DOI 10.1074/jbc.270.7.3414; YAMAZAKI H, 1995, BIOCHEMISTRY-US, V34, P8380, DOI 10.1021/bi00026a020; Yamazaki T, 1998, BIOCHEMISTRY-US, V37, P2800, DOI 10.1021/bi9715066	35	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21204	21211		10.1074/jbc.M301698200	http://dx.doi.org/10.1074/jbc.M301698200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668680	hybrid			2022-12-27	WOS:000183230500098
J	Pedron, T; Girard, R; Chaby, R				Pedron, T; Girard, R; Chaby, R			TLR4-dependent lipopolysaccharide-induced shedding of tumor necrosis factor receptors in mouse bone marrow granulocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA CONVERTING-ENZYME; ACTIVATED PROTEIN-KINASE; SRC-FAMILY KINASES; INDUCED EXPRESSION; DOWN-REGULATION; TNF RECEPTOR; DIFFERENT MECHANISMS; TISSUE INHIBITOR; CD14 EXPRESSION; RESISTANT MICE	We reported previously that bone marrow granulocytes respond to small amounts of enterobacterial lipopolysaccharide (LPS) via a CD14-independent and TLR4-mediated mechanism by de novo expression of an inducible receptor (CD14) and by down-modulation of a constitutive receptor (L-selectin). In this report we address another effect of LPS: the down-regulation of receptors for tumor necrosis factor-alpha. In mouse bone marrow cells (BMC), this down-regulation is detectable soon ( 20 min) after exposure of the cells to low levels (0.5 ng/ml) of LPS. This temperature-dependent effect is rather selective for LPS and requires the presence of a conventional lipid A structure in the LPS molecule and a functional TLR4 molecule in the cells. The down-modulation, due to a shedding of the receptors, is blocked by p38 MAPK inhibitors, by a furin inhibitor, and by three metalloproteinase inhibitors (BB-3103, TIMP-2, and TIMP-3). In contrast, inhibitors of MEK, protein kinase C, cAMP-dependent protein kinase, and kinases of the Src family do not block the shedding. Analysis of BMC from mice lacking tumor necrosis factor receptor-1 (CD120a(-/-)) or tumor necrosis factor receptor-2 (CD120b(-/-)) indicates that the LPS-induced shedding is specific for CD120b. Thus, exposure of BMC to LPS triggers a rapid shedding of CD120b via a protein kinase C- and Src-independent pathway mediated by p38 MAPK, furin, and metalloproteinase. The additive effects of furin and metalloproteinase inhibitors suggest that these enzymes are involved in parallel shedding pathways.	Univ Paris 11, Endotoxin Grp, UMR 8619, Natl Ctr Sci Res, F-91405 Orsay, France; Inst Pasteur, Unite Pathogenie Microbienne Mol, INSERM, U389, F-75015 Paris, France; Inst Pasteur, URA 1961, Natl Ctr Sci Res, F-75015 Paris, France	UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chaby, R (corresponding author), Univ Paris 11, Endotoxin Grp, UMR 8619, Natl Ctr Sci Res, F-91405 Orsay, France.							AGGARWAL BB, 2000, CYTOKINE REFERENCE, V2, P1619; Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BAUER J, 1989, J EXP MED, V170, P1537, DOI 10.1084/jem.170.5.1537; Beer S, 1999, J CELL SCI, V112, P2667; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BIRKEDALHANSEN H, 1995, CURR OPIN CELL BIOL, V7, P728, DOI 10.1016/0955-0674(95)80116-2; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; CARPENTER A, 1995, J IMMUNOL, V155, P2005; CHABY R, 1993, J IMMUNOL, V151, P4476; CHEN BDM, 1983, J IMMUNOL, V130, P2256; Codony-Servat J, 1999, CANCER RES, V59, P1196; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DING AH, 1990, J EXP MED, V171, P715, DOI 10.1084/jem.171.3.715; DING AH, 1989, J BIOL CHEM, V264, P3924; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; GalvedeRochemonteix B, 1996, AM J RESP CELL MOL, V14, P279, DOI 10.1165/ajrcmb.14.3.8845179; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GIBBS LS, 1992, FREE RADICAL BIO MED, V12, P107, DOI 10.1016/0891-5849(92)90003-Y; GIRARD R, 1993, J IMMUNOL, V150, P4504; Haziot A, 2001, J IMMUNOL, V166, P1075, DOI 10.4049/jimmunol.166.2.1075; Herman C, 1998, J IMMUNOL, V160, P2478; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; HWANG CD, 1993, J IMMUNOL, V151, P5631; JACOBSEN FW, 1994, P NATL ACAD SCI USA, V91, P10695, DOI 10.1073/pnas.91.22.10695; Jin FY, 1999, J IMMUNOL, V162, P3596; Lowell CA, 1998, P NATL ACAD SCI USA, V95, P7580, DOI 10.1073/pnas.95.13.7580; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Mocsai A, 2000, J IMMUNOL, V164, P4321, DOI 10.4049/jimmunol.164.8.4321; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; OSHEA JJ, 1985, J IMMUNOL, V135, P1325; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Pedron T, 1999, CLIN DIAGN LAB IMMUN, V6, P885, DOI 10.1128/CDLI.6.6.885-890.1999; Pedron T, 2000, IMMUNOLOGY, V101, P262, DOI 10.1046/j.1365-2567.2000.00107.x; PEDRON T, 1994, J BIOL CHEM, V269, P2426; Pedron T, 1997, MOL PHARMACOL, V52, P692, DOI 10.1124/mol.52.4.692; Pedron T, 2000, FEMS IMMUNOL MED MIC, V28, P247; Pedron T, 2001, INFECT IMMUN, V69, P4287, DOI 10.1128/IAI.69.7.4287-4294.2001; Pedron T, 2000, BIOCHEM PHARMACOL, V60, P1837, DOI 10.1016/S0006-2952(00)00499-8; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Sato H, 1996, FEBS LETT, V393, P101, DOI 10.1016/0014-5793(96)00861-7; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P763, DOI 10.1016/0161-5890(90)90085-E; Takakuwa T, 1996, EUR J IMMUNOL, V26, P2686, DOI 10.1002/eji.1830261121; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; VANLENTEN BJ, 1992, J IMMUNOL, V148, P112; WAAGE A, 1987, LANCET, V1, P355; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	64	15	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20555	20564		10.1074/jbc.M203551200	http://dx.doi.org/10.1074/jbc.M203551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663667	hybrid			2022-12-27	WOS:000183230500016
J	Azmi, S; Sun, H; Ozog, A; Taneja, R				Azmi, S; Sun, H; Ozog, A; Taneja, R			mSharp-1/DEC2, a basic helix-loop-helix protein functions as a transcriptional repressor of E box activity and Stra13 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-SPECIFIC ENHANCER; DIRECT DNA-BINDING; NEURONAL DIFFERENTIATION; GENE; PROMOTER; HAIRY; MYOD; FAMILY; GROWTH; SPLIT	Transcription factors belonging to the basic helix-loop-helix (bHLH) family play critical roles in the regulation of cellular differentiation of distinct cell types. In this study, we have characterized the DNA-binding and transcriptional properties of the bHLH factor mSharp-1/DEC2. mSharp-1 belongs to the Hairy/Enhancer of Split subfamily of bHLH factors and exhibits the highest structural and sequence identity with Stra13. We show that mSharp-1 specifically binds to the E box motif (CANNTG) as a homodimer and acts as a potent transcriptional repressor of MyoD- and E12-induced E box activity and differentiation. The inhibitory activity of mSharp-1 occurs through several mechanisms including occupancy of E box sites by mSharp-1 homodimers and by direct physical interaction with MyoD and E proteins. Furthermore, by using gel mobility shift assays and chromatin immunoprecipitation experiments, we have identified Stra13 as a target for mSharp-1-mediated repression. We demonstrate that transcriptional repression of Stra13 depends, in part, on binding of mSharp-1 to three conserved E box motifs in the Stra13 proximal promoter. Moreover, mSharp-1 directly interacts with the transcriptional activator Sp1 and impairs Sp1 induction of Stra13 promoter. Our results suggest that mSharp-1 functions as a transcriptional repressor by DNA binding dependent and independent mechanisms.	Mt Sinai Sch Med, Brookdale Dept Med Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Taneja, R (corresponding author), Mt Sinai Sch Med, Brookdale Dept Med Cell & Dev Biol, New York, NY 10029 USA.		Taneja, Reshma/F-9658-2014	Taneja, Reshma/0000-0002-2151-2094; Reshma, Taneja/0000-0001-6214-6177				Azmi S, 2002, MECH DEVELOP, V114, P181, DOI 10.1016/S0925-4773(02)00049-7; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bouwman P, 2002, MOL CELL ENDOCRINOL, V195, P27, DOI 10.1016/S0303-7207(02)00221-6; BUSKIN JN, 1989, MOL CELL BIOL, V9, P2627, DOI 10.1128/MCB.9.6.2627; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Davis RL, 2001, ONCOGENE, V20, P8342, DOI 10.1038/sj.onc.1205094; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Gong XQ, 2002, J BIOL CHEM, V277, P12310, DOI 10.1074/jbc.M110228200; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; Iso T, 2001, MOL CELL BIOL, V21, P6080, DOI 10.1128/MCB.21.17.6080-6089.2001; JOHNSON JE, 1992, P NATL ACAD SCI USA, V89, P3596, DOI 10.1073/pnas.89.8.3596; Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Koyano-Nakagawa N, 2000, DEVELOPMENT, V127, P4203; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Lu JR, 1999, P NATL ACAD SCI USA, V96, P552, DOI 10.1073/pnas.96.2.552; Ma QF, 1998, NEURON, V20, P469, DOI 10.1016/S0896-6273(00)80988-5; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; Massari ME, 1998, MOL CELL BIOL, V18, P3130, DOI 10.1128/MCB.18.6.3130; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McFadden DG, 2002, DEVELOPMENT, V129, P3077; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820	53	58	58	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20098	20109		10.1074/jbc.M210427200	http://dx.doi.org/10.1074/jbc.M210427200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657651	hybrid			2022-12-27	WOS:000183078000068
J	Crystal, AS; Morais, VA; Pierson, TC; Pijak, DS; Carlin, D; Lee, VMY; Doms, RW				Crystal, AS; Morais, VA; Pierson, TC; Pijak, DS; Carlin, D; Lee, VMY; Doms, RW			Membrane topology of gamma-secretase component PEN-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; FAMILIAL ALZHEIMERS-DISEASE; CAENORHABDITIS-ELEGANS; BETA-SECRETASE; PRESENILIN-1; NICASTRIN; GLYCOSYLATION; COMPLEX; APH-1; NOTCH	PEN-2 is an integral membrane protein that is a necessary component of the gamma-secretase complex, which is central in the pathogenesis of Alzheimer's disease and is also required for Notch signaling. In the absence of PEN-2, Notch signaling fails to guide normal development in Caenorhabditis elegans, and amyloid beta peptide is not generated from the amyloid precursor protein. Human PEN-2 is a 101-amino acid protein containing two putative transmembrane domains. To understand its interaction with other gamma-secretase components, it is important to know the membrane topology of each member of the complex. To characterize the membrane topology of PEN-2, we introduced single amino acid changes in each of the three hydrophilic regions of PEN-2 to generate N-linked glycosylation sites. We found that the N-linked glycosylation sites present in the N- and C-terminal domains of PEN-2 were utilized, whereas a site in the hydrophilic "loop" region connecting the two transmembrane domains was not. The addition of a carbohydrate structure in the N- terminal domain of PEN-2 prevented association with presenilin 1, whereas glycosylation in the C-terminal region of PEN-2 did not, suggesting that the N- terminal domain is important for interactions with presenilin 1. Immunofluorescence microscopy with selective permeabilization of the plasma membrane of cells expressing epitope-tagged forms of PEN-2 confirmed the lumenal location of both the N and C termini. A protease protection assay also demonstrated that the loop domain of PEN-2 is cytosolic. Thus, PEN-2 spans the membrane twice, with the N and C termini facing the lumen of the endoplasmic reticulum.	Univ Penn, Dept Microbiol, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2780 Oeiras, Portugal; Inst Biol Expt & Tecnol, P-2780 Oeiras, Portugal	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Universidade Nova de Lisboa	Doms, RW (corresponding author), Univ Penn, Dept Microbiol, Sch Med, Ctr Neurodegenerat Dis Res, 225 Johnson Pavil,3610 Hamilton Walk, Philadelphia, PA 19104 USA.			Morais, Vanessa/0000-0002-0830-0548; Crystal, Adam/0000-0002-2302-2654	NIA NIH HHS [AG-00256] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHANG XB, 1994, J BIOL CHEM, V269, P18572; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Fortini ME, 2002, NAT REV MOL CELL BIO, V3, P673, DOI 10.1038/nrm910; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; GU Y, 2002, J BIOL CHEM, V277, P7374; Hamilton SR, 2001, J BIOL CHEM, V276, P27981, DOI 10.1074/jbc.M100518200; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; Lee SF, 2002, J BIOL CHEM, V277, P45013, DOI 10.1074/jbc.M208164200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li J, 2000, BIOCHEM J, V349, P51, DOI 10.1042/0264-6021:3490051; Li XJ, 1996, NEURON, V17, P1015, DOI 10.1016/S0896-6273(00)80231-7; Li XJ, 1998, P NATL ACAD SCI USA, V95, P7109, DOI 10.1073/pnas.95.12.7109; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nakai T, 1999, J BIOL CHEM, V274, P23647, DOI 10.1074/jbc.274.33.23647; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Vannier B, 1998, J BIOL CHEM, V273, P8675, DOI 10.1074/jbc.273.15.8675; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	35	74	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20117	20123		10.1074/jbc.M213107200	http://dx.doi.org/10.1074/jbc.M213107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639958	hybrid			2022-12-27	WOS:000183078000070
J	Houng, A; Polgar, J; Reed, GL				Houng, A; Polgar, J; Reed, GL			Munc18-syntaxin complexes and exocytosis in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-GRANULE SECRETION; SYNAPTIC VESICLE FUSION; MOLECULAR MECHANISMS; GLUT4 TRANSLOCATION; NEGATIVE REGULATOR; 3T3-L1 ADIPOCYTES; VACUOLE FUSION; YEAST SEC1; SYNTAXIN; PROTEINS	The Sec1-Munc18 (SM) proteins are required for cellular exocytosis, but their mechanistic function remains poorly understood. We examined SM-syntaxin complexes in human platelets, which are terminally differentiated, anuclear cells that secrete the contents of their intracellular granules through syntaxin 2- and syntaxin 4-dependent mechanisms. Munc18a, Munc18b, and Munc18c were detected in human platelets by immunoblotting and/or PCR. The SM proteins and syntaxin 2 were found in the membrane and cytosolic fractions of cells, whereas syntaxin 4 was detected only in the membrane. Platelet membranes contain Munc18c-syntaxin 4 complexes, but minimal if any Munc18c-syntaxin 2 complexes were found. No significant amounts of Munc18a or Munc18b complexes were seen with either syntaxin. Munc18c-syntaxin 4 complexes were dissociated when cells were activated to secrete. Two potential inhibitors of Munc18c-syntaxin 4 complexes were generated to examine whether complex dissociation may lead to exocytosis. Peptides that mimic the projected intermolecular contact sites of Munc18c with syntaxin enhanced Ca2+-triggered dense granule exocytosis in permeabilized cells. Similarly, an anti-Munc18c monoclonal antibody that inhibited the Munc18c-syntaxin complex potently amplified Ca2+-induced platelet granule secretion. In summary, Munc18 proteins bind to specific syntaxin isoforms in platelets despite the presence of other potential binding partners. Acute inhibition of the SM-syntaxin complex promotes Ca2+-induced exocytosis, suggesting that complex formation per se has a regulatory effect on triggered secretion.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts General Hospital	Reed, GL (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 665 Huntington Ave, Boston, MA 02115 USA.	reed@cvlab.harvard.edu			NHLBI NIH HHS [HL-64057] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKKERMAN JWN, 1982, THROMB RES, V27, P59, DOI 10.1016/0049-3848(82)90278-X; AKKERMAN JWN, 1983, BIOCHEM J, V210, P145, DOI 10.1042/bj2100145; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Bracher A, 2000, STRUCTURE, V8, P685, DOI 10.1016/S0969-2126(00)00156-8; Brummer MH, 2001, YEAST, V18, P1525, DOI 10.1002/yea.796; Carr CM, 1999, J CELL BIOL, V146, P333, DOI 10.1083/jcb.146.2.333; Chen D, 2000, BLOOD, V96, P1782, DOI 10.1182/blood.V96.5.1782.h8001782_1782_1788; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chung SH, 2000, J BIOL CHEM, V275, P25286, DOI 10.1074/jbc.M004204200; COORSSEN JR, 1990, CELL REGUL, V1, P1027, DOI 10.1091/mbc.1.13.1027; Dulubova I, 2002, EMBO J, V21, P3620, DOI 10.1093/emboj/cdf381; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Fisher RJ, 2001, SCIENCE, V291, P875, DOI 10.1126/science.291.5505.875; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265; Graham ME, 1997, J NEUROCHEM, V69, P2369; Grote E, 2000, J CELL BIOL, V151, P439, DOI 10.1083/jcb.151.2.439; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLMSEN H, 1989, METHOD ENZYMOL, V169, P205; HOLMSEN H, 1982, BIOCHEM J, V208, P9, DOI 10.1042/bj2080009; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; KAPLAN KL, 1979, BLOOD, V53, P604; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; Kauppi M, 2002, J BIOL CHEM, V277, P43973, DOI 10.1074/jbc.M208315200; KNIGHT DE, 1993, METHOD ENZYMOL, V221, P123, DOI 10.1016/0076-6879(93)21012-W; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Matos MF, 2000, EUR J CELL BIOL, V79, P377, DOI 10.1078/0171-9335-00063; MICHELSON AD, 1996, PRACT APPROACH SER, P111; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Peng RW, 2002, J CELL BIOL, V157, P645, DOI 10.1083/jcb.200202006; Polgar J, 1999, BLOOD, V94, P1313, DOI 10.1182/blood.V94.4.1313.416k27_1313_1318; Quinones B, 1999, J CELL SCI, V112, P4291; Reed GL, 2000, BLOOD, V96, P3334; REED GL, 1990, P NATL ACAD SCI USA, V87, P1114, DOI 10.1073/pnas.87.3.1114; Reed GL, 1999, BLOOD, V93, P2617, DOI 10.1182/blood.V93.8.2617.408k19_2617_2626; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Sassa T, 1999, J NEUROSCI, V19, P4772; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Seals DF, 2000, P NATL ACAD SCI USA, V97, P9402, DOI 10.1073/pnas.97.17.9402; Shirakawa R, 2000, J BIOL CHEM, V275, P33844, DOI 10.1074/jbc.M002834200; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Verhage M, 2000, SCIENCE, V287, P864, DOI 10.1126/science.287.5454.864; Verhage M, 1997, NEURON, V18, P453, DOI 10.1016/S0896-6273(00)81245-3; Voets T, 2001, NEURON, V31, P581, DOI 10.1016/S0896-6273(01)00391-9; Wang L, 2002, CELL, V108, P357, DOI 10.1016/S0092-8674(02)00632-3; WITTE LD, 1978, CIRC RES, V42, P402, DOI 10.1161/01.RES.42.3.402; Yamaguchi T, 2002, DEV CELL, V2, P295, DOI 10.1016/S1534-5807(02)00125-9; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Zhang W, 2000, J BIOL CHEM, V275, P41521, DOI 10.1074/jbc.M005479200	54	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19627	19633		10.1074/jbc.M212465200	http://dx.doi.org/10.1074/jbc.M212465200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649283	hybrid			2022-12-27	WOS:000183078000010
J	Koshkin, V; Wang, XL; Scherer, PE; Chan, CB; Wheeler, MB				Koshkin, V; Wang, XL; Scherer, PE; Chan, CB; Wheeler, MB			Mitochondrial functional state in clonal pancreatic beta-cells exposed to free fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED INSULIN-SECRETION; HYDROGEN-PEROXIDE GENERATION; OXYGEN SPECIES GENERATION; ELECTRON-TRANSPORT CHAIN; RAT-LIVER MITOCHONDRIA; UNCOUPLING PROTEIN-2; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; DICARBOXYLATE CARRIER; PERMEABILIZED CELLS; GLUCOSE-METABOLISM	Excessive free fatty acid (FFA) exposure represents a potentially important diabetogenic condition that can impair insulin secretion from pancreatic beta-cells. Because mitochondrial oxidative phosphorylation is a main link between glucose metabolism and insulin secretion, in the present work we investigated the effects of the FFA oleate (OE) on mitochondrial function in the clonal pancreatic beta-cell line, MIN6. Both the long term ( 72 h) and short term ( immediately after application) impact of OE exposure on beta-cells was investigated. After 72 h of exposure to OE (0.4 mM, 0.5% bovine serum albumin) cells were washed and permeabilized, and mitochondrial function ( respiration, phosphorylation, membrane potential formation, production of reactive oxygen species) was measured in the absence or presence of OE. MIN6 cells exposed to OE for 72 h showed impaired glucose-stimulated insulin secretion and decreased cellular ATP. Mitochondria in OE-exposed cells retained normal functional characteristics in FFA-free medium; however, they were significantly more sensitive to the acute uncoupling effect of OE treatment. The mitochondria of OE-exposed cells displayed increased depolarization caused by acute OE treatment, which is attributable to the elevation in the FFA-transporting function of uncoupling protein 2 and the dicarboxylate carrier. These cells also had an increased production of reactive oxygen species in complex I of the mitochondrial respiratory chain that could be activated by FFA. A high level of reduction of respiratory complex I augmented acute FFA-induced uncoupling in a way compatible with activation of mitochondrial uncoupling protein by intramitochondrial superoxide. A stronger augmentation was observed in OE-exposed cells. Together, these events may underlie FFA-induced depression of the ATP/ADP ratio in beta-cells, which accounts for the defective glucose-stimulated insulin secretion associated with lipotoxicity.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA; Univ Prince Edward Isl, Dept Biomed Sci, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; Yeshiva University; Albert Einstein College of Medicine; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.		Chan, Catherine/C-1162-2011; Scherer, Philipp E/K-7819-2012	Chan, Catherine/0000-0003-3882-0592; Scherer, Philipp E/0000-0003-0680-3392; Wheeler, Michael B./0000-0002-7480-7267				Antinozzi PA, 2002, J BIOL CHEM, V277, P11746, DOI 10.1074/jbc.M108462200; Barbu A, 2002, MOL CELL ENDOCRINOL, V190, P75, DOI 10.1016/S0303-7207(02)00009-6; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BOGUCKA K, 1990, BIOCHIM BIOPHYS ACTA, V1015, P503, DOI 10.1016/0005-2728(90)90084-H; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Busch AK, 2002, DIABETES, V51, P977, DOI 10.2337/diabetes.51.4.977; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Carlsson C, 1999, ENDOCRINOLOGY, V140, P3422, DOI 10.1210/en.140.8.3422; Casolo V, 2000, FEBS LETT, V474, P53, DOI 10.1016/S0014-5793(00)01576-3; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; Cocco T, 1999, FREE RADICAL BIO MED, V27, P51, DOI 10.1016/S0891-5849(99)00034-9; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Das K, 1999, BIOCHEM J, V344, P313, DOI 10.1042/0264-6021:3440313; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; ECHTAY KS, 2000, TNATURE, V415, P96; Estabrook R. W., 1967, METHODS ENZYMOLOGY, V10, P41, DOI DOI 10.1016/0076-6879(67)10010-4; Ferrer J, 1996, DIABETES, V45, P262, DOI 10.2337/diabetes.45.2.262; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Gorogawa S, 2002, DIABETES RES CLIN PR, V57, P1, DOI 10.1016/S0168-8227(02)00005-0; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Ho E, 1999, FASEB J, V13, P1845, DOI 10.1096/fasebj.13.13.1845; Hofmann WE, 2001, J BIOL CHEM, V276, P12460, DOI 10.1074/jbc.M100466200; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Joseph JW, 2002, DIABETES, V51, P3211, DOI 10.2337/diabetes.51.11.3211; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; KOHNKE D, 1993, FEBS LETT, V336, P90, DOI 10.1016/0014-5793(93)81616-8; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; KRAUS S, 2002, P NATL ACAD SCI USA, V99, P15858; Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121; Kwong LK, 2002, METHOD ENZYMOL, V349, P341, DOI 10.1016/S0076-6879(02)49349-4; Kwong LK, 1998, ARCH BIOCHEM BIOPHYS, V350, P118, DOI 10.1006/abbi.1997.0489; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Langin D, 2001, NEW ENGL J MED, V345, P1772, DOI 10.1056/NEJM200112133452412; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Liang Y, 1997, DIABETOLOGIA, V40, P1018, DOI 10.1007/s001250050783; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; Medvedev AV, 2002, J BIOL CHEM, V277, P42639, DOI 10.1074/jbc.M208645200; Minami K, 2000, AM J PHYSIOL-ENDOC M, V279, pE773, DOI 10.1152/ajpendo.2000.279.4.E773; MNCGARRY JD, 1925, DIABETES, V5, P7; Ouhabi R, 1998, ANAL BIOCHEM, V263, P169, DOI 10.1006/abio.1998.2776; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; Saks VA, 1998, MOL CELL BIOCHEM, V184, P81, DOI 10.1023/A:1006834912257; Sakurai K, 2001, BIOL PHARM BULL, V24, P876, DOI 10.1248/bpb.24.876; Saleh MC, 2002, DIABETOLOGIA, V45, P174, DOI 10.1007/s00125-001-0737-x; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Simonyan RA, 2001, BBA-BIOENERGETICS, V1505, P271, DOI 10.1016/S0005-2728(01)00168-2; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; VERCESI AE, 1991, J BIOL CHEM, V266, P14431; WANG X, 2002, DIABETES S2, V1; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; WOELDERS H, 1988, BIOCHIM BIOPHYS ACTA, V934, P123, DOI 10.1016/0005-2728(88)90127-2; Yamagishi SI, 2001, J BIOL CHEM, V276, P25096, DOI 10.1074/jbc.M007383200; ZORATTI M, 1982, EUR J BIOCHEM, V126, P443, DOI 10.1111/j.1432-1033.1982.tb06800.x	60	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19709	19715		10.1074/jbc.M209709200	http://dx.doi.org/10.1074/jbc.M209709200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642585	hybrid			2022-12-27	WOS:000183078000020
J	Lagorce, A; Hauser, NC; Labourdette, D; Rodriguez, C; Martin-Yken, H; Arroyo, J; Hoheisel, JRD; Francois, J				Lagorce, A; Hauser, NC; Labourdette, D; Rodriguez, C; Martin-Yken, H; Arroyo, J; Hoheisel, JRD; Francois, J			Genome-wide analysis of the response to cell wall mutations in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOBAL GENE-EXPRESSION; PROTEIN-KINASE-C; MAP KINASE; TRANSCRIPTION FACTOR; STRESS-RESPONSE; SIGNALING PATHWAY; CYCLE REGULATOR; INTEGRITY; MUTANTS; CHITIN	Perturbations of the yeast cell wall trigger a repair mechanism that reconfigures its molecular structure to preserve cell integrity. To investigate this mechanism, we compared the global gene expression in five mutant strains, each bearing a mutation (i.e. fks1, kre6, mnn9, gas1, and knr4 mutants) that affects in a different manner the cell wall construction. Altogether, 300 responsive genes were kept based on high stringency criteria during data processing. Functional classification of these differentially expressed genes showed a substantial subset of induced genes involved in cell wall construction and an enrichment of metabolic, energy generation, and cell defense categories, whereas families of genes belonging to transcription, protein synthesis, and cellular growth were underrepresented. Clustering methods isolated a single group of similar to80 up-regulated genes that could be considered as the stereotypical transcriptional response of the cell wall compensatory mechanism. The in silico analysis of the DNA upstream region of these co-regulated genes revealed pairwise combinations of DNA-binding sites for transcriptional factors implicated in stress and heat shock responses (Msn2/4p and Hsf1p) with Rlm1p and Swi4p, two PKC1-regulated transcription factors involved in the activation genes related to cell wall biogenesis and G(1)/S transition. Moreover, this computational analysis also uncovered the 6-bp 5'-AGCCTC-3' CDRE (calcineurin-dependent response element) motif in 40% of the coregulated genes. This motif was recently shown to be the DNA binding site for Crz1p, the major effector of calcineurin-regulated gene expression in yeast. Taken altogether, the data presented here lead to the conclusion that the cell wall compensatory mechanism, as triggered by cell wall mutations, integrates three major regulatory systems: namely the PKC1-SLT2 mitogen-activated protein kinase-signaling module, the "global stress" response mediated by Msn2/4p, and the Ca2+/calcineurin-dependent pathway. The relative importance of these regulatory systems in the cell wall compensatory mechanism is discussed.	Ctr Bioingn Gilbert Durand, CNRS, UMR 5504, F-31077 Toulouse, France; INRA 792, Genopole Toulouse, F-31077 Toulouse, France; Deutsch Krebsforschungszentrum, Div Funct Genome Anal, D-69120 Heidelberg, Germany; Univ Complutense Madrid, Fac Farm, Dept Microbiol 2, E-28040 Madrid, Spain	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; German Cancer Research Center (DKFZ); Complutense University of Madrid	Francois, J (corresponding author), Ctr Bioingn Gilbert Durand, CNRS, UMR 5504, 135 Ave Rangeuil, F-31077 Toulouse, France.	fran_jm@insa-tlse.fr	Arroyo, Javier/E-9308-2016; Martin-Yken, Helene/H-5250-2011; MARTIN-YKEN, Helene/O-7826-2019	Arroyo, Javier/0000-0002-1971-1721; Martin-Yken, Helene/0000-0002-2024-3232; MARTIN-YKEN, Helene/0000-0002-2024-3232; Francois, Jean marie/0000-0001-9884-5535; LAGORCE, ARNAUD/0000-0002-7828-0300				Alexandre H, 2001, FEBS LETT, V498, P98, DOI 10.1016/S0014-5793(01)02503-0; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; Baetz K, 2001, MOL CELL BIOL, V21, P6515, DOI 10.1128/MCB.21.19.6515-6528.2001; BAILEY TL, 1994, P SEC INT C INTELL S, V3, P28; Beier M, 1999, NUCLEIC ACIDS RES, V27, P1970, DOI 10.1093/nar/27.9.1970; Beissbarth T, 2000, BIOINFORMATICS, V16, P1014; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Cappellaro C, 1998, J BACTERIOL, V180, P5030, DOI 10.1128/JB.180.19.5030-5037.1998; Causton HC, 2001, MOL BIOL CELL, V12, P323, DOI 10.1091/mbc.12.2.323; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; Dallies N, 1998, YEAST, V14, P1297, DOI 10.1002/(SICI)1097-0061(1998100)14:14<1297::AID-YEA310>3.0.CO;2-L; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740; Devenish RJ, 2000, BBA-BIOENERGETICS, V1458, P428, DOI 10.1016/S0005-2728(00)00092-X; Dihazi H, 2001, BIOCHEMISTRY-US, V40, P14669, DOI 10.1021/bi0155549; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; DRGON T, 1992, FEBS LETT, V304, P277, DOI 10.1016/0014-5793(92)80637-V; Dutton JR, 1997, EMBO J, V16, P5710, DOI 10.1093/emboj/16.18.5710; Edlind T, 2002, MOL MICROBIOL, V46, P257, DOI 10.1046/j.1365-2958.2002.03165.x; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fellenberg K, 2002, BIOINFORMATICS, V18, P423, DOI 10.1093/bioinformatics/18.3.423; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Gancedo JM, 2001, FEMS MICROBIOL REV, V25, P107, DOI 10.1016/S0168-6445(00)00056-5; Garcia-Rodriguez LJ, 2000, J BACTERIOL, V182, P2428, DOI 10.1128/JB.182.9.2428-2437.2000; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GOLDMAN RC, 1995, EUR J BIOCHEM, V227, P372, DOI 10.1111/j.1432-1033.1995.tb20399.x; Hahn JS, 2002, J BIOL CHEM, V277, P21278, DOI 10.1074/jbc.M202557200; Hauser NC, 1998, YEAST, V14, P1209, DOI 10.1002/(SICI)1097-0061(19980930)14:13<1209::AID-YEA311>3.0.CO;2-N; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; Hohmann S, 2002, MICROBIOL MOL BIOL R, V66, P300, DOI 10.1128/MMBR.66.2.300-372.2002; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P177; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Jiang B, 2002, CURR OPIN MICROBIOL, V5, P466, DOI 10.1016/S1369-5274(02)00361-2; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kapteyn JC, 1999, MOL MICROBIOL, V31, P1835, DOI 10.1046/j.1365-2958.1999.01320.x; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Kitagaki H, 2002, MOL MICROBIOL, V46, P1011, DOI 10.1046/j.1365-2958.2002.03244.x; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1016/S0168-6445(02)00087-6; KOLLAR R, 1995, J BIOL CHEM, V270, P1170, DOI 10.1074/jbc.270.3.1170; Kollar R, 1997, J BIOL CHEM, V272, P17762, DOI 10.1074/jbc.272.28.17762; KONOPKA JB, 1995, MOL CELL BIOL, V15, P723; Lagorce A, 2002, EUR J BIOCHEM, V269, P1697, DOI 10.1046/j.1432-1327.2002.02814.x; Lenburg ME, 1996, TRENDS BIOCHEM SCI, V21, P383, DOI 10.1016/S0968-0004(96)90127-9; Lussier M, 1996, J BIOL CHEM, V271, P11001, DOI 10.1074/jbc.271.18.11001; Lussier M, 1997, GENETICS, V147, P435; Madden K, 1997, SCIENCE, V275, P1781, DOI 10.1126/science.275.5307.1781; Martin H, 1999, MICROBIOL-SGM, V145, P249, DOI 10.1099/13500872-145-1-249; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Martin-Yken H, 2002, CURR GENET, V41, P323, DOI 10.1007/s00294-002-0299-6; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; Muller S, 1997, MICROBIOL-UK, V143, P3055, DOI 10.1099/00221287-143-9-3055; NEBREDA AR, 1986, GENE, V47, P245, DOI 10.1016/0378-1119(86)90068-5; NGUYEN C, 1995, GENOMICS, V29, P207, DOI 10.1006/geno.1995.1233; Okar DA, 1999, BIOFACTORS, V10, P1, DOI 10.1002/biof.5520100101; Olsen V, 1999, BIOCHEM J, V339, P407, DOI 10.1042/0264-6021:3390407; Orlean P., 1997, MOL CELLULAR BIOL YE, P229; Pan XW, 2000, MOL CELL BIOL, V20, P8364, DOI 10.1128/MCB.20.22.8364-8372.2000; Popolo L, 1999, BBA-GEN SUBJECTS, V1426, P385, DOI 10.1016/S0304-4165(98)00138-X; Popolo L, 2001, MED MYCOL, V39, P111, DOI 10.1080/744118881; POPOLO L, 1993, J BACTERIOL, V175, P1879, DOI 10.1128/JB.175.7.1879-1885.1993; Popolo L, 1997, J BACTERIOL, V179, P463, DOI 10.1128/jb.179.2.463-469.1997; Puig S, 2000, YEAST, V16, P139, DOI 10.1002/(SICI)1097-0061(20000130)16:2<139::AID-YEA512>3.3.CO;2-A; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Ram AFJ, 1998, J BACTERIOL, V180, P1418, DOI 10.1128/JB.180.6.1418-1424.1998; RAM AFJ, 1994, YEAST, V10, P1019, DOI 10.1002/yea.320100804; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rose MD., 1990, METHODS YEAST GENETI; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Shahinian S, 2000, MOL MICROBIOL, V35, P477, DOI 10.1046/j.1365-2958.2000.01713.x; Sherlock G, 2000, CURR OPIN IMMUNOL, V12, P201, DOI 10.1016/S0952-7915(99)00074-6; Shimoi H, 1998, J BACTERIOL, V180, P3381, DOI 10.1128/JB.180.13.3381-3387.1998; Siderius M, 1997, MICROBIOL-SGM, V143, P3241, DOI 10.1099/00221287-143-10-3241; Smits GJ, 1999, CURR OPIN MICROBIOL, V2, P348; Smits GJ, 2001, MICROBIOL-SGM, V147, P781, DOI 10.1099/00221287-147-4-781; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; Takabatake R, 2001, J BIOCHEM, V129, P827, DOI 10.1093/oxfordjournals.jbchem.a002926; Terashima H, 2000, MOL GEN GENET, V264, P64, DOI 10.1007/s004380000285; Uemura H, 1997, GENETICS, V147, P521; Van Helden J, 2000, YEAST, V16, P177, DOI 10.1002/(SICI)1097-0061(20000130)16:2<177::AID-YEA516>3.0.CO;2-9; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WALSH RB, 1991, GENETICS, V128, P521; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Woods R. A., 2001, METH MOL B, V177, P85; YIP CL, 1994, P NATL ACAD SCI USA, V91, P2723, DOI 10.1073/pnas.91.7.2723; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhao C, 1998, MOL CELL BIOL, V18, P1013, DOI 10.1128/MCB.18.2.1013	97	213	224	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20345	20357		10.1074/jbc.M211604200	http://dx.doi.org/10.1074/jbc.M211604200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644457	Green Published, hybrid			2022-12-27	WOS:000183078000099
J	Lin, ZC; Zhang, PW; Zhu, XG; Melgari, JM; Huff, R; Spieldoch, RL; Uhl, GR				Lin, ZC; Zhang, PW; Zhu, XG; Melgari, JM; Huff, R; Spieldoch, RL; Uhl, GR			Phosphatidylinositol 3-kinase, protein kinase C, and MEK1/2 kinase regulation of dopamine transporters (DAT) require N-terminal DAT phosphoacceptor sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCAINE ANALOG RECOGNITION; FUNCTIONAL REGULATION; PHORBOL ESTERS; STRIATAL SYNAPTOSOMES; RAT STRIATUM; PHOSPHORYLATION; EXPRESSION; RECEPTORS; CLONING; CELLS	The dopamine transporter (DAT) modulates dopamine neurotransmission and is a primary target for psychostimulant influences on locomotion and reward. Selective DAT expression by dopaminergic neurons has led to use of cocaine analog DAT radioligands to assess rates of progression of dopamine neuronal degeneration in Parkinson's disease. We have documented that DAT is a phosphoprotein that is regulated by phosphorylation through pathways that include protein kinase C cascades. We now extend this work using drugs selective for phosphatidylinositol 3-kinase (PI3K), protein kinase C, MEK1/2, p38 kinase, and Ca2+/calmodulin kinase II. We compare the drug effects on wild type DAT to the effects on 20 DAT mutants and a DAT deletion. PI3K and MEK1/2 modulators exert strong effects on DAT expression patterns and dopamine uptake V-max. PKC principally modulates V-max. Neither p38 nor Ca2+/calmodulin kinase II agents exert significant influences on wild type DAT. Several mutants and a DAT with an N-terminal deletion display alterations that interact with the effects of kinase modulators, especially S7A for PKC effects; T62A, S581A, and T612A for PI3K effects; and S12A and T595A mutants for MEK1/2 effects. P-32-Labeling studies confirm several of these effects of kinase pathway modulators on DAT phosphorylation. DAT expression and activities can be regulated by kinase cascades that require phosphoacceptor sites most concentrated in its N terminus. These results have a number of implications for DAT regulation and mandate caution in using DAT radioligand binding to infer changes in dopaminergic neuronal integrity after treatments that alter activities of these kinase pathways.	NIDA, Mol Neurobiol Branch, IRP, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Uhl, GR (corresponding author), NIDA, Mol Neurobiol Branch, IRP, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000159, Z01DA000076, Z01DA000160] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Al-Hasani H, 2002, J CELL SCI, V115, P131; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azam L, 2002, J COMP NEUROL, V444, P260, DOI 10.1002/cne.10138; Bauman AL, 2000, J NEUROSCI, V20, P7571; BERGMAN J, 1989, J PHARMACOL EXP THER, V251, P150; Carvelli L, 2002, J NEUROCHEM, V81, P859, DOI 10.1046/j.1471-4159.2002.00892.x; Champtiaux N, 2002, J NEUROSCI, V22, P1208, DOI 10.1523/JNEUROSCI.22-04-01208.2002; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Doolen S, 2001, J PHARMACOL EXP THER, V296, P931; Foster JD, 2002, J BIOL CHEM, V277, P25178, DOI 10.1074/jbc.M200294200; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; Guttman M, 2001, NEUROLOGY, V56, P1559, DOI 10.1212/WNL.56.11.1559; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; Huff RA, 1997, J NEUROCHEM, V68, P225; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; Kim YJ, 2002, MOVEMENT DISORD, V17, P303, DOI 10.1002/mds.10042; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; Kugaya A, 2000, ANN NUCL MED, V14, P1, DOI 10.1007/BF02990472; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Nocjar C, 2002, NEUROSCIENCE, V111, P163, DOI 10.1016/S0306-4522(01)00593-0; PFENNING MA, 1990, NEUROTRANSMITTER REC, P147; Porras G, 2002, NEUROPSYCHOPHARMACOL, V26, P311, DOI 10.1016/S0893-133X(01)00333-5; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rodriguez-Pallares J, 2001, RECEPTOR CHANNEL, V7, P471; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Shistik E, 1999, J BIOL CHEM, V274, P31145, DOI 10.1074/jbc.274.44.31145; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; UCHIKAWA T, 1995, J NEUROCHEM, V65, P2065; Uhl GR, 2002, MOL PSYCHIATR, V7, P21, DOI 10.1038/sj/mp/4000964; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; VANDENBERGH DJ, 1992, MOL BRAIN RES, V15, P161, DOI 10.1016/0169-328X(92)90165-8; Varrone A, 2001, MOVEMENT DISORD, V16, P1023, DOI 10.1002/mds.1256; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; VAUGHAN RA, 1993, MOL CELL NEUROSCI, V4, P209, DOI 10.1006/mcne.1993.1025; Vrindavanam NS, 1996, NEUROSCI LETT, V216, P133; Yang JM, 2002, BIOCHEM PHARMACOL, V63, P959, DOI 10.1016/S0006-2952(02)00838-9; Zhang L, 1996, EUR J PHARMACOL, V315, P345, DOI 10.1016/S0014-2999(96)00646-2; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2	44	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20162	20170		10.1074/jbc.M209584200	http://dx.doi.org/10.1074/jbc.M209584200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660249	hybrid			2022-12-27	WOS:000183078000075
J	Murumagi, A; Vahamurto, P; Peterson, P				Murumagi, A; Vahamurto, P; Peterson, P			Characterization of regulatory elements and methylation pattern of the autoimmune regulator (AIRE) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE; BINDING PROTEIN; GENE; EXPRESSION; DNA; TRANSCRIPTION; LOCALIZATION; DEFICIENT; THYMUS; MOUSE	Defects in the AIRE gene cause a monogenic autoimmune syndrome APECED (autoimmune polyendocrinopathy candidiasis ectodermal dystrophy), which is characterized by loss of self-tolerance to multiple organs. In concordance with its role in immune tolerance, AIRE is most strongly expressed in thymic epithelial cells and in cells of monocytic-dendritic lineage. The AIRE protein has been shown to function as a transcriptional regulator, however, the mechanisms regulating AIRE gene expression are not known. Here we have characterized the AIRE promoter region by identifying a minimal promoter region within 350 bp of the translation initiation codon. Electrophoretic mobility shift assays and transient transfections with mutated promoter constructs revealed a functional TATA box (-163 to -153) and binding sites for transcription complexes AP-1 (-307 to -296), NF-Y (-213 to -202), and Sp1 (-202 to -189). The presence of a 390-bp CpG island within the proximal promoter suggested that cytosine methylation has a role in transcriptional regulation of AIRE, which was supported by in vitro methylation experiments of promoter constructs. Sodium bisulfite sequencing showed a less methylated status of AIRE promoter in the thymic epithelial cell line TEC1A3 compared with HeLa and monocytic cells U937 and THP-1. Real-time PCR analysis showed that treatment with 5-aza-2'-deoxycytidine (5-azaCdR), a DNA methyltransferase inhibitor, up-regulated AIRE transcript levels in TEC1A3, U937, and HeLa cells and that even greater activations in TEC1A3 and U937 cells were observed using combined treatments with deacetylase inhibitor trichostatin A. These results suggest that AIRE gene expression is modulated through modifications in chromatin methylation and acetylation.	Univ Tampere, Inst Med Technol, Tampere 33014, Finland; Tampere Univ Hosp, Dept Pathol, Tampere 33014, Finland; Univ Tartu, Dept Biotechnol, EE-51010 Tartu, Estonia	Tampere University; Tampere University; Tampere University Hospital; University of Tartu	Peterson, P (corresponding author), Univ Tampere, Inst Med Technol, Lenkkeilijankatu 6, Tampere 33014, Finland.		Peterson, Pärt/A-5788-2009	Peterson, Pärt/0000-0001-6755-791X				AHONEN P, 1990, NEW ENGL J MED, V322, P1829, DOI 10.1056/NEJM199006283222601; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65; Heino M, 1999, BIOCHEM BIOPH RES CO, V257, P821, DOI 10.1006/bbrc.1999.0308; Heino M, 2000, EUR J IMMUNOL, V30, P1884, DOI 10.1002/1521-4141(200007)30:7<1884::AID-IMMU1884>3.0.CO;2-P; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Mittaz L, 1999, BIOCHEM BIOPH RES CO, V255, P483, DOI 10.1006/bbrc.1999.0223; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Pitkanen J, 2001, J BIOL CHEM, V276, P19597, DOI 10.1074/jbc.M008322200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Ramsey C, 2002, HUM MOL GENET, V11, P397, DOI 10.1093/hmg/11.4.397; Sambrook J., 2002, MOL CLONING LAB MANU	25	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19784	19790		10.1074/jbc.M210437200	http://dx.doi.org/10.1074/jbc.M210437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651856	hybrid			2022-12-27	WOS:000183078000029
J	Puglielli, L; Ellis, BC; Saunders, AJ; Kovacs, DM				Puglielli, L; Ellis, BC; Saunders, AJ; Kovacs, DM			Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis (Withdrawn Publication. See vol. 298, 2022) (Withdrawn Publication. See vol. 298, 2022)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Withdrawn Publication							NERVE GROWTH-FACTOR; ALZHEIMERS-DISEASE; SECRETASE; DEATH; EXPRESSION; GENERATION; SURVIVAL; LIVER; AGE	The lipid second messenger ceramide regulates several biochemical events that occur during aging. In addition, its level is highly elevated in the amyloid-burdened brains of Alzheimer's disease patients. Here, we analyzed the impact of aberrant ceramide levels on amyloid beta- peptide (Abeta) generation by using a cell-permeable analog of ceramide, C6-ceramide, and several biochemical inhibitors of the sphingomyelin/glycosphingolipid biosynthetic pathway. We found that C6-ceramide increased the biogenesis of Abeta by affecting beta- but not gamma-cleavage of the amyloid precursor protein. Similarly to C6-ceramide, increased levels of endogenous ceramide induced by neutral sphingomyelinase treatment also promoted the biogenesis of Abeta. Conversely, fumonisin B1, which inhibits the biosynthesis of endogenous ceramide, reduced Abeta production. Exogenous C6-ceramide restored both intracellular ceramide levels and Abeta generation in fumonisin B1-treated cells. These events were specific for amyloid precursor protein and were not associated with apoptotic cell death. Pulse-chase and time-course degradation experiments showed that ceramide post-translationally stabilizes the beta-secretase BACE1. Taken together, these data indicate that the lipid second messenger ceramide, which is elevated in the brains of Alzheimer's disease patients, increases the half-life of BACE1 and thereby promotes Abeta biogenesis.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit,CAGN, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Kovacs, DM (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurobiol Dis Lab,Genet & Aging Res Unit,CAGN, 114 16th St, Charlestown, MA 02129 USA.	kovacs@helix.mgh.harvard.edu		Saunders, Aleister/0000-0002-7298-7823				Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Cutler RG, 2001, MECH AGEING DEV, V122, P895, DOI 10.1016/S0047-6374(01)00246-9; de Chaves EP, 2001, J BIOL CHEM, V276, P36207, DOI 10.1074/jbc.M104282200; DeFreitas MF, 2001, J NEUROSCI, V21, P5121, DOI 10.1523/JNEUROSCI.21-14-05121.2001; Fukumoto H, 2002, ARCH NEUROL-CHICAGO, V59, P1381, DOI 10.1001/archneur.59.9.1381; Han XL, 2002, J NEUROCHEM, V82, P809, DOI 10.1046/j.1471-4159.2002.00997.x; Holsinger RMD, 2002, ANN NEUROL, V51, P783, DOI 10.1002/ana.10208; Irie F, 1998, J NEUROSCI RES, V54, P475, DOI 10.1002/(SICI)1097-4547(19981115)54:4<475::AID-JNR5>3.0.CO;2-P; ITO A, 1995, J NEUROCHEM, V65, P463; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Merrill Alfred H. Jr., 1994, V40, P361; MILLER CJ, 2001, J GERONTOL A-BIOL, V56, P8; Morris JC, 1999, J CLIN INVEST, V104, P1171, DOI 10.1172/JCI8560; Mouton RE, 2000, MECH AGEING DEV, V113, P169, DOI 10.1016/S0047-6374(99)00105-0; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Platt FM, 1997, J BIOL CHEM, V272, P19365, DOI 10.1074/jbc.272.31.19365; Puglielli L, 2001, NAT CELL BIOL, V3, P905, DOI 10.1038/ncb1001-905; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SLOTTE JP, 1994, CURR TOP MEMBR, V40, P483, DOI 10.1016/S0070-2161(08)60993-4; Tamagno E, 2002, NEUROBIOL DIS, V10, P279, DOI 10.1006/nbdi.2002.0515; Tepper AD, 2000, J BIOL CHEM, V275, P34810, DOI 10.1074/jbc.M005142200; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4	28	210	217	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19777	19783		10.1074/jbc.M300466200	http://dx.doi.org/10.1074/jbc.M300466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649271	hybrid			2022-12-27	WOS:000183078000028
J	Rao, FV; Houston, DR; Boot, RG; Aerts, JMFG; Sakuda, S; van Aalten, DMF				Rao, FV; Houston, DR; Boot, RG; Aerts, JMFG; Sakuda, S; van Aalten, DMF			Crystal structures of allosamidin derivatives in complex with human macrophage chitinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-ASSISTED CATALYSIS; HUMAN CHITOTRIOSIDASE; SACCHAROMYCES-CEREVISIAE; PARASITE INVASION; CELL-SEPARATION; MOSQUITO MIDGUT; INHIBITOR; MECHANISM; LYSOZYME; PROTEIN	The pseudotrisaccharide allosamidin is a potent family 18 chitinase inhibitor with demonstrated biological activity against insects, fungi, and the Plasmodium falciparum life cycle. The synthesis and biological properties of several derivatives have been reported. The structural interactions of allosamidin with several family 18 chitinases have been determined by x-ray crystallography previously. Here, a high resolution structure of chitotriosidase, the human macrophage chitinase, in complex with allosamidin is presented. In addition, complexes of the allosamidin derivatives demethylallosamidin, methylallosamidin, and glucoallosamidin B are described, together with their inhibitory properties. Similar to other chitinases, inhibition of the human chitinase by allosamidin derivatives lacking a methyl group is 10-fold stronger, and smaller effects are observed for the methyl and C3 epimer derivatives. The structures explain the effects on inhibition in terms of altered hydrogen bonding and hydrophobic interactions, together with displaced water molecules. The data reported here represent a first step toward structure-based design of specific allosamidin derivatives.	Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands; Univ Tokyo, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 113, Japan	University of Dundee; University of Amsterdam; Academic Medical Center Amsterdam; University of Tokyo	van Aalten, DMF (corresponding author), Univ Dundee, Sch Life Sci, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Aerts, Johannes/A-1028-2009	Aerts, Johannes/0000-0001-8168-2565; Houston, Douglas/0000-0002-3469-1546; Boot, Rolf/0000-0002-7031-3390; Sakuda, Shohei/0000-0001-7966-1167; van Aalten, Daan/0000-0002-1499-6908				Arai N, 2000, CHEM PHARM BULL, V48, P1442, DOI 10.1248/cpb.48.1442; Berecibar A, 1999, CHEM REV, V99, P779, DOI 10.1021/cr980033l; Boot RG, 2001, J BIOL CHEM, V276, P6770, DOI 10.1074/jbc.M009886200; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Bortone K, 2002, J MOL BIOL, V320, P293, DOI 10.1016/S0022-2836(02)00444-8; Brameld KA, 1998, J AM CHEM SOC, V120, P3571, DOI 10.1021/ja972282h; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi EH, 2001, GENES IMMUN, V2, P248, DOI 10.1038/sj.gene.6363767; COHEN E, 1993, ARCH INSECT BIOCHEM, V22, P245, DOI 10.1002/arch.940220118; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hooft RWW, 1996, PROTEINS, V26, P363; Houston DR, 2002, BIOCHEM J, V368, P23, DOI 10.1042/BJ20021034; Houston DR, 2002, P NATL ACAD SCI USA, V99, P9127, DOI 10.1073/pnas.132060599; Izumida H, 1996, J ANTIBIOT, V49, P829, DOI 10.7164/antibiotics.49.829; Izumida H, 1996, J ANTIBIOT, V49, P76, DOI 10.7164/antibiotics.49.76; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KATO T, 1995, TETRAHEDRON LETT, V36, P2133, DOI 10.1016/0040-4039(95)00194-H; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; RENKEMA GH, 1997, THESIS U AMSTERDAM A; SAKUDA S, 1990, AGR BIOL CHEM TOKYO, V54, P1333, DOI 10.1080/00021369.1990.10870108; SAKUDA S, 1986, TETRAHEDRON LETT, V27, P2475, DOI 10.1016/S0040-4039(00)84560-8; SAKUDA S, 1996, CHITIN ENZYMOLOGY, V2, P203; Shiomi K, 2000, TETRAHEDRON LETT, V41, P2141, DOI 10.1016/S0040-4039(00)00099-X; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsai YL, 2001, INFECT IMMUN, V69, P4048, DOI 10.1128/IAI.69.6.4048-4054.2001; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vinetz JM, 1999, P NATL ACAD SCI USA, V96, P14061, DOI 10.1073/pnas.96.24.14061; Vinetz JM, 2000, J BIOL CHEM, V275, P10331, DOI 10.1074/jbc.275.14.10331; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu Y, 2001, J BIOL CHEM, V276, P42557, DOI 10.1074/jbc.M103479200	41	67	72	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20110	20116		10.1074/jbc.M300362200	http://dx.doi.org/10.1074/jbc.M300362200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639956	Green Published, hybrid			2022-12-27	WOS:000183078000069
J	Baker, TL; Zheng, H; Walker, J; Coloff, JL; Buss, JE				Baker, TL; Zheng, H; Walker, J; Coloff, JL; Buss, JE			Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CYSTEINE-RICH DOMAIN; PLASMA-MEMBRANE; LIPID RAFTS; K-RAS; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; SIGNAL-TRANSDUCTION; ALPHA-SUBUNITS; ZINC-FINGER	H-Ras displays dynamic cycles of GTP binding and palmitate turnover. GTP binding is clearly coupled to activation, but whether the palmitoylated COOH terminus participates in signaling, especially when constrained by membrane tethering, is unknown. As a way to compare COOH termini of membrane-bound, lipid-modified H-Ras, palmitate removal rates were measured for various forms of H-Ras in NIH 3T3 cells. Depalmitoylation occurred slowly (t(1/2) similar to2.4 h) in cellular (H-RasWT) or dominant negative (H-Ras17N) forms and more rapidly (t(1/2) similar to1 h) in oncogenic H-Ras61L or H-RasR12, T59. Combining this data with GTP binding measurements, the palmitate half-life of H-Ras in the fully GTP-bound state was estimated to be less than 10 min. Slow palmitate removal from cellular H-Ras was not explained by sequestration in caveolae, as neither cellular nor oncogenic H-Ras showed alignment with caveolin by immunofluorescence. Conversely, although it had faster palmitate removal, oncogenic H-Ras was located in the same fractions as H-RasWT on four types of density gradients, and remained fully membrane-bound. Thus the different rates of deacylation occurred even though oncogenic and cellular H-Ras appeared to be in similar locations. Instead, these results suggest that acylprotein thioesterases access oncogenic H-Ras more easily because the conformation of its COOH terminus against the membrane is altered. This previously undetected difference could help produce distinctive effector interactions and signaling of oncogenic H-Ras.	Iowa State Univ, Dept Zool Genet, Ames, IA 50011 USA; Iowa State Univ, Dept Biochem, Ames, IA 50011 USA; Iowa State Univ, Dept Biophys, Ames, IA 50011 USA	Iowa State University; Iowa State University; Iowa State University	Buss, JE (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.	jbuss@iastate.edu		Buss, Janice/0000-0002-8086-265X	NATIONAL CANCER INSTITUTE [R01CA051890] Funding Source: NIH RePORTER; NCI NIH HHS [CA51890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avery J, 2000, J CELL BIOL, V148, P317, DOI 10.1083/jcb.148.2.317; Bader B, 2000, NATURE, V403, P223, DOI 10.1038/35003249; Baker TL, 2000, J BIOL CHEM, V275, P22037, DOI 10.1074/jbc.M001813200; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Bijlmakers MJ, 2003, TRENDS CELL BIOL, V13, P32, DOI 10.1016/S0962-8924(02)00008-9; Booden MA, 2000, J BIOL CHEM, V275, P23559, DOI 10.1074/jbc.M001368200; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; BRANDTRAUF PW, 1990, J PROTEIN CHEM, V9, P137, DOI 10.1007/BF01025304; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Buss JE, 1995, CHEM BIOL, V2, P787, DOI 10.1016/1074-5521(95)90083-7; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Chen CA, 2000, J BIOL CHEM, V275, P23516, DOI 10.1074/jbc.M003439200; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P156; Drugan JK, 1996, J BIOL CHEM, V271, P233, DOI 10.1074/jbc.271.1.233; Duncan JA, 2002, J BIOL CHEM, V277, P31740, DOI 10.1074/jbc.M202505200; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Dunphy JT, 2001, J BIOL CHEM, V276, P43300, DOI 10.1074/jbc.M104275200; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Field KA, 2000, MOL BIOL CELL, V11, P3661, DOI 10.1091/mbc.11.10.3661; Gelb MH, 1998, CURR OPIN CHEM BIOL, V2, P40, DOI 10.1016/S1367-5931(98)80034-3; GIBBS JB, 1995, METHOD ENZYMOL, V255, P118; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jaumot M, 2002, J BIOL CHEM, V277, P272, DOI 10.1074/jbc.M108423200; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Kato K, 1992, Semin Cancer Biol, V3, P179; Klinghoffer RA, 1996, MOL CELL BIOL, V16, P5905; Lang T, 2001, EMBO J, V20, P2202, DOI 10.1093/emboj/20.9.2202; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lobo S, 2002, J BIOL CHEM, V277, P41268, DOI 10.1074/JBC.M206573200; Loisel TP, 1996, BIOCHEMISTRY-US, V35, P15923, DOI 10.1021/bi9611321; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; Luo ZJ, 1997, MOL CELL BIOL, V17, P46, DOI 10.1128/MCB.17.1.46; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; MUMBY S M, 1990, Methods (Orlando), V1, P216, DOI 10.1016/S1046-2023(05)80320-2; Mumby SM, 2002, METHOD ENZYMOL, V344, P383; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Okada T, 1999, MOL CELL BIOL, V19, P6057; OLIFF A, 1999, BIOCHIM BIOPHYS ACTA, V1423, P19; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Parmryd I, 2003, EXP CELL RES, V285, P27, DOI 10.1016/S0014-4827(02)00048-4; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Reuter CWM, 2000, BLOOD, V96, P1655, DOI 10.1182/blood.V96.5.1655.h8001655_1655_1669; Rizzo MA, 2001, J BIOL CHEM, V276, P34928, DOI 10.1074/jbc.M105918200; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 2002, MOL CELL BIOL, V22, P5128, DOI 10.1128/MCB.22.14.5128-5140.2002; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; White MA, 2001, NAT CELL BIOL, V3, pE172, DOI 10.1038/35087098; Williams JG, 2000, J BIOL CHEM, V275, P22172, DOI 10.1074/jbc.M000397200; Willumsen BM, 1996, ONCOGENE, V13, P1901; Wittinghofer A, 1996, TRENDS BIOCHEM SCI, V21, P488, DOI 10.1016/S0968-0004(96)10064-5; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhao LH, 2002, J BIOL CHEM, V277, P49352, DOI 10.1074/jbc.M209760200	83	76	76	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19292	19300		10.1074/jbc.M206956200	http://dx.doi.org/10.1074/jbc.M206956200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642594	hybrid			2022-12-27	WOS:000182932200075
J	Hirschler-Laszkiewicz, I; Cavanaugh, AH; Mirza, A; Lun, MY; Hu, QY; Smink, T; Rothblum, LI				Hirschler-Laszkiewicz, I; Cavanaugh, AH; Mirza, A; Lun, MY; Hu, QY; Smink, T; Rothblum, LI			Rrn3 becomes inactivated in the process of ribosomal DNA transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE ENCODES; RDNA TRANSCRIPTION; FACTOR SL1; TIF-IA; PHOSPHORYLATION; INITIATION; GENE; RECRUITMENT; PROMOTER	The human homologue of yeast Rrn3, a 72-kDa protein, is essential for ribosomal DNA (rDNA) transcription. Although the importance of Rrn3 function in rDNA transcription is well established, its mechanism of action has not been determined. It has been suggested that the phosphorylation of either yeast RNA polymerase I or mammalian Rrn3 regulates the formation of RNA polymerase I.Rrn3 complexes that can interact with the committed template. These and other reported differences would have implications with respect to the mechanism by which Rrn3 functions in transcription. For example, in the yeast rDNA transcription system, Rrn3 might function catalytically, but in the mammalian system it might function stoichiometrically. Thus, we examined the question as to whether Rrn3 functions catalytically or stoichiometrically. We report that mammalian Rrn3 becomes the limiting factor as transcription reactions proceed. Moreover, we demonstrate that Rrn3 is inactivated during the transcription reactions. For example, Rrn3 isolated from a reaction that had undergone transcription cannot activate transcription in a subsequent reaction. We also show that this inactivated Rrn3 not only dissociates from RNA polymerase I, but is not capable of forming a stable complex with RNA polymerase I. Our results indicate that Rrn3 functions stoichiometrically in rDNA transcription and that its ability to associate with RNA polymerase I is lost upon transcription.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Danville, PA 17821 USA		Rothblum, LI (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Danville, PA 17821 USA.							Aprikian P, 2001, MOL CELL BIOL, V21, P4847, DOI 10.1128/MCB.21.15.4847-4855.2001; BAZETTJONES DP, 1994, SCIENCE, V264, P1134, DOI 10.1126/science.8178172; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BRUN RP, 1994, MOL CELL BIOL, V14, P5010, DOI 10.1128/MCB.14.7.5010; Cavanaugh AH, 2002, J BIOL CHEM, V277, P27423, DOI 10.1074/jbc.M201232200; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; CAVANAUGH AH, 1984, P NATL ACAD SCI-BIOL, V81, P718, DOI 10.1073/pnas.81.3.718; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; Dundr M, 2002, SCIENCE, V298, P1623, DOI 10.1126/science.1076164; Fath S, 2001, P NATL ACAD SCI USA, V98, P14334, DOI 10.1073/pnas.231181398; GOKAL PK, 1986, J BIOL CHEM, V261, P2536; HAGLUND RE, 1987, MOL CELL BIOCHEM, V73, P11; Hannan RD, 1998, J BIOL CHEM, V273, P1257, DOI 10.1074/jbc.273.2.1257; Heix J, 1998, EMBO J, V17, P7373, DOI 10.1093/emboj/17.24.7373; Hirschler-Laszkiewicz I, 2001, NUCLEIC ACIDS RES, V29, P4114, DOI 10.1093/nar/29.20.4114; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KEYS DA, 1994, GENE DEV, V8, P2349, DOI 10.1101/gad.8.19.2349; Keys DA, 1996, GENE DEV, V10, P887, DOI 10.1101/gad.10.7.887; LEARNED RM, 1985, MOL CELL BIOL, V5, P1358, DOI 10.1128/MCB.5.6.1358; Lin CW, 1996, MOL CELL BIOL, V16, P6436; Milkereit P, 1998, EMBO J, V17, P3692, DOI 10.1093/emboj/17.13.3692; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moorefield B, 2000, P NATL ACAD SCI USA, V97, P4724, DOI 10.1073/pnas.080063997; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; OMAHONY DJ, 1992, NUCLEIC ACIDS RES, V20, P1301; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; Paule MR., 1998, TRANSCRIPTION RIBOSO; Pelletier G, 2000, MOL CELL, V6, P1059, DOI 10.1016/S1097-2765(00)00104-0; Peyroche G, 2000, EMBO J, V19, P5473, DOI 10.1093/emboj/19.20.5473; SCHNAPP A, 1993, MOL CELL BIOL, V13, P6723, DOI 10.1128/MCB.13.11.6723; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; Steffan JS, 1996, GENE DEV, V10, P2551, DOI 10.1101/gad.10.20.2551; THURIAUX P, 1995, J BIOL CHEM, V270, P24252, DOI 10.1074/jbc.270.41.24252; Yamamoto RT, 1996, EMBO J, V15, P3964, DOI 10.1002/j.1460-2075.1996.tb00770.x; Zhai WG, 1997, GENE DEV, V11, P1605, DOI 10.1101/gad.11.12.1605; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	38	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18953	18959		10.1074/jbc.M301093200	http://dx.doi.org/10.1074/jbc.M301093200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646563	hybrid			2022-12-27	WOS:000182932200032
J	Huang, Y; Kim, SO; Jiang, J; Frank, SJ				Huang, Y; Kim, SO; Jiang, J; Frank, SJ			Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells - Modulation of EGF-induced trafficking and signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	84th Annual Meeting of the Endocrine-Society	JUN 19-22, 2002	SAN FRANCISCO, CA	Endocrine Soc			ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; C-CBL; COUPLED RECEPTORS; BINDING-PROTEIN; ANGIOTENSIN-II; TRANSACTIVATION; INHIBITOR; STIMULATION; FAMILY	Growth hormone (GH) promotes signaling by causing activation of the non-receptor tyrosine kinase, JAK2, which associates with the GH receptor. GH causes phosphorylation of epidermal growth factor receptor ( EGFR; ErbB-1) and its family member, ErbB-2. For EGFR, JAK2-mediated GH-induced tyrosine phosphorylation may allow EGFR to serve as a scaffold for GH signaling. For ErbB-2, GH induces serine/threonine phosphorylation that dampens basal and EGF-induced ErbB-2 kinase activation. We now further explore GH-induced EGFR phosphorylation in 3T3-F442A, a preadipocytic fibroblast cell line that expresses endogenous GH receptor, EGFR, and ErbB-2. Using a monoclonal antibody that recognizes ERK consensus site phosphorylation (PTP101), we found that GH caused PTP101-reactive phosphorylation of EGFR. This GH-induced EGFR phosphorylation was prevented by MEK1 inhibitors but not by a protein kinase C inhibitor. Although GH did not discernibly affect EGF-induced EGFR tyrosine phosphorylation, we observed by immunoblotting a substantial decrease of EGF-induced EGFR degradation in the presence of GH. Fluorescence microscopy studies indicated that EGF-induced intracellular redistribution of an EGFR-cyan fluorescent protein chimera was markedly reduced by GH cotreatment, in support of the immunoblotting results. Notably, protection from EGF-induced degradation and inhibition of EGF-induced intracellular redistribution afforded by GH were both prevented by a MEK1 inhibitor, suggesting a role for GH-induced ERK activation in regulating the trafficking itinerary of the EGF-stimulated EGFR. Finally, we observed augmentation of early aspects of EGF signaling ( EGF-induced ERK2 activation and EGF-induced Cbl tyrosine phosphorylation) by GH cotreatment; the GH effect on EGF-induced Cbl tyrosine phosphorylation was also prevented by MEK1 inhibition. These data indicate that GH, by activating ERKs, can modulate EGF-induced EGFR trafficking and signaling and expand our understanding of mechanisms of cross-talk between the GH and EGF signaling systems.	Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Med Serv, Endocrinol Sect, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	frank@endo.dom.uab.edu			NIDDK NIH HHS [DK58259, DK46395] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046395, R01DK046395, R56DK046395, R01DK058259, R56DK058259] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANDERSON NG, 1992, BIOCHEM J, V284, P649, DOI 10.1042/bj2840649; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Buteau J, 2003, DIABETES, V52, P124, DOI 10.2337/diabetes.52.1.124; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Davey HW, 2001, ENDOCRINOLOGY, V142, P3836, DOI 10.1210/en.142.9.3836; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Frank SJ, 2002, CYTOKINE REFERENCE O, P1; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Gschwind A, 2002, CANCER RES, V62, P6329; Guan R, 2001, ENDOCRINOLOGY, V142, P1137, DOI 10.1210/en.142.3.1137; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hall C, 2001, MOL CELL BIOL, V21, P1854, DOI 10.1128/MCB.21.5.1854-1865.2001; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Ihle JN, 1995, ADV IMMUNOL, V60, P1, DOI 10.1016/S0065-2776(08)60582-9; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kawanabe Y, 2002, AM J PHYSIOL-HEART C, V283, pH2671, DOI 10.1152/ajpheart.00350.2002; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Levkowitz G, 1996, ONCOGENE, V12, P1117; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; LUND KA, 1990, J BIOL CHEM, V265, P20517; Marinissen MT, 2001, GENE DEV, V15, P535, DOI 10.1101/gad.855801; McCole DF, 2002, J BIOL CHEM, V277, P42603, DOI 10.1074/jbc.M206487200; MOLLER C, 1992, J BIOL CHEM, V267, P23403; Morrison P, 1996, J BIOL CHEM, V271, P12891, DOI 10.1074/jbc.271.22.12891; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Rui LY, 2000, J BIOL CHEM, V275, P2885, DOI 10.1074/jbc.275.4.2885; Saito S, 2002, BIOCHEM BIOPH RES CO, V294, P1023, DOI 10.1016/S0006-291X(02)00595-8; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamazaki T, 2002, J CELL SCI, V115, P1791; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200	76	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18902	18913		10.1074/jbc.M300939200	http://dx.doi.org/10.1074/jbc.M300939200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	679PY	12642595	hybrid			2022-12-27	WOS:000182932200026
J	Maeda, N; Kawada, N; Seki, S; Arakawa, T; Ikeda, K; Iwao, H; Okuyama, H; Hirabayshi, J; Kasai, K; Yoshizato, K				Maeda, N; Kawada, N; Seki, S; Arakawa, T; Ikeda, K; Iwao, H; Okuyama, H; Hirabayshi, J; Kasai, K; Yoshizato, K			Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; S-TYPE LECTIN; EXTRACELLULAR-MATRIX; ENDOGENOUS LECTIN; MOLECULAR MECHANISMS; SURFACE EXPRESSION; GROWTH-FACTOR; T-CELLS; PROTEIN; ADHESION	We found that the expression of galectin-1 and galectin-3 was significantly up-regulated in hepatic stellate cells (HSCs) both in the course of their transdifferentiation into myofibroblasts, a process of "self-activation," and in the fibrosis of liver tissues. Recombinant galectin-1 and galectin-3 stimulated the proliferation of cultured HSCs via the MEK1/2-ERK1/2 signaling pathway. However, galectin-3 utilized protein kinases C and A to induce this process, whereas galectin-1 did not. We also found that thiodigalactoside, a potent inhibitor of beta-galactoside binding, attenuated the effects of both galectins. In addition, galectin-1, but not galectin-3, promoted the migration of HSCs. Thus, it appears that galectin-1 and galectin-3, generated by activated HSCs, could participate in beta-galactoside binding and induce different intracellular signaling pathways leading to the proliferation of HSCs.	Osaka City Univ, Dept Hepatol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Gastroenterol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Anat, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Dept Pharmacol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan; Kyoto Univ, Dept Surg Gastroenterol, Grad Sch Med, Sakyo Ku, Kyoto 6068397, Japan; Teikyo Univ, Dept Biol Chem, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Hiroshia Univ, Dept Sci Biol, Grad Sch Sci, Hiroshima 7398526, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Kyoto University; Teikyo University; Hiroshima University	Kawada, N (corresponding author), Osaka City Univ, Dept Hepatol, Grad Sch Med, Abeno Ku, Osaka 5458585, Japan.	kawadanori@med.osaka-cu.ac.jp	kawada, norifumi/AAS-1367-2020					BALLARDINI G, 1983, LIVER, V3, P58; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; Belot N, 2001, GLIA, V36, P375, DOI 10.1002/glia.1124; Bianchet MA, 2000, PROTEINS, V40, P378, DOI 10.1002/1097-0134(20000815)40:3<378::AID-PROT40>3.0.CO;2-7; CENACCHI G, 1983, VIRCHOWS ARCH B, V43, P75, DOI 10.1007/BF02932946; Cho MJ, 1997, TRENDS GLYCOSCI GLYC, V9, P47, DOI 10.4052/tigg.9.47; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DO KY, 1990, BIOCHEM BIOPH RES CO, V173, P1123, DOI 10.1016/S0006-291X(05)80902-7; FRIEDMAN SL, 1993, NEW ENGL J MED, V328, P1828; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; FRIGERI LG, 1992, J IMMUNOL, V148, P861; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GRESSNER AM, 1995, DIGESTION, V56, P335, DOI 10.1159/000201257; Hirabayashi J, 2002, BBA-GEN SUBJECTS, V1572, P232, DOI 10.1016/S0304-4165(02)00311-2; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; Holland SJ, 1997, EMBO J, V16, P3877, DOI 10.1093/emboj/16.13.3877; Hsu DK, 1999, INT J CANCER, V81, P519, DOI 10.1002/(SICI)1097-0215(19990517)81:4<519::AID-IJC3>3.0.CO;2-0; Ikeda K, 1999, HEPATOLOGY, V29, P1760, DOI 10.1002/hep.510290640; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; Inohara H, 1996, CANCER RES, V56, P4530; Inohara H, 1998, EXP CELL RES, V245, P294, DOI 10.1006/excr.1998.4253; INOHARA H, 1995, CANCER RES, V55, P3267; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kawada N, 1999, J HEPATOL, V30, P1057, DOI 10.1016/S0168-8278(99)80260-8; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Kristensen DB, 2000, HEPATOLOGY, V32, P268; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; Levy Y, 2001, J BIOL CHEM, V276, P31285, DOI 10.1074/jbc.M100340200; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LIU FT, 1993, IMMUNOL TODAY, V14, P486, DOI 10.1016/0167-5699(93)90263-K; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; Marra F, 1997, GASTROENTEROLOGY, V112, P1297, DOI 10.1016/S0016-5085(97)70144-6; Mey A, 1996, J IMMUNOL, V156, P1572; MIRLECHAIRE FJ, 1978, NATURE, V272, P256, DOI 10.1038/272256a0; Moiseeva EP, 1999, J VASC RES, V36, P47, DOI 10.1159/000025625; Moiseeva EP, 2000, CARDIOVASC RES, V45, P493, DOI 10.1016/S0008-6363(99)00276-X; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; Nakatani K, 2002, VIRCHOWS ARCH, V441, P466, DOI 10.1007/s00428-002-0631-z; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; ODA Y, 1991, GENE, V99, P279; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Okuyama H, 2001, J BIOL CHEM, V276, P28274, DOI 10.1074/jbc.M102995200; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Pinzani M, 1998, LIVER, V18, P2; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 2000, CELL DEATH DIFFER, V7, P747, DOI 10.1038/sj.cdd.4400708; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; Sanjuan X, 1997, GASTROENTEROLOGY, V113, P1906, DOI 10.1016/S0016-5085(97)70010-6; Santucci L, 2000, HEPATOLOGY, V31, P399, DOI 10.1002/hep.510310220; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; SGROI D, 1993, J BIOL CHEM, V268, P7011; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; Shimonishi T, 2001, HUM PATHOL, V32, P302, DOI 10.1053/hupa.2001.22767; SKRINCOSKY DM, 1993, CANCER RES, V53, P2667; TAKEI Y, 1995, J GASTROEN HEPATOL, V10, pS65, DOI 10.1111/j.1440-1746.1995.tb01802.x; Vespa GNR, 1999, J IMMUNOL, V162, P799; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; YAMAOKA K, 1991, BIOCHEM BIOPH RES CO, V179, P272, DOI 10.1016/0006-291X(91)91365-J; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; ZHOU Q, 1990, ARCH BIOCHEM BIOPHYS, V281, P27, DOI 10.1016/0003-9861(90)90408-Q	74	121	129	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18938	18944		10.1074/jbc.M209673200	http://dx.doi.org/10.1074/jbc.M209673200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646584	hybrid			2022-12-27	WOS:000182932200030
J	Wieler, S; Gagne, JP; Vaziri, H; Poirier, GG				Wieler, S; Gagne, JP; Vaziri, H; Poirier, GG			Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G(1) arrest response following ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; P53 IN-VITRO; CELL-DEATH; COVALENT POLY(ADP-RIBOSYL)ATION; CONSENSUS SEQUENCE; GENOMIC INTEGRITY; GAMMA-IRRADIATION; ADP-RIBOSYLATION; MAMMALIAN-CELLS; STRAND BREAKS	Poly(ADP-ribose) polymerase-1 (PARP-1) and the p53 tumor suppressor protein are both involved in the cellular response to genotoxic stress. Upon binding to the site of DNA strand breakage, PARP-1 is activated, leading to rapid and transient poly(ADP-ribosyl)ation of nuclear proteins using NAD(+) as substrate. To investigate the role of PARP-1 in the p53 response to ionizing radiation in human cells, PARP-1 function was disrupted in wild-type p53 expressing MCF-7 and BJ/TERT cells using two strategies: chemical inhibition with 1,5-dihydroxyisoquinoline, and trans-dominant inhibition by overexpression of the PARP-1 DNA-binding domain. Although a number of proteins can catalyze poly(ADP-ribosyl) ation in addition to PARP-1, we show that PARP-1 is the only detectable active species in BJ/TERT and MCF-7 cells. 1,5-Dihydroxyisoquinoline treatment prior to ionizing radiation delayed and attenuated the induction of two p53-responsive genes, p21 and mdm-2, and led to suppression of the p53-mediated G1-arrest response in MCF-7 and BJ/TERT cells. Trans-dominant inhibition of PARP-1 by overexpression of the PARP-1 DNA-binding domain in MCF-7 cells also led to a delay and attenuation in p21 induction and suppression of the p53-mediated G(1)-arrest response to ionizing radiation. Hence, inhibition of endogenous PARP-1 function suppresses the transactivation function of p53 in response to ionizing radiation. This study establishes PARP-1 as a critical regulator of the p53 response to DNA damage.	Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; CHU Laval, Res Ctr, Unit Hlth & Environm, Quebec City, PQ G1V 4G2, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Laval University	Poirier, GG (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X; Poirier, Guy/0000-0002-4869-1424				Agarwal ML, 1997, ONCOGENE, V15, P1035, DOI 10.1038/sj.onc.1201274; ALTHAUS FR, 1993, ENVIRON MOL MUTAGEN, V22, P278, DOI 10.1002/em.2850220417; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; JACOBSON EL, 1985, CARCINOGENESIS, V6, P711, DOI 10.1093/carcin/6.5.711; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kumari SR, 1998, CANCER RES, V58, P5075; KUPPER JH, 1990, J BIOL CHEM, V265, P18721; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; Masutani M, 1999, MOL CELL BIOCHEM, V193, P149; Mendoza-Alvarez H, 2001, J BIOL CHEM, V276, P36425, DOI 10.1074/jbc.M105215200; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; NOZAKI T, 1994, JPN J CANCER RES, V85, P1094, DOI 10.1111/j.1349-7006.1994.tb02912.x; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prives C, 1999, J PATHOL, V187, P112; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; SATOH MS, 1994, BIOCHEMISTRY-US, V33, P7099, DOI 10.1021/bi00189a012; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; Simbulan-Rosenthal CM, 1999, CANCER RES, V59, P2190; Simbulan-Rosenthal CM, 2001, NEOPLASIA, V3, P179, DOI 10.1038/sj.neo.7900155; SIMONIN F, 1993, J BIOL CHEM, V268, P13454; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; VAUGHAN M, 1981, CURR TOP CELL REGUL, V20, P205; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Vaziri H, 1999, MOL CELL BIOL, V19, P2373; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Watson NC, 1997, INT J RADIAT BIOL, V72, P547, DOI 10.1080/095530097143059; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	49	91	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18914	18921		10.1074/jbc.M211641200	http://dx.doi.org/10.1074/jbc.M211641200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642583	hybrid			2022-12-27	WOS:000182932200027
J	Deming, D; Cheng, Q; Jayaraman, V				Deming, D; Cheng, Q; Jayaraman, V			Is the isolated ligand binding domain a good model of the domain in the native receptor?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE GLUTAMATE RECEPTORS; AMPA RECEPTOR; STABLE EXPRESSION; DESENSITIZATION; CORE	Numerous studies have used the atomic level structure of the isolated ligand binding domain of the glutamate receptor to elucidate the agonist-induced activation and desensitization processes in this group of proteins. However, no study has demonstrated the structural equivalence of the isolated ligand binding fragments and the protein in the native receptor. In this report, using visible absorption spectroscopy we show that the electronic environment of the antagonist 6-cyano-7-nitro-2,3-dihydroxyquinoxaline is identical for the isolated protein and the native glutamate receptors expressed in cells. Our results hence establish that the local structure of the ligand binding site is the same in the two proteins and validate the detailed structure-function relationships that have been developed based on a comparison of the structure of the isolated ligand binding domain and electrophysiological consequences in the native receptor.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Jayaraman, V (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, MSB 4-106,6341 Fannin, Houston, TX 77030 USA.							Andersen PH, 1996, EUR J PHARMACOL, V311, P95, DOI 10.1016/0014-2999(96)00399-8; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Hennegriff M, 1997, J NEUROCHEM, V68, P2424; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Madden DR, 2001, J BIOL CHEM, V276, P37821; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; MUNSON PJ, 1988, J RECEPTOR RES, V8, P533, DOI 10.3109/10799898809049010; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N	16	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17589	17592		10.1074/jbc.C300105200	http://dx.doi.org/10.1074/jbc.C300105200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12657650	hybrid			2022-12-27	WOS:000182838300002
J	Mitsopoulos, C; Zihni, C; Garg, R; Ridley, AJ; Morris, JDH				Mitsopoulos, C; Zihni, C; Garg, R; Ridley, AJ; Morris, JDH			The prostate-derived sterile 20-like kinase (PSK) regulates microtubule organization and stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3-BETA; NUCLEOTIDE EXCHANGE FACTOR; P21-ACTIVATED KINASE; 3T3 CELLS; ACTIN; PATHWAYS; DYNAMICS; PHOSPHORYLATION	Sterile 20 (STE20) protein kinases, which include germinal center kinases and p21-activated protein kinases, are known to activate mitogen-activated protein kinase pathways (c-Jun NH2-terminal kinase, p38, or extracellular signal-regulated kinase), leading to changes in gene transcription. Some STE20s can also regulate the cytoskeleton, and we have shown that the germinal center kinase-like kinase prostate-derived STE20-like kinase (PSK) affects actin cytoskeletal organization. Here, we demonstrate that PSK colocalizes with microtubules; and that this localization is disrupted by the microtubule depolymerizing agent nocodazole. The association of PSK with microtubules results in the production of stabilized perinuclear microtubule cables that are nocodazole-resistant and contain increased levels of acetylated alpha-tubulin. Kinase-defective PSK (K57A) or the C terminus of PSK (amino acids 745-1235) lacking the kinase domain are sufficient for microtubule binding and stabilization, demonstrating that the catalytic activity of the protein is not required. The localization of PSK to microtubules occurs via its C terminus, and PSK binds and phosphorylates alpha- and beta-tubulin in vitro. The N terminus of PSK (1-940) is unable to bind or stabilize microtubules, demonstrating that PSK must associate with microtubules for their reorganization to occur. These results demonstrate that PSK interacts with microtubules and affects their organization and stability independently of PSK kinase activity.	GKT Sch Med & Dent, Rayne Inst, Acad Dept Surg, London SE5 9NU, England; Ludwig Inst Canc Res, Univ Coll London Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; King's College London; Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Morris, JDH (corresponding author), GKT Sch Med & Dent, Rayne Inst, Acad Dept Surg, 123 Coldharbour Lane, London SE5 9NU, England.	jonathan.morris@kcl.ac.uk		Mitsopoulos, Costas/0000-0002-9116-5921; Ridley, Anne/0000-0001-8186-5708; Morris, Jonathan/0000-0002-3211-1798				Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9; Best A, 1996, J BIOL CHEM, V271, P3756; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Cau J, 2001, J CELL BIOL, V155, P1029, DOI 10.1083/jcb.200104123; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Danowski BA, 1998, CELL MOTIL CYTOSKEL, V40, P1; Daub H, 2001, J BIOL CHEM, V276, P1677, DOI 10.1074/jbc.C000635200; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Faruki S, 2000, J CELL SCI, V113, P2557; Fu CA, 1999, J BIOL CHEM, V274, P30729, DOI 10.1074/jbc.274.43.30729; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Harrison RE, 2001, NEOPLASIA, V3, P385, DOI 10.1038/sj.neo.7900180; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; Krylova O, 2000, J CELL BIOL, V151, P83, DOI 10.1083/jcb.151.1.83; Li W, 1996, TOXICOL APPL PHARM, V140, P461, DOI 10.1006/taap.1996.0243; Lin PT, 2000, J NEUROSCI, V20, P9152; MacRae TH, 1997, EUR J BIOCHEM, V244, P265, DOI 10.1111/j.1432-1033.1997.00265.x; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Moore TM, 2000, J BIOL CHEM, V275, P4311, DOI 10.1074/jbc.275.6.4311; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Palazzo AF, 2001, NAT CELL BIOL, V3, P723, DOI 10.1038/35087035; Ren Y, 1998, J BIOL CHEM, V273, P34954, DOI 10.1074/jbc.273.52.34954; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P8881, DOI 10.1073/pnas.92.19.8881; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Simon JR, 1998, J NEUROCYTOL, V27, P119, DOI 10.1023/A:1006999306413; SUN W, 2002, J BIOL CHEM, V25, P25; Tsutsumi T, 2000, J BIOL CHEM, V275, P9157, DOI 10.1074/jbc.275.13.9157; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Willard FS, 2001, CELL SIGNAL, V13, P653, DOI 10.1016/S0898-6568(01)00185-1; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605	44	39	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18085	18091		10.1074/jbc.M213064200	http://dx.doi.org/10.1074/jbc.M213064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639963	hybrid			2022-12-27	WOS:000182838300065
J	Schertzer, JW; Brown, ED				Schertzer, JW; Brown, ED			Purified, recombinant TagF protein from Bacillus subtilis 168 catalyzes the polymerization of glycerol phosphate onto a membrane acceptor in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WALL TEICHOIC-ACID; POLY(GLYCEROPHOSPHATE) GLYCEROPHOSPHOTRANSFERASE; CTP-GLYCEROL-3-PHOSPHATE CYTIDYLYLTRANSFERASE; CDP-GLYCEROL; CELL-WALLS; BACILLUS-SUBTILIS-168; GENES; ORGANIZATION; EXPRESSION; RIBITOL	We report the first characterization of a recombinant protein involved in the polymerization of wall teichoic acid. Previously, a study of the teichoic acid polymerase activity associated with membranes from Bacillus subtilis 168 strains bearing thermosensitive mutations in tagB, tagD, and tagF implicated TagF as the poly(glycerol phosphate) polymerase (Pooley, H. M., Abellan, F. X., and Karamata, D. (1992) J. Bacteriol. 174, 646-649). In the work reported here, we have demonstrated an unequivocal role for tagF in the thermosensitivity of one such mutant (tagF1) by conditional complementation at the restrictive temperature with tagF under control of the xylose promoter at the amyE locus. We have overexpressed and purified recombinant B. subtilis TagF protein, and we provide direct biochemical evidence that this enzyme is responsible for polymerization of poly( glycerol phosphate) teichoic acid in B. subtilis 168. Recombinant hexahistidine-tagged TagF protein was purified from Escherichia coli and was used to develop a novel membrane pelleting assay to monitor poly(glycerol phosphate) polymerase activity. Purified TagF was shown to incorporate radioactivity from its substrate CDP-[C-14]glycerol into a membrane fraction in vitro. This activity showed a saturable dependence on the concentration of CDP-glycerol (K-m of 340 muM) and the membrane acceptor (half-maximal activity at 650 mug of protein/ml of purified B. subtilis membranes). High pressure liquid chromatography analysis confirmed the polymeric nature of the reaction product, similar to35 glycerol phosphate units in length.	McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, Hamilton, ON L8N 3Z5, Canada	McMaster University	Brown, ED (corresponding author), McMaster Univ, Dept Biochem, Antimicrobial Res Ctr, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.		Schertzer, Jonathan/P-3395-2017	Schertzer, Jonathan/0000-0002-1547-5856				ANDERSON RG, 1972, BIOCHEM J, V127, P11, DOI 10.1042/bj1270011; Badurina DS, 2003, BBA-PROTEINS PROTEOM, V1646, P196, DOI 10.1016/S1570-9639(03)00019-0; Bhavsar AP, 2001, J BACTERIOL, V183, P6688, DOI 10.1128/JB.183.22.6688-6693.2001; Bhavsar AP, 2001, APPL ENVIRON MICROB, V67, P403, DOI 10.1128/AEM.67.1.403-410.2001; BRIEHL M, 1989, J GEN MICROBIOL, V135, P1325; BURGER MM, 1964, J BIOL CHEM, V239, P3168; CUTTING SM, 1990, MOL BIOL METHODS BAC, P175; FIEDLER F, 1974, J BIOL CHEM, V249, P2684; FIEDLER F, 1974, J BIOL CHEM, V249, P2690; Fitzgerald SN, 2000, J BACTERIOL, V182, P1046, DOI 10.1128/JB.182.4.1046-1052.2000; GLASER L, 1964, J BIOL CHEM, V239, P3178; HONEYMAN AL, 1989, MOL MICROBIOL, V3, P1257, DOI 10.1111/j.1365-2958.1989.tb00276.x; ISHIMOTO N, 1966, J BIOL CHEM, V241, P639; KOJIMA N, 1983, J BIOL CHEM, V258, P9043; Lazarevic V, 2002, MICROBIOL-SGM, V148, P815, DOI 10.1099/00221287-148-3-815; LAZAREVIC V, 1995, MOL MICROBIOL, V16, P345, DOI 10.1111/j.1365-2958.1995.tb02306.x; LEAVER J, 1981, J BACTERIOL, V146, P847, DOI 10.1128/JB.146.3.847-852.1981; MAUCK J, 1972, P NATL ACAD SCI USA, V69, P2386, DOI 10.1073/pnas.69.9.2386; MAUEL C, 1991, J GEN MICROBIOL, V137, P929, DOI 10.1099/00221287-137-4-929; MAUEL C, 1989, MOL GEN GENET, V215, P388, DOI 10.1007/BF00427034; MCARTHUR HAI, 1978, FEBS LETT, V86, P193, DOI 10.1016/0014-5793(78)80561-4; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PARK YS, 1993, J BIOL CHEM, V268, P16648; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; POLLACK JH, 1994, J BACTERIOL, V176, P7252, DOI 10.1128/JB.176.23.7252-7259.1994; POOLEY HM, 1992, J BACTERIOL, V174, P646, DOI 10.1128/jb.174.2.646-649.1992; POOLEY HM, 1994, BACTERIAL CELL WALL, P187; Sambrook J., 1989, MOL CLONING, pA1; Sanker S, 2001, J BIOL CHEM, V276, P37922; SASAKI Y, 1983, EUR J BIOCHEM, V132, P207, DOI 10.1111/j.1432-1033.1983.tb07349.x; Soldo B, 2002, MICROBIOL-SGM, V148, P2079, DOI 10.1099/00221287-148-7-2079	31	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18002	18007		10.1074/jbc.M300706200	http://dx.doi.org/10.1074/jbc.M300706200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637499	hybrid			2022-12-27	WOS:000182838300053
J	Walter, SA; Cutler, RE; Martinez, R; Gishizky, M; Hill, RJ				Walter, SA; Cutler, RE; Martinez, R; Gishizky, M; Hill, RJ			Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; CELL-CYCLE PROGRESSION; XENOPUS EGG EXTRACTS; PROGNOSTIC-SIGNIFICANCE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; DROSOPHILA POLO; PLK EXPRESSION; PROTEIN-KINASE; M-PHASE	The Ste20 family of serine/threonine kinases plays an important role in numerous cellular functions such as growth, apoptosis, and morphogenesis. We have identified a previously cloned but uncharacterized family member termed Stk10, which is a human homolog of murine Lok, a serine/threonine kinase highly expressed in lymphocytes. Northern analysis demonstrated that the Stk10 transcript is present in many tissues, although highest expression levels are seen in hematopoietic cells. Due to close sequence homology to human Slk and Xenopus laevis xPlkk1, two polo-like kinase kinases, we investigated whether Stk10 might also play a role as a Plk1 activator. Plk1 has been shown to be overexpressed in multiple tumor types, thus attracting high interest to its potential upstream regulators. We show here that Stk10 can associate with Plk1 in cells and furthermore can phosphorylate Plk1 in vitro. Engineered NIH-3T3 cell lines that overexpress a dominant negative version of Stk10 display an altered cell cycle phenotype characterized by increased DNA content, raising the possibility that expression of a dominant negative Stk10 may impinge upon Plk1 function in vivo; it has previously been shown that unregulated expression of Plk1 can result in a variety of nuclear defects. We suggest, therefore, that Stk10 is a novel polo-like kinase kinase that cooperates with hSlk to regulate Plk1 function in human cells.	SUGEN Inc, Dept Res, San Francisco, CA 94080 USA; SUGEN Inc, Dept Target Discovery, San Francisco, CA 94080 USA	Pfizer; Pfizer	Walter, SA (corresponding author), SUGEN Inc, Dept Res, 230 E Grand Ave, San Francisco, CA 94080 USA.	sarah-walter@sugen.com						Bin OY, 1999, ONCOGENE, V18, P6029, DOI 10.1038/sj.onc.1202983; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Carmena M, 1998, J CELL BIOL, V143, P659, DOI 10.1083/jcb.143.3.659; Charles JF, 1998, CURR BIOL, V8, P497, DOI 10.1016/S0960-9822(98)70201-5; Chase D, 1998, BIOCHEM J, V333, P655, DOI 10.1042/bj3330655; Cutler RE, 1997, EMBO J, V16, P1953, DOI 10.1093/emboj/16.8.1953; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Ferris DK, 1998, BIOCHEM BIOPH RES CO, V252, P340, DOI 10.1006/bbrc.1998.9648; Golan A, 2002, J BIOL CHEM, V277, P15552, DOI 10.1074/jbc.M111476200; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Jang YJ, 2002, J BIOL CHEM, V277, P44115, DOI 10.1074/jbc.M202172200; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Knecht R, 1999, CANCER RES, V59, P2794; Knecht R, 2000, INT J CANCER, V89, P535; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Kuramochi S, 1999, IMMUNOGENETICS, V49, P369, DOI 10.1007/s002510050509; Kuramochi S, 1997, J BIOL CHEM, V272, P22679, DOI 10.1074/jbc.272.36.22679; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHKURA H, 1995, GENE DEV, V9, P1059, DOI 10.1101/gad.9.9.1059; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; Simizu S, 2000, NAT CELL BIOL, V2, P852, DOI 10.1038/35041102; Smith MR, 1997, BIOCHEM BIOPH RES CO, V234, P397, DOI 10.1006/bbrc.1997.6633; SUNKEL CE, 1988, J CELL SCI, V89, P25; Takai N, 2001, CANCER LETT, V164, P41, DOI 10.1016/S0304-3835(00)00703-5; Tokumitsu Y, 1999, INT J ONCOL, V15, P687; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Wolf G, 1997, ONCOGENE, V14, P543, DOI 10.1038/sj.onc.1200862; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011	40	43	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18221	18228		10.1074/jbc.M212556200	http://dx.doi.org/10.1074/jbc.M212556200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639966	hybrid			2022-12-27	WOS:000182838300083
J	Levin, MK; Gurjar, MM; Patel, SS				Levin, MK; Gurjar, MM; Patel, SS			ATP binding modulates the nucleic acid affinity of hepatitis C virus helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTRUCTURAL PROTEIN-3; DOMAIN; COMPLEXES; ADP	The helicase of hepatitis C virus (HCV) unwinds nucleic acid using the energy of ATP hydrolysis. The ATPase cycle is believed to induce protein conformational changes to drive helicase translocation along the length of the nucleic acid. We have investigated the energetics of nucleic acid binding by HCV helicase to understand how the nucleotide ligation state of the helicase dictates the conformation of its nucleic acid binding site. Because most of the nucleotide ligation states of the helicase are transient due to rapid ATP hydrolysis, several compounds were analyzed to find an efficient unhydrolyzable ATP analog. We found that the beta-gamma methylene/amine analogs of ATP, ATPgammaS, or [AlF4] ADP were not effective in inhibiting the ATPase activity of HCV helicase. On the other hand, [BeF3] ADP was found to be a potent inhibitor of the ATPase activity, and it binds tightly to HCV helicase with a 1:1 stoichiometry. Equilibrium binding studies showed that HCV helicase binds single-stranded nucleic acid with a high affinity in the absence of ATP or in the presence of ADP. Upon binding to the ATP analog, a 100-fold reduction in affinity for ssDNA was observed. The reduction in affinity was also observed in duplex DNA with 3' single-stranded tail and in RNA but not in duplex DNA. The results of this study indicate that the nucleic acid binding site of HCV helicase is allosterically modulated by the ATPase reaction. The binding energy of ATP is used to bring HCV helicase out of a tightly bound state to facilitate translocation, whereas ATP hydrolysis and product release steps promote tight rebinding of the helicase to the nucleic acid. On the basis of these results we propose a Brownian motor model for unidirectional translocation of HCV helicase along the nucleic acid length.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NIGMS NIH HHS [GM55310] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; Cho H, 2001, P NATL ACAD SCI USA, V98, P8525, DOI 10.1073/pnas.131213698; Delagoutte E, 2002, Q REV BIOPHYS, V35, P431, DOI 10.1017/S0033583502003852; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; Gwack Y, 1997, EUR J BIOCHEM, V250, P47, DOI 10.1111/j.1432-1033.1997.00047.x; Gwack Y, 1999, J VIROL, V73, P2909, DOI 10.1128/JVI.73.4.2909-2915.1999; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Levin MK, 1999, J BIOL CHEM, V274, P31839, DOI 10.1074/jbc.274.45.31839; Levin MK, 2002, J BIOL CHEM, V277, P29377, DOI 10.1074/jbc.M112315200; LEVIN MK, 2002, MOL MOTORS, P179; MARTIN RB, 1988, BIOCHEM BIOPH RES CO, V155, P1194; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; PONOMAREV MA, 1995, FEBS LETT, V371, P261, DOI 10.1016/0014-5793(95)00898-J; Porter DJT, 1998, J BIOL CHEM, V273, P7390, DOI 10.1074/jbc.273.13.7390; Preugschat F, 1996, J BIOL CHEM, V271, P24449, DOI 10.1074/jbc.271.40.24449; Shibuya H, 2002, J BIOCHEM, V132, P573, DOI 10.1093/oxfordjournals.jbchem.a003259; Yan D, 1999, P NATL ACAD SCI USA, V96, P14789, DOI 10.1073/pnas.96.26.14789; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	19	73	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23311	23316		10.1074/jbc.M301283200	http://dx.doi.org/10.1074/jbc.M301283200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12660239	hybrid			2022-12-27	WOS:000183638600014
J	Bonamore, A; Gentili, P; Ilari, A; Schinina, ME; Boffi, A				Bonamore, A; Gentili, P; Ilari, A; Schinina, ME; Boffi, A			Escherichia coli flavohemoglobin is an efficient alkylhydroperoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL-HYDROPEROXIDE REDUCTASE; NITRIC-OXIDE DIOXYGENASE; HYDROGEN-PEROXIDE; HEMOGLOBINS; RESPONSES; GLOBIN; FAMILY; SOXR	Escherichia coli flavohemoglobin (HMP) is shown to be capable of catalyzing the reduction of several alkylhydroperoxide substrates into their corresponding alcohols using NADH as an electron donor. In particular, HMP possesses a high catalytic activity and a low K-m toward cumyl, linoleic acid, and tert-butyl hydroperoxides, whereas it is a less efficient hydrogen peroxide scavenger. An analysis of UV-visible spectra during the stationary state reveals that at variance with classical peroxidases, HMP turns over in the ferrous state. In particular, an iron oxygen adduct intermediate whose spectrum is similar to that reported for the oxo-ferryl derivative in peroxidases (Compound II), has been identified during the catalysis of hydrogen peroxide reduction. This finding suggests that hydroperoxide cleavage occurs upon direct binding of a peroxide oxygen atom to the ferrous heme iron. Competitive inhibition of the alkylhydroperoxide reductase activity by carbon monoxide has also been observed, thus confirming that heme iron is directly involved in the catalytic mechanism of hydroperoxide reduction. The alkylhydroperoxide reductase activity taken together with the unique lipid binding properties of HMP suggests that this protein is most likely involved in the repair of the lipid membrane oxidative damage generated during oxidative/nitrosative stress.	Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Chem, I-00185 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Sapienza University Rome; Sapienza University Rome	Boffi, A (corresponding author), Univ Roma La Sapienza, CNR, Ist Biol & Patol Mol, I-00185 Rome, Italy.	alberto.boffi@uniroma1.it	Ilari, Andrea/AAC-7670-2022; Ilari, Andrea/T-5501-2017; Patrizia, Gentili/I-4709-2012; Bonamore, Alessandra/AAB-2587-2019	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Bonamore, Alessandra/0000-0002-3940-4657; GENTILI, Patrizia/0000-0001-7410-7538				Anjum MF, 1998, FEMS MICROBIOL LETT, V166, P219, DOI 10.1111/j.1574-6968.1998.tb13893.x; Baier M, 1999, TRENDS PLANT SCI, V4, P166, DOI 10.1016/S1360-1385(99)01398-9; Bollinger CJT, 2001, BIOTECHNOL PROGR, V17, P798, DOI 10.1021/bp010091j; Bonamore A, 2001, BBA-PROTEIN STRUCT M, V1549, P174, DOI 10.1016/S0167-4838(01)00256-4; BONAMORE A, 2003, IN PRESS BIOCHEMISTR; Bryk R, 2000, NATURE, V407, P211, DOI 10.1038/35025109; Cruz-Ramos H, 2002, EMBO J, V21, P3235, DOI 10.1093/emboj/cdf339; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Gaber A, 2001, FEBS LETT, V499, P32, DOI 10.1016/S0014-5793(01)02517-0; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Hausladen A, 2001, P NATL ACAD SCI USA, V98, P10108, DOI 10.1073/pnas.181199698; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hillas PJ, 2000, J BIOL CHEM, V275, P18801, DOI 10.1074/jbc.M001001200; Hogg N, 1999, BBA-BIOENERGETICS, V1411, P378, DOI 10.1016/S0005-2728(99)00027-4; Ilari A, 2002, J BIOL CHEM, V277, P23725, DOI 10.1074/jbc.M202228200; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Mukai M, 2001, J BIOL CHEM, V276, P7272, DOI 10.1074/jbc.M009280200; NIIMURA Y, 1995, J BIOL CHEM, V270, P25645, DOI 10.1074/jbc.270.43.25645; Nishiyama Y, 2001, J BACTERIOL, V183, P2431, DOI 10.1128/JB.183.8.2431-2438.2001; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Pathania R, 2002, J BIOL CHEM, V277, P15293, DOI 10.1074/jbc.M111478200; Pomposiello PJ, 2001, TRENDS BIOTECHNOL, V19, P109, DOI 10.1016/S0167-7799(00)01542-0; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; Ramandeep, 2001, J BIOL CHEM, V276, P24781, DOI 10.1074/jbc.M009808200; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; Wittenberg JB, 2002, J BIOL CHEM, V277, P871, DOI 10.1074/jbc.R100058200; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	31	41	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22272	22277		10.1074/jbc.M301285200	http://dx.doi.org/10.1074/jbc.M301285200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12663656	hybrid, Green Published			2022-12-27	WOS:000183503900014
J	Higashi, Y; Itabe, H; Fukase, H; Mori, M; Fujimoto, Y; Takano, T				Higashi, Y; Itabe, H; Fukase, H; Mori, M; Fujimoto, Y; Takano, T			Transmembrane lipid transfer is crucial for providing neutral lipids during very low density lipoprotein assembly in endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIGLYCERIDE TRANSFER PROTEIN; UBIQUITIN-PROTEASOME PATHWAY; PLASMA-MEMBRANE CHOLESTEROL; APOLIPOPROTEIN-B SECRETION; HEPG2 CELLS; INTRACELLULAR DEGRADATION; APO-B; MULTIDRUG-RESISTANCE; P-GLYCOPROTEIN; FATTY-ACIDS	Very low density lipoprotein ( VLDL), a large particle containing apolipoprotein B ( apoB) and large amounts of neutral lipids, is formed in the luminal space within the endoplasmic reticulum ( ER) of hepatic cells. The assembly mechanism of VLDL particles is a tightly regulated process where apoB, associated with an insufficient amount of lipids, is selectively degraded intracellularly. In this study we found that treatment of HuH- 7 human hepatoma cells with verapamil inhibited secretion of apoB- containing lipoprotein particles through increasing degradation of apoB. Addition of N- acetyl-leucyl-leucyl- norleucinal, an inhibitor of proteasome and other cysteinyl proteases that are responsible for apoB degradation, restored apoB recovery from verapamil-treated cells. De novo synthesis of lipids from [ C-14] acetate was increased in the presence of verapamil, suggesting that verapamil decreases lipid availability for apoB thus leading to the secretion of apoB- containing lipoprotein. We prepared cytosolic fractions from cells preincubated with [C-14] acetate and used as a donor of radioactive lipids. When this cytosolic fraction was incubated with microsomes isolated separately, radioactive triglyceride ( TG) accumulated in the luminal space of the microsomes. The transfer of radioactive TG from the cytosolic fraction to the microsomal lumen was inhibited in the presence of verapamil, suggesting that there is a verapamil- sensitive mechanism for TG transfer across ER membranes that is involved in formation of apoB- containing lipoprotein particles in ER. Verapamil showed no inhibitory effect on microsomal TG transfer protein, a well known lipid transfer protein in ER. We propose from these results that there is novel machinery for transmembrane movement of neutral lipids, which is involved in providing TG for apoB during VLDL assembly in ER.	Teikyo Univ, Fac Pharmaceut Sci, Dept Mol Pathol, Kanagawa 1990195, Japan	Teikyo University	Takano, T (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Mol Pathol, 1094-1 Suarashi, Kanagawa 1990195, Japan.		板部板部, 洋之/ABC-7746-2020; Higashi, Yukihito/G-5343-2019					Adeli K, 1997, J BIOL CHEM, V272, P22489, DOI 10.1074/jbc.272.36.22489; Anderson RA, 1998, J BIOL CHEM, V273, P26747, DOI 10.1074/jbc.273.41.26747; Cavallo D, 1999, J BIOL CHEM, V274, P23135, DOI 10.1074/jbc.274.33.23135; CIANFLONE KM, 1990, J LIPID RES, V31, P2045; COLEMAN RA, 1983, ENZYMES, V16, P605; DAVIS RA, 1982, J BIOL CHEM, V257, P908; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FERRY DR, 1985, BRIT J PHARMACOL, V84, P811, DOI 10.1111/j.1476-5381.1985.tb17375.x; FIELD FJ, 1995, J LIPID RES, V36, P1533; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; FORD JM, 1990, PHARMACOL REV, V42, P155; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Graham A, 1996, BBA-LIPID LIPID MET, V1302, P46, DOI 10.1016/0005-2760(96)00030-6; Higashi Y, 2002, BBA-MOL CELL BIOL L, V1581, P127, DOI 10.1016/S1388-1981(02)00157-9; Itabe H, 2000, BBA-MOL CELL BIOL L, V1487, P233, DOI 10.1016/S1388-1981(00)00098-6; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; KWONG TC, 1989, BIOCHEM J, V263, P411, DOI 10.1042/bj2630411; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Liang JS, 2001, J BIOL CHEM, V276, P28606, DOI 10.1074/jbc.M100294200; Luker GD, 1999, J BIOL CHEM, V274, P6979, DOI 10.1074/jbc.274.11.6979; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; PLUMB JA, 1990, BIOCHEM PHARMACOL, V39, P787, DOI 10.1016/0006-2952(90)90160-M; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Sakashita N, 2000, AM J PATHOL, V156, P227, DOI 10.1016/S0002-9440(10)64723-2; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; SATO R, 1990, J BIOL CHEM, V265, P11880; SATO R, 1990, BIOCHIM BIOPHYS ACTA, V1042, P36, DOI 10.1016/0005-2760(90)90053-Z; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SUCKLING KE, 1985, J LIPID RES, V26, P647; TANAKA M, 1993, J BIOL CHEM, V268, P12713; THRIFT RN, 1986, J LIPID RES, V27, P236; WATTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; Wetterau JR, 1998, SCIENCE, V282, P751, DOI 10.1126/science.282.5389.751; Wilcox LJ, 1999, ARTERIOSCL THROM VAS, V19, P939, DOI 10.1161/01.ATV.19.4.939; Wilcox LJ, 1999, J LIPID RES, V40, P1078; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yang LY, 1996, J LIPID RES, V37, P262; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	41	36	38	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21450	21458		10.1074/jbc.M301376200	http://dx.doi.org/10.1074/jbc.M301376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670935	hybrid			2022-12-27	WOS:000183354200019
J	Fuentes, EJ; Karnoub, AE; Booden, MA; Der, CJ; Campbell, SL				Fuentes, EJ; Karnoub, AE; Booden, MA; Der, CJ; Campbell, SL			Critical role of the pleckstrin homology domain in Dbs signaling and growth regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; CYSTEINE-RICH DOMAINS; RHO-GTPASES; FAMILY PROTEINS; GUANOSINE TRIPHOSPHATASES; CRYSTAL-STRUCTURE; ONCOGENE PRODUCT; DISTINCT ROLES; PH DOMAINS; TRANSFORMATION	Dbl family proteins act as guanine nucleotide exchange factors and positive regulators of Rho GTPase function by stimulating formation of the active, GTP-bound state. All Dbl family Rho guanine nucleotide exchange factors possess an invariant tandem domain structure consisting of a Dbl homology (DH) catalytic domain followed by a pleckstrin homology (PH) regulatory domain. We determined previously that the PH domain of Dbs was critical for the intrinsic catalytic activity of the DH domain in vitro and for Dbs transformation in vivo. In this study, we evaluated the role of phosphoinositide binding to the PH domain in regulating the DH domain function of Dbs in vitro and in vivo. We determined that mutation of basic amino acids located within the beta(1)- beta(2) and beta(3)-beta(4) loops of the PH domain resulted in impaired phospholipid binding in vitro, yet full guanine nucleotide exchange activity in vitro was retained for RhoA and Cdc42. Surprisingly, these mutants were compromised in their ability to activate Rho GTPases in vivo and to cause transformation of NIH 3T3 cells. However, Dbs subcellular localization was impaired by these PH domain mutations, supporting a role for phospholipid interactions in facilitating membrane association. Despite the importance of phospholipid binding for Dbs function in vivo, we found that Dbs signaling and transforming activity was not stimulated by phosphatidylinositol 3-kinase activation. We suggest that the PH domain of Dbs facilitates two distinct roles in the regulation of DH domain function, one critical for GTPase association and activation in vitro and one critical for phosphoinositide binding and GTPase interaction in vivo, that together promote Dbs association with membranes.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		Fuentes, Ernesto/F-5129-2010	Fuentes, Ernesto/0000-0001-5812-8187; campbell, sharon/0000-0003-0311-409X; Der, Channing/0000-0002-7751-2747				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Baumeister MA, 2003, J BIOL CHEM, V278, P11457, DOI 10.1074/jbc.M211901200; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; Huth JR, 1997, PROTEIN SCI, V6, P2359; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Russo C, 2001, J BIOL CHEM, V276, P19524, DOI 10.1074/jbc.M009742200; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Wennerberg K, 2002, J BIOL CHEM, V277, P47810, DOI 10.1074/jbc.M203816200; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wherlock M, 2002, J CELL SCI, V115, P239; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; WHITEHEAD IP, 1996, J BIOL CHEM, V271, P18388; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	46	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21188	21196		10.1074/jbc.M211792200	http://dx.doi.org/10.1074/jbc.M211792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637530	hybrid			2022-12-27	WOS:000183230500096
J	Leimkuhler, S; Hodson, R; George, GN; Rajagopalan, KV				Leimkuhler, S; Hodson, R; George, GN; Rajagopalan, KV			Recombinant Rhodobacter capsulatus xanthine dehydrogenase, a useful model system for the characterization of protein variants leading to xanthinuria I in humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-NIDULANS; MOLYBDENUM COFACTOR; CRYSTAL-STRUCTURES; NITRATE REDUCTASE; ESCHERICHIA-COLI; OXIDASE; GENE; MECHANISM; FORMS; IDENTIFICATION	Rhodobacter capsulatus xanthine dehydrogenase (XDH) forms an (alphabeta)(2) heterotetramer and is highly homologous to homodimeric eukaryotic XDHs. The crystal structures of bovine XDH and R. capsulatus XDH showed that the two proteins have highly similar folds. We have developed an efficient system for the recombinant expression of R. capsulatus XDH in Escherichia coli. The recombinant protein shows spectral features and a range of substrate specificities similar to bovine milk xanthine oxidase. However, R. capsulatus XDH is at least 5 times more active than bovine XDH and, unlike mammalian XDH, does not undergo the conversion to the oxidase form. EPR spectra were obtained for the FeS centers of the enzyme showing an axial signal for FeSI, which is different from that reported for xanthine oxidase. X-ray absorption spectroscopy at the iron and molybdenum K-edge and the tungsten L-III-edge have been used to probe the different metal coordinations of variant forms of the enzyme. Based on a mutation identified in a patient suffering from xanthinuria I, the corresponding arginine 135 was substituted to a cysteine in R. capsulatus XDH, and the protein variant was purified and characterized. Two different forms of XDH-R135C were purified, an active (alphabeta)(2) heterotetrameric form and an inactive (alphabeta) heterodimeric form. The active form contains a full complement of redox centers, whereas in the inactive form the FeSI center is likely to be missing.	Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Braunschweig University of Technology; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Duke University	Leimkuhler, S (corresponding author), Tech Univ Braunschweig, Dept Plant Biol, D-38023 Braunschweig, Germany.	S.Leimkuehler@tu-bs.de	George, Graham N/E-3290-2013	Leimkuhler, Silke/0000-0003-3238-2122; George, Graham/0000-0002-0420-7493	NIGMS NIH HHS [GM 44283] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams B, 2002, BIOCHEM J, V362, P223, DOI 10.1042/0264-6021:3620223; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Amrani L, 2000, MOL MICROBIOL, V38, P114, DOI 10.1046/j.1365-2958.2000.02119.x; Amrani L, 1999, MOL MICROBIOL, V31, P1065, DOI 10.1046/j.1365-2958.1999.01242.x; Bittner F, 2001, J BIOL CHEM, V276, P40381, DOI 10.1074/jbc.C100472200; CRAMER SP, 1988, NUCL INSTRUM METH A, V266, P586, DOI 10.1016/0168-9002(88)90449-4; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; Doyle WA, 1996, BIOCHEM SOC T, V24, pS31, DOI 10.1042/bst024031s; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; FAEDER EJ, 1973, ANAL BIOCHEM, V53, P332, DOI 10.1016/0003-2697(73)90442-9; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; George GN, 1996, J AM CHEM SOC, V118, P1113, DOI 10.1021/ja953317l; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1985, J BIOL CHEM, V260, P569; Ichida K, 1997, J CLIN INVEST, V99, P2391, DOI 10.1172/JCI119421; Iwasaki T, 2000, J BIOCHEM, V127, P771, DOI 10.1093/oxfordjournals.jbchem.a022669; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Levartovsky D, 2000, KIDNEY INT, V57, P2215, DOI 10.1046/j.1523-1755.2000.00082.x; Nishino T, 2002, J BIOCHEM, V132, P597, DOI 10.1093/oxfordjournals.jbchem.a003262; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; Sakamoto N, 2001, HUM GENET, V108, P279, DOI 10.1007/s004390100477; Simmonds H.A., 1995, METABOLIC MOL BASES, P1781; STEWART V, 1982, J BACTERIOL, V151, P788, DOI 10.1128/JB.151.2.788-799.1982; STIRPE F, 1969, J BIOL CHEM, V244, P3855; Temple CA, 2000, ARCH BIOCHEM BIOPHYS, V383, P281, DOI 10.1006/abbi.2000.2089; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WAHL RC, 1982, J BIOL CHEM, V257, P1354; WAUD WR, 1975, ARCH BIOCHEM BIOPHYS, V169, P695, DOI 10.1016/0003-9861(75)90214-3; [No title captured]	33	51	51	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20802	20811		10.1074/jbc.M303091200	http://dx.doi.org/10.1074/jbc.M303091200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670960	hybrid			2022-12-27	WOS:000183230500048
J	Blackshear, PJ; Lai, WS; Kennington, EA; Brewer, G; Wilson, GM; Guan, XJ; Zhou, P				Blackshear, PJ; Lai, WS; Kennington, EA; Brewer, G; Wilson, GM; Guan, XJ; Zhou, P			Characteristics of the interaction of a synthetic human tristetraprolin tandem zinc finger peptide with AU-rich element-containing RNA substrates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; DEFICIENCY SYNDROME; PROTEINS; ALPHA; BINDING; DESTABILIZATION; DEADENYLATION; ASSOCIATION; RESONANCES; UBIQUITIN	Tristetraprolin (TTP) and its two known mammalian family members are tandem CCCH zinc finger proteins that can bind to AU-rich elements (AREs) in cellular mRNAs and destabilize those transcripts, apparently by initiating their deadenylation. Previous studies have shown that the similar to70-amino acid tandem zinc finger domain of TTP is required and sufficient for RNA binding, and that the integrity of both zinc fingers is also required. However, little is known about the kinetics or structure of the peptide-RNA interaction, in part because of difficulties in obtaining soluble recombinant protein or peptides. We characterized the binding of a synthetic 73-amino acid peptide from human TTP to the tumor necrosis factor (TNF) ARE by gel mobility shift analyses and fluorescence anisotropy experiments. Both types of studies yielded a peptide-RNA dissociation constant of similar to10 nM. Surprisingly, we found that the "footprint" from the TNF ARE required for peptide binding was only similar to9 bases and that two molecules of peptide could bind to probes containing as little as 19 bases. An identical recombinant peptide exhibited gel shift characteristics similar to those of the synthetic peptide. NMR analysis of the N-15-labeled recombinant peptide suggested that its first zinc finger was structured in solution but that the second was not. The titration of oligonucleotides representing 17, 13, and even 9 bases of the TNF ARE caused an essentially identical, dramatic shift of existing resonances, and the appearance of new resonances in the peptide spectra, so that all amino acids could be assigned. These data suggest that this TTP peptide-RNA complex is structured in solution and might be amenable to NMR structure determination.	NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Off Clin Res, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Microbiol Mol Genet & Immunol, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Blackshear, PJ (corresponding author), NIEHS, Lab Signal Transduct, NIH, Dept Hlth & Human Serv, A2-05,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019; Wilson, Gerald/AAF-3874-2019; Zhou, Pei/O-6704-2019	Blackshear, Perry J./0000-0002-9561-8529; Zhou, Pei/0000-0002-7823-3416; Wilson, Gerald/0000-0002-1273-7507	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080, Z01ES090080] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Bakheet T, 2001, NUCLEIC ACIDS RES, V29, P246, DOI 10.1093/nar/29.1.246; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Blackshear PJ, 2002, BIOCHEM SOC T, V30, P945, DOI 10.1042/BST0300945; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; De J, 1999, GENE, V228, P133, DOI 10.1016/S0378-1119(98)00617-9; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Kronnie GT, 1999, DEV GENES EVOL, V209, P443, DOI 10.1007/s004270050276; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; RAMAGE R, 1989, TETRAHEDRON LETT, V30, P2149, DOI 10.1016/S0040-4039(01)93735-9; RAMAGE R, 1994, BIOCHEM J, V299, P151, DOI 10.1042/bj2990151; Stevens CJM, 1998, INT J DEV BIOL, V42, P181; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; WITTEKIND M, 1993, J MAGN RESON SER B, V101, P201, DOI 10.1006/jmrb.1993.1033; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754	26	98	99	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19947	19955		10.1074/jbc.M301290200	http://dx.doi.org/10.1074/jbc.M301290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639954	hybrid			2022-12-27	WOS:000183078000050
J	Ferri, N; Garton, KJ; Raines, EW				Ferri, N; Garton, KJ; Raines, EW			An NF-kappa B-dependent transcriptional program is required for collagen remodeling by human smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MATRIX; ACTIVATION; ALPHA; FIBROBLASTS; PROLIFERATION; CONTRACTION; INDUCTION; PATHWAYS; INTEGRIN	Although remodeling of vessels can dramatically alter lumen diameter and clinical sequelae, the molecular mechanisms regulating extracellular matrix turnover and remodeling are still not well understood. To investigate these processes in human smooth muscle, we have compared their culture on monomer and polymerized collagen gels, conditions that mimic some of the features of injured and normal vessels, respectively. We show that culture on polymerized, but not monomer, collagen leads to the activation of the transcription factor NF-kappaB through phosphorylation and degradation of its inhibitor, IkappaBalpha. Coincident with NF-kappaB activation, expression of MMP1, MMP2, and alpha(2) integrin increases on polymerized collagen. Specific inhibition of NF-kappaB by retroviral overexpression of wild-type IkappaBalpha or phosphorylation-resistant, IkappaBalpha-stabilized mutant (IkappaBalpha(Ser32,36/Ala)) reverses the increases in MMP1 and alpha(2)beta(1) on polymerized collagen and decreases collagen gel contraction and degradation. However, forced overexpression of alpha(2)beta(1) integrin or MMP1 in smooth muscle cells expressing IkappaBalpha(Ser32,36/Ala) rescues their ability to contract collagen gels. Thus, polymerized collagen induces NF-kappaB-dependent expression of MMP1 and alpha(2)beta(1) integrin, that are required for smooth muscle extracellular matrix remodeling.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA	Harborview Medical Center; University of Washington; University of Washington Seattle	Raines, EW (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, 325 9th Ave,Box 359675, Seattle, WA 98104 USA.	ewraines@u.washington.edu	Ferri, Nicola/F-4879-2013; ferri, nicola/K-7085-2019	Ferri, Nicola/0000-0001-8898-7441; ferri, nicola/0000-0001-8898-7441	NHLBI NIH HHS [HL18645] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arora PD, 1999, AM J PATHOL, V154, P871, DOI 10.1016/S0002-9440(10)65334-5; Bond M, 1999, BIOCHEM BIOPH RES CO, V264, P561, DOI 10.1006/bbrc.1999.1551; Bond M, 2001, CARDIOVASC RES, V50, P556, DOI 10.1016/S0008-6363(01)00220-6; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Bourcier T, 1997, J BIOL CHEM, V272, P15817, DOI 10.1074/jbc.272.25.15817; Brand K, 1996, J CLIN INVEST, V97, P1715, DOI 10.1172/JCI118598; Breuss JM, 2002, CIRCULATION, V105, P633, DOI 10.1161/hc0502.102966; Cooke ME, 2000, J CELL SCI, V113, P2375; Deryugina EI, 1998, CANCER RES, V58, P3743; Dumin JA, 2001, J BIOL CHEM, V276, P29368, DOI 10.1074/jbc.M104179200; Faxon DP, 1997, PROG CARDIOVASC DIS, V40, P129, DOI 10.1016/S0033-0620(97)80005-9; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Gotwals PJ, 1996, J CLIN INVEST, V97, P2469, DOI 10.1172/JCI118693; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LAWRENCE R, 1994, J BIOL CHEM, V269, P28913; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Lindner V, 1998, PATHOBIOLOGY, V66, P311, DOI 10.1159/000028039; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; Rectenwald JE, 2000, CIRCULATION, V102, P1697, DOI 10.1161/01.CIR.102.14.1697; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Scherberich A, 1998, ARTERIOSCL THROM VAS, V18, P1691, DOI 10.1161/01.ATV.18.11.1691; SCHIRO JA, 1991, CELL, V67, P403, DOI 10.1016/0092-8674(91)90191-Z; Viedt C, 2002, ARTERIOSCL THROM VAS, V22, P914, DOI 10.1161/01.ATV.0000019009.73586.7F; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Wilson SH, 2002, ATHEROSCLEROSIS, V160, P147, DOI 10.1016/S0021-9150(01)00546-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Xu J, 2001, BIOCHEM J, V355, P437, DOI 10.1042/0264-6021:3550437; Xu JH, 1998, J CELL BIOL, V140, P709, DOI 10.1083/jcb.140.3.709	37	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19757	19764		10.1074/jbc.M212714200	http://dx.doi.org/10.1074/jbc.M212714200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649281	hybrid			2022-12-27	WOS:000183078000026
J	Enguita, FJ; Martins, LO; Henriques, AO; Carrondo, MA				Enguita, FJ; Martins, LO; Henriques, AO; Carrondo, MA			Crystal structure of a bacterial endospore coat component - A laccase with enhanced thermostability properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; SPORE-COAT; ASCORBATE OXIDASE; PROTEIN; PEROXIDE; SURFACE; GENES; BIOSYNTHESIS; RECOGNITION; OXIDATION	Endospores produced by the Gram-positive soil bacterium Bacillus subtilis are shielded by a proteinaceous coat formed by over 30 structural components, which self-assemble into a lamellar inner coat and a thicker striated electrodense outer coat. The 65-kDa CotA protein is an abundant component of the outer coat layer. CotA is a highly thermostable laccase, assembly of which into the coat is required for spore resistance against hydrogen peroxide and UV light. Here, we report the structure of CotA at 1.7-Angstrom resolution, as determined by x-ray crystallography. This is the first structure of an endospore coat component, and also the first structure of a bacterial laccase. The overall fold of CotA comprises three cupredoxin-like domains and includes one mononuclear and one trinuclear copper center. This arrangement is similar to that of other multicopper oxidases and most similar to that of the copper tolerance protein CueO of Escherichia coli. However, the three cupredoxin domains in CotA are further linked by external interdomain loops, which increase the packing level of the structure. We propose that these interdomain loops contribute to the remarkable thermostability of the enzyme, but our results suggest that additional factors are likely to play a role. Comparisons with the structure of other monomeric multicopper oxidases containing four copper atoms suggest that CotA may accept the largest substrates of any known laccase. Moreover, and unlike other laccases, CotA appears to have a flexible lidlike region close to the substrate-binding site that may mediate substrate accessibility. The implications of these findings for the properties of CotA, its assembly and the properties of the bacterial spore coat structure are discussed.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, Prot Crystallog Lab, P-2781901 Oeiras, Portugal; Univ Lusofona Humanidades & Tecnol, Dept Engn & Tecnol, P-1749024 Lisbon, Portugal	Universidade Nova de Lisboa; Lusofona University	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Prot Crystallog Lab, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Enguita, Francisco J./A-2347-2009; Martins, Lígia O./C-2513-2009	Enguita, Francisco J./0000-0002-8072-8557; Martins, Lígia O./0000-0003-0082-9591; Henriques, Adriano/0000-0003-4292-4802; Carrondo, Maria Armenia/0000-0002-1261-1162				Alexandre G, 2000, TRENDS BIOTECHNOL, V18, P41, DOI 10.1016/S0167-7799(99)01406-7; Alexandre G, 1999, FEMS MICROBIOL LETT, V174, P371, DOI 10.1111/j.1574-6968.1999.tb13592.x; Bertrand T, 2002, BIOCHEMISTRY-US, V41, P7325, DOI 10.1021/bi0201318; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; Brossier F, 2002, INFECT IMMUN, V70, P661; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DeDecker BS, 1996, J MOL BIOL, V264, P1072, DOI 10.1006/jmbi.1996.0697; DeLano W, 2002, PYMOL 0 99; deMarco A, 1997, PHYTOCHEMISTRY, V46, P421, DOI 10.1016/S0031-9422(97)00301-4; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; Driks A, 1999, MICROBIOL MOL BIOL R, V63, P1; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Edens WA, 1999, APPL ENVIRON MICROB, V65, P3071; EGGERT C, 1995, FEBS LETT, V376, P202, DOI 10.1016/0014-5793(95)01274-9; Enguita FJ, 2002, ACTA CRYSTALLOGR D, V58, P1490, DOI 10.1107/S0907444902011575; Fleming PJ, 2000, J MOL BIOL, V299, P487, DOI 10.1006/jmbi.2000.3750; Francis CA, 2001, APPL ENVIRON MICROB, V67, P4272, DOI 10.1128/AEM.67.9.4272-4278.2001; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Grass G, 2001, BIOCHEM BIOPH RES CO, V286, P902, DOI 10.1006/bbrc.2001.5474; Gray HB, 2000, J BIOL INORG CHEM, V5, P551, DOI 10.1007/s007750000146; Hakulinen N, 2002, NAT STRUCT BIOL, V9, P601, DOI 10.1038/nsb823; Henriques AO, 2000, METHODS, V20, P95, DOI 10.1006/meth.1999.0909; Henriques AO, 1998, J BACTERIOL, V180, P2285, DOI 10.1128/JB.180.9.2285-2291.1998; HENRIQUES AO, 1995, J BACTERIOL, V177, P3394, DOI 10.1128/jb.177.12.3394-3406.1995; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Huang HW, 1999, J BIOL CHEM, V274, P32718, DOI 10.1074/jbc.274.46.32718; Hullo MF, 2001, J BACTERIOL, V183, P5426, DOI 10.1128/JB.183.18.5426-5430.2001; Ichikawa H, 2000, J BIOL CHEM, V275, P13849, DOI 10.1074/jbc.275.18.13849; Isticato R, 2001, J BACTERIOL, V183, P6294, DOI 10.1128/JB.183.21.6294-6301.2001; Kim C, 2001, J BACTERIOL, V183, P4866, DOI 10.1128/JB.183.16.4866-4875.2001; Kroos L, 2000, CURR OPIN MICROBIOL, V3, P553, DOI 10.1016/S1369-5274(00)00140-5; Kumar S, 2001, CELL MOL LIFE SCI, V58, P1216, DOI 10.1007/PL00000935; Kumar S, 2000, PROTEIN ENG, V13, P179, DOI 10.1093/protein/13.3.179; Lai EM, 2003, J BACTERIOL, V185, P1443, DOI 10.1128/JB.185.4.1443-1454.2003; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE NL, 1954, J BACTERIOL, V68, P334, DOI 10.1128/JB.68.3.334-337.1954; Liang J, 1998, PROTEIN SCI, V7, P1884, DOI 10.1002/pro.5560070905; Lindley PF, 2001, HANDBOOK ON METALLOPROTEINS, P763; Little S, 2001, MOL MICROBIOL, V42, P1107, DOI 10.1046/j.1365-2958.2001.02708.x; Martins LO, 2002, J BIOL CHEM, V277, P18849, DOI 10.1074/jbc.M200827200; McGuirl MA, 1999, CURR OPIN CHEM BIOL, V3, P138, DOI 10.1016/S1367-5931(99)80025-8; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MESSERSCHMIDT A, 1993, J MOL BIOL, V230, P997, DOI 10.1006/jmbi.1993.1215; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Murphy MEP, 1997, PROTEIN SCI, V6, P761; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NORRIS JR, 1964, J BACTERIOL, V88, P264, DOI 10.1128/JB.88.1.264-265.1964; Ozin AJ, 2000, J BACTERIOL, V182, P1828, DOI 10.1128/JB.182.7.1828-1833.2000; Ozin AJ, 2001, J BACTERIOL, V183, P3041, DOI 10.1128/JB.183.10.3041-3049.2001; Ozin AJ, 2001, J BACTERIOL, V183, P2032, DOI 10.1128/JB.183.6.2032-2040.2001; Palmer AE, 2001, J AM CHEM SOC, V123, P6591, DOI 10.1021/ja010365z; Pattabiraman N, 1995, J MOL RECOGNIT, V8, P334, DOI 10.1002/jmr.300080603; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Piontek K, 2002, J BIOL CHEM, V277, P37663, DOI 10.1074/jbc.M204571200; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; Riesenman PJ, 2000, APPL ENVIRON MICROB, V66, P620, DOI 10.1128/AEM.66.2.620-626.2000; Roberts SA, 2002, P NATL ACAD SCI USA, V99, P2766, DOI 10.1073/pnas.052710499; ROGOLSKY M, 1968, J BACTERIOL, V95, P2426, DOI 10.1128/JB.95.6.2426-2427.1968; SACCO M, 1995, J BACTERIOL, V177, P372, DOI 10.1128/jb.177.2.372-377.1995; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SanchezAmat A, 1997, BIOCHEM BIOPH RES CO, V240, P787, DOI 10.1006/bbrc.1997.7748; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Seyler RW, 1997, MOL MICROBIOL, V25, P955, DOI 10.1111/j.1365-2958.1997.mmi532.x; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Williamson PR, 1998, J BACTERIOL, V180, P1570, DOI 10.1128/JB.180.6.1570-1572.1998; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZHENG LB, 1988, GENE DEV, V2, P1047, DOI 10.1101/gad.2.8.1047	72	269	295	2	80	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19416	19425		10.1074/jbc.M301251200	http://dx.doi.org/10.1074/jbc.M301251200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637519	hybrid			2022-12-27	WOS:000182932200090
J	Fehr, M; Lalonde, S; Lager, I; Wolff, MW; Frommer, WB				Fehr, M; Lalonde, S; Lager, I; Wolff, MW; Frommer, WB			In vivo imaging of the dynamics of glucose uptake in the cytosol of COS-7 cells by fluorescent nanosensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALTOSE-BINDING PROTEIN; SUGAR-TRANSPORT; ESCHERICHIA-COLI; GLUCOKINASE; GLUT1; SPECIFICITY; MEMBRANE; CARRIER; BLOOD	Glucose homeostasis is a function of glucose supply, transport across the plasma membrane, and metabolism. To monitor glucose dynamics in individual cells, a glucose nanosensor was developed by flanking the Escherichia coli periplasmic glucose/galactose-binding protein with two different green fluorescent protein variants. Upon binding of substrate the FLIPglu-170n sensor showed a concentration-dependent decrease in fluorescence resonance energy transfer between the attached chromophores with a binding affinity for glucose of 170 nM. Fluorescence resonance energy transfer measurements with different sugars indicated a broad selectivity for monosaccharides. An affinity mutant with a K-d of similar to600 muM was generated, which showed higher substrate specificity, and thus allowed specific monitoring of reversible glucose dynamics in COS-7 cells in the physiological range. At external glucose concentrations between 0.5 and 10 mM, reflecting typical blood levels, free cytosolic glucose concentrations remained at similar to50% of external levels. The removal of glucose lead to reduced glucose levels in the cell, demonstrating reversibility and visualizing homeostasis. Glucose levels dropped even in the presence of the transport inhibitor cytochalasin B, indicating rapid metabolism. Consistently, the addition of 2-deoxyglucose, which is not recognized by the sensor, affects glucose uptake and metabolism rates. Within the physiological range, glucose utilization, i.e. hexokinase activity, was not limiting. Furthermore, the results show that in COS-7 cells, cytosolic glucose concentrations can vary over at least two orders of magnitude. The glucose nanosensor provides a novel tool with numerous scientific, medical, and environmental applications.	Zentrum Mol Biol Pflanzen Tubingen, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Frommer, WB (corresponding author), Carnegie Inst, 260 Panama St, Stanford, CA 94305 USA.	frommer@andrew2.stanford.edu	Frommer, Wolf B/A-8256-2008; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Wolff, Michael/0000-0001-7443-3122				BASKETTER DA, 1978, J PHYSIOL-LONDON, V278, P389, DOI 10.1113/jphysiol.1978.sp012311; Borisjuk L, 1998, PLANT J, V15, P583, DOI 10.1046/j.1365-313X.1998.00214.x; Burcelin R, 2000, DIABETES, V49, P1643, DOI 10.2337/diabetes.49.10.1643; Burdakov D, 2002, J PHYSIOL-LONDON, V544, P334, DOI 10.1113/jphysiol.2002.029090; CARRUTHERS A, 1991, BIOCHEMISTRY-US, V30, P3907, DOI 10.1021/bi00230a015; Cesar MD, 2002, ARCH BIOCHEM BIOPHYS, V397, P106, DOI 10.1006/abbi.2001.2639; Cloherty EK, 1996, BIOCHEMISTRY-US, V35, P13231, DOI 10.1021/bi961208t; Cloherty EK, 2001, BIOCHEMISTRY-US, V40, P15549, DOI 10.1021/bi015586w; De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860; DONOVAN CM, 1994, P NATL ACAD SCI USA, V91, P2863, DOI 10.1073/pnas.91.7.2863; EFRAT S, 1994, TRENDS BIOCHEM SCI, V19, P535, DOI 10.1016/0968-0004(94)90056-6; EHRLICH KC, 1978, IN VITRO CELL DEV B, V14, P443, DOI 10.1007/BF02616106; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Fehr M, 2002, P NATL ACAD SCI USA, V99, P9846, DOI 10.1073/pnas.142089199; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fukami-Kobayashi K, 1999, J MOL BIOL, V286, P279, DOI 10.1006/jmbi.1998.2454; GILARDI G, 1994, ANAL CHEM, V66, P3840, DOI 10.1021/ac00093a047; GRUETTER R, 1992, P NATL ACAD SCI USA, V89, P1109, DOI 10.1073/pnas.89.3.1109; Guillemain G, 2000, J CELL SCI, V113, P841; Hall JA, 1997, J BIOL CHEM, V272, P17615, DOI 10.1074/jbc.272.28.17615; Harpur AG, 2001, NAT BIOTECHNOL, V19, P167, DOI 10.1038/84443; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Heim R, 1999, METHOD ENZYMOL, V302, P408, DOI 10.1016/S0076-6879(99)02036-4; KLETZIEN RF, 1973, J BIOL CHEM, V252, P2226; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; LUNDANDERSEN H, 1979, PHYSIOL REV, V59, P305, DOI 10.1152/physrev.1979.59.2.305; Mayordomo I, 2001, YEAST, V18, P923, DOI 10.1002/yea.737; Mayordomo I, 2001, YEAST, V18, P1309, DOI 10.1002/yea.780; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Murata T, 1997, FEBS LETT, V406, P109, DOI 10.1016/S0014-5793(97)00253-6; Oh-hashi K, 2003, J BIOL CHEM, V278, P10531, DOI 10.1074/jbc.M212083200; Pascual JM, 2002, ANN NEUROL, V52, P458, DOI 10.1002/ana.10311; POST RL, 1961, J BIOL CHEM, V236, P269; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; PURICH DL, 1971, J BIOL CHEM, V246, P3456; QUIOCHO FA, 1980, J BIOL CHEM, V255, P6559; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; SCHURMANN A, 1992, BIOCHIM BIOPHYS ACTA, V1131, P245, DOI 10.1016/0167-4781(92)90022-R; Sultzman LA, 1999, BIOCHEMISTRY-US, V38, P6640, DOI 10.1021/bi990130o; Thorens B, 2001, MOL MEMBR BIOL, V18, P265, DOI 10.1080/09687680110100995; Vayro S, 1998, BIOCHEM J, V332, P119, DOI 10.1042/bj3320119; VYAS MN, 1994, BIOCHEMISTRY-US, V33, P4762, DOI 10.1021/bi00182a003; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; Yu R, 2000, J BIOL CHEM, V275, P23648, DOI 10.1074/jbc.M002684200; ZUKIN RS, 1977, P NATL ACAD SCI USA, V74, P1932, DOI 10.1073/pnas.74.5.1932	45	224	242	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19127	19133		10.1074/jbc.M301333200	http://dx.doi.org/10.1074/jbc.M301333200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649277	hybrid			2022-12-27	WOS:000182932200054
J	Ogawa, M; Limsirichaikul, S; Niimi, A; Iwai, S; Yoshida, S; Suzuki, M				Ogawa, M; Limsirichaikul, S; Niimi, A; Iwai, S; Yoshida, S; Suzuki, M			Distinct function of conserved amino acids in the fingers of Saccharomyces cerevisiae DNA polymerase alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ACTIVE-SITE; O-HELIX; MUTATOR PHENOTYPE; DEOXYNUCLEOSIDE TRIPHOSPHATE; NUCLEOTIDE INCORPORATION; REVERSE-TRANSCRIPTASE; RANDOM MUTAGENESIS	Structural differences between class A and B DNA polymerases suggest that the motif B region, a wall of the catalytic pocket, may have evolved differentially in the two polymerase families. This study examines the function of the motif B residues in Saccharomyces cerevisiae DNA polymerase alpha (pol alpha). Effects of the mutations were determined by biochemical analysis and genetic complementation of a yeast strain carrying a temperature-sensitive pol alpha mutant. Many conserved residues were viable with a variety of substitutions. Among them, mutations at Asn-948 or Tyr-951 conferred up to 8-fold higher colony formation frequency in a URA3 forward mutation assay, and 79-fold higher trp1 reversion frequency was observed for Y951P in yeast. Purified Y951P was as accurate as wild type in DNA synthesis but similar to6-fold less processive and 22-fold less active in vitro. Therefore, Y951P may increase the frequency of mutant colony formation because of its low level of DNA polymerase activity in yeast. Mutations at Lys-944 or Gly-952 were not viable, which is consistent with the observation that mutants with substitutions at Gly-952 have strongly reduced catalytic activity in vitro. Gly-952 may provide a space for the nascent base pair and thus may play an essential function in S. cerevisiae DNA pol alpha. These results suggest that class B DNA polymerases have a unique structure in the catalytic pocket, which is distinct from the corresponding region in class A DNA polymerases.	Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan	Nagoya University; University of Tokyo	Suzuki, M (corresponding author), Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Bebenek A, 2001, J BIOL CHEM, V276, P10387, DOI 10.1074/jbc.M007707200; Bebenek K, 2001, J BIOL CHEM, V276, P2317, DOI 10.1074/jbc.C000690200; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; BUDD M, 1987, P NATL ACAD SCI USA, V84, P2838, DOI 10.1073/pnas.84.9.2838; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Canitrot Y, 1998, P NATL ACAD SCI USA, V95, P12586, DOI 10.1073/pnas.95.21.12586; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Clairmont CA, 1999, P NATL ACAD SCI USA, V96, P9580, DOI 10.1073/pnas.96.17.9580; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DONG Q, 1995, J BIOL CHEM, V270, P21563, DOI 10.1074/jbc.270.37.21563; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FALCONI MM, 1993, P NATL ACAD SCI USA, V90, P10519, DOI 10.1073/pnas.90.22.10519; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; GORDENIN DA, 1992, P NATL ACAD SCI USA, V89, P3785, DOI 10.1073/pnas.89.9.3785; Hopfner KP, 1999, P NATL ACAD SCI USA, V96, P3600, DOI 10.1073/pnas.96.7.3600; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kim B, 1996, J BIOL CHEM, V271, P4872, DOI 10.1074/jbc.271.9.4872; Kokoska RJ, 2000, MOL CELL BIOL, V20, P7490, DOI 10.1128/MCB.20.20.7490-7504.2000; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Limsirichaikul S, 2003, J BIOL CHEM, V278, P19079, DOI 10.1074/jbc.M208604200; Liu VF, 1999, MOL CELL BIOL, V19, P1126; Luria SE, 1943, GENETICS, V28, P491; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2001, NAT STRUCT BIOL, V8, P656, DOI 10.1038/90344; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; Pavlov YI, 2001, GENETICS, V159, P47; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Rodriguez AC, 2000, J MOL BIOL, V299, P447, DOI 10.1006/jmbi.2000.3728; Saturno J, 1997, J MOL BIOL, V269, P313, DOI 10.1006/jmbi.1997.1053; Shinkai A, 2001, J BIOL CHEM, V276, P46759, DOI 10.1074/jbc.M104780200; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Suzuki M, 1996, MOL DIVERS, V2, P111, DOI 10.1007/BF01718708; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Tosaka A, 2001, J BIOL CHEM, V276, P27562, DOI 10.1074/jbc.M010635200; TRAN HT, 1995, MOL CELL BIOL, V15, P5607; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w; Yoshida K, 2001, NUCLEIC ACIDS RES, V29, P4206, DOI 10.1093/nar/29.20.4206; YOSHIDA S, 1974, BIOCHIM BIOPHYS ACTA, V353, P463, DOI 10.1016/0005-2787(74)90052-5; Zhao YX, 1999, STRUCTURE, V7, P1189, DOI 10.1016/S0969-2126(00)80053-2	58	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19071	19078		10.1074/jbc.M208605200	http://dx.doi.org/10.1074/jbc.M208605200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637557	hybrid			2022-12-27	WOS:000182932200047
J	Wakula, P; Beullens, M; Ceulemans, H; Stalmans, W; Bollen, M				Wakula, P; Beullens, M; Ceulemans, H; Stalmans, W; Bollen, M			Degeneracy and function of the ubiquitous RVXF motif that mediates binding to protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-TARGETING SUBUNIT; CATALYTIC SUBUNIT; MYOSIN PHOSPHATASE; SKELETAL-MUSCLE; TYPE-1; KINASE; PHOSPHORYLATION; INHIBITOR-2; ASSOCIATION; PROTEIN-PHOSPHATASE-1	Most interactors of protein phosphatase-1 (PP1) contain a variant of a so-called " RVXF" sequence that binds to a hydrophobic groove of the catalytic subunit. A combination of sequence alignments and site-directed mutagenesis has enabled us to further define the consensus sequence for this degenerate motif as [RK]-X0-1-[VI]-{P}[ FW], where X denotes any residue and {P} any residue except Pro. Naturally occurring RVXF sequences differ in their affinity for PP1, and we show by swapping experiments that this binding affinity is an important determinant of the inhibitory potency of the regulators NIPP1 and inhibitor-1. Also, inhibition by NIPP1-(143 224) was retained when the RVXF motif ( plus the preceding Ser) was swapped for either of two unrelated PP1-binding sequences from human inhibitor-2, i.e. KGILK or RKLHY. Conversely, the KGILK motif of inhibitor-2 could be functionally replaced by the RVXF motif of NIPP1. Our data provide additional evidence for the view that the RVXF and KGILK motifs function as anchors for PP1 and thereby promote the interaction of secondary binding sites that determine the activity and substrate specificity of the enzyme.	Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	KU Leuven	Bollen, M (corresponding author), Katholieke Univ Leuven, Fac Geneeskunde, Afdeling Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.			Ceulemans, Hugo/0000-0002-7059-4399				Ayllon V, 2002, EUR J IMMUNOL, V32, P1847, DOI 10.1002/1521-4141(200207)32:7<1847::AID-IMMU1847>3.0.CO;2-7; Ayllon V, 2001, J IMMUNOL, V166, P7345, DOI 10.4049/jimmunol.166.12.7345; BEULLENS M, 1992, J BIOL CHEM, V267, P16538; Beullens M, 1999, J BIOL CHEM, V274, P14053, DOI 10.1074/jbc.274.20.14053; Beullens M, 2000, BIOCHEM J, V352, P651, DOI 10.1042/0264-6021:3520651; BOLLEN M, 1988, BIOCHEM J, V250, P659, DOI 10.1042/bj2500659; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BOLLEN M, 1988, BIOCHIM BIOPHYS ACTA, V969, P66, DOI 10.1016/0167-4889(88)90089-4; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; Ceulemans H, 2002, BIOESSAYS, V24, P371, DOI 10.1002/bies.10069; Ceulemans H, 2002, J BIOL CHEM, V277, P47331, DOI 10.1074/jbc.M206838200; Cohen PTW, 2002, J CELL SCI, V115, P241; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Endo S, 1996, BIOCHEMISTRY-US, V35, P5220, DOI 10.1021/bi952940f; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hayashi Y, 2001, J BIOL CHEM, V276, P39858, DOI 10.1074/jbc.M107302200; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P297, DOI 10.1111/j.1432-1033.1983.tb07362.x; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kreivi JP, 1997, FEBS LETT, V420, P57, DOI 10.1016/S0014-5793(97)01485-3; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Liu J, 2000, J BIOL CHEM, V275, P26074, DOI 10.1074/jbc.M003843200; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Muranyi A, 2002, BIOCHEM J, V366, P211, DOI 10.1042/BJ20020401; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PARK IK, 1994, J BIOL CHEM, V269, P944; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Steen RL, 2000, J CELL BIOL, V150, P1251, DOI 10.1083/jcb.150.6.1251; Toth A, 2000, EUR J BIOCHEM, V267, P1687, DOI 10.1046/j.1432-1327.2000.01158.x; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	42	144	149	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18817	18823		10.1074/jbc.M300175200	http://dx.doi.org/10.1074/jbc.M300175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12657641	hybrid			2022-12-27	WOS:000182932200016
J	Kim, JS; Kang, SO; Lee, JK				Kim, JS; Kang, SO; Lee, JK			The protein complex composed of nickel-binding SrnQ and DNA binding motif-bearing SrnR of Streptomyces griseus represses sodF transcription in the presence of nickel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTAINING SUPEROXIDE-DISMUTASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; COELICOLOR A3(2); GENE; IDENTIFICATION; EXPRESSION; REGULATOR; CLONING; OPERON	Nickel-responsive transcriptional repression of sodF, which codes for iron- and zinc-containing superoxide dismutase of Streptomyces griseus, was mediated through an operator (-2 to +15) spanning over the 5' end (+1) of the transcript. Two open reading frames, SrnR (12,343 Da) and SrnQ (12,486 Da), with overlapping stop-start codons were identified downstream from sodF and found responsible for the repression of sodF. The deduced amino acid sequence of SrnR revealed a DNA binding motif and showed homology to the transcriptional regulators of ArsR family, whereas SrnQ did not show any similarity to any known proteins. When srnRQ DNA was maintained in trans in S. griseus on a multicopy plasmid, sodF transcription was highly repressed by nickel, but neither srnR nor srnQ alone showed the effect. Consistently, the sodF transcription of srnR-interrupted mutant was no longer repressed by nickel, which was complemented only with srnRQ DNA. Nickel-dependent binding of SrnR and SrnQ to the sodF operator DNA was observed only when the two proteins were provided together. The maximum protein-DNA interaction was shown when SrnR and SrnQ were present in one-to-one stoichiometric ratio. The two proteins appear to constitute an octamer composed of four subunits of each protein. SrnR directly interacted with SrnQ, and the protein interaction did not require nickel. The conformation of SrnQ was changed upon nickel binding, which was in the ratio of one Ni2+ ion per protein molecule. A model is proposed in which SrnQ of the protein complex senses nickel and subsequently enhances the DNA binding activity of SrnR through the protein-protein interaction.	Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Seoul Natl Univ, Sch Biol Sci, Inst Microbiol, Seoul 151742, South Korea	Sogang University; Seoul National University (SNU)	Lee, JK (corresponding author), Sogang Univ, Dept Life Sci, Shinsu 1, Seoul 121742, South Korea.	jgklee@ccs.sogang.ac.kr	LEE, JIN-WON/L-1116-2016	LEE, JIN-WON/0000-0002-1201-8254				Ahmad S., 1995, OXIDATIVE STRESS ANT, P238, DOI DOI 10.1007/978-1-4615-9689-9_7; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BIERMAN M, 1992, GENE, V116, P43, DOI 10.1016/0378-1119(92)90627-2; Cannio R, 2000, FRONT BIOSCI-LANDMRK, V5, pD768, DOI 10.2741/cannio; Chivers PT, 1999, PROTEIN SCI, V8, P2494, DOI 10.1110/ps.8.11.2494; Chivers PT, 2000, J BIOL CHEM, V275, P19735, DOI 10.1074/jbc.M002232200; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; DEHOFF BS, 1988, J BACTERIOL, V170, P4681, DOI 10.1128/jb.170.10.4681-4692.1988; Dempsey BR, 2002, J MOL BIOL, V315, P831, DOI 10.1006/jmbi.2001.5279; DENIS F, 1992, GENE, V111, P115, DOI 10.1016/0378-1119(92)90611-R; ERASO JM, 1994, MICROBIOLOGY, V141, P1805; GREENER A, 1990, STRATEGIES, V5, P81; Hopwood DA, 1985, GENETIC MANIPULATION, P69; HORINOUCHI S, 1986, J BACTERIOL, V168, P257, DOI 10.1128/jb.168.1.257-269.1986; Imlay KRC, 1996, J BACTERIOL, V178, P2564, DOI 10.1128/jb.178.9.2564-2571.1996; INGRAM C, 1989, J BACTERIOL, V171, P6617, DOI 10.1128/jb.171.12.6617-6624.1989; Kawachi R, 2000, MOL MICROBIOL, V36, P302, DOI 10.1046/j.1365-2958.2000.01819.x; Kim EJ, 1998, MOL MICROBIOL, V27, P187, DOI 10.1046/j.1365-2958.1998.00674.x; Kim EJ, 1998, J BACTERIOL, V180, P2014, DOI 10.1128/JB.180.8.2014-2020.1998; Kim EJ, 1996, EUR J BIOCHEM, V241, P178, DOI 10.1111/j.1432-1033.1996.0178t.x; Kim JS, 2000, BBA-GENE STRUCT EXPR, V1493, P200, DOI 10.1016/S0167-4781(00)00178-0; Kinoshita H, 1997, J BACTERIOL, V179, P6986, DOI 10.1128/jb.179.22.6986-6993.1997; KONDOROSI E, 1991, J MOL BIOL, V222, P885, DOI 10.1016/0022-2836(91)90583-R; Lee CK, 1999, J BACTERIOL, V181, P3293, DOI 10.1128/JB.181.10.3293-3297.1999; Luo ZQ, 2000, J BIOL CHEM, V275, P7713, DOI 10.1074/jbc.275.11.7713; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCPHERSON MJ, 1991, DIRECTED MUTAGENESIS; NAVARRO C, 1993, MOL MICROBIOL, V9, P1181, DOI 10.1111/j.1365-2958.1993.tb01247.x; Oh SH, 1997, J BACTERIOL, V179, P122, DOI 10.1128/jb.179.1.122-127.1997; Ohnishi Y, 1999, MOL MICROBIOL, V34, P102, DOI 10.1046/j.1365-2958.1999.01579.x; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; RETZLAFF L, 1995, MOL MICROBIOL, V18, P151, DOI 10.1111/j.1365-2958.1995.mmi_18010151.x; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SEDLMEIER R, 1992, MOL GEN GENET, V236, P76, DOI 10.1007/BF00279645; STEINMAN HM, 1987, J BIOL CHEM, V262, P1882; STEINMAN HM, 1985, J BACTERIOL, V162, P1255, DOI 10.1128/JB.162.3.1255-1260.1985; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; WILLIAMS SG, 1993, MOL MICROBIOL, V9, P751, DOI 10.1111/j.1365-2958.1993.tb01735.x; Youn HD, 1996, ARCH BIOCHEM BIOPHYS, V334, P341, DOI 10.1006/abbi.1996.0463	41	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18455	18463		10.1074/jbc.M211740200	http://dx.doi.org/10.1074/jbc.M211740200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644473	hybrid			2022-12-27	WOS:000182838300113
J	Liu, CY; Xu, ZH; Kaufman, RJ				Liu, CY; Xu, ZH; Kaufman, RJ			Structure and intermolecular interactions of the luminal dimerization domain of human IRE1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; TRANSLATIONAL CONTROL; SELECTIVE PROTEINS; BINDING; ER; SIGNALS; CELLS; BIP; DISSOCIATION	Accumulation of unfolded proteins in the lumen of the endoplasmic reticulum activates a signal transduction cascade that culminates in the transcriptional induction of genes encoding adaptive functions. One proximal sensor for this unfolded protein response is the protein kinase/endoribonuclease IRE1alpha. IRE1alpha is a type-I transmembrane glycoprotein for which the N-terminal luminal domain (NLD) senses the accumulation of unfolded proteins. Previously we demonstrated that the NLD forms a stable ligand-independent dimer linked by disulfide bridges. In this report we have identified the cysteine residues responsible for intermolecular disulfide bonding. However, this covalent interaction was not required for dimerization and/or signaling, suggesting that a cryptic dimer interface exists in the NLD that is independent of covalent disulfide interactions. Limited proteolysis of the NLD revealed characteristic fragments, all retaining the same N-terminal sequences as full-length NLD. Biochemical and functional studies using NLD truncation mutants indicated that the dimerization domain of the NLD is confined to the conserved motifs at the N-terminal regions where putative hydrophobic interactions exist. In addition, the peptide binding domain of the endoplasmic reticulum protein chaperone BiP interacted with the N-terminal region within the NLD. Our findings suggest that the NLD has at least two distinct types of interactions mediating dimerization and function in signaling, i.e. covalent interactions involving disulfide bond formation and hydrophobic interactions, with the hydrophobic interaction being the driving force for dimerization.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052173] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52173] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GAUT JR, 1993, J BIOL CHEM, V268, P7248; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	23	78	84	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17680	17687		10.1074/jbc.M300418200	http://dx.doi.org/10.1074/jbc.M300418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637535	hybrid			2022-12-27	WOS:000182838300014
J	Park, JM; Kunieda, T; Kubo, T				Park, JM; Kunieda, T; Kubo, T			The activity of Mblk-1, a mushroom body-selective transcription factor from the honeybee, is modulated by the Ras/MAPK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; APLYSIA SENSORY NEURONS; LONG-TERM FACILITATION; PHOSPHORYLATION SITES; APIS-MELLIFERA; SUBSTRATE RECOGNITION; SYNAPTIC PLASTICITY; TYROSINE KINASE; BODIES; GENE	We previously identified a gene, termed Mblk-1, that encodes a putative transcription factor with two DNA-binding motifs expressed preferentially in the mushroom body of the honeybee brain, and its preferred binding sequence, termed Mblk-1-binding element (MBE) (Takeuchi, H., Kage, E., Sawata, M., Kamikouchi, A., Ohashi, K., Ohara, M., Fujiyuki, T., Kunieda, T., Sekimizu, K., Natori, S., and Kubo, T. (2001) Insect Mol Biol 10, 487-494; Park, J.-M., Kunieda. T., Takeuchi, H., and Kubo, T. (2002) Biochem. Biophys. Res. Commun. 291, 23-28). In the present study, the effect of Mblk-1 on transcription of genes containing MBE in Drosophila Schneider's Line 2 cells was examined using a luciferase assay. Mblk-1 expression transactivated promoters containing MBEs similar to2-7-fold. Deletion experiments revealed that RHF2, the second DNA-binding domain of Mblk-1, was necessary for the transcriptional activity. Furthermore, mitogen-activated protein kinase (MAPK) phosphorylated Mblk-1 at Ser-444 in vitro, and the Mblk-1-induced transactivation was stimulated by phosphorylation of Ser-444 by the Ras/MAPK pathway in the luciferase assay. These results suggest that Mblk-1 is a transcription factor that might function in the mushroom body neuronal circuits downstream of the Ras/MAPK pathway in the honeybee brain.	Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Kubo, T (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan.	stkubo@mail.ecc.u-tokyo.ac.jp	Kunieda, Takekazu/G-4946-2014	Kunieda, Takekazu/0000-0002-6256-1335; Park, Jung-Min/0000-0001-9751-1592; Kubo, Takeo/0000-0002-5914-5269				Aozasa N, 2001, EUR J BIOCHEM, V268, P2506, DOI 10.1046/j.1432-1327.2001.02133.x; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BAEHRECKE EH, 1995, DEV BIOL, V171, P85, DOI 10.1006/dbio.1995.1262; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Berman DE, 1998, J NEUROSCI, V18, P10037; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; Blum S, 1999, J NEUROSCI, V19, P3535; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Crow T, 1998, J NEUROSCI, V18, P3480; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Heisenberg M, 1998, LEARN MEMORY, V5, P1; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; Kamikouchi A, 1998, BIOCHEM BIOPH RES CO, V242, P181, DOI 10.1006/bbrc.1997.7870; Kamikouchi A, 2000, J COMP NEUROL, V417, P501, DOI 10.1002/(SICI)1096-9861(20000221)417:4&lt;501::AID-CNE8&gt;3.0.CO;2-4; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; KUBOTA K, 1993, BIOCHEM J, V296, P497, DOI 10.1042/bj2960497; Kunieda T, 2003, FEBS LETT, V535, P61, DOI 10.1016/S0014-5793(02)03858-9; Lee CY, 2000, MOL CELL, V6, P433, DOI 10.1016/S1097-2765(00)00042-3; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Mantrova EY, 1998, GENE DEV, V12, P1166; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mobbs P.G., 1985, P299; MOBBS PG, 1984, J INSECT PHYSIOL, V30, P43, DOI 10.1016/0022-1910(84)90107-0; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; Muller U, 1997, J NEUROBIOL, V33, P33, DOI 10.1002/(SICI)1097-4695(199707)33:1<33::AID-NEU4>3.0.CO;2-E; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Park JM, 2002, BIOCHEM BIOPH RES CO, V291, P23, DOI 10.1006/bbrc.2002.6397; Rosenblum K, 2002, J NEUROSCI, V22, P5432; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHOLZ KP, 1988, SCIENCE, V240, P1664, DOI 10.1126/science.2837826; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Takeuchi H, 2002, FEBS LETT, V513, P230, DOI 10.1016/S0014-5793(02)02319-0; Takeuchi H, 2001, INSECT MOL BIOL, V10, P487, DOI 10.1046/j.0962-1075.2001.00288.x; VONFRISCH K, 1967, SCIENCE, V158, P1072; Walz R, 2000, NEUROBIOL LEARN MEM, V73, P11, DOI 10.1006/nlme.1999.3913; Winston, 1987, BIOL HONEYBEE; Wustenberg D, 1998, EUR J NEUROSCI, V10, P2742, DOI 10.1046/j.1460-9568.1998.t01-1-00319.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YANG MY, 1995, NEURON, V15, P45	54	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18689	18694		10.1074/jbc.M300486200	http://dx.doi.org/10.1074/jbc.M300486200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637500	hybrid			2022-12-27	WOS:000182838300142
J	Rachidi, W; Mange, A; Senator, A; Guiraud, P; Riondel, J; Benboubetra, M; Favier, A; Lehmann, S				Rachidi, W; Mange, A; Senator, A; Guiraud, P; Riondel, J; Benboubetra, M; Favier, A; Lehmann, S			Prion infection impairs copper binding of cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; WILD-TYPE; PROTEIN; MUTANT; TRANSPORT; BRAIN	The molecular mechanism of neurodegeneration in transmissible spongiform encephalopathies (TSEs) remains unclear. Using radioactive copper (Cu-64) at physiological concentration, we showed that prion infected cells display a marked reduction in copper binding. The level of full-length prion protein known to bind the metal ion was not modified in infected cells, but a fraction of this protein was not releasable from the membrane by phosphatidylinositol-specific phospholipase C. Our results suggest that prion infection modulates copper content at a cellular level and that modification of copper homeostasis plays a determinant role in the neuropathology of TSE.	CNRS, IGH, UPR 1142, F-34396 Montpellier 5, France; Fac Pharm, Lab Biol Stress Oxydant, F-38706 La Tronche, France; CNRS, UPR 1142, Inst Genet Humaine, F-34396 Montpellier, France; CNRS, CEA, Lab Les Acides Nucleiques, F-38000 Grenoble, France; Univ Setif, Fac Sci, Lab Appl Biochem, Setif 19000, Algeria	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; Centre National de la Recherche Scientifique (CNRS); Universite Ferhat Abbas Setif	Lehmann, S (corresponding author), CNRS, IGH, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.	Sylvain.Lehmann@igh.cnrs.fr	Mange, Alain/U-1157-2017; Rachidi, Walid/U-6423-2019; Lehmann, Sylvain/P-1301-2017; Rachidi, Walid/H-1016-2018	Mange, Alain/0000-0002-1566-9407; Lehmann, Sylvain/0000-0001-6117-562X; Rachidi, Walid/0000-0002-0829-7799; Abderrahmane, Senator/0000-0002-3472-0538				Beranger F, 2002, J BIOL CHEM, V277, P38972, DOI 10.1074/jbc.M205110200; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 2001, TRENDS NEUROSCI, V24, P85, DOI 10.1016/S0166-2236(00)01689-1; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Horn N, 1999, J TRACE ELEM EXP MED, V12, P297; KRETZSCHMAR HA, 1986, AM J PATHOL, V122, P1; Lehmann S, 2002, CURR OPIN CHEM BIOL, V6, P187, DOI 10.1016/S1367-5931(02)00295-8; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Milhavet O, 2000, P NATL ACAD SCI USA, V97, P13937, DOI 10.1073/pnas.250289197; Milhavet O, 2002, BRAIN RES REV, V38, P328, DOI 10.1016/S0165-0173(01)00150-3; Milhavet O, 2000, J NEUROCHEM, V74, P222, DOI 10.1046/j.1471-4159.2000.0740222.x; Narwa R, 1999, BIOCHEMISTRY-US, V38, P8770, DOI 10.1021/bi990736c; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Opazo C, 2003, BIOMETALS, V16, P91, DOI 10.1023/A:1020795422185; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rachidi W, 2003, J BIOL CHEM, V278, P9064, DOI 10.1074/jbc.M211830200; Sayre LM, 2000, CELL MOL BIOL, V46, P731; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; VIRET J, 1981, BIOCHEM BIOPH RES CO, V101, P830, DOI 10.1016/0006-291X(81)91825-8; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Wong BS, 2001, J NEUROCHEM, V78, P1400, DOI 10.1046/j.1471-4159.2001.00522.x	34	53	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14595	14598		10.1074/jbc.C300092200	http://dx.doi.org/10.1074/jbc.C300092200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637548	hybrid			2022-12-27	WOS:000182516100003
J	Singh, R				Singh, R			Interaction of guanylyl cyclase C with SH3 domain of Src tyrosine kinase - Yet another mechanism for desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE ENTEROTOXIN; NATRIURETIC PEPTIDE RECEPTOR; DEPENDENT PROTEIN-KINASE; ESCHERICHIA-COLI; CGMP-BINDING; CYCLIC-GMP; PHOSPHODIESTERASE PDE5; FUNCTIONAL EXPRESSION; PARTIAL-PURIFICATION; SIGNALING PROTEINS	Protein-protein interactions mediated by the Src homology 3 (SH3) domain have been implicated in the regulation of receptor functions for subcellular localization of proteins and the reorganization of cytoskeleton. The experiments described in this article begin to identify the interaction of the SH3 domain of Src tyrosine kinase with the guanylyl cyclase C receptor after activation with Escherichia coli heat-stable enterotoxin (ST). Only one of two post-translationally modified forms of guanylyl cyclase C from T84 colonic carcinoma cells bind to GST-SH3 fusion protein of Src and Hck tyrosine kinases. Interestingly, the GST-Src-SH3 fusion protein showed 2-fold more affinity to native guanylyl cyclase C in solution than the GST-Hck-SH3 fusion protein. The affinity of the GST-Src-SH3 fusion protein to guanylyl cyclase C increased on desensitization of receptor in vivo. An in vitro cyclase assay in the presence of GST-Src-SH3 fusion protein indicated inhibition of the catalytic activity of guanylyl cyclase C. The catalytic domain recombinant protein (GST-GCD) of guanylyl cyclase C could pull-down a 60-kDa protein that reacted with Src tyrosine antibody and also showed autophosphorylation. These data suggest that SH3 domain-mediated protein-protein interaction with the catalytic domain of guanylyl cyclase C inhibited the cyclase activity and that such an interaction, possibly mediated by Src tyrosine kinase or additional proteins, might be pivotal for the desensitization phenomenon of the guanylyl cyclase C receptor.	Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India	University of Delhi	Singh, R (corresponding author), Univ Delhi, Dr BR Ambedkar Ctr Biomed Res, Delhi 110007, India.							Bakre MM, 1997, FEBS LETT, V408, P345, DOI 10.1016/S0014-5793(97)00458-4; Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; Bakre MM, 2000, J CELL BIOCHEM, V77, P159; BENTLEY JK, 1986, J BIOL CHEM, V261, P4859; Bhandari R, 2000, J BIOSCIENCES, V25, P339, DOI 10.1007/BF02703787; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brooker G, 1979, Adv Cyclic Nucleotide Res, V10, P1; CHAO AC, 1994, EMBO J, V13, P1065, DOI 10.1002/j.1460-2075.1994.tb06355.x; Crane JK, 1996, MOL CELL BIOCHEM, V165, P111; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DESAUVAGE FJ, 1991, J BIOL CHEM, V266, P17912; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DWARAKANATH P, 1989, GENE, V81, P219, DOI 10.1016/0378-1119(89)90182-0; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; FIELD M, 1989, NEW ENGL J MED, V321, P800; Forte LR, 1999, REGUL PEPTIDES, V81, P25, DOI 10.1016/S0167-0115(99)00033-6; FORTE LR, 1995, FASEB J, V9, P643, DOI 10.1096/fasebj.9.8.7768356; Garbers DL, 1999, METHODS, V19, P477, DOI 10.1006/meth.1999.0890; Gouri BSV, 1997, INDIAN J BIOCHEM BIO, V34, P29; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; KIM TD, 1994, J BIOL CHEM, V269, P15540; Kuwayama H, 1996, J BIOL CHEM, V271, P23718, DOI 10.1074/jbc.271.39.23718; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Laskey R A, 1980, Methods Enzymol, V65, P363; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mayer BJ, 2001, J CELL SCI, V114, P1253; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Potter LR, 1998, BIOCHEMISTRY-US, V37, P2422, DOI 10.1021/bi972303k; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Qian X, 2000, ENDOCRINOLOGY, V141, P3210, DOI 10.1210/en.141.9.3210; RAMARAO CS, 1985, J BIOL CHEM, V260, P8360; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Scott RO, 2002, J BIOL CHEM, V277, P22934, DOI 10.1074/jbc.M202434200; SINGH S, 1991, BIOCHEM BIOPH RES CO, V179, P1455, DOI 10.1016/0006-291X(91)91736-V; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Turko IV, 1998, BIOCHEM J, V329, P505; URBANSKI R, 1995, BIOCHIM BIOPHYS ACTA, V1249, P29; Vaandrager AB, 1997, GASTROENTEROLOGY, V112, P437, DOI 10.1053/gast.1997.v112.pm9024297; Vaandrager AB, 2002, MOL CELL BIOCHEM, V230, P73, DOI 10.1023/A:1014231722696; VISWESWARIAH SS, 1994, EUR J BIOCHEM, V219, P727, DOI 10.1111/j.1432-1033.1994.tb18551.x; VISWESWARIAH SS, 1992, MICROB PATHOGENESIS, V12, P209, DOI 10.1016/0882-4010(92)90055-S; WADA A, 1994, MICROBIOL IMMUNOL, V38, P535, DOI 10.1111/j.1348-0421.1994.tb01819.x; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	49	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 4	2003	278	27					24342	24349		10.1074/jbc.M301153200	http://dx.doi.org/10.1074/jbc.M301153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	695HJ	12649275	hybrid			2022-12-27	WOS:000183824800015
J	Inomata, H; Nakamura, Y; Hayakawa, A; Takata, H; Suzuki, T; Miyazawa, K; Kitamura, N				Inomata, H; Nakamura, Y; Hayakawa, A; Takata, H; Suzuki, T; Miyazawa, K; Kitamura, N			A scaffold protein JIP-1b enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXONAL-TRANSPORT; DEPENDENT REGULATION; SIGNAL-TRANSDUCTION; CYTOPLASMIC DOMAIN; FAMILY; APOPTOSIS; BINDING; FE65; OVEREXPRESSION; ACTIVATION	Amyloid precursor protein (APP) is the precursor molecule of beta-amyloid peptides, the major components of amyloid plaque in patients with Alzheimer's disease. In this study, we isolated JIP-1b, a JNK signaling scaffold protein, as a binding protein of APP, and analyzed the roles of JIP-1b in APP phosphorylation by JNK and the association of kinesin light chain 1 with APP. APP phosphorylation at threonine 668 by JNK was enhanced on the JIP-1b scaffold in vitro and in cultured cells exogenously expressing APP. APP phosphorylation in nerve growth factor-differentiated PC12 cells was mediated by activation of JNK signaling. JIP-1b also enhanced the association of kinesin light chain 1 with APP. Our results suggest that JIP-1b may function as a protein linking the kinesin-I motor protein to the cargo receptor, APP, and that the JNK signaling pathway may regulate the phosphorylation of this cargo protein through the JIP-1b scaffold.	Tokyo Inst Technol, Dept Sci Biol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Hokkaido Univ, Neurosci Lab, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan	Tokyo Institute of Technology; Hokkaido University	Kitamura, N (corresponding author), Tokyo Inst Technol, Dept Sci Biol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	nkitamur@bio.titech.ac.jp	MIYAZAWA, KEIJI/I-9713-2014; Suzuki, Toshiharu/B-5342-2013					Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; Ando K, 1999, J NEUROSCI, V19, P4421; Aplin AE, 1996, J NEUROCHEM, V67, P699; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FERREIRA A, 1993, J NEUROSCI, V13, P3112; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Harding TC, 2001, J BIOL CHEM, V276, P4531, DOI 10.1074/jbc.C000815200; Heber S, 2000, J NEUROSCI, V20, P7951; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Liu YF, 1998, J BIOL CHEM, V273, P28873, DOI 10.1074/jbc.273.44.28873; Matsuda S, 2001, J NEUROSCI, V21, P6597; Mota M, 2001, J NEUROSCI, V21, P4949, DOI 10.1523/JNEUROSCI.21-14-04949.2001; Nakagawa T, 2000, CELL, V103, P569, DOI 10.1016/S0092-8674(00)00161-6; Nakano K, 2000, J BIOL CHEM, V275, P20533, DOI 10.1074/jbc.M001009200; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Standen CL, 2001, J NEUROCHEM, V76, P316, DOI 10.1046/j.1471-4159.2001.00102.x; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; Takata H, 2000, GENES CELLS, V5, P57, DOI 10.1046/j.1365-2443.2000.00303.x; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Torroja L, 1999, CURR BIOL, V9, P489, DOI 10.1016/S0960-9822(99)80215-2; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	38	132	139	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22946	22955		10.1074/jbc.M212160200	http://dx.doi.org/10.1074/jbc.M212160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665528	hybrid			2022-12-27	WOS:000183503900101
J	Jung, IL; Kim, IG				Jung, IL; Kim, IG			Polyamines and glutamate decarboxylase-based acid resistance in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN H-NS; SIGMA(S)-DEPENDENT GENES; K-12; SYSTEM; GROWTH; PUTRESCINE; SPERMINE; SIGMA(S); SEQUENCE; MUTANTS	The expression of gadA and gadB, which encode two glutamate decarboxylases ( GADs) of Escherichia coli, is induced by an acidic environment and participate in acid resistance. In this study, we constructed a polyamine-deficient mutant and investigated the role of polyamines in acid resistance. The expression of gadA and gadB was shown to be dependent on polyamines. For that reason, the polyamine- deficient mutant was completely devoid of GAD activity and was very susceptible to low pH if large amounts of polyamines were not provided. We also showed that the polyamine- deficient mutant contained higher cAMP levels than the isogenic polyamine- proficient wild type, and cAMP negatively regulated the expression of gadA and gadB. Therefore, introduction of the cya ( encoding adenylate cyclase) mutation allele into the polyamine- deficient mutant resulted in the increment of GAD activity and thus restored the reduced acid resistance of the mutant. The positive regulators, H- NS ( histone- like protein, encoded by the hns gene) and RpoS ( alternative RNA polymerase sigma subunit, encoded by rpoS gene), also significantly governed the expression of gadA and gadB, respectively. However, polyamines did not regulate either the intracellular H- NS level or rpoS expression under these culture conditions. These results strongly suggest that there are at least two different regulatory systems in acid resistance, one is positive regulation via a H- NS/ RpoS system and the other is negative regulation via a polyamine/ cAMP system.	Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, Taejon 305600, South Korea	Korea Atomic Energy Research Institute (KAERI)	Kim, IG (corresponding author), Korea Atom Energy Res Inst, Dept Radiat Biol, Environm Radiat Res Grp, POB 105, Taejon 305600, South Korea.							BARTH M, 1995, J BACTERIOL, V177, P3455, DOI 10.1128/jb.177.12.3455-3464.1995; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Castanie-Cornet MP, 1999, J BACTERIOL, V181, P3525, DOI 10.1128/JB.181.11.3525-3535.1999; Castanie-Cornet MP, 2001, MICROBIOL-UK, V147, P709, DOI 10.1099/00221287-147-3-709; Cotter PD, 2001, MOL MICROBIOL, V40, P465, DOI 10.1046/j.1365-2958.2001.02398.x; De Biase D, 1999, MOL MICROBIOL, V32, P1198, DOI 10.1046/j.1365-2958.1999.01430.x; DeBiase D, 1996, PROTEIN EXPRES PURIF, V8, P430; DERSCH P, 1993, MOL MICROBIOL, V8, P875, DOI 10.1111/j.1365-2958.1993.tb01634.x; Foster JW, 2000, BACTERIAL STRESS RESPONSES, P99; Ha HC, 1998, P NATL ACAD SCI USA, V95, P11140, DOI 10.1073/pnas.95.19.11140; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; Hersh BM, 1996, J BACTERIOL, V178, P3978, DOI 10.1128/jb.178.13.3978-3981.1996; Hwang DF, 1997, J CHROMATOGR B, V693, P23, DOI 10.1016/S0378-4347(97)00067-4; Igarashi K, 2000, BIOCHEM BIOPH RES CO, V271, P559, DOI 10.1006/bbrc.2000.2601; ILLIANO G, 1982, INT J BIOCHEM, V14, P247, DOI 10.1016/0020-711X(82)90082-9; Kim IG, 2000, TOXICOL LETT, V116, P143, DOI 10.1016/S0378-4274(00)00215-0; Lambert LA, 1997, J BACTERIOL, V179, P7595, DOI 10.1128/jb.179.23.7595-7599.1997; MALOY SR, 1981, J BACTERIOL, V145, P1110, DOI 10.1128/JB.145.2.1110-1111.1981; Miller J. H, 1972, EXPT MOL GENETICS; MINTON KW, 1990, P NATL ACAD SCI USA, V87, P2851, DOI 10.1073/pnas.87.7.2851; RICE EW, 1993, APPL ENVIRON MICROB, V59, P4347, DOI 10.1128/AEM.59.12.4347-4349.1993; SMITH DK, 1992, J BACTERIOL, V174, P5820, DOI 10.1128/jb.174.18.5820-5826.1992; Tkachenko A, 2001, ARCH MICROBIOL, V176, P155, DOI 10.1007/s002030100301; Tramonti A, 2002, J BACTERIOL, V184, P2603, DOI 10.1128/JB.184.10.2603-2613.2002; TSURUOKA T, 1978, J ANTIBIOT, V31, P192, DOI 10.7164/antibiotics.31.192; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; Waterman SR, 1996, MOL MICROBIOL, V21, P925, DOI 10.1046/j.1365-2958.1996.00058.x; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; Yatin SM, 2001, J NEUROSCI RES, V63, P395, DOI 10.1002/1097-4547(20010301)63:5<395::AID-JNR1034>3.0.CO;2-Q; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; ZILBERSTEIN D, 1984, J BACTERIOL, V158, P246, DOI 10.1128/JB.158.1.246-252.1984	33	39	40	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22846	22852		10.1074/jbc.M212055200	http://dx.doi.org/10.1074/jbc.M212055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12670930	hybrid			2022-12-27	WOS:000183503900089
J	Kauth, CW; Epp, C; Bujard, H; Lutz, R				Kauth, CW; Epp, C; Bujard, H; Lutz, R			The merozoite surface protein 1 complex of human malaria parasite Plasmodium falciparum - Interactions and arrangements of subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; IDENTIFICATION; MSP-1; GLYCOPROTEIN; FRAGMENTS; ANTIGENS; INVASION; SEQUENCE; PROTEASE; GENE	The major protein component at the surface of merozoites, the infectious form of blood stage malaria parasites, is the merozoite surface protein 1 ( MSP-1) complex. In the human malaria parasite Plasmodium falciparum, this complex is generated by proteolytic cleavage of a 190-kDa glycosylphosphatidylinositol-anchored precursor into four major fragments, which remain non-covalently associated. Here, we describe the in vitro reconstitution of the MSP-1 complex of P. falciparum strain 3D7 from its heterologously produced subunits. We provide evidence for the arrangement of the subunits within the complex and show how they interact with each other. Our data indicate that the conformation assumed by the reassembled complex as well as by the heterologously produced 190-kDa precursor corresponds to the native one. Based on these results we propose a first structural model for the MSP-1 complex. Together with access to faithfully produced material, this information will advance further structure-function studies of MSP-1 that plays an essential role during invasion of erythrocytes by the parasite and that is considered a promising candidate for a malaria vaccine.	Heidelberg Univ, ZMBH, Zentrum Mol Biol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bujard, H (corresponding author), Heidelberg Univ, ZMBH, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	h.bujard@zmbh.uni-heidelberg.de						Berhe S, 2000, EXP PARASITOL, V94, P194, DOI 10.1006/expr.1999.4481; BLACKMAN MJ, 1992, MOL BIOCHEM PARASIT, V50, P307, DOI 10.1016/0166-6851(92)90228-C; BLACKMAN MJ, 1991, MOL BIOCHEM PARASIT, V49, P35, DOI 10.1016/0166-6851(91)90128-S; BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379; BLACKMAN MJ, 1994, J EXP MED, V180, P389, DOI 10.1084/jem.180.1.389; Chitarra V, 1999, MOL CELL, V3, P457, DOI 10.1016/S1097-2765(00)80473-6; Daly TM, 2001, MOL BIOCHEM PARASIT, V117, P27, DOI 10.1016/S0166-6851(01)00329-2; Epp C, 2003, J CHROMATOGR B, V786, P61, DOI 10.1016/S1570-0232(02)00722-5; Good MF, 1998, ANNU REV IMMUNOL, V16, P57, DOI 10.1146/annurev.immunol.16.1.57; Guevara-Patino JA, 1997, J EXP MED, V186, P1689, DOI 10.1084/jem.186.10.1689; HOLDER AA, 1984, J EXP MED, V160, P624, DOI 10.1084/jem.160.2.624; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; LYON JA, 1987, J IMMUNOL, V138, P895; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; Mello K, 2002, EUKARYOT CELL, V1, P915, DOI 10.1128/EC.1.6.915-925.2002; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Morgan WD, 1999, J MOL BIOL, V289, P113, DOI 10.1006/jmbi.1999.2753; Nikodem DP, 2000, MOL BIOCHEM PARASIT, V108, P79, DOI 10.1016/S0166-6851(00)00206-1; O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595; Pachebat JA, 2001, MOL BIOCHEM PARASIT, V117, P83, DOI 10.1016/S0166-6851(01)00336-X; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; SIDDIQUI WA, 1986, INFECT IMMUN, V52, P314, DOI 10.1128/IAI.52.1.314-318.1986; STAFFORD WHL, 1994, MOL BIOCHEM PARASIT, V66, P157, DOI 10.1016/0166-6851(94)90048-5; Stafford WHL, 1996, MOL BIOCHEM PARASIT, V80, P159, DOI 10.1016/0166-6851(96)02696-5; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TOLLE R, 1994, THESIS U HEIDELBERG; Trucco C, 2001, MOL BIOCHEM PARASIT, V112, P91, DOI 10.1016/S0166-6851(00)00350-9; TUERBACHOVA I, 2000, THESIS U HEIDELBERG	28	41	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22257	22264		10.1074/jbc.M302299200	http://dx.doi.org/10.1074/jbc.M302299200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12654909	hybrid			2022-12-27	WOS:000183503900012
J	Priet, S; Navarro, JM; Querat, G; Sire, J				Priet, S; Navarro, JM; Querat, G; Sire, J			Reversion of the lethal phenotype of an HIV-1 integrase mutant virus by overexpression of the same integrase mutant protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; URACIL DNA GLYCOSYLASE; TYPE-1 INTEGRASE; IN-VITRO; PREINTEGRATION COMPLEXES; PRECURSOR PROTEIN; REPAIR ENZYME; ZINC-BINDING; VPR; IDENTIFICATION	The human immunodeficiency virus type 1 (HIV-1) integrase (IN) is essential for integration of viral DNA into host cell chromatin. We have reported previously (Priet, S., Navarro, J.M., Gros, N., Querat, G., and Sire, J. (2003) J. Biol. Chem. 278, 4566-4571) that IN also plays a role in the packaging of the host uracil DNA glycosylase UNG2 into viral particles and that the region of IN encompassing residues 170-180 was responsible for the interaction with UNG2 and for its packaging into virions. In this work, we aimed to investigate the replication of HIV-1 viruses rendered deficient in virion-associated UNG2 by single or double point mutations in the region 170-180 of IN. We show that the L172A/K173A IN mutant virus was deficient for UNG2 packaging and was defective for replication because of a blockage at the stage of proviral DNA integration in host cell DNA. In vitro assays using long term repeat mimics, however, demonstrate that the L172A/K173A IN mutant was catalytically active. Moreover, trans-complementation experiments show that the viral propagation of L172A/K173A viruses could be rescued by the overexpression of Vpr.L172A/K173A IN fusion protein in a dose-dependent manner and that this rescue is independent of UNG2 packaging. Altogether, our data indicate that L172A/K173A mutations of IN induce a subtle defect in the function of IN, which nevertheless dramatically impairs viral replication. Unexpectedly, this blockage of replication could be overcome by forcing the packaging of higher amounts of this same mutated integrase. This is the first study reporting that blockage of the integration process of HIV-1 provirus carrying a mutation of IN could be alleviated by increasing amounts of IN even carrying the same mutations.	INSERM, U372, F-13276 Marseille 9, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Sire, J (corresponding author), INSERM, U372, 163 Ave Luminy,BP 178, F-13276 Marseille 9, France.		Priet, Stéphane/ABD-4869-2020; Querat, Gilles/E-9577-2014; Priet, Stéphane/N-7952-2017	Priet, Stéphane/0000-0001-7102-3654; Querat, Gilles/0000-0003-1897-8210; Priet, Stéphane/0000-0001-7102-3654				Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; BURLESON DG, 1992, P SOC EXP BIOL MED, V199, P305; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Dettenhofer M, 1999, J VIROL, V73, P1460, DOI 10.1128/JVI.73.2.1460-1467.1999; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; Engelman A, 1999, ADV VIRUS RES, V52, P411, DOI 10.1016/S0065-3527(08)60309-7; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; Harris D, 2000, J BIOL CHEM, V275, P39671, DOI 10.1074/jbc.M002626200; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAFEMINA RL, 1992, J VIROL, V66, P7414, DOI 10.1128/JVI.66.12.7414-7419.1992; LAFEMINA RL, 1991, J VIROL, V65, P5624, DOI 10.1128/JVI.65.10.5624-5630.1991; Liu HM, 1997, J VIROL, V71, P7704, DOI 10.1128/JVI.71.10.7704-7710.1997; Liu HM, 1999, J VIROL, V73, P8831, DOI 10.1128/JVI.73.10.8831-8836.1999; Mansky LM, 2000, J VIROL, V74, P7039, DOI 10.1128/JVI.74.15.7039-7047.2000; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; MUMM SR, 1991, J VIROL, V65, P1160, DOI 10.1128/JVI.65.3.1160-1167.1991; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; Oz I, 2002, BIOCHEM J, V361, P557, DOI 10.1042/0264-6021:3610557; Priet S, 2003, J BIOL CHEM, V278, P4566, DOI 10.1074/jbc.M209311200; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Yung E, 2001, NAT MED, V7, P920, DOI 10.1038/90959; ZHENG R, P NATL ACAD SCI US, V93, P13659	36	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20724	20730		10.1074/jbc.M301768200	http://dx.doi.org/10.1074/jbc.M301768200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670953	hybrid			2022-12-27	WOS:000183230500038
J	Tsutsui, S; Tasumi, S; Suetake, H; Suzuki, Y				Tsutsui, S; Tasumi, S; Suetake, H; Suzuki, Y			Lectins homologous to those of monocotyledonous plants in the skin mucus and intestine of pufferfish, Fugu rubripes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING LECTIN; CONGER EEL; PURIFICATION; MYRIASTER; GALECTINS; FAMILY; AGGLUTININS; INFECTION; CELLS; FISH	We have characterized pufflectin, a novel mannose-specific lectin, from the skin mucus of the pufferfish, Fugu rubripes. Molecular mass estimations by gel filtration and matrix-assisted laser desorption ionization time-of-flight mass spectrometry and the SDS-PAGE pattern suggest that pufflectin is a homodimer composed of non-covalently associated subunits of 13 kDa. The full-length pufflectin cDNA consists of 527 bp, with 116 amino acid residues deduced from the open reading frame. The amino acid sequence of pufflectin shows no homology with any known animal lectin. Surprisingly, pufflectin shares sequence homology with mannose-binding lectins of monocotyledonous plants and has conserved two of three carbohydrate recognition domains of these plant lectins. The pufflectin gene is expressed in gills, oral cavity wall, esophagus, and skin. In addition, an isoform occurs exclusively in the intestine. Pufflectin differs from mannose-binding lectins purified from the blood plasma of Fugu. Whereas pufflectin did not agglutinate five bacterial species tested, it was demonstrated to bind to the parasitic trematode, Heterobothrium okamotoi. This finding suggests that pufflectin contributes to the parasite-defense system in Fugu.	Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan	University of Tokyo	Suzuki, Y (corresponding author), Univ Tokyo, Fisheries Lab, Shizuoka 4310211, Japan.	ayuzuru@mail.ecc.u-tokyo.ac.jp		Tasumi, Satoshi/0000-0003-3047-6942				Alexander John B., 1992, Annual Review of Fish Diseases, V2, P249, DOI 10.1016/0959-8030(92)90066-7; ALHASSAN JM, 1986, COMP BIOCHEM PHYS B, V85, P31, DOI 10.1016/0305-0491(86)90217-8; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARONDES SH, 1988, TRENDS BIOCHEM SCI, V13, P480, DOI 10.1016/0968-0004(88)90235-6; Damme E.J.V., 1991, EUR J BIOCHEM, V202, P23; DAMME EJM, 1993, PLANT MOL BIOL, V23, P365; DAMME EJM, 1994, PLANT MOL BIOL, V24, P825; DAY AJ, 1994, BIOCHEM SOC T, V22, P83, DOI 10.1042/bst0220083; Force A, 1999, GENETICS, V151, P1531; GOTONANCE R, 1995, FISHERIES SCI, V61, P137, DOI 10.2331/fishsci.61.137; INGRAM GA, 1980, J FISH BIOL, V16, P23, DOI 10.1111/j.1095-8649.1980.tb03685.x; KAMIYA H, 1988, DEV COMP IMMUNOL, V12, P309, DOI 10.1016/0145-305X(88)90007-9; KAMIYA H, 1980, BIOCHIM BIOPHYS ACTA, V622, P171, DOI 10.1016/0005-2795(80)90028-8; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kawagishi H, 2001, BIOSCI BIOTECH BIOCH, V65, P2437, DOI 10.1271/bbb.65.2437; KILPATRICK DC, 2000, HDB ANIMAL LECTINS; Kiyono H., 1996, MUCOSAL VACCINES; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laursen SB, 1998, IMMUNOLOGY, V93, P421, DOI 10.1046/j.1365-2567.1998.00446.x; Mistry AC, 2001, BIOCHEM J, V360, P107, DOI 10.1042/0264-6021:3600107; Muramoto K, 1999, COMP BIOCHEM PHYS B, V123, P33, DOI 10.1016/S0305-0491(99)00037-1; MURAMOTO K, 1992, BIOCHIM BIOPHYS ACTA, V1116, P129, DOI 10.1016/0304-4165(92)90109-8; Nakamura O, 2001, DEV COMP IMMUNOL, V25, P431, DOI 10.1016/S0145-305X(01)00012-X; Nakao M, 1998, IMMUNOL REV, V166, P27, DOI 10.1111/j.1600-065X.1998.tb01250.x; ODA Y, 1984, J PHARMACOBIO-DYNAM, V7, P614; OGAWA K, 1991, Japanese Journal of Parasitology, V40, P388; Ogawa K, 1997, FISH PATHOL, V32, P15, DOI 10.3147/jsfp.32.15; OGRA PLM, 1999, MUCOSAL IMMUNOLOGY; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; SHIOMI K, 1987, NIPPON SUISAN GAKK, V53, P1275; SHIOMI K, 1990, NIPPON SUISAN GAKK, V56, P119; SHIOMI K, 1989, COMP BIOCHEM PHYS B, V92, P255, DOI 10.1016/0305-0491(89)90275-7; Skin Suzuki Y, 1995, ATLAS FISH HISTOLOGY, P8; Smeets K, 1997, PLANT MOL BIOL, V33, P223, DOI 10.1023/A:1005717020021; Tasumi S, 2002, J BIOL CHEM, V277, P27305, DOI 10.1074/jbc.M202648200; Toda M, 1996, FISHERIES SCI, V62, P138, DOI 10.2331/fishsci.62.138; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Vitved L, 2000, IMMUNOGENETICS, V51, P955, DOI 10.1007/s002510000232; YANO T, 1996, FISH IMMUNE SYSTEM O, P129	42	81	84	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20882	20889		10.1074/jbc.M301038200	http://dx.doi.org/10.1074/jbc.M301038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654913	hybrid			2022-12-27	WOS:000183230500058
J	Young, KW; Nash, MS; Challiss, RAJ; Nahorski, SR				Young, KW; Nash, MS; Challiss, RAJ; Nahorski, SR			Role of Ca2+ feedback on single cell inositol 1,4,5-trisphosphate oscillations mediated by G-protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; CALCIUM OSCILLATIONS; KINASE-C; ALPHA(1B)-ADRENERGIC RECEPTOR; CYTOSOLIC CA2+; PHOSPHORYLATION; DESENSITIZATION; IP3; TRISPHOSPHATE; MOBILIZATION	The dynamics of inositol 1,4,5-trisphosphate (Ins (1,4,5)P-3) production during periods of G-protein-coupled receptor-mediated Ca2+ oscillations have been investigated using the pleckstrin homology (PH) domain of phospholipase C (PLC) delta(1) tagged with enhanced green fluorescent protein (eGFP-PHPLCdelta1). Activation of noradrenergic alpha(1B) and muscarinic M-3 receptors recombinantly expressed in the same Chinese hamster ovary cell indicates that Ca(2+)responses to these G-protein-coupled receptors are stimulus strength-dependent. Thus, activation of alpha(1B) receptors produced transient base-line Ca2+ oscillations, sinusoidal Ca2+ oscillations, and then a steady-state plateau level of Ca2+ as the level of agonist stimulation increased. Activation of M-3 receptors, which have a higher coupling efficiency than alpha(1B) receptors, produced a sustained increase in intracellular Ca2+ even at low levels of agonist stimulation. Confocal imaging of eGFP-PHPLCdelta1 visualized periodic increases in Ins(1,4,5)P-3 production underlying the base-line Ca2+ oscillations. Ins(1,4,5)P-3 oscillations were blocked by thapsigargin but not by protein kinase C down-regulation. The net effect of increasing intracellular Ca2+ was stimulatory to Ins(1,4,5)P-3 production, and dual imaging experiments indicated that receptor-mediated Ins(1,4,5)P-3 production was sensitive to changes in intracellular Ca2+ between basal and similar to200 nM. Together, these data suggest that alpha(1B) receptor-mediated Ins(1,4,5)P-3 oscillations result from a positive feedback effect of Ca2+ onto phospholipase C. The mechanisms underlying alpha(1B) receptor-mediated Ca(2+)responses are therefore different from those for the metabotropic glutamate receptor 5a, where Ins(1,4,5)P-3 oscillations are the primary driving force for oscillatory Ca(2+)responses (Nash, M.S., Young, K.W., Challiss, R. A. J., and Nahorski, S. R. (2001) Nature 413, 381-382). For alpha(1B) receptors the Ca2+-dependent Ins(1,4,5)P-3 production may serve to augment the existing regenerative Ca2+-induced Ca2+-release process; however, the sensitivity to Ca2+ feedback is such that only transient base-line Ca2+ spikes may be capable of causing Ins(1,4,5)P-3 oscillations.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Young, KW (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.		Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Alcantara-Hernandez R, 2000, BRIT J PHARMACOL, V129, P724, DOI 10.1038/sj.bjp.0703073; Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Bootman MD, 1999, CURR BIOL, V9, pR876, DOI 10.1016/S0960-9822(00)80072-X; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; DELRIO E, 1994, J NEUROCHEM, V63, P535; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; EBERHARD DA, 1988, TRENDS NEUROSCI, V11, P517, DOI 10.1016/0166-2236(88)90174-9; Garcia-Sainz JA, 2000, EUR J PHARMACOL, V389, P1, DOI 10.1016/S0014-2999(99)00896-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAROOTUNIAN AT, 1991, SCIENCE, V251, P75, DOI 10.1126/science.1986413; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; KENDALL DA, 1984, J NEUROCHEM, V42, P1388, DOI 10.1111/j.1471-4159.1984.tb02799.x; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; Luo X, 2001, MOL CELL, V7, P651, DOI 10.1016/S1097-2765(01)00211-8; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; Nash MS, 2002, J BIOL CHEM, V277, P35947, DOI 10.1074/jbc.M205622200; Nash MS, 2001, NATURE, V413, P381, DOI 10.1038/35096643; Nash MS, 2001, BIOCHEM J, V356, P137, DOI 10.1042/0264-6021:3560137; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Okubo Y, 2001, NEURON, V32, P113, DOI 10.1016/S0896-6273(01)00464-0; Putney JW, 1998, SCIENCE, V279, P191, DOI 10.1126/science.279.5348.191; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; RENARD D, 1987, BIOCHEM J, V243, P391, DOI 10.1042/bj2430391; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Stauffer TP, 1998, CURR BIOL, V8, P343, DOI 10.1016/S0960-9822(98)70135-6; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THOMPSON NT, 1991, BRIT J PHARMACOL, V103, P1592, DOI 10.1111/j.1476-5381.1991.tb09832.x; Thrower EC, 2001, TRENDS PHARMACOL SCI, V22, P580, DOI 10.1016/S0165-6147(00)01809-5; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177	39	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20753	20760		10.1074/jbc.M211555200	http://dx.doi.org/10.1074/jbc.M211555200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670945	hybrid			2022-12-27	WOS:000183230500042
J	Carter, RS; Pennington, KN; Ungurait, BJ; Ballard, DW				Carter, RS; Pennington, KN; Ungurait, BJ; Ballard, DW			In vivo identification of inducible phosphoacceptors in the IKK gamma/NEMO subunit of human I kappa B kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAX TRANSFORMING PROTEIN; NECROSIS-FACTOR RECEPTOR; LEUKEMIA-VIRUS TYPE-1; PERSISTENT ACTIVATION; TRANSCRIPTION FACTORS; IMMUNE-RESPONSES; NEMO/IKK-GAMMA; COMPLEX; PHOSPHORYLATION; BETA	Transcription factor NF-kappaB plays a pivotal regulatory role in the genetic programs for cell cycle progression and inflammation. Nuclear translocation of NF-kappaB is controlled by an inducible protein kinase called IKK, which earmarks cytoplasmic inhibitors of NF-kappaB for proteolytic destruction. IKK contains two structurally related catalytic subunits termed IKKalpha and IKKbeta as well as a noncatalytic subunit called IKKgamma/NEMO. Mutations in the X-linked gene encoding IKKgamma can interfere with NF-kappaB signaling and lead to immunodeficiency disease. Although its precise mechanism of action remains unknown, IKKgamma is phosphorylated in concert with the induction of NF-kappaB by the viral oncoprotein Tax and the proinflammatory cytokine tumor necrosis factor alpha (TNF). We now demonstrate that TNF-induced phosphorylation of IKKgamma is blocked in cells deficient for IKKbeta but not IKKalpha. Phosphopeptide-mapping experiments with metabolically radiolabeled cells indicate that IKKbeta phosphorylates human IKKgamma at Ser-31, Ser-43, and Ser-376 following the enforced expression of either the Tax oncoprotein or the type 1 TNF receptor. Inducible phosphorylation of IKKgamma is attenuated following the deletion of its COOH-terminal zinc finger domain ( amino acids 397-419), a frequent target for mutations that occur in IKKgamma-associated immunodeficiencies. As such, IKKbeta-mediated phosphorylation of IKKgamma at these specific serine targets may facilitate proper regulation of NF-kappaB signaling in the immune system.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Ballard, DW (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, A4301 Med Ctr N,1161 21st Ave S, Nashville, TN 37232 USA.	dean.ballard@vanderbilt.edu			NATIONAL CANCER INSTITUTE [T32CA009385, R01CA082556] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI052379] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09385, R01 CA082556] Funding Source: Medline; NIAID NIH HHS [AI052379] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hawiger J, 1999, BLOOD, V94, P1711, DOI 10.1182/blood.V94.5.1711.417k20_1711_1716; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; LUO KX, 1991, METHOD ENZYMOL, V201, P149; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; McFarlane SM, 2002, FEBS LETT, V515, P119, DOI 10.1016/S0014-5793(02)02450-X; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; MULLER MM, 1989, NUCLEIC ACIDS RES, V17, P6420, DOI 10.1093/nar/17.15.6420; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tarassishin L, 2001, BIOCHEM BIOPH RES CO, V285, P555, DOI 10.1006/bbrc.2001.5197; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	40	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19642	19648		10.1074/jbc.M301705200	http://dx.doi.org/10.1074/jbc.M301705200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657630	hybrid			2022-12-27	WOS:000183078000012
J	Planque, S; Taguchi, H; Burr, G; Bhatia, G; Karle, S; Zhou, YX; Nishiyama, Y; Paul, S				Planque, S; Taguchi, H; Burr, G; Bhatia, G; Karle, S; Zhou, YX; Nishiyama, Y; Paul, S			Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE-INTESTINAL-PEPTIDE; GROWTH-FACTOR RECEPTOR; CATALYTIC ANTIBODY; MONOCLONAL-ANTIBODY; INHIBITORS; CHAIN; AUTOANTIBODIES; HYDROLYSIS; MECHANISM; PROTEINS	Antibody (Ab) nucleophilic reactivity was studied using hapten and polypeptide antigens containing biotinylated phosphonate diester groups ( covalently reactive antigen analogs, CRAs). Polyclonal IgG from healthy donors formed covalent adducts with a positively charged hapten CRA at levels superior to trypsin. Each of the 16 single chain Fv clones studied expressed a similar reactivity, indicating the V domain location of the nucleophiles and their broad distribution in diverse Abs. The formation of hapten CRA-Fv adducts was correlated with Fv proteolytic activity determined by cleavage of a model peptide substrate. Despite excellent nucleophilicity, proteolysis by IgG proceeded at lower rates than trypsin, suggesting that events occurring after nucleophilic attack on the substrate limit the rate of Ab proteolysis. The extracellular domain of the epidermal growth factor receptor with phosphonate diester groups at Lys side chains and a synthetic peptide corresponding to residues 421 - 431 of human immunodeficiency virus glycoprotein (gp) 120 with the phosphonate diester at the C terminus formed covalent adducts with specific polyclonal and monoclonal Abs raised by immunization with epidermal growth factor receptor and synthetic gp120-(421-436) devoid of phosphonate diester groups, respectively. Adduct formation was inhibited by extracellular domain of the epidermal growth factor receptor (exEGFB) and synthetic gp120-( 421 - 436) devoid of phosphonate groups, suggesting that the nucleophiles are located within the antigen binding sites. These results suggest the innate character of the Ab nucleophilic reactivity, its functional coordination with non-covalent adaptive binding interactions developing over the course of B cell maturation, and novel routes toward permanent inhibition of Abs.	Univ Texas, Sch Med, Dept Pathol & Lab Med, Chem Immunol & Therapeut Res Ctr, Houston, TX 77030 USA	University of Texas System	Paul, S (corresponding author), Univ Texas, Sch Med, Dept Pathol, 6431 Fannin, Houston, TX 77030 USA.	sudhir.paul@uth.tmc.edu			NATIONAL CANCER INSTITUTE [R01CA080312] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031268, R21AI031268, P01AI046029] Funding Source: NIH RePORTER; NCI NIH HHS [CA80312] Funding Source: Medline; NIAID NIH HHS [AI46029, AI31268] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Berisha HI, 2002, PULM PHARMACOL THER, V15, P121, DOI 10.1006/pupt.2001.0337; BERMAS BL, 1994, AIDS RES HUM RETROV, V10, P1071, DOI 10.1089/aid.1994.10.1071; BRADEN BC, 1995, FASEB J, V9, P9, DOI 10.1096/fasebj.9.1.7821765; BROWN PM, 1994, EUR J BIOCHEM, V225, P223, DOI 10.1111/j.1432-1033.1994.00223.x; Crennell SJ, 1996, J MOL BIOL, V259, P264, DOI 10.1006/jmbi.1996.0318; Fersht A., 1985, ENZYME STRUCTURE MEC; GAO QS, 1995, J MOL BIOL, V253, P658, DOI 10.1006/jmbi.1995.0580; Gololobov G, 1999, MOL IMMUNOL, V36, P1215, DOI 10.1016/S0161-5890(99)00141-8; GREEN NM, 1965, BIOCHEM J, V94, pC23, DOI 10.1042/bj0940023C; Hifumi E, 1999, J BIOSCI BIOENG, V88, P323, DOI 10.1016/S1389-1723(00)80018-3; Interthal H, 2001, P NATL ACAD SCI USA, V98, P12009, DOI 10.1073/pnas.211429198; IZADYAR L, 1993, P NATL ACAD SCI USA, V90, P8876, DOI 10.1073/pnas.90.19.8876; Jia Y, 2000, BIOCHEMISTRY-US, V39, P3927, DOI 10.1021/bi9928086; Jimenez R, 2003, P NATL ACAD SCI USA, V100, P92, DOI 10.1073/pnas.262411399; KALAGA R, 1995, J IMMUNOL, V155, P2695; Karle S, 2003, VACCINE, V21, P1213, DOI 10.1016/S0264-410X(02)00504-2; Kolesnikov AV, 2000, P NATL ACAD SCI USA, V97, P13526, DOI 10.1073/pnas.200360497; Lacroix-Desmazes S, 1999, NAT MED, V5, P1044, DOI 10.1038/12483; Lefevre S, 2001, FEBS LETT, V489, P25, DOI 10.1016/S0014-5793(01)02075-0; Matsuura K, 1996, BIOL CHEM, V377, P587, DOI 10.1515/bchm3.1996.377.9.587; Nevinsky GA, 1998, APPL BIOCHEM BIOTECH, V75, P77, DOI 10.1007/BF02787710; Nishiyama Y, 2002, ARCH BIOCHEM BIOPHYS, V402, P281, DOI 10.1016/S0003-9861(02)00087-5; OLEKSYSZYN J, 1994, J MED CHEM, V37, P226, DOI 10.1021/jm00028a004; OLEKSYSZYN J, 1994, METHOD ENZYMOL, V244, P423; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1992, J BIOL CHEM, V267, P13142; Paul S, 2001, J BIOL CHEM, V276, P28314, DOI 10.1074/jbc.M102530200; PAUL S, 1990, J BIOL CHEM, V265, P11910; Planque S, 2003, FASEB J, V17, P136, DOI 10.1096/fj.01-0847com; RAO G, 1991, J PROTEIN CHEM, V10, P117, DOI 10.1007/BF01024661; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHUSTER AM, 1992, SCIENCE, V256, P665, DOI 10.1126/science.1585181; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; Sun M, 1997, J MOL BIOL, V271, P374, DOI 10.1006/jmbi.1997.1196; Taguchi H, 2002, BIOORG MED CHEM LETT, V12, P3167, DOI 10.1016/S0960-894X(02)00640-6; TAKAGI M, 1995, FEBS LETT, V375, P273, DOI 10.1016/0014-5793(95)01224-3; Tramontano A, 2000, CHEM IMMUNOL, V77, P1, DOI 10.1159/000058794; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Voice JK, 2003, J IMMUNOL, V170, P308, DOI 10.4049/jimmunol.170.1.308; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WUILMART C, 1976, J IMMUNOGENET, V3, P1; ZHAO QJ, 1994, BIOCHEMISTRY-US, V33, P8128, DOI 10.1021/bi00192a018; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	45	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20436	20443		10.1074/jbc.M301468200	http://dx.doi.org/10.1074/jbc.M301468200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668670	hybrid			2022-12-27	WOS:000183078000110
J	Diviani, D; Lattion, AL; Abuin, L; Staub, O; Cotecchia, S				Diviani, D; Lattion, AL; Abuin, L; Staub, O; Cotecchia, S			The adaptor complex 2 directly interacts with the alpha(1b)-adrenergic receptor and plays a role in receptor endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-ADAPTER; SORTING SIGNALS; BETA-ARRESTIN; BINDING-SITE; INTERNALIZATION; PHOSPHORYLATION; DESENSITIZATION; EXPRESSION; MOTIF; AP-2	Using the yeast two-hybrid system, we identified the mu(2) subunit of the clathrin adaptor complex 2 as a protein interacting with the C-tail of the alpha(1b)-adrenergic receptor (AR). Direct association between the alpha(1b)-AR and mu(2) was demonstrated using a solid phase overlay assay. The alpha(1b)-AR/mu(2) interaction occurred inside the cells, as shown by the finding that the transfected alpha(1b)-AR and the endogenous mu(2) could be coimmunoprecipitated from HEK-293 cell extracts. Mutational analysis of the alpha(1b)-AR revealed that the binding site for mu(2) does not involve canonical YXXPhi or dileucine motifs but a stretch of eight arginines on the receptor C-tail. The binding domain of mu(2) for the receptor C-tail involves both its N terminus and the subdomain B of its C-terminal portion. The alpha(1b)-AR specifically interacted with mu(2), but not with the mu(1), mu(3), or mu(4) subunits belonging to other AP complexes. The deletion of the mu(2) binding site in the C-tail markedly decreased agonist-induced receptor internalization as demonstrated by confocal microscopy as well as by the results of a surface receptor biotinylation assay. The direct association of the adaptor complex 2 with a G protein-coupled receptor has not been reported so far and might represent a common mechanism underlying clathrin-mediated receptor endocytosis.	Fac Med, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Geneva	Cotecchia, S (corresponding author), Fac Med, Inst Pharmacol & Toxicol, Rue Bugnon 27, CH-1005 Lausanne, Switzerland.			Diviani, Dario/0000-0003-4375-3718				Bjorklof K, 2002, BIOCHEMISTRY-US, V41, P4281, DOI 10.1021/bi015790j; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; Collins BM, 2002, CELL, V109, P523, DOI 10.1016/S0092-8674(02)00735-3; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Diviani D, 1996, J BIOL CHEM, V271, P5049; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; FONSECA MI, 1995, J BIOL CHEM, V270, P8902, DOI 10.1074/jbc.270.15.8902; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Haucke V, 2000, EMBO J, V19, P6011, DOI 10.1093/emboj/19.22.6011; Kim YM, 2002, J BIOL CHEM, V277, P30760, DOI 10.1074/jbc.M204528200; Kohout TA, 2003, MOL PHARMACOL, V63, P9, DOI 10.1124/mol.63.1.9; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Laporte SA, 2002, J BIOL CHEM, V277, P9247, DOI 10.1074/jbc.M108490200; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LEEBLUNDBERG LMF, 1987, J BIOL CHEM, V262, P3098; Madrid R, 2001, EMBO J, V20, P7008, DOI 10.1093/emboj/20.24.7008; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Pearse BMF, 2000, CURR OPIN STRUC BIOL, V10, P220, DOI 10.1016/S0959-440X(00)00071-3; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Simmen T, 2002, NAT CELL BIOL, V4, P154, DOI 10.1038/ncb745; Sorkin A, 1996, J BIOL CHEM, V271, P13377, DOI 10.1074/jbc.271.23.13377; Weixel KM, 2001, J BIOL CHEM, V276, P46251, DOI 10.1074/jbc.M104545200	30	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19331	19340		10.1074/jbc.M302110200	http://dx.doi.org/10.1074/jbc.M302110200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644451	hybrid			2022-12-27	WOS:000182932200080
J	Michel, G; Roszak, AW; Sauve, V; Maclean, J; Matte, A; Coggins, JR; Cygler, M; Lapthorn, AJ				Michel, G; Roszak, AW; Sauve, V; Maclean, J; Matte, A; Coggins, JR; Cygler, M; Lapthorn, AJ			Structures of shikimate dehydrogenase AroE and its paralog YdiB - A common structural framework for different activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERBICIDE GLYPHOSATE; GENE-CLUSTER; PROTEIN; ACID; ORGANIZATION; SYNTHASE; PATHWAY; DEHYDROQUINASE; BIOSYNTHESIS; SEQUENCE	Shikimate dehydrogenase catalyzes the fourth step of the shikimate pathway, the essential route for the biosynthesis of aromatic compounds in plants and microorganisms. Absent in metazoans, this pathway is an attractive target for nontoxic herbicides and drugs. Escherichia coli expresses two shikimate dehydrogenase paralogs, the NADP-specific AroE and a putative enzyme YdiB. Here we characterize YdiB as a dual specificity quinate/shikimate dehydrogenase that utilizes either NAD or NADP as a cofactor. Structures of AroE and YdiB with bound cofactors were determined at 1.5 and 2.5 Angstrom resolution, respectively. Both enzymes display a similar architecture with two alpha/beta domains separated by a wide cleft. Comparison of their dinucleotide-binding domains reveals the molecular basis for cofactor specificity. Independent molecules display conformational flexibility suggesting that a switch between open and closed conformations occurs upon substrate binding. Sequence analysis and structural comparison led us to propose the catalytic machinery and a model for 3-dehydroshikimate recognition. Furthermore, we discuss the evolutionary and metabolic implications of the presence of two shikimate dehydrogenases in E. coli and other organisms.	Natl Res Council Canada, Biotechnol Res Inst, Macromol Struct Grp, Montreal, PQ H4P 2R2, Canada; Univ Glasgow, Inst Biomed & Life Sci, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	National Research Council Canada; University of Glasgow; University of Glasgow	Lapthorn, AJ (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Macromol Struct Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	adrian@chem.gla.ac.uk	MICHEL, Gurvan/B-3490-2008; Maclean, John/E-6149-2012	Maclean, John/0000-0001-7069-7745; Lapthorn, Adrian/0000-0002-2197-8134; MICHEL, Gurvan/0000-0002-3009-6205				ADAMS MJ, 1973, P NATL ACAD SCI USA, V70, P1968, DOI 10.1073/pnas.70.7.1968; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSSON P, 1981, EUR J BIOCHEM, V113, P425, DOI 10.1111/j.1432-1033.1981.tb05082.x; ANTON IA, 1988, BIOCHEM J, V249, P319, DOI 10.1042/bj2490319; Baerson SR, 2002, PLANT PHYSIOL, V129, P1265, DOI 10.1104/pp.001560; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALINSKY D, 1961, BIOCHEM J, V80, P296, DOI 10.1042/bj0800296; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUGG TDH, 1988, TETRAHEDRON LETT, V29, P6779, DOI 10.1016/S0040-4039(00)82453-3; Carpenter EP, 1998, NATURE, V394, P299, DOI 10.1038/28431; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Carugo O, 1997, PROTEINS, V28, P10, DOI 10.1002/(SICI)1097-0134(199705)28:1<10::AID-PROT2>3.3.CO;2-R; CHACKREWARTHY S, 1996, THESIS U GLASGOW; CHAKRABARTI P, 1995, J MOL BIOL, V251, P9, DOI 10.1006/jmbi.1995.0411; CHAUDHURI S, 1985, BIOCHEM J, V226, P217, DOI 10.1042/bj2260217; DANSETTE P, 1974, BIOCHIMIE, V56, P751, DOI 10.1016/S0300-9084(74)80046-5; DAVIES GM, 1994, ANTIMICROB AGENTS CH, V38, P403, DOI 10.1128/AAC.38.2.403; DEKA RK, 1994, FEBS LETT, V349, P397, DOI 10.1016/0014-5793(94)00710-1; DENNIS AW, 1972, INT J BIOCHEM, V3, P93, DOI 10.1016/0020-711X(72)90031-6; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1577, DOI 10.1021/bi00405a027; GEEVER RF, 1989, J MOL BIOL, V207, P15, DOI 10.1016/0022-2836(89)90438-5; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Gourley DG, 1999, NAT STRUCT BIOL, V6, P521; HAWKINS AR, 1993, J GEN MICROBIOL, V139, P2891, DOI 10.1099/00221287-139-12-2891; HAWKINS AR, 1988, MOL GEN GENET, V214, P224, DOI 10.1007/BF00337715; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; Herrmann KM, 1999, ANNU REV PLANT PHYS, V50, P473, DOI 10.1146/annurev.arplant.50.1.473; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KISHORE GM, 1988, ANNU REV BIOCHEM, V57, P627, DOI 10.1146/annurev.bi.57.070188.003211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krell T, 1998, J MOL BIOL, V278, P983, DOI 10.1006/jmbi.1998.1755; Krell T, 1998, J PEPT RES, V51, P201; LAMBERT JM, 1985, BIOCHEM J, V226, P817, DOI 10.1042/bj2260817; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 1999, J MOL BIOL, V285, P2177; Maclean J, 2000, ACTA CRYSTALLOGR D, V56, P512, DOI 10.1107/S0907444900002377; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONRSTON LN, 2003, BIOL ACINETOBACTER, P201; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Roberts F, 1998, NATURE, V393, P801, DOI 10.1038/31723; Romanowski MJ, 2002, PROTEINS, V47, P558, DOI 10.1002/prot.10099; Roszak AW, 2002, STRUCTURE, V10, P493, DOI 10.1016/S0969-2126(02)00747-5; Salgado H, 2001, NUCLEIC ACIDS RES, V29, P72, DOI 10.1093/nar/29.1.72; Schonbrunn E, 2001, P NATL ACAD SCI USA, V98, P1376, DOI 10.1073/pnas.98.4.1376; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P80; STEINRUCKEN HC, 1980, BIOCHEM BIOPH RES CO, V94, P1207, DOI 10.1016/0006-291X(80)90547-1; Walkinshaw MD, 2002, MOL CELL, V9, P187, DOI 10.1016/S1097-2765(02)00435-5	50	89	103	1	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19463	19472		10.1074/jbc.M300794200	http://dx.doi.org/10.1074/jbc.M300794200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637497	hybrid			2022-12-27	WOS:000182932200096
J	Uttamsingh, S; Zong, CS; Wang, LH				Uttamsingh, S; Zong, CS; Wang, LH			Matrix-independent activation of phosphatidylinositol 3-kinase, Stat3, and cyclin A-associated Cdk2 is essential for anchorage-independent growth of v-Ros-transformed chicken embryo fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTOONCOGENE C-ROS; SARCOMA VIRUS UR2; SIGNAL-TRANSDUCTION PATHWAYS; RECEPTOR TYROSINE KINASES; FOCAL ADHESION KINASE; FACTOR-I RECEPTOR; CELL-CYCLE; PROTEIN-KINASE; INSULIN-RECEPTOR; EXTRACELLULAR-MATRIX	The question remains open whether the signaling pathways shown to be important for growth and transformation in adherent cultures proceed similarly and play similar roles for cells grown under anchorage-independent conditions. Chicken embryo fibroblasts (CEF) infected with the avian sarcoma virus UR2, encoding the oncogenic receptor protein-tyrosine kinase ( RPTK) v-Ros, or with two of its transformation-impaired mutants were grown in nonadherent conditions in methylcellulose (MC)-containing medium, and the signaling functions essential for Ros-induced anchorage-independent growth were analyzed. We found that the overall tyrosine phosphorylation of cellular proteins in CEF transformed by v-Ros or by two oncogenic nonreceptor protein-tyrosine kinases ( PTKs), v-Src and v-Yes, was dramatically reduced in nonadherent conditions compared with that in adherent conditions, indicating that cell adhesion to the extracellular matrix plays an important role in efficient substrate phosphorylation by these constitutively activated PTKs. The UR2 transformation-defective mutants were differentially impaired compared with UR2 in the activation of phosphatidylinositol 3-kinase ( PI 3-kinase) and Stat3 in nonadherent conditions. Consistently, the constitutively activated mutants of PI 3-kinase and Stat3 rescued the ability of the UR2 mutants to promote anchorage-independent growth. Conversely, dominant negative mutants of PI 3-kinase and Stat3 inhibited UR2-induced anchorage-independent growth. UR2-infected CEF grown in nonadherent conditions displayed faster cell cycle progression than the control or the UR2 mutant-infected cells, and this appeared to correlate with a PI 3-kinase-dependent increase in cyclin A-associated Cdk2 activity. Treatment of UR2-infected cells with Cdk2 inhibitors led to the loss of the anchorage-independent growth-promoting activity of UR2. In conclusion, we have adopted an experimental system enabling us to study the signaling pathways in cells grown under anchorage-independent conditions and have identified matrix-independent activation of PI 3-kinase and Stat3 signaling functions, as well as the PI 3-kinase-dependent increase of cyclin A-associated Cdk2 kinase activity, to be critical for the Ros-PTK-induced anchorage-independent growth.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, Box 1124, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010		NCI NIH HHS [CA55054, CA29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055054, R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSOIAN RK, 1989, ANAL BIOCHEM, V177, P95, DOI 10.1016/0003-2697(89)90020-1; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; Bohmer RM, 1996, MOL BIOL CELL, V7, P101; Bottazzi ME, 1997, TRENDS CELL BIOL, V7, P348, DOI 10.1016/S0962-8924(97)01114-8; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cao XM, 1996, MOL CELL BIOL, V16, P1595; CARY LA, 1999, FRONT BIOSCI, V4, P102; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; CHEN JM, 1994, ONCOGENE, V9, P773; CHEN JM, 1991, ONCOGENE, V6, P257; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Collado M, 2000, J BIOL CHEM, V275, P21960, DOI 10.1074/jbc.M000759200; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; Ito T, 1996, MOL CELL BIOL, V16, P943; Jiang YX, 1996, J BIOL CHEM, V271, P160, DOI 10.1074/jbc.271.1.160; JONG SMJ, 1987, ONCOGENE RES, V1, P7; Kang JS, 1996, MOL CELL BIOL, V16, P3370; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; KRAUSS RS, 1992, MOL CELL BIOL, V12, P3117, DOI 10.1128/MCB.12.7.3117; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lin TH, 1997, J BIOL CHEM, V272, P8849; LIU DL, 1993, J VIROL, V67, P9, DOI 10.1128/JVI.67.1.9-18.1993; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Magun R, 1996, ENDOCRINOLOGY, V137, P3590, DOI 10.1210/en.137.8.3590; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; NECKAMEYER WS, 1984, J VIROL, V50, P914, DOI 10.1128/JVI.50.3.914-921.1984; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Philip A, 2000, J BIOL CHEM, V275, P5911, DOI 10.1074/jbc.275.8.5911; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schulze A, 1996, MOL CELL BIOL, V16, P4632; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Schwartz MA, 2001, J CELL SCI, V114, P2553; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SONNENBERG E, 1991, EMBO J, V10, P3693, DOI 10.1002/j.1460-2075.1991.tb04937.x; SonnenbergRiethmacher E, 1996, GENE DEV, V10, P1184, DOI 10.1101/gad.10.10.1184; Suzuki K, 2000, BIOCHEM BIOPH RES CO, V272, P111, DOI 10.1006/bbrc.2000.2737; TESSAROLLO L, 1992, DEVELOPMENT, V115, P11; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou Q, 2000, BREAST CANCER RES TR, V59, P27, DOI 10.1023/A:1006370603147; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391; ZONG CS, 1993, J VIROL, V67, P6453, DOI 10.1128/JVI.67.11.6453-6462.1993; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065; ZONG CS, 1994, P NATL ACAD SCI USA, V91, P10982, DOI 10.1073/pnas.91.23.10982; Zong CS, 1997, J BIOL CHEM, V272, P1500, DOI 10.1074/jbc.272.3.1500	88	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18798	18810		10.1074/jbc.M211522200	http://dx.doi.org/10.1074/jbc.M211522200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646574	hybrid			2022-12-27	WOS:000182932200014
J	Son, GH; Jung, H; Seong, JY; Choe, Y; Geum, D; Kim, K				Son, GH; Jung, H; Seong, JY; Choe, Y; Geum, D; Kim, K			Excision of the first intron from the gonadotropin-releasing hormone (GnRH) transcript serves as a key regulatory step for GnRH biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; PRE-MESSENGER-RNA; EXPRESSION IN-VIVO; GENE TRANSCRIPTS; TRANSLATIONAL CONTROL; MOUSE HYPOTHALAMUS; RAT; RECEPTOR; LOCALIZATION; SEQUENCES	The mammalian gonadotropin-releasing hormone (GnRH) gene consists of four short exons (denoted as 1, 2, 3, and 4) and three intervening introns (A, B, and C). Recently, we demonstrated that excision of the first intron (intron A) from the GnRH transcript is regulated in a tissue- and developmental stage-specific fashion and is severely attenuated in hypogonadal (hpg) mouse because of its lack of exonic splicing enhancers (ESE) 3 and 4. In the present study, we examined the influence of intron A on translational efficiency, thereby establishing a post-transcriptional control over GnRH biosynthesis. First, we verified that an intron A-retained GnRH transcript is a splicing variant but not a splicing intermediate. Intron A-retained transcripts can be transported to the cytoplasm in contrast to intron B-containing transcripts, which are restricted to the nucleus. This result implicates the intron A-retained GnRH transcript as a splicing variant; it has a long 5'-untranslated region, as the GnRH prohormone open reading frame (ORF) begins on exon 2. We investigated whether an intron A-retained GnRH transcript can properly initiate translation at the appropriate start codon and found that intron A completely blocks the translation initiation of its downstream reporter ORF both in vivo and in vitro. The inhibition of translation initiation appears to be due to the presence of a tandem repeat of ATG sequences within intron A. Constructs bearing mutations of ATGs to AAGs restored translation initiation at the downstream start codon; the extent of this restoration correlated with the number of mutated ATGs. Besides the failure in the translation initiation of GnRH-coding region in the intron A-containing variant, the present study also suggests that the interference between mature GnRH mRNA and intron A-retained splicing variant could occur to lower the efficiency of GnRH biosynthesis in the GT1-1-immortalized GnRH-producing cell line. Therefore, our results indicate that the precise and efficient excision of intron A and the joining of adjacent exons may be a critical regulatory step for the post-transcriptional regulation of GnRH biosynthesis.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea	Seoul National University (SNU); Chonnam National University	Kim, K (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.		Jung, Hosung/A-4401-2012; Seong, Jae Young/A-5794-2012	Jung, Hosung/0000-0002-5059-8050; Seong, Jae Young/0000-0002-3312-6924				ADELMAN JP, 1986, P NATL ACAD SCI USA, V83, P179, DOI 10.1073/pnas.83.1.179; Child SJ, 1999, J BIOL CHEM, V274, P24335, DOI 10.1074/jbc.274.34.24335; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Gore AC, 1997, FRONT NEUROENDOCRIN, V18, P209, DOI 10.1006/frne.1996.0149; GOUBAU S, 1992, ENDOCRINOLOGY, V130, P3098, DOI 10.1210/en.130.5.3098; Han J, 2001, MOL CELL ENDOCRINOL, V173, P157, DOI 10.1016/S0303-7207(00)00409-3; JAKUBOWSKI M, 1994, J BIOL CHEM, V269, P4078; Kang SS, 2000, J NEUROENDOCRINOL, V12, P421; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lawson MA, 2002, ENDOCRINOLOGY, V143, P1404, DOI 10.1210/en.143.4.1404; Lincoln AJ, 1998, J BIOL CHEM, V273, P9552, DOI 10.1074/jbc.273.16.9552; MASON AJ, 1986, SCIENCE, V234, P1366, DOI 10.1126/science.3024317; Mize GJ, 1998, J BIOL CHEM, V273, P32500, DOI 10.1074/jbc.273.49.32500; MIZOKAMI A, 1994, J BIOL CHEM, V269, P25655; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OLIVEIRA CC, 1995, J BIOL CHEM, V270, P8936, DOI 10.1074/jbc.270.15.8936; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; Seong JY, 1999, MOL ENDOCRINOL, V13, P1882, DOI 10.1210/me.13.11.1882; Seong JY, 2002, MOL ENDOCRINOL, V16, P2426, DOI 10.1210/me.2001-0297; Seong JY, 2001, ENDOCRINOLOGY, V142, P4454, DOI 10.1210/en.142.10.4454; SHEWARD WJ, 1985, BRAIN RES, V345, P362, DOI 10.1016/0006-8993(85)91017-0; Silverman Ann-Judith, 1994, P1683; Steinmetz EJ, 1997, CELL, V89, P491, DOI 10.1016/S0092-8674(00)80230-5; Trembleau A, 1998, BIOL CELL, V90, P39, DOI 10.1016/S0248-4900(98)80231-1; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; Yeo TTS, 1996, MOL BRAIN RES, V42, P255, DOI 10.1016/S0169-328X(96)00129-5; ZHANG GH, 1994, NATURE, V372, P809; Zhen SJ, 1997, J BIOL CHEM, V272, P12620, DOI 10.1074/jbc.272.19.12620	30	24	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18037	18044		10.1074/jbc.M209850200	http://dx.doi.org/10.1074/jbc.M209850200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639969	hybrid			2022-12-27	WOS:000182838300058
J	Stortchevoi, A; Varshney, U; RajBhandary, UL				Stortchevoi, A; Varshney, U; RajBhandary, UL			Common location of determinants in initiator transfer RNAs for initiator-elongator discrimination in bacteria and in eukaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYLMETHIONINE TRANSFER-RNA; AMINOACYL-TRANSFER-RNAS; TRANSFER RIBONUCLEIC-ACID; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; FACTOR TU; EF-TU; CRYSTAL-STRUCTURE; TRANSFER RNA(MET); INSERTION MODULE	Initiator tRNAs are used exclusively for initiation of protein synthesis and not for elongation. We show that both Escherichia coli and eukaryotic initiator tRNAs have negative determinants, at the same positions, that block their activity in elongation. The primary negative determinant in E. coli initiator tRNA is the C1xA72 mismatch at the end of the acceptor stem. The primary negative determinant in eukaryotic initiator tRNAs is located in the TPsiC stem, whereas a secondary negative determinant is the A1:U72 base pair at the end of the acceptor stem. Here we show that E. coli initiator tRNA also has a secondary negative determinant for elongation and that it is the U50.G64 wobble base pair, located at the same position in the TPsiC stem as the primary negative determinant in eukaryotic initiator tRNAs. Mutation of the U50.G64 wobble base pair to C50:G64 or U50:A64 base pairs increases the in vivo amber suppressor activity of initiator tRNA mutants that have changes in the acceptor stem and in the anticodon sequence necessary for amber suppressor activity. Binding assays of the mutant aminoacyl-tRNAs carrying the C50 and A64 changes to the elongation factor EF-Tu.GTP show marginally higher affinity of the C50 and A64 mutant tRNAs and increased stability of the EF-Tu.GTP-aminoacyl-tRNA ternary complexes. Other results show a large effect of the amino acid attached to a tRNA, glutamine versus methionine, on the binding affinity toward EF-Tu.GTP and on the stability of the EF-Tu.GTP.aminoacyl-tRNA ternary complex.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	RajBhandary, UL (corresponding author), MIT, Dept Biol, Rm 68-671, Cambridge, MA 02139 USA.		Varshney, Umesh/A-8062-2009; Varshney, Umesh/Q-6914-2019		NIGMS NIH HHS [R37GM17151] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017151] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asahara H, 2002, P NATL ACAD SCI USA, V99, P3499, DOI 10.1073/pnas.052028599; ASTROM SU, 1993, J MOL BIOL, V233, P43, DOI 10.1006/jmbi.1993.1483; ASTROM SU, 1994, CELL, V79, P535, DOI 10.1016/0092-8674(94)90262-3; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; CANONACO MA, 1986, FEBS LETT, V207, P198, DOI 10.1016/0014-5793(86)81488-0; CELIS JE, 1976, J MOL BIOL, V104, P729, DOI 10.1016/0022-2836(76)90132-7; CLARK BFC, 1966, J MOL BIOL, V17, P394, DOI 10.1016/S0022-2836(66)80150-X; DESGRES J, 1989, NUCLEIC ACIDS RES, V17, P865, DOI 10.1093/nar/17.3.865; DICKERMA.HW, 1967, J BIOL CHEM, V242, P1522; Drabkin HJ, 1998, MOL CELL BIOL, V18, P1459, DOI 10.1128/MCB.18.3.1459; Drabkin HJ, 1998, MOL CELL BIOL, V18, P5140, DOI 10.1128/MCB.18.9.5140; Dreher TW, 1999, J BIOL CHEM, V274, P666, DOI 10.1074/jbc.274.2.666; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; FORSTER C, 1993, NUCLEIC ACIDS RES, V21, P5679; GHOSH HP, 1982, NUCLEIC ACIDS RES, V10, P3241, DOI 10.1093/nar/10.10.3241; GIEGE R, 1973, FEBS LETT, V30, P291, DOI 10.1016/0014-5793(73)80672-6; GUILLON JM, 1993, J BACTERIOL, V175, P4507, DOI 10.1128/JB.175.14.4507-4514.1993; HERSHEY JWB, 1987, ESCHERICHIA COLI SAL, V1, P613; KIESEWETTER S, 1990, NUCLEIC ACIDS RES, V18, P4677, DOI 10.1093/nar/18.16.4677; KNOWLTON RG, 1980, J MOL BIOL, V139, P721, DOI 10.1016/0022-2836(80)90057-1; KOSSEL H, 1968, J MOL BIOL, V35, P539, DOI 10.1016/S0022-2836(68)80013-0; KOZAK M, 1983, MICROBIOL REV, V47, P1; LaRiviere FJ, 2001, SCIENCE, V294, P165, DOI 10.1126/science.1064242; LEE CP, 1991, J BIOL CHEM, V266, P18012; LEE CP, 1992, P NATL ACAD SCI USA, V89, P9262, DOI 10.1073/pnas.89.19.9262; Li SH, 1996, J BIOL CHEM, V271, P1022, DOI 10.1074/jbc.271.2.1022; LOUIE A, 1984, J BIOL CHEM, V259, P5010; MARCKER K, 1964, J MOL BIOL, V8, P835, DOI 10.1016/S0022-2836(64)80164-9; MEINNEL T, 1993, J BACTERIOL, V175, P7737, DOI 10.1128/JB.175.23.7737-7740.1993; Miller JH., 1992, SHORT COURSE BACTERI, P72; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; PERONA JJ, 1989, SCIENCE, V246, P1152, DOI 10.1126/science.2686030; PIPER PW, 1974, NATURE, V247, P516, DOI 10.1038/247516a0; Pleiss JA, 2001, J MOL BIOL, V308, P895, DOI 10.1006/jmbi.2001.4612; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Rajbhandary Uttam L., 1995, P511; Ramesh V, 1997, P NATL ACAD SCI USA, V94, P13524, DOI 10.1073/pnas.94.25.13524; Ramesh V, 1998, BIOCHEMISTRY-US, V37, P15925, DOI 10.1021/bi981873x; Rudinger J, 1996, EMBO J, V15, P650, DOI 10.1002/j.1460-2075.1996.tb00397.x; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SEONG BL, 1989, J BIOL CHEM, V264, P6504; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SIMSEK M, 1974, NATURE, V247, P518, DOI 10.1038/247518a0; SIMSEK M, 1972, BIOCHEM BIOPH RES CO, V49, P508, DOI 10.1016/0006-291X(72)90440-8; SOLL L, 1969, NATURE, V223, P1340, DOI 10.1038/2231340a0; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUNDARI RM, 1976, J BIOL CHEM, V251, P3338; Takeuchi N, 2001, J BIOL CHEM, V276, P20064, DOI 10.1074/jbc.M101007200; Thanedar S, 2000, J BIOL CHEM, V275, P20361, DOI 10.1074/jbc.M001238200; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; VARSHNEY U, 1993, P NATL ACAD SCI USA, V90, P2305, DOI 10.1073/pnas.90.6.2305; WAGNER T, 1984, J BIOL CHEM, V259, P4706; Wu XQ, 1996, EMBO J, V15, P4734, DOI 10.1002/j.1460-2075.1996.tb00850.x; Wu XQ, 1997, J BIOL CHEM, V272, P1891, DOI 10.1074/jbc.272.3.1891; Zhang YL, 1996, FEBS LETT, V391, P330, DOI 10.1016/0014-5793(96)00789-2	59	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17672	17679		10.1074/jbc.M212890200	http://dx.doi.org/10.1074/jbc.M212890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639964	hybrid			2022-12-27	WOS:000182838300013
J	Vang, T; Abrahamsen, H; Myklebust, S; Horejsi, V; Tasken, K				Vang, T; Abrahamsen, H; Myklebust, S; Horejsi, V; Tasken, K			Combined spatial and enzymatic regulation of Csk by cAMP and protein kinase A inhibits T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL SRC KINASE; ENRICHED MICRODOMAINS; TYROSINE KINASES; LIPID RAFTS; ACTIVATION	Raft-associated Csk controls signaling through the T cell receptor (TCR) and was mainly anchored to Cbp/PAG (phosphoprotein associated with glycosphingolipid-enriched membrane domains). Treatment of cells with the cAMP-elevating agent prostaglandin E-2 (PGE(2)) augmented the level of Cbp/PAG phosphorylation with a concomitant increase in amounts of Csk bound to Cbp/PAG. While TCR-triggering resulted in transient dissociation of Csk from Cbp/PAG/rafts allowing TCR-induced tyrosine phosphorylation to occur, pretreatment with PGE(2) reduced Csk dissociation upon TCR triggering. This correlated with lowered TCR-induced phosphorylation of CD3 zeta-chain and linker for activation of T cells. Moreover, competition of endogenous Csk from lipid rafts abolished PGE(2)-mediated inhibition of TCR-induced zeta-chain phosphorylation and activation of the nuclear factor of activated T cells (NFAT) activator protein 1 (AP-1). Finally, raft-associated Csk already activated via Cbp/PAG binding, gained additional increase in phosphotransferase activity upon protein kinase A-mediated phosphorylation of Csk. We propose that cAMP regulates Csk via both spatial and enzymatic mechanisms, thereby inhibiting signaling through the TCR.	Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, N-0317 Oslo, Norway; Univ Oslo, Sch Pharm, Dept Pharmacol, N-0317 Oslo, Norway; Acad Sci Czech Republ, Inst Mol Genet, CR-14220 Prague, Czech Republic	University of Oslo; University of Oslo; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Tasken, K (corresponding author), Univ Oslo, Inst Basic Med Sci, Dept Med Biochem, POB 1112, N-0317 Oslo, Norway.		Abrahamsen, Hilde/E-5323-2010; Horejsi, Vaclav/G-3113-2014	Horejsi, Vaclav/0000-0003-4925-0142; Tasken, Kjetil/0000-0003-2841-4697				Aandahl EM, 1998, FASEB J, V12, P855, DOI 10.1096/fasebj.12.10.855; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; Davidson D, 2003, MOL CELL BIOL, V23, P2017, DOI 10.1128/MCB.23.6.2017-2028.2003; Hermiston ML, 2002, J CLIN INVEST, V109, P9; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Schmedt C, 1998, NATURE, V394, P901, DOI 10.1038/29802; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Werlen G, 2002, CURR OPIN IMMUNOL, V14, P299, DOI 10.1016/S0952-7915(02)00339-4; Yasuda K, 2002, J IMMUNOL, V169, P2813, DOI 10.4049/jimmunol.169.6.2813	15	59	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17597	17600		10.1074/jbc.C300077200	http://dx.doi.org/10.1074/jbc.C300077200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12665526	hybrid			2022-12-27	WOS:000182838300004
J	Yan, LM; Nairn, AC; Palfrey, HC; Brady, MJ				Yan, LM; Nairn, AC; Palfrey, HC; Brady, MJ			Glucose regulates EF-2 phosphorylation and protein translation by a protein phosphatase-2A-dependent mechanism in INS-1-derived 832/13 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ELONGATION FACTOR-II; PROINSULIN BIOSYNTHESIS; INSULIN EXOCYTOSIS; PHOSPHATASE 2A; RAT ISLETS; KINASE-III; LANGERHANS; DEPHOSPHORYLATION; IDENTIFICATION	The role of elongation factor (EF)-2 phosphorylation in the regulation of pancreatic beta-cell protein synthesis by glucose was investigated in the INS-1-derived cell line 832/13. Incubation of cells in media containing 1 mM glucose resulted in a progressive increase in EF-2 phosphorylation that was maximal by 1-2 h. Readdition of 10 mM glucose promoted a rapid dephosphorylation of EF-2 that was complete in 10 min and maintained over the ensuing 2 h. Similar results were obtained using primary rat islets or Min-6 insulinoma cells. The glucose effect in 832/13 cells was replicated by addition of pyruvate or alpha-ketocaproate, but not 2-deoxyglucose, suggesting that mitochondrial metabolism was required. Accordingly, glucose-mediated dephosphorylation of EF-2 was completely blocked by the mitochondrial respiratory antagonists antimycin A and oligomycin. The hyperglycemic effect was not mimicked by incubation of cells in 100 nM insulin, 30 mM potassium chloride, or 0.25 mM diazoxide, indicating that insulin secretion and/or depolarization of beta cells was not required. The locus of the high glucose effect appeared to be protein phosphatase-2A, the principal phosphatase acting on EF-2. Protein phosphatase-2A activity was stimulated by glucose addition to 832/13 cells, but neither protein phosphatase-1 nor calmodulin kinase III ( EF-2 kinase) activity was affected under these conditions. The slower rephosphorylation of EF-2 during the transition from high to low glucose may involve effects on EF-2 kinase activity. Addition of 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside in high glucose led to a marked stimulation of EF-2 phosphorylation, consistent with the possibility that increased AMP kinase activity in low glucose stimulates EF-2 kinase. In parallel with the effects on EF-2 dephosphorylation, addition of high glucose to 832/13 cells markedly increased the incorporation of [S-35]methionine into total protein. Taken together, these results suggest that modulation of extracellular glucose impacts protein translation rate in beta cells at least in part through regulation of the elongation step, via phosphorylation/dephosphorylation of EF-2.	Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA	University of Chicago; University of Chicago; Yale University	Brady, MJ (corresponding author), Univ Chicago, Dept Med, MC 1027,5841 S Maryland Ave, Chicago, IL 60637 USA.			Nairn, Angus/0000-0002-7075-0195				Brady MJ, 1997, J BIOL CHEM, V272, P29698, DOI 10.1074/jbc.272.47.29698; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Donelan MJ, 2002, J BIOL CHEM, V277, P24232, DOI 10.1074/jbc.M203345200; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Gilligan M, 1996, J BIOL CHEM, V271, P2121, DOI 10.1074/jbc.271.4.2121; Goodge KA, 2000, SEMIN CELL DEV BIOL, V11, P235, DOI 10.1006/scdb.2000.0172; GRIMALDI KA, 1987, BIOCHEM J, V245, P567, DOI 10.1042/bj2450567; GUEST PC, 1991, BIOCHEM J, V274, P73, DOI 10.1042/bj2740073; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Knebel A, 2002, BIOCHEM J, V367, P525, DOI 10.1042/BJ20020916; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Marin P, 1997, J NEUROSCI, V17, P3445; MCDANIEL ML, 1983, METHOD ENZYMOL, V98, P182; MITSUI K, 1993, J BIOL CHEM, V268, P13422; Murphy LI, 1996, MOL CELL ENDOCRINOL, V117, P195, DOI 10.1016/0303-7207(95)03747-0; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; Nairn AC, 2001, PROG MOLEC, V27, P91; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; Salt IP, 1998, BIOCHEM J, V335, P533, DOI 10.1042/bj3350533; Sjoholm A, 2002, ENDOCRINOLOGY, V143, P4592, DOI 10.1210/en.2002-220672; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Traugh J A, 2001, Prog Mol Subcell Biol, V26, P33; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Webb GC, 2000, P NATL ACAD SCI USA, V97, P5773, DOI 10.1073/pnas.100126597; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; Xu G, 1998, J BIOL CHEM, V273, P4485, DOI 10.1074/jbc.273.8.4485; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8	36	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18177	18183		10.1074/jbc.M301116200	http://dx.doi.org/10.1074/jbc.M301116200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12644453	hybrid			2022-12-27	WOS:000182838300077
J	Kozlov, S; Gueven, N; Keating, K; Ramsay, J; Lavin, MF				Kozlov, S; Gueven, N; Keating, K; Ramsay, J; Lavin, MF			ATP activates ataxia-telangiectasia mutated (ATM) in vitro - Importance of autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; DNA-DAMAGE; CELL-CYCLE; IONIZING-RADIATION; FUNCTIONAL-LINK; PHOSPHORYLATION; P53; GENE	Ataxia-telangiectasia Mutated (ATM), mutated in the human disorder ataxia-telangiectasia, is rapidly activated by DNA double strand breaks. The mechanism of activation remains unresolved, and it is uncertain whether autophosphorylation contributes to activation. We describe an in vitro immunoprecipitation system demonstrating activation of ATM kinase from unirradiated extracts by preincubation with ATP. Activation is both time- and ATP concentration-dependent, other nucleotides fail to activate ATM, and DNA is not required. ATP activation is specific for ATM since it is not observed with kinase-dead ATM, it requires Mn2+, and it is inhibited by wortmannin. Exposure of activated ATM to phosphatase abrogates activity, and repeat cycles of ATP and phosphatase treatment reveal a requirement for autophosphorylation in the activation process. Phosphopeptide mapping revealed similarities between the patterns of autophosphorylation for irradiated and ATP-treated ATM. Caffeine inhibited ATM kinase activity for substrates but did not interfere with ATM autophosphorylation. ATP failed to activate either A-T and rad3-related protein (ATR) or DNA-dependent protein kinase under these conditions, supporting the specificity for ATM. These data demonstrate that ATP can specifically induce activation of ATM by a mechanism involving autophosphorylation. The relationship of this activation to DNA damage activation remains unclear but represents a useful model for understanding in vivo activation.	Queensland Inst Med Res, Canc Fund Res Unit, Brisbane, Qld 4029, Australia; Univ Queensland, Dept Surg, Herston, Qld 4029, Australia; Mater Hosp, Queensland Radium Inst, Brisbane, Qld 4101, Australia; ERIX Therapeut Ltd, Cork, Ireland	QIMR Berghofer Medical Research Institute; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, Canc Fund Res Unit, POB Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	martinL@qimr.edu.au	Ramsay, Jonathan/F-7009-2013; Lavin, Martin F/F-5961-2014; Kozlov, Sergei/M-2067-2014; Kozlov, Sergei/T-9779-2019	Lavin, Martin F/0000-0002-5940-4769; Kozlov, Sergei/0000-0001-6183-7339; Guven, Nuri/0000-0003-3782-767X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chen G, 1999, J BIOL CHEM, V274, P12748, DOI 10.1074/jbc.274.18.12748; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deak JC, 1997, BIOCHEM J, V322, P185, DOI 10.1042/bj3220185; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gerlach AC, 2001, J BIOL CHEM, V276, P10963, DOI 10.1074/jbc.M007716200; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KATOH T, 1991, J BIOL CHEM, V266, P3039; Keating KE, 2001, ONCOGENE, V20, P4281, DOI 10.1038/sj.onc.1204527; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KHANNA KK, 1995, ONCOGENE, V11, P609; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LeesMiller SP, 1996, BIOCHEM CELL BIOL, V74, P503, DOI 10.1139/o96-054; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Roseman AM, 2001, J STRUCT BIOL, V135, P115, DOI 10.1006/jsbi.2001.4374; Sarkaria JN, 1999, CANCER RES, V59, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Scott SP, 1998, BIOCHEM BIOPH RES CO, V245, P144, DOI 10.1006/bbrc.1998.8137; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; Sowadski JM, 1999, PHARMACOL THERAPEUT, V82, P157, DOI 10.1016/S0163-7258(98)00054-0; Szczepanowska J, 1997, P NATL ACAD SCI USA, V94, P8503, DOI 10.1073/pnas.94.16.8503; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Wang Y, 2000, GENE DEV, V14, P927; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; ZIV Y, 2000, METHODS MOL BIOL STR, P99	62	73	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9309	9317		10.1074/jbc.M300003200	http://dx.doi.org/10.1074/jbc.M300003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645530	hybrid			2022-12-27	WOS:000181524000056
J	Chen, Z; Raman, M; Chen, L; Lee, SF; Gilman, AG; Cobb, MH				Chen, Z; Raman, M; Chen, L; Lee, SF; Gilman, AG; Cobb, MH			TAO (thousand-and-one amino acid) protein kinases mediate signaling from carbachol to p38 mitogen-activated protein kinase and ternary complex factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; JUN NH2-TERMINAL KINASE; REGULATED KINASE; BETA-GAMMA; PATHWAYS; PHOSPHORYLATION; JNK; EXPRESSION; ERK2; IDENTIFICATION	The TAO ( for thousand-and-one amino acids) protein kinases activate p38 mitogen-activated protein ( MAP) kinase cascades in vitro and in cells by phosphorylating the MAP/ERK kinases ( MEKs) 3 and 6. We found that TAO2 activity was increased by carbachol and that carbachol and the heterotrimeric G protein Galpha(o) could activate p38 in 293 cells. Using dominant interfering kinase mutants, we found that MEKs 3 and 6 and TAOs were required for p38 activation by carbachol or the constitutively active mutant Galpha(o) Q205L. To explore events downstream of TAOs, the effects of TAO2 on ternary complex factors ( TCFs) were investigated. Transfection studies demonstrated that TAO2 stimulates phosphorylation of the TCF Elk1 on the major activating site, Ser(383), and that TAO2 stimulates transactivation of Elk1 and the related TCF, Sap1. Reporter activity was reduced by the p38-selective inhibitor SB203580. Taken together, these studies suggest that TAO protein kinases relay signals from carbachol through heterotrimeric G proteins to the p38 MAP kinase, which then activates TCFs in the nucleus.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			raman, malavika/0000-0002-4773-8673; Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53032, GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen LT, 1999, J BIOL CHEM, V274, P26931, DOI 10.1074/jbc.274.38.26931; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; Chen Z, 1999, J BIOL CHEM, V274, P28803, DOI 10.1074/jbc.274.40.28803; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Cuenda A, 1998, BIOCHEM J, V333, P11, DOI 10.1042/bj3330011; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Hirai S, 1996, ONCOGENE, V12, P641; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tassi E, 1999, J BIOL CHEM, V274, P33287, DOI 10.1074/jbc.274.47.33287; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yamauchi JJ, 1997, J BIOL CHEM, V272, P27771, DOI 10.1074/jbc.272.44.27771	42	36	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22278	22283		10.1074/jbc.M301173200	http://dx.doi.org/10.1074/jbc.M301173200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665513	hybrid			2022-12-27	WOS:000183503900015
J	Muhia, DK; Swales, CA; Eckstein-Ludwig, U; Saran, S; Polley, SD; Kelly, JM; Schaap, P; Krishna, S; Baker, DA				Muhia, DK; Swales, CA; Eckstein-Ludwig, U; Saran, S; Polley, SD; Kelly, JM; Schaap, P; Krishna, S; Baker, DA			Multiple splice variants encode a novel adenylyl cyclase of possible plastid origin expressed in the sexual stage of the malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE ANTIGEN-1; GUANYLYL CYCLASE; DICTYOSTELIUM DEVELOPMENT; CYCLIC-NUCLEOTIDES; CATALYTIC DOMAINS; GAMETOCYTES; PARAMECIUM; CULTURE; GENE; SYNCHRONIZATION	We report the characterization of an unusual adenylyl cyclase gene from Plasmodium falciparum, here designated PfACalpha. The level of mRNA expression is maximum during development of gametocytes (the sexual blood stage of the parasite life cycle). The gene is highly interrupted by 22 introns, and reverse transcriptase-PCR analysis revealed that there are multiple mRNA splice variants. One intron has three alternative 3'-splice sites that confer the potential to encode distinct forms of the enzyme using alternative start codons. Deduced amino acid sequences predict membrane-spanning regions, the number of which can vary between two and six depending on the splice variant. Expression of a synthetic form of two of these variants in Xenopus oocytes and in Dictyostelium adenylyl cyclase-deficient mutants, confirms that PfACalpha is a functional adenylyl cyclase. These results identify a novel mechanism in P. falciparum for the generation of multiple isoforms of a key, membrane-bound signaling molecule from a single genomic copy. Comparisons of the catalytic domains of PfACalpha and a second putative P. falciparum adenylyl cyclase (PfACbeta) with those from other species reveal an unexpected similarity with adenylyl cyclases from certain prokaryotes including the cyanobacteria (blue green algae). In addition, the presence of an unusual active site substitution in a position that determines substrate specificity, also characteristic of these prokaryotic forms of the enzyme, further suggests a plastid origin for the Plasmodium cyclases.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England; St George Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England; Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland	University of London; London School of Hygiene & Tropical Medicine; St Georges University London; University of Dundee	Baker, DA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Keppel St, London WC1E 7HT, England.		Polley, Spencer/F-7766-2013; Schaap, Pauline/A-3682-2009; Schaap, Pauline/M-5355-2019	Schaap, Pauline/0000-0003-4500-2555; Schaap, Pauline/0000-0003-4500-2555; Baker, David/0000-0002-5490-8933; Krishna, Sanjeev/0000-0003-0066-0634				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER DA, 1994, PARASITOLOGY, V108, P129, DOI 10.1017/S0031182000068219; Bieger B, 2001, EMBO J, V20, P433, DOI 10.1093/emboj/20.3.433; Buck J, 1999, P NATL ACAD SCI USA, V96, P79, DOI 10.1073/pnas.96.1.79; Carter R, 1993, Methods Mol Biol, V21, P67; Carucci DJ, 2000, J BIOL CHEM, V275, P22147, DOI 10.1074/jbc.M001021200; Chen YQ, 2000, SCIENCE, V289, P625, DOI 10.1126/science.289.5479.625; DANCHIN A, 1993, ADV SEC MESS PHOSPH, V27, P109; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GILMAN AG, 1972, ADV CYCL NUCL RES<D>, V2, P9; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GOULD GW, 1989, BIOCHEMISTRY-US, V28, P9447, DOI 10.1021/bi00450a030; Greengard P, 2001, SCIENCE, V294, P1024, DOI 10.1126/science.294.5544.1024; HAWKING F, 1971, T ROY SOC TROP MED H, V65, P549, DOI 10.1016/0035-9203(71)90036-8; Kanacher T, 2002, EMBO J, V21, P3672, DOI 10.1093/emboj/cdf375; Katayama M, 1997, J BACTERIOL, V179, P3588, DOI 10.1128/jb.179.11.3588-3593.1997; KAUSHAL DC, 1980, NATURE, V286, P490, DOI 10.1038/286490a0; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; Kim HJ, 1998, J BIOL CHEM, V273, P30859, DOI 10.1074/jbc.273.47.30859; Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LEPPLA SH, 1982, P NATL ACAD SCI-BIOL, V79, P3162, DOI 10.1073/pnas.79.10.3162; Linder JU, 2000, J BIOL CHEM, V275, P11235, DOI 10.1074/jbc.275.15.11235; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; MAEDA T, 1990, P NATL ACAD SCI USA, V87, P7814, DOI 10.1073/pnas.87.20.7814; McFadden GI, 1996, NATURE, V381, P482, DOI 10.1038/381482a0; Meima ME, 1999, DEV BIOL, V212, P182, DOI 10.1006/dbio.1999.9352; Muhia DK, 2001, MOL MICROBIOL, V42, P553, DOI 10.1046/j.1365-2958.2001.02665.x; OGWANG RA, 1993, AM J TROP MED HYG, V49, P25, DOI 10.4269/ajtmh.1993.49.25; Pace T, 1998, MOL BIOCHEM PARASIT, V97, P45, DOI 10.1016/S0166-6851(98)00130-3; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; PONNUDURAI T, 1986, PARASITOLOGY, V93, P263, DOI 10.1017/S003118200005143X; READ LK, 1991, J PARASITOL, V77, P346, DOI 10.2307/3283117; READ LK, 1991, MOL BIOCHEM PARASIT, V45, P109, DOI 10.1016/0166-6851(91)90032-2; Roelofs J, 2002, MOL BIOL EVOL, V19, P2239, DOI 10.1093/oxfordjournals.molbev.a004047; Roelofs J, 2001, EMBO J, V20, P4341, DOI 10.1093/emboj/20.16.4341; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZ JE, 1993, ADV SEC MESS PHOSPH, V27, P25; SCHULTZ JE, 1992, SCIENCE, V255, P600, DOI 10.1126/science.1371017; Soderbom F, 1999, DEVELOPMENT, V126, P5463; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sutherland E W, 1971, Lakartidningen, V68, P4991; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Taylor MC, 1999, MOL BIOCHEM PARASIT, V104, P205, DOI 10.1016/S0166-6851(99)00154-1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; vanEs S, 1996, J BIOL CHEM, V271, P23623, DOI 10.1074/jbc.271.39.23623; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wong ST, 2000, NEURON, V27, P487, DOI 10.1016/S0896-6273(00)00060-X; Woodrow CJ, 1999, J BIOL CHEM, V274, P7272, DOI 10.1074/jbc.274.11.7272; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	59	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					22014	22022		10.1074/jbc.M301639200	http://dx.doi.org/10.1074/jbc.M301639200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668669	hybrid			2022-12-27	WOS:000183354200088
J	Ahn, JW; Urist, M; Prives, C				Ahn, JW; Urist, M; Prives, C			Questioning the role of checkpoint kinase 2 in the p53 DNA damage response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY EMBRYONIC LETHALITY; P53-MEDIATED G(1) ARREST; CELL-CYCLE REGULATION; LI-FRAUMENI-SYNDROME; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; PROTEIN-KINASE; INDUCED PHOSPHORYLATION; IONIZING-RADIATION; HUMAN CHK1	Cdc25C and p53 have been reported to be physiological targets of checkpoint kinase 2 (Chk2). Surprisingly, although Chk2 purified from DNA damage sustaining cells has dramatically increased ability to phosphorylate Cdc25C when compared with untreated cells, its ability to phosphorylate p53 is weak before treatment, and there is no increase in its activity toward p53 after DNA damage by gamma irradiation or the radiomimetic agent neocarzinostatin. Furthermore, introduction of Chk2 short interfering RNA into three different human tumor cell lines leads to marked reduction of Chk2 protein, but p53 is still stabilized and active after DNA damage. The results with Chk1 short interfering RNA indicate as well that Chk1 does not play a role in human p53 stabilization after DNA damage. Thus, Chk1 and Chk2 are unlikely to be regulators of p53 in at least some human tumor cells. We discuss our results in the context of previous findings demonstrating a requirement for Chk2 in p53 stabilization and activity.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prives, C (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL CANCER INSTITUTE [P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [CA87497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2000, CANCER RES, V60, P5934; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Brown EJ, 2000, GENE DEV, V14, P397; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dalal SN, 1999, MOL CELL BIOL, V19, P4465; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; Dornan D, 2001, EMBO REP, V2, P139, DOI 10.1093/embo-reports/kve025; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Liu QH, 2000, GENE DEV, V14, P1448; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Matsuoka S, 2001, CANCER RES, V61, P5362; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Vahteristo P, 2001, CANCER RES, V61, P5718; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	61	93	93	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20480	20489		10.1074/jbc.M213185200	http://dx.doi.org/10.1074/jbc.M213185200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654916	hybrid			2022-12-27	WOS:000183230500007
J	Peinado, H; Quintanilla, M; Cano, A				Peinado, H; Quintanilla, M; Cano, A			Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines - Mechanisms for epithelial mesenchymal transitions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; E-CADHERIN EXPRESSION; TGF-BETA; SMAD PROTEINS; HA-RAS; CARCINOMA; KINASE; TRANSDIFFERENTIATION; TGF-BETA-1; INDUCTION	The Snail transcription factor has been described recently as a strong repressor of E-cadherin in epithelial cell lines, where its stable expression leads to the loss of E-cadherin expression and induces epithelial-mesenchymal transitions and an invasive phenotype. The mechanisms regulating Snail expression in development and tumor progression are not yet known. We show here that transforming growth factor beta-1 (TGFbeta1) induces Snail expression in Madin-Darby canine kidney cells and triggers epithelial-mesenchymal transitions by a mechanism dependent on the MAPK signaling pathway. Furthermore, TGFbeta1 induces the activity of Snail promoter, whereas fibroblast growth factor-2 has a milder effect but cooperates with TGFbeta1 in the induction of Snail promoter. Interestingly, TGFbeta1-mediated induction of Snail promoter is blocked by a dominant negative form of H-Ras (N17Ras), whereas oncogenic H-Ras ( V12Ras) induces Snail promoter activity and synergistically cooperates with TGFbeta1. The effects of TGFbeta1 on Snail promoter are dependent of MEK1/2 activity but are apparently independent of Smad4 activity. In addition, H-Ras-mediated induction of Snail promoter, alone or in the presence of TGFbeta1, depends on both MAPK and phosphatidylinositol 3-kinase activities. These data support that MAPK and phosphatidylinositol 3-kinase signaling pathways are implicated in TGFbeta1-mediated induction of Snail promoter, probably through Ras activation and its downstream effectors.	CSIC UAM, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; UAM, Dept Bioquim, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Cano, A (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Peinado, Hector/A-6417-2013; Quintanilla, Miguel/K-9293-2017	Peinado, Hector/0000-0002-4256-3413; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BECKER KF, 1994, CANCER RES, V54, P3845; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; CAULIN C, 1995, CELL GROWTH DIFFER, V6, P1027; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Cui W, 1996, CELL, V86, P531, DOI 10.1016/S0092-8674(00)80127-0; DERYNCK R, 1987, CANCER RES, V47, P707; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hajra KM, 2002, CANCER RES, V62, P1613; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay ED, 1995, ACTA ANAT, V154, P8; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Iglesias M, 2000, ONCOGENE, V19, P4134, DOI 10.1038/sj.onc.1203764; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; LaBonne C, 1998, DEVELOPMENT, V125, P2403; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; MIGDAL M, 1995, J CELL PHYSIOL, V162, P266, DOI 10.1002/jcp.1041620212; Montesano R, 1999, CELL GROWTH DIFFER, V10, P317; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oft M, 1996, GENE DEV, V10, P2462, DOI 10.1101/gad.10.19.2462; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Piek E, 1999, J CELL SCI, V112, P4557; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Savagner P, 1997, J CELL BIOL, V137, P1403, DOI 10.1083/jcb.137.6.1403; Spagnoli FM, 2000, J CELL SCI, V113, P3639; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Strutz F, 2002, KIDNEY INT, V61, P1714, DOI 10.1046/j.1523-1755.2002.00333.x; Sun DZ, 2000, DEV BIOL, V228, P337, DOI 10.1006/dbio.2000.9946; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Valdes F, 2002, MOL CANCER RES, V1, P68; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; Yanez-Mo M, 2003, NEW ENGL J MED, V348, P403, DOI 10.1056/NEJMoa020809	59	508	541	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21113	21123		10.1074/jbc.M211304200	http://dx.doi.org/10.1074/jbc.M211304200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665527	hybrid			2022-12-27	WOS:000183230500087
J	Glatz, R; Schmidt, O; Asgari, S				Glatz, R; Schmidt, O; Asgari, S			Characterization of a novel protein with homology to C-type lectins expressed by the Cotesia rubecula bracovirus in larvae of the lepidopteran host, Pieris rapae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITOID WASP; POLYDNAVIRUS REPLICATION; HELIOTHIS-VIRESCENS; VIRUS; PURIFICATION; GENOME; SUPPRESSION; CONGREGATA; HEMOLYMPH; IMMUNITY	Polydnaviruses are essential for the survival of many Ichneumonoid endoparasitoids, providing active immune suppression of the host in which parasitoid larvae develop. The Cotesia rubecula bracovirus is unique among polydnaviruses in that only four major genes are detected in parasitized host ( Pieris rapae) tissues, and gene expression is transient. Here we describe a novel C. rubecula bracovirus gene (CrV3) encoding a lectin monomer composed of 159 amino acids, which has conserved residues consistent with invertebrate and mammalian C-type lectins. Bacterially expressed CrV3 agglutinated sheep red blood cells in a divalent ion-dependent but Ca2+-independent manner. Agglutination was inhibited by EDTA but not by biological concentrations of any saccharides tested. Two monomers of similar to14 and similar to17 kDa in size were identified on SDS-PAGE in parasitized P. rapae larvae. The 17-kDa monomer was found to be an N-glyscosylated form of the 14-kDa monomer. CrV3 is produced in infected hemocytes and fat body cells and subsequently secreted into hemolymph. We propose that CrV3 is a novel lectin, the first characterized from an invertebrate virus. CrV3 shows over 60% homology with hypothetical proteins isolated from polydnaviruses in two other Cotesia wasps, indicating that these proteins may also be C-type lectins and that a novel polydnavirus lectin family exists in Cotesia-associated bracoviruses. CrV3 is probably interacting with components in host hemolymph, resulting in suppression of the Pieris immune response. The high similarity of CrV3 with invertebrate lectins, as opposed to those from viruses, may indicate that some bracovirus functions were acquired from their hosts.	Univ Adelaide, Dept Appl & Mol Ecol, Glen Osmond, SA 5064, Australia	University of Adelaide	Asgari, S (corresponding author), Univ Adelaide, Dept Appl & Mol Ecol, Waite Campus, Glen Osmond, SA 5064, Australia.	sassan.asgari@adelaide.edu.au	Glatz, Richard/AAF-9483-2019; Asgari, Sassan/G-2678-2011	Glatz, Richard/0000-0001-8889-3701; Asgari, Sassan/0000-0001-7885-6544				ALBRECHT U, 1994, J GEN VIROL, V75, P3353, DOI 10.1099/0022-1317-75-12-3353; ASGARI S, 1994, J INSECT PHYSIOL, V40, P789, DOI 10.1016/0022-1910(94)90008-6; Asgari S, 1996, J GEN VIROL, V77, P2653, DOI 10.1099/0022-1317-77-10-2653; Asgari S, 1997, J GEN VIROL, V78, P3061, DOI 10.1099/0022-1317-78-11-3061; Asgari S, 1998, P NATL ACAD SCI USA, V95, P3690, DOI 10.1073/pnas.95.7.3690; Balgopal MM, 1996, J INSECT PHYSIOL, V42, P337, DOI 10.1016/0022-1910(95)00111-5; BECKAGE NE, 1994, ARCH INSECT BIOCHEM, V26, P165, DOI 10.1002/arch.940260209; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cui LW, 1997, ARCH INSECT BIOCHEM, V36, P251, DOI 10.1002/(SICI)1520-6327(1997)36:4<251::AID-ARCH2>3.0.CO;2-V; Cui LW, 1997, J VIROL, V71, P8504, DOI 10.1128/JVI.71.11.8504-8513.1997; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; EDSON KM, 1981, SCIENCE, V211, P582, DOI 10.1126/science.7455695; FLEMING JAGW, 1986, J VIROL, V57, P552, DOI 10.1128/JVI.57.2.552-562.1986; GIGA Y, 1968, BIOCHEMISTRY-US, V8, P2629; GUZO D, 1987, J INSECT PHYSIOL, V33, P19, DOI 10.1016/0022-1910(87)90100-4; HAMMARST.S, 1971, BIOCHEMISTRY-US, V10, P1681; Haq S, 1996, J BIOL CHEM, V271, P20213, DOI 10.1074/jbc.271.33.20213; HARWOOD SH, 1994, INSECT BIOCHEM MOLEC, V24, P685, DOI 10.1016/0965-1748(94)90056-6; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; KRELL PJ, 1982, J VIROL, V43, P859, DOI 10.1128/JVI.43.3.859-870.1982; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavine MD, 1996, J INSECT PHYSIOL, V42, P41, DOI 10.1016/0022-1910(95)00081-X; Lawrence Pauline O., 1993, P59; LI XS, 1994, J VIROL, V68, P7482, DOI 10.1128/JVI.68.11.7482-7489.1994; Loukas A, 2000, PARASITOL TODAY, V16, P333, DOI 10.1016/S0169-4758(00)01704-X; Luckhart S, 1996, DEV COMP IMMUNOL, V20, P1, DOI 10.1016/0145-305X(95)00040-Z; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MURAMOTO K, 1990, BIOCHIM BIOPHYS ACTA, V1039, P42, DOI 10.1016/0167-4838(90)90224-4; NORTON WN, 1983, CELL TISSUE RES, V231, P387; Pasquier-Barre F, 2002, J GEN VIROL, V83, P2035, DOI 10.1099/0022-1317-83-8-2035; Saito T, 1997, J BIOL CHEM, V272, P30703, DOI 10.1074/jbc.272.49.30703; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHARON N, 1989, LECTINS; Stoltz D., 1992, Journal of Hymenoptera Research, V1, P125; Stoltz D B, 1979, Adv Virus Res, V24, P125, DOI 10.1016/S0065-3527(08)60393-0; STOLTZ DB, 1986, J INSECT PHYSIOL, V32, P377, DOI 10.1016/0022-1910(86)90051-X; STOLTZ DB, 1986, VIROLOGY, V155, P120, DOI 10.1016/0042-6822(86)90173-X; STOLTZ DB, 1990, J GEN VIROL, V71, P1051, DOI 10.1099/0022-1317-71-5-1051; STRAND MR, 1992, J GEN VIROL, V73, P1627, DOI 10.1099/0022-1317-73-7-1627; STRAND MR, 1991, J INSECT PHYSIOL, V37, P839, DOI 10.1016/0022-1910(91)90080-J; Tanaka K, 2002, APPL ENTOMOL ZOOL, V37, P323, DOI 10.1303/aez.2002.323; Turnbull M, 2002, ADV VIRUS RES, V58, P203, DOI 10.1016/S0065-3527(02)58006-4; VINSON SB, 1980, Q REV BIOL, V55, P143, DOI 10.1086/411731; WEBB BA, 1986, J INSECT PHYSIOL, V32, P339, DOI 10.1016/0022-1910(86)90046-6; Webb BA, 1998, VIRUSES, P105; Webb BA, 1998, J INSECT PHYSIOL, V44, P785, DOI 10.1016/S0022-1910(98)00011-0	49	41	46	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19743	19750		10.1074/jbc.M301396200	http://dx.doi.org/10.1074/jbc.M301396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644452	hybrid			2022-12-27	WOS:000183078000024
J	Jakopitsch, C; Auer, M; Ivancich, A; Ruker, F; Furtmuller, PG; Obinger, C				Jakopitsch, C; Auer, M; Ivancich, A; Ruker, F; Furtmuller, PG; Obinger, C			Total conversion of bifunctional catalase-peroxidase (KatG) to monofunctional peroxidase by exchange of a conserved distal side tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; COMPOUND-I; HORSERADISH-PEROXIDASE; ASCORBATE PEROXIDASE; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; KINETIC CHARACTERIZATION; ANACYSTIS-NIDULANS; HEME CAVITY; IDENTIFICATION	Catalase-peroxidases (KatGs) are unique peroxidases exhibiting a high catalase activity and a peroxidase activity with a wide range of artificial electron donors. Exchange of tyrosine 249 in Synechocystis KatG, a distal side residue found in all as yet sequenced KatGs, had dramatic consequences on the bifunctional activity and the spectral features of the redox intermediate compound II. The Y249F variant lost catalase activity but retained a peroxidase activity (substrates o-dianisidine, pyrogallol, guaiacol, tyrosine, and ascorbate) similar to the wild-type protein. In contrast to wild-type KatG and similar to monofunctional peroxidases, the formation of the redox intermediate compound I could be followed spectroscopically even by addition of equimolar hydrogen peroxide to ferric Y249F. The corresponding bimolecular rate constant was determined to be (1.1+/-0.1) x 10(7) M-1 s(-1) (pH 7 and 15degreesC), which is typical for most peroxidases. Additionally, for the first time a clear transition of compound I to an oxoferryl-like compound II with peaks at 418, 530, and 558 nm was monitored when one-electron donors were added to compound I. Rate constants of reaction of compound I and compound II with tyrosine ((5.0+/-0.3) x 10(4) M-1 s(-1) and (1.7+/-0.4) x 10(2) M-1 s(-1)) and ascorbate ((1.3+/-0.2) x 10(4) M-1 s(-1) and (8.8+/-0.1) x 10(1) M-1 s(-1) at pH 7 and 15degreesC) were determined by using the sequential stopped-flow technique. The relevance of these findings is discussed with respect to the bifunctional activity of KatGs and the recently published first crystal structure.	Univ Agr Sci, Inst Chem, A-1190 Vienna, Austria; CEA Saclay, Dept Biol Joliot Curie, CNRS,URA 2096, Serv Bioenerget, F-91191 Gif Sur Yvette, France; Univ Agr Sci, Inst Appl Microbiol, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University of Natural Resources & Life Sciences, Vienna	Obinger, C (corresponding author), Univ Agr Sci, Inst Chem, Muthgasse 18, A-1190 Vienna, Austria.		Obinger, Christian/AAV-3173-2021; Furtmüller, Paul G./Y-5819-2018	Furtmüller, Paul G./0000-0002-1199-2469; Obinger, Christian/0000-0002-7133-3430; Rueker, Florian/0000-0001-7639-2686; Jakopitsch, Christa/0000-0002-5855-2057; Ivancich, Anabella/0000-0002-4275-0980				BALNY C, 1987, FEBS LETT, V221, P349, DOI 10.1016/0014-5793(87)80954-7; BENECKY MJ, 1993, BIOCHEMISTRY-US, V32, P11929, DOI 10.1021/bi00095a024; Chouchane S, 2000, BIOCHEMISTRY-US, V39, P9975, DOI 10.1021/bi0005815; Chouchane S, 2002, J BIOL CHEM, V277, P42633, DOI 10.1074/jbc.M207916200; Dunford H. B., 1999, HEME PEROXIDASES; Engleder M, 2000, BIOCHIMIE, V82, P211, DOI 10.1016/S0300-9084(00)00204-2; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Heering HA, 2002, BIOCHEMISTRY-US, V41, P9237, DOI 10.1021/bi025740u; Hillar A, 2000, BIOCHEMISTRY-US, V39, P5868, DOI 10.1021/bi0000059; HINER ANP, 1995, EUR J BIOCHEM, V234, P506, DOI 10.1111/j.1432-1033.1995.506_b.x; Ivancich A, 2001, BIOCHEMISTRY-US, V40, P6860, DOI 10.1021/bi002826j; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Jakopitsch C, 2002, J INORG BIOCHEM, V91, P78, DOI 10.1016/S0162-0134(02)00374-4; Jakopitsch C, 1999, BIOL CHEM, V380, P1087, DOI 10.1515/BC.1999.135; LOO S, 1975, BIOCHEMISTRY-US, V14, P3467, DOI 10.1021/bi00686a027; Mandelman D, 1998, BIOCHEMISTRY-US, V37, P17610, DOI 10.1021/bi981958y; Marquez LA, 1996, FEBS LETT, V389, P153, DOI 10.1016/0014-5793(96)00562-5; NAKAJIMA R, 1987, J BIOL CHEM, V262, P2576; Obinger C, 1997, BIOCHEM BIOPH RES CO, V235, P545, DOI 10.1006/bbrc.1997.6847; OHLSSON PI, 1986, BIOCHIM BIOPHYS ACTA, V874, P160, DOI 10.1016/0167-4838(86)90113-5; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4342, DOI 10.1021/bi00013a024; POULOS TL, 1980, J BIOL CHEM, V255, P8199; RALSTON I, 1978, CAN J BIOCHEM CELL B, V56, P1115, DOI 10.1139/o78-175; Regelsberger G, 2000, J BIOL CHEM, V275, P22854, DOI 10.1074/jbc.M002371200; Regelsberger G, 2001, BIOCHEM SOC T, V29, P99; SCHULZ CE, 1979, FEBS LETT, V103, P102, DOI 10.1016/0014-5793(79)81259-4; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; Yamada Y, 2002, NAT STRUCT BIOL, V9, P691, DOI 10.1038/nsb834	29	74	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20185	20191		10.1074/jbc.M211625200	http://dx.doi.org/10.1074/jbc.M211625200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649295	hybrid			2022-12-27	WOS:000183078000078
J	Mosley, AL; Ozcan, S				Mosley, AL; Ozcan, S			Glucose regulates insulin gene transcription by hyperacetylation of histone H4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; DNA-BINDING ACTIVITY; FACTOR 1-ALPHA; FACTOR PDX-1; GLUT2 GENE; C-MYC; EXPRESSION; PROTEIN; CHROMATIN; HOMEODOMAIN	Induction of insulin gene expression in response to high blood glucose levels is essential for maintaining glucose homeostasis. Although several transcription factors including Beta-2, Ribe3b1, and Pdx-1 have been shown to play a role in glucose stimulation of insulin gene expression, the exact molecular mechanism(s) by which this regulation occurs is unknown. Previous data demonstrate that the transcription factors Beta-2/NeuroD1 and Pdx-1, which are involved in glucose-stimulated insulin gene expression, interact with the histone acetylase p300, suggesting a role for histone acetylation in glucose regulation of the insulin gene expression. We report that exposure of mouse insulinoma 6 cells to high concentrations of glucose results in hyperacetylation of histone H4 at the insulin gene promoter, which correlates with the increased level of insulin gene transcription. In addition, we demonstrate that hyperacetylation of histone H4 in response to high concentrations of glucose also occurs at the glucose transporter-2 gene promoter. Using histone deacetylase inhibitors, we show that increases in histone H4 acetylation cause stimulation of insulin gene transcription even in the absence of high concentrations of glucose. Furthermore, we show that fibroblasts, which lack insulin gene expression, also lack histone acetylation at the insulin gene promoter. In summary, our data support the idea that high concentrations of glucose stimulate insulin gene expression by causing hyperacetylation of histone H4 at the insulin gene promoter.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Albert B Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Albert B Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.	sozcan@uky.edu						Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bonny C, 1997, MOL CELL ENDOCRINOL, V135, P59, DOI 10.1016/S0303-7207(97)00190-1; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CANDIDO EPM, 1978, CELL, V14, P105, DOI 10.1016/0092-8674(78)90305-7; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kataoka K, 2002, J BIOL CHEM, V277, P49903, DOI 10.1074/jbc.M206796200; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LeRoith D., 2000, DIABETES MELLITUS FU; Lomvardas S, 2002, CELL, V110, P261, DOI 10.1016/S0092-8674(02)00822-X; Macfarlane WM, 2000, DIABETES, V49, P418, DOI 10.2337/diabetes.49.3.418; Macfarlane WM, 1999, J BIOL CHEM, V274, P1011, DOI 10.1074/jbc.274.2.1011; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roderigo-Milne H, 2002, BIOCHEM BIOPH RES CO, V296, P589, DOI 10.1016/S0006-291X(02)00913-0; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Rout UK, 2002, REPROD TOXICOL, V16, P253, DOI 10.1016/S0890-6238(02)00022-9; Sander M, 1998, P NATL ACAD SCI USA, V95, P11572, DOI 10.1073/pnas.95.20.11572; Semenza GL, 2002, P NATL ACAD SCI USA, V99, P11570, DOI 10.1073/pnas.192442299; SERUP P, 1995, BIOCHEM J, V310, P997, DOI 10.1042/bj3100997; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; Sharma A, 1999, MOL CELL BIOL, V19, P704; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Shinozuka Y, 2001, BIOCHEM BIOPH RES CO, V287, P229, DOI 10.1006/bbrc.2001.5573; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 2001, SCIENCE, V293, P1054, DOI 10.1126/science.1064050; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; WAEBER G, 1994, J BIOL CHEM, V269, P26912; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wells J, 2002, METHODS, V26, P48, DOI 10.1016/S1046-2023(02)00007-5; Xavier GD, 2000, J BIOL CHEM, V275, P36269, DOI 10.1074/jbc.M006597200; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	66	82	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19660	19666		10.1074/jbc.M212375200	http://dx.doi.org/10.1074/jbc.M212375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665509	hybrid			2022-12-27	WOS:000183078000014
J	Ravindranath, RMH; Basilrose, RM; Ravindranath, NH; Vaitheesvaran, B				Ravindranath, RMH; Basilrose, RM; Ravindranath, NH; Vaitheesvaran, B			Amelogenin interacts with cytokeratin-5 in ameloblasts during enamel growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; ACETYL-D-GLUCOSAMINE; HUMAN KERATIN-14; TETRATRICOPEPTIDE REPEATS; GLCNAC TRANSFERASE; MATRIX PROTEINS; IN-VITRO; EXPRESSION; TOOTH; ORGAN	The enamel protein amelogenin binds to GlcNAc (Ravindranath, R. M. H., Moradian-Oldak, R., and Fincham, A. G. ( 1999) J. Biol. Chem. 274, 2464 - 2471) and to the GlcNAc-mimicking peptide (GMp) ( Ravindranath, R. M. H., Tam, W., Nguyen, P., and Fincham, A. G. ( 2000) J. Biol. Chem. 275, 39654 - 39661). The GMp motif in the N-terminal region of the cytokeratin 14 of ameloblasts binds to trityrosyl motif peptide ( ATMP) of amelogenin ( Ravindranath, R. M. H., Tam, W., Bringas, P., Santos, V., and Fincham, A. G. ( 2001) J. Biol. Chem. 276, 36586 36597). K14 ( Type I) pairs with K5 ( Type II) in basal epithelial cells; GlcNAc-acylated K5 is identified in ameloblasts. Dosimetric analysis showed the binding affinity of amelogenin to K5 and to GlcNAc-acylated-positive control, ovalbumin. The specific binding of [H-3] ATMP with K5 or ovalbumin was confirmed by Scatchard analysis. [H-3] ATMP failed to bind to K5 after removal of GlcNAc. Blocking K5 with ATMP abrogates the K5-amelogenin interaction. K5 failed to bind to ATMP when the third proline was substituted with threonine, as in some cases of human X-linked amelogenesis imperfecta or when tyrosyl residues were substituted with phenylalanine. Confocal laser scan microscopic observations on ameloblasts during postnatal (PN) growth of the teeth showed that the K5-amelogenin complex migrated from the cytoplasm to the periphery ( on PN day 1) and accumulated at the apical region on day 3. Secretion of amelogenin commences from day 1. K5, similar to K14, may play a role of chaperone during secretion of amelogenin. Upon secretion of amelogenin, K5 pairs with K14. Pairing of K5 and K14 commences on day 3 and ends on day 9. The pairing of K5 and K14 marks the end of secretion of amelogenin.	Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, Los Angeles, CA 90033 USA	University of Southern California	Ravindranath, RMH (corresponding author), Univ So Calif, Ctr Craniofacial Mol Biol, Sch Dent, 2250 Alcazar St, Los Angeles, CA 90033 USA.				NIDCR NIH HHS [DE-03660] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHAN YM, 1994, GENE DEV, V8, P2574, DOI 10.1101/gad.8.21.2574; CHRISTNER PJ, 1983, ARCH ORAL BIOL, V28, P773, DOI 10.1016/0003-9969(83)90114-0; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; Domingues MG, 2000, EUR J ORAL SCI, V108, P43, DOI 10.1034/j.1600-0722.2000.00717.x; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEORGOPOULOS G, 1993, ANN REV CELL BIOL, V3, P75; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; KASPER M, 1989, DIFFERENTIATION, V40, P207, DOI 10.1111/j.1432-0436.1989.tb00600.x; Kreppel LK, 1997, J BIOL CHEM, V272, P9308; KU NO, 1994, J CELL BIOL, V127, P161, DOI 10.1083/jcb.127.1.161; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lubas WA, 1997, J BIOL CHEM, V272, P9316; MERRIFIELD B, 1996, SCIENCE, V232, P341; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NANCI A, 1985, J HISTOCHEM CYTOCHEM, V33, P1153, DOI 10.1177/33.11.4056379; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; Omary M B, 1998, Subcell Biochem, V31, P105; RAVINDRANATH MH, 1997, TECHNIQUES GLYCOBIOL, P137; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; Ravindranath RMH, 2000, J BIOL CHEM, V275, P39654, DOI 10.1074/jbc.M006471200; Ravindranath RMH, 2001, J BIOL CHEM, V276, P36586, DOI 10.1074/jbc.M104656200; RUGG EL, 1994, GENE DEV, V8, P2563, DOI 10.1101/gad.8.21.2563; SILVA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P465; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; SLAVKIN HC, 1982, DIFFERENTIATION, V23, P73, DOI 10.1111/j.1432-0436.1982.tb01268.x; SLAVKIN HC, 1984, INSERM, V125, P341; STEPHENS K, 1993, J INVEST DERMATOL, V101, P240, DOI 10.1111/1523-1747.ep12365079; Sun T T, 1983, Curr Probl Dermatol, V11, P277; SUN TT, 1984, TRANSFORMED PHENOTYP, V1, P169; Tabata MJ, 1996, ARCH ORAL BIOL, V41, P1019, DOI 10.1016/S0003-9969(96)00087-8; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; TERMINE JD, 1980, J BIOL CHEM, V255, P9769; VIDRICH A, 1985, ANN NY ACAD SCI, V455, P354, DOI 10.1111/j.1749-6632.1985.tb50422.x; WILSON AK, 1992, J CELL BIOL, V119, P401, DOI 10.1083/jcb.119.2.401	37	21	21	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20293	20302		10.1074/jbc.M211184200	http://dx.doi.org/10.1074/jbc.M211184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657653	hybrid			2022-12-27	WOS:000183078000092
J	Budd, DC; McDonald, J; Emsley, N; Cain, K; Tobin, AB				Budd, DC; McDonald, J; Emsley, N; Cain, K; Tobin, AB			The C-terminal tail of the M-3-muscarinic receptor possesses anti-apoptotic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; ACTIVATED PROTEIN-KINASE; COUPLED RECEPTORS; PHOSPHORYLATION; CELLS; JUN; EXPRESSION; PATHWAY; CALCIUM; SYSTEM	This study investigates the mechanisms by which the muscarinic receptor gene family can protect against apoptosis. Chinese hamster ovary cells transfected with human muscarinic receptor subtypes underwent apoptotic cell death following treatment with the DNA-damaging agent etoposide. Apoptosis was significantly reduced following muscarinic receptor stimulation of cells that were transfected with receptor subtypes that couple to the G(q/11)/phospholipase C pathway, namely M-1, M-3, and M-5. No protection was detected in cells transfected with the G(i)-coupled M-2 and M-4 receptors. Further analysis of the G(q/11)-coupled M-3 receptor revealed that truncation of the carboxyl-tail (Delta565-M-3 mutant) removed the ability of the receptor to protect against etoposide-induced cell death. This mutation did not affect the ability of the receptor to signal through the phospholipase C pathway. Furthermore, activation of the Delta565-M-3 receptor resulted in robust activation of the extracellular-regulated kinase (ERK) and c-Jun kinase (JNK). The Delta565-M-3 receptor mutant also underwent agonist-driven phosphorylation in a similar manner to the wild-type receptor indicating that the anti-apoptotic effect of the M3 receptor is independent of receptor phosphorylation. Consistent with this was the fact that two M-3-muscarinic receptor mutants deficient in agonist-induced receptor phosphorylation were capable of producing a full anti-apoptotic response. We conclude that the anti-apoptotic response of the muscarinic receptor family was confined to the G(q/11)-coupled members of this family. The direct involvement of G(q/11)/phospholipase C signaling and the ERK-1/2 and JNK pathways together with receptor phosphorylation in the anti-apoptotic response were eliminated. Mutation of a poly-basic region within the short C-terminal tail of the M-3-muscarinic receptor inhibited the ability of the receptor to induce an anti-apoptotic response. We conclude that the conserved poly-basic region in the C-terminal tail of the M-1, M-3, and M-5 receptors contributes to the ability of these receptors to mediate protection against apoptotic cell death.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England	University of Leicester; University of Leicester	Budd, DC (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Budd DC, 1999, MOL PHARMACOL, V56, P813; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Communal C, 2000, J BIOL CHEM, V275, P19395, DOI 10.1074/jbc.M910471199; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Fujii T, 2000, N-S ARCH PHARMACOL, V362, P14, DOI 10.1007/s002100000251; Ham J, 2000, BIOCHEM PHARMACOL, V60, P1015, DOI 10.1016/S0006-2952(00)00372-5; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Kawashima K, 2000, PHARMACOL THERAPEUT, V86, P29, DOI 10.1016/S0163-7258(99)00071-6; Kiselev A, 2000, NEURON, V28, P139, DOI 10.1016/S0896-6273(00)00092-1; Konopleva M, 1999, ADV EXP MED BIOL, V457, P217; Leloup C, 2000, CELL DEATH DIFFER, V7, P825, DOI 10.1038/sj.cdd.4400713; LINDENBOIM L, 1995, J NEUROCHEM, V64, P2491; MILLER WE, 2001, SCI STKE; Montaville P, 2002, J BIOL CHEM, V277, P24684, DOI 10.1074/jbc.M109595200; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Tanaka K, 1999, BIOSCI BIOTECH BIOCH, V63, P368, DOI 10.1271/bbb.63.368; Tang XW, 2002, J BIOL CHEM, V277, P338, DOI 10.1074/jbc.M108927200; Tobin AB, 1997, PHARMACOL THERAPEUT, V75, P135, DOI 10.1016/S0163-7258(97)00053-3; TREJO J, 1991, J BIOL CHEM, V266, P7876; Ueda H, 2001, J BIOL CHEM, V276, P42527, DOI 10.1074/jbc.M102529200; Wu-Wong JR, 2000, J PHARMACOL EXP THER, V293, P514; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; YAN GM, 1995, MOL PHARMACOL, V47, P248	33	55	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19565	19573		10.1074/jbc.M211670200	http://dx.doi.org/10.1074/jbc.M211670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649280	hybrid			2022-12-27	WOS:000182932200108
J	Glick, E; Chau, JS; Vigna, KL; McCulloch, SD; Adman, ET; Kunkel, TA; Loeb, LA				Glick, E; Chau, JS; Vigna, KL; McCulloch, SD; Adman, ET; Kunkel, TA; Loeb, LA			Amino acid substitutions at conserved tyrosine 52 alter fidelity and bypass efficiency of human DNA polymerase eta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DINB; THYMINE DIMER BYPASS; CRYSTAL-STRUCTURE; ERROR-PRONE; REPLICATION; MUTATIONS; PROTEIN; LOCALIZATION; MECHANISM; REPAIR	DNA polymerase eta (Poleta) is a member of a new class of DNA polymerases that is able to copy DNA containing damaged nucleotides. These polymerases are highly error-prone during copying of unaltered DNA templates. We analyzed the relationship between bypass efficiency and fidelity of DNA synthesis by introducing substitutions for Tyr-52, a highly conserved amino acid, within the human DNA polymerase eta (hPoleta) finger domain. Most substitutions for Tyr-52 caused reduction in bypass of UV-associated damage, measured by the ability to rescue the viability of UV-sensitive yeast cells at a high UV dose. For most mutants, the reduction in bypass ability paralleled the reduction in polymerization activity. Interestingly, the hPoleta Y52E mutant exhibited a greater reduction in bypass efficiency than polymerization activity. The reduction in bypass efficiency was accompanied by an up to 11-fold increase in the incorporation of complementary nucleotides relative to non-complementary nucleotides. The fidelity of DNA synthesis, measured by copying a gapped M13 DNA template in vitro, was also enhanced as much as 15-fold; the enhancement resulted from a decrease in transitions, which were relatively frequent, and a large decrease in transversions. Our demonstration that an amino acid substitution within the active site enhances the fidelity of DNA synthesis by hPoleta, one of the most inaccurate of DNA polymerases, supports the hypothesis that even error-prone DNA polymerases function in base selection.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA.	laloeb@u.washington.edu	Kunkel, Thomas A./D-5088-2019	Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES065070, U01ES011045, P30ES007033, Z01ES065070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NIA NIH HHS [AG01751] Funding Source: Medline; NIEHS NIH HHS [P30ES07033, ES11045] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1991, MUTAT RES, V250, P3, DOI 10.1016/0027-5107(91)90157-J; Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Berman HM, 2002, ACTA CRYSTALLOGR D, V58, P899, DOI 10.1107/S0907444902003451; Boudsocq F, 2002, DNA REPAIR, V1, P343, DOI 10.1016/S1568-7864(02)00019-8; Cleaver JC, 1999, SCIENCE, V285, P212, DOI 10.1126/science.285.5425.212; Cleaver JE, 1999, CANCER RES, V59, P1102; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Glick E, 2001, EMBO J, V20, P7303, DOI 10.1093/emboj/20.24.7303; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Holmquist GP, 2002, MUTAT RES-FUND MOL M, V510, P1, DOI 10.1016/S0027-5107(02)00247-6; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; Kondratick CM, 2001, MOL CELL BIOL, V21, P2018, DOI 10.1128/MCB.21.6.2018-2025.2001; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LIVNEH Z, 2001, J BIOL CHEM, V22, P22; LOEB LA, 1991, CANCER RES, V51, P3075; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2001, J MOL BIOL, V312, P335, DOI 10.1006/jmbi.2001.4937; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1997, GENETICS, V147, P1557; McDonald JP, 2001, PHILOS T R SOC B, V356, P53, DOI 10.1098/rstb.2000.0748; Mildvan A S, 1974, Annu Rev Biochem, V43, P357, DOI 10.1146/annurev.bi.43.070174.002041; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Suzuki M, 1997, J BIOL CHEM, V272, P11228; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	43	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19341	19346		10.1074/jbc.M300686200	http://dx.doi.org/10.1074/jbc.M300686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644469	hybrid			2022-12-27	WOS:000182932200081
J	Paine, ML; Wang, HJ; Luo, W; Krebsbach, PH; Snead, ML				Paine, ML; Wang, HJ; Luo, W; Krebsbach, PH; Snead, ML			A transgenic animal model resembling amelogenesis imperfecta related to ameloblastin overexpression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENTAL ENAMEL; RAT INCISORS; DNA-SEQUENCE; GENE; LOCALIZATION; EXPRESSION; PROTEIN; ANTIBODIES; MUTATION; CLONING	Genetic diseases that affect tooth enamel are grouped under the classification amelogenesis imperfecta. Human pedigrees and experiments on transgenic and null mice have all demonstrated that mutations to the secreted proteins amelogenin, enamelin, and enamelysin result in visibly, structurally, or mechanically defective enamel. In an attempt to better define a physiologic function for ameloblastin during enamel formation, we have produced transgenic mice that misexpress the ameloblastin gene. These transgenic animals exhibit imperfections in their enamel that is evident at the nanoscale level. Specifically, ameloblastin overexpression influences enamel crystallite habit and enamel rod morphology. These findings suggest enamel crystallite habit and rod morphology are influenced by the temporal and spatial expression of ameloblastin and may implicate the role of the ameloblastin gene locus in the etiology of a number of undiagnosed autosomally dominant cases of amelogenesis imperfecta.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA	University of Southern California; University of Michigan System; University of Michigan	Paine, ML (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA.	paine@usc.edu	Krebsbach, Paul H./AAC-4765-2021		NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013045, R01DE006988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R29DE012502, R01DE013404, R37DE013045] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE06988, DE13045, DE13404, DE12502] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; Caterina JJ, 2002, J BIOL CHEM, V277, P49598, DOI 10.1074/jbc.M209100200; Cerny R, 1996, J BONE MINER RES, V11, P883; Dhamija S, 2001, J BIOL CHEM, V276, P35159, DOI 10.1074/jbc.M010719200; Dong J, 2000, EUR J ORAL SCI, V108, P353, DOI 10.1034/j.1600-0722.2000.108005353.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FORSMAN K, 1994, HUM MOL GENET, V3, P1621, DOI 10.1093/hmg/3.9.1621; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hart PS, 2002, ARCH ORAL BIOL, V47, P261, DOI 10.1016/S0003-9969(02)00003-1; HAYASHI Y, 1986, BASIC APPL HISTOCHEM, V30, P291; Hu CC, 1997, J DENT RES, V76, P1720, DOI 10.1177/00220345970760110201; Hu CC, 1997, J DENT RES, V76, P648, DOI 10.1177/00220345970760020501; Hu CC, 2000, J DENT RES, V79, P912, DOI 10.1177/00220345000790040501; Iijima M, 2002, J DENT RES, V81, P69, DOI 10.1177/154405910208100115; Kida M, 2002, J DENT RES, V81, P738, DOI 10.1177/0810738; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Krebsbach PH, 1996, J BIOL CHEM, V271, P4431; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Lee SK, 1996, INT J DEV BIOL, V40, P1141; Li W, 2001, MATRIX BIOL, V19, P755, DOI 10.1016/S0945-053X(00)00121-9; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; MacDougall M, 1997, J BIOL CHEM, V272, P835, DOI 10.1074/jbc.272.2.835; Mardh CK, 2001, EUR J ORAL SCI, V109, P8; Mardh CK, 2002, HUM MOL GENET, V11, P1069, DOI 10.1093/hmg/11.9.1069; Nanci A, 1998, J HISTOCHEM CYTOCHEM, V46, P911, DOI 10.1177/002215549804600806; Paine CT, 2000, J BIOL CHEM, V275, P22284, DOI 10.1074/jbc.M000118200; Paine ML, 2001, MATRIX BIOL, V20, P273, DOI 10.1016/S0945-053X(01)00153-6; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; RISNES S, 1985, SCAND J DENT RES, V93, P135; ROBINSON C, 1986, J DENT RES, V65, P500; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; Snead ML, 1996, CONNECT TISSUE RES, V35, P41, DOI 10.3109/03008209609029173; Snead ML, 1998, CONNECT TISSUE RES, V38, P279, DOI 10.3109/03008209809017048; STAATZ WD, 1991, J BIOL CHEM, V266, P7363; WARSHAWSKY H, 1987, SCANNING MICROSCOPY, V1, P1913; Yamada Yoshihiko, 1992, Current Opinion in Cell Biology, V4, P819, DOI 10.1016/0955-0674(92)90105-L	39	70	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19447	19452		10.1074/jbc.M300445200	http://dx.doi.org/10.1074/jbc.M300445200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12657627	hybrid			2022-12-27	WOS:000182932200094
J	Maki, N; Hafkemeyer, P; Dey, S				Maki, N; Hafkemeyer, P; Dey, S			Allosteric modulation of human P-glycoprotein - Inhibition of transport by preventing substrate translocation and dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; CYCLOSPORINE-A; BINDING-SITES; TUMOR-CELLS; VERAPAMIL; REVERSAL; RESIDUES; DOMAIN; MDR1; GENE	The human multidrug transporter P-glycoprotein (Pgp, ABCB1) contributes to the poor bioavailability of many anticancer and antimicrobial agents as well as to drug resistance at the cellular level. For rational design of effective Pgp inhibitors, a clear understanding of its mechanism of action and functional regulation is essential. In this study, we demonstrate that inhibition of Pgp-mediated drug transport by cis-(Z)-flupentixol, a thioxanthene derivative, occurs through an allosteric mechanism. Unlike competitive inhibitors, such as cyclosporin A and verapamil, cis-(Z)-flupentixol does not interfere with substrate ([I-125]iodoarylazidoprazosin) recognition by Pgp, instead it prevents substrate translocation and dissociation, resulting in a stable but reversible Pgp-substrate complex. cis-(Z)-Flupentixol-induced complex formation requires involvement of the Pgp substrate site, because agents that either physically compete (cyclosporin A) for or indirectly occlude (vanadate) the substrate-binding site prevent formation of the complex. Allosteric modulation by cis-(Z)-flupentixol involves a conformational change in Pgp detectable by monoclonal antibody UIC2 binding to a conformation-sensitive external epitope of Pgp. The conformational change observed is distinct from that induced by Pgp substrates or competitive inhibitors. A single amino acid substitution (F983A) in TM12 of Pgp that impairs inhibition by cis-(Z)-flupentixol of Pgp-mediated drug transport also affects stabilization of the Pgp-substrate complex as well as the characteristic conformational change. Taken together, our results describe the molecular mechanism by which the Pgp modulator cis-(Z)flupentixol allosterically inhibits drug transport.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, F Edward Hebert Sch Med, Bethesda, MD 20814 USA; Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany	Uniformed Services University of the Health Sciences - USA; University of Freiburg	Dey, S (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, F Edward Hebert Sch Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.							Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AMBUDKAR SV, 1997, J BIOL CHEM, V272, P21260; Ayesh S, 1996, BBA-MOL BASIS DIS, V1316, P8, DOI 10.1016/0925-4439(96)00008-7; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; Boer R, 1996, BIOCHEMISTRY-US, V35, P1387, DOI 10.1021/bi951912u; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Dey S, 1999, BIOCHEMISTRY-US, V38, P6630, DOI 10.1021/bi983038l; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; DIDIER A, 1995, ANTI-CANCER DRUG, V6, P669, DOI 10.1097/00001813-199510000-00006; FERRY DR, 1995, BIOCHEM PHARMACOL, V49, P1851, DOI 10.1016/0006-2952(94)00517-P; FORD JM, 1993, CYTOTECHNOLOGY, V12, P171, DOI 10.1007/BF00744664; FORD JM, 1990, CANCER RES, V50, P1748; FORD JM, 1989, MOL PHARMACOL, V35, P105; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1990, J BIOL CHEM, V265, P4394; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Hafkemeyer P, 1998, BIOCHEMISTRY-US, V37, P16400, DOI 10.1021/bi980871+; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Liu RH, 1996, BIOCHEMISTRY-US, V35, P11865, DOI 10.1021/bi960823u; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; Martin C, 1999, BRIT J PHARMACOL, V128, P403, DOI 10.1038/sj.bjp.0702807; Mechetner EB, 1997, P NATL ACAD SCI USA, V94, P12908, DOI 10.1073/pnas.94.24.12908; METZ MZ, 1995, VIROLOGY, V208, P634, DOI 10.1006/viro.1995.1194; Murren JR, 2002, CLIN CANCER RES, V8, P633; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; SAEKI T, 1993, J BIOL CHEM, V268, P6077; SAFA AR, 1994, BIOCHEMISTRY-US, V33, P256, DOI 10.1021/bi00167a034; Sikic BI, 1999, ONCOLOGY-NY, V13, P183; Sonveaux N, 1996, J BIOL CHEM, V271, P24617, DOI 10.1074/jbc.271.40.24617; SPOELSTRA EC, 1994, EUR J BIOCHEM, V221, P363, DOI 10.1111/j.1432-1033.1994.tb18748.x; STEIN WD, 1994, MOL PHARMACOL, V45, P763; Tan B, 2000, CURR OPIN ONCOL, V12, P450, DOI 10.1097/00001622-200009000-00011; TSUJI A, 1993, BIOCHEM PHARMACOL, V46, P1096, DOI 10.1016/0006-2952(93)90677-O; TSURUO T, 1981, CANCER RES, V41, P1967; TWENTYMAN PR, 1990, BRIT J CANCER, V62, P89, DOI 10.1038/bjc.1990.235	42	85	88	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18132	18139		10.1074/jbc.M210413200	http://dx.doi.org/10.1074/jbc.M210413200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642584	hybrid			2022-12-27	WOS:000182838300071
J	Niu, WY; Huang, C; Nawaz, Z; Levy, M; Somwar, R; Li, DL; Bilan, PJ; Klip, A				Niu, WY; Huang, C; Nawaz, Z; Levy, M; Somwar, R; Li, DL; Bilan, PJ; Klip, A			Maturation of the regulation of GLUT4 activity by p38 MAPK during l6 cell myogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; ACTIVATED PROTEIN-KINASE; GLUCOSE-TRANSPORT ACTIVITY; INSULIN-INDUCED TRANSLOCATION; SKELETAL-MUSCLE; 3T3-L1 ADIPOCYTES; POTENTIAL ROLE; GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PHOSPHATIDYLINOSITOL 3-KINASE; SUBCELLULAR TRAFFICKING	Insulin stimulates glucose uptake in skeletal muscle cells and fat cells by promoting the rapid translocation of GLUT4 glucose transporters to the plasma membrane. Recent work from our laboratory supports the concept that insulin also stimulates the intrinsic activity of GLUT4 through a signaling pathway that includes p38 MAPK. Here we show that regulation of GLUT4 activity by insulin develops during maturation of skeletal muscle cells into myotubes in concert with the ability of insulin to stimulate p38 MAPK. In L6 myotubes expressing GLUT4 that carries an exofacial myc-epitope (L6-GLUT4myc), insulin-stimulated GLUT4myc translocation equals in magnitude the glucose uptake response. Inhibition of p38 MAPK with SB203580 reduces insulin-stimulated glucose uptake without affecting GLUT4myc translocation. In contrast, in myoblasts, the magnitude of insulin-stimulated glucose uptake is significantly lower than that of GLUT4myc translocation and is insensitive to SB203580. Activation of p38 MAPK by insulin is considerably higher in myotubes than in myoblasts, as is the activation of upstream kinases MKK3/MKK6. In contrast, the activation of all three Akt isoforms and GLUT4 translocation are similar in myoblasts and myotubes. Furthermore, GLUT4myc translocation and phosphorylation of regulatory sites on Akt in L6-GLUT4myc myotubes are equally sensitive to insulin, whereas glucose uptake and phosphorylation of regulatory sites on p38 MAPK show lower sensitivity to the hormone. These observations draw additional parallels between Akt and GLUT4 translocation and between p38 MAPK and GLUT4 activation. Regulation of GLUT4 activity by insulin develops upon muscle cell differentiation and correlates with p38 MAPK activation by insulin.	Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Klip, A (corresponding author), Hosp Sick Children, Cell Biol Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.		Huang, Carol/H-2248-2014					Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Barnes K, 2002, J CELL SCI, V115, P2433; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BEGUINOT F, 1986, ENDOCRINOLOGY, V118, P446, DOI 10.1210/endo-118-1-446; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Ciaraldi TP, 2001, J CLIN ENDOCR METAB, V86, P5838, DOI 10.1210/jc.86.12.5838; CLARK AE, 1991, BIOCHEM J, V278, P235, DOI 10.1042/bj2780235; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; Ferrara CM, 1999, BIOCHEM J, V343, P571, DOI 10.1042/0264-6021:3430571; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; GOODYEAR LJ, 1991, AM J PHYSIOL, V261, pE556, DOI 10.1152/ajpendo.1991.261.5.E556; GUMA A, 1995, AM J PHYSIOL-ENDOC M, V268, pE613, DOI 10.1152/ajpendo.1995.268.4.E613; HANSEN P, 1995, AM J PHYSIOL-CELL PH, V268, pC30, DOI 10.1152/ajpcell.1995.268.1.C30; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HIRSHMAN MF, 1990, J BIOL CHEM, V265, P987; Hruz PW, 2002, DIABETES, V51, P937, DOI 10.2337/diabetes.51.4.937; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; JOOST HG, 1988, BIOCHEM J, V249, P155, DOI 10.1042/bj2490155; KAHN BB, 1988, J CLIN INVEST, V82, P691, DOI 10.1172/JCI113649; KING PA, 1992, J CLIN INVEST, V90, P1568, DOI 10.1172/JCI116025; Kishi K, 1998, DIABETES, V47, P550, DOI 10.2337/diabetes.47.4.550; KLIP A, 1982, BIOCHIM BIOPHYS ACTA, V687, P265, DOI 10.1016/0005-2736(82)90555-7; KLIP A, 1983, CAN J BIOCHEM CELL B, V61, P644, DOI 10.1139/o83-081; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; KLIP A, 1984, AM J PHYSIOL, V247, pE494; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KONO T, 1982, J BIOL CHEM, V257, P942; Konrad D, 2002, DIABETES, V51, P2719, DOI 10.2337/diabetes.51.9.2719; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li DL, 2001, J BIOL CHEM, V276, P22883, DOI 10.1074/jbc.M010143200; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Murata H, 2002, AIDS, V16, P859, DOI 10.1097/00002030-200204120-00005; OmatsuKanbe M, 1996, BIOCHEM J, V315, P25, DOI 10.1042/bj3150025; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; RODNICK KJ, 1992, J BIOL CHEM, V267, P6278; ROSHOLT MN, 1994, AM J PHYSIOL, V266, pR95, DOI 10.1152/ajpregu.1994.266.1.R95; RUDICH A, 2003, IN PRESS DIABETOLOGI; Ryder JW, 1999, BIOCHEM J, V342, P321, DOI 10.1042/0264-6021:3420321; SATOH S, 1993, J BIOL CHEM, V268, P17820; SATOH S, 1991, DIABETES S1, V40, pA85; SHETTY M, 1993, J BIOL CHEM, V268, P17225; Shimizu Y, 1998, BIOCHEM J, V330, P397, DOI 10.1042/bj3300397; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Somwar R, 2002, J BIOL CHEM, V277, P50386, DOI 10.1074/jbc.M205277200; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Ueyama A, 1999, AM J PHYSIOL-ENDOC M, V277, pE572, DOI 10.1152/ajpendo.1999.277.3.E572; Wang QH, 1998, FEBS LETT, V427, P193, DOI 10.1016/S0014-5793(98)00423-2; Wang QH, 1999, MOL CELL BIOL, V19, P4008; WILSON CM, 1994, BIOCHEM J, V299, P755, DOI 10.1042/bj2990755; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YANG J, 1993, J BIOL CHEM, V268, P4600; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693	62	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17953	17962		10.1074/jbc.M211136200	http://dx.doi.org/10.1074/jbc.M211136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637564	hybrid			2022-12-27	WOS:000182838300046
J	Skabkina, OV; Skabkin, MA; Popova, NV; Lyabin, DN; Penalva, LO; Ovchinnikov, LP				Skabkina, OV; Skabkin, MA; Popova, NV; Lyabin, DN; Penalva, LO; Ovchinnikov, LP			Poly(A)-binding protein positively affects YB-1 mRNA translation through specific interaction with YB-1 mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK DOMAIN; Y-BOX PROTEINS; IMMUNODEFICIENCY-VIRUS TYPE-1; 3 UNTRANSLATED REGION; MAJOR CORE PROTEIN; ESCHERICHIA-COLI; RIBONUCLEOPROTEIN PARTICLES; DEPENDENT TRANSLATION; TRANSCRIPTION FACTOR; CYTOPLASMIC MRNP	The major protein of cytoplasmic mRNPs from rabbit reticulocytes, YB-1, is a member of an ancient family of proteins containing a common structural feature, cold-shock domain. In eukaryotes, this family is represented by multifunctional mRNA/Y-box DNA-binding proteins that control gene expression at different stages. To address possible post-transcriptional regulation of YB-1 gene expression, we examined effects of exogenous 5'- and 3'-untranslatable region-containing fragments of YB-1 mRNA on its translation and stability in a cell-free system. The addition of the 3' mRNA fragment as well as its subfragment I shut off protein synthesis at the initiation stage without affecting mRNA stability. UV cross-linking revealed four proteins (69, 50, 46, and 44 kDa) that specifically interacted with the 3' mRNA fragment; the inhibitory subfragment I bound two of them, 69- and 50-kDa proteins. We have identified these proteins as PABP (poly(A)-binding protein) (69 kDa) and YB-1 (50 kDa) and demonstrated that titrating out of PABP by poly(A) strongly and specifically inhibits YB-1 mRNA cap(+)poly(A)(-) translation in a cell-free system. Thus, PABP is capable of positively affecting YB-1 mRNA translation in a poly(A) tail-independent manner.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia; Duke Univ, Med Ctr, Ctr RNA Biol, Dept Mol Genet & Microbiol, Durham, NC 27710 USA	Russian Academy of Sciences; Duke University	Ovchinnikov, LP (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	ovchinn@vega.protres.ru	Lyabin, Dmitry/K-3178-2013; Popova, Nadezhda/ABD-7185-2021; Popova, Nadezhda/AAJ-8312-2020; Ovchinnikov, Lev/L-2397-2015	Popova, Nadezhda/0000-0002-6761-589X; Popova, Nadezhda/0000-0002-6761-589X; Penalva, Luiz/0000-0003-4491-6769				BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BOUVET P, 1995, J BIOL CHEM, V270, P28297; Braun RE, 2000, INT J ANDROL, V23, P92, DOI 10.1046/j.1365-2605.2000.00027.x; Chung DJ, 1998, BIOCHEMISTRY-US, V37, P16298, DOI 10.1021/bi980935g; Davydova EK, 1997, NUCLEIC ACIDS RES, V25, P2911, DOI 10.1093/nar/25.14.2911; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; Di Liegro CM, 2000, BIOCHEM J, V352, P109, DOI 10.1042/0264-6021:3520109; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Evdokimova VM, 1998, J BIOL CHEM, V273, P3574, DOI 10.1074/jbc.273.6.3574; Evdokimova VM, 1999, INT J BIOCHEM CELL B, V31, P139, DOI 10.1016/S1357-2725(98)00137-X; EVDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186, DOI 10.1074/jbc.270.7.3186; Fajardo MA, 1997, DEV BIOL, V191, P42, DOI 10.1006/dbio.1997.8705; Fang L, 1997, MOL MICROBIOL, V23, P355, DOI 10.1046/j.1365-2958.1997.2351592.x; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Grzybowska EA, 2001, BIOCHEM BIOPH RES CO, V288, P291, DOI 10.1006/bbrc.2001.5738; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hornstein E, 1999, FEBS LETT, V457, P209, DOI 10.1016/S0014-5793(99)01039-X; ITO K, 1994, NUCLEIC ACIDS RES, V22, P2036, DOI 10.1093/nar/22.11.2036; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Knirsch L, 2000, BIOCHEM BIOPH RES CO, V272, P164, DOI 10.1006/bbrc.2000.2754; Knirsch L, 2001, BIOCHEMISTRY-US, V40, P7890, DOI 10.1021/bi010197n; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; LEE SJ, 1994, MOL MICROBIOL, V11, P833, DOI 10.1111/j.1365-2958.1994.tb00361.x; Li WW, 1997, MOL CELL BIOL, V17, P61, DOI 10.1128/MCB.17.1.61; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; MAEKAWA T, 1989, J BIOL CHEM, V264, P5488; Marenstein DR, 2001, J BIOL CHEM, V276, P21242, DOI 10.1074/jbc.M101594200; Matsumoto K, 1996, J BIOL CHEM, V271, P22706, DOI 10.1074/jbc.271.37.22706; MINICH WB, 1993, EUR J BIOCHEM, V212, P633, DOI 10.1111/j.1432-1033.1993.tb17701.x; MINICH WB, 1992, BIOCHIMIE, V74, P477, DOI 10.1016/0300-9084(92)90088-V; Ohga T, 1996, CANCER RES, V56, P4224; Ovchinnikov L. P., 2001, Molekulyarnaya Biologiya (Moscow), V35, P548; PARKIN NT, 1988, EMBO J, V7, P2831, DOI 10.1002/j.1460-2075.1988.tb03139.x; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Pisarev AV, 2002, J BIOL CHEM, V277, P15445, DOI 10.1074/jbc.M111954200; POKROVSKAYA ID, 1994, ANAL BIOCHEM, V220, P420, DOI 10.1006/abio.1994.1360; RICHTER JD, 1984, NATURE, V309, P378, DOI 10.1038/309378a0; SABATH DE, 1990, J BIOL CHEM, V265, P12671; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; Sawaya BE, 1998, J GEN VIROL, V79, P239, DOI 10.1099/0022-1317-79-2-239; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Sommerville J, 1996, CHROMOSOMA, V104, P469, DOI 10.1007/s004120050139; SPIRIN AS, 1994, MOL REPROD DEV, V38, P107, DOI 10.1002/mrd.1080380117; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Stickeler E, 2001, EMBO J, V20, P3821, DOI 10.1093/emboj/20.14.3821; Swamynathan SK, 1998, FASEB J, V12, P515, DOI 10.1096/fasebj.12.7.515; TING JPY, 1994, J EXP MED, V179, P1605, DOI 10.1084/jem.179.5.1605; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; Wakiyama M, 1997, BIOCHIMIE, V79, P781, DOI 10.1016/S0300-9084(97)86937-4; Wallstrom EL, 2001, BIOCHEM J, V356, P627, DOI 10.1042/bj3560627; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; WOLFFE AP, 1992, NEW BIOL, V4, P290; Wu J, 1998, J BIOL CHEM, V273, P34535, DOI 10.1074/jbc.273.51.34535; Xia B, 2002, J BIOL CHEM, V277, P6005, DOI 10.1074/jbc.M109700200; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Yurkova MS, 1997, J BIOL CHEM, V272, P10870; Zhou B, 1997, J CLIN INVEST, V100, P3070, DOI 10.1172/JCI119862	60	42	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18191	18198		10.1074/jbc.M209073200	http://dx.doi.org/10.1074/jbc.M209073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646583	hybrid			2022-12-27	WOS:000182838300079
J	Vu-Dac, N; Gervois, P; Jakel, H; Nowak, M; Bauge, E; Dehondt, N; Staels, B; Pennacchio, LA; Rubin, EM; Fruchart-Najib, J; Fruchart, JC				Vu-Dac, N; Gervois, P; Jakel, H; Nowak, M; Bauge, E; Dehondt, N; Staels, B; Pennacchio, LA; Rubin, EM; Fruchart-Najib, J; Fruchart, JC			Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; CORONARY HEART-DISEASE; C-III EXPRESSION; GENE-CLUSTER; PPAR-ALPHA; HYPERTRIGLYCERIDEMIA; MICE; OVEREXPRESSION; POLYMORPHISMS; SUPERFAMILY	The recently discovered APOA5 gene has been shown in humans and mice to be important in determining plasma triglyceride levels, a major cardiovascular disease risk factor. apoAV represents the first described apolipoprotein where overexpression lowers triglyceride levels. Since fibrates represent a commonly used therapy for lowering plasma triglycerides in humans, we investigated their ability to modulate APOA5 gene expression and consequently influence plasma triglyceride levels. Human primary hepatocytes treated with Wy 14,643 or fenofibrate displayed a strong induction of APOA5 mRNA. Deletion and mutagenesis analyses of the proximal APOA5 promoter firmly demonstrate the presence of a functional peroxisome proliferator-activated receptor response element. These findings demonstrate that APOA5 is a highly responsive peroxisome proliferator-activated receptor alpha target gene and support its role as a major mediator for how fibrates reduce plasma triglycerides in humans.	Inst Pasteur, INSERM, U545, Dept Atherosclerose, F-59019 Lille, France; Fac Pharm Lille 1, F-59019 Lille, France; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Sci Dept, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Joint Genome Inst, Berkeley, CA 94720 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Joint Genome Institute - JGI; Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Vu-Dac, N (corresponding author), Inst Pasteur, INSERM, U545, Dept Atherosclerose, BP 245, F-59019 Lille, France.		Staels, Bart/N-9497-2016; Bauge, Eric/R-6522-2018	Staels, Bart/0000-0002-3784-1503; Pennacchio, Len/0000-0002-8748-3732; Dehondt, Helene/0000-0003-2900-4673; Bauge, Eric/0000-0001-9994-8667				Allayee H, 1998, AM J HUM GENET, V63, P577, DOI 10.1086/301983; Boisfer E, 1999, J BIOL CHEM, V274, P11564, DOI 10.1074/jbc.274.17.11564; Coste H, 2002, J BIOL CHEM, V277, P27120, DOI 10.1074/jbc.M203421200; Cullen P, 2000, AM J CARDIOL, V86, P943, DOI 10.1016/S0002-9149(00)01127-9; DAMMERMAN M, 1993, P NATL ACAD SCI USA, V90, P4562, DOI 10.1073/pnas.90.10.4562; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Haim M, 1999, CIRCULATION, V100, P475, DOI 10.1161/01.CIR.100.5.475; HAYDEN MR, 1987, AM J HUM GENET, V40, P421; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; Huang YD, 1998, J BIOL CHEM, V273, P26388, DOI 10.1074/jbc.273.41.26388; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lawrence JW, 2001, J BIOL CHEM, V276, P31521, DOI 10.1074/jbc.M103306200; Lemieux I, 2002, CAN J CARDIOL, V18, P725; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Pennacchio LA, 2002, HUM MOL GENET, V11, P3031, DOI 10.1093/hmg/11.24.3031; Pennacchio LA, 2001, SCIENCE, V294, P169, DOI 10.1126/science.1064852; Ribalta J, 2002, CLIN CHEM, V48, P1597; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; SHACHTER NS, 1994, J CLIN INVEST, V93, P1683, DOI 10.1172/JCI117151; STAELS B, 1995, J CLIN INVEST, V95, P705, DOI 10.1172/JCI117717; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van der Vliet HN, 2002, BIOCHEM BIOPH RES CO, V295, P1156, DOI 10.1016/S0006-291X(02)00808-2; van der Vliet HN, 2001, J BIOL CHEM, V276, P44512, DOI 10.1074/jbc.M106888200; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WOJCIECHOWSKI AP, 1991, NATURE, V349, P161, DOI 10.1038/349161a0	31	177	193	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17982	17985		10.1074/jbc.M212191200	http://dx.doi.org/10.1074/jbc.M212191200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637506	hybrid			2022-12-27	WOS:000182838300050
J	Bobkova, EV; Yan, YP; Jordan, DB; Kurilla, MG; Pompliano, DL				Bobkova, EV; Yan, YP; Jordan, DB; Kurilla, MG; Pompliano, DL			Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL TRANSFERASE CENTER; PROTEIN-SYNTHESIS; BOND FORMATION; DOMAIN-V; A-SITES; P-SITES; RNA; MUTATIONS; BACTERIA; SUBUNIT	Kinetic analysis of ribosomal peptidyltransferase activity in a methanolic puromycin reaction with wild type and drug-resistant 23 S RNA mutants was used to probe the structural basis of catalysis and mechanism of resistance to antibiotics. 23 S RNA mutants G2032A and G2447A are resistant to oxazolidinones both in vitro and in vivo with the latter displaying a 5-fold increase in the value of K-m for initiator tRNA and a 100-fold decrease in V-max in puromycin reaction. Comparison of the K-i values for oxazolidinones, chloramphenicol, and sparsomycin revealed partial cross-resistance between oxazolidinones and chloramphenicol; no cross-resistance was observed with sparsomycin, a known inhibitor of the peptidyltransferase A-site. Inhibition of the mutants using a truncated CCA-Phe-X-Biotin fragment as a P-site substrate is similar to that observed with the intact initiator tRNA, indicating that the inhibition is substrate-independent and that the peptidyltransferase itself is the oxazolidinone target. Mapping of all known mutations that confer resistance to these drugs onto the spatial structure of the 50 S ribosomal subunit allows for docking of an oxazolidinone into a proposed binding pocket. The model suggests that oxazolidinones bind between the P- and A-loops, partially overlapping with the peptidyltransferase P-site. Thus, kinetic, mutagenesis, and structural data suggest that oxazolidinones interfere with initiator fMet-tRNA binding to the P-site of the ribosomal peptidyltransferase center.	Bristol Myers Squibb Co, Wilmington, DE 19880 USA	Bristol-Myers Squibb	Bobkova, EV (corresponding author), Johnson & Johnson PRD, San Diego, CA 92121 USA.							Asai T, 1999, P NATL ACAD SCI USA, V96, P1971, DOI 10.1073/pnas.96.5.1971; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Baranov PV, 1998, NUCLEIC ACIDS RES, V26, P187, DOI 10.1093/nar/26.1.187; BOBKOVA EV, 1999, RIBOSOME STRUCTURE F, P30; Burghardt H, 1998, FEBS LETT, V425, P40, DOI 10.1016/S0014-5793(98)00194-X; CELMA ML, 1971, FEBS LETT, V13, P247, DOI 10.1016/0014-5793(71)80546-X; EUSTICE DC, 1988, ANTIMICROB AGENTS CH, V32, P1218, DOI 10.1128/AAC.32.8.1218; FERNANDEZMUNOZ R, 1973, MOL BIOL REP, V1, P75, DOI 10.1007/BF00357584; GARRET RA, 2000, RIBOSOMES STRUCTURE, P217; Green R, 1998, SCIENCE, V280, P286, DOI 10.1126/science.280.5361.286; HARRIS R, 1973, J BIOL CHEM, V248, P1168; HERNER AE, 1969, BIOCHEMISTRY-US, V8, P1335, DOI 10.1021/bi00832a006; HILL WH, 1990, RIBOSOME STRUCTURE F, P217; Kloss P, 1999, J MOL BIOL, V294, P93, DOI 10.1006/jmbi.1999.3247; Lin AH, 1997, ANTIMICROB AGENTS CH, V41, P2127, DOI 10.1128/AAC.41.10.2127; Matassova NB, 1999, RNA, V5, P939, DOI 10.1017/S1355838299990210; MILLS JA, 1999, RIBOSOME STRUCTURE F; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MONRO RE, 1967, J MOL BIOL, V28, P161, DOI 10.1016/S0022-2836(67)80085-8; MONRO RE, 1969, NATURE, V222, P356, DOI 10.1038/222356a0; Muth GW, 2000, SCIENCE, V289, P947, DOI 10.1126/science.289.5481.947; Patel U, 2001, J BIOL CHEM, V276, P37199, DOI 10.1074/jbc.M102966200; PESTKA S, 1970, ARCH BIOCHEM BIOPHYS, V136, P80, DOI 10.1016/0003-9861(70)90329-2; PESTKA S, 1969, P NATL ACAD SCI USA, V64, P709, DOI 10.1073/pnas.64.2.709; Polacek N, 2001, NATURE, V411, P498, DOI 10.1038/35078113; Shinabarger DL, 1997, ANTIMICROB AGENTS CH, V41, P2132, DOI 10.1128/AAC.41.10.2132; SLEE AM, 1987, ANTIMICROB AGENTS CH, V31, P1791, DOI 10.1128/AAC.31.11.1791; SPIRIN AS, 1999, RIBOSOMES, P133; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; Swaney SM, 1998, ANTIMICROB AGENTS CH, V42, P3251, DOI 10.1128/AAC.42.12.3251; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Thompson J, 2002, J MOL BIOL, V322, P273, DOI 10.1016/S0022-2836(02)00784-2; Xiong LQ, 2000, J BACTERIOL, V182, P5325, DOI 10.1128/JB.182.19.5325-5331.2000	34	32	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9802	9807		10.1074/jbc.M209249200	http://dx.doi.org/10.1074/jbc.M209249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645571	hybrid			2022-12-27	WOS:000181524000123
J	Boffa, MB; Hamill, JD; Maret, D; Brown, D; Scott, ML; Nesheim, ME; Koschinsky, ML				Boffa, MB; Hamill, JD; Maret, D; Brown, D; Scott, ML; Nesheim, ME; Koschinsky, ML			Acute phase mediators modulate thrombin-activable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-1-ACID GLYCOPROTEIN; PLASMA PROCARBOXYPEPTIDASE-B; MESSENGER-RNA STABILITY; PRO-CARBOXYPEPTIDASE-R; GLUCOCORTICOID RECEPTOR; BINDING PROTEIN; MAMMALIAN-CELLS; ANTIGEN LEVELS; CROSS-TALK; ACTIVATION	Thrombin-activable fibrinolysis inhibitor (TAFI) has recently been identified as a positive acute phase protein in mice, an observation that may have important implications for the interaction of the coagulation, fibrinolytic, and inflammatory systems. Activated TAFI (TAFIa) inhibits fibrinolysis by removing the carboxyl-terminal lysines from partially degraded fibrin that are important for maximally efficient plasminogen activation. In addition, TAFIa has been shown to be capable of removing the carboxyl-terminal arginine residues from the anaphylatoxins and bradykinin, thus implying a role for the TAFI pathway in the vascular responses to inflammation. In the current study, we investigated the ability of acute phase mediators to modulate human TAFI gene expression in cultured human hepatoma (HepG2) cells. Surprisingly, we found that treatment of HepG2 cells with a combination of interleukin (IL)-1beta and IL-6 suppressed endogenous TAFI mRNA abundance in HepG2 cells (similar to60% decrease), while treatment with IL-1beta or IL-6 alone had no effect. Treatment with IL-1beta and/or IL-6 had no effect on TAFI promoter activity as measured using a luciferase reporter plasmid containing the human TAFI 5'-flanking region, whereas treatment with IL-1beta and IL-6 in combination, but not alone, decreased the stability of the endogenous TAFI mRNA. Treatment with the synthetic glucocorticoid dexamethasone resulted in a 2-fold increase of both TAFI mRNA levels and promoter activity. We identified a functional glucocorticoid response element (GRE) in the human TAFI promoter between nucleotides -92 and -78. The GRE was capable of binding the glucocorticoid receptor, as assessed by gel mobility shift assays, and mutation of this element markedly decreased the ability of the TAFI promoter to be activated by dexamethasone.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Koschinsky, ML (corresponding author), Queens Univ, Dept Biochem, Room A208 Botterell Hall, Kingston, ON K7L 3N6, Canada.		Boffa, Michael/N-6539-2019	Boffa, Michael/0000-0003-1211-3064; Koschinsky, Marlys/0000-0002-2643-2288				Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAUMANN H, 1990, J BIOL CHEM, V265, P22275; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Boffa MB, 1999, BIOCHEMISTRY-US, V38, P6547, DOI 10.1021/bi990229v; Boffa MB, 2002, J BIOL CHEM, V277, P25329, DOI 10.1074/jbc.M203688200; BOLYARD MG, 1988, GENE, V66, P183, DOI 10.1016/0378-1119(88)90355-1; Boruk M, 1998, MOL ENDOCRINOL, V12, P1749, DOI 10.1210/me.12.11.1749; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Campbell W, 2001, IMMUNOL REV, V180, P162, DOI 10.1034/j.1600-065X.2001.1800114.x; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; EATON DL, 1991, J BIOL CHEM, V266, P21833; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Gottlicher M, 1998, J MOL MED-JMM, V76, P480, DOI 10.1007/s001090050242; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Guo XY, 1999, MICROBIOL IMMUNOL, V43, P691, DOI 10.1111/j.1348-0421.1999.tb02457.x; Hendriks D, 1992, Agents Actions Suppl, V38 ( Pt 1), P407; HENDRIKS D, 1989, J CLIN CHEM CLIN BIO, V27, P277; Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489; Juhan-Vague I, 2000, ARTERIOSCL THROM VAS, V20, P2156, DOI 10.1161/01.ATV.20.9.2156; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; MARI SS, 1999, J BIOL CHEM, V274, P35046; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; Mosnier LO, 1998, THROMB HAEMOSTASIS, V80, P829; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OTTO JM, 1987, J CELL BIOL, V105, P1067, DOI 10.1083/jcb.105.3.1067; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Sato T, 2000, J IMMUNOL, V165, P1053, DOI 10.4049/jimmunol.165.2.1053; SCHMID E, 1987, EUR J BIOCHEM, V165, P499, DOI 10.1111/j.1432-1033.1987.tb11467.x; SHINOHARA T, 1994, INT ARCH ALLERGY IMM, V103, P400, DOI 10.1159/000236661; Silveira A, 2000, THROMB HAEMOSTASIS, V84, P364; Stromqvist M, 2001, THROMB HAEMOSTASIS, V85, P12, DOI 10.1055/s-0037-1612656; Takeda T, 1998, J ENDOCRINOL, V159, P323, DOI 10.1677/joe.0.1590323; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176; WILSON GM, 1995, PLASMID, V33, P198, DOI 10.1006/plas.1995.1021; WRIGHT APH, 1993, J STEROID BIOCHEM, V47, P11, DOI 10.1016/0960-0760(93)90052-X; Zhang ZX, 2000, BLOOD, V96, P3466, DOI 10.1182/blood.V96.10.3466.h8003466_3466_3472; ZHANG ZX, 1995, J BIOL CHEM, V270, P24287, DOI 10.1074/jbc.270.41.24287	46	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9250	9257		10.1074/jbc.M209588200	http://dx.doi.org/10.1074/jbc.M209588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645517	hybrid			2022-12-27	WOS:000181524000049
J	Johnsen, U; Hansen, T; Schonheit, P				Johnsen, U; Hansen, T; Schonheit, P			Comparative analysis of pyruvate kinases from the hyperthermophilic archaea Archaeoglobus fulgidus, Aeropyrum pernix, and Pyrobaculum aerophilum and the hyperthermophilic bacterium Thermotoga maritima - Unusual regulatory properties in hyperthermophilic archaea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT 6-PHOSPHOFRUCTOKINASE; EMBDEN-MEYERHOF PATHWAY; NON-ALLOSTERIC ENZYME; ESCHERICHIA-COLI; THERMOPROTEUS-TENAX; SUGAR UTILIZATION; GENOME SEQUENCE; PURIFICATION; PHOSPHOFRUCTOKINASE; ISOENZYMES	Pyruvate kinases (PK, EC 2.7.1.40) from three hyperthermophilic archaea ( Archaeoglobus fulgidus strain 7324, Aeropyrum pernix, and Pyrobaculum aerophilum) and from the hyperthermophilic bacterium Thermotoga maritima were compared with respect to their thermophilic, kinetic, and regulatory properties. PKs from the archaea are 200-kDa homotetramers composed of 50-kDa subunits. The enzymes required divalent cations, Mg2+ and Mn2+ being most effective, but were independent of K+. Temperature optima for activity were 85 degreesC (A. fulgidus) and above 98 degreesC (A. pernix and P. aerophilum). The PKs were highly thermostable up to 110 degreesC (A. pernix) and showed melting temperatures for thermal unfolding at 93 degreesC (A. fulgidus) or above 98 degreesC (A. pernix and P. aerophilum). All archaeal PKs exhibited sigmoidal saturation kinetics with phosphoenolpyruvate ( PEP) and ADP indicating positive homotropic cooperative response with both substrates. Classic heterotropic allosteric regulators of PKs from eukarya and bacteria, e. g. fructose 1,6-bisphosphate or AMP, did not affect PK activity of hyperthermophilic archaea, suggesting the absence of heterotropic allosteric regulation. PK from the bacterium T. maritima is also a homotetramer of 50-kDa subunits. The enzyme was independent of K+ ions, had a temperature optimum of 80 degreesC, was highly thermostable up to 90 degreesC, and had a melting temperature above 98 degreesC. The enzyme showed cooperative response to PEP and ADP. In contrast to its archaeal counterparts, the T. maritima enzyme exhibited the classic allosteric response to the activator AMP and to the inhibitor ATP. Sequences of hyperthermophilic PKs showed significant similarity to characterized PKs from bacteria and eukarya. Phylogenetic analysis of PK sequences of all three domains indicates a distinct archaeal cluster that includes the PK from the hyperthermophilic bacterium T. maritima.	Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany	University of Kiel	Schonheit, P (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Bot Garten 1-9, D-24118 Kiel, Germany.	peter.schoenheit@ifam.uni-kiel.de						Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BEEDER J, 1994, APPL ENVIRON MICROB, V60, P1227, DOI 10.1128/AEM.60.4.1227-1231.1994; de Vos WM, 1998, EXTREMOPHILES, V2, P201, DOI 10.1007/s007920050061; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; Ernest I, 1998, PROTEIN EXPRES PURIF, V13, P373, DOI 10.1006/prep.1998.0918; GARCIAOLALLA C, 1987, BIOCHEM J, V241, P573, DOI 10.1042/bj2410573; Hansen T, 2002, ARCH MICROBIOL, V177, P401, DOI 10.1007/s00203-002-0405-7; Hansen T, 2001, ARCH MICROBIOL, V177, P62, DOI 10.1007/s00203-001-0359-1; Hansen T, 2000, ARCH MICROBIOL, V173, P103, DOI 10.1007/s002039900114; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JETTEN MSM, 1994, APPL ENVIRON MICROB, V60, P2501, DOI 10.1128/AEM.60.7.2501-2507.1994; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; Kengen SWM, 2001, METHOD ENZYMOL, V331, P41; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; Labes A, 2001, ARCH MICROBIOL, V176, P329, DOI 10.1007/s002030100330; LARSEN TM, 1994, BIOCHEMISTRY-US, V33, P6301, DOI 10.1021/bi00186a033; Mattevi A, 1996, FEBS LETT, V389, P15, DOI 10.1016/0014-5793(96)00462-0; MATTEVI A, 1995, STRUCTURE, V3, P729, DOI 10.1016/S0969-2126(01)00207-6; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193; MUIRHEAD H, 1987, BIOL MACROMOL, P143; Nairn J, 1998, PROTEIN EXPRES PURIF, V14, P247, DOI 10.1006/prep.1998.0938; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; PAWLUK A, 1986, BIOCHEM J, V238, P275, DOI 10.1042/bj2380275; POTTER S, 1992, FEMS MICROBIOL LETT, V94, P235, DOI 10.1111/j.1574-6968.1992.tb05324.x; Rigden DJ, 1999, J MOL BIOL, V291, P615, DOI 10.1006/jmbi.1999.2918; Ronimus RS, 1999, EXTREMOPHILES, V3, P121, DOI 10.1007/s007920050107; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Schramm A, 2000, J BACTERIOL, V182, P2001, DOI 10.1128/JB.182.7.2001-2009.2000; SCHRODER C, 1994, ARCH MICROBIOL, V161, P460, DOI 10.1007/s002030050083; Selig M, 1997, ARCH MICROBIOL, V167, P217, DOI 10.1007/BF03356097; SIEBERS B, 1993, FEMS MICROBIOL LETT, V111, P1; Siebers B, 1998, J BACTERIOL, V180, P2137, DOI 10.1128/JB.180.8.2137-2143.1998; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; WAYGOOD EB, 1974, J BIOL CHEM, V249, P265; WAYGOOD EB, 1976, BIOCHEMISTRY-US, V15, P277, DOI 10.1021/bi00647a006; WAYGOOD EB, 1975, CAN J BIOCHEM CELL B, V53, P444, DOI 10.1139/o75-061; YOSHIZAKI F, 1979, AGR BIOL CHEM TOKYO, V43, P527, DOI 10.1080/00021369.1979.10863482	41	30	35	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25417	25427		10.1074/jbc.M210288200	http://dx.doi.org/10.1074/jbc.M210288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12654928	hybrid			2022-12-27	WOS:000183920200021
J	Schreiter, C; Hovius, R; Costioli, M; Pick, H; Kellenberger, S; Schild, L; Vogel, H				Schreiter, C; Hovius, R; Costioli, M; Pick, H; Kellenberger, S; Schild, L; Vogel, H			Characterization of the ligand-binding site of the serotonin 5-HT3 receptor - The role of glutamate residues 97, 224, and 235	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; 5HT(3) RECEPTOR; DOMAIN; IDENTIFICATION; RECOGNITION; SUBUNIT; MODEL	Ligand- gated ion channels of the Cys loop family are receptors for small amine- containing neurotransmitters. Charged amino acids are strongly conserved in the ligand- binding domain of these receptor proteins. To investigate the role of particular residues in ligand binding of the serotonin 5-HT3AS receptor (5-HT3R), glutamate amino acid residues at three different positions, Glu(97), Glu(224), and Glu(235), in the extracellular N- terminal domain were substituted with aspartate and glutamine using site- directed mutagenesis. Wild type and mutant receptor proteins were expressed in HEK293 cells and analyzed by electrophysiology, radioligand binding, fluorescence measurements, and immunochemistry. A structural model of the ligand- binding domain of the 5- HT3R based on the acetylcholine binding protein revealed the position of the mutated amino acids. Our results demonstrate that mutations of Glu(97), distant from the ligand- binding site, had little effect on the receptor, whereas mutations Glu(224) and Glu(235), close to the predicted binding site, are indeed important for ligand binding. Mutations E224Q, E224D, and E235Q decreased EC50 and K-d values 5 - 20- fold, whereas E235D was functionally expressed at a low level and had a more than 100- fold increased EC50 value. Comparison of the fluorescence properties of a fluorescein- labeled antagonist upon binding to wild type 5- HT3R and E235Q, allowed us to localize Glu(235) within a distance of 1 nm around the ligand- binding site, as proposed by our model.	Swiss Fed Inst Technol, Inst Biomol Sci, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne	Vogel, H (corresponding author), Swiss Fed Inst Technol, Inst Biomol Sci, Lab Phys Chem Polymers & Membranes, CH-1015 Lausanne, Switzerland.	Horst.Vogel@epfl.ch	Hovius, Ruud/B-5647-2009	Hovius, Ruud/0000-0001-9258-6587; Kellenberger, Stephan/0000-0003-1755-6198				Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Boess FG, 1997, NEUROPHARMACOLOGY, V36, P637, DOI 10.1016/S0028-3908(97)00044-0; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; DUBIN AE, 2001, Patent No. 0116297; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hope AG, 1999, MOL PHARMACOL, V55, P1037, DOI 10.1124/mol.55.6.1037; Hovius R, 1998, J NEUROCHEM, V70, P824; Hucho F, 1996, EUR J BIOCHEM, V239, P539, DOI 10.1111/j.1432-1033.1996.0539u.x; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MIQUEL MC, 1991, BIOCHEM PHARMACOL, V42, P1453, DOI 10.1016/0006-2952(91)90459-I; Mochizuki S, 1999, EUR J PHARMACOL, V369, P125, DOI 10.1016/S0014-2999(99)00058-8; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; Pick H, 2003, BIOCHEMISTRY-US, V42, P877, DOI 10.1021/bi026576d; Pitera JW, 2001, BIOPHYS J, V80, P2546, DOI 10.1016/S0006-3495(01)76226-1; Reeves DC, 2002, MOL MEMBR BIOL, V19, P11, DOI 10.1080/09687680110110048; Spier AD, 2000, J BIOL CHEM, V275, P5620, DOI 10.1074/jbc.275.8.5620; Spier AD, 1999, MOL BRAIN RES, V67, P221; Steward LJ, 2000, MOL PHARMACOL, V57, P1249; SZABO A, 1984, J CHEM PHYS, V81, P150, DOI 10.1063/1.447378; Tairi AP, 1998, BIOCHEMISTRY-US, V37, P15850, DOI 10.1021/bi981812z; Vallotton P, 2001, BIOCHEMISTRY-US, V40, P12237, DOI 10.1021/bi0106989; Vallotton P, 2001, CHEMBIOCHEM, V2, P205, DOI 10.1002/1439-7633(20010302)2:3<205::AID-CBIC205>3.3.CO;2-A; WERNER P, 1994, MOL BRAIN RES, V26, P233, DOI 10.1016/0169-328X(94)90095-7; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537	30	30	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22709	22716		10.1074/jbc.M301801200	http://dx.doi.org/10.1074/jbc.M301801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12660235	hybrid			2022-12-27	WOS:000183503900072
J	Forouhar, F; Huang, WN; Liu, JH; Chien, KY; Wu, WG; Hsiao, CD				Forouhar, F; Huang, WN; Liu, JH; Chien, KY; Wu, WG; Hsiao, CD			Structural basis of membrane-induced cardiotoxin A3 oligomerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE CARDIOTOXIN; NAJA-NAJA-ATRA; COBRA CARDIOTOXIN; BINDING MOTIF; VENOM; GAMMA; CRYSTALLOGRAPHY; PHOSPHOLIPIDS; FLUORESCENCE; NIGRICOLLIS	Cobra cardiotoxins (CTXs) have previously been shown to induce membrane fusion of vesicles formed by phospholipids such as cardiolipin or sphingomyelin. CTX can also form a pore in membrane bilayers containing a anionic lipid such as phosphatidylserine or phosphatidylglycerol. Herein, we show that the interaction of CTX with negatively charged lipids causes CTX dimerization, an important intermediate for the eventual oligomerization of CTX during the CTX-induced fusion and pore formation process. The structural basis of the lipid-induced oligomerization of CTX A3, a major CTX from Naja atra, is then illustrated by the crystal structure of CTX A3 in complex with SDS; SDS likely mimics anionic lipids of the membrane under micelle conditions at 1.9-Angstrom resolution. The crystal packing reveals distinct SDS-free and SDS-rich regions; in the latter two types of interconnecting CTX A3 dimers, D1 and D2, and several SDS molecules can be identified to stabilize D1 and D2 by simultaneously interacting with residues at each dimer interface. When the three CTX-SDS complexes in the asymmetric unit are overlaid, the orientation of CTX A3 monomers relative to the SDS molecules in the crystal is strikingly similar to that of the toxin with respect to model membranes as determined by NMR and Fourier transform infrared methods. These results not only illustrate how lipid-induced CTX dimer formation may be transformed into oligomers either as inverted micelles of fusion intermediates or as membrane pore of anionic lipid bilayers but also underscore a potential role for SDS in x-ray diffraction study of protein-membrane interactions in the future.	Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan; Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan	National Tsing Hua University; Academia Sinica - Taiwan; National Defense Medical Center	Wu, WG (corresponding author), Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan.		Hsiao, Chwan-Deng/D-7327-2013; Hsiao, Chwan-Deng/AAZ-8869-2021; Liu, Jyung-Hurng/C-1340-2010	Hsiao, Chwan-Deng/0000-0002-7012-1532; Liu, Jyung-Hurng/0000-0002-7173-0372				ARIPOV TF, 1989, GEN PHYSIOL BIOPHYS, V8, P459; BATENBURG AM, 1985, BIOCHEMISTRY-US, V24, P7101, DOI 10.1021/bi00346a013; BHASKARAN R, 1994, J MOL BIOL, V235, P1291, DOI 10.1006/jmbi.1994.1082; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BOHRER MP, 1979, J GEN PHYSIOL, V74, P583, DOI 10.1085/jgp.74.5.583; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARLSSON FHH, 1987, INT J BIOCHEM, V19, P915, DOI 10.1016/0020-711X(87)90172-8; Chiang CM, 1996, BIOCHEMISTRY-US, V35, P9177, DOI 10.1021/bi960077t; CHIEN KY, 1994, J BIOL CHEM, V269, P14473; CHIEN KY, 1991, J BIOL CHEM, V266, P3252; DAUPLAIS M, 1995, EUR J BIOCHEM, V230, P213, DOI 10.1111/j.1432-1033.1995.0213i.x; Dubovskii PV, 2001, J MOL BIOL, V305, P137, DOI 10.1006/jmbi.2000.4283; DUFOURCQ J, 1978, BIOCHEMISTRY-US, V17, P1170, DOI 10.1021/bi00600a006; DUFTON MJ, 1987, PHARMACOL THERAPEUT, V36, P1; Efremov RG, 2002, BIOPHYS J, V83, P144, DOI 10.1016/S0006-3495(02)75156-4; Fyfe PK, 2001, TRENDS BIOCHEM SCI, V26, P106, DOI 10.1016/S0968-0004(00)01746-1; HOUSSET D, 1996, PROTEIN TOXIN STRUCT, P271; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KLOWDEN MJ, 1992, TOXICON, V30, P295, DOI 10.1016/0041-0101(92)90870-B; Ladokhin AS, 1997, BIOPHYS J, V72, P1762, DOI 10.1016/S0006-3495(97)78822-2; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; Lin YH, 2000, INT J BIOL MACROMOL, V27, P171, DOI 10.1016/S0141-8130(00)00117-3; Lo CC, 1998, BIOPHYS J, V75, P2382, DOI 10.1016/S0006-3495(98)77682-9; Lo Conte L, 1999, J MOL BIOL, V285, P2177; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REES B, 1993, CHEM RES TOXICOL, V6, P285; RUNNELS LW, 1995, BIOPHYS J, V69, P1569, DOI 10.1016/S0006-3495(95)80030-5; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SARMA VR, 1971, J BIOL CHEM, V246, P3753; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; Sue SC, 1997, BIOCHEMISTRY-US, V36, P9826, DOI 10.1021/bi970413l; Sue SC, 2002, J BIOL CHEM, V277, P2666, DOI 10.1074/jbc.M104887200; Sue SC, 2001, BIOCHEMISTRY-US, V40, P12782, DOI 10.1021/bi010848f; Sun YJ, 1997, BIOCHEMISTRY-US, V36, P2403, DOI 10.1021/bi962594h; SUREWICZ WK, 1988, J BIOL CHEM, V263, P786; Wu WG, 1997, J TOXICOL-TOXIN REV, V16, P115, DOI 10.3109/15569549709016451	40	78	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21980	21988		10.1074/jbc.M208650200	http://dx.doi.org/10.1074/jbc.M208650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660250	hybrid			2022-12-27	WOS:000183354200084
J	Takeyama, K; Aguiar, RCT; Gu, LQ; He, CY; Freeman, GJ; Kutok, JL; Aster, JC; Shipp, MA				Takeyama, K; Aguiar, RCT; Gu, LQ; He, CY; Freeman, GJ; Kutok, JL; Aster, JC; Shipp, MA			The BAL-binding protein BBAP and related deltex family members exhibit ubiquitin-protein isopeptide ligase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FINGER; REGULATOR; GENE; MDM2; BRCA1-BARD1; DOMAIN	Members of the DTX (Deltex) family act as Notch signaling modifiers and may also regulate transcription through interactions with specific transcription factors. DTX proteins have a basic N terminus; a central proline-rich region; and a C-terminal RING finger domain, a motif often found in ubiquitin-protein isopeptide ligases (E3). Recently, we identified and characterized a unique diffuse large B-cell lymphoma risk-related gene named BAL (B aggressive lymphoma). Using a yeast two-hybrid screen for BAL-binding partners, we have now identified a novel protein termed BBAP (B-lymphoma- and BAL-associated protein). Although BBAP has a unique N terminus, the C-terminal region is highly homologous to that of DTX family members. Herein, we report that BBAP and the human family of DTX proteins (DTX1, DTX2, and DTX3) function as E3 ligases based on their capacity for self-ubiquitination. DTX family members homodimerize and heterodimerize in vivo, suggesting that physical interactions between various DTX family members modify E3 activity and/or substrate availability. Consistent with this idea, BBAP and DTX1 associate via their unique N termini, resulting in enhanced self-ubiquitination.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Shipp, MA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	margaret_shipp@dfci.harvard.edu	Freeman, Gordon/AAC-5380-2019	Freeman, Gordon/0000-0002-7210-5616				Aguiar RCT, 2000, BLOOD, V96, P4328, DOI 10.1182/blood.V96.13.4328.h8004328_4328_4334; Aravind L, 2001, TRENDS BIOCHEM SCI, V26, P273, DOI 10.1016/S0968-0004(01)01787-X; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275; FREEDMAN AS, 1987, J IMMUNOL, V139, P3260; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kishi N, 2001, INT J DEV NEUROSCI, V19, P21, DOI 10.1016/S0736-5748(00)00071-X; Lai EC, 2002, CURR BIOL, V12, pR74, DOI 10.1016/S0960-9822(01)00679-0; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Matsuno K, 2002, DEVELOPMENT, V129, P1049; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Matsuno K, 1997, DEVELOPMENT, V124, P4265; Matsuno K, 1998, NAT GENET, V19, P74, DOI 10.1038/ng0598-74; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Perche PY, 2000, CURR BIOL, V10, P1531, DOI 10.1016/S0960-9822(00)00832-0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shipp Margaret A., 1997, P2165; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Yamamoto N, 2001, J BIOL CHEM, V276, P45031, DOI 10.1074/jbc.M105245200	33	93	99	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21930	21937		10.1074/jbc.M301157200	http://dx.doi.org/10.1074/jbc.M301157200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670957	hybrid			2022-12-27	WOS:000183354200078
J	Wentworth, M; Ruban, AV; Horton, P				Wentworth, M; Ruban, AV; Horton, P			Thermodynamic investigation into the mechanism of the chlorophyll fluorescence quenching in isolated photosystem II light-harvesting complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENERGY-DISSIPATION; IN-VITRO; XANTHOPHYLL CYCLE; KINETIC-ANALYSIS; AGGREGATION; STATE; PH; ZEAXANTHIN; BINDING; PLANTS	Chlorophyll fluorescence quenching can be stimulated in vitro in purified photosystem II antenna complexes. It has been shown to resemble nonphotochemical quenching observed in isolated chloroplasts and leaves in several important respects, providing a model system for study of the mechanism of photoprotective energy dissipation. The effect of temperature on the rate of quenching in trimeric and monomeric antenna complexes revealed the presence of two temperature-dependent processes with different activation energies, one between similar to15 and 35degreesC and another between similar to40 and 60degreesC. The temperature of the transition between the two phases was higher for trimers than for monomers. Throughout this temperature range, the quenching was almost completely reversible, the protein CD was unchanged, and pigment binding was maintained. The activation energy for the low temperature phase was consistent with local rearrangements of pigments within some of the protein domains, whereas the higher temperature phase seemed to arise from large scale conformational transitions. For both phases, there was a strong linear correlation between the quenching rate and the appearance of an absorption band at 685 nm. In addition, quenching was correlated with a loss of CD at similar to495 nm from Lutein 1 and at 680 nm from chlorophylls a1 and a2, the terminal emitters. The results obtained indicate that quenching of chlorophyll fluorescence in antenna complexes is brought about by perturbation of the lutein 1/chlorophyll a1/chlorophyll a2 locus, forming a poorly fluorescing chlorophyll associate, either a dimer or an excimer.	Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield	Horton, P (corresponding author), Univ Sheffield, Robert Hill Inst, Dept Mol Biol & Biotechnol, Western Bank, Sheffield S10 2TN, S Yorkshire, England.	p.horton@sheffield.ac.uk	Horton, Peter/A-3958-2012	Horton, Peter/0000-0002-6095-1460				AGOSTIANO A, 1991, J PHOTOCH PHOTOBIO A, V58, P201, DOI 10.1016/1010-6030(91)85047-K; Aspinall-O'Dea M, 2002, P NATL ACAD SCI USA, V99, P16331, DOI 10.1073/pnas.252500999; Bassi R, 1999, P NATL ACAD SCI USA, V96, P10056, DOI 10.1073/pnas.96.18.10056; BASSI R, 1991, J PHOTOCH PHOTOBIO B, V9, P335, DOI 10.1016/1011-1344(91)80170-M; BEDDARD GS, 1976, NATURE, V260, P366, DOI 10.1038/260366a0; Boekema EJ, 2000, J MOL BIOL, V301, P1123, DOI 10.1006/jmbi.2000.4037; Crimi M, 2001, EUR J BIOCHEM, V268, P260, DOI 10.1046/j.1432-1033.2001.01874.x; Dominici P, 2002, J BIOL CHEM, V277, P22750, DOI 10.1074/jbc.M200604200; Elrad D, 2002, PLANT CELL, V14, P1801, DOI 10.1105/tpc.002154; Formaggio E, 2001, J MOL BIOL, V314, P1157, DOI 10.1006/jmbi.2000.5179; FRANK HA, 1994, PHOTOSYNTH RES, V41, P389, DOI 10.1007/BF02183041; Gilmore AM, 1998, BIOCHEMISTRY-US, V37, P13582, DOI 10.1021/bi981384x; Horton P, 1999, ADV PHOTOSYNTH, V8, P271; Horton P, 1996, ANNU REV PLANT PHYS, V47, P655, DOI 10.1146/annurev.arplant.47.1.655; HORTON P, 1991, FEBS LETT, V292, P1, DOI 10.1016/0014-5793(91)80819-O; HORTON P, 2000, PHILOS T R SOC LON B, V355, P1; Horton P., 1994, PHOTOINHIBITION PHOT, P111; KRAUSE GH, 1992, PHOTOSYNTHETICA, V27, P249; KUHLBRANDT W, 1994, NATURE, V367, P614, DOI 10.1038/367614a0; Li XP, 2002, FUNCT PLANT BIOL, V29, P1131, DOI 10.1071/FP02065; Li XP, 2002, J BIOL CHEM, V277, P33590, DOI 10.1074/jbc.M204797200; Li XP, 2002, P NATL ACAD SCI USA, V99, P15222, DOI 10.1073/pnas.232447699; Li XP, 2000, NATURE, V403, P391, DOI 10.1038/35000131; Naqvi KR, 1997, SPECTROCHIM ACTA A, V53, P2659, DOI 10.1016/S1386-1425(97)00160-1; Naqvi KR, 1999, SPECTROCHIM ACTA A, V55, P193; Owens T. G., 1994, PHOTOINHIBITION PHOT, P95; Pieper J, 1999, J PHYS CHEM A, V103, P2422, DOI 10.1021/jp983958d; Polivka T, 2002, BIOCHEMISTRY-US, V41, P439, DOI 10.1021/bi011589x; Rogl H, 1999, BIOCHEMISTRY-US, V38, P16214, DOI 10.1021/bi990739p; Ruban AV, 2000, FEBS LETT, V477, P181, DOI 10.1016/S0014-5793(00)01799-3; Ruban AV, 1998, BIOCHEMISTRY-US, V37, P11586, DOI 10.1021/bi9809369; RUBAN AV, 1994, PLANT PHYSIOL, V104, P227, DOI 10.1104/pp.104.1.227; Ruban AV, 2002, J BIOL CHEM, V277, P7785, DOI 10.1074/jbc.M110693200; Ruban AV, 1999, PLANT PHYSIOL, V119, P531, DOI 10.1104/pp.119.2.531; Ruban AV, 1996, BIOCHEMISTRY-US, V35, P674, DOI 10.1021/bi9524878; RUBAN AV, 1994, BBA-BIOENERGETICS, V1186, P123, DOI 10.1016/0005-2728(94)90143-0; RUBAN AV, 1992, BIOCHIM BIOPHYS ACTA, V1102, P39, DOI 10.1016/0167-4838(92)90496-Z; Ruban AV, 2001, BIOCHEMISTRY-US, V40, P9896, DOI 10.1021/bi010370f; Ruban AV, 1997, BBA-BIOENERGETICS, V1321, P61, DOI 10.1016/S0005-2728(97)00047-9; UEHARA K, 1991, PHOTOCHEM PHOTOBIOL, V53, P371, DOI 10.1111/j.1751-1097.1991.tb03643.x; WALTERS RG, 1994, EUR J BIOCHEM, V226, P1063, DOI 10.1111/j.1432-1033.1994.01063.x; Wentworth M, 2000, FEBS LETT, V471, P71, DOI 10.1016/S0014-5793(00)01369-7; Wentworth M, 2001, BIOCHEMISTRY-US, V40, P9902, DOI 10.1021/bi0103718	43	59	60	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21845	21850		10.1074/jbc.M302586200	http://dx.doi.org/10.1074/jbc.M302586200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670939	hybrid			2022-12-27	WOS:000183354200068
J	Ghiran, I; Klickstein, LB; Nicholson-Weller, A				Ghiran, I; Klickstein, LB; Nicholson-Weller, A			Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; CELL-SURFACE; ACTIVATED NEUTROPHILS; SUPEROXIDE PRODUCTION; COLLECTIN RECEPTOR; HUMAN-ERYTHROCYTES; MEMBRANE-PROTEIN; APOPTOTIC CELLS; BINDING LECTIN; CROSS-LINKING	Calreticulin, which has been proposed to be a C1q receptor on neutrophils, has neither a transmembrane domain nor a GPI-anchor attachment site and must utilize an adaptor molecule to attach to the plasma membrane. The expression of ecto-calreticulin on purified human neutrophils did not result from contamination by soluble or intracellular calreticulin released during cell fractionation because it was expressed on circulating neutrophils, and the expression did not increase significantly with neutrophil isolation. All neutrophils expressed calreticulin with a unimodal distribution. Treatment of neutrophils with either a cholesterol-binding agent or phosphatidylinositol-specific phospholipase C dramatically decreased ecto-calreticulin expression indicating that the adaptor molecule(s) are located in lipid rafts and have a GPI-anchor. Analysis for the co-expression of specific GPI-anchored proteins and ecto-calreticulin in cells that were deficient in specific GPI-anchored proteins, indicated that ecto-calreticulin was best associated with CD59. Calreticulin reciprocally immunoprecipited with CD59, which provided direct evidence that CD59 is an adaptor for ecto-calreticulin. Immunofluorescence and confocal microscopy demonstrated that ecto-calreticulin co-localized with a fraction of CD59 at the cell surface. Cross-linking ecto-calreticulin with antibodies induced a Ca2+ flux, which suggests that ecto-calreticulin is capable of signaling following ligand binding. Ecto-calreticulin has been associated with diverse cellular functions. An appreciation that the adaptors for ecto-calreticulin are GPI-anchored will provide a framework for understanding any common features underlying ecto-calreticulin ligation.	Beth Israel Deaconess Med Ctr, Div Allergy Inflammat, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol & Immunol, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Ghiran, I (corresponding author), Beth Israel Deaconess Med Ctr, Div Allergy Inflammat, Dna Bldg,Rm 617,330 Brookline Ave, Boston, MA 02215 USA.				NIAID NIH HHS [R01 AI 42987] Funding Source: Medline; NIDDK NIH HHS [P30 DK 34845] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042987] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Berwin B, 2001, TRAFFIC, V2, P690, DOI 10.1034/j.1600-0854.2001.21003.x; Bordin S, 2003, J IMMUNOL, V170, P667, DOI 10.4049/jimmunol.170.2.667; DAVIES A, 1989, J EXP MED, V170, P637, DOI 10.1084/jem.170.3.637; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; Dunn DE, 2000, PAROXYSMAL NOCTURNAL, P113; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; EGGLETON P, 1994, BLOOD, V84, P1640; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; ERDEI A, 1988, BIOCHEM J, V255, P493; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GHEBREHIWET B, 1988, J IMMUNOL METHODS, V110, P251, DOI 10.1016/0022-1759(88)90111-1; Ghiran I, 2002, IMMUNOBIOLOGY, V205, P407, DOI 10.1078/0171-2985-00142; Ghiran I, 2000, J EXP MED, V192, P1797, DOI 10.1084/jem.192.12.1797; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; GOODMAN EB, 1992, J IMMUNOL, V148, P3920; GRAY AJ, 1995, J BIOL CHEM, V270, P26602, DOI 10.1074/jbc.270.44.26602; HALPERIN JA, 1993, J CLIN INVEST, V91, P1974, DOI 10.1172/JCI116418; HOLGUIN MH, 1989, J CLIN INVEST, V84, P7, DOI 10.1172/JCI114172; HUIZINGA TWJ, 1988, NATURE, V333, P667, DOI 10.1038/333667a0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; KLICKSTEIN LB, 1995, LEUCOCYTE TYPING 5, V2, P1476; KLICKSTEIN LB, 1993, LEUKOCYTE TYPING 5, V2, P1478; Kwon MS, 2000, MOL BIOL CELL, V11, P1433, DOI 10.1091/mbc.11.4.1433; Llewellyn DH, 1996, BIOCHEM J, V318, P555, DOI 10.1042/bj3180555; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; MERI S, 1990, J EXP MED, V172, P367, DOI 10.1084/jem.172.1.367; MORGAN BP, 1993, EUR J IMMUNOL, V23, P2841, DOI 10.1002/eji.1830231118; Murray EW, 1998, J BIOL CHEM, V273, P25279, DOI 10.1074/jbc.273.39.25279; NICHOLSONWELLER A, 1985, BLOOD, V65, P1237; NICULESCU F, 1993, J IMMUNOL, V150, P214; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Persson S, 2002, GENE, V297, P151, DOI 10.1016/S0378-1119(02)00880-6; ROLLINS SA, 1990, J IMMUNOL, V144, P3478; Seddiki N, 2001, J IMMUNOL, V166, P6423, DOI 10.4049/jimmunol.166.10.6423; SHAW S, 1995, LEUCOCYTE TYPING 5, V1, P87; STEFANOVA I, 1989, MOL IMMUNOL, V26, P153, DOI 10.1016/0161-5890(89)90097-7; SUGITA Y, 1988, J BIOCHEM-TOKYO, V104, P633, DOI 10.1093/oxfordjournals.jbchem.a122524; Tas SW, 1999, J IMMUNOL, V163, P5056; Tyagi S, 2000, ARTHRITIS RHEUM, V43, P2248, DOI 10.1002/1529-0131(200010)43:10<2248::AID-ANR12>3.0.CO;2-S; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926; YAMASHINA M, 1990, NEW ENGL J MED, V323, P1184, DOI 10.1056/NEJM199010253231707	49	84	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21024	21031		10.1074/jbc.M302306200	http://dx.doi.org/10.1074/jbc.M302306200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646570	hybrid			2022-12-27	WOS:000183230500076
J	Hayakawa, J; Depatie, C; Ohmichi, M; Mercola, D				Hayakawa, J; Depatie, C; Ohmichi, M; Mercola, D			The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; REGULATED PROTEIN-KINASE; NUCLEAR ANTIGEN GENE; OVARIAN-CANCER; CELL-LINES; TOPOISOMERASE GENE; RESPONSE ELEMENT; BINDING PROTEIN; MELANOMA-CELLS	The activating transcription factor 2 (ATF2) is a member of the ATF/cAMP-response element-binding protein family of basic-leucine zipper proteins involved in cellular stress response. The transcription potential of ATF2 is enhanced markedly by NH2-terminal phosphorylation by c-Jun NH2-terminal kinase (JNK) and mediates stress responses including DNA-damaging events. We have observed that four DNA-damaging agents ( cisplatin, actinomycin D, MMS, and etoposide), but not the cisplatin isomer, transplatin, which does not readily damage DNA, strongly activate JNK, p38, and extracellular signal-regulated kinase (ERK), and strongly increase phosphorylation and ATF2-dependent transcriptional activity. Selective inhibition studies with PD98059, SB202190, SP600125, and the dominant negative JNK indicate that activation of JNK but not p38 kinase or ERK kinase is required for the phosphorylation and transcriptional activation of ATF2. Stable expression of ATF2 in human breast carcinoma BT474 cells increases transcriptional activity and confers resistance to the four DNA-damaging agents, but not to transplatin. Conversely, stable expression of a dominant negative ATF2 ( dnATF2) quantitatively blocks phosphorylation of endogenous ATF2 leading to a marked decrease in transcriptional activity by endogenous ATF2 and a markedly increased sensitivity to the four agents as judged by decreased cell viability. Similarly, application of SB202190 at 50 muM or SP600125 inhibited JNK activity, blocked transactivation, and sensitized parental cells to the four DNA-damaging drugs. Moreover, the wild type ATF2-expressing clones exhibited rapid DNA repair after treatment with the four DNA-damaging agents but not transplatin. Conversely, expression of dnATF2 quantitatively blocks DNA repair. These results indicate that JNK-dependent phosphorylation of ATF2 plays an important role in the drug resistance phenotype likely by mediating enhanced DNA repair by a p53-independent mechanism. JNK may be a rational target for sensitizing tumor cells to DNA-damaging chemotherapy agents.	Sidney Kimmel Canc Ctr, Dept Canc Gene Therapy, San Diego, CA 92121 USA; Osaka Univ, Dept Obstet & Gynecol, Sch Med, Osaka 5650871, Japan; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA	Osaka University; University of California System; University of California San Diego	Mercola, D (corresponding author), Sidney Kimmel Canc Ctr, Dept Canc Gene Therapy, 10835 Altman Row, San Diego, CA 92121 USA.		mercola, dan/L-4182-2013	mercola, dan/0000-0002-0281-9840	NCI NIH HHS [R01 CA084107, CA84107, R01 CA063783, CA63783] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063783, R01CA084107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; Baselga J, 2001, ANN ONCOL, V12, P49, DOI 10.1023/A:1011167909059; BAUMGARTNER B, 1994, BBA-GENE STRUCT EXPR, V1218, P123, DOI 10.1016/0167-4781(94)90114-7; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Crenesse D, 2000, HEPATOLOGY, V32, P1029, DOI 10.1053/jhep.2000.19065; Cripe LD, 2002, LEUKEMIA, V16, P799, DOI 10.1038/sj.leu.2402457; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Davis PL, 1998, ANTICANCER RES, V18, P2919; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; ELSTNER E, 1995, CANCER RES, V55, P2822; ENGLANDER EW, 1991, NUCLEIC ACIDS RES, V19, P3369, DOI 10.1093/nar/19.12.3369; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; Gjerset RA, 1999, CELL GROWTH DIFFER, V10, P545; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Haghighi A, 1999, BIOCHEMISTRY-US, V38, P12432, DOI 10.1021/bi991079r; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hayakawa J, 1999, J BIOL CHEM, V274, P31648, DOI 10.1074/jbc.274.44.31648; Hayakawa J, 2000, CANCER RES, V60, P5988; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HEILAND S, 1993, EUR J BIOCHEM, V217, P813, DOI 10.1111/j.1432-1033.1993.tb18309.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; Iordanov MS, 1997, MOL CELL BIOL, V17, P3373, DOI 10.1128/MCB.17.6.3373; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; JENNERWEIN MM, 1991, NUCLEIC ACIDS RES, V19, P6209, DOI 10.1093/nar/19.22.6209; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARPINSKI BA, 1992, P NATL ACAD SCI USA, V89, P4820, DOI 10.1073/pnas.89.11.4820; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; Kim R, 2002, ONCOL REP, V9, P3; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANS DRA, 1991, BIOCHEM PHARMACOL, V42, P2131, DOI 10.1016/0006-2952(91)90348-9; Ming XF, 1998, EMBO J, V17, P6039, DOI 10.1093/emboj/17.20.6039; NEWELL CL, 1994, J LEUKOCYTE BIOL, V56, P27, DOI 10.1002/jlb.56.1.27; Niedner H, 2001, MOL PHARMACOL, V60, P1153, DOI 10.1124/mol.60.6.1153; Perez RP, 1998, EUR J CANCER, V34, P1535, DOI 10.1016/S0959-8049(98)00227-5; PIGRAM WJ, 1972, NATURE-NEW BIOL, V235, P17, DOI 10.1038/newbio235017a0; Potapova O, 1996, CANCER RES, V56, P280; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; SCHWARTZ JL, 1986, CARCINOGENESIS, V7, P159, DOI 10.1093/carcin/7.1.159; SHERMAN SE, 1985, SCIENCE, V230, P412, DOI 10.1126/science.4048939; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wang SC, 2001, SEMIN ONCOL, V28, P21, DOI 10.1053/sonc.2001.29724; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; ZHANG X, 1989, ONCOGENE, V4, P985	64	143	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20582	20592		10.1074/jbc.M210992200	http://dx.doi.org/10.1074/jbc.M210992200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663670	hybrid, Green Published			2022-12-27	WOS:000183230500019
J	Janvilisri, T; Venter, H; Shahi, S; Reuter, G; Balakrishnan, L; van Veen, HW				Janvilisri, T; Venter, H; Shahi, S; Reuter, G; Balakrishnan, L; van Veen, HW			Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; MULTIDRUG-RESISTANCE; HALF-TRANSPORTER; PLASMA-MEMBRANE; ATPASE ACTIVITY; GENE; OVEREXPRESSION; MITOXANTRONE; CELLS; CHOLESTEROL	The human breast cancer resistance protein (BCRP, also know as ABCG2, MXR, or ABCP) is one of the more recently discovered ATP-binding cassette (ABC) transporters that confer resistance on cancer cells by mediating multidrug efflux. In the present study, we have obtained functional expression of human BCRP in the Gram-positive bacterium Lactococcus lactis. BCRP expression conferred multidrug resistance on the lactococcal cells, which was based on ATP-dependent drug extrusion. BCRP-mediated ATPase and drug transport activities were inhibited by the BCRP-specific modulator fumitremorgin C. To our knowledge these data represent the first example of the functional expression of a mammalian ABC half-transporter in bacteria. Although members of the ABCG subfamily (such as ABCG1 and ABCG5/8) have been implicated in the transport of sterols, such a role has not yet been established for BCRP. Interestingly, the BCRP-associated ATPase activity in L. lactis was significantly stimulated by (i) sterols including cholesterol and estradiol, (ii) natural steroids such as progesterone and testosterone, and (iii) the antiestrogen anticancer drug tamoxifen. In addition, BCRP mediated the efflux of [H-3] estradiol from lactococcal cells. Our findings suggest that BCRP may play a role in the transport of sterols in human, in addition to its ability to transport multiple drugs and toxins.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	van Veen, HW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	hwv20@cam.ac.uk	Venter, Rietie/E-4795-2013; van Veen, Hendrik W./A-4162-2008; Janvilisri, Tavan/O-6679-2019; Janvilisri, Tavan/C-8391-2015	Venter, Rietie/0000-0001-5569-7755; van Veen, Hendrik W./0000-0002-9658-8077; Janvilisri, Tavan/0000-0002-6376-5575; Janvilisri, Tavan/0000-0002-6376-5575				Albrecht C, 2002, BBA-BIOMEMBRANES, V1567, P133, DOI 10.1016/S0005-2736(02)00608-9; Allen JD, 1999, CANCER RES, V59, P4237; Brangi M, 1999, CANCER RES, V59, P5938; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; DREESEN TD, 1988, MOL CELL BIOL, V8, P5206, DOI 10.1128/MCB.8.12.5206; Garrigues A, 2002, P NATL ACAD SCI USA, V99, P10347, DOI 10.1073/pnas.162366399; Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kage K, 2002, INT J CANCER, V97, P626, DOI 10.1002/ijc.10100; Kim M, 2002, CLIN CANCER RES, V8, P22; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Litman T, 2002, BBA-BIOMEMBRANES, V1565, P6, DOI 10.1016/S0005-2736(02)00492-3; Litman T, 2000, J CELL SCI, V113, P2011; Maliepaard M, 1999, CANCER RES, V59, P4559; Maliepaard M, 2001, CANCER RES, V61, P3458; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Nielsen D, 2000, BIOCHEM PHARMACOL, V60, P363, DOI 10.1016/S0006-2952(00)00337-3; Oram JF, 2001, J LIPID RES, V42, P1173; Ozvegy C, 2002, J BIOL CHEM, V277, P47980, DOI 10.1074/jbc.M207857200; Rabindran SK, 2000, CANCER RES, V60, P47; Rebbeor JF, 1998, BBA-BIOMEMBRANES, V1369, P85, DOI 10.1016/S0005-2736(97)00185-5; Robey RW, 2001, CLIN CANCER RES, V7, P145; Ross DD, 2000, BLOOD, V96, P365, DOI 10.1182/blood.V96.1.365.013k46_365_368; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SALTON MRJ, 1976, ANNU REV MICROBIOL, V30, P451, DOI 10.1146/annurev.mi.30.100176.002315; Scheffer GL, 2000, CANCER RES, V60, P2589; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; URBATSCH IL, 1995, ARCH BIOCHEM BIOPHYS, V316, P135, DOI 10.1006/abbi.1995.1020; van der Kolk DM, 2002, BLOOD, V99, P3763, DOI 10.1182/blood.V99.10.3763; van Helvoort A, 1997, J CELL SCI, V110, P75; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	39	140	148	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20645	20651		10.1074/jbc.M301358200	http://dx.doi.org/10.1074/jbc.M301358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668685	hybrid			2022-12-27	WOS:000183230500027
J	Koropatkin, NM; Liu, HW; Holden, HM				Koropatkin, NM; Liu, HW; Holden, HM			High resolution X-ray structure of tyvelose epimerase from Salmonella typhi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; GLUCOSE; ENTERICA; INSIGHTS; PATHWAY; ENZYMES; SUGARS	Tyvelose epimerase catalyzes the last step in the biosynthesis of tyvelose by converting CDP-D-paratose to CDP-D-tyvelose. This unusual 3,6-dideoxyhexose occurs in the O-antigens of some types of Gram-negative bacteria. Here we describe the cloning, protein purification, and high-resolution x-ray crystallographic analysis of tyvelose epimerase from Salmonella typhi complexed with CDP. The enzyme from S. typhi is a homotetramer with each subunit containing 339 amino acid residues and a tightly bound NAD(+) cofactor. The quaternary structure of the enzyme displays 222 symmetry and can be aptly described as a dimer of dimers. Each subunit folds into two distinct lobes: the N-terminal motif responsible for NAD(+) binding and the C-terminal region that harbors the binding site for CDP. The analysis described here demonstrates that tyvelose epimerase belongs to the short-chain dehydrogenase/reductase superfamily of enzymes. Indeed, its active site is reminiscent to that observed for UDP-galactose 4-epimerase, an enzyme that plays a key role in galactose metabolism. Unlike UDP-galactose 4-epimerase where the conversion of configuration occurs about C-4 of the UDP-glucose or UDP-galactose substrates, in the reaction catalyzed by tyvelose epimerase, the inversion of stereochemistry occurs at C-2. On the basis of the observed binding mode for CDP, it is possible to predict the manner in which the substrate, CDP-paratose, and the product, CDP-tyvelose, might be accommodated within the active site of tyvelose epimerase.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	University of Wisconsin System; University of Wisconsin Madison; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Holden, HM (corresponding author), Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047814, R56DK047814] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035906, R01GM035906] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47814] Funding Source: Medline; NIGMS NIH HHS [GM35906] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard STM, 2001, CELL MOL LIFE SCI, V58, P1650, DOI 10.1007/PL00000803; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; Frey PA, 1996, FASEB J, V10, P461, DOI 10.1096/fasebj.10.4.8647345; Hallis TM, 2000, J AM CHEM SOC, V122, P10493, DOI 10.1021/ja0022021; Hallis TM, 1999, ACCOUNTS CHEM RES, V32, P579, DOI 10.1021/ar9602056; He XMM, 2002, ANNU REV BIOCHEM, V71, P701, DOI 10.1146/annurev.biochem.71.110601.135339; Hirose K, 2002, J CLIN MICROBIOL, V40, P633, DOI 10.1128/JCM.40.02.633-636.2002; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Madigan M. T., 1996, BIOL MICROORGANISMS; Mulichak AM, 2002, BIOCHEMISTRY-US, V41, P15578, DOI 10.1021/bi0266683; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roussel A, 1990, ACTA CRYSTALLOGR A, V46, pC66; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; Thoden JB, 1996, PROTEIN SCI, V5, P2149, DOI 10.1002/pro.5560051102; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P2557, DOI 10.1021/bi952715y; Thoden JB, 1996, BIOCHEMISTRY-US, V35, P5137, DOI 10.1021/bi9601114; Thoden JB, 1998, BIOCHEMISTRY-US, V37, P11469, DOI 10.1021/bi9808969; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012	24	19	21	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20874	20881		10.1074/jbc.M301948200	http://dx.doi.org/10.1074/jbc.M301948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12642575	hybrid			2022-12-27	WOS:000183230500057
J	Steinle, JJ; Booz, GW; Meininger, CJ; Day, JNE; Granger, HJ				Steinle, JJ; Booz, GW; Meininger, CJ; Day, JNE; Granger, HJ			beta(3)-Adrenergic receptors regulate retinal endothelial cell migration and proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-3-ADRENERGIC RECEPTOR; DIABETIC-RETINOPATHY; MACULAR DEGENERATION; ADRENERGIC-RECEPTORS; GROWTH-FACTOR; IN-VITRO; PATHWAY; RAT; AGONISTS; BINDING	Sympathetic nerves may play a role in vascular disorders of the eye. In the present study, we hypothesized that activation of beta(3)-adrenergic receptors on retinal endothelial cells would promote migration and proliferation of these cells, two markers of an angiogenic phenotype. We show, for the first time, expression of beta(3)-adrenergic receptors on cultured retinal endothelial cells. Activation of these receptors with BRL37344, a specific beta(3)-adrenergic receptor agonist, promoted migration that was blocked by inhibitors of phosphatidylinositol 3-kinase (PI3K), the mitogen activated protein kinase component MEK, and matrix metalloproteinases (MMPs) 2 and 9. BRL37344 stimulated proliferation, which could be blocked by inhibitors of Src, PI3K, and MEK. These cells also express the beta(1)-adrenergic receptor with no beta(2)-adrenergic receptor expression observed. Stimulation of the beta(1)-adrenergic receptor with xamoterol, a specific partial agonist, did not promote proliferation or migration. These results support the hypothesis that beta(3)-adrenergic receptors play a role in proliferation and migration of cultured human retinal endothelial cells.	Texas A&M Univ Syst, Dept Med Physiol, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, Temple, TX 76504 USA; Texas A&M Univ Syst, Dept Internal Med, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, Temple, TX 76504 USA	Texas A&M University System; Texas A&M University System	Steinle, JJ (corresponding author), Texas A&M Univ Syst, Dept Med Physiol, Inst Cardiovasc Res, Ctr Hlth Sci,Coll Med, 702 SWHK Loop,Rm 202A, Temple, TX 76504 USA.		Meininger, Cynthia/D-2846-2014	Meininger, Cynthia/0000-0002-1314-5044; Steinle, Jena/0000-0002-7539-2892				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BRAUTBOUCHER F, 1995, J IMMUNOL METHODS, V178, P41, DOI 10.1016/0022-1759(94)00239-S; de Souza CJ, 2001, CURR PHARM DESIGN, V7, P1433, DOI 10.2174/1381612013397339; Ferro A, 1999, BRIT J PHARMACOL, V126, P1872, DOI 10.1038/sj.bjp.0702512; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; FULK GW, 1991, OPTOMETRY VISION SCI, V68, P954, DOI 10.1097/00006324-199112000-00008; Harris A, 1999, PROG RETIN EYE RES, V18, P669; ISHIKAWA S, 1985, OPHTHALMOLOGICA, V191, P172, DOI 10.1159/000309582; Kim Lincoln R., 1998, Wound Repair and Regeneration, V6, P194, DOI 10.1046/j.1524-475X.1998.60305.x; Klein R, 1996, ANNU REV PUBL HEALTH, V17, P137; KRIEF S, 1993, J CLIN INVEST, V91, P344, DOI 10.1172/JCI116191; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; MUZZIN P, 1992, FEBS LETT, V298, P162, DOI 10.1016/0014-5793(92)80046-J; Naga Prasad SV, 2001, TRENDS GENET, V17, pS44; OShea JG, 1996, MED J AUSTRALIA, V165, P561, DOI 10.5694/j.1326-5377.1996.tb138643.x; Schmidt RE, 1997, BRAIN RES, V769, P375, DOI 10.1016/S0006-8993(97)00806-8; Steinle JJ, 2002, J BIOL CHEM, V277, P43830, DOI 10.1074/jbc.M207221200; Steinle JJ, 2002, EXP EYE RES, V74, P761, DOI 10.1006/exer.2002.1182; Steinle JJ, 2002, BRIT J PHARMACOL, V136, P730, DOI 10.1038/sj.bjp.0704771; TOEWS ML, 1983, P NATL ACAD SCI-BIOL, V80, P3553, DOI 10.1073/pnas.80.12.3553; Yang A, 2002, CELL BIOL TOXICOL, V18, P97, DOI 10.1023/A:1015328100876	21	71	75	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20681	20686		10.1074/jbc.M300368200	http://dx.doi.org/10.1074/jbc.M300368200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670949	hybrid			2022-12-27	WOS:000183230500032
J	Kerschensteiner, D; Monje, F; Stocker, M				Kerschensteiner, D; Monje, F; Stocker, M			Structural determinants of the regulation of the voltage-gated potassium channel Kv2.1 by the modulatory alpha-subunit Kv9.3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 INACTIVATION MECHANISMS; C-TYPE INACTIVATION; K+ CHANNEL; RAT-BRAIN; TETRAETHYLAMMONIUM BLOCKADE; XENOPUS-OOCYTES; TERMINAL DOMAIN; BETA-SUBUNIT; N-TERMINUS; EXPRESSION	Voltage-gated potassium (Kv) channels containing alpha-subunits of the Kv2 subfamily mediate delayed rectifier currents in excitable cells. Channels formed by Kv2.1 alpha-subunits inactivate from open- and closed states with both forms of inactivation serving different physiological functions. Here we show that open- and closed-state inactivation of Kv2.1 can be distinguished by the sensitivity to intracellular tetraethylammonium and extracellular potassium and lead to the same inactivated conformation. The functional properties of Kv2.1 are regulated by its association with modulatory alpha-subunits (Kv5, Kv6, Kv8, and Kv9). For instance, Kv9.3 changes the state preference of Kv2.1 inactivation by accelerating closed-state inactivation and inhibiting open- state inactivation. An N-terminal regulatory domain (NRD) has been suggested to determine the function of the modulatory alpha-subunit Kv8.1. However, when we tested the NRD of Kv9.3, we found that the functional properties of chimeric Kv2.1 channels containing the NRD of Kv9.3 (Kv2.1(NRD)) did not resemble those of Kv2.1/Kv9.3 heteromers, thus questioning the role of the NRD in Kv9 subunits. A further region of interest is a PXP motif in the sixth transmembrane segment. This motif is conserved among all alpha-subunits of the Kv1, Kv2, Kv3, and Kv4 subfamilies, whereas the second proline is not conserved in any modulatory alpha-subunit. Exchanging this proline in Kv2.1 for the corresponding residue of Kv9.3 resulted in channels (Kv2.1-P410T) that show all hallmarks of the regulation of Kv2.1 by Kv9.3. The effect prevailed in heteromeric channels following co-expression of Kv2.1-P410T with Kv2.1. These data suggest that the alteration of the PXP motif is an important determinant of the regulatory function of modulatory alpha-subunits.	Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, D-37075 Gottingen, Germany; Univ Gottingen, Neurol Klin, D-37075 Gottingen, Germany; Ctr Int Fis, Edificio Manuel Ancizar, Bogota AA4948, Colombia; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England	Max Planck Society; University of Gottingen; University of London; University College London	Kerschensteiner, D (corresponding author), Max Planck Inst Expt Med, Abt Mol Biol Neuronaler Signale, Herman Rein Str 3, D-37075 Gottingen, Germany.	dkersch@gwdg.de	Stocker, Martin/C-1844-2008					An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bahring R, 2001, J BIOL CHEM, V276, P23888, DOI 10.1074/jbc.M101320200; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; BAUKROWITZ T, 1995, NEURON, V15, P951, DOI 10.1016/0896-6273(95)90185-X; Beck EJ, 2002, J PHYSIOL-LONDON, V538, P691, DOI 10.1113/jphysiol.2001.013127; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; Blaine JT, 2001, J NEUROSCI, V21, P1473, DOI 10.1523/JNEUROSCI.21-05-01473.2001; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Castellano A, 1997, J NEUROSCI, V17, P4652; Chiara MD, 1999, J NEUROSCI, V19, P6865, DOI 10.1523/JNEUROSCI.19-16-06865.1999; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; DECOURSEY TE, 1990, J GEN PHYSIOL, V95, P617, DOI 10.1085/jgp.95.4.617; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Du J, 2000, J PHYSIOL-LONDON, V522, P19, DOI 10.1111/j.1469-7793.2000.t01-2-00019.xm; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; Frazier CJ, 2000, BIOPHYS J, V78, P1872, DOI 10.1016/S0006-3495(00)76736-1; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; GRISSMER S, 1989, BIOPHYS J, V55, P203, DOI 10.1016/S0006-3495(89)82793-6; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Holmqvist MH, 2002, P NATL ACAD SCI USA, V99, P1035, DOI 10.1073/pnas.022509299; Hugnot JP, 1996, EMBO J, V15, P3322, DOI 10.1002/j.1460-2075.1996.tb00697.x; IKEDA SR, 1995, J PHYSIOL-LONDON, V486, P267, DOI 10.1113/jphysiol.1995.sp020809; Immke D, 1999, J GEN PHYSIOL, V113, P819, DOI 10.1085/jgp.113.6.819; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; Javadpour MM, 1999, BIOPHYS J, V77, P1609, DOI 10.1016/S0006-3495(99)77009-8; Jerng HH, 1999, J GEN PHYSIOL, V113, P641, DOI 10.1085/jgp.113.5.641; Johnston D, 2000, J PHYSIOL-LONDON, V525, P75, DOI 10.1111/j.1469-7793.2000.00075.x; Kerschensteiner D, 1999, BIOPHYS J, V77, P248, DOI 10.1016/S0006-3495(99)76886-4; Kiss L, 1999, BIOPHYS J, V76, P253, DOI 10.1016/S0006-3495(99)77194-8; Klemic KG, 1998, BIOPHYS J, V74, P1779, DOI 10.1016/S0006-3495(98)77888-9; Kramer JW, 1998, AM J PHYSIOL-CELL PH, V274, pC1501, DOI 10.1152/ajpcell.1998.274.6.C1501; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; KURATA HT, 2002, J BIOL CHEM, V20, P20; Levy DI, 1996, BIOPHYS J, V70, P798, DOI 10.1016/S0006-3495(96)79619-4; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MacDonald PE, 2002, J BIOL CHEM, V277, P44938, DOI 10.1074/jbc.M205532200; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Malin SA, 2002, J NEUROSCI, V22, P10094; Molina A, 1997, J PHYSIOL-LONDON, V499, P361, DOI 10.1113/jphysiol.1997.sp021933; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; Pascual JM, 1997, AM J PHYSIOL-CELL PH, V273, pC1849, DOI 10.1152/ajpcell.1997.273.6.C1849; Patel AJ, 1997, EMBO J, V16, P6615, DOI 10.1093/emboj/16.22.6615; Post MA, 1996, FEBS LETT, V399, P177, DOI 10.1016/S0014-5793(96)01316-6; QUATTROCKI EA, 1994, NEURON, V12, P73, DOI 10.1016/0896-6273(94)90153-8; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; Salinas M, 1997, J BIOL CHEM, V272, P24371, DOI 10.1074/jbc.272.39.24371; Salinas M, 1997, J BIOL CHEM, V272, P8774, DOI 10.1074/jbc.272.13.8774; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sano A, 2002, EPILEPSIA, V43, P26, DOI 10.1046/j.1528-1157.43.s.9.7.x; Schultz JH, 2001, CIRC RES, V88, P483, DOI 10.1161/01.RES.88.5.483; SHEN NV, 1993, NEURON, V11, P67; Smirnov SV, 2002, J PHYSIOL-LONDON, V538, P867, DOI 10.1113/jphysiol.2001.013003; Starkus JG, 1997, J GEN PHYSIOL, V110, P539, DOI 10.1085/jgp.110.5.539; Stocker M, 1998, BIOCHEM BIOPH RES CO, V248, P927, DOI 10.1006/bbrc.1998.9072; Stocker M, 1999, J NEUROCHEM, V72, P1725, DOI 10.1046/j.1471-4159.1999.721725.x; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Takimoto K, 2002, J BIOL CHEM, V277, P26904, DOI 10.1074/jbc.M203651200; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Xu HD, 1999, CIRC RES, V85, P623, DOI 10.1161/01.RES.85.7.623; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	66	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18154	18161		10.1074/jbc.M213117200	http://dx.doi.org/10.1074/jbc.M213117200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642579	hybrid			2022-12-27	WOS:000182838300074
J	Kietzmann, T; Samoylenko, A; Immenschuh, S				Kietzmann, T; Samoylenko, A; Immenschuh, S			Transcriptional regulation of heme oxygenase-1 gene expression by MAP kinases of the JNK and p38 pathways in primary cultures of rat Hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; RESPONSE ELEMENT; MAMMALIAN-CELLS; SODIUM ARSENITE; MESSENGER-RNA; NITRIC-OXIDE; SIGNALING PATHWAY; HEPATOMA-CELLS	Heme oxygenase-1 (HO-1) gene expression is induced by various oxidative stress stimuli including sodium arsenite. Since mitogen-activated protein kinases (MAPKs) are involved in stress signaling we investigated the role of arsenite and MAPKs for HO-1 gene regulation in primary rat hepatocytes. The Jun N-terminal kinase (JNK) inhibitor SP600125 decreased sodium arsenite-mediated induction of HO-1 mRNA expression. HO-1 protein and luciferase activity of reporter gene constructs with -754 bp of the HO-1 promoter were induced by overexpression of kinases of the JNK pathway and MKK3. By contrast, overexpression of Raf-1 and ERK2 did not affect expression whereas overexpression of p38alpha, beta, and delta decreased and p38gamma increased HO-1 expression. Electrophoretic mobility shift assays (EMSA) revealed that a CRE/AP-1 element (-668/-654) bound c-Jun, a target of the JNK pathway. Deletion or mutation of the CRE/AP-1 obliterated the JNK- and c-Jun-dependent up-regulation of luciferase activity. EMSA also showed that an E-box (-47/-42) was bound by a putative p38 target c-Max. Mutation of the E-box strongly reduced MKK3, p38 isoform-, and c-Max-dependent effects on luciferase activity. Thus, the HO-1 CRE/AP-1 element mediates HO-1 gene induction via activation of JNK/c-Jun whereas p38 isoforms act through a different mechanism via the E-box.	Univ Gottingen, Inst Biochem & Mol Zellbiol, D-37073 Gottingen, Germany; Univ Giessen, Inst Klin Chem & Pathobiochem, D-35393 Giessen, Germany	University of Gottingen; Justus Liebig University Giessen	Kietzmann, T (corresponding author), Univ Gottingen, Inst Biochem & Mol Zellbiol, Humboldtallee 23, D-37073 Gottingen, Germany.	tkietzm@gwdg.de	Samoylenko, Anatoliy/AAZ-9623-2021; Samoylenko, Anatoliy/HDM-7330-2022; Immenschuh, Stephan/AAM-9181-2020; Samoylenko, Anatoliy/AAN-1992-2021	Samoylenko, Anatoliy/0000-0002-0240-897X; Immenschuh, Stephan/0000-0003-3722-5791; Samoylenko, Anatoliy/0000-0002-0240-897X; Kietzmann, Thomas/0000-0003-0242-8636				Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALAM J, 1994, J BIOL CHEM, V269, P1001; ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; APPLEGATE LA, 1991, CANCER RES, V51, P974; Chen G, 2000, J BIOL CHEM, V275, P38973, DOI 10.1074/jbc.M002856200; Chen K, 2000, CELL MOL BIOL, V46, P609; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; DENT P, 1995, MOL CELL BIOL, V15, P4125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Elbirt KK, 1998, J BIOL CHEM, V273, P8922, DOI 10.1074/jbc.273.15.8922; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Immenschuh S, 1998, MOL PHARMACOL, V53, P483, DOI 10.1124/mol.53.3.483; Immenschuh S, 1998, BIOCHEM J, V334, P141, DOI 10.1042/bj3340141; IMMENSCHUH S, 1995, BIOCHEMISTRY-US, V34, P13407, DOI 10.1021/bi00041a018; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; Jacobs JM, 1999, TOXICOL APPL PHARM, V157, P51, DOI 10.1006/taap.1999.8659; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; Kietzmann T, 1999, BLOOD, V94, P4177, DOI 10.1182/blood.V94.12.4177.424k14_4177_4185; Kietzmann T, 1997, BIOCHEM J, V321, P17, DOI 10.1042/bj3210017; Kietzmann T, 1999, MOL PHARMACOL, V56, P46, DOI 10.1124/mol.56.1.46; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; Lu TH, 1998, GENE, V207, P177, DOI 10.1016/S0378-1119(97)00623-9; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Maeshima H, 1996, NUCLEIC ACIDS RES, V24, P2959, DOI 10.1093/nar/24.15.2959; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Masuya Y, 1998, J BIOCHEM-TOKYO, V124, P628; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; MULLER RM, 1987, J BIOL CHEM, V262, P6795; MURRE C, 1994, BBA-GENE STRUCT EXPR, V1218, P129, DOI 10.1016/0167-4781(94)90001-9; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Oguro T, 1998, J PHARMACOL EXP THER, V287, P773; OKINAGA S, 1993, EUR J BIOCHEM, V212, P167, DOI 10.1111/j.1432-1033.1993.tb17647.x; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; RIZZARDINI M, 1993, BIOCHEM J, V290, P343, DOI 10.1042/bj2900343; Sandau KB, 1999, MOL PHARMACOL, V56, P744; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHONTHAL A, 1989, ONCOGENE, V4, P629; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takeda A, 2000, J BIOL CHEM, V275, P5395, DOI 10.1074/jbc.275.8.5395; Tchan MC, 2000, J BIOL CHEM, V275, P37454, DOI 10.1074/jbc.M004264200; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; Zhang H, 1997, J BIOL CHEM, V272, P17416, DOI 10.1074/jbc.272.28.17416	78	164	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17927	17936		10.1074/jbc.M203929200	http://dx.doi.org/10.1074/jbc.M203929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637567	hybrid			2022-12-27	WOS:000182838300043
J	Tan, LJ; Peng, HB; Osaki, M; Choy, BK; Auron, PE; Sandell, LJ; Goldring, MB				Tan, LJ; Peng, HB; Osaki, M; Choy, BK; Auron, PE; Sandell, LJ; Goldring, MB			Egr-1 mediates transcriptional repression of COL2A1 promoter activity by interleukin-1 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; IMMEDIATE-EARLY GENE; II PROCOLLAGEN GENE; NF-KAPPA-B; HUMAN CHONDROCYTES; FACTOR-ALPHA; CELL-LINE; C-FOS; DIFFERENTIAL EXPRESSION; NEGATIVE MODULATOR	Following induction and activation of the early growth response (Egr)-1 transcription factor in human chondrocytes, interleukin-1beta (IL-1beta) suppresses the expression of the type II collagen gene (COL2A1), associated with induction of Egr-1 binding activity in nuclear extracts. The COL2A1 proximal promoter contains overlapping binding sites for Egr-1 and Sp1 family members at -119/-112 bp and -81/-74 bp. Mutations that block binding of Sp1 and Sp3 to either site markedly reduce constitutive expression of the core promoter. IL-1beta-induced Egr-1 binds strongly to the -119/-112 bp site, and mutations that block Egr-1 binding prevent inhibition by IL-1beta. Cotransfection with pCMV-Egr1 potentiates the inhibition of COL2A1 promoter activity by IL-1beta, whereas overexpression of dominant-negative Egr-1 mutant, Wilm's tumor-1 (WT1)/Egr1, Sp1, or Sp3 reverses the inhibition by IL-1beta. Cotransfection of pGL2-COL2/Gal4,in which we substituted the critical residue for Egr-1 binding with a Gal4 binding domain and a pCMV-Gal4-Egr1 chimera permits an inhibitory response to IL-1beta that is reversed by overexpression of Gal4-CBP. Our results indicate that IL-1beta-induced activation of Egr-1 binding is required for inhibition of COL2A1 proximal promoter activity and suggest that Egr-1 acts as a repressor of a constitutively expressed collagen gene by preventing interactions between Sp1 and the general transcriptional machinery.	Harvard Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Washington University (WUSTL)	Goldring, MB (corresponding author), Harvard Inst Med, New England Baptist Bone & Joint Inst, Room 246,4 Blackfan Circle, Boston, MA 02115 USA.	mgoldrin@bidmc.harvard.edu			NCI NIH HHS [CA68544] Funding Source: Medline; NIAMS NIH HHS [AR45378] Funding Source: Medline; NIA NIH HHS [AG22021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG022021, R56AG022021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AICHER WK, 1994, J IMMUNOL, V152, P5940; ALAKOKKO L, 1995, BIOCHEM J, V308, P923, DOI 10.1042/bj3080923; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; BENTON HP, 1988, BIOCHEM BIOPH RES CO, V154, P421, DOI 10.1016/0006-291X(88)90703-6; CAO XM, 1992, J BIOL CHEM, V267, P1345; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; Chaudhary LR, 1996, MOL CELL BIOCHEM, V156, P69; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Dharmavaram RM, 1997, J BIOL CHEM, V272, P26918, DOI 10.1074/jbc.272.43.26918; Di Battista JA, 1999, OSTEOARTHR CARTILAGE, V7, P395, DOI 10.1053/joca.1998.0222; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Fitzgerald KA, 1999, J IMMUNOL, V162, P4920; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Ghayor C, 2001, J BIOL CHEM, V276, P36881, DOI 10.1074/jbc.M105083200; Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; GOLDRING MB, 1994, J CELL BIOCHEM, V54, P85, DOI 10.1002/jcb.240540110; GOLDRING MB, 1988, J CLIN INVEST, V82, P2026, DOI 10.1172/JCI113823; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; Haas TL, 1999, J BIOL CHEM, V274, P22679, DOI 10.1074/jbc.274.32.22679; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hallahan DE, 1995, J BIOL CHEM, V270, P30303, DOI 10.1074/jbc.270.51.30303; HORTON WE, 1992, DNA CELL BIOL, V11, P193, DOI 10.1089/dna.1992.11.193; Huang RP, 1999, J CELL BIOCHEM, V73, P227, DOI 10.1002/(SICI)1097-4644(19990501)73:2<227::AID-JCB9>3.0.CO;2-B; Inagaki Y, 2001, J BIOL CHEM, V276, P16573, DOI 10.1074/jbc.M010485200; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lefebvre V, 1998, MATRIX BIOL, V16, P529; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Leung KKH, 1998, J CELL BIOL, V141, P1291, DOI 10.1083/jcb.141.6.1291; Lim CP, 1998, ONCOGENE, V16, P2915, DOI 10.1038/sj.onc.1201834; Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199; Liu CT, 1999, J BIOL CHEM, V274, P4400, DOI 10.1074/jbc.274.7.4400; LIU JW, 1993, CELL GROWTH DIFFER, V4, P611; Loeser RF, 2000, OSTEOARTHR CARTILAGE, V8, P96, DOI 10.1053/joca.1999.0277; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Marshall OJ, 2000, MOL GENET METAB, V71, P455, DOI 10.1006/mgme.2000.3081; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MINOWA T, 1994, J BIOL CHEM, V269, P11656; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Murakami S, 2000, P NATL ACAD SCI USA, V97, P1113, DOI 10.1073/pnas.97.3.1113; Murakami S, 2000, J BIOL CHEM, V275, P3687, DOI 10.1074/jbc.275.5.3687; Murray D, 2000, J BIOL CHEM, V275, P3610, DOI 10.1074/jbc.275.5.3610; MUTHUKKUMAR S, 1995, MOL CELL BIOL, V15, P6262; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Okazaki K, 2002, J BIOL CHEM, V277, P31526, DOI 10.1074/jbc.M202815200; Osaki M, 2003, BIOCHEM J, V369, P103, DOI 10.1042/BJ20020928; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Poole A.R., 1997, ARTHRITIS ALLIED CON, P255; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Robbins JR, 2000, ARTHRITIS RHEUM, V43, P2189, DOI 10.1002/1529-0131(200010)43:10<2189::AID-ANR6>3.0.CO;2-S; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; SANDELL LJ, 1991, J CELL BIOL, V114, P1307, DOI 10.1083/jcb.114.6.1307; Sandell LJ, 1996, CONNECT TISSUE RES, V35, P1, DOI 10.3109/03008209609029168; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; SAVAGNER P, 1995, DNA CELL BIOL, V14, P501, DOI 10.1089/dna.1995.14.501; Silverman ES, 1999, AM J PATHOL, V154, P665, DOI 10.1016/S0002-9440(10)65312-6; Silverman ES, 1998, BIOCHEM J, V336, P183, DOI 10.1042/bj3360183; Sperling P, 2000, EUR J BIOCHEM, V267, P3801, DOI 10.1046/j.1432-1327.2000.01418.x; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; TYLER JA, 1988, COLLAGEN REL RES, V8, P393; VIKKULA M, 1992, BIOCHEM J, V285, P287, DOI 10.1042/bj2850287; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Wang FL, 2000, OSTEOARTHR CARTILAGE, V8, P161, DOI 10.1053/joca.1999.0295; WANG LQ, 1991, J BIOL CHEM, V266, P19878; Xu SC, 2001, DNA CELL BIOL, V20, P359, DOI 10.1089/10445490152122479	77	106	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17688	17700		10.1074/jbc.M301676200	http://dx.doi.org/10.1074/jbc.M301676200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637574	hybrid			2022-12-27	WOS:000182838300015
J	Wildey, GM; Patil, S; Howe, PH				Wildey, GM; Patil, S; Howe, PH			Smad3 potentiates transforming growth factor beta (TGF beta)-induced apoptosis and expression of the BH3-only protein bim in WEHI 231 B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY-MEMBER; SIGNAL-REGULATED KINASE; FYVE DOMAIN PROTEIN; TGF-BETA; INDUCE APOPTOSIS; BINDING PROTEIN; DOWN-REGULATION; BH3 DOMAIN; SURVIVAL; ACTIVATION	Transforming growth factor-beta (TGFbeta) is a potent growth inhibitor and inducer of apoptosis in B lymphocytes and is essential for immune regulation and maintenance of self-tolerance. Here we show that exogenous overexpression of Smad3 potentiates TGFbeta-induced apoptosis and expression of the pro-apoptotic protein Bim in WEHI 231 B lymphocytes. Overexpression of dominant-negative forms of Smad3 abrogate these TGFbeta-induced responses. We also demonstrate that TGFbeta induces Bim protein expression concomitant with its induction of apoptosis in the mouse progenitor B lymphocyte cell line, Ba/F3. Enhanced expression of Bim protein induced by TGFbeta is associated with an increased association of Bim with Bcl-2 and a concomitant loss of mitochondrial membrane potential. Furthermore, we find that the anti-apoptotic effect of the pro-survival cytokine CD40 results in the abrogation of TGFbeta-mediated Bim induction. Our data provide the first evidence of Bim expression levels that are increased by the addition of a pro-apoptotic cytokine, TGFbeta, and also suggest that the TGFbeta-specific transcription factor Smad3 plays a role in mediating Bim expression levels and apoptosis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, NC-1, Cleveland, OH 44195 USA.	howep@ccf.org		Wildey, Gary/0000-0001-7105-1313	NATIONAL CANCER INSTITUTE [R01CA055536, R29CA055536, R01CA080095] Funding Source: NIH RePORTER; NCI NIH HHS [CA80095, CA55536] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2001, MAMM GENOME, V12, P163, DOI 10.1007/s003350010242; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Brodin G, 1999, CANCER RES, V59, P2731; Brown TL, 1999, J BIOL CHEM, V274, P23256, DOI 10.1074/jbc.274.33.23256; Chen RH, 1997, CELL GROWTH DIFFER, V8, P821; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Curnock AP, 1998, CELL IMMUNOL, V187, P77, DOI 10.1006/cimm.1998.1335; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Francis JM, 2000, J BIOL CHEM, V275, P39137, DOI 10.1074/jbc.M007212200; Frey RS, 1997, CANCER RES, V57, P628; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Harris CA, 2001, J BIOL CHEM, V276, P37754; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hsing AY, 1996, CANCER RES, V56, P5146; Ishisaki A, 1999, J BIOL CHEM, V274, P13637, DOI 10.1074/jbc.274.19.13637; Ishisaki A, 1998, J BIOL CHEM, V273, P24293, DOI 10.1074/jbc.273.38.24293; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIN JK, 1992, CANCER RES, V52, P385; MAMI Y, 2001, FEBS LETT, V509, P135; Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Patil S, 2000, J BIOL CHEM, V275, P38363, DOI 10.1074/jbc.M004861200; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Whitfield J, 2001, NEURON, V29, P629, DOI 10.1016/S0896-6273(01)00239-2; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yanagisawa K, 1998, ONCOGENE, V17, P1743, DOI 10.1038/sj.onc.1202052; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zamzami N, 2000, METHOD ENZYMOL, V322, P208; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	68	84	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18069	18077		10.1074/jbc.M211958200	http://dx.doi.org/10.1074/jbc.M211958200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637528	hybrid			2022-12-27	WOS:000182838300063
J	Wu, J; Woodard, RW				Wu, J; Woodard, RW			Escherichia coli YrbI is 3-deoxy-D-manno-octulosonate 8-phosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTINUOUS SPECTROPHOTOMETRIC ASSAY; P-TYPE ATPASE; SALMONELLA-TYPHIMURIUM; INORGANIC-PHOSPHATE; MOLECULAR-CLONING; DATABASE SEARCH; GENE-EXPRESSION; LETHAL MUTANT; SYNTHETASE; SYNTHASE	3-Deoxy-D-manno-octulosonate 8-phosphate (KDO 8-P) phosphatase, which catalyzes the hydrolysis of KDO 8-P to KDO and inorganic phosphate, is the last enzyme in the KDO biosynthetic pathway for which the gene has not been identified. Wild-type KDO 8-P phosphatase was purified from Escherichia coli B, and the N-terminal amino acid sequence matched a hypothetical protein encoded by the E. coli open reading frame, yrbI. The yrbI gene, which encodes for a protein of 188 amino acids, was cloned, and the gene product was overexpressed in E. coli. The recombinant enzyme is a tetramer and requires a divalent metal cofactor for activity. Optimal enzymatic activity is observed at pH 5.5. The enzyme is highly specific for KDO 8-P with an apparent K-m of 75 muM and a k(cat) of 175 s(-1) in the presence of 1 mM Mg2+. Amino acid sequence analysis indicates that KDO 8-P phosphatase is a member of the haloacid dehalogenase hydrolase superfamily.	Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Woodard, RW (corresponding author), Univ Michigan, Coll Pharm, 428 Church St, Ann Arbor, MI 48109 USA.			Woodard, Ronald/0000-0002-7472-3653	NIGMS NIH HHS [GM 53069] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053069] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; Baranov PV, 2001, NUCLEIC ACIDS RES, V29, P264, DOI 10.1093/nar/29.1.264; BELUNIS CJ, 1995, J BIOL CHEM, V270, P27646, DOI 10.1074/jbc.270.46.27646; BERGER H, 1975, BIOCHEM SOC T, V3, P1096, DOI 10.1042/bst0031096; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; DOTSON GD, 1995, J BIOL CHEM, V270, P13698, DOI 10.1074/jbc.270.23.13698; ENGELBERGKULKA H, 1994, MOL MICROBIOL, V11, P3, DOI 10.1111/j.1365-2958.1994.tb00283.x; GHALAMBOR MA, 1966, J BIOL CHEM, V241, P3222; GOLDMAN RC, 1986, J BIOL CHEM, V261, P5831; GOLDMAN RC, 1985, J BACTERIOL, V163, P256, DOI 10.1128/JB.163.1.256-261.1985; Jelakovic S, 1996, FEBS LETT, V391, P157, DOI 10.1016/0014-5793(96)00724-7; KOONIN EV, 1994, J MOL BIOL, V244, P125, DOI 10.1006/jmbi.1994.1711; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lunn JE, 2000, P NATL ACAD SCI USA, V97, P12914, DOI 10.1073/pnas.230430197; Parsons JF, 2002, PROTEINS, V46, P393, DOI 10.1002/prot.10057; Radaev S, 2000, ACTA CRYSTALLOGR D, V56, P516, DOI 10.1107/S0907444900002389; Radaev S, 2000, J BIOL CHEM, V275, P9476, DOI 10.1074/jbc.275.13.9476; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAY PH, 1980, J BACTERIOL, V142, P60, DOI 10.1128/JB.142.1.60-68.1980; RICK PD, 1982, J BACTERIOL, V150, P447, DOI 10.1128/JB.150.2.447-455.1982; RICK PD, 1977, J BIOL CHEM, V252, P4895; RICK PD, 1972, P NATL ACAD SCI USA, V69, P3756, DOI 10.1073/pnas.69.12.3756; Ridder IS, 1999, BIOCHEM J, V339, P223, DOI 10.1042/0264-6021:3390223; Rieger CE, 1997, ANAL BIOCHEM, V246, P86, DOI 10.1006/abio.1996.9962; SEKINE Y, 1994, J MOL BIOL, V235, P1406, DOI 10.1006/jmbi.1994.1097; Selengut JD, 2001, BIOCHEMISTRY-US, V40, P12704, DOI 10.1021/bi011405e; Sheflyan GY, 1998, J AM CHEM SOC, V120, P11027, DOI 10.1021/ja9816281; Stukey J, 1997, PROTEIN SCI, V6, P469; Tate WP, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1342; Thaller MC, 1998, PROTEIN SCI, V7, P1647, DOI 10.1002/pro.5560070722; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tzeng YL, 2002, J BIOL CHEM, V277, P24103, DOI 10.1074/jbc.M200931200; Wang WR, 2001, STRUCTURE, V9, P65, DOI 10.1016/S0969-2126(00)00558-X; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; WOISETSCHLAGER M, 1988, J BACTERIOL, V170, P5382, DOI 10.1128/jb.170.11.5382-5384.1988; WOISETSCHLAGER M, 1987, MOL GEN GENET, V207, P369, DOI 10.1007/BF00331603	38	57	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18117	18123		10.1074/jbc.M301983200	http://dx.doi.org/10.1074/jbc.M301983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639950	hybrid			2022-12-27	WOS:000182838300069
J	Spiller, OB; Blackbourn, DJ; Mark, L; Proctor, DG; Blom, AM				Spiller, OB; Blackbourn, DJ; Mark, L; Proctor, DG; Blom, AM			Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL PROTEIN; C4B-BINDING PROTEIN; FACTOR-I; VIRUS; INHIBITION; C3B; PURIFICATION; DEGRADATION; SEQUENCES; HOMOLOG	Kaposi's sarcoma-associated herpesvirus (KSHV) is closely associated with Kaposi's sarcoma and certain B-cell lymphomas. The fourth open reading frame of the KSHV genome encodes a protein (KSHV complement control protein (KCP, previously termed ORF4)) predicted to have complement-regulating activity. Here, we show that soluble KCP strongly enhanced the decay of classical C3-convertase but not the alternative pathway C3-convertase, when compared with the host complement regulators: factor H, C4b-binding protein, and decay-accelerating factor. The equilibrium affinity constant (K-D) of KCP for C3b and C4b was determined by surface plasmon resonance analysis to range between 0.47-10 muM and 0.025-6.1 muM, respectively, depending on NaCl concentration and cation presence. Soluble and cell-associated KCP acted as a cofactor for factor I (FI)-mediated cleavage of both C4b and C3b and induced the cleavage products C4d and iC3b, respectively. In the presence of KCP, FI further cleaved iC3b to C3d, which has never been described before as complement receptor 1 only mediates the production of C3dg by FI. KCP would enhance virus pathogenesis through evading complement attack, opsonization, and anaphylaxis but may also aid in targeting KSHV to one of its host reservoirs since C3d is a ligand for complement receptor 2 on B-cells.	Lund Univ, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden; Univ Glasgow, Inst Biomed & Life Sci, Div Virol, Glasgow G11 5JR, Lanark, Scotland; Cardiff Univ, Coll Med, Virus Receptor & Immune Evas Grp, Dept Med Biochem, Cardiff CF14 4XX, S Glam, Wales	Lund University; Skane University Hospital; University of Glasgow; Cardiff University	Blom, AM (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Clin Chem, S-20502 Malmo, Sweden.	Anna.Blom@klkemi.mas.lu.se	Blom, Anna/B-9607-2009; Blom, Anna/AFS-7369-2022; Spiller, Owen Brad/AAC-2474-2020	Blom, Anna/0000-0002-1348-1734; Spiller, Owen Brad/0000-0002-9117-6911; Blackbourn, David/0000-0002-6703-4497				ALBRECHT JC, 1992, J VIROL, V66, P3937, DOI 10.1128/JVI.66.6.3937-3940.1992; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; ANDERSSON M, 1991, EUR J CLIN PHARMACOL, V40, P261, DOI 10.1007/BF00315206; Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Blom AM, 2003, MOL IMMUNOL, V39, P547, DOI 10.1016/S0161-5890(02)00213-4; Cesarman E, 1999, SEMIN CANCER BIOL, V9, P165, DOI 10.1006/scbi.1998.0118; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CROSSLEY LG, 1980, BIOCHEM J, V191, P173, DOI 10.1042/bj1910173; DAHLBACK B, 1983, BIOCHEM J, V209, P857, DOI 10.1042/bj2090857; DAHLBACK B, 1983, BIOCHEM J, V209, P847, DOI 10.1042/bj2090847; DODDS AW, 1997, PRACTICAL APPROACH S, P182; EKDAHL KN, 1990, J IMMUNOL, V144, P4269; FODOR WL, 1995, J VIROL, V69, P3889, DOI 10.1128/JVI.69.6.3889-3892.1995; GIGLI I, 1976, BIOCHEM J, V157, P541, DOI 10.1042/bj1570541; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; Harris CL, 2000, IMMUNOLOGY, V100, P462, DOI 10.1046/j.1365-2567.2000.00066.x; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Kapadia SB, 2002, IMMUNITY, V17, P143, DOI 10.1016/S1074-7613(02)00369-2; Kapadia SB, 1999, J VIROL, V73, P7658, DOI 10.1128/JVI.73.9.7658-7670.1999; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kotwal GJ, 1998, MOL CELL BIOCHEM, V185, P39, DOI 10.1023/A:1006844624825; KOTWAL GJ, 1988, NATURE, V335, P176, DOI 10.1038/335176a0; KOTWAL GJ, 1990, SCIENCE, V250, P827, DOI 10.1126/science.2237434; MCKENZIE R, 1992, J INFECT DIS, V166, P1245, DOI 10.1093/infdis/166.6.1245; MEDOF ME, 1984, J EXP MED, V159, P1669, DOI 10.1084/jem.159.6.1669; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Miller CG, 1997, VIROLOGY, V229, P126, DOI 10.1006/viro.1996.8396; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Rosengard AM, 1999, MOL IMMUNOL, V36, P685, DOI 10.1016/S0161-5890(99)00081-4; Rosengard AM, 2002, P NATL ACAD SCI USA, V99, P8808, DOI 10.1073/pnas.112220499; ROTHER RP, 1994, J VIROL, V68, P730, DOI 10.1128/JVI.68.2.730-737.1994; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sahu A, 1998, J IMMUNOL, V160, P5596; Schulz TF, 2001, EUR J CANCER, V37, P1217, DOI 10.1016/S0959-8049(01)00115-0; Spiller OB, 2003, J VIROL, V77, P592, DOI 10.1128/JVI.77.1.592-599.2003; Uvarova EA, 2001, VIRUS RES, V81, P39, DOI 10.1016/S0168-1702(01)00332-X; Virgin HW, 1997, J VIROL, V71, P5894, DOI 10.1128/JVI.71.8.5894-5904.1997; ZABERN I, 1982, J IMMUNOL, V128, P1433	39	66	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9283	9289		10.1074/jbc.M211579200	http://dx.doi.org/10.1074/jbc.M211579200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645526	hybrid			2022-12-27	WOS:000181524000053
J	Mikule, K; Sunpaweravong, S; Gatlin, JC; Pfenninger, KH				Mikule, K; Sunpaweravong, S; Gatlin, JC; Pfenninger, KH			Eicosanoid activation of protein kinase C epsilon - Involvement in growth cone repellent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL-RAT-BRAIN; HUMAN NEUROBLASTOMA-CELLS; ARACHIDONIC-ACID; NERVE GROWTH; PHOSPHOLIPASE A(2); NEURITE OUTGROWTH; MARCKS FAMILY; PKC-EPSILON; FATTY-ACIDS; PC12 CELLS	Exposure of growing neurons to thrombin or semaphorin 3A stimulates a receptor-mediated signaling cascade that results in collapse of their growth cones. This collapse response necessitates eicosanoid production, as we have shown earlier. The present report investigates whether and which protein kinase C (PKC) isoforms may be activated by such eicosanoids. To examine these questions, we isolated growth cones from fetal rat brain and tested whether thrombin or the eicosanoid, 12(S)-hydroxyeicosatetraenoic acid (12(S)-HETE), could activate endogenous growth cone PKC. We show that both thrombin and 12(S)-HETE stimulate the phosphorylation of the myristoylated alanine-rich protein kinase C substrate, an 87-kDa adhesion site protein. Furthermore, we show both with immunoprecipitated and with recombinant PKC that 12(S)-HETE activation is selective for the epsilon isoform and does not require accessory proteins. Last, we demonstrate that PKC activation is necessary for thrombin-induced growth cone collapse. These data indicate that eicosanoid-mediated repellent effects result from the direct and selective activation of PKCepsilon and suggest the involvement of myristoylated alanine-rich protein kinase C substrate phosphorylation in growth cone collapse.	Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA; Univ Colorado, Sch Med, Ctr Canc, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Pfenninger, KH (corresponding author), Univ Colorado, Sch Med, Dept Cellular & Struct Biol, 4200 E 9th Ave, Denver, CO 80262 USA.				NINDS NIH HHS [5F31 NS44705, 1R01 NS41029] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS044705, R01NS041029] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADEREM A, 1995, BIOCHEM SOC T, V23, P587, DOI 10.1042/bst0230587; ALBERT KA, 1986, P NATL ACAD SCI USA, V83, P2822, DOI 10.1073/pnas.83.9.2822; ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; Bell R M, 1986, Methods Enzymol, V124, P353; Berrier AL, 2000, J CELL BIOL, V151, P1549, DOI 10.1083/jcb.151.7.1549; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bonsall J, 1999, BRAIN RES, V839, P120, DOI 10.1016/S0006-8993(99)01725-4; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Cabell CH, 1996, P ASSOC AM PHYSICIAN, V108, P37; CAMPENOT RB, 1994, J NEUROCHEM, V63, P868; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; Cheng S, 2000, CELL MOTIL CYTOSKEL, V47, P337, DOI 10.1002/1097-0169(200012)47:4<337::AID-CM7>3.3.CO;2-2; CHO H, 1991, J MED CHEM, V34, P1503, DOI 10.1021/jm00108a039; Clark GD, 2000, NEUROCHEM RES, V25, P603, DOI 10.1023/A:1007598617374; de la Houssaye BA, 1999, J NEUROSCI, V19, P10843, DOI 10.1523/JNEUROSCI.19-24-10843.1999; Disatnik MH, 2002, J CELL SCI, V115, P2151; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; FIELDS RD, 1993, J NEUROBIOL, V24, P1080, DOI 10.1002/neu.480240807; Fu WM, 1997, NEUROREPORT, V8, P2005, DOI 10.1097/00001756-199705260-00041; Gomez TM, 2000, J NEUROBIOL, V44, P174, DOI 10.1002/1097-4695(200008)44:2<174::AID-NEU7>3.3.CO;2-I; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; Helmke S, 1998, J CELL SCI, V111, P2465; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Isbister CM, 2000, J NEUROBIOL, V44, P271, DOI 10.1002/1097-4695(200008)44:2<271::AID-NEU15>3.3.CO;2-1; Ivaska J, 2002, EMBO J, V21, P3608, DOI 10.1093/emboj/cdf371; IVINS JK, 1991, J NEUROSCI, V11, P1597; Kabir N, 2001, J CELL BIOL, V152, P1033, DOI 10.1083/jcb.152.5.1033; KATZ F, 1985, J NEUROSCI, V5, P1402; KHAN WA, 1995, CELL SIGNAL, V7, P171, DOI 10.1016/0898-6568(94)00089-T; Kitano T, 1986, Methods Enzymol, V124, P349; LI HN, 1992, J NEUROSCI, V12, P2393; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Lohse K, 1996, DEV BRAIN RES, V96, P83, DOI 10.1016/0165-3806(96)00076-4; LOPEZRUIZ MP, 1992, ENDOCRINOLOGY, V130, P1122, DOI 10.1210/en.130.3.1122; Loschinger J, 1997, J NEUROBIOL, V33, P825, DOI 10.1002/(SICI)1097-4695(19971120)33:6<825::AID-NEU9>3.0.CO;2-B; Mackay K, 2001, CARDIOVASC RES, V50, P65, DOI 10.1016/S0008-6363(00)00322-9; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; MOORMAN SJ, 1993, J NEUROSCI, V13, P4727; MURAKAMI K, 1985, FEBS LETT, V192, P189, DOI 10.1016/0014-5793(85)80105-8; Nakayama T, 1999, J NEUROBIOL, V41, P326, DOI 10.1002/(SICI)1097-4695(19991115)41:3<326::AID-NEU2>3.0.CO;2-W; NATARAJAN R, 1994, MOL CELL ENDOCRINOL, V101, P59, DOI 10.1016/0303-7207(94)90219-4; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1992, J BIOL CHEM, V267, P15263; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARROW V, 1995, J NEUROSCI RES, V41, P782, DOI 10.1002/jnr.490410609; PFENNINGER KH, 1983, CELL, V35, P573, DOI 10.1016/0092-8674(83)90191-5; PFENNINGER KH, 1981, J CELL BIOL, V89, P536, DOI 10.1083/jcb.89.3.536; PFENNINGER KH, 1991, MOL NEUROBIOL, V5, P143, DOI 10.1007/BF02935543; PIOMELLI D, 1989, P NATL ACAD SCI USA, V86, P8550, DOI 10.1073/pnas.86.21.8550; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Renaudin A, 1999, J NEUROSCI RES, V55, P458, DOI 10.1002/(SICI)1097-4547(19990215)55:4<458::AID-JNR6>3.0.CO;2-D; ROBINSON PJ, 1993, ANAL BIOCHEM, V210, P172, DOI 10.1006/abio.1993.1169; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; Rosner H, 1999, EUR J CELL BIOL, V78, P698; Ross S, 2000, CELL GROWTH DIFFER, V11, P19; SCHAECHTER JD, 1993, J NEUROSCI, V13, P4361; Schwartz Z, 1999, ENDOCRINOLOGY, V140, P2991, DOI 10.1210/en.140.7.2991; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shibata K, 2000, PROSTAG OTH LIPID M, V62, P385, DOI 10.1016/S0090-6980(00)00090-3; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Suter DM, 2000, J NEUROBIOL, V42, P370, DOI 10.1002/(SICI)1097-4695(20000215)42:3<370::AID-NEU8>3.3.CO;2-M; Suter DM, 1998, J CELL BIOL, V141, P227, DOI 10.1083/jcb.141.1.227; Szekeres CK, 2000, J BIOL CHEM, V275, P38831, DOI 10.1074/jbc.M002673200; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; THEODORE L, 1995, J NEUROSCI, V15, P7158; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uberall F, 1997, J BIOL CHEM, V272, P4072, DOI 10.1074/jbc.272.7.4072; Ueki S, 1999, J CELL PHYSIOL, V178, P63, DOI 10.1002/(SICI)1097-4652(199901)178:1<63::AID-JCP8>3.0.CO;2-J; Wen Y, 2000, BIOCHEM J, V349, P481, DOI 10.1042/0264-6021:3490481; Zheng JQ, 2000, NATURE, V403, P89, DOI 10.1038/47501	78	27	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21168	21177		10.1074/jbc.M211828200	http://dx.doi.org/10.1074/jbc.M211828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665507	hybrid			2022-12-27	WOS:000183230500094
J	Paterson, AD; Parton, RG; Ferguson, C; Stow, JL; Yap, AS				Paterson, AD; Parton, RG; Ferguson, C; Stow, JL; Yap, AS			Characterization of E-cadherin endocytosis in isolated MCF-7 and Chinese hamster ovary cells - The initial fate of unbound E-cadherin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; ADHERENS JUNCTIONS; ADHESION MOLECULES; MEMBRANE DOMAINS; ENDOSOMES; INHIBITION; RAC1; ARF6; RAB5; LOCALIZATION	The endocytosis of E-cadherin has recently emerged as an important determinant of cadherin function with the potential to participate in remodeling adhesive contacts. In this study we focused on the initial fate of E-cadherin when it predominantly exists free on the cell surface prior to adhesive binding or incorporation into junctions. Surface-labeling techniques were used to define the endocytic itinerary of E-cadherin in MCF-7 cells and in Chinese hamster ovary cells stably expressing human E-cadherin. We found that in this experimental system E-cadherin entered a transferrin-negative compartment before transport to the early endosomal compartment, where it merged with classical clathrin-mediated uptake pathways. E-cadherin endocytosis was inhibited by mutant dynamin, but not by an Eps15 mutant that effectively blocked transferrin internalization. Furthermore, sustained signaling by the ARF6 GTPase appeared to trap endocytosed E-cadherin in large peripheral structures. We conclude that in isolated cells unbound E-cadherin on the cell surface is predominantly endocytosed by a clathrin-independent pathway resembling macropinocytotic internalization, which then fuses with the early endosomal system. Taken with earlier reports, this suggests the possibility that multiple pathways exist for E-cadherin entry into cells that are likely to reflect cell context and regulation.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Mircoanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Mol & Microbial Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Yap, AS (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	a.yap@mailbox.uq.edu.au	Stow, Jennifer L/I-4723-2013; Yap, Alpha S./J-1554-2014; Parton, Robert G/C-5673-2009	Stow, Jennifer L/0000-0002-5409-9101; Yap, Alpha S./0000-0002-1038-8956; Parton, Robert G/0000-0002-7494-5248				Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Benmerah A, 1999, J CELL SCI, V112, P1303; BRIEHER WM, 1994, J CELL BIOL, V126, P519, DOI 10.1083/jcb.126.2.519; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Damke H, 2001, MOL BIOL CELL, V12, P2578, DOI 10.1091/mbc.12.9.2578; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Ghosh RN, 1998, J CELL BIOL, V142, P923, DOI 10.1083/jcb.142.4.923; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Jarrett O, 2002, INT J DEV BIOL, V46, P467; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kovacs EM, 2002, CURR BIOL, V12, P379, DOI 10.1016/S0960-9822(02)00661-9; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Krueger EW, 2003, MOL BIOL CELL, V14, P1085, DOI 10.1091/mbc.E02-08-0466; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Palacios F, 2002, NAT CELL BIOL, V4, P929, DOI 10.1038/ncb881; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Radhakrishna H, 1999, J CELL SCI, V112, P855; Radhakrishna H, 1997, J CELL BIOL, V139, P49, DOI 10.1083/jcb.139.1.49; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tepass U, 2000, NAT REV MOL CELL BIO, V1, P91, DOI 10.1038/35040042; Tepass U, 1999, CURR OPIN CELL BIOL, V11, P540, DOI 10.1016/S0955-0674(99)00025-3; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774	51	153	156	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21050	21057		10.1074/jbc.M300082200	http://dx.doi.org/10.1074/jbc.M300082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657640	hybrid			2022-12-27	WOS:000183230500079
J	Sah, NK; Munshi, A; Kurland, JF; McDonnell, TJ; Su, B; Meyn, RE				Sah, NK; Munshi, A; Kurland, JF; McDonnell, TJ; Su, B; Meyn, RE			Translation inhibitors sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by activating c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; JNK; INDUCTION; RECEPTOR; DEATH; PATHWAY; SURVIVAL; MEMBER	Tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL) induces apoptosis in several human tumors both in vitro and in vivo, however, some tumors remain resistant for poorly understood reasons. Using a quantitative DNA fragmentation assay for apoptosis, we have shown that human prostate cancer cells are resistant to a wide range of TRAIL doses up to 500 ng/ml. However, translation inhibitors, such as anisomycin, cycloheximide, emetine, harringtonine, and puromycin, unlike several transcription inhibitors, significantly sensitized PC3-neomycin (PC3-neo) cells to TRAIL-induced apoptosis. These effects were inhibited in PC3 cells engineered to express bcl2 (PC3-bcl2). Translation inhibitors led to activation of c-JunN-terminal kinase (JNK), which plays a role in this sensitization process because inhibition of JNK activation resulted in protection against TRAIL plus translation inhibitor-induced apoptosis. JNK activation may be required for this process, but it is not sufficient because activation of JNK using an MEKK2 expression vector did not mimic the sensitizing effect of translation inhibitors. Other stress-activated protein kinases, such as ERK and p38, play an insignificant role in determining the apoptotic sensitivity. We conclude that activation of JNK is required for sensitization of PC3 cells to TRAIL-induced apoptosis by translation inhibitors in cells that are otherwise TRAIL-resistant. However, in addition to JNK activation, other aspects of translation inhibition such as the suppressed activity of apoptosis-inhibitory proteins or activation of other signal transduction pathways must also be involved.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Meyn, RE (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	rmeyn@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA069003] Funding Source: NIH RePORTER; NCI NIH HHS [CA69003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Donovan N, 2002, J BIOL CHEM, V277, P40944, DOI 10.1074/jbc.M206113200; Eggert A, 2001, CANCER RES, V61, P1314; Eid MA, 2002, INT J ONCOL, V21, P111; Emery JG, 1998, J BIOL CHEM, V273, P14363, DOI 10.1074/jbc.273.23.14363; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; Hernandez A, 2001, J GASTROINTEST SURG, V5, P56, DOI 10.1016/S1091-255X(01)80014-7; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jobin C, 1999, J IMMUNOL, V163, P3474; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kim SJ, 1997, BIOCHEM BIOPH RES CO, V234, P681, DOI 10.1006/bbrc.1997.6699; Kolbus A, 2000, MOL CELL BIOL, V20, P575, DOI 10.1128/MCB.20.2.575-582.2000; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Lipton SA, 2002, CELL, V111, P147, DOI 10.1016/S0092-8674(02)01046-2; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Mazars A, 2001, J BIOL CHEM, V276, P36797, DOI 10.1074/jbc.M101672200; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shifrin VI, 1999, J BIOL CHEM, V274, P13985, DOI 10.1074/jbc.274.20.13985; Sidhu JS, 1998, J BIOL CHEM, V273, P4769, DOI 10.1074/jbc.273.8.4769; Srivastava RK, 1999, MOL CELL BIOL, V19, P5659; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Su B, 2001, J BIOL CHEM, V276, P14784, DOI 10.1074/jbc.M010134200; SUSIN CA, 1999, NAT STRUCT BIOL, V9, P442; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thomas RP, 2002, SURGERY, V132, P127, DOI 10.1067/msy.2002.124930; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Watanabe N, 2002, ARCH BIOCHEM BIOPHYS, V405, P231, DOI 10.1016/S0003-9861(02)00399-5; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang XD, 1999, CANCER RES, V59, P2747	60	57	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20593	20602		10.1074/jbc.M211010200	http://dx.doi.org/10.1074/jbc.M211010200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663665	hybrid			2022-12-27	WOS:000183230500020
J	Sowa, H; Kaji, H; Canaff, L; Hendy, GN; Tsukamoto, T; Yamaguchi, T; Miyazono, K; Sugimoto, T; Chihara, K				Sowa, H; Kaji, H; Canaff, L; Hendy, GN; Tsukamoto, T; Yamaguchi, T; Miyazono, K; Sugimoto, T; Chihara, K			Inactivation of menin, the product of the multiple endocrine neoplasia type 1 gene, inhibits the commitment of multipotential mesenchymal stem cells into the osteoblast lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; DIFFERENTIATION; EXPRESSION; CBFA1; TRANSCRIPTION; C3H10T1/2; INTERACTS; GROWTH; BMP-2; OVEREXPRESSION	The physiological roles of menin, the product of the multiple endocrine neoplasia type 1 gene, are not known. Homozygous menin knockout mice exhibit cranial and facial hypoplasia. We, therefore, investigated the role of menin in the regulation of osteoblastic differentiation. Menin antisense oligonucleotides (AS-oligo) reduced endogenous menin expression in the C3H10T1/2 (10T1/2) mouse mesenchymal stem cells and antagonized alkaline phosphatase ( ALP) activity and the expression of type I collagen, Runx2/cbfa1 (Runx2), and osteocalcin (OCN) induced by bone morphogenetic protein 2 (BMP-2). AS-oligo did not affect adipogenic markers ( Oil red staining and PPARgamma expression) and chondrogenic markers ( Alcian blue staining and type IX collagen) induced by BMP-2 in 10T1/2 cells. Menin co-immunoprecipitated with Smad1 and Smad5, and inactivation of menin antagonized BMP-2-induced transcriptional activity of Smad1/5. In osteoblastic MC3T3-E1 cells, AS-oligo affected neither BMP-2-stimulated ALP activity nor the expression of Runx2 and OCN. Stable inactivation of menin in MC3T3-E1 cells increased ALP activity, mineralization, and the expression of type I collagen and OCN. In 21-day cultures of MC3T3-E1 cells and BMP-2-treated 10T1/2 cells, endogenous menin expression increased up to day 14 and declined thereafter. These data indicate that menin inactivation specifically inhibits the commitment of pluripotent mesenchymal stem cells to the osteoblast lineage, mediated by menin and Smad1/5 interactions. Menin is important for both early differentiation of osteoblasts and inhibition of their later differentiation, and it might be crucial for intramembranous ossification.	Kobe Univ, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med, Grad Sch Med,Chuo Ku, Kobe, Hyogo 6500017, Japan; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Human Genet, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Montreal, PQ H3A 1A1, Canada; Japanese Fdn Canc Res, Dept Biochem, Inst Canc, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan	Kobe University; McGill University; McGill University; McGill University; McGill University; Royal Victoria Hospital; Japanese Foundation for Cancer Research; University of Tokyo	Sugimoto, T (corresponding author), Kobe Univ, Div Endocrinol Metab Neurol & Hematol Oncol, Dept Clin Mol Med, Grad Sch Med,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	sugimot@med.kobe-u.ac.jp	Kaji, Hiroshi/AAI-5628-2020					Agarwal SK, 1997, HUM MOL GENET, V6, P1169, DOI 10.1093/hmg/6.7.1169; AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Asahina I, 1996, EXP CELL RES, V222, P38, DOI 10.1006/excr.1996.0005; Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097-4644(19970701)66:1<1::AID-JCB1>3.0.CO;2-V; Bi WM, 1999, NAT GENET, V22, P85, DOI 10.1038/8792; Bostrom K, 2001, J BIOL CHEM, V276, P14044, DOI 10.1074/jbc.M008103200; Chen D, 1997, CALCIFIED TISSUE INT, V60, P283, DOI 10.1007/s002239900230; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Elbrecht A, 1996, BIOCHEM BIOPH RES CO, V224, P431, DOI 10.1006/bbrc.1996.1044; Fang JM, 1997, ANAT EMBRYOL, V196, P349, DOI 10.1007/s004290050104; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HARRIS SE, 1994, J BONE MINER RES, V9, P389; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Ikeo Y, 2000, LAB INVEST, V80, P797, DOI 10.1038/labinvest.3780084; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lebrun JJ, 1999, MOL ENDOCRINOL, V13, P15, DOI 10.1210/me.13.1.15; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052; LOWRY OH, 1954, ANAL BIOCHEM, V17, P19; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/s0092-8674(01)00622-5; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6; Sato M, 1998, ONCOGENE, V17, P1517, DOI 10.1038/sj.onc.1202064; Smits P, 2001, DEV CELL, V1, P277, DOI 10.1016/S1534-5807(01)00003-X; Sowa H, 2002, J BONE MINER RES, V17, P1190, DOI 10.1359/jbmr.2002.17.7.1190; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WANG EA, 1990, P NATL ACAD SCI USA, V87, P2220, DOI 10.1073/pnas.87.6.2220; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yamaguchi A, 1996, BIOCHEM BIOPH RES CO, V220, P366, DOI 10.1006/bbrc.1996.0411; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zehentner BK, 2000, DNA CELL BIOL, V19, P275, DOI 10.1089/10445490050021186	58	76	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21058	21069		10.1074/jbc.M302044200	http://dx.doi.org/10.1074/jbc.M302044200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649288	hybrid			2022-12-27	WOS:000183230500080
J	Chiang, PW; Oiso, N; Gautam, R; Suzuki, T; Swank, RT; Spritz, RA				Chiang, PW; Oiso, N; Gautam, R; Suzuki, T; Swank, RT; Spritz, RA			The Hermansky-Pudlak Syndrome 1 (HPS1) and HPS4 proteins are components of two complexes, BLOC-3 and BLOC-4, involved in the biogenesis of lysosome-related organelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PALE EAR EP; MUTATION; MELANOSOMES; HOMOLOG; CELLS; GENE; MELANOCYTES; DISORDERS; TRANSPORT; MELANOMA	Hermansky-Pudlak syndrome (HPS) is a genetic disease of lysosome, melanosome, and granule biogenesis. Mutations of six different loci have been associated with HPS in humans, the most frequent of which are mutations of the HPS1 and HPS4 genes. Here, we show that the HPS1 and HPS4 proteins are components of two novel protein complexes involved in biogenesis of melanosome and lysosome-related organelles: biogenesis of lysosome-related organelles complex-(BLOC) 3 and BLOC-4. The phenotypes of Hps1-mutant (pale-ear; ep) and Hps4-mutant (light-ear; le) mice and humans are very similar, and cells from ep and le mice exhibit similar abnormalities of melanosome morphology. HPS1 protein is absent from ep-mutant cells, and HPS4 from le-mutant cells, but le-mutant cells also lack HPS1 protein. HPS4 protein seems to be necessary for stabilization of HPS1, and the HPS1 and HPS4 proteins co-immunoprecipitate, indicating that they are in a complex. HPS1 and HPS4 do not interact directly in a yeast two-hybrid system, although HPS4 interacts with itself. In a partially purified vesicular/organellar fraction, HPS1 and HPS4 are both components of a complex with a molecular mass of similar to500 kDa, termed BLOC-3. Within BLOC-3, HPS1 and HPS4 are components of a discrete similar to200-kDa module termed BLOC-4. In the cytosol, HPS1 ( but not HPS4) is part of yet another complex, termed BLOC-5. We propose that the BLOC-3 and BLOC-4 HPS1 . HPS4 complexes play a central role in trafficking cargo proteins to newly formed cytoplasmic organelles.	Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Roswell Park Cancer Institute	Spritz, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Human Med Genet Program, 4200 E 9th Ave,Box B161, Denver, CO 80262 USA.		Oiso, Naoki/H-6540-2019	Oiso, Naoki/0000-0001-5593-6496	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031698, R01HL051480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039892] Funding Source: NIH RePORTER; NCI NIH HHS [CA16506] Funding Source: Medline; NEI NIH HHS [EY12104] Funding Source: Medline; NHLBI NIH HHS [HL31698, HL51480] Funding Source: Medline; NIAMS NIH HHS [AR39892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anikster Y, 2001, NAT GENET, V28, P376, DOI 10.1038/ng576; BENNETT DC, 1993, INT REV CYTOL, V146, P191, DOI 10.1016/S0074-7696(08)60383-6; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; CICIOTTE SL, 2003, IN PRESS BLOOD; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Falcon-Perez JM, 2002, J BIOL CHEM, V277, P28191, DOI 10.1074/jbc.M204011200; Feng GH, 1997, HUM MOL GENET, V6, P793, DOI 10.1093/hmg/6.5.793; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Gardner JM, 1997, P NATL ACAD SCI USA, V94, P9238, DOI 10.1073/pnas.94.17.9238; Huizing M, 2000, TRAFFIC, V1, P823, DOI 10.1034/j.1600-0854.2000.011103.x; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; LANE PW, 1967, J HERED, V58, P17, DOI 10.1093/oxfordjournals.jhered.a107529; LANE PW, 1967, J HERED, V58, P21, DOI 10.1093/oxfordjournals.jhered.a107531; MEISLER M, 1980, AM J PATHOL, V101, P581; MEISLER MH, 1984, J HERED, V75, P103, DOI 10.1093/oxfordjournals.jhered.a109881; Oh J, 2000, HUM MOL GENET, V9, P375, DOI 10.1093/hmg/9.3.375; Oh J, 1996, NAT GENET, V14, P300, DOI 10.1038/ng1196-300; Peden AA, 2002, J CELL BIOL, V156, P327, DOI 10.1083/jcb.200107140; PIANTELLI M, 1995, J INVEST DERMATOL, V105, P248, DOI 10.1111/1523-1747.ep12317599; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; Starcevic M, 2002, SEMIN CELL DEV BIOL, V13, P271, DOI 10.1016/S1084952102000563; Suzuki T, 2003, P NATL ACAD SCI USA, V100, P1146, DOI 10.1073/pnas.0237292100; Suzuki T, 2002, NAT GENET, V30, P321, DOI 10.1038/ng835; Suzuki T, 2001, GENOMICS, V78, P30, DOI 10.1006/geno.2001.6644; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Zhang Q, 2003, NAT GENET, V33, P145, DOI 10.1038/ng1087	30	72	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20332	20337		10.1074/jbc.M300090200	http://dx.doi.org/10.1074/jbc.M300090200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663659	hybrid			2022-12-27	WOS:000183078000097
J	Gill, SK; Bhattacharya, M; Ferguson, SSG; Rylett, RJ				Gill, SK; Bhattacharya, M; Ferguson, SSG; Rylett, RJ			Identification of a novel nuclear localization signal common to 69-and 82-kDa human choline acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING-PROTEINS; EXPORT SIGNAL; IMPORT; TRANSPORT; PHOSPHORYLATION; EXPRESSION; PATHWAY; DOMAIN; GENE; ACTIVATION	We demonstrated previously that 69- and 82-kDa human choline acetyltransferase are localized predominantly to the cytoplasm and the nucleus, respectively. We have now identified a nuclear localization signal common to both forms of enzyme using confocal microscopy to study the subcellular compartmentalization of choline acetyltransferase tagged with green fluorescent protein in living HEK 293 cells. To identify functional nuclear localization and export signals, portions of full-length 69-kDa choline acetyltransferase were cloned into the vector peGFP-N1 and the cellular distribution patterns of the fusion proteins observed. Of the nine constructs studied, one yielded a protein with nuclear localization and another produced a protein with cytoplasmic localization. Mutation of the critical amino acids in this novel putative nuclear localization signal in the 69- and 82-kDa enzymes demonstrated that it is functional in both proteins. Moreover, 69-kDa choline acetyltransferase but not the 82-kDa enzyme is transported out of the nucleus by the leptomycin B-sensitive Crm-1 export pathway. By using bikaryon cells expressing both 82-kDa choline acetyltransferase and the nuclear protein heterogeneous nuclear ribonucleoprotein with green and red fluorescent tags, respectively, we found that the 82-kDa enzyme does not shuttle out of the nucleus in measurable amounts. These data suggest that 69- kDa choline acetyltransferase is a nucleocytoplasmic shuttling protein with a predominantly cytoplasmic localization determined by a functional nuclear localization signal and unidentified putative nuclear export signal. For 82-kDa choline acetyltransferase, the presence of the unique amino-terminal nuclear localization signal plus the newly identified nuclear localization signal may be involved in a process leading to predominantly nuclear accumulation of this enzyme, or alternatively, the two nuclear localization signals may be sufficient to overcome the force(s) driving nuclear export.	Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; Univ Western Ontario, Robarts Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Rylett, RJ (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	jane.rylett@fmd.uwo.ca	Rylett, Rebecca Jane/K-3597-2013	Rylett, Rebecca Jane/0000-0002-9158-9599				BEJANIN S, 1994, J BIOL CHEM, V269, P21944; Bhattacharya M, 2002, NAT CELL BIOL, V4, P547, DOI 10.1038/ncb821; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; Chalfie M, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, pVII; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dobransky T, 2003, J BIOL CHEM, V278, P5883, DOI 10.1074/jbc.M212080200; Dobransky T, 2001, J BIOL CHEM, V276, P22244, DOI 10.1074/jbc.M011702200; Dobransky T, 2000, BIOCHEM J, V349, P141, DOI 10.1042/0264-6021:3490141; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; Dunn HG, 2001, CAN J NEUROL SCI, V28, P16; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; ERICKSON JD, 1994, J BIOL CHEM, V269, P21929; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FONNUM F, 1969, BIOCHEM J, V115, P465, DOI 10.1042/bj1150465; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Howell JL, 2002, BIOTECHNIQUES, V32, P80, DOI 10.2144/02321st04; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAIN SR, 1995, BIOTECHNIQUES, V19, P650; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kasa P, 1997, PROG NEUROBIOL, V52, P511, DOI 10.1016/S0301-0082(97)00028-2; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lee DCY, 1999, J BIOL CHEM, V274, P29031, DOI 10.1074/jbc.274.41.29031; LIND GJ, 1993, INVEST OPHTH VIS SCI, V34, P2943; LIND GJ, 1995, INVEST OPHTH VIS SCI, V36, P1492; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Meyer BE, 1996, J VIROL, V70, P2350, DOI 10.1128/JVI.70.4.2350-2359.1996; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MICHAEL WM, 1995, CELL, V83, P415; Misawa H, 1997, MOL BRAIN RES, V44, P323, DOI 10.1016/S0169-328X(96)00231-8; Oda Y, 1999, PATHOL INT, V49, P921, DOI 10.1046/j.1440-1827.1999.00977.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Pollard VW, 1996, CELL, V86, P985, DOI 10.1016/S0092-8674(00)80173-7; Resendes MC, 1999, J BIOL CHEM, V274, P19417, DOI 10.1074/jbc.274.27.19417; Rizzuto R, 1996, CURR BIOL, V6, P183, DOI 10.1016/S0960-9822(02)00451-7; Robert I, 2001, J NEUROCHEM, V79, P9, DOI 10.1046/j.1471-4159.2001.00508.x; Rosario M, 2001, MOL CELL BIOL, V21, P3750, DOI 10.1128/MCB.21.11.3750-3762.2001; Tachibana T, 1999, FEBS LETT, V442, P235, DOI 10.1016/S0014-5793(98)01664-0; Tang H, 1999, MOL CELL BIOL, V19, P3540; Wang AH, 2001, MOL CELL BIOL, V21, P5992, DOI 10.1128/MCB.21.17.5992-6005.2001; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Whitehouse PJ, 1998, J CLIN PSYCHIAT, V59, P19; Wu J, 1999, J BIOL CHEM, V274, P29202, DOI 10.1074/jbc.274.41.29202; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200	50	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20217	20224		10.1074/jbc.M213153200	http://dx.doi.org/10.1074/jbc.M213153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637523	hybrid			2022-12-27	WOS:000183078000083
J	Gonzalez-Sapienza, G; Cachau, RE				Gonzalez-Sapienza, G; Cachau, RE			Identification of critical residues of an immunodominant region of Echinococcus granulosus antigen B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDES; PHAGE	Immune evasion strategies often shape the immunogenicity of parasite components. We recently found that the N-terminal extension of the major subunit of Echinococcus granulosus antigen B (AgB), the causative agent of hydatid disease, concentrates the immunoreactive B cell epitopes of the native molecule. The nature of this immunodominance was analyzed using four monoclonal antibodies (mAbs) defining overlapping epitopes in this region of the AgB molecule. The minimal epitope requirements of these mAbs were determined using phage display peptide libraries. The consensus sequences isolated with the mAbs, and alanine replacement analysis with synthetic peptides mapped the relevant molecular contacts within a short stretch corresponding to residues 17-24 of the AgB major subunit. Substitution of two critical residues within this stretch produced a dramatic loss of antigenicity, as determined by using patient sera. The circular dichroism spectra of the antigen, together with the distribution of the contact residues, suggest that this region adopts an amphipathic alpha-helix structure that clusters the contact residues on its polar side. To provide further insight in the interpretation of the structure activity relationships for this immunoreactive region of E. granulosus AgB, we developed a model for the N-terminal extension of the AgB major subunit, which helps to rationalize our data.	Univ Republica, Fac Quim, Catedra Inmunol, Inst Higiene, Montevideo 11600, Uruguay; NCI, Adv Biomed Comp Ctr, NIH, Sci Applicat Int Corp, Frederick, MD 21702 USA	Universidad de la Republica, Uruguay; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Gonzalez-Sapienza, G (corresponding author), Univ Republica, Fac Quim, Catedra Inmunol, Inst Higiene, Av A Navarro 3051, Montevideo 11600, Uruguay.	ggonzal@fg.edu.uy		Gonzalez-Sapienza, Gualberto/0000-0003-1824-0611	NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barbieri M, 1998, PARASITE IMMUNOL, V20, P51, DOI 10.1046/j.1365-3024.1998.00117.x; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; BERZOFSKY JA, 1985, SCIENCE, V229, P932, DOI 10.1126/science.2410982; BRUNGER A, 1993, X PLOR VERSION 3 1 M; CACHAU RE, 1996, ADV COMPUTATIONAL BI, V2, P66; CAZZULO JJ, 1992, FASEB J, V6, P3259, DOI 10.1096/fasebj.6.14.1426764; Chemale G, 2001, MOL BIOCHEM PARASIT, V116, P233, DOI 10.1016/S0166-6851(01)00316-4; Cwirla SE, 1999, METH MOL B, V128, P131; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gonzalez G, 1996, PARASITE IMMUNOL, V18, P587, DOI 10.1046/j.1365-3024.1996.d01-38.x; Gonzalez-Sapienza G, 2000, J CLIN MICROBIOL, V38, P3979; JANIN J, 1990, J BIOL CHEM, V265, P16027; Lazaridis T, 1996, J CHEM PHYS, V105, P4294, DOI 10.1063/1.472247; LEGGATT GR, 1994, PARASITE IMMUNOL, V16, P87, DOI 10.1111/j.1365-3024.1994.tb00327.x; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; ORIOL C, 1975, AM J TROP MED HYG, V24, P96, DOI 10.4269/ajtmh.1975.24.96; Rigano R, 2001, INFECT IMMUN, V69, P288, DOI 10.1128/IAI.69.1.288-296.2001; Rodi DJ, 1999, CURR OPIN BIOTECH, V10, P87, DOI 10.1016/S0958-1669(99)80016-0; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SHEPHERD JC, 1991, MOL BIOCHEM PARASIT, V44, P81, DOI 10.1016/0166-6851(91)90223-S; Starovasnik MA, 1996, BIOCHEMISTRY-US, V35, P15558, DOI 10.1021/bi961409x	22	33	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20179	20184		10.1074/jbc.M212724200	http://dx.doi.org/10.1074/jbc.M212724200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660242	hybrid			2022-12-27	WOS:000183078000077
J	Valdes, VJ; Sampieri, A; Sepulveda, J; Vaca, L				Valdes, VJ; Sampieri, A; Sepulveda, J; Vaca, L			Using double-stranded RNA to prevent in vitro and in vivo viral infections by recombinant baculovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; ENVELOPE FUSION PROTEIN; GENE-FUNCTION; INTERFERENCE; GP64; CELLS; MICE	Introduction of double-stranded RNA (dsRNA) into a wide variety of cells and organisms results in post-transcriptional depletion of the homologue endogenous mRNA. This well-preserved phenomenon known as RNA interference (RNAi) is present in evolutionarily diverse organisms such as plants, fungi, insects, metazoans, and mammals. Because the identification of the targeted mRNA by the RNAi machinery depends upon Watson-Crick base-pairing interactions, RNAi can be exquisitely specific. We took advantage of this powerful and flexible technique to demonstrate that selective silencing of genes essential for viral propagation prevents in vitro and in vivo viral infection. Using the baculovirus Autographa californica, a rapidly replicating and highly cytolytic double-stranded DNA virus that infects many different insect species, we show for the first time that introduction of dsRNA from gp64 and ie1, two genes essential for baculovirus propagation, results in prevention of viral infection in vitro and in vivo. This is the first report demonstrating the use of RNAi to inhibit a viral infection in animals. This inhibition was specific, because dsRNA from the polyhedrin promoter (used as control) or unrelated dsRNAs did not affect the time course of viral infection. The most relevant consequences from the present study are: 1) RNAi offers a rapid and efficient way to interfere with viral genes to assess the role of specific proteins in viral function and 2) using RNAi to interfere with viral genes essential for cell infection may provide a powerful therapeutic tool for the treatment of viral infections.	Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Vaca, L (corresponding author), Univ Nacl Autonoma Mexico, Inst Fisiol Celular, Dept Biol Celular, Mexico City 04510, DF, Mexico.		Sampieri, Alicia/L-3896-2019; Valdes, Julian/C-1840-2017	Valdes, Julian/0000-0001-6157-1358; Vaca, Luis/0000-0003-2266-4847				Dernburg AF, 2002, CELL, V111, P159, DOI 10.1016/S0092-8674(02)01039-5; Finnegan EJ, 2001, CURR BIOL, V11, pR99, DOI 10.1016/S0960-9822(01)00039-2; Gitlin L, 2002, NATURE, V418, P430, DOI 10.1038/nature00873; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; HUH NE, 1990, J GEN VIROL, V71, P195, DOI 10.1099/0022-1317-71-1-195; Jackson J A, 1991, Bioprocess Technol, V13, P402; Jacque JM, 2002, NATURE, V418, P435, DOI 10.1038/nature00896; KOVACS GR, 1991, J VIROL, V65, P5281, DOI 10.1128/JVI.65.10.5281-5288.1991; Kuwabara PE, 2000, PARASITOL TODAY, V16, P347, DOI 10.1016/S0169-4758(00)01677-X; Maeda I, 2001, CURR BIOL, V11, P171, DOI 10.1016/S0960-9822(01)00052-5; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; Molinari JL, 1998, PARASITOL RES, V84, P173, DOI 10.1007/s004360050379; Monsma SA, 1996, J VIROL, V70, P4607, DOI 10.1128/JVI.70.7.4607-4616.1996; Oomens AGP, 1999, VIROLOGY, V254, P297, DOI 10.1006/viro.1998.9523; OOMENS AGP, 1995, VIROLOGY, V209, P592, DOI 10.1006/viro.1995.1291; PORFIRI E, 1995, METHOD ENZYMOL, V255, P13; Reyes-Cruz G, 2000, J CELL BIOCHEM, V76, P658, DOI 10.1002/(SICI)1097-4644(20000315)76:4<658::AID-JCB14>3.3.CO;2-Z; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Ueda R, 2001, J NEUROGENET, V15, P193, DOI 10.3109/01677060109167376; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168	21	44	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19317	19324		10.1074/jbc.M212039200	http://dx.doi.org/10.1074/jbc.M212039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646552	hybrid			2022-12-27	WOS:000182932200078
J	Ferry, G; Tellier, E; Try, A; Gres, S; Naime, I; Simon, MF; Rodriguez, M; Boucher, J; Tack, I; Gesta, S; Chomarat, P; Dieu, M; Raes, M; Galizzi, JP; Valet, P; Boutin, JA; Saulnier-Blache, JS				Ferry, G; Tellier, E; Try, A; Gres, S; Naime, I; Simon, MF; Rodriguez, M; Boucher, J; Tack, I; Gesta, S; Chomarat, P; Dieu, M; Raes, M; Galizzi, JP; Valet, P; Boutin, JA; Saulnier-Blache, JS			Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation - Up-regulated expression with adipocyte differentiation and obesity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOPHOSPHOLIPASE-D ACTIVITY; INSULIN-RESISTANCE; ADIPOSE-TISSUE; MOTILITY; RECEPTOR; PYROPHOSPHATASE; PROTEIN; CLONING; GROWTH; IDENTIFICATION	Our group has recently demonstrated (Gesta, S., Simon, M., Rey, A., Sibrac, D., Girard, A., Lafontan, M., Valet, P., and Saulnier-Blache, J. S. (2002) J. Lipid Res. 43, 904-910) the presence, in adipocyte conditioned-medium, of a soluble lysophospholipase D-activity (LPLDact) involved in synthesis of the bioactive phospholipid lysophosphatidic acid (LPA). In the present report, LPLDact was purified from 3T3F442A adipocyte-conditioned medium and identified as the type II ecto-nucleotide pyrophosphatase phosphodiesterase, autotaxin (ATX). A unique ATX cDNA was cloned from 3T3F442A adipocytes, and its recombinant expression in COS-7 cells led to extracellular release of LPLDact. ATX mRNA expression was highly up-regulated during adipocyte differentiation of 3T3F442A-preadipocytes. This up-regulation was paralleled by the ability of newly differentiated adipocytes to release LPLDact and LPA. Differentiation-dependent up-regulation of ATX expression was also observed in a primary culture of mouse preadipocytes. Treatment of 3T3F442A-preadipocytes with concentrated conditioned medium from ATX-expressing COS-7 cells led to an increase in cell number as compared with concentrated conditioned medium from ATX non-expressing COS-7 cells. The specific effect of ATX on preadipocyte proliferation was completely suppressed by co-treatment with a LPA-hydrolyzing phospholipase, phospholipase B. Finally, ATX expression was found in mature adipocytes isolated from mouse adipose tissue and was substantially increased in genetically obese-diabetic db/db mice when compared with their lean siblings. In conclusion, the present work shows that ATX is responsible for the LPLDact released by adipocytes and exerts a paracrine control on preadipocyte growth via an LPA-dependent mechanism. Up-regulations of ATX expression with adipocyte differentiation and genetic obesity suggest a possible involvement of this released protein in the development of adipose tissue and obesity-associated pathologies.	CHU Rangueil, INSERM, U586, Inst Louis Bugnard, F-31403 Toulouse 4, France; CHU Rangueil, INSERM, U388, F-31403 Toulouse 4, France; Ctr Rech Croissy, Inst Rech Servier, F-78290 Croissy Sur Seine, France; Univ Namur, B-5000 Namur, Belgium	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Servier; Institut de Recherches Internationales Servier; University of Namur	Saulnier-Blache, JS (corresponding author), CHU Rangueil, INSERM, U586, Inst Louis Bugnard, F-31403 Toulouse 4, France.	saulnier@toulouse.inserm.fr	Valet, Philippe/N-7472-2017; Saulnier-Blache, Jean Sebastien/X-7729-2018; Boutin, Jean Albert/W-9103-2019; Boucher, Jeremie/G-6602-2015	Valet, Philippe/0000-0001-6520-7393; Boutin, Jean Albert/0000-0003-0068-7204; Dieu, Marc/0000-0002-3902-542X; Saulnier-Blache, Jean Sebastien/0000-0002-8971-7723				Aoki J, 2002, J BIOL CHEM, V277, P48737, DOI 10.1074/jbc.M206812200; Betuing S, 1997, BIOCHEM BIOPH RES CO, V235, P765, DOI 10.1006/bbrc.1997.6887; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; CRANDALL DL, 1990, FASEB J, V4, P141, DOI 10.1096/fasebj.4.2.2404816; DESLEX S, 1987, EXP CELL RES, V168, P15, DOI 10.1016/0014-4827(87)90412-5; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gesta S, 2002, J LIPID RES, V43, P904; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; Hausman D B, 2001, Obes Rev, V2, P239, DOI 10.1046/j.1467-789X.2001.00042.x; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HY, 1996, J BIOL CHEM, V271, P24408, DOI 10.1074/jbc.271.40.24408; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; Lee HY, 2002, FEBS LETT, V515, P137, DOI 10.1016/S0014-5793(02)02457-2; Liliom K, 1998, AM J PHYSIOL-CELL PH, V274, pC1065, DOI 10.1152/ajpcell.1998.274.4.C1065; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nam SW, 2001, CANCER RES, V61, P6938; Pages C, 2001, J BIOL CHEM, V276, P11599, DOI 10.1074/jbc.M010111200; Pender C, 2002, METABOLISM, V51, P465, DOI 10.1053/meta.2002.31327; Piao JH, 1999, CYTOGENET CELL GENET, V87, P172, DOI 10.1159/000015459; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sakoda H, 1999, DIABETES, V48, P1365, DOI 10.2337/diabetes.48.7.1365; Saulnier-Blache JS, 2000, J LIPID RES, V41, P1947; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 1999, BIOL REPROD, V61, P195, DOI 10.1095/biolreprod61.1.195; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Xu Y, 1995, CLIN CANCER RES, V1, P1223	42	185	196	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18162	18169		10.1074/jbc.M301158200	http://dx.doi.org/10.1074/jbc.M301158200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642576	Green Accepted, Green Submitted, hybrid			2022-12-27	WOS:000182838300075
J	Gidda, SK; Miersch, O; Levitin, A; Schmidt, J; Wasternack, C; Varin, L				Gidda, SK; Miersch, O; Levitin, A; Schmidt, J; Wasternack, C; Varin, L			Biochemical and molecular characterization of a hydroxyjasmonate sulfotransferase from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLENE OXIDE CYCLASE; JASMONIC ACID; GENE-EXPRESSION; OXYLIPIN SIGNATURE; CIS-JASMONE; OCTADECANOIDS; BIOSYNTHESIS; SULFATION; POTATO; INACTIVATION	12-Hydroxyjasmonate, also known as tuberonic acid, was first isolated from Solanum tuberosum and was shown to have tuber-inducing properties. It is derived from the ubiquitously occurring jasmonic acid, an important signaling molecule mediating diverse developmental processes and plant defense responses. We report here that the gene AtST2a from Arabidopsis thaliana encodes a hydroxyjasmonate sulfotransferase. The recombinant AtST2a protein was found to exhibit strict specificity for 11- and 12-hydroxyjasmonate with Km values of 50 and 10 muM, respectively. Furthermore, 12-hydroxyjasmonate and its sulfonated derivative are shown to be naturally occurring in A. thaliana. The exogenous application of methyljasmonate to A. thaliana plants led to increased levels of both metabolites, whereas treatment with 12-hydroxyjasmonate led to increased level of 12-hydroxyjasmonate sulfate without affecting the endogenous level of jasmonic acid. AtST2a expression was found to be induced following treatment with methyljasmonate and 12-hydroxyjasmonate. In contrast, the expression of the methyljasmonate-responsive gene Thi2.1, a marker gene in plant defense responses, is not induced upon treatment with 12-hydroxyjasmonate indicating the existence of independent signaling pathways responding to jasmonic acid and 12-hydroxyjasmonic acid. Taken together, the results suggest that the hydroxylation and sulfonation reactions might be components of a pathway that inactivates excess jasmonic acid in plants. Alternatively, the function of AtST2a might be to control the biological activity of 12-hydroxyjasmonic acid.	Concordia Univ, Dept Biol, Ctr Struct & Funct Genom, Montreal, PQ H3G 1M8, Canada; Leibniz Inst Plant Biochem, D-06120 Halle An Der Saale, Germany	Concordia University - Canada; Leibniz Institut fur Pflanzenbiochemie	Varin, L (corresponding author), Concordia Univ, Dept Biol, Ctr Struct & Funct Genom, 1455 De Maisonneuve Blvd W, Montreal, PQ H3G 1M8, Canada.	varinl@clone.concordia.ca						ACHENBACH H, 1994, PHYTOCHEMISTRY, V35, P1527, DOI 10.1016/S0031-9422(00)86890-9; Banoglu E, 1997, DRUG METAB DISPOS, V25, P1304; Birkett MA, 2000, P NATL ACAD SCI USA, V97, P9329, DOI 10.1073/pnas.160241697; Blechert S, 1999, PLANTA, V207, P470, DOI 10.1007/s004250050506; Bohlmann H, 1998, FEBS LETT, V437, P281, DOI 10.1016/S0014-5793(98)01251-4; Boss B, 1999, PHYTOCHEMISTRY, V50, P219, DOI 10.1016/S0031-9422(98)00526-3; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CUI BL, 1993, CHEM PHARM BULL, V41, P178, DOI 10.1248/cpb.41.178; EPPLE P, 1995, PLANT PHYSIOL, V109, P813, DOI 10.1104/pp.109.3.813; Hause B, 2000, PLANT J, V24, P113, DOI 10.1046/j.1365-313x.2000.00861.x; HELDER H, 1993, PHYSIOL PLANTARUM, V88, P647, DOI 10.1111/j.1399-3054.1993.tb01384.x; HOBKIRK R, 1993, TRENDS ENDOCRIN MET, V4, P69, DOI 10.1016/S1043-2760(05)80018-9; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; Koch T, 1997, HELV CHIM ACTA, V80, P838, DOI 10.1002/hlca.19970800318; KODA Y, 1992, INT REV CYTOL, V135, P155, DOI 10.1016/S0074-7696(08)62040-9; Kramell R, 2000, PLANT PHYSIOL, V123, P177, DOI 10.1104/pp.123.1.177; Kramell R, 1997, FEBS LETT, V414, P197, DOI 10.1016/S0014-5793(97)01005-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu MC, 1999, BIOCHEM BIOPH RES CO, V254, P65, DOI 10.1006/bbrc.1998.9872; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 2000, RECENT ADV PHYTOCHEM, V34, P433, DOI 10.1016/S0079-9920(00)80015-5; Marsolais F, 1999, BIOCHEMISTRY-US, V38, P4066, DOI 10.1021/bi982239m; MATSUURA H, 1993, BIOSCI BIOTECH BIOCH, V57, P1253, DOI 10.1271/bbb.57.1253; MCMASTER GK, 1977, P NATL ACAD SCI USA, V74, P4835, DOI 10.1073/pnas.74.11.4835; Miersch O, 1998, PHYTOCHEMISTRY, V47, P327, DOI 10.1016/S0031-9422(97)00617-1; MIERSCH O, 1991, PHYTOCHEMISTRY, V30, P4049, DOI 10.1016/0031-9422(91)83464-V; Miersch O, 1999, PHYTOCHEMISTRY, V50, P353, DOI 10.1016/S0031-9422(98)00597-4; ROTH JA, 1986, TRENDS PHARMACOL SCI, V7, P404, DOI 10.1016/0165-6147(86)90402-5; Rouleau M, 1999, J BIOL CHEM, V274, P20925, DOI 10.1074/jbc.274.30.20925; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; SEMBDNER G, 1994, PLANT MOL BIOL, V26, P1459, DOI 10.1007/BF00016485; Seo HS, 2001, P NATL ACAD SCI USA, V98, P4788, DOI 10.1073/pnas.081557298; Staswick PE, 2002, PLANT CELL, V14, P1405, DOI 10.1105/tpc.000885; Stenzel I, 2003, PLANT J, V33, P577, DOI 10.1046/j.1365-313X.2003.01647.x; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; Strott CA, 1996, ENDOCR REV, V17, P670, DOI 10.1210/er.17.6.670; Thomas SG, 1999, P NATL ACAD SCI USA, V96, P4698, DOI 10.1073/pnas.96.8.4698; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; Varin L, 1997, PLANT J, V12, P831, DOI 10.1046/j.1365-313X.1997.12040831.x; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; VISSER TJ, 1994, CHEM-BIOL INTERACT, V92, P293, DOI 10.1016/0009-2797(94)90071-X; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wasternack C, 2002, PROG NUCLEIC ACID RE, V72, P165, DOI 10.1016/S0079-6603(02)72070-9; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473; Windsor ML, 1997, PHYTOCHEMISTRY, V45, P931, DOI 10.1016/S0031-9422(97)00022-8; Yoshihara T, 1996, PLANT CELL PHYSIOL, V37, P586, DOI 10.1093/oxfordjournals.pcp.a028985; YOSHIHARA T, 1989, AGR BIOL CHEM TOKYO, V53, P2835, DOI 10.1080/00021369.1989.10869712; Ziegler J, 2000, J BIOL CHEM, V275, P19132, DOI 10.1074/jbc.M002133200	49	135	145	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17895	17900		10.1074/jbc.M211943200	http://dx.doi.org/10.1074/jbc.M211943200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637544	hybrid			2022-12-27	WOS:000182838300039
J	Hartigan, N; Garrigue-Antar, L; Kadler, KE				Hartigan, N; Garrigue-Antar, L; Kadler, KE			Bone morphogenetic protein-1 (BMP-1) - Identification of the minimal domain structure for procollagen C-proteinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY; METALLOPROTEINASES; HOMOLOG; OXIDASE; GENE	Bone morphogenetic protein-1 (BMP-1) is a shorter spliced variant of mammalian tolloid (mTld), both of which cleave the C-propeptides of type I procollagen during the synthesis of extracellular matrix collagen fibrils. The fact that BMP-1 and mTld both exhibit procollagen C-proteinase (PCP) activity and that BMP-1 is the smaller variant might indicate that BMP-1 comprises the minimal required sequences for PCP activity. BMP-1 comprises a metalloproteinase domain, three CUB domains, and an epidermal growth factor (EGF)-like domain, which is located between the second and third CUB (complement components C1r/C1s,the sea urchin protein Uegf, and BMP-1) domains. In this study we showed the following. 1) The CUB1 domain is required for secretion of the molecule. Domain swapping experiments, in which CUB1 and other CUB domains were interchanged, resulted in retention of the proteins by cells. Therefore, CUB1 and its location immediately adjacent to the metalloproteinase domain are essential for secretion of the protein. 2) Mutants lacking the EGF-like and CUB3 domains exhibited full C-proteinase activity. In contrast, mutants lacking the CUB2 domain were poor C-proteinases. 3) Further studies showed that Glu-483 on the beta4-beta5 loop of CUB2 is essential for C-proteinase activity of BMP-1. In conclusion, the study showed that the minimal domain structure for PCP activity is considerably shorter than expected and comprises the metalloproteinase domain and the CUB1 and CUB2 domains of BMP-1.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg 2-205,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683; Garrigue-Antar, Laure/0000-0001-6331-8882				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; BORK P, 1993, J MOL BIOL, V17, P565; CHILDS SR, 1994, DEV BIOL, V162, P209, DOI 10.1006/dbio.1994.1079; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Panchenko MV, 1996, J BIOL CHEM, V271, P7113, DOI 10.1074/jbc.271.12.7113; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Romao MJ, 1997, J MOL BIOL, V274, P650, DOI 10.1006/jmbi.1997.1423; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; Suzuki N, 1996, DEVELOPMENT, V122, P3587; TAKAHARA K, 1994, J BIOL CHEM, V269, P32572; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	21	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18045	18049		10.1074/jbc.M211448200	http://dx.doi.org/10.1074/jbc.M211448200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637537	hybrid			2022-12-27	WOS:000182838300059
J	Nedialkov, YA; Gong, XQ; Hovde, SL; Yamaguchi, Y; Handa, H; Geiger, JH; Yan, HG; Burton, ZF				Nedialkov, YA; Gong, XQ; Hovde, SL; Yamaguchi, Y; Handa, H; Geiger, JH; Yan, HG; Burton, ZF			NTP-driven translocation by human RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIF; HEPATITIS-DELTA VIRUS; 3.3 ANGSTROM RESOLUTION; NUCLEOTIDE INCORPORATION; ELONGATION COMPLEX; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; SINGLE-MOLECULE; PROMOTER ESCAPE; DNA	We report a "running start, two-bond" protocol to analyze elongation by human RNA polymerase II (RNAP II). In this procedure, the running start allowed us to measure rapid rates of elongation and provided detailed insight into the RNAP II mechanism. Formation of two bonds was tracked to ensure that at least one translocation event was analyzed. By using this method, RNAP II is stalled briefly at a defined template position before restoring the next NTP. Significantly, slow reaction steps are identified both before and after phosphodiester bond synthesis, and both of these steps can be highly dependent on the next templated NTP. The initial and final NTP-driven events, however, are not identical, because the slow step after chemistry, which includes translocation and pyrophosphate release, is regulated differently by elongation factors hepatitis delta antigen and transcription factor IIF. Because recovery from a stall and the processive transition from one bond to the next can be highly NTP-dependent, we conclude that translocation can be driven by the incoming substrate NTP, a model fully consistent with the RNAP II elongation complex structure.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Chem, E Lansing, MI 48824 USA; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Yokohama, Kanagawa 2268503, Japan; Tokyo Inst Technol, Frontier Collaborat Res Ctr, Yokohama, Kanagawa 2268503, Japan	Michigan State University; Michigan State University; Tokyo Institute of Technology; Tokyo Institute of Technology	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	Burton@msu.edu	Yamaguchi, Yuki/B-9390-2015; gong, xue/GYQ-8649-2022	Yamaguchi, Yuki/0000-0002-0197-614X; Geiger, James/0000-0002-9443-4488				Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Arndt JW, 2001, BIOCHEMISTRY-US, V40, P5368, DOI 10.1021/bi002176j; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Chang JH, 2002, EMBO J, V21, P157, DOI 10.1093/emboj/21.1.157; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Dunlap CA, 2002, BIOCHEMISTRY-US, V41, P11226, DOI 10.1021/bi025837g; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; Epshtein V, 2002, MOL CELL, V10, P623, DOI 10.1016/S1097-2765(02)00640-8; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; Foster JE, 2001, CELL, V106, P243, DOI 10.1016/S0092-8674(01)00420-2; FU TB, 1993, J VIROL, V67, P6965, DOI 10.1128/JVI.67.12.6965-6972.1993; Funk JD, 2002, J BIOL CHEM, V277, P46998, DOI 10.1074/jbc.M206249200; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1998, J MOL BIOL, V281, P777, DOI 10.1006/jmbi.1998.1988; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Guthold M, 2001, CHEMBIOCHEM, V2, P167; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Julicher F, 1998, BIOPHYS J, V74, P1169, DOI 10.1016/S0006-3495(98)77833-6; Kim D, 2001, MOL CELLS, V11, P267; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lei L, 1999, MOL CELL BIOL, V19, P8372; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Li Y, 2001, PROTEIN SCI, V10, P1225, DOI 10.1110/ps.250101; Macnaughton TB, 2002, J VIROL, V76, P3920, DOI 10.1128/JVI.76.8.3920-3927.2002; Modahl LE, 2000, MOL CELL BIOL, V20, P6030, DOI 10.1128/MCB.20.16.6030-6039.2000; NEDIALKOV YA, 2003, IN PRESS METHODS ENZ; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Showalter AK, 2002, BIOCHEMISTRY-US, V41, P10571, DOI 10.1021/bi026021i; TAN SY, 1994, J BIOL CHEM, V269, P25684; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027; Wang HY, 1998, BIOPHYS J, V74, P1186, DOI 10.1016/S0006-3495(98)77834-8; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yamaguchi Y, 2001, SCIENCE, V293, P124, DOI 10.1126/science.1057925; Yamaguchi Y, 2002, MICROBES INFECT, V4, P1169, DOI 10.1016/S1286-4579(02)01641-6; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	53	70	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18303	18312		10.1074/jbc.M301103200	http://dx.doi.org/10.1074/jbc.M301103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637520	hybrid			2022-12-27	WOS:000182838300094
J	Wu, SC; Castellino, FJ; Wong, SL				Wu, SC; Castellino, FJ; Wong, SL			A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT STAPHYLOKINASE; LIGAND-BINDING; BACILLUS-SUBTILIS; SECRETION SYSTEM; PLASMA CLOTS; AMINO-ACIDS; ACTIVATOR; EXPRESSION; VARIANTS; FRAGMENT	To develop a fast-acting clot dissolving agent, a clot-targeting domain derived from the Kringle-1 domain in human plasminogen was fused to the C-terminal end of staphylokinase with a linker sequence in between. Production of this fusion protein in Bacillus subtilis and Pichia pastoris was examined. The Kringle domain in the fusion protein produced from B. subtilis was improperly folded because of its complicated disulfide-bond profile, whereas the staphylokinase domain produced from P. pastoris was only partially active because of an N-linked glycosylation. A change of the glycosylation residue, Thr-30, to alanine resulted in a non-glycosylated biologically active fusion. The resulting mutein, designated SAKM3-L-K1, was overproduced in P. pastoris. Each domain in SAKM3-L-K1 was functional, and this fusion showed fibrin binding ability by binding directly to plasmin-digested clots. In vitro fibrin clot lysis in a static environment and plasma clot lysis in a flow-cell system demonstrated that the engineered fusion outperformed the non-fused staphylokinase. The time required for 50% clot lysis was reduced by 20 to 500% under different conditions. Faster clot lysis can potentially reduce the degree of damage to occluded heart tissues.	Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, Calgary, AB T2N 1N4, Canada; Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA	University of Calgary; University of Notre Dame; University of Notre Dame	Wong, SL (corresponding author), Univ Calgary, Dept Biol Sci, Div Cellular Mol & Microbial Biol, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	slwong@ucalgary.ca			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL013423, R01HL013423] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL13423] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Braunwald E, 2000, EUR HEART J, V21, P2005; BYEON IJL, 1995, BIOCHEMISTRY-US, V34, P2739, DOI 10.1021/bi00009a002; Castellino FJ, 1997, CIBA F SYMP, V212, P46; Chang Y, 1998, BIOCHEMISTRY-US, V37, P3258, DOI 10.1021/bi972284e; Collen D, 2000, CIRCULATION, V102, P1766; Collen D, 1998, NAT MED, V4, P279, DOI 10.1038/nm0398-279; DEWERCHIN M, 1989, EUR J BIOCHEM, V185, P141, DOI 10.1111/j.1432-1033.1989.tb15095.x; Douglas JT, 2002, BIOCHEMISTRY-US, V41, P3302, DOI 10.1021/bi016018j; Gase A, 1996, THROMB HAEMOSTASIS, V76, P755; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guzman, 1997, J Thromb Thrombolysis, V4, P337, DOI 10.1023/A:1008889030954; HABER E, 1989, SCIENCE, V243, P51, DOI 10.1126/science.2492113; Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074; HAUPTMANN J, 1995, BLOOD COAGUL FIBRIN, V6, P579, DOI 10.1097/00001721-199509000-00013; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HENNING WP, 1995, S AFR J ANIM SCI, V25, P7; HOOVER GJ, 1993, BIOCHEMISTRY-US, V32, P10936, DOI 10.1021/bi00092a002; Icke C, 2002, MOL PHARMACOL, V62, P203, DOI 10.1124/mol.62.2.203; Laroche Y, 2000, BLOOD, V96, P1425, DOI 10.1182/blood.V96.4.1425; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MARTI D, 1994, EUR J BIOCHEM, V219, P455, DOI 10.1111/j.1432-1033.1994.tb19959.x; Mathews II, 1996, BIOCHEMISTRY-US, V35, P2567, DOI 10.1021/bi9521351; MENHART N, 1991, BIOCHEMISTRY-US, V30, P1948, DOI 10.1021/bi00221a031; Miele RG, 1999, J BIOL CHEM, V274, P7769, DOI 10.1074/jbc.274.12.7769; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; Rosenfeld SA, 1999, METHOD ENZYMOL, V306, P154; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUNGE MS, 1988, BIOCHEMISTRY-US, V27, P1153, DOI 10.1021/bi00404a012; Sakharov DV, 1996, J BIOL CHEM, V271, P27912, DOI 10.1074/jbc.271.44.27912; Sakharov DV, 2000, THROMB HAEMOSTASIS, V83, P469; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; Schlott B, 1998, J BIOL CHEM, V273, P22346, DOI 10.1074/jbc.273.35.22346; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SERIZAWA K, 1993, THROMB RES, V71, P289, DOI 10.1016/0049-3848(93)90198-W; SILENCE K, 1993, J BIOL CHEM, V268, P9811; Sinnaeve P, 2001, THROMB RES, V103, pS71, DOI 10.1016/S0049-3848(01)00301-2; SUEHIRO A, 1995, THROMB RES, V80, P135, DOI 10.1016/0049-3848(95)00159-O; Szarka SJ, 1999, APPL ENVIRON MICROB, V65, P506; SZEMRAJ J, 2001, THROMB HAEMOSTASI SP, V86, P438; TREXLER M, 1983, P NATL ACAD SCI-BIOL, V80, P2457, DOI 10.1073/pnas.80.9.2457; Tsikouris JP, 2001, PHARMACOTHERAPY, V21, P207, DOI 10.1592/phco.21.2.207.34103; Vanderschueren S, 1997, AM HEART J, V134, P213, DOI 10.1016/S0002-8703(97)70127-3; VANDERSCHUEREN S, 1995, CIRCULATION, V92, P2044, DOI 10.1161/01.CIR.92.8.2044; WONG SL, 1989, GENE, V83, P215, DOI 10.1016/0378-1119(89)90107-8; WONG SL, 1994, APPL ENVIRON MICROB, V60, P517, DOI 10.1128/AEM.60.2.517-523.1994; Wu SC, 2002, APPL ENVIRON MICROB, V68, P3261, DOI 10.1128/AEM.68.7.3261-3269.2002; WU TP, 1994, BLOOD COAGUL FIBRIN, V5, P157, DOI 10.1097/00001721-199404000-00001; WU XC, 1991, J BACTERIOL, V173, P4952, DOI 10.1128/jb.173.16.4952-4958.1991; Ye RQ, 1999, BIOTECHNOL BIOENG, V62, P87; Zajicek J, 2000, J MOL BIOL, V301, P333, DOI 10.1006/jmbi.2000.3972; Zhu YH, 1999, CIRCULATION, V99, P3050, DOI 10.1161/01.CIR.99.23.3050	51	28	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18199	18206		10.1074/jbc.M210919200	http://dx.doi.org/10.1074/jbc.M210919200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646571	hybrid			2022-12-27	WOS:000182838300080
J	Agasoster, AV; Halskau, O; Fuglebakk, E; Froystein, NA; Muga, A; Holmsen, H; Martinez, A				Agasoster, AV; Halskau, O; Fuglebakk, E; Froystein, NA; Muga, A; Holmsen, H; Martinez, A			The interaction of peripheral proteins and membranes studied with alpha-lactalbumin and phospholipid bilayers of various compositions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PARTIALLY FOLDED CONFORMATIONS; FATTY-ACID COMPOSITION; MOLTEN GLOBULE; HYDROGEN-EXCHANGE; LIPID-COMPOSITION; MODEL MEMBRANES; APOLIPOPHORIN-III; BREAST-CANCER; MILK-PROTEINS	To characterize the interaction of peripheral proteins and membranes at the molecular level, we studied the reversible association of bovine alpha-lactalbumin (BLA) with lipid bilayers composed of different molecular forms of phosphatidylserine or equimolar mixtures of these phosphatidylserine forms and egg yolk phosphatidylcholine. At pH 4.5, almost all BLA (>90%) associates to negatively charged small unilamellar vesicles. The conformational changes that binding to these bilayers induced on the protein were characterized by circular dichroism and fluorescence spectroscopy. Because binding of BLA to negatively charged vesicles is reverted by adjusting the pH back to >6.0, we also investigated the conformation of the membrane-bound protein by NMR-monitored H-D exchange of the backbone amide protons. The conformation adopted by BLA bound to these bilayers resembles a molten globule-like state but the negative ellipticity at 222 nm and the apparent alpha-helix content of the bound protein senses the changes in the physical properties of the membrane. Binding to bilayers in the gel state appears to correlate with an increased amount of alpha-helical structure and with a lower extent of integration into the membrane, corresponding to the adsorbed protein, while the opposite is found for BLA bound to vesicles in the liquid-crystalline phase, corresponding to the embedded conformation. A common feature for the membrane-bound conformations of BLA is that the amphipathic helix C (residues 86 to 99) is an important determinant for the adsorption and further integration of the protein into the membrane.	Univ Bergen, Dept Biochem & Mol Biol, N-5009 Bergen, Norway; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Univ Basque Country, Dept Biochem & Mol Biol, E-48080 Bilbao, Spain	University of Bergen; University of Bergen; University of Basque Country	Martinez, A (corresponding author), Univ Bergen, Dept Biochem & Mol Biol, Jonas Liesvei 91, N-5009 Bergen, Norway.		Fuglebakk, Edvin/P-4596-2019; Martinez, Aurora/M-3088-2019; Fuglebakk, Edvin/K-8396-2012; Muga, Arturo/N-1174-2014	Fuglebakk, Edvin/0000-0002-3192-6768; Martinez, Aurora/0000-0003-1643-6506; Fuglebakk, Edvin/0000-0002-3192-6768; Muga, Arturo/0000-0003-0345-6882; Halskau, Oyvind/0000-0003-2517-1060				Agasosler AV, 2001, BIOCHEM PHARMACOL, V61, P817, DOI 10.1016/S0006-2952(01)00542-1; ALEXANDRESCU AT, 1992, EUR J BIOCHEM, V210, P699, DOI 10.1111/j.1432-1033.1992.tb17471.x; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Banuelos S, 1996, BIOCHEMISTRY-US, V35, P3892, DOI 10.1021/bi951468v; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; Banuelos S, 1996, FEBS LETT, V386, P21, DOI 10.1016/0014-5793(96)00406-1; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Braschi S, 1999, J LIPID RES, V40, P522; Caaveiro JMM, 2001, BIOPHYS J, V80, P1343, DOI 10.1016/S0006-3495(01)76107-3; CAFFREY M, 1992, CHEM PHYS LIPIDS, V61, P1, DOI 10.1016/0009-3084(92)90002-7; CHAJES V, 1995, INT J CANCER, V63, P169, DOI 10.1002/ijc.2910630204; Chajes V, 1999, INT J CANCER, V83, P585, DOI 10.1002/(SICI)1097-0215(19991126)83:5&lt;585::AID-IJC2&gt;3.0.CO;2-Z; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; CULLIS PR, 1991, BIOCH LIPIDS LIPOPRO, V20, P1; Dahim M, 1998, BIOCHEMISTRY-US, V37, P8369, DOI 10.1021/bi973015r; ENGLANDER SW, 1992, ANNU REV BIOPH BIOM, V21, P243, DOI 10.1146/annurev.biophys.21.1.243; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Farrell HM, 2002, J DAIRY SCI, V85, P459, DOI 10.3168/jds.S0022-0302(02)74096-4; Fisher CA, 1999, J LIPID RES, V40, P93; Forge V, 1999, J MOL BIOL, V288, P673, DOI 10.1006/jmbi.1999.2687; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Goddard T. D., 1999, SPARKY 3; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hakansson A, 1999, EXP CELL RES, V246, P451, DOI 10.1006/excr.1998.4265; Halskau O, 2002, J MOL BIOL, V321, P99, DOI 10.1016/S0022-2836(02)00565-X; HIETANEN E, 1986, CARCINOGENESIS, V7, P1965, DOI 10.1093/carcin/7.12.1965; HWANG TL, 1995, J MAGN RESON SER A, V112, P275, DOI 10.1006/jmra.1995.1047; Imafidon GI, 1997, CRIT REV FOOD SCI, V37, P663, DOI 10.1080/10408399709527794; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; Killian JA, 2000, TRENDS BIOCHEM SCI, V25, P429, DOI 10.1016/S0968-0004(00)01626-1; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kirsch T, 1997, BIOCHEMISTRY-US, V36, P3359, DOI 10.1021/bi9626867; Kohler C, 2001, EUR J BIOCHEM, V268, P186, DOI 10.1046/j.1432-1327.2001.01870.x; Krishnamurthy VV, 1997, MAGN RESON CHEM, V35, P9, DOI 10.1002/(SICI)1097-458X(199701)35:1<9::AID-OMR930>3.0.CO;2-R; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAKEY JH, 1994, EUR J BIOCHEM, V220, P155, DOI 10.1111/j.1432-1033.1994.tb18610.x; Liu ML, 1998, J MAGN RESON, V132, P125, DOI 10.1006/jmre.1998.1405; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Monteggia E, 2000, CANCER DETECT PREV, V24, P207; Nerdal W, 2000, BBA-BIOMEMBRANES, V1464, P165, DOI 10.1016/S0005-2736(00)00125-5; Permyakov EA, 2000, FEBS LETT, V473, P269, DOI 10.1016/S0014-5793(00)01546-5; PHILLIPS MC, 1970, BIOCHIM BIOPHYS ACTA, V196, P35, DOI 10.1016/0005-2736(70)90163-X; Pike ACW, 1996, STRUCTURE, V4, P691, DOI 10.1016/S0969-2126(96)00075-5; Sahoo D, 1998, J BIOL CHEM, V273, P1403, DOI 10.1074/jbc.273.3.1403; SCHANBACHER FL, 1971, BIOCHIM BIOPHYS ACTA, V229, P226, DOI 10.1016/0005-2795(71)90337-0; SCHULMAN BA, 1995, J MOL BIOL, V253, P651, DOI 10.1006/jmbi.1995.0579; Soulages JL, 2000, J BIOL CHEM, V275, P17501, DOI 10.1074/jbc.M909661199; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; VANBLITTERSWIJK WJ, 1982, BIOCHIM BIOPHYS ACTA, V688, P495, DOI 10.1016/0005-2736(82)90361-3; VANDIJCK PWM, 1978, BIOCHIM BIOPHYS ACTA, V512, P84, DOI 10.1016/0005-2736(78)90219-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wang SX, 2000, BIOCHEM J, V348, P103, DOI 10.1042/0264-6021:3480103; Wang W, 1998, J BIOL CHEM, V273, P27438, DOI 10.1074/jbc.273.42.27438; White SH, 1999, ANNU REV BIOPH BIOM, V28, P319, DOI 10.1146/annurev.biophys.28.1.319; YANG W, 1995, J BIOL CHEM, V270, P23951, DOI 10.1074/jbc.270.41.23951	58	60	62	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21790	21797		10.1074/jbc.M211466200	http://dx.doi.org/10.1074/jbc.M211466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660251	hybrid			2022-12-27	WOS:000183354200061
J	Tsuboi, Y; Inoue, H; Nakamura, N; Kanazawa, H				Tsuboi, Y; Inoue, H; Nakamura, N; Kanazawa, H			Identification of membrane domains of the Na(+)/H(+) antiporter (NhaA) protein from Helicobacter pylori required for ion transport and pH sensing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GENE; CLONING; OVERPRODUCTION; EXPRESSION; RESIDUES; ANT; H+	The Na(+)/H(+) antiporter from Helicobacter pylori ( HP NhaA) is normally active within the pH range 6.0 - 8.5. In contrast, the NhaA from Escherichia coli ( EC NhaA) is active only within the alkaline pH range 7.5 - 8.5. We studied structures of HP NhaA involved in ion transport and pH sensing by analyzing mutants with defects in NhaA activity. The 36 mutants were classified into three types. The first type exhibited very low or null activity at all pH levels and had amino acid substitutions in the transmembrane segments ( TM) 4, 5, 10, and 11, implicating these TMs in ion transport. The second type, which had amino acid substitutions at Met- 138, Phe- 144, and Lys- 347 in TM 4 and 10, exhibited very low antiporter activity at acidic pH but had significantly higher activity at alkaline pH. These results imply that TM 4 ( Met-138 and Phe- 144) and 10 ( Lys- 347) are involved in supporting transport activity at acidic pH, in addition to their essential role in the overall transport mechanism. The third type of mutant exhibited very low antiporter activity at alkaline pH but relatively normal activity at acidic pH and had amino acid substitutions in loop 7 ( a hydrophilic region between TM 7 and 8) as well as in TM 8, suggesting that these regions are involved in antiporter activation at alkaline pH. Three revertants that suppress a Lys- 347 mutation were identified. Two of three suppressor mutations were located in loops 2 and 4, suggesting a functional interaction between these regions ( loops 2 and 4 and TM 10). Thus, HP NhaA activity may be modulated by two independent factors that are dependent on pH: an activation mechanism at acidic pH, which is regulated by residues within TM 4 and 10 and another mechanism functioning at alkaline pH regulated by residues within loop 7 and TM 8.	Osaka Univ, Grad Sch Sci, Dept Biol Sci, Osaka 5600043, Japan	Osaka University	Kanazawa, H (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol Sci, Machikaneyama Cho 1-16, Osaka 5600043, Japan.	kanazawa@bio.sci.osaka-u.ac.jp						Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; INOUE H, 1995, FEBS LETT, V363, P264, DOI 10.1016/0014-5793(95)00331-3; Inoue H, 1998, BIOL PHARM BULL, V21, P1128; Inoue H, 1999, FEBS LETT, V443, P11, DOI 10.1016/S0014-5793(98)01652-4; Inoue S, 2001, J BIOCHEM, V129, P569, DOI 10.1093/oxfordjournals.jbchem.a002892; IVEY DM, 1993, J BIOL CHEM, V268, P11296; KANAZAWA H, 1979, P NATL ACAD SCI USA, V76, P1126, DOI 10.1073/pnas.76.3.1126; KARPEL R, 1988, J BIOL CHEM, V263, P10408; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MIKI J, 1994, J BIOL CHEM, V269, P4227; Noumi T, 1997, J BIOCHEM-TOKYO, V121, P661; Nozaki K, 1996, BIOCHEM BIOPH RES CO, V222, P774, DOI 10.1006/bbrc.1996.0820; PADAN E, 1994, BBA-BIOENERGETICS, V1185, P129, DOI 10.1016/0005-2728(94)90204-6; Padan E, 1998, MICR EXTREM UNUSUAL, P163; PADAN E, 1992, ALKALI CATION TRANSP, P3; PINNER E, 1992, J BIOL CHEM, V267, P11064; PINNER E, 1994, J BIOL CHEM, V269, P26274; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Rothman A, 1996, J BIOL CHEM, V271, P32288, DOI 10.1074/jbc.271.50.32288; Schuldiner S., 1992, ALKALI CATION TRANSP, P25; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534	24	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21467	21473		10.1074/jbc.M301932200	http://dx.doi.org/10.1074/jbc.M301932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670937	hybrid			2022-12-27	WOS:000183354200021
J	Chinault, SL; Blumer, KJ				Chinault, SL; Blumer, KJ			The C-terminal tail preceding the CAAX box of a yeast G protein gamma subunit is dispensable for receptor-mediated G protein activation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE-RESPONSE PATHWAY; ALPHA-FACTOR RECEPTOR; RHODOPSIN TRANSDUCIN INTERACTIONS; HETEROTRIMERIC G-PROTEIN; DUAL LIPID MODIFICATION; G-BETA-GAMMA; SACCHAROMYCES-CEREVISIAE; MUSCARINIC RECEPTOR; SIGNAL-TRANSDUCTION; ADENOSINE RECEPTORS	The gamma subunits of heterotrimeric G proteins are required for receptor-G protein coupling. The C-terminal domains of Ggamma subunits can contact receptors and influence the efficiency of receptor-G protein coupling in vitro. However, it is unknown whether receptor interaction with the C terminus of Ggamma is required for signaling in vivo. To address this question, we cloned Ggamma homologs with diverged C-terminal sequences from five species of budding yeast. Each Ggamma homolog functionally replaced the Ggamma subunit of the yeast Saccharomyces cerevisiae (STE18 gene product). Mutagenesis of S. cerevisiae Ste18 likewise indicated that specific C-terminal sequence motifs are not required for signaling. Strikingly, an internal in-frame deletion removing sequences preceding the C-terminal CAAX box of Ste18 did not impair signaling by either of its cognate G protein-coupled pheromone receptors. Therefore, receptor interaction with the C-terminal domain of yeast Ggamma is not required for receptor-mediated G protein activation in vivo. Because the mechanism of G protein activation by receptors is conserved from yeast to humans, mammalian receptors may not require interaction with the tail of Ggamma for G protein activation in vivo. However, receptor-Ggamma interaction may modulate the efficiency of receptor-G protein coupling or promote activation of Gbetagamma effectors that co-cluster with receptors.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Blumer, KJ (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, 660 S Euclid Ave, St Louis, MO 63110 USA.		Blumer, Kendall J/C-5268-2012		NIGMS NIH HHS [GM44592] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044592] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azpiazu I, 2001, J BIOL CHEM, V276, P41742, DOI 10.1074/jbc.M104034200; Azpiazu I, 1999, J BIOL CHEM, V274, P35305, DOI 10.1074/jbc.274.50.35305; BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Brown AJ, 2000, YEAST, V16, P11, DOI 10.1002/(SICI)1097-0061(20000115)16:1<11::AID-YEA502>3.0.CO;2-K; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; Cliften PF, 2001, GENOME RES, V11, P1175, DOI 10.1101/gr.182901; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dosil M, 2000, MOL CELL BIOL, V20, P5321, DOI 10.1128/MCB.20.14.5321-5329.2000; GRISHIN AV, 1994, MOL CELL BIOL, V14, P4571, DOI 10.1128/MCB.14.7.4571; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HIRSCH JP, 1991, GENE DEV, V5, P467, DOI 10.1101/gad.5.3.467; Hirschman JE, 1999, MOL CELL BIOL, V19, P7705; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Hou YM, 2001, J BIOL CHEM, V276, P19982, DOI 10.1074/jbc.M010424200; Hou YM, 2000, J BIOL CHEM, V275, P38961, DOI 10.1074/jbc.C000604200; Iiri T, 1998, NATURE, V394, P35, DOI 10.1038/27831; Jian XY, 2001, J BIOL CHEM, V276, P48518, DOI 10.1074/jbc.M107129200; Kallal L, 1997, MOL CELL BIOL, V17, P2897, DOI 10.1128/MCB.17.5.2897; KANG YS, 1990, MOL CELL BIOL, V10, P2582, DOI 10.1128/MCB.10.6.2582; KISSELEV O, 1993, J BIOL CHEM, V268, P24519; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Lim WK, 2001, BIOCHEMISTRY-US, V40, P10532, DOI 10.1021/bi010950c; Manahan CL, 2000, MOL BIOL CELL, V11, P957, DOI 10.1091/mbc.11.3.957; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; McIntire WE, 2001, J BIOL CHEM, V276, P15801, DOI 10.1074/jbc.M011233200; Mentesana PE, 2002, METHOD ENZYMOL, V344, P92; Murphree LJ, 2002, MOL PHARMACOL, V61, P455, DOI 10.1124/mol.61.2.455; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Ongay-Larios L, 2000, FEBS LETT, V467, P22, DOI 10.1016/S0014-5793(00)01106-6; Onrust R, 1997, SCIENCE, V275, P381, DOI 10.1126/science.275.5298.381; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17040; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PRICE LA, 1995, MOL CELL BIOL, V15, P6188; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; Rondard P, 2001, P NATL ACAD SCI USA, V98, P6150, DOI 10.1073/pnas.101136198; SPRAGUE GF, 1992, MOL CELLULAR BIOL YE; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; STEFAN CJ, 1994, MOL CELL BIOL, V14, P3339, DOI 10.1128/MCB.14.5.3339; Stefan CJ, 1998, MOL BIOL CELL, V9, P885, DOI 10.1091/mbc.9.4.885; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WHITEWAY MS, 1994, GENETICS, V137, P967; WILDMAN DE, 1993, P NATL ACAD SCI USA, V90, P794, DOI 10.1073/pnas.90.3.794	46	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20638	20644		10.1074/jbc.M212701200	http://dx.doi.org/10.1074/jbc.M212701200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665529	hybrid			2022-12-27	WOS:000183230500026
J	Gralnick, JA; Downs, DM				Gralnick, JA; Downs, DM			The YggX protein of Salmonella enterica is involved in Fe(II) trafficking and minimizes the DNA damage caused by hydroxyl radicals - Residue Cys-7 is essential for YggX function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SEROVAR TYPHIMURIUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; STRAND SCISSION; OXYGEN RADICALS; REGULATED GENES; FUR MUTANTS; FREE-IRON; SUPEROXIDE	Previous work from our laboratory identified YggX as a protein whose accumulation increased the resistance of Salmonella enterica to superoxide stress, reversed defects attributed to oxidized [Fe-S] clusters, and decreased the spontaneous mutation frequency of the cells. Here we present work aimed at determining why the accumulation of YggX correlates with reduced mutation frequency. Genetic and biochemical data showed that accumulation of YggX reduced the damage to DNA by hydroxyl radicals. The ability of purified YggX to protect DNA from Fenton chemistry mediated damage in vitro and to decrease the concentration of Fe(II) ions in solution available for chelation provided a framework for the interpretation of data obtained from in vivo experiments. The interpretation of in vitro assay results, within the context of the in vivo phenotypes, was validated by a mutant variant of YggX (C7S) that was unable to function in vivo or in vitro. We propose a model, based on data presented here and reported earlier, that suggests YggX is a player in Fe( II) trafficking in bacteria.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Downs, DM (corresponding author), Univ Wisconsin, Dept Bacteriol, 1550 Linden Dr, Madison, WI 53706 USA.			Gralnick, Jeffrey/0000-0001-9250-7770	NIGMS NIH HHS [GM 47296] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047296] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdul-Tehrani H, 1999, J BACTERIOL, V181, P1415, DOI 10.1128/JB.181.5.1415-1428.1999; Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Andrews SC, 1998, ADV MICROB PHYSIOL, V40, P281, DOI 10.1016/S0065-2911(08)60134-4; ARUOMA OI, 1989, J BIOL CHEM, V264, P20509; Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun V, 1997, BIOL CHEM, V378, P779; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CUPPLES CG, 1989, P NATL ACAD SCI USA, V86, P5345, DOI 10.1073/pnas.86.14.5345; Davis R., 1980, ADV BACTERIAL GENETI; Demple B, 1999, BIOCHEM SOC SYMP, P119; DOWNS DM, 1992, J BACTERIOL, V174, P1515, DOI 10.1128/jb.174.5.1515-1521.1992; Expert D, 1999, ANNU REV PHYTOPATHOL, V37, P307, DOI 10.1146/annurev.phyto.37.1.307; GARDNER PR, 1993, ARCH BIOCHEM BIOPHYS, V301, P98, DOI 10.1006/abbi.1993.1120; Gifford CM, 1999, J BACTERIOL, V181, P4223, DOI 10.1128/JB.181.14.4223-4236.1999; Gralnick J, 2000, J BACTERIOL, V182, P5180, DOI 10.1128/JB.182.18.5180-5187.2000; Gralnick J, 2001, P NATL ACAD SCI USA, V98, P8030, DOI 10.1073/pnas.151243198; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Hantke K, 2001, CURR OPIN MICROBIOL, V4, P172, DOI 10.1016/S1369-5274(00)00184-3; Hantke K, 2003, P NATL ACAD SCI USA, V100, P3677, DOI 10.1073/pnas.0737682100; Harlow E., 1988, ANTIBODIES LAB MANUA; Hudson RE, 2002, MOL BIOL EVOL, V19, P85, DOI 10.1093/oxfordjournals.molbev.a003986; HUTCHINSON F, 1985, PROG NUCLEIC ACID RE, V32, P115, DOI 10.1016/S0079-6603(08)60347-5; IMLAY JA, 1991, J BIOL CHEM, V266, P6957; KAMMLER M, 1993, J BACTERIOL, V175, P6212, DOI 10.1128/JB.175.19.6212-6219.1993; KEYER K, 1995, J BACTERIOL, V177, P6782, DOI 10.1128/jb.177.23.6782-6790.1995; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; LESKO SA, 1980, BIOCHEMISTRY-US, V19, P3023, DOI 10.1021/bi00554a029; LIOCHEV SI, 1994, FREE RADICAL BIO MED, V16, P29, DOI 10.1016/0891-5849(94)90239-9; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; Lu AL, 2001, CELL BIOCHEM BIOPHYS, V35, P141, DOI 10.1385/CBB:35:2:141; LUCKEY M, 1972, Journal of Bacteriology, V111, P731; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; Miller J.H., 1972, EXPT MOL GENETICS; Nakamura J, 1998, CANCER RES, V58, P222; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; Nunoshiba T, 1999, J BIOL CHEM, V274, P34832, DOI 10.1074/jbc.274.49.34832; Petrat F, 2002, BIOL CHEM, V383, P489, DOI 10.1515/BC.2002.051; Pomposiello PJ, 2000, J BACTERIOL, V182, P23, DOI 10.1128/JB.182.1.23-29.2000; Ratledge C, 2000, ANNU REV MICROBIOL, V54, P881, DOI 10.1146/annurev.micro.54.1.881; SCHMIEGER H, 1972, MOL GEN GENET, V119, P75, DOI 10.1007/BF00270447; Skovran E, 2003, J BACTERIOL, V185, P98, DOI 10.1128/JB.185.1.98-106.2003; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; TOUATI D, 1995, J BACTERIOL, V177, P2305, DOI 10.1128/jb.177.9.2305-2314.1995; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; Van Houten B, 2000, MUTAT RES-DNA REPAIR, V460, P81, DOI 10.1016/S0921-8777(00)00018-5; WAY JC, 1984, GENE, V32, P369, DOI 10.1016/0378-1119(84)90012-X; Woodmansee AN, 2002, J BIOL CHEM, V277, P34055, DOI 10.1074/jbc.M203977200; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	51	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20708	20715		10.1074/jbc.M301577200	http://dx.doi.org/10.1074/jbc.M301577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670952	hybrid			2022-12-27	WOS:000183230500036
J	Chen, FS; Tandon, A; Sanjo, N; Gu, YJ; Hasegawa, H; Arawaka, S; Lee, FJS; Ruan, XY; Mastrangelo, P; Erdebil, S; Wang, L; Westaway, D; Mount, HTJ; Yankner, B; Fraser, PE; St George-Hyslop, P				Chen, FS; Tandon, A; Sanjo, N; Gu, YJ; Hasegawa, H; Arawaka, S; Lee, FJS; Ruan, XY; Mastrangelo, P; Erdebil, S; Wang, L; Westaway, D; Mount, HTJ; Yankner, B; Fraser, PE; St George-Hyslop, P			Presenilin 1 and presenilin 2 have differential effects on the stability and maturation of nicastrin in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE CLEAVAGE; BETA-PEPTIDE PRODUCTION; MISSENSE MUTATIONS; NOTCH; DROSOPHILA; CELLS; RELEASE; MICE	The presenilins and nicastrin form high molecular mass, multimeric protein complexes involved in the intramembranous proteolysis of several proteins. Post-translational glycosylation and trafficking of nicastrin is necessary for the activity of these complexes. We report here that although there are differences in the post-translational processing of nicastrin in neurons and glia, both of the presenilins are required for the physiological post-translational modification and for the correct subcellular distribution of nicastrin. Absence of presenilin 1 (PS1) is associated with dramatic reductions in the level of mature glycosylated nicastrin and with redistribution of nicastrin away from the cell surface. In contrast, absence of presenilin 2 (PS2) is associated with only modest reductions in the levels of immature nicastrin. It is notable that these differential effects parallel the differential effects of null mutations in PS1 and PS2 on APP and Notch processing. Our data therefore suggest that the differential interactions of PS1 and PS2 with nicastrin reflect different functions for the PS1 and PS2 complexes.	Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02049 USA; Toronto Western Hosp, Univ Hlth Network, Dept Med, Div Neurol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med Biophys & Med, Toronto, ON M5S 1A8, Canada	University of Toronto; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	St George-Hyslop, P (corresponding author), Univ Toronto, Ctr Res Neurodegenerat Dis, 6 Queens Pk Crescent W,Tanz Neurosci Bldg, Toronto, ON M5S 3H2, Canada.		Lee, Frank J.S./D-5899-2017; Mount, Howard/B-4097-2013	Lee, Frank J.S./0000-0002-5768-3776; Arawaka, Shigeki/0000-0002-1505-3012; St George-Hyslop, Peter/0000-0003-0796-7209; Sanjo, Nobuo/0000-0002-1226-2425				Arawaka S, 2002, J NEUROCHEM, V83, P1065, DOI 10.1046/j.1471-4159.2002.01207.x; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LHERNAULT SW, 1992, J CELL BIOL, V119, P55, DOI 10.1083/jcb.119.1.55; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Rozmahel R, 2002, P NATL ACAD SCI USA, V99, P14452, DOI 10.1073/pnas.222413999; Rozmahel R, 2002, NEUROBIOL AGING, V23, P187, DOI 10.1016/S0197-4580(01)00267-6; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	26	32	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19974	19979		10.1074/jbc.M210049200	http://dx.doi.org/10.1074/jbc.M210049200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646573	hybrid			2022-12-27	WOS:000183078000053
J	Clausen, JD; McIntosh, DB; Vilsen, B; Woolley, DG; Andersen, JP				Clausen, JD; McIntosh, DB; Vilsen, B; Woolley, DG; Andersen, JP			Importance of conserved N-domain residues Thr(441), Glu(442), Lys(515), Arg(560), and Leu(562) of sarcoplasmic reticulum Ca2+-ATPase for MgATP binding and subsequent catalytic steps - Plasticity of the nucleotide-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; FUNCTIONAL CONSEQUENCES; ATP-BINDING; AMINO-ACIDS; ACTIVE-SITE; FLUORESCEIN ISOTHIOCYANATE; PHOSPHOENZYME INTERMEDIATE; CONFORMATIONAL-CHANGES; PHOSPHORYLATION LOOP; STRUCTURAL-CHANGES	Nine single mutations were introduced to amino acid residues Thr(441), Glu(442), Lys(515), Arg(560), Cys(561), and Leu(562) located in the nucleotide-binding domain of sarcoplasmic reticulum Ca2+-ATPase, and the functional consequences were studied in a direct nucleotide binding assay, as well as by steady-state and transient kinetic measurements of the overall and partial reactions of the transport cycle. Some partial reaction steps were also examined in mutants with alterations to Phe(487), Arg(489), and Lys(492). The results implicate all these residues, except Cys(561), in high affinity nucleotide binding at the substrate site. Mutations Thr(441)-->Ala, Glu(442)-->Ala, and Leu(562) --> Phe were more detrimental to MgATP binding than to ATP binding, thus pointing to a role for these residues in the binding of Mg2+ or to a difference between the interactions with MgATP and ATP. Subsequent catalytic steps were also selectively affected by the mutations, showing the involvement of the nucleotide-binding domain in these reactions. Mutation of Arg560 inhibited phosphoryl transfer but enhanced the E1PCa2 --> E2P conformational transition, whereas mutations Thr(441) --> Ala, Glu(442) --> Ala, Lys(492) --> Leu, and Lys(515) --> Ala inhibited the E1PCa2 --> E2P transition. Hydrolysis of the E2P phosphoenzyme intermediate was enhanced in Glu(442) --> Ala, Lys(492) --> Leu, Lys(515) --> Ala, and Arg(560)-->Glu. None of the mutations affected the low affinity activation by nucleotide of the phosphoenzyme-processing steps, indicating that modulatory nucleotide interacts differently from substrate nucleotide. Mutation Glu(442) --> Ala greatly enhanced reaction of Lys(515) with fluorescein isothiocyanate, indicating that the two residues form a salt link in the native protein.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark; Univ Cape Town, Div Chem Pathol, Dept Clin Lab Sci, Fac Hlth Sci, ZA-7925 Cape Town, South Africa	Aarhus University; University of Cape Town	McIntosh, DB (corresponding author), Univ Cape Town, Div Chem Pathol, Dept Clin Lab Sci, Fac Hlth Sci, ZA-7925 Cape Town, South Africa.	davidmci@chempath.uct.ac.za; jpa@fi.au.dk		Andersen, Jens Peter/0000-0003-0654-4300; Vilsen, Bente/0000-0002-4727-9382				Abu-Abed M, 2002, BIOCHEMISTRY-US, V41, P1156, DOI 10.1021/bi015703n; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BISHOP JE, 1987, J BIOL CHEM, V262, P4658; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CABLE MB, 1985, BIOCHEMISTRY-US, V24, P5612, DOI 10.1021/bi00341a049; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2001, J BIOL CHEM, V276, P35741, DOI 10.1074/jbc.M105434200; COAN C, 1993, J BIOL CHEM, V268, P6917; COLL RJ, 1991, BIOCHEMISTRY-US, V30, P1456, DOI 10.1021/bi00220a002; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEJESUS F, 1993, FEBS LETT, V332, P229, DOI 10.1016/0014-5793(93)80638-B; DUPONT Y, 1977, EUR J BIOCHEM, V72, P185, DOI 10.1111/j.1432-1033.1977.tb11238.x; HONIG BH, 1984, P NATL ACAD SCI-BIOL, V81, P5412, DOI 10.1073/pnas.81.17.5412; Hua SM, 2002, BIOCHEMISTRY-US, V41, P2264, DOI 10.1021/bi015684h; Hua SM, 2002, BIOCHEMISTRY-US, V41, P11405, DOI 10.1021/bi026181u; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1983, BIOCHEMISTRY-US, V22, P2867, DOI 10.1021/bi00281a015; MCINTOSH DB, 1992, J BIOL CHEM, V267, P22328; MCINTOSH DB, 1992, J BIOL CHEM, V267, P5301; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; MOCZYDLOWSKI EG, 1981, J BIOL CHEM, V256, P2357; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MURPHY AJ, 1988, BIOCHIM BIOPHYS ACTA, V946, P57, DOI 10.1016/0005-2736(88)90457-9; MURPHY AJ, 1978, J BIOL CHEM, V253, P385; NAKAMOTO RK, 1984, J BIOL CHEM, V259, P2961; PATCHORNIK G, BIOCHEMISTRY, V41, P11740; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; SCHEINERBOBIS G, 1993, BIOCHEMISTRY-US, V32, P9592, DOI 10.1021/bi00088a011; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; SEEBREGTS CJ, 1989, J BIOL CHEM, V264, P2043; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; Sorensen TLM, 2000, J BIOL CHEM, V275, P5400, DOI 10.1074/jbc.275.8.5400; STAHL N, 1984, BIOCHEMISTRY-US, V23, P5389, DOI 10.1021/bi00318a002; STEFANOVA HI, 1992, BIOCHEMISTRY-US, V31, P6023, DOI 10.1021/bi00141a010; Stokes DL, 2000, BIOPHYS J, V78, P1765, DOI 10.1016/S0006-3495(00)76727-0; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; Teramachi S, 2002, J BIOL CHEM, V277, P37394, DOI 10.1074/jbc.M204772200; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VERJOVSKIALMEIDA S, 1979, J BIOL CHEM, V254, P18; VIANNA AL, 1975, BIOCHIM BIOPHYS ACTA, V410, P389, DOI 10.1016/0005-2744(75)90241-7; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WAKABAYASHI S, 1990, BIOCHEMISTRY-US, V29, P7309, DOI 10.1021/bi00483a022; WAKABAYASHI S, 1986, J BIOL CHEM, V261, P9762; WAKABAYASHI S, 1987, J BIOL CHEM, V262, P11524; Ward DG, 1998, J BIOL CHEM, V273, P33759, DOI 10.1074/jbc.273.50.33759; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	64	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20245	20258		10.1074/jbc.M301122200	http://dx.doi.org/10.1074/jbc.M301122200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649284	hybrid			2022-12-27	WOS:000183078000087
J	Mahapatra, NR; Mahata, M; O'Connor, DT; Mahata, SK				Mahapatra, NR; Mahata, M; O'Connor, DT; Mahata, SK			Secretin activation of chromogranin A gene transcription - Identification of the signaling pathways in cis and in trans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-HYDROXYLASE ACTIVITY; CYCLIC ADENOSINE-MONOPHOSPHATE; VASOACTIVE-INTESTINAL-PEPTIDE; SECRETOGRANIN-II GENE; NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; PROTEIN-KINASE; ADENYLATE-CYCLASE; CATECHOLAMINE RELEASE; CRUCIAL ROLE	Secretin evokes catecholamine secretion from PC12 pheochromocytoma cells. We tested whether secretin activates transcription of the major vesicular core protein chromogranin A (CgA). Secretin stimulated both endogenous CgA gene transcription (similar to4-6-fold) as well as transfected CgA promoter activity (similar to8-10-fold; EC50, similar to7 nM) in PC12 cells. Studies on CgA promoter 5'-deletion mutant/luciferase reporter constructs, point mutations of the CgA cAMP response element (CRE), and their transfer to a heterologous promoter implicated CRE in cis as both necessary and sufficient for secretin-stimulated CgA gene transcription. Secretin-induced CgA gene transcription was inhibited/abolished by cytosolic Ca2+ chelation, chemical blockade of phospholipase C, protein kinase A (PKA), or mitogen-activated protein ( MAP) kinase extracellular signal regulated kinase (ERK) 1/2 and the expression of dominant negative mutants of ERK1/2, CRE binding protein (CREB) kinase RSK2, or CREB. Secretin also augmented (similar to4-fold) phosphorylation of ERK1/2. Trans-activation (similar to21-fold) of GAL4-CREB fusion protein by secretin indicates involvement of CREB in secretin signaling to gene transcription. Electrophoretic mobility shift assays also identified CREB as the mediator of secretin-induced CgA gene transcription, and pCREB supershifts indicated Ser-133 as the active CREB moiety in vitro. This conclusion was reinforced in vivo by results of chromatin pCREB immunoprecipitation assays. We conclude that secretin signals to CgA gene transcription through the CRE domain in cis and through cAMP, Ca2+, PKA, MAP kinase, and the transcription factor CREB in trans. Thus, multiple signal transduction pathways seem to subserve the function of stimulus-transcription coupling after this peptidergic stimulus to chromaffin cells.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; San Diego Vet Affairs Healthcare Syst, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Mahata, SK (corresponding author), Univ Calif San Diego, Dept Med 0838, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Mahapatra, Nitish R/D-4123-2014; Mahata, Sushil/AAF-8781-2021	Mahapatra, Nitish R/0000-0002-0695-3510; 	NHLBI NIH HHS [HL58120, HL55583, HL69758] Funding Source: Medline; NIDA NIH HHS [DA11311] Funding Source: Medline; NIDDK NIH HHS [DK60702] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055583, U01HL069758, P01HL058120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011311, R29DA011311] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BEIJER HJM, 1979, ARCH INT PHARMACOD T, V240, P269; BOLONDI L, 1990, GUT, V31, P1306, DOI 10.1136/gut.31.11.1306; CHATELAIN P, 1980, PFLUG ARCH EUR J PHY, V389, P29, DOI 10.1007/BF00587925; DAY RN, 1989, J BIOL CHEM, V264, P431; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Fowkes RC, 2001, J ENDOCRINOL, V171, pR5, DOI 10.1677/joe.0.171R005; Fox T, 1998, PROTEIN SCI, V7, P2249, DOI 10.1002/pro.5560071102; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Grewal SS, 2000, J BIOL CHEM, V275, P3722, DOI 10.1074/jbc.275.5.3722; GUNNES P, 1986, EUR HEART J, V7, P146, DOI 10.1093/oxfordjournals.eurheartj.a062037; GUNNES P, 1983, SCAND J CLIN LAB INV, V43, P637; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HASEL KW, 1990, NUCLEIC ACIDS RES, V18, P4019, DOI 10.1093/nar/18.13.4019; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; IP NY, 1984, PEPTIDES, V5, P309, DOI 10.1016/0196-9781(84)90225-0; Ip NY, 2000, J NEUROBIOL, V42, P14, DOI 10.1002/(SICI)1097-4695(200001)42:1<14::AID-NEU2>3.0.CO;2-Y; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; KOPIN AS, 1990, P NATL ACAD SCI USA, V87, P2299, DOI 10.1073/pnas.87.6.2299; Kornhauser JM, 2002, NEURON, V34, P221, DOI 10.1016/S0896-6273(02)00655-4; Mahapatra NR, 2000, ENDOCRINOLOGY, V141, P3668, DOI 10.1210/en.141.10.3668; Mahata M, 2001, HYPERTENSION, V38, P508; Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; Mahata SK, 1999, ENDOCRINOLOGY, V140, P739, DOI 10.1210/en.140.2.739; Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686; MEYER TE, 1993, ENDOCRINOLOGY, V132, P770, DOI 10.1210/en.132.2.770; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Nozaki S, 2002, BIOCHEM BIOPH RES CO, V292, P133, DOI 10.1006/bbrc.2002.6640; OLSEN O, 1993, SCAND J GASTROENTERO, V28, P622, DOI 10.3109/00365529309096100; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PARMER RJ, 1993, J CLIN INVEST, V92, P1042, DOI 10.1172/JCI116609; PARMER RJ, 1989, HYPERTENSION, V14, P435, DOI 10.1161/01.HYP.14.4.435; ROSKOSKI R, 1989, MOL PHARMACOL, V36, P925; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TAKIYYUDDIN MA, 1995, HYPERTENSION, V26, P213, DOI 10.1161/01.HYP.26.1.213; TAKIYYUDDIN MA, 1990, CIRCULATION, V81, P185, DOI 10.1161/01.CIR.81.1.185; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Tang KC, 1997, J CLIN INVEST, V100, P1180, DOI 10.1172/JCI119630; Tang KC, 1996, J BIOL CHEM, V271, P28382, DOI 10.1074/jbc.271.45.28382; TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0; Taupenot L, 1998, J CLIN INVEST, V101, P863, DOI 10.1172/JCI1129; Turquier V, 2001, MOL PHARMACOL, V60, P42, DOI 10.1124/mol.60.1.42; Ulrich CD, 1998, GASTROENTEROLOGY, V114, P382, DOI 10.1016/S0016-5085(98)70491-3; VIDEEN JS, 1992, J BIOL CHEM, V267, P3066; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WESTWICK JK, 1994, P NATL ACAD SCI USA, V91, P6030, DOI 10.1073/pnas.91.13.6030; WU HJ, 1994, J CLIN INVEST, V94, P118, DOI 10.1172/JCI117297; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yung WH, 2001, J NEUROSCI, V21, P7063, DOI 10.1523/JNEUROSCI.21-18-07063.2001	58	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19986	19994		10.1074/jbc.M207983200	http://dx.doi.org/10.1074/jbc.M207983200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646581	hybrid			2022-12-27	WOS:000183078000055
J	Bischofberger, P; Han, WJ; Feifel, B; Schonfeld, HJ; Christen, P				Bischofberger, P; Han, WJ; Feifel, B; Schonfeld, HJ; Christen, P			D-Peptides as inhibitors of the DnaK/DnaJ/GrpE chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; ESCHERICHIA-COLI; DNAK; GRPE; CYCLE	DnaK, a Hsp70 homolog of Escherichia coli, together with its co-chaperones DnaJ and GrpE protects denatured proteins from aggregation and promotes their refolding by an ATP-consuming mechanism. DnaJ not only stimulates the gamma-phosphate cleavage of DnaK-bound ATP but also binds polypeptide substrates on its own. Unfolded polypeptides, such as denatured luciferase, thus form ternary complexes with DnaJ and DnaK. A previous study has shown that D-peptides compete with L-peptides for the same binding site in DnaJ but do not bind to DnaK (Feifel, B., Schonfeld, H.-J., and Christen, P. (1998) J. Biol. Chem. 273, 11999-12002). Here we report that D-peptides efficiently inhibit the refolding of denatured luciferase by the DnaK/DnaJ/GrpE chaperone system (EC50 = 1-2 muM). The inhibition of the chaperone action is due to the binding of D-peptide to DnaJ (K-d = 1-2 muM), which seems to preclude DnaJ from forming ternary (ATP.DnaK)(m).substrate.DnaJ(n) complexes. Apparently, simultaneous binding of DnaJ and DnaK to one and the same target polypeptide is essential for effective chaperone action.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; F Hoffmann La Roche & Co Ltd, Pharmaceut Res, CH-4070 Basel, Switzerland	University of Zurich; Roche Holding	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						BUCHBERGER A, 1994, EMBO J, V13, P1687, DOI 10.1002/j.1460-2075.1994.tb06433.x; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Fink A.L., 1998, MOL CHAPERONES LIFE, P123; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Grimshaw JPA, 2001, J BIOL CHEM, V276, P6098, DOI 10.1074/jbc.M009290200; Han WJ, 2003, J BIOL CHEM, V278, P19038, DOI 10.1074/jbc.M300756200; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Kudlicki W, 1996, J BIOL CHEM, V271, P31160, DOI 10.1074/jbc.271.49.31160; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	18	30	31	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19044	19047		10.1074/jbc.M300922200	http://dx.doi.org/10.1074/jbc.M300922200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637539	hybrid			2022-12-27	WOS:000182932200043
J	Kalogeraki, VS; Tornaletti, S; Hanawalt, PC				Kalogeraki, VS; Tornaletti, S; Hanawalt, PC			Transcription arrest at a lesion in the transcribed DNA strand in vitro is not affected by a nearby lesion in the opposite strand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMER; ELONGATION-FACTOR-SII; THYMINE DIMER; REPAIR; SITE; COMPLEXES; TEMPLATE; DAMAGE; ADDUCTS	Cis-syn cyclobutane pyrimidine dimers (CPDs) are the most frequently formed lesions in UV-irradiated DNA. CPDs are repaired by the nucleotide excision repair pathway. Additionally, they are subject to transcription-coupled DNA repair. In the general model for transcription-coupled DNA repair, an RNA polymerase arrested at a lesion on the transcribed DNA strand facilitates repair by recruiting the repair machinery to the site of the lesion. Consistent with this model, transcription experiments in vitro have shown that CPDs in the transcribed DNA strand interfere with the translocation of prokaryotic and eukaryotic RNA polymerases. Here, we study the behavior of RNA polymerase when transcribing a template that contains two closely spaced lesions, one on each DNA strand. Similar DNA templates containing no CPD, or a single CPD on either the transcribed or the nontranscribed strand were used as controls. Using an in vitro transcription system with purified T7 RNA polymerase ( T7 RNAP) or rat liver RNAP II, we characterized transcript length and efficiency of transcription in vitro. We also tested the sensitivity of the arrested RNAP II-DNA-RNA ternary complex, at a CPD in the transcribed strand, to transcription factor TFIIS. The presence of a nearby CPD in the nontranscribed strand did not affect the behavior of either RNA polymerase nor did it affect the reverse translocation ability of the RNAP II-arrested complex. Our results additionally indicate that the sequence context of a CPD affects the efficiency of T7 RNAP arrest more significantly than that of RNAP II.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Stanford University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Hanawalt, PC (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.				NATIONAL CANCER INSTITUTE [R56CA077712, R01CA063503, R01CA077712] Funding Source: NIH RePORTER; NCI NIH HHS [CA-63503, CA-77712, R01 CA077712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONURA T, 1975, PHOTOCHEM PHOTOBIOL, V22, P243, DOI 10.1111/j.1751-1097.1975.tb06743.x; BRADLEY MO, 1981, P NATL ACAD SCI-BIOL, V78, P3619, DOI 10.1073/pnas.78.6.3619; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; CHEN YH, 1993, J BIOL CHEM, V268, P5849; CHOI DJ, 1994, BIOCHEMISTRY-US, V33, P780, DOI 10.1021/bi00169a020; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CORDA Y, 1991, BIOCHEMISTRY-US, V30, P222, DOI 10.1021/bi00215a032; CORDA Y, 1993, BIOCHEMISTRY-US, V32, P8582, DOI 10.1021/bi00084a027; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cullinane C, 1999, BIOCHEMISTRY-US, V38, P6204, DOI 10.1021/bi982685+; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; Donahue BA, 1996, J BIOL CHEM, V271, P10588, DOI 10.1074/jbc.271.18.10588; EILAT D, 1982, P NATL ACAD SCI-BIOL, V79, P3818, DOI 10.1073/pnas.79.12.3818; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; GORDON LK, 1980, J BIOL CHEM, V255, P2047; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; HATAHET Z, 1994, ANN NY ACAD SCI, V726, P346, DOI 10.1111/j.1749-6632.1994.tb52847.x; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; JACQUES JP, 1991, GENE DEV, V5, P707, DOI 10.1101/gad.5.5.707; LAM LH, 1986, MUTAT RES, V166, P199, DOI 10.1016/0167-8817(86)90018-0; LEADON SA, 1992, J BIOL CHEM, V267, P23175; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; MIKITA T, 1994, BIOCHEMISTRY-US, V33, P9195, DOI 10.1021/bi00197a023; MINTON K, 1974, INT J RADIAT BIOL, V26, P81, DOI 10.1080/09553007414550981; NATH ST, 1991, CARCINOGENESIS, V12, P973, DOI 10.1093/carcin/12.6.973; Ordoukhanian P, 1997, NUCLEIC ACIDS RES, V25, P3783, DOI 10.1093/nar/25.19.3783; Perlow RA, 2002, J MOL BIOL, V321, P29, DOI 10.1016/S0022-2836(02)00593-4; REINES D, 1991, J BIOL CHEM, V266, P10510; REYNOLDS JR, 1987, MUTAT RES, V184, P197; Roth RB, 2001, BIOCHEMISTRY-US, V40, P5200, DOI 10.1021/bi0024355; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SHI YB, 1988, J BIOL CHEM, V263, P527; Smith CA, 1998, J BIOL CHEM, V273, P21933, DOI 10.1074/jbc.273.34.21933; Svejstrup JQ, 2002, NAT REV MOL CELL BIO, V3, P21, DOI 10.1038/nrm703; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; TAYLOR JS, 1988, NUCLEIC ACIDS RES, V16, P5123, DOI 10.1093/nar/16.11.5123; Tornaletti S, 2001, J BIOL CHEM, V276, P45367, DOI 10.1074/jbc.M105282200; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tornaletti S, 1997, J BIOL CHEM, V272, P31719, DOI 10.1074/jbc.272.50.31719; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; Wang ZY, 1997, P NATL ACAD SCI USA, V94, P6688, DOI 10.1073/pnas.94.13.6688; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; ZHOU W, 1995, CELL, V82, P577, DOI 10.1016/0092-8674(95)90030-6	48	15	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19558	19564		10.1074/jbc.M301060200	http://dx.doi.org/10.1074/jbc.M301060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646562	hybrid			2022-12-27	WOS:000182932200107
J	Das, S; El-Deiry, WS; Somasundaram, K				Das, S; El-Deiry, WS; Somasundaram, K			Regulation of the p53 homolog p73 by adenoviral oncogene E1A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P73; P53-RELATED PROTEIN P73; TUMOR-SUPPRESSOR; CELL-CYCLE; HUMAN NEUROBLASTOMAS; HUMAN CANCERS; GENE; EXPRESSION; APOPTOSIS; ACTIVATION	p73 is a p53 homolog, as they are similar structurally and functionally. Unlike p53, p73 is not inactivated by the products of viral oncogenes such as SV40 T antigen and human papilloma virus E6. Here we show that the product of adenoviral oncogene E1A inhibits the transcriptional activation by both p73alpha and p73beta. Electrophoretic mobility shift assays revealed that E1A does not inhibit the sequence-specific DNA binding by p73. Transcriptional activation by a fusion protein containing the Gal4 DNA-binding domain and either of the activation domains of p73 was inhibited by wild-type (WT) E1A, but not by the N-terminal deletion mutant E1A(Delta2-36). E1A(Delta2-36), which does not bind to the p300/CBP family of coactivators, failed to inhibit p73-mediated transcription, whereas E1A(DeltaCR2), a deletion mutant that does not bind to the pRb family of proteins, inhibited p73-mediated transcription as efficiently as WT E1A. Consistent with these observations, growth arrest induced by p73 expressed from a recombinant adenovirus was abrogated by WT E1A, which correlated with inhibition of p73-mediated induction of p21(WAF1/CIP1) by E1A. However, p73 was able to induce p21(WAF1/CIP1) and to mediate growth arrest in the presence of E1A(Delta2-36). Furthermore, the expression of either wild-type E1A or E1A(Delta2-36) resulted in the stabilization of endogenous p73. However, p73 stabilized in response to the expression of E1A(Delta2-36), but not WT E1A, was able to activate the expression of p21(WAF1/CIP1). These results suggest that the transcriptional activation function of p73 is specifically targeted by E1A through a mechanism involving p300/CBP proteins during the process of transformation and that p73 may have a role to play as a tumor suppressor.	Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	Indian Institute of Science (IISC) - Bangalore; Howard Hughes Medical Institute; University of Pennsylvania	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India.		El-Deiry, Wafik/AAJ-6080-2020	El-Deiry, Wafik/0000-0002-9577-8266; Das, Sanjeev/0000-0002-3594-1033				AVANTAGGIATI MI, 1997, CELL, V8, P1175; BALABAN GB, 1986, CANCER GENET CYTOGEN, V19, P113, DOI 10.1016/0165-4608(86)90378-X; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARBONETTI J, 1993, GENE DEV, V7, P2565; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Imyanitov EN, 1999, ONCOGENE, V18, P4640, DOI 10.1038/sj.onc.1202863; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kang MJ, 2000, CLIN CANCER RES, V6, P1767; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; LAVIGUEUR A, 1989, MOL CELL BIOL, V9, P3982, DOI 10.1128/MCB.9.9.3982; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mai M, 1998, CANCER RES, V58, P2347; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Marin MC, 2000, BBA-REV CANCER, V1470, pM93, DOI 10.1016/S0304-419X(00)00010-X; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nomoto S, 1998, CANCER RES, V58, P1380; Ongkeko WM, 1999, CURR BIOL, V9, P829, DOI 10.1016/S0960-9822(99)80367-4; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Peters UR, 1999, CANCER RES, V59, P4233; Prabhu NS, 1998, INT J ONCOL, V13, P5; SHEPHERD SE, 1993, J VIROL, V67, P2944, DOI 10.1128/JVI.67.5.2944-2949.1993; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Takada N, 1999, CANCER RES, V59, P2810; TAYLOR DA, 1993, MOL CELL BIOL, V13, P4714, DOI 10.1128/MCB.13.8.4714; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zaika AI, 1999, CANCER RES, V59, P3257; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	58	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18313	18320		10.1074/jbc.M211704200	http://dx.doi.org/10.1074/jbc.M211704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639967	hybrid			2022-12-27	WOS:000182838300095
J	Sparrow, JR; Vollmer-Snarr, HR; Zhou, JL; Jang, YP; Jockusch, S; Itagaki, Y; Nakanishi, K				Sparrow, JR; Vollmer-Snarr, HR; Zhou, JL; Jang, YP; Jockusch, S; Itagaki, Y; Nakanishi, K			A2E-epoxides damage DNA in retinal pigment epithelial cells - Vitamin E and other antioxidants inhibit A2E-epoxide formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-INDUCED DAMAGE; MACULAR DEGENERATION; LIPOFUSCIN FLUOROPHORE; PHOTOPHYSICAL PROPERTIES; GEOGRAPHIC ATROPHY; COMET ASSAY; FUNDUS AUTOFLUORESCENCE; LIPOPROTEIN OXIDATION; AGING RETINA; IN-VITRO	The autofluorescent pigments that accumulate in retinal pigment epithelial cells with aging and in some retinal disorders have been implicated in the etiology of macular degeneration. The major constituent is the fluorophore A2E, a pyridinium bisretinoid. Light-exposed A2E-laden retinal pigment epithelium exhibits a propensity for apoptosis with light in the blue region of the spectrum being most damaging. Efforts to understand the events precipitating the death of the cells have revealed that during irradiation (430 nm), A2E self-generates singlet oxygen with the singlet oxygen in turn reacting with A2E to generate epoxides at carbon-carbon double bonds. Here we demonstrate that A2E-epoxides, independent of singlet oxygen, exhibit reactivity toward DNA with oxidative base changes being at least one of these lesions. Mass spectrometry revealed that the antioxidants vitamins E and C, butylated hydroxytoluene, resveratrol, a trolox analogue (PNU-83836-E), and bilberry extract reduce A2E-epoxidation, whereas single cell gel electrophoresis and cell viability studies revealed a corresponding reduction in the incidence of DNA damage and cell death. Vitamin E, a lipophilic antioxidant, produced a more pronounced decrease in A2E-epoxidation than vitamin C, and treatment with both vitamins simultaneously did not confer additional benefit. Studies in which singlet oxygen was generated by endoperoxide in the presence of A2E revealed that vitamin E, butylated hydroxytoluene, resveratrol, the trolox analogue, and bilberry reduced A2E-epoxidation by quenching singlet oxygen. Conversely, vitamin C and ginkgolide B were not efficient quenchers of singlet oxygen under these conditions.	Columbia Univ, Dept Ophthalmol, New York, NY 10028 USA; Columbia Univ, Dept Chem, New York, NY 10028 USA	Columbia University; Columbia University	Nakanishi, K (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.	kn5@columbia.edu	Jang, Young Pyo/AAJ-8782-2020	Jang, Young Pyo/0000-0001-5865-9228; Jockusch, Steffen/0000-0002-4592-5280; Vollmer-Snarr, Heidi/0000-0002-7312-4907	NATIONAL EYE INSTITUTE [R01EY012951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034509, R37GM034509] Funding Source: NIH RePORTER; NEI NIH HHS [EY 12951] Funding Source: Medline; NIGMS NIH HHS [GM 34509] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVELINE BM, 1995, J PHOTOCH PHOTOBIO B, V30, P161, DOI 10.1016/1011-1344(95)07174-Z; Baynes JW, 2002, ANN NY ACAD SCI, V959, P360, DOI 10.1111/j.1749-6632.2002.tb02107.x; Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5; Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Bohr VA, 2002, FREE RADICAL BIO MED, V32, P804, DOI 10.1016/S0891-5849(02)00787-6; Bohr VA, 2001, ADV CELL AGING GERON, V4, P191; BUNTING JR, 1992, PHOTOCHEM PHOTOBIOL, V55, P81, DOI 10.1111/j.1751-1097.1992.tb04212.x; Burkle A, 2001, EYE, V15, P371, DOI 10.1038/eye.2001.139; Busch EM, 1999, VISION RES, V39, P1233, DOI 10.1016/S0042-6989(98)00233-8; Cabelof DC, 2002, MUTAT RES-FUND MOL M, V500, P135, DOI 10.1016/S0027-5107(02)00003-9; Campo GM, 1997, FREE RADICAL RES, V27, P577, DOI 10.3109/10715769709097861; Carnelley TJ, 2001, CHEM RES TOXICOL, V14, P1513, DOI 10.1021/tx0100946; CASOLI U, 1967, IND ITAL CONSERVE, V42, P11; Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236; Delaey E, 2000, J PHOTOCH PHOTOBIO B, V55, P27, DOI 10.1016/S1011-1344(00)00021-X; DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691; Egner PA, 2001, P NATL ACAD SCI USA, V98, P14601, DOI 10.1073/pnas.251536898; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FAIRBAIRN DW, 1995, MUTAT RES-REV GENET, V339, P37, DOI 10.1016/0165-1110(94)00013-3; FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Giri I, 2002, CHEM RES TOXICOL, V15, P638, DOI 10.1021/tx010187n; Green MHL, 1996, METHOD ENZYMOL, V269, P243; GREEN WR, 1985, OPHTHALMOLOGY, V92, P615; HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198; HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029; Henderson RF, 2001, CHEM-BIOL INTERACT, V135, P53, DOI 10.1016/S0009-2797(01)00170-3; Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051; Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; Huang HY, 2002, AM J CLIN NUTR, V76, P549, DOI 10.1093/ajcn/76.3.549; JEFFREY AM, 1979, SCIENCE, V206, P1309, DOI 10.1126/science.316186; JEFFREY AM, 1977, NATURE, V269, P348, DOI 10.1038/269348a0; JEFFREY AM, 1976, P NATL ACAD SCI USA, V73, P2311, DOI 10.1073/pnas.73.7.2311; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417; KOHDA K, 1986, BIOCHEM BIOPH RES CO, V139, P626, DOI 10.1016/S0006-291X(86)80036-5; Koivisto P, 1999, CARCINOGENESIS, V20, P1253, DOI 10.1093/carcin/20.7.1253; Kontush A, 2001, FREE RADICAL BIO MED, V31, P345, DOI 10.1016/S0891-5849(01)00595-0; Koskinen M, 2000, CHEM-BIOL INTERACT, V129, P209, DOI 10.1016/S0009-2797(00)00206-4; KRIEG M, 1993, BIOCHIM BIOPHYS ACTA, V1151, P168, DOI 10.1016/0005-2736(93)90101-5; Krieg M, 1996, BIOCHEM PHARMACOL, V51, P1461, DOI 10.1016/0006-2952(96)00087-1; Lamb LE, 2001, J PHYS CHEM B, V105, P11507, DOI 10.1021/jp0123177; LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; McCarthy PJ, 1997, MUTAGENESIS, V12, P209, DOI 10.1093/mutage/12.4.209; MOAN J, 1991, PHOTOCHEM PHOTOBIOL, V53, P549, DOI 10.1111/j.1751-1097.1991.tb03669.x; Muth E R, 2000, Altern Med Rev, V5, P164; Nyman NA, 2001, J AGR FOOD CHEM, V49, P4183, DOI 10.1021/jf010572i; Olshansky SJ, 2002, SCI AM, V286, P92, DOI 10.1038/scientificamerican0602-92; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286; Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8; Ren RXF, 1997, J AM CHEM SOC, V119, P3619, DOI 10.1021/ja9700414; Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2; Rojas E, 1999, J CHROMATOGR B, V722, P225, DOI 10.1016/S0378-4347(98)00313-2; Sakai N, 1996, J AM CHEM SOC, V118, P1559, DOI 10.1021/ja953480g; SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; Selzer RR, 1999, CARCINOGENESIS, V20, P285, DOI 10.1093/carcin/20.2.285; SHEN HM, 1995, CARCINOGENESIS, V16, P419, DOI 10.1093/carcin/16.2.419; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Smela ME, 2002, P NATL ACAD SCI USA, V99, P6655, DOI 10.1073/pnas.102167699; SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222; Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; SPARROW JR, 2003, IN PRESS INVEST OPHT; Stocker Roland, 1994, Current Opinion in Lipidology, V5, P422, DOI 10.1097/00041433-199412000-00005; SUN DY, 1993, BIOCHEMISTRY-US, V32, P8068, DOI 10.1021/bi00083a003; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Szeto YT, 2002, MUTAT RES-FUND MOL M, V500, P31, DOI 10.1016/S0027-5107(01)00298-6; TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035; VANBEEK TA, 2000, GINKGO BILOBA MED AR; WEINSTEIN IB, 1976, SCIENCE, V193, P592, DOI 10.1126/science.959820; WELCH RW, 1995, J BIOL CHEM, V270, P12584, DOI 10.1074/jbc.270.21.12584; Yarborough A, 1996, CANCER RES, V56, P683; YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9; Zadok D, 1999, EYE, V13, P734, DOI 10.1038/eye.1999.218	85	210	229	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18207	18213		10.1074/jbc.M300457200	http://dx.doi.org/10.1074/jbc.M300457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12646558	hybrid			2022-12-27	WOS:000182838300081
J	Wielinga, PR; van der Heijden, I; Reid, G; Beijnen, JH; Wijnholds, J; Borst, P				Wielinga, PR; van der Heijden, I; Reid, G; Beijnen, JH; Wijnholds, J; Borst, P			Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE 3',5'-CYCLIC-MONOPHOSPHATE CGMP; MULTIDRUG-RESISTANCE PROTEIN-4; ORGANIC ANION TRANSPORTER; SMOOTH-MUSCLE; CEREBELLAR NEURONS; HUMAN ERYTHROCYTES; GUANYLATE-CYCLASE; GMP EFFLUX; CAMP; PHOSPHODIESTERASE	Cyclic nucleotides are known to be effluxed from cultured cells or isolated tissues. Two recently described members of the multidrug resistance protein family, MRP4 and MRP5, might be involved in this process, because they transport the 3',5'-cyclic nucleotides, cAMP and cGMP, into inside-out membrane vesicles. We have investigated cGMP and cAMP efflux from intact HEK293 cells overexpressing MRP4 or MRP5. The intracellular production of cGMP and cAMP was stimulated with the nitric oxide releasing compound sodium nitroprusside and the adenylate cyclase stimulator forskolin, respectively. MRP4- and MRP5-overexpressing cells effluxed more cGMP and cAMP than parental cells in an ATP-dependent manner. In contrast to a previous report we found no glutathione requirement for cyclic nucleotide transport. Transport increased proportionally with intracellular cyclic nucleotide concentrations over a calculated range of 20-600 muM, indicating low affinity transport. In addition to several classic inhibitors of organic anion transport, prostaglandins A(1) and E-1, the steroid progesterone and the anti-cancer drug estramustine all inhibited cyclic nucleotide efflux. The efflux mediated by MRP4 and MRP5 did not lead to a proportional decrease in the intracellular cGMP or cAMP levels but reduced cGMP by maximally 2-fold over the first hour. This was also the case when phosphodiesterase-mediated cyclic nucleotide hydrolysis was inhibited by 3-isobutyl-1-methylxanthine, conditions in which efflux was maximal. These data indicate that MRP4 and MRP5 are low affinity cyclic nucleotide transporters that may at best function as overflow pumps, decreasing steep increases in cGMP levels under conditions where cGMP synthesis is strongly induced and phosphodiesterase activity is limiting.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands; Slotervaart Hosp, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands; Royal Dutch Acad Sci, Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute; Slotervaart Hospital; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Wijnholds, Jan/V-3896-2018	Wijnholds, Jan/0000-0003-0099-460X; Reid, Glen/0000-0001-6465-5223; Wielinga, Peter/0000-0002-8830-0010				Ahlstrom M, 1999, BIOCHEM PHARMACOL, V58, P1335, DOI 10.1016/S0006-2952(99)00199-9; ARDAILLOU N, 1993, EXP NEPHROL, V1, P253; Bakre MM, 2000, EUR J BIOCHEM, V267, P179, DOI 10.1046/j.1432-1327.2000.00986.x; Bankir L, 2002, AM J PHYSIOL-RENAL, V282, pF376, DOI 10.1152/ajprenal.00202.2001; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Bera TK, 2001, MOL MED, V7, P509, DOI 10.1007/BF03401856; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BROADUS AE, 1970, J CLIN INVEST, V49, P2222, DOI 10.1172/JCI106441; BRUNTON LL, 1988, METHOD ENZYMOL, V159, P83; Chen ZS, 2002, CANCER RES, V62, P3144; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; Conrad KP, 1999, AM J PHYSIOL-RENAL, V277, pF48, DOI 10.1152/ajprenal.1999.277.1.F48; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; Crane JK, 2000, ARCH BIOCHEM BIOPHYS, V376, P163, DOI 10.1006/abbi.2000.1703; Evers R, 1997, FEBS LETT, V419, P112, DOI 10.1016/S0014-5793(97)01442-7; HAMET P, 1989, J BIOL CHEM, V264, P12364; HEASLEY LE, 1985, J BIOL CHEM, V260, P1514; HEASLEY LE, 1985, MOL PHARMACOL, V27, P60; Jackson EK, 2001, AM J PHYSIOL-RENAL, V281, pF597, DOI 10.1152/ajprenal.2001.281.4.F597; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; KANAI N, 1995, SCIENCE, V268, P866, DOI 10.1126/science.7754369; Keppler D, 1997, BIOL CHEM, V378, P787; Lai LQ, 2002, BIOCHEM J, V361, P497, DOI 10.1042/0264-6021:3610497; Li YH, 1997, J CELL BIOL, V139, P1317, DOI 10.1083/jcb.139.5.1317; LOLLEY RN, 1977, SCIENCE, V196, P664, DOI 10.1126/science.193183; Mercapide J, 1999, BIOCHEM PHARMACOL, V58, P1675, DOI 10.1016/S0006-2952(99)00252-X; Montoliu C, 1999, NEUROPHARMACOLOGY, V38, P1883, DOI 10.1016/S0028-3908(99)00071-4; Murthy KS, 2001, BIOCHEM J, V360, P199, DOI 10.1042/0264-6021:3600199; Okada D, 2002, BIOCHEMISTRY-US, V41, P9672, DOI 10.1021/bi025727+; Orbo A, 1998, EUR J CANCER, V34, P1460, DOI 10.1016/S0959-8049(98)00079-3; PATEL MJ, 1995, J PHARMACOL EXP THER, V273, P16; Pedraza CE, 2001, FEBS LETT, V507, P303, DOI 10.1016/S0014-5793(01)03003-4; Poulopoulou C, 1998, J PHARMACOL EXP THER, V286, P99; Reid G, 2003, MOL PHARMACOL, V63, P1094, DOI 10.1124/mol.63.5.1094; RINDLER MJ, 1978, J BIOL CHEM, V253, P5431; Schuetz JD, 1999, NAT MED, V5, P1048, DOI 10.1038/12487; Schuster VL, 1998, ANNU REV PHYSIOL, V60, P221, DOI 10.1146/annurev.physiol.60.1.221; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Stoos BA, 1997, BIOCHEM PHARMACOL, V53, P631, DOI 10.1016/S0006-2952(96)00858-1; Sundkvist E, 2002, BIOCHEM PHARMACOL, V63, P945, DOI 10.1016/S0006-2952(01)00940-6; Sundkvist E, 2000, BBA-BIOMEMBRANES, V1463, P121, DOI 10.1016/S0005-2736(99)00184-4; Tammur J, 2001, GENE, V273, P89, DOI 10.1016/S0378-1119(01)00572-8; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; TJORNHAMMAR ML, 1983, J BIOL CHEM, V258, P6882; Touyz RM, 1997, J NEUROCHEM, V68, P1451; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133595; VANHAASTERT PJ, 1997, FEBS LETT, V410, P285; Wielinga PR, 2002, MOL PHARMACOL, V62, P1321, DOI 10.1124/mol.62.6.1321; Wijnholds J, 2000, P NATL ACAD SCI USA, V97, P7476, DOI 10.1073/pnas.120159197; WU XB, 1993, MOL PHARMACOL, V43, P564; Yabuuchi H, 2001, BIOCHEM BIOPH RES CO, V288, P933, DOI 10.1006/bbrc.2001.5865	52	226	233	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17664	17671		10.1074/jbc.M212723200	http://dx.doi.org/10.1074/jbc.M212723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637526	hybrid			2022-12-27	WOS:000182838300012
J	Xiong, SG; She, HY; Takeuchi, H; Han, B; Engelhardt, JF; Barton, CH; Zandi, E; Giulivi, C; Tsukamoto, H				Xiong, SG; She, HY; Takeuchi, H; Han, B; Engelhardt, JF; Barton, CH; Zandi, E; Giulivi, C; Tsukamoto, H			Signaling role of intracellular iron in NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; RAT KUPFFER CELLS; NITRIC-OXIDE; LIPID-PEROXIDATION; FACTOR-ALPHA; TYROSINE PHOSPHORYLATION; HYDROGEN-PEROXIDE; MACROPHAGES; PEROXYNITRITE	Iron chelators inhibit endotoxin-induced NF-kappaB activation in hepatic macrophages (HMs), suggesting a role for the intracellular chelatable pool of iron in NF-kappaB activation. The present study tested this hypothesis. Analysis of Fe-59-loaded HMs stimulated with lipopolysaccharide (LPS), revealed a previously unreported, transient rise in intracellular low molecular weight (LMW).Fe-59 complex ([LMW.Fe](i)) at less than or equal to2 min returning to the basal level within 15 min. The [LMW.Fe](i) response preceded IkappaB kinase (IKK) (greater than or equal to15 min) and NF-kappaB (greater than or equal to30 min) activation. Iron chelators (1,2-dimethyl-3-hydroxypyridin-4-one and N,N'-bis-2-hydroxybenzylethylenediamine-N, N'-diacetic acid) abrogated the [LMW.Fe](i) response and IKK and NF-kappaB activation. The [LMW.Fe](i) response was also observed in tumor necrosis factor alpha (TNFalpha)-stimulated HMs and RAW264.7 cells treated with LPS and interferon-gamma but not in primary rat hepatocytes or myofibroblastic cells exposed to LPS or TNFalpha. Both [LMW.Fe](i) response and IKK activation in LPS-stimulated HMs were inhibited by diphenylene iodonium (nonspecific inhibitor for flavin-containing oxidases), L-N-6-(1-iminoethyl)lysine (selective iNOS inhibitor), and adenoviral-mediated expression of a dominant negative mutant of Rac1 or Cu, Zn-superoxide dismutase, suggesting the role of (NO)-N-. and O-2(-). in mediating the iron signaling. In fact, this inhibition was recapitulated by a cell-permeable scavenger of ONOO-, 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrinato iron (III) chloride. Conversely, ONOO- alone induced both [LMW.Fe](i) response and IKK activation. Finally, direct addition of ferrous iron to cultured HMs activated IKK and NF-kappaB. These results support a novel signaling role for [LMW.Fe](i) in IKK activation, which appears to be induced by ONOO- and selectively operative in macrophages.	Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Ctr Gene Therapy, Iowa City, IA 52242 USA; Univ Southampton, Div Biochem & Mol Biol, Southampton S016 6YD, Hants, England; Univ Minnesota, Dept Chem, Duluth, MN 55812 USA; Greater Los Angeles Healthcare Syst, Dept Vet Affairs, Los Angeles, CA 90073 USA	University of Southern California; University of Southern California; University of Iowa; University of Iowa; University of Southampton; University of Minnesota System; University of Minnesota Duluth	Tsukamoto, H (corresponding author), Univ So Calif, Keck Sch Med, Dept Pathol, 1333 San Pablo St,NMMR-402, Los Angeles, CA 90033 USA.		Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435; Engelhardt, John/0000-0003-2389-9277	NIAAA NIH HHS [R37AA06603, P50AA11999, R24AA12885, T32-AA07578] Funding Source: Medline; NIDDK NIH HHS [P30DK48522] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK048522] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007578, R37AA006603, R24AA012885, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Atkinson PGP, 1999, IMMUNOLOGY, V96, P656; Az-ma T, 1999, BRIT J PHARMACOL, V126, P1462, DOI 10.1038/sj.bjp.0702438; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; Boldt DH, 1999, AM J MED SCI, V318, P207, DOI 10.1097/00000441-199910000-00001; Bonizzi G, 1997, J IMMUNOL, V159, P5264; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bootman MD, 2001, J CELL SCI, V114, P2213; Cairo G, 2002, BIOCHEMISTRY-US, V41, P7435, DOI 10.1021/bi025756k; CAIRO G, 1995, J BIOL CHEM, V270, P700, DOI 10.1074/jbc.270.2.700; CHAUDHRI G, 1989, J IMMUNOL, V143, P1290; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Filep JG, 1998, J IMMUNOL, V161, P5656; Fox ES, 1998, J LEUKOCYTE BIOL, V63, P509, DOI 10.1002/jlb.63.4.509; FUHRMAN B, 1994, ATHEROSCLEROSIS, V111, P65, DOI 10.1016/0021-9150(94)90192-9; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gogvadze V, 2002, ARCH BIOCHEM BIOPHYS, V398, P198, DOI 10.1006/abbi.2001.2721; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; IKEBUCHI Y, 1991, J BIOL CHEM, V266, P13233; JIANG XS, 1993, CELL IMMUNOL, V148, P397, DOI 10.1006/cimm.1993.1121; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; Kang JL, 2000, MOL CELL BIOCHEM, V215, P1, DOI 10.1023/A:1026581301366; KONDO H, 1988, HEPATOLOGY, V8, P32, DOI 10.1002/hep.1840080108; Kurose I, 1997, J CLIN INVEST, V99, P867, DOI 10.1172/JCI119251; LIH M, 1997, AM J PHYSIOL, V272, pG1355; Loegering DJ, 1996, J LEUKOCYTE BIOL, V59, P357, DOI 10.1002/jlb.59.3.357; LU SC, 1993, J CLIN INVEST, V92, P1188, DOI 10.1172/JCI116689; MASINI A, 1989, BIOCHIM BIOPHYS ACTA, V1014, P133, DOI 10.1016/0167-4889(89)90025-6; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; MITOMO K, 1994, GENE, V145, P197; Olynyk JK, 2001, J GASTROEN HEPATOL, V16, P438, DOI 10.1046/j.1440-1746.2001.02456.x; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; ROVERI A, 1992, ARCH BIOCHEM BIOPHYS, V297, P265, DOI 10.1016/0003-9861(92)90671-I; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; SCHRECK R, 1994, METHOD ENZYMOL, V234, P151; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHIBANUMA M, 1994, FEBS LETT, V353, P62, DOI 10.1016/0014-5793(94)01014-5; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; VANASBECK BS, 1984, J INFECTION, V8, P232, DOI 10.1016/S0163-4453(84)93955-0; Virag L, 1999, MOL PHARMACOL, V56, P824; WARREN S, 1993, LYMPHOKINE CYTOK RES, V12, P75; Watts RN, 2002, EUR J BIOCHEM, V269, P3383, DOI 10.1046/j.1432-1033.2002.02987.x; Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x; Wyllie S, 2002, MICROBES INFECT, V4, P351, DOI 10.1016/S1286-4579(02)01548-4; YEGOROV DY, 1993, FREE RADICAL BIO MED, V15, P565, DOI 10.1016/0891-5849(93)90158-Q	55	134	143	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17646	17654		10.1074/jbc.M210905200	http://dx.doi.org/10.1074/jbc.M210905200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637578	hybrid			2022-12-27	WOS:000182838300010
J	Ghosh-Choudhury, NG; Abboud, SL; Mahimainathan, L; Chandrasekar, B; Choudhury, GG				Ghosh-Choudhury, NG; Abboud, SL; Mahimainathan, L; Chandrasekar, B; Choudhury, GG			Phosphatidylinositol 3-kinase regulates bone morphogenetic protein-2 (BMP-2)-induced myocyte enhancer factor 2A-dependent transcription of BMP-2 gene in cardiomyocyte precursor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR MESANGIAL CELLS; C-FOS; PHOSPHOINOSITIDE 3-KINASE; RETINOBLASTOMA PROTEIN; MUSCLE DIFFERENTIATION; MEF2 PROTEINS; DNA-SYNTHESIS; KINASE; GROWTH; ACTIVATION	The growth and differentiation factor bone morphogenetic protein-2 (BMP-2) regulates cardiac development during vertebrate embryogenesis. In cardiac precursor cells, BMP-2 has recently been shown to induce expression of cardiac transcription factors, including myocyte enhancer factor 2A (MEF-2A). The specific signal transduction mechanism by which BMP-2 regulates these actions is not known. We investigated the role of phosphatidylinositol (PI) 3-kinase in regulating these processes in cardiomyocyte precursor CL6 cells. BMP-2 increased PI 3-kinase activity in these cells in a time-dependent manner, resulting in increased expression of sarcomeric myosin heavy chain (MHC) and MEF-2A. Inhibition of PI 3-kinase abolished these actions of BMP-2, indicating the involvement of PI 3-kinase in these processes. Furthermore, BMP-2 stimulated specific protein.DNA complex formation when an MEF-2 DNA recognition element was used as probe. Antibody supershift assay confirmed the presence of MEF-2A in this protein.DNA complex. Inhibition of PI 3-kinase activity completely prevented the MEF-2A.DNA complex formation. BMP-2 also increased transcription of a reporter gene driven by an MEF-2-specific DNA element in a PI 3-kinase-dependent manner. Ectopic expression of MEF-2A increased BMP-2 transcription to the same extent induced by BMP-2, indicating that MEF-2A may participate in BMP-2 autoregulation in CL6 cells. Expression of dominant negative PI 3-kinase completely abolished BMP-2-induced as well as MEF-2A-mediated BMP-2 transcription. Furthermore expression of MEF-2A increased MHC expression in a PI 3-kinase-dependent manner. Together these data provide the first evidence that BMP-2-induced PI 3-kinase signaling regulates MEF-2A expression and define a mechanism of MEF-2A-dependent BMP-2 transcription.	Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78229 USA; S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; Geriatric Research Education & Clinical Center	Ghosh-Choudhury, NG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.			/0000-0001-5077-3552	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055815] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 68020] Funding Source: Medline; NIAMS NIH HHS [AR 42306] Funding Source: Medline; NIDDK NIH HHS [R01 DK 55815] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdelwahid E, 2001, CELL TISSUE RES, V305, P67, DOI 10.1007/s004410100399; Bardgette J, 1999, J RECEPT SIGNAL TR R, V19, P865, DOI 10.3109/10799899909042878; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet LJ, 1998, SCIENCE, V280, P1455, DOI 10.1126/science.280.5368.1455; Chanut F, 1997, DEVELOPMENT, V124, P559; Choudhury GG, 2001, J BIOL CHEM, V276, P35636, DOI 10.1074/jbc.M100946200; Choudhury GG, 1998, J CLIN INVEST, V101, P2751, DOI 10.1172/JCI1044; Choudhury GG, 2000, KIDNEY INT, V57, P908, DOI 10.1046/j.1523-1755.2000.00907.x; Choudhury GG, 2000, BIOCHEM BIOPH RES CO, V273, P1069, DOI 10.1006/bbrc.2000.3081; CHOUDHURY GG, 1997, AM J PHYSIOL, V273, P931; Choundhury GG, 1999, J BIOL CHEM, V274, P10897; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Ghosh-Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200; Ghosh-Choudhury N, 2000, BIOCHEM BIOPH RES CO, V272, P705, DOI 10.1006/bbrc.2000.2844; Ghosh-Choudhury N, 2001, BIOCHEM BIOPH RES CO, V286, P101, DOI 10.1006/bbrc.2001.5351; Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4; Ghosh-Choudhury Nandini, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P345; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; Groppe J, 2002, NATURE, V420, P636, DOI 10.1038/nature01245; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Izumi M, 2001, J BIOL CHEM, V276, P31133, DOI 10.1074/jbc.M101463200; Jamali M, 2001, FEBS LETT, V509, P126, DOI 10.1016/S0014-5793(01)03151-9; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Knochel S, 2001, MECH DEVELOP, V109, P79, DOI 10.1016/S0925-4773(01)00506-8; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, MOL CELL BIOL, V16, P3814; Monzen K, 1999, MOL CELL BIOL, V19, P7096; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; POWELLBRAXTON L, 1993, GENE DEV, V7, P2609, DOI 10.1101/gad.7.12b.2609; Quinn ZA, 2001, NUCLEIC ACIDS RES, V29, P732, DOI 10.1093/nar/29.3.732; Sakou T, 1998, BONE, V22, P591, DOI 10.1016/S8756-3282(98)00053-2; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; Zhang HB, 1996, DEVELOPMENT, V122, P2977; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	50	34	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21998	22005		10.1074/jbc.M302277200	http://dx.doi.org/10.1074/jbc.M302277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663654	hybrid			2022-12-27	WOS:000183354200086
J	Blevins, MB; Smith, AM; Phillips, EM; Powers, MA				Blevins, MB; Smith, AM; Phillips, EM; Powers, MA			Complex formation among the RNA export proteins Nup98, Rae1/Gle2, and TAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; MESSENGER-RNA; NUCLEOPORIN NUP98; RAE1 GENE; POLY(A)(+) RNA; BINDING-SITES; TRANSPORT; DOMAIN; INTERACTS; CYTOPLASM	Most nucleocytoplasmic traffic through the nuclear pore complex is mediated by soluble receptors of the importin/exportin or karyopherin family. mRNA export is unique in that no receptor of this family has been implicated in trafficking of the bulk of mRNAs. Instead, many diverse proteins have been linked to mRNA export, but an all-encompassing model remains elusive. Understanding how these proteins interact with each other is central to the development of such a model. Here, we have focused on the interactions between three proteins implicated in mRNA export, Nup98, Rae1/Gle2, and TAP. We have defined the binary complexes that form among these proteins. We find that Gle2 requires two sites within TAP for stable interaction. Strikingly, rather than a general affinity for all nucleoporin FG repeats, TAP has highest affinity for a specific region within the GLFG domain of Nup98, indicating that not all repeats are identical in function. We have established that the ternary complex can form through simultaneous binding of both Gle2 and TAP to adjacent sites on Nup98. In contrast, Nup98 competes with TAP for Gle2 binding; when bound to Nup98, Gle2 no longer interacts directly with TAP. From these interactions, we propose that Gle2 may act to deliver TAP to Nup98 and that this may represent the first in a series of interactions between an export complex and a nucleoporin.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA	Emory University	Powers, MA (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA.			Blevins, Melanie/0000-0002-5135-7099	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059975] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-59975] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Bachi A, 2000, RNA, V6, P136, DOI 10.1017/S1355838200991994; Bharathi A, 1997, GENE, V198, P251, DOI 10.1016/S0378-1119(97)00322-3; Braun IC, 2002, MOL CELL BIOL, V22, P5405, DOI 10.1128/MCB.22.15.5405-5418.2002; Braun IC, 2001, J BIOL CHEM, V276, P20536, DOI 10.1074/jbc.M100400200; Braun IC, 1999, EMBO J, V18, P1953, DOI 10.1093/emboj/18.7.1953; BROWN JA, 1995, J BIOL CHEM, V270, P7411, DOI 10.1074/jbc.270.13.7411; Campbell L, 2003, J CELL SCI, V116, P617, DOI 10.1242/jcs.00255; Cronshaw JA, 2002, J CELL BIOL, V158, P915, DOI 10.1083/jcb.200206106; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Denning DP, 2002, J BIOL CHEM, V277, P33447, DOI 10.1074/jbc.M203499200; Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760; Fahrenkrog B, 2001, CURR TOP MICROBIOL, V259, P95; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fontoura BMA, 2000, J BIOL CHEM, V275, P31289, DOI 10.1074/jbc.M004651200; Fontoura BMA, 2001, P NATL ACAD SCI USA, V98, P3208, DOI 10.1073/pnas.061014698; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grant RP, 2002, NAT STRUCT BIOL, V9, P247, DOI 10.1038/nsb773; Griffis ER, 2003, MOL BIOL CELL, V14, P600, DOI 10.1091/mbc.E02-09-0582; Griffis ER, 2002, MOL BIOL CELL, V13, P1282, DOI 10.1091/mbc.01-11-0538; Guzik BW, 2001, MOL CELL BIOL, V21, P2545, DOI 10.1128/MCB.21.7.2545-2554.2001; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; Jones AL, 2000, P NATL ACAD SCI USA, V97, P3224, DOI 10.1073/pnas.050432997; Kraemer D, 1997, P NATL ACAD SCI USA, V94, P9119, DOI 10.1073/pnas.94.17.9119; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Liker E, 2000, EMBO J, V19, P5587, DOI 10.1093/emboj/19.21.5587; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MACAULAY C, 1995, J BIOL CHEM, V270, P254, DOI 10.1074/jbc.270.1.254; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; POWERS MA, 1995, J CELL BIOL, V128, P721, DOI 10.1083/jcb.128.5.721; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Pritchard CEJ, 1999, J CELL BIOL, V145, P237, DOI 10.1083/jcb.145.2.237; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rost B, 2000, METH MOL B, V143, P71; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Sabri N, 2000, RNA, V6, P1597, DOI 10.1017/S1355838200001138; Schmitt I, 2001, J BIOL CHEM, V276, P42355, DOI 10.1074/jbc.M103916200; Shamsher MK, 2002, P NATL ACAD SCI USA, V99, P14195, DOI 10.1073/pnas.212518199; Snay-Hodge CA, 1998, EMBO J, V17, P2663, DOI 10.1093/emboj/17.9.2663; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Vasu S, 2001, J CELL BIOL, V155, P339, DOI 10.1083/jcb.200108007; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Wang XS, 2001, J BIOL CHEM, V276, P26559, DOI 10.1074/jbc.M101083200; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; Weis K, 2002, CURR OPIN CELL BIOL, V14, P328, DOI 10.1016/S0955-0674(02)00337-X; Whalen WA, 1997, YEAST, V13, P1167, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1167::AID-YEA154>3.3.CO;2-F; Wiegand HL, 2002, MOL CELL BIOL, V22, P245, DOI 10.1128/MCB.22.1.245-256.2002; Yoon JH, 2000, MOL CELL BIOL, V20, P8767, DOI 10.1128/MCB.20.23.8767-8782.2000; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200	59	102	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20979	20988		10.1074/jbc.M302061200	http://dx.doi.org/10.1074/jbc.M302061200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637516	hybrid			2022-12-27	WOS:000183230500070
J	Duval, M; Bedard-Goulet, S; Delisle, C; Gratton, JP				Duval, M; Bedard-Goulet, S; Delisle, C; Gratton, JP			Vascular endothelial growth factor-dependent down-regulation of Flk-1/KDR involves Cbl-mediated ubiquitination - Consequences on nitric oxide production from endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; FACTOR RECEPTOR; C-CBL; ACTIN REORGANIZATION; SIGNALING PATHWAYS; EGF RECEPTOR; P85 SUBUNIT; IN-VIVO; ACTIVATION; PHOSPHORYLATION	Ligand-stimulated degradation of receptor tyrosine kinase (RTK) is an important regulatory step of signal transduction. The vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is responsible for the VEGF-stimulated nitric oxide (NO) production from endothelial cells. Cellular mechanisms mediating the negative regulation of Flk-1 signaling in endothelial cells have not been investigated. Here we show that Flk-1 is rapidly down-regulated following VEGF stimulation of bovine aortic endothelial cells (BAECs). Consequently, VEGF pretreatment of endothelial cells prevents any further stimulation of Flk-1, resulting in decreased NO production from subsequent VEGF challenges. Ubiquitination of RTKs targets them for degradation; we demonstrate that activation of Flk-1 by VEGF leads to its polyubiquitination in BAECs. Furthermore, VEGF stimulation of BAECs or COS-7 cells transiently transfected with Flk-1 results in the phosphorylation of the ubiquitin ligase Cbl, the enhanced association of Cbl with Flk-1, and the relocalization of Cbl to vesicular structures in BAECs. Overexpression of Cbl in COS-7 cells enhances VEGF-induced ubiquitination of Flk-1, whereas a Cbl mutant lacking the ubiquitin ligase RING finger domain, 70Z/3-Cbl, does not. Moreover, expression of Cbl in contrast to 70Z/3-Cbl inhibits the Flk-1-dependent activation of eNOS and, thus, NO release. In BAEC overexpressing Cbl, the degradation of Flk-1 upon VEGF stimulation is accelerated compared with cells transfected with a control vector (green fluorescent protein). Our findings demonstrate that Flk-1 is rapidly down-regulated following sustained VEGF stimulation and identify Cbl as a negative regulator of Flk-1 signaling to eNOS. Cbl thus plays a role in the regulation of VEGF signaling by mediating the stimulated ubiquitination and, consequently, degradation of Flk-1 in endothelial cells.	Inst Rech Clin Montreal, Lan Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Gratton, JP (corresponding author), Inst Rech Clin Montreal, Lan Endothelial Cell Biol, 110 Pins Ave W, Montreal, PQ H2W 1R7, Canada.	jean-philippe.gratton@ircm.qc.ca		Gratton, Jean-Philippe/0000-0001-9877-8520; Bedard-Goulet, Sara/0000-0002-7966-8569				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; Bonita DP, 1997, MOL CELL BIOL, V17, P4597, DOI 10.1128/MCB.17.8.4597; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; D'Angelo G, 1999, MOL ENDOCRINOL, V13, P692, DOI 10.1210/me.13.5.692; de Melker AA, 2001, J CELL SCI, V114, P2167; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Doanes AM, 1999, BIOCHEM BIOPH RES CO, V255, P545, DOI 10.1006/bbrc.1999.0227; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fukumura D, 2001, P NATL ACAD SCI USA, V98, P2604, DOI 10.1073/pnas.041359198; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GALLAND F, 1993, ONCOGENE, V8, P1233; Gelinas DS, 2002, BRIT J PHARMACOL, V137, P1021, DOI 10.1038/sj.bjp.0704956; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; JONGEWARD GD, 1995, GENETICS, V139, P1553; Kallies A, 2002, BLOOD, V99, P3213, DOI 10.1182/blood.V99.9.3213; Kovala AT, 2000, FASEB J, V14, P2486, DOI 10.1096/fj.00-0147com; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Marengere LEM, 1997, J IMMUNOL, V159, P70; Matsumoto T, 2001, Sci STKE, V2001, pre21, DOI 10.1126/stke.2001.112.re21; Miao H, 2002, BIOCHEM BIOPH RES CO, V292, P892, DOI 10.1006/bbrc.2002.6750; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Ratcliffe KE, 2002, ONCOGENE, V21, P6307, DOI 10.1038/sj.onc.1205781; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thien CBF, 1997, ONCOGENE, V15, P2909, DOI 10.1038/sj.onc.1201468; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	44	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20091	20097		10.1074/jbc.M301410200	http://dx.doi.org/10.1074/jbc.M301410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649282	hybrid			2022-12-27	WOS:000183078000067
J	Marszal, E; Danino, D; Shrake, A				Marszal, E; Danino, D; Shrake, A			A novel mode of polymerization of alpha(1)-proteinase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ALPHA-1-PROTEINASE INHIBITOR; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; CONFORMATIONAL DISEASE; ALPHA-1-ANTITRYPSIN; ALPHA(1)-ANTITRYPSIN; SERPINS; LIVER; DEFICIENCY	Patients homozygous for the Z mutant form of alpha(1)-proteinase inhibitor (alpha(1)-PI) have an increased risk for the development of liver disease because of the accumulation in hepatocytes of inclusion bodies containing linear polymers of mutant alpha(1)-PI. The most widely accepted model of polymerization proposes that a linear, head-to-tail polymer forms by sequential insertion of the reactive center loop (RCL) of one alpha(1)-PI monomer between the central strands of the A beta-sheet of an adjacent monomer. This model derives primarily from two observations: peptides that are homologous with the RCL insert into the A beta-sheet of alpha(1)-PI monomer and this insertion prevents alpha(1)-PI polymerization. Normal alpha(1)-PI monomer does not spontaneously polymerize; however, here we show that the disulfide-linked dimer of normal alpha(1)-PI spontaneously forms linear polymers in buffer. The monomers within this dimer are joined head-to-head. Thus, the arrangement of monomers in these polymers must be different from that predicted by the loop-A sheet model. Therefore, we propose a new model for alpha(1)-PI polymer. In addition, polymerization of disulfide-linked dimer is not inhibited by the presence of the peptide even though dimer appears to interact with the peptide. Thus, RCL insertion into A beta-sheets may not occur during polymerization of this dimer.	US FDA, Ctr Biol Evaluat & Res, Div Hematol, Off Blood Res & Review, Bethesda, MD 20892 USA; NIDDK, Lab Cell Biochem & Biol, NIH, Bethesda, MD 20892 USA	US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shrake, A (corresponding author), US FDA, Ctr Biol Evaluat & Res, Div Hematol, Off Blood Res & Review, Bethesda, MD 20892 USA.		Danino, Dganit/D-6832-2016	Danino, Dganit/0000-0002-9782-4940				BATHURST IC, 1984, FEBS LETT, V177, P179, DOI 10.1016/0014-5793(84)81279-X; BAUMANN U, 1991, J MOL BIOL, V218, P595, DOI 10.1016/0022-2836(91)90704-A; Beleski-Carneiro EB, 1999, INT J BIOL MACROMOL, V26, P219, DOI 10.1016/S0141-8130(99)00086-0; BRANTLY M, 1988, AM J MED, V84, P13; BRUCH M, 1988, J BIOL CHEM, V263, P16626; Carrell RW, 1996, CHEST, V110, pS243, DOI 10.1378/chest.110.6_Supplement.243S; CARRELL RW, 1991, NATURE, V353, P576, DOI 10.1038/353576a0; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; CHASE T, 1967, BIOCHEM BIOPH RES CO, V29, P508, DOI 10.1016/0006-291X(67)90513-X; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DOTY P, 1953, PROTEINS           A, V1, P393; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; ERIKSSON S, 1975, NEW ENGL J MED, V292, P176, DOI 10.1056/NEJM197501232920403; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FRAIZER GC, 1989, AM J HUM GENET, V44, P894; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; Heyer AG, 1998, CARBOHYD RES, V313, P165, DOI 10.1016/S0008-6215(98)00281-X; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Janciauskiene S, 2001, BBA-MOL BASIS DIS, V1535, P221, DOI 10.1016/S0925-4439(01)00025-4; JEPPSSON JO, 1976, FEBS LETT, V65, P195, DOI 10.1016/0014-5793(76)80478-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kang HA, 1997, J BIOL CHEM, V272, P510; Laurell CB, 1979, CHEM PHYSL HUMAN PLA, P329; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LOMAS DA, 1993, BIOCHEMISTRY-US, V32, P500, DOI 10.1021/bi00053a014; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; LOMAS DA, 1995, J BIOL CHEM, V270, P5282, DOI 10.1074/jbc.270.10.5282; Mahadeva R, 1999, J CLIN INVEST, V103, P999, DOI 10.1172/JCI4874; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MCELVANEY NG, 1997, LUNG SCI FDN, P2537; MEMORANDA, 1997, B WHO, V75, P397; Morrison ED, 2000, POSTGRAD MED, V107, P147, DOI 10.3810/pgm.2000.02.872; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; Pace C N, 1986, Methods Enzymol, V131, P266; Perlmutter D H, 2000, Clin Liver Dis, V4, P387, DOI 10.1016/S1089-3261(05)70115-X; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; RINEHART AR, 1993, AM J RESP CELL MOL, V9, P666, DOI 10.1165/ajrcmb/9.6.666; SCHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48, DOI 10.1038/nsb0194-48; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; Sharp AM, 1999, STRUCTURE, V7, P111, DOI 10.1016/S0969-2126(99)80018-5; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sreerama N, 1999, PROTEIN SCI, V8, P370; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; Tran ST, 2001, ARCH BIOCHEM BIOPHYS, V385, P322, DOI 10.1006/abbi.2000.2186; Villain-Simonnet A, 2000, INT J BIOL MACROMOL, V27, P65, DOI 10.1016/S0141-8130(99)00120-8; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; 2002, CDPRO SOFTWARE PACKA	58	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19611	19618		10.1074/jbc.M210720200	http://dx.doi.org/10.1074/jbc.M210720200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649292	hybrid			2022-12-27	WOS:000183078000008
J	Savina, A; Furlan, M; Vidal, M; Colombo, MI				Savina, A; Furlan, M; Vidal, M; Colombo, MI			Exosome release is regulated by a calcium-dependent mechanism in K562 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFERRIN RECEPTOR; SIGNAL-TRANSDUCTION; SECRETORY GRANULES; MONENSIN; EXOCYTOSIS; PATHWAY; INSULIN; RETICULOCYTES; CA2+-ATPASE; ENDOCYTOSIS	Multivesicular bodies (MVBs) are endocytic structures that contain small vesicles formed by the budding of an endosomal membrane into the lumen of the compartment. Fusion of MVBs with the plasma membrane results in secretion of the small internal vesicles termed exosomes. K562 cells are a hematopoietic cell line that releases exosomes. The application of monensin (MON) generated large MVBs that were labeled with a fluorescent lipid. Exosome release was markedly enhanced by MON treatment, a Na+/H+ exchanger that induces changes in intracellular calcium (Ca2+). To explore the possibility that the effect of MON on exosome release was caused via an increase in Ca2+, we have used a calcium ionophore and a chelator of intracellular Ca2+. Our results indicate that increasing intracellular Ca2+ stimulates exosome secretion. Furthermore, MON-stimulated exosome release was completely eliminated by 1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid acetoxymethyl ester (BAPTA-AM), implying a requirement for Ca2+ in this process. We have observed that the large MVBs generated in the presence of MON accumulated Ca2+ as determined by labeling with Fluo3-AM, suggesting that intralumenal Ca2+ might play a critical role in the secretory process. Interestingly, our results indicate that transferrin (Tf) stimulated exosome release in a Ca2+-dependent manner, suggesting that Tf might be a physiological stimulus for exosome release in K562 cells.	Univ Nacl Cuyo, Fac Ciencias Med, IHEM,CONICET, Lab Biol Celular & Mol, RA-5500 Mendoza, Argentina; Univ Montpellier 2, Unite Mixte Rech 5539, F-34095 Montpellier, France	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Universite de Montpellier	Colombo, MI (corresponding author), Univ Nacl Cuyo, Fac Ciencias Med, IHEM,CONICET, Lab Biol Celular & Mol, Casilla de Correo 56, RA-5500 Mendoza, Argentina.	mcolombo@fmed2.uncu.edu.ar						Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Beraldo FH, 2001, CELL CALCIUM, V29, P439, DOI 10.1054/ceca.2001.0207; BLONDEL O, 1994, P NATL ACAD SCI USA, V91, P7777, DOI 10.1073/pnas.91.16.7777; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; Christensen KA, 2002, J CELL SCI, V115, P599; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Clayton A, 2001, J IMMUNOL METHODS, V247, P163, DOI 10.1016/S0022-1759(00)00321-5; Cullen PJ, 2002, NAT REV MOL CELL BIO, V3, P339, DOI 10.1038/nrm808; Denzer K, 2000, J CELL SCI, V113, P3365; Domotor E, 1999, J PHYSIOL-LONDON, V515, P147, DOI 10.1111/j.1469-7793.1999.147ad.x; FITTSCHEN C, 1991, J LEUKOCYTE BIOL, V50, P517, DOI 10.1002/jlb.50.5.517; Gerber SH, 2002, DIABETES, V51, pS3, DOI 10.2337/diabetes.51.2007.S3; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; HARDING C, 1984, EUR J CELL BIOL, V35, P256; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HO IK, 1969, J NEUROCHEM, V16, P1505, DOI 10.1111/j.1471-4159.1969.tb09905.x; IZUMI F, 1986, BIOCHEM PHARMACOL, V35, P2937, DOI 10.1016/0006-2952(86)90489-2; JOHNSTONE RM, 1989, BLOOD, V74, P1844; Johnstone RM, 1996, J CELL PHYSIOL, V168, P333, DOI 10.1002/(SICI)1097-4652(199608)168:2<333::AID-JCP12>3.0.CO;2-4; JOHNSTONE RM, 1991, J CELL PHYSIOL, V147, P27, DOI 10.1002/jcp.1041470105; Knight DE, 2002, TRAFFIC, V3, P298, DOI 10.1034/j.1600-0854.2002.030407.x; Kohgo Y, 2002, INT J HEMATOL, V76, P213, DOI 10.1007/BF02982790; KOK JW, 1990, EUR J CELL BIOL, V53, P173; Marta CB, 2002, J NEUROSCI RES, V69, P488, DOI 10.1002/jnr.10317; Martinez JR, 1996, BIOCHEM J, V320, P627, DOI 10.1042/bj3200627; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; Mills IG, 2001, J CELL SCI, V114, P1959; Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0; NASSARGENTINA V, 1994, CELL CALCIUM, V16, P475, DOI 10.1016/0143-4160(94)90077-9; Passos APD, 1998, BIOCHEM BIOPH RES CO, V245, P155, DOI 10.1006/bbrc.1998.8338; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; PRESSMAN BC, 1976, ANNU REV BIOCHEM, V45, P501, DOI 10.1146/annurev.bi.45.070176.002441; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Reinhardt TA, 2000, AM J PHYSIOL-CELL PH, V279, pC1595, DOI 10.1152/ajpcell.2000.279.5.C1595; Rizzuto R, 2001, CURR OPIN NEUROBIOL, V11, P306, DOI 10.1016/S0959-4388(00)00212-9; Sainte-Marie J, 1997, EUR J BIOCHEM, V250, P689, DOI 10.1111/j.1432-1033.1997.00689.x; Savina A, 2002, J CELL SCI, V115, P2505; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Sorin A, 1997, J BIOL CHEM, V272, P9895; STEIN BS, 1984, J BIOL CHEM, V259, P4762; Stoorvogel W, 2002, TRAFFIC, V3, P321, DOI 10.1034/j.1600-0854.2002.30502.x; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; THORSTENSEN K, 1993, SCAND J CLIN LAB INV, V53, P113, DOI 10.3109/00365519309090703; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Vidal M, 1997, J CELL SCI, V110, P1867; VIDAL M, 1995, BIOCHEM MOL BIOL INT, V35, P889; Wang XD, 1999, J INVEST MED, V47, P388; Wasle B, 2002, CELL SIGNAL, V14, P191, DOI 10.1016/S0898-6568(01)00257-1; Zitvogel L, 1998, NAT MED, V4, P594, DOI 10.1038/nm0598-594	54	540	555	6	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20083	20090		10.1074/jbc.M301642200	http://dx.doi.org/10.1074/jbc.M301642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639953	hybrid			2022-12-27	WOS:000183078000066
J	Sharma, P; Fatma, N; Kubo, E; Shinohara, T; Chylack, LT; Singh, DP				Sharma, P; Fatma, N; Kubo, E; Shinohara, T; Chylack, LT; Singh, DP			Lens epithelium-derived growth factor relieves transforming growth factor-beta 1-induced transcription repression of heat shock proteins in human lens epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN AQUEOUS-HUMOR; FACTOR-BETA; OXIDATIVE-STRESS; GENE-EXPRESSION; DOWN-REGULATION; MATRIX METALLOPROTEINASE-1; FIBER DIFFERENTIATION; APAF-1 APOPTOSOME; AKR-2B CELLS; FACTOR LEDGF	Lens epithelium-cell derived growth factor ( LEDGF) is a transcriptional activator. It protects the cells by binding to cis-stress response ((A/T) GGGG(T/A)), and heat shock (HSE; nGAAn) elements in the stress genes and activating their transcription. Transforming growth factor-beta(TGF-beta) has been implicated in the control of tissue homeostasis, terminal differentiation, and apoptosis. Here we provide evidence that TGF-beta1 down-regulates LEDGF expression and diminishes its affinity for DNA during TGF-beta1-induced phenotypic changes and apoptosis in human lens epithelial cells. Surprisingly, TGF-beta1 treatment for 48 h markedly decreased the LEDGF, Hsp27, and alphaB-crystallin promoter activities with the decrease of abundance of LEDGF mRNA and protein. Deletion mutants of the LEDGF promoter showed that one TGF-beta1 inhibitory element (TIE) like sequence nnnTTGGnnn (-444 to -433) contributed to this negative regulation. Mutation of TIE ( TTGG to TATT) abolished the down-regulation of the LEDGF promoter. Gel mobility and supershift assays showed that LEDGF in the nuclear extracts of TGF-beta1-treated human lens epithelial cells did not bind to stress-response elements and HSE. The TGF-beta1-induced down-regulation of LEDGF, Hsp27, and alphaB-crystallin promoters activity was reversed by cotransfection with a plasmid expressing LEDGF. Because overexpression of LEDGF was able to relieve TGF-beta1 and/or stress-induced changes, it would be a candidate molecule to postpone age-related degenerating disorders.	Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Ophthalm Res, Boston, MA 02115 USA; Fukui Med Univ, Dept Ophthalmol, Fukui 9101193, Japan	University of Nebraska System; University of Nebraska Medical Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Fukui	Singh, DP (corresponding author), Univ Nebraska, Med Ctr, Dept Ophthalmol, Wittsin Hall,Rm 2008-9, Omaha, NE 68198 USA.	dpsingh@unmc.edu		Shinohara, Toshimichi/0000-0002-7197-9039	NEI NIH HHS [EY13394-01A1] Funding Source: Medline; PHS HHS [GA01051] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013394] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahuja P, 2001, NEUROREPORT, V12, P2951, DOI 10.1097/00001756-200109170-00039; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BARLTROP JA, 1991, BIOORG MED CHEM LETT, V1, P611, DOI 10.1016/S0960-894X(01)81162-8; BASSNETT S, 1992, DEV DYNAM, V194, P85, DOI 10.1002/aja.1001940202; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bidwell JP, 1998, J BONE MINER RES, V13, P155, DOI 10.1359/jbmr.1998.13.2.155; BONIFACINO JS, 1999, CURRENT PROTOCOLS CE, V1; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG LY, 1994, ANTICANCER RES, V14, P147; CONNOR AM, 1989, BIOCHIM BIOPHYS ACTA, V1009, P75, DOI 10.1016/0167-4781(89)90081-X; COUSINS SW, 1991, INVEST OPHTH VIS SCI, V32, P2201; Dahm R, 1998, EUR J CELL BIOL, V75, P237, DOI 10.1016/S0171-9335(98)80118-0; Dahm R, 1997, BIOCHEM SOC T, V25, pS584, DOI 10.1042/bst025s584; Dahm R, 1999, OPHTHALMIC RES, V31, P163, DOI 10.1159/000055530; De Iongh RU, 2001, EXP EYE RES, V72, P649, DOI 10.1006/exer.2001.1001; de Longh RU, 2001, DEVELOPMENT, V128, P3995; EINSTEIN R, 1991, CURR EYE RES, V10, P157; Fatma N, 2001, J BIOL CHEM, V276, P48899, DOI 10.1074/jbc.M100733200; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GRANSTEIN RD, 1990, J IMMUNOL, V144, P3021; HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091; HALES AM, 1995, INVEST OPHTH VIS SCI, V36, P1709; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; HOWE PH, 1989, BIOCHEM J, V261, P879, DOI 10.1042/bj2610879; Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JAMPEL HD, 1990, CURR EYE RES, V9, P963, DOI 10.3109/02713689009069932; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; JONES CM, 1991, DEVELOPMENT, V111, P531; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; Kidd VJ, 1998, ANNU REV PHYSIOL, V60, P533, DOI 10.1146/annurev.physiol.60.1.533; Kubo E, 2002, J MOL BIOL, V320, P1053, DOI 10.1016/S0022-2836(02)00551-X; KUROSAKA D, 1994, INVEST OPHTH VIS SCI, V35, P3408; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Lim JM, 2001, BIOCHEM BIOPH RES CO, V284, P33; LIN JK, 1992, CANCER RES, V52, P385; LIU J, 1994, INVEST OPHTH VIS SCI, V35, P388; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087; Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Matsui H, 2001, INVEST OPHTH VIS SCI, V42, P2935; MCAVOY JW, 1998, INVEST OPHTH VIS SCI, V39, P7; Mostert V, 1999, FEBS LETT, V460, P23, DOI 10.1016/S0014-5793(99)01298-3; MURTHY US, 1988, BIOCHEM BIOPH RES CO, V152, P1228, DOI 10.1016/S0006-291X(88)80416-9; Nakamura M, 2000, INVEST OPHTH VIS SCI, V41, P1168; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OBERHAMMER F, 1993, HEPATOLOGY, V18, P1238; Oberhammer F, 1996, MICROSC RES TECHNIQ, V34, P247, DOI 10.1002/(SICI)1097-0029(19960615)34:3<247::AID-JEMT7>3.0.CO;2-M; Parsell D.A., 1994, BIOL HEAT SHOCK PROT, P457; Ritter SJ, 1998, J BIOL CHEM, V273, P12798, DOI 10.1074/jbc.273.21.12798; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schroen DJ, 1996, GENE EXPRESSION, V6, P197; Sharma P, 2000, BIOCHEM BIOPH RES CO, V276, P1320, DOI 10.1006/bbrc.2000.3606; Singh DP, 2000, BIOCHEM BIOPH RES CO, V267, P373, DOI 10.1006/bbrc.1999.1979; Singh DP, 1999, INVEST OPHTH VIS SCI, V40, P1444; Singh DP, 2000, GENE, V242, P265, DOI 10.1016/S0378-1119(99)00506-5; Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887; SINGH DP, 2002, INVESTIG OPHTHALMO S, V2345, P342; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; STEVENSON BJ, 1986, NUCLEIC ACIDS RES, V14, P8307, DOI 10.1093/nar/14.21.8307; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; TRIPATHI BJ, 1991, AM J ANAT, V192, P442, DOI 10.1002/aja.1001920411; White LA, 2000, BBA-GENE STRUCT EXPR, V1490, P259, DOI 10.1016/S0167-4781(00)00002-6; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Wride MA, 1999, DEV BIOL, V213, P142, DOI 10.1006/dbio.1999.9375; Wride MA, 2000, APOPTOSIS, V5, P203, DOI 10.1023/A:1009653326511; Wu X, 2002, CELL DEATH DIFFER, V9, P915, DOI 10.1038/sj.cdd.4401063; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200; Yokouchi Y, 1996, DEVELOPMENT, V122, P3725; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zou HY, 1996, SCIENCE, V272, P738, DOI 10.1126/science.272.5262.738	81	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20037	20046		10.1074/jbc.M212016200	http://dx.doi.org/10.1074/jbc.M212016200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649267	hybrid			2022-12-27	WOS:000183078000061
J	Vella, F; Thielens, NM; Bersch, B; Arlaud, GJ; Frachet, P				Vella, F; Thielens, NM; Bersch, B; Arlaud, GJ; Frachet, P			A recombinant chimeric epidermal growth factor-like module with high binding affinity for integrins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; POLYMERASE CHAIN-REACTION; GLYCOPROTEIN IIB-IIIA; ALPHA-V INTEGRINS; CELL-ADHESION; CRYSTAL-STRUCTURE; EXTRACELLULAR SEGMENT; CHEMICAL SYNTHESIS; BACKBONE DYNAMICS; OVERLAP EXTENSION	Integrins are cell surface receptors involved in numerous pathological processes such as metastasis invasion and abnormal angiogenesis. To target these receptors, the epidermal growth factor (EGF)-like domain of human complement protease C1r was used as a natural scaffold to design chimeric modules containing the RGD motif. Here we report a high yield bacterial expression system and its application to the production of two such modules, EGF-RGD and V2, the latter variant mimicking the RGD-containing domain of disintegrins. These modules were characterized chemically, and their biological activity was investigated by cellular assays using various Chinese hamster ovary cell lines expressing beta(1) and beta(3) integrins and by surface plasmon resonance spectroscopy. Remarkably, the modifications leading to the V2 variant had differential effects on the interaction with beta(3) and beta(1) integrins. The disintegrin-like V2 module exhibited enhanced binding affinities compared with EGF-RGD, with K-D values of 7.2 nM for alpha(5)beta(1) ( a 4-fold decrease) and 3.5 nM for alpha(v)beta(3) (a 1.5-fold decrease), comparable with the values determined for natural integrin ligands. Analysis by NMR spectroscopy also revealed a differential dynamic behavior of the RGD motif in the EGF-RGD and V2 variants, providing insights into the structural basis of their relative binding efficiency. These novel RGD-containing EGF modules open the way to the design of improved variants with selective affinity for particular integrins and their use as carriers for other biologically active modules.	Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, CNRS,CEA, F-38027 Grenoble 1, France; Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Resonance Magnet Nucl, CNRS,CEA, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Frachet, P (corresponding author), Univ Grenoble 1, Inst Biol Struct Jean Pierre Ebel, Lab Enzymol Mol, CNRS,CEA, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.		Thielens, Nicole M/F-2512-2013; frachet, philippe/Q-2869-2019; Bersch, Beate/A-7011-2013; Frachet, philippe/C-3797-2018	Thielens, Nicole M/0000-0002-7354-0302; frachet, philippe/0000-0002-1658-3859; Bersch, Beate/0000-0003-1138-4911; Frachet, philippe/0000-0002-1658-3859				AOTA S, 1994, J BIOL CHEM, V269, P24756; ARLAUD GJ, 1977, BIOCHIM BIOPHYS ACTA, V485, P215, DOI 10.1016/0005-2744(77)90208-X; Bersch B, 1998, BIOCHEMISTRY-US, V37, P1204, DOI 10.1021/bi971851v; Blobel Carl P., 1992, Current Opinion in Cell Biology, V4, P760; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Carr PA, 1997, STRUCTURE, V5, P949, DOI 10.1016/S0969-2126(97)00248-7; Colin M, 2000, GENE THER, V7, P139, DOI 10.1038/sj.gt.3301056; Copie V, 1998, J MOL BIOL, V277, P663; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768; Eliceiri BP, 1999, J CLIN INVEST, V103, P1227, DOI 10.1172/JCI6869; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Felding-Habermann B, 2001, P NATL ACAD SCI USA, V98, P1853, DOI 10.1073/pnas.98.4.1853; FRACHET P, 1992, BIOCHEMISTRY-US, V31, P2408, DOI 10.1021/bi00123a028; FRACHET P, 1990, MOL BIOL REP, V14, P27, DOI 10.1007/BF00422712; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; HANTGAN RR, 1992, THROMB HAEMOSTASIS, V68, P694; Hernandez JF, 1997, J PEPT RES, V49, P221; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hu B, 2000, BIOCHEMISTRY-US, V39, P12284, DOI 10.1021/bi000144q; Hu DD, 1996, J BIOL CHEM, V271, P21745, DOI 10.1074/jbc.271.36.21745; HUBER W, 1995, EUR J BIOCHEM, V227, P647, DOI 10.1111/j.1432-1033.1995.tb20184.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 1996, J CLIN INVEST, V98, P2193, DOI 10.1172/JCI119027; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jansson M, 1996, J BIOMOL NMR, V7, P131; Jenkins RG, 2000, GENE THER, V7, P393, DOI 10.1038/sj.gt.3301095; JOURNET A, 1986, BIOCHEM J, V240, P783, DOI 10.1042/bj2400783; Kamata T, 1996, J BIOL CHEM, V271, P18610, DOI 10.1074/jbc.271.31.18610; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Marcinkiewicz C, 1997, BLOOD, V90, P1565, DOI 10.1182/blood.V90.4.1565.1565_1565_1575; Markley JL, 1998, J MOL BIOL, V280, P933, DOI 10.1006/jmbi.1998.1852; Mizejewski GJ, 1999, P SOC EXP BIOL MED, V222, P124, DOI 10.1046/j.1525-1373.1999.d01-122.x; O'Neal VK, 2000, MOL MED, V6, P179, DOI 10.1007/BF03402113; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; Parkes RJ, 2000, ADV DRUG DELIVER REV, V44, P135, DOI 10.1016/S0169-409X(00)00091-0; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; PFAFF M, 1994, EUR J BIOCHEM, V225, P975, DOI 10.1111/j.1432-1033.1994.0975b.x; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Rossi V, 1998, J BIOL CHEM, V273, P1232, DOI 10.1074/jbc.273.2.1232; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Ruoslahti E, 1999, ADV CANCER RES, V76, P1, DOI 10.1016/S0065-230X(08)60772-1; SAUDEK V, 1991, EUR J BIOCHEM, V202, P329, DOI 10.1111/j.1432-1033.1991.tb16380.x; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Vella F, 1999, J PEPT RES, V54, P415, DOI 10.1034/j.1399-3011.1999.00137.x; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	57	6	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19834	19843		10.1074/jbc.M301470200	http://dx.doi.org/10.1074/jbc.M301470200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654911	hybrid			2022-12-27	WOS:000183078000035
J	Volz, A; Ehlers, A; Younger, R; Forbes, S; Trowsdale, J; Schnorr, D; Beck, S; Ziegler, A				Volz, A; Ehlers, A; Younger, R; Forbes, S; Trowsdale, J; Schnorr, D; Beck, S; Ziegler, A			Complex transcription and splicing of odorant receptor genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PUTATIVE OLFACTORY RECEPTOR; GERM-CELLS; FUNCTIONAL IDENTIFICATION; MOLECULAR-MECHANISMS; MATING PREFERENCES; GENOMIC STRUCTURE; EXPRESSION; MOUSE; SEQUENCE	Human major histocompatibility ( human leucocyte antigen (HLA)) complex-linked odorant receptor ( OR) genes are among the best characterized OR genes in the human genome. In addition to their functions as odorant receptors in olfactory epithelium, they have been suggested to play a role in the fertilization process. Here, we report the first in-depth analysis of their expression and regulation within testicular tissue. Sixteen HLA-linked OR and three non-HLA-linked OR were analyzed. One OR gene ( hs6M1-16, in positive transcriptional orientation) exhibited six different transcriptional start sites combined with extensive alternative splicing within the 5'-untranslated region, the coding exon, and the 3'-untranslated region. Long distance splicing, exon sharing, and premature polyadenylation were features of another three OR loci ( hs6M1-18, -21, and -27, all upstream of hs6M1-16, but in negative transcriptional orientation). Determination of the transcriptional start sites of these OR genes identified a region of 81 bp with potential bi-directional transcriptional activity. The results demonstrate that HLA-linked OR genes are subject to unusually complex transcriptional regulatory mechanisms.	Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Humboldt Univ, Univ Klinikum Charite, Urol Klin, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Wellcome Trust Sanger Institute; University of Cambridge; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Ziegler, A (corresponding author), Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, Spandauer Damm 130, D-14050 Berlin, Germany.	andreas.ziegler@charite.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asai H, 1996, BIOCHEM BIOPH RES CO, V221, P240, DOI 10.1006/bbrc.1996.0580; Barth AL, 1997, NEURON, V19, P359, DOI 10.1016/S0896-6273(00)80945-9; Beaudoing E, 2000, GENOME RES, V10, P1001, DOI 10.1101/gr.10.7.1001; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; Borst P, 2002, CELL, V109, P5, DOI 10.1016/S0092-8674(02)00711-0; Boulanger LM, 2001, CURR OPIN NEUROBIOL, V11, P568, DOI 10.1016/S0959-4388(00)00251-8; Branscomb A, 2000, GENETICS, V156, P785; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Bulger M, 2000, P NATL ACAD SCI USA, V97, P14560, DOI 10.1073/pnas.97.26.14560; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; Dixon AK, 1998, NUCLEIC ACIDS RES, V26, P4426, DOI 10.1093/nar/26.19.4426; Down TA, 2002, GENOME RES, V12, P458, DOI 10.1101/gr.216102; Dreyer WJ, 1998, P NATL ACAD SCI USA, V95, P9072, DOI 10.1073/pnas.95.16.9072; Dreyer WJ, 1999, GENETICA, V107, P249, DOI 10.1023/A:1003909311678; DRUTEL G, 1995, RECEPTOR CHANNEL, V3, P33; Dryer L, 1999, TRENDS PHARMACOL SCI, V20, P413, DOI 10.1016/S0165-6147(99)01381-4; Dryer L, 2000, BIOESSAYS, V22, P803, DOI 10.1002/1521-1878(200009)22:9&lt;803::AID-BIES5&gt;3.0.CO;2-K; Ehlers A, 2000, GENOME RES, V10, P1968, DOI 10.1101/gr.10.12.1968; Fuchs T, 2001, HUM GENET, V108, P1, DOI 10.1007/s004390000436; Glusman G, 2001, GENOME RES, V11, P685, DOI 10.1101/gr.171001; Glusman G, 1996, GENOMICS, V37, P147, DOI 10.1006/geno.1996.0536; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Hecht NB, 1998, BIOESSAYS, V20, P555, DOI 10.1002/(SICI)1521-1878(199807)20:7<555::AID-BIES6>3.3.CO;2-J; Kim J, 2000, GENOMICS, V64, P114, DOI 10.1006/geno.1999.6112; Klingenhoff A, 1999, BIOINFORMATICS, V15, P180, DOI 10.1093/bioinformatics/15.3.180; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kyewski B, 2002, TRENDS IMMUNOL, V23, P364, DOI 10.1016/S1471-4906(02)02248-2; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lane RP, 2002, GENOME RES, V12, P81, DOI 10.1101/gr.197901; Lane RP, 2001, P NATL ACAD SCI USA, V98, P7390, DOI 10.1073/pnas.131215398; Lee SG, 2000, MOL CELLS, V10, P47, DOI 10.1007/s10059-000-0047-z; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Mombaerts P, 1996, CURR OPIN NEUROBIOL, V6, P481, DOI 10.1016/S0959-4388(96)80053-5; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mombaerts P, 2001, ANNU REV GENOM HUM G, V2, P493, DOI 10.1146/annurev.genom.2.1.493; Murrell JR, 1999, J NEUROSCI, V19, P8260; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; Penn D, 1998, ADV IMMUNOL, V69, P411, DOI 10.1016/S0065-2776(08)60612-4; Proudfoot N, 1996, CELL, V87, P779, DOI 10.1016/S0092-8674(00)81982-0; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rawson NE, 2000, J NEUROCHEM, V75, P185, DOI 10.1046/j.1471-4159.2000.0750185.x; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; Rouquier S, 1998, HUM MOL GENET, V7, P1337, DOI 10.1093/hmg/7.9.1337; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; SINGER MS, 1995, NATURE, V377, P19, DOI 10.1038/377019b0; Sosinsky A, 2000, GENOMICS, V70, P49, DOI 10.1006/geno.2000.6363; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; Tatsura H, 2001, FEBS LETT, V488, P139, DOI 10.1016/S0014-5793(00)02411-X; Touhara K, 1999, P NATL ACAD SCI USA, V96, P4040, DOI 10.1073/pnas.96.7.4040; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; Vanderhaeghen P, 1997, BIOCHEM BIOPH RES CO, V237, P283, DOI 10.1006/bbrc.1997.7043; Vanderhaeghen P, 1997, GENOMICS, V39, P239, DOI 10.1006/geno.1996.4490; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WALENSKY LD, 1995, MOL MED, V1, P130, DOI 10.1007/BF03401561; Walensky LD, 1998, J BIOL CHEM, V273, P9378, DOI 10.1074/jbc.273.16.9378; Wang F, 1998, CELL, V93, P47, DOI 10.1016/S0092-8674(00)81145-9; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; Wang SS, 1997, J NEUROSCI, V17, P4149; Wetzel CH, 1999, J NEUROSCI, V19, P7426, DOI 10.1523/JNEUROSCI.19-17-07426.1999; YAMAZAKI K, 1976, J EXP MED, V144, P1324, DOI 10.1084/jem.144.5.1324; Young JM, 2002, HUM MOL GENET, V11, P535, DOI 10.1093/hmg/11.5.535; Younger RM, 2001, GENOME RES, V11, P519, DOI 10.1101/gr.GR-1603R; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237; Ziegler A, 2000, MAJOR HISTOCOMPATIBILITY COMPLEX, P110; Ziegler A, 2002, AM J REPROD IMMUNOL, V48, P34, DOI 10.1034/j.1600-0897.2002.01097.x; Ziegler A, 2000, HUM IMMUNOL, V61, P1281, DOI 10.1016/S0198-8859(00)00219-6; ZIEGLER A, 2003, IN PRESS HLA 2002 IM; Zozulya S, 2001, GENOME BIOL, V2	74	28	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19691	19701		10.1074/jbc.M212424200	http://dx.doi.org/10.1074/jbc.M212424200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637542	hybrid			2022-12-27	WOS:000183078000018
J	Ma, DD; Zhou, P; Harbour, JW				Ma, DD; Zhou, P; Harbour, JW			Distinct mechanisms for regulating the tumor suppressor and antiapoptotic functions of Rb	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; CELL-CYCLE; UVEAL MELANOMA; G(1) CONTROL; G1 ARREST; PHOSPHORYLATION; E2F; INHIBITION; PRB	The retinoblastoma protein, Rb, suppresses tumorigenesis by inhibiting cell proliferation and promoting senescence and differentiation. Paradoxically, Rb also inhibits apoptosis, which would seem to oppose its tumor suppressor function. Further, most human cancer cells inactivate Rb by hyperphosphorylation and demonstrate increased proliferative capacity but not high levels of apoptosis. As a potential explanation for these findings, we show here that the tumor suppressor and antiapoptotic functions of Rb are regulated by distinct phosphorylation events. Phosphorylation of sites in the C terminus occurs efficiently every cell cycle and regulates proliferation. Phosphorylation of Ser(567) is inefficient and does not occur during the normal cell cycle. However, high cyclin-dependent kinase activity promotes phosphorylation of Ser(567) by inducing an intramolecular interaction that leads to release of E2F, degradation of Rb, and susceptibility to apoptosis. Thus, phosphorylation of Ser(567) may limit excessive proliferation by triggering cell death under hyperproliferative conditions. These findings suggest that the antiproliferative and antiapoptotic activities of Rb may represent complementary functions that work in concert to maintain the proliferation rate of cells within certain limits. As a survival strategy, some cancer cells may exploit this dual role of Rb by phosphorylating sites that regulate tumor suppression but avoiding phosphorylation of Ser(567) and consequent apoptotic stimulus.	Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Harbour, JW (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Campus Box 8069,660 S Euclid Ave, St Louis, MO 63110 USA.	harbour@vision.wustl.edu	Harbour, J. William/B-1448-2015	Harbour, J. William/0000-0002-1104-9809	NEI NIH HHS [R01 EY13169, K08 EY00382] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013169, K08EY000382] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Ashizawa S, 2001, J BIOL CHEM, V276, P11362, DOI 10.1074/jbc.M007992200; Berry DE, 1996, ONCOGENE, V12, P1809; Brantey MA, 2000, CANCER RES, V60, P4320; Brown VD, 1999, MOL CELL BIOL, V19, P3246; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Chen WD, 1997, ONCOGENE, V14, P1243, DOI 10.1038/sj.onc.1201096; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Ezhevsky SA, 1997, P NATL ACAD SCI USA, V94, P10699, DOI 10.1073/pnas.94.20.10699; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Harbour JW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1341, DOI 10.1001/archopht.120.10.1341; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KARANTZA V, 1993, MOL CELL BIOL, V13, P6640, DOI 10.1128/MCB.13.11.6640; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Lukas J, 1999, ONCOGENE, V18, P3930, DOI 10.1038/sj.onc.1202777; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; Pan WJ, 2001, CANCER RES, V61, P2885; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rigberg DA, 1999, J SURG RES, V84, P101, DOI 10.1006/jsre.1999.5617; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shackney SE, 1999, CYTOMETRY, V35, P97, DOI 10.1002/(SICI)1097-0320(19990201)35:2<97::AID-CYTO1>3.3.CO;2-X; Shan B, 1996, CELL GROWTH DIFFER, V7, P689; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Wang J, 1997, CANCER RES, V57, P351; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xin SJ, 2002, DEVELOPMENT, V129, P1345; Xu HJ, 1997, ONCOGENE, V15, P2589, DOI 10.1038/sj.onc.1201446; Yilmaz S, 1998, Hum Mutat, V12, P434, DOI 10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU16>3.3.CO;2-Z; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19358	19366		10.1074/jbc.M301761200	http://dx.doi.org/10.1074/jbc.M301761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646568	hybrid			2022-12-27	WOS:000182932200084
J	Meskiene, I; Baudouin, E; Schweighofer, A; Liwosz, A; Jonak, C; Rodriguez, PL; Jelinek, H; Hirt, H				Meskiene, I; Baudouin, E; Schweighofer, A; Liwosz, A; Jonak, C; Rodriguez, PL; Jelinek, H; Hirt, H			Stress-induced protein phosphatase 2C is a negative regulator of a mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID SIGNAL-TRANSDUCTION; MAP KINASE; TYROSINE-PHOSPHATASE; SUBSTRATE-SPECIFICITY; ARABIDOPSIS-THALIANA; ABI1; THREONINE; PATHWAYS; RESPONSES; CLONING	Protein phosphatases of type 2C (PP2Cs) play important roles in eukaryotic signal transduction. In contrast to other eukaryotes, plants such as Arabidopsis have an unusually large group of 69 different PP2C genes. At present, little is known about the functions and substrates of plant PP2Cs. We have previously shown that MP2C, a wound-induced alfalfa PP2C, is a negative regulator of mitogen-activated protein kinase (MAPK) pathways in yeast and plants. In this report, we provide evidence that alfalfa salt stress-inducible MAPK (SIMK) and stress-activated MAPK (SAMK) are activated by wounding and that MP2C is a MAPK phosphatase that directly inactivates SIMK but not the wound-activated MAPK, SAMK. SIMK is inactivated through threonine dephosphorylation of the pTEpY motif, which is essential for MAPK activity. Mutant analysis indicated that inactivation of SIMK depends on the catalytic activity of MP2C. A comparison of MP2C with two other PP2Cs, ABI2 and AtP2CHA, revealed that although all three phosphatases have similar activities toward casein as a substrate, only MP2C is able to dephosphorylate and inactivate SIMK. In agreement with the notion that MP2C interacts directly with SIMK, the MAPK was identified as an interacting partner of MP2C in a yeast two-hybrid screen. MP2C can be immunoprecipitated with SIMK in a complex in vivo and shows direct binding to SIMK in vitro in protein interaction assays. Wound-induced MP2C expression correlates with the time window when SIMK is inactivated, corroborating the notion that MP2C is involved in resetting the SIMK signaling pathway.	Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria; Univ Politecn Valencia, Inst Biol Mol & Cellular Plantas, SCIC, Valencia 46022, Spain	Vienna Biocenter (VBC); Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Meskiene, I (corresponding author), Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.	irute@gem.univie.ac.at	Hirt, Heribert/A-2061-2013; Jonak, Claudia/G-1362-2016; Rodriguez, Pedro L./K-4605-2014	Rodriguez, Pedro L./0000-0002-5886-9425; Jonak, Claudia/0000-0001-9605-6751; Schweighofer, Alois/0000-0002-8466-0924; baudouin, emmanuel/0000-0002-9716-4954				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bertauche N, 1996, EUR J BIOCHEM, V241, P193, DOI 10.1111/j.1432-1033.1996.0193t.x; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Bogre L, 1997, PLANT CELL, V9, P75, DOI 10.1105/tpc.9.1.75; Cardinale F, 2000, J BIOL CHEM, V275, P36734, DOI 10.1074/jbc.M007418200; Cardinale F, 2002, PLANT CELL, V14, P703, DOI 10.1105/tpc.010256; Cheong YH, 2002, PLANT PHYSIOL, V129, P661, DOI 10.1104/pp.002857; Cherel I, 2002, PLANT CELL, V14, P1133, DOI 10.1105/tpc.000943; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; James P, 1996, GENETICS, V144, P1425; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1998, SEMIN CELL DEV BIOL, V9, P143, DOI 10.1006/scdb.1997.0219; Kiegerl S, 2000, PLANT CELL, V12, P2247, DOI 10.1105/tpc.12.11.2247; KUROMORI T, 1994, NUCLEIC ACIDS RES, V22, P5296, DOI 10.1093/nar/22.24.5296; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; MAEDA T, 1993, MOL CELL BIOL, V13, P5408, DOI 10.1128/MCB.13.9.5408; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; Munnik T, 1999, PLANT J, V20, P381, DOI 10.1046/j.1365-313x.1999.00610.x; Nguyen AN, 1999, GENE DEV, V13, P1653, DOI 10.1101/gad.13.13.1653; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rodriguez PL, 1998, PLANT MOL BIOL, V38, P879, DOI 10.1023/A:1006012218704; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Seo S, 1999, PLANT CELL, V11, P289, DOI 10.1105/tpc.11.2.289; SEO S, 1995, SCIENCE, V270, P1988, DOI 10.1126/science.270.5244.1988; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; TOPFER R, 1987, NUCLEIC ACIDS RES, V15, P5890, DOI 10.1093/nar/15.14.5890; VANDELOCHT U, 1990, EMBO J, V9, P2945, DOI 10.1002/j.1460-2075.1990.tb07486.x; Warmka J, 2001, MOL CELL BIOL, V21, P51, DOI 10.1128/MCB.21.1.51-60.2001; WurglerMurphy SM, 1997, MOL CELL BIOL, V17, P1289, DOI 10.1128/MCB.17.3.1289; Zhang SQ, 1998, P NATL ACAD SCI USA, V95, P7225, DOI 10.1073/pnas.95.12.7225; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	46	130	156	2	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18945	18952		10.1074/jbc.M300878200	http://dx.doi.org/10.1074/jbc.M300878200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646559	hybrid			2022-12-27	WOS:000182932200031
J	Rodeheffer, MS; Shadel, GS				Rodeheffer, MS; Shadel, GS			Multiple interactions involving the amino-terminal domain of yeast mtRNA polymerase determine the efficiency of mitochondrial protein synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RNA-POLYMERASE; GENE-EXPRESSION; MEMBRANE; TRANSCRIPTION; RIBOSOMES; TRANSLATION; STABILITY; PRODUCT; INTRONS	The amino-terminal domain (ATD) of Saccharomyces cerevisiae mitochondrial RNA polymerase has been shown to provide a functional link between transcription and post-transcriptional events during mitochondrial gene expression. This connection is mediated in large part by its interactions with the matrix protein Nam1p and, based on genetic phenotypes, the mitochondrial membrane protein Sls1p. These observations led us to propose previously that mtRNA polymerase, Nam1p, and Sls1p work together to coordinate transcription and translation of mtDNA-encoded gene products. Here we demonstrate by specific labeling of mitochondrial gene products in vivo that Nam1p and Sls1p indeed work together in a pathway that is required globally for efficient mitochondrial translation. Likewise, mutations in the ATD result in similar global reductions in mitochondrial translation efficiency and sensitivity to the mitochondrial translation inhibitor erythromycin. These data, coupled with the observation that the ATD is required to co-purify Sls1p in association with mtDNA nucleoids, suggest that efficient expression of mtDNA-encoded genes in yeast involves a complex series of interactions that localize active transcription complexes to the inner membrane in order to coordinate translation with transcription.	Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Rollins Res Ctr, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA	Emory University; Emory University	Shadel, GS (corresponding author), Emory Univ, Sch Med, Rollins Res Ctr, Dept Biochem, Atlanta, GA 30322 USA.	gshadel@emory.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059655] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL059655, HL59655, R01 HL059655-05A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHER E B, 1989, Molecular and General Genetics, V215, P517, DOI 10.1007/BF00427051; Bryan AC, 2002, GENETICS, V160, P75; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; FOX TD, 1991, METHOD ENZYMOL, V194, P149; GREENLEAF AL, 1986, P NATL ACAD SCI USA, V83, P3391, DOI 10.1073/pnas.83.10.3391; GROUDINSKY O, 1993, MOL GEN GENET, V240, P419, DOI 10.1007/BF00280396; Kaufman BA, 2000, P NATL ACAD SCI USA, V97, P7772, DOI 10.1073/pnas.140063197; KURIYAMA Y, 1973, J CELL BIOL, V59, P776, DOI 10.1083/jcb.59.3.776; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; LISOWSKY T, 1990, MOL GEN GENET, V220, P186; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; MARZUKI S, 1986, BIOCHIM BIOPHYS ACTA, V866, P120, DOI 10.1016/0167-4781(86)90108-9; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Naithani S, 2003, MOL BIOL CELL, V14, P324, DOI 10.1091/mbc.E02-08-0490; O'Rourke TW, 2002, MOL CELL BIOL, V22, P4086, DOI 10.1128/MCB.22.12.4086-4093.2002; PEL HJ, 1993, MOL BIOL REP, V18, P1, DOI 10.1007/BF01006890; Poyton R O, 1996, Methods Enzymol, V264, P36, DOI 10.1016/S0076-6879(96)64006-3; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rodeheffer MS, 2001, J BIOL CHEM, V276, P8616, DOI 10.1074/jbc.M009901200; Rouillard JM, 1996, MOL GEN GENET, V252, P700, DOI 10.1007/s004380050279; Sambrook J., 2001, MOL CLONING LAB MANU; Sanchirico ME, 1998, EMBO J, V17, P5796, DOI 10.1093/emboj/17.19.5796; Shadel GS, 1999, AM J HUM GENET, V65, P1230, DOI 10.1086/302630; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPITHILL TW, 1978, MOL GEN GENET, V164, P155, DOI 10.1007/BF00267380; WALLIS MG, 1994, EUR J BIOCHEM, V222, P27, DOI 10.1111/j.1432-1033.1994.tb18837.x; Wang YH, 1999, P NATL ACAD SCI USA, V96, P8046, DOI 10.1073/pnas.96.14.8046; Zhang Y, 2000, RNA, V6, P937, DOI 10.1017/S1355838200991726	30	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18695	18701		10.1074/jbc.M301399200	http://dx.doi.org/10.1074/jbc.M301399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637560	Green Accepted, hybrid			2022-12-27	WOS:000182838300143
J	Singh, S; Zlotnick, A				Singh, S; Zlotnick, A			Observed hysteresis of virus capsid disassembly is implicit in kinetic models of assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT ASSOCIATION; PROTEIN; DISSOCIATION; PERSPECTIVE; PARTICLES; SURFACE	For many protein multimers, association and dissociation reactions fail to reach the same end point; there is hysteresis preventing one and/or the other reaction from equilibrating. We have studied in vitro assembly of dimeric hepatitis B virus (HBV) capsid protein and dissociation of the resulting T = 4 icosahedral capsids. Empty HBV capsids composed of 120 capsid protein dimers were more resistant to dissociation by dilution or denaturants than anticipated from assembly experiments. Using intrinsic fluorescence, circular dichroism, and size exclusion chromatography, we showed that denaturants dissociate the HBV capsids without unfolding the capsid protein; unfolding of dimer only occurred at higher denaturant concentrations. The apparent energy of interaction between dimers measured in dissociation experiments was much stronger than when measured in assembly studies. Unlike assembly, capsid dissociation did not have the concentration dependence expected for a 120-subunit complex; consequently the apparent association energy systematically varied with reactant concentration. These data are evidence of hysteresis for HBV capsid dissociation. Simulations of capsid assembly and dissociation reactions recapitulate and provide an explanation for the observed behavior; these results are also applicable to oligomeric and multidomain proteins. In our calculations, we find that dissociation is impeded by temporally elevated concentrations of intermediates; this has the paradoxical effect of favoring re-assembly of those intermediates despite the global trend toward dissociation. Hysteresis masks all but the most dramatic decreases in contact energy. In contrast, assembly reactions rapidly approach equilibrium. These results provide the first rigorous explanation of how virus capsids can remain intact under extreme conditions but are still capable of "breathing." A biological implication of enhanced stability is that a triggering event may be required to initiate virus uncoating.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	Zlotnick, A (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	adam-zlotnick@ouhsc.edu		Zlotnick, Adam/0000-0001-9945-6267				Bothner B, 1998, J BIOL CHEM, V273, P673, DOI 10.1074/jbc.273.2.673; Brooks CL, 1998, P NATL ACAD SCI USA, V95, P11037, DOI 10.1073/pnas.95.19.11037; Ceres P, 2002, BIOCHEMISTRY-US, V41, P11525, DOI 10.1021/bi0261645; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Clementi C, 1999, P NATL ACAD SCI USA, V96, P9616, DOI 10.1073/pnas.96.17.9616; CROWTHER RA, 1994, CELL, V77, P943, DOI 10.1016/0092-8674(94)90142-2; DAPOIAN AT, 1993, J MOL BIOL, V231, P999, DOI 10.1006/jmbi.1993.1347; DAVIS JM, 1993, J BIOL CHEM, V268, P25965; DILL KA, 1995, PROTEIN SCI, V4, P561; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Endres D, 2002, BIOPHYS J, V83, P1217, DOI 10.1016/S0006-3495(02)75245-4; Fasshauer D, 2002, NAT STRUCT BIOL, V9, P144, DOI 10.1038/nsb750; FERSHT AR, 1999, STRUCTURE MECH PROTE, P93; *HOUGHT MIFFL CO, 1996, AM HERITAGE DICT, P652; KENNEY JM, 1995, STRUCTURE, V3, P1009, DOI 10.1016/S0969-2126(01)00237-4; Lewis JK, 1998, P NATL ACAD SCI USA, V95, P6774, DOI 10.1073/pnas.95.12.6774; LI QH, 1994, J VIROL, V68, P3965, DOI 10.1128/JVI.68.6.3965-3970.1994; ONUCHIC JN, 1995, P NATL ACAD SCI USA, V92, P3626, DOI 10.1073/pnas.92.8.3626; Oosawa F., 1975, THERMODYNAMICS POLYM; Pace C N, 1986, Methods Enzymol, V131, P266; Pace CN, 2000, PROTEINS, P1; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; SILVA JL, 1988, J MOL BIOL, V199, P149, DOI 10.1016/0022-2836(88)90385-3; STANNARD LM, 1979, J GEN VIROL, V45, P509, DOI 10.1099/0022-1317-45-2-509; THOMSEN JS, 1953, PHYS REV, V91, P1263, DOI 10.1103/PhysRev.91.1263; Tsang SK, 2001, J VIROL, V75, P4984, DOI 10.1128/JVI.75.11.4984-4989.2001; Watts NR, 2002, EMBO J, V21, P876, DOI 10.1093/emboj/21.5.876; Weber G, 1996, BIOPHYS J, V70, P167, DOI 10.1016/S0006-3495(96)79557-7; WINGFIELD PT, 1995, BIOCHEMISTRY-US, V34, P4919, DOI 10.1021/bi00015a003; Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5; Zlotnick A, 1999, BIOCHEMISTRY-US, V38, P14644, DOI 10.1021/bi991611a; ZLOTNICK A, 1994, J MOL BIOL, V241, P59, DOI 10.1006/jmbi.1994.1473; Zlotnick A, 2002, J VIROL, V76, P4848, DOI 10.1128/JVI.76.10.4848-4854.2002; Zlotnick A, 1996, BIOCHEMISTRY-US, V35, P7412, DOI 10.1021/bi9604800	35	122	122	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18249	18255		10.1074/jbc.M211408200	http://dx.doi.org/10.1074/jbc.M211408200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639968	hybrid			2022-12-27	WOS:000182838300087
J	Yang, SW; Kim, DH; Lee, JJ; Chun, YJ; Lee, JH; Kim, YJ; Chung, IK; Kim, WT				Yang, SW; Kim, DH; Lee, JJ; Chun, YJ; Lee, JH; Kim, YJ; Chung, IK; Kim, WT			Expression of the telomeric repeat binding factor gene NgTRF1 is closely coordinated with the cell division program in tobacco BY-2 suspension culture cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC BINDING; MYB-LIKE DOMAIN; REVERSE-TRANSCRIPTASE; DNA RECOGNITION; PROTEIN; LENGTH; YEAST; TRF1; TELOBOX; RAP1	Telomeres are vital for preserving chromosome integrity during cell division. Several genes encoding potential telomere- binding proteins have recently been identified in higher plants, but nothing is known about their function or regulation during cell division. In this study, we have isolated and characterized a cDNA clone, pNgTRF1, encoding a putative double- stranded telomeric repeat binding factor of Nicotiana glutinosa, a diploid tobacco plant. The predicted protein sequence of NgTRF1 ( M-r = 75,000) contains a single Myb- like domain with significant homology to a corresponding motif in human TRF1/ Pin2 and TRF2. Gel retardation assays revealed that bacterially expressed full- length NgTRF1 was able to form a specific complex only with probes containing three or more contiguous telomeric TTTAGGG repeats. The Myb- like domain of NgTRF1 is essential, but not sufficient, to bind the telomeric repeat sequence. The glutamine- rich extreme C- terminal region, which does not exist in animal proteins, was additionally required to form a specific telomere- protein complex. The dissociation constant ( K-d) of the Myb motif plus the glutamine- rich domain of NgTRF1 to the two-telomeric repeat sequence was evaluated to be 4.5 +/- 0.2 x 10(-9) M, which is comparable to that of the Myb domain of human TRF1. Expression analysis showed that NgTRF1 gene activity was inversely correlated with the cell division capacity of tobacco root cells and during the 9- day culture period of BY- 2 suspension cells, while telomerase activity was positively correlated with cell division. In synchronized BY- 2 cells, NgTRF1 was selectively expressed in G(1) phase, whereas telomerase activity peaked in S phase. These findings suggest that telomerase activity and NgTRF1 expression are differentially regulated in an opposing fashion during growth and cell division in tobacco plants. The possible physiological functions of NgTRF1 in tobacco cells are also discussed.	Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea	Yonsei University	Kim, WT (corresponding author), Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea.	wtkim@yonsei.ac.kr						ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Autexier C, 1996, TRENDS BIOCHEM SCI, V21, P387, DOI 10.1016/S0968-0004(96)90128-0; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Bilaud T, 1996, NUCLEIC ACIDS RES, V24, P1294, DOI 10.1093/nar/24.7.1294; Blackburn EH, 2001, CELL, V106, P661, DOI 10.1016/S0092-8674(01)00492-5; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Buchberger A, 2002, TRENDS CELL BIOL, V12, P216, DOI 10.1016/S0962-8924(02)02269-9; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; Chen CM, 2001, J BIOL CHEM, V276, P16511, DOI 10.1074/jbc.M009659200; Choi D, 2000, BBA-GENE STRUCT EXPR, V1492, P211, DOI 10.1016/S0167-4781(00)00073-7; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Fitzgerald MS, 1996, P NATL ACAD SCI USA, V93, P14422, DOI 10.1073/pnas.93.25.14422; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Froelich-Ammon SJ, 1998, GENE DEV, V12, P1504, DOI 10.1101/gad.12.10.1504; Fulneckova J, 2000, FEBS LETT, V467, P305, DOI 10.1016/S0014-5793(00)01178-9; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Heller K, 1996, MOL GEN GENET, V252, P342, DOI 10.1007/BF02173780; Hwang MG, 2001, FEBS LETT, V503, P35, DOI 10.1016/S0014-5793(01)02685-0; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Killan A, 1998, PLANT MOL BIOL, V37, P621, DOI 10.1023/A:1005994629814; Kim JH, 1998, PLANT MOL BIOL, V36, P661, DOI 10.1023/A:1005994719175; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; Lee JH, 2000, PLANT MOL BIOL, V42, P547, DOI 10.1023/A:1006373917321; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; Lundblad V, 1998, P NATL ACAD SCI USA, V95, P8415, DOI 10.1073/pnas.95.15.8415; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; McKnight TD, 2002, PLANT MOL BIOL, V48, P331, DOI 10.1023/A:1014091032750; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; PETRACEK ME, 1994, EMBO J, V13, P3648, DOI 10.1002/j.1460-2075.1994.tb06672.x; Planchais S, 2000, FEBS LETT, V476, P78, DOI 10.1016/S0014-5793(00)01675-6; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; REGAD F, 1994, J MOL BIOL, V239, P163, DOI 10.1006/jmbi.1994.1360; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Riha K, 1998, PLANT CELL, V10, P1691, DOI 10.1105/tpc.10.10.1691; Riha K, 2000, PLANT J, V23, P633, DOI 10.1046/j.1365-313x.2000.00831.x; Riha K, 2001, SCIENCE, V291, P1797, DOI 10.1126/science.1057110; Shen MH, 1997, P NATL ACAD SCI USA, V94, P13618, DOI 10.1073/pnas.94.25.13618; Shippen DE, 1998, TRENDS PLANT SCI, V3, P126, DOI 10.1016/S1360-1385(98)01214-X; Shore D, 2001, CURR OPIN GENET DEV, V11, P189, DOI 10.1016/S0959-437X(00)00178-7; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Spink KG, 2000, NUCLEIC ACIDS RES, V28, P527, DOI 10.1093/nar/28.2.527; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; TAKEUCHI Y, 1992, PLANT MOL BIOL, V18, P835, DOI 10.1007/BF00020031; Tamura K, 1999, J BIOL CHEM, V274, P20997, DOI 10.1074/jbc.274.30.20997; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Vassetzky NS, 1999, NUCLEIC ACIDS RES, V27, P4687, DOI 10.1093/nar/27.24.4687; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; Yang Seong Wook, 2001, Journal of Plant Biology, V44, P168; Yang SW, 2002, PLANT J, V29, P617, DOI 10.1046/j.0960-7412.2001.01244.x; Yu EY, 2000, J BIOL CHEM, V275, P24208, DOI 10.1074/jbc.M003250200; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601; ZENTGRAF U, 1995, PLANT MOL BIOL, V27, P467, DOI 10.1007/BF00019314; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	67	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21395	21407		10.1074/jbc.M209973200	http://dx.doi.org/10.1074/jbc.M209973200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12646586	hybrid			2022-12-27	WOS:000183354200013
J	Elam, JS; Malek, K; Rodriguez, JA; Doucette, PA; Taylor, AB; Hayward, LJ; Cabelli, DE; Valentine, JS; Hart, PJ				Elam, JS; Malek, K; Rodriguez, JA; Doucette, PA; Taylor, AB; Hayward, LJ; Cabelli, DE; Valentine, JS; Hart, PJ			An alternative mechanism of bicarbonate-mediated peroxidation by copper-zinc superoxide dismutase - Rates enhanced via proposed enzyme-associated peroxycarbonate intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; ELECTRON-DENSITY MAPS; HYDROGEN-PEROXIDE; CU,ZN-SUPEROXIDE DISMUTASE; MUTANT SUPEROXIDE-DISMUTASE-1; RADICAL PRODUCTION; AXONAL-TRANSPORT; MOUSE MODEL; K-M; INACTIVATION	Hydrogen peroxide can interact with the active site of copper-zinc superoxide dismutase (SOD1) to generate a powerful oxidant. This oxidant can either damage amino acid residues at the active site, inactivating the enzyme (the self-oxidative pathway), or oxidize substrates exogenous to the active site, preventing inactivation (the external oxidative pathway). It is well established that the presence of bicarbonate anion dramatically enhances the rate of oxidation of exogenous substrates. Here, we show that bicarbonate also substantially enhances the rate of self-inactivation of human wild type SOD1. Together, these observations suggest that the strong oxidant formed by hydrogen peroxide and SOD1 in the presence of bicarbonate arises from a pathway mechanistically distinct from that producing the oxidant in its absence. Self-inactivation rates are further enhanced in a mutant SOD1 protein (L38V) linked to the fatal neurodegenerative disorder, familial amyotrophic lateral sclerosis. The 1.4 Angstrom resolution crystal structure of pathogenic SOD1 mutant D125H reveals the mode of oxyanion binding in the active site channel and implies that phosphate anion attenuates the bicarbonate effect by competing for binding to this site. The orientation of the enzyme-associated oxyanion suggests that both the self-oxidative and external oxidative pathways can proceed through an enzyme-associated peroxycarbonate intermediate.	Univ Texas, Hlth Sci Ctr, Dept Biochem, X Ray Crystallog Core Lab, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Brookhaven Natl Lab, Dept Chem, Upton, NY 11973 USA	University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; United States Department of Energy (DOE); Brookhaven National Laboratory	Valentine, JS (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, X Ray Crystallog Core Lab, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	jsv@chem.ucla.edu	Valentine, Joan S/B-6665-2008	Valentine, Joan S/0000-0002-7174-925X; Taylor, Alexander/0000-0003-3517-6033; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112, R01NS044170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [NS39112, R01 NS044170, NS44170, R01 NS039112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BLECH DM, 1983, ARCH BIOCHEM BIOPHYS, V224, P579, DOI 10.1016/0003-9861(83)90245-X; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORDERS CL, 1985, ARCH BIOCHEM BIOPHYS, V241, P472, DOI 10.1016/0003-9861(85)90572-7; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CABELLI DE, 1989, J BIOL CHEM, V264, P9967; Ciriolo MR, 2000, J BIOL CHEM, V275, P5065, DOI 10.1074/jbc.275.7.5065; DEFREITAS DM, 1987, INORG CHEM, V26, P2788; ELAM JS, 2003, IN PRESS NAT STRUCT; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; Goss SPA, 1999, J BIOL CHEM, V274, P28233, DOI 10.1074/jbc.274.40.28233; Gunther MR, 2002, J BIOL CHEM, V277, P9160, DOI 10.1074/jbc.M107342200; Gurney ME, 1998, J INHERIT METAB DIS, V21, P587, DOI 10.1023/A:1005475206997; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5299, DOI 10.1021/bi00695a011; HODGSON EK, 1975, BIOCHEMISTRY-US, V14, P5294, DOI 10.1021/bi00695a010; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kalyanaraman R, 2001, NUCL INSTRUM METH B, V175, P182, DOI 10.1016/S0168-583X(00)00662-5; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurahashi T, 2001, J AM CHEM SOC, V123, P9268, DOI 10.1021/ja015953r; LEVINSKI AM, 1983, HARRISONS PRINCIPLES; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 1999, FREE RADICAL BIO MED, V27, P1444, DOI 10.1016/S0891-5849(99)00190-2; Liochev SI, 1998, ARCH BIOCHEM BIOPHYS, V352, P237, DOI 10.1006/abbi.1998.0616; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; *POV TEAM, PERS VIS RAY TRAC VE; Rakhit R, 2002, J BIOL CHEM, V277, P47551, DOI 10.1074/jbc.M207356200; RIGO A, 1975, BIOCHEM BIOPH RES CO, V63, P1013, DOI 10.1016/0006-291X(75)90670-1; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; Sankarapandi S, 1999, J BIOL CHEM, V274, P34576, DOI 10.1074/jbc.274.49.34576; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; UCHIDA K, 1994, J BIOL CHEM, V269, P2405; Urushitani M, 2002, J NEUROCHEM, V83, P1030, DOI 10.1046/j.1471-4159.2002.01211.x; Valentine JS, 2003, P NATL ACAD SCI USA, V100, P3617, DOI 10.1073/pnas.0730423100; Valentine JS, 1999, ADV EXP MED BIOL, V448, P193; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1999, NAT NEUROSCI, V2, P50, DOI 10.1038/4553; Yim HS, 1997, J BIOL CHEM, V272, P8861; YIM MB, 1993, J BIOL CHEM, V268, P4099; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709; Zhang H, 2000, J BIOL CHEM, V275, P14038, DOI 10.1074/jbc.275.19.14038; Zhang H, 2002, J BIOL CHEM, V277, P1013, DOI 10.1074/jbc.M108585200	53	71	72	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21032	21039		10.1074/jbc.M300484200	http://dx.doi.org/10.1074/jbc.M300484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649272	hybrid			2022-12-27	WOS:000183230500077
J	Harrison, CA; Gray, PC; Koerber, SC; Fischer, W; Vale, W				Harrison, CA; Gray, PC; Koerber, SC; Fischer, W; Vale, W			Identification of a functional binding site for activin on the type I receptor ALK4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE KINASE; BETA; INHIBIN; DEFICIENT; ROLES; FOLLISTATIN; ECTODOMAIN; COMPLEXES; RESPONSES; LIGAND	Activins, like other members of the transforming growth factor-beta (TGF-beta) superfamily, initiate signaling by assembling a complex of two types of transmembrane serine/threonine receptor kinases classified as type II (ActRII or ActRIIB) and type I (ALK4). A kinase-deleted version of ALK4 can form an inactive complex with activin and ActRII/IIB and thereby acts in a dominant negative manner to block activin signaling. Using the complex structure of bone morphogenetic protein-2 bound to its type I receptor (ALK3) as a guide, we introduced extracellular domain mutations in the context of the truncated ALK4 (ALK4-trunc) construct and assessed the ability of the mutants to inhibit activin function. We have identified five hydrophobic amino acid residues on the ALK4 extracellular domain (Leu(40), Ile(70), Val(73), Leu(75), and Pro(77)) that, when mutated to alanine, have substantial effects on ALK4-trunc dominant negative activity. In addition, eleven mutants partially affected activin binding to ALK4. Together, these residues likely constitute the binding surface for activin on ALK4. Cross-linking studies measuring binding of I-125-activin-A to the ALK4-trunc mutants in the presence of ActRII implicated the same residues. Our results indicate that there is only a partial overlap of the binding sites on ALK4 and ALK3 for activin-A and bone morphogenetic protein-2, respectively. In addition three of the residues required for activin binding to ALK4 are conserved on the type I TGF-beta receptor ALK5, suggesting the corresponding region on ALK5 may be important for TGF-beta binding.	Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA	Salk Institute	Vale, W (corresponding author), Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	vale@salk.edu		Harrison, Craig/0000-0003-1059-3682				Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BILEZIKJIAN LM, 1992, TRENDS ENDOCRIN MET, V3, P218, DOI 10.1016/1043-2760(92)90031-U; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BROSH N, 1995, J BIOL CHEM, V270, P29594, DOI 10.1074/jbc.270.49.29594; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cheng SK, 2003, GENE DEV, V17, P31, DOI 10.1101/gad.1041203; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Fischer WH, 2003, J ENDOCRINOL, V176, P61, DOI 10.1677/joe.0.1760061; Gray PC, 2000, J BIOL CHEM, V275, P3206, DOI 10.1074/jbc.275.5.3206; Greenwald J, 1999, NAT STRUCT BIOL, V6, P18; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Gu ZY, 1998, GENE DEV, V12, P844, DOI 10.1101/gad.12.6.844; Guimond A, 2002, FEBS LETT, V513, P147, DOI 10.1016/S0014-5793(01)03231-8; Hogan BLM, 1996, CURR OPIN GENET DEV, V6, P432, DOI 10.1016/S0959-437X(96)80064-5; ISAACS NW, 1995, CURR OPIN STRUC BIOL, V5, P391, DOI 10.1016/0959-440X(95)80102-2; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Kirsch T, 2000, EMBO J, V19, P3314, DOI 10.1093/emboj/19.13.3314; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1994, P NATL ACAD SCI USA, V91, P8817, DOI 10.1073/pnas.91.19.8817; Matzuk MM, 1996, RECENT PROG HORM RES, V51, P123; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; Phillips DJ, 2001, MOL CELL ENDOCRINOL, V180, P155, DOI 10.1016/S0303-7207(01)00516-0; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; SCHUBERT D, 1990, NATURE, V344, P868, DOI 10.1038/344868a0; SCHWALL RH, 1993, HEPATOLOGY, V18, P347, DOI 10.1016/0270-9139(93)90018-I; Su GH, 2001, P NATL ACAD SCI USA, V98, P3254, DOI 10.1073/pnas.051484398; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; VALE W, 1988, RECENT PROG HORM RES, V44, P1; Vale W., 1990, HDB EXPT PHARM, P211; Whitman M, 2001, DEV CELL, V1, P605, DOI 10.1016/S1534-5807(01)00076-4; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Wuytens G, 1999, J BIOL CHEM, V274, P9821, DOI 10.1074/jbc.274.14.9821; Yan YT, 2002, MOL CELL BIOL, V22, P4439, DOI 10.1128/MCB.22.13.4439-4449.2002; Zhou YL, 2000, MOL ENDOCRINOL, V14, P2066, DOI 10.1210/me.14.12.2066	43	44	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21129	21135		10.1074/jbc.M302015200	http://dx.doi.org/10.1074/jbc.M302015200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665502	hybrid			2022-12-27	WOS:000183230500089
J	Feng, ZP; Doering, CJ; Winkfein, RJ; Beedle, AM; Spafford, JD; Zamponi, GW				Feng, ZP; Doering, CJ; Winkfein, RJ; Beedle, AM; Spafford, JD; Zamponi, GW			Determinants of inhibition of transiently expressed voltage-gated calcium channels by omega-conotoxins GVIA and MVIIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; NEUROPATHIC PAIN; CA2+ CHANNELS; BLOCKADE; ZICONOTIDE; CONOPEPTIDES; CATIONS; PEPTIDE; RAT	The Conus magus peptide toxin omega-conotoxin MVIIA is considered an irreversible, specific blocker of N-type calcium channels, and is now in clinical trials as an intrathecal analgesic. Here, we have examined the action of MVIIA on mutant and wild type calcium channels transiently expressed in tsA-201 cells. Although we have shown previously that mutations in a putative external EF-hand motif in the domain IIIS5-H5 region alters block by both omega-conotoxin GVIA and MVIIA (Feng, Z.P., Hamid, J., Doering, C., Bosey, G.M., Snutch, T.P., and Zamponi, G.W. (2001) J. Biol. Chem. 276, 15728-15735), the introduction of five point mutations known to affect GVIA blocking ( and located downstream of the EF-hand) affected MVIIA block to a smaller degree compared with GVIA. These data suggest that despite some overlap, MVIIA and GVIA block does not share identical channel structural determinants. At higher concentrations (similar to3 muM), MVIIA reversibly blocked L-, P/Q-, and R-type, but not T-type channels, indicating that the overall architecture of the MVIIA site is conserved in all types of high voltage-activated calcium channels. A kinetic analysis of the MVIIA effects on the N-type channel showed that MVIIA blocked resting, open, and inactivated channels. Although the development of MVIIA block did not appear to be voltage-, nor frequency-dependent, the degree of recovery from block strongly depended on the potential applied during washout. Interestingly, the degree of washout was highly variable and appeared to weakly depend on the holding potential applied during toxin application. We propose a model in which N-type calcium channels can form both reversible and irreversible complexes with MVIIA.	Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, Calgary, AB T2N 4N1, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada	University of Calgary	Zamponi, GW (corresponding author), Univ Calgary, Dept Physiol & Biophys, Cellular & Mol Neurobiol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.		Tuluc, Petronel/C-2527-2011; Beedle, Aaron/AAI-7014-2020; Beedle, Aaron M/K-1902-2015	Beedle, Aaron M/0000-0002-1019-3235; Zamponi, Gerald W./0000-0002-0644-9066				Adams DJ, 2003, J BIOL CHEM, V278, P4057, DOI 10.1074/jbc.M209969200; Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P3908, DOI 10.1021/bi992651h; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; Bourinet E, 2001, BIOPHYS J, V81, P79, DOI 10.1016/S0006-3495(01)75681-0; CARBONE E, 1988, PFLUG ARCH EUR J PHY, V413, P14, DOI 10.1007/BF00581223; Dudley SC, 1995, BIOPHYS J, V69, P1657, DOI 10.1016/S0006-3495(95)80045-7; ELLINOR PT, 1994, NATURE, V372, P272, DOI 10.1038/372272a0; Feng ZP, 2001, J BIOL CHEM, V276, P15728, DOI 10.1074/jbc.M100406200; Feng ZP, 2001, J BIOL CHEM, V276, P5726, DOI 10.1074/jbc.C000791200; FOX JA, 1995, PFLUG ARCH EUR J PHY, V429, P873, DOI 10.1007/BF00374813; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P2403, DOI 10.1517/13543784.9.10.2403; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; Levin T, 2002, PSYCHOSOMATICS, V43, P63, DOI 10.1176/appi.psy.43.1.63; Liang HY, 2002, J NEUROSCI, V22, P8884; MCDONOUGH SI, 1995, SOC NEUR ABSTR, V21, P1409; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Penn RD, 2000, PAIN, V85, P291, DOI 10.1016/S0304-3959(99)00254-7; Roullet JB, 1999, J BIOL CHEM, V274, P25439, DOI 10.1074/jbc.274.36.25439; Saegusa H, 2002, NEUROSCI RES, V43, P1, DOI 10.1016/S0168-0102(02)00017-2; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; Scott DA, 2002, EUR J PHARMACOL, V451, P279, DOI 10.1016/S0014-2999(02)02247-1; Sidach SS, 2000, J NEUROSCI, V20, P7174; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; Stocker JW, 1997, J NEUROSCI, V17, P3002; Stotz SC, 2000, J MEMBRANE BIOL, V174, P157, DOI 10.1007/s002320001040; WOPPMANN A, 1994, MOL CELL NEUROSCI, V5, P350, DOI 10.1006/mcne.1994.1042	27	77	86	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20171	20178		10.1074/jbc.M300581200	http://dx.doi.org/10.1074/jbc.M300581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654924	hybrid			2022-12-27	WOS:000183078000076
J	Huang, LE; Bunn, HF				Huang, LE; Bunn, HF			Hypoxia-inducible factor and its biomedical relevance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ENDOTHELIAL GROWTH-FACTOR; MICE PARTIALLY DEFICIENT; PAS DOMAIN PROTEIN; TRANSCRIPTION FACTOR; FACTOR 1-ALPHA; HIF-ALPHA; STRUCTURAL BASIS; EFFICIENT TRANSLATION; SIGNAL-TRANSDUCTION; DEGRADATION DOMAIN		NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, LE (corresponding author), NCI, Human Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA.	huange@mail.nih.gov; HFBunn@rics.bwh.harvard.edu		Huang, Eric/0000-0002-6444-1708	DIVISION OF BASIC SCIENCES - NCI [Z01BC010424] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Bae MK, 2002, J BIOL CHEM, V277, P9, DOI 10.1074/jbc.C100442200; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gradin K, 2002, J BIOL CHEM, V277, P23508, DOI 10.1074/jbc.M201307200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu J, 2001, J BIOL CHEM, V276, P3550, DOI 10.1074/jbc.M009522200; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 2002, J BIOL CHEM, V277, P41750, DOI 10.1074/jbc.M207280200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Jiang BH, 1997, CANCER RES, V57, P5328; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kline DD, 2002, P NATL ACAD SCI USA, V99, P821, DOI 10.1073/pnas.022634199; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; KONDO K, 2000, CANCER CELL, V1, P237; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904; Li H, 1996, J BIOL CHEM, V271, P21262, DOI 10.1074/jbc.271.35.21262; Mabjeesh NJ, 2002, CANCER RES, V62, P2478; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ravi R, 2000, GENE DEV, V14, P34; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schipani E, 2001, GENE DEV, V15, P2865; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; Vincent KA, 2000, CIRCULATION, V102, P2255; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Willam C, 2002, P NATL ACAD SCI USA, V99, P10423, DOI 10.1073/pnas.162119399; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zhong H, 1999, CANCER RES, V59, P5830; Zundel W, 2000, GENE DEV, V14, P391	79	252	283	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19575	19578		10.1074/jbc.R200030200	http://dx.doi.org/10.1074/jbc.R200030200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12639949	hybrid			2022-12-27	WOS:000183078000001
J	Marienfeld, R; May, MJ; Berberich, I; Serfling, E; Ghosh, S; Neumann, M				Marienfeld, R; May, MJ; Berberich, I; Serfling, E; Ghosh, S; Neumann, M			RelB forms transcriptionally inactive complexes with RelA/p65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MULTIORGAN INFLAMMATION; IMMUNE-RESPONSES; DEFICIENT MICE; IKK-ALPHA; T-CELLS; I-REL; ACTIVATION; FAMILY; PHOSPHORYLATION	RelB is an unusual member of the NF-kappaB transcription factor family that acts as both a transcriptional activator as well as a repressor of NF-kappaB-dependent gene expression. Although RelB promotes gene expression when it associates with p50/NF-kappaB1 or p52/NF-kappaB2, the precise molecular mechanisms through which it represses NF-kappaB remain unclear. To examine this inhibitory function in more detail, we employed reporter gene assays and found that RelB represses at the level of RelA. Furthermore, electrophoretic mobility shift analysis revealed that in vitro translated RelB impaired the DNA binding activity of RelA and that overexpressed RelB significantly reduced tumor necrosis factor-alpha-induced RelA activity in murine embryonic fibroblasts. Intriguingly, this inhibitory effect was due to the formation of RelA.RelB heterodimers that were unable to bind to kappaB sites in vitro strongly suggesting that these newly described NF-kappaB dimers cannot bind DNA. Expression pattern analysis revealed that RelA.RelB heterodimers appeared at relatively low levels in both lymphoid and non-lymphoid cells. However, the presence of these complexes increased following stimulation with phorbolesters or lipopolysaccharide or by overexpression of constitutively active IKKbeta. Functional characterization of RelA.RelB heterodimers in NIH3T3 murine embryonic fibroblasts revealed that they are not regulated by IkappaB proteins and are located in both the cytoplasm and the nucleus. Taken together, our findings demonstrate that sequestration of RelA in transcriptionally inactive RelA.RelB complexes provides a molecular mechanism that may explain the repressive role of RelB on NF-kappaB-dependent gene expression.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Univ Wurzburg, Inst Virol & Immunobiol, D-97080 Wurzburg, Germany; Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany; Univ Magdeburg, Inst Expt Internal Med, D-39120 Magdeburg, Germany	Yale University; Yale University; University of Wurzburg; University of Wurzburg; Otto von Guericke University	Marienfeld, R (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, 300 Cedar St, New Haven, CT 06520 USA.		Serfling, Edgar/X-7212-2019	May, Michael/0000-0002-2485-3716				BOURS V, 1994, ONCOGENE, V9, P1699; Bren GD, 2001, ONCOGENE, V20, P7722, DOI 10.1038/sj.onc.1204868; Chapman NR, 2002, BIOCHEM J, V366, P459, DOI 10.1042/BJ20020444; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Francis DA, 1998, INT IMMUNOL, V10, P285, DOI 10.1093/intimm/10.3.285; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Jiang HY, 2002, J VIROL, V76, P5737, DOI 10.1128/JVI.76.11.5737-5747.2002; Kistler B, 1998, J IMMUNOL, V160, P2308; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Neumann M, 1996, J IMMUNOL, V157, P4862; Neumann M, 2000, BLOOD, V95, P277; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Weih F, 1997, J IMMUNOL, V158, P5211; Weih F, 1996, J IMMUNOL, V157, P3974; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Xia YY, 1999, MOL CELL BIOL, V19, P7688; Xia YY, 1997, AM J PATHOL, V151, P375; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	35	123	127	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19852	19860		10.1074/jbc.M301945200	http://dx.doi.org/10.1074/jbc.M301945200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657634	hybrid			2022-12-27	WOS:000183078000037
J	Stevens, LA; Bourgeois, C; Bortell, R; Moss, J				Stevens, LA; Bourgeois, C; Bortell, R; Moss, J			Regulatory role of arginine 204 in the catalytic activity of rat alloantigens ART2a and ART2b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; AUTO-ADP-RIBOSYLATION; NAD GLYCOHYDROLASE; RT6; RIBOSYLTRANSFERASES; EXPRESSION; MONO(ADP-RIBOSYL)TRANSFERASES; AUTOMODIFICATION; ACTIVATION; IDENTIFY	ART2a (RT6.1) and ART2b (RT6.2) are NAD glycohydrolases (NADases) that are linked to T lymphocytes by glycosylphosphatidylinositol anchors. Although both mature proteins possess three conserved regions ( I, II, III) that form the NAD-binding site and differ by only ten amino acids, only ART2b is auto-ADP-ribosylated and only ART2a is glycosylated. To investigate the structural basis for these differences, wild-type and mutant ART2a and ART2b were expressed in rat mammary adenocarcinoma (NMU) cells and released with phosphatidylinositol-specific phospholipase C. All mutants were immunoreactive NADases. Arginine 204 (Arg(204)), NH2-terminal to essential glutamate 209 in Region III, is found in ART2b, but not ART2a. Replacement of Arg(204) in ART2b with lysine, tyrosine, or glutamate abolished auto-ADP-ribosylation. Unlike wild-type ART2a, ART2a( Y204R) was auto-ADP-ribosylated. The tryptophan mutant ART2b( R204W) was auto-ADP-ribosylated and exhibited enhanced NADase activity. Incubation with NAD and auto-ADP-ribosylation decreased the NADase activities of wild-type ART2b and ART2b ( R204W), whereas activity of ART2b( R204K), which is not auto-modified, was unchanged by NAD. Facilitation of auto-ADP-ribosylation by tryptophan 204 suggests that the hydrophobic amino acid mimics an ADP-ribosylated arginine. Thus, Arg(204) in ART2b serves as a regulatory switch whose presence is required for additional auto-ADP-ribosylation and regulation of catalytic activity.	NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Univ Massachusetts, Med Ctr, Diabet Div, Worcester, MA 01605 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Massachusetts System; University of Massachusetts Worcester	Stevens, LA (corresponding author), NHLBI, Pulm Crit Care Med Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bortell R, 2001, AUTOIMMUNITY, V33, P199, DOI 10.3109/08916930109008047; Bortell R, 2001, J IMMUNOL, V167, P2049, DOI 10.4049/jimmunol.167.4.2049; Bredehorst K, 1997, ADV EXP MED BIOL, V419, P185; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; GREINER DL, 1986, J IMMUNOL, V136, P148; HAAG F, 1995, EUR J IMMUNOL, V25, P2355, DOI 10.1002/eji.1830250835; HAAG F, 1994, J MOL BIOL, V243, P537, DOI 10.1006/jmbi.1994.1680; Han S, 2002, INT J MED MICROBIOL, V291, P523; Hara N, 1996, J BIOL CHEM, V271, P29552, DOI 10.1074/jbc.271.47.29552; Karsten S, 1997, ADV EXP MED BIOL, V419, P175; KOCH F, 1988, IMMUNOLOGY, V65, P259; Maehama T, 1996, FEBS LETT, V388, P189, DOI 10.1016/0014-5793(96)00568-6; Mojcik C F, 1991, Dev Immunol, V1, P191, DOI 10.1155/1991/87067; Moss J, 1999, MOL CELL BIOCHEM, V193, P109, DOI 10.1023/A:1006924514074; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; PAYNE DM, 1985, BIOCHEMISTRY-US, V24, P7540, DOI 10.1021/bi00347a006; Rigby MR, 1996, J IMMUNOL, V156, P4259; Rigby MR, 1996, DIABETES, V45, P1419, DOI 10.2337/diabetes.45.10.1419; TAKADA T, 1994, J BIOL CHEM, V269, P9420; Thiele HG, 2001, IMMUNOL REV, V184, P96, DOI 10.1034/j.1600-065x.2001.1840109.x; Thiele HG, 1997, ADV EXP MED BIOL, V419, P109; THIELE HG, 1986, IMMUNOLOGY, V59, P195; Weng BY, 1999, J BIOL CHEM, V274, P31797, DOI 10.1074/jbc.274.45.31797; Williamson K., 1990, ADP RIBOSYLATING TOX, P493; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004	25	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19591	19596		10.1074/jbc.M210364200	http://dx.doi.org/10.1074/jbc.M210364200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649291	hybrid			2022-12-27	WOS:000183078000005
J	Hotchkiss, KA; Ashton, AW; Schwartz, EL				Hotchkiss, KA; Ashton, AW; Schwartz, EL			Thymidine phosphorylase and 2-deoxyribose stimulate human endothelial cell migration by specific activation of the integrins alpha(5)beta(1) and alpha(V)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; RIBOSE-BINDING-PROTEIN; GROWTH-FACTOR; TUMOR-GROWTH; TYROSINE PHOSPHORYLATION; FIBRONECTIN RECEPTOR; ANGIOGENIC ACTIVITY; MESODERMAL DEFECTS; BLOOD-VESSELS; MICE LACKING	Thymidine phosphorylase is an angiogenic factor that is frequently overexpressed in solid tumors, in rheumatoid arthritis, and in response to inflammatory cytokines. Our previous studies showed that cells expressing thymidine phosphorylase stimulated endothelial cell migration in vitro. This was a consequence of the intracellular metabolism of thymidine by thymidine phosphorylase and subsequent extracellular release of 2-deoxyribose. The mechanisms by which 2-deoxyribose might mediate thymidine phosphorylase-induced cell migration in vitro, however, are obscure. Here we show that both thymidine phosphorylase and 2-deoxyribose stimulated the formation of focal adhesions and the tyrosine 397 phosphorylation of focal adhesion kinase in human umbilical vein endothelial cells. Although similar actions occurred upon treatment with the angiogenic factor vascular endothelial growth factor (VEGF), thymidine phosphorylase differed from VEGF in that its effect on endothelial cell migration was blocked by antibodies to either integrin alpha(5)beta(1) or alpha(v)beta(3), whereas VEGF-induced endothelial cell migration was only blocked by the alpha(v)beta(3) antibody. Further, thymidine phosphorylase and 2-deoxyribose, but not VEGF, increased the association of both focal adhesion kinase and the focal adhesion-associated protein vinculin with integrin alpha(5)beta(1) and, in intact cells, increased the co-localization of focal adhesion kinase with alpha(5)beta(1). Thymidine phosphorylase and 2-deoxyribose-induced focal adhesion kinase phosphorylation was blocked by the antibodies to alpha(5)beta(1) and alpha(v)beta(3), directly linking the migration and signaling components of thymidine phosphorylase and 2-deoxyribose action. Cell surface expression of alpha(5)beta(1) was also increased by thymidine phosphorylase and 2-deoxyribose. These experiments are the first to demonstrate a direct effect of thymidine phosphorylase and 2-deoxyribose on signaling pathways associated with endothelial cell migration.	Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Med Cardiol, Bronx, NY 10467 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Schwartz, EL (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.				NATIONAL CANCER INSTITUTE [R01CA054422, R01CA089352] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA89352, R01-CA54422, P01-CA13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKSAMIT RR, 1974, BIOCHEMISTRY-US, V13, P4473, DOI 10.1021/bi00719a001; ASAI K, 1992, J BIOL CHEM, V267, P20311; Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BLYSTONE SD, 1995, J CELL BIOL, V130, P745, DOI 10.1083/jcb.130.3.745; BLYSTONE SD, 1994, J CELL BIOL, V127, P1129, DOI 10.1083/jcb.127.4.1129; BODARY SC, 1990, J BIOL CHEM, V265, P5938; Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092-8674(00)81246-5; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FINNIS C, 1993, EUR J BIOCHEM, V212, P201, DOI 10.1111/j.1432-1033.1993.tb17651.x; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; FURUKAWA T, 1992, NATURE, V356, P668, DOI 10.1038/356668a0; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Goh KL, 1997, DEVELOPMENT, V124, P4309; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARAGUCHI M, 1994, NATURE, V368, P198, DOI 10.1038/368198a0; Hotchkiss KA, 2003, CANCER RES, V63, P527; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ikeda R, 2002, BIOCHEM BIOPH RES CO, V291, P806, DOI 10.1006/bbrc.2002.6432; ISHIKAWA F, 1989, NATURE, V338, P557, DOI 10.1038/338557a0; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kim E, 2002, BBA-MOL CELL RES, V1593, P9, DOI 10.1016/S0167-4889(02)00275-6; Kim S, 2000, J BIOL CHEM, V275, P33920, DOI 10.1074/jbc.M003668200; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kletsas D, 1998, BIOCHEM BIOPH RES CO, V243, P416, DOI 10.1006/bbrc.1997.7975; Lahav J, 2002, BLOOD, V100, P2472, DOI 10.1182/blood-2001-12-0339; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LUCCIONI C, 1994, INT J CANCER, V58, P517, DOI 10.1002/ijc.2910580411; Maeda K, 1996, BRIT J CANCER, V73, P884, DOI 10.1038/bjc.1996.177; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MOGHADDAM A, 1992, BIOCHEMISTRY-US, V31, P12141, DOI 10.1021/bi00163a024; MOGHADDAM A, 1995, P NATL ACAD SCI USA, V92, P998, DOI 10.1073/pnas.92.4.998; O'Byrne KJ, 2000, BRIT J CANCER, V82, P1427, DOI 10.1054/bjoc.1999.1129; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Relf M, 1997, CANCER RES, V57, P963; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 2001, TRENDS CELL BIOL, V11, P466, DOI 10.1016/S0962-8924(01)02152-3; Senger DR, 1996, AM J PATHOL, V149, P293; Simon KO, 1997, J BIOL CHEM, V272, P29380, DOI 10.1074/jbc.272.46.29380; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; SUMIZAWA T, 1993, J BIOCHEM-TOKYO, V114, P9, DOI 10.1093/oxfordjournals.jbchem.a124146; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; TAKABAYASHI Y, 1996, J NATL CANCER I, V88, P1110; Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146; Taverna D, 2001, CANCER RES, V61, P5255; van Triest B, 2000, CLIN CANCER RES, V6, P1063; XU YL, 1994, J INVEST DERMATOL, V102, P833, DOI 10.1111/1523-1747.ep12382086; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i; YANG JT, 1993, DEVELOPMENT, V119, P1093; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	70	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19272	19279		10.1074/jbc.M212670200	http://dx.doi.org/10.1074/jbc.M212670200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639965	hybrid			2022-12-27	WOS:000182932200072
J	Robin, MA; Prabu, SK; Raza, H; Anandatheerthavarada, HK; Avadhani, NG				Robin, MA; Prabu, SK; Raza, H; Anandatheerthavarada, HK; Avadhani, NG			Phosphorylation enhances mitochondrial targeting of GSTA4-4 through increased affinity for binding to cytoplasmic Hsp70	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; PROTEIN-KINASE-C; OXIDATIVE STRESS; LIPID-PEROXIDATION; ALPHA-CLASS; MEDIATED PHOSPHORYLATION; ENDOPLASMIC-RETICULUM; LIVER-MITOCHONDRIA; IMPORT; INDUCTION	Recently we showed that three different isoforms of cytosolic glutathione S-transferases (GST), including GSTA4-4, are also localized in the mitochondrial compartment. In this study, we have investigated the mechanism of mouse GSTA4-4 targeting to mitochondria, using a combination of in vitro mitochondrial import assay and in vivo targeting in COS cells transfected with cDNA. Our results show that the mitochondrial GSTA4-4 is more heavily phosphorylated compared with its cytosolic counterpart. Protein kinase activators (cAMP, forskolin, or phorbol-12-myristate-13-acetate) markedly increased GSTA4-4 targeting to mitochondria, whereas kinase inhibitors caused its retention in the cytosol. Immunoinhibition and immunodepletion studies showed that the Hsp70 chaperone is required for the efficient translation of GSTA4-4 as well as its translocation to mitochondria. Co-immunoprecipitation studies showed that kinase inhibitors attenuate the affinity of GSTA4-4 for cytoplasmic Hsp70 suggesting the importance of phosphorylation for binding to the chaperone. Mutational analysis show that the putative mitochondrial targeting signal resides within the C-terminal 20 amino acid residues of the protein and that the targeting signal requires activation by phosphorylation at the C-terminal-most protein kinase A (PKA) site at Ser-189 or protein kinase C (PKC) site at Thr-193. We demonstrate for the first time that PKA and PKC modulate the cytoplasmic and mitochondrial pools of GSTA4-4.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Marie Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Avadhani, NG (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA.	narayan@vet.upenn.edu		Raza, Haider/0000-0001-9680-5388	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034883] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34883-18] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDYA S, 1994, ARCH BIOCHEM BIOPHYS, V310, P82, DOI 10.1006/abbi.1994.1143; Addya S, 1997, J CELL BIOL, V139, P589, DOI 10.1083/jcb.139.3.589; ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Anandatheerthavarada HK, 1999, EMBO J, V18, P5494, DOI 10.1093/emboj/18.20.5494; Bai JX, 2001, BIOL SIGNAL RECEPT, V10, P189; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Ceccarelli EA, 1996, EUR J BIOCHEM, V238, P192, DOI 10.1111/j.1432-1033.1996.0192q.x; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crossthwaite AJ, 2002, J NEUROCHEM, V80, P24, DOI 10.1046/j.0022-3042.2001.00637.x; Desmots F, 2002, FREE RADICAL BIO MED, V32, P93, DOI 10.1016/S0891-5849(01)00767-5; ECKL PM, 1993, MUTAT RES, V290, P183, DOI 10.1016/0027-5107(93)90158-C; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HARRIS JM, 1991, BIOCHEM J, V278, P137, DOI 10.1042/bj2780137; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; JARVIS WD, 1994, CANCER RES, V54, P1707; KOCH JA, 1991, METHOD ENZYMOL, V206, P305; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIN B, 1995, J BIOL CHEM, V270, P24732, DOI 10.1074/jbc.270.42.24732; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Matouschek A, 1997, EMBO J, V16, P6727, DOI 10.1093/emboj/16.22.6727; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; Mottaran E, 2002, FREE RADICAL BIO MED, V32, P38, DOI 10.1016/S0891-5849(01)00757-2; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Prabhu KS, 2001, BIOCHEM J, V360, P345, DOI 10.1042/0264-6021:3600345; Raza H, 2002, BIOCHEM J, V366, P45, DOI 10.1042/BJ20020533; Rimon G, 1998, BBA-GEN SUBJECTS, V1380, P289, DOI 10.1016/S0304-4165(97)00153-0; Robin MA, 2002, J BIOL CHEM, V277, P40583, DOI 10.1074/jbc.M203292200; Robin MA, 2001, J BIOL CHEM, V276, P24680, DOI 10.1074/jbc.M100363200; Sass E, 2001, J BIOL CHEM, V276, P46111, DOI 10.1074/jbc.M106061200; Sayre LM, 1999, METHOD ENZYMOL, V309, P133; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; SUNDBERG AGM, 1993, PHARMACOL TOXICOL, V72, P321, DOI 10.1111/j.1600-0773.1993.tb01658.x; TERADA K, 1995, MOL CELL BIOL, V15, P3708; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Woodgett JR, 1996, CANCER SURV, V27, P127	49	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18960	18970		10.1074/jbc.M301807200	http://dx.doi.org/10.1074/jbc.M301807200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646569	hybrid			2022-12-27	WOS:000182932200033
J	Tordjman, J; Chauvet, G; Quette, J; Beale, EG; Forest, C; Antoine, B				Tordjman, J; Chauvet, G; Quette, J; Beale, EG; Forest, C; Antoine, B			Thiazolidinediones block fatty acid release by inducing glyceroneogenesis in fat cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; INSULIN-RESISTANCE; PPAR-GAMMA; GENE; PATHOGENESIS; ADIPOCYTES; EXPRESSION; OBESITY; PROTEIN	Thiazolidinediones are used to treat type 2 diabetes mellitus because they decrease plasma glucose, insulin, triglyceride, and fatty acid levels. Thiazolidinediones are agonists for peroxisome proliferator-activated receptor gamma, a nuclear receptor that is highly expressed in fat tissue. We identify glyceroneogenesis as a target of thiazolidinediones in cultured adipocytes and fat tissues of Wistar rats. The activation of glyceroneogenesis by thiazolidinediones occurs mainly in visceral fat, the same fat depot that is specifically implicated in the progression of obesity to type 2 diabetes. The increase in glyceroneogenesis is a result of the induction of its key enzyme, phosphoenolpyruvate carboxykinase, whose gene expression is peroxisome proliferator-activated receptor gamma-dependent in adipocytes. The main role of this metabolic pathway is to allow the re-esterification of fatty acids via a futile cycle in adipocytes, thus lowering fatty acid release into the plasma. The importance of such a fatty acid re-esterification process in the control of lipid homeostasis is highlighted by the existence of a second thiazolidinedione-induced pathway involving glycerol kinase. We show that glyceroneogenesis accounts for at least 75% of the whole thiazolidinedione effect. Because elevated plasma fatty acids promote insulin resistance, these results suggest that the glyceroneogenesis-dependent fatty acid-lowering effect of thiazolidinediones could be an essential aspect of the antidiabetic action of these drugs.	Univ Paris 05, Ctr Univ, INSERM, UMRS 530, F-75006 Paris, France; Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Antoine, B (corresponding author), Univ Paris 05, Ctr Univ, INSERM, UMRS 530, 45 Rue St Peres, F-75006 Paris, France.	benedicte.antoine@biomedicale.univ-paris5.fr	Beale, Elmus/GNM-8181-2022	Beale, Elmus/0000-0002-7758-0600; Forest, Claude/0000-0003-3401-8148	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039895] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM39895] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Boyko EJ, 2000, DIABETES CARE, V23, P465, DOI 10.2337/diacare.23.4.465; CHANG HC, 1966, J BIOL CHEM, V241, P2413; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Franckhauser S, 2002, DIABETES, V51, P624, DOI 10.2337/diabetes.51.3.624; Glorian M, 2001, BIOCHIMIE, V83, P933, DOI 10.1016/S0300-9084(01)01343-8; Guan HP, 2002, NAT MED, V8, P1122, DOI 10.1038/nm780; HUBBARD RW, 1969, LIPIDS, V5, P114; Lebovitz HE, 2001, J CLIN ENDOCR METAB, V86, P280, DOI 10.1210/jc.86.1.280; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MACDONALD MJ, 1981, BIOCHIM BIOPHYS ACTA, V663, P302, DOI 10.1016/0005-2760(81)90216-2; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; Oakes ND, 2001, DIABETES, V50, P1158, DOI 10.2337/diabetes.50.5.1158; Olswang Y, 2002, P NATL ACAD SCI USA, V99, P625, DOI 10.1073/pnas.022616299; RANDLE PJ, 1963, LANCET, V1, P785; RESHEF L, 1969, J BIOL CHEM, V244, P1994; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; TCHKONIA T, 2001, CURR OPIN ENDOCRINOL, V8, P227; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; Way JM, 2001, ENDOCRINOLOGY, V142, P1269, DOI 10.1210/en.142.3.1269	27	149	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18785	18790		10.1074/jbc.M206999200	http://dx.doi.org/10.1074/jbc.M206999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644461	hybrid			2022-12-27	WOS:000182932200012
J	Wolk, K; Kunz, S; Crompton, NEA; Volk, HD; Sabat, R				Wolk, K; Kunz, S; Crompton, NEA; Volk, HD; Sabat, R			Multiple mechanisms of reduced major histocompatibility complex class II expression in endotoxin tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL SELECTION; INVARIANT CHAIN; ANTIGEN PRESENTATION; MICE LACKING; IFN-GAMMA; MONOCYTES; TRANSPORT; ALPHA; INTERLEUKIN-10; DEGRADATION	Patients after polytrauma, burns, or septic shock frequently develop a life-threatening immunodeficiency. This state is associated with specific functional alterations of monocytic cells. We previously proposed endotoxin tolerance, the monocyte state after acute response to lipopolysaccharide, as a respective model system. One major feature in both the clinical situation and the in vitro model is the dramatic down-regulation of monocyte major histocompatibility complex (MHC) class II surface expression, which is associated with impaired antigen presentation capacity. This study focused on the mechanisms behind reduced MHC class II expression in endotoxin tolerance. Endotoxin priming provoked a decrease of monocyte intracellular MHC class II. It also led to a reduced expression of the chaperonic invariant chain and to an inhibited synthesis of the major lysosomal enzyme for final cleavage of the invariant chain going along with a relative accumulation of p10. The expression of HLA-DM necessary for loading MHC class II with antigenic peptide was also decreased. Additionally, reduced export of MHC class II alphabeta complexes to the cell surface was observed. The down-regulation of HLA-DR, invariant chain, and HLA-DM was regulated at the mRNA level and may be the consequence of reduced class II transactivator expression observed in this study. The simultaneous interference at different regulatory levels may explain the uniquely strong and long lasting MHC class II down-modulating effect of endotoxin priming compared with transforming growth factor-beta and interleukin-10. These results not only contribute to a better understanding of experimental endotoxin tolerance but may also give rise to new therapeutics for temporary immunodeficiency and, conversely, for MHC class II-dependent diseases such as autoimmunity and transplant rejection.	Humboldt Univ, Med Sch Charite, Inst Med Immunol, D-10117 Berlin, Germany; Paul Scherrer Inst, CH-5232 Villigen, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Sabat, R (corresponding author), Humboldt Univ, Med Sch Charite, Interdisciplinary Grp Mol Immunopathol, Schumannstr 20-21, D-10098 Berlin, Germany.	robert.sabat@charite.de	Wolk, Kerstin/O-1205-2013; volk, hans-dieter/AAV-8053-2021	volk, hans-dieter/0000-0002-7743-6668; Wolk, Kerstin/0000-0002-7689-4130				Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Brachet V, 1997, J CELL BIOL, V137, P51, DOI 10.1083/jcb.137.1.51; Chang CH, 1996, IMMUNITY, V4, P167, DOI 10.1016/S1074-7613(00)80681-0; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; CZARNIECKI CW, 1988, J IMMUNOL, V140, P4217; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Fiebiger E, 2001, J EXP MED, V193, P881, DOI 10.1084/jem.193.8.881; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Galati G, 1997, CYTOMETRY, V27, P77, DOI 10.1002/(SICI)1097-0320(19970101)27:1<77::AID-CYTO10>3.0.CO;2-P; HAAS JG, 1990, P NATL ACAD SCI USA, V87, P9563, DOI 10.1073/pnas.87.24.9563; HENRICSON BE, 1993, INFECT IMMUN, V61, P2325, DOI 10.1128/IAI.61.6.2325-2333.1993; Karp CL, 1998, EUR J IMMUNOL, V28, P3128, DOI 10.1002/(SICI)1521-4141(199810)28:10<3128::AID-IMMU3128>3.0.CO;2-T; Kern F, 1998, NAT MED, V4, P975, DOI 10.1038/nm0898-975; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; Nakagawa T, 1998, SCIENCE, V280, P450, DOI 10.1126/science.280.5362.450; Nakagawa TY, 1999, IMMUNITY, V10, P207, DOI 10.1016/S1074-7613(00)80021-7; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Piskurich JF, 1998, J IMMUNOL, V160, P233; RANDOW F, 1995, J EXP MED, V181, P1887, DOI 10.1084/jem.181.5.1887; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Shi GP, 2000, J EXP MED, V191, P1177, DOI 10.1084/jem.191.7.1177; Shi GP, 1999, IMMUNITY, V10, P197, DOI 10.1016/S1074-7613(00)80020-5; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Wolk K, 2000, BLOOD, V96, P218, DOI 10.1182/blood.V96.1.218.013k04_218_223; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787; Wysocka M, 2001, J IMMUNOL, V166, P7504, DOI 10.4049/jimmunol.166.12.7504; ZHANG XK, 1993, J EXP MED, V177, P511, DOI 10.1084/jem.177.2.511; ZIEGLERHEITBROCK HWL, 1992, IMMUNOLOGY, V75, P264	32	61	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18030	18036		10.1074/jbc.M207714200	http://dx.doi.org/10.1074/jbc.M207714200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637533	hybrid			2022-12-27	WOS:000182838300057
J	Suh, JM; Song, JH; Kim, DW; Kim, H; Chung, HK; Hwang, JH; Kim, JM; Hwang, ES; Chung, JK; Han, JH; Cho, BY; Ro, HK; Shong, MH				Suh, JM; Song, JH; Kim, DW; Kim, H; Chung, HK; Hwang, JH; Kim, JM; Hwang, ES; Chung, JK; Han, JH; Cho, BY; Ro, HK; Shong, MH			Regulation of the phosphatidylinositol 3-kinase, Akt/protein kinase B, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 signaling pathways by thyroid-stimulating hormone (TSH) and stimulating type TSH receptor antibodies in the thyroid gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYCLIC-AMP; CELL PROLIFERATION; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; PHOSPHORYLATION SITES; ACTIVATION; GROWTH; THYROTROPIN; INSULIN; RAP1	Thyroid-stimulating hormone (TSH) regulates the growth and differentiation of thyrocytes by activating the TSH receptor (TSHR). This study investigated the roles of the phosphatidylinositol 3-kinase (PI3K), PDK1, FRAP/mammalian target of rapamycin, and ribosomal S6 kinase 1 (S6K1) signaling mechanism by which TSH and the stimulating type TSHR antibodies regulate thyrocyte proliferation and the follicle activities in vitro and in vivo. The TSHR immunoprecipitates exhibited PI3K activity, which was higher in the cells treated with either TSH or 8-bromo-cAMP. TSH and cAMP increased the tyrosine phosphorylation of TSHR and the association between TSHR and the p85alpha regulatory subunit of PI3K. TSH induced a redistribution of PDK1 from the cytoplasm to the plasma membrane in the cells in a PI3K- and protein kinase A-dependent manner. TSH induced the PDK1-dependent phosphorylation of S6K1 but did not induce Akt/protein kinase B phosphorylation. The TSH-induced S6K1 phosphorylation was inhibited by a dominant negative p85alpha regulatory subunit or by the PI3K inhibitors wortmannin and LY294002. Rapamycin inhibited the phosphorylation of S6K1 in the cells treated with either TSH or 8-bromo-cAMP. The stimulating type TSHR antibodies from patients with Graves disease also induced S6K1 activation, whereas the blocking type TSHR antibodies from patients with primary myxedema inhibited TSH- but not the insulin-induced phosphorylation of S6K1. In addition, rapamycin treatment in vivo inhibited the TSH- stimulated thyroid follicle hyperplasia and follicle activity. These findings suggest an interaction between TSHR and PI3K, which is stimulated by TSH and cAMP and might involve the downstream S6K1 but not Akt/protein kinase B. This pathway may play a role in the TSH/stimulating type TSH receptor antibody-mediated thyrocyte proliferation in vitro and in the response to TSH in vivo.	Chungnam Natl Univ, Dept Internal Med, Lab Endocrine Cell Biol, Taejon 301721, South Korea; Chungnam Natl Univ, Dept Pathol, Taejon 301721, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Sungkyunkwan Univ, Coll Pharm, Dept Biochem, Suwon 440756, South Korea; Seoul Natl Univ, Dept Internal Med, Seoul 110744, South Korea	Chungnam National University; Chungnam National University; Korea Advanced Institute of Science & Technology (KAIST); Sungkyunkwan University (SKKU); Seoul National University (SNU)	Shong, MH (corresponding author), Chungnam Natl Univ, Sch Med, Dept Internal Med, Lab Endocrine Cell Biol, 640 Daesadong Chungku, Taejon 301040, South Korea.	minhos@cnu.ac.kr	/H-7803-2012	KIM, JIN MAN/0000-0003-0905-9730; shong, minho/0000-0002-0247-7115				Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; BANDI HR, 1993, J BIOL CHEM, V268, P4530; Bell A, 2002, AM J PHYSIOL-CELL PH, V283, pC1056, DOI 10.1152/ajpcell.00058.2002; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Cass LA, 1998, ENDOCRINOLOGY, V139, P1991, DOI 10.1210/en.139.4.1991; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Coulonval K, 2000, BIOCHEM J, V348, P351, DOI 10.1042/0264-6021:3480351; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; De Vita G, 2000, CANCER RES, V60, P3916; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Kim WB, 1997, J CLIN ENDOCR METAB, V82, P1953, DOI 10.1210/jc.82.6.1953; Kimura T, 2001, ENDOCR REV, V22, P631, DOI 10.1210/er.22.5.631; Kohn L D, 1995, Vitam Horm, V50, P287, DOI 10.1016/S0083-6729(08)60658-5; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; LUCIA ER, 1999, J BIOL CHEM, V274, P8347; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NAGAYAMA Y, 1992, MOL ENDOCRINOL, V6, P145, DOI 10.1210/me.6.2.145; Nedachi T, 2000, ENDOCRINOLOGY, V141, P2429, DOI 10.1210/en.141.7.2429; OKKENHAUG K, 2001, SCI STKE; Park ES, 2000, MOL ENDOCRINOL, V14, P662, DOI 10.1210/mend.14.5.0458; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Saito J, 2001, THYROID, V11, P339, DOI 10.1089/10507250152039073; SAMAYOR A, 1999, BIOCHEM J, V342, P287; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SUSA M, 1989, CELL, V57, P817, DOI 10.1016/0092-8674(89)90796-4; TERADA N, 1995, J IMMUNOL, V155, P3418; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tonacchera M, 1996, CLIN ENDOCRINOL, V44, P621, DOI 10.1046/j.1365-2265.1996.746567.x; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Vinals F, 1999, J BIOL CHEM, V274, P26776, DOI 10.1074/jbc.274.38.26776; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000	58	61	68	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21960	21971		10.1074/jbc.M300805200	http://dx.doi.org/10.1074/jbc.M300805200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668683	hybrid			2022-12-27	WOS:000183354200082
J	Zhu, K; Amin, MA; Kim, MJ; Katschke, KJ; Park, CC; Koch, AE				Zhu, K; Amin, MA; Kim, MJ; Katschke, KJ; Park, CC; Koch, AE			A novel function for a glucose analog of blood group H antigen as a mediator of leukocyte-endothelial adhesion via intracellular adhesion molecule 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; RHEUMATOID-ARTHRITIS; INTERFERON-GAMMA; SYNOVIAL TISSUE; STAT PATHWAY; EXPRESSION; CELLS; ICAM-1; ACTIVATION; INHIBITION	The 4A11 antigen is a unique cytokine-inducible antigen up-regulated on rheumatoid arthritis synovial endothelium compared with normal endothelium. In soluble form, this antigen, Lewis(y)-6/H-5-2 (Le(y)/H), or its glucose analog, 2-fucosyllactose (H-2g), mediates angiogenesis. The Le(y)/H antigen is structurally related to the soluble E-selectin ligand, sialyl Lewis(x), and is selectively expressed in skin, lymphoid organs, thymus, and synovium, suggesting that it may be important in leukocyte homing or adhesion. In the present study, we used H-2g as a functional substitute to demonstrate a novel property for Le(y)/H antigen in inducing leukocyte-endothelial adhesion. H-2g significantly enhanced the expression of human dermal microvascular endothelial cells (HM-VECs) intercellular adhesion molecule-1 (ICAM-1), but not vascular cell adhesion molecule-1, E-selectin, and P-selectin. Immunoprecipitation and Western blotting showed glycolipids Le(y)-6, H-5-2, or the glucose analog H-2g quickly activated human microvascular endothelial cell line-1 (HMEC-1) Janus kinase 2 (JAK2) and that the JAK2 inhibitor, AG-490, completely inhibited HMVEC ICAM-1 expression and HL-60 adhesion to HMEC-1s. Use of a JAK/signal transducer and activator of transcription ( STAT) profiling system confirmed that H-2g selectively activated STAT3 but not STAT1 and STAT2. AG-490 inhibited H-2g-induced Erk1/2 and PI3K-Akt activation, suggesting that JAK2 is upstream of the Erk1/2 and PI3K-Akt pathways. Furthermore, the JAK2 inhibitor AG-490, the Erk1/2 inhibitor PD98059, or the phosphatidylinositol 3-kinase inhibitor LY294002 or antisense oligodeoxynucleotides directed against JAK2, Erk1/2, or phosphatidylinositol 3-kinase blocked H-2g-induced HMVEC ICAM-1 expression and HL-60 adhesion to HMEC-1s. Hence, H-2g signals through JAK2 and its downstream signal transducers STAT3, Erk1/2, and phosphatidylinositol 3-kinase result in ICAM-1 expression and cell adhesion. Potential treatment strategies through the inhibition of JAK-dependent pathways to target H-2g signals may provide a useful approach in inflammation-driven diseases like rheumatoid arthritis.	Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Koch, AE (corresponding author), 303 E Chicago Ave,Ward Bldg 3-315, Chicago, IL 60611 USA.		Koch, Alisa E/B-6894-2011; Park, Christy/AAH-1543-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058695] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040987, K08AI049287, R21AI040987] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58695] Funding Source: Medline; NIAID NIH HHS [AI 49287, AI 40987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Duperray A, 1997, J BIOL CHEM, V272, P435; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Feizi T, 2000, GLYCOCONJUGATE J, V17, P553, DOI 10.1023/A:1011022509500; Furuzawa-Carballeda J, 1999, SCAND J IMMUNOL, V50, P215; Halloran MM, 2000, J IMMUNOL, V164, P4868, DOI 10.4049/jimmunol.164.9.4868; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; Innocenti M, 2002, INFECT IMMUN, V70, P4581, DOI 10.1128/IAI.70.8.4581-4590.2002; Katagiri K, 1996, BLOOD, V87, P4276, DOI 10.1182/blood.V87.10.4276.bloodjournal87104276; Kim OS, 2002, J BIOL CHEM, V277, P40594, DOI 10.1074/jbc.M203885200; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; KOCH AE, 1994, CLIN IMMUNOL IMMUNOP, V71, P208, DOI 10.1006/clin.1994.1074; KOCH AE, 1995, NATURE, V376, P517, DOI 10.1038/376517a0; KOCH AE, 1994, AM J PATHOL, V144, P244; Lacha J, 2002, J LEUKOCYTE BIOL, V71, P311; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; LINDSLEY HB, 1992, SEMIN ARTHRITIS RHEU, V21, P330, DOI 10.1016/0049-0172(92)90026-A; LINDSLEY HB, 1993, CLIN IMMUNOL IMMUNOP, V68, P311, DOI 10.1006/clin.1993.1132; Madamanchi NR, 2001, J BIOL CHEM, V276, P18915, DOI 10.1074/jbc.M008802200; Matsumiya T, 2002, LIFE SCI, V70, P3179, DOI 10.1016/S0024-3205(02)01560-6; MIZOGUCHI A, 1984, J BIOL CHEM, V259, P1949; Morel JCM, 2002, J BIOL CHEM, V277, P34679, DOI 10.1074/jbc.M206337200; Morel JCM, 2001, J BIOL CHEM, V276, P37069, DOI 10.1074/jbc.M103574200; POBER JS, 1986, J IMMUNOL, V136, P1680; Porter JC, 1997, J CELL BIOL, V138, P1437, DOI 10.1083/jcb.138.6.1437; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Striz I, 1999, AM J PHYSIOL-LUNG C, V277, pL58, DOI 10.1152/ajplung.1999.277.1.L58; SZEKANECZ Z, 1994, ARTHRITIS RHEUM, V37, P221, DOI 10.1002/art.1780370211; TAK PP, 1995, CLIN IMMUNOL IMMUNOP, V77, P236, DOI 10.1006/clin.1995.1149; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Wilson JL, 1998, J RHEUMATOL, V25, P499; Wu AJ, 1997, J CELL PHYSIOL, V173, P110, DOI 10.1002/(SICI)1097-4652(199710)173:1<110::AID-JCP13>3.0.CO;2-M; Yusuf-Makagiansar H, 2002, MED RES REV, V22, P146, DOI 10.1002/med.10001	32	29	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21869	21877		10.1074/jbc.M213052200	http://dx.doi.org/10.1074/jbc.M213052200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12672794	hybrid			2022-12-27	WOS:000183354200071
J	Bjornberg, O; Neuhard, J; Nyman, PO				Bjornberg, O; Neuhard, J; Nyman, PO			A bifunctional dCTP deaminase-dUTP nucleotidohydrolase from the hyperthermophilic archaeon Methanocaldococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTIOUS-ANEMIA VIRUS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; DNA-POLYMERASES; BINDING MOTIF; PYROPHOSPHATASE; EXPRESSION; PROTEIN; RNA	By the sequential action of dCTP deaminase and dUTPase, dCTP is converted to dUMP, the precursor of thymidine nucleotides. In addition, dUTPase has an essential role as a safeguard against uracil incorporation in DNA. The putative dCTP deaminase (MJ0430) and dUTPase (MJ1102) from the hyperthermophilic archaeon Methanocaldococcus jannaschii were overproduced in Escherichia coli. Unexpectedly, we found the MJ0430 protein capable of both reactions, i.e. hydrolytic deamination of the cytosine ring and hydrolytic cleavage of the phosphoanhydride bond between the alpha- and beta-phosphates. When the reaction was followed by thin layer chromatography using [H-3] dCTP as substrate, dUMP and not dUTP was identified as a reaction product. In the presence of unlabeled dUTP, which acted as an inhibitor, no label was transferred from [H-3] dCTP to the pool of dUTP. This finding strongly suggests that the two consecutive steps of the reaction are tightly coupled within the enzyme. The hitherto unknown bifunctionality of the MJ0430 protein appears beneficial for the cells because the toxic intermediate dUTP is never released. The MJ0430 protein also catalyzed the hydrolysis of dUTP to dUMP but with a low affinity for the substrate (K-m>100 muM). According to limited proteolysis, the C-terminal residues constitute a flexible region. The other protein investigated, MJ1102, is a specific dUTPase with a K-m for dUTP (0.4 muM) comparable in magnitude with that found for previously characterized dUTPases. Its physiological function is probably to degrade dUTP derived from other reactions in nucleotide metabolism.	Univ Copenhagen, Dept Biol Chem, Inst Mol Biol, DK-1307 Copenhagen K, Denmark; Univ Copenhagen, Dept Chem, Ctr Crystallog Studies, DK-2100 Copenhagen O, Denmark; Lund Univ, Dept Biochem, S-22100 Lund, Sweden	University of Copenhagen; University of Copenhagen; Lund University	Neuhard, J (corresponding author), Univ Copenhagen, Dept Biol Chem, Inst Mol Biol, Solvgade 83 H, DK-1307 Copenhagen K, Denmark.	neuhard@mermaid.molbio.ku.dk						BECK CF, 1975, J BIOL CHEM, V250, P609; BERGMAN AC, 1995, PROTEIN EXPRES PURIF, V6, P379, DOI 10.1006/prep.1995.1050; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CEDERGRENZEPPEZAUER ES, 1992, NATURE, V355, P740, DOI 10.1038/355740a0; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; DELTITO BJD, 1995, J BACTERIOL, V177, P7086, DOI 10.1128/jb.177.24.7086-7091.1995; Hogrefe HH, 2002, P NATL ACAD SCI USA, V99, P596, DOI 10.1073/pnas.012372799; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; Koonin EV, 1996, NUCLEIC ACIDS RES, V24, P2411, DOI 10.1093/nar/24.12.2411; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Lasken RS, 1996, J BIOL CHEM, V271, P17692, DOI 10.1074/jbc.271.30.17692; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; Myllykallio H, 2002, SCIENCE, V297, P105, DOI 10.1126/science.1072113; Neuhard J., 1996, ESCHERICHIA COLI SAL, V2nd, P580; Nord J, 1997, FEBS LETT, V414, P271, DOI 10.1016/S0014-5793(97)00935-6; Nord J, 2001, FEBS LETT, V492, P228, DOI 10.1016/S0014-5793(01)02257-8; NORD J, 2000, NUCLEOTIDE BINDING T; Prangishvili D, 1998, J BIOL CHEM, V273, P6024, DOI 10.1074/jbc.273.11.6024; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; REIZER J, 1994, PROTEIN SCI, V3, P853; Shao H, 1997, BBA-PROTEIN STRUCT M, V1339, P181, DOI 10.1016/S0167-4838(96)00229-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSUNASAWA S, 1985, J BIOL CHEM, V260, P5382; TYE BK, 1977, P NATL ACAD SCI USA, V74, P154, DOI 10.1073/pnas.74.1.154; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; WANG LH, 1992, J BACTERIOL, V174, P5647, DOI 10.1128/JB.174.17.5647-5653.1992	31	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20667	20672		10.1074/jbc.M213010200	http://dx.doi.org/10.1074/jbc.M213010200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670946	hybrid			2022-12-27	WOS:000183230500030
J	Guerin, M; Parodi, AJ				Guerin, M; Parodi, AJ			The UDP-glucose : glycoprotein glucosyltransferase is organized in at least two tightly bound domains from yeast to mammals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; ENDOPLASMIC-RETICULUM; MESSENGER-RNA; ENZYME; OLIGOSACCHARIDES; PURIFICATION; HOMOGENEITY; VIABILITY; PROTEIN; STRESS	The endoplasmic reticulum UDP-Glc:glycoprotein glucosyltransferase (GT) exclusively glucosylates nonnative glycoprotein conformers. GT sequence analysis suggests that it is composed of at least two domains: the N-terminal domain, which composes 80% of the molecule, has no significant similarity to other known proteins and was proposed to be involved in the recognition of non-native conformers and the C-terminal or catalytic domain, which displays a similar size and significant similarity to members of glycosyltransferase family 8. Here, we show that N- and C-terminal domains from Rattus norvegicus and Schizosaccharomyces pombe GTs remained tightly but not covalently bound upon a mild proteolytic treatment and could not be separated without loss of enzymatic activity. The notion of a two-domain protein was reinforced by the synthesis of an active enzyme upon transfection of S. pombe GT null mutants with two expression vectors, each of them encoding one of both domains. Transfection with the C-terminal domain-encoding vector alone yielded an inactive, rapidly degraded protein, thus indicating that the N- terminal domain is required for proper folding of the C-terminal catalytic portion. If, indeed, the N- terminal domain is, as proposed, also involved in glycoprotein conformation recognition, the tight association between N- and C-terminal domains may explain why only N-glycans in close proximity to protein structural perturbations are glucosylated by the enzyme. Although S. pombe and Drosophila melanogaster GT N- terminal domains display an extremely poor similarity (16.3%), chimeras containing either yeast N- terminal and fly C-terminal domains or the inverse construction were enzymatically and functionally active in vivo, thus indicating that the N- terminal domains of both GTs shared three-dimensional features.	Univ San Martin, Biotechnol Res Inst, RA-1650 San Martin, Argentina		Parodi, AJ (corresponding author), Univ San Martin, Biotechnol Res Inst, CC30, RA-1650 San Martin, Argentina.		Guerin, Marcelo M/N-7245-2016	Guerin, Marcelo M/0000-0001-9524-3184	NIGMS NIH HHS [GM 44500] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C, 1993, EXPT FISSION YEAST L; Arnold SM, 2000, BIOCHEMISTRY-US, V39, P2149, DOI 10.1021/bi9916473; Caramelo JJ, 2003, P NATL ACAD SCI USA, V100, P86, DOI 10.1073/pnas.262661199; Fanchiotti S, 1998, J CELL BIOL, V143, P625, DOI 10.1083/jcb.143.3.625; Fernandez F, 1996, EMBO J, V15, P705, DOI 10.1002/j.1460-2075.1996.tb00406.x; FERNANDEZ FS, 1994, J BIOL CHEM, V269, P30701; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; QUIRIN K, 2002, THESIS SWISS FEDERAL; Ritter C, 2000, NAT STRUCT BIOL, V7, P278; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; Tessier DC, 2000, GLYCOBIOLOGY, V10, P403, DOI 10.1093/glycob/10.4.403; Trombetta ES, 2000, J CELL BIOL, V148, P1123, DOI 10.1083/jcb.148.6.1123; Trombetta ES, 2002, ADV PROTEIN CHEM, V59, P303; TROMBETTA SE, 1989, BIOCHEMISTRY-US, V28, P8108, DOI 10.1021/bi00446a022; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; WRIGHT A, 1965, BIOCHIM BIOPHYS ACTA, V104, P594, DOI 10.1016/0304-4165(65)90366-1	19	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20540	20546		10.1074/jbc.M300891200	http://dx.doi.org/10.1074/jbc.M300891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649273	hybrid			2022-12-27	WOS:000183230500014
J	Heinz, U; Bauer, R; Wommer, S; Meyer-Klaucke, W; Papamichaels, C; Bateson, J; Adolph, HW				Heinz, U; Bauer, R; Wommer, S; Meyer-Klaucke, W; Papamichaels, C; Bateson, J; Adolph, HW			Coordination geometries of metal ions in D- or L-captopril-inhibited metallo-beta-lactamases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME-INHIBITORS; PERTURBED-ANGULAR-CORRELATION; BINDING; DYNAMICS; POTENT; SITES; EXAFS	D- and L-captopril are competitive inhibitors of metallo-beta-lactamases. For the enzymes from Bacillus cereus (BcII) and Aeromonas hydrophila (CphA), we found that the mononuclear enzymes are the favored targets for inhibition. By combining results from extended x-ray absorption fine structure, perturbed angular correlation of gamma-rays spectroscopy, and a study of metal ion binding, we derived that for Cd(II)(1)-BcII, the thiolate sulfur of D-captopril binds to the metal ion located at the site defined by three histidine ligand residues. This is also the case for the inhibited Co(II)(1) and Co(II)(2) enzymes as observed by UV-visible spectroscopy. Although the single metal ion in Cd(II)(1)-BcII is distributed between both available binding sites in both the uninhibited and the inhibited enzyme, Cd(II)(1)-CphA shows only one defined ligand geometry with the thiolate sulfur coordinating to the metal ion in the site composed of 1 Cys, 1 His, and 1 Asp. CphA shows a strong preference for D- captopril, which is also reflected in a very rigid structure of the complex as determined by perturbed angular correlation spectroscopy. For BcII and CphA, which are representatives of the metallo-beta-lactamase subclasses B1 and B2, we find two different inhibitor binding modes.	Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany; Univ Saarland, Dept Biochem, D-66041 Saarbrucken, Germany; Royal Vet & Agr Univ, Dept Math & Phys, DK-1871 Frederiksberg, Denmark; DESY, European Mol Biol Lab Outstn Hamburg, D-22603 Hamburg, Germany; Univ Oxford, Dyson Perrins Lab, Dept Chem, Oxford OX1 3QY, England; GlaxoSmithKline, Dept Med Chem, MMPD, CEDD, Harlow CM19 5AW, Essex, England	Saarland University; Saarland University; University of Copenhagen; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); University of Oxford; GlaxoSmithKline	Adolph, HW (corresponding author), Univ Saarland, Ctr Bioinformat, D-66041 Saarbrucken, Germany.	hwadolph@mx.uni-saarland.de	Adolph, Hans W/A-2104-2008; Meyer-Klaucke, Wolfram/G-1148-2010					Bauer R, 1997, BIOCHEMISTRY-US, V36, P11514, DOI 10.1021/bi970936t; BAUER R, 1985, Q REV BIOPHYS, V18, P1, DOI 10.1017/S0033583500004972; BICKNELL R, 1985, BIOCHEMISTRY-US, V24, P6876, DOI 10.1021/bi00345a021; Carfi A, 1998, ACTA CRYSTALLOGR D, V54, P313, DOI 10.1107/S0907444997010627; CARFI A, 1995, EMBO J, V14, P4914, DOI 10.1002/j.1460-2075.1995.tb00174.x; Concha NO, 2000, BIOCHEMISTRY-US, V39, P4288, DOI 10.1021/bi992569m; de Seny D, 2001, J BIOL CHEM, V276, P45065, DOI 10.1074/jbc.M106447200; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Hemmingsen L, 1996, EUR J BIOCHEM, V241, P546, DOI 10.1111/j.1432-1033.1996.00546.x; Hemmingsen L, 2001, J AM CHEM SOC, V123, P10329, DOI 10.1021/ja0112240; JOYNER RW, 1987, J PHYS C SOLID STATE, V20, P4005, DOI 10.1088/0022-3719/20/25/028; LEE PA, 1975, PHYS REV B, V11, P2795, DOI 10.1103/PhysRevB.11.2795; MASSIDDA O, 1991, J BACTERIOL, V173, P4611, DOI 10.1128/jb.173.15.4611-4617.1991; Mollard C, 2001, J BIOL CHEM, V276, P45015, DOI 10.1074/jbc.M107054200; Paul-Soto R, 1999, BIOCHEMISTRY-US, V38, P16500, DOI 10.1021/bi9911381; Paul-Soto R, 1999, J BIOL CHEM, V274, P13242, DOI 10.1074/jbc.274.19.13242; Payne DJ, 2000, EXPERT OPIN INV DRUG, V9, P247, DOI 10.1517/13543784.9.2.247; SKILES JW, 1986, J MED CHEM, V29, P784, DOI 10.1021/jm00155a032; SMITH EM, 1988, J MED CHEM, V31, P875, DOI 10.1021/jm00399a033; SUH JT, 1985, J MED CHEM, V28, P57, DOI 10.1021/jm00379a013; Teo, 1986, EXAFS BASIC PRINCIPL; Toney JH, 2001, J BIOL CHEM, V276, P31913, DOI 10.1074/jbc.M104742200; Valladares MH, 1997, BIOCHEMISTRY-US, V36, P11534, DOI 10.1021/bi971056h; Valladares MH, 2000, FEBS LETT, V467, P221, DOI 10.1016/S0014-5793(00)01102-9; Villadares MH, 1996, MICROB DRUG RESIST, V2, P253, DOI 10.1089/mdr.1996.2.253; Wang ZG, 1999, CURR OPIN CHEM BIOL, V3, P614, DOI 10.1016/S1367-5931(99)00017-4; Wommer S, 2002, J BIOL CHEM, V277, P24142, DOI 10.1074/jbc.M202467200; Zervosen A, 2001, EUR J BIOCHEM, V268, P3840, DOI 10.1046/j.1432-1327.2001.02298.x	29	72	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20659	20666		10.1074/jbc.M212581200	http://dx.doi.org/10.1074/jbc.M212581200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668674	hybrid			2022-12-27	WOS:000183230500029
J	Murata, T; Arechaga, I; Fearnley, IM; Kakinuma, Y; Yamato, I; Walker, JE				Murata, T; Arechaga, I; Fearnley, IM; Kakinuma, Y; Yamato, I; Walker, JE			The membrane domain of the Na+-motive V-ATPase from Enterococcus hirae contains a heptameric rotor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; 16-KDA PROTEOLIPID SUBUNIT; SACCHAROMYCES-CEREVISIAE; 3-DIMENSIONAL STRUCTURE; MOLECULAR ARCHITECTURE; TRANSLOCATING ATPASE; CHROMAFFIN GRANULES; UNDECAMERIC ROTOR; ROTARY CATALYSIS; COUPLING RATIO	In F-ATPases, ATP hydrolysis is coupled to translocation of ions through membranes by rotation of a ring of c subunits in the membrane. The ring is attached to a central shaft that penetrates the catalytic domain, which has pseudo-3-fold symmetry. The ion translocation pathway lies between the external circumference of the ring and another hydrophobic protein. The H+ or Na+: ATP ratio depends upon the number of ring protomers, each of which has an essential carboxylate involved directly in ion translocation. This number and the ratio differ according to the source, and 10, 11, and 14 protomers have been found in various enzymes, with corresponding calculated H+ or Na+: ATP ratios of 3.3, 3.7, and 4.7. V-ATPases are related in structure and function to F-ATPases. Oligomers of subunit K from the Na+-motive V-ATPase of Enterococcus hirae also form membrane rings but, as reported here, with 7-fold symmetry. Each protomer has one essential carboxylate. Thus, hydrolysis of one ATP provides energy to extrude 2.3 sodium ions. Symmetry mismatch between the catalytic and membrane domains appears to be an intrinsic feature of both V- and F-ATPases.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Muroran Inst Technol, Dept Appl Chem, Muroran, Hokkaido 0508585, Japan; Sci Univ Tokyo, Dept Biol Sci & Technol, Chiba 2788510, Japan	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Muroran Institute of Technology; Tokyo University of Science	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Murata, Takeshi/F-6114-2011; Murata, Takeshi/J-6181-2017; Arechaga, Ignacio/K-2198-2014	Murata, Takeshi/0000-0002-5748-4670; Arechaga, Ignacio/0000-0002-1342-9370; Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, BIOCHEMISTRY-US, V41, P11301, DOI 10.1021/bi0262449; Arechaga I, 2002, FEBS LETT, V515, P189, DOI 10.1016/S0014-5793(02)02447-X; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; CROWTHER RA, 1971, J MOL BIOL, V60, P123, DOI 10.1016/0022-2836(71)90452-9; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; DUBE P, 1993, EMBO J, V12, P1303, DOI 10.1002/j.1460-2075.1993.tb05775.x; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Ferguson SJ, 2000, CURR BIOL, V10, pR804, DOI 10.1016/S0960-9822(00)00765-X; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FINBOW ME, 1984, EMBO J, V3, P2271, DOI 10.1002/j.1460-2075.1984.tb02125.x; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gibson LCD, 2002, BIOCHEM J, V366, P911, DOI 10.1042/BJ20020171; HARRISON MA, 1994, EUR J BIOCHEM, V221, P111, DOI 10.1111/j.1432-1033.1994.tb18719.x; Harrison MA, 1999, J BIOL CHEM, V274, P25461, DOI 10.1074/jbc.274.36.25461; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; HOLZENBURG A, 1993, EUR J BIOCHEM, V213, P21, DOI 10.1111/j.1432-1033.1993.tb17730.x; Imamura H, 2003, P NATL ACAD SCI USA, V100, P2312, DOI 10.1073/pnas.0436796100; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; JOHNSON RG, 1982, J BIOL CHEM, V257, P701; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; KAKINUMA Y, 1993, BIOCHEM BIOPH RES CO, V195, P1063, DOI 10.1006/bbrc.1993.2152; Kakinuma Y, 1999, J BIOENERG BIOMEMBR, V31, P7, DOI 10.1023/A:1005499126939; KARRASCH S, 1995, EMBO J, V14, P631, DOI 10.1002/j.1460-2075.1995.tb07041.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Muller DJ, 2001, FEBS LETT, V504, P219, DOI 10.1016/S0014-5793(01)02708-9; Muller ML, 1996, J BIOL CHEM, V271, P1916; Murata T, 1997, J BIOL CHEM, V272, P24885, DOI 10.1074/jbc.272.40.24885; Murata T, 1996, J BIOL CHEM, V271, P10042, DOI 10.1074/jbc.271.17.10042; Murata T, 1999, J BIOCHEM, V125, P414, DOI 10.1093/oxfordjournals.jbchem.a022302; Nelson N, 2002, NAT REV MOL CELL BIO, V3, P876, DOI 10.1038/nrm955; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Neumann S, 1998, J BACTERIOL, V180, P3312, DOI 10.1128/JB.180.13.3312-3316.1998; Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729; Nishi T, 2003, J BIOL CHEM, V278, P5821, DOI 10.1074/jbc.M209875200; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 1997, BBA-BIOENERGETICS, V1322, P183, DOI 10.1016/S0005-2728(97)00079-0; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stahlberg H, 2001, EMBO REP, V2, P229, DOI 10.1093/embo-reports/kve047; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VanWalraven HS, 1996, FEBS LETT, V379, P309, DOI 10.1016/0014-5793(95)01536-1; Vonck J, 2002, J MOL BIOL, V321, P307, DOI 10.1016/S0022-2836(02)00597-1; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; Yabe I, 1999, J BIOL CHEM, V274, P34903, DOI 10.1074/jbc.274.49.34903; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	59	25	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21162	21167		10.1074/jbc.M301620200	http://dx.doi.org/10.1074/jbc.M301620200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12651848	hybrid			2022-12-27	WOS:000183230500093
J	Papo, N; Shahar, M; Eisenbach, L; Shai, Y				Papo, N; Shahar, M; Eisenbach, L; Shai, Y			A novel lytic peptide composed of DL-Amino acids selectively kills cancer cells in culture and in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDES; ALPHA-HELIX; MEMBRANE; SPECTROSCOPY; RESONANCE; PHASE	The high toxicity of most chemotherapeutic drugs and their inactivation by multidrug resistance phenotypes motivated extensive search for drugs with new modes of action. We designed a short cationic diastereomeric peptide composed of D- and L-leucines, lysines, and arginines that has selective toxicity toward cancer cells and significantly inhibits lung metastasis formation in mice (86%) with no detectable side effects. Its ability to depolarize the transmembrane potential of cancer cells at the same rate (within minutes) and concentration (3 muM), at which it shows biological activity, suggests a killing mechanism that involves plasma membrane perturbation. Confocal microscopy experiments verified that the cells died as a result of acute injury, swelling, and bursting, suggesting necrosis. Biosensor binding experiments and attenuated total reflectance-Fourier transform infrared spectroscopy using model membranes have substantiated its high selectivity toward cancer cells. Although this is an initial study that looked at tumor formation rather than the ability of the peptides to reduce established tumors, the simple sequence of the peptide, its high solubility, substantial resistance to degradation, and inactivation by serum components might make it a good candidate for future anticancer treatment.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Papo, Niv/R-3946-2017	Eisenbach, Lea R/0000-0002-4816-1968				Abu-Raya S, 1998, J PHARMACOL EXP THER, V287, P889; BAKER MA, 1993, CANCER RES, V53, P3052; BENKIRANE N, 1993, J BIOL CHEM, V268, P26279; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; CAMERON DG, 1980, BIOCHIM BIOPHYS ACTA, V596, P463, DOI 10.1016/0005-2736(80)90135-2; Chan SC, 1998, J PEPT SCI, V4, P413, DOI 10.1002/(SICI)1099-1387(1998110)4:7<413::AID-PSC160>3.3.CO;2-X; Chen YX, 2001, CANCER RES, V61, P2434; DWIVEDI AM, 1984, BIOPOLYMERS, V23, P923, DOI 10.1002/bip.360230509; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; ISHIGURO R, 1993, BIOCHEMISTRY-US, V32, P9792, DOI 10.1021/bi00088a034; JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140; KRAUSE E, 1995, ANAL CHEM, V67, P252, DOI 10.1021/ac00098a003; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Oren Z, 2000, BIOCHEMISTRY-US, V39, P6103, DOI 10.1021/bi992408i; Oren Z, 1997, J BIOL CHEM, V272, P14643, DOI 10.1074/jbc.272.23.14643; PORGADOR A, 1993, J IMMUNOL, V150, P1458; ROTHEMUND S, 1995, BIOCHEMISTRY-US, V34, P12954, DOI 10.1021/bi00040a005; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; Sharon M, 1999, BIOCHEMISTRY-US, V38, P15305, DOI 10.1021/bi991225t; Smith LL, 2000, CRIT REV TOXICOL, V30, P571, DOI 10.1080/10408440008951120; Tatulian SA, 1997, J MOL BIOL, V268, P809, DOI 10.1006/jmbi.1997.1014; VERKLEIJ AJ, 1973, BIOCHIM BIOPHYS ACTA, V323, P178, DOI 10.1016/0005-2736(73)90143-0; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	24	134	144	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21018	21023		10.1074/jbc.M211204200	http://dx.doi.org/10.1074/jbc.M211204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646578	hybrid			2022-12-27	WOS:000183230500075
J	Davies, BA; Topp, JD; Sfeir, AJ; Katzmann, DJ; Carney, DS; Tall, GG; Friedberg, AS; Deng, L; Chen, ZJ; Horazdovsky, BF				Davies, BA; Topp, JD; Sfeir, AJ; Katzmann, DJ; Carney, DS; Tall, GG; Friedberg, AS; Deng, L; Chen, ZJ; Horazdovsky, BF			Vps9p CUE domain ubiquitin binding is required for efficient endocytic protein traffic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; NUCLEOTIDE EXCHANGE; GENE; RAS; LOCALIZATION; INTERACTS; IDENTIFICATION; DEGRADATION; EXPRESSION; REGULATOR	Rab5 GTPases are key regulators of protein trafficking through the early stages of the endocytic pathway. The yeast Rab5 ortholog Vps21p is activated by its guanine nucleotide exchange factor Vps9p. Here we show that Vps9p binds ubiquitin and that the CUE domain is necessary and sufficient for this interaction. Vps9p ubiquitin binding is required for efficient endocytosis of Ste3p but not for the delivery of the biosynthetic cargo carboxypeptidase Y to the vacuole. In addition, Vps9p is itself monoubiquitylated. Ubiquitylation is dependent on a functional CUE domain and Rsp5p, an E3 ligase that participates in cell surface receptor endocytosis. These findings define a new ubiquitin binding domain and implicate ubiquitin as a modulator of Vps9p function in the endocytic pathway.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Mayo Clinic; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Horazdovsky, BF (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	Horazdovsky.Bruce@mayo.edu	Chen, Zhijian/C-6039-2012	Chen, Zhijian/0000-0002-8475-8251	NIGMS NIH HHS [GM-055301] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; BANROQUES J, 1986, CELL, V46, P837, DOI 10.1016/0092-8674(86)90065-6; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Burd CG, 1996, MOL CELL BIOL, V16, P2369; Chen YJ, 1996, EUR J CELL BIOL, V70, P289; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DAVIS NG, 1993, J CELL BIOL, V122, P53, DOI 10.1083/jcb.122.1.53; Donaldson KM, 2003, CURR BIOL, V13, P258, DOI 10.1016/S0960-9822(03)00043-5; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Eymard-Pierre E, 2002, AM J HUM GENET, V71, P518, DOI 10.1086/342359; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; Gerrard SR, 2000, MOL BIOL CELL, V11, P613, DOI 10.1091/mbc.11.2.613; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Hadano S, 2001, NAT GENET, V29, P166, DOI 10.1038/ng1001-166; Hama H, 1999, J BIOL CHEM, V274, P15284, DOI 10.1074/jbc.274.21.15284; HAN LM, 1995, MOL CELL BIOL, V15, P1318; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Horazdovsky BF, 1996, J BIOL CHEM, V271, P33607, DOI 10.1074/jbc.271.52.33607; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Huibregtse JM, 1997, P NATL ACAD SCI USA, V94, P3656, DOI 10.1073/pnas.94.8.3656; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kaminska J, 2002, MOL CELL BIOL, V22, P6946, DOI 10.1128/MCB.22.20.6946-6958.2002; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nagase T, 2000, DNA RES, V7, P273; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; Saito K, 2002, J BIOL CHEM, V277, P3412, DOI 10.1074/jbc.M106276200; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; Sherman F, 1979, METHODS YEAST GENETI; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; SMITH BJ, 1991, MOL CELL BIOL, V11, P2647, DOI 10.1128/MCB.11.5.2647; Tall GG, 2001, DEV CELL, V1, P73, DOI 10.1016/S1534-5807(01)00008-9; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang GL, 2001, MOL CELL BIOL, V21, P3564, DOI 10.1128/MCB.21.10.3564-3575.2001; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wiemann S, 2001, GENOME RES, V11, P422, DOI 10.1101/gr.GR1547R; Yang Y, 2001, NAT GENET, V29, P160, DOI 10.1038/ng1001-160; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	49	57	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19826	19833		10.1074/jbc.M301059200	http://dx.doi.org/10.1074/jbc.M301059200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654912	hybrid			2022-12-27	WOS:000183078000034
J	Liu, XH; Tesfai, J; Evrard, YA; Dent, SYR; Martinez, E				Liu, XH; Tesfai, J; Evrard, YA; Dent, SYR; Martinez, E			C-Myc transformation domain recruits the human STAGA complex and requires TRRAP and GCN5 acetylase activity for transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; IN-VIVO; ESSENTIAL COFACTOR; ONCOGENIC TRANSFORMATION; MYC/MAX/MAD NETWORK; HISTONE ACETYLATION; GENE ACTIVATION; CAD PROMOTER; SAGA; COACTIVATOR	Deregulation of the c-Myc oncoprotein (Myc) is implicated in many types of cancer. Myc is a sequence-specific transcription factor that regulates transcription of genes involved in the control of cell proliferation and apoptosis via mechanisms that are still poorly understood. Cell transformation by Myc involves its association with the transformation-transactivation domain-associated protein ( TRRAP) and the human histone acetyltransferase ( HAT) GCN5. TRRAP and GCN5 are components of a variety of shared and distinct multiprotein HAT complexes with diverse functions. Myc induces TRRAP recruitment and histone hyperacetylation at specific Myc-activated genes in vivo. However, the identity of the HAT complexes recruited by Myc and the roles of TRRAP and GCN5 in Myc function are still unclear. Here we show that Myc co-recruits TRRAP and GCN5 via direct physical interactions of its N-terminal activation/transformation domain with the human STAGA (SPT3-TAF-GCN5 acetylase) coactivator complex. We demonstrate that GCN5 and TRRAP cooperate to enhance transcription activation by the N-terminal activation domain of Myc in vivo and that this synergy requires both the SPT3/GCN5 interaction domain of TRRAP and the HAT activity of GCN5. Thus, TRRAP might function as an adaptor within the STAGA complex, which helps recruit GCN5 HAT activity to Myc during transcription activation.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of California System; University of California Riverside; University of Texas System; UTMD Anderson Cancer Center	Martinez, E (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	NIGMS NIH HHS [T34 GM062756] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T34GM062756] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Ard PG, 2002, MOL CELL BIOL, V22, P5650, DOI 10.1128/MCB.22.16.5650-5661.2002; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Bhaumik SR, 2002, MOL CELL BIOL, V22, P7365, DOI 10.1128/MCB.22.21.7365-7371.2002; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Brand M, 1999, J BIOL CHEM, V274, P18285, DOI 10.1074/jbc.274.26.18285; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2002, J BIOL CHEM, V277, P40156, DOI 10.1074/jbc.M207441200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hardy S, 2002, J BIOL CHEM, V277, P32875, DOI 10.1074/jbc.M205860200; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Lang SE, 2001, J BIOL CHEM, V276, P32627, DOI 10.1074/jbc.M102067200; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez E, 1998, J BIOL CHEM, V273, P23781, DOI 10.1074/jbc.273.37.23781; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1	43	90	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20405	20412		10.1074/jbc.M211795200	http://dx.doi.org/10.1074/jbc.M211795200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660246	hybrid, Green Accepted			2022-12-27	WOS:000183078000106
J	Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD				Moeckel, GW; Zhang, L; Fogo, AB; Hao, CM; Pozzi, A; Breyer, MD			COX2 activity promotes organic osmolyte accumulation and adaptation of renal medullary interstitial cells to hypertonic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOOXYGENASE-2; EXPRESSION; INHIBITORS; SURVIVAL; CLONING; CULTURE; BETAINE; KIDNEY	The mechanism by which COX2 inhibition decreases renal cell survival is poorly understood. In the present study we examined the effect of COX2 activity on organic osmolyte accumulation in renal medulla and in cultured mouse renal medullary interstitial cells (MMICs) and its role in facilitating cell survival. Hypertonicity increased accumulation of the organic osmolytes inositol, sorbitol, and betaine in cultured mouse medullary interstitial cells. Pretreatment of MMICs with a COX2-specific inhibitor (SC58236, 10 mumol/liter) dramatically reduced osmolyte accumulation ( by 79 +/- 9, 57 +/- 12, and 96 +/- 10% for inositol, sorbitol, and betaine respectively, p < 0.05). Similarly, 24 h of dehydration increased inner medullary inositol, sorbitol, and betaine concentrations in vivo by 85 +/- 10, 197 +/- 28, and 190 +/- 24 pmol/&mu;g of protein, respectively, but this increase was also blunted ( by 100 +/- 5, 66 +/- 15, and 81 +/- 9% for inositol, sorbitol, and betaine, respectively, p < 0.05) by pretreatment with an oral COX2 inhibitor. Dehydrated COX2-/- mice also exhibited an impressive defect in sorbitol accumulation ( 88 +/- 9% less than wild type, p < 0.05) after dehydration. COX2 inhibition ( COX2 inhibitor-treated or COX2-/- MMICs) dramatically reduced the expression of organic osmolyte uptake mechanisms including betaine (BGT1) and sodium-myo-inositol transporter and aldose reductase mRNA expression under hypertonic conditions. Importantly, preincubation of COX2 inhibitor-treated MMICs with organic osmolytes restored their ability to survive hypertonic stress. In conclusion, osmolyte accumulation in the kidney inner medulla is dependent on COX2 activity, and providing exogenous osmolytes reverses COX2-induced cell death. These findings may have implications for the pathogenesis of analgesic nephropathy.	Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Div Nephrol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Moeckel, GW (corresponding author), Vanderbilt Univ, Med Ctr, Sch Med, Dept Pathol,Renal Pathol Div, MCN C-2317,1161 21st Ave So, Nashville, TN 37232 USA.			Breyer, Matthew/0000-0003-1880-371X; Moeckel, Gilbert/0000-0002-6059-0837	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039261, K08DK059975] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39261, K08 DK59975] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BECK FX, 1990, CELL VOLUME REGULATI, P132; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burger-Kentischer A, 1999, KIDNEY INT, V55, P1417, DOI 10.1046/j.1523-1755.1999.00382.x; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crofford LJ, 1997, J RHEUMATOL, V24, P15; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DUNN MJ, 1976, PROSTAG OTH LIPID M, V12, P37, DOI 10.1016/S0090-6980(76)80005-6; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Grupp C, 1999, EXP NEPHROL, V7, P377; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF18, DOI 10.1152/ajprenal.1997.273.1.F18; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hao CM, 1999, AM J PHYSIOL-RENAL, V277, pF352, DOI 10.1152/ajprenal.1999.277.3.F352; Hao CM, 2000, J CLIN INVEST, V106, P973, DOI 10.1172/JCI9956; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HLA T, 1991, J BIOL CHEM, V266, P24059; Horio M, 2001, NEPHROL DIAL TRANSPL, V16, P483, DOI 10.1093/ndt/16.3.483; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Komhoff M, 2000, KIDNEY INT, V57, P414; Komhoff M., 1997, AM J PHYSIOL, V272, P460; Lim H, 1997, CELL, V91, P197, DOI 10.1016/S0092-8674(00)80402-X; MACKNIGHT ADC, 1988, RENAL PHYSIOL BIOCH, V11, P114; MOECKEL GW, 1994, AM J PHYSIOL, V266, pF512, DOI 10.1152/ajprenal.1994.266.3.F512; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF100, DOI 10.1152/ajprenal.1997.272.1.F100; Moeckel GW, 1997, AM J PHYSIOL-RENAL, V272, pF94, DOI 10.1152/ajprenal.1997.272.1.F94; MOLLAND EA, 1978, KIDNEY INT, V13, P5, DOI 10.1038/ki.1978.2; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; WEINHOLD PA, 1963, P SOC EXP BIOL MED, V112, P165; YANCEY PH, 1990, AM J PHYSIOL, V258, pC156, DOI 10.1152/ajpcell.1990.258.1.C156; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF1, DOI 10.1152/ajprenal.1999.277.1.F1	31	58	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19352	19357		10.1074/jbc.M302209200	http://dx.doi.org/10.1074/jbc.M302209200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637551	hybrid			2022-12-27	WOS:000182932200083
J	Hatae, N; Kita, A; Tanaka, S; Sugimoto, Y; Ichikawa, A				Hatae, N; Kita, A; Tanaka, S; Sugimoto, Y; Ichikawa, A			Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E-2 receptor subtypes, EP3 and EP4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELLS; PROSTANOID RECEPTORS; TERMINAL DOMAINS; EP(3) SUBTYPE; 2 ISOFORMS; LAMININ; ADHESION; EXPRESSION; CLONING; KINASE	In this study, we investigated the role of PGE(2) in mouse mastocytoma P-815 cell adhesion to extracellular matrix proteins (ECMs) in vitro. We report that PGE(2) accelerated ProNectin F-TM ( a proteolytic fragment of fibronectin)-mediated adhesion, which was abolished by addition of the GRGDS peptide, an inhibitor of the RDG binding site of ProNectin F-TM. We show that the cAMP level and cAMP-regulated protein kinase (PKA) activity are critical mediators of this PGE(2) effect, because the cell-permeable cAMP analogue 8-Br-cAMP accelerated P-815 cell adhesion to ProNectin FTM and the pharmacological inhibitor of PKA, H-89, blocked PGE(2)-mediated adhesion. Consistent with mRNA expression of the G(s)-coupled EP4- and G(i)-coupled EP3-PGE receptor subtypes, P-815 cell adhesion was accelerated by treatment with a selective EP4 agonist, ONO-AE1-329, but not a selective EP1/EP3 agonist, sulprostone. However, simultaneous treatment with ONO-AE1-329 and sulprostone resulted in augmentation of both the cAMP level and cell adhesion. The augmentation of EP3-mediated cAMP synthesis was dose-dependent, without affecting the half-maximal concentration for EP4- mediated G(s)-activity, which was inhibited by a G(i) inhibitor, pertussis toxin. In conclusion, these findings suggest that PGE2 accelerates RGD-dependent adhesion via cooperative activation between EP3 and EP4 and contributes to the recruitment of mast cells to the ECM during inflammation.	Kyoto Univ, Fac Sci,Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan	Kyoto University	Ichikawa, A (corresponding author), Kyoto Univ, Fac Sci,Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 606, Japan.		TANAKA, Satoshi/B-1624-2011; Sugimoto, Yukihiko/AAV-6470-2021; Tanaka, Satoshi/H-6800-2019	TANAKA, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; Tanaka, Satoshi/0000-0002-3468-7694				AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; ANDERSON JP, 1994, BIOPOLYMERS, V34, P1049, DOI 10.1002/bip.360340808; BIANCHINE PJ, 1992, J IMMUNOL, V149, P3665; COLEMAN RA, 1994, PHARMACOL REV, V46, P205; DASTYCH J, 1991, IMMUNOLOGY, V73, P478; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Dormond O, 2001, NAT MED, V7, P1041, DOI 10.1038/nm0901-1041; FEREMAN AD, 1992, NATURE, V356, P159; Hanke S, 2001, MOL CELL BIOL, V21, P8452, DOI 10.1128/MCB.21.24.8452-8460.2001; Hatae N, 2002, BIOCHEM BIOPH RES CO, V290, P162, DOI 10.1006/bbrc.2001.6169; HONDA A, 1993, J BIOL CHEM, V268, P7759; HU ZQ, 1995, J IMMUNOL, V155, P2134; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; IRIE A, 1994, BIOCHEM BIOPH RES CO, V204, P303, DOI 10.1006/bbrc.1994.2460; Kameyoshi Y, 2000, ARCH DERMATOL RES, V292, P240, DOI 10.1007/s004030050481; KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014-5793(95)00966-D; KINASHI T, 1995, BLOOD, V86, P2086, DOI 10.1182/blood.V86.6.2086.bloodjournal8662086; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; NEGISHI M, 1995, J BIOL CHEM, V270, P16122, DOI 10.1074/jbc.270.27.16122; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; OHUCHI K, 1982, INT ARCH ALLER A IMM, V68, P326, DOI 10.1159/000233121; Saito H, 1996, J IMMUNOL, V157, P343; Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; THOMPSON HL, 1989, J IMMUNOL, V143, P4188; THOMPSON HL, 1991, IMMUNOLOGY, V72, P144; THOMPSON HL, 1990, J IMMUNOL, V145, P3425; THOMPSON HL, 1989, J IMMUNOL, V143, P2323; WALSH LJ, 1991, LAB INVEST, V65, P433; Wu CY, 1999, J CELL SCI, V112, P4485	32	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17977	17981		10.1074/jbc.M301312200	http://dx.doi.org/10.1074/jbc.M301312200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637575	hybrid			2022-12-27	WOS:000182838300049
J	Vreede, J; van der Horst, MA; Hellingwerf, KJ; Crielaard, W; van Aalten, DMF				Vreede, J; van der Horst, MA; Hellingwerf, KJ; Crielaard, W; van Aalten, DMF			PAS domains - Common structure and common flexibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOACTIVE YELLOW PROTEIN; INDUCED CONFORMATIONAL-CHANGES; PURPLE PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; ESSENTIAL DYNAMICS; CRYSTAL-STRUCTURE; PHOTOCYCLE INTERMEDIATE; SIGNAL-TRANSDUCTION; ANGSTROM RESOLUTION; MOLECULAR-DYNAMICS	PAS ((P) under bar ER-(A) under bar RNT-(S) under bar IM) domains are a family of sensor protein domains involved in signal transduction in a wide range of organisms. Recent structural studies have revealed that these domains contain a structurally conserved alpha/beta-fold, whereas almost no conservation is observed at the amino acid sequence level. The photoactive yellow protein, a bacterial light sensor, has been proposed as the PAS structural prototype yet contains an N-terminal helix-turn-helix motif not found in other PAS domains. Here we describe the atomic resolution structure of a photoactive yellow protein deletion mutant lacking this motif, revealing that the PAS domain is indeed able to fold independently and is not affected by the removal of these residues. Computer simulations of currently known PAS domain structures reveal that these domains are not only structurally conserved but are also similar in their conformational flexibilities. The observed motions point to a possible common mechanism for communicating ligand binding/activation to downstream transducer proteins.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Amsterdam, Swammerdam Inst Life Sci, Dept Microbiol, NL-1018 WV Amsterdam, Netherlands	University of Dundee; University of Amsterdam	van der Horst, MA (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland.		Vreede, Jocelyne/G-4525-2010	van Aalten, Daan/0000-0002-1499-6908				AMADEI A, 1993, PROTEINS, V17, P412, DOI 10.1002/prot.340170408; Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Changenet P, 1998, CHEM PHYS LETT, V282, P276, DOI 10.1016/S0009-2614(97)01334-1; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; de Groot BL, 1998, PROTEINS, V31, P116, DOI 10.1002/(SICI)1097-0134(19980501)31:2<116::AID-PROT2>3.0.CO;2-K; deGroot BL, 1997, PROTEINS, V29, P240, DOI 10.1002/(SICI)1097-0134(199710)29:2<240::AID-PROT11>3.0.CO;2-O; deGroot BL, 1996, BIOPHYS J, V71, P1707, DOI 10.1016/S0006-3495(96)79372-4; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Hendriks J, 1999, J BIOL CHEM, V274, P17655, DOI 10.1074/jbc.274.25.17655; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Hoff WD, 1999, BIOCHEMISTRY-US, V38, P1009, DOI 10.1021/bi980504y; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Imamoto Y, 2002, BIOCHEMISTRY-US, V41, P13595, DOI 10.1021/bi0264768; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; Mello LV, 2002, J BIOL CHEM, V277, P36678, DOI 10.1074/jbc.M205140200; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MILLER A, 1998, BIOCHIM BIOPHYS ACTA, V1141, P190; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Perman B, 1998, SCIENCE, V279, P1946, DOI 10.1126/science.279.5358.1946; Rubinstenn G, 1998, NAT STRUCT BIOL, V5, P568, DOI 10.1038/823; Sasaki J, 2002, BIOCHEMISTRY-US, V41, P1915, DOI 10.1021/bi011721t; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; van Aalten DMF, 2000, BIOCHEMISTRY-US, V39, P10082, DOI 10.1021/bi000952h; van Aalten DMF, 1998, PROTEIN ENG, V11, P873, DOI 10.1093/protein/11.10.873; van Aalten DMF, 2002, J BIOL CHEM, V277, P6463, DOI 10.1074/jbc.M109313200; van Aalten DMF, 2002, ACTA CRYSTALLOGR D, V58, P585, DOI 10.1107/S0907444902001257; Van Aalten DMF, 2000, PROTEIN SCI, V9, P64; van der Horst MA, 2001, FEBS LETT, V497, P26, DOI 10.1016/S0014-5793(01)02427-9; VanAalten DMF, 1997, J COMPUT CHEM, V18, P169, DOI 10.1002/(SICI)1096-987X(19970130)18:2<169::AID-JCC3>3.0.CO;2-T; VANAALTEN DMF, 1995, PROTEINS, V22, P45, DOI 10.1002/prot.340220107; vanAalten DMF, 1996, BIOPHYS J, V70, P684, DOI 10.1016/S0006-3495(96)79608-X; vanAalten DMF, 1995, PROTEIN ENG, V8, P1129; vanAalten DMF, 1997, BIOPHYS J, V73, P2891, DOI 10.1016/S0006-3495(97)78317-6; VanBrederode ME, 1996, BIOPHYS J, V71, P365, DOI 10.1016/S0006-3495(96)79234-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Xie AH, 2001, BIOCHEMISTRY-US, V40, P1510, DOI 10.1021/bi002449a; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	57	71	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18434	18439		10.1074/jbc.M301701200	http://dx.doi.org/10.1074/jbc.M301701200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639952	hybrid, Green Submitted			2022-12-27	WOS:000182838300110
J	Nimonkar, AV; Boehmer, PE				Nimonkar, AV; Boehmer, PE			The herpes simplex virus type-1 single-strand DNA-binding protein (ICP8) promotes strand invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION; ORIGIN; RECA; RECOMBINATION; EXCHANGE; HELIX	ICP8, the herpes simplex virus type-1 single-strand DNA-binding protein, was recently shown to promote strand exchange in conjunction with the viral replicative helicase (Nimonkar, A. V., and Boehmer, P. E. (2002) J. Biol. Chem. 277,15182-15189). Here we show that ICP8 also catalyzes strand invasion in an ATP-independent manner. Thus, ICP8 promotes the assimilation of a single-stranded donor molecule into a homologous plasmid, resulting in the formation of a displacement loop. Invasion of a homologous duplex by single-stranded DNA requires homology at either 3' or 5' end of the invading strand. The reaction is dependent on the free energy of supercoiling and alters the topology of the acceptor plasmid. Hence, strand invasion products formed by ICP8 are resistant to the action of restriction endonucleases that cleave outside of the area of pairing. The ability to catalyze strand invasion is a novel activity of ICP8 and the first demonstration of a eukaryotic viral single-strand DNA-binding protein to promote this reaction. In this regard ICP8 is functionally similar to the prototypical prokaryotic recombinase RecA and its eukaryotic homologs. This strand invasion activity of ICP8 coupled with DNA synthesis may explain the high prevalence of branched DNA structures during viral replication.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, R-629,POB 016129, Miami, FL 33101 USA.			Boehmer, Paul/0000-0003-4479-0529	NIGMS NIH HHS [GM62643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER WR, 1980, SCI AM, V243, P118; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; Boehmer PE, 1997, ANNU REV BIOCHEM, V66, P347, DOI 10.1146/annurev.biochem.66.1.347; DEAN FB, 1991, J BIOL CHEM, V266, P5062; DUTCH RE, 1992, J VIROL, V66, P277, DOI 10.1128/JVI.66.1.277-285.1992; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; Huang KJ, 2002, J BIOL CHEM, V277, P21071, DOI 10.1074/jbc.M201785200; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Nimonkar AV, 2002, J BIOL CHEM, V277, P15182, DOI 10.1074/jbc.M109988200; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; Xu LW, 2002, J BIOL CHEM, V277, P14321, DOI 10.1074/jbc.M112418200	19	31	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9678	9682		10.1074/jbc.M212555200	http://dx.doi.org/10.1074/jbc.M212555200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645567	hybrid			2022-12-27	WOS:000181524000106
J	Tiralongo, E; Schrader, S; Lange, H; Lemke, H; Tiralongo, J; Schauer, R				Tiralongo, E; Schrader, S; Lange, H; Lemke, H; Tiralongo, J; Schauer, R			Two trans-sialidase forms with different sialic acid transfer and sialidase activities from Trypanosoma congolense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCYCLIC CULTURE FORMS; LOW-DENSITY-LIPOPROTEIN; CHEMOENZYMATIC SYNTHESIS; NEURAMINIDASE ACTIVITIES; SUBSTRATE-SPECIFICITY; MICROGRAM QUANTITIES; RICH PROTEINS; CRUZI; BRUCEI; IDENTIFICATION	Trypanosomes express an enzyme called trans-sialidase (TS), which enables the parasites to transfer sialic acids from the environment onto trypanosomal surface molecules. Here we describe the purification and characterization of two TS forms from the African trypanosome Trypanosoma congolense. The purification of the two TS forms using a combination of anion exchange chromatography, isoelectric focusing, gel filtration, and subsequently, antibody affinity chromatography resulted, in both cases, in the isolation of a 90-kDa monomer on SDS-PAGE, which was identified as trans-sialidase using micro-sequencing. Monoclonal antibody 7/23, which bound and partially inhibited TS activity, was found in both cases to bind to a 90-kDa protein. Both TS forms possessed sialidase and transfer activity, but markedly differed in their activity ratios. The TS form with a high transfer-to-sialidase activity ratio, referred to as TS-form 1, possessed a pI of pH 4-5 and a molecular mass of 350-600 kDa. In contrast, the form with a low transfer-to-sialidase activity ratio, referred to as TS-form 2, exhibited a pI of pH 5-6.5 and a molecular mass of 130-180 kDa. Both TS forms were not significantly inhibited by known sialidase inhibitors and revealed no significant differences in donor and acceptor substrate specificities; however, TS-form 1 utilized various acceptor substrates with a higher catalytic efficiency. Interestingly, glutamic acid-alanine-rich protein, the surface glycoprotein, was co-purified with TS-form 1 suggesting an association between both proteins.	Univ Kiel, Inst Biochem, D-24098 Kiel, Germany	University of Kiel	Schauer, R (corresponding author), Univ Kiel, Inst Biochem, Olshaussenstr 40, D-24098 Kiel, Germany.	schauer@biochem.uni-kiel.de		Tiralongo, Evelin/0000-0002-1337-0321; Tiralongo, Joe/0000-0002-3529-6310; Lemke, Hilmar/0000-0002-8120-4843				Allsopp R, 2001, TRENDS PARASITOL, V17, P15, DOI 10.1016/S1471-4922(00)01828-6; ANSORGE W, 1985, J BIOCHEM BIOPH METH, V11, P13, DOI 10.1016/0165-022X(85)90037-5; BEECROFT RP, 1993, MOL BIOCHEM PARASIT, V61, P285, DOI 10.1016/0166-6851(93)90074-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brody EP, 2000, BRIT J NUTR, V84, pS39, DOI 10.1017/S0007114500002233; BRUN R, 1979, ACTA TROP, V36, P289; Buschiazzo A, 1997, GLYCOBIOLOGY, V7, P1167, DOI 10.1093/glycob/7.8.1167; Buschiazzo A, 2002, MOL CELL, V10, P757, DOI 10.1016/S1097-2765(02)00680-9; Buschiazzo A, 1996, CELL MOL BIOL, V42, P703; Butikofer P, 2002, MOL BIOCHEM PARASIT, V119, P7, DOI 10.1016/S0166-6851(01)00382-6; CHAVES LB, 1993, MOL BIOCHEM PARASIT, V61, P97, DOI 10.1016/0166-6851(93)90162-Q; Chuenkova MV, 2001, NEUROREPORT, V12, P3715, DOI 10.1097/00001756-200112040-00022; CORFIELD AP, 1981, SIALIDASES SIALIDOSE, P3; Cremona ML, 1999, GLYCOBIOLOGY, V9, P581, DOI 10.1093/glycob/9.6.581; CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125; DECARVALHO LCP, 1993, J EXP MED, V177, P465, DOI 10.1084/jem.177.2.465; DESOUZA W, 1984, INT REV CYTOL, V86, P197, DOI 10.1016/S0074-7696(08)60180-1; ENGSTLER M, 1995, ACTA TROP, V59, P117, DOI 10.1016/0001-706X(95)00077-R; ENGSTLER M, 1994, PARASITOL TODAY, V10, P180, DOI 10.1016/0169-4758(94)90022-1; ENGSTLER M, 1993, MOL BIOCHEM PARASIT, V61, P1, DOI 10.1016/0166-6851(93)90153-O; ENGSTLER M, 1992, MOL BIOCHEM PARASIT, V54, P21, DOI 10.1016/0166-6851(92)90091-W; Estabrook MM, 1997, INFECT IMMUN, V65, P4436, DOI 10.1128/IAI.65.11.4436-4444.1997; Gao W, 2001, EUR J IMMUNOL, V31, P1503, DOI 10.1002/1521-4141(200105)31:5&lt;1503::AID-IMMU1503&gt;3.0.CO;2-W; George SK, 2001, J AM CHEM SOC, V123, P11117, DOI 10.1021/ja015570t; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; Kopitz J, 1997, EUR J BIOCHEM, V248, P527, DOI 10.1111/j.1432-1033.1997.00527.x; Korschen HG, 1999, NATURE, V400, P761, DOI 10.1038/23468; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mattos-Guaraldi AL, 1998, FEMS MICROBIOL LETT, V168, P167; MEDINAACOSTA E, 1994, MOL BIOCHEM PARASIT, V64, P273, DOI 10.1016/0166-6851(94)00029-8; MEYER TS, 1965, BIOCHIM BIOPHYS ACTA, V107, P144, DOI 10.1016/0304-4165(65)90403-4; Montagna G, 2002, EUR J BIOCHEM, V269, P2941, DOI 10.1046/j.1432-1033.2002.02968.x; Oehler C, 2002, BIOL CHEM, V383, P1735, DOI 10.1515/BC.2002.194; Paris G, 2001, GLYCOBIOLOGY, V11, P305, DOI 10.1093/glycob/11.4.305; PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179; Peters J, 1992, MONOCLONAL ANTIBODIE; Poetsch A, 2001, J BIOL CHEM, V276, P48009, DOI 10.1074/jbc.M108941200; POTIER M, 1990, BIOCHEM BIOPH RES CO, V173, P449, DOI 10.1016/S0006-291X(05)81079-4; REUTER G, 1987, GLYCOCONJUGATE J, V4, P339, DOI 10.1007/BF01048367; Saavedra E, 1999, J EXP MED, V190, P1825, DOI 10.1084/jem.190.12.1825; SCHAUER R, 1987, METHOD ENZYMOL, V138, P132, DOI 10.1016/0076-6879(87)38012-7; Schauer R., 1997, GLYCOPROTEINS, P243; SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1994, J BIOL CHEM, V269, P7970; SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435; SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567; Schmidt D, 2000, J ORG CHEM, V65, P8518, DOI 10.1021/jo000871r; SCUDDER P, 1993, J BIOL CHEM, V268, P9886; TAKAHASHI N, 1995, ANAL BIOCHEM, V230, P333, DOI 10.1006/abio.1995.1483; Tertov VV, 2001, ATHEROSCLEROSIS, V159, P103, DOI 10.1016/S0021-9150(01)00498-1; UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x; VANDEKERCKHOVE F, 1992, GLYCOBIOLOGY, V2, P541, DOI 10.1093/glycob/2.6.541; VEH RW, 1981, J CHROMATOGR, V212, P313, DOI 10.1016/S0021-9673(01)84044-9; Vetere A, 1997, EUR J BIOCHEM, V247, P1083, DOI 10.1111/j.1432-1033.1997.01083.x; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WARNER TG, 1979, BIOCHEMISTRY-US, V18, P2783, DOI 10.1021/bi00580a014	59	33	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23301	23310		10.1074/jbc.M212909200	http://dx.doi.org/10.1074/jbc.M212909200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12649268	hybrid			2022-12-27	WOS:000183638600013
J	Hernandez-Guzman, FG; Higashiyama, T; Pangborn, W; Osawa, Y; Ghosh, D				Hernandez-Guzman, FG; Higashiyama, T; Pangborn, W; Osawa, Y; Ghosh, D			Structure of human estrone sulfatase suggests functional roles of membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ICHTHYOSIS; STEROID-SULFATASE; BREAST-CANCER; CRYSTAL-STRUCTURE; ARYLSULFATASE-C; PURIFICATION; INHIBITION; EXPRESSION; ENZYME; PROLIFERATION	Estrone sulfatase (ES; 562 amino acids), one of the key enzymes responsible for maintaining high levels of estrogens in breast tumor cells, is associated with the membrane of the endoplasmic reticulum ( ER). The structure of ES, purified from the microsomal fraction of human placentas, has been determined at 2.60-Angstrom resolution by x-ray crystallography. This structure shows a domain consisting of two antiparallel alpha-helices that protrude from the roughly spherical molecule, thereby giving the molecule a "mushroom-like" shape. These highly hydrophobic helices, each about 40 Angstrom long, are capable of traversing the membrane, thus presumably anchoring the functional domain on the membrane surface facing the ER lumen. The location of the transmembrane domain is such that the opening to the active site, buried deep in a cavity of the "gill" of the "mushroom," rests near the membrane surface, thereby suggesting a role of the lipid bilayer in catalysis. This simple architecture could be a prototype utilized by the ER membrane in dictating the form and the function of ER-resident enzymes.	Hauptman Woodward Med Res Inst, Dept Biol Struct, Buffalo, NY 14203 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biophys, Buffalo, NY 14263 USA	Hauptman Woodward Medical Research Institute; Roswell Park Cancer Institute	Ghosh, D (corresponding author), Hauptman Woodward Med Res Inst, Dept Biol Struct, 73 High St, Buffalo, NY 14203 USA.	ghosh@hwi.buffalo.edu			NCRR NIH HHS [RR-01646] Funding Source: Medline; NIGMS NIH HHS [GM62794] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062794] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alperin ES, 1997, J BIOL CHEM, V272, P20756, DOI 10.1074/jbc.272.33.20756; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Billich A, 2000, J STEROID BIOCHEM, V73, P225, DOI 10.1016/S0960-0760(00)00077-7; Bond CS, 1997, STRUCTURE, V5, P277, DOI 10.1016/S0969-2126(97)00185-8; Bracey MH, 2002, SCIENCE, V298, P1793, DOI 10.1126/science.1076535; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURNS GRJ, 1983, BIOCHIM BIOPHYS ACTA, V759, P199, DOI 10.1016/0304-4165(83)90313-6; de Planque MRR, 1999, J BIOL CHEM, V274, P20839, DOI 10.1074/jbc.274.30.20839; DIBBELT L, 1986, BIOL CHEM H-S, V367, P1223, DOI 10.1515/bchm3.1986.367.2.1223; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fleming KG, 2001, PROTEINS, V45, P313, DOI 10.1002/prot.1151; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Ghosh D, 2001, CHEM-BIOL INTERACT, V130, P637, DOI 10.1016/S0009-2797(00)00255-6; Hernandez-Guzman FG, 2001, J STEROID BIOCHEM, V78, P441, DOI 10.1016/S0960-0760(01)00119-4; Hernandez-Martin A, 1999, BRIT J DERMATOL, V141, P617; Leslie AGW, 1990, CRYSTALLOGRAPHIC COM; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOEL H, 1983, J STEROID BIOCHEM, V19, P1591, DOI 10.1016/0022-4731(83)90375-8; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasqualini JR, 2002, BREAST CANCER: PROGNOSIS, TREATMENT, AND PREVENTION, P187; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; Purohit A, 1998, CHEM-BIOL INTERACT, V109, P183, DOI 10.1016/S0009-2797(97)00132-4; Purohit A, 1999, J STEROID BIOCHEM, V69, P227, DOI 10.1016/S0960-0760(99)00039-4; Reed MJ, 1997, ENDOCR REV, V18, P701, DOI 10.1210/er.18.5.701; Reed MJ, 1996, ENDOCR-RELAT CANCER, V3, P9, DOI 10.1677/erc.0.0030009; Rossmann MG, 1999, ACTA CRYSTALLOGR D, V55, P1631, DOI 10.1107/S0907444999008379; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; Selcer KW, 1997, CANCER RES, V57, P702; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; STEIN C, 1989, J BIOL CHEM, V264, P13865; SUZUKI T, 1992, ENDOCRINOL JAPON, V39, P93; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VACCARO AM, 1987, ENZYME, V37, P115, DOI 10.1159/000469248; VANDERLOOS CM, 1984, J INHERIT METAB DIS, V7, P97, DOI 10.1007/BF01801762; Wendt KU, 1997, SCIENCE, V277, P1811, DOI 10.1126/science.277.5333.1811; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; Yanaihara A, 2001, STEROIDS, V66, P87, DOI 10.1016/S0039-128X(00)00204-X	41	141	142	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22989	22997		10.1074/jbc.M211497200	http://dx.doi.org/10.1074/jbc.M211497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12657638	hybrid			2022-12-27	WOS:000183503900106
J	Martinez-Morales, JR; Dolez, V; Rodrigo, I; Zaccarini, R; Leconte, L; Bovolenta, P; Saule, S				Martinez-Morales, JR; Dolez, V; Rodrigo, I; Zaccarini, R; Leconte, L; Bovolenta, P; Saule, S			OTX2 activates the molecular network underlying retina pigment epithelium differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZIPPER TRANSCRIPTION FACTOR; DNA-BINDING DOMAINS; NEURAL RETINA; GENE-EXPRESSION; IN-VITRO; MICROPHTHALMIA; PROTEIN; HOMEODOMAIN; PROMOTER; MOUSE	The retina pigment epithelium ( RPE) is fundamental for the development and function of the vertebrate eye. Molecularly, the presumptive RPE can be identified by the early expression of two transcription factors, Mitf and Otx. In mice deficient for either gene, RPE development is impaired with loss of melanogenic gene expression, raising the possibility that in the eye OTX proteins operate either in a feedback loop or in cooperation with MITF for the control of RPE- specific gene expression. Here we show that Otx2 induces a pigmented phenotype when overexpressed in avian neural retina cells. In addition, OTX2 binds specifically to a bicoid motif present in the promoter regions of three Mitf target genes, QNR71, TRP- 1, and tyrosinase, leading to their transactivation. OTX2 and MITF co- localize in the nuclei of RPE cells and physically interact, and their co- expression results in a cooperative activation of QNR71 and tyrosinase promoters. Collectively, these data suggest that both transcription factors operate at the same hierarchical level to establish the identity of the RPE.	CSIC, Inst Cajal, E-28002 Madrid, Spain; Ctr Univ, Inst Curie, Sect Rech, Unitee Mixte Res 146, F-91405 Orsay, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Bovolenta, P (corresponding author), CSIC, Inst Cajal, Dr Arce 37, E-28002 Madrid, Spain.		Martinez-Morales, Juan R/K-7622-2014	Martinez-Morales, Juan R/0000-0002-4650-4293				Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838; Arnheiter H, 1998, NATURE, V391, P632, DOI 10.1038/35487; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2; Boncinelli E, 2001, TRENDS GENET, V17, P633, DOI 10.1016/S0168-9525(01)02418-0; Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141; Bovolenta P, 1997, J NEUROSCI, V17, P4243; Briata P, 1999, FEBS LETT, V445, P160, DOI 10.1016/S0014-5793(99)00113-1; Bumsted KM, 2000, INVEST OPHTH VIS SCI, V41, P903; Courtois V, 2003, J NEUROCHEM, V84, P840, DOI 10.1046/j.1471-4159.2003.01583.x; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; Gammill LS, 1997, DEVELOPMENT, V124, P471; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Goding CR, 2000, GENE DEV, V14, P1712; Guazzi S, 1998, J BIOL CHEM, V273, P11092, DOI 10.1074/jbc.273.18.11092; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Kelley CG, 2000, MOL ENDOCRINOL, V14, P1246, DOI 10.1210/me.14.8.1246; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Knoepfler PS, 1999, NUCLEIC ACIDS RES, V27, P3752, DOI 10.1093/nar/27.18.3752; Mahalingam H, 1997, EXP CELL RES, V237, P83, DOI 10.1006/excr.1997.3773; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Martinez-Morales JR, 2001, DEVELOPMENT, V128, P2019; Morgan R, 1999, MECH DEVELOP, V85, P97, DOI 10.1016/S0925-4773(99)00091-X; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Nguyen MTT, 2000, DEVELOPMENT, V127, P3581; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; PANNESE M, 1995, DEVELOPMENT, V121, P707; Pittack C, 1997, DEVELOPMENT, V124, P805; Planque N, 1999, CELL GROWTH DIFFER, V10, P525; Planque N, 2001, J BIOL CHEM, V276, P29330, DOI 10.1074/jbc.M101812200; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; Poulin G, 2000, MOL CELL BIOL, V20, P4826, DOI 10.1128/MCB.20.13.4826-4837.2000; RAYMOND SM, 1995, CURR BIOL, V5, P1286, DOI 10.1016/S0960-9822(95)00255-7; Sato S, 2001, PIGM CELL RES, V14, P428, DOI 10.1034/j.1600-0749.2001.140602.x; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Simeone A, 2002, CURR OPIN GENET DEV, V12, P409, DOI 10.1016/S0959-437X(02)00318-0; SIMEONE A, 1993, EMBO J, V12, P2735, DOI 10.1002/j.1460-2075.1993.tb05935.x; Takeda K, 2002, BBA-GENE STRUCT EXPR, V1574, P15, DOI 10.1016/S0167-4781(01)00339-6; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Udono T, 2000, BBA-GENE STRUCT EXPR, V1491, P205, DOI 10.1016/S0167-4781(00)00051-8; Wada S, 2002, DEV DYNAM, V225, P46, DOI 10.1002/dvdy.10135; YASUMOTO K, 1995, J BIOCHEM-TOKYO, V118, P874, DOI 10.1093/jb/118.5.874; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Yasumoto K, 1997, J BIOL CHEM, V272, P503	48	135	139	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21721	21731		10.1074/jbc.M301708200	http://dx.doi.org/10.1074/jbc.M301708200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663655	hybrid			2022-12-27	WOS:000183354200053
J	Santra, MK; Panda, D				Santra, MK; Panda, D			Detection of an intermediate during unfolding of bacterial cell division protein FtsZ - Loss of functional properties precedes the global unfolding of FtsZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; TUBULIN POLYMERIZATION; GTP HYDROLYSIS; MECHANISM; CONFORMATION; FLUORESCENCE; BINDING	Using environment- sensitive fluorescence of 1- anilinonaphthalene-8- sulfonic acid, polarization of fluorescein 5 '- isothiocyanate- labeled FtsZ, and far- UV circular dichroism spectroscopy, the chemical unfolding of FtsZ was found to proceed through two steps. The first step of the urea- induced unfolding produced an intermediate, which then unfolded at higher concentrations of urea. The intermediate state contains native- like secondary structure and much less tertiary structure compared with the native state. It is distinct from the native state as well as from the unfolded state. Similar to urea- induced unfolding of FtsZ, thermal unfolding of FtsZ also occurs in two steps. The midpoints for the first and second thermal unfolding transitions were found to be 38 +/- 4 and 77 +/- 5 degreesC, respectively. Further, the functional properties of FtsZ are extremely sensitive to urea, guanidium chloride, and sodium dodecyl sulfate. For example, 50% inhibition of the FtsZ assembly and GTP hydrolysis occurred at 0.1 and 0.2 M of urea, respectively. FtsZ lost its functional properties before any significant perturbation in the secondary or tertiary structure was detected by using several fluorescence techniques and far UV- CD indicating preferential local unfolding of the functional region( s). In addition, the unfolded FtsZ regains its ability to polymerize fully upon removal of urea. The data taken together suggest that FtsZ unfolds reversibly through a multistep process, and local responses that inhibit functional properties precede the global transition of FtsZ to the unfolded state.	Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India	Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Panda, D (corresponding author), Indian Inst Technol, Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India.	panda@btc.iitb.ac.in						Andreu JM, 2002, J BIOL CHEM, V277, P43262, DOI 10.1074/jbc.M206723200; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; Beuria TK, 2003, J BIOL CHEM, V278, P3735, DOI 10.1074/jbc.M205760200; BI E, 1990, J BACTERIOL, V172, P2765, DOI 10.1128/jb.172.5.2765-2768.1990; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clarke AR, 1997, CURR OPIN BIOTECH, V8, P400, DOI 10.1016/S0958-1669(97)80060-2; Daggett V, 2003, TRENDS BIOCHEM SCI, V28, P18, DOI 10.1016/S0968-0004(02)00012-9; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; Diaz JF, 2001, J BIOL CHEM, V276, P17307, DOI 10.1074/jbc.M010920200; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Erickson HP, 1996, P NATL ACAD SCI USA, V93, P519, DOI 10.1073/pnas.93.1.519; EWBANK JJ, 1991, NATURE, V350, P518, DOI 10.1038/350518a0; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; GUHA S, 1995, BIOCHEMISTRY-US, V34, P6925, DOI 10.1021/bi00021a003; Guha S, 1997, BIOCHEMISTRY-US, V36, P13208, DOI 10.1021/bi970993m; Gupta K, 2002, BIOCHEMISTRY-US, V41, P13029, DOI 10.1021/bi025952r; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; LALA AK, 1992, J BIOL CHEM, V267, P19914; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Lowe J, 1998, J STRUCT BIOL, V124, P235, DOI 10.1006/jsbi.1998.4041; Mukherjee A, 1999, J BACTERIOL, V181, P823, DOI 10.1128/JB.181.3.823-832.1999; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Mukherjee A, 1998, EMBO J, V17, P462, DOI 10.1093/emboj/17.2.462; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; NOLTING B, 1995, P NATL ACAD SCI USA, V92, P10668, DOI 10.1073/pnas.92.23.10668; PANDA D, 1992, BIOCHEMISTRY-US, V31, P9709, DOI 10.1021/bi00155a026; Panda M, 2000, J BIOL CHEM, V275, P63, DOI 10.1074/jbc.275.1.63; Plaxco KW, 1996, CURR OPIN STRUC BIOL, V6, P630, DOI 10.1016/S0959-440X(96)80029-7; PRASAD ARS, 1986, BIOCHEMISTRY-US, V25, P739, DOI 10.1021/bi00351a035; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SACKETT DL, 1994, BIOCHEMISTRY-US, V33, P12868, DOI 10.1021/bi00209a019; Sau AK, 2002, BIOPHYS CHEM, V98, P267, DOI 10.1016/S0301-4622(02)00076-5; Scheffers DJ, 2002, BIOCHEMISTRY-US, V41, P521, DOI 10.1021/bi011370i; Scheffers DJ, 2002, MOL MICROBIOL, V43, P1517, DOI 10.1046/j.1365-2958.2002.02828.x; van den Ent F, 2001, CURR OPIN MICROBIOL, V4, P634, DOI 10.1016/S1369-5274(01)00262-4; WARD JL, 1971, METHOD ENZYMOL, V117, P509; Wolff J, 1996, BIOCHEMISTRY-US, V35, P5910, DOI 10.1021/bi9527395; YI QM, 1985, GENE, V36, P241; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455; Yu XC, 1999, J CELL SCI, V112, P2301; Yu XC, 1998, J BIOL CHEM, V273, P10216, DOI 10.1074/jbc.273.17.10216	48	33	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21336	21343		10.1074/jbc.M301303200	http://dx.doi.org/10.1074/jbc.M301303200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12649276	hybrid			2022-12-27	WOS:000183354200006
J	Hortala, M; Ferjoux, G; Estival, A; Bertrand, C; Schulz, S; Pradayrol, L; Susini, C; Clemente, F				Hortala, M; Ferjoux, G; Estival, A; Bertrand, C; Schulz, S; Pradayrol, L; Susini, C; Clemente, F			Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform - Implication of JAK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; FACTOR-II; NUCLEAR-LOCALIZATION; FGF-2 ISOFORMS; MESSENGER-RNA; G-PROTEINS; EXPRESSION; MODULATION; TRANSLATION; AR4-2J	The fibroblast growth factor (FGF)-2 isoform of 210 amino acids ( HMW FGF-2) contains a nuclear localization sequence (NLS) and is targeted to the nucleus. This FGF-2 isoform allows cells to grow in low serum concentrations through still unknown mechanisms called intracrine regulations. Different peptide hormones and cytokines have been found to be nuclearized through NLS and to induce cell proliferation. The existence of molecules acting as negative regulators of the intracrine-induced cell growth has not been explored. Pancreatic cells AR4-2J were stably transfected to express selectively the HMW FGF-2. We demonstrated that activation of the somatostatin receptor subtype SST2 by the somatostatin analogue RC-160 in serum-deprived medium inhibits the mitogenic effect of the HMW FGF-2, without affecting growth of control cells. The signaling pathway implicates Galpha(i)/ JAK2/SHP-1. The Galpha(i) inhibitor pertussis toxin and the JAK2 inhibitor AG490 abrogate the inhibitory effect of RC-160 on HMW FGF-2-induced cell growth. Co-immunoprecipitation studies demonstrate the constitutive association of JAK2 and SHP-1, and RC-160 induces a rapid activation of both proteins followed by the dissociation of the complex. AG490 prevents the RC-160 induced SHP-1 activation indicating the implication of JAK2 in this process. JAK2 and SHP-1 are immunoprecipitated with SST2 in basal conditions indicating the existence of a functional signaling complex at the receptor level. In summary, these data provide the following evidence: 1) the intracrine-induced proliferation can be reversed by extracellular acting polypeptides; 2) SST2 inhibitory signaling may involve the JAK2/SHP-1 pathway.	CHU Rangueil, INSERM, U531, Inst Louis Bugnard, F-31403 Toulouse 4, France; Otto Von Guericke Univ, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Otto von Guericke University	Clemente, F (corresponding author), CHU Rangueil, INSERM, U531, Inst Louis Bugnard, Bat L3,Av Jean Poulhes, F-31403 Toulouse 4, France.		Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				Amiri F, 1999, J BIOL CHEM, V274, P32382, DOI 10.1074/jbc.274.45.32382; Arnaud E, 1999, MOL CELL BIOL, V19, P505; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; Dahl JP, 2000, BIOCHEMISTRY-US, V39, P14877, DOI 10.1021/bi001073y; Delrieu I, 1999, BIOCHEM J, V340, P201, DOI 10.1042/0264-6021:3400201; Delrieu I, 2000, FEBS LETT, V468, P6, DOI 10.1016/S0014-5793(00)01189-3; Escaffit F, 2000, INT J CANCER, V85, P555, DOI 10.1002/(SICI)1097-0215(20000215)85:4<555::AID-IJC18>3.0.CO;2-H; Estival A, 1996, J BIOL CHEM, V271, P5663, DOI 10.1074/jbc.271.10.5663; ESTIVAL A, 1993, CANCER RES, V53, P1182; Estival A, 1996, BIOCHEM J, V315, P619, DOI 10.1042/bj3150619; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Gaubert F, 2001, J BIOL CHEM, V276, P1545, DOI 10.1074/jbc.M001184200; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; Gu YZ, 1997, MOL ENDOCRINOL, V11, P527, DOI 10.1210/me.11.5.527; Gualandris A, 1999, J CELL PHYSIOL, V181, P273, DOI 10.1002/(SICI)1097-4652(199911)181:2<273::AID-JCP9>3.0.CO;2-#; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Keresztes M, 1999, J CELL BIOL, V145, P421, DOI 10.1083/jcb.145.3.421; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Klein S, 1996, J BIOL CHEM, V271, P22583, DOI 10.1074/jbc.271.37.22583; Korc M, 1998, Surg Oncol Clin N Am, V7, P25; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Monzat V, 1996, EUR J CELL BIOL, V69, P316; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; Re RN, 2002, REGUL PEPTIDES, V106, P1, DOI 10.1016/S0167-0115(02)00031-9; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; Schulz S, 1998, CLIN CANCER RES, V4, P2047; SHERMAN L, 1993, DEVELOPMENT, V118, P1313; THEVENIAU MA, 1994, J NEUROCHEM, V63, P447; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VIDAL C, 1994, MOL PHARMACOL, V46, P97; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Wu DW, 2000, BLOOD CELL MOL DIS, V26, P15, DOI 10.1006/bcmd.2000.0273; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; Yu CL, 1997, J IMMUNOL, V159, P5206; ZEGGARI M, 1994, BIOCHEM J, V303, P441, DOI 10.1042/bj3030441	50	21	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20574	20581		10.1074/jbc.M210767200	http://dx.doi.org/10.1074/jbc.M210767200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665520	hybrid			2022-12-27	WOS:000183230500018
J	Jallepalli, PV; Lengauer, C; Vogelstein, B; Bunz, F				Jallepalli, PV; Lengauer, C; Vogelstein, B; Bunz, F			The Chk2 tumor suppressor is not required for p53 responses in human cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-MEDIATED G(1) ARREST; LI-FRAUMENI-SYNDROME; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; CHECKPOINT PATHWAY; COLORECTAL-CANCER; BREAST-CANCER; PHOSPHORYLATION; ACTIVATION; KINASE	Ionizing radiation damages chromosomal DNA and activates p53-dependent transcription in mammalian cells. The Chk2 protein kinase has been hypothesized to be the primary mediator of this response. We have rigorously tested this hypothesis in human cells by disrupting the CHK2 gene through homologous recombination. We found that the p53 response was unexpectedly robust in such cells. Phosphorylation of p53 at serine 20, accumulation of p53 protein, transcriptional activation of p53 target genes, and cell cycle arrest and apoptotic death phenotypes were completely intact regardless of CHK2 status. Our results indicate that Chk2 kinase is not required for p53 activation in human cells and explain why CHK2 and TP53 mutations can jointly occur in human tumors.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University	Bunz, F (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.				NATIONAL CANCER INSTITUTE [R01CA043460, R37CA043460] Funding Source: NIH RePORTER; NCI NIH HHS [CA43460] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JW, 2003, J BIOL CHEM, V278, P20480, DOI 10.1074/jbc.M213185200; Ahn JY, 2000, CANCER RES, V60, P5934; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; BROWN KD, 2002, NAT GENET, V225, P25; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1994, CANCER RES, V54, P5054; Chan TA, 2000, GENE DEV, V14, P1584; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Lee SB, 2001, CANCER RES, V61, P8062; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shieh SY, 2000, GENE DEV, V14, P289; Sodha N, 2000, Science, V289, P359; Sparks AB, 1998, CANCER RES, V58, P1130; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xie SQ, 2001, J BIOL CHEM, V276, P36194, DOI 10.1074/jbc.M104157200; Yu Q, 2002, CANCER RES, V62, P5743; Zhao RB, 2000, GENE DEV, V14, P981	44	134	135	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20475	20479		10.1074/jbc.M213159200	http://dx.doi.org/10.1074/jbc.M213159200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654917	hybrid			2022-12-27	WOS:000183230500006
J	Li, ZY; Wang, CC				Li, ZY; Wang, CC			A PHO80-like cyclin and a B-type cyclin control the cell cycle of the procyclic form of Trypanosoma brucei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; DNA-REPLICATION; KINETOPLAST; COMPLEX; GENES; TRANSCRIPTION; CYTOKINESIS; SEGREGATION; EXPRESSION; GAMBIENSE	Cyclins bind and activate cyclin-dependent kinases that regulate cell cycle progression in eukaryotes. Cell cycle control in Trypanosoma brucei was analyzed in the present study. Genes encoding four PHO80 cyclin homologues and three B-type cyclin homologues but no G(1) cyclin homologues were identified in this organism. Through knocking down expression of the seven cyclin genes with the RNA interference technique in the procyclic form of T. brucei, we demonstrated that one PHO80 homologue (CycE1/CYC2) and a B-type cyclin homologue (CycB2) are the essential cyclins regulating G(1)/S and G(2)/M transitions, respectively. This lack of overlapping cyclin function differs significantly from that observed in the other eukaryotes. Also, PHO80 cyclin is known for its involvement only in phosphate signaling in yeast with no known function in cell cycle control. Both observations thus suggest the presence of simple and novel cell cycle regulators in trypanosomes. T. brucei cells deficient in CycE1/CYC2 displayed a long slender morphology, whereas those lacking CycB2 assumed a fat stumpy form. These cells apparently still can undergo cytokinesis generating small numbers of anucleated daughter cells, each containing a single kinetoplast known as a zoid. Two different types of zoids were identified, the slender zoid derived from reduced CycE1/CYC2 expression and the stumpy zoid from CycB2 deficiency. This observation indicates an uncoupling between the kinetoplast and the nuclear cycle, resulting in cell division driven by kinetoplast segregation with neither a priori S phase nor mitosis in the trypanosome.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu		Li, Ziyin/0000-0002-3960-9716	NIAID NIH HHS [R01 AI021786, R01 AI-21786] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021786] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aerne BL, 1998, MOL BIOL CELL, V9, P945, DOI 10.1091/mbc.9.4.945; Bastin P, 2000, J CELL SCI, V113, P3321; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; Carroll AS, 2002, TRENDS BIOCHEM SCI, V27, P87, DOI 10.1016/S0968-0004(01)02040-0; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; HEMERLY A, 1992, P NATL ACAD SCI USA, V89, P3295, DOI 10.1073/pnas.89.8.3295; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Jacobs HW, 1998, GENE DEV, V12, P3741, DOI 10.1101/gad.12.23.3741; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KOUCHI H, 1995, PLANT CELL, V7, P1143, DOI 10.1105/tpc.7.8.1143; Kuntzel H, 1996, BIOL CHEM, V377, P481; Lamb JR, 2001, J BIOL CHEM, V276, P21512, DOI 10.1074/jbc.M100235200; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Li ZY, 2002, J BIOL CHEM, V277, P15486, DOI 10.1074/jbc.M109029200; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; MOTTRAM JC, 1995, GENE, V162, P147, DOI 10.1016/0378-1119(95)00350-F; ONO T, 1976, BIKEN J, V19, P63; ONO T, 1975, BIKEN J, V18, P257; Ploubidou A, 1999, J CELL SCI, V112, P4641; RICHARDSON H, 1992, GENE DEV, V6, P2021, DOI 10.1101/gad.6.11.2021; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; Timms MW, 2002, MOL BIOL CELL, V13, P3747, DOI 10.1091/mbc.E02-05-0266; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; Van Hellemond JJ, 2000, MOL BIOCHEM PARASIT, V111, P275, DOI 10.1016/S0166-6851(00)00318-2; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	34	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20652	20658		10.1074/jbc.M301635200	http://dx.doi.org/10.1074/jbc.M301635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665514	hybrid			2022-12-27	WOS:000183230500028
J	Goubaeva, F; Ghosh, M; Malik, S; Yang, J; Hinkle, PM; Griendling, KK; Neubig, RR; Smrcka, AV				Goubaeva, F; Ghosh, M; Malik, S; Yang, J; Hinkle, PM; Griendling, KK; Neubig, RR; Smrcka, AV			Stimulation of cellular signaling and G protein subunit dissociation by G protein beta gamma subunit-binding peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; CRYSTAL-STRUCTURE; RECEPTOR; SITE; ACTIVATION; PHOSDUCIN; CELLS; DETERMINANTS; RESOLUTION; CYCLASE	We previously developed peptides that bind to G protein betagamma subunits and selectively block interactions between betagamma subunits and a subset of effectors in vitro (Scott, J. K., Huang, S. F., Gangadhar, B. P., Samoriski, G. M., Clapp, P., Gross, R. A., Taussig, R., and Smrcka, A. V. (2001) EMBO J. 20, 767-776). Here, we created cell-permeating versions of some of these peptides by N-terminal modification with either myristate or the cell permeation sequence from human immunodeficiency virus TAT protein. The myristoylated betagamma-binding peptide (mSIRK) applied to primary rat arterial smooth muscle cells caused rapid activation of extracellular signal-regulated kinase 1/2 in the absence of an agonist. This activation did not occur if the peptide lacked a myristate at the N terminus, if the peptide had a single point mutation to eliminate betagamma subunit binding, or if the cells stably expressed the C terminus of betaARK1. A human immunodeficiency virus TAT-modified peptide (TAT-SIRK) and a myristoylated version of a second peptide (mSCAR) that binds to the same site on betagamma subunits as mSIRK, also caused extracellular signal-regulated kinase activation. mSIRK also stimulated Jun N-terminal kinase phosphorylation, p38 mitogen-activated protein kinase phosphorylation, and phospholipase C activity and caused Ca2+ release from internal stores. When tested with purified G protein subunits in vitro, SIRK promoted alpha subunit dissociation from betagamma subunits without stimulating nucleotide exchange. These data suggest a novel mechanism by which selective betagamma-binding peptides can release G protein betagamma subunits from heterotrimers to stimulate G protein pathways in cells.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Emory Univ, Dept Med, Atlanta, GA 30322 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Rochester; Emory University; University of Michigan System; University of Michigan	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.		Ghosh, Mousumi/D-3180-2011	Griendling, Kathy/0000-0002-9456-8582; Neubig, Richard/0000-0003-0501-0008	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46417] Funding Source: Medline; NIDDK NIH HHS [DK19974] Funding Source: Medline; NIGMS NIH HHS [GM60286] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bluml K, 1997, EMBO J, V16, P4908, DOI 10.1093/emboj/16.16.4908; Cismowski MJ, 2001, LIFE SCI, V68, P2301, DOI 10.1016/S0024-3205(01)01019-0; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Duffy S, 1998, ANAL BIOCHEM, V262, P122, DOI 10.1006/abio.1998.2770; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; Fairbrother WJ, 1998, BIOCHEMISTRY-US, V37, P17754, DOI 10.1021/bi981931e; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GUTKIND JS, 2001, SCI STKE; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Hartman JL, 1996, J BIOL CHEM, V271, P22591, DOI 10.1074/jbc.271.37.22591; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1997, ADV SEC MESS PHOSPH, V31, P263; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; Panchenko MP, 1998, J BIOL CHEM, V273, P28298, DOI 10.1074/jbc.273.43.28298; Romoser VA, 2001, MOL ENDOCRINOL, V15, P125, DOI 10.1210/me.15.1.125; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Sarvazyan NA, 2002, BIOCHEMISTRY-US, V41, P12858, DOI 10.1021/bi026212l; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Ushio-Fukai M, 1999, MOL PHARMACOL, V55, P142, DOI 10.1124/mol.55.1.142; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Yoshikawa DM, 2001, J BIOL CHEM, V276, P11246, DOI 10.1074/jbc.M006073200	31	58	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19634	19641		10.1074/jbc.M300052200	http://dx.doi.org/10.1074/jbc.M300052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649269	hybrid			2022-12-27	WOS:000183078000011
J	Ni, CW; Hsieh, HJ; Chao, YJ; Wang, DL				Ni, CW; Hsieh, HJ; Chao, YJ; Wang, DL			Shear flow attenuates serum-induced STAT3 activation in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIGNAL-REGULATED KINASE; EARLY GROWTH RESPONSE-1; GENE-EXPRESSION; SUPEROXIDE-DISMUTASE; STRESS; IL-6; PHOSPHORYLATION; MECHANISMS; APOPTOSIS	Vascular endothelial cells (ECs) are constantly exposed to flow-induced shear stress. Shear stress is known to induce signaling cascades, including the extracellular signal-regulated protein kinase (ERK) pathway. STAT3 transcription factor plays a key role in cytokine stimulation. Recent studies indicate that STAT3 is involved in growth factor-induced cell cycle. In the present study, we have examined STAT3 activation of ECs under conditions of shear flow. Bovine aortic ECs cultured with serum at static state show a serum concentration-dependent phosphorylation at Tyr-705 of STAT3, whereas there is a constant basal phosphorylation at Ser-727. In ECs subjected to shear flow, a shear dose-dependent phosphorylation of Ser-727 and ERK1/2 was observed. In contrast, a concomitantly shear dose-dependent inhibition of phosphorylation at Tyr-705 was exhibited. Shear stress on ECs increased the association of ERK1/2 to STAT3. ECs treated with MEK inhibitor (U0126 or PD98059) consistently and significantly reduced the shear-induced ERK1/2 and Ser727 phosphorylation, indicating that ERK1/2 is upstream of Ser-727 phosphorylation. Interestingly, shear-induced inhibition in Tyr-705 phosphorylation was abolished in these same inhibitor-treated ECs. Similarly, ECs transfected with a dominant positive mutant of MEK1 enhanced the phosphorylation of Ser-727 with the attenuation of the Tyr-705 phosphorylation. In contrast, when ECs were transfected with dominant positive mutant of MEKK1, JNK upstream, no change in the phosphorylation of Ser-727 and Tyr-705 was observed. These results indicate that shear flow induces the phosphorylation of Ser727 via ERK1/2 pathway, and this Ser-727 phosphorylation inhibits Tyr-705 phosphorylation in STAT3. As a result, shear flow reduced the translocation of STAT3 into nucleus. This study shows for the first time that shear flow may play a significant role by attenuating STAT3 activation and thus may reduce inflammatory responses and/or serum-induced endothelial proliferation.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wang, DL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan.	lingwang@ibms.sinica.edu.tw		Ni, Chih-Wen/0000-0002-7343-282X				Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEODD, 2002, J BIOL CHEM, V277, P21237; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Fleming I, 1998, CIRC RES, V82, P686, DOI 10.1161/01.RES.82.6.686; GOMIKIEWICZ A, 2000, FASEB J, V14, P1093; Hermann C, 1997, ARTERIOSCL THROM VAS, V17, P3588, DOI 10.1161/01.ATV.17.12.3588; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Masuda M, 2002, CANCER RES, V62, P3351; Matsumoto Y, 1998, BLOOD, V91, P4164, DOI 10.1182/blood.V91.11.4164.411k29_4164_4172; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; Ni CW, 2003, J CELL PHYSIOL, V195, P428, DOI 10.1002/jcp.10259; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Stankova J, 1996, AM J PHYSIOL-CELL PH, V271, pC1073, DOI 10.1152/ajpcell.1996.271.4.C1073; Sundaresan M, 1996, BIOCHEM J, V318, P379, DOI 10.1042/bj3180379; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; Vignais ML, 1999, MOL CELL BIOL, V19, P3727; Volk T, 2000, MOL CELL BIOCHEM, V206, P105, DOI 10.1023/A:1007059616914; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Wung BS, 2001, ARTERIOSCL THROM VAS, V21, P1941, DOI 10.1161/hq1201.099428; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Wung BS, 1999, CIRC RES, V84, P804; Zeng ZZ, 2002, J BIOL CHEM, V277, P41213, DOI 10.1074/jbc.M204508200; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200; Zou YP, 1998, INT J MOL MED, V1, P827	49	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19702	19708		10.1074/jbc.M300893200	http://dx.doi.org/10.1074/jbc.M300893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637510	Green Published, hybrid			2022-12-27	WOS:000183078000019
J	Royle, L; Roos, A; Harvey, DJ; Wormald, MR; van Gijlswijk-Janssen, D; Redwan, EM; Wilson, IA; Daha, MR; Dwek, RA; Rudd, PM				Royle, L; Roos, A; Harvey, DJ; Wormald, MR; van Gijlswijk-Janssen, D; Redwan, EM; Wilson, IA; Daha, MR; Dwek, RA; Rudd, PM			Secretory IgA N- and O-glycans provide a link between the innate and adaptive immune systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MEDIATED EPITHELIAL TRANSPORT; HUMAN GASTRIC EPITHELIUM; BINDING LECTIN PATHWAY; NORMAL HUMAN SERUM; FC-ALPHA-R; IMMUNOGLOBULIN-A; HUMAN-MILK; J-CHAIN; MASS-SPECTROMETRY	Secretory IgA (SIgA) is a multi-polypeptide complex consisting of a secretory component (SC) covalently attached to dimeric IgA containing one joining (J) chain. We present the analysis of both the N- and O-glycans on the individual peptides from this complex. Based on these data, we have constructed a molecular model of SIgA1 with all its glycans, in which the Fab arms form a T shape and the SC is wrapped around the heavy chains. The O-glycan regions on the heavy (H) chains and the SC N- glycans have adhesin-binding glycan epitopes including galactose-linked beta1-4 and beta1-3 to GlcNAc, fucose-linked alpha1-3 and alpha1-4 to GlcNAc and alpha1-2 to galactose, and alpha2-3 and alpha2-6-linked sialic acids. These glycan epitopes provide SIgA with further bacteria-binding sites in addition to the four Fab-binding sites, thus enabling SIgA to participate in both innate and adaptive immunity. We also show that the N- glycans on the H chains of both SIgA1 and SIgA2 present terminal GlcNAc and mannose residues that are normally masked by SC, but that can be unmasked and recognized by mannose-binding lectin, by disrupting the SC-H chain noncovalent interactions.	Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England; Leiden Univ, Med Ctr, Dept Nephrol, Leiden, Netherlands; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	University of Oxford; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Scripps Research Institute	Rudd, PM (corresponding author), Univ Oxford, Dept Biochem, Glycobiol Inst, Oxford OX1 3QU, England.		Redwan, Elrashdy Moustafa/I-1769-2012; Redwan, Elrashdy M/M-9586-2019; Wormald, Mark R/G-2785-2011; Harvey, David/A-5579-2013	Redwan, Elrashdy Moustafa/0000-0001-8246-0075; Redwan, Elrashdy M/0000-0001-8246-0075; Wormald, Mark R/0000-0002-4853-2773; Harvey, David/0000-0003-0544-771X; Redwan, Elarshdy/0000-0001-5246-8164				Atkin JD, 1996, J IMMUNOL, V157, P156; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P4063; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Bos NA, 1996, INFECT IMMUN, V64, P616, DOI 10.1128/IAI.64.2.616-623.1996; Burns JW, 1996, SCIENCE, V272, P104, DOI 10.1126/science.272.5258.104; Chuang PD, 1997, J IMMUNOL, V158, P724; Corthesy B, 2002, TRENDS BIOTECHNOL, V20, P65, DOI 10.1016/S0167-7799(01)01874-1; Corthesy B, 1999, BIOL CHEM, V380, P1251, DOI 10.1515/BC.1999.160; Crottet P, 1998, J IMMUNOL, V161, P5445; Dallas SD, 1998, J MED MICROBIOL, V47, P879, DOI 10.1099/00222615-47-10-879; de Oliveira IR, 2001, FEMS MICROBIOL LETT, V203, P29, DOI 10.1016/S0378-1097(01)00332-9; DEFIJTER JW, 1995, J IMMUNOL METHODS, V187, P221, DOI 10.1016/0022-1759(95)00188-8; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALLGRENGEBAUER E, 1995, ADV EXP MED BIOL, V371, P625; FEINSTEIN A, 1971, ANN NY ACAD SCI, V190, P104, DOI 10.1111/j.1749-6632.1971.tb13526.x; FIELD MC, 1994, BIOCHEM J, V299, P261, DOI 10.1042/bj2990261; GENESTE C, 1986, IMMUNOL LETT, V13, P221, DOI 10.1016/0165-2478(86)90105-7; Guile GR, 1996, ANAL BIOCHEM, V240, P210, DOI 10.1006/abio.1996.0351; GUILE GR, 1994, ANAL BIOCHEM, V222, P231, DOI 10.1006/abio.1994.1478; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; HARVEY DJ, 1993, RAPID COMMUN MASS SP, V7, P614, DOI 10.1002/rcm.1290070712; Hexham JM, 1999, J EXP MED, V189, P747, DOI 10.1084/jem.189.4.747; Heystek HC, 2002, J IMMUNOL, V168, P102, DOI 10.4049/jimmunol.168.1.102; Hough MA, 1999, J MOL BIOL, V287, P579, DOI 10.1006/jmbi.1999.2610; Hughes GJ, 1999, BBA-PROTEIN STRUCT M, V1434, P86, DOI 10.1016/S0167-4838(99)00168-5; IMBERTY A, 1995, PROTEIN ENG, V8, P699, DOI 10.1093/protein/8.7.699; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P393; Johansen FE, 2001, J IMMUNOL, V167, P5185, DOI 10.4049/jimmunol.167.9.5185; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1997, BIOCHEM SOC T, V25, pS323, DOI 10.1042/bst025323s; Kuster B, 1997, ANAL BIOCHEM, V250, P82, DOI 10.1006/abio.1997.2199; Lamm ME, 1997, ANNU REV MICROBIOL, V51, P311, DOI 10.1146/annurev.micro.51.1.311; Mattu TS, 1998, J BIOL CHEM, V273, P2260, DOI 10.1074/jbc.273.4.2260; MIZOGUCHI A, 1982, J BIOL CHEM, V257, P9612; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; Norderhaug IN, 1999, CRIT REV IMMUNOL, V19, P481; Novak J, 2000, MOL IMMUNOL, V37, P1047, DOI 10.1016/S0161-5890(01)00019-0; PATEL T, 1993, BIOCHEMISTRY-US, V32, P679, DOI 10.1021/bi00053a037; Petersen SV, 2001, MOL IMMUNOL, V38, P133; Petrescu AJ, 1999, GLYCOBIOLOGY, V9, P343, DOI 10.1093/glycob/9.4.343; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PIERCECRETEL A, 1984, EUR J BIOCHEM, V139, P337, DOI 10.1111/j.1432-1033.1984.tb08012.x; PIERCECRETEL A, 1982, EUR J BIOCHEM, V125, P383, DOI 10.1111/j.1432-1033.1982.tb06694.x; PIERCECRETEL A, 1981, EUR J BIOCHEM, V114, P169, DOI 10.1111/j.1432-1033.1981.tb06188.x; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; PURKAYASTHA S, 1979, J BIOL CHEM, V254, P6583; Roos A, 2001, J IMMUNOL, V167, P2861, DOI 10.4049/jimmunol.167.5.2861; Royle L, 2002, ANAL BIOCHEM, V304, P70, DOI 10.1006/abio.2002.5619; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Schroten H, 1998, INFECT IMMUN, V66, P3971, DOI 10.1128/IAI.66.8.3971-3973.1998; Sharon N, 2000, GLYCOCONJUGATE J, V17, P659, DOI 10.1023/A:1011091029973; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Tanaka A, 1998, GLYCOCONJUGATE J, V15, P995, DOI 10.1023/A:1006989910120; TAYLOR AK, 1988, MOL CELL BIOL, V8, P4197, DOI 10.1128/MCB.8.10.4197; Thornton BP, 1996, J IMMUNOL, V156, P1235; Uemura K, 2002, J IMMUNOL, V169, P6945, DOI 10.4049/jimmunol.169.12.6945; Vaerman JP, 1998, IMMUNOLOGY, V95, P90; van Egmond M, 2001, TRENDS IMMUNOL, V22, P205, DOI 10.1016/S1471-4906(01)01873-7; van Spriel AB, 2002, J IMMUNOL, V169, P3831, DOI 10.4049/jimmunol.169.7.3831; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; WOLD AE, 1990, INFECT IMMUN, V58, P3073, DOI 10.1128/IAI.58.9.3073-3077.1990; Wright A, 1997, TRENDS BIOTECHNOL, V15, P26, DOI 10.1016/S0167-7799(96)10062-7; Zamze S, 1998, EUR J BIOCHEM, V258, P243, DOI 10.1046/j.1432-1327.1998.2580243.x; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; ZIKAN J, 1985, P NATL ACAD SCI USA, V82, P5905, DOI 10.1073/pnas.82.17.5905	73	243	262	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20140	20153		10.1074/jbc.M301436200	http://dx.doi.org/10.1074/jbc.M301436200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12637583	hybrid			2022-12-27	WOS:000183078000073
J	Jensen, A; Calvayrac, G; Karahalil, B; Bohr, VA; Stevnsner, T				Jensen, A; Calvayrac, G; Karahalil, B; Bohr, VA; Stevnsner, T			Mammalian 8-oxoguanine DNA glycosylase 1 incises 8-oxoadenine opposite cytosine in nuclei and mitochondria, while a different glycosylase incises 8-oxoadenine opposite guanine in nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; OXIDATIVE DAMAGE; LIVER-MITOCHONDRIA; REACTION-MECHANISM; HUMAN HOMOLOG; HUMAN-CELLS; RAT-LIVER; ENDONUCLEASE; PROTEIN; LESIONS	Cells are continuously exposed to oxidative species, which cause several types of oxidative DNA lesions. Repair of some of these lesions has been well characterized but little is known about the repair of many DNA lesions. The oxidized adenine base, 7,8-dihydro-8-oxoadenine (8-oxoA), is a relatively common DNA lesion, which is believed to be mutagenic in mammalian cells. This study investigates repair of 8-oxoA in nuclear and mitochondrial mammalian extracts. In nuclei, 8-oxoA: C and 8-oxoA: G base pairs are recognized and cleaved; in contrast, only 8-oxoA: C base pairs are cleaved in mitochondria. High stability of the DNA helix increased the efficiency of incision of 8-oxoA, and the efficiency decreased at DNA bends and condensed regions of the helix. Using liver extracts from mice knocked out for 8-oxoguanine DNA glycosylase 1 (OGG1), we demonstrated that OGG1 is the only glycosylase that incises 8-oxoA, when base-paired with cytosine in mitochondria and nuclei, but a different enzyme incises 8-oxoA when base-paired with guanine in the nucleus. Consistent with this result, a covalent DNA-protein complex was trapped using purified human OGG1 or human nuclear or mitochondrial extracts with a DNA substrate containing an 8-oxoA: C base pair.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark; Gazi Univ, Fac Pharm, Dept Toxicol, TR-06330 Ankara, Turkey	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; Gazi University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Karahalil, Bensu/AFU-8097-2022; Bohr, Vilhelm/AAP-5931-2020	Stevnsner, Tinna/0000-0003-1007-0427	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733, Z01AG000727, ZIAAG000727] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOUKHALIL S, 1985, BIOCHEM BIOPH RES CO, V127, P1039, DOI 10.1016/S0006-291X(85)80049-8; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; ARNOTT S, 1974, J MOL BIOL, V88, P509, DOI 10.1016/0022-2836(74)90498-7; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Bernards AS, 2002, J BIOL CHEM, V277, P20960, DOI 10.1074/jbc.C200181200; Bjoras M, 2002, J MOL BIOL, V317, P171, DOI 10.1006/jmbi.2002.5400; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; FEIG DI, 1994, CANCER RES, V54, pS1890; Girard PM, 1998, CARCINOGENESIS, V19, P1299, DOI 10.1093/carcin/19.7.1299; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Ide H, 1997, CELL BIOL TOXICOL, V13, P405, DOI 10.1023/A:1007467726635; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; KAMIYA H, 1995, NUCLEIC ACIDS RES, V23, P2893, DOI 10.1093/nar/23.15.2893; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KAWAKAMI K, 1993, FEBS LETT, V335, P251, DOI 10.1016/0014-5793(93)80740-L; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mambo E, 2002, CANCER RES, V62, P1349; Masuda Y, 1998, J BIOL CHEM, V273, P30360, DOI 10.1074/jbc.273.46.30360; Matsumoto Y, 2001, NUCLEIC ACIDS RES, V29, P1975, DOI 10.1093/nar/29.9.1975; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; Morland I, 2002, NUCLEIC ACIDS RES, V30, P4926, DOI 10.1093/nar/gkf618; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Ozawa T, 1997, BIOSCIENCE REP, V17, P237, DOI 10.1023/A:1027324410022; Parker A, 2000, NUCLEIC ACIDS RES, V28, P3206, DOI 10.1093/nar/28.17.3206; PAYNE CM, 1995, LEUKEMIA LYMPHOMA, V19, P43, DOI 10.3109/10428199509059662; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Shinmura A, 2000, NUCLEIC ACIDS RES, V28, P4912, DOI 10.1093/nar/28.24.4912; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Souza-Pinto NC, 1999, NUCLEIC ACIDS RES, V27, P1935, DOI 10.1093/nar/27.8.1935; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	50	43	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19541	19548		10.1074/jbc.M301504200	http://dx.doi.org/10.1074/jbc.M301504200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644468	hybrid			2022-12-27	WOS:000182932200105
J	Mayo, MW; Denlinger, CE; Broad, RM; Yeung, F; Reilly, ET; Shi, Y; Jones, DR				Mayo, MW; Denlinger, CE; Broad, RM; Yeung, F; Reilly, ET; Shi, Y; Jones, DR			Ineffectiveness of histone deacetylase inhibitors to induce apoptosis involves the transcriptional activation of NF-kappa B through the Akt pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; CELL LUNG-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; DNA METHYLTRANSFERASE; RELA/P65 SUBUNIT; GENE-EXPRESSION; RETINOIC ACID; P65 SUBUNIT; PHOSPHORYLATION; KINASE	Histone deacetylase (HDAC) inhibitors are emerging as a new class of anticancer agents for the treatment of solid and hematological malignancies. Although HDAC inhibitors induce cell death through an apoptotic process, little is known about the molecular events that control their effectiveness. In this study, we demonstrate that HDAC inhibitors are limited in their ability to induce apoptosis in non-small cell lung cancer (NSCLC) cell lines despite their ability to effectively inhibit deacetylase activity. Because the anti-apoptotic transcription factor NF-kappaB has been shown to be under the control of HDAC-mediated repression, we analyzed whether HDAC inhibitors activated NF-kappaB in NSCLC cells. HDAC inhibitors effectively stimulated endogenous NF-kappaB-dependent gene expression by up-regulating IL-8, Bcl-XL, and MMP-9 transcripts. The ability of HDAC inhibitors to increase NF-kappaB transcriptional activity was not associated with signaling events that stimulated nuclear translocation, but rather modulated the transactivation potential of the RelA/p65 subunit of NF-kappaB. The inhibition of HDAC activity was associated with the recruitment of the p300 transcriptional co-activator to chromatin in an Akt-dependent manner. Moreover, Akt directly phosphorylated p300 in vitro and was required for stimulating the transactivation potential of the co-activator following the addition of HDAC inhibitors. Selective inhibition of either the phosphoinositide 3-kinase/Akt pathway, or NF-kappaB itself blocked the ability of HDAC inhibitors to activate NF-kappaB and dramatically sensitized NSCLC cells to apoptosis following of the addition of HDAC inhibitors. Our study indicates that the ineffectiveness of HDAC inhibitors to induce apoptosis in NSCLC cancer cells is associated with the ability of these molecules to stimulate NF-kappaB-dependent transcription and cell survival.	Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	University of Virginia; University of Virginia; Harvard University; Harvard Medical School	Jones, DR (corresponding author), Univ Virginia, Dept Surg, Box 800679, Charlottesville, VA 22908 USA.	djones@virginia.edu		Broad, R Michael/0000-0002-0383-3847; Jones, David/0000-0002-3318-0146	NATIONAL CANCER INSTITUTE [K01CA078595, K08CA083920, R01CA095644] Funding Source: NIH RePORTER; NCI NIH HHS [CA83920, CA095644, CA78595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Brockmann D, 2001, GENE, V277, P111, DOI 10.1016/S0378-1119(01)00703-X; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)02125-0; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH S, 2002, GENE DEV, V109, pS81; Goodman RH, 2000, GENE DEV, V14, P1553; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Jones DR, 2002, J THORAC CARDIOV SUR, V123, P310, DOI 10.1067/mtc.2002.118684; Jones DR, 2000, ANN THORAC SURG, V70, P930, DOI 10.1016/S0003-4975(00)01635-0; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; LEDINKO N, 1990, ANTICANCER RES, V10, P1335; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Novick S, 1999, BLOOD, V94, p61A; Ozes ON, 1999, NATURE, V401, P82; Pan ZK, 1999, J BIOL CHEM, V274, P9918, DOI 10.1074/jbc.274.15.9918; Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sandor V, 2002, CLIN CANCER RES, V8, P718; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sontag E, 1997, EMBO J, V16, P5662, DOI 10.1093/emboj/16.18.5662; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; Vigushin DM, 2002, ANTI-CANCER DRUG, V13, P1, DOI 10.1097/00001813-200201000-00001; Warrell RP, 1998, JNCI-J NATL CANCER I, V90, P1621, DOI 10.1093/jnci/90.21.1621; Weiser TS, 2001, ANN THORAC SURG, V71, P295, DOI 10.1016/S0003-4975(00)02421-8; Yang CL, 2001, J BIOL CHEM, V276, P47277, DOI 10.1074/jbc.M105396200; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhu WG, 2001, CANCER RES, V61, P1327	64	162	172	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18980	18989		10.1074/jbc.M211695200	http://dx.doi.org/10.1074/jbc.M211695200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12649266	hybrid			2022-12-27	WOS:000182932200035
J	Osterhout, JL; Waheed, AA; Hiol, A; Ward, RJ; Davey, PC; Nini, L; Wang, J; Milligan, G; Jones, TLZ; Druey, KM				Osterhout, JL; Waheed, AA; Hiol, A; Ward, RJ; Davey, PC; Nini, L; Wang, J; Milligan, G; Jones, TLZ; Druey, KM			Palmitoylation regulates regulator of G-protein signaling (RGS) 16 function - II. Palmitoylation of a cysteine residue in the RGS box is critical for RGS16 GTPase accelerating activity and regulation of G(i)-coupled signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-CONSTITUTIVE ACTIVITY; PLASMA-MEMBRANE LOCALIZATION; ACTIVATING PROTEINS; PHOSPHORYLATION; GAIP; INHIBITION; INTERACTS; BINDING; KINASE; DOMAIN	Palmitoylation is a reversible post-translational modification used by cells to regulate protein activity. The regulator of G-protein signaling (RGS) proteins RGS4 and RGS16 share conserved cysteine (Cys) residues that undergo palmitoylation. In the accompanying article (Hiol, A., Davey, P. C., Osterhout, J. L., Waheed, A. A., Fischer, E. R., Chen, C. K., Milligan, G., Druey, K. M., and Jones, T. L. Z. (2003) J. Biol. Chem. 278, 19301-19308), we determined that mutation of NH2-terminal cysteine residues in RGS16 (Cys-2 and Cys-12) reduced GTPase accelerating (GAP) activity toward a 5-hydroxytryptamine (5-HT1A)/Galpha(o1) receptor fusion protein in cell membranes. NH2-terminal acylation also permitted palmitoylation of a cysteine residue in the RGS box of RGS16 (Cys-98). Here we investigated the role of internal palmitoylation in RGS16 localization and GAP activity. Mutation of RGS16 Cys-98 or RGS4 Cys-95 to alanine reduced GAP activity on the 5-HT1A/Galpha(o1) fusion protein and regulation of adenylyl cyclase inhibition. The C98A mutation had no effect on RGS16 localization or GAP activity toward purified G-protein alpha subunits. Enzymatic palmitoylation of RGS16 resulted in internal palmitoylation on residue Cys-98. Palmitoylated RGS16 or RGS4 WT but not C98A or C95A preincubated with membranes expressing 5-HT1a/Galpha(o1) displayed increased GAP activity over time. These results suggest that palmitoylation of a Cys residue in the RGS box is critical for RGS16 and RGS4 GAP activity and their ability to regulate G(i)-coupled signaling in mammalian cells.	NIDDK, Metab Dis Branch, NIH, Bethesda, MD 20892 USA; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Mol Pharmacol Grp, Glasgow G12 8QQ, Lanark, Scotland	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Glasgow	Jones, TLZ (corresponding author), NIDDK, Metab Dis Branch, NIH, Bldg 10,Rm 9C101, Bethesda, MD 20892 USA.	tlzj@helix.nih.gov	Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519	Biotechnology and Biological Sciences Research Council [C17789] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK043010] Funding Source: NIH RePORTER	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benzing T, 2002, J BIOL CHEM, V277, P32954, DOI 10.1074/jbc.M200859200; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Bhattacharyya R, 2000, J BIOL CHEM, V275, P14992, DOI 10.1074/jbc.M000415200; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Castro-Fernandez C, 2002, ENDOCRINOLOGY, V143, P1310, DOI 10.1210/en.143.4.1310; Chen CA, 2001, ONCOGENE, V20, P1643, DOI 10.1038/sj.onc.1204185; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 2001, FEBS LETT, V504, P16, DOI 10.1016/S0014-5793(01)02757-0; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Cunningham ML, 2001, J BIOL CHEM, V276, P5438, DOI 10.1074/jbc.M007699200; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Derrien A, 2001, J BIOL CHEM, V276, P48532, DOI 10.1074/jbc.M108862200; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1997, P NATL ACAD SCI USA, V94, P12851, DOI 10.1073/pnas.94.24.12851; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; Hiol A, 2003, J BIOL CHEM, V278, P19301, DOI 10.1074/jbc.M210123200; Hollinger S, 2002, PHARMACOL REV, V54, P527, DOI 10.1124/pr.54.3.527; Hu G, 2001, J BIOL CHEM, V276, P22287, DOI 10.1074/jbc.M011539200; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hughes TE, 2001, J BIOL CHEM, V276, P4227, DOI 10.1074/jbc.M007608200; Iiri T, 1996, P NATL ACAD SCI USA, V93, P14592, DOI 10.1073/pnas.93.25.14592; Kellett E, 1999, MOL PHARMACOL, V56, P684; Moy FJ, 2000, BIOCHEMISTRY-US, V39, P7063, DOI 10.1021/bi992760w; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; Niu JX, 2002, BIOCHEM J, V365, P677, DOI 10.1042/BJ20020390; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; Ouyang YS, 2003, J BIOL CHEM, V278, P11115, DOI 10.1074/jbc.M212606200; Popov SG, 2000, J BIOL CHEM, V275, P18962, DOI 10.1074/jbc.M001128200; Rose JJ, 2000, J NEUROCHEM, V75, P2103, DOI 10.1046/j.1471-4159.2000.0752103.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 1999, J BIOL CHEM, V274, P38260, DOI 10.1074/jbc.274.53.38260; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Welsby PJ, 2002, MOL PHARMACOL, V61, P1211, DOI 10.1124/mol.61.5.1211; Wieland T, 2000, J BIOL CHEM, V275, P28500, DOI 10.1074/jbc.M004187200; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 2000, P NATL ACAD SCI USA, V97, P3999, DOI 10.1073/pnas.97.8.3999	43	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19309	19316		10.1074/jbc.M210124200	http://dx.doi.org/10.1074/jbc.M210124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642592	hybrid			2022-12-27	WOS:000182932200077
J	Gilch, S; Wopfner, F; Renner-Muller, I; Kremmer, E; Bauer, C; Wolf, E; Brem, G; Groschup, MH; Schatzl, HM				Gilch, S; Wopfner, F; Renner-Muller, I; Kremmer, E; Bauer, C; Wolf, E; Brem, G; Groschup, MH; Schatzl, HM			Polyclonal anti-PrP auto-antibodies induced with dimeric PrP interfere efficiently with PrPSc propagation in prion-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN ISOFORMS; DELAYS ONSET; SCRAPIE; MICE; INFECTIVITY; REPLICATION; MODEL; PATHOGENESIS; CONVERSION	Prion diseases are neurodegenerative infectious disorders for which no prophylactic regimens are known. In order to induce antibodies/auto-antibodies directed against surface-located PrPc, we used a covalently linked dimer of mouse prion protein expressed recombinantly in Escherichia coli. Employing dimeric PrP as an immunogen we were able to effectively overcome autotolerance against murine PrP in PrP wild-type mice without inducing obvious side effects. Treatment of prion-infected mouse cells with polyclonal anti-PrP antibodies generated in rabbit or auto-antibodies produced in mice significantly inhibited endogenous PrPSc synthesis. We show that polyclonal antibodies are binding to surface-located PrPc, thereby interfering with prion biogenesis. This effect is much more pronounced in the presence of full IgG molecules, which, unlike Fab fragments, seem to induce a significant cross-linking of surface PrP. In addition, we found immune responses against different epitopes when comparing antibodies induced in rabbits and PrP wild-type mice. Only in the auto-antibody situation in mice an immune reaction against a region of PrP is found that was reported to be involved in the PrPSc conversion process. Our data point to the possibility of developing means for an active immunoprophylaxis against prion diseases.	Univ Munich, Max Von Pettenkofer Inst Virol, Gene Ctr Munich, D-81377 Munich, Germany; Gene Ctr Munich, Inst Mol Anim Breeding, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Mol Immunol, Munich, Germany; Ludwig Boltzmann Inst Cyto Immuno & Mol Genet Res, A-1210 Vienna, Austria; Fed Res Ctr Virus Dis Anim, D-17498 Isle Riems, Germany; Tech Univ Munich, Inst Virol, D-80802 Munich, Germany	University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Ludwig Boltzmann Institute; Technical University of Munich	Schatzl, HM (corresponding author), Univ Munich, Max Von Pettenkofer Inst Virol, Gene Ctr Munich, Feodor Lynen Str 25, D-81377 Munich, Germany.		Schatzl, Hermann/G-4958-2011	Schatzl, Hermann/0000-0003-4972-8740; Wolf, Eckhard/0000-0002-0430-9510				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Betemps D, 2001, BIOCHEM BIOPH RES CO, V281, P101, DOI 10.1006/bbrc.2001.4326; Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown KL, 1999, NAT MED, V5, P1308, DOI 10.1038/15264; BUELER HR, 1992, NATURE, V256, P577; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Enari M, 2001, P NATL ACAD SCI USA, V98, P9295, DOI 10.1073/pnas.151242598; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Ingram DK, 2001, TRENDS NEUROSCI, V24, P305, DOI 10.1016/S0166-2236(00)01796-3; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Mabbott NA, 2001, NAT MED, V7, P485, DOI 10.1038/86562; Mallucci GR, 2002, EMBO J, V21, P202, DOI 10.1093/emboj/21.3.202; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Perrier V, 2000, P NATL ACAD SCI USA, V97, P6073, DOI 10.1073/pnas.97.11.6073; Proske D, 2002, CHEMBIOCHEM, V3, P717, DOI 10.1002/1439-7633(20020802)3:8<717::AID-CBIC717>3.0.CO;2-C; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; Sethi S, 2002, LANCET, V360, P229, DOI 10.1016/S0140-6736(02)09513-2; Sigurdsson EM, 2002, AM J PATHOL, V161, P13, DOI 10.1016/S0002-9440(10)64151-X; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Weissmann C, 2001, PHILOS T R SOC B, V356, P177, DOI 10.1098/rstb.2000.0763; Williamson RA, 1996, P NATL ACAD SCI USA, V93, P7279, DOI 10.1073/pnas.93.14.7279; Wopfner F, 1999, J MOL BIOL, V289, P1163, DOI 10.1006/jmbi.1999.2831	37	91	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18524	18531		10.1074/jbc.M210723200	http://dx.doi.org/10.1074/jbc.M210723200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637572	hybrid			2022-12-27	WOS:000182838300122
J	Minamisawa, S; Wang, YB; Chen, J; Ishikawa, Y; Chien, KR; Matsuoka, R				Minamisawa, S; Wang, YB; Chen, J; Ishikawa, Y; Chien, KR; Matsuoka, R			Atrial chamber-specific expression of sarcolipin is regulated during development and hypertrophic remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; PHOSPHOLAMBAN GENE-EXPRESSION; MYOCARDIAL-CONTRACTILITY; CARDIOMYOPATHY; ABLATION; INVITRO; SERCA1; CHAIN; HEART; MICE	Intracellular Ca2+ regulation is critical in the normal cardiac function and development of pathologic hearts. Phospholamban, an endogenous inhibitor of sarcoplasmic reticulum Ca2+ ATPase in the sarcoplasmic reticulum, plays an important role in Ca2+ cycling in heart. Recently, sarcolipin has been identified as having a similar function as phospholamban in skeletal muscle. Because phospholamban is differentially expressed in atrial and ventricular myocardia and its expression is often altered in diseased hearts, we investigated the cardiac chamber specificity of sarcolipin expression and its regulation during development and hypertrophic remodeling. Northern blot analysis revealed that the expression of mouse sarcolipin mRNA was most abundant in the atria and was undetectable in the ventricles, indicating an atrial chamber-specific expression pattern. Atrial chamber-specific expression of sarcolipin mRNA was increased during development. These findings were confirmed by in situ hybridization studies. In addition, sarcolipin expression was down-regulated in the atria of hypertrophic heart when induced by ventricular specific overexpression of the activated H-ras gene. In humans, sarcolipin mRNA was also expressed in the atria but not detected in the ventricles, although sarcolipin expression was most abundant in skeletal muscle. Taken together, sarcolipin is likely to be an atrial chamber-specific regulator of Ca2+ cycling in heart.	Tokyo Womens Med Univ, Grad Sch Med, Dept Pediat Cardiol, Tokyo 1628666, Japan; Tokyo Womens Med Univ, Grad Sch Med, Div Genom Med, Inst Adv Biomed Engn & Sci, Tokyo 1628666, Japan; Yokohama City Univ, Sch Med, Dept Physiol, Yokohama, Kanagawa 2360004, Japan; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA; Univ Calif San Diego, Inst Mol Med, La Jolla, CA 92093 USA; Univ Med & Dent New Jersey, Dept Cell Biol & Mol Med, Newark, NJ 07103 USA	Tokyo Women's Medical University; Tokyo Women's Medical University; Yokohama City University; University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego; Rutgers State University New Brunswick; Rutgers State University Medical Center	Minamisawa, S (corresponding author), Tokyo Womens Med Univ, Heart Inst Japan, Dept Pediat, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.		Chen, Ju/E-5579-2011	Minamisawa, Susumu/0000-0003-4728-2116; Wang, Yibin/0000-0003-0852-0767				Asahi M, 2002, J BIOL CHEM, V277, P26725, DOI 10.1074/jbc.C200269200; Dash R, 2001, CIRCULATION, V103, P889, DOI 10.1161/01.CIR.103.6.889; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; GANIM JR, 1992, CIRC RES, V71, P1021, DOI 10.1161/01.RES.71.5.1021; Gayan-Ramirez G, 2000, J PHYSIOL-LONDON, V524, P387, DOI 10.1111/j.1469-7793.2000.t01-2-00387.x; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; KOSS KL, 1995, CIRC RES, V77, P342, DOI 10.1161/01.RES.77.2.342; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; Liao P, 2001, P NATL ACAD SCI USA, V98, P12283, DOI 10.1073/pnas.211086598; Luo WS, 1996, CIRC RES, V78, P839, DOI 10.1161/01.RES.78.5.839; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; Machida S, 2000, DEV DYNAM, V217, P37, DOI 10.1002/(SICI)1097-0177(200001)217:1<37::AID-DVDY4>3.0.CO;2-3; Mascioni A, 2002, BIOCHEMISTRY-US, V41, P475, DOI 10.1021/bi011243m; Minamisawa S, 1999, J BIOL CHEM, V274, P10066, DOI 10.1074/jbc.274.15.10066; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; NAKANISHI T, 1984, AM J PHYSIOL, V246, pH61; Odermatt A, 1997, GENOMICS, V45, P541, DOI 10.1006/geno.1997.4967; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; Sato Y, 2001, J BIOL CHEM, V276, P9392, DOI 10.1074/jbc.M006889200; Tada M, 1998, ANN NY ACAD SCI, V853, P116, DOI 10.1111/j.1749-6632.1998.tb08261.x; Tada M, 1996, J Card Fail, V2, pS77, DOI 10.1016/S1071-9164(96)80062-5; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; WAWRZYNOW A, 1992, ARCH BIOCHEM BIOPHYS, V298, P620, DOI 10.1016/0003-9861(92)90457-8	25	90	90	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9570	9575		10.1074/jbc.M213132200	http://dx.doi.org/10.1074/jbc.M213132200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645548	hybrid			2022-12-27	WOS:000181524000092
J	Liang, JS; Kim, T; Fang, SY; Yamaguchi, J; Weissman, AM; Fisher, EA; Ginsberg, HN				Liang, JS; Kim, T; Fang, SY; Yamaguchi, J; Weissman, AM; Fisher, EA; Ginsberg, HN			Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CONTAINING LIPOPROTEINS; TRIGLYCERIDE TRANSFER PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DEGRADATION; PROTEASOME PATHWAY; APOPROTEIN B100; TRANSLOCATION; COMPLEX; HEAT-SHOCK-PROTEIN-70; MECHANISMS	Apolipoprotein B100 (apoB) is a large (520-kDa) complex secretory protein; its secretion is regulated post-transcriptionally by several degradation pathways. The best described of these degradative processes is co-translational ubiquitinylation and proteasomal degradation of nascent apoB, involving the 70- and 90-kDa heat shock proteins and the multiple components of the proteasomal pathway. Ubiquitinylation involves several proteins, including ligases called E3s, that coordinate the covalent binding of ubiquitin to target proteins. The recent discovery that tumor autocrine motility factor receptor, also known as gp78, is an endoplasmic reticulum (ER)-associated E3, raised the possibility that this E3 might be involved in the ER-associated degradation of nascent apoB. In a series of experiments in HepG2 cells, we demonstrated that overexpression of gp78 was sufficient for increased ubiquitinylation and proteasomal degradation of apoB, with reduced secretion of apoB-lipoproteins. This action of gp78 was specific: overexpression of the protein did not affect secretion of either albumin or apolipoprotein AI. Furthermore, overexpression of a cytosolic E3, Itch, had no effect on apoB secretion. Finally, using an in vitro translation system, we demonstrated that gp78 led to increased ubiquitinylation and proteasomal degradation of apoB48. Together, these results indicate that an ER-associated protein, gp78, is a bona fide E3 ligase in the apoB ER-associated degradation pathway.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Mt Sinai Sch Med, Dept Med, New York, NY 10025 USA; Mt Sinai Sch Med, Dept Biochem, New York, NY 10025 USA; NCI, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Columbia University; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ginsberg, HN (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.		Fisher, Edward/ABE-7469-2020; Fang, Shengyun/H-3802-2011	Fisher, Edward/0000-0001-9802-143X; Fang, Shengyun/0000-0001-7280-5463	NHLBI NIH HHS [HL58541, HL55368] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC009392] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058541] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; Chen Y, 1998, J BIOL CHEM, V273, P11887, DOI 10.1074/jbc.273.19.11887; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Gardner RG, 2001, MOL CELL BIOL, V21, P4276, DOI 10.1128/MCB.21.13.4276-4291.2001; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; Gusarova V, 2001, J BIOL CHEM, V276, P24891, DOI 10.1074/jbc.M100633200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Liang JS, 2000, J BIOL CHEM, V275, P32003, DOI 10.1074/jbc.M004646200; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Mitchell DM, 1998, P NATL ACAD SCI USA, V95, P14733, DOI 10.1073/pnas.95.25.14733; NABI IR, 1987, INT J CANCER, V40, P396, DOI 10.1002/ijc.2910400319; NABI IR, 1991, CELL MOTILITY FACTOR, V59, P163; Pan MH, 2002, J BIOL CHEM, V277, P4413, DOI 10.1074/jbc.M107460200; Pariyarath R, 2001, J BIOL CHEM, V276, P541, DOI 10.1074/jbc.M007944200; Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298-143; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WU XJ, 1994, J LIPID RES, V35, P1200; WU XJ, 1994, J BIOL CHEM, V269, P12375; Yao ZM, 1997, J LIPID RES, V38, P1937; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777; ZHOU MY, 1995, J BIOL CHEM, V270, P25220, DOI 10.1074/jbc.270.42.25220; Zhou MY, 1998, J BIOL CHEM, V273, P24649, DOI 10.1074/jbc.273.38.24649	34	91	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23984	23988		10.1074/jbc.M302683200	http://dx.doi.org/10.1074/jbc.M302683200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12670940	hybrid			2022-12-27	WOS:000183638600098
J	Wang, YQ; Ge, Q; Houston, D; Thorner, J; Errede, B; Dohlman, HG				Wang, YQ; Ge, Q; Houston, D; Thorner, J; Errede, B; Dohlman, HG			Regulation of Ste7 ubiquitination by Ste11 phosphorylation and the Skp1-cullin-F-box complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEROMONE RESPONSE PATHWAY; PROTEIN-PROTEIN INTERACTIONS; MAP KINASE CASCADE; END RULE PATHWAY; SACCHAROMYCES-CEREVISIAE; DEPENDENT DEGRADATION; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; FACTOR RECEPTOR; IN-VITRO	Ste7 is a mitogen-activated protein kinase kinase that mediates pheromone signaling in Saccharomyces cerevisiae. We showed previously that Ste7 is ubiquitinated upon prolonged stimulation by pheromone and that accumulation of ubiquitinated Ste7 results in enhanced transcription and cell division arrest responses (Wang, Y., and Dohlman, H. G. ( 2002) J. Biol. Chem. 277, 15766 15772). We now report that ubiquitination of Ste7 requires Ste11 kinase and Skp1/Cullin/F-box (SCF) ubiquitin-conjugating activities. Ste7 is not ubiquitinated in Ste11-deficient cells or when the Ste11 phosphorylation sites have been mutated. Ste7 ubiquitination and degradation ( but not phosphorylation) is specifically blocked in mutants defective for the E2 ubiquitin-conjugating enzyme Cdc34 or the cullin homologue Cdc53. Both are components of the SCF complex that ubiquitinates proteins during the G(1)-S transition of the cell cycle. Our findings suggest that SCF promotes the ubiquitination and degradation of Ste7, thereby favoring the resumption of cell division cycling after pheromone-induced growth arrest.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California Berkeley	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.		THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Dohlman, Henrik/0000-0003-2443-0729	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021841, R29GM055316, R01GM039582, R01GM021841, R01GM055316, R01GM059167] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM055316, GM39582, GM55316, R01 GM059167, GM021841, GM59167] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; CHOI KY, 1994, CELL, V78, P499; Chung CY, 1998, GENE DEV, V12, P3564, DOI 10.1101/gad.12.22.3564; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Davydov IV, 2000, J BIOL CHEM, V275, P22931, DOI 10.1074/jbc.M001605200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Errede B, 1996, PHILOS T ROY SOC B, V351, P143, DOI 10.1098/rstb.1996.0010; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; Esch RK, 2002, P NATL ACAD SCI USA, V99, P9160, DOI 10.1073/pnas.142034399; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; MA D, 1995, MOL BIOL CELL, V6, P889, DOI 10.1091/mbc.6.7.889; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MARCHESE A, 2001, J BIOL CHEM, V18, P18; Marotti LA, 2002, BIOCHEMISTRY-US, V41, P5067, DOI 10.1021/bi015940q; Mathias N, 1996, MOL CELL BIOL, V16, P6634; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Obin M, 2002, J BIOL CHEM, V277, P44566, DOI 10.1074/jbc.M205308200; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PRINTEN JA, 1994, GENETICS, V138, P609; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Sette C, 2000, MOL BIOL CELL, V11, P4033, DOI 10.1091/mbc.11.11.4033; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Sobko A, 2002, DEV CELL, V2, P745, DOI 10.1016/S1534-5807(02)00186-7; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang YQ, 2002, J BIOL CHEM, V277, P15766, DOI 10.1074/jbc.M111733200; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069	47	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22284	22289		10.1074/jbc.M301272200	http://dx.doi.org/10.1074/jbc.M301272200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668671	hybrid			2022-12-27	WOS:000183503900016
J	Maun, HR; Eigenbrot, C; Lazarus, RA				Maun, HR; Eigenbrot, C; Lazarus, RA			Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR; COAGULATION-FACTOR; BINDING; SPECIFICITY; SITE; SELECTION; AFFINITY; IDENTIFICATION; ANTICOAGULANT; RECOGNITION	Limitations of current anticoagulant therapies have led us to develop two distinct classes of exosite peptide inhibitors for the initiator of the clotting process, the tissue factor-factor VIIa (TF.FVIIa) complex (Roberge, M., Santell, L., Dennis, M. S., Eigenbrot, C., Dwyer, M. A., and Lazarus, R. A. ( 2001) Biochemistry 40, 9522-9531). Although both peptide classes are potent and selective inhibitors of TF.FVIIa, neither showed 100% inhibition at saturating concentrations. Crystal structures of these peptides in complex with the FVII/FVIIa protease domain revealed their distinct binding sites and close proximity to the active site. The favorable orientation of the 15-mer A-site peptide A-183 (EEWEVLCWTWETCER) suggested that a C-terminal extension into the FVIIa active site could yield a chimeric inhibitor that was not only potent and selective but complete as well. A novel two-step "protease switch" approach using substrate phage display was developed by first binding all phage containing A-183 and C-terminal extension libraries to immobilized and inactive FVIIa. Upon altering pH and adding TF to switch on FVIIa enzymatic activity, only those phage released by proteolytic cleavage within the extension were propagated. This process selected for both preferred sequence and length in the extension, leading to a 27-mer peptide A-183X (EEWEVLCWTWET-CERGEGVEEELWEWR) with a C-terminal 12-mer extension containing an Arg in the P-1 position. A-183X was a more potent and complete inhibitor of FX activation, having a maximal extent of inhibition of similar to99% with an IC50 of 230 pM versus A-183 which maximally inhibited to 74% with an IC50 of 1.5 nM. A-183X also had a maximal prolongation of the prothrombin time of 7.6-versus 1.9-fold for A-183, making it a more effective anticoagulant.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany	Roche Holding; Genentech; University of Freiburg	Lazarus, RA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	lazarus.bob@gene.com						Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; DAVIE EW, 1995, THROMB HAEMOSTASIS, V74, P1; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; DENNIS MS, 1993, PROTEINS, V15, P312, DOI 10.1002/prot.340150308; Dennis MS, 2001, BIOCHEMISTRY-US, V40, P9513, DOI 10.1021/bi010591l; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; DING L, 1995, P NATL ACAD SCI USA, V92, P7627, DOI 10.1073/pnas.92.17.7627; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; Harris JL, 1998, J BIOL CHEM, V273, P27364, DOI 10.1074/jbc.273.42.27364; Hervio LS, 2000, CHEM BIOL, V7, P443, DOI 10.1016/S1074-5521(00)00125-3; Hirsh J, 2001, AM HEART J, V142, pS3, DOI 10.1067/mhj.2001.117031; Ke SH, 1997, J BIOL CHEM, V272, P20456, DOI 10.1074/jbc.272.33.20456; Kelley RF, 1997, BLOOD, V89, P3219, DOI 10.1182/blood.V89.9.3219; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZARUS RA, 2002, PROTEINASE PEPTIDASE, P202; Leblond L, 1999, HANDB EXP PHARM, V132, P1; Lee GF, 1997, BIOCHEMISTRY-US, V36, P5607, DOI 10.1021/bi970388j; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MARAGANORE JM, 1990, BIOCHEMISTRY-US, V29, P7095, DOI 10.1021/bi00482a021; MATTHEWS DJ, 1993, SCIENCE, V260, P1113, DOI 10.1126/science.8493554; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; Mcree D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; Moll S, 2002, SEMIN HEMATOL, V39, P145, DOI 10.1053/shem.2002.34087; Morrissey JH, 2001, THROMB HAEMOSTASIS, V86, P66; NEUENSCHWANDER PF, 1993, THROMB HAEMOSTASIS, V70, P970; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; PARRY MAA, 1994, BIOCHEMISTRY-US, V33, P14807, DOI 10.1021/bi00253a020; Roberge M, 2002, BIOCHEM J, V363, P387, DOI 10.1042/0264-6021:3630387; Roberge M, 2001, BIOCHEMISTRY-US, V40, P9522, DOI 10.1021/bi010592d; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SIDHU SS, 1994, J BIOL CHEM, V269, P20167; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Starovasnik MA, 1999, PROTEIN SCI, V8, P1423, DOI 10.1110/ps.8.7.1423; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6	44	32	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21823	21830		10.1074/jbc.M300951200	http://dx.doi.org/10.1074/jbc.M300951200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657647	hybrid			2022-12-27	WOS:000183354200065
J	Stevens, JM; Daltrop, O; Higham, CW; Ferguson, SJ				Stevens, JM; Daltrop, O; Higham, CW; Ferguson, SJ			Interaction of heme with variants of the heme chaperone CcmE carrying active site mutations and a cleavable N-terminal His tag	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C MATURATION; ESCHERICHIA-COLI; APOCYTOCHROME-C; PROTEIN; BINDING; OXIDASE; SYSTEM	Cytochrome c maturation in the periplasms of many bacteria requires the heme chaperone CcmE, which binds heme covalently both in vivo and in vitro via a histidine residue before transferring the heme to apocytochromes c. To investigate the mechanism and specificity of heme attachment to CcmE, we have mutated the conserved histidine 130 of a soluble C-terminally His-tagged version of CcmE ( CcmE(sol)-C-His(6)) from Escherichia coli to alanine or cysteine. Remarkably, covalent bond formation with heme occurs with the protein carrying the cysteine mutation, and the process occurs both in vivo and in vitro. The yield of holo-H130C CcmE(sol)-C-His(6) produced in vivo is low compared with the wild type. In vitro heme attachment occurs only under reducing conditions. We demonstrate the involvement of one of the heme vinyl groups and a side chain at residue 130 in the bond formation by showing that in vitro attachment does not occur either with the heme analogue mesoheme or when alanine is present at residue 130. These results have implications for the mechanism of heme attachment to the histidine of CcmE. In vitro, CcmE(sol) lacking a His tag binds 8-anilino-1-naphthalenesulphonate and heme, the latter both noncovalently and via a covalent bond from the histidine side chain, similarly to the tagged proteins, thus countering a recent proposal that the His tag causes the heme binding. However, the His tag does appear to enhance the rate of in vitro covalent heme binding and to affect the heme ligation in the ferric b-type cytochrome form.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Oxford	Ferguson, SJ (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.							Allen JWA, 2002, J BIOL CHEM, V277, P33559, DOI 10.1074/jbc.M204963200; Arnesano F, 2002, BIOCHEMISTRY-US, V41, P13587, DOI 10.1021/bi026362w; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Bartsch R. G., 1971, METHODS ENZYMOL, V23, P344, DOI [10.1016/S0076-6879(71)23110-4, DOI 10.1016/S0076-6879(71)23110-4]; BODUSZEK B, 1980, MONATSH CHEM, V111, P1111, DOI 10.1007/BF00909667; Cook GM, 2000, MICROBIOL-SGM, V146, P527, DOI 10.1099/00221287-146-2-527; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P9703, DOI 10.1073/pnas.152120699; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; DUMONT ME, 1994, BIOCHEMISTRY-US, V33, P7368, DOI 10.1021/bi00189a043; Enggist E, 2003, J BACTERIOL, V185, P175, DOI 10.1128/JB.185.1.175-183.2003; Enggist E, 2002, STRUCTURE, V10, P1551, DOI 10.1016/S0969-2126(02)00885-7; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; GOODHEW CF, 1986, BIOCHIM BIOPHYS ACTA, V852, P288, DOI 10.1016/0005-2728(86)90234-3; KOJO S, 1981, J CHEM SOC PERK T 1, P2864, DOI 10.1039/p19810002864; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; Ren Q, 2002, J BIOL CHEM, V277, P7657, DOI 10.1074/jbc.M110979200; Ren Q, 2001, J BIOL CHEM, V276, P32591, DOI 10.1074/jbc.M103058200; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Spielewoy N, 2001, J BIOL CHEM, V276, P5491, DOI 10.1074/jbc.M008853200; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; TOHJO M, 1963, ARCH BIOCHEM BIOPHYS, V103, P401, DOI 10.1016/0003-9861(63)90429-6; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200; Vu BC, 2002, J AM CHEM SOC, V124, P8544, DOI 10.1021/ja026569c	27	42	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20500	20506		10.1074/jbc.M212925200	http://dx.doi.org/10.1074/jbc.M212925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657624	hybrid			2022-12-27	WOS:000183230500009
J	Zeng, HY; Zhao, DZ; Yang, SP; Datta, K; Mukhopadhyay, D				Zeng, HY; Zhao, DZ; Yang, SP; Datta, K; Mukhopadhyay, D			Heterotrimeric G alpha(q)/G alpha(11) proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; CELL PROLIFERATION; DEPENDENT ACTIVATION; TYROSINE KINASE; DNA-SYNTHESIS; TUMOR-CELLS; PLC-GAMMA; MIGRATION; ANGIOGENESIS; FLT-1	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) functions by activating two receptor-tyrosine kinases, Flt-1 (VEGF receptor (VEGFR)-1) and KDR (VEGFR-2), both of which are selectively expressed on primary vascular endothelium. KDR is responsible for VPF/VEGF-stimulated endothelial cell proliferation and migration, whereas Flt-1 down-modulates KDR-mediated endothelial cell proliferation. Our most recent works show that pertussis toxin-sensitive G proteins and Gbetagamma subunits are required for Flt-1-mediated down-regulation of human umbilical vein endothelial cell (HUVEC) proliferation and that G(q/11) proteins are required for KDR-mediated RhoA activation and HUVEC migration. In this study, we demonstrate that G(q/11) proteins are also required for VPF/VEGF-stimulated HUVEC proliferation. Our results further indicate that G(q/11) proteins specifically mediate KDR signaling such as intracellular Ca2+ mobilization rather than Flt-1-induced CDC42 activation and that a G(q/11) antisense oligonucleotide completely inhibits MAPK phosphorylation induced by KDR but has no effect on Flt-1-induced MAPK activation. More importantly, we demonstrate that G(q/11) proteins interact with KDR in vivo, and the interaction of G(q/11) proteins with KDR does not require KDR tyrosine phosphorylation. Surprisingly, the G(q/11) antisense oligonucleotide completely inhibits VPF/VEGF-stimulated KDR phosphorylation. Expression of a constitutively active mutant of G(11) but not G(q) can cause phosphorylation of KDR and MAPK. In addition, a Gbetagamma minigene, hbetaARK1(495), inhibits VPF/VEGF-stimulated HUVEC proliferation, MAPK phosphorylation, and intracellular Ca2+ mobilization but has no effect on KDR phosphorylation. Taken together, this study demonstrates that G(q/11) proteins mediate KDR tyrosine phosphorylation and KDR-mediated HUVEC proliferation through interaction with KDR.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.	dmukhopa@caregroup.harvard.edu			NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567, HL072178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078383, R01CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072178, R01HL070567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; BROCK TA, 1991, AM J PATHOL, V138, P213; Clague MJ, 2001, J CELL SCI, V114, P3075; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; DEVIVO M, 1994, J BIOL CHEM, V269, P19671; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1979, J IMMUNOL, V122, P166; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Folkman J, 1997, EXS, V79, P1; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gagnon ML, 2000, P NATL ACAD SCI USA, V97, P2573, DOI 10.1073/pnas.040337597; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Sanchez-Blazquez P, 1998, J PHARMACOL EXP THER, V285, P820; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thodeti CK, 2000, J BIOL CHEM, V275, P9849, DOI 10.1074/jbc.275.13.9849; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P6059, DOI 10.1074/jbc.275.9.6059; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zeng HY, 2002, J BIOL CHEM, V277, P46791, DOI 10.1074/jbc.M206133200; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200	49	59	65	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20738	20745		10.1074/jbc.M209712200	http://dx.doi.org/10.1074/jbc.M209712200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670961	hybrid			2022-12-27	WOS:000183230500040
J	Fechter, P; Mingay, L; Sharps, J; Chambers, A; Fodor, E; Brownlee, GG				Fechter, P; Mingay, L; Sharps, J; Chambers, A; Fodor, E; Brownlee, GG			Two aromatic residues in the PB2 subunit of influenza A RNA polymerase are crucial for cap binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL COMPLEMENTARY RNA; AMINO-ACID MUTATION; MESSENGER-RNA; VIRUS POLYMERASE; STRUCTURAL BASIS; VIRION RNA; PA SUBUNIT; RECOGNITION; PROTEIN; ENDONUCLEASE	mRNAs are capped at their 5'-end by a unique cap structure containing N-7-methyl guanine. Recognition of the cap structure is of paramount importance in some of the most central processes of gene expression as well as in some viral processes, such as priming of influenza virus transcription. The recent resolution of the structure of three evolutionary unrelated cap binding proteins, the vaccinia viral protein VP39, the eukaryotic translation factor eIF4E, and the nuclear cap-binding protein CBP20 showed that the recognition of the cap structure is achieved by the same general mechanism, i.e. by "sandwiching" of the N-7-methyl guanine of the cap structure between two aromatic amino acid residues. The purpose of the present study was to test whether a similar cap recognition mechanism had independently evolved for the RNA polymerase of influenza virus. Combining in vivo and in vitro methods, we characterized two crucial aromatic amino acids, Phe(363) and Phe(404), in the PB2 subunit of the viral RNA polymerase that are essential for cap binding. The aromaticity of these two residues is conserved in influenza A, B, and C and even in the divergent Thogoto virus PB2 subunits. Thus, our results favor a similar mechanism of cap binding by the influenza RNA polymerase as in the evolutionary unrelated VP39, eIF4E, and CBP20.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Brownlee, GG (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	George.Brownlee@path.ox.ac.uk		Fodor, Ervin/0000-0003-3249-196X; Chambers, Anna/0000-0001-8133-6240				BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BLAAS D, 1982, NUCLEIC ACIDS RES, V10, P4803; BOULOY M, 1980, P NATL ACAD SCI-BIOL, V77, P3952, DOI 10.1073/pnas.77.7.3952; BOULOY M, 1979, J VIROL, V32, P895, DOI 10.1128/JVI.32.3.895-904.1979; BROWNLEE GG, 1995, NUCLEIC ACIDS RES, V23, P2641, DOI 10.1093/nar/23.14.2641; Brownlee GG, 2002, J VIROL, V76, P7103, DOI 10.1128/JVI.76.14.7103-7113.2002; Calero G, 2002, NAT STRUCT BIOL, V9, P912, DOI 10.1038/nsb874; CIANCI C, 1995, J VIROL, V69, P3995, DOI 10.1128/JVI.69.7.3995-3999.1995; DIGARD P, 1989, VIROLOGY, V171, P162, DOI 10.1016/0042-6822(89)90523-0; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; Fodor E, 2003, J VIROL, V77, P5017, DOI 10.1128/JVI.77.8.5017-5020.2003; FODOR E, 1993, J GEN VIROL, V74, P1327, DOI 10.1099/0022-1317-74-7-1327; Fodor E, 1999, J VIROL, V73, P9679, DOI 10.1128/JVI.73.11.9679-9682.1999; Fodor E, 2002, J VIROL, V76, P8989, DOI 10.1128/JVI.76.18.8989-9001.2002; Fodor E, 2002, PERSP MED V, V7, P1; Fodor E, 1998, J VIROL, V72, P6283, DOI 10.1128/JVI.72.8.6283-6290.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; Hodel AE, 1997, NAT STRUCT BIOL, V4, P350, DOI 10.1038/nsb0597-350; Honda A, 1999, GENES CELLS, V4, P475, DOI 10.1046/j.1365-2443.1999.00275.x; HOOKER L, 2002, 12 C VIR PAR FRANC J; Hsu PC, 2000, BIOCHEMISTRY-US, V39, P13730, DOI 10.1021/bi000623p; Hu GH, 2002, BIOCHEMISTRY-US, V41, P7677, DOI 10.1021/bi0201926; ISHIDA T, 1988, NUCLEIC ACIDS RES, V16, P6175, DOI 10.1093/nar/16.13.6175; KONARSKA MM, 1984, CELL, V38, P731, DOI 10.1016/0092-8674(84)90268-X; Lamb RA, 2001, FIELDS VIROL, V1, P1487; Leahy MB, 1998, J VIROL, V72, P2305, DOI 10.1128/JVI.72.3.2305-2309.1998; Li ML, 1998, EMBO J, V17, P5844, DOI 10.1093/emboj/17.19.5844; Li ML, 2001, EMBO J, V20, P2078, DOI 10.1093/emboj/20.8.2078; MADER S, 1995, BIOCHIMIE, V77, P40, DOI 10.1016/0300-9084(96)88102-8; MAHY BWJ, 1981, REPLICATION NEGATIVE, P379; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mazza C, 2002, EMBO J, V21, P5548, DOI 10.1093/emboj/cdf538; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Niedzwiecka A, 2002, J MOL BIOL, V319, P615, DOI 10.1016/S0022-2836(02)00328-5; Pleschka S, 1996, J VIROL, V70, P4188, DOI 10.1128/JVI.70.6.4188-4192.1996; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; PLOTCH SJ, 1979, P NATL ACAD SCI USA, V76, P1618, DOI 10.1073/pnas.76.4.1618; POCH O, 1989, EMBO J, V8, P3867, DOI 10.1002/j.1460-2075.1989.tb08565.x; Portela A, 1999, ADV VIRUS RES, V54, P319, DOI 10.1016/S0065-3527(08)60370-X; Quiocho FA, 2000, CURR OPIN STRUC BIOL, V10, P78, DOI 10.1016/S0959-440X(99)00053-6; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; ULMANEN I, 1981, P NATL ACAD SCI-BIOL, V78, P7355, DOI 10.1073/pnas.78.12.7355; Wilson KF, 1999, J BIOL CHEM, V274, P4166, DOI 10.1074/jbc.274.7.4166	47	125	139	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20381	20388		10.1074/jbc.M300130200	http://dx.doi.org/10.1074/jbc.M300130200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646557	hybrid			2022-12-27	WOS:000183078000103
J	Fitzpatrick, TB; Amrhein, N; Macheroux, P				Fitzpatrick, TB; Amrhein, N; Macheroux, P			Characterization of YqjM, an old yellow enzyme homolog from Bacillus subtilis involved in the oxidative stress response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PENTAERYTHRITOL TETRANITRATE REDUCTASE; ENTEROBACTER-CLOACAE PB2; SPECTRAL PROPERTIES; 2,4,6-TRINITROTOLUENE; SEQUENCE; DEGRADATION; SPECIFICITY; EXPLOSIVES; TRINITRATE; COMPLEXES	In this paper, we demonstrate that a protein from Bacillus subtilis (YqjM) shares many characteristic biochemical properties with the homologous yeast Old Yellow Enzyme (OYE); the enzyme binds FMN tightly but noncovalently, preferentially uses NADPH as a source of reducing equivalents, and forms charge transfer complexes with phenolic compounds such as p-hydroxybenzaldehyde. Like yeast OYE and other members of the family, YqjM catalyzes the reduction of the double bond of an array of alpha,beta-unsaturated aldehydes and ketones including nitroester and nitroaromatic compounds. Although yeast OYE was the first member of this family to be discovered in 1933 and was the first flavoenzyme ever to be isolated, the physiological role of the family still remains obscure. The finding that alpha, beta-unsaturated compounds are substrates provoked speculation that the OYE family might be involved in reductive degradation of xenobiotics or lipid peroxidation products. Here, for the first time, we demonstrate on the protein level that whereas YqjM shows a basal level of expression in B. subtilis, the addition of the toxic xenobiotic, trinitrotoluene, leads to a rapid induction of the protein in vivo denoting a role in detoxification. Moreover, we show that YqjM is rapidly induced in response to oxidative stress as exerted by hydrogen peroxide, demonstrating a potential physiological role for this enigmatic class of proteins.	ETH, Inst Pflanzenwissensch, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Fitzpatrick, TB (corresponding author), ETH, Inst Pflanzenwissensch, Univ Str 2, CH-8092 Zurich, Switzerland.		Macheroux, Peter/AAB-5157-2019	Macheroux, Peter/0000-0002-0242-454X				ABRAMOVITZ AS, 1976, J BIOL CHEM, V251, P5327; Aliverti A, 1999, METH MOL B, V131, P9; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Barna TM, 2001, J MOL BIOL, V310, P433, DOI 10.1006/jmbi.2001.4779; Binks PR, 1996, APPL ENVIRON MICROB, V62, P1214, DOI 10.1128/AEM.62.4.1214-1219.1996; Blehert DS, 1997, J BACTERIOL, V179, P6912, DOI 10.1128/jb.179.22.6912-6920.1997; Blehert DS, 1999, J BACTERIOL, V181, P6254, DOI 10.1128/JB.181.20.6254-6263.1999; Breithaupt C, 2001, STRUCTURE, V9, P419, DOI 10.1016/S0969-2126(01)00602-5; Cenas N, 2001, BBA-GEN SUBJECTS, V1528, P31, DOI 10.1016/S0304-4165(01)00169-6; Craig DH, 1998, BIOCHEMISTRY-US, V37, P7598, DOI 10.1021/bi980345i; Fitzpatrick TB, 2001, J BIOL CHEM, V276, P18052, DOI 10.1074/jbc.M100867200; French CE, 1999, NAT BIOTECHNOL, V17, P491, DOI 10.1038/8673; French CE, 1998, APPL ENVIRON MICROB, V64, P2864; French CE, 1996, J BACTERIOL, V178, P6623, DOI 10.1128/jb.178.22.6623-6627.1996; Hannink N, 2001, NAT BIOTECHNOL, V19, P1168, DOI 10.1038/nbt1201-1168; Harlow E., 1988, ANTIBODIES LAB MANUA; HARWOOD CR, 1992, TRENDS BIOTECHNOL, V10, P247, DOI 10.1016/0167-7799(92)90233-L; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Homma-Takeda S, 2002, FREE RADICAL RES, V36, P555, DOI 10.1080/10715760290025933; Kohli RM, 1998, J BIOL CHEM, V273, P32763, DOI 10.1074/jbc.273.49.32763; Kong L Y, 1989, Biomed Environ Sci, V2, P72; Kumagai Y, 2000, FEBS LETT, V478, P295, DOI 10.1016/S0014-5793(00)01841-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; MASSEY V, 1978, BIOCHEMISTRY-US, V17, P1, DOI 10.1021/bi00594a001; MATTHEWS RG, 1969, J BIOL CHEM, V244, P1779; Meah Y, 2001, P NATL ACAD SCI USA, V98, P8560, DOI 10.1073/pnas.151249098; MULLER F, 1973, BIOCHEMISTRY-US, V12, P4654; Pak JW, 2000, APPL ENVIRON MICROB, V66, P4742, DOI 10.1128/AEM.66.11.4742-4750.2000; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; Snape JR, 1997, J BACTERIOL, V179, P7796, DOI 10.1128/jb.179.24.7796-7802.1997; SPIZIZEN J, 1958, P NATL ACAD SCI USA, V44, P1072, DOI 10.1073/pnas.44.10.1072; STEWART RC, 1985, J BIOL CHEM, V260, P3639; STOTT K, 1993, J BIOL CHEM, V268, P6097; Strassner J, 1999, J BIOL CHEM, V274, P35067, DOI 10.1074/jbc.274.49.35067; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; Warburg O, 1933, BIOCHEM Z, V266, P377; WARBURG O, 1932, NATURWISSENSCHAFTEN, V20, P688	39	128	134	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19891	19897		10.1074/jbc.M211778200	http://dx.doi.org/10.1074/jbc.M211778200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660247	Green Published, hybrid			2022-12-27	WOS:000183078000042
J	Geiszt, M; Lekstrom, K; Witta, J; Leto, TL				Geiszt, M; Lekstrom, K; Witta, J; Leto, TL			Proteins homologous to p47(phox) and p67(phox) support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHAGOCYTE NADPH OXIDASE; CHRONIC GRANULOMATOUS-DISEASE; RESPIRATORY BURST OXIDASE; FLAVOCYTOCHROME B(558); ACTIVATION DOMAIN; PHOSPHORYLATION; TRANSFORMATION; IDENTIFICATION; COMPONENTS; CLONING	Superoxide production by phagocytes involves activation of a multi-component NADPH oxidase. Recently, several homologues of the catalytic component of the phagocyte oxidase, gp91(phox), were identified in various tissues. Here we describe two proteins, p41 and p51, with significant homology to two cytosolic components of the phagocytic oxidase, p47(phox) and p67(phox). Like p47(phox), p41 contains an amino-terminal Phox homology domain, two SH3 domains, and a conserved carboxyl-terminal, proline-rich motif. Similarly, p51 is homologous to p67(phox), containing four amino-terminal tetratricopeptide repeats, a conserved "activation domain" motif, a PB1 domain, and a carboxyl-terminal SH3 domain. The highest levels of p41 transcript are detected in the colon and in other gastrointestinal tissues that express Nox1, the predominant gp91(phox) homologue in these tissues. In contrast, the p51 transcript showed a more widespread expression pattern, suggesting that it may support other tissue-specific oxidases. Mouse colon in situ hybridization detected both transcripts in the epithelial cells of colon crypts. Heterologous co-expression of p41 and p51 significantly enhances the superoxide-generating activity of Nox1-expressing cells; thus, p41 and p51 appear to be novel regulators of Nox1. These proteins also support the activity of gp91(phox), albeit at much lower levels than the cytosolic phox counterparts. Our results suggest colon epithelial cells contain a multi-component NAD(P) H oxidase with a molecular architecture similar to the phagocytic oxidase.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Semmelweis University; Uniformed Services University of the Health Sciences - USA	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000614, Z01AI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Banfi B, 2003, J BIOL CHEM, V278, P3510, DOI 10.1074/jbc.C200613200; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Biberstine-Kinkade KJ, 2001, J BIOL CHEM, V276, P31105, DOI 10.1074/jbc.M103327200; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DELEO FR, 1995, J BIOL CHEM, V270, P26246, DOI 10.1074/jbc.270.44.26246; DeLeo FR, 1996, J BIOL CHEM, V271, P17013, DOI 10.1074/jbc.271.29.17013; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ElBenna J, 1996, J BIOL CHEM, V271, P6374; FINAN P, 1994, J BIOL CHEM, V269, P13752; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leto TL., 1999, INFLAMMATION BASIC P, P769; LEUSEN JHW, 1995, J BIOL CHEM, V270, P11216, DOI 10.1074/jbc.270.19.11216; LI F, 1994, BLOOD, V84, P53, DOI 10.1182/blood.V84.1.53.bloodjournal84153; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Teshima S, 2000, AM J PHYSIOL-GASTR L, V279, pG1169, DOI 10.1152/ajpgi.2000.279.6.G1169	28	241	253	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20006	20012		10.1074/jbc.M301289200	http://dx.doi.org/10.1074/jbc.M301289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657628	hybrid			2022-12-27	WOS:000183078000057
J	Sugimoto, H; Sugimoto, S; Tatei, K; Obinata, H; Bakovic, M; Izumi, T; Vance, DE				Sugimoto, H; Sugimoto, S; Tatei, K; Obinata, H; Bakovic, M; Izumi, T; Vance, DE			Identification of Ets-1 as an important transcriptional activator of CTP : phosphocholine cytidylyltransferase alpha in COS-7 cells and co-activation with transcriptional enhancer factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; RAT-LIVER CTP; KAPPA-B; CTPPHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHATIDYLCHOLINE SYNTHESIS; PHOSPHORYLCHOLINE CYTIDYLYLTRANSFERASE; PHOSPHORYLATION SITES; PHYSICAL INTERACTIONS; SIGNAL-TRANSDUCTION; REGULATORY ELEMENT	Phosphatidylcholine biosynthesis via the CDP-choline pathway is primarily regulated by CTP: phosphocholine cytidylyltransferase (CT). Transcriptional enhancer factor-4 (TEF-4) enhances the transcription of CTalpha in COS-7 cells by interactions with the basal transcription machinery (Sugimoto, H., Bakovic, M., Yamashita, S., and Vance, D. E. ( 2001) J. Biol. Chem. 276, 12338 - 12344). To identify the most important transcription factor involved in basal CTalpha transcription, we made CTalpha promoter-deletion and - mutated constructs linked to a luciferase reporter and transfected them into COS-7 cells. The results indicate that an important site regulating basal CTalpha transcription is -53/-47 (GACTTCC), which is a putative consensus-binding site of Ets transcription factors (GGAA) in the opposite orientation. Gel shift analyses indicated the existence of a binding protein for -53/-47 ( GACTTCC) in nuclear extracts of COS-7 cells. When anti-Ets-1 antibody was incubated with the probe in gel shift analyses, the intensity of the binding protein was decreased. The binding of endogenous Ets-1 to the promoter probe was increased when TEF-4 was expressed; however, the amount of Ets-1 detected by immunoblotting was unchanged. When cells were transfected with Ets-1 cDNA, the luciferase activity of CTalpha promoter constructs was greatly enhanced. Co-transfection experiments with Ets-1 and TEF-4 showed enhanced expression of reporter constructs as well as CTalpha mRNA. These results suggest that Ets-1 is an important transcriptional activator of the CTalpha gene and that Ets-1 activity is enhanced by TEF-4.	Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan; Univ Guelph, Dept Human Biol & Nutr Sci, Guelph, ON N1G 2W1, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	Gunma University; Japan Science & Technology Agency (JST); University of Guelph; University of Alberta; University of Alberta	Izumi, T (corresponding author), Gunma Univ, Sch Med, Dept Biochem, Maebashi, Gumma 3718511, Japan.	takizumi@med.gunma-u.ac.jp; dennis.vance@ualberta.ca						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Arnold RS, 1997, BIOCHEMISTRY-US, V36, P6149, DOI 10.1021/bi970023z; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; Bakovic M, 2000, J LIPID RES, V41, P583; Bakovic M, 2003, J BIOL CHEM, V278, P14753, DOI 10.1074/jbc.M300162200; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BHAT NK, 1990, P NATL ACAD SCI USA, V87, P3723, DOI 10.1073/pnas.87.10.3723; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; FELDMAN DA, 1987, J BIOL CHEM, V262, P9075; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; Gri G, 1998, J BIOL CHEM, V273, P6431, DOI 10.1074/jbc.273.11.6431; Hadri L, 2002, J BIOL CHEM, V277, P36471, DOI 10.1074/jbc.M204731200; Hogan M, 1996, BIOCHEM J, V314, P799, DOI 10.1042/bj3140799; HOUWELING M, 1994, J BIOL CHEM, V269, P7544; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; Jacquemin P, 1996, J BIOL CHEM, V271, P21775, DOI 10.1074/jbc.271.36.21775; JOHN S, 1995, MOL CELL BIOL, V15, P1786; Johnson JE, 1999, MOL MEMBR BIOL, V16, P217, DOI 10.1080/096876899294544; KALMAR GB, 1990, P NATL ACAD SCI USA, V87, P6029, DOI 10.1073/pnas.87.16.6029; Kast HR, 2001, J LIPID RES, V42, P1266; Kavurma MM, 2002, J BIOL CHEM, V277, P36244, DOI 10.1074/jbc.M200463200; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; Krehan A, 2000, J BIOL CHEM, V275, P18327, DOI 10.1074/jbc.M909736199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lagace TK, 2000, J BIOL CHEM, V275, P14367, DOI 10.1074/jbc.275.19.14367; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Li RZ, 2000, ONCOGENE, V19, P6514, DOI 10.1038/sj.onc.1204035; Lykidis A, 2001, PROG NUCLEIC ACID RE, V65, P361; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; LYMKIDIS A, 1998, J BIOL CHEM, V237, P14022; MACDONALD JIS, 1994, J BIOL CHEM, V269, P10529; Mallampalli RK, 2002, BIOCHEM J, V362, P81, DOI 10.1042/0264-6021:3620081; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PELECH SL, 1982, J BIOL CHEM, V257, P4198; SACCHI N, 1986, SCIENCE, V231, P379, DOI 10.1126/science.3941901; Sapi E, 1998, CANCER RES, V58, P1027; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sementchenko VI, 1998, ONCOGENE, V17, P2883, DOI 10.1038/sj.onc.1202220; Sesca E, 1996, BIOCHEM BIOPH RES CO, V229, P158, DOI 10.1006/bbrc.1996.1773; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SOHAL PS, 1990, J BIOL CHEM, V265, P11746; Sugimoto H, 2001, J BIOL CHEM, V276, P12338, DOI 10.1074/jbc.M100090200; Tang W, 1997, J BIOL CHEM, V272, P13146, DOI 10.1074/jbc.272.20.13146; Tessitore L, 1999, CARCINOGENESIS, V20, P561, DOI 10.1093/carcin/20.4.561; Tessitore L, 1999, BIOCHEM J, V337, P23, DOI 10.1042/0264-6021:3370023; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; Valter MM, 1999, CANCER RES, V59, P5608; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; WANG YL, 1995, J BIOL CHEM, V270, P17843, DOI 10.1074/jbc.270.30.17843; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; Werner MH, 1997, J BIOMOL NMR, V10, P317, DOI 10.1023/A:1018399711996; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; Yang BS, 1996, MOL CELL BIOL, V16, P538; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhang DJ, 2000, J BIOL CHEM, V275, P35368, DOI 10.1074/jbc.M007099200	72	13	14	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19716	19722		10.1074/jbc.M301590200	http://dx.doi.org/10.1074/jbc.M301590200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12642588	hybrid			2022-12-27	WOS:000183078000021
J	McLellan, CA; Raynes, DA; Guerriero, V				McLellan, CA; Raynes, DA; Guerriero, V			HspBP1, an Hsp70 cochaperone, has two structural domains and is capable of altering the conformation of the Hsp70 ATPase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; PROTEIN	We present here the first structural information for HspBP1, an Hsp70 cochaperone. Using circular dichroism, HspBP1 was determined to be 35% helical. Although HspBP1 is encoded by seven exons, limited proteolysis shows that it has only two structural domains. Domain I, amino acids 1-83, is largely unstructured. Domain II, amino acids 84-359, is predicted to be 43% helical using circular dichroism. Using limited proteolysis we have also shown that HspBP1 association changes the conformation of the ATPase domain of Hsp70. Only domain II of HspBP1 is required to bring about this conformational change. Truncation mutants of HspBP1 were tested for their ability to inhibit the renaturation of luciferase and bind to Hsp70 in reticulocyte lysate. A carboxyl terminal truncation mutant that was slightly longer than domain I was inactive in these assays, but domain II was sufficient to perform both functions. Domain II was less active than full-length HspBP1 in these assays, and addition of amino acids from domain I improved both functions. These studies show that HspBP1 domain II can bind Hsp70, change the conformation of the ATPase domain, and inhibit Hsp70-associated protein folding.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Dept Anim Sci, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Guerriero, V (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.	Guerrier@email.arizona.edu			ORS NIH HHS [SIORR13838] Funding Source: Medline	ORS NIH HHS		CHAPPELL TG, 1987, J BIOL CHEM, V262, P746; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Chung KT, 2002, J BIOL CHEM, V277, P47557, DOI 10.1074/jbc.M208377200; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GUERRIERO V, 1989, J CELL PHYSIOL, V140, P471, DOI 10.1002/jcp.1041400310; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; KABANI M, 2002, FEBS LETT; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Nollen EAA, 2002, J CELL SCI, V115, P2809; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; SCHUMACHER RJ, 1994, J BIOL CHEM, V269, P9493; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440	18	24	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19017	19022		10.1074/jbc.M301109200	http://dx.doi.org/10.1074/jbc.M301109200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12651857	hybrid			2022-12-27	WOS:000182932200039
J	Salt, IP; Morrow, VA; Brandie, FM; Connell, JMC; Petrie, JR				Salt, IP; Morrow, VA; Brandie, FM; Connell, JMC; Petrie, JR			High glucose inhibits insulin-stimulated nitric oxide production without reducing endothelial nitric-oxide synthase Ser(1177) phosphorylation in human aortic endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT DIABETES-MELLITUS; PROTEIN-KINASE-C; CARDIOVASCULAR-DISEASE; 3T3-L1 ADIPOCYTES; IN-VIVO; ACTIVATION; AKT; EXPRESSION; VASODILATION; RELEASE	Recent studies have indicated that insulin activates endothelial nitric-oxide synthase ( eNOS) by protein kinase B (PKB)-mediated phosphorylation at Ser(1177) in endothelial cells. Because hyperglycemia contributes to endothelial dysfunction and decreased NO availability in types 1 and 2 diabetes mellitus, we have studied the effects of high glucose ( 25 mM, 48 h) on insulin signaling pathways that regulate NO production in human aortic endothelial cells. High glucose inhibited insulin-stimulated NO synthesis but was without effect on NO synthesis stimulated by increasing intracellular Ca2+ concentration. This was accompanied by reduced expression of IRS-2 and attenuated insulin-stimulated recruitment of PI3K to IRS-1 and IRS-2, yet insulin-stimulated PKB activity and phosphorylation of eNOS at Ser(1177) were unaffected. Inhibition of insulin-stimulated NO synthesis by high glucose was unaffected by an inhibitor of PKC. Furthermore, high glucose down-regulated the expression of CAP and Cbl, and insulin-stimulated Cbl phosphorylation, components of an insulin signaling cascade previously characterized in adipocytes. These data suggest that high glucose specifically inhibits insulin-stimulated NO synthesis and down-regulates some aspects of insulin signaling, including the CAP-Cbl signaling pathway, yet this is not a result of reduced PKB-mediated eNOS phosphorylation at Ser(1177). Therefore, we propose that phosphorylation of eNOS at Ser(1177) is not sufficient to stimulate NO production in cells cultured at 25 mM glucose.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Western Infirm, Gardiner Inst, Div Cardiovasc & Med Sci, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow; University of Glasgow	Salt, IP (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Henry Wellcome Lab Cell Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.			Salt, Ian/0000-0003-0055-3724; s, hema/0000-0002-3440-9475				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; CALVER AL, 1992, J CLIN INVEST, V90, P2546; CHESTER AH, 1990, LANCET, V336, P897, DOI 10.1016/0140-6736(90)92269-N; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cleland SJ, 1998, CLIN EXP PHARMACOL P, V25, P175, DOI 10.1111/j.1440-1681.1998.t01-15-.x; Cleland SJ, 2000, HYPERTENSION, V35, P507, DOI 10.1161/01.HYP.35.1.507; Cosentino F, 1997, CIRCULATION, V96, P25; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Ding YX, 2000, AM J PHYSIOL-ENDOC M, V279, pE11, DOI 10.1152/ajpendo.2000.279.1.E11; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Hsueh WA, 1997, DIABETES REV, V5, P343; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Kim F, 2001, AM J PHYSIOL-CELL PH, V280, pC1057, DOI 10.1152/ajpcell.2001.280.5.C1057; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; MONCADA S, 1991, PHARMACOL REV, V43, P109; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Nadler ST, 2001, AM J PHYSIOL-ENDOC M, V281, pE1249, DOI 10.1152/ajpendo.2001.281.6.E1249; Petrie JR, 1996, CIRCULATION, V93, P1331, DOI 10.1161/01.CIR.93.7.1331; Previs SF, 2000, J BIOL CHEM, V275, P38990, DOI 10.1074/jbc.M006490200; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; SCHNYDER B, 2002, AM J PHYSIOL, V282, pE89; STEINBERG HO, 1994, J CLIN INVEST, V94, P1172, DOI 10.1172/JCI117433; Ting HH, 1996, J CLIN INVEST, V97, P22, DOI 10.1172/JCI118394; Vallance P, 1999, CLIN SCI, V97, P343, DOI 10.1042/CS19990175; Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILLIAMS SB, 1996, J AM COLL CARDIOL, V27, P564; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	34	68	70	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18791	18797		10.1074/jbc.M210618200	http://dx.doi.org/10.1074/jbc.M210618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644458	hybrid			2022-12-27	WOS:000182932200013
J	Shah, BH; Farshori, MP; Jambusaria, A; Catt, KJ				Shah, BH; Farshori, MP; Jambusaria, A; Catt, KJ			Roles of Src and epidermal growth factor receptor transactivation in transient and sustained ERK1/2 responses to gonadotropin-releasing hormone receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SIGNAL-REGULATED KINASE-1/2; PROLONGED NUCLEAR RETENTION; ANGIOTENSIN-II; EGF RECEPTOR; BETA-ARRESTIN; MAPK CASCADE; C-FOS; RAS; MECHANISMS	The duration as well as the magnitude of mitogen-activated protein kinase activation has been proposed to regulate gene expression and other specific intracellular responses in individual cell types. Activation of ERK1/2 by the hypothalamic neuropeptide gonadotropin-releasing hormone (GnRH) is relatively sustained in alphaT3-1 pituitary gonadotropes and HEK293 cells but is transient in immortalized GT1-7 neurons. Each of these cell types expresses the epidermal growth factor receptor (EGFR) and responds to EGF stimulation with significant but transient ERK1/2 phosphorylation. However, GnRH-induced ERK1/2 phosphorylation caused by EGFR transactivation was confined to GT1-7 cells and was attenuated by EGFR kinase inhibition. Neither EGF nor GnRH receptor activation caused translocation of phospho-ERK1/2 into the nucleus in GT1-7 cells. In contrast, agonist stimulation of GnRH receptors expressed in HEK293 cells caused sustained phosphorylation and nuclear translocation of ERK1/2 by a protein kinase C-dependent but EGFR-independent pathway. GnRH-induced activation of ERK1/2 was attenuated by the selective Src kinase inhibitor PP2 and the negative regulatory C-terminal Src kinase in GT1-7 cells but not in HEK293 cells. In GT1-7 cells, GnRH stimulated phosphorylation and nuclear translocation of the ERK1/2-dependent protein, p90(RSK-1) (RSK-1). These results indicate that the duration of ERK1/2 activation depends on the signaling pathways utilized by GnRH in specific target cells. Whereas activation of the G(q)/protein kinase C pathway in HEK293 cells causes sustained phosphorylation and translocation of ERK1/2 to the nucleus, transactivation of the EGFR by GnRH in GT1-7 cells elicits transient ERK1/2 signals without nuclear accumulation. These findings suggest that transactivation of the tightly regulated EGFR can account for the transient ERK1/2 responses that are elicited by stimulation of certain G protein-coupled receptors.	NICHD, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Catt, KJ (corresponding author), NICHD, ERRB, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	catt@helix.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000184] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000184] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abe K, 2000, NEUROSCI LETT, V282, P89, DOI 10.1016/S0304-3940(00)00867-3; Adachi T, 2002, J CELL PHYSIOL, V192, P151, DOI 10.1002/jcp.10124; Benard O, 2001, J BIOL CHEM, V276, P4554, DOI 10.1074/jbc.M006995200; Boglari G, 1998, EUR J CELL BIOL, V75, P54, DOI 10.1016/S0171-9335(98)80046-0; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brightman FA, 2000, FEBS LETT, V482, P169, DOI 10.1016/S0014-5793(00)02037-8; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CESNJAJ M, 1993, ENDOCRINOLOGY, V133, P3042, DOI 10.1210/en.133.6.3042; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; Eguchi S, 2001, J BIOL CHEM, V276, P7957, DOI 10.1074/jbc.M008570200; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Grosse R, 2000, J BIOL CHEM, V275, P12251, DOI 10.1074/jbc.275.16.12251; Gschwind A, 2001, ONCOGENE, V20, P1594, DOI 10.1038/sj.onc.1204192; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; Hislop JN, 2001, J BIOL CHEM, V276, P39685, DOI 10.1074/jbc.M104542200; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Krsmanovic LZ, 2001, MOL ENDOCRINOL, V15, P429, DOI 10.1210/me.15.3.429; Liang CC, 2001, J BIOL CHEM, V276, P21146, DOI 10.1074/jbc.M010669200; Liu FJ, 2002, MOL ENDOCRINOL, V16, P419, DOI 10.1210/me.16.3.419; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McArdle CA, 2002, J ENDOCRINOL, V173, P1, DOI 10.1677/joe.0.1730001; Ochoa A, 1997, J NEUROSCI RES, V49, P739, DOI 10.1002/(SICI)1097-4547(19970915)49:6<739::AID-JNR8>3.3.CO;2-3; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pouyssegur J, 2002, BIOCHEM PHARMACOL, V64, P755, DOI 10.1016/S0006-2952(02)01135-8; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seta K, 2002, J BIOL CHEM, V277, P9268, DOI 10.1074/jbc.M109221200; Shah BH, 2003, J BIOL CHEM, V278, P2866, DOI 10.1074/jbc.m208783200; Shah BH, 2002, MOL PHARMACOL, V61, P343, DOI 10.1124/mol.61.2.343; Stanciu M, 2002, J BIOL CHEM, V277, P4010, DOI 10.1074/jbc.M104479200; Tanimura S, 2002, J BIOL CHEM, V277, P28256, DOI 10.1074/jbc.M202866200; Tari AM, 2001, SEMIN ONCOL, V28, P142, DOI 10.1053/sonc.2001.28555; Tohgo AK, 2002, J BIOL CHEM, V277, P9429, DOI 10.1074/jbc.M106457200; Turner NA, 2001, CELL SIGNAL, V13, P269, DOI 10.1016/S0898-6568(01)00135-8; Vrecl M, 1998, MOL ENDOCRINOL, V12, P1818, DOI 10.1210/me.12.12.1818; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yao Z, 2001, ONCOGENE, V20, P7588, DOI 10.1038/sj.onc.1204963; Zhang J, 1996, J BIOL CHEM, V271, P18302, DOI 10.1074/jbc.271.31.18302; Zwick E, 2002, TRENDS MOL MED, V8, P17, DOI 10.1016/S1471-4914(01)02217-1; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	49	77	78	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19118	19126		10.1074/jbc.M212932200	http://dx.doi.org/10.1074/jbc.M212932200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642580	hybrid			2022-12-27	WOS:000182932200053
J	Clarke, P; Meintzer, SM; Moffitt, LA; Tyler, KL				Clarke, P; Meintzer, SM; Moffitt, LA; Tyler, KL			Two distinct phases of virus-induced nuclear factor kappa B regulation enhance tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in virus-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REOVIRUS-INDUCED APOPTOSIS; TRAIL-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; CANCER-CELLS; FACTOR-ALPHA; TRANSFORMING PROTEIN; REQUIRES ACTIVATION; SENSITIZES CELLS; DEATH RECEPTORS; PATHWAY	Cellular transcription factors are often utilized by infecting viruses to promote viral growth and influence cell fate. We have previously shown that nuclear factor kappaB (NF-kappaB) is activated after reovirus infection and that this activation is required for virus-induced apoptosis. In this report we identify a second phase of reovirus-induced NF-kappaB regulation. We show that at later times post-infection NF-kappaB activation is blocked in reovirus-infected cells. This results in the termination of virus-induced NF-kappaB activity and the inhibition of tumor necrosis factor alpha and etoposide-induced NF-kappaB activation in infected cells. Reovirus-induced inhibition of NF-kappaB activation occurs by a mechanism that prevents IkappaBalpha degradation and that is blocked in the presence of the viral RNA synthesis inhibitor, ribavirin. Reovirus-induced apoptosis is mediated by tumor necrosis factor-related apoptosis inducing ligand (TRAIL) in a variety of epithelial cell lines. Herein we show that ribavirin inhibits reovirus-induced apoptosis in TRAIL-resistant HEK293 cells and prevents the ability of reovirus infection to sensitize TRAIL-resistant cells to TRAIL-induced apoptosis. Furthermore, TRAIL-induced apoptosis is enhanced in HEK293 cells expressing IkappaBDeltaN2, which blocks NF-kappaB activation. These results indicate that the ability of reovirus to inhibit NF-kappaB activation sensitizes HEK293 cells to TRAIL and facilitates virus-induced apoptosis in TRAIL-resistant cells. Our findings demonstrate that two distinct phases of virus-induced NF-kappaB regulation are required to efficiently activate host cell apoptotic responses to reovirus infection.	Univ Colorado, Hlth Sci Ctr, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med Microbiol & Immunol, Denver, CO 80262 USA; Denver Vet Affairs Med Ctr, Denver, CO 80220 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver	Tyler, KL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Neurol B 182, 4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888	NIA NIH HHS [1R01AG14071] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014071] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barton ES, 2001, CELL, V104, P441, DOI 10.1016/S0092-8674(01)00231-8; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Casola A, 2002, VIROLOGY, V298, P8, DOI 10.1006/viro.2002.1475; CHEN Z, 1995, GENE DEV, V9, P1585; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Clarke P, 2001, ONCOGENE, V20, P6910, DOI 10.1038/sj.onc.1204842; Clarke P, 2003, APOPTOSIS, V8, P141, DOI 10.1023/A:1022966508671; Conaldi PG, 1998, J CLIN INVEST, V102, P2041, DOI 10.1172/JCI3480; Connolly JL, 2000, J VIROL, V74, P2981, DOI 10.1128/JVI.74.7.2981-2989.2000; Connolly JL, 2002, J VIROL, V76, P1632, DOI 10.1128/JVI.76.4.1632-1641.2002; Connolly JL, 2001, J VIROL, V75, P4029, DOI 10.1128/JVI.75.9.4029-4039.2001; DeBiasi RL, 2001, J VIROL, V75, P351, DOI 10.1128/JVI.75.1.351-361.2001; Debiasi RL, 1999, J VIROL, V73, P695, DOI 10.1128/JVI.73.1.695-701.1999; DUKE RC, 1992, CURRENT PROTOCOLS IM; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Herbein G, 1998, NATURE, V395, P189, DOI 10.1038/26026; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Jan JT, 2000, J VIROL, V74, P8680, DOI 10.1128/JVI.74.18.8680-8691.2000; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; Kaplan D, 1998, J VIROL, V72, P6279, DOI 10.1128/JVI.72.8.6279-6282.1998; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kominsky DJ, 2002, CELL DEATH DIFFER, V9, P926, DOI 10.1038/sj.cdd.4401045; LIN KI, 1995, J CELL BIOL, V131, P1149, DOI 10.1083/jcb.131.5.1149; Lin KI, 1998, J CELL BIOL, V141, P1479, DOI 10.1083/jcb.141.7.1479; May MJ, 1997, SEMIN CANCER BIOL, V8, P63, DOI 10.1006/scbi.1997.0057; Oberhaus SM, 1997, J VIROL, V71, P2100, DOI 10.1128/JVI.71.3.2100-2106.1997; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1998, J VIROL, V72, P8893, DOI 10.1128/JVI.72.11.8893-8903.1998; Richardson-Burns SM, 2002, J NEUROVIROL, V8, P365, DOI 10.1080/13550280260422677; ROULSTON A, 1995, MICROBIOL REV, V59, P481, DOI 10.1128/MMBR.59.3.481-505.1995; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Shetty S, 2002, APOPTOSIS, V7, P413, DOI 10.1023/A:1020031023947; Shrivastava A, 1998, J VIROL, V72, P9722, DOI 10.1128/JVI.72.12.9722-9728.1998; Sieg S, 1996, J VIROL, V70, P8747, DOI 10.1128/JVI.70.12.8747-8751.1996; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thomas RP, 2002, SURGERY, V132, P127, DOI 10.1067/msy.2002.124930; Tollefson AE, 1998, NATURE, V392, P726, DOI 10.1038/33712; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Tyler KL, 1996, J VIROL, V70, P7984, DOI 10.1128/JVI.70.11.7984-7991.1996; TYLER KL, 1995, J VIROL, V69, P6972, DOI 10.1128/JVI.69.11.6972-6979.1995; Tyler KL, 2001, TRENDS MICROBIOL, V9, P560, DOI 10.1016/S0966-842X(01)02103-5; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Weil R, 1999, MOL CELL BIOL, V19, P6345; You LR, 1999, J VIROL, V73, P1672, DOI 10.1128/JVI.73.2.1672-1681.1999	62	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18092	18100		10.1074/jbc.M300265200	http://dx.doi.org/10.1074/jbc.M300265200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637521	hybrid			2022-12-27	WOS:000182838300066
J	Storz, P; Doppler, H; Johannes, FJ; Toker, A				Storz, P; Doppler, H; Johannes, FJ; Toker, A			Tyrosine phosphorylation of protein kinase D in the pleckstrin homology domain leads to activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MU PKC-MU; C-MU; PROTEOLYTIC CLEAVAGE; MOLECULAR-CLONING; IDENTIFICATION; PATHWAY; MEMBER; FAMILY; CELLS	Protein kinase D (PKD) is a member of the AGC family of Ser/Thr kinases and is distantly related to protein kinase C (PKC). Formerly known as PKCmu, PKD contains protein domains not found in conventional PKC isoforms. A functional pleckstrin homology (PH) domain is critical for the regulation of PKD activity. Here we report that PKD is tyrosine-phosphorylated within the PH domain, leading to activation. This phosphorylation is mediated by a pathway that consists of the Src and Abl tyrosine kinases and occurs in response to stimulation with pervanadate and oxidative stress. Mutational analysis revealed three tyrosine phosphorylation sites (Tyr(432), Tyr(463), and Tyr(502)), which are regulated by the Src-Abl pathway, and phosphorylation of only one of these (Tyr(463)) leads to PKD activation. By using a phospho-specific antibody, we show that Abl directly phosphorylates PKD at Tyr(463) in vitro, and in cells phosphorylation of this site is sufficient to mediate full activation of PKD. Mutation of the other two sites, Tyr(432) and Tyr(502), had no significant influence on PKD activity. These data reveal a tyrosine phosphorylation-dependent activation mechanism for PKD and suggest that this event contributes to the release of the autoinhibitory PKD PH domain leading to kinase activation and downstream responses.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Fraunhofer Inst Interfacial Engn & Biotechnol, D-70569 Stuttgart, Germany	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Fraunhofer Gesellschaft	Toker, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [R01CA075134] Funding Source: NIH RePORTER; NCI NIH HHS [CA 75134] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Brandlin I, 2002, J BIOL CHEM, V277, P45451, DOI 10.1074/jbc.M205299200; Brandlin I, 2002, J BIOL CHEM, V277, P6490, DOI 10.1074/jbc.M106083200; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; Hausser A, 2002, J CELL BIOL, V156, P65, DOI 10.1083/jcb.200110047; Hausser A, 2001, FEBS LETT, V492, P39, DOI 10.1016/S0014-5793(01)02219-0; Haussermann S, 1999, FEBS LETT, V462, P442, DOI 10.1016/S0014-5793(99)01577-X; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Iglesias T, 1998, J BIOL CHEM, V273, P410, DOI 10.1074/jbc.273.1.410; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Maeda Y, 2001, EMBO J, V20, P5982, DOI 10.1093/emboj/20.21.5982; Matthews SA, 2000, J EXP MED, V191, P2075, DOI 10.1084/jem.191.12.2075; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Rey O, 2001, J BIOL CHEM, V276, P32616, DOI 10.1074/jbc.M101649200; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Toker Alex, 1998, Frontiers in Bioscience, V3, pD1134; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Van Lint J, 1998, J BIOL CHEM, V273, P7038, DOI 10.1074/jbc.273.12.7038; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Waldron RT, 2003, J BIOL CHEM, V278, P154, DOI 10.1074/jbc.M208075200; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	34	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17969	17976		10.1074/jbc.M213224200	http://dx.doi.org/10.1074/jbc.M213224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637538	hybrid			2022-12-27	WOS:000182838300048
J	Ogasahara, K; Ishida, M; Yutani, K				Ogasahara, K; Ishida, M; Yutani, K			Stimulated interaction between alpha and beta subunits of tryptophan synthase from hyperthermophile enhances its thermal stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIUM THERMOTOGA-MARITIMA; TRIOSEPHOSPHATE ISOMERASE TIM; ANTIGEN-ANTIBODY INTERACTION; SALT BRIDGE FORMATION; CRYSTAL-STRUCTURE; PYROCOCCUS-FURIOSUS; ESCHERICHIA-COLI; ALPHA(2)BETA(2) COMPLEX; THERMODYNAMIC ANALYSIS; ENTROPIC CONTRIBUTION	Tryptophan synthase from hyperthermophile, Pyrococcus furiosus, was found to be a tetrameric form (alpha(2)beta(2)) composed of a and 132 subunits. To elucidate the relationship between the features of the subunit association and the thermal stability of the tryptophan synthase, the subunit association and thermal stability were examined by isothermal titration calorimetry and differential scanning calorimetry, respectively, in comparison with those of the counterpart from Escherichia coli. The association constants between the a and P subunits in the hyperthermophile protein were of the order of 108 M-1, which were higher by two orders of magnitude than those in the mesophile one. The negative values of the heat capacity change and enthalpy change upon the subunit association were much lower in the hyperthermophile protein than in the mesophile one, indicating that the conformational change of the hyperthermophile protein coupled to the subunit association is slight. The denaturation temperature of the a subunit from the hyperthermophile was enhanced by 17 degreesC due to the formation of the alpha(2)beta(2) complex. This increment in denaturation temperature due to complex formation could be quantitatively estimated by the increase in the association constant compared with that of the counterpart from E. coli.	Kwansei Gakuin Univ, Grad Sch Sci, Sanda City, Hyogo 6671337, Japan; Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan; Tokyo Univ Fisheries, Minato Ku, Tokyo 1088477, Japan	Kwansei Gakuin University; Osaka University; Tokyo University of Marine Science & Technology	Yutani, K (corresponding author), Kwansei Gakuin Univ, Grad Sch Sci, Gakuen 2-1, Sanda City, Hyogo 6671337, Japan.	yutani@ksc.kwansei.ac.jp	ISHIDA, Masami/O-1909-2014					Arnott MA, 2000, J MOL BIOL, V304, P657, DOI 10.1006/jmbi.2000.4240; Auerbach G, 1998, STRUCTURE, V6, P769, DOI 10.1016/S0969-2126(98)00078-1; Backmann J, 2001, METHOD ENZYMOL, V334, P328; Beaucamp N, 1997, PROTEIN SCI, V6, P2159; Bell GS, 1998, ACTA CRYSTALLOGR D, V54, P1419, DOI 10.1107/S0907444998004910; Dams T, 1996, EUR J BIOCHEM, V240, P274, DOI 10.1111/j.1432-1033.1996.0274h.x; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; HARTLEY RW, 1993, BIOCHEMISTRY-US, V32, P5978, DOI 10.1021/bi00074a008; HATHAWAY GM, 1970, BIOCHEMISTRY-US, V9, P1801, DOI 10.1021/bi00810a020; Hettwer S, 2002, J BIOL CHEM, V277, P8194, DOI 10.1074/jbc.M111541200; Hiraga K, 1996, EUR J BIOCHEM, V240, P63, DOI 10.1111/j.1432-1033.1996.0063h.x; Hiraga K, 1997, J BIOL CHEM, V272, P4935, DOI 10.1074/jbc.272.8.4935; HYDE CC, 1988, J BIOL CHEM, V263, P17857; Ishida M, 2002, FEMS MICROBIOL LETT, V216, P179, DOI 10.1111/j.1574-6968.2002.tb11433.x; Ishikawa K, 2002, STRUCTURE, V10, P877, DOI 10.1016/S0969-2126(02)00779-7; Jaenicke R, 1996, ADV PROTEIN CHEM, V48, P181; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Jaenicke R, 2001, METHOD ENZYMOL, V334, P438; KIRINO H, 1994, EUR J BIOCHEM, V220, P275, DOI 10.1111/j.1432-1033.1994.tb18623.x; Kohlhoff M, 1996, FEBS LETT, V383, P245, DOI 10.1016/0014-5793(96)00249-9; Lim JH, 1997, J MOL BIOL, V270, P259, DOI 10.1006/jmbi.1997.1105; Maes D, 1999, PROTEINS, V37, P441, DOI 10.1002/(SICI)1097-0134(19991115)37:3<441::AID-PROT11>3.3.CO;2-Z; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; OGASAHARA K, 1980, J BIOCHEM-TOKYO, V88, P1733, DOI 10.1093/oxfordjournals.jbchem.a133148; Ogasahara K, 2001, EUR J BIOCHEM, V268, P3233, DOI 10.1046/j.1432-1327.2001.02220.x; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; Pan P, 1997, TRENDS BIOCHEM SCI, V22, P22, DOI 10.1016/S0968-0004(96)10066-9; Petsko GA, 2001, METHOD ENZYMOL, V334, P469; Rees DC, 2001, METHOD ENZYMOL, V334, P423; REMETA DP, 1995, PURE APPL CHEM, V67, P1859, DOI 10.1351/pac199567111859; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Russell RJM, 1997, BIOCHEMISTRY-US, V36, P9983, DOI 10.1021/bi9705321; SCHELLMAN JA, 1976, BIOPOLYMERS, V15, P999, DOI 10.1002/bip.1976.360150513; SCHELLMAN JA, 1975, BIOPOLYMERS, V14, P999, DOI 10.1002/bip.1975.360140509; Schneider TR, 1998, BIOCHEMISTRY-US, V37, P5394, DOI 10.1021/bi9728957; Shiroishi M, 2001, J BIOL CHEM, V276, P23042, DOI 10.1074/jbc.M100480200; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tanaka H, 2001, J BIOCHEM-TOKYO, V130, P107, DOI 10.1093/oxfordjournals.jbchem.a002948; Tang XF, 2000, EUR J BIOCHEM, V267, P6369, DOI 10.1046/j.1432-1327.2000.01721.x; Thoma R, 2000, STRUCTURE, V8, P265, DOI 10.1016/S0969-2126(00)00106-4; TSUMOTO K, 1995, J BIOL CHEM, V270, P18551, DOI 10.1074/jbc.270.31.18551; TSUMOTO K, 1994, J BIOL CHEM, V269, P28777; Tsumoto K, 1996, J BIOL CHEM, V271, P32612, DOI 10.1074/jbc.271.51.32612; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; Walden H, 2001, J MOL BIOL, V306, P745, DOI 10.1006/jmbi.2000.4433; Weyand M, 1999, BIOCHEMISTRY-US, V38, P16469, DOI 10.1021/bi9920533; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Yamagata Y, 2001, J BIOL CHEM, V276, P11062, DOI 10.1074/jbc.M009987200; YANOFSKY C, 1972, ENZYMES, V3, P1; YIP KSP, 1995, STRUCTURE, V3, P1147, DOI 10.1016/S0969-2126(01)00251-9; YUTANI K, 1987, J BIOL CHEM, V262, P13429; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; ZHAO GP, 1992, J BIOL CHEM, V267, P526	57	29	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8922	8928		10.1074/jbc.M210893200	http://dx.doi.org/10.1074/jbc.M210893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643278	hybrid			2022-12-27	WOS:000181524000009
J	Liepinsh, E; Banyai, L; Pintacuda, G; Trexler, M; Patthy, L; Otting, G				Liepinsh, E; Banyai, L; Pintacuda, G; Trexler, M; Patthy, L; Otting, G			NMR structure of the netrin-like domain (NTR) of human type I procollagen C-proteinase enhancer defines structural consensus of NTR domains and assesses potential proteinase inhibitory activity and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COUPLING-CONSTANTS; BIOLOGICAL MACROMOLECULES; 3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; TISSUE INHIBITOR; MULTIPLE TYPES; ALIGNMENT; METALLOPROTEINASE; GLYCOPROTEIN; EXPRESSION	Procollagen C-proteinase enhancer (PCOLCE) proteins are extracellular matrix proteins that enhance the activities of procollagen C-proteinases by binding to the C-propeptide of procollagen I. PCOLCE proteins are built of three structural modules, consisting of two CUB domains followed by a C-terminal netrin-like (NTR) domain. While the enhancement of proteinase activity can be ascribed solely to the CUB domains, sequence homology of the NTR domain with tissue inhibitors of metalloproteinases suggest proteinase inhibitory activity for the NTR domain. Here we present the three-dimensional structure of the NTR domain of human PCOLCE1 as the first example of a structural domain with the canonical features of an NTR module. The structure rules out a binding mode to metalloproteinases similar to that of tissue inhibitors of metalloproteinases but suggests possible inhibitory function toward specific serine proteinases. Sequence conservation between 13 PCOLCE proteins from different organisms suggests a conserved binding surface for other protein partners.	Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1113 Budapest, Hungary	Australian National University; Karolinska Institutet; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences	Otting, G (corresponding author), Australian Natl Univ, Res Sch Chem, Canberra, ACT 0200, Australia.		Otting, Gottfried/H-8413-2014; Patthy, Laszlo/Q-6058-2019; Patthy, Laszlo/A-2353-2013	Otting, Gottfried/0000-0002-0563-0146; 				ADAR R, 1986, COLLAGEN REL RES, V6, P267; Andersson P, 1998, J BIOMOL NMR, V12, P435, DOI 10.1023/A:1008239027287; Banyai L, 1999, PROTEIN SCI, V8, P1636, DOI 10.1110/ps.8.8.1636; Bernocco S, 2003, J BIOL CHEM, V278, P7199, DOI 10.1074/jbc.M210857200; Billeter M, 1995, J BIOMOL NMR, V5, P1; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Chong JM, 2002, J BIOL CHEM, V277, P5134, DOI 10.1074/jbc.M108533200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KESSLER E, 1989, EUR J BIOCHEM, V186, P115, DOI 10.1111/j.1432-1033.1989.tb15184.x; KESSLER E, 1990, BIOCHEM BIOPH RES CO, V173, P81, DOI 10.1016/S0006-291X(05)81024-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI M, 1987, BIOCHEMISTRY-US, V26, P202, DOI 10.1021/bi00375a028; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Luginbuhl P, 1996, J BIOMOL NMR, V8, P136; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; Mott JD, 2000, J BIOL CHEM, V275, P1384, DOI 10.1074/jbc.275.2.1384; Ofran Y, 2003, J MOL BIOL, V325, P377, DOI 10.1016/S0022-2836(02)01223-8; Ponstingl H, 1998, J BIOMOL NMR, V12, P319, DOI 10.1023/A:1008293016073; Ricard-Blum S, 2002, J BIOL CHEM, V277, P33864, DOI 10.1074/jbc.M205018200; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SEVILLASIERRA P, 1994, J MOL BIOL, V235, P1003, DOI 10.1006/jmbi.1994.1053; Steiglitz BM, 2002, J BIOL CHEM, V277, P49820, DOI 10.1074/jbc.M209891200; Stetefeld J, 2001, NAT STRUCT BIOL, V8, P705, DOI 10.1038/90422; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tompa P, 2002, TRENDS BIOCHEM SCI, V27, P527, DOI 10.1016/S0968-0004(02)02169-2; Trexler M, 2002, BIOL CHEM, V383, P223, DOI 10.1515/BC.2002.023; Trexler M, 2001, P NATL ACAD SCI USA, V98, P3705, DOI 10.1073/pnas.061028398; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Xu H, 2000, GENOMICS, V66, P264, DOI 10.1006/geno.2000.6229; Zweckstetter M, 2000, J AM CHEM SOC, V122, P3791, DOI 10.1021/ja0000908	40	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 11	2003	278	28					25982	25989		10.1074/jbc.M302734200	http://dx.doi.org/10.1074/jbc.M302734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	697AN	12670942	hybrid			2022-12-27	WOS:000183920200093
J	Elsby, R; Kitteringham, NR; Goldring, CE; Lovatt, CA; Chamberlain, M; Henderson, CJ; Wolf, CR; Park, BK				Elsby, R; Kitteringham, NR; Goldring, CE; Lovatt, CA; Chamberlain, M; Henderson, CJ; Wolf, CR; Park, BK			Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MICROSOMAL EPOXIDE HYDROLASE; TRANSCRIPTION FACTOR NRF2; HEME OXYGENASE-1 GENE; OXIDATIVE STRESS; ACETAMINOPHEN HEPATOTOXICITY; RAT-LIVER; HUMAN-TISSUES; BASAL LEVEL; CELL-LINES	Glutathione S-transferase Pi (GSTP) detoxifies electrophiles by catalyzing their conjugation with reduced glutathione. A second function of this protein in cell defense has recently been proposed that is related to its ability to interact with c-Jun N-terminal kinase (JNK). The present study aimed to determine whether this interaction results in increased constitutive JNK activity in the absence of GSTP in GstP1/P2((-/-)) mice and whether such a phenomenon leads to the up-regulation of genes that are relevant to cell defense. We found a significant increase in constitutive JNK activity in the liver and lung of GstP1/P2(-/-) compared with GstP1/ P2((+/+)) mice. The greatest increase in constitutive JNK activity was observed in null liver and was accompanied by a significant increase in activator protein-1 DNA binding activity (8-fold) and in the mRNA levels for the antioxidant protein heme oxygenase-1 compared with wild type. Furthermore UDP-glucuronosyltransferase 1A6 mRNA levels were significantly higher in the livers of GstP1/P2((-/-)) compared with GstP1/ P2((+/+)) mice, which correlated to a 2- fold increase in constitutive activity both in vitro and in vivo. There was no difference in the gene expression of other UDP-glucuronosyltransferase isoforms, manganese superoxide dismutase, microsomal epoxide hydrolase, or GSTA1 between GstP1/ P2((-/-)) and GstP1/ P2((+/+)) mice. Additionally there was no phenotypic difference in the induction of heme oxygenase-1 mRNA after acetaminophen administration. This study not only demonstrates the role of GSTP as a direct inhibitor of JNK in vivo but also its role in regulating the constitutive expression of specific downstream molecular targets of the JNK signaling pathway.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Canc Res UK Mol Pharmacol Unit, Dundee DD1 9SY, Scotland	University of Liverpool; University of Dundee	Park, BK (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Sherrington Bldgs,Ashton St, Liverpool L69 3GE, Merseyside, England.	bkpark@liverpool.ac.uk	Henderson, Colin J/A-6347-2009; Henderson, Colin/AAE-7141-2019	Henderson, Colin/0000-0002-4764-639X; Wolf, Charles Roland/0000-0002-6969-0113; Chamberlain, Mark/0000-0001-5198-9865				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALAM J, 1992, J BIOL CHEM, V267, P21894; Ariyoshi N, 2001, TOXICOL PATHOL, V29, P161, DOI 10.1080/019262301753178573; Bernardini S, 2000, J CELL BIOCHEM, V77, P645, DOI 10.1002/(SICI)1097-4644(20000615)77:4<645::AID-JCB12>3.3.CO;2-0; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chiu H, 2002, TOXICOL APPL PHARM, V181, P106, DOI 10.1006/taap.2002.9409; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; Court MH, 2000, PHARMACOGENETICS, V10, P355, DOI 10.1097/00008571-200006000-00009; DAVIES MH, 1991, TOXICOL APPL PHARM, V109, P29, DOI 10.1016/0041-008X(91)90188-K; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211; Elsby R, 2001, J PHARMACOL EXP THER, V297, P103; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fisher MB, 2000, DRUG METAB DISPOS, V28, P560; Gill HJ, 1995, BRIT J CLIN PHARMACO, V40, P531, DOI 10.1111/j.1365-2125.1995.tb05797.x; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAZELTON GA, 1986, TOXICOL APPL PHARM, V83, P474, DOI 10.1016/0041-008X(86)90230-9; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Henderson CJ, 2000, P NATL ACAD SCI USA, V97, P12741, DOI 10.1073/pnas.220176997; Ishisaki A, 2001, J NEUROCHEM, V77, P1362, DOI 10.1046/j.1471-4159.2001.00351.x; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Ketterer B, 2001, CHEM-BIOL INTERACT, V138, P27, DOI 10.1016/S0009-2797(01)00277-0; Kitteringham NR, 2000, HEPATOLOGY, V32, P321, DOI 10.1053/jhep.2000.9602; Kitteringham NR, 2003, PROTEOMICS, V3, P191, DOI 10.1002/pmic.200390028; Kleiner HE, 2002, CHEM RES TOXICOL, V15, P226, DOI 10.1021/tx010151v; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lamb JG, 2000, DRUG METAB DISPOS, V28, P1018; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McMahon M, 2001, CANCER RES, V61, P3299; Metz RP, 1998, J BIOL CHEM, V273, P5607, DOI 10.1074/jbc.273.10.5607; Miyata M, 1999, J BIOL CHEM, V274, P23963, DOI 10.1074/jbc.274.34.23963; MOSCOW JA, 1989, CANCER RES, V49, P1422; Oguro T, 1998, J PHARMACOL EXP THER, V287, P773; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Ramaswamy NT, 1999, MOL CARCINOGEN, V25, P262, DOI 10.1002/(SICI)1098-2744(199908)25:4<262::AID-MC5>3.0.CO;2-U; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; RAZA H, 1991, J INVEST DERMATOL, V96, P463, DOI 10.1111/1523-1747.ep12470150; Shklyaev SS, 2001, ANTICANCER RES, V21, P2569; Singh SV, 1998, CANCER LETT, V128, P197, DOI 10.1016/S0304-3835(98)00072-X; Tacchini L, 2002, BIOCHEM PHARMACOL, V63, P139, DOI 10.1016/S0006-2952(01)00836-X; Vasiliou V, 2000, BIOCHEM PHARMACOL, V59, P703, DOI 10.1016/S0006-2952(99)00360-3; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200	52	117	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22243	22249		10.1074/jbc.M301211200	http://dx.doi.org/10.1074/jbc.M301211200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12646564	hybrid			2022-12-27	WOS:000183503900010
J	Lesso, H; Li, RA				Lesso, H; Li, RA			Helical secondary structure of the external S3-S4 linker of pacemaker (HCN) channels revealed by site-dependent perturbations of activation phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALF PURKINJE-FIBERS; PACE-MAKER CURRENT; GATING KINETICS; ION CHANNELS; PREDICTION; IDENTIFICATION; CURRENTS; RESIDUES; FAMILY; ROLES	I-f, encoded by the hyperpolarization-activated cyclic nucleotide- modulated channel family (HCN1-4), contributes significantly to neuronal and cardiac pacing. Recently, we reported that the S3-S4 residue Glu-235 of HCN1 influences activation by acting as a surface charge. However, it is uncertain whether other residues of the external S3-S4 linker are also involved in gating. Furthermore, the secondary conformation of the linker is not known. Here we probed the structural and functional role of the HCN1 S3-S4 linker by introducing systematic mutations into the entire linker ( defined as 229 237) and studying their effects. We found that the mutations K230A (-62.2 +/- 3.4 mV versus -72.2 +/- 1.7 mV of wild type (WT)), G231A (-64.4 +/- 1.3 mV), M232A (V-1/2 = -63.1 +/- 1.1 mV), and E235G (-65.4 +/- 1.5 mV) produced depolarizing activation shifts. Although E229A and M232A decelerated gating kinetics (<13- and 3-fold, respectively), K230A and G231A accelerated both activation and deactivation (< similar to2-3-fold). D233A, S234A, V236A, and Y237A channels exhibited WT properties (p > 0.05). Shortening the linker (EVY235 - 237DeltaDeltaDelta) caused depolarizing activation shift and slowed kinetics that could not be explained by removing the charge at position 235 alone. Secondary structural predictions by the modeling algorithms SSpro2 and PROF, along with refinements by our experimental data, suggest that part of the S3-S4 linker conforms a helical structure with the functionally important residues Met-232, Glu-235, and Gly-231 (\DeltaDeltaG\ > 1 kcal/mol) clustered on one side.	Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Sch Med, Inst Mol Cardiobiol, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.	ronaldli@jhmi.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azene EM, 2003, J PHYSIOL-LONDON, V547, P349, DOI 10.1113/jphysiol.2003.039768; Baldi P, 1999, BIOINFORMATICS, V15, P937, DOI 10.1093/bioinformatics/15.11.937; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BROWN HF, 1977, J PHYSIOL-LONDON, V271, P783, DOI 10.1113/jphysiol.1977.sp012026; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P377, DOI 10.1113/jphysiol.1981.sp013714; DIFRANCESCO D, 1993, ANNU REV PHYSIOL, V55, P455, DOI 10.1146/annurev.physiol.55.1.455; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Gonzalez C, 2000, J GEN PHYSIOL, V115, P193, DOI 10.1085/jgp.115.2.193; Gonzalez C, 2001, P NATL ACAD SCI USA, V98, P9617, DOI 10.1073/pnas.171306298; Henrikson CA, 2002, CIRCULATION, V106, P226; Henrikson CA, 2003, J BIOL CHEM, V278, P13647, DOI 10.1074/jbc.M211025200; Ishii TM, 2001, J PHYSIOL-LONDON, V537, P93, DOI 10.1111/j.1469-7793.2001.0093k.x; Li-Smerin Y, 2001, J GEN PHYSIOL, V117, P205, DOI 10.1085/jgp.117.3.205; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 2003, EMBO J, V22, P216, DOI 10.1093/emboj/cdg032; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Mannikko R, 2002, NATURE, V419, P837, DOI 10.1038/nature01038; Mathur R, 1997, J GEN PHYSIOL, V109, P191, DOI 10.1085/jgp.109.2.191; NAKAI J, 1994, P NATL ACAD SCI USA, V91, P1014, DOI 10.1073/pnas.91.3.1014; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; Pollastri G, 2002, PROTEINS, V47, P228, DOI 10.1002/prot.10082; Rost B, 1996, PROTEIN SCI, V5, P1704, DOI 10.1002/pro.5560050824; Rothberg BS, 2002, J GEN PHYSIOL, V119, P83, DOI 10.1085/jgp.119.1.83; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Schulze-Bahr E, 2001, CIRCULATION, V104, P192; Shi WM, 1999, CIRC RES, V85, pE1; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Xue T, 2002, J BIOL CHEM, V277, P46233, DOI 10.1074/jbc.M204915200; Yamagishi T, 2001, J GEN PHYSIOL, V118, P171, DOI 10.1085/jgp.118.2.171; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V388, P255, DOI 10.1007/BF00658491	40	18	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22290	22297		10.1074/jbc.M302466200	http://dx.doi.org/10.1074/jbc.M302466200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12668666	hybrid			2022-12-27	WOS:000183503900017
J	Urbatsch, IL; Tyndall, GA; Tombline, G; Senior, AE				Urbatsch, IL; Tyndall, GA; Tombline, G; Senior, AE			P-glycoprotein catalytic mechanism - Studies of the ADP-vanadate inhibited state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-BINDING CASSETTE; DISULFIDE CROSS-LINKING; PICHIA-PASTORIS CELLS; MULTIDRUG-RESISTANCE; NUCLEOTIDE-BINDING; TRANSITION-STATE; ABC TRANSPORTER; DRUG-BINDING; CYTOPLASMIC MEMBRANE; ELECTRON-MICROSCOPY	Kinetics of inhibition of ATPase activity of pure mouse Mdr3 P-glycoprotein upon incubation with MgADP and vanadate were studied along with the trapping of [C-14] ADP in presence of vanadate. The presence of verapamil strongly magnified both effects. Inhibition of ATPase was also increased by several other drugs known to bind to drug-binding sites. Inhibition by ADP-vanadate was slow and depended cooperatively on nucleotide binding. Stoichiometry of [C-14] ADP trapping by vanadate was 1 mol/mol P-glycoprotein at full inhibition. Catalytic site mutants prevented [C-14] ADP trapping, whereas interdomain signal communication mutants reduced it in approximate correlation with their effects upon drug stimulation of ATPase. In explanation of the results, we propose that a "closed conformation" involving dimerization and interdigitation of the two nucleotide-binding domains is necessary to allow inhibition by ADP-vanadate. The results suggest that such a conformation occurs naturally during ATP hydrolysis. It is proposed that in order for the catalytic transition state to form, the two nucleotide-binding domains dimerize to form an integrated single entity containing two bound ATP with just one of the two ATP being hydrolyzed per dimerization event.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050156] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50156] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; Beaudet L, 1998, METHOD ENZYMOL, V292, P397; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chen J, 2001, P NATL ACAD SCI USA, V98, P1525, DOI 10.1073/pnas.041542498; Davidson AL, 2002, J BACTERIOL, V184, P1225, DOI 10.1128/JB.184.5.1225-1233.2002; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2003, J BIOL CHEM, V278, P1575, DOI 10.1074/jbc.M211307200; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P31800, DOI 10.1074/jbc.M103498200; Martin C, 2001, BIOCHEMISTRY-US, V40, P15733, DOI 10.1021/bi011211z; Mildvan AS, 1997, PROTEINS, V29, P401, DOI 10.1002/(SICI)1097-0134(199712)29:4<401::AID-PROT1>3.3.CO;2-#; Omote H, 2002, J BIOL CHEM, V277, P45688, DOI 10.1074/jbc.M206479200; Qu Q, 2003, BIOCHEMISTRY-US, V42, P1170, DOI 10.1021/bi026555j; Qu Q, 2002, BIOCHEMISTRY-US, V41, P4744, DOI 10.1021/bi0120897; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Ramachandra M, 1998, BIOCHEMISTRY-US, V37, P5010, DOI 10.1021/bi973045u; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SARKADI B, 1992, J BIOL CHEM, V267, P4854; Sauna ZE, 2001, J BIOENERG BIOMEMBR, V33, P481, DOI 10.1023/A:1012875105006; Sauna ZE, 2001, J BIOL CHEM, V276, P33301, DOI 10.1074/jbc.C100369200; Sauna ZE, 2001, J BIOL CHEM, V276, P21199, DOI 10.1074/jbc.M100886200; SENIOR AE, 1995, J BIOENERG BIOMEMBR, V27, P31, DOI 10.1007/BF02110328; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Szabo K, 1998, J BIOL CHEM, V273, P10132, DOI 10.1074/jbc.273.17.10132; Szakacs G, 2000, BIOCHEM BIOPH RES CO, V276, P1314, DOI 10.1006/bbrc.2000.3576; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P11921, DOI 10.1021/bi001220s; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2001, ARCH BIOCHEM BIOPHYS, V388, P171, DOI 10.1006/abbi.2001.2299; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	56	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					23171	23179		10.1074/jbc.M301957200	http://dx.doi.org/10.1074/jbc.M301957200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12670938	hybrid			2022-12-27	WOS:000183503900125
J	Hasler, U; Mordasini, D; Bianchi, M; Vandewalle, A; Feraille, E; Pierre-Yves, M				Hasler, U; Mordasini, D; Bianchi, M; Vandewalle, A; Feraille, E; Pierre-Yves, M			Dual influence of aldosterone on AQP2 expression in cultured renal collecting duct principal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WATER CHANNEL EXPRESSION; DEPENDENT SODIUM-TRANSPORT; INDUCED DOWN-REGULATION; MESSENGER-RNA; UP-REGULATION; MOUSE KIDNEY; VASOPRESSIN ANTAGONIST; HUMAN AQUAPORIN; RAT; MEMBRANE	In the renal collecting duct ( CD) the major physiological role of aldosterone is to promote Na+ reabsorption. In addition, aldosterone may also influence CD water permeability elicited by vasopressin (AVP). We have previously shown that endogenous expression of the aquaporin-2 (AQP2) water channel in immortalized mouse cortical CD principal cells (mpkCCD(C14)) grown on filters is dramatically increased by administration of physiological concentrations of AVP. In the present study, we investigated the influence of aldosterone on AQP2 expression in mpkCCDC14 cells by RNase protection assay and Western blot analysis. Aldosterone reduced AQP2 mRNA and protein expression when administered together with AVP for short periods of time (less than or equal to 24 h). For longer periods of time, however, aldosterone increased AQP2 protein expression despite sustained low expression levels of AQP2 mRNA. Both events were dependent on mineralocorticoid receptor occupancy because they were both induced by a low concentration of aldosterone ( 10(-9) M) and were abolished by the mineralocorticoid receptor antagonist canrenoate. Inhibition of lysosomal AQP2 protein degradation increased AQP2 protein expression in AVP-treated cells, an effect that was potentiated by aldosterone. Finally, both aldosterone and actinomycin D delayed AQP2 protein decay following AVP washout, but in a non-cumulative manner. Taken together, our data suggest that aldosterone tightly modulates AQP2 protein expression in cultured mpkCCDC14 cells by increasing AQP2 protein turnover while maintaining low levels of AQP2 mRNA expression.	Fdn Rech Med, Div Nephrol, CH-1211 Geneva 4, Switzerland; Univ Paris 07, INSERM, U478, IFR 02, F-75870 Paris 18, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Hasler, U (corresponding author), Fdn Rech Med, Div Nephrol, 64 Ave Roseraie, CH-1211 Geneva 4, Switzerland.	Udo.Hasler@medecine.unige.ch		Feraille, Eric/0000-0003-1656-8365				Apostol E, 1997, J AM SOC NEPHROL, V8, P15; Bens M, 1999, J AM SOC NEPHROL, V10, P923; BOYKIN J, 1979, MINER ELECTROL METAB, V2, P310; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; DIGIOVANNI SR, 1994, P NATL ACAD SCI USA, V91, P8984, DOI 10.1073/pnas.91.19.8984; Earm JH, 1998, J AM SOC NEPHROL, V9, P2181; Ecelbarger CA, 1997, J CLIN INVEST, V99, P1852, DOI 10.1172/JCI119352; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Funder JW, 1998, CLIN EXP PHARMACOL P, V25, pS47, DOI 10.1111/j.1440-1681.1998.tb02300.x; Furuno M, 1996, AM J PHYSIOL-RENAL, V271, pF854, DOI 10.1152/ajprenal.1996.271.4.F854; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; Hasler U, 2002, J BIOL CHEM, V277, P10379, DOI 10.1074/jbc.M111880200; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; ISHIKAWA S, 1982, KIDNEY INT, V22, P587, DOI 10.1038/ki.1982.216; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; Jonassen TEN, 1998, AM J PHYSIOL-RENAL, V275, pF216, DOI 10.1152/ajprenal.1998.275.2.F216; Jonassen TEN, 2000, AM J PHYSIOL-RENAL, V278, pF246, DOI 10.1152/ajprenal.2000.278.2.F246; Kwon TH, 2002, AM J PHYSIOL-RENAL, V283, pF1403, DOI 10.1152/ajprenal.00059.2002; Kwon TH, 1998, AM J PHYSIOL-RENAL, V275, pF724, DOI 10.1152/ajprenal.1998.275.5.F724; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Loffing J, 2000, AM J PHYSIOL-RENAL, V279, pF252, DOI 10.1152/ajprenal.2000.279.2.F252; MacDonald P, 2000, J ENDOCRINOL, V165, P25, DOI 10.1677/joe.0.1650025; Marples D, 1998, AM J PHYSIOL-RENAL, V275, pF400, DOI 10.1152/ajprenal.1998.275.3.F400; Marples D, 1996, J CLIN INVEST, V97, P1960, DOI 10.1172/JCI118628; MARPLES D, 1995, J CLIN INVEST, V95, P1838, DOI 10.1172/JCI117863; Maunsbach AB, 1997, J AM SOC NEPHROL, V8, P358; Nejsum LN, 2000, BIOCHEM BIOPH RES CO, V277, P164, DOI 10.1006/bbrc.2000.3638; Nelson RD, 1998, AM J PHYSIOL-CELL PH, V275, pC216, DOI 10.1152/ajpcell.1998.275.1.C216; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; Ohara M, 1998, J CLIN INVEST, V101, P1076, DOI 10.1172/JCI649; Ohara M, 2002, BIOCHEM BIOPH RES CO, V299, P285, DOI 10.1016/S0006-291X(02)02634-7; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Rajagopalan LE, 1998, NUCLEIC ACIDS RES, V26, P3418, DOI 10.1093/nar/26.14.3418; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; Ruiz-Echevarria MJ, 2001, J BIOL CHEM, V276, P30995, DOI 10.1074/jbc.M010833200; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SCHWARTZ MJ, 1980, J CLIN INVEST, V66, P234, DOI 10.1172/JCI109849; Terris J, 1995, AM J PHYSIOL-RENAL, V269, pF775, DOI 10.1152/ajprenal.1995.269.6.F775; UCHIDA S, 1994, J BIOL CHEM, V269, P23451; UFFERMAN RC, 1972, J CLIN INVEST, V51, P1639, DOI 10.1172/JCI106965; Vandewalle A, 1999, CURR OPIN NEPHROL HY, V8, P581, DOI 10.1097/00041552-199909000-00009; VANVLIET AA, 1993, AM J CARDIOL, V71, pA21, DOI 10.1016/0002-9149(93)90241-4; Verrey F., 2000, KIDNEY PHYSL PATHOPH, P1441; Vilela C, 1999, EMBO J, V18, P3139, DOI 10.1093/emboj/18.11.3139; Westmark CJ, 2001, J BIOL CHEM, V276, P1119, DOI 10.1074/jbc.M009435200; Willson DM, 1939, J CLIN INVEST, V18, P35, DOI 10.1172/JCI101023; Xu DL, 1997, J CLIN INVEST, V99, P1500, DOI 10.1172/JCI119312; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808	54	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21639	21648		10.1074/jbc.M212388200	http://dx.doi.org/10.1074/jbc.M212388200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660245	hybrid			2022-12-27	WOS:000183354200042
J	Baird, TR; Walsh, PN				Baird, TR; Walsh, PN			Factor XI, but not prekallikrein, blocks high molecular weight kininogen binding to human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED PLATELET-AGGREGATION; COAGULATION FACTOR-XI; IX-V COMPLEX; BLOOD-COAGULATION; PLASMA PREKALLIKREIN; HEAVY-CHAIN; LIGHT-CHAIN; ACTIVATED PLATELETS; CONSOLIDATION PHASE; EXPRESSION CLONING	Previous studies on the interaction of high molecular weight kininogen (HK) with endothelial cells have reported a large number of binding sites (10(6)-10(7) sites/cell) with differing relative affinities (K-D = 7-130 nM) and have implicated various receptors or receptor complexes. In this study, we examined the binding of HK to human umbilical vein endothelial cells ( HUVEC) with a novel assay system utilizing HUVEC immobilized on microcarrier beads, which eliminates the detection of the high affinity binding sites found nonspecifically in conventional microtiter well assays. We report that HK binds to 8.5 x 10(4) high affinity (K-D = 21 nM) sites per HUVEC, i.e. 10-100-fold fewer than previously reported. Although HK binding is unaffected by the presence of a physiological concentration of prekallikrein, factor XI abrogates HK binding to HUVEC in a concentration-dependent manner. Disruption of the naturally occurring complex between factor XI and HK by the addition of a 31-amino acid peptide mimicking the factor XI-binding site on HK restored HK binding to HUVEC. Furthermore, HK inhibited thrombin-stimulated von Willebrand factor release by HUVEC but not thrombin receptor activation peptide (SFLLRN-amide)-stimulated von Willebrand factor release. Factor XI restored the ability of thrombin to stimulate von Willebrand factor release in the presence of low HK concentrations. These results suggest that free HK, or HK in complex with prekallikrein but not in complex with factor XI, interacts with the endothelium and can maintain endothelial cell quiescence by preventing endothelial stimulation by thrombin.	Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Biochem, Sch Med, Philadelphia, PA 19140 USA; Temple Univ, Dept Med, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sol Sherry Thrombosis Res Ctr, Sch Med, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, P01HL056914, R01HL070683] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL46213, HL56914, HL64943, HL70683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; Baglia FA, 2000, J BIOL CHEM, V275, P31954, DOI 10.1074/jbc.M005465200; Baglia FA, 2002, J BIOL CHEM, V277, P1662, DOI 10.1074/jbc.M108319200; BAGLIA FA, 1995, BLOOD, V85, P2078, DOI 10.1182/blood.V85.8.2078.bloodjournal8582078; Baglia FA, 1996, J BIOL CHEM, V271, P3652; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BAGLIA FA, 1989, BLOOD, V74, P244; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; Baird TR, 2002, J BIOL CHEM, V277, P38462, DOI 10.1074/jbc.M205902200; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Colman R. W., 2001, HEMOSTASIS THROMBOSI, P103; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; Dedio J, 1998, J IMMUNOL, V160, P3534; FISHER CA, 1982, BLOOD, V59, P963; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Guo YL, 2001, ARTERIOSCL THROM VAS, V21, P1427, DOI 10.1161/hq0901.095277; Hasan AAK, 1996, CIRCULATION, V94, P517, DOI 10.1161/01.CIR.94.3.517; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; HASAN AAK, 1995, BLOOD, V85, P3134, DOI 10.1182/blood.V85.11.3134.bloodjournal85113134; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; Ho DH, 2000, J BIOL CHEM, V275, P25139, DOI 10.1074/jbc.M001890200; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; JACOBSEN S, 1967, BRIT J PHARM CHEMOTH, V29, P25, DOI 10.1111/j.1476-5381.1967.tb01935.x; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; Joseph K, 2001, BIOL CHEM, V382, P71, DOI 10.1515/BC.2001.012; Kunapuli SP, 1996, J BIOL CHEM, V271, P11228, DOI 10.1074/jbc.271.19.11228; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MANDLE RJ, 1976, P NATL ACAD SCI USA, V73, P4179, DOI 10.1073/pnas.73.11.4179; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; PURI RN, 1991, BLOOD, V77, P500; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Renne T, 2002, J BIOL CHEM, V277, P4892, DOI 10.1074/jbc.M105221200; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHINI VB, 1990, J PHARMACOL EXP THER, V252, P581; SCHMAIER AH, 1986, J CLIN INVEST, V77, P1565, DOI 10.1172/JCI112472; SCHMAIER AH, 1988, J BIOL CHEM, V263, P16327; Schmaier AH, 1999, THROMB HAEMOSTASIS, V82, P226; SCOTT CF, 1985, J BIOL CHEM, V260, P856; Scott CF, 1997, THROMB HAEMOSTASIS, V77, P109; SCOTT CF, 1980, J CLIN INVEST, V65, P413, DOI 10.1172/JCI109684; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; TAIT JF, 1986, J BIOL CHEM, V261, P5396; TAIT JF, 1987, J BIOL CHEM, V262, P11651; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; VANDERGRAAF F, 1983, J BIOL CHEM, V258, P9669; VANIWAARDEN F, 1988, J BIOL CHEM, V263, P4698; VANIWAARDEN F, 1988, BLOOD, V71, P1268; WACHTFOGEL YT, 1994, J BIOL CHEM, V269, P19307; WIGGINS RC, 1983, J BIOL CHEM, V258, P8963; Zhao YQ, 2001, AM J PHYSIOL-HEART C, V280, pH1821, DOI 10.1152/ajpheart.2001.280.4.H1821	57	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20618	20623		10.1074/jbc.M300224200	http://dx.doi.org/10.1074/jbc.M300224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12663668	hybrid			2022-12-27	WOS:000183230500023
J	Okada, Y; Montero, A; Zhang, XX; Sobue, T; Lorenzo, J; Doetschman, T; Coffin, JD; Hurley, MM				Okada, Y; Montero, A; Zhang, XX; Sobue, T; Lorenzo, J; Doetschman, T; Coffin, JD; Hurley, MM			Impaired osteoclast formation in bone marrow cultures of Fgf2 null mice in response to parathyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; CELL-FORMATION; MULTINUCLEATED CELLS; INHIBITORY FACTOR; DIFFERENTIATION FACTOR; OSTEOTROPIC HORMONES; OSTEOBLASTIC CELLS; RIBONUCLEIC-ACID; MESSENGER-RNA	Fibroblast growth factor (FGF)-2 and parathyroid hormone (PTH) are potent inducers of osteoclast (OCL) formation, and PTH increases FGF-2 mRNA and protein expression in osteoblasts. To elucidate the role of endogenous FGF-2 in PTH responses, we examined PTH-induced OCL formation in bone marrow cultures from wild type and mice with a disruption of the Fgf2 gene. FGF-2-induced OCL formation was similar in marrow culture from both genotypes. In contrast, PTH-stimulated OCL formation in bone marrow cultures or cocultures of osteoblast-spleen cells from Fgf2 -/- mice was significantly impaired. PTH increased RANKL mRNA expression in osteoblasts cultures from both genotypes. After 6 days of treatment, osteoprotegerin protein in cell supernatants was 40-fold higher in vehicle-treated and 30-fold higher in PTH-treated co-cultures of osteoblast and spleen cells from Fgf2 -/- mice compared with Fgf2 -/- mice. However, a neutralizing antibody to osteoprotegerin did not rescue reduced OCL formation in response to PTH. Injection of PTH caused hypercalcemia in Fgf2 -/- but not Fgf2 -/- mice. We conclude that PTH stimulates OCL formation and bone resorption in mice in part by endogenous FGF-2 synthesis by osteoblasts. Because RANKL- and interleukin-11-induced OCL formation was also reduced in bone marrow cultures from Fgf2 -/- mice, we further conclude that endogenous FGF-2 is necessary for maximal OCL formation by multiple bone resorbing factors.	Univ Connecticut, Ctr Hlth, Div Endocrinol & Metab, Dept Med, Farmington, CT 06030 USA; Univ Connecticut, Dept Mol Genet, Farmington, CT 06030 USA; Univ Montana, Dept Pharmaceut Sci, Sch Pharm & Allied Hlth Sci, Missoula, MT 59812 USA	University of Connecticut; University of Connecticut; University of Montana System; University of Montana	Hurley, MM (corresponding author), Univ Connecticut, Ctr Hlth, Div Endocrinol & Metab, Dept Med, Farmington, CT 06030 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046025] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-46025] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; BOYDE A, 1984, BRIT DENT J, V156, P216, DOI 10.1038/sj.bdj.4805313; BRUNERBRUNNER G, 1993, BLOOD, V3, P631; CHAPOTEAU E, 1993, CLIN CHEM, V39, P1820; Chikazu D, 2000, J BIOL CHEM, V275, P31444, DOI 10.1074/jbc.M910132199; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; Fitzpatrick Lorraine A., 1996, P339; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GABRILOVE JL, 1994, BLOOD, V83, P907; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; GLOBUS RK, 1989, ENDOCRINOLOGY, V124, P1539, DOI 10.1210/endo-124-3-1539; GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo-123-1-98; HATTERSLEY G, 1990, J CELL PHYSIOL, V142, P201, DOI 10.1002/jcp.1041420125; HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665; Hock J. M., 2001, PARATHYROIDS BASIC C, P183; Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226; Hurley MM, 1998, BONE, V22, P309, DOI 10.1016/S8756-3282(97)00292-5; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; HURLEY MM, 1994, J BIOL CHEM, V269, P9392; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Kodama Y, 1998, J BONE MINER RES, V13, P1370, DOI 10.1359/jbmr.1998.13.9.1370; KURIHARA N, 1990, J IMMUNOL, V144, P4226; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo-120-6-2326; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; Miyamoto A, 1998, BIOCHEM BIOPH RES CO, V242, P703, DOI 10.1006/bbrc.1997.8046; Mohan S, 2000, BONE, V27, P471, DOI 10.1016/S8756-3282(00)00355-0; Montero A, 2000, J CLIN INVEST, V105, P1085, DOI 10.1172/JCI8641; Mundy G.R., 1987, BONE MINERAL RES ANN, P209; MURRILLS RJ, 1989, J BONE MINER RES, V4, P259; Nakagawa N, 1999, BIOCHEM BIOPH RES CO, V265, P158, DOI 10.1006/bbrc.1999.1601; Oliver LJ, 1990, GROWTH FACTORS, V3, P231, DOI 10.3109/08977199009043907; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; Rifas L, 1999, CALCIFIED TISSUE INT, V64, P1, DOI 10.1007/s002239900570; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; ROODMAN GD, 1985, P NATL ACAD SCI USA, V82, P8213, DOI 10.1073/pnas.82.23.8213; ROODMAN GD, 1995, CALCIFIED TISSUE INT, V56, pS22, DOI 10.1007/BF03354645; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; TAKAHASHI N, 1988, ENDOCRINOLOGY, V122, P1373, DOI 10.1210/endo-122-4-1373; TAKAHASHI S, 1995, ENDOCRINOLOGY, V136, P1441, DOI 10.1210/en.136.4.1441; WILSON EL, 1991, BLOOD, V77, P954; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; WONG GL, 1975, P NATL ACAD SCI USA, V72, P3167, DOI 10.1073/pnas.72.8.3167; Yang XH, 2002, BIOCHEM BIOPH RES CO, V290, P42, DOI 10.1006/bbrc.2001.6176; Yano K, 1999, J BONE MINER RES, V14, P518, DOI 10.1359/jbmr.1999.14.4.518; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zhou M, 1998, NAT MED, V4, P201, DOI 10.1038/nm0298-201	55	37	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21258	21266		10.1074/jbc.M302113200	http://dx.doi.org/10.1074/jbc.M302113200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665515	hybrid			2022-12-27	WOS:000183230500104
J	Peisajovich, SG; Gallo, SA; Blumenthal, R; Shai, Y				Peisajovich, SG; Gallo, SA; Blumenthal, R; Shai, Y			C-terminal octylation rescues an inactive T20 mutant - Implications for the mechanism of HIV/simian immunodeficiency virus-induced membrane fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-1 ENVELOPE GLYCOPROTEIN; HIV-1 ENTRY; INFLUENZA HEMAGGLUTININ; 3(10)-HELICAL PEPTIDES; TRANSMEMBRANE PROTEIN; ACTIVE CONFORMATION; VIRAL FUSION; SIV GP41; ECTODOMAIN; INHIBITION	T20, a synthetic peptide corresponding to a C-terminal segment of the envelope glycoprotein (gp41) of human and simian immunodeficiency viruses, is a potent inhibitor of viral infection. We report here that C-terminal octylation of simian immunodeficiency virus gp41-derived T20 induces a significant increase in its inhibitory potency. Furthermore, when C-terminally octylated, an otherwise inactive mutant in which the C-terminal residues GNWF were replaced by ANAA has potency similar to that of the wild type T20. This effect cannot be explained by a trivial inhibitory effect of the octyl group added to the peptides, because the N-terminally octylated peptides have the same activity as the non-octylated parent peptides. The effects caused by octylation on the oligomerization, secondary structure, and membrane-interaction properties of the peptides were investigated. Our results shed light on the mechanism of inhibition by T20 and provide experimental support for the existence of a pre-hairpin intermediate.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; NCI, Lab Expt & Computat Biol, NIH, Ft Detrick, MD 21702 USA	Weizmann Institute of Science; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Shai, Y (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Yechiel.Shai@weizmann.ac.il	Peisajovich, Sergio/C-6641-2011	Gallo, Stephen/0000-0001-6043-2153	NATIONAL CANCER INSTITUTE [ZIABC008303, Z01BC008303] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; Biron Z, 2002, BIOCHEMISTRY-US, V41, P12687, DOI 10.1021/bi026261y; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Crisma M, 2002, BIOPOLYMERS, V64, P236, DOI 10.1002/bip.10178; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dehner A, 2001, J AM CHEM SOC, V123, P6678, DOI 10.1021/ja010635d; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Formaggio F, 2000, CHEM-EUR J, V6, P4498, DOI 10.1002/1521-3765(20001215)6:24<4498::AID-CHEM4498>3.3.CO;2-W; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1987, CELL, V50, P327, DOI 10.1016/0092-8674(87)90485-5; George C, 1996, PEPTIDE RES, V9, P315; Hackeng TM, 1999, P NATL ACAD SCI USA, V96, P10068, DOI 10.1073/pnas.96.18.10068; HARTER C, 1989, J BIOL CHEM, V264, P6459; Hildinger M, 2001, J VIROL, V75, P3038, DOI 10.1128/JVI.75.6.3038-3042.2001; Jin BS, 2000, AIDS RES HUM RETROV, V16, P1797, DOI 10.1089/08892220050195757; Judice JK, 1997, P NATL ACAD SCI USA, V94, P13426, DOI 10.1073/pnas.94.25.13426; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lawless MK, 1996, BIOCHEMISTRY-US, V35, P13697, DOI 10.1021/bi9606962; MERRIFIELD RB, 1982, BIOCHEMISTRY-US, V21, P5020, DOI 10.1021/bi00263a028; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Munoz-Barroso I, 1999, J VIROL, V73, P6089; Otaka A, 2002, ANGEW CHEM INT EDIT, V41, P2938, DOI 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>3.0.CO;2-J; Pereira FB, 1999, CHEM PHYS LIPIDS, V103, P11, DOI 10.1016/S0009-3084(99)00087-0; Pispisa B, 2002, BIOPOLYMERS, V67, P247, DOI 10.1002/bip.10118; Ryu JR, 1999, BIOCHEM BIOPH RES CO, V265, P625, DOI 10.1006/bbrc.1999.1739; SHAI Y, 1990, J BIOL CHEM, V265, P20202; Sia SK, 2002, P NATL ACAD SCI USA, V99, P14664, DOI 10.1073/pnas.232566599; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Suarez T, 2000, J VIROL, V74, P8038, DOI 10.1128/JVI.74.17.8038-8047.2000; VERONESE FD, 1985, SCIENCE, V229, P1402, DOI 10.1126/science.2994223; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	41	55	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21012	21017		10.1074/jbc.M212773200	http://dx.doi.org/10.1074/jbc.M212773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12646555	hybrid			2022-12-27	WOS:000183230500074
J	Quinlivan, EP; Roje, S; Basset, G; Shachar-Hill, Y; Gregory, JF; Hanson, AD				Quinlivan, EP; Roje, S; Basset, G; Shachar-Hill, Y; Gregory, JF; Hanson, AD			The folate precursor p-aminobenzoate is reversibly converted to its glucose ester in the plant cytosol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION CULTURES; GTP-CYCLOHYDROLASE-I; SACCHAROMYCES-CEREVISIAE; LIQUID-CHROMATOGRAPHY; CARBON METABOLISM; FOLIC-ACID; BIOSYNTHESIS; SYNTHASE; BIOTRANSFORMATION; 4-AMINOBENZOATE	Plants synthesize p-aminobenzoate (pABA) in chloroplasts and use it for folate synthesis in mitochondria. It has generally been supposed that pABA exists as the free acid in plant cells and that it moves between organelles in this form. Here we show that fruits and leaves of tomato and leaves of a diverse range of other plants have a high capacity to convert exogenously supplied pABA to its beta-D-glucopyranosyl ester (pABA-Glc), whereas yeast and Escherichia coli do not. High performance liquid chromatography analysis indicated that much of the endogenous pABA in fruit and leaf tissues is esterified and that the total pool of pABA ( free plus esterified) varies greatly between tissues (from 0.2 to 11 nmol g(-1) of fresh weight). UDP-glucose: pABA glucosyltransferase activity was readily detected in fruit and leaf extracts, and the reaction was found to be freely reversible. p-Aminobenzoic acid beta-D-glucopyranosyl ester esterase activity was also detected in extracts. Subcellular fractionation indicated that the glucosyltransferase and esterase activities are predominantly if not solely cytosolic. Taken together, these results show that reversible formation of pABA-Glc in the cytosol is interposed between pABA production in chloroplasts and pABA consumption in mitochondria. As pABA is a hydrophobic weak acid, its uncharged form is membrane-permeant, and its anion is consequently prone to distribute itself spontaneously among subcellular compartments according to their pH. Esterification of pABA may eliminate such errant behavior and provide a readily reclaimable storage form of pABA as well as a substrate for membrane transporters.	Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; Michigan State Univ, Dept Plant Biol, E Lansing, MI 48824 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Michigan State University	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@mail.ifas.ufl.edu	Quinlivan, Eoin P/B-8454-2008; Shachar-Hill, Yair/B-6165-2013; Quinlivan, Eoin/AAJ-1979-2021	Quinlivan, Eoin P/0000-0002-0908-1762; Shachar-Hill, Yair/0000-0001-8793-5084; Quinlivan, Eoin/0000-0002-0908-1762; Roje, Sanja/0000-0002-6302-5382; Gregory, Jesse/0000-0002-9976-2085				Appendino G, 2000, FITOTERAPIA, V71, P258, DOI 10.1016/S0367-326X(99)00168-9; BACHER A, 1973, Z NATURFORSCH C, VC 28, P614; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; Basset G, 2002, P NATL ACAD SCI USA, V99, P12489, DOI 10.1073/pnas.192278499; Bouis HE, 2002, J NUTR, V132, p491S, DOI 10.1093/jn/132.3.491S; Cherest H, 2000, J BIOL CHEM, V275, P14056, DOI 10.1074/jbc.275.19.14056; Ciucani G, 2002, PEST MANAG SCI, V58, P467, DOI 10.1002/ps.484; CLINE K, 1986, J BIOL CHEM, V261, P4804; COHEN FS, 1977, J MEMBRANE BIOL, V37, P361, DOI 10.1007/BF01940940; Cossins E, 2000, CAN J BOT, V78, P691, DOI 10.1139/cjb-78-6-691; COSSINS EA, 1987, BIOCH PLANTS, V11, P317, DOI DOI 10.1016/B978-0-12-675411-7.50015-X; COWAN IR, 1982, AUST J PLANT PHYSIOL, V9, P489, DOI 10.1071/PP9820489; DAWSON RMC, 1986, DATA BIOCH RES, P116; DONLON BA, 1995, APPL ENVIRON MICROB, V61, P3889, DOI 10.1128/AEM.61.11.3889-3893.1995; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; ELLIS GP, 1966, CHEM ING, V22, P902; FUKUI S, 1991, J NEUROCHEM, V56, P2007, DOI 10.1111/j.1471-4159.1991.tb03460.x; Furuya T, 1998, PHYTOCHEMISTRY, V49, P109, DOI 10.1016/S0031-9422(97)01016-9; Gambonnet B, 2001, J SCI FOOD AGR, V81, P835, DOI 10.1002/jsfa.870; Green J. C., 1996, ESCHERICHIA COLI SAL, P665; GREGORY JF, 1984, J NUTR, V114, P341, DOI 10.1093/jn/114.2.341; GUANGHUA L, 2001, CHEM J INTERNET, V3, P74; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; KITAMURA M, 1960, J BIOCHEM-TOKYO, V47, P60, DOI 10.1093/oxfordjournals.jbchem.a127040; LEZNICKI AJ, 1988, PLANT PHYSIOL, V88, P1481, DOI 10.1104/pp.88.4.1481; MOCK HP, 1993, PHYTOCHEMISTRY, V32, P575, DOI 10.1016/S0031-9422(00)95139-2; Nardese V, 1996, BIOCHEM BIOPH RES CO, V218, P273, DOI 10.1006/bbrc.1996.0048; Panjaitan TS, 2000, JPC-J PLANAR CHROMAT, V13, P114; Pfeiffer CM, 1997, J AGR FOOD CHEM, V45, P407, DOI 10.1021/jf960633q; RAPPOLD H, 1976, Z NATURFORSCH C, V31, P285; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Rebeille F, 1999, PR PHYT SOC, V42, P53; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; Siebert M, 1996, PLANT PHYSIOL, V112, P811, DOI 10.1104/pp.112.2.811; Syahrani A, 1999, PHYTOCHEMISTRY, V51, P615, DOI 10.1016/S0031-9422(99)00112-0; Tissot G, 1997, BIOCHEM J, V323, P179, DOI 10.1042/bj3230179; Trossat C, 1996, PLANT PHYSIOL, V111, P965, DOI 10.1104/pp.111.4.965; VISWANATHAN VK, 1995, J BACTERIOL, V177, P5918, DOI 10.1128/jb.177.20.5918-5923.1995; WILSON SD, 1984, ANAL BIOCHEM, V142, P529, DOI 10.1016/0003-2697(84)90502-5; Wink M, 1997, ADV BOT RES, V25, P141, DOI 10.1016/S0065-2296(08)60151-2	43	51	54	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20731	20737		10.1074/jbc.M302894200	http://dx.doi.org/10.1074/jbc.M302894200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12668665	hybrid			2022-12-27	WOS:000183230500039
J	Shen, YL; Tang, XF; Matsui, I				Shen, YL; Tang, XF; Matsui, I			Subunit interaction and regulation of activity through terminal domains of the family D DNA polymerase from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; SACCHAROMYCES-CEREVISIAE; HYPERTHERMOPHILIC ARCHAEON; POL-EPSILON; REPLICATION; FURIOSUS; HOMOLOG; DELTA	Functions of the terminal domains of the family D DNA polymerase from Pyrococcus horikoshii (PolDPho) were analyzed by making and characterizing various truncated proteins. Based on a co-expression vector developed previously ( Shen, Y., Musti, K., Hiramoto, M., Kikuchi, H., Kawabayashi, Y., and Matsui, I. ( 2001) J. Biol. Chem. 276, 27376 - 27383), 25 vectors for terminal truncated proteins were constructed. The expressed proteins were characterized in terms of thermostability, subunit interaction, and polymerization and 3'-5' exonuclease activities. The carboxyl-terminal ( 1255 - 1332) of the large subunit (DP2Pho) and two regions, the 201 - 260 and 599 - 622, of the small subunit (DP1Pho) were found to be critical for the complex formation, and probable subunit interaction of PolDPho. The amino-terminal ( 1 300) of DP2Pho is essential for the folding of PolDPho and is likely the oligomerization domain of PolDPho. A short region at the extreme C-terminal of DP2Pho ( from 1385 to 1434) and the N-terminal of DP1Pho( 1 - 200), which forms a stable protein, are not absolutely necessary for either polymerization or the 3'-5' exonuclease activity. We identified a possible regulatory role of DP1Pho( 1 - 200) for the 3'-5' exonuclease. Deletion of DP1Pho( 1 - 200) increased the exonuclease and DNA binding activities of PolDPho. Adding DP1Pho( 1 - 200) to the truncated protein suppressed the elevated exonuclease activity. We also constructed and analyzed three internal deletion mutants and two site-directed mutants in the region of the putative zinc finger motif ( cysteine cluster II) of DP2Pho at the COOH-terminal. We found that the internal region of the zinc finger motif is critical for the 3'-5' exonuclease, but is dispensable for the DNA polymerization.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan	National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 3058566, Japan.	ik-matsui@aist.go.jp						Aravind L, 1998, NUCLEIC ACIDS RES, V26, P3746, DOI 10.1093/nar/26.16.3746; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Connelly JC, 2002, TRENDS BIOCHEM SCI, V27, P410, DOI 10.1016/S0968-0004(02)02144-8; Deppenmeier U, 2002, J MOL MICROB BIOTECH, V4, P453; Dua R, 2000, J BIOL CHEM, V275, P28816, DOI 10.1074/jbc.M002376200; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; FAOUD TI, 2003, J BIOL CHEM, V278, P3145; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Gaspin C, 2000, J MOL BIOL, V297, P895, DOI 10.1006/jmbi.2000.3593; Gueguen Y, 2001, EUR J BIOCHEM, V268, P5961, DOI 10.1046/j.0014-2956.2001.02550.x; Hayashi I, 1999, NUCLEIC ACIDS RES, V27, P4695, DOI 10.1093/nar/27.24.4695; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Ishino Y, 1998, J BACTERIOL, V180, P2232, DOI 10.1128/JB.180.8.2232-2236.1998; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; KADOWAKI H, 1989, GENE, V76, P161, DOI 10.1016/0378-1119(89)90018-8; Kaneko T, 1995, DNA Res, V2, P153, DOI 10.1093/dnares/2.4.153; Kawashima T, 1999, P JPN ACAD B-PHYS, V75, P213, DOI 10.2183/pjab.75.213; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; Motz M, 2002, J BIOL CHEM, V277, P16179, DOI 10.1074/jbc.M107793200; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Robb FT, 2001, METHOD ENZYMOL, V330, P134; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; Shen YL, 2001, J BIOL CHEM, V276, P27376, DOI 10.1074/jbc.M011762200; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; Zuo SJ, 2000, J BIOL CHEM, V275, P5153, DOI 10.1074/jbc.275.7.5153	38	23	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21247	21257		10.1074/jbc.M212286200	http://dx.doi.org/10.1074/jbc.M212286200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12654919	hybrid			2022-12-27	WOS:000183230500103
J	Wu, TY; Yankovskaya, V; McIntire, WS				Wu, TY; Yankovskaya, V; McIntire, WS			Cloning, sequencing, and heterologous expression of the murine peroxisomal flavoprotein, N-1-acetylated polyamine oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-CRESOL METHYLHYDROXYLASE; MONOAMINE-OXIDASE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; CEREBRAL-ISCHEMIA; ESCHERICHIA-COLI; CELL-DEATH; RAT-LIVER; ANALOG; IDENTIFICATION; OXIDATION	The aminoacyl sequences of three regions of pure bovine N-1-acetylated polyamine oxidase (PAO) were obtained and used to search GenBank(TM). This led to the cloning and sequencing of a complete coding cDNA for murine PAO (mPAO) and the 5'-truncated coding region of the bovine pao (bpao) gene. A search of GenBank(TM) indicated that mpao maps to murine chromosome 7 as seven exons. The translated amino acid sequences of mpao and bpao have a - Pro-Arg-Leu peroxisomal targeting signal at the extreme C termini. A beta-alpha-beta FAD-binding motif is present in the N-terminal portion of mPAO. This and several other regions of mPAO and bPAO are highly similar to corresponding sections of other flavoprotein amine oxidases, although the overall identity of aligned sequences indicates that PAO represents a new subfamily of flavoproteins. A fragment of mpao was used as a probe to establish the relative transcription levels of this gene in various mature murine tissues and murine embryonic and breast tissues at different developmental stages. An Escherichia coli expression system has been developed for manufacturing mPAO at a reasonable level. The mPAO so produced was purified to homogeneity and characterized. It was demonstrated definitively that PAO oxidizes N-1-acetylspermine to spermidine and 3-acetamidopropanal and that it also oxidizes N-1-acetylspermidine to putrescine and 3-acetamidopropanal. Thus, this is the classical polyamine oxidase (EC 1.5.3.11) that is defined as the enzyme that oxidizes these N-1-acetylated polyamines on the exo-side of their N-4-amino groups. This enzyme is distinguishable from the plant polyamine oxidase that oxidizes spermine on the endo-side of the N-4-nitrogen. It differs also from mammalian spermine oxidase that oxidizes spermine ( but not N-1-acetylspermine or N-1-acetylspermidine) at the exo-carbon of its N-4-amino group. This report provides details of the biochemical, spectral, oxidation-reduction, and steady-state kinetic properties of pure mPAO.	Dept Vet Affairs Med Ctr, Div Mol Biol, No Calif Inst Res & Educ, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Northern California Institute for Research & Education; University of California System; University of California San Francisco	McIntire, WS (corresponding author), Dept Vet Affairs Med Ctr, Div Mol Biol, No Calif Inst Res & Educ, San Francisco, CA 94121 USA.							BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; Bergeron RJ, 2000, CANCER RES, V60, P4433; Bergeron RJ, 1997, J MED CHEM, V40, P1475, DOI 10.1021/jm960849j; Bergeron RJ, 2000, J MED CHEM, V43, P224, DOI 10.1021/jm990375z; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; BITONTI AJ, 1990, J BIOL CHEM, V265, P382; BOLKENIUS FN, 1989, BIOL CHEM H-S, V370, P525, DOI 10.1515/bchm3.1989.370.1.525; Chopra S, 1998, BIOCHEM PHARMACOL, V55, P1119, DOI 10.1016/S0006-2952(97)00601-1; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; Dym O, 2001, PROTEIN SCI, V10, P1712, DOI 10.1110/ps.12801; EDMONDSON DE, 1973, J BIOL CHEM, V248, P8144; EDMONDSON DE, 1995, XENOBIOTICA, V25, P735, DOI 10.3109/00498259509061889; Efimov I, 2001, BIOCHEMISTRY-US, V40, P2155, DOI 10.1021/bi001644m; Engst S, 1999, BIOCHEMISTRY-US, V38, P16620, DOI 10.1021/bi991273d; Ferioli ME, 1999, BIOCHEM PHARMACOL, V58, P1907, DOI 10.1016/S0006-2952(99)00280-4; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; Gasparian V K, 1995, Biokhimiia, V60, P1632; GASPARYAN VK, 1991, BIOKHIMIYA, V55, P1223; Goudar CT, 1999, BBA-PROTEIN STRUCT M, V1429, P377, DOI 10.1016/S0167-4838(98)00247-7; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; HATCHER J, 2000, SOC NEUR ABSTR, V26; HEBY O, 1990, TRENDS BIOCHEM SCI, V15, P153, DOI 10.1016/0968-0004(90)90216-X; Holt A, 1997, ANAL BIOCHEM, V244, P384, DOI 10.1006/abio.1996.9911; HOLTTA E, 1977, BIOCHEMISTRY-US, V16, P91, DOI 10.1021/bi00620a015; HOLTTA E, 1983, METHOD ENZYMOL, V94, P306; HOUEN G, 1994, ACTA CHEM SCAND, V48, P52, DOI 10.3891/acta.chem.scand.48-0052; Hu RH, 1997, BIOCHEM J, V328, P307, DOI 10.1042/bj3280307; Hunter K J, 1998, Methods Mol Biol, V79, P119; ISHIZUKA H, 1993, J GEN MICROBIOL, V139, P425, DOI 10.1099/00221287-139-3-425; Ivanova S, 2002, P NATL ACAD SCI USA, V99, P5579, DOI 10.1073/pnas.082609299; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Kramer DL, 1999, CANCER RES, V59, P1278; Lindsay GS, 1999, BIOCHEM J, V337, P83, DOI 10.1042/0264-6021:3370083; Mank-Seymour AR, 1998, CLIN CANCER RES, V4, P2003; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCINTIRE W, 1985, BIOCHEM J, V228, P325, DOI 10.1042/bj2280325; McIntire W. S., 1993, COPPER CONTAINING AM, P97; Morgan DML, 1998, BIOCHEM SOC T, V26, P586, DOI 10.1042/bst0260586; Mullis K B, 1991, PCR Methods Appl, V1, P1; Murray-Stewart T, 2002, BIOCHEM J, V368, P673, DOI 10.1042/BJ20021587; Nishikawa M, 2000, FEBS LETT, V476, P150, DOI 10.1016/S0014-5793(00)01708-7; NISHIOKA K, 1993, CANCER RES, V53, P2689; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, ISI ATLAS-BIOCHEM, V1, P11; Rao AM, 2000, J NEUROCHEM, V74, P1106; Roh JH, 2000, BIOCHEM BIOPH RES CO, V268, P293, DOI 10.1006/bbrc.2000.2113; Sablin SO, 1998, J BIOL CHEM, V273, P14074, DOI 10.1074/jbc.273.23.14074; Sablin SO, 1998, EUR J BIOCHEM, V253, P270, DOI 10.1046/j.1432-1327.1998.2530270.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHILLING B, 1995, BBA-GEN SUBJECTS, V1243, P529, DOI 10.1016/0304-4165(94)00183-X; Seiler N, 1995, PROG BRAIN RES, V106, P333; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tavladoraki P, 1998, FEBS LETT, V426, P62, DOI 10.1016/S0014-5793(98)00311-1; TSUKADA T, 1988, INT J BIOCHEM, V20, P695, DOI 10.1016/0020-711X(88)90164-4; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Wallace HM, 2000, CLIN CANCER RES, V6, P3657; Wallace HM, 1998, BIOCHEM SOC T, V26, P569, DOI 10.1042/bst0260569; Wang YL, 2001, CANCER RES, V61, P5370; WEYLER W, 1990, PHARMACOL THERAPEUT, V47, P319; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; Zoli M, 1996, MOL BRAIN RES, V38, P122, DOI 10.1016/0169-328X(95)00339-T; [No title captured]	69	97	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20514	20525		10.1074/jbc.M302149200	http://dx.doi.org/10.1074/jbc.M302149200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12660232	hybrid			2022-12-27	WOS:000183230500011
J	Li, GM; Alexander, EA; Schwartz, JH				Li, GM; Alexander, EA; Schwartz, JH			Syntaxin isoform specificity in the regulation of renal H+-ATPase exocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; IDENTIFICATION; SECRETION; DOMAIN	Intercalated and inner medullary collecting duct (IMCD) cells of the kidney mediate the transport of H+ by a plasma membrane H+-ATPase. The rate of H+ transport in these cells is regulated by exocytic insertion of H+-ATPase-laden vesicles into the apical membrane. We have shown that the exocytic insertion of proton pumps (H+-ATPase) into the apical membrane of rat IMCD cells, in culture, involves SNARE proteins (syntaxin (synt), SNAP-23, and VAMP). The membrane fusion complex observed in IMCD cells with the induction of proton pump exocytosis not only included these SNAREs but also the H+-ATPase. Based on these observations, we suggested that the targeting of these vesicles to the apical membrane is mediated by an interaction between the H+-ATPase and a specific t-SNARE. To evaluate this hypothesis, we utilized a "pull-down" assay in which we identified, by Western analysis, the proteins in a rat kidney medullary homogenate that complexed with glutathione S-transferase (GST) fusion syntaxin isoforms attached to Sepharose 4B-glutathione beads. The syntaxin isoforms employed were 1A, 1B, 2, 4, 5, and also 1A that was truncated to exclude the H3 SNARE binding domain (synt-1ADeltaH3). All full-length syntaxin isoforms formed complexes with SNAP-23 and VAMP. Neither GST nor synt-1ADeltaH3 formed complexes with these SNAREs. H+-ATPase (subunits E, a, and c) bound to syntaxin-1A and to a lesser extent to synt-1B but not to synt-1ADeltaH3 or synt-2, -4, and -5. In cultured IMCD cells transfected to express syntaxin truncated for the membrane binding domain (synt-DeltaC), expression of synt-1ADeltaC, but not synt-4DeltaC, inhibited H+-ATPase exocytosis. In conclusion, because all full-length syntaxins examined bound VAMP-2 and SNAP-23, but only non-H3-truncated syntaxin-1 bound H+-ATPase, and synt-1ADeltaC expression by intact IMCD cells inhibited H+-ATPase exocytosis, it is likely that the H+-ATPase binds directly to the H3 domain of syntaxin-1 and not through VAMP-2 or SNAP-23. Interaction between the syntaxin-1A and H+-ATPase is important in the targeted exocytosis of the proton pump to the apical membrane of intercalated cells.	Boston Univ, Med Ctr, Renal Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Physiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Schwartz, JH (corresponding author), Evans Biomed Res Ctr, 650 Albany St, Boston, MA 02118 USA.	jhsch@bu.edu	Schwartz, John/AAO-8158-2021	Schwartz, John/0000-0002-1660-8681; Alexander, Edward/0000-0002-6659-8186; Li, Guangmu/0000-0001-7115-0928	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059529] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-59529] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Al-Awqati Q, 1985, Soc Gen Physiol Ser, V39, P149; Alexander EA, 1999, AM J PHYSIOL-CELL PH, V276, pC758, DOI 10.1152/ajpcell.1999.276.3.C758; Alexander EA, 1997, AM J PHYSIOL-RENAL, V273, pF1054, DOI 10.1152/ajprenal.1997.273.6.F1054; Banerjee A, 2001, AM J PHYSIOL-CELL PH, V280, pC775; Banerjee A, 1999, J BIOL CHEM, V274, P26518, DOI 10.1074/jbc.274.37.26518; Banfield DK, 2001, TRENDS BIOCHEM SCI, V26, P67, DOI 10.1016/S0968-0004(00)01744-8; Breton S, 2002, AM J PHYSIOL-RENAL, V282, pF523, DOI 10.1152/ajprenal.00128.2001; Breton S, 2000, AM J PHYSIOL-RENAL, V278, pF717, DOI 10.1152/ajprenal.2000.278.5.F717; BROWN D, 1987, J CELL BIOL, V105, P1637, DOI 10.1083/jcb.105.4.1637; BROWN D, 1988, NATURE, V331, P622, DOI 10.1038/331622a0; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; FOTGAC M, 1999, J BIOL CHEM, V274, P12951; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; Gotte M, 1998, TRENDS CELL BIOL, V8, P215, DOI 10.1016/S0962-8924(98)01272-0; INOUE A, 1992, BIOCHEM BIOPH RES CO, V187, P1144, DOI 10.1016/0006-291X(92)91316-I; Naren AP, 1998, P NATL ACAD SCI USA, V95, P10972, DOI 10.1073/pnas.95.18.10972; Pelham HRB, 2001, TRENDS CELL BIOL, V11, P99, DOI 10.1016/S0962-8924(01)01929-8; PERIN MS, 1991, J BIOL CHEM, V266, P3877; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; Zhong PY, 1997, BIOCHEMISTRY-US, V36, P4317, DOI 10.1021/bi9625408	21	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19791	19797		10.1074/jbc.M212250200	http://dx.doi.org/10.1074/jbc.M212250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12651853	hybrid			2022-12-27	WOS:000183078000030
J	Lusa, S; Heino, S; Ikonen, E				Lusa, S; Heino, S; Ikonen, E			Differential mobilization of newly synthesized cholesterol and biosynthetic sterol precursors from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE; ENDOPLASMIC-RETICULUM; SERUM-CHOLESTEROL; CHAPERONE COMPLEX; HUMAN FIBROBLASTS; CORONARY PATIENTS; TRANSPORT; REDUCTASE; PROTEIN	Previous work demonstrates that the biosynthetic precursor of cholesterol, desmosterol, is released from cells and that its efflux to high density lipoprotein or phosphatidylcholine vesicles is greater than that of newly synthesized cholesterol (Johnson, W. J., Fischer, R. T., Phillips, M. C., and Rothblat, G. H. (1995) J. Biol. Chem. 270, 25037-25046). Here we report that the release of individual precursor sterols varies with the efflux of newly synthesized zymosterol being greater than that of lathosterol and both exceeding that of newly synthesized cholesterol when using either methyl-beta-cyclodextrin or complete serum as acceptors. The transfer of newly synthesized lathosterol to methyl-beta-cyclodextrin was inhibited by actin polymerization but not by Golgi disassembly whereas that of newly synthesized cholesterol was inhibited by both conditions. Newly synthesized lathosterol associated with cellular detergent-resistant membranes more rapidly than newly synthesized cholesterol. Upon efflux to serum, newly synthesized cholesterol precursors associated with both high and low density lipoproteins. Stimulation of the formation of direct endoplasmic reticulum-plasma membrane contacts was accompanied by enhanced efflux of newly synthesized lathosterol but not of newly synthesized cholesterol to serum acceptors. The data indicate that the efflux of cholesterol precursors differs not only from that of cholesterol but also from each other, with the more polar zymosterol being more avidly effluxed. Moreover, the results suggest that the intracellular routing of cholesterol precursors differs from that of newly synthesized cholesterol and implicates a potential role for the actin cytoskeleton and endoplasmic reticulum-plasma membrane contacts in the efflux of lathosterol.	Natl Publ Hlth Inst, Biomedicum Helsinki, Dept Mol Med, Helsinki 00251, Finland	Finland National Institute for Health & Welfare; University of Helsinki	Ikonen, E (corresponding author), Natl Publ Hlth Inst, Biomedicum Helsinki, Dept Mol Med, POB 104,Haartmaninkatu 8, Helsinki 00251, Finland.							Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; Berge KE, 2002, J LIPID RES, V43, P486; BJORKHEM I, 1987, J LIPID RES, V28, P1137; Brunetti-Pierri N, 2002, AM J HUM GENET, V71, P952, DOI 10.1086/342668; BURKI E, 1987, J LIPID RES, V28, P1199; BYSKOV AG, 1995, NATURE, V374, P559, DOI 10.1038/374559a0; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DIETSCHY JM, 1993, J LIPID RES, V34, P1637; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gylling H, 2002, J LIPID RES, V43, P1472, DOI 10.1194/jlr.M200155-JLR200; Gylling H, 2002, ATHEROSCLEROSIS, V160, P477, DOI 10.1016/S0021-9150(01)00608-6; Heino S, 2000, P NATL ACAD SCI USA, V97, P8375, DOI 10.1073/pnas.140218797; Hogenboom S, 2002, J LIPID RES, V43, P90; HOKLAND BM, 1993, J BIOL CHEM, V268, P25343; JOHNSON WJ, 1995, J BIOL CHEM, V270, P25037, DOI 10.1074/jbc.270.42.25037; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; Kim JH, 2001, J BIOL CHEM, V276, P18153, DOI 10.1074/jbc.M101661200; KOIVISTO PVI, 1988, SCAND J GASTROENTERO, V23, P422, DOI 10.3109/00365528809093889; Krisans SK, 1996, ANN NY ACAD SCI, V804, P142, DOI 10.1111/j.1749-6632.1996.tb18614.x; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lusa S, 2001, J CELL SCI, V114, P1893; Lutjohann D, 2002, J LIPID RES, V43, P1078, DOI 10.1194/jlr.M200071-JLR200; Maxfield FR, 2002, J CLIN INVEST, V110, P891, DOI 10.1172/JCI200216500; Miettinen TA, 2002, ATHEROSCLEROSIS, V164, P147, DOI 10.1016/S0021-9150(02)00054-0; Moebius FF, 1998, P NATL ACAD SCI USA, V95, P1899, DOI 10.1073/pnas.95.4.1899; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Phillips JE, 1998, J LIPID RES, V39, P2459; REINHART MP, 1987, J BIOL CHEM, V262, P9649; Rothblat GH, 2002, ATHEROSCLEROSIS, V163, P1, DOI 10.1016/S0021-9150(01)00713-4; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; URBANI L, 1990, J BIOL CHEM, V265, P1919; VANHANEN HT, 1993, J LIPID RES, V34, P1535; von Eckardstein A, 2001, ARTERIOSCL THROM VAS, V21, P13, DOI 10.1161/01.ATV.21.1.13	41	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19844	19851		10.1074/jbc.M212503200	http://dx.doi.org/10.1074/jbc.M212503200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657643	hybrid			2022-12-27	WOS:000183078000036
J	Ellerbroek, SM; Wennerberg, K; Burridge, K				Ellerbroek, SM; Wennerberg, K; Burridge, K			Serine phosphorylation negatively regulates RhoA in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CYCLIC-AMP; BINDING PROTEIN; CELL-ADHESION; ACTIVATION; INTEGRIN; GTPASES; RAC; MIGRATION; MYOSIN	Previous work indicates that RhoA phosphorylation on Ser(188) by cAMP or cGMP-dependent kinases inhibits its activity. However, these studies lacked the possibility to directly study phosphorylated RhoA activity in vivo. Therefore, we created RhoA proteins containing phosphomimetic residues in place of the cAMP/cGMP-dependent kinase phosphorylation site. RhoA phosphorylation or phosphomimetic substitution did not affect Rho guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity in vitro but promoted binding to the Rho guanine-dissociation inhibitor as measured by exchange factor competition assays. The in vitro similarities between RhoA phosphomimetic proteins and phosphorylated RhoA allowed us to study function of phosphorylated RhoA in vivo. RhoA phosphomimetic proteins display depressed GTP loading when transiently expressed in NIH 3T3 cells. Stable-expressing RhoA and RhoA(S188A) clones spread significantly slower than mock-transfected or RhoA(S188E) clones. RhoA(S188A) clones were protected from the morphological effects of a cAMP agonist, whereas phosphomimetic clones exhibit stress fiber disassembly similar to control cells. Together, these data provide in vivo evidence that addition of a charged group to Ser(188) upon phosphorylation negatively regulates RhoA activity and indicates that this occurs through enhanced Rho guanine-dissociation inhibitor interaction rather than direct perturbation of guanine nucleotide exchange factor, GTPase activating protein, or geranylgeranyl transferase activity.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ellerbroek, SM (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Cell & Dev Biol, CB 7295, Chapel Hill, NC 27599 USA.	hawkeye@med.unc.edu	Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline; NIGMS NIH HHS [GM29860] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; Dong JM, 1998, J BIOL CHEM, V273, P22554, DOI 10.1074/jbc.273.35.22554; Dormond O, 2002, J BIOL CHEM, V277, P45838, DOI 10.1074/jbc.M209213200; Essler M, 2000, J IMMUNOL, V164, P6543, DOI 10.4049/jimmunol.164.12.6543; Faucheux N, 2002, BIOMATERIALS, V23, P2295, DOI 10.1016/S0142-9612(01)00363-5; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Feoktistov I, 2000, MOL PHARMACOL, V58, P903, DOI 10.1124/mol.58.5.903; Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; Gosser YQ, 1997, NATURE, V387, P814, DOI 10.1038/42961; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gudi T, 2002, J BIOL CHEM, V277, P37382, DOI 10.1074/jbc.M204491200; HORI Y, 1991, ONCOGENE, V6, P515; Hu CD, 1999, J BIOL CHEM, V274, P48, DOI 10.1074/jbc.274.1.48; KHOSRAVIFAR R, 1995, METHOD ENZYMOL, V255, P46; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kwak JY, 2000, BIOCHEM BIOPH RES CO, V267, P305, DOI 10.1006/bbrc.1999.1941; LAMB NJC, 1988, J CELL BIOL, V106, P1955, DOI 10.1083/jcb.106.6.1955; Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x; LANG P, 1993, BIOCHEM BIOPH RES CO, V196, P1522, DOI 10.1006/bbrc.1993.2424; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; LEONARD DA, 1994, BIOCHEMISTRY-US, V33, P12323, DOI 10.1021/bi00206a040; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; Manganello JM, 2003, J BIOL CHEM, V278, P124, DOI 10.1074/jbc.M209219200; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Sawada N, 2001, BIOCHEM BIOPH RES CO, V280, P798, DOI 10.1006/bbrc.2000.4194; Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	40	245	253	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19023	19031		10.1074/jbc.M213066200	http://dx.doi.org/10.1074/jbc.M213066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654918	Green Published, hybrid			2022-12-27	WOS:000182932200040
J	Habermeier, A; Wolf, S; Martine, U; Graf, P; Closs, EI				Habermeier, A; Wolf, S; Martine, U; Graf, P; Closs, EI			Two amino acid residues determine the low substrate affinity of human cationic amino acid transporter-2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ECOTROPIC MURINE RETROVIRUSES; CELL-SURFACE RECEPTOR; MEMBRANE; FAMILY; IDENTIFICATION; EXPRESSION; MEMBER	Mammalian cationic amino acid transporters ( CAT) differ in their substrate affinity and sensitivity to trans-stimulation. The apparent K-m values for cationic amino acids and the sensitivity to trans-stimulation of CAT-1, -2B, and -3 are characteristic of system y(+). In contrast, CAT-2A exhibits a 10-fold lower substrate affinity and is largely independent of substrate at the trans-side of the membrane. CAT-2A and -2B demonstrate such divergent transport properties, even though their amino acid sequences differ only in a stretch of 42 amino acids. Here, we identify two amino acid residues within this 42-amino acid domain of the human CAT-2A protein that are responsible for the apparent low affinity of both the extracellular and intracellular substrate-binding sites. These residues are located in the fourth intracellular loop, suggesting that they are not part of the translocation pathway. Rather, they may be responsible for the low affinity conformation of the substrate-binding sites. The sensitivity to trans-stimulation is not determined by the same amino acid residues as the substrate affinity and must involve a more complex interaction between individual amino acid residues. In addition to the 42-amino acid domain, the adjacent transmembrane domain X seems to be involved in this function.	Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-55101 Mainz, Germany	Johannes Gutenberg University of Mainz	Closs, EI (corresponding author), Johannes Gutenberg Univ Mainz, Dept Pharmacol, Obere Zahlbacher Str 67, D-55101 Mainz, Germany.	Closs@mail.uni-mainz.de	Closs, Ellen/ABD-5217-2020	Closs, Ellen/0000-0002-9505-2289				Closs E, 2000, NITRIC OXIDE BIOL PA, P225; CLOSS EI, 1993, J BIOL CHEM, V268, P20796; CLOSS EI, 1993, J BIOL CHEM, V268, P7538; Closs EI, 1997, BIOCHEMISTRY-US, V36, P6462, DOI 10.1021/bi962829p; CLOSS EI, 1999, MEMBRANE TRANSPORTER, P229; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Ito K, 1997, J BIOL CHEM, V272, P26780, DOI 10.1074/jbc.272.42.26780; Kakuda DK, 1993, TRANSGENE, V1, P91; KAVANAUGH MP, 1994, J BIOL CHEM, V269, P15445; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Simons P C, 1981, Methods Enzymol, V77, P235; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WANG H, 1994, VIROLOGY, V202, P1058, DOI 10.1006/viro.1994.1439; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084	18	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19492	19499		10.1074/jbc.M210254200	http://dx.doi.org/10.1074/jbc.M210254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637504	hybrid			2022-12-27	WOS:000182932200099
J	Han, WJ; Christen, P				Han, WJ; Christen, P			Mechanism of the targeting action of DnaJ in the DnaK molecular chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ENDOPLASMIC-RETICULUM; SUBSTRATE-SPECIFICITY; ATP HYDROLYSIS; J-DOMAIN; BINDING; HOMOLOG; HSP70; CYCLE	In the DnaK (Hsp70) molecular chaperone system of Escherichia coli, the substrate polypeptide is fed into the chaperone cycle by association with the fast-binding, ATP-liganded form of the DnaK. The substrate binding properties of DnaK are controlled by its two co-chaperones DnaJ (Hsp40) and GrpE. DnaJ stimulates the hydrolysis of DnaK-bound ATP, and GrpE accelerates ADP/ATP exchange. DnaJ has been described as targeting the substrate to DnaK, a concept that has remained rather obscure. Based on binding experiments with peptides and polypeptides we propose here a novel mechanism for the targeting action of DnaJ: ATP.DnaK and DnaJ with its substrate-binding domain bind to different segments of one and the same polypeptide chain forming (ATP.DnaK)(m).substrate.DnaJ(n) complexes; in these ternary complexes efficient cis-interaction of the J-domain of DnaJ with DnaK is favored by their propinquity and triggers the hydrolysis of DnaK-bound ATP, converting DnaK to its ADP-liganded high affinity state and thus locking it onto the substrate polypeptide.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterhurerstr 190, CH-8057 Zurich, Switzerland.	christen@bioc.unizh.ch						Bischofberger P, 2003, J BIOL CHEM, V278, P19044, DOI 10.1074/jbc.M300922200; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; FERSHT A, 1999, STRUCTURE MECH PROTE, P65; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Han WJ, 2003, BIOCHEM J, V369, P627, DOI 10.1042/BJ20020943; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; Holstein SEH, 1996, J CELL BIOL, V135, P925, DOI 10.1083/jcb.135.4.925; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P7; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LUKE MM, 1991, J CELL BIOL, V114, P623, DOI 10.1083/jcb.114.4.623; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Merlin A, 1999, J CELL BIOL, V145, P961, DOI 10.1083/jcb.145.5.961; Minami Y, 1999, GENES CELLS, V4, P721, DOI 10.1046/j.1365-2443.1999.00299.x; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; Nishikawa S, 1997, J BIOL CHEM, V272, P12889, DOI 10.1074/jbc.272.20.12889; Pierpaoli EV, 1998, J BIOL CHEM, V273, P6643, DOI 10.1074/jbc.273.12.6643; PIERRE G, 2001, J BIOL CHEM, V276, P7906; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SADLER I, 1989, J CELL BIOL, V109, P2665, DOI 10.1083/jcb.109.6.2665; SCHLENSTEDT G, 1995, J CELL BIOL, V129, P979, DOI 10.1083/jcb.129.4.979; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; Westermann B, 1997, J MOL BIOL, V272, P477, DOI 10.1006/jmbi.1997.1267; Westermann B, 1996, MOL CELL BIOL, V16, P7063; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER SH, 1990, P NATL ACAD SCI USA, V87, P2690, DOI 10.1073/pnas.87.7.2690; YAMASHINO T, 1994, MOL MICROBIOL, V13, P475, DOI 10.1111/j.1365-2958.1994.tb00442.x; Yan W, 1998, EMBO J, V17, P4809, DOI 10.1093/emboj/17.16.4809	49	94	96	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19038	19043		10.1074/jbc.M300756200	http://dx.doi.org/10.1074/jbc.M300756200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12654915	hybrid			2022-12-27	WOS:000182932200042
J	Coeytaux, E; Coulaud, D; Le Cam, E; Danos, O; Kichler, A				Coeytaux, E; Coulaud, D; Le Cam, E; Danos, O; Kichler, A			The cationic amphipathic alpha-helix of HIV-1 viral protein R (Vpr) binds to nucleic acids, permeabilizes membranes, and efficiently transfects cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; C-TERMINAL DOMAIN; GENE-TRANSFER; NMR STRUCTURE; DNA; CYCLE; CHOLESTEROL; INFECTION; MECHANISM; PEPTIDES	Viral protein R (Vpr) is a small protein of 96 amino acids that is conserved among the lentiviruses human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus. We recently sought to determine whether the karyophilic properties of Vpr, as well as its ability to bind nucleic acids, could be used to deliver DNA into cells. We have found that the C-terminal domain of Vpr-(52-96) is able to efficiently transfect various cell lines. Here, we show that the shortest active sequence for gene transfer corresponds to the domain that adopts a alpha-helix conformation. DNA binding studies and permeabilization assays performed on cells demonstrated that the peptides that are efficient in transfection condense plasmid DNA and are membranolytic. Electron microscopy studies and transfection experiments performed in the presence of inhibitors of the endocytic processes indicated that the major entry pathway of Vpr- DNA complexes is through endocytosis. Taken together, the results show that the cationic C-terminal alpha-helix of Vpr has DNA-condensing as well as membrane-destabilizing capabilities, both properties that are indispensable for efficient DNA transfection.	Genethon, CNRS, Unite Mixte Rech 8115, F-91002 Evry, France; Inst Gustave Roussy, CNRS, UMR 8126, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Kichler, A (corresponding author), Genethon, CNRS, Unite Mixte Rech 8115, 1 Bis Rue Int,BP 60, F-91002 Evry, France.	akich@genethon.fr		Kichler, Antoine/0000-0003-0593-2424; Le cam, Eric/0000-0002-6832-6117				Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; BLONDELLE SE, 1991, BIOCHEMISTRY-US, V30, P4671, DOI 10.1021/bi00233a006; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Brunner S, 2000, GENE THER, V7, P401, DOI 10.1038/sj.gt.3301102; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Colin M, 2000, GENE THER, V7, P139, DOI 10.1038/sj.gt.3301056; CONNOR RI, 1995, VIROLOGY, V206, P935, DOI 10.1006/viro.1995.1016; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 2000, EUR J BIOCHEM, V267, P3654, DOI 10.1046/j.1432-1327.2000.01397.x; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; Fouchier RAM, 1998, J VIROL, V72, P6004, DOI 10.1128/JVI.72.7.6004-6013.1998; Fujimoto T, 2000, J CELL SCI, V113, P3509; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kichler A, 2000, J VIROL, V74, P5424, DOI 10.1128/JVI.74.12.5424-5431.2000; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Macreadie IG, 1996, MOL MICROBIOL, V19, P1185, DOI 10.1111/j.1365-2958.1996.tb02464.x; Matsui H, 1997, J BIOL CHEM, V272, P1117, DOI 10.1074/jbc.272.2.1117; Nemerow GR, 2000, VIROLOGY, V274, P1, DOI 10.1006/viro.2000.0468; Nicol F, 1996, BIOPHYS J, V71, P3288, DOI 10.1016/S0006-3495(96)79521-8; Nie ZL, 1998, J VIROL, V72, P4104, DOI 10.1128/JVI.72.5.4104-4115.1998; Niidome T, 1997, J BIOL CHEM, V272, P15307, DOI 10.1074/jbc.272.24.15307; OHTANI Y, 1989, EUR J BIOCHEM, V186, P17, DOI 10.1111/j.1432-1033.1989.tb15171.x; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; PLANK C, 1994, J BIOL CHEM, V269, P12918; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; Rittner K, 2002, MOL THER, V5, P104, DOI 10.1006/mthe.2002.0523; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Wyman TB, 1997, BIOCHEMISTRY-US, V36, P3008, DOI 10.1021/bi9618474; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; Zauner W, 1998, ADV DRUG DELIVER REV, V30, P97, DOI 10.1016/S0169-409X(97)00110-5; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 1998, GENE, V212, P157, DOI 10.1016/S0378-1119(98)00178-4; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	47	51	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18110	18116		10.1074/jbc.M300248200	http://dx.doi.org/10.1074/jbc.M300248200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12639957	hybrid			2022-12-27	WOS:000182838300068
J	Le Page, F; Schreiber, V; Dherin, C; de Murcia, G; Boiteux, S				Le Page, F; Schreiber, V; Dherin, C; de Murcia, G; Boiteux, S			Poly(ADP-ribose) polymerase-1 (PARP-1) is required in murine cell lines for base excision repair of oxidative DNA damage in the absence of DNA polymerase beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION-COUPLED REPAIR; PURIFIED HUMAN PROTEINS; OGG1 GENE; SACCHAROMYCES-CEREVISIAE; LIGASE III; AP LYASE; ESCHERICHIA-COLI; HUMAN HOMOLOG; ABASIC SITE; GLYCOSYLASE	Oxidative DNA base damage is mainly corrected by the base excision repair (BER) pathway, which can be divided into two subpathways depending on the length of the resynthetized patch, either one nucleotide for short patch BER or several nucleotides for long patch BER. The role of proteins in the course of BER processes has been investigated in vitro using purified enzymes and cell-free extracts. In this study, we have investigated the repair of 8-oxo-7,8-dihydroguanine (8-oxoG) in vivo using wild-type, polymerase beta(-/-) (Polbeta(-/-)), poly(ADP-ribose) polymerase-1(-/-) (PARP-1(-/-)), and Polbeta(-/-)PARP-1(-/-) 3T3 cell lines. We used non replicating plasmids containing a 8-oxoG:C base pair to study the repair of the lesion located in a transcribed sequence (TS) or in a non-transcribed sequence (NTS). The results show that 8-oxoG repair in TS is not significantly impaired in cells deficient in Polbeta or PARP-1 or both. Whereas 8-oxoG repair in NTS is normal in Polbeta-null cells, it is delayed in PARP-1-null cells and greatly impaired in cells deficient in both Polbeta and PARP-1. The removal of 8-oxoG and presumably the cleavage at the resulting apurinic/apyrimidinic site are not affected in the PARP-1(-/-)Polbeta(-/-) cell lines. However, 8-oxoG repair is incomplete, yielding plasmid molecules with a nick at the site of the lesion. Therefore, PARP-1(-/-)Polbeta(-/-) cell lines cannot perform 5'-dRP removal and/or DNA repair synthesis. Furthermore, the poly(ADP-ribosyl) ation activity of PARP-1 is essential for 8-oxoG repair in a Polbeta(-/-) context, because expression of the catalytically inactive PARP-1 (E988K) mutant does not restore 8-oxoG repair, whereas an wild type PARP-1 does.	CEA Radiobiol Mol & Cellulaire, CNRS,UMR 217, Dept Radiobiol & Radiopathol, Direct Sci Vivant, F-92265 Fontenay Aux Roses, France; Univ Strasbourg 1, Ecole Super Biotechnol Strasbourg, CNRS, Unite Propre Rech 9003, F-67400 Illkirch Graffenstaden, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Le Page, F (corresponding author), CEA Radiobiol Mol & Cellulaire, CNRS,UMR 217, Dept Radiobiol & Radiopathol, Direct Sci Vivant, F-92265 Fontenay Aux Roses, France.	lepage@dsvidf.cea.fr	Schreiber, Valérie/M-5007-2016	Schreiber, Valérie/0000-0003-0507-639X				Aburatani H, 1997, CANCER RES, V57, P2151; Allinson SL, 2001, EMBO J, V20, P6919, DOI 10.1093/emboj/20.23.6919; Arai K, 1997, ONCOGENE, V14, P2857, DOI 10.1038/sj.onc.1201139; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beneke R, 2000, MOL CELL BIOL, V20, P6695, DOI 10.1128/MCB.20.18.6695-6703.2000; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Caldecott KW, 1995, NUCLEIC ACIDS RES, V23, P4836, DOI 10.1093/nar/23.23.4836; Cappelli E, 1997, J BIOL CHEM, V272, P23970, DOI 10.1074/jbc.272.38.23970; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DUWAT P, 1995, MICROBIOL-UK, V141, P411, DOI 10.1099/13500872-141-2-411; FEIG DI, 1994, CANCER RES, V54, pS1890; Fernet M, 2000, INT J RADIAT BIOL, V76, P1621, DOI 10.1080/09553000050201118; Fortini P, 2000, NUCLEIC ACIDS RES, V28, P3040, DOI 10.1093/nar/28.16.3040; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; FREIDBERG EC, 1995, DNA REPAIR MUTAGENES; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gentil A, 1997, BIOL CHEM, V378, P1287; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7; Horton JK, 2000, J BIOL CHEM, V275, P2211, DOI 10.1074/jbc.275.3.2211; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUPPER JH, 1995, MOL CELL BIOL, V15, P3154; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CANCER RES, V60, P5548; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 2002, METHOD ENZYMOL, V353, P536; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Lu RZ, 1997, CURR BIOL, V7, P397, DOI 10.1016/S0960-9822(06)00187-4; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Masutani M, 2000, MUTAT RES-REV MUTAT, V462, P159, DOI 10.1016/S1383-5742(00)00033-8; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MATSUMOTO Y, 1991, MOL CELL BIOL, V11, P4441, DOI 10.1128/MCB.11.9.4441; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MENCK CFM, 1989, MUTAT RES, V220, P101, DOI 10.1016/0165-1110(89)90015-8; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; Mitra S, 2001, ENVIRON MOL MUTAGEN, V38, P180, DOI 10.1002/em.1070; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicholl ID, 1997, BIOCHEMISTRY-US, V36, P7557, DOI 10.1021/bi962950w; Nishimura S, 2002, FREE RADICAL BIO MED, V32, P813, DOI 10.1016/S0891-5849(02)00778-5; Osterod M, 2002, ONCOGENE, V21, P8232, DOI 10.1038/sj.onc.1206027; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Podlutsky AJ, 2001, EMBO J, V20, P1477, DOI 10.1093/emboj/20.6.1477; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Rolli V, 1997, BIOCHEMISTRY-US, V36, P12147, DOI 10.1021/bi971055p; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sanderson RJ, 2002, DNA REPAIR, V1, P547, DOI 10.1016/S1568-7864(02)00054-X; SCHREIBER V, 1992, EMBO J, V11, P3263, DOI 10.1002/j.1460-2075.1992.tb05404.x; Schreiber V, 2002, J BIOL CHEM, V277, P23028, DOI 10.1074/jbc.M202390200; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; STARY A, 1992, J GEN VIROL, V73, P1679, DOI 10.1099/0022-1317-73-7-1679; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; Thomas D, 1997, MOL GEN GENET, V254, P171, DOI 10.1007/s004380050405; Trucco C, 1998, NUCLEIC ACIDS RES, V26, P2644, DOI 10.1093/nar/26.11.2644; Tulin A, 2002, GENE DEV, V16, P2108, DOI 10.1101/gad.1003902; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WISEMAN H, 1995, CANCER LETT, V93, P113, DOI 10.1016/0304-3835(95)03792-U; Yung TMC, 2001, J BIOL CHEM, V276, P11279, DOI 10.1074/jbc.M008044200; Ziegler M, 2001, BIOESSAYS, V23, P543, DOI 10.1002/bies.1074	84	60	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18471	18477		10.1074/jbc.M212905200	http://dx.doi.org/10.1074/jbc.M212905200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637553	hybrid			2022-12-27	WOS:000182838300115
J	Kuhn, U; Nemeth, A; Meyer, S; Wahle, E				Kuhn, U; Nemeth, A; Meyer, S; Wahle, E			The RNA binding domains of the nuclear poly(A)-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE METHYLATION; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; IN-VITRO; SACCHAROMYCES-CEREVISIAE; RICH DOMAIN; POLY(A); RECOGNITION; GENE; NUCLEOLIN	The nuclear poly(A)-binding protein (PABPN1) is involved in the synthesis of the mRNA poly(A) tails in most eukaryotes. We report that the protein contains two RNA binding domains, a ribonucleoprotein-type RNA binding domain (RNP domain) located approximately in the middle of the protein sequence and an arginine-rich C-terminal domain. The C-terminal domain also promotes self-association of PABPN1 and moderately cooperative binding to RNA. Whereas the isolated RNP domain binds specifically to poly(A), the isolated C-terminal domain binds non-specifically to RNA and other polyanions. Despite this nonspecific RNA binding by the C-terminal domain, selection experiments show that adenosine residues throughout the entire minimal binding site of similar to11 nucleotides are recognized specifically. UV-induced cross-links with oligo(A) carrying photoactivatable nucleotides at different positions all map to the RNP domain, suggesting that most or all of the base-specific contacts are made by the RNP domain, whereas the C-terminal domain may contribute nonspecific contacts, conceivably to the same nucleotides. Asymmetric dimethylation of 13 arginine residues in the C-terminal domain has no detectable influence on the interaction of the protein with RNA. The N-terminal domain of PABPN1 is not required for RNA binding but is essential for the stimulation of poly(A) polymerase.	Univ Halle Wittenberg, Inst Biochem, D-06099 Halle An Der Saale, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany	Martin Luther University Halle Wittenberg; Justus Liebig University Giessen	Wahle, E (corresponding author), Univ Halle Wittenberg, Inst Biochem, D-06099 Halle An Der Saale, Germany.	ewahle@biochemtech.uni-halle.de		Wahle, Elmar/0000-0003-2504-0677				AbdulMana N, 1996, BIOCHEMISTRY-US, V35, P3545, DOI 10.1021/bi952298p; ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; Adinolfi S, 1999, RNA, V5, P1248, DOI 10.1017/S1355838299990647; Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; Avis JM, 1996, J MOL BIOL, V257, P398, DOI 10.1006/jmbi.1996.0171; Bagni C, 1998, J BIOL CHEM, V273, P10868, DOI 10.1074/jbc.273.18.10868; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Benoit B, 1999, NUCLEIC ACIDS RES, V27, P3771, DOI 10.1093/nar/27.19.3771; BIENROTH S, 1993, EMBO J, V12, P585, DOI 10.1002/j.1460-2075.1993.tb05690.x; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164; BRINKMANN U, 1989, GENE, V85, P109, DOI 10.1016/0378-1119(89)90470-8; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1991, MOL CELL BIOL, V11, P3419, DOI 10.1128/MCB.11.7.3419; Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924; Calado A, 2000, RNA, V6, P245, DOI 10.1017/S1355838200991908; Calado A, 2000, J CELL SCI, V113, P2309; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; CASASFINET JR, 1993, J MOL BIOL, V229, P873, DOI 10.1006/jmbi.1993.1093; Chen ZY, 1999, EMBO J, V18, P2273, DOI 10.1093/emboj/18.8.2273; COBIANCHI F, 1988, J BIOL CHEM, V263, P1063; Cote J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deardorff JA, 1997, J MOL BIOL, V269, P67, DOI 10.1006/jmbi.1997.1013; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Ding JZ, 1999, GENE DEV, V13, P1102, DOI 10.1101/gad.13.9.1102; Fan XP, 2001, HUM MOL GENET, V10, P2341, DOI 10.1093/hmg/10.21.2341; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Kambach C, 1999, CELL, V96, P375, DOI 10.1016/S0092-8674(00)80550-4; Keller RW, 2000, J MOL BIOL, V297, P569, DOI 10.1006/jmbi.2000.3572; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRAUSE S, 1994, EXP CELL RES, V214, P75, DOI 10.1006/excr.1994.1235; Kuhn U, 1996, J MOL BIOL, V256, P20, DOI 10.1006/jmbi.1996.0065; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; Meyer S, 2002, BIOCHEMISTRY-US, V41, P6082, DOI 10.1021/bi0160866; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; Nagai K, 1996, CURR OPIN STRUC BIOL, V6, P53, DOI 10.1016/S0959-440X(96)80095-9; NEMETH A, 1995, NUCLEIC ACIDS RES, V23, P4034, DOI 10.1093/nar/23.20.4034; Nichols RC, 2000, EXP CELL RES, V256, P522, DOI 10.1006/excr.2000.4827; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; Pintucci G, 1996, MOL BIOL CELL, V7, P1249, DOI 10.1091/mbc.7.8.1249; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Raman B, 2001, NUCLEIC ACIDS RES, V29, P3377, DOI 10.1093/nar/29.16.3377; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Sachs A, 2000, COLD SPRING HARBOR M, V39, P447; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schwartz DC, 2000, COLD SPRING HARBOR M, V39, P807; Shen EC, 1998, GENE DEV, V12, P679, DOI 10.1101/gad.12.5.679; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; STAYTON MM, 1983, J BIOL CHEM, V258, P3205; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Vanhamme L, 1998, J BIOL CHEM, V273, P21825, DOI 10.1074/jbc.273.34.21825; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; WAHLE E, 1993, J BIOL CHEM, V268, P2937; WAHLE E, 1991, CELL, V66, P759, DOI 10.1016/0092-8674(91)90119-J; WAHLE E, 1995, J BIOL CHEM, V270, P2800, DOI 10.1074/jbc.270.6.2800; Winstall E, 2000, J BIOL CHEM, V275, P21817, DOI 10.1074/jbc.M002412200; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yun CY, 2000, J CELL BIOL, V150, P707, DOI 10.1083/jcb.150.4.707	70	65	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 9	2003	278	19					16916	16925		10.1074/jbc.M209886200	http://dx.doi.org/10.1074/jbc.M209886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677QG	12637556	hybrid			2022-12-27	WOS:000182818600064
J	Mashima, H; Ueda, N; Ohno, H; Suzuki, J; Ohnishi, H; Yasuda, H; Tsuchida, T; Kanamaru, C; Makita, N; Iiri, T; Omata, M; Kojima, I				Mashima, H; Ueda, N; Ohno, H; Suzuki, J; Ohnishi, H; Yasuda, H; Tsuchida, T; Kanamaru, C; Makita, N; Iiri, T; Omata, M; Kojima, I			A novel mitochondrial Ca2+-dependent solute carrier in the liver identified by mRNA differential display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC AR42J CELLS; STRUCTURAL RELATIONSHIP; PROTEINS; BETACELLULIN; EXOCRINE; GLUCAGON; SEQUENCE; MEMBER	Pancreatic AR42J cells have the feature of pluripotency of the precursor cells of the gut endoderm. Dexamethasone converts them to exocrine cells or liver cells. Using mRNA differential display techniques, we have identified a novel Ca2+-dependent member of the mitochondrial solute carrier superfamily, which is expressed during the course of differentiation, and have designated it MCSC. The corresponding cDNA comprises an open reading frame of 1407 base pairs encoding a polypeptide of 469 amino acids. The carboxyl-terminal-half of MCSC has high similarity with other mitochondrial carriers, and the amino-terminal-half has three canonical elongation factor-hand motifs and has calcium binding capacity. The deduced amino acid sequence revealed 79.1% homology to the rabbit peroxisomal Ca2+-dependent member of the mitochondrial superfamily, but the subcellular localization of the protein was exclusively mitochondrial, not peroxisomal. Northern blot and Western blot analyses revealed its predominant expression in the liver and the skeletal muscle. In the liver, the expression level of MCSC was higher in the adult stage than in the fetal stage, and MCSC was highly up-regulated in dexamethasone-treated AR42J cells before the expression of albumin. Taken together, MCSC may play an important role in regulating the function of hepatocytes rather than in differentiation in vivo.	Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan; Univ Tokyo, Sch Med, Dept Endocrinol & Nephrol, Tokyo 1138655, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Maebashi, Gumma 3718512, Japan	University of Tokyo; University of Tokyo; Gunma University	Mashima, H (corresponding author), Univ Tokyo, Sch Med, Dept Gastroenterol, Tokyo 1138655, Japan.	hmashima1-tky@umin.ac.jp	Mashima, Hirosato/ABE-6412-2020					Ahlgren U, 1997, NATURE, V385, P257, DOI 10.1038/385257a0; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Deutsch G, 2001, DEVELOPMENT, V128, P871; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kikuno R, 2002, NUCLEIC ACIDS RES, V30, P166, DOI 10.1093/nar/30.1.166; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krapp A, 1998, GENE DEV, V12, P3752, DOI 10.1101/gad.12.23.3752; LOGSDON CD, 1985, J CELL BIOL, V100, P1200, DOI 10.1083/jcb.100.4.1200; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Mashima H, 1999, DIABETES, V48, P304, DOI 10.2337/diabetes.48.2.304; Mashima H, 1996, ENDOCRINOLOGY, V137, P3969, DOI 10.1210/en.137.9.3969; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; ROSEWICZ S, 1992, EUR J CELL BIOL, V59, P80; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; RUNSWICK MJ, 1990, BIOCHEMISTRY-US, V29, P11033, DOI 10.1021/bi00502a004; Seno M, 1996, GROWTH FACTORS, V13, P181, DOI 10.3109/08977199609003220; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; TEITELMAN G, 1987, DEV BIOL, V121, P454, DOI 10.1016/0012-1606(87)90182-5; Weber FE, 1997, P NATL ACAD SCI USA, V94, P8509, DOI 10.1073/pnas.94.16.8509; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3	31	24	25	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9520	9527		10.1074/jbc.M208398200	http://dx.doi.org/10.1074/jbc.M208398200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645546	hybrid			2022-12-27	WOS:000181524000086
J	Haller, D; Holt, L; Kim, SC; Schwabe, RF; Sartor, RB; Jobin, C				Haller, D; Holt, L; Kim, SC; Schwabe, RF; Sartor, RB; Jobin, C			Transforming growth factor-beta 1 inhibits non-pathogenic gram-negative bacteria-induced NF-kappa B recruitment to the interleukin-6 gene promoter in intestinal epithelial cells through modulation of histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; BETA SIGNAL-TRANSDUCTION; TGF-BETA; MUCOSAL INFLAMMATION; TRANSGENIC RATS; SMAD PROTEINS; COLITIS; CBP/P300; PHOSPHORYLATION; INDUCTION	We have shown that non-pathogenic enteric Gram-negative Bacteroides vulgatus induces RelA phosphorylation, NF-kappaB activation, and proinflammatory gene expression in primary and intestinal epithelial cell (IEC) lines. We now demonstrate the transient induction of nuclear phospho-RelA (day 3) followed by persistent activation of phospho-Smad2 (days 3 and 7) in IEC from mucosal tissue sections of B. vulgatus-monoassociated rats, indicating that both NF-kappaB and transforming growth factor-beta1 (TGF-beta1) signaling are induced in vivo following bacterial colonization. Interestingly, TGF-beta1 inhibited B. vulgatus- and lipopolysaccharide (LPS)-induced NF-kappaB transcriptional activity as well as interleukin-6 (IL-6) mRNA accumulation and protein secretion in IEC. The inhibitory effect of TGF-beta1 is mediated independently of B. vulgatus/LPS-induced IkappaBalpha, Akt, and RelA phosphorylation as well as NF-kappaB DNA binding activity. Moreover, the specific histone deacetylase inhibitor trichostatin A blocked B. vulgatus/LPS-induced histone acetylation/phosphorylation (Lys-9/Ser-10) and reversed TGF-beta1-mediated inhibition of IL-6 gene expression. Chromatin immunoprecipitation analysis revealed that B. vulgatus/LPS-induced RelA recruitment to the IL-6 promoter is inhibited by TGF-beta1 treatment. Adenoviral delivery of Smad7 and dominant negative Smad3 (SmadDelta3) reversed the TGF-beta1-mediated inhibition of NF-kappaB transcriptional activity and NF-kappaB recruitment to the IL-6 promoter. In addition, TGF-beta1 and Ad5Smad3/4 prevent B. vulgatus/LPS-induced CBP/p300 and p65 nuclear co-association. We concluded that the TGF-beta1/Smad signaling pathway helps maintain normal intestinal homeostasis to commensal luminal enteric bacteria by regulating NF-kappaB signaling in IEC through altered histone acetylation.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, CB 7038,Glaxo Bldg, Chapel Hill, NC 27599 USA.		Schwabe, Robert/AAY-6506-2021	Haller, Dirk/0000-0002-6977-4085	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034987, R01DK047700, R56DK047700, R01DK040249] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK34987, DK47700, DK40249] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bhan AK, 1999, IMMUNOL REV, V169, P195, DOI 10.1111/j.1600-065X.1999.tb01316.x; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; Bouzahzah B, 2000, CANCER RES, V60, P4531; Chen WJ, 1998, J IMMUNOL, V161, P6297; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Horn PJ, 2002, SCIENCE, V297, P1824, DOI 10.1126/science.1074200; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; Jobin C, 1997, J IMMUNOL, V158, P226; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kitani A, 2000, J EXP MED, V192, P41, DOI 10.1084/jem.192.1.41; KULKARNI AB, 1995, AM J PATHOL, V146, P264; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Massague J, 2000, GENE DEV, V14, P627; Melhuish TA, 2001, J BIOL CHEM, V276, P32109, DOI 10.1074/jbc.M103377200; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 2001, J CELL SCI, V114, P4359; Muegge K, 2002, NAT IMMUNOL, V3, P16, DOI 10.1038/ni0102-16; Neurath MF, 1996, J EXP MED, V183, P2605, DOI 10.1084/jem.183.6.2605; ONDERDONK AB, 1981, INFECT IMMUN, V32, P225, DOI 10.1128/IAI.32.1.225-231.1981; Piek E, 1999, FASEB J, V13, P2105, DOI 10.1096/fasebj.13.15.2105; Pouponnot C, 1998, J BIOL CHEM, V273, P22865, DOI 10.1074/jbc.273.36.22865; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2002, GENE DEV, V16, P2219, DOI 10.1101/gad.232502; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; SARTOR RB, 1997, AM J GASTROENTEROL, V92, P5; Song XY, 1999, J IMMUNOL, V163, P4020; Strober W, 1998, ANN NY ACAD SCI, V859, P37, DOI 10.1111/j.1749-6632.1998.tb11109.x; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	45	112	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23851	23860		10.1074/jbc.M300075200	http://dx.doi.org/10.1074/jbc.M300075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12672795	hybrid, Green Published			2022-12-27	WOS:000183638600081
J	He, QM; Wei, YQ; Tian, L; Zhao, X; Su, JM; Yang, L; Lu, Y; Kan, B; Lou, YY; Huang, MJ; Xiao, F; Liu, JY; Hu, B; Luo, F; Jiang, Y; Wen, YJ; Deng, HX; Li, J; Niu, T; Yang, JL				He, QM; Wei, YQ; Tian, L; Zhao, X; Su, JM; Yang, L; Lu, Y; Kan, B; Lou, YY; Huang, MJ; Xiao, F; Liu, JY; Hu, B; Luo, F; Jiang, Y; Wen, YJ; Deng, HX; Li, J; Niu, T; Yang, JL			Inhibition of tumor growth with a vaccine based on xenogeneic homologous fibroblast growth factor receptor-1 in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; IN-VIVO; ANGIOGENESIS; CANCER; IMMUNITY; TOLERANCE; GENE; DNA; AUTOIMMUNITY; EXPRESSION	Angiogenesis is important for the growth of solid tumors. The breaking of the immune tolerance against the molecule associated with angiogenesis should be a useful approach for cancer therapy. However, the immunity to self-molecules is difficult to elicit by a vaccine based on autologous or syngeneic molecules due to immune tolerance. Basic fibroblast growth factor ( bFGF) is a specific and potent angiogenic factor implicated in tumor growth. The biological activity of bFGF is mediated through interaction with its high-affinity receptor, fibroblast growth factor receptor-1 (FGFR-1). In this study, we selected Xenopus FGFR-1 as a model antigen by the breaking of immune tolerance to explore the feasibility of cancer therapy in murine tumor models. We show here that vaccination with Xenopus FGFR-1 (pxFR1) is effective at antitumor immunity in three murine models. FGFR-1-specific autoantibodies in sera of pxFR1-immunized mice could be found in Western blotting analysis. The purified immunoglobulins were effective at the inhibition of endothelial cell proliferation in vitro and at the antitumor activity in vivo. The antitumor activity and production of FGFR-1-specific autoantibodies could be abrogated by depletion of CD4(+) T lymphocytes. Histological examination revealed that the autoantibody was deposited on the endothelial cells within tumor tissues from pxFR1-immunized mice, and intratumoral angiogenesis was significantly suppressed. Furthermore, the inhibition of angiogenesis could also be found in alginate-encapsulate tumor cell assay. These observations may provide a new vaccine strategy for cancer therapy through the induction of autoimmunity against FGFR-1 associated with angiogenesis in a cross-reaction.	Minist Educ, Key Lab Biotherapy Human Dis, Beijing, Peoples R China; W China Hosp, Ctr Canc, Chengdu 610041, Sichuan, Peoples R China; Sichuan Univ, W China Med Sch, W China Hosp 2, Dept Gynecol & Obstet, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Sichuan University	Wei, YQ (corresponding author), Minist Educ, Key Lab Biotherapy Human Dis, Beijing, Peoples R China.		Niu, Tao/B-7983-2008; Hu, Bing/G-9745-2011	Hu, Bing/0000-0003-0810-6670; Wei, Yu-quan/0000-0002-6211-3217				Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Auguste P, 2001, CANCER RES, V61, P1717; Barinaga M, 2000, SCIENCE, V288, P245; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Bowne WB, 1999, J EXP MED, V190, P1717, DOI 10.1084/jem.190.11.1717; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cheng WF, 2001, J CLIN INVEST, V108, P669, DOI 10.1172/JCI200112346; Cleaver O, 1997, DEV DYNAM, V210, P66, DOI 10.1002/(SICI)1097-0177(199709)210:1<66::AID-AJA7>3.3.CO;2-S; De Silva HD, 1998, IMMUNOLOGY, V93, P405; Ding L, 2002, J BIOL CHEM, V277, P31056, DOI 10.1074/jbc.M203658200; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Folkman J, 1996, NAT MED, V2, P167, DOI 10.1038/nm0296-167; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; Gouttefangeas C, 2000, NAT BIOTECHNOL, V18, P491, DOI 10.1038/75343; Grossman Z, 2000, SEMIN IMMUNOL, V12, P197, DOI 10.1006/smim.2000.0232; Guddo F, 1999, HUM PATHOL, V30, P788, DOI 10.1016/S0046-8177(99)90139-9; Hedges SB, 2002, SCIENCE, V297, P1283; Hoffmann J, 1997, CANCER RES, V57, P3847; Horton HM, 1999, P NATL ACAD SCI USA, V96, P1553, DOI 10.1073/pnas.96.4.1553; Houghton AN, 2001, CURR OPIN IMMUNOL, V13, P134, DOI 10.1016/S0952-7915(00)00195-3; Jayson GC, 1999, INT J CANCER, V82, P298, DOI 10.1002/(SICI)1097-0215(19990719)82:2<298::AID-IJC23>3.3.CO;2-0; Kang L, 2002, J EXP MED, V196, P1091; Kornberg TB, 2000, SCIENCE, V287, P2218, DOI 10.1126/science.287.5461.2218; Krieg AM, 1998, P NATL ACAD SCI USA, V95, P12631, DOI 10.1073/pnas.95.21.12631; Kumar V, 1996, J EXP MED, V184, P1609, DOI 10.1084/jem.184.5.1609; Marx J, 2000, SCIENCE, V289, P1121; Mural RJ, 2002, SCIENCE, V296, P1661, DOI 10.1126/science.1069193; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; MUSCI TJ, 1990, P NATL ACAD SCI USA, V87, P8365, DOI 10.1073/pnas.87.21.8365; Ohashi PS, 1996, CURR OPIN IMMUNOL, V8, P808, DOI 10.1016/S0952-7915(96)80009-4; Overwijk WW, 1999, P NATL ACAD SCI USA, V96, P2982, DOI 10.1073/pnas.96.6.2982; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; Plum SM, 2000, VACCINE, V19, P1294, DOI 10.1016/S0264-410X(00)00210-3; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; ROBBIE EP, 1995, DEVELOPMENT, V121, P1775; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rosenberg SA, 1997, IMMUNOL TODAY, V18, P175, DOI 10.1016/S0167-5699(97)84664-6; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schwartz RH, 1997, CURR OPIN IMMUNOL, V9, P351, DOI 10.1016/S0952-7915(97)80081-7; Shortman K, 2001, NAT IMMUNOL, V2, P988, DOI 10.1038/ni1101-988; Sigmund K, 2001, NATURE, V414, P403, DOI 10.1038/35106672; St Croix B, 2000, SCIENCE, V289, P1197; Takanami I, 1997, NEOPLASMA, V44, P295; Valesky M, 2002, MOL MED, V8, P103, DOI 10.1007/BF03402080; Weber LW, 1998, J CLIN INVEST, V102, P1258, DOI 10.1172/JCI4004; Wei YQ, 2000, NAT MED, V6, P1160, DOI 10.1038/80506; Yancopoulos GD, 1998, CELL, V93, P661, DOI 10.1016/S0092-8674(00)81426-9	49	65	83	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21831	21836		10.1074/jbc.M300880200	http://dx.doi.org/10.1074/jbc.M300880200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12651849	hybrid			2022-12-27	WOS:000183354200066
J	Jonsson, M; Eklund, E; Fransson, LA; Oldberg, A				Jonsson, M; Eklund, E; Fransson, LA; Oldberg, A			Initiation of the decorin glycosaminoglycan chain in the endoplasmic reticulum-Golgi intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; LEUCINE-RICH PROTEOGLYCANS; BETA-D-XYLOSYLTRANSFERASE; LUMINAL ER PROTEINS; HEPARAN-SULFATE; CHONDROITIN SULFATE; MOLECULAR-CLONING; BREFELDIN-A; KEY ENZYME; IN-VIVO	We have transiently expressed decorin with a C- terminal KDEL endoplasmic reticulum retention signal peptide in COS- 7 cells to study initiation of galactosaminoglycan synthesis in the endoplasmic reticulum- Golgi intermediate compartment. All decorin- KDEL molecules were substituted with N- linked oligosaccharides sensitive to endoglycosidase H, indicating that the core protein was located proximal to the medial- Golgi. O-Linked glycosylation was only initiated in a minor fraction of the molecules. The O- linked saccharides were characterized by gel filtration after stepwise degradations using chondroitin ABC/ AC-I lyases, beta1 - 3- glycuronidase, beta-galactosidase, and alkaline phosphatase. The major O- linked saccharide was the linkage region pentasaccharide GalNAcbeta1-4GlcUAbeta1-3Galbeta1-3Galbeta1-4-Xyl- 2- phosphate, demonstrating initiation of chondroitin synthesis in the endoplasmic reticulum- Golgi intermediate compartment. In the presence of brefeldin A, partial elongation of a chondroitin chain took place, indicating retrieval of polymerases but not of sulfotransferases.	Lund Univ, Dept Cell & Mol Biol, SE-22184 Lund, Sweden	Lund University	Oldberg, A (corresponding author), Lund Univ, Dept Cell & Mol Biol, BMC C13, SE-22184 Lund, Sweden.	Ake.Oldberg@medkem.lu.se						Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRESSE H, 1971, EUR J BIOCHEM, V22, P557, DOI 10.1111/j.1432-1033.1971.tb01577.x; Moriarity JL, 2002, J BIOL CHEM, V277, P16968, DOI 10.1074/jbc.M109316200; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; Oldberg A, 1996, FEBS LETT, V386, P29, DOI 10.1016/0014-5793(96)00407-3; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Prydz K, 2000, J CELL SCI, V113, P193; SCHWARTZ NB, 1974, BIOCHEM BIOPH RES CO, V56, P717, DOI 10.1016/0006-291X(74)90664-0; SPIRO RC, 1991, J CELL BIOL, V115, P1463, DOI 10.1083/jcb.115.5.1463; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; UhlinHansen L, 1997, J BIOL CHEM, V272, P3200, DOI 10.1074/jbc.272.6.3200; UHLINHANSEN L, 1993, J BIOL CHEM, V268, P17370; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563	40	12	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21415	21420		10.1074/jbc.M210977200	http://dx.doi.org/10.1074/jbc.M210977200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668676	hybrid			2022-12-27	WOS:000183354200015
J	Liang, Y; Fotiadis, D; Filipek, S; Saperstein, DA; Palczewski, K; Engel, A				Liang, Y; Fotiadis, D; Filipek, S; Saperstein, DA; Palczewski, K; Engel, A			Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENT; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; MONOCLONAL-ANTIBODIES; LATERAL DIFFUSION; DISK MEMBRANES; VISUAL PIGMENT; TRANSDUCIN; ARRESTIN; ACTIVATION	G protein- coupled receptors ( GPCRs), which constitute the largest and structurally best conserved family of signaling molecules, are involved in virtually all physiological processes. Crystal structures are available only for the detergent-solubilized light receptor rhodopsin. In addition, this receptor is the only GPCR for which the presumed higher order oligomeric state in native membranes has been demonstrated ( Fotiadis, D., Liang, Y., Filipek, S., Saperstein, D. A., Engel, A., and Palczewski, K. ( 2003) Nature 421, 127 - 128). Here, we have determined by atomic force microscopy the organization of rhodopsin in native membranes obtained from wild- type mouse photoreceptors and opsin isolated from photoreceptors of Rpe65 -/- mutant mice, which do not produce the chromophore 11- cis-retinal. The higher order organization of rhodopsin was present irrespective of the support on which the membranes were adsorbed for imaging. Rhodopsin and opsin form structural dimers that are organized in paracrystalline arrays. The intradimeric contact is likely to involve helices IV and V, whereas contacts mainly between helices I and II and the cytoplasmic loop connecting helices V and VI facilitate the formation of rhodopsin dimer rows. Contacts between rows are on the extracellular side and involve helix I. This is the first semi- empirical model of a higher order structure of a GPCR in native membranes, and it has profound implications for the understanding of how this receptor interacts with partner proteins.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Basel, ME Muller Inst Microscopy, Biozentrum, CH-4056 Basel, Switzerland; Warsaw Univ, Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Warsaw Univ, Fac Chem, PL-02109 Warsaw, Poland	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Basel; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.	palczews@u.washington.edu	Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858	NATIONAL EYE INSTITUTE [R29EY008061, R01EY008061, P30EY001730, R03EY013726] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008061, P30 EY001730, EY 017301, EY08061, EY 13726, R03 EY013726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Arimoto R, 2001, BIOPHYS J, V81, P3285, DOI 10.1016/S0006-3495(01)75962-0; Ballesteros J, 2001, Curr Opin Drug Discov Devel, V4, P561; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; BLASIE JK, 1965, J MOL BIOL, V14, P143, DOI 10.1016/S0022-2836(65)80236-4; BLASIE JK, 1969, J MOL BIOL, V39, P417, DOI 10.1016/0022-2836(69)90136-3; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUCKERT F, 1992, BIOPHYS J, V63, P616, DOI 10.1016/S0006-3495(92)81650-8; CONE RA, 1972, NATURE-NEW BIOL, V236, P39, DOI 10.1038/newbio236039a0; CORLESS JM, 1982, P NATL ACAD SCI-BIOL, V79, P1116, DOI 10.1073/pnas.79.4.1116; Dean MK, 2001, J MED CHEM, V44, P4595, DOI 10.1021/jm010290+; DRATZ EA, 1985, BIOCHIM BIOPHYS ACTA, V832, P337, DOI 10.1016/0167-4838(85)90268-7; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; Gehring WJ, 2002, INT J DEV BIOL, V46, P65; George SR, 2002, NAT REV DRUG DISCOV, V1, P808, DOI 10.1038/nrd913; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HENDERSON R, 1990, PHILOS T ROY SOC B, V326, P379, DOI 10.1098/rstb.1990.0019; Humphries MM, 1997, NAT GENET, V15, P216, DOI 10.1038/ng0297-216; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Lem J, 1999, P NATL ACAD SCI USA, V96, P736, DOI 10.1073/pnas.96.2.736; LIEBMAN PA, 1982, METHOD ENZYMOL, V81, P660; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LIEBMAN PA, 1974, SCIENCE, V185, P457, DOI 10.1126/science.185.4149.457; MACKENZIE D, 1984, BIOCHEMISTRY-US, V23, P6544, DOI 10.1021/bi00321a041; Marshall GR, 2001, BIOPOLYMERS, V60, P246, DOI 10.1002/1097-0282(2001)60:3<246::AID-BIP10044>3.0.CO;2-V; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Min KC, 2000, PROTEIN EXPRES PURIF, V20, P514, DOI 10.1006/prep.2000.1326; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; Muller DJ, 1997, BIOPHYS J, V73, P1633, DOI 10.1016/S0006-3495(97)78195-5; Nair KS, 2002, CURR BIOL, V12, P421, DOI 10.1016/S0960-9822(02)00691-7; OHGURO H, 1993, P NATL ACAD SCI USA, V90, P3241, DOI 10.1073/pnas.90.8.3241; Okada T, 2001, CURR OPIN STRUC BIOL, V11, P420, DOI 10.1016/S0959-440X(00)00227-X; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; PALCZEWSKI K, 1994, BIOCHEMISTRY-US, V33, P13741, DOI 10.1021/bi00250a027; PALCZEWSKI K, 1988, J BIOL CHEM, V263, P14067; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Rios CD, 2001, PHARMACOL THERAPEUT, V92, P71, DOI 10.1016/S0163-7258(01)00160-7; SAIBIL H, 1976, NATURE, V262, P266, DOI 10.1038/262266a0; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SCHERTLER GFX, 1995, P NATL ACAD SCI USA, V92, P11578, DOI 10.1073/pnas.92.25.11578; Scheuring S, 1999, EMBO J, V18, P4981, DOI 10.1093/emboj/18.18.4981; Schubert C, 1999, J BIOL CHEM, V274, P21186, DOI 10.1074/jbc.274.30.21186; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; STRYER L, 1985, BIOPOLYMERS, V24, P29, DOI 10.1002/bip.360240105; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Wagner HJ, 1998, PROG RETIN EYE RES, V17, P637, DOI 10.1016/S1350-9462(98)00003-2; Walz T, 1996, J MOL BIOL, V264, P907, DOI 10.1006/jmbi.1996.0686; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YEAGER MJ, 1976, BROOKHAVEN SYM BIOL, pR3	60	522	536	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21655	21662		10.1074/jbc.M302536200	http://dx.doi.org/10.1074/jbc.M302536200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12663652	hybrid, Green Accepted			2022-12-27	WOS:000183354200044
J	Chastain, PD; Makhov, AM; Nossal, NG; Griffith, J				Chastain, PD; Makhov, AM; Nossal, NG; Griffith, J			Architecture of the replication complex and DNA loops at the fork generated by the bacteriophage T4 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND SYNTHESIS; POLYMERASE-III HOLOENZYME; HELICASE ASSEMBLY PROTEIN; LEADING-STRAND; ESCHERICHIA-COLI; PURIFICATION; BINDING; VISUALIZATION; PROCESSIVITY; TEMPLATE	Rolling circle replication has previously been reconstituted in vitro using M13 duplex circles containing preformed forks and the 10 purified T4 bacteriophage replication proteins. Leading and lagging strand synthesis in these reactions is coupled and the size of the Okazaki fragments produced is typical of those generated in T4 infections. In this study the structure of the DNAs and DNA-protein complexes engaged in these in vitro reactions has been examined by electron microscopy. Following deproteinization, circular duplex templates with linear tails as great as 100 kb are observed. The tails are fully duplex except for one to three single-stranded DNA segments close to the fork. This pattern reflects Okazaki fragments stopped at different stages in their synthesis. Examination of the DNA-protein complexes in these reactions reveals M13 duplex circles in which 64% contain a single large protein mass ( replication complex) and a linear duplex tail. In 56% of the replicating molecules with a tail there is at least one fully duplex loop at the replication complex resulting from the portion of the lagging strand engaged in Okazaki fragment synthesis folding back to the replisome. The single-stranded DNA segments at the fork bound by gene 32 and 59 proteins are not extended but rather appear organized into highly compact structures ("bobbins"). These bobbins constitute a major portion of the mass of the full replication complex.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; NIDDK, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Griffith, J (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu	Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31819] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; Alley SC, 2000, BIOCHEMISTRY-US, V39, P3076, DOI 10.1021/bi992377r; BARRY J, 1994, J BIOL CHEM, V269, P33049; Benkovic SJ, 2001, ANNU REV BIOCHEM, V70, P181, DOI 10.1146/annurev.biochem.70.1.181; Bhagwat M, 2001, J BIOL CHEM, V276, P28516, DOI 10.1074/jbc.M103914200; CAPSON TL, 1991, CELL, V65, P249, DOI 10.1016/0092-8674(91)90159-V; Chastain PD, 2000, MOL CELL, V6, P803, DOI 10.1016/S1097-2765(05)00093-6; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; Delagoutte E, 2001, BIOCHEMISTRY-US, V40, P4459, DOI 10.1021/bi001306l; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; FORMOSA T, 1983, P NATL ACAD SCI-BIOL, V80, P2442, DOI 10.1073/pnas.80.9.2442; GRIFFITH JD, 1995, J MOL BIOL, V246, P576, DOI 10.1016/S0022-2836(05)80107-X; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; Ishmael FT, 2003, J BIOL CHEM, V278, P3145, DOI 10.1074/jbc.M209858200; Jones CE, 2000, J BIOL CHEM, V275, P27145; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KIM YT, 1992, J BIOL CHEM, V267, P15022; Lee J, 2002, J MOL BIOL, V316, P19, DOI 10.1006/jmbi.2001.5325; Lee J, 1998, MOL CELL, V1, P1001, DOI 10.1016/S1097-2765(00)80100-8; Lefebvre SD, 1999, J BIOL CHEM, V274, P22830, DOI 10.1074/jbc.274.32.22830; MACE DC, 1984, J MOL BIOL, V177, P313, DOI 10.1016/0022-2836(84)90459-5; MAKI H, 1988, J BIOL CHEM, V263, P6570; MORRICAL SW, 1991, J BIOL CHEM, V266, P14031; Mueser TC, 2000, J MOL BIOL, V296, P597, DOI 10.1006/jmbi.1999.3438; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; Nossal NG, 1995, METHOD ENZYMOL, V262, P560; NOSSAL NG, 1971, J BIOL CHEM, V246, P5414; Park K, 1998, J BIOL CHEM, V273, P5260, DOI 10.1074/jbc.273.9.5260; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; RICHARDSON RW, 1990, UCLA SYM BI, V127, P247; Salinas F, 2000, P NATL ACAD SCI USA, V97, P7196, DOI 10.1073/pnas.97.13.7196; Schrock RD, 1996, J BIOL CHEM, V271, P16678, DOI 10.1074/jbc.271.28.16678; SELICK HE, 1987, DNA REPLICATION RECO, V47, P183; SINHA NK, 1980, J BIOL CHEM, V255, P4290; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; Tougu K, 1996, J BIOL CHEM, V271, P21398, DOI 10.1074/jbc.271.35.21398; WU CA, 1992, J BIOL CHEM, V267, P4064; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	40	47	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21276	21285		10.1074/jbc.M301573200	http://dx.doi.org/10.1074/jbc.M301573200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12649286	hybrid			2022-12-27	WOS:000183230500106
J	Reddy, RK; Mao, CH; Baumeister, P; Austin, RC; Kaufman, RJ; Lee, AS				Reddy, RK; Mao, CH; Baumeister, P; Austin, RC; Kaufman, RJ; Lee, AS			Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors - Role of ATP binding site in suppression of caspase-7 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-REGULATED PROTEINS; STRESS-PROTEIN; OXIDATIVE STRESS; DEATH PROGRAM; CANCER-CELLS; RESISTANCE; EXPRESSION; INDUCTION; BIP; MECHANISM	A large number of correlative studies have established that the activation of the unfolded protein response (UPR) alters the cell's sensitivity to chemotherapeutic agents. Although the induction of the glucose-regulated proteins (GRPs) is commonly used as an indicator for the UPR, the direct role of the GRPs in conferring resistance to DNA damaging agents has not been proven. We report here that without the use of endoplasmic reticulum (ER) stress inducers, specific overexpression of GRP78 results in reduced apoptosis and higher colony survival when challenged with topoisomerase II inhibitors, etoposide and doxorubicin, and topoisomerase I inhibitor, camptothecin. While investigating the mechanism for the GRP78 protective effect against etoposide-induced cell death, we discovered that in contrast to the UPR, GRP78 overexpression does not result in G(1) arrest or depletion of topoisomerase II. Caspase-7, an executor caspase that is associated with the ER, is activated by etoposide. We show here that specific expression of GRP78 blocks caspase-7 activation by etoposide both in vivo and in vitro, and this effect can be reversed by addition of dATP in a cell-free system. Recently, it was reported that ectopically expressed GRP78 and caspases-7 and -12 form a complex, thus coupling ER stress to the cell death program. However, the mechanism of how GRP78, a presumably ER lumen protein, can regulate cytosolic effectors of apoptosis is not known. Here we provide evidence that a subpopulation of GRP78 can exist as an ER transmembrane protein, as well as co-localize with caspase-7, as confirmed by fluorescence microscopy. Co-immunoprecipitation studies further reveal endogenous GRP78 constitutively associates with procaspase-7 but not with procaspase-3. Lastly, a GRP78 mutant deleted of its ATP binding domain fails to bind procaspase-7 and loses its protective effect against etoposide-induced apoptosis.	Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; McMaster Univ, Dept Pathol & Mol Biol, Hamilton, ON L8V 1C3, Canada; Henerson Res Ctr, Hamilton, ON L8V 1C3, Canada; Univ Michigan, Howard Hughes Med Inst, Dept Biol Chem, Med Ctr, Ann Arbor, MI 48109 USA	University of Southern California; University of Southern California; McMaster University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Lee, AS (corresponding author), Univ So Calif, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave,Rm 5308,MC-9176, Los Angeles, CA 90089 USA.	amylee@hsc.usc.edu		Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R01CA027607, R37CA027607, P30CA014089] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042394] Funding Source: NIH RePORTER; NCI NIH HHS [2P30 CA14089, CA27607] Funding Source: Medline; NEI NIH HHS [EY03040] Funding Source: Medline; NIAID NIH HHS [AI42394] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bini L, 1997, ELECTROPHORESIS, V18, P2832, DOI 10.1002/elps.1150181519; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Brown JM, 1998, CANCER RES, V58, P1408; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; CHATTERJEE S, 1994, CANCER RES, V54, P4405; CHATTERJEE S, 1990, CANCER RES, V50, P2713; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; Fernandez PM, 2000, BREAST CANCER RES TR, V59, P15, DOI 10.1023/A:1006332011207; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; Gazit G, 1999, BREAST CANCER RES TR, V54, P135, DOI 10.1023/A:1006102411439; Gazit G, 1999, CANCER RES, V59, P3100; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; HENDERSHOT LM, 1995, MOL BIOL CELL, V6, P283, DOI 10.1091/mbc.6.3.283; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Holcik M, 2000, MOL CELL BIOL, V20, P4648, DOI 10.1128/MCB.20.13.4648-4657.2000; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; KANG HS, 1991, J BIOL CHEM, V266, P5643; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Koomagi R, 1999, ANTICANCER RES, V19, P4333; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; LI LJ, 1992, J CELL PHYSIOL, V153, P575, DOI 10.1002/jcp.1041530319; Lin ZP, 1998, CANCER RES, V58, P3059; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751; MEMON SA, 1995, J IMMUNOL METHODS, V180, P15, DOI 10.1016/0022-1759(94)00294-7; Miyake H, 2000, J CELL BIOCHEM, V77, P396, DOI 10.1002/(SICI)1097-4644(20000601)77:3<396::AID-JCB5>3.0.CO;2-5; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; PATIERNO SR, 1987, CANCER RES, V47, P6220; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 1999, J BIOL CHEM, V274, P28476, DOI 10.1074/jbc.274.40.28476; Sacchi CM, 1996, ANTICANCER RES, V16, P3659; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; SHEN J, 1987, P NATL ACAD SCI USA, V84, P3278, DOI 10.1073/pnas.84.10.3278; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Tomida A, 1999, ANTI-CANCER DRUG DES, V14, P169; Triantafilou M, 2001, HUM IMMUNOL, V62, P764, DOI 10.1016/S0198-8859(01)00269-5; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Wooden S.K., 1992, DNA Sequence, V3, P41, DOI 10.3109/10425179209039694; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; Yun J, 1995, ONCOL RES, V7, P583; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381	48	582	611	0	59	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20915	20924		10.1074/jbc.M212328200	http://dx.doi.org/10.1074/jbc.M212328200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665508	hybrid			2022-12-27	WOS:000183230500062
J	Yin, F; Li, P; Zheng, M; Chen, L; Xu, Q; Chen, K; Wang, YY; Zhang, YY; Han, C				Yin, F; Li, P; Zheng, M; Chen, L; Xu, Q; Chen, K; Wang, YY; Zhang, YY; Han, C			Interleukin-6 family of cytokines mediates isoproterenol-induced delayed STAT3 activation in mouse heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC MYOCYTE HYPERTROPHY; BETA-ADRENERGIC STIMULATION; ANGIOTENSIN-II; TRANSCRIPTIONAL ACTIVATION; PROINFLAMMATORY CYTOKINES; RECEPTOR STIMULATION; NITRIC-OXIDE; RAT-HEART; EXPRESSION; FAILURE	This study was aimed to determine whether beta-adrenergic receptor ( beta-AR) stimulated by isoproterenol (ISO) activates signal transducers and activators of transcription ( STAT) in mouse heart and, if so, to examine the underlying mechanism. We found that treatment of adult male mice by ISO ( 15 mg/kg body weight, intraperitoneal) caused a delayed STAT3 activation ( at 60 120 min), which was fully abolished by beta-AR antagonist, propranolol. ISO-induced phosphorylation of STAT3 was markedly enhanced by phosphodiesterase inhibitor amrinone, indicating that cAMP is critically involved in beta-AR-mediated STAT3 activation. In addition, beta-AR stimulation significantly increased gene expression of interleukin-6 (IL-6) family of cytokines (IL-6, leukemia inhibitory factor, ciliary neurotrophic factor, and cardiotrophin-1). IL-6 protein levels in serum and mouse myocardium were also significantly increased in response to ISO treatment. In cultured cardiac fibroblasts, IL-6 level was enhanced significantly after ISO (10(-6) mol/liter) stimulation for 2 h and then peaked at 12 h, whereas the response of IL-6 in cultured cardiomyocytes to ISO stimulation was not significant, suggesting that ISO-induced increase in IL-6 is primarily from cardiac fibroblasts rather than cardiomyocytes. Most importantly, IL-6 could activate STAT3 in a time-dependent manner in cultured cardiomyocytes, and inhibition of IL-6 level by anti-IL-6-neutralizing antibody clearly attenuated ISO-induced phosphorylation of STAT3 in myocardium. Taken together, these results indicate that beta-AR stimulation leads to a delayed STAT3 activation via an IL-6 family of cytokine-mediated pathway and that cardiac fibroblasts, but not cardiomyocytes, is probably the predominant source of IL-6 in response to ISO stimulation in mouse myocardium.	Peking Univ, Inst Vasc Med, Hosp 3, Hlth Sci Ctr, Beijing 100083, Peoples R China; Peking Univ, Reference Lab Educ, Minist Mol Cardiol, Hlth Sci Ctr, Beijing 100083, Peoples R China; Peking Univ, Inst Cardiovasc Sci, Hlth Sci Ctr, Beijing 100083, Peoples R China	Peking University; Peking University; Peking University	Zhang, YY (corresponding author), Peking Univ, Inst Vasc Med, Hosp 3, Hlth Sci Ctr, Beijing 100083, Peoples R China.		Yin, Feng/F-6052-2010; Wang, Yongyu/F-9039-2011; YIN, FENG/AAM-3823-2020	Wang, Yongyu/0000-0002-8804-3472; YIN, FENG/0000-0002-8444-1123; Wang, Yongyu/0000-0002-6088-8887				Baumgarten G, 2000, TRENDS CARDIOVAS MED, V10, P216, DOI 10.1016/S1050-1738(00)00063-3; BRODDE OE, 1991, PHARMACOL REV, V43, P203; Burger A, 2001, AM J PHYSIOL-HEART C, V281, pH14, DOI 10.1152/ajpheart.2001.281.1.H14; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dzimiri N, 1999, PHARMACOL REV, V51, P465; Funamoto M, 2000, J MOL CELL CARDIOL, V32, P1275, DOI 10.1006/jmcc.2000.1161; GERSHENWALD JE, 1990, P NATL ACAD SCI USA, V87, P4966, DOI 10.1073/pnas.87.13.4966; Gray MO, 1998, CARDIOVASC RES, V40, P352, DOI 10.1016/S0008-6363(98)00121-7; Gustafsson AB, 2000, MOL PHARMACOL, V58, P1470, DOI 10.1124/mol.58.6.1470; HAVELL EA, 1991, J IMMUNOL, V146, P756; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Ito Y, 1998, BRAIN RES, V793, P321, DOI 10.1016/S0006-8993(98)00242-X; Kubota T, 2000, J HEART LUNG TRANSPL, V19, P819, DOI 10.1016/S1053-2498(00)00173-X; Kucharz, 2000, Eur J Intern Med, V11, P253, DOI 10.1016/S0953-6205(00)00098-4; LONG CS, 1989, J CLIN INVEST, V83, P1078, DOI 10.1172/JCI113951; MAY LT, 1993, J IMMUNOL, V151, P3225; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Murray DR, 2000, CIRCULATION, V101, P2338, DOI 10.1161/01.CIR.101.20.2338; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Orus J, 2000, J HEART LUNG TRANSPL, V19, P419, DOI 10.1016/S1053-2498(00)00083-8; Pan J, 1999, CIRC RES, V84, P1127, DOI 10.1161/01.RES.84.10.1127; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Prabhu SD, 2000, CIRCULATION, V101, P2103, DOI 10.1161/01.CIR.101.17.2103; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; Sano M, 2000, J BIOL CHEM, V275, P29717, DOI 10.1074/jbc.M003128200; SANO M, 2001, EUR J HEART FAIL, V3, P415; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka T, 2001, J MOL CELL CARDIOL, V33, P1627, DOI 10.1006/jmcc.2001.1428; Van Andel RA, 2000, J MED MICROBIOL, V49, P171, DOI 10.1099/0022-1317-49-2-171; Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4	33	58	66	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21070	21075		10.1074/jbc.M211028200	http://dx.doi.org/10.1074/jbc.M211028200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665506	hybrid			2022-12-27	WOS:000183230500081
J	Henry, PC; Kanelis, V; O'Brien, MC; Kim, B; Gautschi, I; Forman-Kay, J; Schild, L; Rotin, D				Henry, PC; Kanelis, V; O'Brien, MC; Kim, B; Gautschi, I; Forman-Kay, J; Schild, L; Rotin, D			Affinity and specificity of interactions between Nedd4 isoforms and the epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; PROTEIN LIGASE NEDD4; SODIUM-CHANNEL; LIDDLES-SYNDROME; WW DOMAIN; BETA-SUBUNIT; C2 DOMAIN; HUMAN HYPERTENSION; MISSENSE MUTATION; APICAL MEMBRANE	The epithelial Na+ channel (alphabetagammaENaC) regulates salt and fluid homeostasis and blood pressure. Each ENaC subunit contains a PY motif (PPXY) that binds to the WW domains of Nedd4, a Hect family ubiquitin ligase containing 3-4 WW domains and usually a C2 domain. It has been proposed that Nedd4-2, but not Nedd4-1, isoforms can bind to and suppress ENaC activity. Here we challenge this notion and show that, instead, the presence of a unique WW domain (WW3*) in either Nedd4-2 or Nedd4-1 determines high affinity interactions and the ability to suppress ENaC. WW3* from either Nedd4-2 or Nedd4-1 binds ENaC-PY motifs equally well (e.g. K(d)similar to10 muM for alpha- or betaENaC, 3-6-fold higher affinity than WW4), as determined by intrinsic tryptophan fluorescence. Moreover, dNedd4-1, which naturally contains a WW3* instead of WW2, is able to suppress ENaC function equally well as Nedd4-2. Homology models of the WW3*.beta ENaC-PY complex revealed that a Pro and Ala conserved in all WW3*, but not other Nedd4-WW domains, help form the binding pocket for PY motif prolines. Extensive contacts are formed between the betaENaC-PY motif and the Pro in WW3*, and the small Ala creates a large pocket to accommodate the peptide. Indeed, mutating the conserved Pro and Ala in WW3* reduces binding affinity 2-3-fold. Additionally, we demonstrate that mutations in PY motif residues that form contacts with the WW domain based on our previously solved structure either abolish or severely reduce binding affinity to the WW domain and that the extent of binding correlates with the level of ENaC suppression. Independently, we show that a peptide encompassing the PY motif of sgk1, previously proposed to bind to Nedd4-2 and alter its ability to regulate ENaC, does not bind (or binds poorly) the WW domains of Nedd4-2. Collectively, domain-PY-motif interactions rather than affiliation with Nedd4-1/Nedd-2 is critical for ENaC suppression by Nedd4 proteins.	Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Struct Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Biochem, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Lausanne	Rotin, D (corresponding author), Hosp Sick Children, Cell Biol Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	drotin@sickkids.ca		Forman-Kay, Julie/0000-0001-8265-972X				Abriel H, 1999, J CLIN INVEST, V103, P667, DOI 10.1172/JCI5713; Adams CM, 1998, J CELL BIOL, V140, P143, DOI 10.1083/jcb.140.1.143; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; CUTHBERT AW, 1977, NATURE, V266, P468, DOI 10.1038/266468a0; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Dinudom A, 1998, P NATL ACAD SCI USA, V95, P7169, DOI 10.1073/pnas.95.12.7169; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Fotia AB, 2002, FASEB J, V16, P70, DOI 10.1096/fj.02-0497fje; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; Goulet CC, 1998, J BIOL CHEM, V273, P30012, DOI 10.1074/jbc.273.45.30012; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Harvey KF, 2001, J BIOL CHEM, V276, P8597, DOI 10.1074/jbc.C000906200; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Huang X, 2000, NAT STRUCT BIOL, V7, P634, DOI 10.1038/77923; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; Inoue T, 1998, EUR J ENDOCRINOL, V138, P691, DOI 10.1530/eje.0.1380691; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kamynina E, 2001, FASEB J, V15, P204, DOI 10.1096/fj.00-0191com; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Komwatana P, 1996, P NATL ACAD SCI USA, V93, P8107, DOI 10.1073/pnas.93.15.8107; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lifton RP, 2001, CELL, V104, P545, DOI 10.1016/S0092-8674(01)00241-0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lott JS, 2002, BIOCHEM J, V361, P481, DOI 10.1042/0264-6021:3610481; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Macias MJ, 1996, NATURE, V382, P646, DOI 10.1038/382646a0; McDonald FJ, 2002, AM J PHYSIOL-RENAL, V283, pF431, DOI 10.1152/ajprenal.00080.2002; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pires JR, 2001, J MOL BIOL, V314, P1147, DOI 10.1006/jmbi.2000.5199; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Rossier BC, 2002, ANNU REV PHYSIOL, V64, P877, DOI 10.1146/annurev.physiol.64.082101.143243; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; ROTIN D, 1994, EMBO J, V13, P4440, DOI 10.1002/j.1460-2075.1994.tb06766.x; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SELVIN S, 2001, EPIDEMIOLOGIC ANAL; Shi HK, 2002, J BIOL CHEM, V277, P13539, DOI 10.1074/jbc.M111717200; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Tamura H, 1996, J CLIN INVEST, V97, P1780, DOI 10.1172/JCI118606; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; Yamashita Y, 2001, AM J KIDNEY DIS, V37, P499	62	70	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20019	20028		10.1074/jbc.M211153200	http://dx.doi.org/10.1074/jbc.M211153200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654927	hybrid			2022-12-27	WOS:000183078000059
J	Hobbs, RM; Watt, FM				Hobbs, RM; Watt, FM			Regulation of interleukin-1 alpha expression by integrins and epidermal growth factor receptor in keratinocytes from a mouse model of inflammatory skin disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ACTIVATED PROTEIN-KINASE; CULTURED HUMAN KERATINOCYTES; HEPARIN-BINDING; FACTOR-ALPHA; EGF RECEPTOR; COLLAGENASE-1 EXPRESSION; MURINE KERATINOCYTES; PSORIATIC EPIDERMIS	Transgenic mice expressing beta(1) integrins in the suprabasal epidermal layers have sporadic skin hyperproliferation and inflammation correlated with activation of extracellular signal-regulated kinase (Erk) mitogen-activated protein kinase and increased interleukin (IL)-1alpha production. We investigated the link between aberrant integrin expression, Erk activation, and expression of IL-1alpha. Transgenic keratinocytes had higher basal Erk activity and IL-1alpha levels than nontransgenic controls and were more sensitive to stimulation of Erk activity and IL-1alpha production by IL-1alpha, 12-O-tetradecanoylphorbol-13-acetate (TPA), epidermal growth factor (EGF), and serum. Inhibition of Erk in transgenic keratinocytes reduced basal IL-1alpha levels and the stimulation of IL-1alpha production by serum or phorbol ester, demonstrating that Erk could regulate IL-1alpha expression. TPA or IL-1alpha treatment resulted in rapid down-regulation of the EGF receptor in transgenic cells, indicative of transactivation. Inhibition of transactivation blocked basal and TPA or IL-1alpha induced Erk activation, but not IkappaBalpha degradation, and abolished increased IL-1alpha production in transgenic cells. In transgene-negative cells, constitutive activation of IL-1-dependent signaling by wild type or kinase-dead IRAK1 stimulated IL-1alpha production independent of Erk. We conclude that suprabasal integrin expression leads to Erk activation and increased IL-1alpha expression by potentiating activation of the EGF receptor. These results provide a mechanism by which aberrant integrin expression triggers epidermal hyperproliferation and inflammation.	Canc Res UK London Res Inst, Keratinocyte Lab, London WC2A 3PX, England	Cancer Research UK	Watt, FM (corresponding author), Canc Res UK London Res Inst, Keratinocyte Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Watt, Fiona/AHB-0226-2022; Hobbs, Robin/I-2577-2014	Watt, Fiona/0000-0001-9151-5154; Hobbs, Robin/0000-0002-3853-2614				ANSEL JC, 1988, J IMMUNOL, V140, P2274; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019; CARROLL JM, 1995, CELL, V83, P957, DOI 10.1016/0092-8674(95)90211-2; Carter KB, 2000, J BIOL CHEM, V275, P27858; CHEN JD, 1995, J INVEST DERMATOL, V104, P729, DOI 10.1111/1523-1747.ep12606970; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; COOK PW, 1995, J CELL PHYSIOL, V163, P407, DOI 10.1002/jcp.1041630221; COOK PW, 1992, IN VITRO CELL DEV-AN, V28A, P218; Cooke EL, 2001, BIOCHEM J, V359, P403, DOI 10.1042/0264-6021:3590403; CORRADI A, 1995, EXP CELL RES, V217, P355, DOI 10.1006/excr.1995.1097; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Debets R, 1997, J IMMUNOL, V158, P2955; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Fujimoto W, 1997, J INVEST DERMATOL, V108, P200, DOI 10.1111/1523-1747.ep12334240; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; GROVES RW, 1995, J IMMUNOL, V154, P4065; GRUAZCHATELLARD D, 1991, FEBS LETT, V294, P137, DOI 10.1016/0014-5793(91)81360-K; Haase I, 2001, J CLIN INVEST, V108, P527, DOI 10.1172/JCI200112153; Haase I, 2002, J INVEST DERMATOL, V118, P891, DOI 10.1046/j.1523-1747.2002.17631.x; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hirota K, 2001, J BIOL CHEM, V276, P25953, DOI 10.1074/jbc.M011021200; IMAMOTO A, 1991, MOL CARCINOGEN, V4, P52, DOI 10.1002/mc.2940040109; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Kalmes A, 2000, CIRC RES, V87, P92, DOI 10.1161/01.RES.87.2.92; Kanakaraj P, 1998, J EXP MED, V187, P2073, DOI 10.1084/jem.187.12.2073; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Knop J, 1998, EUR J IMMUNOL, V28, P3100, DOI 10.1002/(SICI)1521-4141(199810)28:10<3100::AID-IMMU3100>3.0.CO;2-7; Komine M, 2001, J INVEST DERMATOL, V116, P330, DOI 10.1046/j.1523-1747.2001.01249.x; Kondo S, 1999, J INVEST DERM SYMP P, V4, P177, DOI 10.1038/sj.jidsp.5640205; KUPPER TS, 1995, J INVEST DERMATOL, V105, P62; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; La E, 1999, MOL CARCINOGEN, V24, P276, DOI 10.1002/(SICI)1098-2744(199904)24:4<276::AID-MC5>3.0.CO;2-#; Lee RT, 1997, J IMMUNOL, V159, P5084; LEE WY, 1994, J BIOL CHEM, V269, P17971; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li ER, 2000, EXP DERMATOL, V9, P431, DOI 10.1034/j.1600-0625.2000.009006431.x; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Mamidipudi V, 2002, J BIOL CHEM, V277, P28010, DOI 10.1074/jbc.M109730200; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; MARIKOVSKY M, 1993, P NATL ACAD SCI USA, V90, P3889, DOI 10.1073/pnas.90.9.3889; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; Murphy JE, 2000, J INVEST DERMATOL, V114, P602, DOI 10.1046/j.1523-1747.2000.00917.x; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Ng T, 1999, EMBO J, V18, P3909, DOI 10.1093/emboj/18.14.3909; Owens DM, 2001, CANCER RES, V61, P5248; PHILLIPS WG, 1995, CLIN EXP IMMUNOL, V101, P177; PIEPKORN M, 1994, J CELL PHYSIOL, V159, P114, DOI 10.1002/jcp.1041590115; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Pilcher BK, 1999, J BIOL CHEM, V274, P10372, DOI 10.1074/jbc.274.15.10372; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; Rikimaru K, 1997, EXP DERMATOL, V6, P214, DOI 10.1111/j.1600-0625.1997.tb00165.x; ROGERS HW, 1992, P NATL ACAD SCI USA, V89, P1011, DOI 10.1073/pnas.89.3.1011; Romero MR, 1999, EXP DERMATOL, V8, P53, DOI 10.1111/j.1600-0625.1999.tb00348.x; Roper E, 2001, EMBO REP, V2, P145, DOI 10.1093/embo-reports/kve020; ROSS K, 2002, J BIOL CHEM, V23, P23; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stoll S, 1997, J CLIN INVEST, V100, P1271, DOI 10.1172/JCI119641; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Thomas JA, 1999, J IMMUNOL, V163, P978; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wan YS, 2001, INT J MOL MED, V7, P329; Watt FM, 2002, EMBO J, V21, P3919, DOI 10.1093/emboj/cdf399; Werner E, 2001, J CELL SCI, V114, P3333; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; Xiao YQ, 2002, J BIOL CHEM, V277, P14884, DOI 10.1074/jbc.M111718200; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	85	35	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19798	19807		10.1074/jbc.M300513200	http://dx.doi.org/10.1074/jbc.M300513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654926	hybrid			2022-12-27	WOS:000183078000031
J	Price, GB; Allarakhia, M; Cossons, N; Nielsen, T; Diaz-Perez, M; Friedlander, P; Tao, L; Zannis-Hadjopoulos, M				Price, GB; Allarakhia, M; Cossons, N; Nielsen, T; Diaz-Perez, M; Friedlander, P; Tao, L; Zannis-Hadjopoulos, M			Identification of a cis-element that determines autonomous DNA replication in eukaryotic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; MAMMALIAN ORIGIN; CPG ISLANDS; HELA-CELLS; IN-VIVO; INITIATION ZONE; DELETION ANALYSIS; DEPENDENT ATPASE; HUMAN GENOME; MONKEY DNA	A 36-bp human consensus sequence (CCTMDAWKSG-BYTSMAAWTWBCMYTTRSCAAATTCC) is capable of supporting autonomous replication of a plasmid after transfection into eukaryotic cells. After transfection and in vitro DNA replication, replicated plasmid DNA containing a mixture of oligonucleotides of this consensus was found to reiterate the consensus. Initiation of DNA replication in vitro occurs within the consensus. One version, A3/4, in pYACneo, could be maintained under selection in HeLa cells, unrearranged and replicating continuously for > 170 cell doublings. Stability of plasmid without selection was high (greater than or equal to0.9/ cell/generation). Homologs of the consensus are found consistently at mammalian chromosomal sites of initiation and within CpG islands. Versions of the consensus function as origins of DNA replication in normal and malignant human cells, immortalized monkey and mouse cells, and normal cow, chicken, and fruit fly cells. Random mutagenesis studies suggest an internal 20-bp consensus sequence of the 36 bp may be sufficient to act as a core origin element. This cis-element consensus sequence is an opportunity for focused analyses of core origin elements and the regulation of initiation of DNA replication.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; Ottawa Hosp, Dept Internal Med, Ottawa, ON K1H 8L6, Canada; Univ British Columbia, Fac Med, Vancouver, BC V6T 1Z3, Canada	McGill University; University of Ottawa; Ottawa Hospital Research Institute; University of British Columbia	Price, GB (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Sir William Osler Promenade, Montreal, PQ H3G 1Y6, Canada.							Abdurashidova G, 2000, SCIENCE, V287, P2023, DOI 10.1126/science.287.5460.2023; ALADJEM MI, 1995, SCIENCE, V270, P815, DOI 10.1126/science.270.5237.815; ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335; ARIIZUMI K, 1993, P NATL ACAD SCI USA, V90, P3695, DOI 10.1073/pnas.90.8.3695; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CROSS SH, 1994, NAT GENET, V6, P236, DOI 10.1038/ng0394-236; Delgado S, 1998, EMBO J, V17, P2426, DOI 10.1093/emboj/17.8.2426; DiazPerez MJ, 1996, J CELL BIOCHEM, V61, P444, DOI 10.1002/(SICI)1097-4644(19960601)61:3<444::AID-JCB11>3.0.CO;2-J; Dimitrova DS, 1996, P NATL ACAD SCI USA, V93, P1498, DOI 10.1073/pnas.93.4.1498; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; Fox JL, 2000, NAT BIOTECHNOL, V18, P377, DOI 10.1038/74422; Fox JL, 1999, NAT BIOTECHNOL, V17, P1153, DOI 10.1038/70689; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; GIACCA M, 1994, P NATL ACAD SCI USA, V91, P7119, DOI 10.1073/pnas.91.15.7119; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HELD PG, 1992, BIOCHIM BIOPHYS ACTA, V1130, P235, DOI 10.1016/0167-4781(92)90435-3; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; Newlon C. S., 1996, DNA REPLICATION EUKA, P873; NIELSEN T, 1994, MOL GEN GENET, V242, P280, DOI 10.1007/BF00280417; Nielsen TO, 2000, J CELL BIOCHEM, V76, P674, DOI 10.1002/(SICI)1097-4644(20000315)76:4<674::AID-JCB15>3.0.CO;2-2; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; PEARSON CE, 1994, SOMAT CELL MOLEC GEN, V20, P147, DOI 10.1007/BF02254755; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; POPPERL H, 1992, EMBO J, V11, P3673, DOI 10.1002/j.1460-2075.1992.tb05452.x; Ruiz MT, 1999, MOL BIOL CELL, V10, P567, DOI 10.1091/mbc.10.3.567; RUIZ MT, 1995, J CELL BIOCHEM, V58, P221, DOI 10.1002/jcb.240580211; Schild-Poulter C, 2003, DNA CELL BIOL, V22, P65, DOI 10.1089/104454903321515887; Sinnett D, 1996, GENE, V173, P171, DOI 10.1016/0378-1119(96)00106-0; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; Strehl S, 1997, MOL CELL BIOL, V17, P6157, DOI 10.1128/MCB.17.10.6157; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; Tao L, 1997, J MOL BIOL, V273, P509, DOI 10.1006/jmbi.1997.1352; Tao L, 2000, J CELL BIOCHEM, V78, P442, DOI 10.1002/1097-4644(20000901)78:3<442::AID-JCB9>3.0.CO;2-1; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; TOTH EC, 1993, NUCLEIC ACIDS RES, V21, P3257, DOI 10.1093/nar/21.14.3257; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VISHWANATHA JK, 1990, BIOCHEMISTRY-US, V29, P8753, DOI 10.1021/bi00489a036; Waltz SE, 1996, NUCLEIC ACIDS RES, V24, P1887, DOI 10.1093/nar/24.10.1887; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P241, DOI 10.1016/0167-4781(93)90193-H; WU CL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P258, DOI 10.1016/0167-4781(93)90194-I; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1; ZANNISHADJOPOULOS M, 1994, GENE, V151, P273, DOI 10.1016/0378-1119(94)90670-X; ZHAO YP, 1994, NUCLEIC ACIDS RES, V22, P5385, DOI 10.1093/nar/22.24.5385	51	24	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19649	19659		10.1074/jbc.M207002200	http://dx.doi.org/10.1074/jbc.M207002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665518	hybrid			2022-12-27	WOS:000183078000013
J	Soto, P; Price-Schiavi, SA; Carraway, KL				Soto, P; Price-Schiavi, SA; Carraway, KL			SMAD2 and SMAD7 involvement in the post-translational regulation of Muc4 via the transforming growth factor-beta and interferon-gamma pathways in rat mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE SIALOMUCIN COMPLEX; INTRAMEMBRANE MODULATOR; ADENOCARCINOMA CELLS; SIGNAL-TRANSDUCTION; OVEREXPRESSION; KINASE	Muc4/sialomucin complex (SMC) is a heterodimeric glycoprotein complex derived from a single gene that is post-translationally processed into mucin (ASGP-1) and transmembrane (ASGP-2) subunits. Muc4/SMC is tightly regulated in the rat mammary gland, low in the virgin, increased during pregnancy and lactation, and overexpressed in some aggressive mammary tumors. Investigations of primary rat mammary epithelial cells (MEC) have shown that Muc4/SMC expression is post-translationally regulated through inhibition of Muc4/SMC precursor processing by transforming growth factor-beta (TGF-beta). Localization studies suggest that TGF-beta inhibition of Muc4/SMC expression is mediated through SMAD2, a TGF-beta effector that, when activated, functions as a transcription factor. SMAD2 antisense oligonucleotide blocks the inhibition of Muc4/SMC expression by TGF-beta. The TGF-beta effect on Muc4/SMC expression is repressed by interferon-gamma (IFN-gamma). IFN-gamma treatment of MEC activates and relocalizes signal transducer and activator of transcription-1 (STAT-1) to induce an inhibitor SMAD, SMAD7. SMAD7 antisense oligonucleotide prevents IFN-gamma from blocking the TGF-beta inhibition of Muc4/SMC expression. These results suggest that TGF-beta regulates Muc4/SMC expression via the SMAD pathway by a transcriptional effect on a protein in the Muc4/SMC processing step, possibly the protease that cleaves the precursor.	Univ Miami, Sch Med, Dept Cell Biol & Anat R124, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami; University of Miami	Carraway, KL (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat R124, POB 016960, Miami, FL 33101 USA.	kcarrawa@med.miami.edu			NCI NIH HHS [CA 52498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; Carraway KL, 2003, BIOESSAYS, V25, P66, DOI 10.1002/bies.10201; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 2001, PROG NUCL ACIDS RES, V171, P149; Chen TP, 1998, CANCER RES, V58, P4805; He W, 2002, EMBO J, V21, P2580, DOI 10.1093/emboj/21.11.2580; Heasman J, 2002, DEV BIOL, V243, P209, DOI 10.1006/dbio.2001.0565; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Moustakas A, 2002, GENE DEV, V16, P1867, DOI 10.1101/gad.1016802; Moustakas A, 2001, J CELL SCI, V114, P4359; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2000, J BIOL CHEM, V275, P17800, DOI 10.1074/jbc.275.23.17800; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P63, DOI 10.1089/oli.1.1997.7.63; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Yue JB, 2001, PHARMACOL THERAPEUT, V91, P1, DOI 10.1016/S0163-7258(01)00143-7	28	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20338	20344		10.1074/jbc.M301886200	http://dx.doi.org/10.1074/jbc.M301886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12668667	hybrid			2022-12-27	WOS:000183078000098
J	Tietz, PS; Marinelli, RA; Chen, XM; Huang, B; Cohn, J; Kole, J; McNiven, MA; Alper, S; LaRusso, NF				Tietz, PS; Marinelli, RA; Chen, XM; Huang, B; Cohn, J; Kole, J; McNiven, MA; Alper, S; LaRusso, NF			Agonist-induced coordinated trafficking of functionally related transport proteins for water and ions in cholangiocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCT EPITHELIAL-CELLS; TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; RAT-LIVER; SUBCELLULAR FRACTIONATION; MEDIATED MECHANISM; SJOGRENS-SYNDROME; AQUAPORIN CHIP; BILE FORMATION; CYCLIC-AMP	We previously proposed that ductal bile formation is regulated by secretin-responsive relocation of aquaporin 1 (AQP1), a water-selective channel protein, from an intracellular vesicular compartment to the apical membrane of cholangiocytes. In this study, we immunoisolated AQP1-containing vesicles from cholangiocytes prepared from rat liver; quantitative immunoblotting revealed enrichment in these vesicles of not only AQP1 but also cystic fibrosis transmembrane regulator (CFTR) and AE2, a Cl- channel and a Cl-/ HCO3- exchanger, respectively. Dual labeled immunogold electron microscopy of cultured polarized mouse cholangiocytes showed significant colocalization of AQP1, CFTR, and AE2 in an intracellular vesicular compartment; exposure of cholangiocytes to dibutyryl-cAMP ( 100 muM) resulted in co-redistribution of all three proteins to the apical cholangiocyte plasma membrane. After administration of secretin to rats in vivo, bile flow increased, and AQP1, CFTR, and AE2 co-redistributed to the apical cholangiocyte membrane; both events were blocked by pharmacologic disassembly of microtubules. Based on these in vitro and in vivo observations utilizing independent and complementary approaches, we propose that cholangiocytes contain an organelle that sequesters functionally related proteins that can account for ion-driven water transport, that this organelle moves to the apical cholangiocyte membrane in response to secretory agonists, and that these events account for ductal bile secretion at a molecular level.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Biochem & Mol Biol, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Fac Ciencias Bioquim, Dept Fisiol, RA-2000 Rosario, Santa Fe, Argentina; Duke Univ, Med Ctr, Durham, NC USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Mayo Clinic; Mayo Clinic; Duke University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	LaRusso, NF (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Dept Internal Med, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.	larusso.nicholas@mayo.edu			NIDDK NIH HHS [DK24031, DK44650] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK024031, R01DK024031, R37DK044650, R01DK044650, R29DK044650] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acher R, 2002, ANN ENDOCRINOL-PARIS, V63, P197; ALPINI G, 1988, J CLIN INVEST, V81, P569, DOI 10.1172/JCI113355; ALVARO D, 1993, J CLIN INVEST, V92, P1314, DOI 10.1172/JCI116705; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BENEDETTI A, 1994, P NATL ACAD SCI USA, V91, P792, DOI 10.1073/pnas.91.2.792; Berry V, 2000, NAT GENET, V25, P15, DOI 10.1038/75538; Biner HL, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V134836; BISHOP YMM, 1975, DISCRETE MULTIVARIAT, P344; BOYER JL, 1995, GASTROENTEROLOGY, V109, P1600, DOI 10.1016/0016-5085(95)90649-5; Boyer JL, 1996, AM J PHYSIOL-GASTR L, V270, pG1, DOI 10.1152/ajpgi.1996.270.1.G1; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; COHN JA, 1992, P NATL ACAD SCI USA, V89, P2340, DOI 10.1073/pnas.89.6.2340; Cole TJ, 2000, STAT MED, V19, P3109, DOI 10.1002/1097-0258(20001130)19:22<3109::AID-SIM558>3.0.CO;2-F; Colombo C, 1998, SEMIN LIVER DIS, V18, P227, DOI 10.1055/s-2007-1007159; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DUPOURQUE D, 1969, METHOD ENZYMOL, V13, P116; ELKJAER ML, 1995, EUR J CELL BIOL, V67, P57; FARQUHAR MG, 1974, J CELL BIOL, V60, P8, DOI 10.1083/jcb.60.1.8; Garcia F, 2001, J BIOL CHEM, V276, P12147, DOI 10.1074/jbc.M009403200; HOWELL KE, 1989, METHOD CELL BIOL, V31, P265; ISHII M, 1989, GASTROENTEROLOGY, V97, P1236, DOI 10.1016/0016-5085(89)91695-8; KATO A, 1992, J BIOL CHEM, V267, P15523; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; Marinelli RA, 1997, HEPATOLOGY, V26, P1081, DOI 10.1002/hep.510260539; Marinelli RA, 1996, SEMIN LIVER DIS, V16, P221, DOI 10.1055/s-2007-1007234; Marinelli RA, 1999, AM J PHYSIOL-GASTR L, V276, pG280, DOI 10.1152/ajpgi.1999.276.1.G280; MCCAFFERY JM, 1995, METHOD ENZYMOL, V257, P259; Mennone A, 2002, AM J PHYSIOL-GASTR L, V283, pG739, DOI 10.1152/ajpgi.00540.2001; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1995, J CLIN INVEST, V96, P1834, DOI 10.1172/JCI118229; O'Reilly CM, 2000, GASTROENTEROLOGY, V118, P1187, DOI 10.1016/S0016-5085(00)70372-6; Oh P, 1999, J BIOL CHEM, V274, P23144, DOI 10.1074/jbc.274.33.23144; PETERS TJ, 1972, J EXP MED, V136, P1117, DOI 10.1084/jem.136.5.1117; PRIETO J, 1993, GASTROENTEROLOGY, V105, P572, DOI 10.1016/0016-5085(93)90735-U; RAEDER MG, 1995, CURR OPIN GASTROEN, V11, P439; REEVES WJ, 1966, METHOD ENZYMOL, V9, P288; ROBERTS SK, 1994, P NATL ACAD SCI USA, V91, P13009, DOI 10.1073/pnas.91.26.13009; Shukla A, 2001, AM J PHYSIOL-RENAL, V281, pF546, DOI 10.1152/ajprenal.2001.281.3.F546; Steinfeld S, 2001, LAB INVEST, V81, P143, DOI 10.1038/labinvest.3780221; TIETZ PS, 1995, BIOCHEMISTRY-US, V34, P15436, DOI 10.1021/bi00047a007; Tsubota K, 2001, LANCET, V357, P688, DOI 10.1016/S0140-6736(00)04140-4; UDENFRIEND S, 1972, SCIENCE, V178, P871, DOI 10.1126/science.178.4063.871; Yahagi K, 1998, IN VITRO CELL DEV-AN, V34, P512; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546	45	93	95	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20413	20419		10.1074/jbc.M302108200	http://dx.doi.org/10.1074/jbc.M302108200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660234	hybrid			2022-12-27	WOS:000183078000107
J	Wu, RY; Zhang, RG; Zagnitko, O; Dementieva, I; Maltzev, N; Watson, JD; Laskowski, R; Gornicki, P; Joachimiak, A				Wu, RY; Zhang, RG; Zagnitko, O; Dementieva, I; Maltzev, N; Watson, JD; Laskowski, R; Gornicki, P; Joachimiak, A			Crystal structure of Enterococcus faecalis SlyA-like transcriptional factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEINS; EXPRESSION; YERSINIA; ACTIVATION; REGULATORS; FAMILY; CLYA	The crystal structure of a SlyA transcriptional regulator at 1.6 Angstrom resolution is presented, and structural relationships between members of the MarR/SlyA family are discussed. The SlyA family, which includes SlyA, Rap, Hor, and RovA proteins, is widely distributed in bacterial and archaeal genomes. Current evidence suggests that SlyA-like factors act as repressors, activators, and modulators of gene transcription. These proteins have been shown to up-regulate the expression of molecular chaperones, acid-resistance proteins, and cytolysin, and down-regulate several biosynthetic enzymes. The structure of SlyA from Enterococcus faecalis, determined as a part of an ongoing structural genomics initiative (www.mcsg.anl.gov), revealed the same winged helix DNA-binding motif that was recently found in the MarR repressor from Escherichia coli and the MexR repressor from Pseudomonas aeruginosa, a sequence homologue of MarR. Phylogenetic analysis of the MarR/ SlyA family suggests that Sly is placed between the SlyA and MarR subfamilies and shows significant sequence similarity to members of both subfamilies.	Argonne Natl Lab, Biosci Div, Struct Biol Ctr, Argonne, IL 60439 USA; Argonne Natl Lab, Div Math & Comp Sci, Argonne, IL 60439 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Wellcome Trust Genome Campus, European Bioinformat Inst, Cambridge CB10 1SD, England	United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Chicago; European Molecular Biology Laboratory (EMBL); Wellcome Trust Sanger Institute	Joachimiak, A (corresponding author), Argonne Natl Lab, Biosci Div, Struct Biol Ctr, 9700 S Cass Ave,Bldg 202, Argonne, IL 60439 USA.	andrzejj@anl.gov		Laskowski, Roman/0000-0001-5528-0087	NIGMS NIH HHS [P50 GM062414, GM62414, P50 GM062414-02] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		*ACC, 2000, QUANTA; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DEHOUX P, 1995, MOL MICROBIOL, V15, P591, DOI 10.1111/j.1365-2958.1995.tb02272.x; Finnin MS, 1997, EMBO J, V16, P1992, DOI 10.1093/emboj/16.8.1992; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Huffman JL, 2002, CURR OPIN STRUC BIOL, V12, P98, DOI 10.1016/S0959-440X(02)00295-6; Kenney LJ, 2002, CURR OPIN MICROBIOL, V5, P135, DOI 10.1016/S1369-5274(02)00310-7; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lim D, 2002, J BIOL CHEM, V277, P29253, DOI 10.1074/jbc.M111381200; LITTLEWOOD TD, 1994, PROTEIN PROFILE, V1, P639; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; Oscarsson J, 2002, INFECT IMMUN, V70, P5759, DOI 10.1128/IAI.70.10.5759-5769.2002; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Rueda E, 2001, J MOL EVOL, V53, P172, DOI 10.1007/s002390010207; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Revell PA, 2001, FEMS MICROBIOL LETT, V205, P159, DOI [10.1111/j.1574-6968.2001.tb10941.x, 10.1016/S0378-1097(01)00476-1]; Spory A, 2002, J BACTERIOL, V184, P3549, DOI 10.1128/JB.184.13.3549-3559.2002; Thomson NR, 1997, MOL MICROBIOL, V26, P531, DOI 10.1046/j.1365-2958.1997.5981976.x; Walsh MA, 1999, ACTA CRYSTALLOGR D, V55, P1168, DOI 10.1107/S0907444999003698; Westermark M, 2000, J BACTERIOL, V182, P6347, DOI 10.1128/JB.182.22.6347-6357.2000; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200	23	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20240	20244		10.1074/jbc.M300292200	http://dx.doi.org/10.1074/jbc.M300292200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649270	hybrid, Green Accepted			2022-12-27	WOS:000183078000086
J	Barletta, GM; Kovari, IA; Verma, RK; Kerjaschki, D; Holzman, LB				Barletta, GM; Kovari, IA; Verma, RK; Kerjaschki, D; Holzman, LB			Nephrin and Neph1 co-localize at the podocyte foot process intercellular junction and form cis hetero-oligomers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLOMERULAR SLIT DIAPHRAGM; CONGENITAL NEPHROTIC SYNDROME; EPITHELIAL-CELL; PROTEIN; GENE; COMPONENT; ADHESION; MICE; IDENTIFICATION; DIMERIZATION	Glomerular visceral epithelial cells (podocytes) appear to play a central role in maintaining the selective filtration barrier of the renal glomerulus. While the immunoglobulin superfamily member Nephrin was proposed to act as a cell adhesion molecule at the podocyte intercellular junction necessary for maintaining glomerular perm selectivity, the Nephrin ligand has not been identified. The existence of a new subfamily of Nephrin-like molecules including Neph1 was recently described. Genetic deletion of Nephrin or Neph1 resulted in similar phenotypes of podocyte foot process effacement and proteinuria. The subcellular localization of Neph1 and the possibility that Nephrin and Neph1 interact was investigated. Polyclonal antiserum for Neph1 was raised and characterized. Neph1 migrated as a 90-kDa protein on SDS-PAGE under reducing conditions. Neph1 was identified in a glomerular and podocyte-specific distribution in adult rat kidney. Like Nephrin and Podocin, Neph1 was enriched in Triton X-100 detergent-resistant membrane fractions. Consistent with this observation, immunogold electron microscopy demonstrated that Neph1 localized exclusively to lateral margins of podocyte foot processes at the insertion of the slit diaphragm. Neph1 and Nephrin participate in a direct cis-interaction involving their cytoplasmic domains. In addition, interactions between the extracellular domain of Nephrin and itself and between the extracellular domain of Nephrin and that of Neph1 were detected. Neph1 did not interact via a homophilic interaction. These observations suggest that Nephrin and Neph1 form a hetero-oligomeric receptor complex in the plane of the membrane that might interact across the foot process intercellular junction through interactions between Nephrin with itself and Neph1.	Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Vienna, Allgemeines Krankenhaus, Inst Clin Pathol, A-1090 Vienna, Austria; Dept Vet Affairs, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Vienna	Holzman, LB (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, 1560 MSRB II, Ann Arbor, MI 48109 USA.	lholzman@umich.edu		Holzman, Lawrence/0000-0002-8961-234X				Ahrens T, 2002, J BIOL CHEM, V277, P19455, DOI 10.1074/jbc.M200606200; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BreitenederGeleff S, 1997, AM J PATHOL, V151, P1141; Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001; Dworak HA, 2001, DEVELOPMENT, V128, P4265; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; FUCHSHUBER A, 1995, HUM MOL GENET, V4, P2155, DOI 10.1093/hmg/4.11.2155; Gil OD, 1998, J NEUROSCI, V18, P9312; Holzman LB, 1999, KIDNEY INT, V56, P1481, DOI 10.1046/j.1523-1755.1999.00719.x; Huber TB, 2001, J BIOL CHEM, V276, P41543, DOI 10.1074/jbc.C100452200; Inoue T, 2001, KIDNEY INT, V59, P1003, DOI 10.1046/j.1523-1755.2001.00583.x; Jalanko H, 2001, ANN MED, V33, P526, DOI 10.3109/07853890108995962; KANWAR YS, 1991, SEMIN NEPHROL, V11, P390; Karle SM, 2002, J AM SOC NEPHROL, V13, P388, DOI 10.1681/ASN.V132388; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; Kestila M, 1998, MOL CELL, V1, P575, DOI 10.1016/S1097-2765(00)80057-X; Kiselyov VV, 1997, J BIOL CHEM, V272, P10125; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Moeller MJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000015614.68893.0B; Nihalani D, 2000, J BIOL CHEM, V275, P7273, DOI 10.1074/jbc.275.10.7273; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; Regele HM, 2000, J AM SOC NEPHROL, V11, P403, DOI 10.1681/ASN.V113403; Reiser J, 2000, J AM SOC NEPHROL, V11, P1, DOI 10.1681/ASN.V1111; RODEWALD R, 1974, J CELL BIOL, V60, P423, DOI 10.1083/jcb.60.2.423; Ruotsalainen V, 1999, P NATL ACAD SCI USA, V96, P7962, DOI 10.1073/pnas.96.14.7962; SALANT DJ, 1980, J CLIN INVEST, V66, P71, DOI 10.1172/JCI109837; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI12849; Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Simons M, 2001, AM J PATHOL, V159, P1069, DOI 10.1016/S0002-9440(10)61782-8; THOMAS PE, 1994, J BIOL CHEM, V269, P19953; Tryggvason K, 1999, J AM SOC NEPHROL, V10, P2440; Yuan HP, 2002, AM J PHYSIOL-RENAL, V282, pF585, DOI 10.1152/ajprenal.00290.2001	34	140	147	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19266	19271		10.1074/jbc.M301279200	http://dx.doi.org/10.1074/jbc.M301279200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12646566	hybrid			2022-12-27	WOS:000182932200071
J	Ghorbel, MT; Sharman, G; Leroux, M; Barrett, T; Donovan, DM; Becker, KG; Murphy, D				Ghorbel, MT; Sharman, G; Leroux, M; Barrett, T; Donovan, DM; Becker, KG; Murphy, D			Microarray analysis reveals interleukin-6 as a novel secretory product of the hypothalamo-neurohypophyseal system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PITUITARY-ADRENAL AXIS; GENE-EXPRESSION; MESSENGER-RNA; HYPOTHALAMONEUROHYPOPHYSEAL SYSTEM; RAT-BRAIN; CDNA MICROARRAYS; DNA ARRAYS; IN-VITRO; VASOPRESSIN; NEURONS	Physiological activation of the hypothalamo-neurohypophyseal system (HNS) by dehydration results is a massive release of vasopressin (VP) from the posterior pituitary. This is accompanied by a functional remodeling of the HNS. In this study we used cDNA arrays in an attempt to identify genes that exhibit differential expression in the hypothalamus following dehydration. Our study revealed nine candidate genes, including interleukin-6 (IL-6) as a putative novel secretory product of HNS worthy of further analysis. In situ hybridization and immunocytochemistry confirmed that IL-6 is robustly expressed in the supraoptic (SON) and the paraventricular (PVN) nuclei of the hypothalamus. By double-staining immunofluorescence we showed that IL-6 is largely co-localized with VP in the SON and PVN. In situ hybridization, immunocytochemistry, and Western blotting all revealed IL-6 up-regulation in the SON and PVN following dehydration, thus validating the array data. The same dehydration stimulus resulted in an increase in IL-6 immunoreactivity in the axons of the internal zone of the median eminence and a marked reduction in IL-6-like material in the posterior pituitary gland. We thus suggest that IL-6 takes the same secretory pathway as VP and is secreted from the posterior pituitary following a physiological stimulus.	Univ Bristol, Bristol Royal Infirm, Univ Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England; NIA, DNA Array Unit, NIH, Baltimore, MD 21224 USA; USDA, Biotechnol & Germplasm Lab, Beltsville, MD 20705 USA	Bristol Royal Infirmary; University of Bristol; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); United States Department of Agriculture (USDA)	Ghorbel, MT (corresponding author), Univ Bristol, Sch Med Sci, Dept Anat, MRC Ctr Synapt Plast, Univ Walk, Bristol BS8 1TD, Avon, England.	m.ghorbel@bris.ac.uk	Murphy, David/C-3967-2012	Murphy, David/0000-0003-2946-0353; Becker, Kevin/0000-0002-6794-6656				BARGMANN W., 1966, INT REV CYTOL, V19, P183; BOURQUE CW, 1994, FRONT NEUROENDOCRIN, V15, P231, DOI 10.1006/frne.1994.1010; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Cartmell T, 2000, J PHYSIOL-LONDON, V526, P653, DOI 10.1111/j.1469-7793.2000.00653.x; De Laurentiis A, 2000, NEUROIMMUNOMODULAT, V7, P77, DOI 10.1159/000026423; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; GADIENT RA, 1994, NEUROSCI LETT, V182, P243, DOI 10.1016/0304-3940(94)90807-9; Gionis D, 2003, J PEDIATR ENDOCR MET, V16, P49; Hatton GI, 1997, ANNU REV NEUROSCI, V20, P375, DOI 10.1146/annurev.neuro.20.1.375; HONDA K, 1990, J PHYSIOL-LONDON, V431, P225, DOI 10.1113/jphysiol.1990.sp018328; JHAMANDAS JH, 1989, BRAIN RES, V487, P52, DOI 10.1016/0006-8993(89)90939-6; King HC, 2001, JAMA-J AM MED ASSOC, V286, P2280, DOI 10.1001/jama.286.18.2280; KRUKOFF TL, 1994, NEUROENDOCRINOLOGY, V59, P590, DOI 10.1159/000126709; LENG G, 1982, J PHYSIOL-LONDON, V326, P35, DOI 10.1113/jphysiol.1982.sp014175; LI ZH, 1993, AM J PHYSIOL, V265, pR302, DOI 10.1152/ajpregu.1993.265.2.R302; LIGHTMAN SL, 1987, J PHYSIOL-LONDON, V394, P23, DOI 10.1113/jphysiol.1987.sp016858; Lipsitt DR, 1999, GEN HOSP PSYCHIAT, V21, P1; Mastorakos G, 1995, ANN NY ACAD SCI, V771, P438, DOI 10.1111/j.1749-6632.1995.tb44700.x; MASTORAKOS G, 1994, J CLIN ENDOCR METAB, V79, P934, DOI 10.1210/jc.79.4.934; MCALLEN RM, 1990, AM J PHYSIOL, V259, pR593, DOI 10.1152/ajpregu.1990.259.3.R593; MEISTER B, 1990, CELL TISSUE RES, V260, P279, DOI 10.1007/BF00318631; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Murphy D, 1998, BIOESSAYS, V20, P741, DOI 10.1002/(SICI)1521-1878(199809)20:9<741::AID-BIES7>3.0.CO;2-J; NISSEN R, 1994, NEUROSCIENCE, V59, P115, DOI 10.1016/0306-4522(94)90103-1; Raber J, 1997, J NEUROSCI, V17, P9473; REEVES WB, 1992, POSTERIOR PITUITARY; RUSSELL JA, 1995, EXP PHYSIOL, V80, P307, DOI 10.1113/expphysiol.1995.sp003850; SCHAFER MKH, 1994, BIOL CHEM H-S, V375, P737; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SHERMAN TG, 1986, NEUROENDOCRINOLOGY, V44, P222, DOI 10.1159/000124649; SHERMAN TG, 1986, FASEB J, V45, P2323; Tanaka M, 1999, P NATL ACAD SCI USA, V96, P1088, DOI 10.1073/pnas.96.3.1088; Theodosis DT, 1998, CELL MOL NEUROBIOL, V18, P285, DOI 10.1023/A:1022577105819; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; YANG CR, 1994, J PHYSIOL-LONDON, V477, P59, DOI 10.1113/jphysiol.1994.sp020171; YASIN SA, 1994, J NEUROENDOCRINOL, V6, P179, DOI 10.1111/j.1365-2826.1994.tb00570.x; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2; ZENG Q, 1994, J NEUROENDOCRINOL, V6, P469, DOI 10.1111/j.1365-2826.1994.tb00610.x	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19280	19285		10.1074/jbc.M209902200	http://dx.doi.org/10.1074/jbc.M209902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12639960	hybrid			2022-12-27	WOS:000182932200073
J	Ibarra, CA; Chowdhury, P; Petrich, JW; Atkins, WM				Ibarra, CA; Chowdhury, P; Petrich, JW; Atkins, WM			The anomalous pK(a) of Tyr-9 in glutathione S-transferase A1-1 catalyzes product release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL HELIX; ACTIVE-SITE; DRUG-RESISTANCE; HEXYL GLUTATHIONE; CRYSTAL-STRUCTURE; KINETIC-ANALYSIS; PROTON RELEASE; ALPHA-CLASS; BINDING; MECHANISM	The pK(a) of the catalytic Tyr-9 in glutathione S-transferase (GST) A1-1 is lowered from 10.3 to similar to8.1 in the apoenzyme and similar to9.0 with a GSH conjugate bound at the active site. However, a clear functional role for the unusual Tyr-9 pK(a) has not been elucidated. GSTA1-1 also includes a dynamic C terminus that undergoes a ligand-dependent disorder-to-order transition. Previous studies suggest a functional link between Tyr-9 ionization and C-terminal dynamics. Here we directly probe the role of Tyr-9 ionization in ligand binding and C-terminal conformation. An engineered mutant of rGSTA1-1, W21F/F222W, which contains a single Trp at the C terminus, was used as a fluorescent reporter of pH-dependent C-terminal dynamics. This mutant exhibited a pH-dependent change in Trp-222 emission properties consistent with changes in C-terminal solvation or conformation. The apparent pK(a) values for the conformational transition were 7.9 +/- 0.1 and 9.3 +/- 0.1 for the apoenzyme and ligand-bound enzyme, respectively, in excellent agreement with the pK(a) for Tyr-9 in these states. The Y9F/W21F/F222W mutant, however, exhibited no such pH-dependent changes. Time-resolved fluorescence anisotropy studies revealed a ligand-dependent, Tyr-9-dependent, change in the order parameter of Trp-222. However, no pH dependence was observed. In equilibrium and pre-steady-state ligand binding studies, product conjugate had a decreased equilibrium binding affinity (K-D), concomitant with increased binding and dissociation rates, at higher pH values. Furthermore, the recovered pK(a) values for the pH-dependent microscopic rate constants ranged from 7.7 to 8.4, also in agreement with the pK(a) of Tyr-9. In contrast, the Y9F/W21F/F222W mutant had no pH-dependent transition in K-D or rate constants for ligand binding or dissociation. The combined results indicate that the macroscopic populations of "open" and "closed" states of the C terminus are not determined solely by the ionization state of Tyr-9. However, the rates of transition between these states are faster for the ionized Tyr-9. The ionized Tyr-9 states provide a parallel pathway for product dissociation, which is kinetically and thermodynamically favored. In silico kinetic models further support the functional role for the parallel dissociation pathway provided by ionized Tyr-9.	Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Iowa State Univ, Dept Chem, Ames, IA 50011 USA	University of Washington; University of Washington Seattle; Iowa State University	Atkins, WM (corresponding author), Univ Washington, Dept Med Chem, Box 357610, Seattle, WA 98195 USA.		Petrich, Jacob/L-1005-2015; Chowdhury, Pramit/AAP-8164-2021	Chowdhury, Pramit/0000-0002-9593-2577	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020088, R01GM062284] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM020088, R01 GM062284, GM62284] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adman ET, 2001, PROTEINS, V42, P192, DOI 10.1002/1097-0134(20010201)42:2<192::AID-PROT60>3.0.CO;2-#; Allardyce CS, 1999, BIOCHEM J, V343, P525, DOI 10.1042/0264-6021:3430525; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; ATKINS WM, 1993, J BIOL CHEM, V268, P19188; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Codreanu SG, 2002, BIOCHEMISTRY-US, V41, P15161, DOI 10.1021/bi026776p; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; Dirr HW, 1999, BIOCHEMISTRY-US, V38, P15631, DOI 10.1021/bi991179x; Gustafsson A, 1999, BIOCHEMISTRY-US, V38, P16268, DOI 10.1021/bi991482y; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; LAKOWICZ JR, 1999, PRINCIPLES FLUORESCE, P156; Le Trong I, 2002, PROTEINS, V48, P618, DOI 10.1002/prot.10162; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Nieslanik BS, 1999, BIOCHEMISTRY-US, V38, P6971, DOI 10.1021/bi9829130; Nieslanik BS, 2001, BIOCHEMISTRY-US, V40, P3536, DOI 10.1021/bi001869x; Nieslanik BS, 2000, J BIOL CHEM, V275, P17447, DOI 10.1074/jbc.M002083200; Nilsson LO, 2000, P NATL ACAD SCI USA, V97, P9408, DOI 10.1073/pnas.150084897; O'Brien M, 2000, J PHARMACOL EXP THER, V294, P480; Parsons JF, 1996, J AM CHEM SOC, V118, P2295, DOI 10.1021/ja960022e; TEW KD, 1994, CANCER RES, V54, P4313; Thorson JS, 1998, J AM CHEM SOC, V120, P451, DOI 10.1021/ja9731682; WANG RW, 1989, ARCH BIOCHEM BIOPHYS, V269, P536, DOI 10.1016/0003-9861(89)90137-9; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; Widersten M, 1996, BIOCHEMISTRY-US, V35, P7731, DOI 10.1021/bi9601619	31	18	18	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19257	19265		10.1074/jbc.M301566200	http://dx.doi.org/10.1074/jbc.M301566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637518	hybrid, Green Accepted			2022-12-27	WOS:000182932200070
J	Diaz-Lopez, T; Lages-Gonzalo, M; Serrano-Lopez, A; Alfonso, C; Rivas, G; Diaz-Orejas, R; Giraldo, R				Diaz-Lopez, T; Lages-Gonzalo, M; Serrano-Lopez, A; Alfonso, C; Rivas, G; Diaz-Orejas, R; Giraldo, R			Structural changes in RepA, a plasmid replication initiator, upon binding to origin DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DOUBLE-STRANDED-DNA; MINI-F PLASMID; HOST-RANGE; ESCHERICHIA-COLI; RECOGNITION COMPLEX; NEGATIVE CONTROL; ATPASE ACTIVITY; CLPA CHAPERONE; COPY NUMBER	RepA protein is the DNA replication initiator of the Pseudomonas plasmid pPS10. RepA dimers bind to an inversely repeated operator sequence in repA promoter, thus repressing its own synthesis, whereas monomers bind to four directly repeated sequences (iterons) to initiate DNA replication. We had proposed previously that RepA is composed of two winged-helix (WH) domains, a structural unit also present in eukaryotic and archaeal initiators. To bind to the whole iteron sequence through both domains, RepA should couple monomerization to a conformational change in the N-terminal WH, which includes a leucine zipper-like sequence motif. We show for the first time that, by itself, binding to iteron DNA in vitro dissociates RepA dimers into monomers and alters RepA conformation, suggesting an allosteric effect. Furthermore, we also show that similar changes in RepA are promoted by mutations that substitute two Leu residues of the putative leucine zipper by Ala, destabilizing the hydrophobic core of the first WH. We propose that this mutant (RepA-2L2A) resembles a transient folding intermediate in the pathway leading to active monomers. These findings, together with the known activation of other Rep-type proteins by chaperones, are relevant to understand the molecular basis of plasmid DNA replication initiation.	CSIC, Dept Mol Microbiol, E-28006 Madrid, Spain; CSIC, Dept Prot Struct & Funct, E-28006 Madrid, Spain; CSIC, Analyt Ultracentrifugat Facil, Ctr Invest Biol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Giraldo, R (corresponding author), CSIC, Dept Mol Microbiol, C Velazquez 144, E-28006 Madrid, Spain.		Rivas, German/AAG-7458-2022; Alfonso, Carlos/K-1316-2014; Rivas, German/AFL-7528-2022; Giraldo, Rafael/P-3289-2014	Rivas, German/0000-0003-3450-7478; Alfonso, Carlos/0000-0001-7165-4800; Rivas, German/0000-0003-3450-7478; Giraldo, Rafael/0000-0002-5358-7488				Abril AM, 1997, BIOCHEMISTRY-US, V36, P11901, DOI 10.1021/bi970994e; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRENNER M, 1991, P NATL ACAD SCI USA, V88, P405, DOI 10.1073/pnas.88.2.405; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Chattoraj DK, 2000, MOL MICROBIOL, V37, P467, DOI 10.1046/j.1365-2958.2000.01986.x; Chattoraj DK, 1996, GENES CELLS, V1, P189, DOI 10.1046/j.1365-2443.1996.d01-235.x; COHEN S, 2000, HORIZONTAL GENE POOL, P1; Cruickshank J, 2000, J BIOL CHEM, V275, P22273, DOI 10.1074/jbc.M001414200; Dao-Thi MH, 2000, J MOL BIOL, V299, P1373, DOI 10.1006/jmbi.2000.3815; DASGUPTA S, 1993, J MOL BIOL, V232, P23, DOI 10.1006/jmbi.1993.1367; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEVIEDMA DG, 1995, J MOL BIOL, V247, P211, DOI 10.1006/jmbi.1994.0134; deViedma DG, 1996, EMBO J, V15, P925, DOI 10.1002/j.1460-2075.1996.tb00427.x; deViedma DG, 1995, NUCLEIC ACIDS RES, V23, P5048, DOI 10.1093/nar/23.24.5048; Dibbens JA, 1997, MOL MICROBIOL, V26, P185, DOI 10.1046/j.1365-2958.1997.5691920.x; DURLAND RH, 1990, J BACTERIOL, V172, P3849, DOI 10.1128/jb.172.7.3849-3858.1990; FERNANDEZTRESGUERRES ME, 1995, J BACTERIOL, V177, P4377, DOI 10.1128/jb.177.15.4377-4384.1995; FILUTOWICZ M, 1986, P NATL ACAD SCI USA, V83, P9645, DOI 10.1073/pnas.83.24.9645; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Giraldo R, 1998, EMBO J, V17, P4511, DOI 10.1093/emboj/17.15.4511; GIRALDO R, 1989, NATURE, V342, P866, DOI 10.1038/342866a0; Giraldo R, 2001, P NATL ACAD SCI USA, V98, P4938, DOI 10.1073/pnas.081079298; Giraldo R., 1992, DNA REPLICATION REGU, P225; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Hoskins JR, 2000, P NATL ACAD SCI USA, V97, P8892, DOI 10.1073/pnas.97.16.8892; Hoskins JR, 2000, J BIOL CHEM, V275, P35361, DOI 10.1074/jbc.M006288200; INGMER H, 1995, J MOL BIOL, V250, P309, DOI 10.1006/jmbi.1995.0378; ISHIAI M, 1994, P NATL ACAD SCI USA, V91, P3839, DOI 10.1073/pnas.91.9.3839; Ishikawa T, 2001, P NATL ACAD SCI USA, V98, P4328, DOI 10.1073/pnas.081543698; Jen-Jacobson L, 2000, STRUCTURE, V8, P1015, DOI 10.1016/S0969-2126(00)00501-3; Kawasaki Y, 1996, MOL GEN GENET, V253, P42, DOI 10.1007/s004380050294; KAWASAKI Y, 1990, MOL GEN GENET, V220, P277; Kim SY, 2002, J BIOL CHEM, V277, P44778, DOI 10.1074/jbc.M206176200; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Komori H, 1999, EMBO J, V18, P4597, DOI 10.1093/emboj/18.17.4597; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; Kornberg A., 1992, DNA REPLICATION; Kruger R, 2001, J MOL BIOL, V306, P945, DOI 10.1006/jmbi.2000.4426; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Mauricio L, 1997, J BIOL CHEM, V272, P19295, DOI 10.1074/jbc.272.31.19295; Messer W, 2002, FEMS MICROBIOL REV, V26, P355, DOI 10.1016/S0168-6445(02)00127-4; MUKHOPADHYAY G, 1994, EMBO J, V13, P2089, DOI 10.1002/j.1460-2075.1994.tb06484.x; NIETO C, 1992, J MOL BIOL, V223, P415, DOI 10.1016/0022-2836(92)90661-3; Pacek M, 2001, J BIOL CHEM, V276, P23639, DOI 10.1074/jbc.M100255200; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; PAPP PP, 1994, J BIOL CHEM, V269, P23563; Park K, 1998, J BIOL CHEM, V273, P24906, DOI 10.1074/jbc.273.38.24906; Park K, 2001, EMBO J, V20, P7323, DOI 10.1093/emboj/20.24.7323; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Schuck P, 2000, BIOPOLYMERS, V54, P328, DOI 10.1002/1097-0282(20001015)54:5<328::AID-BIP40>3.0.CO;2-P; Sharma R, 2001, EMBO J, V20, P4577, DOI 10.1093/emboj/20.16.4577; SOZHAMANNAN S, 1993, J BACTERIOL, V175, P3546, DOI 10.1128/jb.175.11.3546-3555.1993; Speck C, 2001, EMBO J, V20, P1469, DOI 10.1093/emboj/20.6.1469; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; SWACK JA, 1987, J BACTERIOL, V169, P3737, DOI 10.1128/jb.169.8.3737-3742.1987; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; Urh M, 1998, J MOL BIOL, V283, P619, DOI 10.1006/jmbi.1998.2120; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; Wang H, 2002, J BIOL CHEM, V277, P2225, DOI 10.1074/jbc.M109430200; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1991, P NATL ACAD SCI USA, V88, P7903, DOI 10.1073/pnas.88.18.7903; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; Wu JZ, 1997, P NATL ACAD SCI USA, V94, P13967, DOI 10.1073/pnas.94.25.13967; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666	69	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18606	18616		10.1074/jbc.M212024200	http://dx.doi.org/10.1074/jbc.M212024200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637554	hybrid, Green Submitted			2022-12-27	WOS:000182838300133
J	Hirayama, S; Sugiura, R; Lu, YB; Maeda, T; Kawagishi, K; Yokoyama, M; Tohda, H; Giga-Hama, Y; Shuntoh, H; Kuno, T				Hirayama, S; Sugiura, R; Lu, YB; Maeda, T; Kawagishi, K; Yokoyama, M; Tohda, H; Giga-Hama, Y; Shuntoh, H; Kuno, T			Zinc finger protein Prz1 regulates Ca2+ but not Cl- homeostasis in fission yeast - Identification of distinct branches of calcineurin signaling pathway in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-GENETIC-ANALYSIS; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TRANSCRIPTION FACTOR; BINDING PROTEIN; CYCLOSPORINE-A; PHOSPHATASE; EXPRESSION; HOMOLOG; CYTOKINESIS	Calcineurin is an important mediator that connects the Ca2+-dependent signaling to various cellular responses in a wide variety of cell types and organisms. In budding yeast, activated calcineurin exerts its function mainly by regulating the Crz1p/Tcn1 transcription factor. Here, we cloned the fission yeast prz1(+) gene, which encodes a zinc finger transcription factor highly homologous to Crz1/Tcn1. Similar to the results in budding yeast, calcineurin dephosphorylated Prz1 and resulted in the trans-location of Prz1 from the cytoplasm to the nucleus. Prz1 expression was stimulated by high extracellular Ca2+ in a calcineurin-dependent fashion. However, unlike in budding yeast, the prz1-null cells did not show any phenotype similar to those previously reported in calcineurin deletion such as aberrant cell morphology, mating defect, or hypersensitivity to Cl-. Instead, the prz1-null cells showed hypersensitivity to Ca2+, consistent with a dramatic decrease in transcription of Pmc1 Ca2+ pump. Interestingly, overexpression of Prz1 did not suppress the Cl- hypersensitivity of calcineurin deletion, and overexpression of Pmp1 MAPK phosphatase suppressed the Cl- hypersensitivity of calcineurin deletion but not the Ca2+ hypersensitivity of prz1 deletion. In addition, mutations in the its2(+)/cps1(+), its8(+), and its10(+)/cdc7(+) genes that showed synthetic lethal genetic interaction with calcineurin deletion did not exhibit synthetic lethality with the prz1 deletion. Our results suggest that calcineurin activates at least two distinct signaling branches, i.e. the Prz1-dependent transcriptional regulation and an unknown mechanism, which functions antagonistically with the Pmk1 MAPK pathway.	Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Div Cardiovasc & Resp Med, Chuo Ku, Kobe, Hyogo 6500017, Japan; Asahi Glass Co Ltd, Res Ctr, ASPEX Div, Kanagawa Ku, Yokohama, Kanagawa 2218755, Japan; Kobe Univ, Sch Med, Fac Hlth Sci, Suma Ku, Kobe, Hyogo 6500142, Japan	Kobe University; Kobe University; AGC Inc; Kobe University	Kuno, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Genome Sci, Div Mol Pharmacol & Pharmacogenom,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	tkuno@med.kobe-u.ac.jp	Tohda, Hideki/H-3162-2013; Tohda, Hideki/O-5132-2019					Cheng H, 2002, MOL BIOL CELL, V13, P2963, DOI 10.1091/mbc.01-09-0463; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; FARCASANU IC, 1995, EUR J BIOCHEM, V232, P712, DOI 10.1111/j.1432-1033.1995.tb20865.x; Fujita M, 2002, GENETICS, V161, P971; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Ishiguro J, 1997, J BACTERIOL, V179, P7653, DOI 10.1128/jb.179.24.7653-7662.1997; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; Lafuente MJ, 1997, FEBS LETT, V420, P39, DOI 10.1016/S0014-5793(97)01486-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Lu YB, 2002, GENES CELLS, V7, P1009, DOI 10.1046/j.1365-2443.2002.00582.x; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MENDOZA I, 1994, J BIOL CHEM, V269, P8792; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MUKAI H, 1991, J BIOCHEM, V110, P402, DOI 10.1093/oxfordjournals.jbchem.a123593; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Sugiura R, 1999, NATURE, V399, P479, DOI 10.1038/20951; Sugiura R, 1998, EMBO J, V17, P140, DOI 10.1093/emboj/17.1.140; Sugiura R, 2002, GENES CELLS, V7, P619, DOI 10.1046/j.1365-2443.2002.00557.x; Sugiura R, 2001, CELL MOL LIFE SCI, V58, P278, DOI 10.1007/PL00000855; Toda T, 1996, MOL CELL BIOL, V16, P6752; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Yada T, 2001, J BIOL CHEM, V276, P13579, DOI 10.1074/jbc.M009260200; YOSHIDA T, 1994, J CELL SCI, V107, P1725; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200; Zhang YJ, 2000, J BIOL CHEM, V275, P35600, DOI 10.1074/jbc.M005575200	44	71	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18078	18084		10.1074/jbc.M212900200	http://dx.doi.org/10.1074/jbc.M212900200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637524	hybrid			2022-12-27	WOS:000182838300064
J	Kassavetis, GA; Han, SL; Naji, S; Geiduschek, EP				Kassavetis, GA; Han, SL; Naji, S; Geiduschek, EP			The role of transcription initiation factor IIIB subunits in promoter opening probed by photochemical cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-III; START-SITE SELECTION; OPEN COMPLEX-FORMATION; RESTRICTION-ENDONUCLEASE; PREINITIATION COMPLEX; PHOTOAFFINITY PROBES; PROTEIN INTERACTIONS; ESCHERICHIA-COLI; BINDING PROTEIN; FACTOR TFIIIB	The core transcription initiation factor (TF) IIIB recruits its conjugate RNA polymerase (pol) III to the promoter and also plays an essential role in promoter opening. TFIIIB assembled with certain deletion mutants of its Brf1 and Bdp1 subunits is competent in pol III recruitment, but the resulting preinitiation complex does not open the promoter. Whether Brf1 and Bdp1 participate in opening the promoter by direct DNA interaction (as sigma subunits of bacterial RNA polymerases do) or indirectly by their action on pol III has been approached by site-specific photochemical protein-DNA cross-linking of TFIIIB-pol III-U6 RNA gene promoter complexes. Brf1, Bdp1, and several pol III subunits can be crosslinked to the nontranscribed strand of the U6 promoter at base pair -9/-8 and +2/+3 (relative to the transcriptional start as +1), respectively the upstream and downstream ends of the DNA segment that opens up into the transcription bubble. Cross-linking of Bdp1 and Brf1 is detected at 0 AdegreesC in closed preinitiation complexes and at 30 degreesC in complexes that are partly open, but also it is detected in mutant TFIIIB-pol III-DNA complexes that are unable to open the promoter. In contrast, promoter opening-defective TFIIIB mutants generate significant changes of cross-linking of polymerase subunits. The weight of this evidence argues in favor of an indirect mode of action of TFIIIB in promoter opening.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kassavetis, GA (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.							Andrau JC, 1999, J MOL BIOL, V288, P511, DOI 10.1006/jmbi.1999.2724; Andrau JC, 2001, EUR J BIOCHEM, V268, P5167, DOI 10.1046/j.0014-2956.2001.02445.x; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bartholomew B, 1995, METHOD ENZYMOL, V262, P476; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BARTHOLOMEW B, 1994, J BIOL CHEM, V269, P18090; Brun I, 1997, EMBO J, V16, P5730, DOI 10.1093/emboj/16.18.5730; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Chedin S, 1998, COLD SPRING HARB SYM, V63, P381, DOI 10.1101/sqb.1998.63.381; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Douziech M, 2000, MOL CELL BIOL, V20, P8168, DOI 10.1128/MCB.20.21.8168-8177.2000; Favre A, 1998, J PHOTOCH PHOTOBIO B, V42, P109, DOI 10.1016/S1011-1344(97)00116-4; Flores A, 1999, P NATL ACAD SCI USA, V96, P7815, DOI 10.1073/pnas.96.14.7815; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Grove A, 2002, EMBO J, V21, P704, DOI 10.1093/emboj/21.4.704; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Hahn S, 2000, GENE DEV, V14, P719; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; Helmann JD, 1999, BIOCHEMISTRY-US, V38, P5959, DOI 10.1021/bi990206g; Holstege FCP, 1997, METHODS, V12, P203, DOI 10.1006/meth.1997.0472; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Joazeiro CAP, 1996, GENE DEV, V10, P725, DOI 10.1101/gad.10.6.725; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; Kassavetis GA, 1999, EMBO J, V18, P5042, DOI 10.1093/emboj/18.18.5042; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Kassavetis GA, 1997, MOL CELL BIOL, V17, P5299, DOI 10.1128/MCB.17.9.5299; Kassavetis GA, 2002, EMBO J, V21, P5508, DOI 10.1093/emboj/cdf533; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kim TK, 2000, SCIENCE, V288, P1418, DOI 10.1126/science.288.5470.1418; Kovach MJ, 2002, J BIOL CHEM, V277, P14530, DOI 10.1074/jbc.M108197200; Kumar A, 1998, COLD SPRING HARB SYM, V63, P121, DOI 10.1101/sqb.1998.63.121; Lannutti BJ, 1996, BIOCHEMISTRY-US, V35, P9821, DOI 10.1021/bi960525x; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Nickels BE, 2002, MOL CELL, V10, P611, DOI 10.1016/S1097-2765(02)00648-2; NIKIFOROV TT, 1992, NUCLEIC ACIDS RES, V20, P1209, DOI 10.1093/nar/20.6.1209; Nudler E, 2002, GENES CELLS, V7, P755, DOI 10.1046/j.1365-2443.2002.00563.x; Pardee TS, 1998, J BIOL CHEM, V273, P17859, DOI 10.1074/jbc.273.28.17859; PINTO I, 1994, J BIOL CHEM, V269, P30569; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; RECORD J, 1996, ESCHERICHIA COLI SAL, P792; Roberts JW, 1998, COLD SPRING HARB SYM, V63, P319, DOI 10.1101/sqb.1998.63.319; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Schramm L, 2002, GENE DEV, V16, P2593, DOI 10.1101/gad.1018902; Shah SMA, 1999, J BIOL CHEM, V274, P28736, DOI 10.1074/jbc.274.40.28736; Thorogood H, 1996, BIOCHEMISTRY-US, V35, P8723, DOI 10.1021/bi960230j; THUILLIER V, 1995, EMBO J, V14, P351, DOI 10.1002/j.1460-2075.1995.tb07009.x; Wang ZX, 1997, GENE DEV, V11, P1315, DOI 10.1101/gad.11.10.1315; WHITE RJ, 2002, GENE TRANSCRIPTION M, P113; WHITEHALL SK, 1995, GENE DEV, V9, P2974, DOI 10.1101/gad.9.23.2974; Willis IM, 2002, GENE DEV, V16, P1337, DOI 10.1101/gad.998102	52	21	21	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17912	17917		10.1074/jbc.M300743200	http://dx.doi.org/10.1074/jbc.M300743200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637540	hybrid			2022-12-27	WOS:000182838300041
J	Matsushima-Hibiya, Y; Watanabe, M; Hidari, KIPJ; Miyamoto, D; Suzuki, Y; Kasama, T; Kanazawa, T; Koyama, K; Sugimura, T; Wakabayashi, K				Matsushima-Hibiya, Y; Watanabe, M; Hidari, KIPJ; Miyamoto, D; Suzuki, Y; Kasama, T; Kanazawa, T; Koyama, K; Sugimura, T; Wakabayashi, K			Identification of glycosphingolipid receptors for pierisin-1, a guanine-specific ADP-ribosylating toxin from the cabbage butterfly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING PROTEIN; BOTULINUM TYPE-C; RICIN B-CHAIN; CYTOTOXIC ACTIVITY; MOLECULAR-CLONING; CARCINOMA-CELLS; BINDING; RAPAE; PURIFICATION; GLYCOLIPIDS	Pierisin-1, a cytotoxic protein found naturally in the cabbage butterfly, induces apoptosis of mammalian cells. Our recent studies suggest that pierisin-1 consists of an N-terminal ADP-ribosyltransferase domain, and a C-terminal region that binds to receptors on the surfaces of target cells and incorporates the protein into cells. The present study was undertaken to identify receptors for pierisin-1. The cross-linking and cloning experiments suggested that the proteins on cell membrane had no binding ability to pierisin-1. Inhibitory assays of fractionated lipids from human cervical carcinoma HeLa cells, which are highly sensitive to pierisin-1, indicated neutral glycosphingolipids on the cell surface to show receptor activity. Inhibitory assays and TLC immunostaining using anti-pierisin-1 antibodies demonstrated two neutral glycosphingolipids as active components. Analysis of their structures with glycosphingolipid-specific antibodies and negative secondary ion mass spectrometry identified them as globotriaosylceramide (Gb3) and globotetraosylceramide (Gb4). The receptor activities of Gb3 and Gb4 for pierisin-1 were also confirmed with these authentic compounds. Pierisin-l-insensitive mouse melanoma MEB4 cells were found to lack pierisin-1 receptors, including Gb3 and Gb4, but pretreatment of the cells with glycosphingolipid Gb3 or Gh4 enhanced their sensitivity to pierisin-1. Thus, Gb3 and Gb4 were proven to serve as pierisin-1 receptors. The C-terminal region of pierisin-1 consists of possible lectin domains of a ricin B-chain, containing QXW sequences, which are essential for its structural organization. Alteration of QXW by site-directed mutagenesis caused marked reduction of pierisin-1 cytotoxicity. Thus, our results suggest that pierisin-1 binds to Gb3 and Gb4 receptors at the C-terminal region, in a manner similar to ricin, and then exhibits cytotoxicity after incorporation into the cell.	Natl Canc Ctr, Res Inst, Canc Prevent Div, Chuo Ku, Tokyo 1040045, Japan; Univ Shizuoka, Sch Pharmaceut Sci, Dept Biochem, Shizuoka 4228526, Japan; Tokyo Med & Dent Univ, Instrumental Anal Res Ctr Life Sci, Bunkyo Ku, Tokyo 1138510, Japan	National Cancer Center - Japan; University of Shizuoka; Tokyo Medical & Dental University (TMDU)	Matsushima-Hibiya, Y (corresponding author), Natl Canc Ctr, Res Inst, Canc Prevent Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	yhibiya@gan2.ncc.go.jp		Yasuo, Suzuki/0000-0003-3518-5642				ALMENOFF JS, 1993, MOL MICROBIOL, V8, P865, DOI 10.1111/j.1365-2958.1993.tb01633.x; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Fujinaga Y, 2000, FEBS LETT, V467, P179, DOI 10.1016/S0014-5793(00)01147-9; HAZES B, 1995, NAT STRUCT BIOL, V2, P358, DOI 10.1038/nsb0595-358; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; HIRAI R, 1992, EXP CELL RES, V201, P119, DOI 10.1016/0014-4827(92)90355-C; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Inoue K, 1996, INFECT IMMUN, V64, P1589, DOI 10.1128/IAI.64.5.1589-1594.1996; Inoue K, 1999, MICROBIOL-UK, V145, P2533, DOI 10.1099/00221287-145-9-2533; ITASAKA O, 1983, BIOCHIM BIOPHYS ACTA, V751, P8, DOI 10.1016/0005-2760(83)90250-3; Kanazawa T, 2001, P NATL ACAD SCI USA, V98, P2226, DOI 10.1073/pnas.051628898; Kasama T, 1996, GLYCOCONJUGATE J, V13, P461, DOI 10.1007/BF00731479; Kono T, 1999, CANCER LETT, V137, P75, DOI 10.1016/S0304-3835(98)00346-2; Koyama K, 1996, JPN J CANCER RES, V87, P1259, DOI 10.1111/j.1349-7006.1996.tb03141.x; Matsushima-Hibiya Y, 2000, EUR J BIOCHEM, V267, P5742, DOI 10.1046/j.1432-1327.2000.01640.x; Miyamoto D, 1997, GLYCOCONJUGATE J, V14, P379, DOI 10.1023/A:1018578829997; MURAYAMA K, 1986, CANCER RES, V46, P1395; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; Sandvig K, 1996, PHYSIOL REV, V76, P949, DOI 10.1152/physrev.1996.76.4.949; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; Seppo A, 2000, EUR J BIOCHEM, V267, P3549, DOI 10.1046/j.1432-1327.2000.01383.x; SPHYRIS N, 1995, J BIOL CHEM, V270, P20292, DOI 10.1074/jbc.270.35.20292; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; Takamura-Enya T, 2001, P NATL ACAD SCI USA, V98, P12414, DOI 10.1073/pnas.221444598; Tao Bernard Y., 1994, P69; TSUZUKI K, 1990, INFECT IMMUN, V58, P3173, DOI 10.1128/IAI.58.10.3173-3177.1990; VONDEMBORNE AEGK, 1986, BRIT J HAEMATOL, V63, P35; Watanabe M, 1999, P NATL ACAD SCI USA, V96, P10608, DOI 10.1073/pnas.96.19.10608; Watanabe M, 1998, JPN J CANCER RES, V89, P556, DOI 10.1111/j.1349-7006.1998.tb03297.x; WIEGANDT H, 1992, BIOCHIM BIOPHYS ACTA, V1123, P117, DOI 10.1016/0005-2760(92)90101-Z	31	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9972	9978		10.1074/jbc.M212114200	http://dx.doi.org/10.1074/jbc.M212114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12645583	hybrid			2022-12-27	WOS:000181524000145
J	Van Eck, M; Twisk, J; Hoekstra, M; Van Rij, BT; Van der Lans, CAC; Bos, IST; Kruijt, JK; Kuipers, F; Van Berkel, TJC				Van Eck, M; Twisk, J; Hoekstra, M; Van Rij, BT; Van der Lans, CAC; Bos, IST; Kruijt, JK; Kuipers, F; Van Berkel, TJC			Differential effects of scavenger receptor BI deficiency on lipid metabolism in cells of the arterial wall and in the liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; BILIARY CHOLESTEROL SECRETION; SR-BI; OVEREXPRESSION; EXPRESSION; DISEASE; BINDING; GENE; ATHEROSCLEROSIS; IDENTIFICATION	Scavenger receptor class B, type I (SRBI) is a key regulator of high density lipoprotein (HDL) metabolism. It facilitates the efflux of cholesterol from cells in peripheral tissues to HDL and mediates the selective uptake of cholesteryl esters from HDL in the liver. We investigated the effects of SRBI deficiency in the arterial wall and in the liver using SRBI-deficient mice and wild-type littermates fed a Western-type diet. The SRBI-deficient mice showed massive accumulation of cholesterol-rich HDL in the circulation, reflecting impaired delivery to the liver. Strikingly, SRBI deficiency did not alter hepatic cholesterol ( ester) content nor did it affect the expression of key regulators of hepatic cholesterol homeostasis, including HMG-CoA reductase, the low density lipoprotein receptor, and cholesterol 7alpha-hydroxylase. However, a similar to40% reduction in biliary cholesterol content was observed, and the expression of ABCG8 and ABCG5, ATP half-transporters implicated in the transport of sterols from the liver to the bile, was attenuated by 70 and 35%, respectively. In contrast to the situation in the liver, SRBI deficiency did result in lipid deposition in the aorta and atherosclerosis. Vascular mRNA analysis showed increased expression of inflammatory markers as well as of genes involved in cellular cholesterol homeostasis. Our data show that, although hepatic cholesterol homeostasis is maintained upon feeding a Western-type diet, SRBI deficiency is associated with de-regulation of cholesterol homeostasis in the arterial wall that results in an increased susceptibility to atherosclerosis.	Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, NL-2300 RA Leiden, Netherlands; Univ Groningen Hosp, Dept Pediat, Ctr Liver Digest Metab Dis, NL-9700 RB Groningen, Netherlands	Leiden University; Leiden University - Excl LUMC; University of Groningen	Van Eck, M (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Amsterdam Ctr Drug Res, Div Biopharmaceut, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	m.eck@LACDR.LeidenUniv.nl	Van Berkel, Theo/ABD-7677-2021	van Eck, Miranda/0000-0003-3936-3194; Kuipers, Folkert/0000-0003-2518-737X; Hoekstra, Menno/0000-0001-7463-2893				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Braun A, 2002, CIRC RES, V90, P270, DOI 10.1161/hh0302.104462; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Chinetti G, 2000, CIRCULATION, V101, P2411, DOI 10.1161/01.CIR.101.20.2411; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; GAMBLE W, 1978, J LIPID RES, V19, P1068; Glomset J A, 1980, Adv Intern Med, V25, P91; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Hirano K, 1999, CIRC RES, V85, P108; Ito T, 2000, CIRCULATION, V102, P311; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Ji Y, 1999, J BIOL CHEM, V274, P33398, DOI 10.1074/jbc.274.47.33398; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817; Kosek AB, 1999, BIOCHEM BIOPH RES CO, V258, P548, DOI 10.1006/bbrc.1999.0690; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Lee MH, 2001, CURR OPIN LIPIDOL, V12, P141, DOI 10.1097/00041433-200104000-00007; Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; Mardones P, 2001, J LIPID RES, V42, P170; PIETERS MN, 1991, BIOCHEM J, V280, P359, DOI 10.1042/bj2800359; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Reardon CA, 2001, CURR OPIN LIPIDOL, V12, P167, DOI 10.1097/00041433-200104000-00010; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; RHOADS GG, 1976, NEW ENGL J MED, V294, P293, DOI 10.1056/NEJM197602052940601; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL DW, 1992, CARDIOVASC DRUG THER, V6, P103, DOI 10.1007/BF00054556; Schmitz G, 2001, J LIPID RES, V42, P1513; SCHWARTZ CC, 1978, SCIENCE, V200, P62, DOI 10.1126/science.204996; SETCHELL KDR, 1983, J LIPID RES, V24, P1085; Silver DL, 2001, J BIOL CHEM, V276, P25287, DOI 10.1074/jbc.M101726200; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Van Lenten BJ, 2001, TRENDS CARDIOVAS MED, V11, P155, DOI 10.1016/S1050-1738(01)00095-0; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Wellington CL, 2002, LAB INVEST, V82, P273, DOI 10.1038/labinvest.3780421; Yeh YC, 2002, ATHEROSCLEROSIS, V161, P95, DOI 10.1016/S0021-9150(01)00642-6; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	50	184	185	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2003	278	26					23699	23705		10.1074/jbc.M211233200	http://dx.doi.org/10.1074/jbc.M211233200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	692AR	12639961	hybrid, Green Published			2022-12-27	WOS:000183638600063
J	Filomatori, CV; Rega, AF				Filomatori, CV; Rega, AF			On the mechanism of activation of the plasma membrane Ca2+-ATPase by ATP and acidic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANES; STEADY-STATE PHOSPHORYLATION; HUMAN-ERYTHROCYTE-MEMBRANES; SARCOPLASMIC-RETICULUM; ADENOSINE-TRIPHOSPHATASE; CALCIUM-PUMP; CA2+ PUMP; PARTIAL PROTEOLYSIS; CATALYTIC CYCLE; CALMODULIN	The activation of purified and phospholipid-depleted plasma membrane Ca2+-ATPase by phospholipids and ATP was studied. Enzyme activity increased with [ ATP] along biphasic curves representing the sum of two Michaelis-Menten equations. Acidic phospholipids ( phosphatidylinositol ( PI) and phosphatidylserine ( PS)) increased V-max without affecting apparent affinities of the ATP sites. In the presence of 20 muM ATP, phosphorylation of the enzyme preincubated with Ca2+ (CaE1) was very fast (k(app) congruent to 400 s(-1)). v(o) of phosphorylation of CaE1 increased with [ ATP] along a Michaelis-Menten curve (K-m of 15 muM) and was phospholipid-independent. Without Ca2+ preincubation (E-1 + E-2), v(o) of phosphorylation was also phospholipid-independent, but was slower and increased with [ATP] along biphasic curves. The high affinity component reflected rapid phosphorylation of CaE1, the low affinity component the E-2 --> E-1 shift, which accelerated to a rate higher than that of the ATPase activity when ATP was bound to the regulatory site. Dephosphorylation of EP did not occur without ATP. Dephosphorylation increased along a biphasic curve with increasing [ ATP], showing that ATP accelerated dephosphorylation independently of phospholipid. PI, but not phosphatidylethanolamine ( PE), accelerated dephosphorylation even in the absence of ATP. k(app) for dephosphorylation was 57 s(-1) at 0 muM ATP; that rate was further increased by ATP. Steady-state [EP] x k(app) for dephosphorylation varied with [ATP], and matched the Ca2+-ATPase activity measured under the same conditions. Apparently, the catalytic cycle is rate-limited by dephosphorylation. Acidic phospholipids stimulate Ca2+-ATPase activity by accelerating dephosphorylation, while ATP accelerates both dephosphorylation and the conformational change from E-2 to E-1, further stimulating the ATPase activity.	Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires	Rega, AF (corresponding author), Univ Buenos Aires, Fac Farm & Bioquim, Inst Quim & Fisicoquim Biol, Junin 956, RA-1113 Buenos Aires, DF, Argentina.	rega@qb.ffyb.uba.ar	FILOMATORI, Claudia/W-9924-2019					ADAMO HP, 1990, J BIOL CHEM, V265, P3789; ADAMO HP, 1988, J BIOL CHEM, V263, P17548; Bredeston LM, 2002, BIOCHEM J, V361, P355, DOI 10.1042/0264-6021:3610355; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CARIDE AJ, 1982, BIOCHIM BIOPHYS ACTA, V689, P421, DOI 10.1016/0005-2736(82)90298-X; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; Cornelius F, 2001, J BIOENERG BIOMEMBR, V33, P415, DOI 10.1023/A:1010671607911; Dalton KA, 1998, BIOCHEM J, V329, P637; Echarte MM, 2001, ANAL BIOCHEM, V289, P267, DOI 10.1006/abio.2000.4950; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; FROEHLICH JP, 1976, J BIOL CHEM, V251, P2186; FROHELICH JP, 1997, ANN NY ACAD SCI, V834, P280; GIETZEN K, 1980, BIOCHEM J, V189, P81, DOI 10.1042/bj1890081; GLYNN IM, 1964, BIOCHEM J, V90, P147, DOI 10.1042/bj0900147; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; HERSCHER CJ, 1994, J BIOL CHEM, V269, P10400; Hua SM, 2002, BIOCHEMISTRY-US, V41, P2264, DOI 10.1021/bi015684h; IKEMOTO N, 1984, J BIOL CHEM, V259, P1790; INESI G, 1980, J BIOL CHEM, V255, P3025; JOHANNSSON A, 1981, BIOCHIM BIOPHYS ACTA, V641, P416, DOI 10.1016/0005-2736(81)90498-3; KOSKOSICKA D, 1986, J BIOL CHEM, V261, P3333; LEHOTSKY J, 1991, BIOCHIM BIOPHYS ACTA, V1105, P118; Levi V, 2000, J MEMBRANE BIOL, V173, P215, DOI 10.1007/s002320001021; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARDH S, 1974, BIOCHIM BIOPHYS ACTA, V350, P473, DOI 10.1016/0005-2744(74)90523-3; MUALEM S, 1979, NATURE, V277, P238, DOI 10.1038/277238a0; NEET KE, 1977, ARCH BIOCHEM BIOPHYS, V178, P588, DOI 10.1016/0003-9861(77)90230-2; NIGGLI V, 1981, J BIOL CHEM, V256, P8588; PENNISTON JT, 1988, METHOD ENZYMOL, V157, P340; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIKULA S, 1991, BIOCHIM BIOPHYS ACTA, V1061, P206, DOI 10.1016/0005-2736(91)90286-H; REGA AF, 1975, J MEMBRANE BIOL, V22, P313, DOI 10.1007/BF01868177; RICHARDS DE, 1978, BIOCHIM BIOPHYS ACTA, V511, P194, DOI 10.1016/0005-2736(78)90313-9; RICHARDS DE, 1977, J MEMBRANE BIOL, V35, P125, DOI 10.1007/BF01869944; ROBINSON JD, 1976, BIOCHIM BIOPHYS ACTA, V429, P1006, DOI 10.1016/0005-2744(76)90345-4; RONNER P, 1977, ARCH BIOCHEM BIOPHYS, V179, P578, DOI 10.1016/0003-9861(77)90146-1; ROSSI JPFC, 1989, BIOCHIM BIOPHYS ACTA, V996, P153, DOI 10.1016/0167-4838(89)90241-0; ROSSI JPFC, 1986, BIOCHIM BIOPHYS ACTA, V858, P21, DOI 10.1016/0005-2736(86)90287-7; SCHWARZBAUM PJ, 1995, BBA-BIOMEMBRANES, V1233, P33, DOI 10.1016/0005-2736(94)00229-I; SCOFANO HM, 1979, J BIOL CHEM, V254, P227; STARLING AP, 1995, J BIOL CHEM, V270, P14467, DOI 10.1074/jbc.270.24.14467; STEINBERG M, 1989, J BIOL CHEM, V264, P27726; VARSANYI M, 1983, EMBO J, V2, P1543, DOI 10.1002/j.1460-2075.1983.tb01621.x; VERMA AK, 1984, BIOCHEMISTRY-US, V23, P5010, DOI 10.1021/bi00316a028; WHEELER KP, 1975, BIOCHEM J, V146, P729, DOI 10.1042/bj1460729	45	46	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22265	22271		10.1074/jbc.M302657200	http://dx.doi.org/10.1074/jbc.M302657200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12660230	hybrid			2022-12-27	WOS:000183503900013
J	Plambeck, CA; Kwan, AHY; Adams, DJ; Westman, BJ; van der Weyden, L; Medcalf, RL; Morris, BJ; Mackay, JP				Plambeck, CA; Kwan, AHY; Adams, DJ; Westman, BJ; van der Weyden, L; Medcalf, RL; Morris, BJ; Mackay, JP			The structure of the zinc finger domain from human splicing factor ZNF265 fold	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRANDED-RNA-BINDING; HIV REV PEPTIDE; PROTEIN-KINASE; TRANSCRIPTION FACTOR; SR PROTEINS; RECOGNITION; GENE; DROSOPHILA; QUALITY; SITE	Identification of the protein domains that are responsible for RNA recognition has lagged behind the characterization of protein- DNA interactions. However, it is now becoming clear that a range of structural motifs bind to RNA and their structures and molecular mechanisms of action are beginning to be elucidated. In this report, we have expressed and purified one of the two putative RNA- binding domains from ZNF265, a protein that has been shown to bind to the spliceosomal components U1- 70K and U2AF(35) and to direct alternative splicing. We show that this domain, which contains four highly conserved cysteine residues, forms a stable, monomeric structure upon the addition of 1 molar eq of Zn( II). Determination of the solution structure of this domain reveals a conformation comprising two stacked beta- hairpins oriented at similar to80degrees to each other and sandwiching the zinc ion; the fold resembles the zinc ribbon class of zinc- binding domains, although with one less beta- strand than most members of the class. Analysis of the structure reveals a striking resemblance to known RNA-binding motifs in terms of the distribution of key surface residues responsible for making RNA contacts, despite a complete lack of structural homology. Furthermore, we have used an RNA gel shift assay to demonstrate that a single crossed finger domain from ZNF265 is capable of binding to an RNA message. Taken together, these results define a new RNA- binding motif and should provide insight into the functions of the > 100 uncharacterized proteins in the sequence data bases that contain this domain.	Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ Sydney, Basic & Clin Genom Lab, Sch Med Sci, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Monash Univ, Dept Med, Box Hill Hosp, Box Hill, Vic 3128, Australia	University of Sydney; University of Sydney; University of Sydney; Box Hill Hospital; Monash University	Mackay, JP (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia.	j.mackay@mmb.usyd.edu.au	van der Weyden, Louise/AAV-5711-2021; Medcalf, Robert L/E-9632-2011; Mackay, Joel/D-6834-2011	van der Weyden, Louise/0000-0002-0645-1879; Mackay, Joel/0000-0001-7508-8033; Adams, David/0000-0001-9490-0306; Kwan, Ann/0000-0002-1506-2226				Adams DJ, 2001, J CELL BIOL, V154, P25, DOI 10.1083/jcb.200010059; Adams DJ, 2000, CYTOGENET CELL GENET, V88, P68, DOI 10.1159/000015487; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CLARKE PA, 1995, RNA, V1, P7; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DELANEY SJ, 1991, P NATL ACAD SCI USA, V88, P7214, DOI 10.1073/pnas.88.16.7214; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; FASANO L, 1991, CELL, V64, P63, DOI 10.1016/0092-8674(91)90209-H; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; FU XD, 1995, RNA, V1, P663; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hall KB, 2002, CURR OPIN STRUC BIOL, V12, P283, DOI 10.1016/S0959-440X(02)00323-8; Hayes DB, 1994, SEDNTERP INTERPRETAT; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Karginova EA, 1997, AM J PHYSIOL-RENAL, V273, pF731, DOI 10.1152/ajprenal.1997.273.5.F731; KLINE AD, 1988, J MOL BIOL, V204, P675, DOI 10.1016/0022-2836(88)90364-6; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; Ladomery M, 2000, GENE, V256, P293, DOI 10.1016/S0378-1119(00)00375-9; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Linge JP, 1999, J BIOMOL NMR, V13, P51, DOI 10.1023/A:1008365802830; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Markus MA, 1997, NAT STRUCT BIOL, V4, P70, DOI 10.1038/nsb0197-70; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Nakano M, 1998, GENE, V225, P59, DOI 10.1016/S0378-1119(98)00536-8; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Nilges M, 1997, FOLD DES, V2, pS53, DOI 10.1016/S1359-0278(97)00064-3; Patel RC, 1996, J BIOL CHEM, V271, P25657, DOI 10.1074/jbc.271.41.25657; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; Scanlon MJ, 1997, STRUCTURE, V5, P1585, DOI 10.1016/S0969-2126(97)00307-9; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Searles MA, 2000, J MOL BIOL, V301, P47, DOI 10.1006/jmbi.2000.3946; Singh BB, 1999, J BIOL CHEM, V274, P37370, DOI 10.1074/jbc.274.52.37370; SZYPERSKI T, 1992, J MAGN RESON, V99, P552, DOI 10.1016/0022-2364(92)90209-P; TAN RY, 1994, BIOCHEMISTRY-US, V33, P14579, DOI 10.1021/bi00252a025; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0	68	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22805	22811		10.1074/jbc.M301896200	http://dx.doi.org/10.1074/jbc.M301896200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12657633	hybrid			2022-12-27	WOS:000183503900084
J	Maton, G; Thibier, C; Castro, A; Lorca, T; Prigent, C; Jessus, C				Maton, G; Thibier, C; Castro, A; Lorca, T; Prigent, C; Jessus, C			Cdc2-cyclin B triggers H3 kinase activation of Aurora-A in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CELL-DIVISION; CHROMOSOME SEGREGATION; MEIOTIC MATURATION; CAENORHABDITIS-ELEGANS; SIGNALING PATHWAY; LAEVIS OOCYTES; MESSENGER-RNA; METAPHASE-I; HISTONE H3	Xenopus oocytes are arrested in meiotic prophase I and resume meiotic divisions in response to progesterone. Progesterone triggers activation of M- phase promoting factor ( MPF) or Cdc2- cyclin B complex and neosynthesis of Mos kinase, responsible for MAPK activation. Both Cdc2 and MAPK activities are required for the success of meiotic maturation. However, the signaling pathway induced by progesterone and leading to MPF activation is poorly understood, and most of the targets of both Cdc2 and MAPK in the oocyte remain to be determined. Aurora- A is a Ser/ Thr kinase involved in separation of centrosomes and in spindle assembly during mitosis. It has been proposed that in Xenopus oocytes Aurora- A could be an early component of the progesterone-transduction pathway, acting through the regulation of Mos synthesis upstream Cdc2 activation. We addressed here the question of Aurora- A regulation during meiotic maturation by using new in vitro and in vivo experimental approaches. We demonstrate that Cdc2 kinase activity is necessary and sufficient to trigger both Aurora- A phosphorylation and kinase activation in Xenopus oocyte. In contrast, these events are independent of the Mos/ MAPK pathway. Aurora- A is phosphorylated in vivo at least on three residues that regulate differentially its kinase activity. Therefore, Aurora-A is under the control of Cdc2 in the Xenopus oocyte and could be involved in meiotic spindle establishment.	Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, F-75252 Paris 05, France; Ctr Rech Biochim Macromol, CNRS, UPR 1086, F-34293 Montpellier 5, France; Univ Rennes 1, Grp Cycle Cellulaire, UMR 6061, CNRS,IFR 97, F-34317 Rennes, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Rennes	Jessus, C (corresponding author), Univ Paris 06, Dev Biol Lab, UMR 7622, CNRS, Boite 24,4 Pl Jussieu, F-75252 Paris 05, France.	jessus@ccr.jussieu.fr	CASTRO, ANNA/F-4350-2010	CASTRO, ANNA/0000-0002-3655-1352; Lorca, Thierry/0000-0003-2007-8924				ANDERSON CW, 1973, J VIROL, V12, P241, DOI 10.1128/JVI.12.2.241-252.1973; Andresson T, 1998, EMBO J, V17, P5627, DOI 10.1093/emboj/17.19.5627; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOUVET P, 1994, MOL CELL BIOL, V14, P1893, DOI 10.1128/MCB.14.3.1893; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; Castro A, 2003, J BIOL CHEM, V278, P2236, DOI 10.1074/jbc.M207894200; CHAN CSM, 1993, GENETICS, V135, P677; De Smedt V, 2002, J BIOL CHEM, V277, P28592, DOI 10.1074/jbc.M202742200; Dupre A, 2002, EMBO J, V21, P4026, DOI 10.1093/emboj/cdf400; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; ERIKSON E, 1989, J BIOL CHEM, V264, P19577; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fisher DL, 1999, DEVELOPMENT, V126, P4537; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Frank-Vaillant M, 1999, MOL BIOL CELL, V10, P3279, DOI 10.1091/mbc.10.10.3279; Frank-Vaillant M, 2000, J CELL SCI, V113, P1127; Frank-Vaillant M, 2001, DEV BIOL, V231, P279, DOI 10.1006/dbio.2000.0142; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; HACCARD O, 1993, MOL REPROD DEV, V36, P96, DOI 10.1002/mrd.1080360114; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hochegger H, 2001, DEVELOPMENT, V128, P3795; Hsu JY, 2000, CELL, V102, P279, DOI 10.1016/S0092-8674(00)00034-9; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; HUCHON D, 1981, REPROD NUTR DEV, V21, P135, DOI 10.1051/rnd:19810112; Jessus C, 1995, Prog Cell Cycle Res, V1, P215; JESSUS C, 1993, COMP BIOCHEM PHYS A, V106, P431, DOI 10.1016/0300-9629(93)90236-W; JESSUS C, 1986, BIOL CELL, V56, P113, DOI 10.1111/j.1768-322X.1986.tb00448.x; JESSUS C, 1987, J CELL SCI, V87, P705; Karaiskou A, 1999, J CELL SCI, V112, P3747; Karaiskou A, 1998, EXP CELL RES, V244, P491, DOI 10.1006/excr.1998.4220; Karaiskou A, 2001, BIOL CELL, V93, P35, DOI 10.1016/S0248-4900(01)01126-1; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; LORCA T, 1992, FEBS LETT, V306, P90, DOI 10.1016/0014-5793(92)80844-7; MALLER J, 1977, DEV BIOL, V58, P295, DOI 10.1016/0012-1606(77)90093-8; MALLER JL, 1977, J BIOL CHEM, V252, P1712; MALLER JL, 1993, MOL CELL BIOCHEM, V128, P267, DOI 10.1007/BF01076777; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Roghi C, 1998, J CELL SCI, V111, P557; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Scrittori L, 2001, J BIOL CHEM, V276, P30002, DOI 10.1074/jbc.M102701200; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	61	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21439	21449		10.1074/jbc.M300811200	http://dx.doi.org/10.1074/jbc.M300811200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12670933	hybrid, Green Published			2022-12-27	WOS:000183354200018
J	Breukink, E; van Heusden, HE; Vollmerhaus, PJ; Swiezewska, E; Brunner, L; Walker, S; Heck, AJR; de Kruijff, B				Breukink, E; van Heusden, HE; Vollmerhaus, PJ; Swiezewska, E; Brunner, L; Walker, S; Heck, AJR; de Kruijff, B			Lipid II is an intrinsic component of the pore induced by nisin in bacterial membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL BIOSYNTHESIS; ESCHERICHIA-COLI; PEPTIDOGLYCAN; PRECURSOR; BINDING; SPECIFICITY; PROXIMITY; VESICLES	The peptidoglycan layers surrounding bacterial membranes are essential for bacterial cell survival and provide an important target for antibiotics. Many antibiotics have mechanisms of action that involve binding to Lipid II, the prenyl chain-linked donor of the peptidoglycan building blocks. One of these antibiotics, the pore-forming peptide nisin uses Lipid II as a receptor molecule to increase its antimicrobial efficacy dramatically. Nisin is the first example of a targeted membrane-permeabilizing peptide antibiotic. However, it was not known whether Lipid II functions only as a receptor to recruit nisin to bacterial membranes, thus increasing its specificity for bacterial cells, or whether it also plays a role in pore formation. We have developed a new method to produce large amounts of Lipid II and variants thereof so that we can address the role of the lipid-linked disaccharide in the activity of nisin. We show here that Lipid II is not only the receptor for nisin but an intrinsic component of the pore formed by nisin, and we present a new model for the pore complex that includes Lipid II.	Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, NL-3584 CH Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Biomol Mass Spectrometry, NL-3584 CA Utrecht, Netherlands; Univ Utrecht, Utrecht Inst Pharmaceut Sci, NL-3584 CA Utrecht, Netherlands; Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Utrecht University; Utrecht University; Utrecht University; Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; Princeton University	Breukink, E (corresponding author), Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, Ctr Biomembranes & Lipid Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Heck, Albert/D-7098-2011; Breukink, Eefjan/I-3039-2016	Heck, Albert/0000-0002-2405-4404; Breukink, Eefjan/0000-0002-7311-0660; Swiezewska, Ewa/0000-0002-3439-8948				BETCHERLANGE SL, 1978, J BIOL CHEM, V253, P3757; Breukink E, 2000, BIOCHEMISTRY-US, V39, P10247, DOI 10.1021/bi000915q; Breukink E, 1999, SCIENCE, V286, P2361, DOI 10.1126/science.286.5448.2361; Breukink E, 1997, BIOCHEMISTRY-US, V36, P6968, DOI 10.1021/bi970008u; Brotz H, 1998, MOL MICROBIOL, V30, P317, DOI 10.1046/j.1365-2958.1998.01065.x; DANILOV LL, 1989, CHEM PHYS LIPIDS, V51, P191, DOI 10.1016/0009-3084(89)90006-6; GALLA HJ, 1980, CHEM PHYS LIPIDS, V27, P199, DOI 10.1016/0009-3084(80)90036-5; Ha S, 2000, PROTEIN SCI, V9, P1045, DOI 10.1110/ps.9.6.1045; Hsu ST, 2002, BIOCHEMISTRY-US, V41, P7670, DOI 10.1021/bi025679t; KOHLRAUSCH U, 1991, FEMS MICROBIOL LETT, V78, P253; KONINGS WN, 1973, J BACTERIOL, V116, P1456, DOI 10.1128/JB.116.3.1456-1465.1973; KUIPERS OP, 1992, J BIOL CHEM, V267, P24340; PALAMARCZYK G, 1980, EUR J BIOCHEM, V105, P517, DOI 10.1111/j.1432-1033.1980.tb04527.x; PLESS DD, 1978, BIOCHIM BIOPHYS ACTA, V529, P21, DOI 10.1016/0005-2760(78)90099-1; Rush JS, 1997, GLYCOBIOLOGY, V7, P315, DOI 10.1093/glycob/7.2.315; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; Schwartz B, 2001, J AM CHEM SOC, V123, P11638, DOI 10.1021/ja0166848; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHELDRICK GM, 1978, NATURE, V271, P223, DOI 10.1038/271223a0; Somerharju P, 2002, CHEM PHYS LIPIDS, V116, P57, DOI 10.1016/S0009-3084(02)00020-8; Swiezewska Ewa, 1994, Acta Biochimica Polonica, V41, P221; van Heijenoort J, 2001, GLYCOBIOLOGY, V11, p25R; van Heusden HE, 2002, BIOCHEMISTRY-US, V41, P12171, DOI 10.1021/bi026090x; VANHEIJENOORT J, 1994, N COMP BIOC, V27, P39; VanNieuwenhze MS, 2002, J AM CHEM SOC, V124, P3656, DOI 10.1021/ja017386d; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; Ye XY, 2001, J AM CHEM SOC, V123, P3155, DOI 10.1021/ja010028q; Zhao M, 1999, BIOCHEMISTRY-US, V38, P7407, DOI 10.1021/bi9906524	28	249	253	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19898	19903		10.1074/jbc.M301463200	http://dx.doi.org/10.1074/jbc.M301463200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12663672	Green Published, hybrid			2022-12-27	WOS:000183078000043
J	Choi, KM; McMahon, LP; Lawrence, JC				Choi, KM; McMahon, LP; Lawrence, JC			Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; SIGNALING PATHWAY; (S/T)P SITES; PROTEIN; INSULIN; IDENTIFICATION; REGULATOR; TOR; ASSOCIATION; ACTIVATION	Mammalian target of rapamycin ( mTOR) is the central element of a signaling pathway involved in the control of mRNA translation and cell growth. The actions of mTOR are mediated in part through the phosphorylation of the eukaryotic initiation factor 4E-binding protein, PHAS-I. In vitro mTOR phosphorylates PHAS-I in sites that control PHAS-I binding to eukaryotic initiation factor 4E; however, whether mTOR directly phosphorylates PHAS-I in cells has been a point of debate. The Arg-Ala-Ile-Pro (RAIP motif) and Phe-Glu-Met-Asp-Ile ( tor signaling motif) sequences found in the NH2- and COOH-terminal regions of PHAS-I, respectively, are required for the efficient phosphorylation of PHAS-I in cells. Here we show that mutations in either motif markedly decreased the phosphorylation of recombinant PHAS-I by mTOR in vitro. Wild-type PHAS-I, but none of the mutant proteins, was coimmunoprecipitated with hemagglutinin-tagged raptor, an mTOR-associated protein, after extracts of cells overexpressing raptor had been supplemented with recombinant PHAS-I proteins. Moreover, raptor overexpression enhanced the phosphorylation of wild-type PHAS-I by mTOR but not the phosphorylation of the mutant proteins. The results not only provide direct evidence that both the RAIP and tor signaling motifs are important for the phosphorylation by mTOR, possibly by allowing PHAS-I binding to raptor, but also support the view that mTOR phosphorylates PHAS-I in cells.	Univ Virginia, Sch Med, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Med, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Lawrence, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jcl3p@virginia.edu			NIDDK NIH HHS [DK28312, DK52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1998, CURR OPIN IMMUNOL, V10, P330, DOI 10.1016/S0952-7915(98)80172-6; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Fadden P, 1997, J BIOL CHEM, V272, P10240; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence J C Jr, 2001, Prog Mol Subcell Biol, V26, P1; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; McMahon LP, 2002, MOL CELL BIOL, V22, P7428, DOI 10.1128/MCB.22.21.7428-7438.2002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Sekulic A, 2000, CANCER RES, V60, P3504; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; Yang DQ, 1999, FEBS LETT, V453, P387, DOI 10.1016/S0014-5793(99)00762-0	37	93	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19667	19673		10.1074/jbc.M301142200	http://dx.doi.org/10.1074/jbc.M301142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12665511	hybrid			2022-12-27	WOS:000183078000015
J	Fenster, SD; Kessels, MM; Qualmann, B; Chung, WJ; Nash, J; Gundelfinger, ED; Garner, CC				Fenster, SD; Kessels, MM; Qualmann, B; Chung, WJ; Nash, J; Gundelfinger, ED; Garner, CC			Interactions between Piccolo and the actin/dynamin-binding protein Abp1 link vesicle endocytosis to presynaptic active zones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; DENDRITIC SPINES; SH3 DOMAINS; SYNAPSES; CYTOSKELETON; CYTOMATRIX; BASSOON; LOCALIZATION	Piccolo is a high molecular weight multi-domain protein shown to be a structural component of the presynaptic CAZ ( cytoskeletal matrix assembled at active zones). These features indicate that Piccolo may act to scaffold proteins involved in synaptic vesicle endo- and exocytosis near their site of action. To test this hypothesis, we have utilized a functional cell-based endocytosis assay and identified the N-terminal proline-rich Q domain in Piccolo as a region that interferes with clathrin-mediated endocytosis. Utilizing the Piccolo Q domain as bait in a yeast two-hybrid screen, we have identified the F-actin-binding protein Abp1 ( also called SH3P7 or HIP55) as a potential binding partner for this domain. The physiological relevance of this interaction is supported by in vitro binding studies, colocalization in nerve terminals, in vivo recruitment studies, and immunoprecipitation experiments. Intriguingly, Abp1 binds to both F-actin and the GTPase dynamin and has been implicated in linking the actin cytoskeleton to clathrin-mediated endocytosis. Our results suggest that Piccolo, as a structural protein of the CAZ, may serve to localize Abp1 at active zones where it can actively participate in creating a functional connection between the dynamic actin cytoskeleton and synaptic vesicle recycling.	Stanford Univ, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, Palo Alto, CA 94304 USA; Univ Alabama Birmingham, Dept Neurobiol, Civitan Int Res Ctr, Birmingham, AL 35294 USA; Leibniz Inst Neurobiol, D-39118 Magdeburg, Germany	Stanford University; University of Alabama System; University of Alabama Birmingham; Leibniz Institut fur Neurobiologie (LIN)	Garner, CC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Nancy Friend Pritzker Lab, 1200 Welch Rd, Palo Alto, CA 94304 USA.	cgarner@stanford.edu		Garner, Craig/0000-0003-1970-5417; Fenster, Steven/0000-0002-4470-8145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P50HD032901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG006569, R01AG012978] Funding Source: NIH RePORTER; NIA NIH HHS [AG 06569-09, AG 12978-02] Funding Source: Medline; NICHD NIH HHS [P30 HD38985-03, P50 HD32901] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altrock WD, 2003, NEURON, V37, P787, DOI 10.1016/S0896-6273(03)00088-6; Bernstein BW, 1998, MOL BRAIN RES, V53, P236, DOI 10.1016/S0169-328X(97)00319-7; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; CasesLanghoff C, 1996, EUR J CELL BIOL, V69, P214; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Colicos MA, 2001, CELL, V107, P605, DOI 10.1016/S0092-8674(01)00579-7; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; Dresbach T, 2001, CELL MOL LIFE SCI, V58, P94, DOI 10.1007/PL00000781; ENGQVISTGOLDSTE.AE, 1999, J CELL BIOL, V154, P1209; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Figueroa C, 2001, J BIOL CHEM, V276, P28219, DOI 10.1074/jbc.M101763200; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; Garner CC, 2002, TRENDS NEUROSCI, V25, P243, DOI 10.1016/S0166-2236(02)02152-5; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Goda Y, 2002, NEURON, V35, P1, DOI 10.1016/S0896-6273(02)00765-1; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Goslin K., 1998, CULTURING NERVE CELL, P339; Gundelfinger ED, 2003, NAT REV MOL CELL BIO, V4, P127, DOI 10.1038/nrm1016; Hibino H, 2002, NEURON, V34, P411, DOI 10.1016/S0896-6273(02)00667-0; HONORE B, 1993, FEBS LETT, V330, P151, DOI 10.1016/0014-5793(93)80262-S; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kessels MM, 2000, MOL BIOL CELL, V11, P393, DOI 10.1091/mbc.11.1.393; Kessels MM, 2002, EMBO J, V21, P6083, DOI 10.1093/emboj/cdf604; Kessels MM, 2001, J CELL BIOL, V153, P351, DOI 10.1083/jcb.153.2.351; Kim S, 2003, J BIOL CHEM, V278, P6291, DOI 10.1074/jbc.M212287200; LANDIS DMD, 1988, NEURON, V1, P201, DOI 10.1016/0896-6273(88)90140-7; Lappalainen P, 1998, MOL BIOL CELL, V9, P1951, DOI 10.1091/mbc.9.8.1951; Larbolette O, 1999, MOL CELL BIOL, V19, P1539; Lin JL, 2001, J BIOL CHEM, V276, P41733, DOI 10.1074/jbc.M103475200; Matus A, 2000, HIPPOCAMPUS, V10, P555, DOI 10.1002/1098-1063(2000)10:5<555::AID-HIPO5>3.0.CO;2-Z; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; MAYER BJ, 1995, CURR BIOL, V5, P364, DOI 10.1016/S0960-9822(95)00073-X; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Ohtsuka T, 2002, J CELL BIOL, V158, P577, DOI 10.1083/jcb.200202083; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Qualmann B, 2000, J CELL BIOL, V148, P1047, DOI 10.1083/jcb.148.5.1047; Qualmann B, 2002, INT REV CYTOL, V220, P93; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Righter K, 1999, J COMP NEUROL, V408, P437, DOI 10.1002/(SICI)1096-9861(19990607)408:3<437::AID-CNE9>3.0.CO;2-5; Rosenmund C, 2002, NEURON, V33, P411, DOI 10.1016/S0896-6273(02)00568-8; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Sparks AB, 1996, NAT BIOTECHNOL, V14, P741, DOI 10.1038/nbt0696-741; Spilker C, 2002, J NEUROSCI, V22, P7331; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; Yamazaki H, 2001, EUR J NEUROSCI, V14, P998, DOI 10.1046/j.0953-816x.2001.01727.x; Zamorano PL, 2001, NEURON, V32, P3, DOI 10.1016/S0896-6273(01)00458-5; Zhai R, 2000, MOL CELL NEUROSCI, V15, P417, DOI 10.1006/mcne.2000.0839; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	65	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20268	20277		10.1074/jbc.M210792200	http://dx.doi.org/10.1074/jbc.M210792200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654920	hybrid			2022-12-27	WOS:000183078000089
J	Fiorentini, C; Gardoni, F; Spano, PF; Di Luca, M; Missale, C				Fiorentini, C; Gardoni, F; Spano, PF; Di Luca, M; Missale, C			Regulation of dopamine D-1 receptor trafficking and desensitization by oligomerization with glutamate N-methyl-D-aspartate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; NMDA RECEPTOR; BASAL GANGLIA; STRIATAL NEURONS; EXPRESSION; SUBUNIT; RAT; NR2A; PHOSPHORYLATION; INTERNALIZATION	Activation of dopamine D-1 receptors is critical for the generation of glutamate-induced long-term potentiation at corticostriatal synapses. In this study, we report that, in striatal neurons, D-1 receptors are co-localized with N-methyl-D-aspartate ( NMDA) receptors in the postsynaptic density and that they co-immunoprecipitate with NMDA receptor subunits from postsynaptic density preparations. Using modified bioluminescence resonance energy transfer, we demonstrate that D-1 and NMDA receptor clustering reflects the existence of direct interactions. The tagged D-1 receptor and NR1 subunit cotransfected in COS-7 cells generated a significant bioluminescence resonance energy transfer signal that was insensitive to agonist stimulation and that did not change in the presence of the NR2B subunit, suggesting that the D-1 receptor constitutively and selectively interacts with the NR1 subunit of the NMDA channel. Oligomerization with the NR1 subunit substantially modified D-1 receptor trafficking. In individually transfected HEK293 cells, NR1 was localized in the endoplasmic reticulum, whereas the D-1 receptor was targeted to the plasma membrane. In cotransfected cells, both the D-1 receptor and NR1 subunit were retained in cytoplasmic compartments. In the presence of the NR2B subunit, the NR1-D-1 receptor complex was translocated to the plasma membrane. These data suggest that D-1 and NMDA receptors are assembled within intracellular compartments as constitutive heteromeric complexes that are delivered to functional sites. Coexpression with NR1 and NR2B subunits also abolished agonist-induced D-1 receptor cytoplasmic sequestration, indicating that oligomerization with the NMDA receptor could represent a novel regulatory mechanism modulating D-1 receptor desensitization and cellular trafficking.	Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, I-25123 Brescia, Italy; Univ Brescia, Ctr Excellence Diagnost & Therapeut Innovat, I-25123 Brescia, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy	University of Brescia; University of Brescia; University of Milan	Missale, C (corresponding author), Univ Brescia, Div Pharmacol, Dept Biomed Sci & Biotechnol, Viale Europa 11, I-25123 Brescia, Italy.	cmissale@med.unibs.it	Missale, Mariacristina/E-6600-2010; Gardoni, Fabrizio/A-3135-2009; Spano, Pier Franco F/J-9944-2016; DiLuca, Monica/A-7632-2012; Spano, Pier Franco A/E-7621-2010	Gardoni, Fabrizio/0000-0003-4598-5563; Spano, Pier Franco F/0000-0002-9906-0964; DiLuca, Monica/0000-0003-2298-615X; 				Aizman O, 2000, NAT NEUROSCI, V3, P226, DOI 10.1038/72929; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bergson C, 1995, J NEUROSCI, V15, P7821; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bernard V, 1998, EUR J NEUROSCI, V10, P3721, DOI 10.1046/j.1460-9568.1998.00380.x; Blank T, 1997, P NATL ACAD SCI USA, V94, P14859, DOI 10.1073/pnas.94.26.14859; Calabresi P, 2000, J NEUROSCI, V20, P8443, DOI 10.1523/JNEUROSCI.20-22-08443.2000; Calabresi P, 1996, TRENDS NEUROSCI, V19, P19, DOI 10.1016/0166-2236(96)81862-5; Caputi A, 1999, EUR J NEUROSCI, V11, P141, DOI 10.1046/j.1460-9568.1999.00414.x; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; COLWELL CS, 1995, J NEUROSCI, V15, P1704, DOI 10.1523/JNEUROSCI.15-03-01704.1995; Dumartin B, 1998, J NEUROSCI, V18, P1650; Flores-Hernandez J, 2002, J NEUROPHYSIOL, V88, P3010, DOI 10.1152/jn.00361.2002; Gardoni F, 1999, FEBS LETT, V456, P394, DOI 10.1016/S0014-5793(99)00985-0; Gardoni F, 1998, J NEUROCHEM, V71, P1733; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; HERSCH SM, 1995, J NEUROSCI, V15, P5222; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Kennedy MB, 2000, SCIENCE, V290, P750, DOI 10.1126/science.290.5492.750; Kerr JND, 2001, J NEUROPHYSIOL, V85, P117, DOI 10.1152/jn.2001.85.1.117; Lamey M, 2002, J BIOL CHEM, V277, P9415, DOI 10.1074/jbc.M111811200; LANDWEHRMEYER GB, 1995, J NEUROSCI, V15, P5297; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Levine MS, 1996, J NEUROSCI, V16, P5870; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McIlhinney RAJ, 1998, NEUROPHARMACOLOGY, V37, P1355, DOI 10.1016/S0028-3908(98)00121-X; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MISSALE C, 1991, J BIOL CHEM, V266, P23392; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Obeso JA, 2000, TRENDS NEUROSCI, V23, pS1, DOI 10.1016/S1471-1931(00)00060-4; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Scott L, 2002, P NATL ACAD SCI USA, V99, P1661, DOI 10.1073/pnas.032654599; Sheng M, 2001, P NATL ACAD SCI USA, V98, P7058, DOI 10.1073/pnas.111146298; SMITH AD, 1990, TRENDS NEUROSCI, V13, P259; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; Tiberi M, 1996, J BIOL CHEM, V271, P3771; YUNG KKL, 1995, NEUROSCIENCE, V65, P709, DOI 10.1016/0306-4522(94)00536-E; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	43	174	180	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20196	20202		10.1074/jbc.M213140200	http://dx.doi.org/10.1074/jbc.M213140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646556	hybrid			2022-12-27	WOS:000183078000080
J	Kawatani, M; Imoto, M				Kawatani, M; Imoto, M			Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; X-L; FAMILY-MEMBERS; MITOCHONDRIAL DYSFUNCTION; YEAST MITOCHONDRIA; CONSERVED DOMAINS; CELL-DEATH; BAX; PROTEIN; HETERODIMERIZATION	To investigate the exact biochemical functions by which Bcl-2 regulates apoptosis, we established a stable human small cell lung carcinoma cell line, Ms-1, overexpressing wild-type human Bcl-2 or various deletion and point mutants thereof, and examined the effect of these Bcl-2 mutants on apoptosis induced by antitumor drugs such as camptothecin. Cytochrome c release, caspase-3(-like) protease activation, and apoptosis induced by antitumor drugs were accelerated by overexpression of Bcl-2 lacking a Bcl-2 homology (BH) 1 domain (Bcl-2/ DeltaBH1), but not by that of BH2, BH3, or BH4 domain-deleted Bcl-2. A similar result was obtained upon the substitution of glycine 145 with alanine in the BH1 domain (Bcl-2/G145A),which failed to interact with either Bax or Bak. Pro-apoptotic Bax and Bak have been known to be activated in response to antitumor drugs, and Bcl-2/ G145A as well as Bcl-2/DeltaBH1 also accelerated Bax- or Bak-induced apoptosis in HEK293T cells. These two mutants still retained the ability to interact with wild-type Bcl-2 and Bcl-x(L), and abrogated the inhibitory effect of wild-type Bcl-2 or Bcl-x(L) on Bax- or Bak-induced apoptosis. In addition, immunoprecipitation studies revealed that Bcl-2/DeltaBH1 and Bcl-2/ G145A interrupted the association between wild-type Bcl-2 and Bax/Bak. Taken together, our results demonstrate that Bcl2/DeltaBH1 or Bcl-2/ G145A acts as a dominant negative of endogenous anti-apoptotic proteins such as Bcl-2 and Bcl-x(L), thereby enhancing antitumor drug-induced apoptosis, and that this dominant negative activity requires both a failure of interaction with Bax and Bak through the BH1 domain of Bcl-2 and retention of the ability to interact with Bcl-2 and Bcl-x(L).	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan	Keio University	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyohi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp		Kawatani, Makoto/0000-0002-9571-4916				Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Choi WS, 2000, J NEUROCHEM, V74, P1621, DOI 10.1046/j.1471-4159.2000.0741621.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Godlewski MM, 2001, ANTI-CANCER DRUG, V12, P607, DOI 10.1097/00001813-200108000-00008; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; KAWATANI M, 2003, IN PRESS EXP CELL RE; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Lee LC, 1996, J BIOL CHEM, V271, P23284, DOI 10.1074/jbc.271.38.23284; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; Mikhailov V, 2001, J BIOL CHEM, V276, P18361, DOI 10.1074/jbc.M100655200; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oh YJ, 1997, MOL BRAIN RES, V51, P133, DOI 10.1016/S0169-328X(97)00229-5; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; StClair EG, 1997, J BIOL CHEM, V272, P29347; Theodorakis P, 2002, CANCER RES, V62, P3373; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Wang HG, 1998, HISTOL HISTOPATHOL, V13, P521, DOI 10.14670/HH-13.521; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	27	38	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19732	19742		10.1074/jbc.M213038200	http://dx.doi.org/10.1074/jbc.M213038200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644466	hybrid			2022-12-27	WOS:000183078000023
J	Pause, A; Kukolj, G; Bailey, M; Brault, M; Do, F; Halmos, T; Lagace, L; Maurice, R; Marquis, M; McKercher, G; Pellerin, C; Pilote, L; Thibeault, D; Lamarre, D				Pause, A; Kukolj, G; Bailey, M; Brault, M; Do, F; Halmos, T; Lagace, L; Maurice, R; Marquis, M; McKercher, G; Pellerin, C; Pilote, L; Thibeault, D; Lamarre, D			An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL PROTEINASE DOMAIN; PEPTIDE-BASED INHIBITORS; CRYSTAL-STRUCTURE; PEPTIDOMIMETIC INHIBITORS; NON-A; IDENTIFICATION; INTERFERON; ASSAY; TRANSLATION; ACTIVATION	The hepatitis C virus (HCV) NS3 protease is essential for polyprotein maturation and viral propagation, and it has been proposed as a suitable target for antiviral drug discovery. An N-terminal hexapeptide cleavage product of a dodecapeptide substrate identified as a weak competitive inhibitor of the NS3 protease activity was optimized to a potent and highly specific inhibitor of the enzyme. The effect of this potent NS3 protease inhibitor was evaluated on replication of subgenomic HCV RNA and compared with interferon-alpha (IFN-alpha), which is currently used in the treatment of HCV-infected patients. Treatment of replicon-containing cells with the NS3 protease inhibitor or IFN-alpha showed a dose-dependent decrease in subgenomic HCV RNA that reached undetectable levels following a 14-day treatment. Kinetic studies in the presence of either NS3 protease inhibitor or IFN-alpha also revealed similar profiles in HCV RNA decay with half-lives of 11 and 14 h, respectively. The finding that an antiviral specifically targeting the NS3 protease activity inhibits HCV RNA replication further validates the NS3 enzyme as a prime target for drug discovery and supports the development of NS3 protease inhibitors as a novel therapeutic approach for HCV infection.	Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Res & Dev, Laval, PQ H7S 2G5, Canada; Boehringer Ingelheim Canada Ltd, Dept Chem, Res & Dev, Laval, PQ H7S 2G5, Canada	Boehringer Ingelheim; Boehringer Ingelheim	Lamarre, D (corresponding author), Boehringer Ingelheim Canada Ltd, Dept Biol Sci, Res & Dev, 2100 Cunard St, Laval, PQ H7S 2G5, Canada.	dlamarre@lav.boehringer-ingelheim.com						Andrews DM, 2002, ORG LETT, V4, P4475, DOI 10.1021/ol027013x; Barbato G, 1999, J MOL BIOL, V289, P371, DOI 10.1006/jmbi.1999.2745; BARTENSCHLAGER R, 1994, J VIROL, V68, P5045, DOI 10.1128/JVI.68.8.5045-5055.1994; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cicero DO, 1999, J MOL BIOL, V289, P385, DOI 10.1006/jmbi.1999.2746; De Francesco R, 2000, CURR TOP MICROBIOL, V242, P149; Dhanak D, 2002, J BIOL CHEM, V277, P38322, DOI 10.1074/jbc.M205566200; Di Bisceglie AM, 1998, LANCET, V351, P351, DOI 10.1016/S0140-6736(97)07361-3; Diamond MS, 2001, VIROLOGY, V289, P297, DOI 10.1006/viro.2001.1114; Dymock BW, 2000, ANTIVIR CHEM CHEMOTH, V11, P79, DOI 10.1177/095632020001100201; Frese M, 2001, J GEN VIROL, V82, P723, DOI 10.1099/0022-1317-82-4-723; Fukuda K, 2000, EUR J BIOCHEM, V267, P3685, DOI 10.1046/j.1432-1327.2000.01400.x; Gallinari P, 1999, BIOCHEMISTRY-US, V38, P5620, DOI 10.1021/bi982892+; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Han JQ, 2002, RNA, V8, P512, DOI 10.1017/S1355838202020617; He YP, 2002, VIRAL IMMUNOL, V15, P95, DOI 10.1089/088282402317340260; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; Ingallinella P, 2002, BIOCHEMISTRY-US, V41, P5483, DOI 10.1021/bi025603x; Kim JL, 1996, CELL, V87, P343, DOI 10.1016/S0092-8674(00)81351-3; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; Kumar PKR, 1997, VIROLOGY, V237, P270, DOI 10.1006/viro.1997.8773; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LaPlante SR, 1999, J BIOL CHEM, V274, P18618, DOI 10.1074/jbc.274.26.18618; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Llinas-Brunet M, 2000, BIOORG MED CHEM LETT, V10, P2267, DOI 10.1016/S0960-894X(00)00465-0; Llinas-Brunet M, 1998, BIOORG MED CHEM LETT, V8, P1713, DOI 10.1016/S0960-894X(98)00299-6; LLINASBRUNET M, 1998, Patent No. 6143715; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Martell M, 1999, J CLIN MICROBIOL, V37, P327, DOI 10.1128/JCM.37.2.327-332.1999; MIZUSHIMA H, 1994, J VIROL, V68, P2731, DOI 10.1128/JVI.68.4.2731-2734.1994; Morrison J.F., 1985, COMMENTS MOL CELL BI, V2, P347; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Murray EM, 2003, J VIROL, V77, P2928, DOI 10.1128/JVI.77.5.2928-2935.2003; Ogilvie W, 1997, J MED CHEM, V40, P4113, DOI 10.1021/jm970104t; Poupart MA, 2001, J ORG CHEM, V66, P4743, DOI 10.1021/jo010164d; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; Steinkuhler C, 1998, BIOCHEMISTRY-US, V37, P8899, DOI 10.1021/bi980313v; Taliani M, 1996, ANAL BIOCHEM, V240, P60, DOI 10.1006/abio.1996.0331; Thibeault D, 2001, J BIOL CHEM, V276, P46678, DOI 10.1074/jbc.M108266200; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WANG CY, 1993, J VIROL, V67, P3338, DOI 10.1128/JVI.67.6.3338-3344.1993; Yan YW, 1998, PROTEIN SCI, V7, P837; Yao NH, 1999, STRUCTURE, V7, P1353, DOI 10.1016/S0969-2126(00)80025-8; Zhang RM, 2002, BIOORG MED CHEM LETT, V12, P1005, DOI 10.1016/S0960-894X(02)00102-6	50	81	93	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20374	20380		10.1074/jbc.M210785200	http://dx.doi.org/10.1074/jbc.M210785200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12646587	hybrid			2022-12-27	WOS:000183078000102
J	Mukai, Y; Davie, JK; Dent, SYR				Mukai, Y; Davie, JK; Dent, SYR			Physical and functional interaction of the yeast corepressor Tup1 with mRNA 5 '-triphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXY-TERMINAL DOMAIN; GROUCHO/TRANSDUCIN-LIKE ENHANCER; DEPENDENT PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; CAPPING ENZYME; GLUCOSE REPRESSION; TRANSCRIPTIONAL REPRESSOR; CYC8-TUP1 COREPRESSOR	The Tup1-Ssn6 complex is an important corepressor in Saccharomyces cerevisiae that inhibits transcription through interactions with the basal transcription machinery and by remodeling chromatin. In a two-hybrid screen for factors that interact with the Schizosaccharomyces pombe Tup1 ortholog, Tup11, we isolated the pct1(+) cDNA. The pct1(+) gene encodes an mRNA 5'-triphosphatase, which catalyzes the first step of mRNA capping reactions. Pct1 did not interact with the S. pombe Ssn6 ortholog. In vitro glutathione S-transferase pull-down experiments revealed that Pct1 binds to the WD repeat regions of Tup11 and the functionally redundant Tup12 protein. Similarly, the S. cerevisiae Tup1 protein associates with the mRNA 5'-triphosphatase encoded by the CET1 gene. The highly conserved C-terminal domain of Cet1 interacts with Tup1 in vitro, and Tup1-Ssn6 complexes co-purify with the Cet1 protein, indicating that in vivo interactions also occur between these proteins. Over-expression of CET1 compromised repression of an MFA2-lacZ reporter gene that is subject to Tup1-Ssn6 repression. These genetic and biochemical interactions between Tup1-Ssn6 and Cet1 indicate that the capping enzyme associated with RNA polymerase II is a target of the corepressor complex.	Osaka Univ, Grad Sch Engn, Dept Biotechnol, Suita, Osaka 5650871, Japan; Univ Texas, MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Osaka University; University of Texas System; UTMD Anderson Cancer Center	Mukai, Y (corresponding author), Osaka Univ, Grad Sch Engn, Dept Biotechnol, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.		Dent, Sharon YR/F-1746-2011	Dent, Sharon YR/0000-0002-4824-3269	NIGMS NIH HHS [GM51189] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALASUBRAMANIAN B, 1993, MOL CELL BIOL, V13, P6071, DOI 10.1128/MCB.13.10.6071; BALCIUNAS D, 1995, NUCLEIC ACIDS RES, V23, P4421, DOI 10.1093/nar/23.21.4421; Bone JR, 2001, J BIOL CHEM, V276, P1808, DOI 10.1074/jbc.M008668200; BURKE D, 2000, METHODS YEAST GENETI, P123; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; CHEN SM, 1993, MOL CELL BIOL, V13, P831, DOI 10.1128/MCB.13.2.831; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Conlan RS, 2001, J MOL BIOL, V309, P1007, DOI 10.1006/jmbi.2001.4742; Davie JK, 2002, MOL CELL BIOL, V22, P693, DOI 10.1128/MCB.22.3.693-703.2002; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Edmondson DG, 1998, COLD SPRING HARB SYM, V63, P459, DOI 10.1101/sqb.1998.63.459; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Grbavec D, 1999, BIOCHEM J, V337, P13, DOI 10.1042/0264-6021:3370013; Gromoller A, 2000, EMBO J, V19, P6845, DOI 10.1093/emboj/19.24.6845; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; JIANG YW, 1992, MOL CELL BIOL, V12, P4503, DOI 10.1128/MCB.12.10.4503; JOVE R, 1984, J BIOL CHEM, V259, P8513; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KUCHIN S, 1995, P NATL ACAD SCI USA, V92, P4006, DOI 10.1073/pnas.92.9.4006; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mukai Y, 1999, MOL CELL BIOL, V19, P8461; Myers LC, 2002, MOL CELL, V10, P883, DOI 10.1016/S1097-2765(02)00644-5; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; NEIMAN AM, 1994, P NATL ACAD SCI USA, V91, P3398, DOI 10.1073/pnas.91.8.3398; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Papamichos-Chronakis M, 2000, J BIOL CHEM, V275, P8397, DOI 10.1074/jbc.275.12.8397; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Park SH, 1999, MOL CELL BIOL, V19, P2044; Pei Y, 2001, BMC Microbiol, V1, P29, DOI 10.1186/1471-2180-1-29; Piruat JI, 1997, GENETICS, V147, P1585; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Proft M, 2001, EMBO J, V20, P1123, DOI 10.1093/emboj/20.5.1123; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Redd MJ, 1997, J BIOL CHEM, V272, P11193; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; ROTH SY, 1995, CURR OPIN GENET DEV, V5, P168, DOI 10.1016/0959-437X(95)80004-2; SAKAI A, 1990, MOL CELL BIOL, V10, P4130, DOI 10.1128/MCB.10.8.4130; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH RL, 1995, GENE DEV, V9, P2903, DOI 10.1101/gad.9.23.2903; Song WJ, 1996, MOL CELL BIOL, V16, P115; Sprague ER, 2000, EMBO J, V19, P3016, DOI 10.1093/emboj/19.12.3016; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; TREITEL MA, 1995, P NATL ACAD SCI USA, V92, P3132, DOI 10.1073/pnas.92.8.3132; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; Wahi M, 1998, COLD SPRING HARB SYM, V63, P447, DOI 10.1101/sqb.1998.63.447; WAHI M, 1995, GENETICS, V140, P79; Watson AD, 2000, GENE DEV, V14, P2737, DOI 10.1101/gad.829100; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; ZITOMER RS, 1992, MICROBIOL REV, V56, P1	60	8	8	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18895	18901		10.1074/jbc.M302155200	http://dx.doi.org/10.1074/jbc.M302155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637515	hybrid			2022-12-27	WOS:000182932200025
J	Sazanov, LA; Carroll, J; Holt, P; Toime, L; Fearnley, IM				Sazanov, LA; Carroll, J; Holt, P; Toime, L; Fearnley, IM			A role for native lipids in the stabilization and two-dimensional crystallization of the Escherichia coli NADH-ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; MEMBRANE; PROTEIN; DEHYDROGENASE; RESOLUTION; IDENTIFICATION; MITOCHONDRIA; CONFORMATION	NADH-ubiquinone oxidoreductase ( complex I or NDH-1) was purified from the BL21 strain of Escherichia coli using an improved procedure. The complex was effectively stabilized by addition of divalent cations and lipids, making the preparation suitable for structural studies. The ubiquinone reductase activity of the enzyme was fully restored by addition of native E. coli lipids. Two different two-dimensional crystal forms, with p2 and p3 symmetry, were obtained using lipids containing native E. coli extracts. Analysis of the crystals showed that they are formed by fully intact complex I in an L-shaped conformation. Activity assays and single particle analysis indicated that complex I maintains this structure in detergent solution and does not adopt a different conformation in the active state. Thus, we provide the first experimental evidence that complex I from E. coli has an L-shape in a lipid bilayer and confirm that this is also the case for the active enzyme in solution. This suggests strongly that bacterial complex I exists in an L-shaped conformation in vivo. Our results also indicate that native lipids play an important role in the activation, stabilization and, as a consequence, crystallization of purified complex I from E. coli.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research	Sazanov, LA (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	sazanov@mrc-dunn.cam.ac.uk	Sazanov, Leonid A/ABF-2125-2021	Sazanov, Leonid A/0000-0002-0977-7989				Abramson J, 2001, BBA-PROTEIN STRUCT M, V1544, P1, DOI 10.1016/S0167-4838(00)00241-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bottcher B, 2002, J BIOL CHEM, V277, P17970, DOI 10.1074/jbc.M112357200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun M, 1998, BIOCHEMISTRY-US, V37, P1861, DOI 10.1021/bi971176p; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; David P, 2002, BBA-BIOENERGETICS, V1553, P268, DOI 10.1016/S0005-2728(01)00248-1; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FEARNLEY IM, 1992, BIOCHIM BIOPHYS ACTA, V1140, P105, DOI 10.1016/0005-2728(92)90001-I; FINEL M, 1992, BIOCHEMISTRY-US, V31, P11425, DOI 10.1021/bi00161a022; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; Hatefi Y, 1978, Methods Enzymol, V53, P11; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; KIKUNO R, 1985, FEBS LETT, V189, P85, DOI 10.1016/0014-5793(85)80847-4; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Rigaud JL, 1997, J STRUCT BIOL, V118, P226, DOI 10.1006/jsbi.1997.3848; ROBINSON NC, 1982, BIOCHEMISTRY-US, V21, P184, DOI 10.1021/bi00530a031; Sazanov LA, 2000, BIOCHEMISTRY-US, V39, P7229, DOI 10.1021/bi000335t; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Schapira AHV, 1998, BBA-BIOENERGETICS, V1364, P261, DOI 10.1016/S0005-2728(98)00032-2; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Unden G, 1997, BBA-BIOENERGETICS, V1320, P217, DOI 10.1016/S0005-2728(97)00034-0; Ushakova AV, 1999, BBA-BIOENERGETICS, V1409, P143, DOI 10.1016/S0005-2728(98)00156-X; van Montfort BA, 2002, J MASS SPECTROM, V37, P322, DOI 10.1002/jms.288; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Videira A, 1998, BBA-BIOENERGETICS, V1364, P89, DOI 10.1016/S0005-2728(98)00020-6; Wackwitz B, 1999, MOL GEN GENET, V262, P876, DOI 10.1007/s004380051153; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yagi T, 1998, BBA-BIOENERGETICS, V1364, P125, DOI 10.1016/S0005-2728(98)00023-1	40	68	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19483	19491		10.1074/jbc.M208959200	http://dx.doi.org/10.1074/jbc.M208959200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637579	hybrid			2022-12-27	WOS:000182932200098
J	Erlendsson, LS; Acheson, RM; Hederstedt, L; Le Brun, NE				Erlendsson, LS; Acheson, RM; Hederstedt, L; Le Brun, NE			Bacillus subtilis ResA is a thiol-disulfide oxidoreductase involved in cytochrome c synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOREDOXIN-LIKE PROTEIN; OXIDATION-REDUCTION PROPERTIES; ESCHERICHIA-COLI THIOREDOXIN; BOND FORMATION INVIVO; IN-VIVO; REDOX PROPERTIES; PARACOCCUS-DENITRIFICANS; PERIPLASMIC THIOREDOXIN; ACTIVE-SITE; BIOGENESIS	Covalent attachment of heme to apocytochromes c in bacteria occurs on the outside of the cytoplasmic membrane and requires two reduced cysteinyls at the heme binding site. A constructed ResA-deficient Bacillus subtilis strain was found to lack c-type cytochromes. Cytochrome c synthesis was restored in the mutant by: (i) in trans expression of resA; (ii) deficiency in BdbD, a thioldisulfide oxidoreductase that catalyzes formation of an intramolecular disulfide bond in apocytochrome c after transfer of the polypeptide across the cytoplasmic membrane; or (iii) by addition of the reductant dithiothreitol to the growth medium. In vivo studies of ResA showed that it is membrane-associated with its thioredoxin-like domain on the outside of the cytoplasmic membrane. Analysis of a soluble form of the protein revealed two redox reactive cysteine residues with a midpoint potential of about -340 mV at pH 7. We conclude that ResA, probably together with another thiol-disulfide oxidoreductase, CcdA, is required for the reduction of the cysteinyls in the heme binding site of apocytochrome c.	Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England; Lund Univ, Dept Cell & Organism Biol, SE-22362 Lund, Sweden	University of East Anglia; Lund University	Le Brun, NE (corresponding author), Univ E Anglia, Sch Chem Sci & Pharm, Ctr Met Prot Spect & Biol, Norwich NR4 7TJ, Norfolk, England.	n.le-brun@uea.ac.uk		Le Brun, Nick/0000-0001-9780-4061; Hederstedt, Lars/0000-0002-6650-6296; Erlendsson, Lydur Skuli/0000-0002-6783-3686				ARONSON AI, 1976, BACTERIOL REV, V40, P360, DOI 10.1128/MMBR.40.2.360-402.1976; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Beckett CS, 2000, MOL MICROBIOL, V38, P465, DOI 10.1046/j.1365-2958.2000.02174.x; BENGTSSON J, 1998, J BACTERIOL, V181, P6825; BERGLUND O, 1970, J BIOL CHEM, V245, P6030; CREIGHTON TE, 1980, NATURE, V284, P487, DOI 10.1038/284487a0; Daltrop O, 2002, P NATL ACAD SCI USA, V99, P7872, DOI 10.1073/pnas.132259099; Erlendsson LS, 2002, J BACTERIOL, V184, P1423, DOI 10.1128/JB.184.5.1423-1429.2002; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; FORTNAGEL P, 1968, J BACTERIOL, V95, P1431, DOI 10.1128/JB.95.4.1431-1438.1968; GLEASON FK, 1992, PROTEIN SCI, V1, P609, DOI 10.1002/pro.5560010507; HAIMA P, 1987, MOL GEN GENET, V209, P335, DOI 10.1007/BF00329663; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HEDERSTEDT L, 1986, METHOD ENZYMOL, V126, P399; Hirasawa M, 1999, BIOCHEMISTRY-US, V38, P5200, DOI 10.1021/bi982783v; HOCH JA, 1991, METHOD ENZYMOL, V204, P305; HOFFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166; HOLMGREN A, 1972, J BIOL CHEM, V247, P1992; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; Johansson P, 1999, MICROBIOL-SGM, V145, P529, DOI 10.1099/13500872-145-3-529; Katzen F, 2000, CELL, V103, P769, DOI 10.1016/S0092-8674(00)00180-X; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Krimm I, 1998, EUR J BIOCHEM, V255, P185, DOI 10.1046/j.1432-1327.1998.2550185.x; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Brun NE, 2000, MOL MICROBIOL, V36, P638, DOI 10.1046/j.1365-2958.2000.01883.x; LOFERER H, 1993, EMBO J, V12, P3373, DOI 10.1002/j.1460-2075.1993.tb06011.x; LOFERER H, 1995, J BIOL CHEM, V270, P26178, DOI 10.1074/jbc.270.44.26178; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Meima R, 2002, J BIOL CHEM, V277, P6994, DOI 10.1074/jbc.M111380200; Monika EM, 1997, J MOL BIOL, V271, P679, DOI 10.1006/jmbi.1997.1227; Nakano MM, 2001, J BACTERIOL, V183, P1938, DOI 10.1128/JB.183.6.1938-1944.2001; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Page MD, 1997, MOL MICROBIOL, V24, P977, DOI 10.1046/j.1365-2958.1997.4061775.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PAGE MD, 1990, MOL MICROBIOL, V4, P1181, DOI 10.1111/j.1365-2958.1990.tb00693.x; Pettigrew G.W., 1987, CYTOCHROMES C BIOL A; Reid E, 2001, BIOCHEM J, V355, P51, DOI 10.1042/0264-6021:3550051; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; Roth R, 2001, BBA-BIOENERGETICS, V1504, P352, DOI 10.1016/S0005-2728(00)00265-6; SALAMON Z, 1992, ARCH BIOCHEM BIOPHYS, V299, P193, DOI 10.1016/0003-9861(92)90262-U; Sambrook J., 2001, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schiott T, 2000, J BACTERIOL, V182, P2845, DOI 10.1128/JB.182.10.2845-2854.2000; Schiott T, 1997, J BACTERIOL, V179, P4523, DOI 10.1128/jb.179.14.4523-4529.1997; Schiott T, 1997, J BACTERIOL, V179, P1962, DOI 10.1128/jb.179.6.1962-1973.1997; Setterdahl AT, 2000, BIOCHEMISTRY-US, V39, P10172, DOI 10.1021/bi000663t; Sone M, 1997, J BIOL CHEM, V272, P10349; Sun GF, 1996, J BACTERIOL, V178, P1374, DOI 10.1128/jb.178.5.1374-1385.1996; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDEROOST J, 1991, MOL MICROBIOL, V5, P2063; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yu J, 1998, J BIOL CHEM, V273, P8860, DOI 10.1074/jbc.273.15.8860; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	65	72	78	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17852	17858		10.1074/jbc.M300103200	http://dx.doi.org/10.1074/jbc.M300103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637552	hybrid			2022-12-27	WOS:000182838300034
J	Sano, H; Kane, S; Sano, E; Miinea, CP; Asara, JM; Lane, WS; Garner, CW; Lienhard, GE				Sano, H; Kane, S; Sano, E; Miinea, CP; Asara, JM; Lane, WS; Garner, CW; Lienhard, GE			Insulin-stimulated phosphorylation of a Rab GTPase-activating protein regulates GLUT4 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNIP	Insulin stimulates the rapid translocation of intracellular glucose transporters of the GLUT4 isotype to the plasma membrane in fat and muscle cells. The connections between known insulin signaling pathways and the protein machinery of this membrane-trafficking process have not been fully defined. Recently, we identified a 160-kDa protein in adipocytes, designated AS160, that is phosphorylated by the insulin-activated kinase Akt. This protein contains a GTPase-activating domain (GAP) for Rabs, which are small G proteins required for membrane trafficking. In the present study we have identified six sites of in vivo phosphorylation on AS160. These sites lie in the motif characteristic of Akt phosphorylation, and insulin treatment increased phosphorylation at five of the sites. Expression of AS160 with two or more of these sites mutated to alanine markedly inhibited insulin-stimulated GLUT4 translocation in 3T3-L1 adipocytes. Moreover, this inhibition did not occur when the GAP function in the phosphorylation site mutant was inactivated by a point mutation. These findings strongly indicate that insulin-stimulated phosphorylation of AS160 is required for GLUT4 translocation and that this phosphorylation signals translocation through inactivation of the Rab GAP function.	Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Abilene Christian Univ, Dept Chem, Abilene, TX 79699 USA; Harvard Univ, Microchem & Proteom Anal Facil, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Dartmouth College; Abilene Christian University; Harvard University	Lienhard, GE (corresponding author), Dartmouth Coll Sch Med, Dept Biochem, Vail Bldg, Hanover, NH 03755 USA.	gustav.e.lienhard@dartmouth.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK025336, R56DK042816, R56DK025336, R01DK025336, R01DK042816] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK042816, R01 DK025336, DK25336, DK42816] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cormont M, 2001, MOL MEMBR BIOL, V18, P213; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Dawson K, 2001, BIOCHEM BIOPH RES CO, V287, P445, DOI 10.1006/bbrc.2001.5620; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Wang L, 2003, J CELL BIOL, V160, P365, DOI 10.1083/jcb.200209095; Will E, 2001, J BIOL CHEM, V276, P12135, DOI 10.1074/jbc.M011451200; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yamada E, 2002, DIABETES, V51, pA44; Zeigerer A, 2002, MOL BIOL CELL, V13, P2421, DOI 10.1091/mbc.E02-02-0071; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	14	694	724	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	2003	278	17					14599	14602		10.1074/jbc.C300063200	http://dx.doi.org/10.1074/jbc.C300063200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	672HX	12637568	hybrid			2022-12-27	WOS:000182516100004
J	Apati, A; Janossy, J; Brozik, A; Bauer, PI; Magocsi, M				Apati, A; Janossy, J; Brozik, A; Bauer, PI; Magocsi, M			Calcium induces cell survival and proliferation through the activation of the MAPK pathway in a human hormone-dependent leukemia cell line, TF-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE ERYTHROLEUKEMIA-CELLS; COLONY-STIMULATING FACTOR; REGULATED KINASE PATHWAY; SIGNALING PATHWAY; PROTEIN-KINASE; GENE-EXPRESSION; SARCOPLASMIC-RETICULUM; TYROSINE KINASE; PC12 CELLS; GM-CSF	Survival and proliferation of cells of a human myeloerythroid CD34+ leukemia cell line (TF-1) depend on the presence of granulocyte-macrophage colony-stimulating factor or interleukin-3. Upon hormone withdrawal these cells stop proliferating and undergo apoptotic process. In this report we demonstrate that a controlled increase in [Ca2+](i) induces hormone-independent survival and proliferation of TF-1 cells. We found that moderate elevation of [Ca2+](i) by the addition of cyclopiasonic-acid protected TF1 cells from apoptosis. Furthermore, a higher, but transient elevation of [Ca2+](i) by ionomycin treatment induced cell proliferation. In both cases caspase-3 activity was reduced, and Bcl-2 was upregulated. Higher elevation of [Ca2+](i) by ionomycin induced MEK-dependent biphasic ERK1/2 activation, sufficient to move the cells from G(0)/G(1) to S/M phases. Meanwhile, activation of ERK1/2, phosphorylation of the Elk-1 transcription factor, and, consequently, a substantial elevation of Egr-1 and c-Fos levels and AP-1 DNA binding were observed. Moderate elevation of [Ca2+](i), on the other hand, caused a delayed monophasic activation of ERK1/2 and Elk-1 that was accompanied with only a small increase of Egr-1 and c-Fos levels and AP-1 DNA binding. The specific MEK-1 kinase inhibitor, PD98059, inhibited all the effects of increasing [Ca2+](i), indicating that the MAPK/ERK pathway activation is essential for TF-1 cell survival and proliferation. Based on these results we suggest that the elevation of the [Ca2+](i) may influence the cytokine dependence of hemopoietic progenitors and may contribute to pathological hematopoiesis.	Natl Med Ctr, Dept Cell Metab, Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Semmelweis Univ, Dept Med Biochem, H-1088 Budapest, Hungary	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; Semmelweis University	Magocsi, M (corresponding author), Natl Med Ctr, Dept Cell Metab, Inst Haematol & Immunol, Dioszegi Ut 64, H-1113 Budapest, Hungary.	magocsi@biomembrane.hu	Apáti, Ágota/N-1697-2019	Apáti, Ágota/0000-0003-0380-8139				Adachi T, 2000, J IMMUNOL, V165, P2198, DOI 10.4049/jimmunol.165.4.2198; Alvarado-Moreno JA, 2000, REV INVEST CLIN, V52, P645; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; ASKEW DS, 1991, ONCOGENE, V6, P1915; Barsacchi R, 1999, FEBS LETT, V461, P273, DOI 10.1016/S0014-5793(99)01468-4; BASHEY A, 1994, BLOOD, V83, P949, DOI 10.1182/blood.V83.4.949.bloodjournal834949; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; Chung KC, 2000, EUR J BIOCHEM, V267, P4676, DOI 10.1046/j.1432-1327.2000.01517.x; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Coulon V, 1999, J BIOL CHEM, V274, P30439, DOI 10.1074/jbc.274.43.30439; Cron RQ, 1999, J IMMUNOL, V162, P860; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Egea J, 2000, MOL CELL BIOL, V20, P1931, DOI 10.1128/MCB.20.6.1931-1946.2000; Egea J, 1999, J BIOL CHEM, V274, P75, DOI 10.1074/jbc.274.1.75; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FRANKLIN JL, 1994, PHILOS T ROY SOC B, V345, P251, DOI 10.1098/rstb.1994.0102; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Haverstick DM, 2000, CANCER RES, V60, P1002; Johnson CM, 1997, J NEUROSCI, V17, P6189; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; Katoch SS, 1999, J CELL PHYSIOL, V179, P208, DOI 10.1002/(SICI)1097-4652(199905)179:2<208::AID-JCP11>3.0.CO;2-#; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; Kohn EC, 1996, CANCER RES, V56, P569; Kolonics A, 2001, CELL SIGNAL, V13, P743, DOI 10.1016/S0898-6568(01)00201-7; KOSHIKAWA N, 1992, CANCER RES, V52, P5046; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Liu CT, 1996, P NATL ACAD SCI USA, V93, P11831, DOI 10.1073/pnas.93.21.11831; Lotem J, 1998, P NATL ACAD SCI USA, V95, P4601, DOI 10.1073/pnas.95.8.4601; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; McNeil SE, 1998, J BIOL CHEM, V273, P1114, DOI 10.1074/jbc.273.2.1114; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nguyen HN, 2002, BRAIN RES, V924, P159, DOI 10.1016/S0006-8993(01)03229-2; OKUDA K, 1992, BLOOD, V79, P2880; Palaga T, 1996, EXP CELL RES, V228, P92, DOI 10.1006/excr.1996.0303; Pan Z, 2000, J BIOL CHEM, V275, P19978, DOI 10.1074/jbc.M908329199; Petak I, 1998, CANCER RES, V58, P614; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V148, P1416; Schaefer A, 1998, BIOCHEM J, V335, P505, DOI 10.1042/bj3350505; Schaefer A, 1996, J BIOL CHEM, V271, P13484, DOI 10.1074/jbc.271.23.13484; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Tang H, 2000, J BIOL CHEM, V275, P8389, DOI 10.1074/jbc.275.12.8389; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; WEISINGER G, 1995, BIOCHEM BIOPH RES CO, V214, P530, DOI 10.1006/bbrc.1995.2319; Yuan PX, 2001, J BIOL CHEM, V276, P31674, DOI 10.1074/jbc.M104309200	54	55	57	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9235	9243		10.1074/jbc.M205528200	http://dx.doi.org/10.1074/jbc.M205528200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643264	hybrid			2022-12-27	WOS:000181524000047
J	Godecke, A; Molojavyi, A; Heger, J; Flogel, U; Ding, ZP; Jacoby, C; Schrader, JR				Godecke, A; Molojavyi, A; Heger, J; Flogel, U; Ding, ZP; Jacoby, C; Schrader, JR			Myoglobin protects the heart from inducible nitric-oxide synthase (iNOS)-mediated nitrosative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEART; TUMOR-NECROSIS-FACTOR; DILATED CARDIOMYOPATHY; MITOCHONDRIAL RESPIRATION; CYTOCHROME-OXIDASE; FAILURE; OXYGEN; MICE; EXPRESSION; FLAVOHEMOGLOBIN	The role of inducible nitric-oxide synthase ( iNOS) in the pathogenesis of heart failure is still a matter of controversy. In contrast to early reports favoring a contribution of iNOS because of the negative inotropic and apoptotic potential of NO, more recent clinical and experimental data question a causative role. Here we report that transgenic mice with cardiac specific iNOS-overexpression and concomitant myoglobin-deficiency (tg-iNOS(+)/myo(-/-)) develop signs of heart failure with cardiac hypertrophy, ventricular dilatation, and interstitial fibrosis. In addition, reactivation of the fetal gene expression program typical for heart failure occurs. The structural and molecular changes are accompanied by functional depression such as reduced contractility, ejection fraction, and cardiac energetics. Our findings indicate that excessive cardiac NO formation can cause heart failure; however, under normal circumstances myoglobin constitutes the important barrier that efficiently protects the heart from nitrosative stress.	Univ Dusseldorf, Inst Herz & Kreislaufphysiol, D-40001 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Godecke, A (corresponding author), Univ Dusseldorf, Inst Herz & Kreislaufphysiol, Postfach 101007, D-40001 Dusseldorf, Germany.							Azzawi M, 1999, CARDIOVASC RES, V43, P850, DOI 10.1016/S0008-6363(99)00138-8; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bernstein RD, 1996, CIRC RES, V79, P840, DOI 10.1161/01.RES.79.4.840; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brunner F, 2001, CIRCULATION, V104, P3097, DOI 10.1161/hc5001.101966; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cotton JM, 2001, CIRCULATION, V104, P2318, DOI 10.1161/hc4401.098515; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; DEBELDER AJ, 1995, BRIT HEART J, V74, P426; DECKING UKM, 1995, AM J PHYSIOL-HEART C, V268, pH2460, DOI 10.1152/ajpheart.1995.268.6.H2460; Drexler H, 1998, J AM COLL CARDIOL, V32, P955, DOI 10.1016/S0735-1097(98)00336-2; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Funakoshi H, 2002, CIRC RES, V90, P959, DOI 10.1161/01.RES.0000017632.83720.68; Garry DJ, 1998, NATURE, V395, P905, DOI 10.1038/27681; Godecke A, 1999, P NATL ACAD SCI USA, V96, P10495, DOI 10.1073/pnas.96.18.10495; GOLDSTEIN S, 1995, J AM CHEM SOC, V117, P12078, DOI 10.1021/ja00154a007; Gow AJ, 1998, NATURE, V391, P169, DOI 10.1038/34402; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Heymes C, 1999, CIRCULATION, V99, P3009, DOI 10.1161/01.CIR.99.23.3009; Jurgens KD, 2000, NEWS PHYSIOL SCI, V15, P269; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; Kelm M, 1997, CARDIOVASC RES, V36, P185, DOI 10.1016/S0008-6363(97)00149-1; Kojda G, 1996, CIRC RES, V78, P91, DOI 10.1161/01.RES.78.1.91; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Loke KE, 1999, CIRCULATION, V100, P1291, DOI 10.1161/01.CIR.100.12.1291; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374, DOI 10.1161/01.CIR.85.4.1374; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; OBRIEN PJ, 1992, J MOL CELL CARDIOL, V24, P721, DOI 10.1016/0022-2828(92)93386-X; Paulus WJ, 1997, CIRCULATION, V96, P3436; Paulus WJ, 2001, CIRCULATION, V104, P2260, DOI 10.1161/circ.104.19.2260; PAULUS WJ, 1994, CIRCULATION, V89, P2070, DOI 10.1161/01.CIR.89.5.2070; Pearce LL, 2002, J BIOL CHEM, V277, P13556, DOI 10.1074/jbc.M109838200; SCHUNKERT H, 1990, J CLIN INVEST, V86, P1913, DOI 10.1172/JCI114924; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Taimor G, 2001, FASEB J, V15, P2518, DOI 10.1096/fj.01-0353fje; Weekes J, 1999, ELECTROPHORESIS, V20, P898, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<898::AID-ELPS898>3.0.CO;2-B; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Xie YW, 1996, CIRC RES, V79, P381, DOI 10.1161/01.RES.79.3.381; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhao G, 1999, CORONARY ARTERY DIS, V10, P315, DOI 10.1097/00019501-199907000-00007	43	75	76	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21761	21766		10.1074/jbc.M302573200	http://dx.doi.org/10.1074/jbc.M302573200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12665503	hybrid			2022-12-27	WOS:000183354200057
J	Kopp, DA; Berg, EA; Costello, CE; Lippard, SJ				Kopp, DA; Berg, EA; Costello, CE; Lippard, SJ			Structural features of covalently cross-linked hydroxylase and reductase proteins of soluble methane monooxygenase as revealed by mass spectrometric analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; METHYLOSINUS-TRICHOSPORIUM OB3B; LIGHT-ACTIVATED RHODOPSIN; ELECTRON-TRANSFER; COMPLEX-FORMATION; CRYSTAL-STRUCTURE; COMPONENT-B; BIOLOGICAL OXIDATION; CONTACT SITES; LINKING	Soluble methane monooxygenase requires complexes between its three component proteins for efficient catalysis. The hydroxylase (MMOH) must bind both to the reductase (MMOR) and to the regulatory protein (MMOB) to facilitate oxidation of methane to methanol. Although structures of MMOH, MMOB, and one domain of MMOR have been determined, less geometric information is available for the complexes. To address this deficiency, MMOH and MMOR were cross-linked by a carbodiimide reagent and analyzed by specific proteolysis, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, and capillary high performance liquid chromatography mass spectrometry. Tandem mass spectra conclusively identified two amine-to-carboxylate cross-linked sites involving the alpha subunit of MMOH and the [2Fe-2S] domain of MMOR (MMOR-Fd). In particular, the N terminus of the MMOH alpha subunit forms cross-links to the side chains of MMOR-Fd residues Glu-56 and Glu-91. These Glu residues are close to one another on the surface of MMOR-Fd and >25 Angstrom from the [2Fe-2S] cluster. Because the N terminus of the alpha subunit of MMOH was not located in the crystal structure of MMOH, a detailed structural model of the complex based on the cross-link was precluded; however, a previously proposed binding site for MMOR on MMOH could be ruled out. Based on the cross-linking results, a MMOR E56Q/E91Q double mutant was generated. The mutant retains >80% of MMOR NADH oxidase activity but reduces sMMO activity to similar to65% of the level supported by the wild type reductase. Cross-linking to MMOH was diminished but not abolished in the double mutant, indicating that other residues of MMOR also form cross-links to MMOH.	MIT, Dept Chem, Cambridge, MA 02139 USA; Boston Univ, Sch Med, Mass Spectrometry Resource, Boston, MA 02118 USA	Massachusetts Institute of Technology (MIT); Boston University	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.			Costello, Catherine/0000-0003-1594-5122	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032134, R37GM032134] Funding Source: NIH RePORTER; NCRR NIH HHS [S10-RR15942, P41-RR10888] Funding Source: Medline; NIGMS NIH HHS [GM32134] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alley SC, 2001, J BIOL CHEM, V276, P39340, DOI 10.1074/jbc.M104956200; Balendra S, 2002, BIOCHEMISTRY-US, V41, P2571, DOI 10.1021/bi015714g; Blazyk JL, 2002, BIOCHEMISTRY-US, V41, P15780, DOI 10.1021/bi026757f; Buzy A, 1998, EUR J BIOCHEM, V254, P602, DOI 10.1046/j.1432-1327.1998.2540602.x; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Chang SL, 1999, BIOCHEMISTRY-US, V38, P5799, DOI 10.1021/bi982992f; Chang SL, 2001, BIOCHEMISTRY-US, V40, P9539, DOI 10.1021/bi0103462; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; Elango N, 1997, PROTEIN SCI, V6, P556; FOX BG, 1991, J BIOL CHEM, V266, P540; Furukawa Y, 2002, J AM CHEM SOC, V124, P4008, DOI 10.1021/ja0171916; Gallagher SC, 1999, BIOCHEMISTRY-US, V38, P6752, DOI 10.1021/bi982991n; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; Ishmael FT, 2002, J BIOL CHEM, V277, P20555, DOI 10.1074/jbc.M111951200; Ishmael FT, 2001, J BIOL CHEM, V276, P25236, DOI 10.1074/jbc.M100783200; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P4883, DOI 10.1073/pnas.051632998; Kopp DA, 2001, BIOCHEMISTRY-US, V40, P14932, DOI 10.1021/bi015556t; MacArthur R, 2002, J AM CHEM SOC, V124, P13392, DOI 10.1021/ja0279904; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; Merkx M, 2002, J BIOL CHEM, V277, P5858, DOI 10.1074/jbc.M107712200; Muller EC, 2001, EUR J BIOCHEM, V268, P1837, DOI 10.1046/j.1432-1327.2001.02058.x; Muller J, 2002, BIOCHEMISTRY-US, V41, P42, DOI 10.1021/bi015668k; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Peri S, 2001, TRENDS BIOCHEM SCI, V26, P687, DOI 10.1016/S0968-0004(01)01954-5; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; ROSENZWEIG AC, 1994, ACCOUNTS CHEM RES, V27, P229, DOI 10.1021/ar00044a003; ROSENZWEIG AC, 1995, CHEM BIOL, V2, P409, DOI 10.1016/1074-5521(95)90222-8; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Walters KJ, 1999, P NATL ACAD SCI USA, V96, P7877, DOI 10.1073/pnas.96.14.7877; Whittington DA, 2001, J AM CHEM SOC, V123, P827, DOI 10.1021/ja003240n; Whittington DA, 2001, BIOCHEMISTRY-US, V40, P3476, DOI 10.1021/bi0022487; Whittington DA, 2001, J AM CHEM SOC, V123, P1794, DOI 10.1021/ja0031725; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314	36	13	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20939	20945		10.1074/jbc.M301581200	http://dx.doi.org/10.1074/jbc.M301581200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12660237	hybrid			2022-12-27	WOS:000183230500065
J	Lipschutz, JH; Lingappa, VR; Mostov, KE				Lipschutz, JH; Lingappa, VR; Mostov, KE			The exocyst affects protein synthesis by acting on the translocation machinery of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL LINE; SEC6/8 COMPLEX; SACCHAROMYCES-CEREVISIAE; GLYCOPROTEIN COMPLEX; SECRETORY PROTEINS; MOLECULAR-CLONING; PLASMA-MEMBRANE; SEC61-BETA; EXOCYTOSIS; TRANSPORT	We previously showed that the exocyst complex specifically affected the synthesis and delivery of secretory and basolateral plasma membrane proteins. Significantly, the entire spectrum of secreted proteins was increased when the hSec10 (human Sec10) component of the exocyst complex was overexpressed, suggestive of post-transcriptional regulation (Lipschutz, J. H., Guo, W., O'Brien, L. E., Nguyen, Y. H., Novick, P., and Mostov, K. E. (2000) Mol. Biol. Cell 11, 4259-4275). Here, using an exogenously transfected basolateral protein, the polymeric immunoglobulin receptor (pIgR), and a secretory protein, gp80, we show that pIgR and gp80 protein synthesis and delivery are increased in cells overexpressing Sec10 despite the fact that mRNA levels are unchanged, which is highly indicative of post-transcriptional regulation. To test specificity, we also examined the synthesis and delivery of an exogenous apical protein, CNT1 (concentrative nucleoside transporter 1), and found no increase in CNT1 protein synthesis, delivery, or mRNA levels in cells overexpressing Sec10. Sec10-GFP-overexpressing cell lines were created, and staining was seen in the endoplasmic reticulum. It was demonstrated previously in yeast that high levels of expression of SEB1, the Sec61beta homologue, suppressed sec15-1, an exocyst mutant (Toikkanen, J., Gatti, E., Takei, K., Saloheimo, M., Olkkonen, V. M., Soderlund, H., De Camilli, P., and Keranen, S. (1996) Yeast 12, 425-438). Sec61beta is a member of the Sec61 heterotrimer, which is the main component of the endoplasmic reticulum translocon. By coimmunoprecipitation we show that Sec10, which forms an exocyst subcomplex with Sec15, specifically associates with the Sec61beta component of the translocon and that Sec10 overexpression increases the association of other exocyst complex members with Sec61beta. Proteosome inhibition does not appear to be the mechanism by which increased protein synthesis occurs in the face of equivalent amounts of mRNA. Although the exact mechanism remains to be elucidated, the exocyst/Sec61beta interaction represents an important link between the cellular membrane trafficking and protein synthetic machinery.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Cell & Mol Biol Grad Grp, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biophys, San Francisco, CA 94143 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lipschutz, JH (corresponding author), Univ Penn, Dept Med, Philadelphia, PA 19104 USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; mostov, keith/0000-0002-8123-6247				Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BREITFELD PP, 1989, AM J RESP CELL MOL, V1, P257, DOI 10.1165/ajrcmb/1.4.257; Chapman RE, 1997, CURR BIOL, V7, P850, DOI 10.1016/S0960-9822(06)00373-3; Charron AJ, 2000, J CELL BIOL, V149, P111, DOI 10.1083/jcb.149.1.111; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DEITCHER DL, 1986, J CELL BIOL, V102, P911, DOI 10.1083/jcb.102.3.911; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Gruss OJ, 1999, EUR J BIOCHEM, V260, P785, DOI 10.1046/j.1432-1327.1999.00215.x; GUMBINER B, 1987, AM J PHYSIOL, V253, P749; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Haddad A, 1997, P NATL ACAD SCI USA, V94, P10675, DOI 10.1073/pnas.94.20.10675; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kinch LN, 2002, TRENDS BIOCHEM SCI, V27, P170, DOI 10.1016/S0968-0004(01)02055-2; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; LIPSCHUTZ JH, 2001, CURRENT PROTOCOLS CE; Mangravite LM, 2001, AM J PHYSIOL-RENAL, V280, pF879, DOI 10.1152/ajprenal.2001.280.5.F879; Matern HT, 2001, P NATL ACAD SCI USA, V98, P9648, DOI 10.1073/pnas.171317898; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; O'Brien LE, 2002, NAT REV MOL CELL BIO, V3, P531, DOI 10.1038/nrm859; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; RINDLER MJ, 1979, J CELL BIOL, V81, P635, DOI 10.1083/jcb.81.3.635; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SAMBROOK J, 1989, MOL CLONING LAB MANU, V3; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; SIMONS K, 1985, ANN REV CELL BIOL, V1, P295; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; Toikkanen JH, 2003, J BIOL CHEM, V278, P20946, DOI 10.1074/jbc.M213111200; Tooze SA, 2001, TRENDS CELL BIOL, V11, P116, DOI 10.1016/S0962-8924(00)01907-3; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735	46	76	77	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20954	20960		10.1074/jbc.M213210200	http://dx.doi.org/10.1074/jbc.M213210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665531	hybrid			2022-12-27	WOS:000183230500067
J	Pons, V; Hullin-Matsuda, F; Nauze, M; Barbaras, R; Peres, C; Collet, X; Perret, B; Chap, H; Gassama-Diagne, A				Pons, V; Hullin-Matsuda, F; Nauze, M; Barbaras, R; Peres, C; Collet, X; Perret, B; Chap, H; Gassama-Diagne, A			Enterophilin-1, a new partner of sorting nexin 1, decreases cell surface epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; FAMILY; DOMAIN; ENTEROCYTE; DIFFERENTIATION; LOCALIZATION; DEGRADATION; INTERACTS; COMPLEX; BINDING	We previously described enterophilin-1 (Ent-1), a new intestinal protein bearing an extended leucine zipper and a B30.2 domain. Ent-1 expression is associated with growth arrest and enterocyte differentiation. To investigate the importance of Ent-1 in the differentiation, we performed a yeast two-hybrid screening. We identified sorting nexin 1 ( SNX1) as a novel partner of Ent-1 and confirmed the specificity of interaction by co-immunoprecipitation experiments in mammalian cells. SNX1 is associated with endosomal membranes and triggers the endosome-to-lysosome pathway of epidermal growth factor receptor ( EGFR). We observe by immunofluorescence microscopy that Ent-1 and SNX1 are co-localized on vesicular and tubulovesicular structures, which are different from early endosome antigen 1-containing endosomes. By gel filtration chromatography, we show that Ent-1 and SNX1 co-eluted in macromolecular complexes containing part of EGFR. Furthermore, overexpressed Ent-1 decreases cell surface EGFR. Ent-1 and SNX1 co-overexpression strongly extends EGFR diminution, indicating a synergetic effect of both proteins on cell surface EGFR removal. Interestingly, the increase of endogenous Ent-1 expression correlates with the decrease of EGFR during spontaneous differentiation of Caco-2 cells. We thus propose a role of Ent-1 in the trafficking of EGFR to down-regulate intestinal mitogenic signals, highlighting the mechanisms of cell growth arrest associated with enterocytic differentiation.	Ctr Hosp Univ Toulouse, INSERM,Hop Purpan, Unite 563, Lab Lipoprot & Lipid Mediators, F-31059 Toulouse, France; Univ Toulouse 3, Inst Federatif Rech Claude Preval, IFR 30, F-31062 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Gassama-Diagne, A (corresponding author), Ctr Hosp Univ Toulouse, INSERM,Hop Purpan, Unite 563, Lab Lipoprot & Lipid Mediators, Bat C, F-31059 Toulouse, France.	Ama.Gassama@toulouse.inserm.fr	Peres, Carlos A./ABE-8361-2020; Peres, Carlos A./B-1276-2013; Hullin-Matsuda, Françoise/N-3880-2017; Peres, Carlos Augusto/N-8275-2019; Collet, Xavier/M-6938-2017	Peres, Carlos A./0000-0002-1588-8765; Peres, Carlos A./0000-0002-1588-8765; Hullin-Matsuda, Françoise/0000-0002-6042-2841; PONS, Veronique/0000-0001-5821-8481; Bertrand, PERRET/0000-0001-7568-445X				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENG H, 1974, AM J ANAT, V141, P537, DOI 10.1002/aja.1001410407; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; Gassama-Diagne A, 2001, J BIOL CHEM, V276, P18352, DOI 10.1074/jbc.M009784200; Haft CR, 2000, MOL BIOL CELL, V11, P4105, DOI 10.1091/mbc.11.12.4105; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Kurten RC, 2001, J CELL SCI, V114, P1743; Kuwada SK, 1999, GROWTH FACTORS, V17, P139, DOI 10.3109/08977199909103522; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lin Q, 2002, J BIOL CHEM, V277, P10134, DOI 10.1074/jbc.M110329200; LOEFFLER M, 1993, J THEOR BIOL, V160, P471, DOI 10.1006/jtbi.1993.1031; Loeffler M, 1997, J THEOR BIOL, V186, P41, DOI 10.1006/jtbi.1996.0340; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; PINTO M, 1983, BIOL CELL, V47, P323; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; SCHEVING LA, 1989, J BIOL CHEM, V264, P1735; Schwarz DG, 2002, MOL BIOL CELL, V13, P3588, DOI 10.1091/mbc.E02-03-0145; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; Stockinger W, 2002, EMBO J, V21, P4259, DOI 10.1093/emboj/cdf435; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang YJ, 2002, MOL BIOL CELL, V13, P1965, DOI 10.1091/mbc.E01-11-0131; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757; Zhong Q, 2002, P NATL ACAD SCI USA, V99, P6767, DOI 10.1073/pnas.092142699	28	12	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21155	21161		10.1074/jbc.M211008200	http://dx.doi.org/10.1074/jbc.M211008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657642	hybrid			2022-12-27	WOS:000183230500092
J	Tan, K; Shaw, AL; Madsen, B; Jensen, K; Taylor-Papadimitriou, J; Freemont, PS				Tan, K; Shaw, AL; Madsen, B; Jensen, K; Taylor-Papadimitriou, J; Freemont, PS			Human PLU-1 has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RETINOBLASTOMA BINDING-PROTEIN-2; DNA-BINDING PROTEINS; ONCOGENIC TRANSFORMATION; BREAST-CANCER; QIN PROTEIN; GROUCHO; EXPRESSION; DOMAINS; FAMILY; GENES	PLU-1 is a large ( 1544 amino acids) nuclear protein that is highly expressed in breast cancers and is proposed to function as a regulator of gene expression. A yeast two-hybrid screen using PLU-1 as bait has identified two unrelated PLU-1 interacting proteins, namely brain factor-1 (BF-1) and paired box 9 (PAX9), both of which are developmental transcription factors. BF-1 and PAX9 interact with PLU-1 via a novel conserved sequence motif ( Ala-X-Ala-Ala-X-Val-Pro-X-4-Val-Pro-X(8)Pro, termed the VP motif), because deletion or site-directed mutagenesis of this motif in either protein abolishes PLU-1 interaction in vivo. In a reporter assay system, PLU-1 has potent transcriptional repression activity. BF-1 and PAX9 also represses transcription in the same assay, but co-expression of PLU-1 with BF-1 or PAX9 significantly enhances this repression. Mutation of the PLU-1 binding motifs in BF-1 and PAX9 abolishes the observed PLU-1 co-repression activity. These data support a role for PLU-1 acting as a transcriptional corepressor of two unrelated developmental transcription factors. Because both BF-1 and PAX proteins interact with members of the groucho co-repressor family, it is plausible that PLU-1 has a role in groucho-mediated transcriptional repression.	Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Sci Biol, London SW7 2AZ, England; Lincolns Inn Fields, Mol Struct & Funct Lab, Canc Res UK, London WC2A 3PX, England; Guys Hosp, Breast Canc Biol Grp, Canc Res UK, London SE1 9RT, England	Imperial College London; University of London; Institute of Cancer Research - UK; Cancer Research UK; Cancer Research UK; Guy's & St Thomas' NHS Foundation Trust	Freemont, PS (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Struct Biol, Dept Sci Biol, Armstrong Rd, London SW7 2AZ, England.			Freemont, Paul/0000-0002-5658-8486				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Balciunas D, 2000, TRENDS BIOCHEM SCI, V25, P274, DOI 10.1016/S0968-0004(00)01593-0; Bardos JI, 2000, J BIOL CHEM, V275, P28785, DOI 10.1074/jbc.M001835200; Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644; BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200; Chang HW, 1996, ONCOGENE, V13, P441; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Clissold PM, 2001, TRENDS BIOCHEM SCI, V26, P7, DOI 10.1016/S0968-0004(00)01700-X; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FATTAEY AR, 1993, ONCOGENE, V8, P3149; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Gildea JJ, 2000, GENETICS, V156, P645; Gregory SL, 1996, MOL CELL BIOL, V16, P792; Hardcastle Z, 2000, DEVELOPMENT, V127, P1303; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Hebert JM, 2000, DEV BIOL, V222, P296, DOI 10.1006/dbio.2000.9732; Huh SO, 1999, DEV BIOL, V211, P53, DOI 10.1006/dbio.1999.9303; James P, 1996, GENETICS, V144, P1425; Kashuba V, 2000, EUR J HUM GENET, V8, P407, DOI 10.1038/sj.ejhg.5200474; Keranen SVE, 1999, DEV GENES EVOL, V209, P495, DOI 10.1007/s004270050282; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; MADSEN B, 2002, MECH DEV GENE EXPT P, V2, P275; NEUBUSER A, 1995, DEV BIOL, V170, P701, DOI 10.1006/dbio.1995.1248; Nornes S, 1996, J BIOL CHEM, V271, P26914, DOI 10.1074/jbc.271.43.26914; Palaparti A, 1997, J BIOL CHEM, V272, P26604, DOI 10.1074/jbc.272.42.26604; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; Peters H, 1998, EUR J ORAL SCI, V106, P38, DOI 10.1111/j.1600-0722.1998.tb02151.x; Peters H, 1998, GENE DEV, V12, P2735, DOI 10.1101/gad.12.17.2735; Quadbeck-Seeger C, 2000, MOL MICROBIOL, V38, P154, DOI 10.1046/j.1365-2958.2000.02128.x; Rodriguez C, 2001, J BIOL CHEM, V276, P30224, DOI 10.1074/jbc.M102759200; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Vogt T, 1999, LAB INVEST, V79, P1615; Wilsker D, 2002, CELL GROWTH DIFFER, V13, P95; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yao J, 2001, MOL CELL BIOL, V21, P1962, DOI 10.1128/MCB.21.6.1962-1972.2001	42	74	81	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20507	20513		10.1074/jbc.M301994200	http://dx.doi.org/10.1074/jbc.M301994200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657635	hybrid			2022-12-27	WOS:000183230500010
J	Wright, G; Higgin, JJ; Raines, RT; Steenbergen, C; Murphy, E				Wright, G; Higgin, JJ; Raines, RT; Steenbergen, C; Murphy, E			Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitric-oxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR; NECROSIS-FACTOR-ALPHA; CARDIAC MYOCYTES; HIF-ALPHA; FACTOR-I; EXPRESSION; GENE; 4-HYDROXYLASE; MECHANISM; COLLAGEN	Recently an oxygen-sensing/transducing mechanism has been identified as a family of O-2-dependent prolyl hydroxylase domain-containing enzymes (PHD). In normoxia, PHD hydroxylates a specific proline residue that directs the degradation of constitutively synthesized hypoxia-inducible factor-1alpha. During hypoxia, the cessation of hydroxylation of this proline results in less degradation and thus increases hypoxia-inducible factor-1alpha protein levels. In this study we have examined the consequences of activating the PHD oxygen-sensing pathway in cultured neonatal myocytes using ethyl-3,4 dihydroxybenzoate and dimethyloxalylglycine, inhibitors that, similar to hypoxia, inhibit this family of O-2-dependent PHD enzymes. Increased glucose uptake and enhanced glycolytic metabolism are classical cellular responses to hypoxia. Ethyl-3,4 dihydroxybenzoate treatment of cardiomyocyte cultures for 24 h increased [H-3] deoxy-4-glucose uptake concurrent with an induction of GLUT1 protein. In addition, ethyl-3,4 dihydroxybenzoate, dimethyloxalylglycine, and hypoxia treatments were found to induce protein levels of nitricoxide synthase-2 and heme oxygenase-1, two important cardioregulatory proteins whose expression in response to hypoxic conditions is poorly understood. In conjunction with these changes in gene expression, activation of the PHD oxygen-sensing mechanism was found to preserve myocyte viability in the face of metabolic inhibition with cyanide and 2-deoxyglucose. These results point to a key role for the PHD pathway in the phenotypic changes that are observed in a hypoxic myocyte and may suggest a strategy to pharmacologically induce protection in heart.	NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, Res Triangle Pk, NC 27709 USA; Duke Univ, Sch Med, Dept Pathol, Durham, NC 27710 USA; Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Murphy, E (corresponding author), NIEHS, Lab Signal Transduct, Dept Hlth & Human Serv, NIH, 111 Alexander Dr,Bldg 101,F207, Res Triangle Pk, NC 27709 USA.	murphy1@niehs.nih.gov	Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NHLBI NIH HHS [HL39752, R01 HL039752] Funding Source: Medline; NIAMS NIH HHS [AR44276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039752, R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044276] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; Behrooz A, 1999, NEWS PHYSIOL SCI, V14, P105; Bolli R, 1997, CIRC RES, V81, P1094; Borger DR, 1998, AM J PHYSIOL-HEART C, V274, pH965, DOI 10.1152/ajpheart.1998.274.3.H965; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; EyssenHernandez R, 1996, FEBS LETT, V382, P229, DOI 10.1016/0014-5793(96)00127-5; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Gong PF, 2001, J BIOL CHEM, V276, P27018, DOI 10.1074/jbc.M103658200; Hangaishi M, 2000, BIOCHEM BIOPH RES CO, V279, P582, DOI 10.1006/bbrc.2000.3973; Heusch G, 2000, CIRC RES, V87, P146, DOI 10.1161/01.RES.87.2.146; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jenkins CL, 2002, NAT PROD REP, V19, P49, DOI 10.1039/a903001h; Jung F, 2000, CIRC RES, V86, P319, DOI 10.1161/01.RES.86.3.319; Kacimi R, 1997, CIRCULATION, V96, P1937, DOI 10.1161/01.CIR.96.6.1937; Kalra DK, 2002, CIRCULATION, V105, P1537, DOI 10.1161/01.CIR.0000013846.72805.7E; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Liao RL, 2002, CIRCULATION, V106, P2125, DOI 10.1161/01.CIR.0000034049.61181.F3; MAJAMAA K, 1986, J BIOL CHEM, V261, P7819; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Rouet-Benzineb P, 1999, J MOL CELL CARDIOL, V31, P1697, DOI 10.1006/jmcc.1999.1005; SASAKI T, 1987, J BIOL CHEM, V262, P9397; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; TSCHANK G, 1991, BIOCHEM J, V275, P469, DOI 10.1042/bj2750469; Wang Y, 2002, J MOL CELL CARDIOL, V34, P5, DOI 10.1006/jmcc.2001.1482; Wright G, 2002, AM J PHYSIOL-HEART C, V282, pH872, DOI 10.1152/ajpheart.00256.2001; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	34	54	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20235	20239		10.1074/jbc.M301391200	http://dx.doi.org/10.1074/jbc.M301391200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649278	hybrid			2022-12-27	WOS:000183078000085
J	Lee, TS; Tsai, HL; Chau, LY				Lee, TS; Tsai, HL; Chau, LY			Induction of heme oxygenase-1 expression in murine macrophages is essential for the anti-inflammatory effect of low dose 15-deoxy-Delta(12,14)-prostaglandin J(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; PROTEIN-KINASE PATHWAY; PPAR-GAMMA; CYCLOPENTENONE PROSTAGLANDINS; CARBON-MONOXIDE; GENE-EXPRESSION; FATTY-ACIDS; INHIBITION	15-Deoxy-Delta(12,14)-prostaglandin J(2) (15d-PGJ(2)), a cyclopentenone prostaglandin, displays a potent anti-inflammatory effect at micromolar concentrations (> 2 muM) through direct inhibition of nuclear factor (NF)-kappaB activation. Here we show that at submicromolar concentrations (0.1-0.5 muM) 15d-PGJ(2) retains the ability to suppress the production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide ( NO) in lipopolysaccharide (LPS)-activated murine J774 macrophages under the conditions of a prolonged incubation (> 12 h). Western blot analysis revealed that the expression of the cytoprotective enzyme, heme oxygenase-1 (HO-1), was induced and coincident with the anti-inflammatory action of 15d-PGJ(2). Inhibition of HO-1 activity or scavenging carbon monoxide (CO), a byproduct derived from heme degradation, significantly attenuated the suppressive activity of 15d-PGJ(2). Furthermore, LPS-induced NF-kappaB activation assessed by the inhibitory protein of NF-kappaB (IkappaB) degradation and p50 nuclear translocation was diminished in cells subjected to prolonged treatment with the low concentration of 15d-PGJ(2). Treatment of cells with the protein synthesis inhibitor, cycloheximide, or the specific p38 MAP kinase inhibitor, SB203580, blocked the induction of HO-1 and suppression of LPS-induced IkappaB degradation mediated by 15d-PGJ(2). Likewise, HO inhibitor and CO scavenger were effective in abolishing the inhibitory effects of 15d-PGJ(2) on NF-kappaB activation induced by LPS. The functional role of CO was further demonstrated by the use of a CO releasing molecule, tricarbonyldichlororuthenium(II) dimer, which significantly suppressed LPS-induced nuclear translocation of p50 as assessed by confocal immunofluorescence. Collectively, these data suggest that even at submicromolar concentrations 15d-PGJ(2) can exert an anti-inflammatory effect in macrophages through a mechanism that involves the action of HO/CO.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Chau, LY (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc Res, Taipei 11529, Taiwan.		Lee, Tzong-Shyuan/AAE-5803-2020; Chau, Lee-Young/N-7659-2018	Lee, Tzong-Shyuan/0000-0002-9593-4062; Chau, Lee-Young/0000-0002-6316-2328				Abraham NG, 1996, CELL PHYSIOL BIOCHEM, V6, P129, DOI 10.1159/000154819; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Bureau F, 2002, J IMMUNOL, V168, P5318, DOI 10.4049/jimmunol.168.10.5318; Castrillo A, 2000, MOL CELL BIOL, V20, P1692, DOI 10.1128/MCB.20.5.1692-1698.2000; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; Diab A, 2002, J IMMUNOL, V168, P2508, DOI 10.4049/jimmunol.168.5.2508; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gilmore TD, 1999, ONCOGENE, V18, P6842, DOI 10.1038/sj.onc.1203237; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Harris SG, 2002, J IMMUNOL, V168, P1372, DOI 10.4049/jimmunol.168.3.1372; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kitamura Y, 1999, NEUROSCI LETT, V262, P129, DOI 10.1016/S0304-3940(99)00055-5; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Li M, 2000, MOL CELL BIOL, V20, P4699, DOI 10.1128/MCB.20.13.4699-4707.2000; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Motterlini R, 2002, CIRC RES, V90, pE17, DOI 10.1161/hh0202.104530; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Scapagnini G, 2002, MOL PHARMACOL, V61, P554, DOI 10.1124/mol.61.3.554; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; Wang LJ, 1998, AM J PATHOL, V152, P711; Wayman NS, 2002, FASEB J, V16, P1027, DOI 10.1096/fj.01-0793com; XIE QW, 1994, J BIOL CHEM, V269, P4705; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	36	193	195	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19325	19330		10.1074/jbc.M300498200	http://dx.doi.org/10.1074/jbc.M300498200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12642589	hybrid			2022-12-27	WOS:000182932200079
J	Limsirichaikul, S; Ogawa, M; Niimi, A; Iwai, S; Murate, T; Yoshida, S; Suzuki, M				Limsirichaikul, S; Ogawa, M; Niimi, A; Iwai, S; Murate, T; Yoshida, S; Suzuki, M			The Gly-952 residue of Saccharomyces cerevisiae DNA polymerase alpha is important in discriminating correct deoxyribonucleotides from incorrect ones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; MISPAIR EXTENSION KINETICS; AMINO-ACID SUBSTITUTIONS; ACTIVE-SITE; NUCLEOTIDE INCORPORATION; O-HELIX; REPLICATION FIDELITY; DEOXYNUCLEOSIDE TRIPHOSPHATE; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE	Gly-952 is a conserved residue in Saccharomyces cerevisiae DNA polymerase alpha (pol alpha) that is strictly required for catalytic activity and for genetic complementation of a pol alpha-deficient yeast strain. This study analyzes the role of Gly-952 by characterizing the biochemical properties of Gly-952 mutants. Analysis of the nucleotide incorporation specificity of pol alpha G952A showed that this mutant incorporates nucleotides with extraordinarily low fidelity. In a steady-state kinetic assay to measure nucleotide misincorporation, pol alpha G952A incorporated incorrect nucleotides more efficiently than correct nucleotides opposite template C, G, and T. The fidelity of the G952A mutant polymerase was highest at template A, where the ratio of incorporation of dCMP to dTMP was as high as 0.37. Correct nucleotide insertion was 500- to 3500-fold lower for G952A than for wild type pol alpha, with up to 22-fold increase in pyrimidine misincorporation. The Km for G952A pol alpha bound to mismatched termini T:T, T C, C A, and A C was 71- to 460-fold lower than to a matched terminus. Furthermore, pol alpha G952A preferentially incorporated pyrimidine instead of dAMP opposite an abasic site, cis-syn cyclobutane di-thymine, or (6-4) di-thymine photoproduct. These data demonstrate that Gly-952 is a critical residue for catalytic efficiency and error prevention in S. cerevisiae pol alpha.	Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan; Univ Tokyo, Dept Chem & Biotechnol, Sch Engn, Bunkyo Ku, Tokyo 1138656, Japan; Nagoya Univ, Sch Hlth Sci, Nagoya, Aichi 4618673, Japan	Nagoya University; University of Tokyo; Nagoya University	Suzuki, M (corresponding author), Nagoya Univ, Canc Cell Biol Lab, Dis Mechanism & Control Res Inst, Grad Sch Med, Nagoya, Aichi 4668550, Japan.		Suzuki, Motoshi/I-7246-2014	Suzuki, Motoshi/0000-0003-0682-5006				ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; Astatke M, 1998, J MOL BIOL, V278, P147, DOI 10.1006/jmbi.1998.1672; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P47393, DOI 10.1074/jbc.M210036200; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BLASCO MA, 1993, J BIOL CHEM, V268, P16763; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COPELAND WC, 1993, J BIOL CHEM, V268, P11041; CREIGHTON S, 1992, J BIOL CHEM, V267, P2633; DONG Q, 1995, J BIOL CHEM, V270, P21563, DOI 10.1074/jbc.270.37.21563; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; FREY MW, 1995, BIOCHEMISTRY-US, V34, P9185, DOI 10.1021/bi00028a031; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Iwai S, 1996, J AM CHEM SOC, V118, P7642, DOI 10.1021/ja9603158; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; MENDELMAN LV, 1990, J BIOL CHEM, V265, P2338; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Ogawa M, 2003, J BIOL CHEM, V278, P19071, DOI 10.1074/jbc.M208605200; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; PERRINO FW, 1989, J BIOL CHEM, V264, P2898; Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200; Saturno J, 1997, J MOL BIOL, V269, P313, DOI 10.1006/jmbi.1997.1053; Shah AM, 2001, J BIOL CHEM, V276, P10824, DOI 10.1074/jbc.M008680200; Shah AM, 2001, BIOCHEMISTRY-US, V40, P11372, DOI 10.1021/bi010755y; Shinkai A, 2001, J BIOL CHEM, V276, P18836, DOI 10.1074/jbc.M011472200; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Suzuki M, 1996, P NATL ACAD SCI USA, V93, P9670, DOI 10.1073/pnas.93.18.9670; Suzuki M, 2000, J BIOL CHEM, V275, P32728, DOI 10.1074/jbc.M000097200; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; Tosaka A, 2001, J BIOL CHEM, V276, P27562, DOI 10.1074/jbc.M010635200; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang GW, 2002, BIOCHEMISTRY-US, V41, P2526, DOI 10.1021/bi0119924; Yang GW, 1999, BIOCHEMISTRY-US, V38, P8094, DOI 10.1021/bi990653w; Yoshida K, 2001, NUCLEIC ACIDS RES, V29, P4206, DOI 10.1093/nar/29.20.4206	50	8	9	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					19079	19086		10.1074/jbc.M208604200	http://dx.doi.org/10.1074/jbc.M208604200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637558	hybrid			2022-12-27	WOS:000182932200048
J	Dai, E; Guan, HY; Liu, LY; Little, S; McFadden, G; Vaziri, S; Cao, HN; Ivanova, IA; Bocksch, L; Lucas, A				Dai, E; Guan, HY; Liu, LY; Little, S; McFadden, G; Vaziri, S; Cao, HN; Ivanova, IA; Bocksch, L; Lucas, A			Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; NEOINTIMA FORMATION; GENE-TRANSFER; TRANSPLANT VASCULOPATHY; INCREASED EXPRESSION; KINETIC-ANALYSIS; ARTERIAL INJURY; RECEPTOR; VITRONECTIN; UROKINASE	Complex DNA viruses have tapped into cellular serpin responses that act as key regulatory steps in coagulation and inflammatory cascades. Serp-1 is one such viral serpin that effectively protects virus-infected tissues from host inflammatory responses. When given as purified protein, Serp-1 markedly inhibits vascular monocyte invasion and plaque growth in animal models. We have investigated mechanisms of viral serpin inhibition of vascular inflammatory responses. In vascular injury models, Serp-1 altered early cellular plasminogen activator (tissue plasminogen activator), inhibitor (PAI-1), and receptor (urokinase-type plasminogen activator) expression (p < 0.01). Serp-1, but not a reactive center loop mutant, up-regulated PAI-1 serpin expression in human endothelial cells. Treatment of endothelial cells with antibody to urokinase-type plasminogen activator and vitronectin blocked Serp-1-induced changes. Significantly, Serp-1 blocked intimal hyperplasia (p < 0.0001) after aortic allograft transplant (p < 0.0001) in PAI-1-deficient mice. Serp-1 also blocked plaque growth after aortic isograft transplant and after wire-induced injury (p < 0.05) in PAI-1-deficient mice indicating that increase in PAI-1 expression is not required for Serp-1 to block vasculopathy development. Serp-1 did not inhibit plaque growth in uPAR-deficient mice after aortic allograft transplant. We conclude that the poxviral serpin, Serp-1, attenuates vascular inflammatory responses to injury through a pathway mediated by native uPA receptors and vitronectin.	Univ Western Ontario, John P Robarts Res Inst, Vasc Biol Res Grp, London, ON N6A 5K8, Canada; Univ Western Ontario, Univ Hosp, London Hlth Sci Ctr, Div Cardiol, London, ON N6A 5K8, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5K8, Canada	Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); Western University (University of Western Ontario)	Lucas, A (corresponding author), Univ Western Ontario, John P Robarts Res Inst, Vasc Biol Res Grp, 100 Perth Dr,POB 5015, London, ON N6A 5K8, Canada.	arl@robarts.ca		McFadden, Grant/0000-0002-2556-3526				BARKA T, 1993, J HISTOCHEM CYTOCHEM, V41, P1863, DOI 10.1177/41.12.8245434; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; BOT I, 2002, PRECLINICAL EVALUATI, P11; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; CARMELIET P, 1995, FASEB J, V9, P934, DOI 10.1096/fasebj.9.10.7615162; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chavakis T, 1998, BLOOD, V91, P2305, DOI 10.1182/blood.V91.7.2305.2305_2305_2312; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; ESTREICHER A, 1990, J CELL BIOL, V111, P783, DOI 10.1083/jcb.111.2.783; FALCONE DJ, 1993, J BIOL CHEM, V268, P11951; Falkenberg M, 2002, P NATL ACAD SCI USA, V99, P10665, DOI 10.1073/pnas.162236599; FORSYTH KD, 1994, CLIN EXP IMMUNOL, V95, P277; Germer M, 1998, EUR J BIOCHEM, V253, P669, DOI 10.1046/j.1432-1327.1998.2530669.x; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; Gladson CL, 2000, NEUROSCI LETT, V283, P157, DOI 10.1016/S0304-3940(00)00876-4; Hasenstab D, 1997, CIRC RES, V80, P490, DOI 10.1161/01.RES.80.4.490; Hausen B, 2001, TRANSPLANTATION, V72, P364, DOI 10.1097/00007890-200108150-00003; Hayry P, 1996, TRANSPL P, V28, P2337; JACKSON CL, 1992, ANN NY ACAD SCI, V667, P141, DOI 10.1111/j.1749-6632.1992.tb51606.x; KOULACK J, 1995, MICROSURG, V16, P110, DOI 10.1002/micr.1920160213; Levi M, 2001, CIRCULATION, V103, P2014; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Liu LY, 2000, J CLIN INVEST, V105, P1613, DOI 10.1172/JCI8934; Lucas A, 2000, J HEART LUNG TRANSPL, V19, P1029, DOI 10.1016/S1053-2498(00)00190-X; Lucas A, 1996, CIRCULATION, V94, P2890, DOI 10.1161/01.CIR.94.11.2890; MANEJWALA FM, 1991, DEV BIOL, V144, P301, DOI 10.1016/0012-1606(91)90423-Z; McMahon GA, 2001, J BIOL CHEM, V276, P33964, DOI 10.1074/jbc.M105980200; Miller L, 1995, J HEART LUNG TRANSPL, V14, pS227; Miller LW, 2000, CIRCULATION, V101, P1598, DOI 10.1161/01.CIR.101.13.1598; Moons L, 1998, J CLIN INVEST, V102, P1788, DOI 10.1172/JCI3316; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nash P, 1998, J BIOL CHEM, V273, P20982, DOI 10.1074/jbc.273.33.20982; Ploplis VA, 2001, ANN NY ACAD SCI, V936, P466; Reidy MA, 1996, CIRC RES, V78, P405, DOI 10.1161/01.RES.78.3.405; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAXNE T, 1993, J RHEUMATOL, V20, P91; SEIFFERT D, 1991, BIOCHIM BIOPHYS ACTA, V1078, P23, DOI 10.1016/0167-4838(91)90087-G; SESTINI R, 1995, CLIN CHEM, V41, P826; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sjoland H, 2000, ARTERIOSCL THROM VAS, V20, P846, DOI 10.1161/01.ATV.20.3.846; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Stoop AA, 2000, ARTERIOSCL THROM VAS, V20, P1143, DOI 10.1161/01.ATV.20.4.1143; Strauss BH, 1999, CIRCULATION, V100, P1616, DOI 10.1161/01.CIR.100.15.1616; Turner PC, 2001, ASM NEWS, V67, P201; UPTON C, 1990, VIROLOGY, V179, P618, DOI 10.1016/0042-6822(90)90129-F; Yamamoto M, 1997, CANCER RES, V57, P2799; Zalai CV, 2002, FUND CL CAR, V45, P447	54	45	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18563	18572		10.1074/jbc.M209683200	http://dx.doi.org/10.1074/jbc.M209683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637546	hybrid			2022-12-27	WOS:000182838300128
J	Leighton, M; Kadler, KE				Leighton, M; Kadler, KE			Paired basic/furin-like proprotein convertase cleavage of pro-BMP-1 in the trans-Golgi network	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-1; PROCOLLAGEN C-PROTEINASE; PRECURSOR PROTEINS; ASTACIN FAMILY; BREFELDIN-A; FURIN; ACTIVATION; MATRIX; METALLOPROTEINASES; COLLAGEN	Bone morphogenetic protein (BMP)-1 is a zinc-dependent metalloproteinase that cleaves a variety of extracellular matrix substrates, including type I procollagen. Little is known about the site of action of BMP-1, although the extracellular matrix seems likely to be it. BMP-1 is synthesized with an N-terminal prodomain. The removal of the prodomain presumably activates the proteinase. In this study we show that the prodomain is cleaved in the trans-Golgi network (TGN) and by furin-like/paired basic proprotein convertases. Inhibitors of furin resulted in the secretion of pro-BMP-1, which could not cleave procollagen. Recombinant furin cleaved the prodomain from pro-BMP-1. Site-directed mutagenesis of the prodomain cleavage site (RSRR) to RSAA resulted in efficient secretion of pro-BMP-1. Therefore, prodomain cleavage was not required for secretion. Using peptide N-glycosidase and neuraminidase digestion to determine the post-translational status of pro-BMP-1 during its conversion to BMP-1, we showed that BMP-1 first appears in the TGN during sialylation of the molecule. Furthermore, immunofluorescence studies using an antibody to the nascent N terminus of BMP-1 showed localization to the TGN and plasma membrane. The observation that BMP-1 occurs inside the cell raises the possibility that BMP-1 might begin to cleave its substrates prior to secretion to the extracellular matrix.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Kadler, KE (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Stopford Bldg 2-205,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683				Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; BIRK DE, 1990, J CELL SCI, V95, P649; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Chan M, 2001, EUR J BIOCHEM, V268, P3423, DOI 10.1046/j.1432-1327.2001.02241.x; DENAULT JB, 1995, FEBS LETT, V362, P276, DOI 10.1016/0014-5793(95)00249-9; Denault JB, 1996, FEBS LETT, V379, P113, DOI 10.1016/0014-5793(95)01487-X; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Garrigue-Antar L, 2002, J BIOL CHEM, V277, P43327, DOI 10.1074/jbc.M207342200; Garrigue-Antar L, 2001, J BIOL CHEM, V276, P26237, DOI 10.1074/jbc.M010814200; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; Kang TB, 2002, CANCER RES, V62, P675; Kessler E, 1996, SCIENCE, V271, P360, DOI 10.1126/science.271.5247.360; Kridel SJ, 2001, J BIOL CHEM, V276, P20572, DOI 10.1074/jbc.M100900200; Lee SB, 1997, J BIOL CHEM, V272, P19059, DOI 10.1074/jbc.272.30.19059; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; Molloy SS, 1999, TRENDS CELL BIOL, V9, P28, DOI 10.1016/S0962-8924(98)01382-8; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Prescott AR, 1997, EUR J CELL BIOL, V72, P238; Raghunath M, 1999, J CELL SCI, V112, P1093; Rattenholl A, 2002, J BIOL CHEM, V277, P26372, DOI 10.1074/jbc.M203247200; Reynolds SD, 2000, GENE, V248, P233, DOI 10.1016/S0378-1119(00)00114-1; Sarras MP, 1996, BIOESSAYS, V18, P439, DOI 10.1002/bies.950180604; Scott IC, 2001, NATURE, V410, P475, DOI 10.1038/35068572; Scott IC, 1999, DEV BIOL, V213, P283, DOI 10.1006/dbio.1999.9383; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shapiro J, 1997, J HISTOCHEM CYTOCHEM, V45, P3, DOI 10.1177/002215549704500102; Sieron AL, 2000, BIOCHEMISTRY-US, V39, P3231, DOI 10.1021/bi992312o; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Unsold C, 2002, J BIOL CHEM, V277, P5596, DOI 10.1074/jbc.M110003200; Uzel MI, 2001, J BIOL CHEM, V276, P22537, DOI 10.1074/jbc.M102352200; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	38	75	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18478	18484		10.1074/jbc.M213021200	http://dx.doi.org/10.1074/jbc.M213021200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637569	hybrid			2022-12-27	WOS:000182838300116
J	Migliorini, MM; Behre, EH; Brew, S; Ingham, KC; Strickland, DK				Migliorini, MM; Behre, EH; Brew, S; Ingham, KC; Strickland, DK			Allosteric modulation of ligand binding to low density lipoprotein receptor-related protein by the receptor-associated protein requires critical lysine residues within its carboxyl-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-TYPE REPEATS; ALPHA-2-MACROGLOBULIN RECEPTOR; 39-KDA PROTEIN; MOLECULAR CHAPERONE; RAP; DISSECTION; SITES; ER; IDENTIFICATION; CLUSTER	The low density lipoprotein receptor-related protein (LRP) is a large endocytic receptor that recognizes more than 30 different ligands and plays important roles in protease and lipoprotein catabolism. Ligand binding to newly synthesized LRP is modulated by the receptor-associated protein (RAP), an endoplasmic reticulum-resident protein that functions as a molecular chaperone and prevents ligands from associating with LRP via an allosteric-type mechanism. RAP is a multidomain protein that contains two independent LRP binding sites, one located at the amino-terminal portion of the molecule and the other at the carboxyl-terminal portion of the molecule. The objective of the present investigation was to gain insight into how these two regions of RAP interact with LRP and function to modulate its ligand binding properties. These objectives were accomplished by random mutagenesis of RAP, which identified two critical lysine residues, Lys-256 and Lys-270, within the carboxyl-terminal domain that are necessary for binding of this region of RAP to LRP and to heparin. RAP molecules in which either of these two lysine residues was mutated still bound LRP but with reduced affinity. Furthermore, the mutant RAPs were significantly impaired in their ability to inhibit alpha(2)M* binding to LRP via allosteric mechanisms. In contrast, the mutant RAP molecules were still effective at inhibiting uPA.PAI-1 binding to LRP. These results confirm that both LRP binding sites within RAP cooperate to inhibit ligand binding via an allosteric mechanism.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, Rockville, MD 20855 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Biochem, Rockville, MD 20855 USA	American Red Cross; American Red Cross	Strickland, DK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [HL54710, HL50784] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL050784] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andersen OM, 2001, BIOCHEMISTRY-US, V40, P15408, DOI 10.1021/bi0110692; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; BIEMESDERFER D, 1993, AM J PHYSIOL, V264, pF1011, DOI 10.1152/ajprenal.1993.264.6.F1011; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Ellgaard L, 1997, EUR J BIOCHEM, V244, P544, DOI 10.1111/j.1432-1033.1997.00544.x; Filimonov V V, 1982, Mol Biol (Mosk), V16, P551; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Horn IR, 1997, J BIOL CHEM, V272, P13608, DOI 10.1074/jbc.272.21.13608; Hsieh JC, 2003, CELL, V112, P355, DOI 10.1016/S0092-8674(03)00045-X; JENSEN PH, 1989, FEBS LETT, V255, P275, DOI 10.1016/0014-5793(89)81105-6; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Medved LV, 1999, J BIOL CHEM, V274, P717, DOI 10.1074/jbc.274.2.717; Melman L, 2001, J BIOL CHEM, V276, P29338, DOI 10.1074/jbc.M103717200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Neels JG, 1999, J BIOL CHEM, V274, P31305, DOI 10.1074/jbc.274.44.31305; Nielsen PR, 1997, P NATL ACAD SCI USA, V94, P7521, DOI 10.1073/pnas.94.14.7521; Obermoeller LM, 1997, J BIOL CHEM, V272, P10761; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; ORLANDO RA, 1994, P NATL ACAD SCI USA, V91, P3161, DOI 10.1073/pnas.91.8.3161; Privalov P L, 1986, Methods Enzymol, V131, P4; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Vash B, 1998, BLOOD, V92, P3277, DOI 10.1182/blood.V92.9.3277.421k50_3277_3285; WARSHAWSKY I, 1993, J BIOL CHEM, V268, P22046; WARSHAWSKY I, 1994, J BIOL CHEM, V269, P3325; WARSHAWSKY I, 1995, BIOCHEMISTRY-US, V34, P3404, DOI 10.1021/bi00010a032; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; WILLNOW TE, 1994, J BIOL CHEM, V269, P15827; WILLNOW TE, 1995, P NATL ACAD SCI USA, V92, P4537, DOI 10.1073/pnas.92.10.4537	34	45	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					17986	17992		10.1074/jbc.M212592200	http://dx.doi.org/10.1074/jbc.M212592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12637503	hybrid			2022-12-27	WOS:000182838300051
J	Schuster, B; Kovaleva, M; Sun, Y; Regenhard, P; Matthews, V; Grotzinger, J; Rose-John, S; Kallen, KJ				Schuster, B; Kovaleva, M; Sun, Y; Regenhard, P; Matthews, V; Grotzinger, J; Rose-John, S; Kallen, KJ			Signaling of human ciliary neurotrophic factor (CNTF) revisited - The interleukin-6 receptor can serve as an alpha-receptor for CNTF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA INHIBITORY FACTOR; AMYOTROPHIC-LATERAL-SCLEROSIS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; IL-6-DEFICIENT MICE; FACTOR PREVENTS; ONCOSTATIN-M; REGIONAL DISTRIBUTION; HUNTINGTONS-DISEASE; NULL MUTATION	Human ciliary neurotrophic factor (CNTF) is a neurotrophic cytokine that exerts a neuroprotective effect in multiple sclerosis and amyotrophic lateral sclerosis. Clinical application of human CNTF, however, was prevented by high toxicity at higher dosages. Human CNTF elicits cellular responses by induction of a receptor complex consisting of the CNTF alpha-receptor (CNTFR), which is not involved in signal transduction, and the beta-receptors gp130 and leukemia inhibitory factor receptor (LIFR). Previous studies with rat CNTF demonstrated that rat CNTF is unable to interact with the human interleukin-6 alpha-receptor, whereas at high concentrations, it can directly induce a signaling heterodinter of human gp130 and human LIFR in the absence of the CNTF receptor. Here, we demonstrate that human CNTF cannot directly induce a heterodimer of human gp130 and LIFR. However, human CNTF can use both the membrane-bound and the soluble human IL-6R as a substitute for its cognate alpha-receptor and thus widen the target spectrum of human CNTF. Engineering a CNTFR-specific human CNTF variant may therefore be a prerequisite to improving the safety profile of CNTF.	Univ Kiel, Biochem Inst, D-24098 Kiel, Germany; Zhejiang Univ, Coll Life Sci, Hangzhou 310027, Peoples R China	University of Kiel; Zhejiang University	Kallen, KJ (corresponding author), Univ Kiel, Biochem Inst, Olshaussenstr 40, D-24098 Kiel, Germany.		Schuster, Bjorn/G-6339-2014; Kovaleva, Marina/A-3402-2014; Rose-John, Stefan/A-7998-2010	Kovaleva, Marina/0000-0002-3907-1776; Rose-John, Stefan/0000-0002-7519-3279				Aasland D, 2002, J MOL BIOL, V315, P637, DOI 10.1006/jmbi.2001.5282; Alexander WS, 1999, CURR BIOL, V9, P605, DOI 10.1016/S0960-9822(99)80266-8; ANAND P, 1995, NAT MED, V1, P168, DOI 10.1038/nm0295-168; Anderson KD, 1996, P NATL ACAD SCI USA, V93, P7346, DOI 10.1073/pnas.93.14.7346; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298; CLATTERBUCK RE, 1993, P NATL ACAD SCI USA, V90, P2222, DOI 10.1073/pnas.90.6.2222; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; de Almeida LP, 2001, NEUROBIOL DIS, V8, P433, DOI 10.1006/nbdi.2001.0388; DECHIARA TM, 1995, CELL, V83, P313, DOI 10.1016/0092-8674(95)90172-8; Elson GCA, 1998, J IMMUNOL, V161, P1371; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; GEARING DP, 1994, P NATL ACAD SCI USA, V91, P1119, DOI 10.1073/pnas.91.3.1119; Giess R, 2002, AM J HUM GENET, V70, P1277, DOI 10.1086/340427; Giess R, 2002, ARCH NEUROL-CHICAGO, V59, P407, DOI 10.1001/archneur.59.3.407; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; GRUTZINGER J, 1997, PROTEINS, V27, P96; Guillet C, 1999, J NEUROSCI, V19, P1257; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HELGREN ME, 1994, CELL, V76, P493, DOI 10.1016/0092-8674(94)90113-9; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; Hurst SM, 2001, IMMUNITY, V14, P705, DOI 10.1016/S1074-7613(01)00151-0; IP NY, 1991, J NEUROSCI, V11, P3124; JOSTOCK T, 1998, J IMMUNOL METHODS, V273, P173; Kallen KJ, 2002, BBA-MOL CELL RES, V1592, P323, DOI 10.1016/S0167-4889(02)00325-7; Kallen KJ, 1999, J BIOL CHEM, V274, P11859, DOI 10.1074/jbc.274.17.11859; Kalra SP, 2001, P NATL ACAD SCI USA, V98, P4279, DOI 10.1073/pnas.091101498; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; LARKFORS L, 1994, EUR J NEUROSCI, V6, P1015, DOI 10.1111/j.1460-9568.1994.tb00596.x; LaVail MM, 1998, INVEST OPHTH VIS SCI, V39, P592; Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; Linker RA, 2002, NAT MED, V8, P620, DOI 10.1038/nm0602-620; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x; Meazza C, 1997, NEUROIMMUNOMODULAT, V4, P271, DOI 10.1159/000097347; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Miller RG, 1996, NEUROLOGY, V47, P1329, DOI 10.1212/WNL.47.5.1329; Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; NESBITT JE, 1993, BIOCHEM BIOPH RES CO, V190, P544, DOI 10.1006/bbrc.1993.1082; Okuda Y, 1998, INT IMMUNOL, V10, P703, DOI 10.1093/intimm/10.5.703; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PANAYOTATOS N, 1993, J BIOL CHEM, V268, P19000; Peterson WM, 2000, J NEUROSCI, V20, P4081; Plun-Favreau H, 2001, EMBO J, V20, P1692, DOI 10.1093/emboj/20.7.1692; Robak T, 1998, MEDIAT INFLAMM, V7, P347, DOI 10.1080/09629359890875; Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Samoilova EB, 1998, J IMMUNOL, V161, P6480; SATO K, 1993, CANCER RES, V53, P851; SCHOOLTINK H, 1992, FEBS LETT, V314, P280, DOI 10.1016/0014-5793(92)81489-9; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; Sendtner M, 1996, CURR BIOL, V6, P686, DOI 10.1016/S0960-9822(09)00450-3; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Simon R, 1995, NEUROREPORT, V7, P153, DOI 10.1097/00001756-199512000-00037; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; TAKAHASHI R, 1994, NAT GENET, V7, P79, DOI 10.1038/ng0594-79; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEIERGRABER O, 1995, EUR J BIOCHEM, V234, P661, DOI 10.1111/j.1432-1033.1995.661_b.x	73	116	132	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					9528	9535		10.1074/jbc.M210044200	http://dx.doi.org/10.1074/jbc.M210044200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643274	hybrid			2022-12-27	WOS:000181524000087
J	Harrigan, JA; Opresko, PL; von Kobbe, C; Kedar, PS; Prasad, R; Wilson, SH; Bohr, VA				Harrigan, JA; Opresko, PL; von Kobbe, C; Kedar, PS; Prasad, R; Wilson, SH; Bohr, VA			The Werner syndrome protein stimulates DNA polymerase beta strand displacement synthesis via its helicase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; FUNCTIONAL INTERACTION; REPEAT SEQUENCE; WRN PROTEIN; HUMAN-CELLS; INTERACTS; BINDING; COMPLEX; DELTA; 3'->5'-EXONUCLEASE	Werner syndrome is a hereditary premature aging disorder characterized by genomic instability. Genetic analysis and protein interaction studies indicate that the defective gene product (WRN) may play an important role in DNA replication, recombination, and repair. DNA polymerase beta (polbeta) is a central participant in both short and long-patch base excision repair (BER) pathways, which function to process most spontaneous, alkylated, and oxidative DNA damage. We report here a physical interaction between WRN and pol beta, and using purified proteins reconstitute of a portion of the long-patch BER pathway to examine a potential role for WRN in this repair response. We demonstrate that WRN stimulates pol beta strand displacement DNA synthesis and that this stimulation is dependent on the helicase activity of WRN. In addition, a truncated WRN protein, containing primarily the helicase domain, retains helicase activity and is sufficient to mediate the stimulation of pol beta. The WRN helicase also unwinds a BER substrate, providing evidence that WRN plays a role in unwinding DNA repair intermediates. Based on these findings, we propose a novel mechanism by which WRN may mediate pol beta-directed long-patch BER.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293; Opresko, Patricia/0000-0002-6470-2189; von Kobbe, Cayetano/0000-0003-3895-3790	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, ZIAES050159] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bohr VA, 2001, ENVIRON MOL MUTAGEN, V38, P227, DOI 10.1002/em.1076; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Dantzer F, 1999, BIOCHIMIE, V81, P69, DOI 10.1016/S0300-9084(99)80040-6; DeMott MS, 2002, J BIOL CHEM, V277, P7637, DOI 10.1074/jbc.C100577200; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Hartenstine MJ, 2002, J BIOL CHEM, V277, P41379, DOI 10.1074/jbc.M207013200; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lebel M, 1999, J BIOL CHEM, V274, P37795, DOI 10.1074/jbc.274.53.37795; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Prasad R, 2001, J BIOL CHEM, V276, P32411, DOI 10.1074/jbc.C100292200; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Shen JC, 2001, MECH AGEING DEV, V122, P921, DOI 10.1016/S0047-6374(01)00248-2; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Srivastava DK, 1996, BIOCHEMISTRY-US, V35, P3728, DOI 10.1021/bi952632h; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Strauss PR, 1997, J BIOL CHEM, V272, P1302, DOI 10.1074/jbc.272.2.1302; Szekely AM, 2000, P NATL ACAD SCI USA, V97, P11365, DOI 10.1073/pnas.97.21.11365; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Weinfeld M, 2001, RADIAT RES, V156, P584, DOI 10.1667/0033-7587(2001)156[0584:ROBERE]2.0.CO;2; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	57	95	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2003	278	25					22686	22695		10.1074/jbc.M213103200	http://dx.doi.org/10.1074/jbc.M213103200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	689QF	12665521	hybrid			2022-12-27	WOS:000183503900069
J	Bar, EE; Ellicott, AT; Stone, DE				Bar, EE; Ellicott, AT; Stone, DE			G beta gamma recruits Rho1 to the site of polarized growth during mating in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; HETEROTRIMERIC G-PROTEIN; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; 1,3-BETA-GLUCAN SYNTHASE; GENE; LOCALIZATION	In mating mixtures of Saccharomyces cerevisiae, cells polarize their growth toward their conjugation partners along a pheromone gradient. This chemotropic phenomenon is mediated by structural proteins such as Far1 and Bem1 and by signaling proteins such as Cdc24, Cdc42, and Gbetagamma. The Gbetagamma subunit is thought to provide a positional cue that recruits the polarity establishment proteins, and thereby induces polarization of the actin cytoskeleton. We identified RHO1 in a screen for allele-specific high-copy suppressors of Gbetagamma overexpression, suggesting that Rho1 binds Gbetagamma in vivo. Inactivation of Rho1 GTPase activity augmented the rescue phenotype, suggesting that it is the activated form of Rho1 that binds Gbetagamma. We also found, in a pull-down assay, that Rho1 associates with GST-Ste4 and that Rho1 is localized to the neck and tip of mating projections. Moreover, a mutation in STE4 that disrupts Gbetagamma-Rho1 interaction reduces the projection tip localization of Rho1 and compromises the integrity of pheromone-treated cells deficient in Rho1 activity. In addition to its roles as a positive regulator of 1,3-beta-glucan synthase and of the cell integrity MAP kinase cascade, it was recently shown that Rho1 is necessary for the formation of mating projections. Together, these results suggest that Gbetagamma recruits Rho1 to the site of polarized growth during mating.	Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Stone, DE (corresponding author), Univ Illinois, Dept Biol Sci, Mol Biol Lab, Chicago, IL 60607 USA.		Bar, Eli/A-4592-2008					ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Andrews PD, 2000, J CELL SCI, V113, P2685; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Ayscough KR, 1998, CURR BIOL, V8, P927, DOI 10.1016/S0960-9822(07)00374-0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Drgonova J, 1999, J CELL BIOL, V146, P373, DOI 10.1083/jcb.146.2.373; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; Guthrie C, 1991, GUIDE YEAST GENETICS; Harhammer R, 1996, FEBS LETT, V399, P211, DOI 10.1016/S0014-5793(96)01327-0; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kim JA, 2000, MOL CELL BIOL, V20, P8826, DOI 10.1128/MCB.20.23.8826-8835.2000; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1994, CELL MOL BIOL RES, V40, P229; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Li E, 1998, GENETICS, V148, P947; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MASUDA T, 1994, J BIOL CHEM, V269, P19713; Metodiev MV, 2002, SCIENCE, V296, P1483, DOI 10.1126/science.1070540; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Saka A, 2001, J BIOL CHEM, V276, P46165, DOI 10.1074/jbc.M103805200; Schrick K, 1997, GENETICS, V147, P19; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; Sekiya-Kawasaki M, 2002, GENETICS, V162, P663; SLATER MR, 1987, MOL CELL BIOL, V7, P1906, DOI 10.1128/MCB.7.5.1906; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	51	27	28	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21798	21804		10.1074/jbc.M212636200	http://dx.doi.org/10.1074/jbc.M212636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12660244	hybrid, Green Published			2022-12-27	WOS:000183354200062
J	Noga, AA; Vance, DE				Noga, AA; Vance, DE			A gender-specific role for phosphatidylethanolamine n-methyltransferase-derived phosphatidylcholine in the regulation of plasma high density and very low density lipoproteins in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; TRANSFER PROTEIN; PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; HEPATIC OVEREXPRESSION; CHOLINE DEFICIENCY; APOLIPOPROTEIN-B; APO-B; SECRETION; BIOSYNTHESIS; METHYLATION	Phosphatidylethanolamine N-methyltransferase (PEMT) is involved in a secondary pathway for production of phosphatidylcholine (PC) in liver. We fed Pemt(-/-) mice a high fat/high cholesterol diet for 3 weeks to determine whether or not PC derived from PEMT is required for very low density lipoprotein secretion. Lipid analyses of plasma and liver indicated that male Pemt(-/-) mice accumulated triacylglycerols in their livers and were unable to secrete the same amount of triacylglycerols from the liver as did Pemt-/- mice. Plasma levels of triacylglycerol and both apolipoproteins B100 and B48 were significantly decreased only in male Pemt(-/-) mice. Experiments in which mice were injected with Triton WR1339 showed that, whereas hepatic apoB100 secretion was decreased in male Pemt(-/-) mice, the decrease in plasma apoB48 in male Pemt(-/-) mice was not due to reduced secretion. Moreover, female and, to a lesser extent, male Pemt(-/-) mice showed a striking 40% decrease in plasma PC and cholesterol in high density lipoproteins. These results suggest that, even though the content of hepatic PC was normal in PEMT-deficient mice, plasma lipoprotein levels were profoundly altered in a gender-specific manner.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, DE (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2S2, Canada.							AMADOR E, 1962, CLIN CHEM, V8, P343; BELINA H, 1975, BIOCHEM PHARMACOL, V24, P303; BJORNSTAD P, 1966, J LIPID RES, V7, P38; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MJ, 1986, METHOD ENZYMOL, V128, P70; CHEEMA SK, 1997, J LIPID RES, V38, P157; CHUNG BH, 1986, METHOD ENZYMOL, V128, P181; Cohen DE, 1999, CURR OPIN LIPIDOL, V10, P295, DOI 10.1097/00041433-199908000-00002; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; JAMIL H, 1993, BIOCHEM J, V291, P419, DOI 10.1042/bj2910419; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Kuipers F, 1997, Subcell Biochem, V28, P295; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Leung GK, 2000, J BIOL CHEM, V275, P7515, DOI 10.1074/jbc.275.11.7515; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; NISHIMAKIMOGAMI T, 1996, BIOCHIM BIOPHYS ACTA, V1304, P12; Noga AA, 2003, J BIOL CHEM, V278, P5952, DOI 10.1074/jbc.M212194200; PANI P, 1978, EXP MOL PATHOL, V28, P154, DOI 10.1016/0014-4800(78)90048-5; PORTAL I, 1993, AM J PHYSIOL, V264, pG1052, DOI 10.1152/ajpgi.1993.264.6.G1052; Reo NV, 2002, BBA-MOL CELL BIOL L, V1580, P171, DOI 10.1016/S1388-1981(01)00202-5; SNYDER F, 1959, BIOCHIM BIOPHYS ACTA, V34, P244; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TESSITORE L, 1995, INT J EXP PATHOL, V76, P125; Tietge UJF, 1999, J LIPID RES, V40, P2134; TONHAZY NE, 1950, ARCH BIOCHEM, V28, P36; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; Vance D.E., 2002, BIOCH LIPIDS LIPOPRO, P205; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANCE JE, 1986, J BIOL CHEM, V261, P4486; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1986, FEBS LETT, V204, P243, DOI 10.1016/0014-5793(86)80820-1; VANCE JE, 1986, BIOCHIM BIOPHYS ACTA, V875, P501, DOI 10.1016/0005-2760(86)90070-6; VANCE JE, 1985, CAN J BIOCHEM CELL B, V63, P870, DOI 10.1139/o85-108; Vermeulen PS, 1997, J LIPID RES, V38, P447; Waite KA, 2002, J NUTR, V132, P68, DOI 10.1093/jn/132.1.68; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; Wu XJ, 1996, J LIPID RES, V37, P1198; YAO ZM, 1988, J BIOL CHEM, V263, P2998; YAO ZM, 1989, J BIOL CHEM, V264, P11373; Yokoyama S, 2000, BBA-MOL CELL BIOL L, V1529, P231, DOI 10.1016/S1388-1981(00)00152-9; ZHOU X, 1992, J LIPID RES, V33, P1233	47	150	153	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21851	21859		10.1074/jbc.M301982200	http://dx.doi.org/10.1074/jbc.M301982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12668679	hybrid			2022-12-27	WOS:000183354200069
J	Wakabayashi, M; Ito, T; Mitsushima, M; Aizawa, S; Ueda, K; Amachi, T; Kioka, N				Wakabayashi, M; Ito, T; Mitsushima, M; Aizawa, S; Ueda, K; Amachi, T; Kioka, N			Interaction of lp-dlg/KIAA0583, a membrane-associated guanylate kinase family protein, with vinexin and beta-catenin at sites of cell-cell contact	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCULIN-BINDING PROTEIN; ALPHA-CATENIN; JUNCTIONAL COMPLEX; SIGNALING COMPLEX; STRESS FIBERS; ADHESION; DOMAINS; SRC; ARCHITECTURE; AFADIN	Vinexin is a recently identified cytoskeletal protein and plays a key role in the regulation of cytoskeletal organization and signal transduction. Vinexin localizes at sites of cell- extracellular matrix adhesion in NIH3T3 fibroblasts and at sites of cell- cell contact in epithelial LLC- PK1 cells. Expression of vinexin promotes the formation of actin stress fiber, but the role of vinexin at sites of cell- cell contact is unclear. Here we identified lp- dlg/ KIAA0583 as a novel binding partner for vinexin by using yeast two- hybrid screening. lp- dlg/ KIAA0583 has a NH2- terminal coiled- coil- like domain, in addition to four PDZ domains, an Src homology ( SH) 3 domain, and a guanylate kinase domain, which are conserved structures in membrane- associated guanylate kinase family proteins. The third SH3 domain of vinexin bound to the region between the second and third PDZ domain of lp- dlg, which contains a proline- rich sequence. lp- dlg colocalized with vinexin at sites of cell- cell contact in LLC- PK1 cells. Furthermore, lp- dlg colocalized with beta- catenin, a major adherens junction protein, in LLCPK1 cells. Co- immunoprecipitation experiments revealed that both endogenous and epitope- tagged deletion mutants of lp- dlg/ KIAA0583 associated with beta- catenin. We also showed that these three proteins could form a ternary complex. Together these findings suggest that lp- dlg/ KIAA0583 is a novel scaffolding protein that can link the vinexin- vinculin complex and beta- catenin at sites of cell- cell contact.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Kioka, Noriyuki/0000-0002-2708-537X; Ueda, Kazumitsu/0000-0003-2980-6078				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fukada T, 1998, FEBS LETT, V436, P228, DOI 10.1016/S0014-5793(98)01136-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Harris BZ, 2001, J CELL SCI, V114, P3219; Hazan RB, 1997, J BIOL CHEM, V272, P32448, DOI 10.1074/jbc.272.51.32448; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Kioka N, 2002, CELL STRUCT FUNCT, V27, P1, DOI 10.1247/csf.27.1; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nakamura H, 1998, FEBS LETT, V433, P63, DOI 10.1016/S0014-5793(98)00882-5; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Rudiger M, 1998, BIOESSAYS, V20, P733; Shah G, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-14; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Suwa A, 2002, J BIOL CHEM, V277, P13053, DOI 10.1074/jbc.M108644200; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Watsuji T, 1997, BIOCHEM BIOPH RES CO, V234, P769, DOI 10.1006/bbrc.1997.6705; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	28	53	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2003	278	24					21709	21714		10.1074/jbc.M211004200	http://dx.doi.org/10.1074/jbc.M211004200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	687AT	12657639	hybrid			2022-12-27	WOS:000183354200051
J	Oltean, S; Banerjee, R				Oltean, S; Banerjee, R			Nutritional modulation of gene expression and homocysteine utilization by vitamin B-12	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT METHIONINE BIOSYNTHESIS; MESSENGER-RNA; HEPATITIS-C; BINDING; SYNTHASE; PROTEIN; FOLATE; IDENTIFICATION; TRANSLATION; ENZYMES	Vitamins B-12, B-6, and folic acid converge at the homocysteine metabolic junction where they support the activities of two key enzymes involved in intracellular homocysteine management, methionine synthase (MS) and cystathionine beta-synthase. The molecular mechanism for the regulation of homocysteine metabolism by B-12 supplementation has been investigated in this study. B-12 supplementation does not alter mRNA or protein turnover rates but induces translational up-regulation of MS by shifting the mRNA from the ribonucleoprotein to the polysome pool. The B-12-responsive element has been localized by deletion analysis using a reporter gene assay to a 70-bp region located at the 3' end of the 5'-untranslated region of the MS mRNA. The cellular consequence of the B-12 response is a 2- and 3.5-fold increase in the flux of homocysteine through the MS-dependent transmethylation pathway in HepG2 and 293 cells, respectively. It is speculated that B-12-induced up-regulation of MS may have evolved as an adaptive strategy for rapidly sequestering an essential and rare nutrient whose availability may have been limited in the evolutionary history of mammals, a problem that is exacerbated by the absence of this vitamin from the plant kingdom.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu		Oltean, Sebastian/0000-0001-7890-8439				Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; Chen LH, 1997, J BIOL CHEM, V272, P3628, DOI 10.1074/jbc.272.6.3628; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; Danishpajooh IO, 2001, J BIOL CHEM, V276, P27296, DOI 10.1074/jbc.M104043200; FAZZONE H, 1993, J CLIN INVEST, V92, P1278, DOI 10.1172/JCI116700; Gelfand MS, 1999, TRENDS GENET, V15, P439, DOI 10.1016/S0168-9525(99)01856-9; Gulati S, 1999, BIOCHEM BIOPH RES CO, V259, P436, DOI 10.1006/bbrc.1999.0696; KAMELY D, 1973, P NATL ACAD SCI USA, V70, P2585, DOI 10.1073/pnas.70.9.2585; KOLHOUSE JF, 1977, P NATL ACAD SCI USA, V74, P921, DOI 10.1073/pnas.74.3.921; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; Lott WB, 2001, P NATL ACAD SCI USA, V98, P4916, DOI 10.1073/pnas.081072798; MANGUM JH, 1968, BIOCHEM BIOPH RES CO, V32, P105, DOI 10.1016/0006-291X(68)90433-6; MANGUM JH, 1969, BIOCHEMISTRY-US, V8, P3496, DOI 10.1021/bi00837a002; MARCHAJ A, 1995, J AM CHEM SOC, V117, P11640, DOI 10.1021/ja00152a003; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; MELLMAN IS, 1977, P NATL ACAD SCI USA, V74, P916, DOI 10.1073/pnas.74.3.916; MILLS JL, 1995, LANCET, V345, P149, DOI 10.1016/S0140-6736(95)90165-5; Miranda-Rios J, 2001, P NATL ACAD SCI USA, V98, P9736, DOI 10.1073/pnas.161168098; Nou XW, 2000, P NATL ACAD SCI USA, V97, P7190, DOI 10.1073/pnas.130013897; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Roth JR, 1996, ANNU REV MICROBIOL, V50, P137, DOI 10.1146/annurev.micro.50.1.137; SAVANTBHONSALE S, 1992, GENE DEV, V6, P1927, DOI 10.1101/gad.6.10.1927; Shantz LM, 1999, INT J BIOCHEM CELL B, V31, P107, DOI 10.1016/S1357-2725(98)00135-6; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; Takyar SS, 2002, J MOL BIOL, V319, P1, DOI 10.1016/S0022-2836(02)00300-5; Yamada K, 2000, J NUTR, V130, P1894, DOI 10.1093/jn/130.8.1894	34	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20778	20784		10.1074/jbc.M300845200	http://dx.doi.org/10.1074/jbc.M300845200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670934	hybrid			2022-12-27	WOS:000183230500045
J	Ostrovsky, O; Bengal, E				Ostrovsky, O; Bengal, E			The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21(WAF1) protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; DISTINCT SIGNALING PATHWAYS; MEK-ERK PATHWAY; MYOGENIC DIFFERENTIATION; MAP KINASE; MYOCYTE DIFFERENTIATION; CANCER CELLS; RAS; PROLIFERATION; P21(CIP1)	During myogenesis, proliferating myoblasts withdraw from the cell cycle and are either eliminated by programmed cell death or differentiate into mature myotubes. Previous studies indicate that mitogen-activated protein kinase ( MAPK) activity is significantly induced with the onset of terminal differentiation of C2 myoblasts. We have investigated the part played by the MAPK pathway in the differentiation of C2 myoblasts. Specific activation of MAPK by expression of an active Raf1-estrogen receptor chimera protein reduced significantly the number of myoblasts undergoing programmed cell death in the differentiation medium. Activation of Raf1 prevented the proteolytic activation of the proapoptotic caspase 9-protein during differentiation. The antiapoptotic function of Raf1 correlated with accumulation of the p21(WAF1) protein resulting from its increased stability. Antisense expression of p21 was used to determine whether the p21(WAF1) protein mediated the antiapoptotic activity of Raf1. Reduction of p21(WAF1) protein in muscle cells abolished the antiapoptotic activity of the MAPK pathway. We conclude that MAPK contributes to muscle differentiation by preventing apoptotic cell death of differentiating myoblasts and that this activity is mediated by stabilization of the p21(WAF1) protein.	Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Inst Res Med Sci, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Biochem, Rappaport Inst Res Med Sci, POB 9649, IL-31096 Haifa, Israel.							Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DEL PL, 1997, SCIENCE, V278, P687; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Gauld SB, 2002, J IMMUNOL, V168, P3855, DOI 10.4049/jimmunol.168.8.3855; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Haining WN, 1999, P NATL ACAD SCI USA, V96, P4936, DOI 10.1073/pnas.96.9.4936; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HOLLENBERG SM, 1993, P NATL ACAD SCI USA, V90, P8028, DOI 10.1073/pnas.90.17.8028; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Kim GY, 2002, J BIOL CHEM, V277, P29792, DOI 10.1074/jbc.M201299200; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lawlor MA, 2000, J CELL BIOL, V151, P1131, DOI 10.1083/jcb.151.6.1131; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu Y, 1996, CANCER RES, V56, P31; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McMahon M, 2001, METHOD ENZYMOL, V332, P401; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Park JS, 2000, MOL BIOL CELL, V11, P2915, DOI 10.1091/mbc.11.9.2915; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Ravi RK, 1999, J CELL BIOCHEM, V72, P458, DOI 10.1002/(SICI)1097-4644(19990315)72:4<458::AID-JCB2>3.0.CO;2-C; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Samuel DS, 1999, HORM METAB RES, V31, P55, DOI 10.1055/s-2007-978699; Sarbassov DD, 1997, MOL ENDOCRINOL, V11, P2038, DOI 10.1210/me.11.13.2038; Sarbassov DD, 1998, MOL ENDOCRINOL, V12, P1870, DOI 10.1210/me.12.12.1870; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Tashker JS, 2002, MOL BIOL CELL, V13, P393, DOI 10.1091/mbc.01-06-0291; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tombes RM, 1998, BIOCHEM J, V330, P1451; Tortorella LL, 2001, J BIOL CHEM, V276, P13709, DOI 10.1074/jbc.M100091200; Tureckova J, 2001, J BIOL CHEM, V276, P39264, DOI 10.1074/jbc.M104991200; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Walsh K, 1997, Prog Cell Cycle Res, V3, P53; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wang PH, 1998, BIOCHEM BIOPH RES CO, V245, P912, DOI 10.1006/bbrc.1998.8540; Weyman CM, 1998, ENDOCRINOLOGY, V139, P1794, DOI 10.1210/en.139.4.1794; Weyman CM, 1997, ONCOGENE, V14, P697, DOI 10.1038/sj.onc.1200874; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zetser A, 2001, DEV BIOL, V240, P168, DOI 10.1006/dbio.2001.0465; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	61	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					21221	21231		10.1074/jbc.M211357200	http://dx.doi.org/10.1074/jbc.M211357200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12637563	hybrid			2022-12-27	WOS:000183230500100
J	Pattingre, S; De Vries, L; Bauvy, C; Chantret, I; Cluzeaud, F; Ogier-Denis, E; Vandewalle, A; Codogno, P				Pattingre, S; De Vries, L; Bauvy, C; Chantret, I; Cluzeaud, F; Ogier-Denis, E; Vandewalle, A; Codogno, P			The g-protein regulator AGS3 controls an early event during macroautophagy in human intestinal HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS AUTOPHAGIC SEQUESTRATION; ALPHA-INTERACTING PROTEIN; HETEROTRIMERIC G-PROTEIN; TETRATRICOPEPTIDE REPEAT; SUBCELLULAR-DISTRIBUTION; DISSOCIATION INHIBITOR; RAT HEPATOCYTES; GOLGI MEMBRANES; LINE HT-29; VACUOLES	AGS3 contains GoLoco or G-protein regulatory motifs in its COOH-terminal half that stabilize the GDP-bound conformation of the alpha-subunit of the trimeric G(i3) protein. The latter is part of a signaling pathway that controls the lysosomal-autophagic catabolism in human colon cancer HT-29 cells. In the present work we show that the mRNA encoding for AGS3 is expressed in human intestinal cell lines (Caco-2 and HT-29) whatever their state of differentiation. Together with the full-length form, minute amounts of the mRNA encoding a NH2-terminal truncated form of AGS3, previously characterized in cardiac tissues, were also detected. Both the endogenous form of AGS3 and a tagged expressed form have a localization compatible with a role in the Galpha(i3)-dependent control of autophagy. Accordingly, expressing its non-Galpha(i3)-interacting NH2-terminal domain or its Galpha(i3)-interacting COOH-terminal domain reversed the stimulatory role of AGS3 on autophagy. On the basis of biochemical and morphometric analysis, we conclude that AGS3 is involved in an early event during the autophagic pathway probably prior to the formation of the autophagosome. These data demonstrate that AGS3 is a novel partner of the Galpha(i3) protein in the control of a major catabolic pathway.	INSERM, U504, F-94807 Villejuif, France; Univ Calif San Diego, Dept Mol & Cellular Biol, La Jolla, CA 92093 USA; Univ Paris 07, INSERM, U478, F-75018 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Codogno, P (corresponding author), INSERM, U504, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.		Ogier-Denis, Eric/E-5030-2016; Codogno, Patrice/G-1384-2013; CHANTRET, Isabelle/AAF-7134-2021	Codogno, Patrice/0000-0002-5492-3180; CHANTRET, Isabelle/0000-0002-0896-1274; Pattingre, Sophie/0000-0001-6284-6050; Ogier-Denis, Eric/0000-0002-0057-7593				Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; Ballif BA, 1996, P NATL ACAD SCI USA, V93, P5544, DOI 10.1073/pnas.93.11.5544; Berg TO, 1998, J BIOL CHEM, V273, P21883, DOI 10.1074/jbc.273.34.21883; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Blumer JB, 2002, J BIOL CHEM, V277, P15897, DOI 10.1074/jbc.M112185200; Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Dorn BR, 2002, CELL MICROBIOL, V4, P1, DOI 10.1046/j.1462-5822.2002.00164.x; DUNN WA, 1990, J CELL BIOL, V110, P1923, DOI 10.1083/jcb.110.6.1923; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; FENGSRUD M, 1995, EXP CELL RES, V221, P504, DOI 10.1006/excr.1995.1402; Fengsrud M, 2000, EUR J CELL BIOL, V79, P871, DOI 10.1078/0171-9335-00125; GORDON PB, 1993, J BIOL CHEM, V268, P26107; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; Hariri M, 2000, MOL BIOL CELL, V11, P255, DOI 10.1091/mbc.11.1.255; Holm TM, 2002, BLOOD, V99, P1817, DOI 10.1182/blood.V99.5.1817; HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521; Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690; Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; LAWRENCE BP, 1992, J CELL SCI, V102, P515; LESUFFLEUR T, 1991, INT J CANCER, V49, P721, DOI 10.1002/ijc.2910490516; LESUFFLEUR T, 1990, CANCER RES, V50, P6334; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; Liou W, 1997, J CELL BIOL, V136, P61, DOI 10.1083/jcb.136.1.61; Mortimore G. E., 1994, CELLULAR PROTEOLYTIC, P65; Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593; OGIERDENIS E, 1995, J BIOL CHEM, V270, P13, DOI 10.1074/jbc.270.1.13; Petersen A, 2001, HUM MOL GENET, V10, P1243, DOI 10.1093/hmg/10.12.1243; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Petiot A, 1999, BIOCHEM J, V337, P289, DOI 10.1042/0264-6021:3370289; PINTO M, 1983, BIOL CELL, V47, P323; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STROMHAUG PE, 1993, BIOCHEM J, V291, P115, DOI 10.1042/bj2910115; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; van Sluijters DA, 2000, BIOCHEM J, V351, P545, DOI 10.1042/0264-6021:3510545; Villard L, 2000, EUR J HUM GENET, V8, P125, DOI 10.1038/sj.ejhg.5200432; WEIBEL ER, 1969, J CELL BIOL, V42, P68, DOI 10.1083/jcb.42.1.68; Weiss TS, 2001, P NATL ACAD SCI USA, V98, P14961, DOI 10.1073/pnas.261572098; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; YAMAMOTO A, 1990, J HISTOCHEM CYTOCHEM, V38, P573, DOI 10.1177/38.4.2319125	64	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20995	21002		10.1074/jbc.M300917200	http://dx.doi.org/10.1074/jbc.M300917200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12642577	hybrid			2022-12-27	WOS:000183230500072
J	Puri, V; Jefferson, JR; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE				Puri, V; Jefferson, JR; Singh, RD; Wheatley, CL; Marks, DL; Pagano, RE			Sphingolipid storage induces accumulation of intracellular cholesterol by stimulating SREBP-1 cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1; PICK C1 PROTEIN; NIEMANN-PICK; GOLGI-APPARATUS; GLUCOSYLCERAMIDE; TRANSCRIPTION; INTERNALIZATION; SPHINGOMYELIN; PROTEOLYSIS; METABOLISM	We showed previously that the intracellular transport of sphingolipids (SLs) is altered in SL storage disease fibroblasts, due in part to the secondary accumulation of free cholesterol. In the present study we examined the mechanism of cholesterol elevation in normal human skin fibroblasts induced by treatment with SLs. When cells were incubated with various natural SLs for 44 h, cholesterol levels increased 25-35%, and cholesterol esterification was reduced. Catabolism of the exogenous SLs was not required for elevation of cholesterol because (i) a non-hydrolyzable and a degradable SL analog elevated cellular cholesterol to similar extents, and (ii) incubation of cells with various SL catabolites, including ceramide, had no effect on cholesterol levels. Elevated cholesterol was derived primarily from low density lipoproteins (LDL) and resulted from up-regulation of LDL receptors induced by cleavage of the sterol regulatory element-binding protein-1. Upon SL treatment, cholesterol accumulated with exogenous SLs in late endosomes and lysosomes. These results suggest a model in which excess SLs present in endocytic compartments serve as a "molecular trap" for cholesterol, leading to a reduction in cholesterol at the endoplasmic reticulum, induction of sterol regulatory element-binding protein-1 cleavage, and up-regulation of LDL receptors.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Pagano, RE (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Stabile 8,200 1st St SW, Rochester, MN 55905 USA.	Pagano.richard@mayo.edu	Takhter, Ramandeep/AAG-8977-2019	Takhter, Ramandeep/0000-0002-1441-2722	NIGMS NIH HHS [GM60934] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060934] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHT B, 1995, CARBOHYD RES, V276, P289, DOI 10.1016/0008-6215(95)00189-Z; BITTMAN R, 1994, BIOCHEMISTRY-US, V33, P11776, DOI 10.1021/bi00205a013; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHATTERJEE S, 1993, J BIOL CHEM, V268, P3401; Chen CS, 1999, LANCET, V354, P901, DOI 10.1016/S0140-6736(98)10034-X; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Diomede L, 2001, EUR CYTOKINE NETW, V12, P625; Fielding CJ, 1997, J LIPID RES, V38, P1503; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KOVAL M, 1990, J CELL BIOL, V111, P429, DOI 10.1083/jcb.111.2.429; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lawler JF, 1998, J BIOL CHEM, V273, P5053, DOI 10.1074/jbc.273.9.5053; Leventhal AR, 2001, J BIOL CHEM, V276, P44976, DOI 10.1074/jbc.M106455200; Marks DL, 2002, TRENDS CELL BIOL, V12, P605, DOI 10.1016/S0962-8924(02)02399-1; MARTIN OC, 1993, P NATL ACAD SCI USA, V90, P2661, DOI 10.1073/pnas.90.7.2661; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; Neufeld EB, 1999, J BIOL CHEM, V274, P9627, DOI 10.1074/jbc.274.14.9627; Pagano RE, 2000, METHOD ENZYMOL, V312, P523; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; Patel SC, 1999, P NATL ACAD SCI USA, V96, P1657, DOI 10.1073/pnas.96.4.1657; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Radin N S, 1981, Methods Enzymol, V72, P673; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Scheek S, 1997, P NATL ACAD SCI USA, V94, P11179, DOI 10.1073/pnas.94.21.11179; Schuchman EH, 2001, METABOLIC MOL BASES, V3, P3589; SCHWARZMANN G, 1995, J BIOL CHEM, V270, P21271, DOI 10.1074/jbc.270.36.21271; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SCRIVER CR, 2001, METABOLIC MOL BASES, V3, P3371; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sillence DJ, 2002, J LIPID RES, V43, P1837, DOI 10.1194/jlr.M200232-JLR200; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; THOMAS PD, 1988, BIOCHEM J, V251, P55, DOI 10.1042/bj2510055; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	38	78	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20961	20970		10.1074/jbc.M300304200	http://dx.doi.org/10.1074/jbc.M300304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12657626	hybrid			2022-12-27	WOS:000183230500068
J	Toikkanen, JH; Miller, KJ; Soderlund, H; Jantti, J; Keranen, S				Toikkanen, JH; Miller, KJ; Soderlund, H; Jantti, J; Keranen, S			The beta subunit of the Sec61p endoplasmic reticulum translocon interacts with the exocyst complex in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; PROTEIN TRANSLOCATION; SECRETORY PROTEIN; RIBOSOME RECEPTOR; PLASMA-MEMBRANE; YEAST; COMPONENTS; TRANSPORT; EXOCYTOSIS; BINDING	The exocyst is a conserved protein complex proposed to mediate vesicle tethering at the plasma membrane. Previously, we identified SEB1/SBH1, encoding the beta subunit of the Sec61p ER translocation complex, as a multicopy suppressor of the sec15-1 mutant, defective for one subunit of the exocyst complex. Here we show the functional and physical interaction between components of endoplasmic reticulum translocon and the exocytosis machinery. We show that overexpression of SEB1 suppresses the growth defect in all exocyst sec mutants. In addition, overexpression of SEC61 or SSS1 encoding the other two components of the Sec61p complex suppressed the growth defects of several exocyst mutants. Seb1p was coimmunoprecipitated from yeast cell lysates with Sec15p and Sec8p, components of the exocyst complex, and with Sec4p, a secretory vesicle associated Rab GTPase that binds to Sec15p and is essential for exocytosis. The interaction between Seb1p and Sec15p was abolished in sec15-1 mutant and was restored upon SEB1 overexpression. Furthermore, in wild type cells overexpression of SEB1 as well as SEC4 resulted in increased production of secreted proteins. These findings propose a novel functional and physical link between the endoplasmic reticulum translocation complex and the exocyst.	VTT Biotechnol, FIN-02044 Espoo, Finland	VTT Technical Research Center Finland	Keranen, S (corresponding author), VTT Biotechnol, POB 1500, FIN-02044 Espoo, Finland.	sirkka.keranen@vtt.fi						AALTO MK, 1993, EMBO J, V12, P4095, DOI 10.1002/j.1460-2075.1993.tb06093.x; Adamo JE, 2001, J CELL BIOL, V155, P581, DOI 10.1083/jcb.200106065; Adamo JE, 1999, MOL BIOL CELL, V10, P4121, DOI 10.1091/mbc.10.12.4121; Awasthi S, 2001, J BIOL CHEM, V276, P31004, DOI 10.1074/jbc.M100022200; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; Brachmann CB, 1998, YEAST, V14, P115; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; DESHAIES RJ, 1989, J CELL BIOL, V109, P2653, DOI 10.1083/jcb.109.6.2653; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Finke K, 1996, EMBO J, V15, P1482, DOI 10.1002/j.1460-2075.1996.tb00492.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; Guo W, 1999, J BIOL CHEM, V274, P23558, DOI 10.1074/jbc.274.33.23558; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Haarer BK, 1996, GENETICS, V144, P495; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Hazuka CD, 1999, J NEUROSCI, V19, P1324; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jantti J, 2002, J CELL SCI, V115, P409; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; Lipschutz JH, 2003, J BIOL CHEM, V278, P20954, DOI 10.1074/jbc.M213210200; Lipschutz JH, 2002, CURR BIOL, V12, pR212, DOI 10.1016/S0960-9822(02)00753-4; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Pilon M, 1998, MOL BIOL CELL, V9, P3455, DOI 10.1091/mbc.9.12.3455; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; Prinz A, 2000, BIOL CHEM, V381, P1025, DOI 10.1515/BC.2000.126; Prinz WA, 2000, J CELL BIOL, V150, P461, DOI 10.1083/jcb.150.3.461; Ram RJ, 2002, MOL BIOL CELL, V13, P1484, DOI 10.1091/mbc.01-10-0495; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; RUOHONEN L, 1995, J BIOTECHNOL, V39, P193, DOI 10.1016/0168-1656(95)00024-K; Ruohonen L, 1997, YEAST, V13, P337, DOI 10.1002/(SICI)1097-0061(19970330)13:4<337::AID-YEA98>3.3.CO;2-B; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SALMINEN A, 1989, J CELL BIOL, V109, P1023, DOI 10.1083/jcb.109.3.1023; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; SHERMAN F, 1983, METHODS YEAST GENETI, P61; Shin DM, 2000, J CELL BIOL, V150, P1101, DOI 10.1083/jcb.150.5.1101; Short B, 2002, CURR BIOL, V12, pR18, DOI 10.1016/S0960-9822(01)00641-8; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; Terbush DR, 2001, METHOD ENZYMOL, V329, P100; Toikkanen J, 1996, YEAST, V12, P425, DOI 10.1002/(SICI)1097-0061(199604)12:5<425::AID-YEA924>3.3.CO;2-2; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Whyte JRC, 2001, DEV CELL, V1, P527, DOI 10.1016/S1534-5807(01)00063-6; Wilkinson BM, 2001, DEV CELL, V1, P401, DOI 10.1016/S1534-5807(01)00043-0; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	65	65	67	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20946	20953		10.1074/jbc.M213111200	http://dx.doi.org/10.1074/jbc.M213111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12665530	hybrid			2022-12-27	WOS:000183230500066
J	Wang, PJ; Kim, RB; Chowdhury, JR; Wolkoff, AW				Wang, PJ; Kim, RB; Chowdhury, JR; Wolkoff, AW			The human organic anion transport protein SLC21A6 is not sufficient for bilirubin transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; UNCONJUGATED BILIRUBIN; HEPATIC-UPTAKE; ALBUMIN; SULFOBROMOPHTHALEIN; POLYPEPTIDE; HEPATOCYTES; MECHANISM; MEMBRANE; BINDING	A recent study (Cui, Y., Konig, J., Leier, I., Buchholz, U., and Keppler, D. (2001) J. Biol. Chem. 276, 9626-9630) suggests that human OATP2 (SLC21A6), also known as OATP-C and LST1, mediates hepatic bilirubin transport. Because of methodologic concerns, this study was designed to examine this issue using a bilirubin transport assay that was validated in overnight cultured rat hepatocytes. These studies showed that cultured rat hepatocytes transported bilirubin with kinetics virtually identical to the transport of sulfobromophthalein. This assay was then used to quantify bilirubin transport by HeLa cells that had been stably transfected with OATP2 under regulation of a metallothionein promoter. Immunoblot analysis revealed abundant expression of OATP2 after incubation of cells for 48 h in zinc, whereas uninduced cells had no expression of this protein. In OATP2-expressing (zinc-induced) HeLa cells at 37degreesC, the uptake of [S-35] sulfobromophthalein was substantial (51.6+/-16.5 pmol/15 min/mg protein, n=5) with little cell-associated ligand in non-expressing (uninduced) cells (0.54+/-0.16 pmol/15 min/mg protein, n=5, p<0.002). In contrast, there was no difference (p>0.2) in cell-associated [H-3] bilirubin in induced (OATP2-expressing) as compared with uninduced cells (11.25+/-3.02 pmol/15 min/mg protein versus 9.15+/-1.68 pmol/min/mg protein, respectively, n=5) We obtained similar results in OATP2-transfected HEK293 cells that were used in the original report. The existence of a bilirubin transporter has been an important field of investigation for many years. Although the current study indicates that a role for OATP2 in hepatocyte bilirubin transport is unlikely, it provides new and sensitive tools that can be adapted to examine the function of putative bilirubin transporters in the future.	Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Yeshiva University; Albert Einstein College of Medicine; Vanderbilt University; Vanderbilt University	Wolkoff, AW (corresponding author), Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 625 Ullmann Bldg,1300 Morris Pk Ave, Bronx, NY 10461 USA.	wolkoff@aecom.yu.edu	Kim, Richard/D-6971-2011	Kim, Richard/0000-0001-8148-1632	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK023026, R01DK046057] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM054724, R01GM054724] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK23026, DK46057] Funding Source: Medline; NIGMS NIH HHS [GM54724] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Angeletti RH, 1998, AM J PHYSIOL-CELL PH, V275, pC882, DOI 10.1152/ajpcell.1998.275.3.C882; Bergwerk AJ, 1996, AM J PHYSIOL-GASTR L, V271, pG231, DOI 10.1152/ajpgi.1996.271.2.G231; BLOOMER JR, 1976, AM J PHYSIOL, V230, P736; BONNETT R, 1976, NATURE, V262, P326, DOI 10.1038/262326a0; BRIZ O, 2003, IN PRESS BIOCH J; Cui Y, 2001, J BIOL CHEM, V276, P9626, DOI 10.1074/jbc.M004968200; GARTNER U, 1982, GASTROENTEROLOGY, V83, P1163; HUNTON DB, 1961, J CLIN INVEST, V40, P1648, DOI 10.1172/JCI104387; JACOBSEN J, 1983, J BIOL CHEM, V258, P6319; JACOBSEN J, 1969, FEBS LETT, V5, P112, DOI 10.1016/0014-5793(69)80307-8; Kanai N, 1996, AM J PHYSIOL-RENAL, V270, pF326, DOI 10.1152/ajprenal.1996.270.2.F326; Konig J, 2000, AM J PHYSIOL-GASTR L, V278, pG156, DOI 10.1152/ajpgi.2000.278.1.G156; KULLAKUBLICK GA, 1994, HEPATOLOGY, V20, P411; KURISU H, 1989, ANAL BIOCHEM, V179, P72, DOI 10.1016/0003-2697(89)90202-9; Mediavilla MG, 1999, FEBS LETT, V463, P143, DOI 10.1016/S0014-5793(99)01606-3; MIN AD, 1991, J CLIN INVEST, V87, P1496, DOI 10.1172/JCI115159; NISHIDA T, 1992, J CLIN INVEST, V90, P2130, DOI 10.1172/JCI116098; PAUMGARTNER G, 1976, CLIN SCI MOL MED, V51, P169, DOI 10.1042/cs0510169; SCHARSCHMIDT BF, 1975, J CLIN INVEST, V56, P1280, DOI 10.1172/JCI108204; SHI XY, 1995, J BIOL CHEM, V270, P25591, DOI 10.1074/jbc.270.43.25591; STOLLMAN YR, 1983, J CLIN INVEST, V72, P718, DOI 10.1172/JCI111021; THEILMANN L, 1984, HEPATOLOGY, V4, P923, DOI 10.1002/hep.1840040523; Tirona RG, 2001, J BIOL CHEM, V276, P35669, DOI 10.1074/jbc.M103792200; WOLKOFF AW, 1979, AM J PHYSIOL, V236, pE638, DOI 10.1152/ajpendo.1979.236.6.E638; WOLKOFF AW, 1987, J CLIN INVEST, V79, P1259, DOI 10.1172/JCI112946; Zucker SD, 1999, J BIOL CHEM, V274, P10852, DOI 10.1074/jbc.274.16.10852; Zucker SD, 2000, BBA-BIOMEMBRANES, V1463, P197, DOI 10.1016/S0005-2736(99)00196-0	27	59	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2003	278	23					20695	20699		10.1074/jbc.M301100200	http://dx.doi.org/10.1074/jbc.M301100200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	684WY	12670950	hybrid			2022-12-27	WOS:000183230500034
J	Barrowman, J; Wang, W; Zhang, YY; Ferro-Novick, S				Barrowman, J; Wang, W; Zhang, YY; Ferro-Novick, S			The Yip1p center dot Yif1p complex is required for the fusion competence of endoplasmic reticulum-derived vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MEMBRANE-PROTEIN; GDP-DISSOCIATION INHIBITOR; PRENYLATED RAB ACCEPTOR; TRANSPORT VESICLES; SNARE COMPLEXES; YEAST GENES; GTPASE; BINDING; DOCKING; YPT1P	Here we report that Yip1p and Yif1p, two members of an integral membrane protein complex that bind to the Rab Ypt1p, are required for membrane fusion with the Golgi in vitro. To block fusion, anti-Yip1p or anti-Yif1p antibodies must be added before vesicles bud from the endoplasmic reticulum (ER). These antibodies do not block the packaging of Yip1p, Yif1p, or the soluble NSF attachment protein receptor (SNAREs) into vesicles. We propose that Yip1p and Yif1p perform a critical role in establishing the fusion competence of ER to Golgi vesicles at the time of budding. Consistent with this proposal, we observe that the Yip1p.Yif1p complex binds to the ER to Golgi SNAREs Bos1p and Sec22p, two components of the membrane fusion machinery.	Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Cell Biol, New Haven, CT 06519 USA	Howard Hughes Medical Institute; Yale University	Ferro-Novick, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Cell Biol, 295 Congress Ave,Rm 254B, New Haven, CT 06519 USA.	susan.ferronovick@yale.edu						Abdul-Ghani M, 2001, J BIOL CHEM, V276, P6225, DOI 10.1074/jbc.M009073200; BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; Barrowman J, 2000, EMBO J, V19, P862, DOI 10.1093/emboj/19.5.862; Benli M, 1996, EMBO J, V15, P6460, DOI 10.1002/j.1460-2075.1996.tb01037.x; Bucci C, 1999, BIOCHEM BIOPH RES CO, V258, P657, DOI 10.1006/bbrc.1999.0651; Calero M, 2002, FEBS LETT, V515, P89, DOI 10.1016/S0014-5793(02)02442-0; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Dieter B, 2002, PFLUG ARCH EUR J PHY, V443, P333, DOI 10.1007/s00424-001-0742-4; DiracSvejstrup AB, 1997, EMBO J, V16, P465, DOI 10.1093/emboj/16.3.465; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Gerber SH, 2001, EMBO J, V20, P1605, DOI 10.1093/emboj/20.7.1605; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; JANOUEIXLEROSEY I, 1995, J BIOL CHEM, V270, P14801, DOI 10.1074/jbc.270.24.14801; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; Jedd G, 1997, J CELL BIOL, V137, P563, DOI 10.1083/jcb.137.3.563; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Liang ZM, 2000, BIOCHEM BIOPH RES CO, V275, P509, DOI 10.1006/bbrc.2000.3316; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; Matern H, 2000, EMBO J, V19, P4485, DOI 10.1093/emboj/19.17.4485; Mayer A, 1999, CURR OPIN CELL BIOL, V11, P447, DOI 10.1016/S0955-0674(99)80064-7; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Parlati F, 2002, P NATL ACAD SCI USA, V99, P5424, DOI 10.1073/pnas.082100899; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; RUOHOLA H, 1988, J CELL BIOL, V107, P1465, DOI 10.1083/jcb.107.4.1465; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spang A, 1998, J CELL BIOL, V143, P589, DOI 10.1083/jcb.143.3.589; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Stone S, 1997, MOL BIOL CELL, V8, P1175, DOI 10.1091/mbc.8.7.1175; Tang BL, 2001, J BIOL CHEM, V276, P40008, DOI 10.1074/jbc.M106189200; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; Wang W, 2002, MOL BIOL CELL, V13, P3336, DOI 10.1091/mbc.01-12-0577; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Whyte JRC, 2002, J CELL SCI, V115, P2627; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Yang XP, 1998, EMBO J, V17, P4954, DOI 10.1093/emboj/17.17.4954	50	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19878	19884		10.1074/jbc.M302406200	http://dx.doi.org/10.1074/jbc.M302406200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12657649	hybrid			2022-12-27	WOS:000183078000040
J	Cannon, W; Bordes, P; Wigneshweraraj, SR; Buck, M				Cannon, W; Bordes, P; Wigneshweraraj, SR; Buck, M			Nucleotide-dependent triggering of RNA polymerase-DNA interactions by an AAA regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL-CHANGES; TERMINAL SEQUENCES; ESCHERICHIA-COLI; BINDING PROTEIN; SIGMA(54); SIGMA-54; ATPASE; ROLES; NTRC	Enhancer-dependent activator proteins, which act upon the bacterial RNA polymerase containing the sigma(54) promoter specificity factor, belong to the AAA superfamily of ATPases. Activator-sigma(54) contact is required for the sigma(54)-RNAP to isomerize and engage the DNA template for transcription. How ATP hydrolysis is used to trigger changes in sigma(54)-RNA polymerase and promoter DNA that lead to DNA opening is poorly understood. Here, band shift and footprinting assays were used to investigate the DNA binding activities of sigma(54) and sigma(54)-RNA polymerase in the presence of the activator protein PspF bound to poorly hydrolysable analogues of ATP and the ATP hydrolysis transition-state analogue ADP.AlFx. Results show that different nucleotide-bound forms of PspF can change the interactions between sigma(54), sigma(54)-RNA polymerase, and a DNA fork junction structure present within closed promoter complexes. This provides evidence that in the activation transduction pathway, several functional states of the activator, prior to ATP hydrolysis, can serve to alter the fork junction binding activity of sigma(54) and sigma(54)-RNA polymerase that precede full DNA opening. A sequential set of nucleotide-dependent transitions in sigma(54)-RNA polymerase promoter complexes needed for productive open complex formation may therefore depend upon different nucleotide-bound forms of the activator.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AZ, England	Imperial College London	Buck, M (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Sir Alexander Fleming Bldg,S Kensington Campus, London SW7 2AZ, England.	m.buck@imperial.ac.uk		Wigneshweraraj, Sivaramesh/0000-0002-1418-4029; Bordes, Patricia/0000-0002-5746-0556				Bordes P, 2003, P NATL ACAD SCI USA, V100, P2278, DOI 10.1073/pnas.0537525100; Buck M, 2000, J BACTERIOL, V182, P4129, DOI 10.1128/JB.182.15.4129-4136.2000; CANNON W, 1995, J MOL BIOL, V248, P781, DOI 10.1006/jmbi.1995.0260; Cannon W, 1999, GENE DEV, V13, P357, DOI 10.1101/gad.13.3.357; Cannon W, 2001, J BIOL CHEM, V276, P386, DOI 10.1074/jbc.M007779200; Cannon WV, 2000, NAT STRUCT BIOL, V7, P594; Casaz P, 1999, J MOL BIOL, V292, P229, DOI 10.1006/jmbi.1999.3076; Chaney M, 2001, GENE DEV, V15, P2282, DOI 10.1101/gad.205501; Darst RP, 2003, J BIOL CHEM, V278, P13216, DOI 10.1074/jbc.M211445200; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Guo YL, 2000, GENE DEV, V14, P2242, DOI 10.1101/gad.794800; Guo YL, 1999, EMBO J, V18, P3736, DOI 10.1093/emboj/18.13.3736; MERRICK MJ, 1993, MOL MICROBIOL, V10, P903, DOI 10.1111/j.1365-2958.1993.tb00961.x; MORRIS L, 1994, J BIOL CHEM, V269, P11563; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; Rombel I, 1998, COLD SPRING HARB SYM, V63, P157, DOI 10.1101/sqb.1998.63.157; Rouiller I, 2002, NAT STRUCT BIOL, V9, P950, DOI 10.1038/nsb872; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Wang J, 2001, STRUCTURE, V9, P1107, DOI 10.1016/S0969-2126(01)00670-0; Wigneshweraraj SR, 2003, J BIOL CHEM, V278, P3455, DOI 10.1074/jbc.M209442200; Wigneshweraraj SR, 2001, J MOL BIOL, V306, P681, DOI 10.1006/jmbi.2000.4393; Wosten MMSM, 1998, FEMS MICROBIOL REV, V22, P127, DOI 10.1016/S0168-6445(98)00011-4; Wyman C, 1997, SCIENCE, V275, P1658, DOI 10.1126/science.275.5306.1658; Zhang X, 2002, MOL MICROBIOL, V45, P895, DOI 10.1046/j.1365-2958.2002.03065.x	26	25	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19815	19825		10.1074/jbc.M301296200	http://dx.doi.org/10.1074/jbc.M301296200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12649285	hybrid			2022-12-27	WOS:000183078000033
J	Gamel-Didelon, K; Kunz, L; Fohr, KJ; Gratzl, M; Mayerhofer, A				Gamel-Didelon, K; Kunz, L; Fohr, KJ; Gratzl, M; Mayerhofer, A			Molecular and physiological evidence for functional gamma-aminobutyric acid (GABA)-C receptors in growth hormone-secreting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL BIPOLAR CELLS; GABA(C) RECEPTOR; RHO-SUBUNITS; PHARMACOLOGICAL PROPERTIES; ANTERIOR-PITUITARY; CHLORIDE CHANNELS; XENOPUS OOCYTES; IN-VITRO; SYSTEMS; EXPRESSION	The neurotransmitter gamma-aminobutyric acid (GABA), released by hypothalamic neurons as well as by growth hormone-(GH) and adrenocorticotropin-producing cells, is a regulator of pituitary endocrine functions. Different classes of GABA receptors may be involved. In this study, we report that GH cells, isolated by laser microdissection from rat pituitary slices, possess the GABA-C receptor subunit rho(2). We also demonstrate that in the GH adenoma cell line, GH3, GABA-C receptor subunits are not only expressed but also form functional channels. GABA-induced Cl- currents were recorded using the whole cell patch clamp technique; these currents were insensitive to bicuculline (a GABA-A antagonist) but could be induced by the GABA-C agonist cis-4-aminocrotonic acid. In contrast to typical GABA-C mediated currents in neurons, they quickly desensitized. Ca-i(2+) recordings were also performed on GH3 cells. The application of either GABA or cis-4-aminocrotonic acid led to Ca2+ transients of similar amplitude, indicating that the activation of GABA-C receptors in GH3 cells may cause membrane depolarization, opening of voltage-gated Ca2+ channels, and a subsequent Ca2+ influx. Our results point at a role for GABA in pituitary GH cells and disclose an additional pathway to the one known via GABA-B receptors.	Univ Munich, Inst Anat, D-80802 Munich, Germany; Univ Ulm, Anasthesiol Klin, D-89070 Ulm, Germany	University of Munich; Ulm University	Mayerhofer, A (corresponding author), Univ Munich, Inst Anat, Biedersteiner Str 29, D-80802 Munich, Germany.			Mayerhofer, Artur/0000-0002-9388-4639				Akinci MK, 1999, NEUROSCI RES, V35, P145, DOI 10.1016/S0168-0102(99)00078-4; ANDERSON RA, 1986, J ENDOCRINOL, V108, P1, DOI 10.1677/joe.0.1080001; Barnard EA, 1998, PHARMACOL REV, V50, P291; Boue-Grabot E, 2000, ENDOCRINOLOGY, V141, P1627, DOI 10.1210/en.141.5.1627; BoueGrabot E, 1995, BRAIN RES, V704, P125, DOI 10.1016/0006-8993(95)01192-7; Cherubini E, 1998, PERSPECT DEV NEUROBI, V5, P289; Couve A, 2000, MOL CELL NEUROSCI, V16, P296, DOI 10.1006/mcne.2000.0908; Enz R, 2001, BIOL CHEM, V382, P1111, DOI 10.1515/BC.2001.141; Enz R, 1999, EUR J NEUROSCI, V11, P41, DOI 10.1046/j.1460-9568.1999.00423.x; Enz R, 1996, J NEUROSCI, V16, P4479; FOHR KJ, 1993, J CLIN ENDOCR METAB, V76, P367, DOI 10.1210/jc.76.2.367; Fritz S, 2002, J CLIN ENDOCR METAB, V87, P1362, DOI 10.1210/jc.87.3.1362; Frungieri MB, 2002, FERTIL STERIL, V78, P298, DOI 10.1016/S0015-0282(02)03206-5; Gamel-Didelon K, 2002, NEUROENDOCRINOLOGY, V76, P170, DOI 10.1159/000064523; Hackam AS, 1998, J NEUROCHEM, V70, P40; Han MH, 1997, NEUROREPORT, V8, P1331, DOI 10.1097/00001756-199704140-00003; Hayashi M, 2003, J BIOL CHEM, V278, P1966, DOI 10.1074/jbc.M206758200; Jansen A, 2000, PFLUG ARCH EUR J PHY, V441, P294, DOI 10.1007/s004240000412; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Kullmann PHM, 2002, EUR J NEUROSCI, V15, P1093, DOI 10.1046/j.1460-9568.2002.01946.x; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; Lux-Lantos V, 2001, NEUROENDOCRINOLOGY, V73, P334, DOI 10.1159/000054650; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Mayerhofer A, 1996, BIOL REPROD, V55, P509, DOI 10.1095/biolreprod55.3.509; Mayerhofer Artur, 2001, FASEB Journal, V15, P1089; Pan ZH, 2000, EUR J NEUROSCI, V12, P3137, DOI 10.1046/j.1460-9568.2000.00198.x; POLENZANI L, 1991, P NATL ACAD SCI USA, V88, P4318, DOI 10.1073/pnas.88.10.4318; Qian HH, 1998, J NEUROBIOL, V37, P305, DOI 10.1002/(SICI)1097-4695(19981105)37:2<305::AID-NEU9>3.0.CO;2-6; Safa P, 2001, J BIOL CHEM, V276, P38727, DOI 10.1074/jbc.M103724200; SCHIMCHOWITSCH S, 1991, EXP BRAIN RES, V83, P575; Schutze K, 1998, CELL MOL BIOL, V44, P735; Shields CR, 2000, J NEUROSCI, V20, P2673; SIVILOTTI L, 1991, PROG NEUROBIOL, V36, P35, DOI 10.1016/0301-0082(91)90036-Z; TASHJIAN AH, 1970, J CELL BIOL, V47, P61, DOI 10.1083/jcb.47.1.61; VINCENT SR, 1982, NEUROENDOCRINOLOGY, V34, P117, DOI 10.1159/000123288	35	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20192	20195		10.1074/jbc.M301729200	http://dx.doi.org/10.1074/jbc.M301729200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12660236	hybrid			2022-12-27	WOS:000183078000079
J	Louis, JM; Nesheiwat, I; Chang, LC; Clore, GM; Bewley, CA				Louis, JM; Nesheiwat, I; Chang, LC; Clore, GM; Bewley, CA			Covalent trimers of the internal N-terminal trimeric coiled-coil of gp41 and antibodies directed against them are potent inhibitors of HIV envelope-mediated cell fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PEPTIDE INHIBITOR; NEUTRALIZING ANTIBODIES; ANTIVIRAL ACTIVITY; ATOMIC-STRUCTURE; ENTRY; DESIGN; GLYCOPROTEIN; 2G12; ECTODOMAIN	We have engineered two soluble, covalently linked, trimeric polypeptides, N35(CCG)-N13 and N34(CCG) comprising only the internal trimeric coiled-coil of the ectodomain of HIV-1 gp41. Both trimers inhibit human immunodeficiency virus, type 1 ( HIV-1) envelope (Env)mediated cell fusion at nanomolar concentrations by targeting the exposed C-terminal region of the gp41 ectodomain in the prehairpin intermediate state. The IC50 values for N35(CCG)-N13 and N34(CCG) are similar to15 and similar to95 nM, respectively, in a quantitative vaccinia virus-based reporter gene assay for HIV-1 Env-mediated cell fusion using Env from the T cell tropic strain LAV. Polyclonal antibodies were raised against N35(CCG)-N13 and a tightly binding fraction of anti-N35(CCG)-N13 inhibits T cell and macrophage tropic HIV-1 Env- mediated cell fusion with respective IC50 values of similar to0.5 and similar to1.5 mug/ml at 37 degreesC. The tightly binding anti-N35(CCG)-N13 antibody fraction targets the exposed internal trimeric coiled-coil in the prehairpin intermediate state of gp41 in a manner analogous to peptides derived from the C region of the gp41 ectodomain. The potency of the tightly binding anti-N35(CCG)-N13 antibody fraction in the fusion assay is comparable with that of the broadly neutralizing monoclonal antibody 2G12. These results indicate that N35(CCG)-N13 is a potential anti-HIV therapeutic agent and represents a suitable immunogen for the generation of neutralizing monoclonal antibodies targeted to the internal trimeric coiled-coil of gp41. The data on the tightly binding anti-N35(CCG)-N13 antibody fraction demonstrate that the internal trimeric coiled-coil of gp41 in the prehairpin intermediate state is accessible to antibodies and that access is not restricted by either antibody size or the presence of a kinetic barrier.	NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bewley, CA (corresponding author), NIDDK, Bioorgan Chem Lab, NIH, Bldg 8,Rm 1A-02, Bethesda, MD 20892 USA.	cb194k@nih.gov	Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Bewley, Carole/0000-0003-2203-0852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK029023, Z01DK029023, Z01DK032103, ZIADK032103] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bewley CA, 2002, J BIOL CHEM, V277, P14238, DOI 10.1074/jbc.M201453200; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BRODER CC, 1995, P NATL ACAD SCI USA, V92, P9004, DOI 10.1073/pnas.92.19.9004; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; De Rosny E, 2001, J VIROL, V75, P8859, DOI 10.1128/JVI.75.18.8859-8863.2001; Dimitrov DS, 1999, VIROLOGY, V259, P1, DOI 10.1006/viro.1999.9747; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Harlow E., 1988, ANTIBODIES LAB MANUA; Kilby JM, 2002, AIDS RES HUM RETROV, V18, P685, DOI 10.1089/088922202760072294; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Kliger Y, 2001, J BIOL CHEM, V276, P1391, DOI 10.1074/jbc.M004113200; Koshiba T, 2003, J BIOL CHEM, V278, P7573, DOI 10.1074/jbc.M211154200; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; NASHI LO, 1997, ANAL BIOCHEM, V253, P246; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Stiegler G, 2002, AIDS, V16, P2019, DOI 10.1097/00002030-200210180-00006; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Vaitukaitis J L, 1981, Methods Enzymol, V73, P46; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770	37	96	112	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					20278	20285		10.1074/jbc.M301627200	http://dx.doi.org/10.1074/jbc.M301627200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654905	hybrid			2022-12-27	WOS:000183078000090
J	Pummill, PE; DeAngelis, PL				Pummill, PE; DeAngelis, PL			Alteration of polysaccharide size distribution of a vertebrate hyaluronan synthase by mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATED TERATOCARCINOMA CELLS; CONSERVED CYSTEINE RESIDUES; HUMAN CHONDROSARCOMA CELLS; CHEMOKINE GENE-EXPRESSION; NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; ANGIOGENIC OLIGOSACCHARIDES; MURINE MACROPHAGES; ENDOTHELIAL-CELLS; MOUSE MACROPHAGES	Hyaluronan (HA) is a nonsulfated glycosaminoglycan that has long been known to play structural roles in vertebrates. Recently, it has become increasingly obvious that this linear polysaccharide has many more uses than simply scaffolding or space filler. HA has been found to be involved in development, cell signaling, cell motility, and metastasis. These roles are often dictated by the length of the HA polymer, which can vary from a few to about 10,000 sugar residues in length. Three distinct isoforms of HA synthase exist in mammals. It has been shown previously by others that each isoform produces HA that differs in size distribution, but the regulatory mechanism is not yet known. Mutations have been described that alter the size distribution of the HA produced by the streptococcal HA synthases. We show that by mutating one particular amino acid residue of a vertebrate HA synthase, depending on the introduced side chain, the size of HA produced can be either reduced or increased. We postulate that several cysteine residues and a serine residue may be involved in binding directly or indirectly to the nascent HA chain. These data support the theory that the relative strength of the interaction between the catalyst and the polymer may be a major factor in HA size control.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	DeAngelis, PL (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Dept Biochem & Mol Biol, 940 Stanton L Young Blvd, Oklahoma City, OK 73104 USA.	paul-deangelis@ouhsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asplund T, 1998, BBA-GEN SUBJECTS, V1380, P377, DOI 10.1016/S0304-4165(98)00010-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Camenisch TD, 2000, AM J RESP CELL MOL, V23, P431, DOI 10.1165/ajrcmb.23.4.f201; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; DeAngelis PL, 2000, ANAL BIOCHEM, V284, P167, DOI 10.1006/abio.2000.4699; DeAngelis PL, 1999, CELL MOL LIFE SCI, V56, P670, DOI 10.1007/s000180050461; DeAngelis PL, 1996, J BIOL CHEM, V271, P23657, DOI 10.1074/jbc.271.39.23657; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x; Fujita Y, 2002, FEBS LETT, V528, P101, DOI 10.1016/S0014-5793(02)03262-3; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; HELDERMON C, 1999, NEW FRONTIERS MED SC, P41; Heldermon CD, 2001, GLYCOBIOLOGY, V11, P1017, DOI 10.1093/glycob/11.12.1017; HodgeDufour J, 1997, J IMMUNOL, V159, P2492; Horton MR, 1999, J IMMUNOL, V162, P4171; Horton MR, 1998, J BIOL CHEM, V273, P35088, DOI 10.1074/jbc.273.52.35088; Horton MR, 1998, J IMMUNOL, V160, P3023; Horton MR, 2002, J BIOL CHEM, V277, P43757, DOI 10.1074/jbc.M206007200; Ichikawa T, 1999, J INVEST DERMATOL, V113, P935, DOI 10.1046/j.1523-1747.1999.00804.x; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1999, CANCER RES, V59, P2499; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Koprunner M, 2000, MECH DEVELOP, V90, P275, DOI 10.1016/S0925-4773(99)00238-5; Kosaki R, 1999, CANCER RES, V59, P1141; Kumari K, 2002, J BIOL CHEM, V277, P13943, DOI 10.1074/jbc.M110638200; Laurent T. C., 1996, IMMUNOL CELL BIOL, V74, pA1, DOI [10.1038/icb.1996.32, DOI 10.1038/ICB.1996.32]; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; LEES VC, 1995, LAB INVEST, V73, P259; Li SL, 2000, EMBO J, V19, P1228, DOI 10.1093/emboj/19.6.1228; Liu NF, 2001, CANCER RES, V61, P1022; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Meyer K, 1934, J BIOL CHEM, V107, P629; Nasreen N, 2001, ONCOL RES, V13, P71; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469; Nukui M, 2003, J BIOL CHEM, V278, P3079, DOI 10.1074/jbc.M204999200; Oertli B, 1998, J IMMUNOL, V161, P3431; Ohkawara Y, 2000, AM J RESP CELL MOL, V23, P444, DOI 10.1165/ajrcmb.23.4.3875; PREHM P, 1984, BIOCHEM J, V220, P597, DOI 10.1042/bj2200597; PREHM P, 1983, BIOCHEM J, V211, P181, DOI 10.1042/bj2110181; PREHM P, 1983, BIOCHEM J, V211, P191, DOI 10.1042/bj2110191; Pummill PE, 2002, J BIOL CHEM, V277, P21610, DOI 10.1074/jbc.M202456200; Pummill PE, 1998, J BIOL CHEM, V273, P4976, DOI 10.1074/jbc.273.9.4976; Rockey DC, 1998, HEPATOLOGY, V27, P86, DOI 10.1002/hep.510270115; ROSA F, 1988, DEV BIOL, V129, P114, DOI 10.1016/0012-1606(88)90166-2; SATTAR A, 1994, J INVEST DERMATOL, V103, P576, DOI 10.1111/1523-1747.ep12396880; Sayo T, 2002, J INVEST DERMATOL, V118, P43, DOI 10.1046/j.0022-202x.2001.01613.x; Slevin M, 1998, LAB INVEST, V78, P987; SLEVIN M, 2002, J BIOL CHEM; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1998, J BIOL CHEM, V273, P25117, DOI 10.1074/jbc.273.39.25117; Suzuki M, 2002, BBA-MOL CELL RES, V1591, P37, DOI 10.1016/S0167-4889(02)00246-X; Tammi MI, 2002, J BIOL CHEM, V277, P4581, DOI 10.1074/jbc.R100037200; TANFORD C, 1980, HYDROPHOBIC EFFECT F, P11; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Termeer CC, 2000, J IMMUNOL, V165, P1863, DOI 10.4049/jimmunol.165.4.1863; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WEST DC, 1985, SCIENCE, V228, P1324, DOI 10.1126/science.2408340	70	31	38	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19808	19814		10.1074/jbc.M301097200	http://dx.doi.org/10.1074/jbc.M301097200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12654925	hybrid			2022-12-27	WOS:000183078000032
J	Qin, L; Qiu, P; Wang, LQ; Li, X; Swarthout, JT; Soteropoulos, P; Tolias, P; Partridge, NC				Qin, L; Qiu, P; Wang, LQ; Li, X; Swarthout, JT; Soteropoulos, P; Tolias, P; Partridge, NC			Gene expression profiles and transcription factors involved in parathyroid hormone signaling in osteoblasts revealed by microarray and bioinformatics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ENDOTHELIAL GROWTH-FACTOR; BINDING-PROTEIN; 1,25-DIHYDROXYVITAMIN D-3; BONE-RESORPTION; CELLS; DIFFERENTIATION; RECEPTOR; PROLIFERATION; STIMULATION	Parathyroid hormone (PTH) binds to its receptor PTH1R ( parathyroid hormone 1 receptor) in osteoblastic cells to regulate bone remodeling and calcium homeostasis. While prolonged exposure to PTH causes increased bone resorption, intermittent injections of PTH have an anabolic effect on bone. The molecular mechanisms regulating these processes are still largely unknown. Here, we present our results on gene expression profile changes in the PTH-treated osteoblastic cell line, UMR 106-01, using DNA microarray analysis. A total of 125 known genes and 30 unknown expressed sequence tags ( ESTs) were found to have at least 2-fold expression changes after PTH treatment at 4, 12, and 24 h. 14 genes were previously known to be PTH-regulated but many were unknown to be regulated by PTH prior to our experiments. Real-time reverse transcriptase-PCR confirmed that 90 and 50% of the genes are regulated more than 2-fold by PTH in UMR 106-01 and rat primary osteoblastic cells, respectively. Most genes belong to the following protein families: hormones, growth factors, and receptors; signal transduction pathway proteins; transcription factors; proteases; metabolic enzymes; structural and matrix proteins; transporters; etc. These results provide a comprehensive and deeper knowledge about PTH regulation of osteoblastic gene expression. Next, we designed a computational method to extract information about transcription factors likely involved in regulating these genes. These factors include those previously known to be involved in PTH signaling (AP-1 and the cAMP response element-binding protein), those that were identified by microarray data (C/EBP), and some novel transcription factors ( AP-2, AP-4, SP1, FoxD3, etc.). Our results suggest that a reliable bioinformatics approach can be easily applied for other systems.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Schering Plough Corp, Res Inst, Bioinformat Grp, Kenilworth, NJ 07033 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07107 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Publ Hlth Res Inst, Ctr Appl Genom, Newark, NJ 07107 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Schering Plough Corporation; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Partridge, NC (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	partrinc@umdnj.edu	Qin, Ling/B-3147-2012	Swarthout, John/0000-0002-3043-9386; Partridge, Nicola/0000-0002-5406-4814	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK48109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABASSI ZA, 1992, HYPERTENSION, V20, P89, DOI 10.1161/01.HYP.20.1.89; Ahmed N, 2000, CYTOKINE, V12, P289, DOI 10.1006/cyto.1999.0588; Bassi DE, 2000, MOL CARCINOGEN, V28, P63, DOI 10.1002/1098-2744(200006)28:2<63::AID-MC1>3.3.CO;2-3; Bhangu PS, 2001, BONE, V29, P16, DOI 10.1016/S8756-3282(01)00482-3; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUDER JM, 2001, ENDOCRINOL METAB, P1090; CHASE LR, 1970, J BIOL CHEM, V245, P1520; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; CIVITELLI R, 1988, AM J PHYSIOL, V255, pE660, DOI 10.1152/ajpendo.1988.255.5.E660; Cole JA, 1999, ENDOCRINOLOGY, V140, P5771, DOI 10.1210/en.140.12.5771; Datta HK, 1996, J ENDOCRINOL, V149, P269, DOI 10.1677/joe.0.1490269; Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667; DOBNIG H, 1995, ENDOCRINOLOGY, V136, P3632, DOI 10.1210/en.136.8.3632; Dottori M, 2001, DEVELOPMENT, V128, P4127; Farach-Carson MC, 2002, STEROIDS, V67, P467, DOI 10.1016/S0039-128X(01)00168-4; Feldman D, 1999, AM J MED, V107, P637, DOI 10.1016/S0002-9343(99)00283-1; FORREST SM, 1985, CALCIFIED TISSUE INT, V37, P51, DOI 10.1007/BF02557679; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200; Horwood NJ, 1998, J CLIN INVEST, V101, P595, DOI 10.1172/JCI1333; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; Huang XQ, 1997, GENOMICS, V46, P37, DOI 10.1006/geno.1997.4984; Hurley MM, 1999, J BONE MINER RES, V14, P776, DOI 10.1359/jbmr.1999.14.5.776; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; Kasperk CH, 1997, CALCIFIED TISSUE INT, V60, P368, DOI 10.1007/s002239900245; Kitten AM, 2001, J CELL PHYSIOL, V187, P218, DOI 10.1002/jcp.1072; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; NG KW, 1983, CALCIFIED TISSUE INT, V35, P624, DOI 10.1007/BF02405105; Oklu R, 2000, BIOCHEM J, V352, P601, DOI 10.1042/0264-6021:3520601; Onishi T, 1997, ENDOCRINOLOGY, V138, P1995, DOI 10.1210/en.138.5.1995; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; PARTRIDGE NC, 1980, FEBS LETT, V115, P139, DOI 10.1016/0014-5793(80)80744-7; PARTRIDGE NC, 1982, ENDOCRINOLOGY, V111, P178, DOI 10.1210/endo-111-1-178; PARTRIDGE NC, 1981, ENDOCRINOLOGY, V108, P213, DOI 10.1210/endo-108-1-213; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Qiu P, 2002, MAMM GENOME, V13, P327, DOI 10.1007/s00335-001-2141-8; Raouf A, 2002, BONE, V30, P463, DOI 10.1016/S8756-3282(01)00699-8; Schiller PC, 1999, J BONE MINER RES, V14, P1504, DOI 10.1359/jbmr.1999.14.9.1504; Schlaeppi JM, 1997, ENDOCR RES, V23, P213, DOI 10.3109/07435809709031855; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Semler DE, 2000, CELL CALCIUM, V28, P55, DOI 10.1054/ceca.2000.0129; SHALHOUB V, 1989, BIOCHEMISTRY-US, V28, P5318, DOI 10.1021/bi00439a002; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Swarthout JT, 2002, J BONE MINER RES, V17, P1401, DOI 10.1359/jbmr.2002.17.8.1401; Swarthout JT, 2001, J BIOL CHEM, V276, P7586, DOI 10.1074/jbc.M007400200; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Vaes BLT, 2002, J BONE MINER RES, V17, P2106, DOI 10.1359/jbmr.2002.17.12.2106; VERHEIJEN MHG, 1995, ENDOCRINOLOGY, V136, P3331, DOI 10.1210/en.136.8.3331; Verheijen MHG, 1997, J BIOL CHEM, V272, P3423, DOI 10.1074/jbc.272.6.3423; Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316	55	140	151	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2003	278	22					19723	19731		10.1074/jbc.M212226200	http://dx.doi.org/10.1074/jbc.M212226200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	682EH	12644456	hybrid			2022-12-27	WOS:000183078000022
J	De Gaudenzi, JG; D'Orso, I; Frasch, ACC				De Gaudenzi, JG; D'Orso, I; Frasch, ACC			RNA recognition motif-type RNA-binding proteins in Trypanosoma cruzi form a family involved in the interaction with specific transcripts in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; AU-RICH; POLY(A)-BINDING PROTEIN; 3'-UNTRANSLATED REGION; GENOME; GENES; DESTABILIZATION; STABILITY; DIVERSITY; ELEMENTS	Trypanosomes, protozoan parasites from the order Kinetoplastida, have to deal with environmental changes during the interaction with their hosts. Trypanosoma cruzi, the causative agent of Chagas' disease, uses post-transcriptional mechanisms to regulate gene expression. However, few RNA-binding proteins involved in mRNA turnover control have been identified to date. In this work, an RNA recognition motif (RRM)type RNA-binding protein family named T. cruzi RNA-binding protein ( TcRBP) and composed of at least six members was identified. The genomic organization of four members revealed a head to tail arrangement within a region of 15 kilobase pairs. TcRBP members have a common RRM and different auxiliary domains with a high content of glycine, glutamine, and histidine residues within their N- and C-terminal regions. TcRBPs differ in their expression patterns as well as in their homoribopolymer binding interaction in vitro, although they preferentially recognize poly( U) and poly( G) RNAs. An interesting observation was the relaxed RNA-binding interactions with several trypanosome transcripts in vitro. In contrast, co-immunoprecipitation experiments of TcRBP-containing ribonucleoprotein complexes formed in vivo revealed a highly restricted binding interaction with specific RNAs. Several TcRBP-containing complexes are stage-specific and, in some cases, bear the poly(A)-binding protein TcPABP1. Altogether, these results suggest that TcRBPs might be modulated in vivo, to favor or preclude the interaction with specific transcripts in a developmentally regulated manner.	Consejo Nacl Invest Cient & Tecn, UNSAM, INTI, IIB,Inst Tecnol Chascomus, RA-1650 San Martin, Buenos Aires, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Instituto Nacional de Tecnologia Industrial (INTI)	Frasch, ACC (corresponding author), Consejo Nacl Invest Cient & Tecn, UNSAM, INTI, IIB,Inst Tecnol Chascomus, Av Gral Paz S-N,Edificio 24,Casilla Correo 30, RA-1650 San Martin, Buenos Aires, Argentina.			Frasch, Alberto Carlos/0000-0001-7532-653X				BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BATISTA JAN, 1994, MOL BIOCHEM PARASIT, V67, P301, DOI 10.1016/0166-6851(94)00133-2; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; BRENER Z, 1973, ANNU REV MICROBIOL, V27, P347, DOI 10.1146/annurev.mi.27.100173.002023; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Cazzulo JJ, 1997, BIOL CHEM, V378, P1; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CYA, 2002, MOL CELL BIOL, V22, P7268, DOI 10.1128/MCB.22.20.7268-7278.2002; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; D'Orso I, 2002, J BIOL CHEM, V277, P50520, DOI 10.1074/jbc.M209092200; D'Orso I, 2001, J BIOL CHEM, V276, P15783, DOI 10.1074/jbc.M010959200; D'Orso I, 2001, J BIOL CHEM, V276, P34801, DOI 10.1074/jbc.M102120200; Das A, 2003, P NATL ACAD SCI USA, V100, P80, DOI 10.1073/pnas.262609399; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Di Noia JM, 2000, J BIOL CHEM, V275, P10218, DOI 10.1074/jbc.275.14.10218; Di Noia JM, 2002, J EXP MED, V195, P401, DOI 10.1084/jem.20011433; DiNoia JM, 1996, J BIOL CHEM, V271, P32078, DOI 10.1074/jbc.271.50.32078; Good PJ, 2000, J BIOL CHEM, V275, P28583, DOI 10.1074/jbc.M003083200; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hanke J, 1996, BIOTECHNIQUES, V21, P686; LATCHMAN DS, 1998, EUKARYOTIC TRANSCRIP, P271; Lee MGS, 1997, ANNU REV MICROBIOL, V51, P463, DOI 10.1146/annurev.micro.51.1.463; Li JX, 2002, NATURE, V418, P793, DOI 10.1038/nature00936; Lorkovic ZJ, 2002, NUCLEIC ACIDS RES, V30, P623, DOI 10.1093/nar/30.3.623; Niederberger N, 1998, RNA, V4, P1259, DOI 10.1017/S1355838298980487; Perez-Canadillas JM, 2001, CURR OPIN STRUC BIOL, V11, P53, DOI 10.1016/S0959-440X(00)00164-0; Sambrook J., 2002, MOL CLONING LAB MANU; Shamoo Y, 1997, NAT STRUCT BIOL, V4, P215, DOI 10.1038/nsb0397-215; Silva FP, 2002, MEM I OSWALDO CRUZ, V97, P335, DOI 10.1590/S0074-02762002000300010; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vermel M, 2002, P NATL ACAD SCI USA, V99, P5866, DOI 10.1073/pnas.092019599; von Mering C, 2002, NATURE, V417, P797, DOI 10.1038/417797a; Williams C, 1999, MOL CELL BIOL, V19, P376; Wirth DF, 2002, NATURE, V419, P495, DOI 10.1038/419495a; Zingales B, 1997, ACTA TROP, V68, P159, DOI 10.1016/S0001-706X(97)00088-0	42	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18884	18894		10.1074/jbc.M301756200	http://dx.doi.org/10.1074/jbc.M301756200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12637517	hybrid			2022-12-27	WOS:000182932200024
J	Stary, A; Kannouche, P; Lehmann, AR; Sarasin, A				Stary, A; Kannouche, P; Lehmann, AR; Sarasin, A			Role of DNA polymerase eta in the UV mutation spectrum in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM VARIANT CELLS; THYMINE-THYMINE DIMER; CYCLOBUTANE PYRIMIDINE DIMERS; XERODERMA-PIGMENTOSUM; TRANSLESION SYNTHESIS; MAMMALIAN-CELLS; SHUTTLE VECTOR; TRICHOTHIODYSTROPHY CELLS; 6-4 PHOTOPRODUCT; ESCHERICHIA-COLI	In humans, inactivation of the DNA polymerase eta gene (pol eta) results in sunlight sensitivity and causes the cancer-prone xeroderma pigmentosum variant syndrome (XP-V). Cells from XP-V individuals have a reduced capacity to replicate UV-damaged DNA and show hypermutability after UV exposure. Biochemical assays have demonstrated the ability of pol eta to bypass cis-syn-cyclobutane thymine dimers, the most common lesion generated in DNA by UV. In most cases, this bypass is error-free. To determine the actual requirement of pol eta in vivo, XP-V cells (XP30RO) were complemented by the wild type pol eta gene. We have used two pol eta-corrected clones to study the in vivo characteristics of mutations produced by DNA polymerases during DNA synthesis of UV-irradiated shuttle vectors transfected into human host cells, which had or had not been exposed previously to UV radiation. The functional complementation of XP-V cells by pol eta reduced the mutation frequencies both at CG and TA base pairs and restored UV mutagenesis to a normal level. UV irradiation of host cells prior to transfection strongly increased the mutation frequency in undamaged vectors and, in addition, especially in the pol eta-deficient XP30RO cells at 5'-TT sites in UV-irradiated plasmids. These results clearly show the protective role of pol eta against UV-induced lesions and the activation by UV of pol eta-independent mutagenic processes.	Inst Gustave Roussy, Lab Genet Instabil & Canc, CNRS, UPR 2169, F-94805 Villejuif, France; Univ Sussex, Genome Damage & Stabil Ctr, Brighton BN1 9RQ, E Sussex, England	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; University of Sussex	Stary, A (corresponding author), Inst Gustave Roussy, Lab Genet Instabil & Canc, CNRS, UPR 2169, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	stary@igr.fr	stary, anne/GRY-3781-2022					ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; ARLETT CF, 1975, MUTAT RES, V33, P341, DOI 10.1016/0027-5107(75)90209-2; Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brash DE, 1997, TRENDS GENET, V13, P410, DOI 10.1016/S0168-9525(97)01246-8; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; Broughton BC, 2002, P NATL ACAD SCI USA, V99, P815, DOI 10.1073/pnas.022473899; CARIELLO NF, 1994, CANCER RES, V54, P4454; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Douki T, 2001, BIOCHEMISTRY-US, V40, P2495, DOI 10.1021/bi0022543; Ensch-Simon I, 1998, BIOCHEMISTRY-US, V37, P8218, DOI 10.1021/bi972460j; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gentil A, 1996, NUCLEIC ACIDS RES, V24, P1837, DOI 10.1093/nar/24.10.1837; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Kamiya H, 1998, NUCLEIC ACIDS RES, V26, P2611, DOI 10.1093/nar/26.11.2611; Kannouche P, 2001, GENE DEV, V15, P158, DOI 10.1101/gad.187501; Kannouche P, 2002, EMBO J, V21, P6246, DOI 10.1093/emboj/cdf618; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; LAWRENCE CW, 1993, MUTAT RES, V299, P157, DOI 10.1016/0165-1218(93)90093-S; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Lehmann AR, 2000, GENE, V253, P1, DOI 10.1016/S0378-1119(00)00250-X; MAHER VM, 1976, NATURE, V261, P593, DOI 10.1038/261593a0; Marionnet C, 1998, CANCER RES, V58, P102; MARIONNET C, 1995, J MOL BIOL, V252, P550, DOI 10.1006/jmbi.1995.0519; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; McGregor WG, 1999, MOL CELL BIOL, V19, P147; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; SAGE E, 1993, PHOTOCHEM PHOTOBIOL, V57, P163, DOI 10.1111/j.1751-1097.1993.tb02273.x; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; STARY A, 1992, J GEN VIROL, V73, P1679, DOI 10.1099/0022-1317-73-7-1679; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; Sutton MD, 2001, P NATL ACAD SCI USA, V98, P8342, DOI 10.1073/pnas.111036998; Svoboda DL, 1998, CANCER RES, V58, P2445; Thakur M, 2001, GENE CHROMOSOME CANC, V32, P222, DOI 10.1002/gcc.1186; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; Tissier A, 2001, BIOCHEM SOC T, V29, P183, DOI 10.1042/0300-5127:0290183; Tornaletti S, 1996, BIOESSAYS, V18, P221, DOI 10.1002/bies.950180309; VOLPE JPG, 1995, MUTAT RES-DNA REPAIR, V337, P111, DOI 10.1016/0921-8777(95)00015-C; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; WATERS HL, 1993, J INVEST DERMATOL, V101, P744, DOI 10.1111/1523-1747.ep12371686; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yamada A, 2000, NUCLEIC ACIDS RES, V28, P2473, DOI 10.1093/nar/28.13.2473; Yao JQ, 2001, ENVIRON MOL MUTAGEN, V38, P19, DOI 10.1002/em.1046; You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200; Yu SL, 2001, MOL CELL BIOL, V21, P185, DOI 10.1128/MCB.21.1.185-188.2001	63	112	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2003	278	21					18767	18775		10.1074/jbc.M211838200	http://dx.doi.org/10.1074/jbc.M211838200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	679PY	12644471	hybrid			2022-12-27	WOS:000182932200010
J	Akiyama, Y; Ito, K				Akiyama, Y; Ito, K			Reconstitution of membrane proteolysis by FtsH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; ESCHERICHIA-COLI; MEDIATED PROTEOLYSIS; PLASMA-MEMBRANE; HFLB; PROTEINS; DEGRADATION; COMPLEX; FORMS; ROLES	Escherichia coli FtsH is a membrane-bound and ATP-dependent protease responsible for degradation of several membrane proteins. The FtsH action is processive and presumably involves dislocation of the substrate from the membrane to the cytosol. Although elucidation of its molecular mechanism requires an in vitro reaction system, in vitro activities of this enzyme against membrane protein substrates have only been assayed using detergent-solubilized components. Here we report on the construction of in vitro reaction systems for FtsH-catalyzed membrane protein degradation. A combination of two inverted membrane vesicles or of two proteoliposomes, one bearing the enzyme and the other bearing a substrate, was fused by polyethylene glycol 3350 treatment. Addition of ATP then resulted in degradation of the substrate. It was shown that FtsH can function in the process of membrane proteins degradation without aid from any other cellular factors.	Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan	Kyoto University	Akiyama, Y (corresponding author), Kyoto Univ, Inst Virus Res, Kyoto 6068507, Japan.							AKIYAMA Y, 1992, J BIOL CHEM, V267, P22440; Akiyama Y, 1998, J BIOL CHEM, V273, P22326, DOI 10.1074/jbc.273.35.22326; Akiyama Y, 1999, BIOCHEMISTRY-US, V38, P11693, DOI 10.1021/bi991177c; AKIYAMA Y, 1994, J BIOL CHEM, V269, P5218; AKIYAMA Y, 1995, J BIOL CHEM, V270, P23485, DOI 10.1074/jbc.270.40.23485; AKIYAMA Y, 1993, J BIOL CHEM, V268, P8146; Akiyama Y, 1996, FEBS LETT, V399, P26, DOI 10.1016/S0014-5793(96)01283-5; Akiyama Y, 2002, P NATL ACAD SCI USA, V99, P8066, DOI 10.1073/pnas.122616899; Akiyama Y, 1996, J BIOL CHEM, V271, P31196, DOI 10.1074/jbc.271.49.31196; Akiyama Y, 2001, BIOCHEMISTRY-US, V40, P7687, DOI 10.1021/bi010039w; Akiyama Y, 2000, EMBO J, V19, P3888, DOI 10.1093/emboj/19.15.3888; AKIYAMA Y, 1998, HDB PROTEOLYTIC ENZY, P1502; Chiba S, 2002, J BACTERIOL, V184, P4775, DOI 10.1128/JB.184.17.4775-4782.2002; Chiba S, 2000, EMBO REP, V1, P47, DOI 10.1093/embo-reports/kvd005; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; Gottesman S, 1999, CURR OPIN MICROBIOL, V2, P142, DOI 10.1016/S1369-5274(99)80025-3; Inaba K, 2002, EMBO J, V21, P2646, DOI 10.1093/emboj/21.11.2646; Kihara A, 1996, EMBO J, V15, P6122, DOI 10.1002/j.1460-2075.1996.tb01000.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Kihara A, 1998, J MOL BIOL, V279, P175, DOI 10.1006/jmbi.1998.1781; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; MORI H, 2003, IN PRESS J BIOL CHEM, V278; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; Murphy KC, 1998, J BACTERIOL, V180, P2063, DOI 10.1128/JB.180.8.2063-2071.1998; Ogura T, 1999, MOL MICROBIOL, V31, P833, DOI 10.1046/j.1365-2958.1999.01221.x; Sambrook J., 2002, MOL CLONING LAB MANU; Shimohata N, 2002, GENES CELLS, V7, P653, DOI 10.1046/j.1365-2443.2002.00554.x; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; Weihofen A, 2003, TRENDS CELL BIOL, V13, P71, DOI 10.1016/S0962-8924(02)00041-7	34	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 16	2003	278	20					18146	18153		10.1074/jbc.M302152200	http://dx.doi.org/10.1074/jbc.M302152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	677YX	12642574	hybrid			2022-12-27	WOS:000182838300073
J	Walker, JB; Hughes, B; James, I; Haddock, P; Kluft, C; Bajzar, L				Walker, JB; Hughes, B; James, I; Haddock, P; Kluft, C; Bajzar, L			Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVABLE FIBRINOLYSIS INHIBITOR; JUGULAR-VEIN THROMBOLYSIS; D DOMAIN-II; CRYSTAL-STRUCTURE; PROCARBOXYPEPTIDASE-B; PLASMINOGEN ACTIVATOR; PROTEOLYTIC CLEAVAGE; MEDIATED ACTIVATION; CARBOXYPEPTIDASE-A; THERMAL-STABILITY	Two competitive inhibitors of TAFIa (activated thrombin-activable fibrinolysis inhibitor), 2-guanidinoethyl-mercaptosuccinic acid and potato tuber carboxypeptidase inhibitor, variably affect fibrinolysis of clotted human plasma. Depending on their concentration, the inhibitors shortened, prolonged, or had no effect on lysis in vitro. The inhibitor-induced effects were both tissue-type plasminogenactivator(tPA) andTAFIa concentration- dependent. Inhibitor-dependent prolongation was favored at lower tPA concentrations. The magnitude of the prolongation increased with TAFIa concentration, and the maximal prolongation observed at each TAFIa concentration increased saturably with respect to TAFIa. A theoretical maximal prolongation of 20-fold was derived from a plot of the maximum prolongation versus TAFIa. This represents, for the first time, a measurement of the maximal antifibrinolytic potential of TAFIa in vitro. Because TAFIa spontaneously decays, the stabilization of TAFIa was investigated as a mechanism explaining the inhibitor-dependent prolongation of lysis. Both inhibitors stabilized TAFIa in a concentration-dependent, non-saturable manner. Although their K-1 values differed by three orders of magnitude, TAFIa was identically stabilized when the fraction of inhibitor-bound TAFIa was the same. The data fit a model whereby only free TAFIa decays. Therefore, the variable effects of competitive inhibitors of TAFla on fibrinolysis can be rationalized in terms of free TAFla and lysis time relative to the half-life of TAFIa.	Henerson Res Ctr, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Hamilton, ON L8V 1C3, Canada; Pfizer Ltd, Global Res & Dev, Sandwich Labs, Sandwich CT13 9NJ, Kent, England; TNO PG, Gaubius Inst, NL-2333 CK Leiden, Netherlands	McMaster University; Pfizer; Netherlands Organization Applied Science Research	Bajzar, L (corresponding author), Henerson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.							Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; Bajzar L, 1996, J BIOL CHEM, V271, P16603, DOI 10.1074/jbc.271.28.16603; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; Bajzar L, 1998, J BIOL CHEM, V273, P2792, DOI 10.1074/jbc.273.5.2792; Bajzar L, 1996, BLOOD, V88, P2093, DOI 10.1182/blood.V88.6.2093.bloodjournal8862093; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Boffa MB, 1998, J BIOL CHEM, V273, P2127, DOI 10.1074/jbc.273.4.2127; Boffa MB, 2000, J BIOL CHEM, V275, P12868, DOI 10.1074/jbc.275.17.12868; CAMPBELL W, 1989, BIOCHEM BIOPH RES CO, V162, P933, DOI 10.1016/0006-291X(89)90762-6; EATON DL, 1991, J BIOL CHEM, V266, P21833; FRICKER LD, 1983, BIOCHEM BIOPH RES CO, V111, P994, DOI 10.1016/0006-291X(83)91398-0; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; Klement P, 1999, BLOOD, V94, P2735, DOI 10.1182/blood.V94.8.2735.420k30_2735_2743; Marx PF, 2000, J BIOL CHEM, V275, P12410, DOI 10.1074/jbc.275.17.12410; Marx PF, 2002, BIOCHEMISTRY-US, V41, P1211, DOI 10.1021/bi0115683; Marx PF, 2002, BIOCHEMISTRY-US, V41, P6688, DOI 10.1021/bi015982e; Minnema MC, 1998, J CLIN INVEST, V101, P10, DOI 10.1172/JCI781; MOLINA MA, 1994, J BIOL CHEM, V269, P21467; Nagashima M, 2000, THROMB RES, V98, P333, DOI 10.1016/S0049-3848(00)00184-5; Nesheim M, 1997, THROMB HAEMOSTASIS, V78, P386; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Refino C. J., 1998, Fibrinolysis and Proteolysis, V12, P29; RYAN CA, 1974, J BIOL CHEM, V249, P5495; Schatteman KA, 1999, THROMB HAEMOSTASIS, V82, P1718, DOI 10.1055/s-0037-1614904; Schneider M, 2002, J BIOL CHEM, V277, P1021, DOI 10.1074/jbc.M104444200; Schneider MM, 2001, BLOOD, V98, p254A; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; VondemBorne PAK, 1997, J CLIN INVEST, V99, P2323, DOI 10.1172/JCI119412; Walker JB, 2001, J BIOL CHEM, V276, P3138, DOI 10.1074/jbc.M005876200; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176	31	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 14	2003	278	11					8913	8921		10.1074/jbc.M205006200	http://dx.doi.org/10.1074/jbc.M205006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	654YF	12643276	Green Published, hybrid			2022-12-27	WOS:000181524000008
